DDI-DrugBank.d339.s0|0-12|Carbamazepine|O
DDI-DrugBank.d339.s0|13-13|:|O
DDI-DrugBank.d339.s0|15-22|Elevated|O
DDI-DrugBank.d339.s0|24-36|carbamazepine|O
DDI-DrugBank.d339.s0|38-43|levels|O
DDI-DrugBank.d339.s0|45-48|have|O
DDI-DrugBank.d339.s0|50-53|been|O
DDI-DrugBank.d339.s0|55-62|reported|O
DDI-DrugBank.d339.s0|64-65|in|O
DDI-DrugBank.d339.s0|67-79|postmarketing|O
DDI-DrugBank.d339.s0|81-90|experience|O
DDI-DrugBank.d339.s0|92-95|when|O
DDI-DrugBank.d339.s0|97-102|SUPRAX|O
DDI-DrugBank.d339.s0|104-105|is|O
DDI-DrugBank.d339.s0|107-118|administered|O
DDI-DrugBank.d339.s0|120-132|concomitantly|O
DDI-DrugBank.d339.s0|133-133|.|O
DDI-DrugBank.d339.s1|0-3|Drug|O
DDI-DrugBank.d339.s1|5-14|monitoring|O
DDI-DrugBank.d339.s1|16-18|may|O
DDI-DrugBank.d339.s1|20-21|be|O
DDI-DrugBank.d339.s1|23-24|of|O
DDI-DrugBank.d339.s1|26-35|assistance|O
DDI-DrugBank.d339.s1|37-38|in|O
DDI-DrugBank.d339.s1|40-48|detecting|O
DDI-DrugBank.d339.s1|50-60|alterations|O
DDI-DrugBank.d339.s1|62-63|in|O
DDI-DrugBank.d339.s1|65-77|carbamazepine|O
DDI-DrugBank.d339.s1|79-84|plasma|O
DDI-DrugBank.d339.s1|86-99|concentrations|O
DDI-DrugBank.d339.s1|100-100|.|O
DDI-DrugBank.d339.s2|0-7|Warfarin|O
DDI-DrugBank.d339.s2|9-11|and|O
DDI-DrugBank.d339.s2|13-26|Anticoagulants|O
DDI-DrugBank.d339.s2|27-27|:|O
DDI-DrugBank.d339.s2|29-37|Increased|O
DDI-DrugBank.d339.s2|39-49|prothrombin|O
DDI-DrugBank.d339.s2|51-54|time|O
DDI-DrugBank.d339.s2|55-55|,|O
DDI-DrugBank.d339.s2|57-60|with|O
DDI-DrugBank.d339.s2|62-63|or|O
DDI-DrugBank.d339.s2|65-71|without|O
DDI-DrugBank.d339.s2|73-80|clinical|O
DDI-DrugBank.d339.s2|82-89|bleeding|O
DDI-DrugBank.d339.s2|90-90|,|O
DDI-DrugBank.d339.s2|92-94|has|O
DDI-DrugBank.d339.s2|96-99|been|O
DDI-DrugBank.d339.s2|101-108|reported|O
DDI-DrugBank.d339.s2|110-113|when|O
DDI-DrugBank.d339.s2|115-122|cefixime|O
DDI-DrugBank.d339.s2|124-125|is|O
DDI-DrugBank.d339.s2|127-138|administered|O
DDI-DrugBank.d339.s2|140-152|concomitantly|O
DDI-DrugBank.d339.s2|153-153|.|O
DDI-DrugBank.d339.s3|0-14|Drug/Laboratory|O
DDI-DrugBank.d339.s3|16-19|Test|O
DDI-DrugBank.d339.s3|21-32|Interactions|O
DDI-DrugBank.d339.s3|34-34|A|O
DDI-DrugBank.d339.s3|36-49|false-positive|O
DDI-DrugBank.d339.s3|51-58|reaction|O
DDI-DrugBank.d339.s3|60-62|for|O
DDI-DrugBank.d339.s3|64-70|ketones|O
DDI-DrugBank.d339.s3|72-73|in|O
DDI-DrugBank.d339.s3|75-77|the|O
DDI-DrugBank.d339.s3|79-83|urine|O
DDI-DrugBank.d339.s3|85-87|may|O
DDI-DrugBank.d339.s3|89-93|occur|O
DDI-DrugBank.d339.s3|95-98|with|O
DDI-DrugBank.d339.s3|100-104|tests|O
DDI-DrugBank.d339.s3|106-110|using|O
DDI-DrugBank.d339.s3|112-124|nitroprusside|O
DDI-DrugBank.d339.s3|126-128|but|O
DDI-DrugBank.d339.s3|130-132|not|O
DDI-DrugBank.d339.s3|134-137|with|O
DDI-DrugBank.d339.s3|139-143|those|O
DDI-DrugBank.d339.s3|145-149|using|O
DDI-DrugBank.d339.s3|151-167|nitroferricyanide|O
DDI-DrugBank.d339.s3|168-168|.|O
DDI-DrugBank.d339.s4|0-2|The|O
DDI-DrugBank.d339.s4|4-17|administration|O
DDI-DrugBank.d339.s4|19-20|of|O
DDI-DrugBank.d339.s4|22-27|SUPRAX|O
DDI-DrugBank.d339.s4|29-31|may|O
DDI-DrugBank.d339.s4|33-38|result|O
DDI-DrugBank.d339.s4|40-41|in|O
DDI-DrugBank.d339.s4|43-43|a|O
DDI-DrugBank.d339.s4|45-58|false-positive|O
DDI-DrugBank.d339.s4|60-67|reaction|O
DDI-DrugBank.d339.s4|69-71|for|O
DDI-DrugBank.d339.s4|73-79|glucose|O
DDI-DrugBank.d339.s4|81-82|in|O
DDI-DrugBank.d339.s4|84-86|the|O
DDI-DrugBank.d339.s4|88-92|urine|O
DDI-DrugBank.d339.s4|94-98|using|O
DDI-DrugBank.d339.s4|100-108|Clinitest|O
DDI-DrugBank.d339.s4|110-111|**|O
DDI-DrugBank.d339.s4|112-112|,|O
DDI-DrugBank.d339.s4|114-121|Benedict|O
DDI-DrugBank.d339.s4|123-123|s|O
DDI-DrugBank.d339.s4|125-132|solution|O
DDI-DrugBank.d339.s4|133-133|,|O
DDI-DrugBank.d339.s4|135-136|or|O
DDI-DrugBank.d339.s4|138-144|Fehling|O
DDI-DrugBank.d339.s4|146-146|s|O
DDI-DrugBank.d339.s4|148-155|solution|O
DDI-DrugBank.d339.s4|156-156|.|O
DDI-DrugBank.d339.s5|0-1|It|O
DDI-DrugBank.d339.s5|3-4|is|O
DDI-DrugBank.d339.s5|6-16|recommended|O
DDI-DrugBank.d339.s5|18-21|that|O
DDI-DrugBank.d339.s5|23-29|glucose|O
DDI-DrugBank.d339.s5|31-35|tests|O
DDI-DrugBank.d339.s5|37-41|based|O
DDI-DrugBank.d339.s5|43-44|on|O
DDI-DrugBank.d339.s5|46-54|enzymatic|O
DDI-DrugBank.d339.s5|56-62|glucose|O
DDI-DrugBank.d339.s5|64-70|oxidase|O
DDI-DrugBank.d339.s5|72-80|reactions|O
DDI-DrugBank.d339.s5|82-82|(|O
DDI-DrugBank.d339.s5|83-86|such|O
DDI-DrugBank.d339.s5|88-89|as|O
DDI-DrugBank.d339.s5|91-99|Clinistix|O
DDI-DrugBank.d339.s5|101-102|**|O
DDI-DrugBank.d339.s5|104-105|or|O
DDI-DrugBank.d339.s5|107-114|Tes-Tape|O
DDI-DrugBank.d339.s5|116-117|**|O
DDI-DrugBank.d339.s5|118-118|)|O
DDI-DrugBank.d339.s5|120-121|be|O
DDI-DrugBank.d339.s5|123-126|used|O
DDI-DrugBank.d339.s5|127-127|.|O
DDI-DrugBank.d339.s6|0-0|A|O
DDI-DrugBank.d339.s6|2-15|false-positive|O
DDI-DrugBank.d339.s6|17-22|direct|O
DDI-DrugBank.d339.s6|24-29|Coombs|O
DDI-DrugBank.d339.s6|31-34|test|O
DDI-DrugBank.d339.s6|36-38|has|O
DDI-DrugBank.d339.s6|40-43|been|O
DDI-DrugBank.d339.s6|45-52|reported|O
DDI-DrugBank.d339.s6|54-59|during|O
DDI-DrugBank.d339.s6|61-69|treatment|O
DDI-DrugBank.d339.s6|71-74|with|O
DDI-DrugBank.d339.s6|76-80|other|O
DDI-DrugBank.d339.s6|82-94|cephalosporin|O
DDI-DrugBank.d339.s6|96-106|antibiotics|O
DDI-DrugBank.d339.s6|107-107|;|O
DDI-DrugBank.d339.s7|0-8|therefore|O
DDI-DrugBank.d339.s7|9-9|,|O
DDI-DrugBank.d339.s7|11-12|it|O
DDI-DrugBank.d339.s7|14-19|should|O
DDI-DrugBank.d339.s7|21-22|be|O
DDI-DrugBank.d339.s7|24-33|recognized|O
DDI-DrugBank.d339.s7|35-38|that|O
DDI-DrugBank.d339.s7|40-40|a|O
DDI-DrugBank.d339.s7|42-49|positive|O
DDI-DrugBank.d339.s7|51-56|Coombs|O
DDI-DrugBank.d339.s7|58-61|test|O
DDI-DrugBank.d339.s7|63-65|may|O
DDI-DrugBank.d339.s7|67-68|be|O
DDI-DrugBank.d339.s7|70-72|due|O
DDI-DrugBank.d339.s7|74-75|to|O
DDI-DrugBank.d339.s7|77-79|the|O
DDI-DrugBank.d339.s7|81-84|drug|O
DDI-DrugBank.d339.s7|85-85|.|O
DDI-DrugBank.d383.s0|0-1|No|O
DDI-DrugBank.d383.s0|3-13|information|O
DDI-DrugBank.d383.s0|15-22|provided|O
DDI-DrugBank.d546.s0|0-3|Drug|O
DDI-DrugBank.d546.s0|5-16|Interactions|O
DDI-DrugBank.d546.s0|18-21|with|O
DDI-DrugBank.d546.s0|23-35|Beta-Blockers|O
DDI-DrugBank.d546.s0|36-36|:|O
DDI-DrugBank.d546.s0|38-48|Concomitant|O
DDI-DrugBank.d546.s0|50-52|use|O
DDI-DrugBank.d546.s0|54-55|of|O
DDI-DrugBank.d546.s0|57-66|fenoldopam|O
DDI-DrugBank.d546.s0|68-71|with|O
DDI-DrugBank.d546.s0|73-85|beta-blockers|O
DDI-DrugBank.d546.s0|87-92|should|O
DDI-DrugBank.d546.s0|94-95|be|O
DDI-DrugBank.d546.s0|97-103|avoided|O
DDI-DrugBank.d546.s0|104-104|.|O
DDI-DrugBank.d546.s1|0-1|If|O
DDI-DrugBank.d546.s1|3-5|the|O
DDI-DrugBank.d546.s1|7-11|drugs|O
DDI-DrugBank.d546.s1|13-15|are|O
DDI-DrugBank.d546.s1|17-20|used|O
DDI-DrugBank.d546.s1|22-29|together|O
DDI-DrugBank.d546.s1|30-30|,|O
DDI-DrugBank.d546.s1|32-38|caution|O
DDI-DrugBank.d546.s1|40-45|should|O
DDI-DrugBank.d546.s1|47-48|be|O
DDI-DrugBank.d546.s1|50-58|exercised|O
DDI-DrugBank.d546.s1|60-66|because|O
DDI-DrugBank.d546.s1|68-77|unexpected|O
DDI-DrugBank.d546.s1|79-89|hypotension|O
DDI-DrugBank.d546.s1|91-95|could|O
DDI-DrugBank.d546.s1|97-102|result|O
DDI-DrugBank.d546.s1|104-107|from|O
DDI-DrugBank.d546.s1|109-120|beta-blocker|O
DDI-DrugBank.d546.s1|122-131|inhibition|O
DDI-DrugBank.d546.s1|133-134|of|O
DDI-DrugBank.d546.s1|136-138|the|O
DDI-DrugBank.d546.s1|140-150|sympathetic|O
DDI-DrugBank.d546.s1|152-157|reflex|O
DDI-DrugBank.d546.s1|159-166|response|O
DDI-DrugBank.d546.s1|168-169|to|O
DDI-DrugBank.d546.s1|171-180|fenoldopam|O
DDI-DrugBank.d546.s1|181-181|.|O
DDI-DrugBank.d546.s2|0-3|Drug|O
DDI-DrugBank.d546.s2|5-16|Interactions|O
DDI-DrugBank.d546.s2|17-17|,|O
DDI-DrugBank.d546.s2|19-25|General|O
DDI-DrugBank.d546.s2|26-26|:|O
DDI-DrugBank.d546.s2|28-35|Although|O
DDI-DrugBank.d546.s2|37-41|there|O
DDI-DrugBank.d546.s2|43-46|have|O
DDI-DrugBank.d546.s2|48-51|been|O
DDI-DrugBank.d546.s2|53-54|no|O
DDI-DrugBank.d546.s2|56-61|formal|O
DDI-DrugBank.d546.s2|63-73|interaction|O
DDI-DrugBank.d546.s2|75-81|studies|O
DDI-DrugBank.d546.s2|82-82|,|O
DDI-DrugBank.d546.s2|84-94|intravenous|O
DDI-DrugBank.d546.s2|96-105|fenoldopam|O
DDI-DrugBank.d546.s2|107-109|has|O
DDI-DrugBank.d546.s2|111-114|been|O
DDI-DrugBank.d546.s2|116-127|administered|O
DDI-DrugBank.d546.s2|129-134|safely|O
DDI-DrugBank.d546.s2|136-139|with|O
DDI-DrugBank.d546.s2|141-145|drugs|O
DDI-DrugBank.d546.s2|147-150|such|O
DDI-DrugBank.d546.s2|152-153|as|O
DDI-DrugBank.d546.s2|155-163|digitalis|O
DDI-DrugBank.d546.s2|165-167|and|O
DDI-DrugBank.d546.s2|169-178|sublingual|O
DDI-DrugBank.d546.s2|180-192|nitroglycerin|O
DDI-DrugBank.d546.s2|193-193|.|O
DDI-DrugBank.d546.s3|0-4|There|O
DDI-DrugBank.d546.s3|6-7|is|O
DDI-DrugBank.d546.s3|9-15|limited|O
DDI-DrugBank.d546.s3|17-26|experience|O
DDI-DrugBank.d546.s3|28-31|with|O
DDI-DrugBank.d546.s3|33-43|concomitant|O
DDI-DrugBank.d546.s3|45-60|antihypertensive|O
DDI-DrugBank.d546.s3|62-67|agents|O
DDI-DrugBank.d546.s3|69-72|such|O
DDI-DrugBank.d546.s3|74-75|as|O
DDI-DrugBank.d546.s3|77-90|alpha-blockers|O
DDI-DrugBank.d546.s3|91-91|,|O
DDI-DrugBank.d546.s3|93-99|calcium|O
DDI-DrugBank.d546.s3|101-116|channel-blockers|O
DDI-DrugBank.d546.s3|117-117|,|O
DDI-DrugBank.d546.s3|119-121|ACE|O
DDI-DrugBank.d546.s3|123-132|inhibitors|O
DDI-DrugBank.d546.s3|133-133|,|O
DDI-DrugBank.d546.s3|135-137|and|O
DDI-DrugBank.d546.s3|139-147|diuretics|O
DDI-DrugBank.d546.s3|149-149|(|O
DDI-DrugBank.d546.s3|150-153|both|O
DDI-DrugBank.d546.s3|155-167|thiazide-like|O
DDI-DrugBank.d546.s3|169-171|and|O
DDI-DrugBank.d546.s3|173-176|loop|O
DDI-DrugBank.d546.s3|177-177|)|O
DDI-DrugBank.d546.s3|178-178|.|O
DDI-DrugBank.d197.s0|0-6|General|O
DDI-DrugBank.d197.s0|8-9|In|O
DDI-DrugBank.d197.s0|11-15|vitro|O
DDI-DrugBank.d197.s0|17-23|studies|O
DDI-DrugBank.d197.s0|25-26|in|O
DDI-DrugBank.d197.s0|28-32|human|O
DDI-DrugBank.d197.s0|34-38|liver|O
DDI-DrugBank.d197.s0|40-49|microsomes|O
DDI-DrugBank.d197.s0|51-62|demonstrated|O
DDI-DrugBank.d197.s0|64-65|no|O
DDI-DrugBank.d197.s0|67-74|evidence|O
DDI-DrugBank.d197.s0|76-77|of|O
DDI-DrugBank.d197.s0|79-88|cytochrome|O
DDI-DrugBank.d197.s0|90-102|P450-mediated|O
DDI-DrugBank.d197.s0|104-107|drug|O
DDI-DrugBank.d197.s0|109-120|interactions|O
DDI-DrugBank.d197.s0|122-125|that|O
DDI-DrugBank.d197.s0|127-129|are|O
DDI-DrugBank.d197.s0|131-136|likely|O
DDI-DrugBank.d197.s0|138-139|to|O
DDI-DrugBank.d197.s0|141-142|be|O
DDI-DrugBank.d197.s0|144-145|of|O
DDI-DrugBank.d197.s0|147-154|clinical|O
DDI-DrugBank.d197.s0|156-164|relevance|O
DDI-DrugBank.d197.s0|165-165|.|O
DDI-DrugBank.d197.s1|0-38|Anesthetics/Sedatives/Hypnotics/Opioids|O
DDI-DrugBank.d197.s1|39-39|:|O
DDI-DrugBank.d197.s1|41-57|Co-administration|O
DDI-DrugBank.d197.s1|59-60|of|O
DDI-DrugBank.d197.s1|62-69|PRECEDEX|O
DDI-DrugBank.d197.s1|71-74|with|O
DDI-DrugBank.d197.s1|76-86|anesthetics|O
DDI-DrugBank.d197.s1|87-87|,|O
DDI-DrugBank.d197.s1|89-97|sedatives|O
DDI-DrugBank.d197.s1|98-98|,|O
DDI-DrugBank.d197.s1|100-108|hypnotics|O
DDI-DrugBank.d197.s1|109-109|,|O
DDI-DrugBank.d197.s1|111-113|and|O
DDI-DrugBank.d197.s1|115-121|opioids|O
DDI-DrugBank.d197.s1|123-124|is|O
DDI-DrugBank.d197.s1|126-131|likely|O
DDI-DrugBank.d197.s1|133-134|to|O
DDI-DrugBank.d197.s1|136-139|lead|O
DDI-DrugBank.d197.s1|141-142|to|O
DDI-DrugBank.d197.s1|144-145|an|O
DDI-DrugBank.d197.s1|147-157|enhancement|O
DDI-DrugBank.d197.s1|159-160|of|O
DDI-DrugBank.d197.s1|162-168|effects|O
DDI-DrugBank.d197.s1|169-169|.|O
DDI-DrugBank.d197.s2|0-7|Specific|O
DDI-DrugBank.d197.s2|9-15|studies|O
DDI-DrugBank.d197.s2|17-20|have|O
DDI-DrugBank.d197.s2|22-30|confirmed|O
DDI-DrugBank.d197.s2|32-36|these|O
DDI-DrugBank.d197.s2|38-44|effects|O
DDI-DrugBank.d197.s2|46-49|with|O
DDI-DrugBank.d197.s2|51-61|sevoflurane|O
DDI-DrugBank.d197.s2|62-62|,|O
DDI-DrugBank.d197.s2|64-73|isoflurane|O
DDI-DrugBank.d197.s2|74-74|,|O
DDI-DrugBank.d197.s2|76-83|propofol|O
DDI-DrugBank.d197.s2|84-84|,|O
DDI-DrugBank.d197.s2|86-95|alfentanil|O
DDI-DrugBank.d197.s2|96-96|,|O
DDI-DrugBank.d197.s2|98-100|and|O
DDI-DrugBank.d197.s2|102-110|midazolam|O
DDI-DrugBank.d197.s2|111-111|.|O
DDI-DrugBank.d197.s3|0-1|No|O
DDI-DrugBank.d197.s3|3-17|pharmacokinetic|O
DDI-DrugBank.d197.s3|19-30|interactions|O
DDI-DrugBank.d197.s3|32-38|between|O
DDI-DrugBank.d197.s3|40-54|dexmedetomidine|O
DDI-DrugBank.d197.s3|56-58|and|O
DDI-DrugBank.d197.s3|60-69|isoflurane|O
DDI-DrugBank.d197.s3|70-70|,|O
DDI-DrugBank.d197.s3|72-79|propofol|O
DDI-DrugBank.d197.s3|80-80|,|O
DDI-DrugBank.d197.s3|82-91|alfentanil|O
DDI-DrugBank.d197.s3|92-92|,|O
DDI-DrugBank.d197.s3|94-96|and|O
DDI-DrugBank.d197.s3|98-106|midazolam|O
DDI-DrugBank.d197.s3|108-111|have|O
DDI-DrugBank.d197.s3|113-116|been|O
DDI-DrugBank.d197.s3|118-129|demonstrated|O
DDI-DrugBank.d197.s3|130-130|.|O
DDI-DrugBank.d197.s4|0-6|However|O
DDI-DrugBank.d197.s4|7-7|,|O
DDI-DrugBank.d197.s4|9-11|due|O
DDI-DrugBank.d197.s4|13-14|to|O
DDI-DrugBank.d197.s4|16-23|possible|O
DDI-DrugBank.d197.s4|25-39|pharmacodynamic|O
DDI-DrugBank.d197.s4|41-52|interactions|O
DDI-DrugBank.d197.s4|53-53|,|O
DDI-DrugBank.d197.s4|55-58|when|O
DDI-DrugBank.d197.s4|60-74|co-administered|O
DDI-DrugBank.d197.s4|76-79|with|O
DDI-DrugBank.d197.s4|81-88|PRECEDEX|O
DDI-DrugBank.d197.s4|89-89|,|O
DDI-DrugBank.d197.s4|91-91|a|O
DDI-DrugBank.d197.s4|93-101|reduction|O
DDI-DrugBank.d197.s4|103-104|in|O
DDI-DrugBank.d197.s4|106-111|dosage|O
DDI-DrugBank.d197.s4|113-114|of|O
DDI-DrugBank.d197.s4|116-123|PRECEDEX|O
DDI-DrugBank.d197.s4|125-126|on|O
DDI-DrugBank.d197.s4|128-130|the|O
DDI-DrugBank.d197.s4|132-142|concomitant|O
DDI-DrugBank.d197.s4|144-153|anesthetic|O
DDI-DrugBank.d197.s4|154-154|,|O
DDI-DrugBank.d197.s4|156-163|sedative|O
DDI-DrugBank.d197.s4|164-164|,|O
DDI-DrugBank.d197.s4|166-173|hypnotic|O
DDI-DrugBank.d197.s4|175-176|or|O
DDI-DrugBank.d197.s4|178-183|opioid|O
DDI-DrugBank.d197.s4|185-187|may|O
DDI-DrugBank.d197.s4|189-190|be|O
DDI-DrugBank.d197.s4|192-199|required|O
DDI-DrugBank.d197.s4|200-200|.|O
DDI-DrugBank.d197.s5|0-12|Neuromuscular|O
DDI-DrugBank.d197.s5|14-21|Blockers|O
DDI-DrugBank.d197.s5|22-22|:|O
DDI-DrugBank.d197.s5|24-25|In|O
DDI-DrugBank.d197.s5|27-29|one|O
DDI-DrugBank.d197.s5|31-35|study|O
DDI-DrugBank.d197.s5|37-38|of|O
DDI-DrugBank.d197.s5|40-41|10|O
DDI-DrugBank.d197.s5|43-49|healthy|O
DDI-DrugBank.d197.s5|51-60|volunteers|O
DDI-DrugBank.d197.s5|61-61|,|O
DDI-DrugBank.d197.s5|63-76|administration|O
DDI-DrugBank.d197.s5|78-79|of|O
DDI-DrugBank.d197.s5|81-88|PRECEDEX|O
DDI-DrugBank.d197.s5|90-92|for|O
DDI-DrugBank.d197.s5|94-95|45|O
DDI-DrugBank.d197.s5|97-103|minutes|O
DDI-DrugBank.d197.s5|105-106|at|O
DDI-DrugBank.d197.s5|108-108|a|O
DDI-DrugBank.d197.s5|110-115|plasma|O
DDI-DrugBank.d197.s5|117-129|concentration|O
DDI-DrugBank.d197.s5|131-132|of|O
DDI-DrugBank.d197.s5|134-134|1|O
DDI-DrugBank.d197.s5|136-136|(|O
DDI-DrugBank.d197.s5|137-139|one|O
DDI-DrugBank.d197.s5|140-140|)|O
DDI-DrugBank.d197.s5|142-146|ng/mL|O
DDI-DrugBank.d197.s5|148-155|resulted|O
DDI-DrugBank.d197.s5|157-158|in|O
DDI-DrugBank.d197.s5|160-161|no|O
DDI-DrugBank.d197.s5|163-172|clinically|O
DDI-DrugBank.d197.s5|174-183|meaningful|O
DDI-DrugBank.d197.s5|185-193|increases|O
DDI-DrugBank.d197.s5|195-196|in|O
DDI-DrugBank.d197.s5|198-200|the|O
DDI-DrugBank.d197.s5|202-210|magnitude|O
DDI-DrugBank.d197.s5|212-213|or|O
DDI-DrugBank.d197.s5|215-227|neuromuscular|O
DDI-DrugBank.d197.s5|229-236|blockade|O
DDI-DrugBank.d197.s5|238-247|associated|O
DDI-DrugBank.d197.s5|249-252|with|O
DDI-DrugBank.d197.s5|254-263|rocuronium|O
DDI-DrugBank.d197.s5|265-278|administration|O
DDI-DrugBank.d197.s5|279-279|.|O
DDI-DrugBank.d418.s0|0-1|No|O
DDI-DrugBank.d418.s0|3-8|formal|O
DDI-DrugBank.d418.s0|10-13|drug|O
DDI-DrugBank.d418.s0|15-25|interaction|O
DDI-DrugBank.d418.s0|27-33|studies|O
DDI-DrugBank.d418.s0|35-38|have|O
DDI-DrugBank.d418.s0|40-43|been|O
DDI-DrugBank.d418.s0|45-53|conducted|O
DDI-DrugBank.d418.s0|55-58|with|O
DDI-DrugBank.d418.s0|60-67|Cyanokit|O
DDI-DrugBank.d418.s0|68-68|.|O
DDI-DrugBank.d549.s0|0-1|In|O
DDI-DrugBank.d549.s0|3-9|studies|O
DDI-DrugBank.d549.s0|11-12|in|O
DDI-DrugBank.d549.s0|14-19|normal|O
DDI-DrugBank.d549.s0|21-30|volunteers|O
DDI-DrugBank.d549.s0|31-31|,|O
DDI-DrugBank.d549.s0|33-37|there|O
DDI-DrugBank.d549.s0|39-41|was|O
DDI-DrugBank.d549.s0|43-44|no|O
DDI-DrugBank.d549.s0|46-60|pharmacodynamic|O
DDI-DrugBank.d549.s0|62-72|interaction|O
DDI-DrugBank.d549.s0|74-80|between|O
DDI-DrugBank.d549.s0|82-92|intravenous|O
DDI-DrugBank.d549.s0|94-101|iloprost|O
DDI-DrugBank.d549.s0|103-105|and|O
DDI-DrugBank.d549.s0|107-112|either|O
DDI-DrugBank.d549.s0|114-123|nifedipine|O
DDI-DrugBank.d549.s0|124-124|,|O
DDI-DrugBank.d549.s0|126-134|diltiazem|O
DDI-DrugBank.d549.s0|135-135|,|O
DDI-DrugBank.d549.s0|137-138|or|O
DDI-DrugBank.d549.s0|140-148|captopril|O
DDI-DrugBank.d549.s0|149-149|.|O
DDI-DrugBank.d549.s1|0-6|However|O
DDI-DrugBank.d549.s1|7-7|,|O
DDI-DrugBank.d549.s1|9-16|iloprost|O
DDI-DrugBank.d549.s1|18-20|has|O
DDI-DrugBank.d549.s1|22-24|the|O
DDI-DrugBank.d549.s1|26-34|potential|O
DDI-DrugBank.d549.s1|36-37|to|O
DDI-DrugBank.d549.s1|39-46|increase|O
DDI-DrugBank.d549.s1|48-50|the|O
DDI-DrugBank.d549.s1|52-62|hypotensive|O
DDI-DrugBank.d549.s1|64-69|effect|O
DDI-DrugBank.d549.s1|71-72|of|O
DDI-DrugBank.d549.s1|74-85|vasodilators|O
DDI-DrugBank.d549.s1|87-89|and|O
DDI-DrugBank.d549.s1|91-106|antihypertensive|O
DDI-DrugBank.d549.s1|108-113|agents|O
DDI-DrugBank.d549.s1|114-114|.|O
DDI-DrugBank.d549.s2|0-4|Since|O
DDI-DrugBank.d549.s2|6-13|iloprost|O
DDI-DrugBank.d549.s2|15-22|inhibits|O
DDI-DrugBank.d549.s2|24-31|platelet|O
DDI-DrugBank.d549.s2|33-40|function|O
DDI-DrugBank.d549.s2|41-41|,|O
DDI-DrugBank.d549.s2|43-47|there|O
DDI-DrugBank.d549.s2|49-50|is|O
DDI-DrugBank.d549.s2|52-52|a|O
DDI-DrugBank.d549.s2|54-62|potential|O
DDI-DrugBank.d549.s2|64-66|for|O
DDI-DrugBank.d549.s2|68-76|increased|O
DDI-DrugBank.d549.s2|78-81|risk|O
DDI-DrugBank.d549.s2|83-84|of|O
DDI-DrugBank.d549.s2|86-93|bleeding|O
DDI-DrugBank.d549.s2|94-94|,|O
DDI-DrugBank.d549.s2|96-107|particularly|O
DDI-DrugBank.d549.s2|109-110|in|O
DDI-DrugBank.d549.s2|112-119|patients|O
DDI-DrugBank.d549.s2|121-130|maintained|O
DDI-DrugBank.d549.s2|132-133|on|O
DDI-DrugBank.d549.s2|135-148|anticoagulants|O
DDI-DrugBank.d549.s2|149-149|.|O
DDI-DrugBank.d549.s3|0-5|During|O
DDI-DrugBank.d549.s3|7-14|clinical|O
DDI-DrugBank.d549.s3|16-21|trials|O
DDI-DrugBank.d549.s3|22-22|,|O
DDI-DrugBank.d549.s3|24-31|iloprost|O
DDI-DrugBank.d549.s3|33-35|was|O
DDI-DrugBank.d549.s3|37-40|used|O
DDI-DrugBank.d549.s3|42-53|concurrently|O
DDI-DrugBank.d549.s3|55-58|with|O
DDI-DrugBank.d549.s3|60-73|anticoagulants|O
DDI-DrugBank.d549.s3|74-74|,|O
DDI-DrugBank.d549.s3|76-84|diuretics|O
DDI-DrugBank.d549.s3|85-85|,|O
DDI-DrugBank.d549.s3|87-93|cardiac|O
DDI-DrugBank.d549.s3|95-104|glycosides|O
DDI-DrugBank.d549.s3|105-105|,|O
DDI-DrugBank.d549.s3|107-113|calcium|O
DDI-DrugBank.d549.s3|115-121|channel|O
DDI-DrugBank.d549.s3|123-130|blockers|O
DDI-DrugBank.d549.s3|131-131|,|O
DDI-DrugBank.d549.s3|133-142|analgesics|O
DDI-DrugBank.d549.s3|143-143|,|O
DDI-DrugBank.d549.s3|145-156|antipyretics|O
DDI-DrugBank.d549.s3|157-157|,|O
DDI-DrugBank.d549.s3|159-170|nonsteroidal|O
DDI-DrugBank.d549.s3|172-189|antiinflammatories|O
DDI-DrugBank.d549.s3|190-190|,|O
DDI-DrugBank.d549.s3|192-206|corticosteroids|O
DDI-DrugBank.d549.s3|207-207|,|O
DDI-DrugBank.d549.s3|209-211|and|O
DDI-DrugBank.d549.s3|213-217|other|O
DDI-DrugBank.d549.s3|219-229|medications|O
DDI-DrugBank.d549.s3|230-230|.|O
DDI-DrugBank.d549.s4|0-10|Intravenous|O
DDI-DrugBank.d549.s4|12-19|infusion|O
DDI-DrugBank.d549.s4|21-22|of|O
DDI-DrugBank.d549.s4|24-31|iloprost|O
DDI-DrugBank.d549.s4|33-35|had|O
DDI-DrugBank.d549.s4|37-38|no|O
DDI-DrugBank.d549.s4|40-45|effect|O
DDI-DrugBank.d549.s4|47-48|on|O
DDI-DrugBank.d549.s4|50-52|the|O
DDI-DrugBank.d549.s4|54-69|pharmacokinetics|O
DDI-DrugBank.d549.s4|71-72|of|O
DDI-DrugBank.d549.s4|74-80|digoxin|O
DDI-DrugBank.d549.s4|81-81|.|O
DDI-DrugBank.d549.s5|0-14|Acetylsalicylic|O
DDI-DrugBank.d549.s5|16-19|acid|O
DDI-DrugBank.d549.s5|21-23|did|O
DDI-DrugBank.d549.s5|25-27|not|O
DDI-DrugBank.d549.s5|29-33|alter|O
DDI-DrugBank.d549.s5|35-37|the|O
DDI-DrugBank.d549.s5|39-47|clearance|O
DDI-DrugBank.d549.s5|49-49|(|O
DDI-DrugBank.d549.s5|50-65|pharmacokinetics|O
DDI-DrugBank.d549.s5|66-66|)|O
DDI-DrugBank.d549.s5|68-69|of|O
DDI-DrugBank.d549.s5|71-78|iloprost|O
DDI-DrugBank.d549.s5|79-79|.|O
DDI-DrugBank.d549.s6|0-7|Although|O
DDI-DrugBank.d549.s6|9-16|clinical|O
DDI-DrugBank.d549.s6|18-24|studies|O
DDI-DrugBank.d549.s6|26-29|have|O
DDI-DrugBank.d549.s6|31-33|not|O
DDI-DrugBank.d549.s6|35-38|been|O
DDI-DrugBank.d549.s6|40-48|conducted|O
DDI-DrugBank.d549.s6|49-49|,|O
DDI-DrugBank.d549.s6|51-52|in|O
DDI-DrugBank.d549.s6|54-58|vitro|O
DDI-DrugBank.d549.s6|60-66|studies|O
DDI-DrugBank.d549.s6|68-69|of|O
DDI-DrugBank.d549.s6|71-78|iloprost|O
DDI-DrugBank.d549.s6|80-87|indicate|O
DDI-DrugBank.d549.s6|89-92|that|O
DDI-DrugBank.d549.s6|94-95|no|O
DDI-DrugBank.d549.s6|97-104|relevant|O
DDI-DrugBank.d549.s6|106-115|inhibition|O
DDI-DrugBank.d549.s6|117-118|of|O
DDI-DrugBank.d549.s6|120-129|cytochrome|O
DDI-DrugBank.d549.s6|131-134|P450|O
DDI-DrugBank.d549.s6|136-139|drug|O
DDI-DrugBank.d549.s6|141-150|metabolism|O
DDI-DrugBank.d549.s6|152-156|would|O
DDI-DrugBank.d549.s6|158-159|be|O
DDI-DrugBank.d549.s6|161-168|expected|O
DDI-DrugBank.d549.s6|169-169|.|O
DDI-MedLine.d1.s0|0-0|[|O
DDI-MedLine.d1.s0|1-4|Drug|O
DDI-MedLine.d1.s0|6-14|treatment|O
DDI-MedLine.d1.s0|16-17|of|O
DDI-MedLine.d1.s0|19-26|erection|O
DDI-MedLine.d1.s0|28-36|disorders|O
DDI-MedLine.d1.s0|38-39|in|O
DDI-MedLine.d1.s0|41-48|patients|O
DDI-MedLine.d1.s0|50-53|with|O
DDI-MedLine.d1.s0|55-68|cardiovascular|O
DDI-MedLine.d1.s0|70-76|disease|O
DDI-MedLine.d1.s0|77-77|]|O
DDI-MedLine.d1.s0|79-86|Erectile|O
DDI-MedLine.d1.s0|88-98|dysfunction|O
DDI-MedLine.d1.s0|100-101|is|O
DDI-MedLine.d1.s0|103-103|a|O
DDI-MedLine.d1.s0|105-112|frequent|O
DDI-MedLine.d1.s0|114-122|condition|O
DDI-MedLine.d1.s0|124-125|in|O
DDI-MedLine.d1.s0|127-140|cardiovascular|O
DDI-MedLine.d1.s0|142-149|patients|O
DDI-MedLine.d1.s0|150-150|.|O
DDI-MedLine.d1.s1|0-4|Since|O
DDI-MedLine.d1.s1|6-8|the|O
DDI-MedLine.d1.s1|10-16|arrival|O
DDI-MedLine.d1.s1|18-19|of|O
DDI-MedLine.d1.s1|21-24|oral|O
DDI-MedLine.d1.s1|26-44|erection-supporting|O
DDI-MedLine.d1.s1|46-55|medication|O
DDI-MedLine.d1.s1|56-56|,|O
DDI-MedLine.d1.s1|58-65|patients|O
DDI-MedLine.d1.s1|67-70|want|O
DDI-MedLine.d1.s1|72-73|to|O
DDI-MedLine.d1.s1|75-78|know|O
DDI-MedLine.d1.s1|80-82|how|O
DDI-MedLine.d1.s1|84-87|safe|O
DDI-MedLine.d1.s1|89-94|sexual|O
DDI-MedLine.d1.s1|96-103|activity|O
DDI-MedLine.d1.s1|105-106|is|O
DDI-MedLine.d1.s1|108-109|in|O
DDI-MedLine.d1.s1|111-124|cardiovascular|O
DDI-MedLine.d1.s1|126-132|disease|O
DDI-MedLine.d1.s1|134-135|in|O
DDI-MedLine.d1.s1|137-143|general|O
DDI-MedLine.d1.s1|145-147|and|O
DDI-MedLine.d1.s1|149-154|during|O
DDI-MedLine.d1.s1|156-158|use|O
DDI-MedLine.d1.s1|160-161|of|O
DDI-MedLine.d1.s1|163-181|erection-supporting|O
DDI-MedLine.d1.s1|183-192|medication|O
DDI-MedLine.d1.s1|194-195|in|O
DDI-MedLine.d1.s1|197-206|particular|O
DDI-MedLine.d1.s1|207-207|.|O
DDI-MedLine.d1.s2|0-5|Sexual|O
DDI-MedLine.d1.s2|7-17|intercourse|O
DDI-MedLine.d1.s2|19-22|with|O
DDI-MedLine.d1.s2|24-24|a|O
DDI-MedLine.d1.s2|26-31|steady|O
DDI-MedLine.d1.s2|33-39|partner|O
DDI-MedLine.d1.s2|41-46|causes|O
DDI-MedLine.d1.s2|48-49|no|O
DDI-MedLine.d1.s2|51-54|more|O
DDI-MedLine.d1.s2|56-69|cardiovascular|O
DDI-MedLine.d1.s2|71-74|risk|O
DDI-MedLine.d1.s2|76-79|than|O
DDI-MedLine.d1.s2|81-86|normal|O
DDI-MedLine.d1.s2|88-92|daily|O
DDI-MedLine.d1.s2|94-103|activities|O
DDI-MedLine.d1.s2|105-108|such|O
DDI-MedLine.d1.s2|110-111|as|O
DDI-MedLine.d1.s2|113-119|ironing|O
DDI-MedLine.d1.s2|120-120|,|O
DDI-MedLine.d1.s2|122-122|2|O
DDI-MedLine.d1.s2|124-133|kilometers|O
DDI-MedLine.d1.s2|135-136|of|O
DDI-MedLine.d1.s2|138-144|walking|O
DDI-MedLine.d1.s2|146-152|without|O
DDI-MedLine.d1.s2|154-161|climbing|O
DDI-MedLine.d1.s2|162-162|,|O
DDI-MedLine.d1.s2|164-175|paperhanging|O
DDI-MedLine.d1.s2|176-176|,|O
DDI-MedLine.d1.s2|178-184|playing|O
DDI-MedLine.d1.s2|186-189|golf|O
DDI-MedLine.d1.s2|191-192|or|O
DDI-MedLine.d1.s2|194-202|gardening|O
DDI-MedLine.d1.s2|203-203|.|O
DDI-MedLine.d1.s3|0-2|The|O
DDI-MedLine.d1.s3|4-11|relative|O
DDI-MedLine.d1.s3|13-16|risk|O
DDI-MedLine.d1.s3|18-19|of|O
DDI-MedLine.d1.s3|21-30|myocardial|O
DDI-MedLine.d1.s3|32-41|infarction|O
DDI-MedLine.d1.s3|43-48|during|O
DDI-MedLine.d1.s3|50-55|sexual|O
DDI-MedLine.d1.s3|57-64|activity|O
DDI-MedLine.d1.s3|66-67|is|O
DDI-MedLine.d1.s3|69-71|not|O
DDI-MedLine.d1.s3|73-85|significantly|O
DDI-MedLine.d1.s3|87-92|higher|O
DDI-MedLine.d1.s3|94-97|than|O
DDI-MedLine.d1.s3|99-101|for|O
DDI-MedLine.d1.s3|103-109|healthy|O
DDI-MedLine.d1.s3|111-117|persons|O
DDI-MedLine.d1.s3|118-118|.|O
DDI-MedLine.d1.s4|0-2|The|O
DDI-MedLine.d1.s4|4-12|incidence|O
DDI-MedLine.d1.s4|14-15|of|O
DDI-MedLine.d1.s4|17-30|cardiovascular|O
DDI-MedLine.d1.s4|32-40|morbidity|O
DDI-MedLine.d1.s4|42-44|and|O
DDI-MedLine.d1.s4|46-54|mortality|O
DDI-MedLine.d1.s4|56-57|is|O
DDI-MedLine.d1.s4|59-61|not|O
DDI-MedLine.d1.s4|63-68|higher|O
DDI-MedLine.d1.s4|70-74|among|O
DDI-MedLine.d1.s4|76-80|users|O
DDI-MedLine.d1.s4|82-83|of|O
DDI-MedLine.d1.s4|85-94|sildenafil|O
DDI-MedLine.d1.s4|95-95|.|O
DDI-MedLine.d1.s5|0-9|Sildenafil|O
DDI-MedLine.d1.s5|11-12|is|O
DDI-MedLine.d1.s5|14-28|contraindicated|O
DDI-MedLine.d1.s5|30-31|in|O
DDI-MedLine.d1.s5|33-40|patients|O
DDI-MedLine.d1.s5|42-46|using|O
DDI-MedLine.d1.s5|48-58|long-acting|O
DDI-MedLine.d1.s5|60-67|nitrates|O
DDI-MedLine.d1.s5|69-70|or|O
DDI-MedLine.d1.s5|72-74|who|O
DDI-MedLine.d1.s5|76-78|may|O
DDI-MedLine.d1.s5|80-83|need|O
DDI-MedLine.d1.s5|85-86|to|O
DDI-MedLine.d1.s5|88-90|use|O
DDI-MedLine.d1.s5|92-103|short-acting|O
DDI-MedLine.d1.s5|105-112|nitrates|O
DDI-MedLine.d1.s5|113-113|,|O
DDI-MedLine.d1.s5|115-121|because|O
DDI-MedLine.d1.s5|123-125|the|O
DDI-MedLine.d1.s5|127-137|combination|O
DDI-MedLine.d1.s5|139-141|may|O
DDI-MedLine.d1.s5|143-147|cause|O
DDI-MedLine.d1.s5|149-149|a|O
DDI-MedLine.d1.s5|151-155|sharp|O
DDI-MedLine.d1.s5|157-160|fall|O
DDI-MedLine.d1.s5|162-163|of|O
DDI-MedLine.d1.s5|165-167|the|O
DDI-MedLine.d1.s5|169-173|blood|O
DDI-MedLine.d1.s5|175-182|pressure|O
DDI-MedLine.d1.s5|183-183|.|O
DDI-MedLine.d1.s6|0-1|No|O
DDI-MedLine.d1.s6|3-14|interactions|O
DDI-MedLine.d1.s6|16-19|have|O
DDI-MedLine.d1.s6|21-24|been|O
DDI-MedLine.d1.s6|26-33|observed|O
DDI-MedLine.d1.s6|35-38|with|O
DDI-MedLine.d1.s6|40-52|beta-receptor|O
DDI-MedLine.d1.s6|54-61|blockers|O
DDI-MedLine.d1.s6|62-62|,|O
DDI-MedLine.d1.s6|64-70|calcium|O
DDI-MedLine.d1.s6|72-82|antagonists|O
DDI-MedLine.d1.s6|83-83|,|O
DDI-MedLine.d1.s6|85-92|thiazide|O
DDI-MedLine.d1.s6|94-96|and|O
DDI-MedLine.d1.s6|98-101|loop|O
DDI-MedLine.d1.s6|103-111|diuretics|O
DDI-MedLine.d1.s6|113-115|and|O
DDI-MedLine.d1.s6|117-119|ACE|O
DDI-MedLine.d1.s6|121-130|inhibitors|O
DDI-MedLine.d1.s6|131-131|.|O
DDI-MedLine.d1.s7|0-5|Before|O
DDI-MedLine.d1.s7|7-17|prescribing|O
DDI-MedLine.d1.s7|19-19|a|O
DDI-MedLine.d1.s7|21-31|symptomatic|O
DDI-MedLine.d1.s7|33-33|(|O
DDI-MedLine.d1.s7|34-47|pharmaceutical|O
DDI-MedLine.d1.s7|48-48|)|O
DDI-MedLine.d1.s7|50-58|treatment|O
DDI-MedLine.d1.s7|60-62|for|O
DDI-MedLine.d1.s7|64-71|patients|O
DDI-MedLine.d1.s7|73-76|with|O
DDI-MedLine.d1.s7|78-79|an|O
DDI-MedLine.d1.s7|81-88|erection|O
DDI-MedLine.d1.s7|90-97|disorder|O
DDI-MedLine.d1.s7|98-98|,|O
DDI-MedLine.d1.s7|100-108|attention|O
DDI-MedLine.d1.s7|110-115|should|O
DDI-MedLine.d1.s7|117-118|be|O
DDI-MedLine.d1.s7|120-124|given|O
DDI-MedLine.d1.s7|126-128|tot|O
DDI-MedLine.d1.s7|130-132|the|O
DDI-MedLine.d1.s7|134-144|sexological|O
DDI-MedLine.d1.s7|145-145|,|O
DDI-MedLine.d1.s7|147-159|psychological|O
DDI-MedLine.d1.s7|161-163|and|O
DDI-MedLine.d1.s7|165-171|medical|O
DDI-MedLine.d1.s7|173-183|backgrounds|O
DDI-MedLine.d1.s7|185-186|of|O
DDI-MedLine.d1.s7|188-190|the|O
DDI-MedLine.d1.s7|192-199|disorder|O
DDI-MedLine.d1.s7|200-200|.|O
DDI-MedLine.d1.s8|0-8|Secondary|O
DDI-MedLine.d1.s8|10-19|prevention|O
DDI-MedLine.d1.s8|21-22|of|O
DDI-MedLine.d1.s8|24-38|atherosclerotic|O
DDI-MedLine.d1.s8|40-43|risk|O
DDI-MedLine.d1.s8|45-51|factors|O
DDI-MedLine.d1.s8|53-54|is|O
DDI-MedLine.d1.s8|56-59|also|O
DDI-MedLine.d1.s8|61-69|important|O
DDI-MedLine.d1.s8|70-70|:|O
DDI-MedLine.d1.s8|72-81|regulation|O
DDI-MedLine.d1.s8|83-84|of|O
DDI-MedLine.d1.s8|86-90|blood|O
DDI-MedLine.d1.s8|92-99|pressure|O
DDI-MedLine.d1.s8|101-103|and|O
DDI-MedLine.d1.s8|105-109|blood|O
DDI-MedLine.d1.s8|111-115|sugar|O
DDI-MedLine.d1.s8|117-121|level|O
DDI-MedLine.d1.s8|122-122|,|O
DDI-MedLine.d1.s8|124-138|hyperlipidaemia|O
DDI-MedLine.d1.s8|140-142|and|O
DDI-MedLine.d1.s8|144-150|obesity|O
DDI-MedLine.d1.s8|151-151|,|O
DDI-MedLine.d1.s8|153-154|as|O
DDI-MedLine.d1.s8|156-159|well|O
DDI-MedLine.d1.s8|161-162|as|O
DDI-MedLine.d1.s8|164-164|a|O
DDI-MedLine.d1.s8|166-171|change|O
DDI-MedLine.d1.s8|173-174|of|O
DDI-MedLine.d1.s8|176-184|lifestyle|O
DDI-MedLine.d1.s8|186-186|(|O
DDI-MedLine.d1.s8|187-192|giving|O
DDI-MedLine.d1.s8|194-195|up|O
DDI-MedLine.d1.s8|197-203|smoking|O
DDI-MedLine.d1.s8|204-204|,|O
DDI-MedLine.d1.s8|206-213|adapting|O
DDI-MedLine.d1.s8|215-216|of|O
DDI-MedLine.d1.s8|218-221|diet|O
DDI-MedLine.d1.s8|223-225|and|O
DDI-MedLine.d1.s8|227-230|more|O
DDI-MedLine.d1.s8|232-239|physical|O
DDI-MedLine.d1.s8|241-248|exertion|O
DDI-MedLine.d1.s8|249-249|)|O
DDI-MedLine.d1.s8|250-250|.|O
DDI-MedLine.d1.s9|0-7|Patients|O
DDI-MedLine.d1.s9|9-12|with|O
DDI-MedLine.d1.s9|14-14|a|O
DDI-MedLine.d1.s9|16-19|very|O
DDI-MedLine.d1.s9|21-23|low|O
DDI-MedLine.d1.s9|25-31|cardiac|O
DDI-MedLine.d1.s9|33-40|capacity|O
DDI-MedLine.d1.s9|42-47|should|O
DDI-MedLine.d1.s9|49-50|be|O
DDI-MedLine.d1.s9|52-58|advised|O
DDI-MedLine.d1.s9|60-61|to|O
DDI-MedLine.d1.s9|63-69|refrain|O
DDI-MedLine.d1.s9|71-74|from|O
DDI-MedLine.d1.s9|76-84|treatment|O
DDI-MedLine.d1.s9|86-87|of|O
DDI-MedLine.d1.s9|89-91|the|O
DDI-MedLine.d1.s9|93-100|erection|O
DDI-MedLine.d1.s9|102-109|disorder|O
DDI-MedLine.d1.s9|110-110|.|O
DDI-DrugBank.d78.s0|0-7|Antacids|O
DDI-DrugBank.d78.s0|8-8|,|O
DDI-DrugBank.d78.s0|10-19|Sucralfate|O
DDI-DrugBank.d78.s0|20-20|,|O
DDI-DrugBank.d78.s0|22-26|Metal|O
DDI-DrugBank.d78.s0|28-34|Cations|O
DDI-DrugBank.d78.s0|35-35|,|O
DDI-DrugBank.d78.s0|37-49|Multivitamins|O
DDI-DrugBank.d78.s0|51-60|Quinolones|O
DDI-DrugBank.d78.s0|62-65|form|O
DDI-DrugBank.d78.s0|67-74|chelates|O
DDI-DrugBank.d78.s0|76-79|with|O
DDI-DrugBank.d78.s0|81-88|alkaline|O
DDI-DrugBank.d78.s0|90-94|earth|O
DDI-DrugBank.d78.s0|96-98|and|O
DDI-DrugBank.d78.s0|100-109|transition|O
DDI-DrugBank.d78.s0|111-115|metal|O
DDI-DrugBank.d78.s0|117-123|cations|O
DDI-DrugBank.d78.s0|124-124|.|O
DDI-DrugBank.d78.s1|0-13|Administration|O
DDI-DrugBank.d78.s1|15-16|of|O
DDI-DrugBank.d78.s1|18-27|quinolones|O
DDI-DrugBank.d78.s1|29-32|with|O
DDI-DrugBank.d78.s1|34-41|antacids|O
DDI-DrugBank.d78.s1|43-52|containing|O
DDI-DrugBank.d78.s1|54-61|aluminum|O
DDI-DrugBank.d78.s1|62-62|,|O
DDI-DrugBank.d78.s1|64-72|magnesium|O
DDI-DrugBank.d78.s1|73-73|,|O
DDI-DrugBank.d78.s1|75-76|or|O
DDI-DrugBank.d78.s1|78-84|calcium|O
DDI-DrugBank.d78.s1|85-85|,|O
DDI-DrugBank.d78.s1|87-90|with|O
DDI-DrugBank.d78.s1|92-101|sucralfate|O
DDI-DrugBank.d78.s1|102-102|,|O
DDI-DrugBank.d78.s1|104-107|with|O
DDI-DrugBank.d78.s1|109-113|metal|O
DDI-DrugBank.d78.s1|115-121|cations|O
DDI-DrugBank.d78.s1|123-126|such|O
DDI-DrugBank.d78.s1|128-129|as|O
DDI-DrugBank.d78.s1|131-134|iron|O
DDI-DrugBank.d78.s1|135-135|,|O
DDI-DrugBank.d78.s1|137-138|or|O
DDI-DrugBank.d78.s1|140-143|with|O
DDI-DrugBank.d78.s1|145-157|multivitamins|O
DDI-DrugBank.d78.s1|159-168|containing|O
DDI-DrugBank.d78.s1|170-173|iron|O
DDI-DrugBank.d78.s1|175-176|or|O
DDI-DrugBank.d78.s1|178-181|zinc|O
DDI-DrugBank.d78.s1|182-182|,|O
DDI-DrugBank.d78.s1|184-185|or|O
DDI-DrugBank.d78.s1|187-190|with|O
DDI-DrugBank.d78.s1|192-203|formulations|O
DDI-DrugBank.d78.s1|205-214|containing|O
DDI-DrugBank.d78.s1|216-223|divalent|O
DDI-DrugBank.d78.s1|225-227|and|O
DDI-DrugBank.d78.s1|229-237|trivalent|O
DDI-DrugBank.d78.s1|239-245|cations|O
DDI-DrugBank.d78.s1|247-250|such|O
DDI-DrugBank.d78.s1|252-253|as|O
DDI-DrugBank.d78.s1|255-259|VIDEX|O
DDI-DrugBank.d78.s1|261-261|(|O
DDI-DrugBank.d78.s1|262-271|didanosine|O
DDI-DrugBank.d78.s1|272-272|)|O
DDI-DrugBank.d78.s1|274-290|chewable/buffered|O
DDI-DrugBank.d78.s1|292-298|tablets|O
DDI-DrugBank.d78.s1|300-301|or|O
DDI-DrugBank.d78.s1|303-305|the|O
DDI-DrugBank.d78.s1|307-315|pediatric|O
DDI-DrugBank.d78.s1|317-322|powder|O
DDI-DrugBank.d78.s1|324-326|for|O
DDI-DrugBank.d78.s1|328-331|oral|O
DDI-DrugBank.d78.s1|333-340|solution|O
DDI-DrugBank.d78.s1|341-341|,|O
DDI-DrugBank.d78.s1|343-345|may|O
DDI-DrugBank.d78.s1|347-359|substantially|O
DDI-DrugBank.d78.s1|361-369|interfere|O
DDI-DrugBank.d78.s1|371-374|with|O
DDI-DrugBank.d78.s1|376-378|the|O
DDI-DrugBank.d78.s1|380-389|absorption|O
DDI-DrugBank.d78.s1|391-392|of|O
DDI-DrugBank.d78.s1|394-403|quinolones|O
DDI-DrugBank.d78.s1|404-404|,|O
DDI-DrugBank.d78.s1|406-414|resulting|O
DDI-DrugBank.d78.s1|416-417|in|O
DDI-DrugBank.d78.s1|419-426|systemic|O
DDI-DrugBank.d78.s1|428-441|concentrations|O
DDI-DrugBank.d78.s1|443-454|considerably|O
DDI-DrugBank.d78.s1|456-460|lower|O
DDI-DrugBank.d78.s1|462-465|than|O
DDI-DrugBank.d78.s1|467-473|desired|O
DDI-DrugBank.d78.s1|474-474|.|O
DDI-DrugBank.d78.s2|0-4|These|O
DDI-DrugBank.d78.s2|6-11|agents|O
DDI-DrugBank.d78.s2|13-18|should|O
DDI-DrugBank.d78.s2|20-22|not|O
DDI-DrugBank.d78.s2|24-25|be|O
DDI-DrugBank.d78.s2|27-31|taken|O
DDI-DrugBank.d78.s2|33-38|within|O
DDI-DrugBank.d78.s2|40-40|4|O
DDI-DrugBank.d78.s2|42-46|hours|O
DDI-DrugBank.d78.s2|48-53|before|O
DDI-DrugBank.d78.s2|55-56|or|O
DDI-DrugBank.d78.s2|58-58|4|O
DDI-DrugBank.d78.s2|60-64|hours|O
DDI-DrugBank.d78.s2|66-70|after|O
DDI-DrugBank.d78.s2|72-84|grepafloxacin|O
DDI-DrugBank.d78.s2|86-99|administration|O
DDI-DrugBank.d78.s2|100-100|.|O
DDI-DrugBank.d78.s3|0-7|Caffeine|O
DDI-DrugBank.d78.s3|9-19|Theobromine|O
DDI-DrugBank.d78.s3|21-33|Grepafloxacin|O
DDI-DrugBank.d78.s3|34-34|,|O
DDI-DrugBank.d78.s3|36-39|like|O
DDI-DrugBank.d78.s3|41-45|other|O
DDI-DrugBank.d78.s3|47-56|quinolones|O
DDI-DrugBank.d78.s3|57-57|,|O
DDI-DrugBank.d78.s3|59-61|may|O
DDI-DrugBank.d78.s3|63-69|inhibit|O
DDI-DrugBank.d78.s3|71-73|the|O
DDI-DrugBank.d78.s3|75-84|metabolism|O
DDI-DrugBank.d78.s3|86-87|of|O
DDI-DrugBank.d78.s3|89-96|caffeine|O
DDI-DrugBank.d78.s3|98-100|and|O
DDI-DrugBank.d78.s3|102-112|theobromine|O
DDI-DrugBank.d78.s3|113-113|.|O
DDI-DrugBank.d78.s4|0-4|These|O
DDI-DrugBank.d78.s4|6-15|stimulants|O
DDI-DrugBank.d78.s4|17-19|are|O
DDI-DrugBank.d78.s4|21-28|commonly|O
DDI-DrugBank.d78.s4|30-34|found|O
DDI-DrugBank.d78.s4|36-37|in|O
DDI-DrugBank.d78.s4|39-44|coffee|O
DDI-DrugBank.d78.s4|46-48|and|O
DDI-DrugBank.d78.s4|50-52|tea|O
DDI-DrugBank.d78.s4|53-53|,|O
DDI-DrugBank.d78.s4|55-66|respectively|O
DDI-DrugBank.d78.s4|67-67|.|O
DDI-DrugBank.d78.s5|0-1|In|O
DDI-DrugBank.d78.s5|3-6|some|O
DDI-DrugBank.d78.s5|8-15|patients|O
DDI-DrugBank.d78.s5|16-16|,|O
DDI-DrugBank.d78.s5|18-21|this|O
DDI-DrugBank.d78.s5|23-25|may|O
DDI-DrugBank.d78.s5|27-30|lead|O
DDI-DrugBank.d78.s5|32-33|to|O
DDI-DrugBank.d78.s5|35-41|reduced|O
DDI-DrugBank.d78.s5|43-51|clearance|O
DDI-DrugBank.d78.s5|52-52|,|O
DDI-DrugBank.d78.s5|54-65|prolongation|O
DDI-DrugBank.d78.s5|67-68|of|O
DDI-DrugBank.d78.s5|70-75|plasma|O
DDI-DrugBank.d78.s5|77-85|half-life|O
DDI-DrugBank.d78.s5|86-86|,|O
DDI-DrugBank.d78.s5|88-90|and|O
DDI-DrugBank.d78.s5|92-99|enhanced|O
DDI-DrugBank.d78.s5|101-107|effects|O
DDI-DrugBank.d78.s5|109-110|of|O
DDI-DrugBank.d78.s5|112-119|caffeine|O
DDI-DrugBank.d78.s5|121-123|and|O
DDI-DrugBank.d78.s5|125-135|theobromine|O
DDI-DrugBank.d78.s5|136-136|.|O
DDI-DrugBank.d78.s6|0-11|Theophylline|O
DDI-DrugBank.d78.s6|12-12|:|O
DDI-DrugBank.d78.s6|14-26|Grepafloxacin|O
DDI-DrugBank.d78.s6|28-29|is|O
DDI-DrugBank.d78.s6|31-31|a|O
DDI-DrugBank.d78.s6|33-43|competitive|O
DDI-DrugBank.d78.s6|45-53|inhibitor|O
DDI-DrugBank.d78.s6|55-56|of|O
DDI-DrugBank.d78.s6|58-60|the|O
DDI-DrugBank.d78.s6|62-71|metabolism|O
DDI-DrugBank.d78.s6|73-74|of|O
DDI-DrugBank.d78.s6|76-87|theophylline|O
DDI-DrugBank.d78.s6|88-88|.|O
DDI-DrugBank.d78.s7|0-4|Serum|O
DDI-DrugBank.d78.s7|6-17|theophylline|O
DDI-DrugBank.d78.s7|19-32|concentrations|O
DDI-DrugBank.d78.s7|34-41|increase|O
DDI-DrugBank.d78.s7|43-46|when|O
DDI-DrugBank.d78.s7|48-60|grepafloxacin|O
DDI-DrugBank.d78.s7|62-63|is|O
DDI-DrugBank.d78.s7|65-73|initiated|O
DDI-DrugBank.d78.s7|75-76|in|O
DDI-DrugBank.d78.s7|78-78|a|O
DDI-DrugBank.d78.s7|80-86|patient|O
DDI-DrugBank.d78.s7|88-97|maintained|O
DDI-DrugBank.d78.s7|99-100|on|O
DDI-DrugBank.d78.s7|102-113|theophylline|O
DDI-DrugBank.d78.s7|114-114|.|O
DDI-DrugBank.d78.s8|0-3|When|O
DDI-DrugBank.d78.s8|5-14|initiating|O
DDI-DrugBank.d78.s8|16-16|a|O
DDI-DrugBank.d78.s8|18-26|multi-day|O
DDI-DrugBank.d78.s8|28-33|course|O
DDI-DrugBank.d78.s8|35-36|of|O
DDI-DrugBank.d78.s8|38-50|grepafloxacin|O
DDI-DrugBank.d78.s8|52-53|in|O
DDI-DrugBank.d78.s8|55-55|a|O
DDI-DrugBank.d78.s8|57-63|patient|O
DDI-DrugBank.d78.s8|65-74|maintained|O
DDI-DrugBank.d78.s8|76-77|on|O
DDI-DrugBank.d78.s8|79-90|theophylline|O
DDI-DrugBank.d78.s8|91-91|,|O
DDI-DrugBank.d78.s8|93-95|the|O
DDI-DrugBank.d78.s8|97-108|theophylline|O
DDI-DrugBank.d78.s8|110-120|maintenance|O
DDI-DrugBank.d78.s8|122-125|dose|O
DDI-DrugBank.d78.s8|127-132|should|O
DDI-DrugBank.d78.s8|134-135|be|O
DDI-DrugBank.d78.s8|137-142|halved|O
DDI-DrugBank.d78.s8|144-146|for|O
DDI-DrugBank.d78.s8|148-150|the|O
DDI-DrugBank.d78.s8|152-157|period|O
DDI-DrugBank.d78.s8|159-160|of|O
DDI-DrugBank.d78.s8|162-171|concurrent|O
DDI-DrugBank.d78.s8|173-175|use|O
DDI-DrugBank.d78.s8|177-178|of|O
DDI-DrugBank.d78.s8|180-192|grepafloxacin|O
DDI-DrugBank.d78.s8|194-196|and|O
DDI-DrugBank.d78.s8|198-207|monitoring|O
DDI-DrugBank.d78.s8|209-210|of|O
DDI-DrugBank.d78.s8|212-216|serum|O
DDI-DrugBank.d78.s8|218-229|theophylline|O
DDI-DrugBank.d78.s8|231-244|concentrations|O
DDI-DrugBank.d78.s8|246-251|should|O
DDI-DrugBank.d78.s8|253-254|be|O
DDI-DrugBank.d78.s8|256-264|initiated|O
DDI-DrugBank.d78.s8|266-267|as|O
DDI-DrugBank.d78.s8|269-269|a|O
DDI-DrugBank.d78.s8|271-275|guide|O
DDI-DrugBank.d78.s8|277-278|to|O
DDI-DrugBank.d78.s8|280-286|further|O
DDI-DrugBank.d78.s8|288-293|dosage|O
DDI-DrugBank.d78.s8|295-305|adjustments|O
DDI-DrugBank.d78.s8|306-306|.|O
DDI-DrugBank.d78.s9|0-7|Warfarin|O
DDI-DrugBank.d78.s9|8-8|:|O
DDI-DrugBank.d78.s9|10-11|In|O
DDI-DrugBank.d78.s9|13-20|subjects|O
DDI-DrugBank.d78.s9|22-30|receiving|O
DDI-DrugBank.d78.s9|32-39|warfarin|O
DDI-DrugBank.d78.s9|40-40|,|O
DDI-DrugBank.d78.s9|42-43|no|O
DDI-DrugBank.d78.s9|45-55|significant|O
DDI-DrugBank.d78.s9|57-62|change|O
DDI-DrugBank.d78.s9|64-65|in|O
DDI-DrugBank.d78.s9|67-74|clotting|O
DDI-DrugBank.d78.s9|76-79|time|O
DDI-DrugBank.d78.s9|81-83|was|O
DDI-DrugBank.d78.s9|85-92|observed|O
DDI-DrugBank.d78.s9|94-97|when|O
DDI-DrugBank.d78.s9|99-111|grepafloxacin|O
DDI-DrugBank.d78.s9|113-115|was|O
DDI-DrugBank.d78.s9|117-130|coadministered|O
DDI-DrugBank.d78.s9|131-131|.|O
DDI-DrugBank.d78.s10|0-6|However|O
DDI-DrugBank.d78.s10|7-7|,|O
DDI-DrugBank.d78.s10|9-15|because|O
DDI-DrugBank.d78.s10|17-20|some|O
DDI-DrugBank.d78.s10|22-31|quinolones|O
DDI-DrugBank.d78.s10|33-36|have|O
DDI-DrugBank.d78.s10|38-41|been|O
DDI-DrugBank.d78.s10|43-50|reported|O
DDI-DrugBank.d78.s10|52-53|to|O
DDI-DrugBank.d78.s10|55-61|enhance|O
DDI-DrugBank.d78.s10|63-65|the|O
DDI-DrugBank.d78.s10|67-73|effects|O
DDI-DrugBank.d78.s10|75-76|of|O
DDI-DrugBank.d78.s10|78-85|warfarin|O
DDI-DrugBank.d78.s10|87-88|or|O
DDI-DrugBank.d78.s10|90-92|its|O
DDI-DrugBank.d78.s10|94-104|derivatives|O
DDI-DrugBank.d78.s10|105-105|,|O
DDI-DrugBank.d78.s10|107-117|prothrombin|O
DDI-DrugBank.d78.s10|119-122|time|O
DDI-DrugBank.d78.s10|124-125|or|O
DDI-DrugBank.d78.s10|127-131|other|O
DDI-DrugBank.d78.s10|133-140|suitable|O
DDI-DrugBank.d78.s10|142-156|anticoagulation|O
DDI-DrugBank.d78.s10|158-161|test|O
DDI-DrugBank.d78.s10|163-168|should|O
DDI-DrugBank.d78.s10|170-171|be|O
DDI-DrugBank.d78.s10|173-181|monitored|O
DDI-DrugBank.d78.s10|183-189|closely|O
DDI-DrugBank.d78.s10|191-192|if|O
DDI-DrugBank.d78.s10|194-194|a|O
DDI-DrugBank.d78.s10|196-204|quinolone|O
DDI-DrugBank.d78.s10|206-218|antimicrobial|O
DDI-DrugBank.d78.s10|220-221|is|O
DDI-DrugBank.d78.s10|223-234|administered|O
DDI-DrugBank.d78.s10|236-239|with|O
DDI-DrugBank.d78.s10|241-248|warfarin|O
DDI-DrugBank.d78.s10|250-251|or|O
DDI-DrugBank.d78.s10|253-255|its|O
DDI-DrugBank.d78.s10|257-267|derivatives|O
DDI-DrugBank.d78.s10|268-268|.|O
DDI-DrugBank.d78.s11|0-4|Drugs|O
DDI-DrugBank.d78.s11|6-16|Metabolized|O
DDI-DrugBank.d78.s11|18-19|by|O
DDI-DrugBank.d78.s11|21-30|Cytochrome|O
DDI-DrugBank.d78.s11|32-35|P450|O
DDI-DrugBank.d78.s11|37-43|Enzymes|O
DDI-DrugBank.d78.s11|45-47|The|O
DDI-DrugBank.d78.s11|49-52|drug|O
DDI-DrugBank.d78.s11|54-64|interaction|O
DDI-DrugBank.d78.s11|66-70|study|O
DDI-DrugBank.d78.s11|72-81|evaluating|O
DDI-DrugBank.d78.s11|83-85|the|O
DDI-DrugBank.d78.s11|87-92|effect|O
DDI-DrugBank.d78.s11|94-95|of|O
DDI-DrugBank.d78.s11|97-109|grepafloxacin|O
DDI-DrugBank.d78.s11|111-112|on|O
DDI-DrugBank.d78.s11|114-125|theophylline|O
DDI-DrugBank.d78.s11|127-135|indicates|O
DDI-DrugBank.d78.s11|137-140|that|O
DDI-DrugBank.d78.s11|142-154|grepafloxacin|O
DDI-DrugBank.d78.s11|156-163|inhibits|O
DDI-DrugBank.d78.s11|165-176|theophylline|O
DDI-DrugBank.d78.s11|178-187|metabolism|O
DDI-DrugBank.d78.s11|188-188|,|O
DDI-DrugBank.d78.s11|190-194|which|O
DDI-DrugBank.d78.s11|196-197|is|O
DDI-DrugBank.d78.s11|199-206|mediated|O
DDI-DrugBank.d78.s11|208-209|by|O
DDI-DrugBank.d78.s11|211-216|CYP1A2|O
DDI-DrugBank.d78.s11|217-217|.|O
DDI-DrugBank.d78.s12|0-4|While|O
DDI-DrugBank.d78.s12|6-7|no|O
DDI-DrugBank.d78.s12|9-16|clinical|O
DDI-DrugBank.d78.s12|18-24|studies|O
DDI-DrugBank.d78.s12|26-29|have|O
DDI-DrugBank.d78.s12|31-34|been|O
DDI-DrugBank.d78.s12|36-44|conducted|O
DDI-DrugBank.d78.s12|46-47|to|O
DDI-DrugBank.d78.s12|49-56|evaluate|O
DDI-DrugBank.d78.s12|58-60|the|O
DDI-DrugBank.d78.s12|62-67|effect|O
DDI-DrugBank.d78.s12|69-70|of|O
DDI-DrugBank.d78.s12|72-84|grepafloxacin|O
DDI-DrugBank.d78.s12|86-87|on|O
DDI-DrugBank.d78.s12|89-91|the|O
DDI-DrugBank.d78.s12|93-102|metabolism|O
DDI-DrugBank.d78.s12|104-105|of|O
DDI-DrugBank.d78.s12|107-111|C.P.A|O
DDI-DrugBank.d78.s12|112-112|.|O
DDI-DrugBank.d78.s13|0-9|substrates|O
DDI-DrugBank.d78.s13|10-10|,|O
DDI-DrugBank.d78.s13|12-13|in|O
DDI-DrugBank.d78.s13|15-19|vitro|O
DDI-DrugBank.d78.s13|21-24|data|O
DDI-DrugBank.d78.s13|26-32|suggest|O
DDI-DrugBank.d78.s13|34-40|similar|O
DDI-DrugBank.d78.s13|42-48|effects|O
DDI-DrugBank.d78.s13|50-51|of|O
DDI-DrugBank.d78.s13|53-65|grepafloxacin|O
DDI-DrugBank.d78.s13|67-68|in|O
DDI-DrugBank.d78.s13|70-75|CYP3A4|O
DDI-DrugBank.d78.s13|77-84|mediated|O
DDI-DrugBank.d78.s13|86-95|metabolism|O
DDI-DrugBank.d78.s13|97-99|and|O
DDI-DrugBank.d78.s13|101-112|theophylline|O
DDI-DrugBank.d78.s13|114-123|metabolism|O
DDI-DrugBank.d78.s13|124-124|.|O
DDI-DrugBank.d78.s14|0-1|In|O
DDI-DrugBank.d78.s14|3-10|addition|O
DDI-DrugBank.d78.s14|11-11|,|O
DDI-DrugBank.d78.s14|13-17|other|O
DDI-DrugBank.d78.s14|19-28|quinolones|O
DDI-DrugBank.d78.s14|30-33|have|O
DDI-DrugBank.d78.s14|35-38|been|O
DDI-DrugBank.d78.s14|40-47|reported|O
DDI-DrugBank.d78.s14|49-50|to|O
DDI-DrugBank.d78.s14|52-59|decrease|O
DDI-DrugBank.d78.s14|61-63|the|O
DDI-DrugBank.d78.s14|65-79|CYP3A4-mediated|O
DDI-DrugBank.d78.s14|81-90|metabolism|O
DDI-DrugBank.d78.s14|92-93|of|O
DDI-DrugBank.d78.s14|95-106|cyclosporine|O
DDI-DrugBank.d78.s14|107-107|.|O
DDI-DrugBank.d78.s15|0-4|Other|O
DDI-DrugBank.d78.s15|6-10|drugs|O
DDI-DrugBank.d78.s15|12-22|metabolized|O
DDI-DrugBank.d78.s15|24-25|by|O
DDI-DrugBank.d78.s15|27-31|C.P.A|O
DDI-DrugBank.d78.s15|32-32|.|O
DDI-DrugBank.d78.s16|0-6|include|O
DDI-DrugBank.d78.s16|8-18|terfenadine|O
DDI-DrugBank.d78.s16|19-19|,|O
DDI-DrugBank.d78.s16|21-30|astemizole|O
DDI-DrugBank.d78.s16|31-31|,|O
DDI-DrugBank.d78.s16|33-41|cisapride|O
DDI-DrugBank.d78.s16|42-42|,|O
DDI-DrugBank.d78.s16|44-52|midazolam|O
DDI-DrugBank.d78.s16|53-53|,|O
DDI-DrugBank.d78.s16|55-57|and|O
DDI-DrugBank.d78.s16|59-67|triazolam|O
DDI-DrugBank.d78.s16|68-68|.|O
DDI-DrugBank.d78.s17|0-2|The|O
DDI-DrugBank.d78.s17|4-11|clinical|O
DDI-DrugBank.d78.s17|13-21|relevance|O
DDI-DrugBank.d78.s17|23-24|of|O
DDI-DrugBank.d78.s17|26-28|the|O
DDI-DrugBank.d78.s17|30-38|potential|O
DDI-DrugBank.d78.s17|40-45|effect|O
DDI-DrugBank.d78.s17|47-48|of|O
DDI-DrugBank.d78.s17|50-62|grepafloxacin|O
DDI-DrugBank.d78.s17|64-65|on|O
DDI-DrugBank.d78.s17|67-69|the|O
DDI-DrugBank.d78.s17|71-80|metabolism|O
DDI-DrugBank.d78.s17|82-83|of|O
DDI-DrugBank.d78.s17|85-90|C.P.A.|O
DDI-DrugBank.d78.s17|92-101|substrates|O
DDI-DrugBank.d78.s17|103-104|is|O
DDI-DrugBank.d78.s17|106-108|not|O
DDI-DrugBank.d78.s17|110-114|known|O
DDI-DrugBank.d78.s17|115-115|.|O
DDI-DrugBank.d78.s18|0-7|Patients|O
DDI-DrugBank.d78.s18|9-17|receiving|O
DDI-DrugBank.d78.s18|19-28|concurrent|O
DDI-DrugBank.d78.s18|30-43|administration|O
DDI-DrugBank.d78.s18|45-46|of|O
DDI-DrugBank.d78.s18|48-57|substrates|O
DDI-DrugBank.d78.s18|59-60|of|O
DDI-DrugBank.d78.s18|62-67|C.P.A.|O
DDI-DrugBank.d78.s18|69-72|were|O
DDI-DrugBank.d78.s18|74-76|not|O
DDI-DrugBank.d78.s18|78-85|excluded|O
DDI-DrugBank.d78.s18|87-90|from|O
DDI-DrugBank.d78.s18|92-99|clinical|O
DDI-DrugBank.d78.s18|101-106|trials|O
DDI-DrugBank.d78.s18|108-109|of|O
DDI-DrugBank.d78.s18|111-123|grepafloxacin|O
DDI-DrugBank.d78.s18|124-124|.|O
DDI-DrugBank.d78.s19|0-11|Nonsteroidal|O
DDI-DrugBank.d78.s19|13-29|Anti-inflammatory|O
DDI-DrugBank.d78.s19|31-35|Drugs|O
DDI-DrugBank.d78.s19|37-37|(|O
DDI-DrugBank.d78.s19|38-43|NSAIDs|O
DDI-DrugBank.d78.s19|44-44|)|O
DDI-DrugBank.d78.s19|45-45|:|O
DDI-DrugBank.d78.s19|47-49|The|O
DDI-DrugBank.d78.s19|51-61|concomitant|O
DDI-DrugBank.d78.s19|63-76|administration|O
DDI-DrugBank.d78.s19|78-79|of|O
DDI-DrugBank.d78.s19|81-81|a|O
DDI-DrugBank.d78.s19|83-94|nonsteroidal|O
DDI-DrugBank.d78.s19|96-99|anti|O
DDI-DrugBank.d78.s19|101-112|inflammatory|O
DDI-DrugBank.d78.s19|114-117|drug|O
DDI-DrugBank.d78.s19|119-122|with|O
DDI-DrugBank.d78.s19|124-124|a|O
DDI-DrugBank.d78.s19|126-134|quinolone|O
DDI-DrugBank.d78.s19|136-138|may|O
DDI-DrugBank.d78.s19|140-147|increase|O
DDI-DrugBank.d78.s19|149-151|the|O
DDI-DrugBank.d78.s19|153-157|risks|O
DDI-DrugBank.d78.s19|159-160|of|O
DDI-DrugBank.d78.s19|162-164|CNS|O
DDI-DrugBank.d78.s19|166-176|stimulation|O
DDI-DrugBank.d78.s19|178-180|and|O
DDI-DrugBank.d78.s19|182-192|convulsions|O
DDI-DrugBank.d78.s19|193-193|.|O
DDI-DrugBank.d78.s20|0-11|Antidiabetic|O
DDI-DrugBank.d78.s20|13-18|Agents|O
DDI-DrugBank.d78.s20|19-19|:|O
DDI-DrugBank.d78.s20|21-32|Disturbances|O
DDI-DrugBank.d78.s20|34-35|of|O
DDI-DrugBank.d78.s20|37-41|blood|O
DDI-DrugBank.d78.s20|43-49|glucose|O
DDI-DrugBank.d78.s20|50-50|,|O
DDI-DrugBank.d78.s20|52-60|including|O
DDI-DrugBank.d78.s20|62-74|hyperglycemia|O
DDI-DrugBank.d78.s20|76-78|and|O
DDI-DrugBank.d78.s20|80-91|hypoglycemia|O
DDI-DrugBank.d78.s20|92-92|,|O
DDI-DrugBank.d78.s20|94-97|have|O
DDI-DrugBank.d78.s20|99-102|been|O
DDI-DrugBank.d78.s20|104-111|reported|O
DDI-DrugBank.d78.s20|113-114|in|O
DDI-DrugBank.d78.s20|116-123|patients|O
DDI-DrugBank.d78.s20|125-131|treated|O
DDI-DrugBank.d78.s20|133-145|concomitantly|O
DDI-DrugBank.d78.s20|147-150|with|O
DDI-DrugBank.d78.s20|152-161|quinolones|O
DDI-DrugBank.d78.s20|163-165|and|O
DDI-DrugBank.d78.s20|167-168|an|O
DDI-DrugBank.d78.s20|170-181|antidiabetic|O
DDI-DrugBank.d78.s20|183-187|agent|O
DDI-DrugBank.d78.s20|188-188|.|O
DDI-DrugBank.d78.s21|0-8|Therefore|O
DDI-DrugBank.d78.s21|9-9|,|O
DDI-DrugBank.d78.s21|11-17|careful|O
DDI-DrugBank.d78.s21|19-28|monitoring|O
DDI-DrugBank.d78.s21|30-31|of|O
DDI-DrugBank.d78.s21|33-37|blood|O
DDI-DrugBank.d78.s21|39-45|glucose|O
DDI-DrugBank.d78.s21|47-48|is|O
DDI-DrugBank.d78.s21|50-60|recommended|O
DDI-DrugBank.d78.s21|62-65|when|O
DDI-DrugBank.d78.s21|67-71|these|O
DDI-DrugBank.d78.s21|73-78|agents|O
DDI-DrugBank.d78.s21|80-82|are|O
DDI-DrugBank.d78.s21|84-97|coadministered|O
DDI-DrugBank.d78.s21|98-98|.|O
DDI-DrugBank.d397.s0|0-11|Erythromycin|O
DDI-DrugBank.d397.s0|13-15|use|O
DDI-DrugBank.d397.s0|17-18|in|O
DDI-DrugBank.d397.s0|20-27|patients|O
DDI-DrugBank.d397.s0|29-31|who|O
DDI-DrugBank.d397.s0|33-35|are|O
DDI-DrugBank.d397.s0|37-45|receiving|O
DDI-DrugBank.d397.s0|47-50|high|O
DDI-DrugBank.d397.s0|52-56|doses|O
DDI-DrugBank.d397.s0|58-59|of|O
DDI-DrugBank.d397.s0|61-72|theophylline|O
DDI-DrugBank.d397.s0|74-76|may|O
DDI-DrugBank.d397.s0|78-79|be|O
DDI-DrugBank.d397.s0|81-90|associated|O
DDI-DrugBank.d397.s0|92-95|with|O
DDI-DrugBank.d397.s0|97-98|an|O
DDI-DrugBank.d397.s0|100-107|increase|O
DDI-DrugBank.d397.s0|109-110|in|O
DDI-DrugBank.d397.s0|112-116|serum|O
DDI-DrugBank.d397.s0|118-129|theophylline|O
DDI-DrugBank.d397.s0|131-136|levels|O
DDI-DrugBank.d397.s0|138-140|and|O
DDI-DrugBank.d397.s0|142-150|potential|O
DDI-DrugBank.d397.s0|152-163|theophylline|O
DDI-DrugBank.d397.s0|165-172|toxicity|O
DDI-DrugBank.d397.s0|173-173|.|O
DDI-DrugBank.d397.s1|0-1|In|O
DDI-DrugBank.d397.s1|3-6|case|O
DDI-DrugBank.d397.s1|8-9|of|O
DDI-DrugBank.d397.s1|11-22|theophylline|O
DDI-DrugBank.d397.s1|24-31|toxicity|O
DDI-DrugBank.d397.s1|33-38|and/or|O
DDI-DrugBank.d397.s1|40-47|elevated|O
DDI-DrugBank.d397.s1|49-53|serum|O
DDI-DrugBank.d397.s1|55-66|theophylline|O
DDI-DrugBank.d397.s1|68-73|levels|O
DDI-DrugBank.d397.s1|74-74|,|O
DDI-DrugBank.d397.s1|76-78|the|O
DDI-DrugBank.d397.s1|80-83|dose|O
DDI-DrugBank.d397.s1|85-86|of|O
DDI-DrugBank.d397.s1|88-99|theophylline|O
DDI-DrugBank.d397.s1|101-106|should|O
DDI-DrugBank.d397.s1|108-109|be|O
DDI-DrugBank.d397.s1|111-117|reduced|O
DDI-DrugBank.d397.s1|119-123|while|O
DDI-DrugBank.d397.s1|125-127|the|O
DDI-DrugBank.d397.s1|129-135|patient|O
DDI-DrugBank.d397.s1|137-138|is|O
DDI-DrugBank.d397.s1|140-148|receiving|O
DDI-DrugBank.d397.s1|150-160|concomitant|O
DDI-DrugBank.d397.s1|162-173|erythromycin|O
DDI-DrugBank.d397.s1|175-181|therapy|O
DDI-DrugBank.d397.s1|182-182|.|O
DDI-DrugBank.d397.s2|0-10|Concomitant|O
DDI-DrugBank.d397.s2|12-25|administration|O
DDI-DrugBank.d397.s2|27-28|of|O
DDI-DrugBank.d397.s2|30-41|erythromycin|O
DDI-DrugBank.d397.s2|43-45|and|O
DDI-DrugBank.d397.s2|47-53|digoxin|O
DDI-DrugBank.d397.s2|55-57|has|O
DDI-DrugBank.d397.s2|59-62|been|O
DDI-DrugBank.d397.s2|64-71|reported|O
DDI-DrugBank.d397.s2|73-74|to|O
DDI-DrugBank.d397.s2|76-81|result|O
DDI-DrugBank.d397.s2|83-84|in|O
DDI-DrugBank.d397.s2|86-93|elevated|O
DDI-DrugBank.d397.s2|95-101|digoxin|O
DDI-DrugBank.d397.s2|103-107|serum|O
DDI-DrugBank.d397.s2|109-114|levels|O
DDI-DrugBank.d397.s2|115-115|.|O
DDI-DrugBank.d397.s3|0-4|There|O
DDI-DrugBank.d397.s3|6-9|have|O
DDI-DrugBank.d397.s3|11-14|been|O
DDI-DrugBank.d397.s3|16-22|reports|O
DDI-DrugBank.d397.s3|24-25|of|O
DDI-DrugBank.d397.s3|27-35|increased|O
DDI-DrugBank.d397.s3|37-49|anticoagulant|O
DDI-DrugBank.d397.s3|51-57|effects|O
DDI-DrugBank.d397.s3|59-62|when|O
DDI-DrugBank.d397.s3|64-75|erythromycin|O
DDI-DrugBank.d397.s3|77-79|and|O
DDI-DrugBank.d397.s3|81-84|oral|O
DDI-DrugBank.d397.s3|86-99|anticoagulants|O
DDI-DrugBank.d397.s3|101-104|were|O
DDI-DrugBank.d397.s3|106-109|used|O
DDI-DrugBank.d397.s3|111-123|concomitantly|O
DDI-DrugBank.d397.s3|124-124|.|O
DDI-DrugBank.d397.s4|0-8|Increased|O
DDI-DrugBank.d397.s4|10-24|anticoagulation|O
DDI-DrugBank.d397.s4|26-32|effects|O
DDI-DrugBank.d397.s4|34-36|due|O
DDI-DrugBank.d397.s4|38-39|to|O
DDI-DrugBank.d397.s4|41-52|interactions|O
DDI-DrugBank.d397.s4|54-55|of|O
DDI-DrugBank.d397.s4|57-68|erythromycin|O
DDI-DrugBank.d397.s4|70-73|with|O
DDI-DrugBank.d397.s4|75-81|various|O
DDI-DrugBank.d397.s4|83-86|oral|O
DDI-DrugBank.d397.s4|88-101|anticoagulents|O
DDI-DrugBank.d397.s4|103-105|may|O
DDI-DrugBank.d397.s4|107-108|be|O
DDI-DrugBank.d397.s4|110-113|more|O
DDI-DrugBank.d397.s4|115-124|pronounced|O
DDI-DrugBank.d397.s4|126-127|in|O
DDI-DrugBank.d397.s4|129-131|the|O
DDI-DrugBank.d397.s4|133-139|elderly|O
DDI-DrugBank.d397.s4|140-140|.|O
DDI-DrugBank.d397.s5|0-9|Concurrent|O
DDI-DrugBank.d397.s5|11-13|use|O
DDI-DrugBank.d397.s5|15-16|of|O
DDI-DrugBank.d397.s5|18-29|erythromycin|O
DDI-DrugBank.d397.s5|31-33|and|O
DDI-DrugBank.d397.s5|35-44|ergotamine|O
DDI-DrugBank.d397.s5|46-47|or|O
DDI-DrugBank.d397.s5|49-65|dihydroergotamine|O
DDI-DrugBank.d397.s5|67-69|has|O
DDI-DrugBank.d397.s5|71-74|been|O
DDI-DrugBank.d397.s5|76-85|associated|O
DDI-DrugBank.d397.s5|87-88|in|O
DDI-DrugBank.d397.s5|90-93|some|O
DDI-DrugBank.d397.s5|95-102|patients|O
DDI-DrugBank.d397.s5|104-107|with|O
DDI-DrugBank.d397.s5|109-113|acute|O
DDI-DrugBank.d397.s5|115-119|ergot|O
DDI-DrugBank.d397.s5|121-128|toxicity|O
DDI-DrugBank.d397.s5|130-142|characterized|O
DDI-DrugBank.d397.s5|144-145|by|O
DDI-DrugBank.d397.s5|147-152|severe|O
DDI-DrugBank.d397.s5|154-163|peripheral|O
DDI-DrugBank.d397.s5|165-173|vasospasm|O
DDI-DrugBank.d397.s5|175-177|and|O
DDI-DrugBank.d397.s5|179-189|dysesthesia|O
DDI-DrugBank.d397.s5|190-190|.|O
DDI-DrugBank.d397.s6|0-11|Erythromycin|O
DDI-DrugBank.d397.s6|13-15|has|O
DDI-DrugBank.d397.s6|17-20|been|O
DDI-DrugBank.d397.s6|22-29|reported|O
DDI-DrugBank.d397.s6|31-32|to|O
DDI-DrugBank.d397.s6|34-41|decrease|O
DDI-DrugBank.d397.s6|43-45|the|O
DDI-DrugBank.d397.s6|47-55|clearance|O
DDI-DrugBank.d397.s6|57-58|of|O
DDI-DrugBank.d397.s6|60-68|triazolam|O
DDI-DrugBank.d397.s6|70-72|and|O
DDI-DrugBank.d397.s6|74-82|midazolam|O
DDI-DrugBank.d397.s6|84-86|and|O
DDI-DrugBank.d397.s6|88-91|thus|O
DDI-DrugBank.d397.s6|93-95|may|O
DDI-DrugBank.d397.s6|97-104|increase|O
DDI-DrugBank.d397.s6|106-108|the|O
DDI-DrugBank.d397.s6|110-122|pharmacologic|O
DDI-DrugBank.d397.s6|124-129|effect|O
DDI-DrugBank.d397.s6|131-132|of|O
DDI-DrugBank.d397.s6|134-138|these|O
DDI-DrugBank.d397.s6|140-154|benzodiazepines|O
DDI-DrugBank.d397.s6|155-155|.|O
DDI-DrugBank.d397.s7|0-2|The|O
DDI-DrugBank.d397.s7|4-6|use|O
DDI-DrugBank.d397.s7|8-9|of|O
DDI-DrugBank.d397.s7|11-22|erythromycin|O
DDI-DrugBank.d397.s7|24-25|in|O
DDI-DrugBank.d397.s7|27-34|patients|O
DDI-DrugBank.d397.s7|36-47|concurrently|O
DDI-DrugBank.d397.s7|49-54|taking|O
DDI-DrugBank.d397.s7|56-60|drugs|O
DDI-DrugBank.d397.s7|62-72|metabolized|O
DDI-DrugBank.d397.s7|74-75|by|O
DDI-DrugBank.d397.s7|77-79|the|O
DDI-DrugBank.d397.s7|81-90|cytochrome|O
DDI-DrugBank.d397.s7|92-95|P450|O
DDI-DrugBank.d397.s7|97-102|system|O
DDI-DrugBank.d397.s7|104-106|may|O
DDI-DrugBank.d397.s7|108-109|be|O
DDI-DrugBank.d397.s7|111-120|associated|O
DDI-DrugBank.d397.s7|122-125|with|O
DDI-DrugBank.d397.s7|127-136|elevations|O
DDI-DrugBank.d397.s7|138-139|in|O
DDI-DrugBank.d397.s7|141-145|serum|O
DDI-DrugBank.d397.s7|147-152|levels|O
DDI-DrugBank.d397.s7|154-155|of|O
DDI-DrugBank.d397.s7|157-161|these|O
DDI-DrugBank.d397.s7|163-167|other|O
DDI-DrugBank.d397.s7|169-173|drugs|O
DDI-DrugBank.d397.s7|174-174|.|O
DDI-DrugBank.d397.s8|0-4|There|O
DDI-DrugBank.d397.s8|6-9|have|O
DDI-DrugBank.d397.s8|11-14|been|O
DDI-DrugBank.d397.s8|16-22|reports|O
DDI-DrugBank.d397.s8|24-25|of|O
DDI-DrugBank.d397.s8|27-38|interactions|O
DDI-DrugBank.d397.s8|40-41|of|O
DDI-DrugBank.d397.s8|43-54|erythromycin|O
DDI-DrugBank.d397.s8|56-59|with|O
DDI-DrugBank.d397.s8|61-73|carbamazepine|O
DDI-DrugBank.d397.s8|74-74|,|O
DDI-DrugBank.d397.s8|76-87|cyclosporine|O
DDI-DrugBank.d397.s8|88-88|,|O
DDI-DrugBank.d397.s8|90-99|tacrolimus|O
DDI-DrugBank.d397.s8|100-100|,|O
DDI-DrugBank.d397.s8|102-113|hexobarbital|O
DDI-DrugBank.d397.s8|114-114|,|O
DDI-DrugBank.d397.s8|116-124|phenytoin|O
DDI-DrugBank.d397.s8|125-125|,|O
DDI-DrugBank.d397.s8|127-136|alfentanil|O
DDI-DrugBank.d397.s8|137-137|,|O
DDI-DrugBank.d397.s8|139-147|cisapride|O
DDI-DrugBank.d397.s8|148-148|,|O
DDI-DrugBank.d397.s8|150-161|disopyramide|O
DDI-DrugBank.d397.s8|162-162|,|O
DDI-DrugBank.d397.s8|164-173|lovastatin|O
DDI-DrugBank.d397.s8|174-174|,|O
DDI-DrugBank.d397.s8|176-188|bromocriptine|O
DDI-DrugBank.d397.s8|189-189|,|O
DDI-DrugBank.d397.s8|191-199|valproate|O
DDI-DrugBank.d397.s8|200-200|,|O
DDI-DrugBank.d397.s8|202-212|terfenadine|O
DDI-DrugBank.d397.s8|213-213|,|O
DDI-DrugBank.d397.s8|215-217|and|O
DDI-DrugBank.d397.s8|219-228|astemizole|O
DDI-DrugBank.d397.s8|229-229|.|O
DDI-DrugBank.d397.s9|0-4|Serum|O
DDI-DrugBank.d397.s9|6-19|concentrations|O
DDI-DrugBank.d397.s9|21-22|of|O
DDI-DrugBank.d397.s9|24-28|drugs|O
DDI-DrugBank.d397.s9|30-40|metabolized|O
DDI-DrugBank.d397.s9|42-43|by|O
DDI-DrugBank.d397.s9|45-47|the|O
DDI-DrugBank.d397.s9|49-58|cytochrome|O
DDI-DrugBank.d397.s9|60-63|P450|O
DDI-DrugBank.d397.s9|65-70|system|O
DDI-DrugBank.d397.s9|72-77|should|O
DDI-DrugBank.d397.s9|79-80|be|O
DDI-DrugBank.d397.s9|82-90|monitored|O
DDI-DrugBank.d397.s9|92-98|closely|O
DDI-DrugBank.d397.s9|100-101|in|O
DDI-DrugBank.d397.s9|103-110|patients|O
DDI-DrugBank.d397.s9|112-123|concurrently|O
DDI-DrugBank.d397.s9|125-133|receiving|O
DDI-DrugBank.d397.s9|135-146|erythromycin|O
DDI-DrugBank.d397.s9|147-147|.|O
DDI-DrugBank.d397.s10|0-11|Erythromycin|O
DDI-DrugBank.d397.s10|13-15|has|O
DDI-DrugBank.d397.s10|17-20|been|O
DDI-DrugBank.d397.s10|22-29|reported|O
DDI-DrugBank.d397.s10|31-32|to|O
DDI-DrugBank.d397.s10|34-46|significantly|O
DDI-DrugBank.d397.s10|48-52|alter|O
DDI-DrugBank.d397.s10|54-56|the|O
DDI-DrugBank.d397.s10|58-67|metabolism|O
DDI-DrugBank.d397.s10|69-70|of|O
DDI-DrugBank.d397.s10|72-82|nonsedating|O
DDI-DrugBank.d397.s10|84-97|antihistamines|O
DDI-DrugBank.d397.s10|99-109|terfenadine|O
DDI-DrugBank.d397.s10|111-113|and|O
DDI-DrugBank.d397.s10|115-124|astemizole|O
DDI-DrugBank.d397.s10|126-129|when|O
DDI-DrugBank.d397.s10|131-135|taken|O
DDI-DrugBank.d397.s10|137-149|concomitantly|O
DDI-DrugBank.d397.s10|150-150|.|O
DDI-DrugBank.d397.s11|0-3|Rare|O
DDI-DrugBank.d397.s11|5-9|cases|O
DDI-DrugBank.d397.s11|11-12|of|O
DDI-DrugBank.d397.s11|14-20|serious|O
DDI-DrugBank.d397.s11|22-35|cardiovascular|O
DDI-DrugBank.d397.s11|37-43|adverse|O
DDI-DrugBank.d397.s11|45-50|events|O
DDI-DrugBank.d397.s11|51-51|,|O
DDI-DrugBank.d397.s11|53-61|including|O
DDI-DrugBank.d397.s11|63-82|electrocardiographic|O
DDI-DrugBank.d397.s11|84-89|QT/QTc|O
DDI-DrugBank.d397.s11|91-98|interval|O
DDI-DrugBank.d397.s11|100-111|prolongation|O
DDI-DrugBank.d397.s11|112-112|,|O
DDI-DrugBank.d397.s11|114-120|cardiac|O
DDI-DrugBank.d397.s11|122-127|arrest|O
DDI-DrugBank.d397.s11|128-128|,|O
DDI-DrugBank.d397.s11|130-137|torsades|O
DDI-DrugBank.d397.s11|139-140|de|O
DDI-DrugBank.d397.s11|142-148|pointes|O
DDI-DrugBank.d397.s11|149-149|,|O
DDI-DrugBank.d397.s11|151-153|and|O
DDI-DrugBank.d397.s11|155-159|other|O
DDI-DrugBank.d397.s11|161-171|ventricular|O
DDI-DrugBank.d397.s11|173-183|arrhythmias|O
DDI-DrugBank.d397.s11|185-188|have|O
DDI-DrugBank.d397.s11|190-193|been|O
DDI-DrugBank.d397.s11|195-202|observed|O
DDI-DrugBank.d397.s11|203-203|.|O
DDI-DrugBank.d397.s12|0-1|In|O
DDI-DrugBank.d397.s12|3-10|addition|O
DDI-DrugBank.d397.s12|11-11|,|O
DDI-DrugBank.d397.s12|13-18|deaths|O
DDI-DrugBank.d397.s12|20-23|have|O
DDI-DrugBank.d397.s12|25-28|been|O
DDI-DrugBank.d397.s12|30-37|reported|O
DDI-DrugBank.d397.s12|39-44|rarely|O
DDI-DrugBank.d397.s12|46-49|with|O
DDI-DrugBank.d397.s12|51-61|concomitant|O
DDI-DrugBank.d397.s12|63-76|administration|O
DDI-DrugBank.d397.s12|78-79|of|O
DDI-DrugBank.d397.s12|81-91|terfenadine|O
DDI-DrugBank.d397.s12|93-95|and|O
DDI-DrugBank.d397.s12|97-108|erythromycin|O
DDI-DrugBank.d397.s12|109-109|.|O
DDI-DrugBank.d397.s13|0-4|There|O
DDI-DrugBank.d397.s13|6-9|have|O
DDI-DrugBank.d397.s13|11-14|been|O
DDI-DrugBank.d397.s13|16-28|postmarketing|O
DDI-DrugBank.d397.s13|30-36|reports|O
DDI-DrugBank.d397.s13|38-39|of|O
DDI-DrugBank.d397.s13|41-44|drug|O
DDI-DrugBank.d397.s13|46-57|interactions|O
DDI-DrugBank.d397.s13|59-62|when|O
DDI-DrugBank.d397.s13|64-75|erythromycin|O
DDI-DrugBank.d397.s13|77-78|is|O
DDI-DrugBank.d397.s13|80-93|coadministered|O
DDI-DrugBank.d397.s13|95-98|with|O
DDI-DrugBank.d397.s13|100-108|cisapride|O
DDI-DrugBank.d397.s13|109-109|,|O
DDI-DrugBank.d397.s13|111-119|resulting|O
DDI-DrugBank.d397.s13|121-122|in|O
DDI-DrugBank.d397.s13|124-125|QT|O
DDI-DrugBank.d397.s13|127-138|prolongation|O
DDI-DrugBank.d397.s13|139-139|,|O
DDI-DrugBank.d397.s13|141-147|cardiac|O
DDI-DrugBank.d397.s13|149-158|arrythmias|O
DDI-DrugBank.d397.s13|159-159|,|O
DDI-DrugBank.d397.s13|161-171|ventricular|O
DDI-DrugBank.d397.s13|173-183|tachycardia|O
DDI-DrugBank.d397.s13|184-184|,|O
DDI-DrugBank.d397.s13|186-196|ventricular|O
DDI-DrugBank.d397.s13|198-208|fibrulation|O
DDI-DrugBank.d397.s13|209-209|,|O
DDI-DrugBank.d397.s13|211-213|and|O
DDI-DrugBank.d397.s13|215-222|torsades|O
DDI-DrugBank.d397.s13|224-225|de|O
DDI-DrugBank.d397.s13|227-233|pointes|O
DDI-DrugBank.d397.s13|234-234|,|O
DDI-DrugBank.d397.s13|236-239|most|O
DDI-DrugBank.d397.s13|241-244|like|O
DDI-DrugBank.d397.s13|246-248|due|O
DDI-DrugBank.d397.s13|250-251|to|O
DDI-DrugBank.d397.s13|253-262|inhibition|O
DDI-DrugBank.d397.s13|264-265|of|O
DDI-DrugBank.d397.s13|267-273|hepatic|O
DDI-DrugBank.d397.s13|275-284|metabolism|O
DDI-DrugBank.d397.s13|286-287|of|O
DDI-DrugBank.d397.s13|289-297|cisapride|O
DDI-DrugBank.d397.s13|299-300|by|O
DDI-DrugBank.d397.s13|302-313|erythromycin|O
DDI-DrugBank.d397.s13|314-314|.|O
DDI-DrugBank.d397.s14|0-9|Fatalities|O
DDI-DrugBank.d397.s14|11-14|have|O
DDI-DrugBank.d397.s14|16-19|been|O
DDI-DrugBank.d397.s14|21-28|reported|O
DDI-DrugBank.d397.s14|29-29|.|O
DDI-DrugBank.d397.s15|0-7|Patients|O
DDI-DrugBank.d397.s15|9-17|receiving|O
DDI-DrugBank.d397.s15|19-29|concomitant|O
DDI-DrugBank.d397.s15|31-40|lovastatin|O
DDI-DrugBank.d397.s15|42-44|and|O
DDI-DrugBank.d397.s15|46-57|erythromycin|O
DDI-DrugBank.d397.s15|59-64|should|O
DDI-DrugBank.d397.s15|66-67|be|O
DDI-DrugBank.d397.s15|69-77|carefully|O
DDI-DrugBank.d397.s15|79-87|monitored|O
DDI-DrugBank.d397.s15|88-88|;|O
DDI-DrugBank.d397.s16|0-4|cases|O
DDI-DrugBank.d397.s16|6-7|of|O
DDI-DrugBank.d397.s16|9-22|rhabdomyolysis|O
DDI-DrugBank.d397.s16|24-27|have|O
DDI-DrugBank.d397.s16|29-32|been|O
DDI-DrugBank.d397.s16|34-41|reported|O
DDI-DrugBank.d397.s16|43-44|in|O
DDI-DrugBank.d397.s16|46-54|seriously|O
DDI-DrugBank.d397.s16|56-58|ill|O
DDI-DrugBank.d397.s16|60-67|patients|O
DDI-DrugBank.d397.s16|68-68|.|O
DDI-DrugBank.d756.s0|0-6|Dosages|O
DDI-DrugBank.d756.s0|8-9|of|O
DDI-DrugBank.d756.s0|11-23|concomitantly|O
DDI-DrugBank.d756.s0|25-36|administered|O
DDI-DrugBank.d756.s0|38-44|opioids|O
DDI-DrugBank.d756.s0|46-51|should|O
DDI-DrugBank.d756.s0|53-54|be|O
DDI-DrugBank.d756.s0|56-62|reduced|O
DDI-DrugBank.d756.s0|64-65|by|O
DDI-DrugBank.d756.s0|67-79|approximately|O
DDI-DrugBank.d756.s0|81-84|half|O
DDI-DrugBank.d756.s0|85-85|,|O
DDI-DrugBank.d756.s0|87-93|because|O
DDI-DrugBank.d756.s0|95-109|levomepromazine|O
DDI-DrugBank.d756.s0|111-119|amplifies|O
DDI-DrugBank.d756.s0|121-123|the|O
DDI-DrugBank.d756.s0|125-135|therapeutic|O
DDI-DrugBank.d756.s0|137-143|actions|O
DDI-DrugBank.d756.s0|145-147|and|O
DDI-DrugBank.d756.s0|149-160|side-effects|O
DDI-DrugBank.d756.s0|162-163|of|O
DDI-DrugBank.d756.s0|165-171|opioids|O
DDI-DrugBank.d756.s0|172-172|.|O
DDI-DrugBank.d756.s1|0-10|Combination|O
DDI-DrugBank.d756.s1|12-15|with|O
DDI-DrugBank.d756.s1|17-24|tramadol|O
DDI-DrugBank.d756.s1|26-26|(|O
DDI-DrugBank.d756.s1|27-32|Ultram|O
DDI-DrugBank.d756.s1|33-33|)|O
DDI-DrugBank.d756.s1|35-36|is|O
DDI-DrugBank.d756.s1|38-47|associated|O
DDI-DrugBank.d756.s1|49-52|with|O
DDI-DrugBank.d756.s1|54-62|increased|O
DDI-DrugBank.d756.s1|64-67|risk|O
DDI-DrugBank.d756.s1|69-70|of|O
DDI-DrugBank.d756.s1|72-79|seizures|O
DDI-DrugBank.d756.s1|80-80|.|O
DDI-DrugBank.d756.s2|0-7|Additive|O
DDI-DrugBank.d756.s2|9-16|sedative|O
DDI-DrugBank.d756.s2|18-24|effects|O
DDI-DrugBank.d756.s2|26-28|and|O
DDI-DrugBank.d756.s2|30-40|confusional|O
DDI-DrugBank.d756.s2|42-47|states|O
DDI-DrugBank.d756.s2|49-51|may|O
DDI-DrugBank.d756.s2|53-58|emerge|O
DDI-DrugBank.d756.s2|60-61|if|O
DDI-DrugBank.d756.s2|63-77|levomepromazine|O
DDI-DrugBank.d756.s2|79-80|is|O
DDI-DrugBank.d756.s2|82-86|given|O
DDI-DrugBank.d756.s2|88-91|with|O
DDI-DrugBank.d756.s2|93-107|benzodiazepines|O
DDI-DrugBank.d756.s2|109-110|or|O
DDI-DrugBank.d756.s2|112-123|barbiturates|O
DDI-DrugBank.d756.s2|124-124|.|O
DDI-DrugBank.d756.s3|0-3|This|O
DDI-DrugBank.d756.s3|5-7|may|O
DDI-DrugBank.d756.s3|9-10|be|O
DDI-DrugBank.d756.s3|12-18|avoided|O
DDI-DrugBank.d756.s3|20-21|by|O
DDI-DrugBank.d756.s3|23-27|using|O
DDI-DrugBank.d756.s3|29-31|the|O
DDI-DrugBank.d756.s3|33-38|lowest|O
DDI-DrugBank.d756.s3|40-43|dose|O
DDI-DrugBank.d756.s3|45-52|possible|O
DDI-DrugBank.d756.s3|54-57|with|O
DDI-DrugBank.d756.s3|59-61|the|O
DDI-DrugBank.d756.s3|63-72|substances|O
DDI-DrugBank.d756.s3|74-75|in|O
DDI-DrugBank.d756.s3|77-84|question|O
DDI-DrugBank.d756.s3|85-85|.|O
DDI-DrugBank.d756.s4|0-4|Exert|O
DDI-DrugBank.d756.s4|6-15|particular|O
DDI-DrugBank.d756.s4|17-23|caution|O
DDI-DrugBank.d756.s4|25-26|in|O
DDI-DrugBank.d756.s4|28-36|combining|O
DDI-DrugBank.d756.s4|38-52|levomepromazine|O
DDI-DrugBank.d756.s4|54-57|with|O
DDI-DrugBank.d756.s4|59-63|other|O
DDI-DrugBank.d756.s4|65-79|anticholinergic|O
DDI-DrugBank.d756.s4|81-85|drugs|O
DDI-DrugBank.d756.s4|87-87|(|O
DDI-DrugBank.d756.s4|88-96|tricyclic|O
DDI-DrugBank.d756.s4|98-112|antidepressants|O
DDI-DrugBank.d756.s4|114-116|and|O
DDI-DrugBank.d756.s4|118-140|antiparkinsonian-agents|O
DDI-DrugBank.d756.s4|141-141|)|O
DDI-DrugBank.d756.s4|142-142|:|O
DDI-DrugBank.d756.s4|144-155|Particularly|O
DDI-DrugBank.d756.s4|157-159|the|O
DDI-DrugBank.d756.s4|161-167|elderly|O
DDI-DrugBank.d756.s4|169-171|may|O
DDI-DrugBank.d756.s4|173-179|develop|O
DDI-DrugBank.d756.s4|181-188|delirium|O
DDI-DrugBank.d756.s4|189-189|,|O
DDI-DrugBank.d756.s4|191-194|high|O
DDI-DrugBank.d756.s4|196-200|fever|O
DDI-DrugBank.d756.s4|201-201|,|O
DDI-DrugBank.d756.s4|203-208|severe|O
DDI-DrugBank.d756.s4|210-220|obstipation|O
DDI-DrugBank.d756.s4|221-221|,|O
DDI-DrugBank.d756.s4|223-226|even|O
DDI-DrugBank.d756.s4|228-232|ileus|O
DDI-DrugBank.d756.s4|234-236|and|O
DDI-DrugBank.d756.s4|238-245|glaucoma|O
DDI-DrugBank.d756.s4|246-246|.|O
DDI-DrugBank.d756.s5|0-5|Reduce|O
DDI-DrugBank.d756.s5|7-10|both|O
DDI-DrugBank.d756.s5|12-14|the|O
DDI-DrugBank.d756.s5|16-19|dose|O
DDI-DrugBank.d756.s5|21-22|of|O
DDI-DrugBank.d756.s5|24-38|levomepromazine|O
DDI-DrugBank.d756.s5|40-42|and|O
DDI-DrugBank.d756.s5|44-46|the|O
DDI-DrugBank.d756.s5|48-51|dose|O
DDI-DrugBank.d756.s5|53-54|of|O
DDI-DrugBank.d756.s5|56-58|the|O
DDI-DrugBank.d756.s5|60-64|other|O
DDI-DrugBank.d756.s5|66-69|drug|O
DDI-DrugBank.d756.s5|70-70|.|O
DDI-DrugBank.d756.s6|0-1|If|O
DDI-DrugBank.d756.s6|3-10|possible|O
DDI-DrugBank.d756.s6|11-11|,|O
DDI-DrugBank.d756.s6|13-17|avoid|O
DDI-DrugBank.d756.s6|19-22|such|O
DDI-DrugBank.d756.s6|24-35|combinations|O
DDI-DrugBank.d756.s6|36-36|.|O
DDI-DrugBank.d756.s7|0-7|Caffeine|O
DDI-DrugBank.d756.s7|9-14|and/or|O
DDI-DrugBank.d756.s7|16-26|stimulantes|O
DDI-DrugBank.d756.s7|28-29|of|O
DDI-DrugBank.d756.s7|31-33|the|O
DDI-DrugBank.d756.s7|35-55|ephedrine/amphetamine|O
DDI-DrugBank.d756.s7|57-60|type|O
DDI-DrugBank.d756.s7|62-64|may|O
DDI-DrugBank.d756.s7|66-75|counteract|O
DDI-DrugBank.d756.s7|77-79|the|O
DDI-DrugBank.d756.s7|81-88|specific|O
DDI-DrugBank.d756.s7|90-96|actions|O
DDI-DrugBank.d756.s7|98-99|of|O
DDI-DrugBank.d756.s7|101-115|levomepromazine|O
DDI-DrugBank.d756.s7|116-116|.|O
DDI-DrugBank.d756.s8|0-10|Concomitant|O
DDI-DrugBank.d756.s8|12-14|use|O
DDI-DrugBank.d756.s8|16-17|of|O
DDI-DrugBank.d756.s8|19-23|these|O
DDI-DrugBank.d756.s8|25-34|substances|O
DDI-DrugBank.d756.s8|36-41|should|O
DDI-DrugBank.d756.s8|43-44|be|O
DDI-DrugBank.d756.s8|46-52|avoided|O
DDI-DrugBank.d756.s8|53-53|.|O
DDI-DrugBank.d756.s9|0-5|Coffee|O
DDI-DrugBank.d756.s9|7-9|and|O
DDI-DrugBank.d756.s9|11-15|black|O
DDI-DrugBank.d756.s9|17-19|tea|O
DDI-DrugBank.d756.s9|21-26|should|O
DDI-DrugBank.d756.s9|28-29|be|O
DDI-DrugBank.d756.s9|31-37|avoided|O
DDI-DrugBank.d756.s9|39-45|because|O
DDI-DrugBank.d756.s9|47-50|they|O
DDI-DrugBank.d756.s9|52-59|decrease|O
DDI-DrugBank.d756.s9|61-63|the|O
DDI-DrugBank.d756.s9|65-74|absorption|O
DDI-DrugBank.d756.s9|76-77|of|O
DDI-DrugBank.d756.s9|79-93|levomepromazine|O
DDI-DrugBank.d756.s9|95-106|considerably|O
DDI-DrugBank.d756.s9|107-107|.|O
DDI-DrugBank.d756.s10|0-2|The|O
DDI-DrugBank.d756.s10|4-7|same|O
DDI-DrugBank.d756.s10|9-10|is|O
DDI-DrugBank.d756.s10|12-15|true|O
DDI-DrugBank.d756.s10|17-19|for|O
DDI-DrugBank.d756.s10|21-28|antacids|O
DDI-DrugBank.d756.s10|29-29|;|O
DDI-DrugBank.d756.s11|0-4|these|O
DDI-DrugBank.d756.s11|6-11|should|O
DDI-DrugBank.d756.s11|13-14|be|O
DDI-DrugBank.d756.s11|16-20|given|O
DDI-DrugBank.d756.s11|22-22|1|O
DDI-DrugBank.d756.s11|24-25|to|O
DDI-DrugBank.d756.s11|27-27|2|O
DDI-DrugBank.d756.s11|29-33|hours|O
DDI-DrugBank.d756.s11|35-40|before|O
DDI-DrugBank.d756.s11|42-43|or|O
DDI-DrugBank.d756.s11|45-49|after|O
DDI-DrugBank.d756.s11|51-54|oral|O
DDI-DrugBank.d756.s11|56-69|administration|O
DDI-DrugBank.d756.s11|71-72|of|O
DDI-DrugBank.d756.s11|74-89|leveomepromazine|O
DDI-DrugBank.d756.s11|90-90|.|O
DDI-DrugBank.d171.s0|0-6|Tagamet|O
DDI-DrugBank.d171.s0|7-7|,|O
DDI-DrugBank.d171.s0|9-18|apparently|O
DDI-DrugBank.d171.s0|20-26|through|O
DDI-DrugBank.d171.s0|28-29|an|O
DDI-DrugBank.d171.s0|31-36|effect|O
DDI-DrugBank.d171.s0|38-39|on|O
DDI-DrugBank.d171.s0|41-47|certain|O
DDI-DrugBank.d171.s0|49-58|microsomal|O
DDI-DrugBank.d171.s0|60-65|enzyme|O
DDI-DrugBank.d171.s0|67-73|systems|O
DDI-DrugBank.d171.s0|74-74|,|O
DDI-DrugBank.d171.s0|76-78|has|O
DDI-DrugBank.d171.s0|80-83|been|O
DDI-DrugBank.d171.s0|85-92|reported|O
DDI-DrugBank.d171.s0|94-95|to|O
DDI-DrugBank.d171.s0|97-102|reduce|O
DDI-DrugBank.d171.s0|104-106|the|O
DDI-DrugBank.d171.s0|108-114|hepatic|O
DDI-DrugBank.d171.s0|116-125|metabolism|O
DDI-DrugBank.d171.s0|127-128|of|O
DDI-DrugBank.d171.s0|130-142|warfarin-type|O
DDI-DrugBank.d171.s0|144-157|anticoagulants|O
DDI-DrugBank.d171.s0|158-158|,|O
DDI-DrugBank.d171.s0|160-168|phenytoin|O
DDI-DrugBank.d171.s0|169-169|,|O
DDI-DrugBank.d171.s0|171-181|propranolol|O
DDI-DrugBank.d171.s0|182-182|,|O
DDI-DrugBank.d171.s0|184-193|nifedipine|O
DDI-DrugBank.d171.s0|194-194|,|O
DDI-DrugBank.d171.s0|196-211|chlordiazepoxide|O
DDI-DrugBank.d171.s0|212-212|,|O
DDI-DrugBank.d171.s0|214-221|diazepam|O
DDI-DrugBank.d171.s0|222-222|,|O
DDI-DrugBank.d171.s0|224-230|certain|O
DDI-DrugBank.d171.s0|232-240|tricyclic|O
DDI-DrugBank.d171.s0|242-256|antidepressants|O
DDI-DrugBank.d171.s0|257-257|,|O
DDI-DrugBank.d171.s0|259-267|lidocaine|O
DDI-DrugBank.d171.s0|268-268|,|O
DDI-DrugBank.d171.s0|270-281|theophylline|O
DDI-DrugBank.d171.s0|283-285|and|O
DDI-DrugBank.d171.s0|287-299|metronidazole|O
DDI-DrugBank.d171.s0|300-300|,|O
DDI-DrugBank.d171.s0|302-308|thereby|O
DDI-DrugBank.d171.s0|310-317|delaying|O
DDI-DrugBank.d171.s0|319-329|elimination|O
DDI-DrugBank.d171.s0|331-333|and|O
DDI-DrugBank.d171.s0|335-344|increasing|O
DDI-DrugBank.d171.s0|346-350|blood|O
DDI-DrugBank.d171.s0|352-357|levels|O
DDI-DrugBank.d171.s0|359-360|of|O
DDI-DrugBank.d171.s0|362-366|these|O
DDI-DrugBank.d171.s0|368-372|drugs|O
DDI-DrugBank.d171.s0|373-373|.|O
DDI-DrugBank.d171.s1|0-9|Clinically|O
DDI-DrugBank.d171.s1|11-21|significant|O
DDI-DrugBank.d171.s1|23-29|effects|O
DDI-DrugBank.d171.s1|31-34|have|O
DDI-DrugBank.d171.s1|36-39|been|O
DDI-DrugBank.d171.s1|41-48|reported|O
DDI-DrugBank.d171.s1|50-53|with|O
DDI-DrugBank.d171.s1|55-57|the|O
DDI-DrugBank.d171.s1|59-66|warfarin|O
DDI-DrugBank.d171.s1|68-81|anticoagulants|O
DDI-DrugBank.d171.s1|82-82|;|O
DDI-DrugBank.d171.s2|0-8|therefore|O
DDI-DrugBank.d171.s2|9-9|,|O
DDI-DrugBank.d171.s2|11-15|close|O
DDI-DrugBank.d171.s2|17-26|monitoring|O
DDI-DrugBank.d171.s2|28-29|of|O
DDI-DrugBank.d171.s2|31-41|prothrombin|O
DDI-DrugBank.d171.s2|43-46|time|O
DDI-DrugBank.d171.s2|48-49|is|O
DDI-DrugBank.d171.s2|51-61|recommended|O
DDI-DrugBank.d171.s2|62-62|,|O
DDI-DrugBank.d171.s2|64-66|and|O
DDI-DrugBank.d171.s2|68-77|adjustment|O
DDI-DrugBank.d171.s2|79-80|of|O
DDI-DrugBank.d171.s2|82-84|the|O
DDI-DrugBank.d171.s2|86-98|anticoagulant|O
DDI-DrugBank.d171.s2|100-103|dose|O
DDI-DrugBank.d171.s2|105-107|may|O
DDI-DrugBank.d171.s2|109-110|be|O
DDI-DrugBank.d171.s2|112-120|necessary|O
DDI-DrugBank.d171.s2|122-125|when|O
DDI-DrugBank.d171.s2|127-133|Tagamet|O
DDI-DrugBank.d171.s2|135-136|is|O
DDI-DrugBank.d171.s2|138-149|administered|O
DDI-DrugBank.d171.s2|151-163|concomitantly|O
DDI-DrugBank.d171.s2|164-164|.|O
DDI-DrugBank.d171.s3|0-10|Interaction|O
DDI-DrugBank.d171.s3|12-15|with|O
DDI-DrugBank.d171.s3|17-25|phenytoin|O
DDI-DrugBank.d171.s3|26-26|,|O
DDI-DrugBank.d171.s3|28-36|lidocaine|O
DDI-DrugBank.d171.s3|38-40|and|O
DDI-DrugBank.d171.s3|42-53|theophylline|O
DDI-DrugBank.d171.s3|55-57|has|O
DDI-DrugBank.d171.s3|59-62|also|O
DDI-DrugBank.d171.s3|64-67|been|O
DDI-DrugBank.d171.s3|69-76|reported|O
DDI-DrugBank.d171.s3|78-79|to|O
DDI-DrugBank.d171.s3|81-87|produce|O
DDI-DrugBank.d171.s3|89-95|adverse|O
DDI-DrugBank.d171.s3|97-104|clinical|O
DDI-DrugBank.d171.s3|106-112|effects|O
DDI-DrugBank.d171.s3|113-113|.|O
DDI-DrugBank.d171.s4|0-6|However|O
DDI-DrugBank.d171.s4|7-7|,|O
DDI-DrugBank.d171.s4|9-9|a|O
DDI-DrugBank.d171.s4|11-19|crossover|O
DDI-DrugBank.d171.s4|21-25|study|O
DDI-DrugBank.d171.s4|27-28|in|O
DDI-DrugBank.d171.s4|30-36|healthy|O
DDI-DrugBank.d171.s4|38-45|subjects|O
DDI-DrugBank.d171.s4|47-55|receiving|O
DDI-DrugBank.d171.s4|57-62|either|O
DDI-DrugBank.d171.s4|64-70|Tagamet|O
DDI-DrugBank.d171.s4|72-74|300|O
DDI-DrugBank.d171.s4|76-77|mg|O
DDI-DrugBank.d171.s4|79-84|q.i.d.|O
DDI-DrugBank.d171.s4|86-87|or|O
DDI-DrugBank.d171.s4|89-91|800|O
DDI-DrugBank.d171.s4|93-94|mg|O
DDI-DrugBank.d171.s4|96-99|h.s.|O
DDI-DrugBank.d171.s4|101-113|concomitantly|O
DDI-DrugBank.d171.s4|115-118|with|O
DDI-DrugBank.d171.s4|120-120|a|O
DDI-DrugBank.d171.s4|122-124|300|O
DDI-DrugBank.d171.s4|126-127|mg|O
DDI-DrugBank.d171.s4|129-134|b.i.d.|O
DDI-DrugBank.d171.s4|136-141|dosage|O
DDI-DrugBank.d171.s4|143-144|of|O
DDI-DrugBank.d171.s4|146-157|theophylline|O
DDI-DrugBank.d171.s4|159-159|(|O
DDI-DrugBank.d171.s4|160-167|Theo-Dur|O
DDI-DrugBank.d171.s4|169-169|,|O
DDI-DrugBank.d171.s4|171-173|Key|O
DDI-DrugBank.d171.s4|175-189|Pharmaceuticals|O
DDI-DrugBank.d171.s4|190-190|,|O
DDI-DrugBank.d171.s4|192-195|Inc.|O
DDI-DrugBank.d171.s4|196-196|)|O
DDI-DrugBank.d171.s4|198-209|demonstrated|O
DDI-DrugBank.d171.s4|211-214|less|O
DDI-DrugBank.d171.s4|216-225|alteration|O
DDI-DrugBank.d171.s4|227-228|in|O
DDI-DrugBank.d171.s4|230-241|steady-state|O
DDI-DrugBank.d171.s4|243-254|theophylline|O
DDI-DrugBank.d171.s4|256-259|peak|O
DDI-DrugBank.d171.s4|261-265|serum|O
DDI-DrugBank.d171.s4|267-272|levels|O
DDI-DrugBank.d171.s4|274-277|with|O
DDI-DrugBank.d171.s4|279-281|the|O
DDI-DrugBank.d171.s4|283-285|800|O
DDI-DrugBank.d171.s4|287-288|mg|O
DDI-DrugBank.d171.s4|290-293|h.s.|O
DDI-DrugBank.d171.s4|295-301|regimen|O
DDI-DrugBank.d171.s4|302-302|,|O
DDI-DrugBank.d171.s4|304-315|particularly|O
DDI-DrugBank.d171.s4|317-318|in|O
DDI-DrugBank.d171.s4|320-327|subjects|O
DDI-DrugBank.d171.s4|329-332|aged|O
DDI-DrugBank.d171.s4|334-335|54|O
DDI-DrugBank.d171.s4|337-341|years|O
DDI-DrugBank.d171.s4|343-345|and|O
DDI-DrugBank.d171.s4|347-351|older|O
DDI-DrugBank.d171.s4|352-352|.|O
DDI-DrugBank.d171.s5|0-3|Data|O
DDI-DrugBank.d171.s5|5-10|beyond|O
DDI-DrugBank.d171.s5|12-13|10|O
DDI-DrugBank.d171.s5|15-18|days|O
DDI-DrugBank.d171.s5|20-22|are|O
DDI-DrugBank.d171.s5|24-26|not|O
DDI-DrugBank.d171.s5|28-36|available|O
DDI-DrugBank.d171.s5|37-37|.|O
DDI-DrugBank.d171.s6|0-0|(|O
DDI-DrugBank.d171.s6|1-4|Note|O
DDI-DrugBank.d171.s6|5-5|:|O
DDI-DrugBank.d171.s6|7-9|All|O
DDI-DrugBank.d171.s6|11-18|patients|O
DDI-DrugBank.d171.s6|20-28|receiving|O
DDI-DrugBank.d171.s6|30-41|theophylline|O
DDI-DrugBank.d171.s6|43-48|should|O
DDI-DrugBank.d171.s6|50-51|be|O
DDI-DrugBank.d171.s6|53-61|monitored|O
DDI-DrugBank.d171.s6|63-75|appropriately|O
DDI-DrugBank.d171.s6|76-76|,|O
DDI-DrugBank.d171.s6|78-87|regardless|O
DDI-DrugBank.d171.s6|89-90|of|O
DDI-DrugBank.d171.s6|92-102|concomitant|O
DDI-DrugBank.d171.s6|104-107|drug|O
DDI-DrugBank.d171.s6|109-115|therapy|O
DDI-DrugBank.d171.s6|116-116|.|O
DDI-DrugBank.d171.s6|117-117|)|O
DDI-DrugBank.d171.s7|0-5|Dosage|O
DDI-DrugBank.d171.s7|7-8|of|O
DDI-DrugBank.d171.s7|10-12|the|O
DDI-DrugBank.d171.s7|14-18|drugs|O
DDI-DrugBank.d171.s7|20-28|mentioned|O
DDI-DrugBank.d171.s7|30-34|above|O
DDI-DrugBank.d171.s7|36-38|and|O
DDI-DrugBank.d171.s7|40-44|other|O
DDI-DrugBank.d171.s7|46-54|similarly|O
DDI-DrugBank.d171.s7|56-66|metabolized|O
DDI-DrugBank.d171.s7|68-72|drugs|O
DDI-DrugBank.d171.s7|73-73|,|O
DDI-DrugBank.d171.s7|75-86|particularly|O
DDI-DrugBank.d171.s7|88-92|those|O
DDI-DrugBank.d171.s7|94-95|of|O
DDI-DrugBank.d171.s7|97-99|low|O
DDI-DrugBank.d171.s7|101-111|therapeutic|O
DDI-DrugBank.d171.s7|113-117|ratio|O
DDI-DrugBank.d171.s7|119-120|or|O
DDI-DrugBank.d171.s7|122-123|in|O
DDI-DrugBank.d171.s7|125-132|patients|O
DDI-DrugBank.d171.s7|134-137|with|O
DDI-DrugBank.d171.s7|139-143|renal|O
DDI-DrugBank.d171.s7|145-150|and/or|O
DDI-DrugBank.d171.s7|152-158|hepatic|O
DDI-DrugBank.d171.s7|160-169|impairment|O
DDI-DrugBank.d171.s7|170-170|,|O
DDI-DrugBank.d171.s7|172-174|may|O
DDI-DrugBank.d171.s7|176-182|require|O
DDI-DrugBank.d171.s7|184-193|adjustment|O
DDI-DrugBank.d171.s7|195-198|when|O
DDI-DrugBank.d171.s7|200-207|starting|O
DDI-DrugBank.d171.s7|209-210|or|O
DDI-DrugBank.d171.s7|212-219|stopping|O
DDI-DrugBank.d171.s7|221-233|concomitantly|O
DDI-DrugBank.d171.s7|235-246|administered|O
DDI-DrugBank.d171.s7|248-254|Tagamet|O
DDI-DrugBank.d171.s7|256-257|to|O
DDI-DrugBank.d171.s7|259-266|maintain|O
DDI-DrugBank.d171.s7|268-274|optimum|O
DDI-DrugBank.d171.s7|276-286|therapeutic|O
DDI-DrugBank.d171.s7|288-292|blood|O
DDI-DrugBank.d171.s7|294-299|levels|O
DDI-DrugBank.d171.s7|300-300|.|O
DDI-DrugBank.d171.s8|0-9|Alteration|O
DDI-DrugBank.d171.s8|11-12|of|O
DDI-DrugBank.d171.s8|14-15|pH|O
DDI-DrugBank.d171.s8|17-19|may|O
DDI-DrugBank.d171.s8|21-26|affect|O
DDI-DrugBank.d171.s8|28-37|absorption|O
DDI-DrugBank.d171.s8|39-40|of|O
DDI-DrugBank.d171.s8|42-48|certain|O
DDI-DrugBank.d171.s8|50-54|drugs|O
DDI-DrugBank.d171.s8|56-56|(|O
DDI-DrugBank.d171.s8|57-60|e.g.|O
DDI-DrugBank.d171.s8|61-61|,|O
DDI-DrugBank.d171.s8|63-74|ketoconazole|O
DDI-DrugBank.d171.s8|75-75|)|O
DDI-DrugBank.d171.s8|76-76|.|O
DDI-DrugBank.d171.s9|0-1|If|O
DDI-DrugBank.d171.s9|3-7|these|O
DDI-DrugBank.d171.s9|9-16|products|O
DDI-DrugBank.d171.s9|18-20|are|O
DDI-DrugBank.d171.s9|22-27|needed|O
DDI-DrugBank.d171.s9|28-28|,|O
DDI-DrugBank.d171.s9|30-33|they|O
DDI-DrugBank.d171.s9|35-40|should|O
DDI-DrugBank.d171.s9|42-43|be|O
DDI-DrugBank.d171.s9|45-49|given|O
DDI-DrugBank.d171.s9|51-52|at|O
DDI-DrugBank.d171.s9|54-58|least|O
DDI-DrugBank.d171.s9|60-60|2|O
DDI-DrugBank.d171.s9|62-66|hours|O
DDI-DrugBank.d171.s9|68-73|before|O
DDI-DrugBank.d171.s9|75-84|cimetidine|O
DDI-DrugBank.d171.s9|86-99|administration|O
DDI-DrugBank.d171.s9|100-100|.|O
DDI-DrugBank.d171.s10|0-9|Additional|O
DDI-DrugBank.d171.s10|11-18|clinical|O
DDI-DrugBank.d171.s10|20-29|experience|O
DDI-DrugBank.d171.s10|31-33|may|O
DDI-DrugBank.d171.s10|35-40|reveal|O
DDI-DrugBank.d171.s10|42-46|other|O
DDI-DrugBank.d171.s10|48-52|drugs|O
DDI-DrugBank.d171.s10|54-61|affected|O
DDI-DrugBank.d171.s10|63-64|by|O
DDI-DrugBank.d171.s10|66-68|the|O
DDI-DrugBank.d171.s10|70-80|concomitant|O
DDI-DrugBank.d171.s10|82-95|administration|O
DDI-DrugBank.d171.s10|97-98|of|O
DDI-DrugBank.d171.s10|100-106|Tagamet|O
DDI-DrugBank.d171.s10|107-107|.|O
DDI-DrugBank.d359.s0|0-7|PEGANONE|O
DDI-DrugBank.d359.s0|9-12|used|O
DDI-DrugBank.d359.s0|14-15|in|O
DDI-DrugBank.d359.s0|17-27|combination|O
DDI-DrugBank.d359.s0|29-32|with|O
DDI-DrugBank.d359.s0|34-38|other|O
DDI-DrugBank.d359.s0|40-44|drugs|O
DDI-DrugBank.d359.s0|46-50|known|O
DDI-DrugBank.d359.s0|52-53|to|O
DDI-DrugBank.d359.s0|55-63|adversely|O
DDI-DrugBank.d359.s0|65-70|affect|O
DDI-DrugBank.d359.s0|72-74|the|O
DDI-DrugBank.d359.s0|76-88|hematopoietic|O
DDI-DrugBank.d359.s0|90-95|system|O
DDI-DrugBank.d359.s0|97-102|should|O
DDI-DrugBank.d359.s0|104-105|be|O
DDI-DrugBank.d359.s0|107-113|avoided|O
DDI-DrugBank.d359.s0|115-116|if|O
DDI-DrugBank.d359.s0|118-125|possible|O
DDI-DrugBank.d359.s0|126-126|.|O
DDI-DrugBank.d359.s1|0-11|Considerable|O
DDI-DrugBank.d359.s1|13-19|caution|O
DDI-DrugBank.d359.s1|21-26|should|O
DDI-DrugBank.d359.s1|28-29|be|O
DDI-DrugBank.d359.s1|31-39|exercised|O
DDI-DrugBank.d359.s1|41-42|if|O
DDI-DrugBank.d359.s1|44-51|PEGANONE|O
DDI-DrugBank.d359.s1|53-54|is|O
DDI-DrugBank.d359.s1|56-67|administered|O
DDI-DrugBank.d359.s1|69-80|concurrently|O
DDI-DrugBank.d359.s1|82-85|with|O
DDI-DrugBank.d359.s1|87-95|Phenurone|O
DDI-DrugBank.d359.s1|97-97|(|O
DDI-DrugBank.d359.s1|98-108|phenacemide|O
DDI-DrugBank.d359.s1|109-109|)|O
DDI-DrugBank.d359.s1|111-115|since|O
DDI-DrugBank.d359.s1|117-124|paranoid|O
DDI-DrugBank.d359.s1|126-133|symptoms|O
DDI-DrugBank.d359.s1|135-138|have|O
DDI-DrugBank.d359.s1|140-143|been|O
DDI-DrugBank.d359.s1|145-152|reported|O
DDI-DrugBank.d359.s1|154-159|during|O
DDI-DrugBank.d359.s1|161-167|therapy|O
DDI-DrugBank.d359.s1|169-172|with|O
DDI-DrugBank.d359.s1|174-177|this|O
DDI-DrugBank.d359.s1|179-189|combination|O
DDI-DrugBank.d359.s1|190-190|.|O
DDI-DrugBank.d359.s2|0-0|A|O
DDI-DrugBank.d359.s2|2-8|two-way|O
DDI-DrugBank.d359.s2|10-20|interaction|O
DDI-DrugBank.d359.s2|22-28|between|O
DDI-DrugBank.d359.s2|30-32|the|O
DDI-DrugBank.d359.s2|34-42|hydantoin|O
DDI-DrugBank.d359.s2|44-56|antiepileptic|O
DDI-DrugBank.d359.s2|57-57|,|O
DDI-DrugBank.d359.s2|59-67|phenytoin|O
DDI-DrugBank.d359.s2|68-68|,|O
DDI-DrugBank.d359.s2|70-72|and|O
DDI-DrugBank.d359.s2|74-76|the|O
DDI-DrugBank.d359.s2|78-85|coumarin|O
DDI-DrugBank.d359.s2|87-100|anticoagulants|O
DDI-DrugBank.d359.s2|102-104|has|O
DDI-DrugBank.d359.s2|106-109|been|O
DDI-DrugBank.d359.s2|111-119|suggested|O
DDI-DrugBank.d359.s2|120-120|.|O
DDI-DrugBank.d359.s3|0-9|Presumably|O
DDI-DrugBank.d359.s3|10-10|,|O
DDI-DrugBank.d359.s3|12-20|phenytoin|O
DDI-DrugBank.d359.s3|22-25|acts|O
DDI-DrugBank.d359.s3|27-28|as|O
DDI-DrugBank.d359.s3|30-30|a|O
DDI-DrugBank.d359.s3|32-41|stimulator|O
DDI-DrugBank.d359.s3|43-44|of|O
DDI-DrugBank.d359.s3|46-53|coumarin|O
DDI-DrugBank.d359.s3|55-64|metabolism|O
DDI-DrugBank.d359.s3|66-68|and|O
DDI-DrugBank.d359.s3|70-72|has|O
DDI-DrugBank.d359.s3|74-77|been|O
DDI-DrugBank.d359.s3|79-86|reported|O
DDI-DrugBank.d359.s3|88-89|to|O
DDI-DrugBank.d359.s3|91-95|cause|O
DDI-DrugBank.d359.s3|97-105|decreased|O
DDI-DrugBank.d359.s3|107-111|serum|O
DDI-DrugBank.d359.s3|113-118|levels|O
DDI-DrugBank.d359.s3|120-121|of|O
DDI-DrugBank.d359.s3|123-125|the|O
DDI-DrugBank.d359.s3|127-134|coumarin|O
DDI-DrugBank.d359.s3|136-149|anticoagulants|O
DDI-DrugBank.d359.s3|151-153|and|O
DDI-DrugBank.d359.s3|155-163|increased|O
DDI-DrugBank.d359.s3|165-188|prothrombin-proconvertin|O
DDI-DrugBank.d359.s3|190-203|concentrations|O
DDI-DrugBank.d359.s3|204-204|.|O
DDI-DrugBank.d359.s4|0-9|Conversely|O
DDI-DrugBank.d359.s4|10-10|,|O
DDI-DrugBank.d359.s4|12-14|the|O
DDI-DrugBank.d359.s4|16-23|coumarin|O
DDI-DrugBank.d359.s4|25-38|anticoagulants|O
DDI-DrugBank.d359.s4|40-43|have|O
DDI-DrugBank.d359.s4|45-48|been|O
DDI-DrugBank.d359.s4|50-57|reported|O
DDI-DrugBank.d359.s4|59-60|to|O
DDI-DrugBank.d359.s4|62-69|increase|O
DDI-DrugBank.d359.s4|71-73|the|O
DDI-DrugBank.d359.s4|75-79|serum|O
DDI-DrugBank.d359.s4|81-86|levels|O
DDI-DrugBank.d359.s4|88-90|and|O
DDI-DrugBank.d359.s4|92-98|prolong|O
DDI-DrugBank.d359.s4|100-102|the|O
DDI-DrugBank.d359.s4|104-108|serum|O
DDI-DrugBank.d359.s4|110-118|half-life|O
DDI-DrugBank.d359.s4|120-121|of|O
DDI-DrugBank.d359.s4|123-131|phenytoin|O
DDI-DrugBank.d359.s4|133-134|by|O
DDI-DrugBank.d359.s4|136-145|inhibiting|O
DDI-DrugBank.d359.s4|147-149|its|O
DDI-DrugBank.d359.s4|151-160|metabolism|O
DDI-DrugBank.d359.s4|161-161|.|O
DDI-DrugBank.d359.s5|0-7|Although|O
DDI-DrugBank.d359.s5|9-13|there|O
DDI-DrugBank.d359.s5|15-16|is|O
DDI-DrugBank.d359.s5|18-19|no|O
DDI-DrugBank.d359.s5|21-33|documentation|O
DDI-DrugBank.d359.s5|35-36|of|O
DDI-DrugBank.d359.s5|38-41|such|O
DDI-DrugBank.d359.s5|42-42|,|O
DDI-DrugBank.d359.s5|44-44|a|O
DDI-DrugBank.d359.s5|46-52|similar|O
DDI-DrugBank.d359.s5|54-64|interaction|O
DDI-DrugBank.d359.s5|66-72|between|O
DDI-DrugBank.d359.s5|74-81|ethotoin|O
DDI-DrugBank.d359.s5|83-85|and|O
DDI-DrugBank.d359.s5|87-89|the|O
DDI-DrugBank.d359.s5|91-98|coumarin|O
DDI-DrugBank.d359.s5|100-113|anticoagulants|O
DDI-DrugBank.d359.s5|115-117|may|O
DDI-DrugBank.d359.s5|119-123|occur|O
DDI-DrugBank.d359.s5|124-124|.|O
DDI-DrugBank.d359.s6|0-6|Caution|O
DDI-DrugBank.d359.s6|8-9|is|O
DDI-DrugBank.d359.s6|11-19|therefore|O
DDI-DrugBank.d359.s6|21-27|advised|O
DDI-DrugBank.d359.s6|29-32|when|O
DDI-DrugBank.d359.s6|34-46|administering|O
DDI-DrugBank.d359.s6|48-55|PEGANONE|O
DDI-DrugBank.d359.s6|57-58|to|O
DDI-DrugBank.d359.s6|60-67|patients|O
DDI-DrugBank.d359.s6|69-77|receiving|O
DDI-DrugBank.d359.s6|79-86|coumarin|O
DDI-DrugBank.d359.s6|88-101|anticoagulants|O
DDI-DrugBank.d359.s6|102-102|.|O
DDI-DrugBank.d141.s0|0-16|Immunosuppressive|O
DDI-DrugBank.d141.s0|18-22|Drugs|O
DDI-DrugBank.d141.s0|23-23|,|O
DDI-DrugBank.d141.s0|25-30|Fibric|O
DDI-DrugBank.d141.s0|32-35|Acid|O
DDI-DrugBank.d141.s0|37-47|Derivatives|O
DDI-DrugBank.d141.s0|48-48|,|O
DDI-DrugBank.d141.s0|50-55|Niacin|O
DDI-DrugBank.d141.s0|57-57|(|O
DDI-DrugBank.d141.s0|58-66|Nicotinic|O
DDI-DrugBank.d141.s0|68-71|Acid|O
DDI-DrugBank.d141.s0|72-72|,|O
DDI-DrugBank.d141.s0|74-85|Erythromycin|O
DDI-DrugBank.d141.s0|86-86|,|O
DDI-DrugBank.d141.s0|88-92|Azole|O
DDI-DrugBank.d141.s0|94-104|Antifungals|O
DDI-DrugBank.d141.s0|105-105|:|O
DDI-DrugBank.d141.s0|107-114|Skeletal|O
DDI-DrugBank.d141.s0|116-121|Muscle|O
DDI-DrugBank.d141.s0|122-122|.|O
DDI-DrugBank.d141.s1|0-6|ANTACID|O
DDI-DrugBank.d141.s1|8-8|(|O
DDI-DrugBank.d141.s1|9-26|Magnesium-Aluminum|O
DDI-DrugBank.d141.s1|28-36|Hydroxide|O
DDI-DrugBank.d141.s1|37-37|)|O
DDI-DrugBank.d141.s1|38-38|:|O
DDI-DrugBank.d141.s1|40-51|Cerivastatin|O
DDI-DrugBank.d141.s1|53-58|plasma|O
DDI-DrugBank.d141.s1|60-73|concentrations|O
DDI-DrugBank.d141.s1|75-78|were|O
DDI-DrugBank.d141.s1|80-82|not|O
DDI-DrugBank.d141.s1|84-91|affected|O
DDI-DrugBank.d141.s1|93-94|by|O
DDI-DrugBank.d141.s1|96-112|co-administration|O
DDI-DrugBank.d141.s1|114-115|of|O
DDI-DrugBank.d141.s1|117-123|antacid|O
DDI-DrugBank.d141.s1|124-124|.|O
DDI-DrugBank.d141.s2|0-9|CIMETlDINE|O
DDI-DrugBank.d141.s2|10-10|:|O
DDI-DrugBank.d141.s2|12-23|Cerivastatin|O
DDI-DrugBank.d141.s2|25-30|plasma|O
DDI-DrugBank.d141.s2|32-45|concentrations|O
DDI-DrugBank.d141.s2|47-50|were|O
DDI-DrugBank.d141.s2|52-54|not|O
DDI-DrugBank.d141.s2|56-63|affected|O
DDI-DrugBank.d141.s2|65-66|by|O
DDI-DrugBank.d141.s2|68-84|co-administration|O
DDI-DrugBank.d141.s2|86-87|of|O
DDI-DrugBank.d141.s2|89-98|cimetidine|O
DDI-DrugBank.d141.s2|99-99|.|O
DDI-DrugBank.d141.s3|0-13|CHOLESTYRAMINE|O
DDI-DrugBank.d141.s3|14-14|:|O
DDI-DrugBank.d141.s3|16-18|The|O
DDI-DrugBank.d141.s3|20-28|influence|O
DDI-DrugBank.d141.s3|30-31|of|O
DDI-DrugBank.d141.s3|33-35|the|O
DDI-DrugBank.d141.s3|37-57|bile-acidsequestering|O
DDI-DrugBank.d141.s3|59-63|agent|O
DDI-DrugBank.d141.s3|65-78|cholestyramine|O
DDI-DrugBank.d141.s3|80-81|on|O
DDI-DrugBank.d141.s3|83-85|the|O
DDI-DrugBank.d141.s3|87-102|pharmacokinetits|O
DDI-DrugBank.d141.s3|104-105|of|O
DDI-DrugBank.d141.s3|107-118|cerivastatin|O
DDI-DrugBank.d141.s3|120-125|sodium|O
DDI-DrugBank.d141.s3|127-129|was|O
DDI-DrugBank.d141.s3|131-139|evaluated|O
DDI-DrugBank.d141.s3|141-142|in|O
DDI-DrugBank.d141.s3|144-145|12|O
DDI-DrugBank.d141.s3|147-153|healthy|O
DDI-DrugBank.d141.s3|155-159|males|O
DDI-DrugBank.d141.s3|161-162|in|O
DDI-DrugBank.d141.s3|164-164|2|O
DDI-DrugBank.d141.s3|166-173|separate|O
DDI-DrugBank.d141.s3|175-184|randomized|O
DDI-DrugBank.d141.s3|186-194|crossover|O
DDI-DrugBank.d141.s3|196-202|studies|O
DDI-DrugBank.d141.s3|203-203|.|O
DDI-DrugBank.d141.s4|0-1|In|O
DDI-DrugBank.d141.s4|3-5|the|O
DDI-DrugBank.d141.s4|7-11|first|O
DDI-DrugBank.d141.s4|13-17|study|O
DDI-DrugBank.d141.s4|18-18|,|O
DDI-DrugBank.d141.s4|20-30|concomitant|O
DDI-DrugBank.d141.s4|32-45|administration|O
DDI-DrugBank.d141.s4|47-48|of|O
DDI-DrugBank.d141.s4|50-52|0.2|O
DDI-DrugBank.d141.s4|54-55|mg|O
DDI-DrugBank.d141.s4|57-68|cerivastatin|O
DDI-DrugBank.d141.s4|70-75|sodium|O
DDI-DrugBank.d141.s4|77-79|and|O
DDI-DrugBank.d141.s4|81-82|12|O
DDI-DrugBank.d141.s4|84-84|g|O
DDI-DrugBank.d141.s4|86-99|cholestyramine|O
DDI-DrugBank.d141.s4|101-108|resulted|O
DDI-DrugBank.d141.s4|110-111|in|O
DDI-DrugBank.d141.s4|113-121|decreases|O
DDI-DrugBank.d141.s4|123-124|of|O
DDI-DrugBank.d141.s4|126-129|more|O
DDI-DrugBank.d141.s4|131-134|than|O
DDI-DrugBank.d141.s4|136-137|22|O
DDI-DrugBank.d141.s4|138-138|%|O
DDI-DrugBank.d141.s4|140-142|for|O
DDI-DrugBank.d141.s4|144-146|AUC|O
DDI-DrugBank.d141.s4|148-150|and|O
DDI-DrugBank.d141.s4|152-153|40|O
DDI-DrugBank.d141.s4|154-154|%|O
DDI-DrugBank.d141.s4|156-158|for|O
DDI-DrugBank.d141.s4|160-163|Cmax|O
DDI-DrugBank.d141.s4|165-168|when|O
DDI-DrugBank.d141.s4|170-177|compared|O
DDI-DrugBank.d141.s4|179-180|to|O
DDI-DrugBank.d141.s4|182-187|dosing|O
DDI-DrugBank.d141.s4|189-200|cerivastatin|O
DDI-DrugBank.d141.s4|202-207|sodium|O
DDI-DrugBank.d141.s4|209-213|alone|O
DDI-DrugBank.d141.s4|214-214|.|O
DDI-DrugBank.d141.s5|0-6|However|O
DDI-DrugBank.d141.s5|7-7|,|O
DDI-DrugBank.d141.s5|9-10|in|O
DDI-DrugBank.d141.s5|12-14|the|O
DDI-DrugBank.d141.s5|16-21|second|O
DDI-DrugBank.d141.s5|23-27|study|O
DDI-DrugBank.d141.s5|28-28|,|O
DDI-DrugBank.d141.s5|30-43|administration|O
DDI-DrugBank.d141.s5|45-46|of|O
DDI-DrugBank.d141.s5|48-49|12|O
DDI-DrugBank.d141.s5|51-51|g|O
DDI-DrugBank.d141.s5|53-66|cholestyramine|O
DDI-DrugBank.d141.s5|68-68|1|O
DDI-DrugBank.d141.s5|70-73|hour|O
DDI-DrugBank.d141.s5|75-80|before|O
DDI-DrugBank.d141.s5|82-84|the|O
DDI-DrugBank.d141.s5|86-92|evening|O
DDI-DrugBank.d141.s5|94-97|meal|O
DDI-DrugBank.d141.s5|99-101|and|O
DDI-DrugBank.d141.s5|103-105|0.3|O
DDI-DrugBank.d141.s5|107-108|mg|O
DDI-DrugBank.d141.s5|110-121|cerivastatin|O
DDI-DrugBank.d141.s5|123-128|sodium|O
DDI-DrugBank.d141.s5|130-142|approximately|O
DDI-DrugBank.d141.s5|144-144|4|O
DDI-DrugBank.d141.s5|146-150|hours|O
DDI-DrugBank.d141.s5|152-156|after|O
DDI-DrugBank.d141.s5|158-160|the|O
DDI-DrugBank.d141.s5|162-165|same|O
DDI-DrugBank.d141.s5|167-173|evening|O
DDI-DrugBank.d141.s5|175-178|meal|O
DDI-DrugBank.d141.s5|180-187|resulted|O
DDI-DrugBank.d141.s5|189-190|in|O
DDI-DrugBank.d141.s5|192-192|a|O
DDI-DrugBank.d141.s5|194-201|decrease|O
DDI-DrugBank.d141.s5|203-204|in|O
DDI-DrugBank.d141.s5|206-208|the|O
DDI-DrugBank.d141.s5|210-221|cerivastatin|O
DDI-DrugBank.d141.s5|223-225|AUC|O
DDI-DrugBank.d141.s5|227-228|of|O
DDI-DrugBank.d141.s5|230-233|less|O
DDI-DrugBank.d141.s5|235-238|than|O
DDI-DrugBank.d141.s5|240-240|8|O
DDI-DrugBank.d141.s5|241-241|%|O
DDI-DrugBank.d141.s5|242-242|,|O
DDI-DrugBank.d141.s5|244-246|and|O
DDI-DrugBank.d141.s5|248-248|a|O
DDI-DrugBank.d141.s5|250-257|decrease|O
DDI-DrugBank.d141.s5|259-260|in|O
DDI-DrugBank.d141.s5|262-265|Cmax|O
DDI-DrugBank.d141.s5|267-268|of|O
DDI-DrugBank.d141.s5|270-274|about|O
DDI-DrugBank.d141.s5|276-277|30|O
DDI-DrugBank.d141.s5|278-278|%|O
DDI-DrugBank.d141.s5|280-283|when|O
DDI-DrugBank.d141.s5|285-292|compared|O
DDI-DrugBank.d141.s5|294-295|to|O
DDI-DrugBank.d141.s5|297-302|dosing|O
DDI-DrugBank.d141.s5|304-315|cerivastatin|O
DDI-DrugBank.d141.s5|317-322|sodium|O
DDI-DrugBank.d141.s5|324-328|alone|O
DDI-DrugBank.d141.s5|329-329|.|O
DDI-DrugBank.d141.s6|0-8|Therefore|O
DDI-DrugBank.d141.s6|9-9|,|O
DDI-DrugBank.d141.s6|11-12|it|O
DDI-DrugBank.d141.s6|14-18|would|O
DDI-DrugBank.d141.s6|20-21|be|O
DDI-DrugBank.d141.s6|23-30|expected|O
DDI-DrugBank.d141.s6|32-35|that|O
DDI-DrugBank.d141.s6|37-37|a|O
DDI-DrugBank.d141.s6|39-44|dosing|O
DDI-DrugBank.d141.s6|46-53|schedule|O
DDI-DrugBank.d141.s6|55-56|of|O
DDI-DrugBank.d141.s6|58-69|cerivastatin|O
DDI-DrugBank.d141.s6|71-76|sodium|O
DDI-DrugBank.d141.s6|78-82|given|O
DDI-DrugBank.d141.s6|84-85|at|O
DDI-DrugBank.d141.s6|87-93|bedtime|O
DDI-DrugBank.d141.s6|95-97|and|O
DDI-DrugBank.d141.s6|99-112|cholestyramine|O
DDI-DrugBank.d141.s6|114-118|given|O
DDI-DrugBank.d141.s6|120-125|before|O
DDI-DrugBank.d141.s6|127-129|the|O
DDI-DrugBank.d141.s6|131-137|evening|O
DDI-DrugBank.d141.s6|139-142|meal|O
DDI-DrugBank.d141.s6|144-148|would|O
DDI-DrugBank.d141.s6|150-152|not|O
DDI-DrugBank.d141.s6|154-159|result|O
DDI-DrugBank.d141.s6|161-162|in|O
DDI-DrugBank.d141.s6|164-164|a|O
DDI-DrugBank.d141.s6|166-176|significant|O
DDI-DrugBank.d141.s6|178-185|decrease|O
DDI-DrugBank.d141.s6|187-188|in|O
DDI-DrugBank.d141.s6|190-192|the|O
DDI-DrugBank.d141.s6|194-201|clinical|O
DDI-DrugBank.d141.s6|203-208|effect|O
DDI-DrugBank.d141.s6|210-211|of|O
DDI-DrugBank.d141.s6|213-224|cerivastatin|O
DDI-DrugBank.d141.s6|226-231|sodium|O
DDI-DrugBank.d141.s6|232-232|.|O
DDI-DrugBank.d141.s7|0-6|DIGOXIN|O
DDI-DrugBank.d141.s7|7-7|:|O
DDI-DrugBank.d141.s7|9-14|Plasma|O
DDI-DrugBank.d141.s7|16-22|digoxin|O
DDI-DrugBank.d141.s7|24-29|levels|O
DDI-DrugBank.d141.s7|31-33|and|O
DDI-DrugBank.d141.s7|35-41|digoxin|O
DDI-DrugBank.d141.s7|43-51|clearance|O
DDI-DrugBank.d141.s7|53-54|at|O
DDI-DrugBank.d141.s7|56-67|steady-state|O
DDI-DrugBank.d141.s7|69-72|were|O
DDI-DrugBank.d141.s7|74-76|not|O
DDI-DrugBank.d141.s7|78-85|affected|O
DDI-DrugBank.d141.s7|87-88|by|O
DDI-DrugBank.d141.s7|90-106|co-administration|O
DDI-DrugBank.d141.s7|108-109|of|O
DDI-DrugBank.d141.s7|111-113|0.2|O
DDI-DrugBank.d141.s7|115-116|mg|O
DDI-DrugBank.d141.s7|118-129|cerivastatin|O
DDI-DrugBank.d141.s7|131-136|sodium|O
DDI-DrugBank.d141.s7|137-137|.|O
DDI-DrugBank.d141.s8|0-11|Cerivastatin|O
DDI-DrugBank.d141.s8|13-18|plasma|O
DDI-DrugBank.d141.s8|20-33|concentrations|O
DDI-DrugBank.d141.s8|35-38|were|O
DDI-DrugBank.d141.s8|40-43|also|O
DDI-DrugBank.d141.s8|45-47|not|O
DDI-DrugBank.d141.s8|49-56|affected|O
DDI-DrugBank.d141.s8|58-59|by|O
DDI-DrugBank.d141.s8|61-77|co-administration|O
DDI-DrugBank.d141.s8|79-80|of|O
DDI-DrugBank.d141.s8|82-88|digoxin|O
DDI-DrugBank.d141.s8|89-89|.|O
DDI-DrugBank.d141.s9|0-7|WARFARIN|O
DDI-DrugBank.d141.s9|8-8|:|O
DDI-DrugBank.d141.s9|10-12|Co-|O
DDI-DrugBank.d141.s9|14-27|administration|O
DDI-DrugBank.d141.s9|29-30|of|O
DDI-DrugBank.d141.s9|32-39|warfarin|O
DDI-DrugBank.d141.s9|41-43|and|O
DDI-DrugBank.d141.s9|45-56|cerivastatin|O
DDI-DrugBank.d141.s9|58-59|to|O
DDI-DrugBank.d141.s9|61-67|healthy|O
DDI-DrugBank.d141.s9|69-78|volunteers|O
DDI-DrugBank.d141.s9|80-82|did|O
DDI-DrugBank.d141.s9|84-86|not|O
DDI-DrugBank.d141.s9|88-93|result|O
DDI-DrugBank.d141.s9|95-96|in|O
DDI-DrugBank.d141.s9|98-100|any|O
DDI-DrugBank.d141.s9|102-108|changes|O
DDI-DrugBank.d141.s9|110-111|in|O
DDI-DrugBank.d141.s9|113-123|prothrombin|O
DDI-DrugBank.d141.s9|125-128|time|O
DDI-DrugBank.d141.s9|130-131|or|O
DDI-DrugBank.d141.s9|133-140|clotting|O
DDI-DrugBank.d141.s9|142-147|factor|O
DDI-DrugBank.d141.s9|149-151|VII|O
DDI-DrugBank.d141.s9|153-156|when|O
DDI-DrugBank.d141.s9|158-165|compared|O
DDI-DrugBank.d141.s9|167-168|to|O
DDI-DrugBank.d141.s9|170-186|co-administration|O
DDI-DrugBank.d141.s9|188-189|of|O
DDI-DrugBank.d141.s9|191-198|warfarin|O
DDI-DrugBank.d141.s9|200-202|and|O
DDI-DrugBank.d141.s9|204-210|placebo|O
DDI-DrugBank.d141.s9|211-211|.|O
DDI-DrugBank.d141.s10|0-2|The|O
DDI-DrugBank.d141.s10|4-6|AUC|O
DDI-DrugBank.d141.s10|8-10|and|O
DDI-DrugBank.d141.s10|12-15|Cmax|O
DDI-DrugBank.d141.s10|17-18|of|O
DDI-DrugBank.d141.s10|20-23|both|O
DDI-DrugBank.d141.s10|25-27|the|O
DDI-DrugBank.d141.s10|29-29|(|O
DDI-DrugBank.d141.s10|30-30|R|O
DDI-DrugBank.d141.s10|31-31|)|O
DDI-DrugBank.d141.s10|33-35|and|O
DDI-DrugBank.d141.s10|37-37|(|O
DDI-DrugBank.d141.s10|38-38|S|O
DDI-DrugBank.d141.s10|39-39|)|O
DDI-DrugBank.d141.s10|41-47|isomers|O
DDI-DrugBank.d141.s10|49-50|of|O
DDI-DrugBank.d141.s10|52-59|warfarin|O
DDI-DrugBank.d141.s10|61-64|were|O
DDI-DrugBank.d141.s10|66-75|unaffected|O
DDI-DrugBank.d141.s10|77-78|by|O
DDI-DrugBank.d141.s10|80-89|concurrent|O
DDI-DrugBank.d141.s10|91-96|dosing|O
DDI-DrugBank.d141.s10|98-99|of|O
DDI-DrugBank.d141.s10|101-103|0.3|O
DDI-DrugBank.d141.s10|105-106|mg|O
DDI-DrugBank.d141.s10|108-119|cerivastatin|O
DDI-DrugBank.d141.s10|121-126|sodium|O
DDI-DrugBank.d141.s10|127-127|.|O
DDI-DrugBank.d141.s11|0-16|Co-administration|O
DDI-DrugBank.d141.s11|18-19|of|O
DDI-DrugBank.d141.s11|21-28|warfarin|O
DDI-DrugBank.d141.s11|30-32|and|O
DDI-DrugBank.d141.s11|34-45|cerivastatin|O
DDI-DrugBank.d141.s11|47-49|did|O
DDI-DrugBank.d141.s11|51-53|not|O
DDI-DrugBank.d141.s11|55-59|alter|O
DDI-DrugBank.d141.s11|61-63|the|O
DDI-DrugBank.d141.s11|65-80|pharmacokinetics|O
DDI-DrugBank.d141.s11|82-83|of|O
DDI-DrugBank.d141.s11|85-96|cerivastatin|O
DDI-DrugBank.d141.s11|98-103|sodium|O
DDI-DrugBank.d141.s11|104-104|.|O
DDI-DrugBank.d141.s12|0-11|ERYTHROMYCIN|O
DDI-DrugBank.d141.s12|12-12|:|O
DDI-DrugBank.d141.s12|14-15|In|O
DDI-DrugBank.d141.s12|17-36|hypercholesterolemic|O
DDI-DrugBank.d141.s12|38-45|patients|O
DDI-DrugBank.d141.s12|46-46|,|O
DDI-DrugBank.d141.s12|48-59|steady-state|O
DDI-DrugBank.d141.s12|61-72|cerivastatin|O
DDI-DrugBank.d141.s12|74-76|AUC|O
DDI-DrugBank.d141.s12|78-80|and|O
DDI-DrugBank.d141.s12|82-85|Cmax|O
DDI-DrugBank.d141.s12|87-95|increased|O
DDI-DrugBank.d141.s12|97-109|approximately|O
DDI-DrugBank.d141.s12|111-112|50|O
DDI-DrugBank.d141.s12|113-113|%|O
DDI-DrugBank.d141.s12|115-117|and|O
DDI-DrugBank.d141.s12|119-120|24|O
DDI-DrugBank.d141.s12|121-121|%|O
DDI-DrugBank.d141.s12|123-134|respectively|O
DDI-DrugBank.d141.s12|136-140|after|O
DDI-DrugBank.d141.s12|142-143|10|O
DDI-DrugBank.d141.s12|145-148|days|O
DDI-DrugBank.d141.s12|150-153|with|O
DDI-DrugBank.d141.s12|155-171|co-administration|O
DDI-DrugBank.d141.s12|173-174|of|O
DDI-DrugBank.d141.s12|176-187|erythromycin|O
DDI-DrugBank.d141.s12|188-188|,|O
DDI-DrugBank.d141.s12|190-190|a|O
DDI-DrugBank.d141.s12|192-196|known|O
DDI-DrugBank.d141.s12|198-206|inhibitor|O
DDI-DrugBank.d141.s12|208-209|of|O
DDI-DrugBank.d141.s12|211-220|cytochrome|O
DDI-DrugBank.d141.s12|222-225|P450|O
DDI-DrugBank.d141.s12|227-229|3A4|O
DDI-DrugBank.d141.s12|230-230|.|O
DDI-DrugBank.d141.s13|0-4|OTHER|O
DDI-DrugBank.d141.s13|6-16|CONCOMITANT|O
DDI-DrugBank.d141.s13|18-24|THERAPY|O
DDI-DrugBank.d141.s13|25-25|:|O
DDI-DrugBank.d141.s13|27-34|Although|O
DDI-DrugBank.d141.s13|36-43|specific|O
DDI-DrugBank.d141.s13|45-55|interaction|O
DDI-DrugBank.d141.s13|57-63|studies|O
DDI-DrugBank.d141.s13|65-68|were|O
DDI-DrugBank.d141.s13|70-72|not|O
DDI-DrugBank.d141.s13|74-82|performed|O
DDI-DrugBank.d141.s13|83-83|,|O
DDI-DrugBank.d141.s13|85-86|in|O
DDI-DrugBank.d141.s13|88-95|clinical|O
DDI-DrugBank.d141.s13|97-103|studies|O
DDI-DrugBank.d141.s13|104-104|,|O
DDI-DrugBank.d141.s13|106-117|cerivastatin|O
DDI-DrugBank.d141.s13|119-124|sodium|O
DDI-DrugBank.d141.s13|126-128|was|O
DDI-DrugBank.d141.s13|130-133|used|O
DDI-DrugBank.d141.s13|135-147|concomitantly|O
DDI-DrugBank.d141.s13|149-152|with|O
DDI-DrugBank.d141.s13|154-165|angiotensin-|O
DDI-DrugBank.d141.s13|167-176|converting|O
DDI-DrugBank.d141.s13|178-183|enzyme|O
DDI-DrugBank.d141.s13|185-185|(|O
DDI-DrugBank.d141.s13|186-188|ACE|O
DDI-DrugBank.d141.s13|189-189|)|O
DDI-DrugBank.d141.s13|191-200|inhibitors|O
DDI-DrugBank.d141.s13|201-201|,|O
DDI-DrugBank.d141.s13|203-214|betablockers|O
DDI-DrugBank.d141.s13|215-215|,|O
DDI-DrugBank.d141.s13|217-231|calcium-channel|O
DDI-DrugBank.d141.s13|233-240|blockers|O
DDI-DrugBank.d141.s13|241-241|,|O
DDI-DrugBank.d141.s13|243-251|diuretics|O
DDI-DrugBank.d141.s13|252-252|,|O
DDI-DrugBank.d141.s13|254-256|and|O
DDI-DrugBank.d141.s13|258-269|nonsteroidal|O
DDI-DrugBank.d141.s13|271-287|anti-inflammatory|O
DDI-DrugBank.d141.s13|289-293|drugs|O
DDI-DrugBank.d141.s13|295-295|(|O
DDI-DrugBank.d141.s13|296-301|NSAIDs|O
DDI-DrugBank.d141.s13|302-302|)|O
DDI-DrugBank.d141.s13|304-310|without|O
DDI-DrugBank.d141.s13|312-319|evidence|O
DDI-DrugBank.d141.s13|321-322|of|O
DDI-DrugBank.d141.s13|324-333|clinically|O
DDI-DrugBank.d141.s13|335-345|significant|O
DDI-DrugBank.d141.s13|347-353|adverse|O
DDI-DrugBank.d141.s13|355-366|interactions|O
DDI-DrugBank.d141.s13|367-367|.|O
DDI-DrugBank.d635.s0|0-4|Other|O
DDI-DrugBank.d635.s0|6-17|short-acting|O
DDI-DrugBank.d635.s0|19-22|beta|O
DDI-DrugBank.d635.s0|24-33|adrenergic|O
DDI-DrugBank.d635.s0|35-41|aerosol|O
DDI-DrugBank.d635.s0|43-57|bronchodilators|O
DDI-DrugBank.d635.s0|59-64|should|O
DDI-DrugBank.d635.s0|66-68|not|O
DDI-DrugBank.d635.s0|70-71|be|O
DDI-DrugBank.d635.s0|73-76|used|O
DDI-DrugBank.d635.s0|78-90|concomitantly|O
DDI-DrugBank.d635.s0|92-95|with|O
DDI-DrugBank.d635.s0|97-102|MAXAIR|O
DDI-DrugBank.d635.s0|104-112|AUTOHALER|O
DDI-DrugBank.d635.s0|114-120|because|O
DDI-DrugBank.d635.s0|122-125|they|O
DDI-DrugBank.d635.s0|127-129|may|O
DDI-DrugBank.d635.s0|131-134|have|O
DDI-DrugBank.d635.s0|136-143|additive|O
DDI-DrugBank.d635.s0|145-151|effects|O
DDI-DrugBank.d635.s0|152-152|.|O
DDI-DrugBank.d759.s0|0-6|Limited|O
DDI-DrugBank.d759.s0|8-15|evidence|O
DDI-DrugBank.d759.s0|17-24|suggests|O
DDI-DrugBank.d759.s0|26-29|that|O
DDI-DrugBank.d759.s0|31-38|ascorbic|O
DDI-DrugBank.d759.s0|40-43|acid|O
DDI-DrugBank.d759.s0|45-47|may|O
DDI-DrugBank.d759.s0|49-57|influence|O
DDI-DrugBank.d759.s0|59-61|the|O
DDI-DrugBank.d759.s0|63-71|intensity|O
DDI-DrugBank.d759.s0|73-75|and|O
DDI-DrugBank.d759.s0|77-84|duration|O
DDI-DrugBank.d759.s0|86-87|of|O
DDI-DrugBank.d759.s0|89-94|action|O
DDI-DrugBank.d759.s0|96-97|of|O
DDI-DrugBank.d759.s0|99-116|bishydroxycoumarin|O
DDI-DrugBank.d759.s0|117-117|.|O
DDI-DrugBank.d318.s0|0-3|When|O
DDI-DrugBank.d318.s0|5-16|administered|O
DDI-DrugBank.d318.s0|18-29|concurrently|O
DDI-DrugBank.d318.s0|30-30|,|O
DDI-DrugBank.d318.s0|32-34|the|O
DDI-DrugBank.d318.s0|36-44|following|O
DDI-DrugBank.d318.s0|46-50|drugs|O
DDI-DrugBank.d318.s0|52-54|may|O
DDI-DrugBank.d318.s0|56-63|interact|O
DDI-DrugBank.d318.s0|65-68|with|O
DDI-DrugBank.d318.s0|70-81|amphotericin|O
DDI-DrugBank.d318.s0|83-83|B|O
DDI-DrugBank.d318.s0|84-84|:|O
DDI-DrugBank.d318.s0|86-99|Antineoplastic|O
DDI-DrugBank.d318.s0|101-106|agents|O
DDI-DrugBank.d318.s0|107-107|:|O
DDI-DrugBank.d318.s0|109-111|may|O
DDI-DrugBank.d318.s0|113-119|enhance|O
DDI-DrugBank.d318.s0|121-123|the|O
DDI-DrugBank.d318.s0|125-133|potential|O
DDI-DrugBank.d318.s0|135-137|for|O
DDI-DrugBank.d318.s0|139-143|renal|O
DDI-DrugBank.d318.s0|145-152|toxicity|O
DDI-DrugBank.d318.s0|153-153|,|O
DDI-DrugBank.d318.s0|155-166|bronchospasm|O
DDI-DrugBank.d318.s0|168-170|and|O
DDI-DrugBank.d318.s0|172-182|hypotension|O
DDI-DrugBank.d318.s0|183-183|.|O
DDI-DrugBank.d318.s1|0-13|Antineoplastic|O
DDI-DrugBank.d318.s1|15-20|agents|O
DDI-DrugBank.d318.s1|22-22|(|O
DDI-DrugBank.d318.s1|23-24|e.|O
DDI-DrugBank.d318.s1|26-27|g.|O
DDI-DrugBank.d318.s1|28-28|,|O
DDI-DrugBank.d318.s1|30-37|nitrogen|O
DDI-DrugBank.d318.s1|39-45|mustard|O
DDI-DrugBank.d318.s1|46-46|,|O
DDI-DrugBank.d318.s1|48-51|etc.|O
DDI-DrugBank.d318.s1|52-52|)|O
DDI-DrugBank.d318.s1|54-59|should|O
DDI-DrugBank.d318.s1|61-62|be|O
DDI-DrugBank.d318.s1|64-68|given|O
DDI-DrugBank.d318.s1|70-82|concomitantly|O
DDI-DrugBank.d318.s1|84-87|only|O
DDI-DrugBank.d318.s1|89-92|with|O
DDI-DrugBank.d318.s1|94-98|great|O
DDI-DrugBank.d318.s1|100-106|caution|O
DDI-DrugBank.d318.s1|107-107|.|O
DDI-DrugBank.d318.s2|0-14|Corticosteroids|O
DDI-DrugBank.d318.s2|16-18|and|O
DDI-DrugBank.d318.s2|20-32|Corticotropin|O
DDI-DrugBank.d318.s2|34-34|(|O
DDI-DrugBank.d318.s2|35-38|ACTH|O
DDI-DrugBank.d318.s2|39-39|)|O
DDI-DrugBank.d318.s2|40-40|:|O
DDI-DrugBank.d318.s2|42-44|may|O
DDI-DrugBank.d318.s2|46-55|potentiate|O
DDI-DrugBank.d318.s2|57-68|amphotericin|O
DDI-DrugBank.d318.s2|70-71|B-|O
DDI-DrugBank.d318.s2|73-79|induced|O
DDI-DrugBank.d318.s2|81-91|hypokalemia|O
DDI-DrugBank.d318.s2|93-97|which|O
DDI-DrugBank.d318.s2|99-101|may|O
DDI-DrugBank.d318.s2|103-112|predispose|O
DDI-DrugBank.d318.s2|114-116|the|O
DDI-DrugBank.d318.s2|118-124|patient|O
DDI-DrugBank.d318.s2|126-127|to|O
DDI-DrugBank.d318.s2|129-135|cardiac|O
DDI-DrugBank.d318.s2|137-147|dysfunction|O
DDI-DrugBank.d318.s2|148-148|.|O
DDI-DrugBank.d318.s3|0-4|Avoid|O
DDI-DrugBank.d318.s3|6-16|concomitant|O
DDI-DrugBank.d318.s3|18-20|use|O
DDI-DrugBank.d318.s3|22-27|unless|O
DDI-DrugBank.d318.s3|29-37|necessary|O
DDI-DrugBank.d318.s3|39-40|to|O
DDI-DrugBank.d318.s3|42-48|control|O
DDI-DrugBank.d318.s3|50-53|side|O
DDI-DrugBank.d318.s3|55-61|effects|O
DDI-DrugBank.d318.s3|63-64|of|O
DDI-DrugBank.d318.s3|66-77|amphotericin|O
DDI-DrugBank.d318.s3|79-79|B|O
DDI-DrugBank.d318.s3|80-80|.|O
DDI-DrugBank.d318.s4|0-1|If|O
DDI-DrugBank.d318.s4|3-6|used|O
DDI-DrugBank.d318.s4|8-20|concomitantly|O
DDI-DrugBank.d318.s4|21-21|,|O
DDI-DrugBank.d318.s4|23-29|closely|O
DDI-DrugBank.d318.s4|31-37|monitor|O
DDI-DrugBank.d318.s4|39-43|serum|O
DDI-DrugBank.d318.s4|45-56|electrolytes|O
DDI-DrugBank.d318.s4|58-60|and|O
DDI-DrugBank.d318.s4|62-68|cardiac|O
DDI-DrugBank.d318.s4|70-77|function|O
DDI-DrugBank.d318.s4|78-78|.|O
DDI-DrugBank.d318.s5|0-8|Digitalis|O
DDI-DrugBank.d318.s5|10-19|glycosides|O
DDI-DrugBank.d318.s5|20-20|:|O
DDI-DrugBank.d318.s5|22-33|amphotericin|O
DDI-DrugBank.d318.s5|35-43|B-induced|O
DDI-DrugBank.d318.s5|45-55|hypokalemia|O
DDI-DrugBank.d318.s5|57-59|may|O
DDI-DrugBank.d318.s5|61-70|potentiate|O
DDI-DrugBank.d318.s5|72-80|digitalis|O
DDI-DrugBank.d318.s5|82-89|toxicity|O
DDI-DrugBank.d318.s5|90-90|.|O
DDI-DrugBank.d318.s6|0-4|Serum|O
DDI-DrugBank.d318.s6|6-14|potassium|O
DDI-DrugBank.d318.s6|16-21|levels|O
DDI-DrugBank.d318.s6|23-25|and|O
DDI-DrugBank.d318.s6|27-33|cardiac|O
DDI-DrugBank.d318.s6|35-42|function|O
DDI-DrugBank.d318.s6|44-49|should|O
DDI-DrugBank.d318.s6|51-52|be|O
DDI-DrugBank.d318.s6|54-60|closely|O
DDI-DrugBank.d318.s6|62-70|monitored|O
DDI-DrugBank.d318.s6|72-74|and|O
DDI-DrugBank.d318.s6|76-78|any|O
DDI-DrugBank.d318.s6|80-86|deficit|O
DDI-DrugBank.d318.s6|88-95|promptly|O
DDI-DrugBank.d318.s6|97-105|corrected|O
DDI-DrugBank.d318.s6|106-106|.|O
DDI-DrugBank.d318.s7|0-10|Flucytosine|O
DDI-DrugBank.d318.s7|11-11|:|O
DDI-DrugBank.d318.s7|13-17|while|O
DDI-DrugBank.d318.s7|19-19|a|O
DDI-DrugBank.d318.s7|21-31|synergistic|O
DDI-DrugBank.d318.s7|33-44|relationship|O
DDI-DrugBank.d318.s7|46-49|with|O
DDI-DrugBank.d318.s7|51-62|amphotericin|O
DDI-DrugBank.d318.s7|64-64|B|O
DDI-DrugBank.d318.s7|66-68|has|O
DDI-DrugBank.d318.s7|70-73|been|O
DDI-DrugBank.d318.s7|75-82|reported|O
DDI-DrugBank.d318.s7|83-83|,|O
DDI-DrugBank.d318.s7|85-95|concomitant|O
DDI-DrugBank.d318.s7|97-99|use|O
DDI-DrugBank.d318.s7|101-103|may|O
DDI-DrugBank.d318.s7|105-112|increase|O
DDI-DrugBank.d318.s7|114-116|the|O
DDI-DrugBank.d318.s7|118-125|toxicity|O
DDI-DrugBank.d318.s7|127-128|of|O
DDI-DrugBank.d318.s7|130-140|flucytosine|O
DDI-DrugBank.d318.s7|142-143|by|O
DDI-DrugBank.d318.s7|145-152|possibly|O
DDI-DrugBank.d318.s7|154-163|increasing|O
DDI-DrugBank.d318.s7|165-167|its|O
DDI-DrugBank.d318.s7|169-176|cellular|O
DDI-DrugBank.d318.s7|178-183|uptake|O
DDI-DrugBank.d318.s7|185-190|and/or|O
DDI-DrugBank.d318.s7|192-200|impairing|O
DDI-DrugBank.d318.s7|202-204|its|O
DDI-DrugBank.d318.s7|206-210|renal|O
DDI-DrugBank.d318.s7|212-220|excretion|O
DDI-DrugBank.d318.s7|221-221|.|O
DDI-DrugBank.d318.s8|0-9|Imidazoles|O
DDI-DrugBank.d318.s8|11-11|(|O
DDI-DrugBank.d318.s8|12-13|e.|O
DDI-DrugBank.d318.s8|15-16|g.|O
DDI-DrugBank.d318.s8|17-17|,|O
DDI-DrugBank.d318.s8|19-30|ketoconazole|O
DDI-DrugBank.d318.s8|31-31|,|O
DDI-DrugBank.d318.s8|33-42|miconazole|O
DDI-DrugBank.d318.s8|43-43|,|O
DDI-DrugBank.d318.s8|45-56|clotrimazole|O
DDI-DrugBank.d318.s8|57-57|,|O
DDI-DrugBank.d318.s8|59-69|fluconazole|O
DDI-DrugBank.d318.s8|70-70|,|O
DDI-DrugBank.d318.s8|72-75|etc.|O
DDI-DrugBank.d318.s8|76-76|)|O
DDI-DrugBank.d318.s8|77-77|:|O
DDI-DrugBank.d318.s8|79-80|in|O
DDI-DrugBank.d318.s8|82-86|vitro|O
DDI-DrugBank.d318.s8|88-90|and|O
DDI-DrugBank.d318.s8|92-97|animal|O
DDI-DrugBank.d318.s8|99-105|studies|O
DDI-DrugBank.d318.s8|107-110|with|O
DDI-DrugBank.d318.s8|112-114|the|O
DDI-DrugBank.d318.s8|116-126|combination|O
DDI-DrugBank.d318.s8|128-129|of|O
DDI-DrugBank.d318.s8|131-142|amphotericin|O
DDI-DrugBank.d318.s8|144-144|B|O
DDI-DrugBank.d318.s8|146-148|and|O
DDI-DrugBank.d318.s8|150-159|imidazoles|O
DDI-DrugBank.d318.s8|161-167|suggest|O
DDI-DrugBank.d318.s8|169-172|that|O
DDI-DrugBank.d318.s8|174-183|imidazoles|O
DDI-DrugBank.d318.s8|185-187|may|O
DDI-DrugBank.d318.s8|189-194|induce|O
DDI-DrugBank.d318.s8|196-201|fungal|O
DDI-DrugBank.d318.s8|203-212|resistance|O
DDI-DrugBank.d318.s8|214-215|to|O
DDI-DrugBank.d318.s8|217-228|amphotericin|O
DDI-DrugBank.d318.s8|230-230|B|O
DDI-DrugBank.d318.s8|231-231|.|O
DDI-DrugBank.d318.s9|0-10|Combination|O
DDI-DrugBank.d318.s9|12-18|therapy|O
DDI-DrugBank.d318.s9|20-25|should|O
DDI-DrugBank.d318.s9|27-28|be|O
DDI-DrugBank.d318.s9|30-41|administered|O
DDI-DrugBank.d318.s9|43-46|with|O
DDI-DrugBank.d318.s9|48-54|caution|O
DDI-DrugBank.d318.s9|55-55|,|O
DDI-DrugBank.d318.s9|57-66|especially|O
DDI-DrugBank.d318.s9|68-69|in|O
DDI-DrugBank.d318.s9|71-87|immunocompromised|O
DDI-DrugBank.d318.s9|89-96|patients|O
DDI-DrugBank.d318.s9|97-97|.|O
DDI-DrugBank.d318.s10|0-4|Other|O
DDI-DrugBank.d318.s10|6-16|nephrotoxic|O
DDI-DrugBank.d318.s10|18-28|medications|O
DDI-DrugBank.d318.s10|29-29|:|O
DDI-DrugBank.d318.s10|31-36|agents|O
DDI-DrugBank.d318.s10|38-41|such|O
DDI-DrugBank.d318.s10|43-44|as|O
DDI-DrugBank.d318.s10|46-60|aminoglycosides|O
DDI-DrugBank.d318.s10|61-61|,|O
DDI-DrugBank.d318.s10|63-74|cyclosporine|O
DDI-DrugBank.d318.s10|75-75|,|O
DDI-DrugBank.d318.s10|77-79|and|O
DDI-DrugBank.d318.s10|81-91|pentamidine|O
DDI-DrugBank.d318.s10|93-95|may|O
DDI-DrugBank.d318.s10|97-103|enhance|O
DDI-DrugBank.d318.s10|105-107|the|O
DDI-DrugBank.d318.s10|109-117|potential|O
DDI-DrugBank.d318.s10|119-121|for|O
DDI-DrugBank.d318.s10|123-134|drug-induced|O
DDI-DrugBank.d318.s10|136-140|renal|O
DDI-DrugBank.d318.s10|142-149|toxicity|O
DDI-DrugBank.d318.s10|150-150|,|O
DDI-DrugBank.d318.s10|152-154|and|O
DDI-DrugBank.d318.s10|156-161|should|O
DDI-DrugBank.d318.s10|163-164|be|O
DDI-DrugBank.d318.s10|166-169|used|O
DDI-DrugBank.d318.s10|171-183|concomitantly|O
DDI-DrugBank.d318.s10|185-188|only|O
DDI-DrugBank.d318.s10|190-193|with|O
DDI-DrugBank.d318.s10|195-199|great|O
DDI-DrugBank.d318.s10|201-207|caution|O
DDI-DrugBank.d318.s10|208-208|.|O
DDI-DrugBank.d318.s11|0-8|Intensive|O
DDI-DrugBank.d318.s11|10-19|monitoring|O
DDI-DrugBank.d318.s11|21-22|of|O
DDI-DrugBank.d318.s11|24-28|renal|O
DDI-DrugBank.d318.s11|30-37|function|O
DDI-DrugBank.d318.s11|39-40|is|O
DDI-DrugBank.d318.s11|42-52|recommended|O
DDI-DrugBank.d318.s11|54-55|in|O
DDI-DrugBank.d318.s11|57-64|patients|O
DDI-DrugBank.d318.s11|66-74|requiring|O
DDI-DrugBank.d318.s11|76-78|any|O
DDI-DrugBank.d318.s11|80-90|combination|O
DDI-DrugBank.d318.s11|92-93|of|O
DDI-DrugBank.d318.s11|95-105|nephrotoxic|O
DDI-DrugBank.d318.s11|107-117|medications|O
DDI-DrugBank.d318.s11|119-119|.|O
DDI-DrugBank.d318.s12|0-7|Skeletal|O
DDI-DrugBank.d318.s12|9-14|muscle|O
DDI-DrugBank.d318.s12|16-24|relaxants|O
DDI-DrugBank.d318.s12|25-25|:|O
DDI-DrugBank.d318.s12|27-38|amphotericin|O
DDI-DrugBank.d318.s12|40-48|B-induced|O
DDI-DrugBank.d318.s12|50-60|hypokalemia|O
DDI-DrugBank.d318.s12|62-64|may|O
DDI-DrugBank.d318.s12|66-72|enhance|O
DDI-DrugBank.d318.s12|74-76|the|O
DDI-DrugBank.d318.s12|78-87|curariform|O
DDI-DrugBank.d318.s12|89-94|effect|O
DDI-DrugBank.d318.s12|96-97|of|O
DDI-DrugBank.d318.s12|99-106|skeletal|O
DDI-DrugBank.d318.s12|108-113|muscle|O
DDI-DrugBank.d318.s12|115-123|relaxants|O
DDI-DrugBank.d318.s12|125-125|(|O
DDI-DrugBank.d318.s12|126-129|e.g.|O
DDI-DrugBank.d318.s12|130-130|,|O
DDI-DrugBank.d318.s12|132-143|tubocurarine|O
DDI-DrugBank.d318.s12|144-144|)|O
DDI-DrugBank.d318.s12|145-145|.|O
DDI-DrugBank.d318.s13|0-4|Serum|O
DDI-DrugBank.d318.s13|6-14|potassium|O
DDI-DrugBank.d318.s13|16-21|levels|O
DDI-DrugBank.d318.s13|23-28|should|O
DDI-DrugBank.d318.s13|30-31|be|O
DDI-DrugBank.d318.s13|33-41|monitored|O
DDI-DrugBank.d318.s13|43-45|and|O
DDI-DrugBank.d318.s13|47-58|deficiencies|O
DDI-DrugBank.d318.s13|60-68|corrected|O
DDI-DrugBank.d318.s13|69-69|.|O
DDI-DrugBank.d318.s14|0-8|Leukocyte|O
DDI-DrugBank.d318.s14|10-21|transfusions|O
DDI-DrugBank.d318.s14|22-22|:|O
DDI-DrugBank.d318.s14|24-28|acute|O
DDI-DrugBank.d318.s14|30-38|pulmonary|O
DDI-DrugBank.d318.s14|40-47|toxicity|O
DDI-DrugBank.d318.s14|49-51|has|O
DDI-DrugBank.d318.s14|53-56|been|O
DDI-DrugBank.d318.s14|58-65|reported|O
DDI-DrugBank.d318.s14|67-68|in|O
DDI-DrugBank.d318.s14|70-77|patients|O
DDI-DrugBank.d318.s14|79-87|receiving|O
DDI-DrugBank.d318.s14|89-99|intravenous|O
DDI-DrugBank.d318.s14|101-112|amphotericin|O
DDI-DrugBank.d318.s14|114-114|B|O
DDI-DrugBank.d318.s14|116-118|and|O
DDI-DrugBank.d318.s14|120-128|leukocyte|O
DDI-DrugBank.d318.s14|130-141|transfusions|O
DDI-DrugBank.d318.s14|142-142|.|O
DDI-MedLine.d132.s0|0-2|The|O
DDI-MedLine.d132.s0|4-11|emerging|O
DDI-MedLine.d132.s0|13-17|roles|O
DDI-MedLine.d132.s0|19-20|of|O
DDI-MedLine.d132.s0|22-35|non-nucleoside|O
DDI-MedLine.d132.s0|37-43|reverse|O
DDI-MedLine.d132.s0|45-57|transcriptase|O
DDI-MedLine.d132.s0|59-68|inhibitors|O
DDI-MedLine.d132.s0|70-71|in|O
DDI-MedLine.d132.s0|73-86|antiretroviral|O
DDI-MedLine.d132.s0|88-94|therapy|O
DDI-MedLine.d132.s0|95-95|.|O
DDI-MedLine.d132.s1|0-2|The|O
DDI-MedLine.d132.s1|4-15|availability|O
DDI-MedLine.d132.s1|17-18|of|O
DDI-MedLine.d132.s1|20-25|potent|O
DDI-MedLine.d132.s1|27-40|non-nucleoside|O
DDI-MedLine.d132.s1|42-48|reverse|O
DDI-MedLine.d132.s1|50-62|transcriptase|O
DDI-MedLine.d132.s1|64-72|inhibitor|O
DDI-MedLine.d132.s1|74-74|(|O
DDI-MedLine.d132.s1|75-79|NNRTI|O
DDI-MedLine.d132.s1|80-80|)|O
DDI-MedLine.d132.s1|81-86|-based|O
DDI-MedLine.d132.s1|88-95|regimens|O
DDI-MedLine.d132.s1|97-99|for|O
DDI-MedLine.d132.s1|101-114|antiretroviral|O
DDI-MedLine.d132.s1|116-122|therapy|O
DDI-MedLine.d132.s1|124-126|and|O
DDI-MedLine.d132.s1|128-135|concerns|O
DDI-MedLine.d132.s1|137-145|regarding|O
DDI-MedLine.d132.s1|147-154|protease|O
DDI-MedLine.d132.s1|156-164|inhibitor|O
DDI-MedLine.d132.s1|166-166|(|O
DDI-MedLine.d132.s1|167-168|PI|O
DDI-MedLine.d132.s1|169-169|)|O
DDI-MedLine.d132.s1|170-177|-related|O
DDI-MedLine.d132.s1|179-187|metabolic|O
DDI-MedLine.d132.s1|189-200|disturbances|O
DDI-MedLine.d132.s1|202-205|have|O
DDI-MedLine.d132.s1|207-209|led|O
DDI-MedLine.d132.s1|211-212|to|O
DDI-MedLine.d132.s1|214-224|significant|O
DDI-MedLine.d132.s1|226-231|shifts|O
DDI-MedLine.d132.s1|233-234|in|O
DDI-MedLine.d132.s1|236-244|treatment|O
DDI-MedLine.d132.s1|246-254|practices|O
DDI-MedLine.d132.s1|256-257|in|O
DDI-MedLine.d132.s1|259-261|HIV|O
DDI-MedLine.d132.s1|263-271|infection|O
DDI-MedLine.d132.s1|272-272|.|O
DDI-MedLine.d132.s2|0-10|NNRTI-based|O
DDI-MedLine.d132.s2|12-19|regimens|O
DDI-MedLine.d132.s2|21-23|may|O
DDI-MedLine.d132.s2|25-28|have|O
DDI-MedLine.d132.s2|30-36|several|O
DDI-MedLine.d132.s2|38-47|advantages|O
DDI-MedLine.d132.s2|49-52|over|O
DDI-MedLine.d132.s2|54-61|PI-based|O
DDI-MedLine.d132.s2|63-69|therapy|O
DDI-MedLine.d132.s2|71-73|for|O
DDI-MedLine.d132.s2|75-81|initial|O
DDI-MedLine.d132.s2|83-84|or|O
DDI-MedLine.d132.s2|86-94|prolonged|O
DDI-MedLine.d132.s2|96-102|therapy|O
DDI-MedLine.d132.s2|103-103|,|O
DDI-MedLine.d132.s2|105-113|including|O
DDI-MedLine.d132.s2|115-118|more|O
DDI-MedLine.d132.s2|120-129|convenient|O
DDI-MedLine.d132.s2|131-144|administration|O
DDI-MedLine.d132.s2|146-153|regimens|O
DDI-MedLine.d132.s2|154-154|,|O
DDI-MedLine.d132.s2|156-160|lower|O
DDI-MedLine.d132.s2|162-167|tablet|O
DDI-MedLine.d132.s2|169-174|volume|O
DDI-MedLine.d132.s2|175-175|,|O
DDI-MedLine.d132.s2|177-181|fewer|O
DDI-MedLine.d132.s2|183-186|drug|O
DDI-MedLine.d132.s2|188-199|interactions|O
DDI-MedLine.d132.s2|200-200|,|O
DDI-MedLine.d132.s2|202-204|and|O
DDI-MedLine.d132.s2|206-212|central|O
DDI-MedLine.d132.s2|214-220|nervous|O
DDI-MedLine.d132.s2|222-227|system|O
DDI-MedLine.d132.s2|229-239|penetration|O
DDI-MedLine.d132.s2|240-240|.|O
DDI-MedLine.d132.s3|0-1|No|O
DDI-MedLine.d132.s3|3-6|data|O
DDI-MedLine.d132.s3|8-11|from|O
DDI-MedLine.d132.s3|13-23|prospective|O
DDI-MedLine.d132.s3|25-32|clinical|O
DDI-MedLine.d132.s3|34-39|trials|O
DDI-MedLine.d132.s3|41-49|currently|O
DDI-MedLine.d132.s3|51-55|exist|O
DDI-MedLine.d132.s3|57-65|comparing|O
DDI-MedLine.d132.s3|67-69|the|O
DDI-MedLine.d132.s3|71-71|3|O
DDI-MedLine.d132.s3|73-80|approved|O
DDI-MedLine.d132.s3|82-87|agents|O
DDI-MedLine.d132.s3|89-89|(|O
DDI-MedLine.d132.s3|90-98|efavirenz|O
DDI-MedLine.d132.s3|99-99|,|O
DDI-MedLine.d132.s3|101-110|nevirapine|O
DDI-MedLine.d132.s3|112-113|or|O
DDI-MedLine.d132.s3|115-125|delavirdine|O
DDI-MedLine.d132.s3|126-126|)|O
DDI-MedLine.d132.s3|127-127|.|O
DDI-MedLine.d132.s4|0-3|Both|O
DDI-MedLine.d132.s4|5-13|efavirenz|O
DDI-MedLine.d132.s4|15-17|and|O
DDI-MedLine.d132.s4|19-28|nevirapine|O
DDI-MedLine.d132.s4|30-33|have|O
DDI-MedLine.d132.s4|35-38|been|O
DDI-MedLine.d132.s4|40-47|compared|O
DDI-MedLine.d132.s4|49-50|to|O
DDI-MedLine.d132.s4|52-57|triple|O
DDI-MedLine.d132.s4|59-65|therapy|O
DDI-MedLine.d132.s4|67-70|with|O
DDI-MedLine.d132.s4|72-74|the|O
DDI-MedLine.d132.s4|76-77|PI|O
DDI-MedLine.d132.s4|79-87|indinavir|O
DDI-MedLine.d132.s4|89-92|over|O
DDI-MedLine.d132.s4|94-95|48|O
DDI-MedLine.d132.s4|97-101|weeks|O
DDI-MedLine.d132.s4|103-104|as|O
DDI-MedLine.d132.s4|106-112|initial|O
DDI-MedLine.d132.s4|114-120|therapy|O
DDI-MedLine.d132.s4|121-121|,|O
DDI-MedLine.d132.s4|123-126|with|O
DDI-MedLine.d132.s4|128-134|similar|O
DDI-MedLine.d132.s4|136-144|responses|O
DDI-MedLine.d132.s4|146-150|being|O
DDI-MedLine.d132.s4|152-159|observed|O
DDI-MedLine.d132.s4|161-164|with|O
DDI-MedLine.d132.s4|166-175|nevirapine|O
DDI-MedLine.d132.s4|177-184|regimens|O
DDI-MedLine.d132.s4|186-188|and|O
DDI-MedLine.d132.s4|190-200|superiority|O
DDI-MedLine.d132.s4|202-209|observed|O
DDI-MedLine.d132.s4|211-214|with|O
DDI-MedLine.d132.s4|216-224|efavirenz|O
DDI-MedLine.d132.s4|225-225|.|O
DDI-MedLine.d132.s5|0-0|A|O
DDI-MedLine.d132.s5|2-8|smaller|O
DDI-MedLine.d132.s5|10-16|24-week|O
DDI-MedLine.d132.s5|18-22|study|O
DDI-MedLine.d132.s5|24-26|has|O
DDI-MedLine.d132.s5|28-36|suggested|O
DDI-MedLine.d132.s5|38-47|nevirapine|O
DDI-MedLine.d132.s5|49-51|may|O
DDI-MedLine.d132.s5|53-54|be|O
DDI-MedLine.d132.s5|56-63|superior|O
DDI-MedLine.d132.s5|65-66|to|O
DDI-MedLine.d132.s5|68-70|the|O
DDI-MedLine.d132.s5|72-73|PI|O
DDI-MedLine.d132.s5|75-84|nelfinavir|O
DDI-MedLine.d132.s5|85-85|.|O
DDI-MedLine.d132.s6|0-6|Limited|O
DDI-MedLine.d132.s6|8-18|comparative|O
DDI-MedLine.d132.s6|20-23|data|O
DDI-MedLine.d132.s6|25-26|in|O
DDI-MedLine.d132.s6|28-35|patients|O
DDI-MedLine.d132.s6|37-40|with|O
DDI-MedLine.d132.s6|42-45|high|O
DDI-MedLine.d132.s6|47-51|viral|O
DDI-MedLine.d132.s6|53-57|loads|O
DDI-MedLine.d132.s6|59-65|treated|O
DDI-MedLine.d132.s6|67-70|with|O
DDI-MedLine.d132.s6|72-82|nevirapine-|O
DDI-MedLine.d132.s6|84-85|or|O
DDI-MedLine.d132.s6|87-103|delavirdine-based|O
DDI-MedLine.d132.s6|105-112|regimens|O
DDI-MedLine.d132.s6|114-122|currently|O
DDI-MedLine.d132.s6|124-128|exist|O
DDI-MedLine.d132.s6|129-129|.|O
DDI-MedLine.d132.s7|0-6|However|O
DDI-MedLine.d132.s7|7-7|,|O
DDI-MedLine.d132.s7|9-14|cohort|O
DDI-MedLine.d132.s7|16-19|data|O
DDI-MedLine.d132.s7|21-23|and|O
DDI-MedLine.d132.s7|25-32|selected|O
DDI-MedLine.d132.s7|34-40|patient|O
DDI-MedLine.d132.s7|42-45|data|O
DDI-MedLine.d132.s7|47-50|from|O
DDI-MedLine.d132.s7|52-59|clinical|O
DDI-MedLine.d132.s7|61-66|trials|O
DDI-MedLine.d132.s7|68-74|suggest|O
DDI-MedLine.d132.s7|76-85|comparable|O
DDI-MedLine.d132.s7|87-94|activity|O
DDI-MedLine.d132.s7|96-97|to|O
DDI-MedLine.d132.s7|99-106|PI-based|O
DDI-MedLine.d132.s7|108-115|regimens|O
DDI-MedLine.d132.s7|117-118|in|O
DDI-MedLine.d132.s7|120-124|these|O
DDI-MedLine.d132.s7|126-133|patients|O
DDI-MedLine.d132.s7|134-134|.|O
DDI-MedLine.d132.s8|0-2|The|O
DDI-MedLine.d132.s8|4-14|superiority|O
DDI-MedLine.d132.s8|16-17|of|O
DDI-MedLine.d132.s8|19-27|efavirenz|O
DDI-MedLine.d132.s8|29-32|over|O
DDI-MedLine.d132.s8|34-48|indinavir-based|O
DDI-MedLine.d132.s8|50-57|regimens|O
DDI-MedLine.d132.s8|59-61|has|O
DDI-MedLine.d132.s8|63-66|been|O
DDI-MedLine.d132.s8|68-75|observed|O
DDI-MedLine.d132.s8|77-78|in|O
DDI-MedLine.d132.s8|80-90|comparative|O
DDI-MedLine.d132.s8|92-95|data|O
DDI-MedLine.d132.s8|97-98|in|O
DDI-MedLine.d132.s8|100-100|a|O
DDI-MedLine.d132.s8|102-107|subset|O
DDI-MedLine.d132.s8|109-110|of|O
DDI-MedLine.d132.s8|112-119|patients|O
DDI-MedLine.d132.s8|121-124|with|O
DDI-MedLine.d132.s8|126-129|high|O
DDI-MedLine.d132.s8|131-135|viral|O
DDI-MedLine.d132.s8|137-141|loads|O
DDI-MedLine.d132.s8|142-142|.|O
DDI-MedLine.d132.s9|0-1|In|O
DDI-MedLine.d132.s9|3-23|treatment-experienced|O
DDI-MedLine.d132.s9|25-32|patients|O
DDI-MedLine.d132.s9|33-33|,|O
DDI-MedLine.d132.s9|35-43|available|O
DDI-MedLine.d132.s9|45-56|uncontrolled|O
DDI-MedLine.d132.s9|58-61|data|O
DDI-MedLine.d132.s9|63-69|suggest|O
DDI-MedLine.d132.s9|71-75|these|O
DDI-MedLine.d132.s9|77-82|agents|O
DDI-MedLine.d132.s9|84-93|contribute|O
DDI-MedLine.d132.s9|95-96|to|O
DDI-MedLine.d132.s9|98-104|regimen|O
DDI-MedLine.d132.s9|106-113|efficacy|O
DDI-MedLine.d132.s9|115-116|in|O
DDI-MedLine.d132.s9|118-125|NNRTI-na|O
DDI-MedLine.d132.s9|128-129|ve|O
DDI-MedLine.d132.s9|130-130|,|O
DDI-MedLine.d132.s9|132-152|treatment-experienced|O
DDI-MedLine.d132.s9|154-161|patients|O
DDI-MedLine.d132.s9|162-162|.|O
DDI-MedLine.d132.s10|0-8|Efavirenz|O
DDI-MedLine.d132.s10|10-12|has|O
DDI-MedLine.d132.s10|14-25|demonstrated|O
DDI-MedLine.d132.s10|27-37|superiority|O
DDI-MedLine.d132.s10|39-42|over|O
DDI-MedLine.d132.s10|44-53|nelfinavir|O
DDI-MedLine.d132.s10|55-56|in|O
DDI-MedLine.d132.s10|58-79|nucleoside-experienced|O
DDI-MedLine.d132.s10|81-88|patients|O
DDI-MedLine.d132.s10|89-89|,|O
DDI-MedLine.d132.s10|91-98|although|O
DDI-MedLine.d132.s10|100-108|combining|O
DDI-MedLine.d132.s10|110-114|these|O
DDI-MedLine.d132.s10|116-116|2|O
DDI-MedLine.d132.s10|118-123|agents|O
DDI-MedLine.d132.s10|125-127|may|O
DDI-MedLine.d132.s10|129-137|represent|O
DDI-MedLine.d132.s10|139-141|the|O
DDI-MedLine.d132.s10|143-146|best|O
DDI-MedLine.d132.s10|148-155|approach|O
DDI-MedLine.d132.s10|157-158|in|O
DDI-MedLine.d132.s10|160-164|these|O
DDI-MedLine.d132.s10|166-178|circumstances|O
DDI-MedLine.d132.s10|179-179|.|O
DDI-MedLine.d132.s11|0-2|The|O
DDI-MedLine.d132.s11|4-15|tolerability|O
DDI-MedLine.d132.s11|17-18|of|O
DDI-MedLine.d132.s11|20-25|NNRTIs|O
DDI-MedLine.d132.s11|27-33|appears|O
DDI-MedLine.d132.s11|35-43|generally|O
DDI-MedLine.d132.s11|45-48|good|O
DDI-MedLine.d132.s11|50-53|with|O
DDI-MedLine.d132.s11|55-57|few|O
DDI-MedLine.d132.s11|59-69|individuals|O
DDI-MedLine.d132.s11|71-83|discontinuing|O
DDI-MedLine.d132.s11|85-86|in|O
DDI-MedLine.d132.s11|88-95|clinical|O
DDI-MedLine.d132.s11|97-103|studies|O
DDI-MedLine.d132.s11|105-106|as|O
DDI-MedLine.d132.s11|108-108|a|O
DDI-MedLine.d132.s11|110-115|result|O
DDI-MedLine.d132.s11|117-118|of|O
DDI-MedLine.d132.s11|120-126|adverse|O
DDI-MedLine.d132.s11|128-131|drug|O
DDI-MedLine.d132.s11|133-138|events|O
DDI-MedLine.d132.s11|139-139|.|O
DDI-MedLine.d132.s12|0-2|The|O
DDI-MedLine.d132.s12|4-11|majority|O
DDI-MedLine.d132.s12|13-14|of|O
DDI-MedLine.d132.s12|16-22|adverse|O
DDI-MedLine.d132.s12|24-29|events|O
DDI-MedLine.d132.s12|31-34|with|O
DDI-MedLine.d132.s12|36-41|NNRTIs|O
DDI-MedLine.d132.s12|43-47|occur|O
DDI-MedLine.d132.s12|49-54|within|O
DDI-MedLine.d132.s12|56-58|the|O
DDI-MedLine.d132.s12|60-64|first|O
DDI-MedLine.d132.s12|66-70|month|O
DDI-MedLine.d132.s12|71-71|,|O
DDI-MedLine.d132.s12|73-75|and|O
DDI-MedLine.d132.s12|77-79|are|O
DDI-MedLine.d132.s12|81-91|predictable|O
DDI-MedLine.d132.s12|93-95|and|O
DDI-MedLine.d132.s12|97-106|manageable|O
DDI-MedLine.d132.s12|108-114|without|O
DDI-MedLine.d132.s12|116-122|therapy|O
DDI-MedLine.d132.s12|124-135|interruption|O
DDI-MedLine.d132.s12|136-136|.|O
DDI-DrugBank.d73.s0|0-22|Catecholamine-depleting|O
DDI-DrugBank.d73.s0|24-28|drugs|O
DDI-DrugBank.d73.s0|30-30|(|O
DDI-DrugBank.d73.s0|31-32|eg|O
DDI-DrugBank.d73.s0|33-33|,|O
DDI-DrugBank.d73.s0|35-43|reserpine|O
DDI-DrugBank.d73.s0|44-44|)|O
DDI-DrugBank.d73.s0|46-48|may|O
DDI-DrugBank.d73.s0|50-53|have|O
DDI-DrugBank.d73.s0|55-56|an|O
DDI-DrugBank.d73.s0|58-65|additive|O
DDI-DrugBank.d73.s0|67-72|effect|O
DDI-DrugBank.d73.s0|74-77|when|O
DDI-DrugBank.d73.s0|79-83|given|O
DDI-DrugBank.d73.s0|85-88|with|O
DDI-DrugBank.d73.s0|90-102|beta-blocking|O
DDI-DrugBank.d73.s0|104-109|agents|O
DDI-DrugBank.d73.s0|110-110|.|O
DDI-DrugBank.d73.s1|0-7|Patients|O
DDI-DrugBank.d73.s1|9-15|treated|O
DDI-DrugBank.d73.s1|17-20|with|O
DDI-DrugBank.d73.s1|22-29|TENORMIN|O
DDI-DrugBank.d73.s1|31-34|plus|O
DDI-DrugBank.d73.s1|36-36|a|O
DDI-DrugBank.d73.s1|38-50|catecholamine|O
DDI-DrugBank.d73.s1|52-59|depletor|O
DDI-DrugBank.d73.s1|61-66|should|O
DDI-DrugBank.d73.s1|68-76|therefore|O
DDI-DrugBank.d73.s1|78-79|be|O
DDI-DrugBank.d73.s1|81-87|closely|O
DDI-DrugBank.d73.s1|89-96|observed|O
DDI-DrugBank.d73.s1|98-100|for|O
DDI-DrugBank.d73.s1|102-109|evidence|O
DDI-DrugBank.d73.s1|111-112|of|O
DDI-DrugBank.d73.s1|114-124|hypotension|O
DDI-DrugBank.d73.s1|126-131|and/or|O
DDI-DrugBank.d73.s1|133-138|marked|O
DDI-DrugBank.d73.s1|140-150|bradycardia|O
DDI-DrugBank.d73.s1|152-156|which|O
DDI-DrugBank.d73.s1|158-160|may|O
DDI-DrugBank.d73.s1|162-168|produce|O
DDI-DrugBank.d73.s1|170-176|vertigo|O
DDI-DrugBank.d73.s1|177-177|,|O
DDI-DrugBank.d73.s1|179-185|syncope|O
DDI-DrugBank.d73.s1|186-186|,|O
DDI-DrugBank.d73.s1|188-189|or|O
DDI-DrugBank.d73.s1|191-198|postural|O
DDI-DrugBank.d73.s1|200-210|hypotension|O
DDI-DrugBank.d73.s1|211-211|.|O
DDI-DrugBank.d73.s2|0-6|Calcium|O
DDI-DrugBank.d73.s2|8-14|channel|O
DDI-DrugBank.d73.s2|16-23|blockers|O
DDI-DrugBank.d73.s2|25-27|may|O
DDI-DrugBank.d73.s2|29-32|also|O
DDI-DrugBank.d73.s2|34-37|have|O
DDI-DrugBank.d73.s2|39-40|an|O
DDI-DrugBank.d73.s2|42-49|additive|O
DDI-DrugBank.d73.s2|51-56|effect|O
DDI-DrugBank.d73.s2|58-61|when|O
DDI-DrugBank.d73.s2|63-67|given|O
DDI-DrugBank.d73.s2|69-72|with|O
DDI-DrugBank.d73.s2|74-81|TENORMIN|O
DDI-DrugBank.d73.s2|83-83|.|O
DDI-DrugBank.d73.s3|0-3|Beta|O
DDI-DrugBank.d73.s3|5-12|blockers|O
DDI-DrugBank.d73.s3|14-16|may|O
DDI-DrugBank.d73.s3|18-27|exacerbate|O
DDI-DrugBank.d73.s3|29-31|the|O
DDI-DrugBank.d73.s3|33-39|rebound|O
DDI-DrugBank.d73.s3|41-52|hypertension|O
DDI-DrugBank.d73.s3|54-58|which|O
DDI-DrugBank.d73.s3|60-62|can|O
DDI-DrugBank.d73.s3|64-69|follow|O
DDI-DrugBank.d73.s3|71-73|the|O
DDI-DrugBank.d73.s3|75-84|withdrawal|O
DDI-DrugBank.d73.s3|86-87|of|O
DDI-DrugBank.d73.s3|89-97|clonidine|O
DDI-DrugBank.d73.s3|98-98|.|O
DDI-DrugBank.d73.s4|0-1|If|O
DDI-DrugBank.d73.s4|3-5|the|O
DDI-DrugBank.d73.s4|7-9|two|O
DDI-DrugBank.d73.s4|11-15|drugs|O
DDI-DrugBank.d73.s4|17-19|are|O
DDI-DrugBank.d73.s4|21-34|coadministered|O
DDI-DrugBank.d73.s4|35-35|,|O
DDI-DrugBank.d73.s4|37-39|the|O
DDI-DrugBank.d73.s4|41-44|beta|O
DDI-DrugBank.d73.s4|46-52|blocker|O
DDI-DrugBank.d73.s4|54-59|should|O
DDI-DrugBank.d73.s4|61-62|be|O
DDI-DrugBank.d73.s4|64-72|withdrawn|O
DDI-DrugBank.d73.s4|74-80|several|O
DDI-DrugBank.d73.s4|82-85|days|O
DDI-DrugBank.d73.s4|87-92|before|O
DDI-DrugBank.d73.s4|94-96|the|O
DDI-DrugBank.d73.s4|98-104|gradual|O
DDI-DrugBank.d73.s4|106-115|withdrawal|O
DDI-DrugBank.d73.s4|117-118|of|O
DDI-DrugBank.d73.s4|120-128|clonidine|O
DDI-DrugBank.d73.s4|129-129|.|O
DDI-DrugBank.d73.s5|0-1|If|O
DDI-DrugBank.d73.s5|3-11|replacing|O
DDI-DrugBank.d73.s5|13-21|clonidine|O
DDI-DrugBank.d73.s5|23-24|by|O
DDI-DrugBank.d73.s5|26-37|beta-blocker|O
DDI-DrugBank.d73.s5|39-45|therapy|O
DDI-DrugBank.d73.s5|46-46|,|O
DDI-DrugBank.d73.s5|48-50|the|O
DDI-DrugBank.d73.s5|52-63|introduction|O
DDI-DrugBank.d73.s5|65-66|of|O
DDI-DrugBank.d73.s5|68-71|beta|O
DDI-DrugBank.d73.s5|73-80|blockers|O
DDI-DrugBank.d73.s5|82-87|should|O
DDI-DrugBank.d73.s5|89-90|be|O
DDI-DrugBank.d73.s5|92-98|delayed|O
DDI-DrugBank.d73.s5|100-102|for|O
DDI-DrugBank.d73.s5|104-110|several|O
DDI-DrugBank.d73.s5|112-115|days|O
DDI-DrugBank.d73.s5|117-121|after|O
DDI-DrugBank.d73.s5|123-131|clonidine|O
DDI-DrugBank.d73.s5|133-146|administration|O
DDI-DrugBank.d73.s5|148-150|has|O
DDI-DrugBank.d73.s5|152-158|stopped|O
DDI-DrugBank.d73.s5|159-159|.|O
DDI-DrugBank.d73.s6|0-10|Concomitant|O
DDI-DrugBank.d73.s6|12-14|use|O
DDI-DrugBank.d73.s6|16-17|of|O
DDI-DrugBank.d73.s6|19-31|prostaglandin|O
DDI-DrugBank.d73.s6|33-40|synthase|O
DDI-DrugBank.d73.s6|42-51|inhibiting|O
DDI-DrugBank.d73.s6|53-57|drugs|O
DDI-DrugBank.d73.s6|58-58|,|O
DDI-DrugBank.d73.s6|60-61|eg|O
DDI-DrugBank.d73.s6|62-62|,|O
DDI-DrugBank.d73.s6|64-75|indomethacin|O
DDI-DrugBank.d73.s6|76-76|,|O
DDI-DrugBank.d73.s6|78-80|may|O
DDI-DrugBank.d73.s6|82-89|decrease|O
DDI-DrugBank.d73.s6|91-93|the|O
DDI-DrugBank.d73.s6|95-105|hypotensive|O
DDI-DrugBank.d73.s6|107-113|effects|O
DDI-DrugBank.d73.s6|115-116|of|O
DDI-DrugBank.d73.s6|118-121|beta|O
DDI-DrugBank.d73.s6|123-130|blockers|O
DDI-DrugBank.d73.s6|131-131|.|O
DDI-DrugBank.d73.s7|0-10|Information|O
DDI-DrugBank.d73.s7|12-13|on|O
DDI-DrugBank.d73.s7|15-24|concurrent|O
DDI-DrugBank.d73.s7|26-30|usage|O
DDI-DrugBank.d73.s7|32-33|of|O
DDI-DrugBank.d73.s7|35-42|atenolol|O
DDI-DrugBank.d73.s7|44-46|and|O
DDI-DrugBank.d73.s7|48-54|aspirin|O
DDI-DrugBank.d73.s7|56-57|is|O
DDI-DrugBank.d73.s7|59-65|limited|O
DDI-DrugBank.d73.s7|66-66|.|O
DDI-DrugBank.d73.s8|0-3|Data|O
DDI-DrugBank.d73.s8|5-8|from|O
DDI-DrugBank.d73.s8|10-16|several|O
DDI-DrugBank.d73.s8|18-24|studies|O
DDI-DrugBank.d73.s8|25-25|,|O
DDI-DrugBank.d73.s8|27-28|ie|O
DDI-DrugBank.d73.s8|29-29|,|O
DDI-DrugBank.d73.s8|31-37|TIMI-II|O
DDI-DrugBank.d73.s8|38-38|,|O
DDI-DrugBank.d73.s8|40-45|ISIS-2|O
DDI-DrugBank.d73.s8|46-46|,|O
DDI-DrugBank.d73.s8|48-56|currently|O
DDI-DrugBank.d73.s8|58-59|do|O
DDI-DrugBank.d73.s8|61-63|not|O
DDI-DrugBank.d73.s8|65-71|suggest|O
DDI-DrugBank.d73.s8|73-75|any|O
DDI-DrugBank.d73.s8|77-84|clinical|O
DDI-DrugBank.d73.s8|86-96|interaction|O
DDI-DrugBank.d73.s8|98-104|between|O
DDI-DrugBank.d73.s8|106-112|aspirin|O
DDI-DrugBank.d73.s8|114-116|and|O
DDI-DrugBank.d73.s8|118-121|beta|O
DDI-DrugBank.d73.s8|123-130|blockers|O
DDI-DrugBank.d73.s8|132-133|in|O
DDI-DrugBank.d73.s8|135-137|the|O
DDI-DrugBank.d73.s8|139-143|acute|O
DDI-DrugBank.d73.s8|145-154|myocardial|O
DDI-DrugBank.d73.s8|156-165|infarction|O
DDI-DrugBank.d73.s8|167-173|setting|O
DDI-DrugBank.d73.s8|174-174|.|O
DDI-DrugBank.d73.s9|0-4|While|O
DDI-DrugBank.d73.s9|6-11|taking|O
DDI-DrugBank.d73.s9|13-16|beta|O
DDI-DrugBank.d73.s9|18-25|blockers|O
DDI-DrugBank.d73.s9|26-26|,|O
DDI-DrugBank.d73.s9|28-35|patients|O
DDI-DrugBank.d73.s9|37-40|with|O
DDI-DrugBank.d73.s9|42-42|a|O
DDI-DrugBank.d73.s9|44-50|history|O
DDI-DrugBank.d73.s9|52-53|of|O
DDI-DrugBank.d73.s9|55-66|anaphylactic|O
DDI-DrugBank.d73.s9|68-75|reaction|O
DDI-DrugBank.d73.s9|77-78|to|O
DDI-DrugBank.d73.s9|80-80|a|O
DDI-DrugBank.d73.s9|82-88|variety|O
DDI-DrugBank.d73.s9|90-91|of|O
DDI-DrugBank.d73.s9|93-101|allergens|O
DDI-DrugBank.d73.s9|103-105|may|O
DDI-DrugBank.d73.s9|107-110|have|O
DDI-DrugBank.d73.s9|112-112|a|O
DDI-DrugBank.d73.s9|114-117|more|O
DDI-DrugBank.d73.s9|119-124|severe|O
DDI-DrugBank.d73.s9|126-133|reaction|O
DDI-DrugBank.d73.s9|135-136|on|O
DDI-DrugBank.d73.s9|138-145|repeated|O
DDI-DrugBank.d73.s9|147-155|challenge|O
DDI-DrugBank.d73.s9|156-156|,|O
DDI-DrugBank.d73.s9|158-163|either|O
DDI-DrugBank.d73.s9|165-174|accidental|O
DDI-DrugBank.d73.s9|175-175|,|O
DDI-DrugBank.d73.s9|177-186|diagnostic|O
DDI-DrugBank.d73.s9|188-189|or|O
DDI-DrugBank.d73.s9|191-201|therapeutic|O
DDI-DrugBank.d73.s9|202-202|.|O
DDI-DrugBank.d73.s10|0-3|Such|O
DDI-DrugBank.d73.s10|5-12|patients|O
DDI-DrugBank.d73.s10|14-16|may|O
DDI-DrugBank.d73.s10|18-19|be|O
DDI-DrugBank.d73.s10|21-32|unresponsive|O
DDI-DrugBank.d73.s10|34-35|to|O
DDI-DrugBank.d73.s10|37-39|the|O
DDI-DrugBank.d73.s10|41-45|usual|O
DDI-DrugBank.d73.s10|47-51|doses|O
DDI-DrugBank.d73.s10|53-54|of|O
DDI-DrugBank.d73.s10|56-66|epinephrine|O
DDI-DrugBank.d73.s10|68-71|used|O
DDI-DrugBank.d73.s10|73-74|to|O
DDI-DrugBank.d73.s10|76-80|treat|O
DDI-DrugBank.d73.s10|82-84|the|O
DDI-DrugBank.d73.s10|86-93|allergic|O
DDI-DrugBank.d73.s10|95-102|reaction|O
DDI-DrugBank.d73.s10|103-103|.|O
DDI-DrugBank.d489.s0|0-2|The|O
DDI-DrugBank.d489.s0|4-12|following|O
DDI-DrugBank.d489.s0|14-18|drugs|O
DDI-DrugBank.d489.s0|20-23|have|O
DDI-DrugBank.d489.s0|25-28|been|O
DDI-DrugBank.d489.s0|30-43|coadministered|O
DDI-DrugBank.d489.s0|45-48|with|O
DDI-DrugBank.d489.s0|50-56|Kerlone|O
DDI-DrugBank.d489.s0|58-60|and|O
DDI-DrugBank.d489.s0|62-65|have|O
DDI-DrugBank.d489.s0|67-69|not|O
DDI-DrugBank.d489.s0|71-77|altered|O
DDI-DrugBank.d489.s0|79-81|its|O
DDI-DrugBank.d489.s0|83-98|pharmacokinetics|O
DDI-DrugBank.d489.s0|99-99|:|O
DDI-DrugBank.d489.s0|101-110|cimetidine|O
DDI-DrugBank.d489.s0|111-111|,|O
DDI-DrugBank.d489.s0|113-122|nifedipine|O
DDI-DrugBank.d489.s0|123-123|,|O
DDI-DrugBank.d489.s0|125-138|chlorthalidone|O
DDI-DrugBank.d489.s0|139-139|,|O
DDI-DrugBank.d489.s0|141-143|and|O
DDI-DrugBank.d489.s0|145-163|hydrochlorothiazide|O
DDI-DrugBank.d489.s0|164-164|.|O
DDI-DrugBank.d489.s1|0-10|Concomitant|O
DDI-DrugBank.d489.s1|12-25|administration|O
DDI-DrugBank.d489.s1|27-28|of|O
DDI-DrugBank.d489.s1|30-36|Kerlone|O
DDI-DrugBank.d489.s1|38-41|with|O
DDI-DrugBank.d489.s1|43-45|the|O
DDI-DrugBank.d489.s1|47-50|oral|O
DDI-DrugBank.d489.s1|52-64|anticoagulant|O
DDI-DrugBank.d489.s1|66-73|warfarin|O
DDI-DrugBank.d489.s1|75-77|has|O
DDI-DrugBank.d489.s1|79-82|been|O
DDI-DrugBank.d489.s1|84-88|shown|O
DDI-DrugBank.d489.s1|90-92|not|O
DDI-DrugBank.d489.s1|94-95|to|O
DDI-DrugBank.d489.s1|97-106|potentiate|O
DDI-DrugBank.d489.s1|108-110|the|O
DDI-DrugBank.d489.s1|112-124|anticoagulant|O
DDI-DrugBank.d489.s1|126-131|effect|O
DDI-DrugBank.d489.s1|133-134|of|O
DDI-DrugBank.d489.s1|136-143|warfarin|O
DDI-DrugBank.d489.s1|144-144|.|O
DDI-DrugBank.d489.s2|0-22|Catecholamine-depleting|O
DDI-DrugBank.d489.s2|24-28|drugs|O
DDI-DrugBank.d489.s2|30-30|(|O
DDI-DrugBank.d489.s2|31-34|e.g.|O
DDI-DrugBank.d489.s2|35-35|,|O
DDI-DrugBank.d489.s2|37-45|reserpine|O
DDI-DrugBank.d489.s2|46-46|)|O
DDI-DrugBank.d489.s2|48-50|may|O
DDI-DrugBank.d489.s2|52-55|have|O
DDI-DrugBank.d489.s2|57-58|an|O
DDI-DrugBank.d489.s2|60-67|additive|O
DDI-DrugBank.d489.s2|69-74|effect|O
DDI-DrugBank.d489.s2|76-79|when|O
DDI-DrugBank.d489.s2|81-85|given|O
DDI-DrugBank.d489.s2|87-90|with|O
DDI-DrugBank.d489.s2|92-104|beta-blocking|O
DDI-DrugBank.d489.s2|106-111|agents|O
DDI-DrugBank.d489.s2|112-112|.|O
DDI-DrugBank.d489.s3|0-7|Patients|O
DDI-DrugBank.d489.s3|9-15|treated|O
DDI-DrugBank.d489.s3|17-20|with|O
DDI-DrugBank.d489.s3|22-22|a|O
DDI-DrugBank.d489.s3|24-38|beta-adrenergic|O
DDI-DrugBank.d489.s3|40-47|receptor|O
DDI-DrugBank.d489.s3|49-56|blocking|O
DDI-DrugBank.d489.s3|58-62|agent|O
DDI-DrugBank.d489.s3|64-67|plus|O
DDI-DrugBank.d489.s3|69-69|a|O
DDI-DrugBank.d489.s3|71-83|catecholamine|O
DDI-DrugBank.d489.s3|85-92|depletor|O
DDI-DrugBank.d489.s3|94-99|should|O
DDI-DrugBank.d489.s3|101-109|therefore|O
DDI-DrugBank.d489.s3|111-112|be|O
DDI-DrugBank.d489.s3|114-120|closely|O
DDI-DrugBank.d489.s3|122-129|observed|O
DDI-DrugBank.d489.s3|131-133|for|O
DDI-DrugBank.d489.s3|135-142|evidence|O
DDI-DrugBank.d489.s3|144-145|of|O
DDI-DrugBank.d489.s3|147-157|hypotension|O
DDI-DrugBank.d489.s3|159-160|or|O
DDI-DrugBank.d489.s3|162-167|marked|O
DDI-DrugBank.d489.s3|169-179|bradycardia|O
DDI-DrugBank.d489.s3|180-180|,|O
DDI-DrugBank.d489.s3|182-186|which|O
DDI-DrugBank.d489.s3|188-190|may|O
DDI-DrugBank.d489.s3|192-198|produce|O
DDI-DrugBank.d489.s3|200-206|vertigo|O
DDI-DrugBank.d489.s3|207-207|,|O
DDI-DrugBank.d489.s3|209-215|syncope|O
DDI-DrugBank.d489.s3|216-216|,|O
DDI-DrugBank.d489.s3|218-219|or|O
DDI-DrugBank.d489.s3|221-228|postural|O
DDI-DrugBank.d489.s3|230-240|hypotension|O
DDI-DrugBank.d489.s3|241-241|.|O
DDI-DrugBank.d489.s4|0-5|Should|O
DDI-DrugBank.d489.s4|7-8|it|O
DDI-DrugBank.d489.s4|10-11|be|O
DDI-DrugBank.d489.s4|13-19|decided|O
DDI-DrugBank.d489.s4|21-22|to|O
DDI-DrugBank.d489.s4|24-34|discontinue|O
DDI-DrugBank.d489.s4|36-42|therapy|O
DDI-DrugBank.d489.s4|44-45|in|O
DDI-DrugBank.d489.s4|47-54|patients|O
DDI-DrugBank.d489.s4|56-64|receiving|O
DDI-DrugBank.d489.s4|66-78|beta-blockers|O
DDI-DrugBank.d489.s4|80-82|and|O
DDI-DrugBank.d489.s4|84-92|clonidine|O
DDI-DrugBank.d489.s4|94-105|concurrently|O
DDI-DrugBank.d489.s4|106-106|,|O
DDI-DrugBank.d489.s4|108-110|the|O
DDI-DrugBank.d489.s4|112-123|beta-blocker|O
DDI-DrugBank.d489.s4|125-130|should|O
DDI-DrugBank.d489.s4|132-133|be|O
DDI-DrugBank.d489.s4|135-146|discontinued|O
DDI-DrugBank.d489.s4|148-153|slowly|O
DDI-DrugBank.d489.s4|155-158|over|O
DDI-DrugBank.d489.s4|160-166|several|O
DDI-DrugBank.d489.s4|168-171|days|O
DDI-DrugBank.d489.s4|173-178|before|O
DDI-DrugBank.d489.s4|180-182|the|O
DDI-DrugBank.d489.s4|184-190|gradual|O
DDI-DrugBank.d489.s4|192-201|withdrawal|O
DDI-DrugBank.d489.s4|203-204|of|O
DDI-DrugBank.d489.s4|206-214|clonidine|O
DDI-DrugBank.d489.s4|215-215|.|O
DDI-DrugBank.d489.s5|0-9|Literature|O
DDI-DrugBank.d489.s5|11-17|reports|O
DDI-DrugBank.d489.s5|19-25|suggest|O
DDI-DrugBank.d489.s5|27-30|that|O
DDI-DrugBank.d489.s5|32-35|oral|O
DDI-DrugBank.d489.s5|37-43|calcium|O
DDI-DrugBank.d489.s5|45-55|antagonists|O
DDI-DrugBank.d489.s5|57-59|may|O
DDI-DrugBank.d489.s5|61-62|be|O
DDI-DrugBank.d489.s5|64-67|used|O
DDI-DrugBank.d489.s5|69-70|in|O
DDI-DrugBank.d489.s5|72-82|combination|O
DDI-DrugBank.d489.s5|84-87|with|O
DDI-DrugBank.d489.s5|89-103|beta-adrenergic|O
DDI-DrugBank.d489.s5|105-112|blocking|O
DDI-DrugBank.d489.s5|114-119|agents|O
DDI-DrugBank.d489.s5|121-124|when|O
DDI-DrugBank.d489.s5|126-130|heart|O
DDI-DrugBank.d489.s5|132-139|function|O
DDI-DrugBank.d489.s5|141-142|is|O
DDI-DrugBank.d489.s5|144-149|normal|O
DDI-DrugBank.d489.s5|150-150|,|O
DDI-DrugBank.d489.s5|152-154|but|O
DDI-DrugBank.d489.s5|156-161|should|O
DDI-DrugBank.d489.s5|163-164|be|O
DDI-DrugBank.d489.s5|166-172|avoided|O
DDI-DrugBank.d489.s5|174-175|in|O
DDI-DrugBank.d489.s5|177-184|patients|O
DDI-DrugBank.d489.s5|186-189|with|O
DDI-DrugBank.d489.s5|191-198|impaired|O
DDI-DrugBank.d489.s5|200-206|cardiac|O
DDI-DrugBank.d489.s5|208-215|function|O
DDI-DrugBank.d489.s5|216-216|.|O
DDI-DrugBank.d489.s6|0-10|Hypotension|O
DDI-DrugBank.d489.s6|11-11|,|O
DDI-DrugBank.d489.s6|13-14|AV|O
DDI-DrugBank.d489.s6|16-25|conduction|O
DDI-DrugBank.d489.s6|27-38|disturbances|O
DDI-DrugBank.d489.s6|39-39|,|O
DDI-DrugBank.d489.s6|41-43|and|O
DDI-DrugBank.d489.s6|45-48|left|O
DDI-DrugBank.d489.s6|50-60|ventricular|O
DDI-DrugBank.d489.s6|62-68|failure|O
DDI-DrugBank.d489.s6|70-73|have|O
DDI-DrugBank.d489.s6|75-78|been|O
DDI-DrugBank.d489.s6|80-87|reported|O
DDI-DrugBank.d489.s6|89-90|in|O
DDI-DrugBank.d489.s6|92-95|some|O
DDI-DrugBank.d489.s6|97-104|patients|O
DDI-DrugBank.d489.s6|106-114|receiving|O
DDI-DrugBank.d489.s6|116-130|beta-adrenergic|O
DDI-DrugBank.d489.s6|132-139|blocking|O
DDI-DrugBank.d489.s6|141-146|agents|O
DDI-DrugBank.d489.s6|148-151|when|O
DDI-DrugBank.d489.s6|153-154|an|O
DDI-DrugBank.d489.s6|156-159|oral|O
DDI-DrugBank.d489.s6|161-167|calcium|O
DDI-DrugBank.d489.s6|169-178|antagonist|O
DDI-DrugBank.d489.s6|180-182|was|O
DDI-DrugBank.d489.s6|184-188|added|O
DDI-DrugBank.d489.s6|190-191|to|O
DDI-DrugBank.d489.s6|193-195|the|O
DDI-DrugBank.d489.s6|197-205|treatment|O
DDI-DrugBank.d489.s6|207-213|regimen|O
DDI-DrugBank.d489.s6|214-214|.|O
DDI-DrugBank.d489.s7|0-10|Hypotension|O
DDI-DrugBank.d489.s7|12-14|was|O
DDI-DrugBank.d489.s7|16-19|more|O
DDI-DrugBank.d489.s7|21-26|likely|O
DDI-DrugBank.d489.s7|28-29|to|O
DDI-DrugBank.d489.s7|31-35|occur|O
DDI-DrugBank.d489.s7|37-38|if|O
DDI-DrugBank.d489.s7|40-42|the|O
DDI-DrugBank.d489.s7|44-50|calcium|O
DDI-DrugBank.d489.s7|52-61|antagonist|O
DDI-DrugBank.d489.s7|63-66|were|O
DDI-DrugBank.d489.s7|68-68|a|O
DDI-DrugBank.d489.s7|70-84|dihydropyridine|O
DDI-DrugBank.d489.s7|86-95|derivative|O
DDI-DrugBank.d489.s7|96-96|,|O
DDI-DrugBank.d489.s7|98-101|e.g.|O
DDI-DrugBank.d489.s7|102-102|,|O
DDI-DrugBank.d489.s7|104-113|nifedipine|O
DDI-DrugBank.d489.s7|114-114|,|O
DDI-DrugBank.d489.s7|116-120|while|O
DDI-DrugBank.d489.s7|122-125|left|O
DDI-DrugBank.d489.s7|127-137|ventricular|O
DDI-DrugBank.d489.s7|139-145|failure|O
DDI-DrugBank.d489.s7|147-149|and|O
DDI-DrugBank.d489.s7|151-152|AV|O
DDI-DrugBank.d489.s7|154-163|conduction|O
DDI-DrugBank.d489.s7|165-176|disturbances|O
DDI-DrugBank.d489.s7|177-177|,|O
DDI-DrugBank.d489.s7|179-187|including|O
DDI-DrugBank.d489.s7|189-196|complete|O
DDI-DrugBank.d489.s7|198-202|heart|O
DDI-DrugBank.d489.s7|204-208|block|O
DDI-DrugBank.d489.s7|209-209|,|O
DDI-DrugBank.d489.s7|211-214|were|O
DDI-DrugBank.d489.s7|216-219|more|O
DDI-DrugBank.d489.s7|221-226|likely|O
DDI-DrugBank.d489.s7|228-229|to|O
DDI-DrugBank.d489.s7|231-235|occur|O
DDI-DrugBank.d489.s7|237-240|with|O
DDI-DrugBank.d489.s7|242-247|either|O
DDI-DrugBank.d489.s7|249-257|verapamil|O
DDI-DrugBank.d489.s7|259-260|or|O
DDI-DrugBank.d489.s7|262-270|diltiazem|O
DDI-DrugBank.d489.s7|271-271|.|O
DDI-DrugBank.d489.s8|0-3|Risk|O
DDI-DrugBank.d489.s8|5-6|of|O
DDI-DrugBank.d489.s8|8-19|Anaphylactic|O
DDI-DrugBank.d489.s8|21-28|Reaction|O
DDI-DrugBank.d489.s8|29-29|:|O
DDI-DrugBank.d489.s8|31-38|Although|O
DDI-DrugBank.d489.s8|40-41|it|O
DDI-DrugBank.d489.s8|43-44|is|O
DDI-DrugBank.d489.s8|46-50|known|O
DDI-DrugBank.d489.s8|52-55|that|O
DDI-DrugBank.d489.s8|57-64|patients|O
DDI-DrugBank.d489.s8|66-67|on|O
DDI-DrugBank.d489.s8|69-81|beta-blockers|O
DDI-DrugBank.d489.s8|83-85|may|O
DDI-DrugBank.d489.s8|87-88|be|O
DDI-DrugBank.d489.s8|90-99|refractory|O
DDI-DrugBank.d489.s8|101-102|to|O
DDI-DrugBank.d489.s8|104-114|epinephrine|O
DDI-DrugBank.d489.s8|116-117|in|O
DDI-DrugBank.d489.s8|119-121|the|O
DDI-DrugBank.d489.s8|123-131|treatment|O
DDI-DrugBank.d489.s8|133-134|of|O
DDI-DrugBank.d489.s8|136-147|anaphylactic|O
DDI-DrugBank.d489.s8|149-153|shock|O
DDI-DrugBank.d489.s8|154-154|,|O
DDI-DrugBank.d489.s8|156-168|beta-blockers|O
DDI-DrugBank.d489.s8|170-172|can|O
DDI-DrugBank.d489.s8|173-173|,|O
DDI-DrugBank.d489.s8|175-176|in|O
DDI-DrugBank.d489.s8|178-185|addition|O
DDI-DrugBank.d489.s8|186-186|,|O
DDI-DrugBank.d489.s8|188-196|interfere|O
DDI-DrugBank.d489.s8|198-201|with|O
DDI-DrugBank.d489.s8|203-205|the|O
DDI-DrugBank.d489.s8|207-216|modulation|O
DDI-DrugBank.d489.s8|218-219|of|O
DDI-DrugBank.d489.s8|221-228|allergic|O
DDI-DrugBank.d489.s8|230-237|reaction|O
DDI-DrugBank.d489.s8|239-241|and|O
DDI-DrugBank.d489.s8|243-246|lead|O
DDI-DrugBank.d489.s8|248-249|to|O
DDI-DrugBank.d489.s8|251-252|an|O
DDI-DrugBank.d489.s8|254-262|increased|O
DDI-DrugBank.d489.s8|264-271|severity|O
DDI-DrugBank.d489.s8|273-278|and/or|O
DDI-DrugBank.d489.s8|280-288|frequency|O
DDI-DrugBank.d489.s8|290-291|of|O
DDI-DrugBank.d489.s8|293-299|attacks|O
DDI-DrugBank.d489.s8|300-300|.|O
DDI-DrugBank.d489.s9|0-5|Severe|O
DDI-DrugBank.d489.s9|7-14|allergic|O
DDI-DrugBank.d489.s9|16-24|reactions|O
DDI-DrugBank.d489.s9|26-34|including|O
DDI-DrugBank.d489.s9|36-46|anaphylaxis|O
DDI-DrugBank.d489.s9|48-51|have|O
DDI-DrugBank.d489.s9|53-56|been|O
DDI-DrugBank.d489.s9|58-65|reported|O
DDI-DrugBank.d489.s9|67-68|in|O
DDI-DrugBank.d489.s9|70-77|patients|O
DDI-DrugBank.d489.s9|79-85|exposed|O
DDI-DrugBank.d489.s9|87-88|to|O
DDI-DrugBank.d489.s9|90-90|a|O
DDI-DrugBank.d489.s9|92-98|variety|O
DDI-DrugBank.d489.s9|100-101|of|O
DDI-DrugBank.d489.s9|103-111|allergens|O
DDI-DrugBank.d489.s9|113-118|either|O
DDI-DrugBank.d489.s9|120-121|by|O
DDI-DrugBank.d489.s9|123-130|repeated|O
DDI-DrugBank.d489.s9|132-140|challenge|O
DDI-DrugBank.d489.s9|141-141|,|O
DDI-DrugBank.d489.s9|143-144|or|O
DDI-DrugBank.d489.s9|146-155|accidental|O
DDI-DrugBank.d489.s9|157-163|contact|O
DDI-DrugBank.d489.s9|164-164|,|O
DDI-DrugBank.d489.s9|166-168|and|O
DDI-DrugBank.d489.s9|170-173|with|O
DDI-DrugBank.d489.s9|175-184|diagnostic|O
DDI-DrugBank.d489.s9|186-187|or|O
DDI-DrugBank.d489.s9|189-199|therapeutic|O
DDI-DrugBank.d489.s9|201-206|agents|O
DDI-DrugBank.d489.s9|208-212|while|O
DDI-DrugBank.d489.s9|214-222|receiving|O
DDI-DrugBank.d489.s9|224-236|beta-blockers|O
DDI-DrugBank.d489.s9|237-237|.|O
DDI-DrugBank.d489.s10|0-3|Such|O
DDI-DrugBank.d489.s10|5-12|patients|O
DDI-DrugBank.d489.s10|14-16|may|O
DDI-DrugBank.d489.s10|18-19|be|O
DDI-DrugBank.d489.s10|21-32|unresponsive|O
DDI-DrugBank.d489.s10|34-35|to|O
DDI-DrugBank.d489.s10|37-39|the|O
DDI-DrugBank.d489.s10|41-45|usual|O
DDI-DrugBank.d489.s10|47-51|doses|O
DDI-DrugBank.d489.s10|53-54|of|O
DDI-DrugBank.d489.s10|56-66|epinephrine|O
DDI-DrugBank.d489.s10|68-71|used|O
DDI-DrugBank.d489.s10|73-74|to|O
DDI-DrugBank.d489.s10|76-80|treat|O
DDI-DrugBank.d489.s10|82-89|allergic|O
DDI-DrugBank.d489.s10|91-98|reaction|O
DDI-DrugBank.d489.s10|99-99|.|O
DDI-DrugBank.d439.s0|0-12|Corticotropin|O
DDI-DrugBank.d439.s0|14-16|may|O
DDI-DrugBank.d439.s0|18-27|accentuate|O
DDI-DrugBank.d439.s0|29-31|the|O
DDI-DrugBank.d439.s0|33-43|electrolyte|O
DDI-DrugBank.d439.s0|45-48|loss|O
DDI-DrugBank.d439.s0|50-59|associated|O
DDI-DrugBank.d439.s0|61-64|with|O
DDI-DrugBank.d439.s0|66-73|diuretic|O
DDI-DrugBank.d439.s0|75-81|therapy|O
DDI-DrugBank.d439.s0|82-82|.|O
DDI-MedLine.d74.s0|0-8|Responses|O
DDI-MedLine.d74.s0|10-11|to|O
DDI-MedLine.d74.s0|13-20|arginine|O
DDI-MedLine.d74.s0|22-23|of|O
DDI-MedLine.d74.s0|25-27|the|O
DDI-MedLine.d74.s0|29-36|perfused|O
DDI-MedLine.d74.s0|38-45|pancreas|O
DDI-MedLine.d74.s0|47-48|of|O
DDI-MedLine.d74.s0|50-52|the|O
DDI-MedLine.d74.s0|54-64|genetically|O
DDI-MedLine.d74.s0|66-73|diabetic|O
DDI-MedLine.d74.s0|75-81|Chinese|O
DDI-MedLine.d74.s0|83-89|hamster|O
DDI-MedLine.d74.s0|90-90|.|O
DDI-MedLine.d74.s1|0-9|Nonketotic|O
DDI-MedLine.d74.s1|10-10|,|O
DDI-MedLine.d74.s1|12-22|genetically|O
DDI-MedLine.d74.s1|24-31|diabetic|O
DDI-MedLine.d74.s1|33-38|Cinese|O
DDI-MedLine.d74.s1|40-47|hamsters|O
DDI-MedLine.d74.s1|49-52|show|O
DDI-MedLine.d74.s1|54-62|subnormal|O
DDI-MedLine.d74.s1|64-73|pancreatic|O
DDI-MedLine.d74.s1|75-81|insulin|O
DDI-MedLine.d74.s1|83-89|release|O
DDI-MedLine.d74.s1|91-93|and|O
DDI-MedLine.d74.s1|95-102|impaired|O
DDI-MedLine.d74.s1|104-114|suppression|O
DDI-MedLine.d74.s1|116-117|of|O
DDI-MedLine.d74.s1|119-126|glucagon|O
DDI-MedLine.d74.s1|128-129|in|O
DDI-MedLine.d74.s1|131-138|response|O
DDI-MedLine.d74.s1|140-141|to|O
DDI-MedLine.d74.s1|143-149|glucose|O
DDI-MedLine.d74.s1|150-150|.|O
DDI-MedLine.d74.s2|0-1|To|O
DDI-MedLine.d74.s2|3-7|study|O
DDI-MedLine.d74.s2|9-11|the|O
DDI-MedLine.d74.s2|13-22|pancreatic|O
DDI-MedLine.d74.s2|24-30|effects|O
DDI-MedLine.d74.s2|32-33|of|O
DDI-MedLine.d74.s2|35-39|other|O
DDI-MedLine.d74.s2|41-46|agents|O
DDI-MedLine.d74.s2|47-47|,|O
DDI-MedLine.d74.s2|49-55|dynamic|O
DDI-MedLine.d74.s2|57-63|insulin|O
DDI-MedLine.d74.s2|65-67|and|O
DDI-MedLine.d74.s2|69-76|glucagon|O
DDI-MedLine.d74.s2|78-84|release|O
DDI-MedLine.d74.s2|86-88|was|O
DDI-MedLine.d74.s2|90-97|measured|O
DDI-MedLine.d74.s2|99-102|from|O
DDI-MedLine.d74.s2|104-106|the|O
DDI-MedLine.d74.s2|108-109|in|O
DDI-MedLine.d74.s2|111-115|vitro|O
DDI-MedLine.d74.s2|117-124|perfused|O
DDI-MedLine.d74.s2|126-135|pancreases|O
DDI-MedLine.d74.s2|137-138|of|O
DDI-MedLine.d74.s2|140-145|normal|O
DDI-MedLine.d74.s2|147-149|and|O
DDI-MedLine.d74.s2|151-158|diabetic|O
DDI-MedLine.d74.s2|160-166|Chinese|O
DDI-MedLine.d74.s2|168-175|hamsters|O
DDI-MedLine.d74.s2|177-178|in|O
DDI-MedLine.d74.s2|180-187|response|O
DDI-MedLine.d74.s2|189-190|to|O
DDI-MedLine.d74.s2|192-198|various|O
DDI-MedLine.d74.s2|200-211|combinations|O
DDI-MedLine.d74.s2|213-214|of|O
DDI-MedLine.d74.s2|216-223|arginine|O
DDI-MedLine.d74.s2|225-225|(|O
DDI-MedLine.d74.s2|226-229|20mM|O
DDI-MedLine.d74.s2|230-230|)|O
DDI-MedLine.d74.s2|231-231|,|O
DDI-MedLine.d74.s2|233-239|glucose|O
DDI-MedLine.d74.s2|241-241|(|O
DDI-MedLine.d74.s2|242-244|100|O
DDI-MedLine.d74.s2|246-247|or|O
DDI-MedLine.d74.s2|249-251|150|O
DDI-MedLine.d74.s2|253-255|mg.|O
DDI-MedLine.d74.s2|257-259|per|O
DDI-MedLine.d74.s2|261-263|100|O
DDI-MedLine.d74.s2|265-267|ml.|O
DDI-MedLine.d74.s2|268-268|)|O
DDI-MedLine.d74.s2|269-269|,|O
DDI-MedLine.d74.s2|271-273|and|O
DDI-MedLine.d74.s2|275-286|theophylline|O
DDI-MedLine.d74.s2|288-288|(|O
DDI-MedLine.d74.s2|289-290|10|O
DDI-MedLine.d74.s2|292-293|mM|O
DDI-MedLine.d74.s2|294-294|)|O
DDI-MedLine.d74.s2|295-295|.|O
DDI-MedLine.d74.s3|0-11|Theophylline|O
DDI-MedLine.d74.s3|13-17|alone|O
DDI-MedLine.d74.s3|19-24|caused|O
DDI-MedLine.d74.s3|26-34|identical|O
DDI-MedLine.d74.s3|36-42|insulin|O
DDI-MedLine.d74.s3|44-46|and|O
DDI-MedLine.d74.s3|48-55|glucagon|O
DDI-MedLine.d74.s3|57-63|release|O
DDI-MedLine.d74.s3|65-66|in|O
DDI-MedLine.d74.s3|68-76|diabetics|O
DDI-MedLine.d74.s3|78-80|and|O
DDI-MedLine.d74.s3|82-88|normals|O
DDI-MedLine.d74.s3|89-89|.|O
DDI-MedLine.d74.s4|0-6|Glucose|O
DDI-MedLine.d74.s4|7-7|,|O
DDI-MedLine.d74.s4|9-13|alone|O
DDI-MedLine.d74.s4|15-17|and|O
DDI-MedLine.d74.s4|19-20|in|O
DDI-MedLine.d74.s4|22-24|the|O
DDI-MedLine.d74.s4|26-33|presence|O
DDI-MedLine.d74.s4|35-36|of|O
DDI-MedLine.d74.s4|38-49|theophylline|O
DDI-MedLine.d74.s4|50-50|,|O
DDI-MedLine.d74.s4|52-57|caused|O
DDI-MedLine.d74.s4|59-67|subnormal|O
DDI-MedLine.d74.s4|69-75|insulin|O
DDI-MedLine.d74.s4|77-83|release|O
DDI-MedLine.d74.s4|85-87|and|O
DDI-MedLine.d74.s4|89-92|less|O
DDI-MedLine.d74.s4|94-104|suppression|O
DDI-MedLine.d74.s4|106-107|of|O
DDI-MedLine.d74.s4|109-116|glucagon|O
DDI-MedLine.d74.s4|118-124|release|O
DDI-MedLine.d74.s4|126-127|in|O
DDI-MedLine.d74.s4|129-131|the|O
DDI-MedLine.d74.s4|133-142|diabectics|O
DDI-MedLine.d74.s4|144-147|than|O
DDI-MedLine.d74.s4|149-150|in|O
DDI-MedLine.d74.s4|152-154|the|O
DDI-MedLine.d74.s4|156-162|normals|O
DDI-MedLine.d74.s4|163-163|.|O
DDI-MedLine.d74.s5|0-7|Arginine|O
DDI-MedLine.d74.s5|8-8|,|O
DDI-MedLine.d74.s5|10-11|in|O
DDI-MedLine.d74.s5|13-15|the|O
DDI-MedLine.d74.s5|17-24|presence|O
DDI-MedLine.d74.s5|26-27|of|O
DDI-MedLine.d74.s5|29-35|glucose|O
DDI-MedLine.d74.s5|37-39|and|O
DDI-MedLine.d74.s5|41-52|theophylline|O
DDI-MedLine.d74.s5|53-53|,|O
DDI-MedLine.d74.s5|55-60|caused|O
DDI-MedLine.d74.s5|62-70|excessive|O
DDI-MedLine.d74.s5|72-79|glucagon|O
DDI-MedLine.d74.s5|81-87|release|O
DDI-MedLine.d74.s5|89-91|but|O
DDI-MedLine.d74.s5|93-98|nearly|O
DDI-MedLine.d74.s5|100-105|normal|O
DDI-MedLine.d74.s5|107-113|insulin|O
DDI-MedLine.d74.s5|115-121|release|O
DDI-MedLine.d74.s5|123-124|in|O
DDI-MedLine.d74.s5|126-128|the|O
DDI-MedLine.d74.s5|130-138|diabetics|O
DDI-MedLine.d74.s5|139-139|.|O
DDI-MedLine.d74.s6|0-7|Arginine|O
DDI-MedLine.d74.s6|8-8|,|O
DDI-MedLine.d74.s6|10-11|in|O
DDI-MedLine.d74.s6|13-15|the|O
DDI-MedLine.d74.s6|17-23|absence|O
DDI-MedLine.d74.s6|25-26|of|O
DDI-MedLine.d74.s6|28-34|glucose|O
DDI-MedLine.d74.s6|36-37|or|O
DDI-MedLine.d74.s6|39-50|theophylline|O
DDI-MedLine.d74.s6|51-51|,|O
DDI-MedLine.d74.s6|53-58|caused|O
DDI-MedLine.d74.s6|60-68|excessive|O
DDI-MedLine.d74.s6|70-77|glucagon|O
DDI-MedLine.d74.s6|79-85|release|O
DDI-MedLine.d74.s6|87-88|in|O
DDI-MedLine.d74.s6|90-92|the|O
DDI-MedLine.d74.s6|94-102|diabetics|O
DDI-MedLine.d74.s6|104-106|and|O
DDI-MedLine.d74.s6|108-119|undetectable|O
DDI-MedLine.d74.s6|121-127|insulin|O
DDI-MedLine.d74.s6|129-135|release|O
DDI-MedLine.d74.s6|137-138|in|O
DDI-MedLine.d74.s6|140-145|either|O
DDI-MedLine.d74.s6|147-155|diabetics|O
DDI-MedLine.d74.s6|157-158|or|O
DDI-MedLine.d74.s6|160-166|normals|O
DDI-MedLine.d74.s6|167-167|.|O
DDI-MedLine.d74.s7|0-9|Pancreatic|O
DDI-MedLine.d74.s7|11-17|content|O
DDI-MedLine.d74.s7|19-23|after|O
DDI-MedLine.d74.s7|25-33|perfusion|O
DDI-MedLine.d74.s7|35-37|did|O
DDI-MedLine.d74.s7|39-41|not|O
DDI-MedLine.d74.s7|43-51|correlate|O
DDI-MedLine.d74.s7|53-56|with|O
DDI-MedLine.d74.s7|58-64|release|O
DDI-MedLine.d74.s7|66-71|during|O
DDI-MedLine.d74.s7|73-81|perfusion|O
DDI-MedLine.d74.s7|82-82|.|O
DDI-MedLine.d74.s8|0-7|Infusion|O
DDI-MedLine.d74.s8|9-10|of|O
DDI-MedLine.d74.s8|12-19|arginine|O
DDI-MedLine.d74.s8|21-25|alone|O
DDI-MedLine.d74.s8|27-34|markedly|O
DDI-MedLine.d74.s8|36-44|decreased|O
DDI-MedLine.d74.s8|46-48|the|O
DDI-MedLine.d74.s8|50-55|amount|O
DDI-MedLine.d74.s8|57-58|of|O
DDI-MedLine.d74.s8|60-70|extractable|O
DDI-MedLine.d74.s8|72-81|pancreatic|O
DDI-MedLine.d74.s8|83-89|insulin|O
DDI-MedLine.d74.s8|91-93|and|O
DDI-MedLine.d74.s8|95-102|glucagon|O
DDI-MedLine.d74.s8|103-103|.|O
DDI-MedLine.d74.s9|0-4|These|O
DDI-MedLine.d74.s9|6-12|results|O
DDI-MedLine.d74.s9|14-21|indicate|O
DDI-MedLine.d74.s9|23-26|that|O
DDI-MedLine.d74.s9|28-30|the|O
DDI-MedLine.d74.s9|32-41|pancreatic|O
DDI-MedLine.d74.s9|43-47|alpha|O
DDI-MedLine.d74.s9|49-52|cell|O
DDI-MedLine.d74.s9|54-55|of|O
DDI-MedLine.d74.s9|57-59|the|O
DDI-MedLine.d74.s9|61-68|diabetic|O
DDI-MedLine.d74.s9|70-76|Chinese|O
DDI-MedLine.d74.s9|78-84|hamster|O
DDI-MedLine.d74.s9|86-93|responds|O
DDI-MedLine.d74.s9|95-105|excessively|O
DDI-MedLine.d74.s9|107-108|to|O
DDI-MedLine.d74.s9|110-117|arginine|O
DDI-MedLine.d74.s9|118-118|,|O
DDI-MedLine.d74.s9|120-121|as|O
DDI-MedLine.d74.s9|123-124|is|O
DDI-MedLine.d74.s9|126-129|seen|O
DDI-MedLine.d74.s9|131-132|in|O
DDI-MedLine.d74.s9|134-136|the|O
DDI-MedLine.d74.s9|138-142|human|O
DDI-MedLine.d74.s9|144-151|diabetic|O
DDI-MedLine.d74.s9|152-152|.|O
DDI-MedLine.d74.s10|0-3|This|O
DDI-MedLine.d74.s10|5-10|defect|O
DDI-MedLine.d74.s10|12-13|is|O
DDI-MedLine.d74.s10|15-17|not|O
DDI-MedLine.d74.s10|19-25|related|O
DDI-MedLine.d74.s10|27-28|to|O
DDI-MedLine.d74.s10|30-34|acute|O
DDI-MedLine.d74.s10|36-42|insulin|O
DDI-MedLine.d74.s10|44-50|release|O
DDI-MedLine.d74.s10|52-53|or|O
DDI-MedLine.d74.s10|55-57|the|O
DDI-MedLine.d74.s10|59-66|presence|O
DDI-MedLine.d74.s10|68-69|of|O
DDI-MedLine.d74.s10|71-77|glucose|O
DDI-MedLine.d74.s10|78-78|.|O
DDI-MedLine.d74.s11|0-6|Further|O
DDI-MedLine.d74.s11|7-7|,|O
DDI-MedLine.d74.s11|9-13|these|O
DDI-MedLine.d74.s11|15-21|results|O
DDI-MedLine.d74.s11|23-29|confirm|O
DDI-MedLine.d74.s11|31-34|that|O
DDI-MedLine.d74.s11|36-38|the|O
DDI-MedLine.d74.s11|40-47|diabetic|O
DDI-MedLine.d74.s11|49-55|Chinese|O
DDI-MedLine.d74.s11|57-63|hamster|O
DDI-MedLine.d74.s11|64-65|'s|O
DDI-MedLine.d74.s11|67-71|alpha|O
DDI-MedLine.d74.s11|73-75|and|O
DDI-MedLine.d74.s11|77-80|beta|O
DDI-MedLine.d74.s11|82-86|cells|O
DDI-MedLine.d74.s11|88-94|respond|O
DDI-MedLine.d74.s11|96-103|normally|O
DDI-MedLine.d74.s11|105-106|to|O
DDI-MedLine.d74.s11|108-119|theophylline|O
DDI-MedLine.d74.s11|120-120|,|O
DDI-MedLine.d74.s11|122-124|but|O
DDI-MedLine.d74.s11|126-128|are|O
DDI-MedLine.d74.s11|130-139|relatively|O
DDI-MedLine.d74.s11|141-151|insensitive|O
DDI-MedLine.d74.s11|153-154|to|O
DDI-MedLine.d74.s11|156-162|glucose|O
DDI-MedLine.d74.s11|163-163|.|O
DDI-DrugBank.d715.s0|0-6|Caution|O
DDI-DrugBank.d715.s0|8-13|should|O
DDI-DrugBank.d715.s0|15-16|be|O
DDI-DrugBank.d715.s0|18-25|observed|O
DDI-DrugBank.d715.s0|27-28|in|O
DDI-DrugBank.d715.s0|30-42|administering|O
DDI-DrugBank.d715.s0|44-49|DEMSER|O
DDI-DrugBank.d715.s0|51-52|to|O
DDI-DrugBank.d715.s0|54-61|patients|O
DDI-DrugBank.d715.s0|63-71|receiving|O
DDI-DrugBank.d715.s0|73-86|phenothiazines|O
DDI-DrugBank.d715.s0|88-89|or|O
DDI-DrugBank.d715.s0|91-101|haloperidol|O
DDI-DrugBank.d715.s0|103-109|because|O
DDI-DrugBank.d715.s0|111-113|the|O
DDI-DrugBank.d715.s0|115-128|extrapyramidal|O
DDI-DrugBank.d715.s0|130-136|effects|O
DDI-DrugBank.d715.s0|138-139|of|O
DDI-DrugBank.d715.s0|141-145|these|O
DDI-DrugBank.d715.s0|147-151|drugs|O
DDI-DrugBank.d715.s0|153-155|can|O
DDI-DrugBank.d715.s0|157-158|be|O
DDI-DrugBank.d715.s0|160-167|expected|O
DDI-DrugBank.d715.s0|169-170|to|O
DDI-DrugBank.d715.s0|172-173|be|O
DDI-DrugBank.d715.s0|175-185|potentiated|O
DDI-DrugBank.d715.s0|187-188|by|O
DDI-DrugBank.d715.s0|190-199|inhibition|O
DDI-DrugBank.d715.s0|201-202|of|O
DDI-DrugBank.d715.s0|204-216|catecholamine|O
DDI-DrugBank.d715.s0|218-226|synthesis|O
DDI-DrugBank.d715.s0|227-227|.|O
DDI-DrugBank.d715.s1|0-9|Concurrent|O
DDI-DrugBank.d715.s1|11-13|use|O
DDI-DrugBank.d715.s1|15-16|of|O
DDI-DrugBank.d715.s1|18-23|DEMSER|O
DDI-DrugBank.d715.s1|25-28|with|O
DDI-DrugBank.d715.s1|30-36|alcohol|O
DDI-DrugBank.d715.s1|38-39|or|O
DDI-DrugBank.d715.s1|41-45|other|O
DDI-DrugBank.d715.s1|47-49|CNS|O
DDI-DrugBank.d715.s1|51-61|depressants|O
DDI-DrugBank.d715.s1|63-65|can|O
DDI-DrugBank.d715.s1|67-74|increase|O
DDI-DrugBank.d715.s1|76-80|their|O
DDI-DrugBank.d715.s1|82-89|sedative|O
DDI-DrugBank.d715.s1|91-97|effects|O
DDI-DrugBank.d715.s1|98-98|.|O
DDI-DrugBank.d454.s0|0-0|-|O
DDI-DrugBank.d454.s0|2-11|Lofexidine|O
DDI-DrugBank.d454.s0|13-15|may|O
DDI-DrugBank.d454.s0|17-23|enhance|O
DDI-DrugBank.d454.s0|25-27|the|O
DDI-DrugBank.d454.s0|29-31|CNS|O
DDI-DrugBank.d454.s0|33-42|depressive|O
DDI-DrugBank.d454.s0|44-50|effects|O
DDI-DrugBank.d454.s0|52-53|of|O
DDI-DrugBank.d454.s0|55-61|alcohol|O
DDI-DrugBank.d454.s0|62-62|,|O
DDI-DrugBank.d454.s0|64-75|barbiturates|O
DDI-DrugBank.d454.s0|77-79|and|O
DDI-DrugBank.d454.s0|81-85|other|O
DDI-DrugBank.d454.s0|87-95|sedatives|O
DDI-DrugBank.d454.s1|0-0|.|O
DDI-DrugBank.d454.s2|0-0|-|O
DDI-DrugBank.d454.s2|2-11|Lofexidine|O
DDI-DrugBank.d454.s2|13-15|may|O
DDI-DrugBank.d454.s2|17-23|enhance|O
DDI-DrugBank.d454.s2|25-27|the|O
DDI-DrugBank.d454.s2|29-35|effects|O
DDI-DrugBank.d454.s2|37-38|of|O
DDI-DrugBank.d454.s2|40-56|anti-hypertensive|O
DDI-DrugBank.d454.s2|58-61|drug|O
DDI-DrugBank.d454.s2|63-69|therapy|O
DDI-DrugBank.d454.s3|0-0|.|O
DDI-DrugBank.d454.s4|0-0|-|O
DDI-DrugBank.d454.s4|2-12|Concomitant|O
DDI-DrugBank.d454.s4|14-16|use|O
DDI-DrugBank.d454.s4|18-19|of|O
DDI-DrugBank.d454.s4|21-29|tricyclic|O
DDI-DrugBank.d454.s4|31-45|antidepressants|O
DDI-DrugBank.d454.s4|47-49|may|O
DDI-DrugBank.d454.s4|51-56|reduce|O
DDI-DrugBank.d454.s4|58-60|the|O
DDI-DrugBank.d454.s4|62-69|efficacy|O
DDI-DrugBank.d454.s4|71-72|of|O
DDI-DrugBank.d454.s4|74-83|lofexidine|O
DDI-DrugBank.d454.s4|84-84|.|O
DDI-DrugBank.d639.s0|0-16|Co-administration|O
DDI-DrugBank.d639.s0|18-19|of|O
DDI-DrugBank.d639.s0|21-26|SUTENT|O
DDI-DrugBank.d639.s0|28-31|with|O
DDI-DrugBank.d639.s0|33-38|strong|O
DDI-DrugBank.d639.s0|40-49|inhibitors|O
DDI-DrugBank.d639.s0|51-52|of|O
DDI-DrugBank.d639.s0|54-56|the|O
DDI-DrugBank.d639.s0|58-63|CYP3A4|O
DDI-DrugBank.d639.s0|65-70|family|O
DDI-DrugBank.d639.s0|72-72|(|O
DDI-DrugBank.d639.s0|73-76|e.g.|O
DDI-DrugBank.d639.s0|77-77|,|O
DDI-DrugBank.d639.s0|79-90|ketoconazole|O
DDI-DrugBank.d639.s0|91-91|,|O
DDI-DrugBank.d639.s0|93-104|itraconazole|O
DDI-DrugBank.d639.s0|105-105|,|O
DDI-DrugBank.d639.s0|107-120|clarithromycin|O
DDI-DrugBank.d639.s0|121-121|,|O
DDI-DrugBank.d639.s0|123-132|atazanavir|O
DDI-DrugBank.d639.s0|133-133|,|O
DDI-DrugBank.d639.s0|135-143|indinavir|O
DDI-DrugBank.d639.s0|144-144|,|O
DDI-DrugBank.d639.s0|146-155|nefazodone|O
DDI-DrugBank.d639.s0|156-156|,|O
DDI-DrugBank.d639.s0|158-167|nelfinavir|O
DDI-DrugBank.d639.s0|168-168|,|O
DDI-DrugBank.d639.s0|170-178|ritonavir|O
DDI-DrugBank.d639.s0|179-179|,|O
DDI-DrugBank.d639.s0|181-190|saquinavir|O
DDI-DrugBank.d639.s0|191-191|,|O
DDI-DrugBank.d639.s0|193-205|telithromycin|O
DDI-DrugBank.d639.s0|206-206|,|O
DDI-DrugBank.d639.s0|208-219|voriconizole|O
DDI-DrugBank.d639.s0|220-220|)|O
DDI-DrugBank.d639.s0|222-224|may|O
DDI-DrugBank.d639.s0|226-234|increases|O
DDI-DrugBank.d639.s0|236-244|sunitinib|O
DDI-DrugBank.d639.s0|246-259|concentrations|O
DDI-DrugBank.d639.s0|260-260|.|O
DDI-DrugBank.d639.s1|0-9|Grapefruit|O
DDI-DrugBank.d639.s1|11-13|may|O
DDI-DrugBank.d639.s1|15-18|also|O
DDI-DrugBank.d639.s1|20-27|increase|O
DDI-DrugBank.d639.s1|29-34|plasma|O
DDI-DrugBank.d639.s1|36-49|concentrations|O
DDI-DrugBank.d639.s1|51-52|of|O
DDI-DrugBank.d639.s1|54-59|SUTENT|O
DDI-DrugBank.d639.s1|60-60|.|O
DDI-DrugBank.d639.s2|0-16|Co-administration|O
DDI-DrugBank.d639.s2|18-19|of|O
DDI-DrugBank.d639.s2|21-26|SUTENT|O
DDI-DrugBank.d639.s2|28-31|with|O
DDI-DrugBank.d639.s2|33-40|inducers|O
DDI-DrugBank.d639.s2|42-43|of|O
DDI-DrugBank.d639.s2|45-47|the|O
DDI-DrugBank.d639.s2|49-54|CYP3A4|O
DDI-DrugBank.d639.s2|56-61|family|O
DDI-DrugBank.d639.s2|63-63|(|O
DDI-DrugBank.d639.s2|64-67|e.g.|O
DDI-DrugBank.d639.s2|68-68|,|O
DDI-DrugBank.d639.s2|70-82|dexamethasone|O
DDI-DrugBank.d639.s2|83-83|,|O
DDI-DrugBank.d639.s2|85-93|phenytoin|O
DDI-DrugBank.d639.s2|94-94|,|O
DDI-DrugBank.d639.s2|96-108|carbamazepine|O
DDI-DrugBank.d639.s2|109-109|,|O
DDI-DrugBank.d639.s2|111-118|rifampin|O
DDI-DrugBank.d639.s2|119-119|,|O
DDI-DrugBank.d639.s2|121-129|rifabutin|O
DDI-DrugBank.d639.s2|130-130|,|O
DDI-DrugBank.d639.s2|132-141|rifapentin|O
DDI-DrugBank.d639.s2|142-142|,|O
DDI-DrugBank.d639.s2|144-156|phenobarbital|O
DDI-DrugBank.d639.s2|157-157|,|O
DDI-DrugBank.d639.s2|159-161|St.|O
DDI-DrugBank.d639.s2|163-167|Johns|O
DDI-DrugBank.d639.s2|169-172|Wort|O
DDI-DrugBank.d639.s2|173-173|)|O
DDI-DrugBank.d639.s2|175-177|may|O
DDI-DrugBank.d639.s2|179-186|decrease|O
DDI-DrugBank.d639.s2|188-196|sunitinib|O
DDI-DrugBank.d639.s2|198-211|concentrations|O
DDI-DrugBank.d639.s2|212-212|.|O
DDI-DrugBank.d639.s3|0-1|St|O
DDI-DrugBank.d639.s3|2-2|.|O
DDI-DrugBank.d639.s4|0-4|Johns|O
DDI-DrugBank.d639.s4|6-9|Wort|O
DDI-DrugBank.d639.s4|11-13|may|O
DDI-DrugBank.d639.s4|15-22|decrease|O
DDI-DrugBank.d639.s4|24-29|SUTENT|O
DDI-DrugBank.d639.s4|31-36|plasma|O
DDI-DrugBank.d639.s4|38-51|concentrations|O
DDI-DrugBank.d639.s4|53-65|unpredictably|O
DDI-DrugBank.d639.s4|66-66|.|O
DDI-DrugBank.d639.s5|0-7|Patients|O
DDI-DrugBank.d639.s5|9-17|receiving|O
DDI-DrugBank.d639.s5|19-24|SUTENT|O
DDI-DrugBank.d639.s5|26-31|should|O
DDI-DrugBank.d639.s5|33-35|not|O
DDI-DrugBank.d639.s5|37-40|take|O
DDI-DrugBank.d639.s5|42-43|St|O
DDI-DrugBank.d639.s5|44-44|.|O
DDI-DrugBank.d639.s6|0-4|Johns|O
DDI-DrugBank.d639.s6|6-9|Wort|O
DDI-DrugBank.d639.s6|11-23|concomitantly|O
DDI-DrugBank.d639.s6|24-24|.|O
DDI-DrugBank.d639.s7|0-5|SUTENT|O
DDI-DrugBank.d639.s7|7-10|dose|O
DDI-DrugBank.d639.s7|12-23|modification|O
DDI-DrugBank.d639.s7|25-26|is|O
DDI-DrugBank.d639.s7|28-38|recommended|O
DDI-DrugBank.d639.s7|40-41|in|O
DDI-DrugBank.d639.s7|43-50|patients|O
DDI-DrugBank.d639.s7|52-56|using|O
DDI-DrugBank.d639.s7|58-68|concomitant|O
DDI-DrugBank.d639.s7|70-75|CYP3A4|O
DDI-DrugBank.d639.s7|77-86|inhibitors|O
DDI-DrugBank.d639.s7|88-89|or|O
DDI-DrugBank.d639.s7|91-98|inducers|O
DDI-DrugBank.d639.s7|99-99|.|O
DDI-DrugBank.d776.s0|0-9|Clinically|O
DDI-DrugBank.d776.s0|11-12|or|O
DDI-DrugBank.d776.s0|14-24|potentially|O
DDI-DrugBank.d776.s0|26-36|significant|O
DDI-DrugBank.d776.s0|38-41|drug|O
DDI-DrugBank.d776.s0|43-54|interactions|O
DDI-DrugBank.d776.s0|56-62|between|O
DDI-DrugBank.d776.s0|64-71|DIFLUCAN|O
DDI-DrugBank.d776.s0|73-75|and|O
DDI-DrugBank.d776.s0|77-79|the|O
DDI-DrugBank.d776.s0|81-89|following|O
DDI-DrugBank.d776.s0|91-104|agents/classes|O
DDI-DrugBank.d776.s0|106-109|have|O
DDI-DrugBank.d776.s0|111-114|been|O
DDI-DrugBank.d776.s0|116-123|observed|O
DDI-DrugBank.d776.s0|124-124|.|O
DDI-DrugBank.d776.s1|0-4|These|O
DDI-DrugBank.d776.s1|6-8|are|O
DDI-DrugBank.d776.s1|10-18|described|O
DDI-DrugBank.d776.s1|20-21|in|O
DDI-DrugBank.d776.s1|23-29|greater|O
DDI-DrugBank.d776.s1|31-36|detail|O
DDI-DrugBank.d776.s1|38-42|below|O
DDI-DrugBank.d776.s1|43-43|:|O
DDI-DrugBank.d776.s1|45-52|DIFLUCAN|O
DDI-DrugBank.d776.s1|54-56|and|O
DDI-DrugBank.d776.s1|58-60|the|O
DDI-DrugBank.d776.s1|62-70|following|O
DDI-DrugBank.d776.s1|72-85|agents/classes|O
DDI-DrugBank.d776.s1|87-90|have|O
DDI-DrugBank.d776.s1|92-95|been|O
DDI-DrugBank.d776.s1|97-104|observed|O
DDI-DrugBank.d776.s1|105-105|.|O
DDI-DrugBank.d776.s2|0-4|These|O
DDI-DrugBank.d776.s2|6-8|are|O
DDI-DrugBank.d776.s2|10-18|described|O
DDI-DrugBank.d776.s2|20-21|in|O
DDI-DrugBank.d776.s2|23-29|greater|O
DDI-DrugBank.d776.s2|31-36|detail|O
DDI-DrugBank.d776.s2|38-42|below|O
DDI-DrugBank.d776.s2|43-43|:|O
DDI-DrugBank.d776.s2|46-49|Oral|O
DDI-DrugBank.d776.s2|51-63|hypoglycemics|O
DDI-DrugBank.d776.s2|64-64|,|O
DDI-DrugBank.d776.s2|66-78|Coumarin-type|O
DDI-DrugBank.d776.s2|80-93|anticoagulants|O
DDI-DrugBank.d776.s2|94-94|,|O
DDI-DrugBank.d776.s2|96-104|Phenytoin|O
DDI-DrugBank.d776.s2|105-105|,|O
DDI-DrugBank.d776.s2|107-118|Cyclosporine|O
DDI-DrugBank.d776.s2|119-119|,|O
DDI-DrugBank.d776.s2|121-128|Rifampin|O
DDI-DrugBank.d776.s2|129-129|,|O
DDI-DrugBank.d776.s2|131-142|Theophylline|O
DDI-DrugBank.d776.s2|143-143|,|O
DDI-DrugBank.d776.s2|145-155|Terfenadine|O
DDI-DrugBank.d776.s2|156-156|,|O
DDI-DrugBank.d776.s2|158-166|Cisapride|O
DDI-DrugBank.d776.s2|167-167|,|O
DDI-DrugBank.d776.s2|169-178|Astemizole|O
DDI-DrugBank.d776.s2|179-179|,|O
DDI-DrugBank.d776.s2|181-189|Rifabutin|O
DDI-DrugBank.d776.s2|190-190|,|O
DDI-DrugBank.d776.s2|192-201|Tacrolimus|O
DDI-DrugBank.d776.s2|202-202|,|O
DDI-DrugBank.d776.s2|204-215|Short-acting|O
DDI-DrugBank.d776.s2|217-231|benzodiazepines|O
DDI-DrugBank.d776.s2|232-232|,|O
DDI-DrugBank.d776.s2|235-238|Oral|O
DDI-DrugBank.d776.s2|240-252|hypoglycemics|O
DDI-DrugBank.d776.s2|253-253|:|O
DDI-DrugBank.d776.s2|255-264|Clinically|O
DDI-DrugBank.d776.s2|266-276|significant|O
DDI-DrugBank.d776.s2|278-289|hypoglycemia|O
DDI-DrugBank.d776.s2|291-293|may|O
DDI-DrugBank.d776.s2|295-296|be|O
DDI-DrugBank.d776.s2|298-309|precipitated|O
DDI-DrugBank.d776.s2|311-312|by|O
DDI-DrugBank.d776.s2|314-316|the|O
DDI-DrugBank.d776.s2|318-320|use|O
DDI-DrugBank.d776.s2|322-323|of|O
DDI-DrugBank.d776.s2|325-332|DIFLUCAN|O
DDI-DrugBank.d776.s2|334-337|with|O
DDI-DrugBank.d776.s2|339-342|oral|O
DDI-DrugBank.d776.s2|344-355|hypoglycemic|O
DDI-DrugBank.d776.s2|357-362|agents|O
DDI-DrugBank.d776.s2|363-363|;|O
DDI-DrugBank.d776.s3|0-2|one|O
DDI-DrugBank.d776.s3|4-11|fatality|O
DDI-DrugBank.d776.s3|13-15|has|O
DDI-DrugBank.d776.s3|17-20|been|O
DDI-DrugBank.d776.s3|22-29|reported|O
DDI-DrugBank.d776.s3|31-34|from|O
DDI-DrugBank.d776.s3|36-47|hypoglycemia|O
DDI-DrugBank.d776.s3|49-50|in|O
DDI-DrugBank.d776.s3|52-62|association|O
DDI-DrugBank.d776.s3|64-67|with|O
DDI-DrugBank.d776.s3|69-76|combined|O
DDI-DrugBank.d776.s3|78-85|DIFLUCAN|O
DDI-DrugBank.d776.s3|87-89|and|O
DDI-DrugBank.d776.s3|91-99|glyburide|O
DDI-DrugBank.d776.s3|101-103|use|O
DDI-DrugBank.d776.s3|104-104|.|O
DDI-DrugBank.d776.s4|0-7|DIFLUCAN|O
DDI-DrugBank.d776.s4|9-15|reduces|O
DDI-DrugBank.d776.s4|17-19|the|O
DDI-DrugBank.d776.s4|21-30|metabolism|O
DDI-DrugBank.d776.s4|32-33|of|O
DDI-DrugBank.d776.s4|35-45|tolbutamide|O
DDI-DrugBank.d776.s4|46-46|,|O
DDI-DrugBank.d776.s4|48-56|glyburide|O
DDI-DrugBank.d776.s4|57-57|,|O
DDI-DrugBank.d776.s4|59-61|and|O
DDI-DrugBank.d776.s4|63-71|glipizide|O
DDI-DrugBank.d776.s4|73-75|and|O
DDI-DrugBank.d776.s4|77-85|increases|O
DDI-DrugBank.d776.s4|87-89|the|O
DDI-DrugBank.d776.s4|91-96|plasma|O
DDI-DrugBank.d776.s4|98-110|concentration|O
DDI-DrugBank.d776.s4|112-113|of|O
DDI-DrugBank.d776.s4|115-119|these|O
DDI-DrugBank.d776.s4|121-126|agents|O
DDI-DrugBank.d776.s4|127-127|.|O
DDI-DrugBank.d776.s5|0-3|When|O
DDI-DrugBank.d776.s5|5-12|DIFLUCAN|O
DDI-DrugBank.d776.s5|14-15|is|O
DDI-DrugBank.d776.s5|17-20|used|O
DDI-DrugBank.d776.s5|22-34|concomitantly|O
DDI-DrugBank.d776.s5|36-39|with|O
DDI-DrugBank.d776.s5|41-45|these|O
DDI-DrugBank.d776.s5|47-48|or|O
DDI-DrugBank.d776.s5|50-54|other|O
DDI-DrugBank.d776.s5|56-67|sulfonylurea|O
DDI-DrugBank.d776.s5|69-72|oral|O
DDI-DrugBank.d776.s5|74-85|hypoglycemic|O
DDI-DrugBank.d776.s5|87-92|agents|O
DDI-DrugBank.d776.s5|93-93|,|O
DDI-DrugBank.d776.s5|95-99|blood|O
DDI-DrugBank.d776.s5|101-107|glucose|O
DDI-DrugBank.d776.s5|109-122|concentrations|O
DDI-DrugBank.d776.s5|124-129|should|O
DDI-DrugBank.d776.s5|131-132|be|O
DDI-DrugBank.d776.s5|134-142|carefully|O
DDI-DrugBank.d776.s5|144-152|monitored|O
DDI-DrugBank.d776.s5|154-156|and|O
DDI-DrugBank.d776.s5|158-160|the|O
DDI-DrugBank.d776.s5|162-165|dose|O
DDI-DrugBank.d776.s5|167-168|of|O
DDI-DrugBank.d776.s5|170-172|the|O
DDI-DrugBank.d776.s5|174-185|sulfonylurea|O
DDI-DrugBank.d776.s5|187-192|should|O
DDI-DrugBank.d776.s5|194-195|be|O
DDI-DrugBank.d776.s5|197-204|adjusted|O
DDI-DrugBank.d776.s5|206-207|as|O
DDI-DrugBank.d776.s5|209-217|necessary|O
DDI-DrugBank.d776.s5|218-218|.|O
DDI-DrugBank.d776.s6|0-12|Coumarin-type|O
DDI-DrugBank.d776.s6|14-27|anticoagulants|O
DDI-DrugBank.d776.s6|28-28|:|O
DDI-DrugBank.d776.s6|30-40|Prothrombin|O
DDI-DrugBank.d776.s6|42-45|time|O
DDI-DrugBank.d776.s6|47-49|may|O
DDI-DrugBank.d776.s6|51-52|be|O
DDI-DrugBank.d776.s6|54-62|increased|O
DDI-DrugBank.d776.s6|64-65|in|O
DDI-DrugBank.d776.s6|67-74|patients|O
DDI-DrugBank.d776.s6|76-84|receiving|O
DDI-DrugBank.d776.s6|86-96|concomitant|O
DDI-DrugBank.d776.s6|98-105|DIFLUCAN|O
DDI-DrugBank.d776.s6|107-109|and|O
DDI-DrugBank.d776.s6|111-123|coumarin-type|O
DDI-DrugBank.d776.s6|125-138|anticoagulants|O
DDI-DrugBank.d776.s6|139-139|.|O
DDI-DrugBank.d776.s7|0-1|In|O
DDI-DrugBank.d776.s7|3-16|post-marketing|O
DDI-DrugBank.d776.s7|18-27|experience|O
DDI-DrugBank.d776.s7|28-28|,|O
DDI-DrugBank.d776.s7|30-31|as|O
DDI-DrugBank.d776.s7|33-36|with|O
DDI-DrugBank.d776.s7|38-42|other|O
DDI-DrugBank.d776.s7|44-48|azole|O
DDI-DrugBank.d776.s7|50-60|antifungals|O
DDI-DrugBank.d776.s7|61-61|,|O
DDI-DrugBank.d776.s7|63-70|bleeding|O
DDI-DrugBank.d776.s7|72-77|events|O
DDI-DrugBank.d776.s7|79-79|(|O
DDI-DrugBank.d776.s7|80-87|bruising|O
DDI-DrugBank.d776.s7|88-88|,|O
DDI-DrugBank.d776.s7|90-98|epistaxis|O
DDI-DrugBank.d776.s7|99-99|,|O
DDI-DrugBank.d776.s7|101-116|gastrointestinal|O
DDI-DrugBank.d776.s7|118-125|bleeding|O
DDI-DrugBank.d776.s7|126-126|,|O
DDI-DrugBank.d776.s7|128-136|hematuria|O
DDI-DrugBank.d776.s7|137-137|,|O
DDI-DrugBank.d776.s7|139-141|and|O
DDI-DrugBank.d776.s7|143-148|melena|O
DDI-DrugBank.d776.s7|149-149|)|O
DDI-DrugBank.d776.s7|151-154|have|O
DDI-DrugBank.d776.s7|156-159|been|O
DDI-DrugBank.d776.s7|161-168|reported|O
DDI-DrugBank.d776.s7|170-171|in|O
DDI-DrugBank.d776.s7|173-183|association|O
DDI-DrugBank.d776.s7|185-188|with|O
DDI-DrugBank.d776.s7|190-198|increases|O
DDI-DrugBank.d776.s7|200-201|in|O
DDI-DrugBank.d776.s7|203-213|prothrombin|O
DDI-DrugBank.d776.s7|215-218|time|O
DDI-DrugBank.d776.s7|220-221|in|O
DDI-DrugBank.d776.s7|223-230|patients|O
DDI-DrugBank.d776.s7|232-240|receiving|O
DDI-DrugBank.d776.s7|242-252|fluconazole|O
DDI-DrugBank.d776.s7|254-265|concurrently|O
DDI-DrugBank.d776.s7|267-270|with|O
DDI-DrugBank.d776.s7|272-279|warfarin|O
DDI-DrugBank.d776.s7|280-280|.|O
DDI-DrugBank.d776.s8|0-6|Careful|O
DDI-DrugBank.d776.s8|8-17|monitoring|O
DDI-DrugBank.d776.s8|19-20|of|O
DDI-DrugBank.d776.s8|22-32|prothrombin|O
DDI-DrugBank.d776.s8|34-37|time|O
DDI-DrugBank.d776.s8|39-40|in|O
DDI-DrugBank.d776.s8|42-49|patients|O
DDI-DrugBank.d776.s8|51-59|receiving|O
DDI-DrugBank.d776.s8|61-68|DIFLUCAN|O
DDI-DrugBank.d776.s8|70-72|and|O
DDI-DrugBank.d776.s8|74-86|coumarin-type|O
DDI-DrugBank.d776.s8|88-101|anticoagulants|O
DDI-DrugBank.d776.s8|103-104|is|O
DDI-DrugBank.d776.s8|106-116|recommended|O
DDI-DrugBank.d776.s8|117-117|.|O
DDI-DrugBank.d776.s9|0-0|(|O
DDI-DrugBank.d776.s9|1-3|See|O
DDI-DrugBank.d776.s9|5-5|<|O
DDI-DrugBank.d776.s9|6-6|a|O
DDI-DrugBank.d776.s9|8-12|href=|O
DDI-DrugBank.d776.s9|14-14|"|O
DDI-DrugBank.d776.s9|15-27|flucon_cp.htm|O
DDI-DrugBank.d776.s9|28-28|#|O
DDI-DrugBank.d776.s9|29-30|CP|O
DDI-DrugBank.d776.s9|31-31|"|O
DDI-DrugBank.d776.s9|32-32|>|O
DDI-DrugBank.d776.s9|33-40|CLINICAL|O
DDI-DrugBank.d776.s9|42-53|PHARMACOLOGY|O
DDI-DrugBank.d776.s9|54-54|:|O
DDI-DrugBank.d776.s9|56-59|Drug|O
DDI-DrugBank.d776.s9|61-71|Interaction|O
DDI-DrugBank.d776.s9|73-79|Studies|O
DDI-DrugBank.d776.s9|80-80|.|O
DDI-DrugBank.d776.s9|81-81|)|O
DDI-DrugBank.d776.s10|0-8|Phenytoin|O
DDI-DrugBank.d776.s10|9-9|:|O
DDI-DrugBank.d776.s10|11-18|DIFLUCAN|O
DDI-DrugBank.d776.s10|20-28|increases|O
DDI-DrugBank.d776.s10|30-32|the|O
DDI-DrugBank.d776.s10|34-39|plasma|O
DDI-DrugBank.d776.s10|41-54|concentrations|O
DDI-DrugBank.d776.s10|56-57|of|O
DDI-DrugBank.d776.s10|59-67|phenytoin|O
DDI-DrugBank.d776.s10|68-68|.|O
DDI-DrugBank.d776.s11|0-6|Careful|O
DDI-DrugBank.d776.s11|8-17|monitoring|O
DDI-DrugBank.d776.s11|19-20|of|O
DDI-DrugBank.d776.s11|22-30|phenytoin|O
DDI-DrugBank.d776.s11|32-45|concentrations|O
DDI-DrugBank.d776.s11|47-48|in|O
DDI-DrugBank.d776.s11|50-57|patients|O
DDI-DrugBank.d776.s11|59-67|receiving|O
DDI-DrugBank.d776.s11|69-76|DIFLUCAN|O
DDI-DrugBank.d776.s11|78-80|and|O
DDI-DrugBank.d776.s11|82-90|phenytoin|O
DDI-DrugBank.d776.s11|92-93|is|O
DDI-DrugBank.d776.s11|95-105|recommended|O
DDI-DrugBank.d776.s11|106-106|.|O
DDI-DrugBank.d776.s12|0-0|(|O
DDI-DrugBank.d776.s12|1-3|See|O
DDI-DrugBank.d776.s12|5-5|<|O
DDI-DrugBank.d776.s12|6-6|a|O
DDI-DrugBank.d776.s12|8-12|href=|O
DDI-DrugBank.d776.s12|14-14|"|O
DDI-DrugBank.d776.s12|15-27|flucon_cp.htm|O
DDI-DrugBank.d776.s12|28-28|#|O
DDI-DrugBank.d776.s12|29-30|CP|O
DDI-DrugBank.d776.s12|31-31|"|O
DDI-DrugBank.d776.s12|32-32|>|O
DDI-DrugBank.d776.s12|33-40|CLINICAL|O
DDI-DrugBank.d776.s12|42-53|PHARMACOLOGY|O
DDI-DrugBank.d776.s12|54-54|:|O
DDI-DrugBank.d776.s12|56-59|Drug|O
DDI-DrugBank.d776.s12|61-71|Interaction|O
DDI-DrugBank.d776.s12|73-79|Studies|O
DDI-DrugBank.d776.s12|80-80|.|O
DDI-DrugBank.d776.s12|81-81|)|O
DDI-DrugBank.d776.s13|0-11|Cyclosporine|O
DDI-DrugBank.d776.s13|12-12|:|O
DDI-DrugBank.d776.s13|14-21|DIFLUCAN|O
DDI-DrugBank.d776.s13|23-25|may|O
DDI-DrugBank.d776.s13|27-39|significantly|O
DDI-DrugBank.d776.s13|41-48|increase|O
DDI-DrugBank.d776.s13|50-61|cyclosporine|O
DDI-DrugBank.d776.s13|63-68|levels|O
DDI-DrugBank.d776.s13|70-71|in|O
DDI-DrugBank.d776.s13|73-77|renal|O
DDI-DrugBank.d776.s13|79-88|transplant|O
DDI-DrugBank.d776.s13|90-97|patients|O
DDI-DrugBank.d776.s13|99-102|with|O
DDI-DrugBank.d776.s13|104-105|or|O
DDI-DrugBank.d776.s13|107-113|without|O
DDI-DrugBank.d776.s13|115-119|renal|O
DDI-DrugBank.d776.s13|121-130|impairment|O
DDI-DrugBank.d776.s13|131-131|.|O
DDI-DrugBank.d776.s14|0-6|Careful|O
DDI-DrugBank.d776.s14|8-17|monitoring|O
DDI-DrugBank.d776.s14|19-20|of|O
DDI-DrugBank.d776.s14|22-33|cyclosporine|O
DDI-DrugBank.d776.s14|35-48|concentrations|O
DDI-DrugBank.d776.s14|50-52|and|O
DDI-DrugBank.d776.s14|54-58|serum|O
DDI-DrugBank.d776.s14|60-69|creatinine|O
DDI-DrugBank.d776.s14|71-72|is|O
DDI-DrugBank.d776.s14|74-84|recommended|O
DDI-DrugBank.d776.s14|86-87|in|O
DDI-DrugBank.d776.s14|89-96|patients|O
DDI-DrugBank.d776.s14|98-106|receiving|O
DDI-DrugBank.d776.s14|108-115|DIFLUCAN|O
DDI-DrugBank.d776.s14|117-119|and|O
DDI-DrugBank.d776.s14|121-132|cyclosporine|O
DDI-DrugBank.d776.s14|133-133|.|O
DDI-DrugBank.d776.s15|0-0|(|O
DDI-DrugBank.d776.s15|1-3|See|O
DDI-DrugBank.d776.s15|5-12|CLINICAL|O
DDI-DrugBank.d776.s15|14-25|PHARMACOLOGY|O
DDI-DrugBank.d776.s15|26-26|:|O
DDI-DrugBank.d776.s15|28-31|Drug|O
DDI-DrugBank.d776.s15|33-43|Interaction|O
DDI-DrugBank.d776.s15|45-51|Studies|O
DDI-DrugBank.d776.s15|52-52|.|O
DDI-DrugBank.d776.s15|53-53|)|O
DDI-DrugBank.d776.s16|0-7|Rifampin|O
DDI-DrugBank.d776.s16|8-8|:|O
DDI-DrugBank.d776.s16|10-17|Rifampin|O
DDI-DrugBank.d776.s16|19-26|enhances|O
DDI-DrugBank.d776.s16|28-30|the|O
DDI-DrugBank.d776.s16|32-41|metabolism|O
DDI-DrugBank.d776.s16|43-44|of|O
DDI-DrugBank.d776.s16|46-57|concurrently|O
DDI-DrugBank.d776.s16|59-70|administered|O
DDI-DrugBank.d776.s16|72-79|DIFLUCAN|O
DDI-DrugBank.d776.s16|80-80|.|O
DDI-DrugBank.d776.s17|0-8|Depending|O
DDI-DrugBank.d776.s17|10-11|on|O
DDI-DrugBank.d776.s17|13-20|clinical|O
DDI-DrugBank.d776.s17|22-34|circumstances|O
DDI-DrugBank.d776.s17|35-35|,|O
DDI-DrugBank.d776.s17|37-49|consideration|O
DDI-DrugBank.d776.s17|51-56|should|O
DDI-DrugBank.d776.s17|58-59|be|O
DDI-DrugBank.d776.s17|61-65|given|O
DDI-DrugBank.d776.s17|67-68|to|O
DDI-DrugBank.d776.s17|70-79|increasing|O
DDI-DrugBank.d776.s17|81-83|the|O
DDI-DrugBank.d776.s17|85-88|dose|O
DDI-DrugBank.d776.s17|90-91|of|O
DDI-DrugBank.d776.s17|93-100|DIFLUCAN|O
DDI-DrugBank.d776.s17|102-105|when|O
DDI-DrugBank.d776.s17|107-108|it|O
DDI-DrugBank.d776.s17|110-111|is|O
DDI-DrugBank.d776.s17|113-124|administered|O
DDI-DrugBank.d776.s17|126-129|with|O
DDI-DrugBank.d776.s17|131-138|rifampin|O
DDI-DrugBank.d776.s17|139-139|.|O
DDI-DrugBank.d776.s18|0-11|Theophylline|O
DDI-DrugBank.d776.s18|12-12|:|O
DDI-DrugBank.d776.s18|14-21|DIFLUCAN|O
DDI-DrugBank.d776.s18|23-31|increases|O
DDI-DrugBank.d776.s18|33-35|the|O
DDI-DrugBank.d776.s18|37-41|serum|O
DDI-DrugBank.d776.s18|43-56|concentrations|O
DDI-DrugBank.d776.s18|58-59|of|O
DDI-DrugBank.d776.s18|61-72|theophylline|O
DDI-DrugBank.d776.s18|73-73|.|O
DDI-DrugBank.d776.s19|0-6|Careful|O
DDI-DrugBank.d776.s19|8-17|monitoring|O
DDI-DrugBank.d776.s19|19-20|of|O
DDI-DrugBank.d776.s19|22-26|serum|O
DDI-DrugBank.d776.s19|28-39|theophylline|O
DDI-DrugBank.d776.s19|41-54|concentrations|O
DDI-DrugBank.d776.s19|56-57|in|O
DDI-DrugBank.d776.s19|59-66|patients|O
DDI-DrugBank.d776.s19|68-76|receiving|O
DDI-DrugBank.d776.s19|78-85|DIFLUCAN|O
DDI-DrugBank.d776.s19|87-89|and|O
DDI-DrugBank.d776.s19|91-102|theophylline|O
DDI-DrugBank.d776.s19|104-105|is|O
DDI-DrugBank.d776.s19|107-117|recommended|O
DDI-DrugBank.d776.s19|118-118|.|O
DDI-DrugBank.d776.s20|0-10|Terfenadine|O
DDI-DrugBank.d776.s20|11-11|:|O
DDI-DrugBank.d776.s20|13-19|Because|O
DDI-DrugBank.d776.s20|21-22|of|O
DDI-DrugBank.d776.s20|24-26|the|O
DDI-DrugBank.d776.s20|28-37|occurrence|O
DDI-DrugBank.d776.s20|39-40|of|O
DDI-DrugBank.d776.s20|42-48|serious|O
DDI-DrugBank.d776.s20|50-56|cardiac|O
DDI-DrugBank.d776.s20|58-69|dysrhythmias|O
DDI-DrugBank.d776.s20|71-79|secondary|O
DDI-DrugBank.d776.s20|81-82|to|O
DDI-DrugBank.d776.s20|84-95|prolongation|O
DDI-DrugBank.d776.s20|97-98|of|O
DDI-DrugBank.d776.s20|100-102|the|O
DDI-DrugBank.d776.s20|104-106|QTc|O
DDI-DrugBank.d776.s20|108-115|interval|O
DDI-DrugBank.d776.s20|117-118|in|O
DDI-DrugBank.d776.s20|120-127|patients|O
DDI-DrugBank.d776.s20|129-137|receiving|O
DDI-DrugBank.d776.s20|139-143|azole|O
DDI-DrugBank.d776.s20|145-155|antifungals|O
DDI-DrugBank.d776.s20|157-158|in|O
DDI-DrugBank.d776.s20|160-170|conjunction|O
DDI-DrugBank.d776.s20|172-175|with|O
DDI-DrugBank.d776.s20|177-187|terfenadine|O
DDI-DrugBank.d776.s20|188-188|,|O
DDI-DrugBank.d776.s20|190-200|interaction|O
DDI-DrugBank.d776.s20|202-208|studies|O
DDI-DrugBank.d776.s20|210-213|have|O
DDI-DrugBank.d776.s20|215-218|been|O
DDI-DrugBank.d776.s20|220-228|performed|O
DDI-DrugBank.d776.s20|229-229|.|O
DDI-DrugBank.d776.s21|0-2|One|O
DDI-DrugBank.d776.s21|4-8|study|O
DDI-DrugBank.d776.s21|10-11|at|O
DDI-DrugBank.d776.s21|13-13|a|O
DDI-DrugBank.d776.s21|15-20|200-mg|O
DDI-DrugBank.d776.s21|22-26|daily|O
DDI-DrugBank.d776.s21|28-31|dose|O
DDI-DrugBank.d776.s21|33-34|of|O
DDI-DrugBank.d776.s21|36-46|fluconazole|O
DDI-DrugBank.d776.s21|48-53|failed|O
DDI-DrugBank.d776.s21|55-56|to|O
DDI-DrugBank.d776.s21|58-68|demonstrate|O
DDI-DrugBank.d776.s21|70-70|a|O
DDI-DrugBank.d776.s21|72-83|prolongation|O
DDI-DrugBank.d776.s21|85-86|in|O
DDI-DrugBank.d776.s21|88-90|QTc|O
DDI-DrugBank.d776.s21|92-99|interval|O
DDI-DrugBank.d776.s21|100-100|.|O
DDI-DrugBank.d776.s22|0-6|Another|O
DDI-DrugBank.d776.s22|8-12|study|O
DDI-DrugBank.d776.s22|14-15|at|O
DDI-DrugBank.d776.s22|17-17|a|O
DDI-DrugBank.d776.s22|19-24|400-mg|O
DDI-DrugBank.d776.s22|26-28|and|O
DDI-DrugBank.d776.s22|30-35|800-mg|O
DDI-DrugBank.d776.s22|37-41|daily|O
DDI-DrugBank.d776.s22|43-46|dose|O
DDI-DrugBank.d776.s22|48-49|of|O
DDI-DrugBank.d776.s22|51-61|fluconazole|O
DDI-DrugBank.d776.s22|63-74|demonstrated|O
DDI-DrugBank.d776.s22|76-79|that|O
DDI-DrugBank.d776.s22|81-88|DIFLUCAN|O
DDI-DrugBank.d776.s22|90-94|taken|O
DDI-DrugBank.d776.s22|96-97|in|O
DDI-DrugBank.d776.s22|99-103|doses|O
DDI-DrugBank.d776.s22|105-106|of|O
DDI-DrugBank.d776.s22|108-110|400|O
DDI-DrugBank.d776.s22|112-113|mg|O
DDI-DrugBank.d776.s22|115-117|per|O
DDI-DrugBank.d776.s22|119-121|day|O
DDI-DrugBank.d776.s22|123-124|or|O
DDI-DrugBank.d776.s22|126-132|greater|O
DDI-DrugBank.d776.s22|134-146|significantly|O
DDI-DrugBank.d776.s22|148-156|increases|O
DDI-DrugBank.d776.s22|158-163|plasma|O
DDI-DrugBank.d776.s22|165-170|levels|O
DDI-DrugBank.d776.s22|172-173|of|O
DDI-DrugBank.d776.s22|175-185|terfenadine|O
DDI-DrugBank.d776.s22|187-190|when|O
DDI-DrugBank.d776.s22|192-196|taken|O
DDI-DrugBank.d776.s22|198-210|concomitantly|O
DDI-DrugBank.d776.s22|211-211|.|O
DDI-DrugBank.d776.s23|0-2|The|O
DDI-DrugBank.d776.s23|4-11|combined|O
DDI-DrugBank.d776.s23|13-15|use|O
DDI-DrugBank.d776.s23|17-18|of|O
DDI-DrugBank.d776.s23|20-30|fluconazole|O
DDI-DrugBank.d776.s23|32-33|at|O
DDI-DrugBank.d776.s23|35-39|doses|O
DDI-DrugBank.d776.s23|41-42|of|O
DDI-DrugBank.d776.s23|44-46|400|O
DDI-DrugBank.d776.s23|48-49|mg|O
DDI-DrugBank.d776.s23|51-52|or|O
DDI-DrugBank.d776.s23|54-60|greater|O
DDI-DrugBank.d776.s23|62-65|with|O
DDI-DrugBank.d776.s23|67-77|terfenadine|O
DDI-DrugBank.d776.s23|79-80|is|O
DDI-DrugBank.d776.s23|82-96|contraindicated|O
DDI-DrugBank.d776.s23|97-97|.|O
DDI-DrugBank.d776.s24|0-2|The|O
DDI-DrugBank.d776.s24|4-19|coadministration|O
DDI-DrugBank.d776.s24|21-22|of|O
DDI-DrugBank.d776.s24|24-34|fluconazole|O
DDI-DrugBank.d776.s24|36-37|at|O
DDI-DrugBank.d776.s24|39-43|doses|O
DDI-DrugBank.d776.s24|45-49|lower|O
DDI-DrugBank.d776.s24|51-54|than|O
DDI-DrugBank.d776.s24|56-58|400|O
DDI-DrugBank.d776.s24|60-65|mg/day|O
DDI-DrugBank.d776.s24|67-70|with|O
DDI-DrugBank.d776.s24|72-82|terfenadine|O
DDI-DrugBank.d776.s24|84-89|should|O
DDI-DrugBank.d776.s24|91-92|be|O
DDI-DrugBank.d776.s24|94-102|carefully|O
DDI-DrugBank.d776.s24|104-112|monitored|O
DDI-DrugBank.d776.s24|113-113|.|O
DDI-DrugBank.d776.s25|0-8|Cisapride|O
DDI-DrugBank.d776.s25|9-9|:|O
DDI-DrugBank.d776.s25|11-15|There|O
DDI-DrugBank.d776.s25|17-20|have|O
DDI-DrugBank.d776.s25|22-25|been|O
DDI-DrugBank.d776.s25|27-33|reports|O
DDI-DrugBank.d776.s25|35-36|of|O
DDI-DrugBank.d776.s25|38-44|cardiac|O
DDI-DrugBank.d776.s25|46-51|events|O
DDI-DrugBank.d776.s25|52-52|,|O
DDI-DrugBank.d776.s25|54-62|including|O
DDI-DrugBank.d776.s25|64-70|torsade|O
DDI-DrugBank.d776.s25|72-73|de|O
DDI-DrugBank.d776.s25|75-81|pointes|O
DDI-DrugBank.d776.s25|83-84|in|O
DDI-DrugBank.d776.s25|86-93|patients|O
DDI-DrugBank.d776.s25|95-96|to|O
DDI-DrugBank.d776.s25|98-101|whom|O
DDI-DrugBank.d776.s25|103-113|fluconazole|O
DDI-DrugBank.d776.s25|115-117|and|O
DDI-DrugBank.d776.s25|119-127|cisapride|O
DDI-DrugBank.d776.s25|129-132|were|O
DDI-DrugBank.d776.s25|134-147|coadministered|O
DDI-DrugBank.d776.s25|148-148|.|O
DDI-DrugBank.d776.s26|0-0|A|O
DDI-DrugBank.d776.s26|2-11|controlled|O
DDI-DrugBank.d776.s26|13-17|study|O
DDI-DrugBank.d776.s26|19-23|found|O
DDI-DrugBank.d776.s26|25-28|that|O
DDI-DrugBank.d776.s26|30-40|concomitant|O
DDI-DrugBank.d776.s26|42-52|fluconazole|O
DDI-DrugBank.d776.s26|54-56|200|O
DDI-DrugBank.d776.s26|58-59|mg|O
DDI-DrugBank.d776.s26|61-64|once|O
DDI-DrugBank.d776.s26|66-70|daily|O
DDI-DrugBank.d776.s26|72-74|and|O
DDI-DrugBank.d776.s26|76-84|cisapride|O
DDI-DrugBank.d776.s26|86-87|20|O
DDI-DrugBank.d776.s26|89-90|mg|O
DDI-DrugBank.d776.s26|92-95|four|O
DDI-DrugBank.d776.s26|97-101|times|O
DDI-DrugBank.d776.s26|103-103|a|O
DDI-DrugBank.d776.s26|105-107|day|O
DDI-DrugBank.d776.s26|109-115|yielded|O
DDI-DrugBank.d776.s26|117-117|a|O
DDI-DrugBank.d776.s26|119-129|significant|O
DDI-DrugBank.d776.s26|131-138|increase|O
DDI-DrugBank.d776.s26|140-141|in|O
DDI-DrugBank.d776.s26|143-151|cisapride|O
DDI-DrugBank.d776.s26|153-158|plasma|O
DDI-DrugBank.d776.s26|160-165|levels|O
DDI-DrugBank.d776.s26|167-169|and|O
DDI-DrugBank.d776.s26|171-182|prolongation|O
DDI-DrugBank.d776.s26|184-185|of|O
DDI-DrugBank.d776.s26|187-189|QTc|O
DDI-DrugBank.d776.s26|191-198|interval|O
DDI-DrugBank.d776.s26|199-199|.|O
DDI-DrugBank.d776.s27|0-2|The|O
DDI-DrugBank.d776.s27|4-11|combined|O
DDI-DrugBank.d776.s27|13-15|use|O
DDI-DrugBank.d776.s27|17-18|of|O
DDI-DrugBank.d776.s27|20-30|fluconazole|O
DDI-DrugBank.d776.s27|32-35|with|O
DDI-DrugBank.d776.s27|37-45|cisapride|O
DDI-DrugBank.d776.s27|47-48|is|O
DDI-DrugBank.d776.s27|50-64|contraindicated|O
DDI-DrugBank.d776.s27|65-65|.|O
DDI-DrugBank.d776.s28|0-9|Astemizole|O
DDI-DrugBank.d776.s28|10-10|:|O
DDI-DrugBank.d776.s28|12-14|The|O
DDI-DrugBank.d776.s28|16-18|use|O
DDI-DrugBank.d776.s28|20-21|of|O
DDI-DrugBank.d776.s28|23-33|fluconazole|O
DDI-DrugBank.d776.s28|35-36|in|O
DDI-DrugBank.d776.s28|38-45|patients|O
DDI-DrugBank.d776.s28|47-58|concurrently|O
DDI-DrugBank.d776.s28|60-65|taking|O
DDI-DrugBank.d776.s28|67-76|astemizole|O
DDI-DrugBank.d776.s28|78-79|or|O
DDI-DrugBank.d776.s28|81-85|other|O
DDI-DrugBank.d776.s28|87-91|drugs|O
DDI-DrugBank.d776.s28|93-103|metabolized|O
DDI-DrugBank.d776.s28|105-106|by|O
DDI-DrugBank.d776.s28|108-110|the|O
DDI-DrugBank.d776.s28|112-121|cytochrome|O
DDI-DrugBank.d776.s28|123-126|P450|O
DDI-DrugBank.d776.s28|128-133|system|O
DDI-DrugBank.d776.s28|135-137|may|O
DDI-DrugBank.d776.s28|139-140|be|O
DDI-DrugBank.d776.s28|142-151|associated|O
DDI-DrugBank.d776.s28|153-156|with|O
DDI-DrugBank.d776.s28|158-167|elevations|O
DDI-DrugBank.d776.s28|169-170|in|O
DDI-DrugBank.d776.s28|172-176|serum|O
DDI-DrugBank.d776.s28|178-183|levels|O
DDI-DrugBank.d776.s28|185-186|of|O
DDI-DrugBank.d776.s28|188-192|these|O
DDI-DrugBank.d776.s28|194-198|drugs|O
DDI-DrugBank.d776.s28|199-199|.|O
DDI-DrugBank.d776.s29|0-1|In|O
DDI-DrugBank.d776.s29|3-5|the|O
DDI-DrugBank.d776.s29|7-13|absence|O
DDI-DrugBank.d776.s29|15-16|of|O
DDI-DrugBank.d776.s29|18-27|definitive|O
DDI-DrugBank.d776.s29|29-39|information|O
DDI-DrugBank.d776.s29|40-40|,|O
DDI-DrugBank.d776.s29|42-48|caution|O
DDI-DrugBank.d776.s29|50-55|should|O
DDI-DrugBank.d776.s29|57-58|be|O
DDI-DrugBank.d776.s29|60-63|used|O
DDI-DrugBank.d776.s29|65-68|when|O
DDI-DrugBank.d776.s29|70-84|coadministering|O
DDI-DrugBank.d776.s29|86-96|fluconazole|O
DDI-DrugBank.d776.s29|97-97|.|O
DDI-DrugBank.d776.s30|0-7|Patients|O
DDI-DrugBank.d776.s30|9-14|should|O
DDI-DrugBank.d776.s30|16-17|be|O
DDI-DrugBank.d776.s30|19-27|carefully|O
DDI-DrugBank.d776.s30|29-37|monitored|O
DDI-DrugBank.d776.s30|38-38|.|O
DDI-DrugBank.d776.s31|0-8|Rifabutin|O
DDI-DrugBank.d776.s31|9-9|:|O
DDI-DrugBank.d776.s31|11-15|There|O
DDI-DrugBank.d776.s31|17-20|have|O
DDI-DrugBank.d776.s31|22-25|been|O
DDI-DrugBank.d776.s31|27-33|reports|O
DDI-DrugBank.d776.s31|35-36|of|O
DDI-DrugBank.d776.s31|38-44|uveitis|O
DDI-DrugBank.d776.s31|46-47|in|O
DDI-DrugBank.d776.s31|49-56|patients|O
DDI-DrugBank.d776.s31|58-59|to|O
DDI-DrugBank.d776.s31|61-64|whom|O
DDI-DrugBank.d776.s31|66-76|fluconazole|O
DDI-DrugBank.d776.s31|78-80|and|O
DDI-DrugBank.d776.s31|82-90|rifabutin|O
DDI-DrugBank.d776.s31|92-95|were|O
DDI-DrugBank.d776.s31|97-110|coadministered|O
DDI-DrugBank.d776.s31|111-111|.|O
DDI-DrugBank.d776.s32|0-7|Patients|O
DDI-DrugBank.d776.s32|9-17|receiving|O
DDI-DrugBank.d776.s32|19-27|rifabutin|O
DDI-DrugBank.d776.s32|29-31|and|O
DDI-DrugBank.d776.s32|33-43|fluconazole|O
DDI-DrugBank.d776.s32|45-57|concomitantly|O
DDI-DrugBank.d776.s32|59-64|should|O
DDI-DrugBank.d776.s32|66-67|be|O
DDI-DrugBank.d776.s32|69-77|carefully|O
DDI-DrugBank.d776.s32|79-87|monitored|O
DDI-DrugBank.d776.s32|88-88|.|O
DDI-DrugBank.d776.s33|0-9|Tacrolimus|O
DDI-DrugBank.d776.s33|10-10|:|O
DDI-DrugBank.d776.s33|12-16|There|O
DDI-DrugBank.d776.s33|18-21|have|O
DDI-DrugBank.d776.s33|23-26|been|O
DDI-DrugBank.d776.s33|28-34|reports|O
DDI-DrugBank.d776.s33|36-37|of|O
DDI-DrugBank.d776.s33|39-52|nephrotoxicity|O
DDI-DrugBank.d776.s33|54-55|in|O
DDI-DrugBank.d776.s33|57-64|patients|O
DDI-DrugBank.d776.s33|66-67|to|O
DDI-DrugBank.d776.s33|69-72|whom|O
DDI-DrugBank.d776.s33|74-84|fluconazole|O
DDI-DrugBank.d776.s33|86-88|and|O
DDI-DrugBank.d776.s33|90-99|tacrolimus|O
DDI-DrugBank.d776.s33|101-104|were|O
DDI-DrugBank.d776.s33|106-119|coadministered|O
DDI-DrugBank.d776.s33|120-120|.|O
DDI-DrugBank.d776.s34|0-7|Patients|O
DDI-DrugBank.d776.s34|9-17|receiving|O
DDI-DrugBank.d776.s34|19-28|tacrolimus|O
DDI-DrugBank.d776.s34|30-32|and|O
DDI-DrugBank.d776.s34|34-44|fluconazole|O
DDI-DrugBank.d776.s34|46-58|concomitantly|O
DDI-DrugBank.d776.s34|60-65|should|O
DDI-DrugBank.d776.s34|67-68|be|O
DDI-DrugBank.d776.s34|70-78|carefully|O
DDI-DrugBank.d776.s34|80-88|monitored|O
DDI-DrugBank.d776.s34|89-89|.|O
DDI-DrugBank.d776.s35|0-11|Short-acting|O
DDI-DrugBank.d776.s35|13-27|Benzodiazepines|O
DDI-DrugBank.d776.s35|28-28|:|O
DDI-DrugBank.d776.s35|30-38|Following|O
DDI-DrugBank.d776.s35|40-43|oral|O
DDI-DrugBank.d776.s35|45-58|administration|O
DDI-DrugBank.d776.s35|60-61|of|O
DDI-DrugBank.d776.s35|63-71|midazolam|O
DDI-DrugBank.d776.s35|72-72|,|O
DDI-DrugBank.d776.s35|74-84|fluconazole|O
DDI-DrugBank.d776.s35|86-93|resulted|O
DDI-DrugBank.d776.s35|95-96|in|O
DDI-DrugBank.d776.s35|98-108|substantial|O
DDI-DrugBank.d776.s35|110-118|increases|O
DDI-DrugBank.d776.s35|120-121|in|O
DDI-DrugBank.d776.s35|123-131|midazolam|O
DDI-DrugBank.d776.s35|133-146|concentrations|O
DDI-DrugBank.d776.s35|148-150|and|O
DDI-DrugBank.d776.s35|152-162|psychomotor|O
DDI-DrugBank.d776.s35|164-170|effects|O
DDI-DrugBank.d776.s35|171-171|.|O
DDI-DrugBank.d776.s36|0-3|This|O
DDI-DrugBank.d776.s36|5-10|effect|O
DDI-DrugBank.d776.s36|12-13|on|O
DDI-DrugBank.d776.s36|15-23|midazolam|O
DDI-DrugBank.d776.s36|25-31|appears|O
DDI-DrugBank.d776.s36|33-34|to|O
DDI-DrugBank.d776.s36|36-37|be|O
DDI-DrugBank.d776.s36|39-42|more|O
DDI-DrugBank.d776.s36|44-53|pronounced|O
DDI-DrugBank.d776.s36|55-63|following|O
DDI-DrugBank.d776.s36|65-68|oral|O
DDI-DrugBank.d776.s36|70-83|administration|O
DDI-DrugBank.d776.s36|85-86|of|O
DDI-DrugBank.d776.s36|88-98|fluconazole|O
DDI-DrugBank.d776.s36|100-103|than|O
DDI-DrugBank.d776.s36|105-108|with|O
DDI-DrugBank.d776.s36|110-120|fluconazole|O
DDI-DrugBank.d776.s36|122-133|administered|O
DDI-DrugBank.d776.s36|135-147|intravenously|O
DDI-DrugBank.d776.s36|148-148|.|O
DDI-DrugBank.d776.s37|0-1|If|O
DDI-DrugBank.d776.s37|3-14|short-acting|O
DDI-DrugBank.d776.s37|16-30|benzodiazepines|O
DDI-DrugBank.d776.s37|31-31|,|O
DDI-DrugBank.d776.s37|33-37|which|O
DDI-DrugBank.d776.s37|39-41|are|O
DDI-DrugBank.d776.s37|43-53|metabolized|O
DDI-DrugBank.d776.s37|55-56|by|O
DDI-DrugBank.d776.s37|58-60|the|O
DDI-DrugBank.d776.s37|62-71|cytochrome|O
DDI-DrugBank.d776.s37|73-76|P450|O
DDI-DrugBank.d776.s37|78-83|system|O
DDI-DrugBank.d776.s37|84-84|,|O
DDI-DrugBank.d776.s37|86-88|are|O
DDI-DrugBank.d776.s37|90-102|concomitantly|O
DDI-DrugBank.d776.s37|104-115|administered|O
DDI-DrugBank.d776.s37|117-120|with|O
DDI-DrugBank.d776.s37|122-132|fluconazole|O
DDI-DrugBank.d776.s37|133-133|,|O
DDI-DrugBank.d776.s37|135-147|consideration|O
DDI-DrugBank.d776.s37|149-154|should|O
DDI-DrugBank.d776.s37|156-157|be|O
DDI-DrugBank.d776.s37|159-163|given|O
DDI-DrugBank.d776.s37|165-166|to|O
DDI-DrugBank.d776.s37|168-177|decreasing|O
DDI-DrugBank.d776.s37|179-181|the|O
DDI-DrugBank.d776.s37|183-196|benzodiazepine|O
DDI-DrugBank.d776.s37|198-203|dosage|O
DDI-DrugBank.d776.s37|204-204|,|O
DDI-DrugBank.d776.s37|206-208|and|O
DDI-DrugBank.d776.s37|210-212|the|O
DDI-DrugBank.d776.s37|214-221|patients|O
DDI-DrugBank.d776.s37|223-228|should|O
DDI-DrugBank.d776.s37|230-231|be|O
DDI-DrugBank.d776.s37|233-245|appropriately|O
DDI-DrugBank.d776.s37|247-255|monitored|O
DDI-DrugBank.d776.s37|256-256|.|O
DDI-DrugBank.d776.s38|0-10|Fluconazole|O
DDI-DrugBank.d776.s38|12-18|tablets|O
DDI-DrugBank.d776.s38|20-33|coadministered|O
DDI-DrugBank.d776.s38|35-38|with|O
DDI-DrugBank.d776.s38|40-46|ethinyl|O
DDI-DrugBank.d776.s38|48-57|estradiol-|O
DDI-DrugBank.d776.s38|59-61|and|O
DDI-DrugBank.d776.s38|63-87|levonorgestrel-containing|O
DDI-DrugBank.d776.s38|89-92|oral|O
DDI-DrugBank.d776.s38|94-107|contraceptives|O
DDI-DrugBank.d776.s38|109-116|produced|O
DDI-DrugBank.d776.s38|118-119|an|O
DDI-DrugBank.d776.s38|121-127|overall|O
DDI-DrugBank.d776.s38|129-132|mean|O
DDI-DrugBank.d776.s38|134-141|increase|O
DDI-DrugBank.d776.s38|143-144|in|O
DDI-DrugBank.d776.s38|146-152|ethinyl|O
DDI-DrugBank.d776.s38|154-162|estradiol|O
DDI-DrugBank.d776.s38|164-166|and|O
DDI-DrugBank.d776.s38|168-181|levonorgestrel|O
DDI-DrugBank.d776.s38|183-188|levels|O
DDI-DrugBank.d776.s38|189-189|;|O
DDI-DrugBank.d776.s39|0-6|however|O
DDI-DrugBank.d776.s39|7-7|,|O
DDI-DrugBank.d776.s39|9-10|in|O
DDI-DrugBank.d776.s39|12-15|some|O
DDI-DrugBank.d776.s39|17-24|patients|O
DDI-DrugBank.d776.s39|26-30|there|O
DDI-DrugBank.d776.s39|32-35|were|O
DDI-DrugBank.d776.s39|37-45|decreases|O
DDI-DrugBank.d776.s39|47-48|up|O
DDI-DrugBank.d776.s39|50-51|to|O
DDI-DrugBank.d776.s39|53-54|47|O
DDI-DrugBank.d776.s39|55-55|%|O
DDI-DrugBank.d776.s39|57-59|and|O
DDI-DrugBank.d776.s39|61-62|33|O
DDI-DrugBank.d776.s39|63-63|%|O
DDI-DrugBank.d776.s39|65-66|of|O
DDI-DrugBank.d776.s39|68-74|ethinyl|O
DDI-DrugBank.d776.s39|76-84|estradiol|O
DDI-DrugBank.d776.s39|86-88|and|O
DDI-DrugBank.d776.s39|90-103|levonorgestrel|O
DDI-DrugBank.d776.s39|105-110|levels|O
DDI-DrugBank.d776.s39|111-111|.|O
DDI-DrugBank.d776.s40|0-2|The|O
DDI-DrugBank.d776.s40|4-7|data|O
DDI-DrugBank.d776.s40|9-17|presently|O
DDI-DrugBank.d776.s40|19-27|available|O
DDI-DrugBank.d776.s40|29-36|indicate|O
DDI-DrugBank.d776.s40|38-41|that|O
DDI-DrugBank.d776.s40|43-45|the|O
DDI-DrugBank.d776.s40|47-55|decreases|O
DDI-DrugBank.d776.s40|57-58|in|O
DDI-DrugBank.d776.s40|60-63|some|O
DDI-DrugBank.d776.s40|65-74|individual|O
DDI-DrugBank.d776.s40|76-82|ethinyl|O
DDI-DrugBank.d776.s40|84-92|estradiol|O
DDI-DrugBank.d776.s40|94-96|and|O
DDI-DrugBank.d776.s40|98-111|levonorgestrel|O
DDI-DrugBank.d776.s40|113-115|AUC|O
DDI-DrugBank.d776.s40|117-122|values|O
DDI-DrugBank.d776.s40|124-127|with|O
DDI-DrugBank.d776.s40|129-139|fluconazole|O
DDI-DrugBank.d776.s40|141-149|treatment|O
DDI-DrugBank.d776.s40|151-153|are|O
DDI-DrugBank.d776.s40|155-160|likely|O
DDI-DrugBank.d776.s40|162-164|the|O
DDI-DrugBank.d776.s40|166-171|result|O
DDI-DrugBank.d776.s40|173-174|of|O
DDI-DrugBank.d776.s40|176-181|random|O
DDI-DrugBank.d776.s40|183-191|variation|O
DDI-DrugBank.d776.s40|192-192|.|O
DDI-DrugBank.d776.s41|0-4|While|O
DDI-DrugBank.d776.s41|6-10|there|O
DDI-DrugBank.d776.s41|12-13|is|O
DDI-DrugBank.d776.s41|15-22|evidence|O
DDI-DrugBank.d776.s41|24-27|that|O
DDI-DrugBank.d776.s41|29-39|fluconazole|O
DDI-DrugBank.d776.s41|41-43|can|O
DDI-DrugBank.d776.s41|45-51|inhibit|O
DDI-DrugBank.d776.s41|53-55|the|O
DDI-DrugBank.d776.s41|57-66|metabolism|O
DDI-DrugBank.d776.s41|68-69|of|O
DDI-DrugBank.d776.s41|71-77|ethinyl|O
DDI-DrugBank.d776.s41|79-87|estradiol|O
DDI-DrugBank.d776.s41|89-91|and|O
DDI-DrugBank.d776.s41|93-106|levonorgestrel|O
DDI-DrugBank.d776.s41|107-107|,|O
DDI-DrugBank.d776.s41|109-113|there|O
DDI-DrugBank.d776.s41|115-116|is|O
DDI-DrugBank.d776.s41|118-119|no|O
DDI-DrugBank.d776.s41|121-128|evidence|O
DDI-DrugBank.d776.s41|130-133|that|O
DDI-DrugBank.d776.s41|135-145|fluconazole|O
DDI-DrugBank.d776.s41|147-148|is|O
DDI-DrugBank.d776.s41|150-150|a|O
DDI-DrugBank.d776.s41|152-154|net|O
DDI-DrugBank.d776.s41|156-162|inducer|O
DDI-DrugBank.d776.s41|164-165|of|O
DDI-DrugBank.d776.s41|167-173|ethinyl|O
DDI-DrugBank.d776.s41|175-183|estradiol|O
DDI-DrugBank.d776.s41|185-186|or|O
DDI-DrugBank.d776.s41|188-201|levonorgestrel|O
DDI-DrugBank.d776.s41|203-212|metabolism|O
DDI-DrugBank.d776.s41|213-213|.|O
DDI-DrugBank.d776.s42|0-2|The|O
DDI-DrugBank.d776.s42|4-11|clinical|O
DDI-DrugBank.d776.s42|13-24|significance|O
DDI-DrugBank.d776.s42|26-27|of|O
DDI-DrugBank.d776.s42|29-33|these|O
DDI-DrugBank.d776.s42|35-41|effects|O
DDI-DrugBank.d776.s42|43-44|is|O
DDI-DrugBank.d776.s42|46-54|presently|O
DDI-DrugBank.d776.s42|56-62|unknown|O
DDI-DrugBank.d776.s42|63-63|.|O
DDI-DrugBank.d776.s43|0-9|Physicians|O
DDI-DrugBank.d776.s43|11-16|should|O
DDI-DrugBank.d776.s43|18-19|be|O
DDI-DrugBank.d776.s43|21-25|aware|O
DDI-DrugBank.d776.s43|27-30|that|O
DDI-DrugBank.d776.s43|32-42|interaction|O
DDI-DrugBank.d776.s43|44-50|studies|O
DDI-DrugBank.d776.s43|52-55|with|O
DDI-DrugBank.d776.s43|57-67|medications|O
DDI-DrugBank.d776.s43|69-73|other|O
DDI-DrugBank.d776.s43|75-78|than|O
DDI-DrugBank.d776.s43|80-84|those|O
DDI-DrugBank.d776.s43|86-91|listed|O
DDI-DrugBank.d776.s43|93-94|in|O
DDI-DrugBank.d776.s43|96-98|the|O
DDI-DrugBank.d776.s43|100-100|<|O
DDI-DrugBank.d776.s43|101-101|a|O
DDI-DrugBank.d776.s43|103-107|href=|O
DDI-DrugBank.d776.s43|109-109|"|O
DDI-DrugBank.d776.s43|110-122|flucon_cp.htm|O
DDI-DrugBank.d776.s43|123-123|#|O
DDI-DrugBank.d776.s43|124-125|CP|O
DDI-DrugBank.d776.s43|126-126|"|O
DDI-DrugBank.d776.s43|127-127|>|O
DDI-DrugBank.d776.s43|128-135|CLINICAL|O
DDI-DrugBank.d776.s43|137-148|PHARMACOLOGY|O
DDI-DrugBank.d776.s43|150-156|section|O
DDI-DrugBank.d776.s43|158-161|have|O
DDI-DrugBank.d776.s43|163-165|not|O
DDI-DrugBank.d776.s43|167-170|been|O
DDI-DrugBank.d776.s43|172-180|conducted|O
DDI-DrugBank.d776.s43|181-181|,|O
DDI-DrugBank.d776.s43|183-185|but|O
DDI-DrugBank.d776.s43|187-190|such|O
DDI-DrugBank.d776.s43|192-203|interactions|O
DDI-DrugBank.d776.s43|205-207|may|O
DDI-DrugBank.d776.s43|209-213|occur|O
DDI-DrugBank.d776.s43|214-214|.|O
DDI-DrugBank.d737.s0|0-17|Carbidopa/Levodopa|O
DDI-DrugBank.d737.s0|18-18|:|O
DDI-DrugBank.d737.s0|20-37|Carbidopa/Levodopa|O
DDI-DrugBank.d737.s0|39-42|does|O
DDI-DrugBank.d737.s0|44-46|not|O
DDI-DrugBank.d737.s0|48-56|influence|O
DDI-DrugBank.d737.s0|58-60|the|O
DDI-DrugBank.d737.s0|62-77|pharmacokinetics|O
DDI-DrugBank.d737.s0|79-80|of|O
DDI-DrugBank.d737.s0|82-92|pramipexole|O
DDI-DrugBank.d737.s0|94-95|in|O
DDI-DrugBank.d737.s0|97-103|healthy|O
DDI-DrugBank.d737.s0|105-114|volunteers|O
DDI-DrugBank.d737.s0|116-116|(|O
DDI-DrugBank.d737.s0|117-118|N=|O
DDI-DrugBank.d737.s0|120-121|10|O
DDI-DrugBank.d737.s0|122-122|)|O
DDI-DrugBank.d737.s0|123-123|.|O
DDI-DrugBank.d737.s1|0-0|5|O
DDI-DrugBank.d737.s1|2-6|hours|O
DDI-DrugBank.d737.s1|7-7|.|O
DDI-DrugBank.d737.s2|0-9|Selegiline|O
DDI-DrugBank.d737.s2|10-10|:|O
DDI-DrugBank.d737.s2|12-13|In|O
DDI-DrugBank.d737.s2|15-21|healthy|O
DDI-DrugBank.d737.s2|23-32|volunteers|O
DDI-DrugBank.d737.s2|34-34|(|O
DDI-DrugBank.d737.s2|35-36|N=|O
DDI-DrugBank.d737.s2|38-39|11|O
DDI-DrugBank.d737.s2|40-40|)|O
DDI-DrugBank.d737.s2|41-41|,|O
DDI-DrugBank.d737.s2|43-52|selegiline|O
DDI-DrugBank.d737.s2|54-56|did|O
DDI-DrugBank.d737.s2|58-60|not|O
DDI-DrugBank.d737.s2|62-70|influence|O
DDI-DrugBank.d737.s2|72-74|the|O
DDI-DrugBank.d737.s2|76-91|pharmacokinetics|O
DDI-DrugBank.d737.s2|93-94|of|O
DDI-DrugBank.d737.s2|96-106|pramipexole|O
DDI-DrugBank.d737.s2|107-107|.|O
DDI-DrugBank.d737.s3|0-9|Amantadine|O
DDI-DrugBank.d737.s3|10-10|:|O
DDI-DrugBank.d737.s3|12-21|Population|O
DDI-DrugBank.d737.s3|23-37|pharmacokinetic|O
DDI-DrugBank.d737.s3|39-46|analysis|O
DDI-DrugBank.d737.s3|48-55|suggests|O
DDI-DrugBank.d737.s3|57-60|that|O
DDI-DrugBank.d737.s3|62-71|amantadine|O
DDI-DrugBank.d737.s3|73-74|is|O
DDI-DrugBank.d737.s3|76-83|unlikely|O
DDI-DrugBank.d737.s3|85-86|to|O
DDI-DrugBank.d737.s3|88-92|alter|O
DDI-DrugBank.d737.s3|94-96|the|O
DDI-DrugBank.d737.s3|98-101|oral|O
DDI-DrugBank.d737.s3|103-111|clearance|O
DDI-DrugBank.d737.s3|113-114|of|O
DDI-DrugBank.d737.s3|116-126|pramipexole|O
DDI-DrugBank.d737.s3|128-128|(|O
DDI-DrugBank.d737.s3|129-130|N=|O
DDI-DrugBank.d737.s3|132-133|54|O
DDI-DrugBank.d737.s3|134-134|)|O
DDI-DrugBank.d737.s3|135-135|.|O
DDI-DrugBank.d737.s4|0-9|Cimetidine|O
DDI-DrugBank.d737.s4|10-10|:|O
DDI-DrugBank.d737.s4|12-21|Cimetidine|O
DDI-DrugBank.d737.s4|22-22|,|O
DDI-DrugBank.d737.s4|24-24|a|O
DDI-DrugBank.d737.s4|26-30|known|O
DDI-DrugBank.d737.s4|32-40|inhibitor|O
DDI-DrugBank.d737.s4|42-43|of|O
DDI-DrugBank.d737.s4|45-49|renal|O
DDI-DrugBank.d737.s4|51-57|tubular|O
DDI-DrugBank.d737.s4|59-67|secretion|O
DDI-DrugBank.d737.s4|69-70|of|O
DDI-DrugBank.d737.s4|72-78|organic|O
DDI-DrugBank.d737.s4|80-84|bases|O
DDI-DrugBank.d737.s4|86-88|via|O
DDI-DrugBank.d737.s4|90-92|the|O
DDI-DrugBank.d737.s4|94-101|cationic|O
DDI-DrugBank.d737.s4|103-111|transport|O
DDI-DrugBank.d737.s4|113-118|system|O
DDI-DrugBank.d737.s4|119-119|,|O
DDI-DrugBank.d737.s4|121-126|caused|O
DDI-DrugBank.d737.s4|128-128|a|O
DDI-DrugBank.d737.s4|130-131|50|O
DDI-DrugBank.d737.s4|132-132|%|O
DDI-DrugBank.d737.s4|134-141|increase|O
DDI-DrugBank.d737.s4|143-144|in|O
DDI-DrugBank.d737.s4|146-156|pramipexole|O
DDI-DrugBank.d737.s4|158-160|AUC|O
DDI-DrugBank.d737.s4|162-164|and|O
DDI-DrugBank.d737.s4|166-166|a|O
DDI-DrugBank.d737.s4|168-169|40|O
DDI-DrugBank.d737.s4|170-170|%|O
DDI-DrugBank.d737.s4|172-179|increase|O
DDI-DrugBank.d737.s4|181-182|in|O
DDI-DrugBank.d737.s4|184-192|half-life|O
DDI-DrugBank.d737.s4|194-194|(|O
DDI-DrugBank.d737.s4|195-196|N=|O
DDI-DrugBank.d737.s4|198-199|12|O
DDI-DrugBank.d737.s4|200-200|)|O
DDI-DrugBank.d737.s4|201-201|.|O
DDI-DrugBank.d737.s5|0-9|Probenecid|O
DDI-DrugBank.d737.s5|10-10|:|O
DDI-DrugBank.d737.s5|12-21|Probenecid|O
DDI-DrugBank.d737.s5|22-22|,|O
DDI-DrugBank.d737.s5|24-24|a|O
DDI-DrugBank.d737.s5|26-30|known|O
DDI-DrugBank.d737.s5|32-40|inhibitor|O
DDI-DrugBank.d737.s5|42-43|of|O
DDI-DrugBank.d737.s5|45-49|renal|O
DDI-DrugBank.d737.s5|51-57|tubular|O
DDI-DrugBank.d737.s5|59-67|secretion|O
DDI-DrugBank.d737.s5|69-70|of|O
DDI-DrugBank.d737.s5|72-78|organic|O
DDI-DrugBank.d737.s5|80-84|acids|O
DDI-DrugBank.d737.s5|86-88|via|O
DDI-DrugBank.d737.s5|90-92|the|O
DDI-DrugBank.d737.s5|94-100|aruonic|O
DDI-DrugBank.d737.s5|102-112|transporter|O
DDI-DrugBank.d737.s5|113-113|,|O
DDI-DrugBank.d737.s5|115-117|did|O
DDI-DrugBank.d737.s5|119-121|not|O
DDI-DrugBank.d737.s5|123-132|noticeably|O
DDI-DrugBank.d737.s5|134-142|influence|O
DDI-DrugBank.d737.s5|144-154|pramipexole|O
DDI-DrugBank.d737.s5|156-171|pharmacokinetics|O
DDI-DrugBank.d737.s5|173-173|(|O
DDI-DrugBank.d737.s5|174-175|N=|O
DDI-DrugBank.d737.s5|177-178|12|O
DDI-DrugBank.d737.s5|179-179|)|O
DDI-DrugBank.d737.s5|180-180|.|O
DDI-DrugBank.d737.s6|0-4|Other|O
DDI-DrugBank.d737.s6|6-10|drugs|O
DDI-DrugBank.d737.s6|12-21|eliminated|O
DDI-DrugBank.d737.s6|23-25|via|O
DDI-DrugBank.d737.s6|27-31|renal|O
DDI-DrugBank.d737.s6|33-41|secretion|O
DDI-DrugBank.d737.s6|42-42|:|O
DDI-DrugBank.d737.s6|44-53|Population|O
DDI-DrugBank.d737.s6|55-69|pharmacokinetic|O
DDI-DrugBank.d737.s6|71-78|analysis|O
DDI-DrugBank.d737.s6|80-87|suggests|O
DDI-DrugBank.d737.s6|89-92|that|O
DDI-DrugBank.d737.s6|94-109|coadministration|O
DDI-DrugBank.d737.s6|111-112|of|O
DDI-DrugBank.d737.s6|114-118|drugs|O
DDI-DrugBank.d737.s6|120-123|that|O
DDI-DrugBank.d737.s6|125-127|are|O
DDI-DrugBank.d737.s6|129-136|secreted|O
DDI-DrugBank.d737.s6|138-139|by|O
DDI-DrugBank.d737.s6|141-143|the|O
DDI-DrugBank.d737.s6|145-152|cationic|O
DDI-DrugBank.d737.s6|154-162|transport|O
DDI-DrugBank.d737.s6|164-169|system|O
DDI-DrugBank.d737.s6|171-171|(|O
DDI-DrugBank.d737.s6|172-175|e.g.|O
DDI-DrugBank.d737.s6|176-176|,|O
DDI-DrugBank.d737.s6|178-187|cimetidine|O
DDI-DrugBank.d737.s6|188-188|,|O
DDI-DrugBank.d737.s6|190-199|ranitidine|O
DDI-DrugBank.d737.s6|200-200|,|O
DDI-DrugBank.d737.s6|202-210|diltiazem|O
DDI-DrugBank.d737.s6|211-211|,|O
DDI-DrugBank.d737.s6|213-223|triamterene|O
DDI-DrugBank.d737.s6|224-224|,|O
DDI-DrugBank.d737.s6|226-234|verapamil|O
DDI-DrugBank.d737.s6|235-235|,|O
DDI-DrugBank.d737.s6|237-245|quinidine|O
DDI-DrugBank.d737.s6|246-246|,|O
DDI-DrugBank.d737.s6|248-250|and|O
DDI-DrugBank.d737.s6|252-258|quinine|O
DDI-DrugBank.d737.s6|259-259|)|O
DDI-DrugBank.d737.s6|261-269|decreases|O
DDI-DrugBank.d737.s6|271-273|the|O
DDI-DrugBank.d737.s6|275-278|oral|O
DDI-DrugBank.d737.s6|280-288|clearance|O
DDI-DrugBank.d737.s6|290-291|of|O
DDI-DrugBank.d737.s6|293-303|pramipexole|O
DDI-DrugBank.d737.s6|305-306|by|O
DDI-DrugBank.d737.s6|308-312|about|O
DDI-DrugBank.d737.s6|314-315|20|O
DDI-DrugBank.d737.s6|316-316|%|O
DDI-DrugBank.d737.s6|317-317|,|O
DDI-DrugBank.d737.s6|319-323|while|O
DDI-DrugBank.d737.s6|325-329|those|O
DDI-DrugBank.d737.s6|331-338|secreted|O
DDI-DrugBank.d737.s6|340-341|by|O
DDI-DrugBank.d737.s6|343-345|the|O
DDI-DrugBank.d737.s6|347-353|anionic|O
DDI-DrugBank.d737.s6|355-363|transport|O
DDI-DrugBank.d737.s6|365-370|system|O
DDI-DrugBank.d737.s6|372-372|(|O
DDI-DrugBank.d737.s6|373-376|e.g.|O
DDI-DrugBank.d737.s6|377-377|,|O
DDI-DrugBank.d737.s6|379-392|cephalosporins|O
DDI-DrugBank.d737.s6|393-393|,|O
DDI-DrugBank.d737.s6|395-405|penicillins|O
DDI-DrugBank.d737.s6|406-406|,|O
DDI-DrugBank.d737.s6|408-419|indomethacin|O
DDI-DrugBank.d737.s6|420-420|,|O
DDI-DrugBank.d737.s6|422-440|hydrochlorothiazide|O
DDI-DrugBank.d737.s6|441-441|,|O
DDI-DrugBank.d737.s6|443-445|and|O
DDI-DrugBank.d737.s6|447-460|chlorpropamide|O
DDI-DrugBank.d737.s6|461-461|)|O
DDI-DrugBank.d737.s6|463-465|are|O
DDI-DrugBank.d737.s6|467-472|likely|O
DDI-DrugBank.d737.s6|474-475|to|O
DDI-DrugBank.d737.s6|477-480|have|O
DDI-DrugBank.d737.s6|482-487|little|O
DDI-DrugBank.d737.s6|489-494|effect|O
DDI-DrugBank.d737.s6|496-497|on|O
DDI-DrugBank.d737.s6|499-501|the|O
DDI-DrugBank.d737.s6|503-506|oral|O
DDI-DrugBank.d737.s6|508-516|clearance|O
DDI-DrugBank.d737.s6|518-519|of|O
DDI-DrugBank.d737.s6|521-531|pramipexole|O
DDI-DrugBank.d737.s6|532-532|.|O
DDI-DrugBank.d737.s7|0-2|CYP|O
DDI-DrugBank.d737.s7|4-15|interactions|O
DDI-DrugBank.d737.s7|16-16|:|O
DDI-DrugBank.d737.s7|18-27|Inhibitors|O
DDI-DrugBank.d737.s7|29-30|of|O
DDI-DrugBank.d737.s7|32-41|cytochrome|O
DDI-DrugBank.d737.s7|43-46|P450|O
DDI-DrugBank.d737.s7|48-54|enzymes|O
DDI-DrugBank.d737.s7|56-60|would|O
DDI-DrugBank.d737.s7|62-64|not|O
DDI-DrugBank.d737.s7|66-67|be|O
DDI-DrugBank.d737.s7|69-76|expected|O
DDI-DrugBank.d737.s7|78-79|to|O
DDI-DrugBank.d737.s7|81-86|affect|O
DDI-DrugBank.d737.s7|88-98|pramipexole|O
DDI-DrugBank.d737.s7|100-110|elimination|O
DDI-DrugBank.d737.s7|112-118|because|O
DDI-DrugBank.d737.s7|120-130|pramipexole|O
DDI-DrugBank.d737.s7|132-133|is|O
DDI-DrugBank.d737.s7|135-137|not|O
DDI-DrugBank.d737.s7|139-149|appreciably|O
DDI-DrugBank.d737.s7|151-161|metabolized|O
DDI-DrugBank.d737.s7|163-164|by|O
DDI-DrugBank.d737.s7|166-170|these|O
DDI-DrugBank.d737.s7|172-178|enzymes|O
DDI-DrugBank.d737.s7|180-181|in|O
DDI-DrugBank.d737.s7|183-186|vivo|O
DDI-DrugBank.d737.s7|188-189|or|O
DDI-DrugBank.d737.s7|191-192|in|O
DDI-DrugBank.d737.s7|194-198|vitro|O
DDI-DrugBank.d737.s7|199-199|.|O
DDI-DrugBank.d737.s8|0-10|Pramipexole|O
DDI-DrugBank.d737.s8|12-15|does|O
DDI-DrugBank.d737.s8|17-19|not|O
DDI-DrugBank.d737.s8|21-27|inhibit|O
DDI-DrugBank.d737.s8|29-31|CYP|O
DDI-DrugBank.d737.s8|33-39|enzymes|O
DDI-DrugBank.d737.s8|41-46|CYPIA2|O
DDI-DrugBank.d737.s8|47-47|,|O
DDI-DrugBank.d737.s8|49-54|CYP2C9|O
DDI-DrugBank.d737.s8|55-55|,|O
DDI-DrugBank.d737.s8|57-63|CYP2CI9|O
DDI-DrugBank.d737.s8|64-64|,|O
DDI-DrugBank.d737.s8|66-71|CYP2EI|O
DDI-DrugBank.d737.s8|72-72|,|O
DDI-DrugBank.d737.s8|74-76|and|O
DDI-DrugBank.d737.s8|78-83|CYP3A4|O
DDI-DrugBank.d737.s8|84-84|.|O
DDI-DrugBank.d737.s9|0-9|Inhibition|O
DDI-DrugBank.d737.s9|11-12|of|O
DDI-DrugBank.d737.s9|14-19|CYP2D6|O
DDI-DrugBank.d737.s9|21-23|was|O
DDI-DrugBank.d737.s9|25-32|observed|O
DDI-DrugBank.d737.s9|34-37|with|O
DDI-DrugBank.d737.s9|39-40|an|O
DDI-DrugBank.d737.s9|42-49|apparent|O
DDI-DrugBank.d737.s9|51-52|Ki|O
DDI-DrugBank.d737.s9|54-55|of|O
DDI-DrugBank.d737.s9|57-58|30|O
DDI-DrugBank.d737.s9|60-61|uM|O
DDI-DrugBank.d737.s9|62-62|,|O
DDI-DrugBank.d737.s9|64-73|indicating|O
DDI-DrugBank.d737.s9|75-78|that|O
DDI-DrugBank.d737.s9|80-90|pramipexole|O
DDI-DrugBank.d737.s9|92-95|will|O
DDI-DrugBank.d737.s9|97-99|not|O
DDI-DrugBank.d737.s9|101-107|inhibit|O
DDI-DrugBank.d737.s9|109-111|CYP|O
DDI-DrugBank.d737.s9|113-119|enzymes|O
DDI-DrugBank.d737.s9|121-122|at|O
DDI-DrugBank.d737.s9|124-129|plasma|O
DDI-DrugBank.d737.s9|131-144|concentrations|O
DDI-DrugBank.d737.s9|146-153|observed|O
DDI-DrugBank.d737.s9|155-163|following|O
DDI-DrugBank.d737.s9|165-167|the|O
DDI-DrugBank.d737.s9|169-175|highest|O
DDI-DrugBank.d737.s9|177-187|recommended|O
DDI-DrugBank.d737.s9|189-196|clinical|O
DDI-DrugBank.d737.s9|198-201|dose|O
DDI-DrugBank.d737.s9|203-203|(|O
DDI-DrugBank.d737.s9|204-206|1.5|O
DDI-DrugBank.d737.s9|208-209|mg|O
DDI-DrugBank.d737.s9|211-213|tid|O
DDI-DrugBank.d737.s9|214-214|)|O
DDI-DrugBank.d737.s9|215-215|.|O
DDI-DrugBank.d737.s10|0-7|Dopamine|O
DDI-DrugBank.d737.s10|9-19|antagonists|O
DDI-DrugBank.d737.s10|20-20|:|O
DDI-DrugBank.d737.s10|22-26|Since|O
DDI-DrugBank.d737.s10|28-38|pramipexole|O
DDI-DrugBank.d737.s10|40-41|is|O
DDI-DrugBank.d737.s10|43-43|a|O
DDI-DrugBank.d737.s10|45-52|dopamine|O
DDI-DrugBank.d737.s10|54-60|agonist|O
DDI-DrugBank.d737.s10|61-61|,|O
DDI-DrugBank.d737.s10|63-64|it|O
DDI-DrugBank.d737.s10|66-67|is|O
DDI-DrugBank.d737.s10|69-76|possible|O
DDI-DrugBank.d737.s10|78-81|that|O
DDI-DrugBank.d737.s10|83-90|dopamine|O
DDI-DrugBank.d737.s10|92-102|antagonists|O
DDI-DrugBank.d737.s10|103-103|,|O
DDI-DrugBank.d737.s10|105-108|such|O
DDI-DrugBank.d737.s10|110-111|as|O
DDI-DrugBank.d737.s10|113-115|the|O
DDI-DrugBank.d737.s10|117-128|neuroleptics|O
DDI-DrugBank.d737.s10|130-130|(|O
DDI-DrugBank.d737.s10|131-144|phenothiazines|O
DDI-DrugBank.d737.s10|145-145|,|O
DDI-DrugBank.d737.s10|147-160|butyrophenones|O
DDI-DrugBank.d737.s10|161-161|,|O
DDI-DrugBank.d737.s10|163-175|thioxanthenes|O
DDI-DrugBank.d737.s10|176-176|)|O
DDI-DrugBank.d737.s10|178-179|or|O
DDI-DrugBank.d737.s10|181-194|metoclopramide|O
DDI-DrugBank.d737.s10|195-195|,|O
DDI-DrugBank.d737.s10|197-199|may|O
DDI-DrugBank.d737.s10|201-208|diminish|O
DDI-DrugBank.d737.s10|210-212|the|O
DDI-DrugBank.d737.s10|214-226|effectiveness|O
DDI-DrugBank.d737.s10|228-229|of|O
DDI-DrugBank.d737.s10|231-237|MIRAPEX|O
DDI-DrugBank.d737.s10|238-238|.|O
DDI-DrugBank.d737.s11|0-4|Drug/|O
DDI-DrugBank.d737.s11|6-15|Laboratory|O
DDI-DrugBank.d737.s11|17-20|Test|O
DDI-DrugBank.d737.s11|22-33|Interactions|O
DDI-DrugBank.d737.s11|35-39|There|O
DDI-DrugBank.d737.s11|41-43|are|O
DDI-DrugBank.d737.s11|45-46|no|O
DDI-DrugBank.d737.s11|48-52|known|O
DDI-DrugBank.d737.s11|54-65|interactions|O
DDI-DrugBank.d737.s11|67-73|between|O
DDI-DrugBank.d737.s11|75-81|MIRAPEX|O
DDI-DrugBank.d737.s11|83-85|and|O
DDI-DrugBank.d737.s11|87-96|laboratory|O
DDI-DrugBank.d737.s11|98-102|tests|O
DDI-DrugBank.d737.s11|103-103|.|O
DDI-MedLine.d47.s0|0-7|Activity|O
DDI-MedLine.d47.s0|9-10|of|O
DDI-MedLine.d47.s0|12-18|buforin|O
DDI-MedLine.d47.s0|20-21|II|O
DDI-MedLine.d47.s0|23-27|alone|O
DDI-MedLine.d47.s0|29-31|and|O
DDI-MedLine.d47.s0|33-34|in|O
DDI-MedLine.d47.s0|36-46|combination|O
DDI-MedLine.d47.s0|48-51|with|O
DDI-MedLine.d47.s0|53-64|azithromycin|O
DDI-MedLine.d47.s0|66-68|and|O
DDI-MedLine.d47.s0|70-80|minocycline|O
DDI-MedLine.d47.s0|82-88|against|O
DDI-MedLine.d47.s0|90-104|Cryptosporidium|O
DDI-MedLine.d47.s0|106-111|parvum|O
DDI-MedLine.d47.s0|113-114|in|O
DDI-MedLine.d47.s0|116-119|cell|O
DDI-MedLine.d47.s0|121-127|culture|O
DDI-MedLine.d47.s0|128-128|.|O
DDI-MedLine.d47.s1|0-2|The|O
DDI-MedLine.d47.s1|4-5|in|O
DDI-MedLine.d47.s1|7-11|vitro|O
DDI-MedLine.d47.s1|13-32|anti-cryptosporidial|O
DDI-MedLine.d47.s1|34-41|activity|O
DDI-MedLine.d47.s1|43-44|of|O
DDI-MedLine.d47.s1|46-52|buforin|O
DDI-MedLine.d47.s1|54-55|II|O
DDI-MedLine.d47.s1|57-61|alone|O
DDI-MedLine.d47.s1|63-65|and|O
DDI-MedLine.d47.s1|67-68|in|O
DDI-MedLine.d47.s1|70-80|combination|O
DDI-MedLine.d47.s1|82-85|with|O
DDI-MedLine.d47.s1|87-98|azithromycin|O
DDI-MedLine.d47.s1|100-102|and|O
DDI-MedLine.d47.s1|104-114|minocycline|O
DDI-MedLine.d47.s1|116-118|was|O
DDI-MedLine.d47.s1|120-131|investigated|O
DDI-MedLine.d47.s1|132-132|.|O
DDI-MedLine.d47.s2|0-6|Buforin|O
DDI-MedLine.d47.s2|8-9|II|O
DDI-MedLine.d47.s2|11-16|showed|O
DDI-MedLine.d47.s2|18-25|moderate|O
DDI-MedLine.d47.s2|27-34|activity|O
DDI-MedLine.d47.s2|35-35|,|O
DDI-MedLine.d47.s2|37-41|which|O
DDI-MedLine.d47.s2|43-51|increased|O
DDI-MedLine.d47.s2|53-56|with|O
DDI-MedLine.d47.s2|58-67|increasing|O
DDI-MedLine.d47.s2|69-81|concentration|O
DDI-MedLine.d47.s2|83-84|to|O
DDI-MedLine.d47.s2|86-89|55.7|O
DDI-MedLine.d47.s2|90-90|%|O
DDI-MedLine.d47.s2|92-102|suppression|O
DDI-MedLine.d47.s2|104-105|of|O
DDI-MedLine.d47.s2|107-112|growth|O
DDI-MedLine.d47.s2|114-115|at|O
DDI-MedLine.d47.s2|117-118|20|O
DDI-MedLine.d47.s2|120-125|microM|O
DDI-MedLine.d47.s2|126-126|.|O
DDI-MedLine.d47.s3|0-7|Moreover|O
DDI-MedLine.d47.s3|8-8|,|O
DDI-MedLine.d47.s3|10-12|its|O
DDI-MedLine.d47.s3|14-21|activity|O
DDI-MedLine.d47.s3|23-25|was|O
DDI-MedLine.d47.s3|27-34|enhanced|O
DDI-MedLine.d47.s3|36-39|when|O
DDI-MedLine.d47.s3|41-42|it|O
DDI-MedLine.d47.s3|44-46|was|O
DDI-MedLine.d47.s3|48-55|combined|O
DDI-MedLine.d47.s3|57-60|with|O
DDI-MedLine.d47.s3|62-67|either|O
DDI-MedLine.d47.s3|69-80|azithromycin|O
DDI-MedLine.d47.s3|82-83|or|O
DDI-MedLine.d47.s3|85-95|minocycline|O
DDI-MedLine.d47.s3|97-100|with|O
DDI-MedLine.d47.s3|102-103|90|O
DDI-MedLine.d47.s3|104-104|%|O
DDI-MedLine.d47.s3|106-113|parasite|O
DDI-MedLine.d47.s3|115-123|reduction|O
DDI-MedLine.d47.s3|125-126|at|O
DDI-MedLine.d47.s3|128-130|the|O
DDI-MedLine.d47.s3|132-138|highest|O
DDI-MedLine.d47.s3|140-152|concentration|O
DDI-MedLine.d47.s3|154-159|tested|O
DDI-MedLine.d47.s3|160-160|.|O
DDI-MedLine.d47.s4|0-6|Buforin|O
DDI-MedLine.d47.s4|8-9|II|O
DDI-MedLine.d47.s4|11-13|may|O
DDI-MedLine.d47.s4|15-16|be|O
DDI-MedLine.d47.s4|18-23|active|O
DDI-MedLine.d47.s4|25-26|in|O
DDI-MedLine.d47.s4|28-37|inhibiting|O
DDI-MedLine.d47.s4|39-53|Cryptosporidium|O
DDI-MedLine.d47.s4|55-60|parvum|O
DDI-MedLine.d47.s4|62-67|growth|O
DDI-MedLine.d47.s4|69-70|in|O
DDI-MedLine.d47.s4|72-76|vitro|O
DDI-MedLine.d47.s4|78-81|upon|O
DDI-MedLine.d47.s4|83-93|combination|O
DDI-MedLine.d47.s4|95-98|with|O
DDI-MedLine.d47.s4|100-105|either|O
DDI-MedLine.d47.s4|107-118|azithromycin|O
DDI-MedLine.d47.s4|120-121|or|O
DDI-MedLine.d47.s4|123-133|minocycline|O
DDI-MedLine.d47.s4|134-134|.|O
DDI-DrugBank.d44.s0|0-1|No|O
DDI-DrugBank.d44.s0|3-8|formal|O
DDI-DrugBank.d44.s0|10-13|drug|O
DDI-DrugBank.d44.s0|15-25|interaction|O
DDI-DrugBank.d44.s0|27-33|studies|O
DDI-DrugBank.d44.s0|35-38|have|O
DDI-DrugBank.d44.s0|40-43|been|O
DDI-DrugBank.d44.s0|45-53|performed|O
DDI-DrugBank.d44.s0|55-58|with|O
DDI-DrugBank.d44.s0|60-66|RAPTIVA|O
DDI-DrugBank.d44.s0|67-67|.|O
DDI-DrugBank.d44.s1|0-6|RAPTIVA|O
DDI-DrugBank.d44.s1|8-13|should|O
DDI-DrugBank.d44.s1|15-17|not|O
DDI-DrugBank.d44.s1|19-20|be|O
DDI-DrugBank.d44.s1|22-25|used|O
DDI-DrugBank.d44.s1|27-30|with|O
DDI-DrugBank.d44.s1|32-36|other|O
DDI-DrugBank.d44.s1|38-54|immunosuppressive|O
DDI-DrugBank.d44.s1|56-60|drugs|O
DDI-DrugBank.d44.s1|61-61|.|O
DDI-DrugBank.d44.s2|0-8|Acellular|O
DDI-DrugBank.d44.s2|9-9|,|O
DDI-DrugBank.d44.s2|11-14|live|O
DDI-DrugBank.d44.s2|16-18|and|O
DDI-DrugBank.d44.s2|20-34|live-attenuated|O
DDI-DrugBank.d44.s2|36-43|vaccines|O
DDI-DrugBank.d44.s2|45-50|should|O
DDI-DrugBank.d44.s2|52-54|not|O
DDI-DrugBank.d44.s2|56-57|be|O
DDI-DrugBank.d44.s2|59-70|administered|O
DDI-DrugBank.d44.s2|72-77|during|O
DDI-DrugBank.d44.s2|79-85|RAPTIVA|O
DDI-DrugBank.d44.s2|87-95|treatment|O
DDI-DrugBank.d44.s2|96-96|.|O
DDI-DrugBank.d44.s3|0-14|Drug/Laboratory|O
DDI-DrugBank.d44.s3|16-19|Test|O
DDI-DrugBank.d44.s3|21-32|Interactions|O
DDI-DrugBank.d44.s3|34-42|Increases|O
DDI-DrugBank.d44.s3|44-45|in|O
DDI-DrugBank.d44.s3|47-56|lymphocyte|O
DDI-DrugBank.d44.s3|58-63|counts|O
DDI-DrugBank.d44.s3|65-71|related|O
DDI-DrugBank.d44.s3|73-74|to|O
DDI-DrugBank.d44.s3|76-78|the|O
DDI-DrugBank.d44.s3|80-92|pharmacologic|O
DDI-DrugBank.d44.s3|94-102|mechanism|O
DDI-DrugBank.d44.s3|104-105|of|O
DDI-DrugBank.d44.s3|107-112|action|O
DDI-DrugBank.d44.s3|114-116|are|O
DDI-DrugBank.d44.s3|118-127|frequently|O
DDI-DrugBank.d44.s3|129-136|observed|O
DDI-DrugBank.d44.s3|138-143|during|O
DDI-DrugBank.d44.s3|145-151|RAPTIVA|O
DDI-DrugBank.d44.s3|153-161|treatment|O
DDI-DrugBank.d44.s3|162-162|.|O
DDI-MedLine.d180.s0|0-11|Determinants|O
DDI-MedLine.d180.s0|13-14|of|O
DDI-MedLine.d180.s0|16-26|sensitivity|O
DDI-MedLine.d180.s0|28-29|to|O
DDI-MedLine.d180.s0|31-35|DZNep|O
DDI-MedLine.d180.s0|37-43|induced|O
DDI-MedLine.d180.s0|45-53|apoptosis|O
DDI-MedLine.d180.s0|55-56|in|O
DDI-MedLine.d180.s0|58-65|multiple|O
DDI-MedLine.d180.s0|67-73|myeloma|O
DDI-MedLine.d180.s0|75-79|cells|O
DDI-MedLine.d180.s0|80-80|.|O
DDI-MedLine.d180.s1|0-2|The|O
DDI-MedLine.d180.s1|4-20|3-Deazaneplanocin|O
DDI-MedLine.d180.s1|22-22|A|O
DDI-MedLine.d180.s1|24-24|(|O
DDI-MedLine.d180.s1|25-29|DZNep|O
DDI-MedLine.d180.s1|30-30|)|O
DDI-MedLine.d180.s1|31-31|,|O
DDI-MedLine.d180.s1|33-35|one|O
DDI-MedLine.d180.s1|37-38|of|O
DDI-MedLine.d180.s1|40-61|S-adenosylhomocysteine|O
DDI-MedLine.d180.s1|63-63|(|O
DDI-MedLine.d180.s1|64-69|AdoHcy|O
DDI-MedLine.d180.s1|70-70|)|O
DDI-MedLine.d180.s1|72-80|hydrolase|O
DDI-MedLine.d180.s1|82-91|inhibitors|O
DDI-MedLine.d180.s1|92-92|,|O
DDI-MedLine.d180.s1|94-96|has|O
DDI-MedLine.d180.s1|98-102|shown|O
DDI-MedLine.d180.s1|104-112|antitumor|O
DDI-MedLine.d180.s1|114-123|activities|O
DDI-MedLine.d180.s1|125-126|in|O
DDI-MedLine.d180.s1|128-128|a|O
DDI-MedLine.d180.s1|130-134|broad|O
DDI-MedLine.d180.s1|136-140|range|O
DDI-MedLine.d180.s1|142-143|of|O
DDI-MedLine.d180.s1|145-149|solid|O
DDI-MedLine.d180.s1|151-156|tumors|O
DDI-MedLine.d180.s1|158-160|and|O
DDI-MedLine.d180.s1|162-166|acute|O
DDI-MedLine.d180.s1|168-174|myeloid|O
DDI-MedLine.d180.s1|176-183|leukemia|O
DDI-MedLine.d180.s1|184-184|.|O
DDI-MedLine.d180.s2|0-3|Here|O
DDI-MedLine.d180.s2|4-4|,|O
DDI-MedLine.d180.s2|6-7|we|O
DDI-MedLine.d180.s2|9-16|examined|O
DDI-MedLine.d180.s2|18-20|its|O
DDI-MedLine.d180.s2|22-28|effects|O
DDI-MedLine.d180.s2|30-31|on|O
DDI-MedLine.d180.s2|33-40|multiple|O
DDI-MedLine.d180.s2|42-48|myeloma|O
DDI-MedLine.d180.s2|50-50|(|O
DDI-MedLine.d180.s2|51-52|MM|O
DDI-MedLine.d180.s2|53-53|)|O
DDI-MedLine.d180.s2|55-59|cells|O
DDI-MedLine.d180.s2|61-63|and|O
DDI-MedLine.d180.s2|65-69|found|O
DDI-MedLine.d180.s2|71-74|that|O
DDI-MedLine.d180.s2|75-75|,|O
DDI-MedLine.d180.s2|77-78|at|O
DDI-MedLine.d180.s2|80-82|500|O
DDI-MedLine.d180.s2|84-85|nM|O
DDI-MedLine.d180.s2|86-86|,|O
DDI-MedLine.d180.s2|88-89|it|O
DDI-MedLine.d180.s2|91-98|potently|O
DDI-MedLine.d180.s2|100-108|inhibited|O
DDI-MedLine.d180.s2|110-115|growth|O
DDI-MedLine.d180.s2|117-119|and|O
DDI-MedLine.d180.s2|121-127|induced|O
DDI-MedLine.d180.s2|129-137|apoptosis|O
DDI-MedLine.d180.s2|139-140|in|O
DDI-MedLine.d180.s2|142-142|2|O
DDI-MedLine.d180.s2|144-145|of|O
DDI-MedLine.d180.s2|147-147|8|O
DDI-MedLine.d180.s2|149-150|MM|O
DDI-MedLine.d180.s2|152-155|cell|O
DDI-MedLine.d180.s2|157-161|lines|O
DDI-MedLine.d180.s2|162-162|.|O
DDI-MedLine.d180.s3|0-2|RNA|O
DDI-MedLine.d180.s3|4-7|from|O
DDI-MedLine.d180.s3|9-18|un-treated|O
DDI-MedLine.d180.s3|20-22|and|O
DDI-MedLine.d180.s3|24-28|DZNep|O
DDI-MedLine.d180.s3|30-36|treated|O
DDI-MedLine.d180.s3|38-42|cells|O
DDI-MedLine.d180.s3|44-46|was|O
DDI-MedLine.d180.s3|48-55|profiled|O
DDI-MedLine.d180.s3|57-58|by|O
DDI-MedLine.d180.s3|60-69|Affymetrix|O
DDI-MedLine.d180.s3|71-77|HG-U133|O
DDI-MedLine.d180.s3|79-82|Plus|O
DDI-MedLine.d180.s3|84-86|2.0|O
DDI-MedLine.d180.s3|88-97|microarray|O
DDI-MedLine.d180.s3|99-101|and|O
DDI-MedLine.d180.s3|103-107|genes|O
DDI-MedLine.d180.s3|109-112|with|O
DDI-MedLine.d180.s3|114-114|a|O
DDI-MedLine.d180.s3|116-126|significant|O
DDI-MedLine.d180.s3|128-133|change|O
DDI-MedLine.d180.s3|135-136|in|O
DDI-MedLine.d180.s3|138-141|gene|O
DDI-MedLine.d180.s3|143-152|expression|O
DDI-MedLine.d180.s3|154-157|were|O
DDI-MedLine.d180.s3|159-168|determined|O
DDI-MedLine.d180.s3|170-171|by|O
DDI-MedLine.d180.s3|173-184|significance|O
DDI-MedLine.d180.s3|186-193|analysis|O
DDI-MedLine.d180.s3|195-196|of|O
DDI-MedLine.d180.s3|198-207|microarray|O
DDI-MedLine.d180.s3|209-209|(|O
DDI-MedLine.d180.s3|210-212|SAM|O
DDI-MedLine.d180.s3|213-213|)|O
DDI-MedLine.d180.s3|215-221|testing|O
DDI-MedLine.d180.s3|222-222|.|O
DDI-MedLine.d180.s4|0-4|ALOX5|O
DDI-MedLine.d180.s4|6-8|was|O
DDI-MedLine.d180.s4|10-12|the|O
DDI-MedLine.d180.s4|14-17|most|O
DDI-MedLine.d180.s4|19-32|down-regulated|O
DDI-MedLine.d180.s4|34-37|gene|O
DDI-MedLine.d180.s4|39-39|(|O
DDI-MedLine.d180.s4|40-47|5.8-fold|O
DDI-MedLine.d180.s4|48-48|)|O
DDI-MedLine.d180.s4|50-51|in|O
DDI-MedLine.d180.s4|53-61|sensitive|O
DDI-MedLine.d180.s4|63-67|cells|O
DDI-MedLine.d180.s4|69-71|and|O
DDI-MedLine.d180.s4|73-75|was|O
DDI-MedLine.d180.s4|77-85|expressed|O
DDI-MedLine.d180.s4|87-88|at|O
DDI-MedLine.d180.s4|90-92|low|O
DDI-MedLine.d180.s4|94-98|level|O
DDI-MedLine.d180.s4|100-101|in|O
DDI-MedLine.d180.s4|103-111|resistant|O
DDI-MedLine.d180.s4|113-117|cells|O
DDI-MedLine.d180.s4|118-118|.|O
DDI-MedLine.d180.s5|0-2|The|O
DDI-MedLine.d180.s5|4-10|results|O
DDI-MedLine.d180.s5|12-15|were|O
DDI-MedLine.d180.s5|17-28|corroborated|O
DDI-MedLine.d180.s5|30-31|by|O
DDI-MedLine.d180.s5|33-44|quantitative|O
DDI-MedLine.d180.s5|46-51|RT-PCR|O
DDI-MedLine.d180.s5|52-52|.|O
DDI-MedLine.d180.s6|0-11|Western-blot|O
DDI-MedLine.d180.s6|13-20|analysis|O
DDI-MedLine.d180.s6|22-30|indicated|O
DDI-MedLine.d180.s6|32-36|ALOX5|O
DDI-MedLine.d180.s6|38-40|was|O
DDI-MedLine.d180.s6|42-47|highly|O
DDI-MedLine.d180.s6|49-57|expressed|O
DDI-MedLine.d180.s6|59-62|only|O
DDI-MedLine.d180.s6|64-65|in|O
DDI-MedLine.d180.s6|67-75|sensitive|O
DDI-MedLine.d180.s6|77-80|cell|O
DDI-MedLine.d180.s6|82-85|line|O
DDI-MedLine.d180.s6|87-90|H929|O
DDI-MedLine.d180.s6|92-94|and|O
DDI-MedLine.d180.s6|96-102|greatly|O
DDI-MedLine.d180.s6|104-112|decreased|O
DDI-MedLine.d180.s6|114-117|upon|O
DDI-MedLine.d180.s6|119-123|DZNep|O
DDI-MedLine.d180.s6|125-133|treatment|O
DDI-MedLine.d180.s6|134-134|.|O
DDI-MedLine.d180.s7|0-6|Ectopic|O
DDI-MedLine.d180.s7|8-17|expression|O
DDI-MedLine.d180.s7|19-20|of|O
DDI-MedLine.d180.s7|22-26|ALOX5|O
DDI-MedLine.d180.s7|28-34|reduced|O
DDI-MedLine.d180.s7|36-46|sensitivity|O
DDI-MedLine.d180.s7|48-49|to|O
DDI-MedLine.d180.s7|51-55|DZNep|O
DDI-MedLine.d180.s7|57-58|in|O
DDI-MedLine.d180.s7|60-63|H929|O
DDI-MedLine.d180.s7|65-69|cells|O
DDI-MedLine.d180.s7|70-70|.|O
DDI-MedLine.d180.s8|0-10|Furthermore|O
DDI-MedLine.d180.s8|11-11|,|O
DDI-MedLine.d180.s8|13-27|down-regulation|O
DDI-MedLine.d180.s8|29-30|of|O
DDI-MedLine.d180.s8|32-36|ALOX5|O
DDI-MedLine.d180.s8|38-39|by|O
DDI-MedLine.d180.s8|41-43|RNA|O
DDI-MedLine.d180.s8|45-56|interference|O
DDI-MedLine.d180.s8|58-62|could|O
DDI-MedLine.d180.s8|64-67|also|O
DDI-MedLine.d180.s8|69-74|induce|O
DDI-MedLine.d180.s8|76-84|apoptosis|O
DDI-MedLine.d180.s8|86-87|in|O
DDI-MedLine.d180.s8|89-92|H929|O
DDI-MedLine.d180.s8|93-93|.|O
DDI-MedLine.d180.s9|0-3|Gene|O
DDI-MedLine.d180.s9|5-14|expression|O
DDI-MedLine.d180.s9|16-23|analysis|O
DDI-MedLine.d180.s9|25-26|on|O
DDI-MedLine.d180.s9|28-29|MM|O
DDI-MedLine.d180.s9|31-37|patient|O
DDI-MedLine.d180.s9|39-45|dataset|O
DDI-MedLine.d180.s9|47-55|indicated|O
DDI-MedLine.d180.s9|57-61|ALOX5|O
DDI-MedLine.d180.s9|63-72|expression|O
DDI-MedLine.d180.s9|74-76|was|O
DDI-MedLine.d180.s9|78-90|significantly|O
DDI-MedLine.d180.s9|92-97|higher|O
DDI-MedLine.d180.s9|99-100|in|O
DDI-MedLine.d180.s9|102-103|MM|O
DDI-MedLine.d180.s9|105-112|patients|O
DDI-MedLine.d180.s9|114-121|compared|O
DDI-MedLine.d180.s9|123-124|to|O
DDI-MedLine.d180.s9|126-131|normal|O
DDI-MedLine.d180.s9|133-138|plasma|O
DDI-MedLine.d180.s9|140-144|cells|O
DDI-MedLine.d180.s9|145-145|.|O
DDI-MedLine.d180.s10|0-1|We|O
DDI-MedLine.d180.s10|3-6|also|O
DDI-MedLine.d180.s10|8-12|found|O
DDI-MedLine.d180.s10|14-17|that|O
DDI-MedLine.d180.s10|19-23|Bcl-2|O
DDI-MedLine.d180.s10|25-27|was|O
DDI-MedLine.d180.s10|29-41|overexpressed|O
DDI-MedLine.d180.s10|43-44|in|O
DDI-MedLine.d180.s10|46-50|DZNep|O
DDI-MedLine.d180.s10|52-62|insensitive|O
DDI-MedLine.d180.s10|64-68|cells|O
DDI-MedLine.d180.s10|69-69|,|O
DDI-MedLine.d180.s10|71-73|and|O
DDI-MedLine.d180.s10|75-85|cotreatment|O
DDI-MedLine.d180.s10|87-90|with|O
DDI-MedLine.d180.s10|92-96|DZNep|O
DDI-MedLine.d180.s10|98-100|and|O
DDI-MedLine.d180.s10|102-108|ABT-737|O
DDI-MedLine.d180.s10|109-109|,|O
DDI-MedLine.d180.s10|111-111|a|O
DDI-MedLine.d180.s10|113-117|Bcl-2|O
DDI-MedLine.d180.s10|119-124|family|O
DDI-MedLine.d180.s10|126-134|inhibitor|O
DDI-MedLine.d180.s10|135-135|,|O
DDI-MedLine.d180.s10|137-151|synergistically|O
DDI-MedLine.d180.s10|153-161|inhibited|O
DDI-MedLine.d180.s10|163-168|growth|O
DDI-MedLine.d180.s10|170-172|and|O
DDI-MedLine.d180.s10|174-180|induced|O
DDI-MedLine.d180.s10|182-190|apoptosis|O
DDI-MedLine.d180.s10|192-193|of|O
DDI-MedLine.d180.s10|195-199|DZNep|O
DDI-MedLine.d180.s10|201-211|insensitive|O
DDI-MedLine.d180.s10|213-214|MM|O
DDI-MedLine.d180.s10|216-220|cells|O
DDI-MedLine.d180.s10|221-221|.|O
DDI-MedLine.d180.s11|0-4|Taken|O
DDI-MedLine.d180.s11|6-13|together|O
DDI-MedLine.d180.s11|14-14|,|O
DDI-MedLine.d180.s11|16-19|this|O
DDI-MedLine.d180.s11|21-25|study|O
DDI-MedLine.d180.s11|27-31|shows|O
DDI-MedLine.d180.s11|33-35|one|O
DDI-MedLine.d180.s11|37-38|of|O
DDI-MedLine.d180.s11|40-49|mechanisms|O
DDI-MedLine.d180.s11|51-52|of|O
DDI-MedLine.d180.s11|54-56|the|O
DDI-MedLine.d180.s11|58-62|DZNep|O
DDI-MedLine.d180.s11|64-71|efficacy|O
DDI-MedLine.d180.s11|73-74|on|O
DDI-MedLine.d180.s11|76-77|MM|O
DDI-MedLine.d180.s11|79-88|correlates|O
DDI-MedLine.d180.s11|90-93|with|O
DDI-MedLine.d180.s11|95-97|its|O
DDI-MedLine.d180.s11|99-105|ability|O
DDI-MedLine.d180.s11|107-108|to|O
DDI-MedLine.d180.s11|110-122|down-regulate|O
DDI-MedLine.d180.s11|124-126|the|O
DDI-MedLine.d180.s11|128-132|ALOX5|O
DDI-MedLine.d180.s11|134-139|levels|O
DDI-MedLine.d180.s11|140-140|.|O
DDI-MedLine.d180.s12|0-1|In|O
DDI-MedLine.d180.s12|3-10|addition|O
DDI-MedLine.d180.s12|11-11|,|O
DDI-MedLine.d180.s12|13-17|DZNep|O
DDI-MedLine.d180.s12|19-31|insensitivity|O
DDI-MedLine.d180.s12|33-37|might|O
DDI-MedLine.d180.s12|39-40|be|O
DDI-MedLine.d180.s12|42-51|associated|O
DDI-MedLine.d180.s12|53-56|with|O
DDI-MedLine.d180.s12|58-71|overexpression|O
DDI-MedLine.d180.s12|73-74|of|O
DDI-MedLine.d180.s12|76-80|Bcl-2|O
DDI-MedLine.d180.s12|81-81|,|O
DDI-MedLine.d180.s12|83-85|and|O
DDI-MedLine.d180.s12|87-89|the|O
DDI-MedLine.d180.s12|91-101|combination|O
DDI-MedLine.d180.s12|103-104|of|O
DDI-MedLine.d180.s12|106-112|ABT-737|O
DDI-MedLine.d180.s12|114-116|and|O
DDI-MedLine.d180.s12|118-122|DZNep|O
DDI-MedLine.d180.s12|124-128|could|O
DDI-MedLine.d180.s12|130-144|synergistically|O
DDI-MedLine.d180.s12|146-152|induced|O
DDI-MedLine.d180.s12|154-162|apoptosis|O
DDI-MedLine.d180.s12|163-163|.|O
DDI-MedLine.d180.s13|0-4|These|O
DDI-MedLine.d180.s13|6-12|results|O
DDI-MedLine.d180.s13|14-20|suggest|O
DDI-MedLine.d180.s13|22-25|that|O
DDI-MedLine.d180.s13|27-31|DZNep|O
DDI-MedLine.d180.s13|33-35|may|O
DDI-MedLine.d180.s13|37-38|be|O
DDI-MedLine.d180.s13|40-48|exploited|O
DDI-MedLine.d180.s13|50-64|therapeutically|O
DDI-MedLine.d180.s13|66-68|for|O
DDI-MedLine.d180.s13|70-70|a|O
DDI-MedLine.d180.s13|72-77|subset|O
DDI-MedLine.d180.s13|79-80|of|O
DDI-MedLine.d180.s13|82-83|MM|O
DDI-MedLine.d180.s13|84-84|.|O
DDI-DrugBank.d694.s0|0-6|Digoxin|O
DDI-DrugBank.d694.s0|7-7|:|O
DDI-DrugBank.d694.s0|9-13|There|O
DDI-DrugBank.d694.s0|15-17|was|O
DDI-DrugBank.d694.s0|19-19|a|O
DDI-DrugBank.d694.s0|21-26|slight|O
DDI-DrugBank.d694.s0|28-35|increase|O
DDI-DrugBank.d694.s0|37-38|in|O
DDI-DrugBank.d694.s0|40-42|the|O
DDI-DrugBank.d694.s0|44-47|area|O
DDI-DrugBank.d694.s0|49-53|under|O
DDI-DrugBank.d694.s0|55-57|the|O
DDI-DrugBank.d694.s0|59-63|curve|O
DDI-DrugBank.d694.s0|65-65|(|O
DDI-DrugBank.d694.s0|66-68|AUC|O
DDI-DrugBank.d694.s0|69-69|,|O
DDI-DrugBank.d694.s0|71-72|11|O
DDI-DrugBank.d694.s0|73-73|%|O
DDI-DrugBank.d694.s0|74-74|)|O
DDI-DrugBank.d694.s0|76-78|and|O
DDI-DrugBank.d694.s0|80-83|mean|O
DDI-DrugBank.d694.s0|85-88|peak|O
DDI-DrugBank.d694.s0|90-93|drug|O
DDI-DrugBank.d694.s0|95-107|concentration|O
DDI-DrugBank.d694.s0|109-109|(|O
DDI-DrugBank.d694.s0|110-113|Cmax|O
DDI-DrugBank.d694.s0|114-114|,|O
DDI-DrugBank.d694.s0|116-117|18|O
DDI-DrugBank.d694.s0|118-118|%|O
DDI-DrugBank.d694.s0|119-119|)|O
DDI-DrugBank.d694.s0|121-122|of|O
DDI-DrugBank.d694.s0|124-130|digoxin|O
DDI-DrugBank.d694.s0|132-135|with|O
DDI-DrugBank.d694.s0|137-139|the|O
DDI-DrugBank.d694.s0|141-157|co-administration|O
DDI-DrugBank.d694.s0|159-160|of|O
DDI-DrugBank.d694.s0|162-164|100|O
DDI-DrugBank.d694.s0|166-167|mg|O
DDI-DrugBank.d694.s0|169-179|sitagliptin|O
DDI-DrugBank.d694.s0|181-183|for|O
DDI-DrugBank.d694.s0|185-186|10|O
DDI-DrugBank.d694.s0|188-191|days|O
DDI-DrugBank.d694.s0|192-192|.|O
DDI-DrugBank.d694.s1|0-7|Patients|O
DDI-DrugBank.d694.s1|9-17|receiving|O
DDI-DrugBank.d694.s1|19-25|digoxin|O
DDI-DrugBank.d694.s1|27-32|should|O
DDI-DrugBank.d694.s1|34-35|be|O
DDI-DrugBank.d694.s1|37-45|monitored|O
DDI-DrugBank.d694.s1|47-59|appropriately|O
DDI-DrugBank.d694.s1|60-60|.|O
DDI-DrugBank.d694.s2|0-1|No|O
DDI-DrugBank.d694.s2|3-8|dosage|O
DDI-DrugBank.d694.s2|10-19|adjustment|O
DDI-DrugBank.d694.s2|21-22|of|O
DDI-DrugBank.d694.s2|24-30|digoxin|O
DDI-DrugBank.d694.s2|32-33|or|O
DDI-DrugBank.d694.s2|35-41|JANUVIA|O
DDI-DrugBank.d694.s2|43-44|is|O
DDI-DrugBank.d694.s2|46-56|recommended|O
DDI-DrugBank.d694.s2|57-57|.|O
DDI-DrugBank.d255.s0|0-4|There|O
DDI-DrugBank.d255.s0|6-8|are|O
DDI-DrugBank.d255.s0|10-11|no|O
DDI-DrugBank.d255.s0|13-17|known|O
DDI-DrugBank.d255.s0|19-27|drug/drug|O
DDI-DrugBank.d255.s0|29-40|interactions|O
DDI-DrugBank.d255.s0|42-45|with|O
DDI-DrugBank.d255.s0|47-58|chlorambucil|O
DDI-DrugBank.d255.s0|59-59|.|O
DDI-DrugBank.d30.s0|0-1|No|O
DDI-DrugBank.d30.s0|3-13|significant|O
DDI-DrugBank.d30.s0|15-23|drug-drug|O
DDI-DrugBank.d30.s0|25-39|pharmacokinetic|O
DDI-DrugBank.d30.s0|41-52|interactions|O
DDI-DrugBank.d30.s0|54-57|have|O
DDI-DrugBank.d30.s0|59-62|been|O
DDI-DrugBank.d30.s0|64-68|found|O
DDI-DrugBank.d30.s0|70-71|in|O
DDI-DrugBank.d30.s0|73-83|interaction|O
DDI-DrugBank.d30.s0|85-91|studies|O
DDI-DrugBank.d30.s0|93-96|with|O
DDI-DrugBank.d30.s0|98-116|hydrochlorothiazide|O
DDI-DrugBank.d30.s0|117-117|,|O
DDI-DrugBank.d30.s0|119-125|digoxin|O
DDI-DrugBank.d30.s0|126-126|,|O
DDI-DrugBank.d30.s0|128-135|warfarin|O
DDI-DrugBank.d30.s0|136-136|,|O
DDI-DrugBank.d30.s0|138-147|cimetidine|O
DDI-DrugBank.d30.s0|149-151|and|O
DDI-DrugBank.d30.s0|153-165|phenobarbital|O
DDI-DrugBank.d30.s0|166-166|.|O
DDI-DrugBank.d30.s1|0-7|Rifampin|O
DDI-DrugBank.d30.s1|8-8|,|O
DDI-DrugBank.d30.s1|10-11|an|O
DDI-DrugBank.d30.s1|13-19|inducer|O
DDI-DrugBank.d30.s1|21-22|of|O
DDI-DrugBank.d30.s1|24-27|drug|O
DDI-DrugBank.d30.s1|29-38|metabolism|O
DDI-DrugBank.d30.s1|39-39|,|O
DDI-DrugBank.d30.s1|41-49|decreased|O
DDI-DrugBank.d30.s1|51-53|the|O
DDI-DrugBank.d30.s1|55-68|concentrations|O
DDI-DrugBank.d30.s1|70-71|of|O
DDI-DrugBank.d30.s1|73-80|losartan|O
DDI-DrugBank.d30.s1|82-84|and|O
DDI-DrugBank.d30.s1|86-88|its|O
DDI-DrugBank.d30.s1|90-95|active|O
DDI-DrugBank.d30.s1|97-106|metabolite|O
DDI-DrugBank.d30.s1|107-107|.|O
DDI-DrugBank.d30.s2|0-1|In|O
DDI-DrugBank.d30.s2|3-8|humans|O
DDI-DrugBank.d30.s2|9-9|,|O
DDI-DrugBank.d30.s2|11-13|two|O
DDI-DrugBank.d30.s2|15-24|inhibitors|O
DDI-DrugBank.d30.s2|26-27|of|O
DDI-DrugBank.d30.s2|29-32|P450|O
DDI-DrugBank.d30.s2|34-36|3A4|O
DDI-DrugBank.d30.s2|38-41|have|O
DDI-DrugBank.d30.s2|43-46|been|O
DDI-DrugBank.d30.s2|48-54|studied|O
DDI-DrugBank.d30.s2|55-55|.|O
DDI-DrugBank.d30.s3|0-11|Ketoconazole|O
DDI-DrugBank.d30.s3|13-15|did|O
DDI-DrugBank.d30.s3|17-19|not|O
DDI-DrugBank.d30.s3|21-26|affect|O
DDI-DrugBank.d30.s3|28-30|the|O
DDI-DrugBank.d30.s3|32-41|conversion|O
DDI-DrugBank.d30.s3|43-44|of|O
DDI-DrugBank.d30.s3|46-53|losartan|O
DDI-DrugBank.d30.s3|55-56|to|O
DDI-DrugBank.d30.s3|58-60|the|O
DDI-DrugBank.d30.s3|62-67|active|O
DDI-DrugBank.d30.s3|69-78|metabolite|O
DDI-DrugBank.d30.s3|80-84|after|O
DDI-DrugBank.d30.s3|86-96|intravenous|O
DDI-DrugBank.d30.s3|98-111|administration|O
DDI-DrugBank.d30.s3|113-114|of|O
DDI-DrugBank.d30.s3|116-123|losartan|O
DDI-DrugBank.d30.s3|124-124|,|O
DDI-DrugBank.d30.s3|126-128|and|O
DDI-DrugBank.d30.s3|130-141|erythromycin|O
DDI-DrugBank.d30.s3|143-145|had|O
DDI-DrugBank.d30.s3|147-148|no|O
DDI-DrugBank.d30.s3|150-159|clinically|O
DDI-DrugBank.d30.s3|161-171|significant|O
DDI-DrugBank.d30.s3|173-178|effect|O
DDI-DrugBank.d30.s3|180-184|after|O
DDI-DrugBank.d30.s3|186-189|oral|O
DDI-DrugBank.d30.s3|191-204|administration|O
DDI-DrugBank.d30.s3|205-205|.|O
DDI-DrugBank.d30.s4|0-10|Fluconazole|O
DDI-DrugBank.d30.s4|11-11|,|O
DDI-DrugBank.d30.s4|13-14|an|O
DDI-DrugBank.d30.s4|16-24|inhibitor|O
DDI-DrugBank.d30.s4|26-27|of|O
DDI-DrugBank.d30.s4|29-32|P450|O
DDI-DrugBank.d30.s4|34-36|2C9|O
DDI-DrugBank.d30.s4|37-37|,|O
DDI-DrugBank.d30.s4|39-47|decreased|O
DDI-DrugBank.d30.s4|49-54|active|O
DDI-DrugBank.d30.s4|56-65|metabolite|O
DDI-DrugBank.d30.s4|67-79|concentration|O
DDI-DrugBank.d30.s4|81-83|and|O
DDI-DrugBank.d30.s4|85-93|increased|O
DDI-DrugBank.d30.s4|95-102|losartan|O
DDI-DrugBank.d30.s4|104-116|concentration|O
DDI-DrugBank.d30.s4|117-117|.|O
DDI-DrugBank.d30.s5|0-2|The|O
DDI-DrugBank.d30.s5|4-18|pharmacodynamic|O
DDI-DrugBank.d30.s5|20-31|consequences|O
DDI-DrugBank.d30.s5|33-34|of|O
DDI-DrugBank.d30.s5|36-46|concomitant|O
DDI-DrugBank.d30.s5|48-50|use|O
DDI-DrugBank.d30.s5|52-53|of|O
DDI-DrugBank.d30.s5|55-62|losartan|O
DDI-DrugBank.d30.s5|64-66|and|O
DDI-DrugBank.d30.s5|68-77|inhibitors|O
DDI-DrugBank.d30.s5|79-80|of|O
DDI-DrugBank.d30.s5|82-85|P450|O
DDI-DrugBank.d30.s5|87-89|2C9|O
DDI-DrugBank.d30.s5|91-94|have|O
DDI-DrugBank.d30.s5|96-98|not|O
DDI-DrugBank.d30.s5|100-103|been|O
DDI-DrugBank.d30.s5|105-112|examined|O
DDI-DrugBank.d30.s5|113-113|.|O
DDI-DrugBank.d30.s6|0-7|Subjects|O
DDI-DrugBank.d30.s6|9-11|who|O
DDI-DrugBank.d30.s6|13-14|do|O
DDI-DrugBank.d30.s6|16-18|not|O
DDI-DrugBank.d30.s6|20-29|metabolize|O
DDI-DrugBank.d30.s6|31-38|losartan|O
DDI-DrugBank.d30.s6|40-41|to|O
DDI-DrugBank.d30.s6|43-48|active|O
DDI-DrugBank.d30.s6|50-59|metabolite|O
DDI-DrugBank.d30.s6|61-64|have|O
DDI-DrugBank.d30.s6|66-69|been|O
DDI-DrugBank.d30.s6|71-75|shown|O
DDI-DrugBank.d30.s6|77-78|to|O
DDI-DrugBank.d30.s6|80-83|have|O
DDI-DrugBank.d30.s6|85-85|a|O
DDI-DrugBank.d30.s6|87-94|specific|O
DDI-DrugBank.d30.s6|95-95|,|O
DDI-DrugBank.d30.s6|97-100|rare|O
DDI-DrugBank.d30.s6|102-107|defect|O
DDI-DrugBank.d30.s6|109-110|in|O
DDI-DrugBank.d30.s6|112-121|cytochrome|O
DDI-DrugBank.d30.s6|123-126|P450|O
DDI-DrugBank.d30.s6|128-130|2C9|O
DDI-DrugBank.d30.s6|131-131|.|O
DDI-DrugBank.d30.s7|0-4|These|O
DDI-DrugBank.d30.s7|6-9|data|O
DDI-DrugBank.d30.s7|11-17|suggest|O
DDI-DrugBank.d30.s7|19-22|that|O
DDI-DrugBank.d30.s7|24-26|the|O
DDI-DrugBank.d30.s7|28-37|conversion|O
DDI-DrugBank.d30.s7|39-40|of|O
DDI-DrugBank.d30.s7|42-49|losartan|O
DDI-DrugBank.d30.s7|51-52|to|O
DDI-DrugBank.d30.s7|54-56|its|O
DDI-DrugBank.d30.s7|58-63|active|O
DDI-DrugBank.d30.s7|65-74|metabolite|O
DDI-DrugBank.d30.s7|76-77|is|O
DDI-DrugBank.d30.s7|79-86|mediated|O
DDI-DrugBank.d30.s7|88-96|primarily|O
DDI-DrugBank.d30.s7|98-99|by|O
DDI-DrugBank.d30.s7|101-104|P450|O
DDI-DrugBank.d30.s7|106-108|2C9|O
DDI-DrugBank.d30.s7|110-112|and|O
DDI-DrugBank.d30.s7|114-116|not|O
DDI-DrugBank.d30.s7|118-121|P450|O
DDI-DrugBank.d30.s7|123-125|3A4|O
DDI-DrugBank.d30.s7|126-126|.|O
DDI-DrugBank.d30.s8|0-1|As|O
DDI-DrugBank.d30.s8|3-6|with|O
DDI-DrugBank.d30.s8|8-12|other|O
DDI-DrugBank.d30.s8|14-18|drugs|O
DDI-DrugBank.d30.s8|20-23|that|O
DDI-DrugBank.d30.s8|25-29|block|O
DDI-DrugBank.d30.s8|31-41|angiotensin|O
DDI-DrugBank.d30.s8|43-44|II|O
DDI-DrugBank.d30.s8|46-47|or|O
DDI-DrugBank.d30.s8|49-51|its|O
DDI-DrugBank.d30.s8|53-59|effects|O
DDI-DrugBank.d30.s8|60-60|,|O
DDI-DrugBank.d30.s8|62-72|concomitant|O
DDI-DrugBank.d30.s8|74-76|use|O
DDI-DrugBank.d30.s8|78-79|of|O
DDI-DrugBank.d30.s8|81-97|potassium-sparing|O
DDI-DrugBank.d30.s8|99-107|diuretics|O
DDI-DrugBank.d30.s8|109-109|(|O
DDI-DrugBank.d30.s8|110-113|e.g.|O
DDI-DrugBank.d30.s8|114-114|,|O
DDI-DrugBank.d30.s8|116-129|spironolactone|O
DDI-DrugBank.d30.s8|130-130|,|O
DDI-DrugBank.d30.s8|132-142|triamterene|O
DDI-DrugBank.d30.s8|143-143|,|O
DDI-DrugBank.d30.s8|145-153|amiloride|O
DDI-DrugBank.d30.s8|154-154|)|O
DDI-DrugBank.d30.s8|155-155|,|O
DDI-DrugBank.d30.s8|157-165|potassium|O
DDI-DrugBank.d30.s8|167-177|supplements|O
DDI-DrugBank.d30.s8|178-178|,|O
DDI-DrugBank.d30.s8|180-181|or|O
DDI-DrugBank.d30.s8|183-186|salt|O
DDI-DrugBank.d30.s8|188-198|substitutes|O
DDI-DrugBank.d30.s8|200-209|containing|O
DDI-DrugBank.d30.s8|211-219|potassium|O
DDI-DrugBank.d30.s8|221-223|may|O
DDI-DrugBank.d30.s8|225-228|lead|O
DDI-DrugBank.d30.s8|230-231|to|O
DDI-DrugBank.d30.s8|233-241|increases|O
DDI-DrugBank.d30.s8|243-244|in|O
DDI-DrugBank.d30.s8|246-250|serum|O
DDI-DrugBank.d30.s8|252-260|potassium|O
DDI-DrugBank.d30.s8|261-261|.|O
DDI-DrugBank.d30.s9|0-1|As|O
DDI-DrugBank.d30.s9|3-6|with|O
DDI-DrugBank.d30.s9|8-12|other|O
DDI-DrugBank.d30.s9|14-29|antihypertensive|O
DDI-DrugBank.d30.s9|31-36|agents|O
DDI-DrugBank.d30.s9|37-37|,|O
DDI-DrugBank.d30.s9|39-41|the|O
DDI-DrugBank.d30.s9|43-58|antihypertensive|O
DDI-DrugBank.d30.s9|60-65|effect|O
DDI-DrugBank.d30.s9|67-68|of|O
DDI-DrugBank.d30.s9|70-77|losartan|O
DDI-DrugBank.d30.s9|79-81|may|O
DDI-DrugBank.d30.s9|83-84|be|O
DDI-DrugBank.d30.s9|86-92|blunted|O
DDI-DrugBank.d30.s9|94-95|by|O
DDI-DrugBank.d30.s9|97-99|the|O
DDI-DrugBank.d30.s9|101-113|non-steroidal|O
DDI-DrugBank.d30.s9|115-131|anti-inflammatory|O
DDI-DrugBank.d30.s9|133-136|drug|O
DDI-DrugBank.d30.s9|138-149|indomethacin|O
DDI-DrugBank.d30.s10|0-0|.|O
DDI-DrugBank.d590.s0|0-15|Coadministration|O
DDI-DrugBank.d590.s0|17-18|of|O
DDI-DrugBank.d590.s0|20-25|TRITEC|O
DDI-DrugBank.d590.s0|27-30|with|O
DDI-DrugBank.d590.s0|32-45|clarithromycin|O
DDI-DrugBank.d590.s0|47-54|resulted|O
DDI-DrugBank.d590.s0|56-57|in|O
DDI-DrugBank.d590.s0|59-67|increased|O
DDI-DrugBank.d590.s0|69-74|plasma|O
DDI-DrugBank.d590.s0|76-85|ranitidine|O
DDI-DrugBank.d590.s0|87-100|concentrations|O
DDI-DrugBank.d590.s0|102-102|(|O
DDI-DrugBank.d590.s0|103-104|57|O
DDI-DrugBank.d590.s0|105-105|%|O
DDI-DrugBank.d590.s0|106-106|)|O
DDI-DrugBank.d590.s0|107-107|,|O
DDI-DrugBank.d590.s0|109-117|increased|O
DDI-DrugBank.d590.s0|119-124|plasma|O
DDI-DrugBank.d590.s0|126-132|bismuth|O
DDI-DrugBank.d590.s0|134-139|trough|O
DDI-DrugBank.d590.s0|141-154|concentrations|O
DDI-DrugBank.d590.s0|156-156|(|O
DDI-DrugBank.d590.s0|157-158|48|O
DDI-DrugBank.d590.s0|159-159|%|O
DDI-DrugBank.d590.s0|160-160|)|O
DDI-DrugBank.d590.s0|161-161|,|O
DDI-DrugBank.d590.s0|163-165|and|O
DDI-DrugBank.d590.s0|167-175|increased|O
DDI-DrugBank.d590.s0|177-179|14-|O
DDI-DrugBank.d590.s0|181-188|hydroxy-|O
DDI-DrugBank.d590.s0|190-203|clarithromycin|O
DDI-DrugBank.d590.s0|205-210|plasma|O
DDI-DrugBank.d590.s0|212-225|concentrations|O
DDI-DrugBank.d590.s0|227-227|(|O
DDI-DrugBank.d590.s0|228-229|31|O
DDI-DrugBank.d590.s0|230-230|%|O
DDI-DrugBank.d590.s0|231-231|)|O
DDI-DrugBank.d590.s0|232-232|.|O
DDI-DrugBank.d590.s1|0-15|Coadministration|O
DDI-DrugBank.d590.s1|17-20|with|O
DDI-DrugBank.d590.s1|22-28|aspirin|O
DDI-DrugBank.d590.s1|30-36|results|O
DDI-DrugBank.d590.s1|38-39|in|O
DDI-DrugBank.d590.s1|41-41|a|O
DDI-DrugBank.d590.s1|43-48|slight|O
DDI-DrugBank.d590.s1|50-57|decrease|O
DDI-DrugBank.d590.s1|59-60|in|O
DDI-DrugBank.d590.s1|62-64|the|O
DDI-DrugBank.d590.s1|66-69|rate|O
DDI-DrugBank.d590.s1|71-72|of|O
DDI-DrugBank.d590.s1|74-83|salicylate|O
DDI-DrugBank.d590.s1|85-94|absorption|O
DDI-DrugBank.d590.s1|96-99|that|O
DDI-DrugBank.d590.s1|101-102|is|O
DDI-DrugBank.d590.s1|104-113|clinically|O
DDI-DrugBank.d590.s1|115-125|unimportant|O
DDI-DrugBank.d590.s1|126-126|.|O
DDI-DrugBank.d590.s2|0-15|Coadministration|O
DDI-DrugBank.d590.s2|17-20|with|O
DDI-DrugBank.d590.s2|22-22|a|O
DDI-DrugBank.d590.s2|24-27|high|O
DDI-DrugBank.d590.s2|29-32|dose|O
DDI-DrugBank.d590.s2|34-35|of|O
DDI-DrugBank.d590.s2|37-43|antacid|O
DDI-DrugBank.d590.s2|45-45|(|O
DDI-DrugBank.d590.s2|46-48|170|O
DDI-DrugBank.d590.s2|50-52|mEq|O
DDI-DrugBank.d590.s2|53-53|)|O
DDI-DrugBank.d590.s2|55-61|results|O
DDI-DrugBank.d590.s2|63-64|in|O
DDI-DrugBank.d590.s2|66-66|a|O
DDI-DrugBank.d590.s2|68-69|28|O
DDI-DrugBank.d590.s2|70-70|%|O
DDI-DrugBank.d590.s2|72-79|decrease|O
DDI-DrugBank.d590.s2|81-82|in|O
DDI-DrugBank.d590.s2|84-89|plasma|O
DDI-DrugBank.d590.s2|91-104|concentrations|O
DDI-DrugBank.d590.s2|106-107|of|O
DDI-DrugBank.d590.s2|109-118|ranitidine|O
DDI-DrugBank.d590.s2|120-122|and|O
DDI-DrugBank.d590.s2|124-126|may|O
DDI-DrugBank.d590.s2|128-135|decrease|O
DDI-DrugBank.d590.s2|137-142|plasma|O
DDI-DrugBank.d590.s2|144-157|concentrations|O
DDI-DrugBank.d590.s2|159-160|of|O
DDI-DrugBank.d590.s2|162-168|bismuth|O
DDI-DrugBank.d590.s2|170-173|from|O
DDI-DrugBank.d590.s2|175-180|TRITEC|O
DDI-DrugBank.d590.s2|181-181|.|O
DDI-DrugBank.d590.s3|0-4|These|O
DDI-DrugBank.d590.s3|6-12|effects|O
DDI-DrugBank.d590.s3|14-16|are|O
DDI-DrugBank.d590.s3|18-27|clinically|O
DDI-DrugBank.d590.s3|29-41|insignificant|O
DDI-DrugBank.d590.s3|42-42|.|O
DDI-DrugBank.d590.s4|0-2|For|O
DDI-DrugBank.d590.s4|4-14|information|O
DDI-DrugBank.d590.s4|16-17|on|O
DDI-DrugBank.d590.s4|19-22|drug|O
DDI-DrugBank.d590.s4|24-35|interactions|O
DDI-DrugBank.d590.s4|37-46|associated|O
DDI-DrugBank.d590.s4|48-51|with|O
DDI-DrugBank.d590.s4|53-62|ranitidine|O
DDI-DrugBank.d590.s4|63-63|,|O
DDI-DrugBank.d590.s4|65-69|refer|O
DDI-DrugBank.d590.s4|71-72|to|O
DDI-DrugBank.d590.s4|74-76|the|O
DDI-DrugBank.d590.s4|78-83|ZANTAC|O
DDI-DrugBank.d590.s4|89-95|package|O
DDI-DrugBank.d590.s4|97-102|insert|O
DDI-DrugBank.d590.s4|103-103|.|O
DDI-DrugBank.d65.s0|0-12|Sulfacetamide|O
DDI-DrugBank.d65.s0|14-25|preparations|O
DDI-DrugBank.d65.s0|27-29|are|O
DDI-DrugBank.d65.s0|31-42|incompatible|O
DDI-DrugBank.d65.s0|44-47|with|O
DDI-DrugBank.d65.s0|49-54|silver|O
DDI-DrugBank.d65.s0|56-67|preparations|O
DDI-DrugBank.d65.s0|68-68|.|O
DDI-DrugBank.d497.s0|0-4|AZOPT|O
DDI-DrugBank.d497.s0|6-6|(|O
DDI-DrugBank.d497.s0|7-18|brinzolamide|O
DDI-DrugBank.d497.s0|20-29|ophthalmic|O
DDI-DrugBank.d497.s0|31-40|suspension|O
DDI-DrugBank.d497.s0|41-41|)|O
DDI-DrugBank.d497.s0|43-43|1|O
DDI-DrugBank.d497.s0|44-44|%|O
DDI-DrugBank.d497.s0|46-53|contains|O
DDI-DrugBank.d497.s0|55-55|a|O
DDI-DrugBank.d497.s0|57-64|carbonic|O
DDI-DrugBank.d497.s0|66-74|anhydrase|O
DDI-DrugBank.d497.s0|76-84|inhibitor|O
DDI-DrugBank.d497.s0|85-85|.|O
DDI-DrugBank.d497.s1|0-8|Acid-base|O
DDI-DrugBank.d497.s1|10-12|and|O
DDI-DrugBank.d497.s1|14-24|electrolyte|O
DDI-DrugBank.d497.s1|26-36|alterations|O
DDI-DrugBank.d497.s1|38-41|were|O
DDI-DrugBank.d497.s1|43-45|not|O
DDI-DrugBank.d497.s1|47-54|reported|O
DDI-DrugBank.d497.s1|56-57|in|O
DDI-DrugBank.d497.s1|59-61|the|O
DDI-DrugBank.d497.s1|63-70|clinical|O
DDI-DrugBank.d497.s1|72-77|trials|O
DDI-DrugBank.d497.s1|79-82|with|O
DDI-DrugBank.d497.s1|84-95|brinzolamide|O
DDI-DrugBank.d497.s1|96-96|.|O
DDI-DrugBank.d497.s2|0-6|However|O
DDI-DrugBank.d497.s2|7-7|,|O
DDI-DrugBank.d497.s2|9-10|in|O
DDI-DrugBank.d497.s2|12-19|patients|O
DDI-DrugBank.d497.s2|21-27|treated|O
DDI-DrugBank.d497.s2|29-32|with|O
DDI-DrugBank.d497.s2|34-37|oral|O
DDI-DrugBank.d497.s2|39-46|carbonic|O
DDI-DrugBank.d497.s2|48-56|anhydrase|O
DDI-DrugBank.d497.s2|58-67|inhibitors|O
DDI-DrugBank.d497.s2|68-68|,|O
DDI-DrugBank.d497.s2|70-73|rare|O
DDI-DrugBank.d497.s2|75-83|instances|O
DDI-DrugBank.d497.s2|85-86|of|O
DDI-DrugBank.d497.s2|88-91|drug|O
DDI-DrugBank.d497.s2|93-104|interactions|O
DDI-DrugBank.d497.s2|106-109|have|O
DDI-DrugBank.d497.s2|111-118|occurred|O
DDI-DrugBank.d497.s2|120-123|with|O
DDI-DrugBank.d497.s2|125-133|high-dose|O
DDI-DrugBank.d497.s2|135-144|salicylate|O
DDI-DrugBank.d497.s2|146-152|therapy|O
DDI-DrugBank.d497.s2|153-153|.|O
DDI-DrugBank.d497.s3|0-8|Therefore|O
DDI-DrugBank.d497.s3|9-9|,|O
DDI-DrugBank.d497.s3|11-13|the|O
DDI-DrugBank.d497.s3|15-23|potential|O
DDI-DrugBank.d497.s3|25-27|for|O
DDI-DrugBank.d497.s3|29-32|such|O
DDI-DrugBank.d497.s3|34-37|drug|O
DDI-DrugBank.d497.s3|39-49|interaction|O
DDI-DrugBank.d497.s3|51-56|should|O
DDI-DrugBank.d497.s3|58-59|be|O
DDI-DrugBank.d497.s3|61-70|considered|O
DDI-DrugBank.d497.s3|72-73|in|O
DDI-DrugBank.d497.s3|75-82|patients|O
DDI-DrugBank.d497.s3|84-92|receiving|O
DDI-DrugBank.d497.s3|94-98|AZOPT|O
DDI-DrugBank.d497.s3|100-100|(|O
DDI-DrugBank.d497.s3|101-112|brinzolamide|O
DDI-DrugBank.d497.s3|114-123|ophthalmic|O
DDI-DrugBank.d497.s3|125-134|suspension|O
DDI-DrugBank.d497.s3|135-135|)|O
DDI-DrugBank.d497.s3|137-137|1|O
DDI-DrugBank.d497.s3|138-138|%|O
DDI-DrugBank.d497.s3|139-139|.|O
DDI-DrugBank.d41.s0|0-13|Cholestyramine|O
DDI-DrugBank.d41.s0|15-17|and|O
DDI-DrugBank.d41.s0|19-26|Charcoal|O
DDI-DrugBank.d41.s0|28-41|Administration|O
DDI-DrugBank.d41.s0|43-44|of|O
DDI-DrugBank.d41.s0|46-59|cholestyramine|O
DDI-DrugBank.d41.s0|61-62|or|O
DDI-DrugBank.d41.s0|64-72|activated|O
DDI-DrugBank.d41.s0|74-81|charcoal|O
DDI-DrugBank.d41.s0|83-84|in|O
DDI-DrugBank.d41.s0|86-93|patients|O
DDI-DrugBank.d41.s0|95-95|(|O
DDI-DrugBank.d41.s0|96-99|n=13|O
DDI-DrugBank.d41.s0|100-100|)|O
DDI-DrugBank.d41.s0|102-104|and|O
DDI-DrugBank.d41.s0|106-115|volunteers|O
DDI-DrugBank.d41.s0|117-117|(|O
DDI-DrugBank.d41.s0|118-121|n=96|O
DDI-DrugBank.d41.s0|122-122|)|O
DDI-DrugBank.d41.s0|124-131|resulted|O
DDI-DrugBank.d41.s0|133-134|in|O
DDI-DrugBank.d41.s0|136-136|a|O
DDI-DrugBank.d41.s0|138-142|rapid|O
DDI-DrugBank.d41.s0|144-146|and|O
DDI-DrugBank.d41.s0|148-158|significant|O
DDI-DrugBank.d41.s0|160-167|decrease|O
DDI-DrugBank.d41.s0|169-170|in|O
DDI-DrugBank.d41.s0|172-177|plasma|O
DDI-DrugBank.d41.s0|179-180|M1|O
DDI-DrugBank.d41.s0|182-182|(|O
DDI-DrugBank.d41.s0|183-185|the|O
DDI-DrugBank.d41.s0|187-192|active|O
DDI-DrugBank.d41.s0|194-203|metabolite|O
DDI-DrugBank.d41.s0|205-206|of|O
DDI-DrugBank.d41.s0|208-218|leflunomide|O
DDI-DrugBank.d41.s0|219-219|)|O
DDI-DrugBank.d41.s0|221-233|concentration|O
DDI-DrugBank.d41.s0|235-235|.|O
DDI-DrugBank.d41.s1|0-10|Hepatotoxic|O
DDI-DrugBank.d41.s1|12-16|Drugs|O
DDI-DrugBank.d41.s1|18-26|Increased|O
DDI-DrugBank.d41.s1|28-31|side|O
DDI-DrugBank.d41.s1|33-39|effects|O
DDI-DrugBank.d41.s1|41-43|may|O
DDI-DrugBank.d41.s1|45-49|occur|O
DDI-DrugBank.d41.s1|51-54|when|O
DDI-DrugBank.d41.s1|56-66|leflunomide|O
DDI-DrugBank.d41.s1|68-69|is|O
DDI-DrugBank.d41.s1|71-75|given|O
DDI-DrugBank.d41.s1|77-89|concomitantly|O
DDI-DrugBank.d41.s1|91-94|with|O
DDI-DrugBank.d41.s1|96-106|hepatotoxic|O
DDI-DrugBank.d41.s1|108-117|substances|O
DDI-DrugBank.d41.s1|118-118|.|O
DDI-DrugBank.d41.s2|0-3|This|O
DDI-DrugBank.d41.s2|5-6|is|O
DDI-DrugBank.d41.s2|8-11|also|O
DDI-DrugBank.d41.s2|13-14|to|O
DDI-DrugBank.d41.s2|16-17|be|O
DDI-DrugBank.d41.s2|19-28|considered|O
DDI-DrugBank.d41.s2|30-33|when|O
DDI-DrugBank.d41.s2|35-45|leflunomide|O
DDI-DrugBank.d41.s2|47-55|treatment|O
DDI-DrugBank.d41.s2|57-58|is|O
DDI-DrugBank.d41.s2|60-67|followed|O
DDI-DrugBank.d41.s2|69-70|by|O
DDI-DrugBank.d41.s2|72-75|such|O
DDI-DrugBank.d41.s2|77-81|drugs|O
DDI-DrugBank.d41.s2|83-89|without|O
DDI-DrugBank.d41.s2|91-91|a|O
DDI-DrugBank.d41.s2|93-96|drug|O
DDI-DrugBank.d41.s2|98-108|elimination|O
DDI-DrugBank.d41.s2|110-118|procedure|O
DDI-DrugBank.d41.s2|119-119|.|O
DDI-DrugBank.d41.s3|0-1|In|O
DDI-DrugBank.d41.s3|3-3|a|O
DDI-DrugBank.d41.s3|5-9|small|O
DDI-DrugBank.d41.s3|11-11|(|O
DDI-DrugBank.d41.s3|12-15|n=30|O
DDI-DrugBank.d41.s3|16-16|)|O
DDI-DrugBank.d41.s3|18-28|combination|O
DDI-DrugBank.d41.s3|30-34|study|O
DDI-DrugBank.d41.s3|36-37|of|O
DDI-DrugBank.d41.s3|39-43|ARAVA|O
DDI-DrugBank.d41.s3|45-48|with|O
DDI-DrugBank.d41.s3|50-61|methotrexate|O
DDI-DrugBank.d41.s3|62-62|,|O
DDI-DrugBank.d41.s3|64-64|a|O
DDI-DrugBank.d41.s3|66-67|2-|O
DDI-DrugBank.d41.s3|69-70|to|O
DDI-DrugBank.d41.s3|72-77|3-fold|O
DDI-DrugBank.d41.s3|79-87|elevation|O
DDI-DrugBank.d41.s3|89-90|in|O
DDI-DrugBank.d41.s3|92-96|liver|O
DDI-DrugBank.d41.s3|98-104|enzymes|O
DDI-DrugBank.d41.s3|106-108|was|O
DDI-DrugBank.d41.s3|110-113|seen|O
DDI-DrugBank.d41.s3|115-116|in|O
DDI-DrugBank.d41.s3|118-118|5|O
DDI-DrugBank.d41.s3|120-121|of|O
DDI-DrugBank.d41.s3|123-124|30|O
DDI-DrugBank.d41.s3|126-133|patients|O
DDI-DrugBank.d41.s3|134-134|.|O
DDI-DrugBank.d41.s4|0-2|All|O
DDI-DrugBank.d41.s4|4-13|elevations|O
DDI-DrugBank.d41.s4|15-22|resolved|O
DDI-DrugBank.d41.s4|23-23|,|O
DDI-DrugBank.d41.s4|25-25|2|O
DDI-DrugBank.d41.s4|27-30|with|O
DDI-DrugBank.d41.s4|32-43|continuation|O
DDI-DrugBank.d41.s4|45-46|of|O
DDI-DrugBank.d41.s4|48-51|both|O
DDI-DrugBank.d41.s4|53-57|drugs|O
DDI-DrugBank.d41.s4|59-61|and|O
DDI-DrugBank.d41.s4|63-63|3|O
DDI-DrugBank.d41.s4|65-69|after|O
DDI-DrugBank.d41.s4|71-85|discontinuation|O
DDI-DrugBank.d41.s4|87-88|of|O
DDI-DrugBank.d41.s4|90-100|leflunomide|O
DDI-DrugBank.d41.s4|101-101|.|O
DDI-DrugBank.d41.s5|0-0|A|O
DDI-DrugBank.d41.s5|3-8|3-fold|O
DDI-DrugBank.d41.s5|10-17|increase|O
DDI-DrugBank.d41.s5|19-21|was|O
DDI-DrugBank.d41.s5|23-26|seen|O
DDI-DrugBank.d41.s5|28-29|in|O
DDI-DrugBank.d41.s5|31-37|another|O
DDI-DrugBank.d41.s5|39-39|5|O
DDI-DrugBank.d41.s5|41-48|patients|O
DDI-DrugBank.d41.s5|49-49|.|O
DDI-DrugBank.d41.s6|0-2|All|O
DDI-DrugBank.d41.s6|4-5|of|O
DDI-DrugBank.d41.s6|7-11|these|O
DDI-DrugBank.d41.s6|13-16|also|O
DDI-DrugBank.d41.s6|18-25|resolved|O
DDI-DrugBank.d41.s6|26-26|,|O
DDI-DrugBank.d41.s6|28-28|2|O
DDI-DrugBank.d41.s6|30-33|with|O
DDI-DrugBank.d41.s6|35-46|continuation|O
DDI-DrugBank.d41.s6|48-49|of|O
DDI-DrugBank.d41.s6|51-54|both|O
DDI-DrugBank.d41.s6|56-60|drugs|O
DDI-DrugBank.d41.s6|62-64|and|O
DDI-DrugBank.d41.s6|66-66|3|O
DDI-DrugBank.d41.s6|68-72|after|O
DDI-DrugBank.d41.s6|74-88|discontinuation|O
DDI-DrugBank.d41.s6|90-91|of|O
DDI-DrugBank.d41.s6|93-103|leflunomide|O
DDI-DrugBank.d41.s6|104-104|.|O
DDI-DrugBank.d41.s7|0-4|Three|O
DDI-DrugBank.d41.s7|6-13|patients|O
DDI-DrugBank.d41.s7|15-17|met|O
DDI-DrugBank.d41.s7|19-21|ACR|O
DDI-DrugBank.d41.s7|23-30|criteria|O
DDI-DrugBank.d41.s7|32-34|for|O
DDI-DrugBank.d41.s7|36-40|liver|O
DDI-DrugBank.d41.s7|42-47|biopsy|O
DDI-DrugBank.d41.s7|49-49|(|O
DDI-DrugBank.d41.s7|50-50|1|O
DDI-DrugBank.d41.s7|51-51|:|O
DDI-DrugBank.d41.s7|53-59|Roegnik|O
DDI-DrugBank.d41.s7|61-65|Grade|O
DDI-DrugBank.d41.s7|67-67|I|O
DDI-DrugBank.d41.s7|68-68|,|O
DDI-DrugBank.d41.s7|70-70|2|O
DDI-DrugBank.d41.s7|71-71|:|O
DDI-DrugBank.d41.s7|73-79|Roegnik|O
DDI-DrugBank.d41.s7|81-85|Grade|O
DDI-DrugBank.d41.s7|87-90|IIIa|O
DDI-DrugBank.d41.s7|91-91|)|O
DDI-DrugBank.d41.s7|92-92|.|O
DDI-DrugBank.d41.s8|0-1|No|O
DDI-DrugBank.d41.s8|3-17|pharmacokinetic|O
DDI-DrugBank.d41.s8|19-29|interaction|O
DDI-DrugBank.d41.s8|31-33|was|O
DDI-DrugBank.d41.s8|35-44|identified|O
DDI-DrugBank.d41.s8|45-45|.|O
DDI-DrugBank.d41.s9|0-5|NSAIDs|O
DDI-DrugBank.d41.s9|6-6|:|O
DDI-DrugBank.d41.s9|8-9|In|O
DDI-DrugBank.d41.s9|11-12|in|O
DDI-DrugBank.d41.s9|14-18|vitro|O
DDI-DrugBank.d41.s9|20-26|studies|O
DDI-DrugBank.d41.s9|27-27|,|O
DDI-DrugBank.d41.s9|29-30|M1|O
DDI-DrugBank.d41.s9|32-34|was|O
DDI-DrugBank.d41.s9|36-40|shown|O
DDI-DrugBank.d41.s9|42-43|to|O
DDI-DrugBank.d41.s9|45-49|cause|O
DDI-DrugBank.d41.s9|51-59|increases|O
DDI-DrugBank.d41.s9|61-67|ranging|O
DDI-DrugBank.d41.s9|69-72|from|O
DDI-DrugBank.d41.s9|74-75|13|O
DDI-DrugBank.d41.s9|77-77|-|O
DDI-DrugBank.d41.s9|79-80|50|O
DDI-DrugBank.d41.s9|81-81|%|O
DDI-DrugBank.d41.s9|83-84|in|O
DDI-DrugBank.d41.s9|86-88|the|O
DDI-DrugBank.d41.s9|90-93|free|O
DDI-DrugBank.d41.s9|95-102|fraction|O
DDI-DrugBank.d41.s9|104-105|of|O
DDI-DrugBank.d41.s9|107-116|diclofenac|O
DDI-DrugBank.d41.s9|118-120|and|O
DDI-DrugBank.d41.s9|122-130|ibuprofen|O
DDI-DrugBank.d41.s9|132-133|at|O
DDI-DrugBank.d41.s9|135-148|concentrations|O
DDI-DrugBank.d41.s9|150-151|in|O
DDI-DrugBank.d41.s9|153-155|the|O
DDI-DrugBank.d41.s9|157-164|clinical|O
DDI-DrugBank.d41.s9|166-170|range|O
DDI-DrugBank.d41.s9|171-171|.|O
DDI-DrugBank.d41.s10|0-2|The|O
DDI-DrugBank.d41.s10|4-11|clinical|O
DDI-DrugBank.d41.s10|13-24|significance|O
DDI-DrugBank.d41.s10|26-27|of|O
DDI-DrugBank.d41.s10|29-32|this|O
DDI-DrugBank.d41.s10|34-40|finding|O
DDI-DrugBank.d41.s10|42-43|is|O
DDI-DrugBank.d41.s10|45-51|unknown|O
DDI-DrugBank.d41.s10|52-52|;|O
DDI-DrugBank.d41.s11|0-6|however|O
DDI-DrugBank.d41.s11|7-7|,|O
DDI-DrugBank.d41.s11|9-13|there|O
DDI-DrugBank.d41.s11|15-17|was|O
DDI-DrugBank.d41.s11|19-27|extensive|O
DDI-DrugBank.d41.s11|29-39|concomitant|O
DDI-DrugBank.d41.s11|41-43|use|O
DDI-DrugBank.d41.s11|45-46|of|O
DDI-DrugBank.d41.s11|48-53|NSAIDs|O
DDI-DrugBank.d41.s11|55-56|in|O
DDI-DrugBank.d41.s11|58-65|clinical|O
DDI-DrugBank.d41.s11|67-73|studies|O
DDI-DrugBank.d41.s11|75-77|and|O
DDI-DrugBank.d41.s11|79-80|no|O
DDI-DrugBank.d41.s11|82-93|differential|O
DDI-DrugBank.d41.s11|95-100|effect|O
DDI-DrugBank.d41.s11|102-104|was|O
DDI-DrugBank.d41.s11|106-113|observed|O
DDI-DrugBank.d41.s11|114-114|.|O
DDI-DrugBank.d41.s12|0-10|Tolbutamide|O
DDI-DrugBank.d41.s12|11-11|:|O
DDI-DrugBank.d41.s12|13-14|In|O
DDI-DrugBank.d41.s12|16-17|in|O
DDI-DrugBank.d41.s12|19-23|vitro|O
DDI-DrugBank.d41.s12|25-31|studies|O
DDI-DrugBank.d41.s12|32-32|,|O
DDI-DrugBank.d41.s12|34-35|M1|O
DDI-DrugBank.d41.s12|37-39|was|O
DDI-DrugBank.d41.s12|41-45|shown|O
DDI-DrugBank.d41.s12|47-48|to|O
DDI-DrugBank.d41.s12|50-54|cause|O
DDI-DrugBank.d41.s12|56-64|increases|O
DDI-DrugBank.d41.s12|66-72|ranging|O
DDI-DrugBank.d41.s12|74-77|from|O
DDI-DrugBank.d41.s12|79-80|13|O
DDI-DrugBank.d41.s12|82-82|-|O
DDI-DrugBank.d41.s12|84-85|50|O
DDI-DrugBank.d41.s12|86-86|%|O
DDI-DrugBank.d41.s12|88-89|in|O
DDI-DrugBank.d41.s12|91-93|the|O
DDI-DrugBank.d41.s12|95-98|free|O
DDI-DrugBank.d41.s12|100-107|fraction|O
DDI-DrugBank.d41.s12|109-110|of|O
DDI-DrugBank.d41.s12|112-122|tolbutamide|O
DDI-DrugBank.d41.s12|124-125|at|O
DDI-DrugBank.d41.s12|127-140|concentrations|O
DDI-DrugBank.d41.s12|142-143|in|O
DDI-DrugBank.d41.s12|145-147|the|O
DDI-DrugBank.d41.s12|149-156|clinical|O
DDI-DrugBank.d41.s12|158-162|range|O
DDI-DrugBank.d41.s12|163-163|.|O
DDI-DrugBank.d41.s13|0-2|The|O
DDI-DrugBank.d41.s13|4-11|clinical|O
DDI-DrugBank.d41.s13|13-24|significance|O
DDI-DrugBank.d41.s13|26-27|of|O
DDI-DrugBank.d41.s13|29-32|this|O
DDI-DrugBank.d41.s13|34-40|finding|O
DDI-DrugBank.d41.s13|42-43|is|O
DDI-DrugBank.d41.s13|45-51|unknown|O
DDI-DrugBank.d41.s13|52-52|.|O
DDI-DrugBank.d41.s14|0-7|Rifampin|O
DDI-DrugBank.d41.s14|8-8|:|O
DDI-DrugBank.d41.s14|10-18|Following|O
DDI-DrugBank.d41.s14|20-30|concomitant|O
DDI-DrugBank.d41.s14|32-45|administration|O
DDI-DrugBank.d41.s14|47-48|of|O
DDI-DrugBank.d41.s14|50-50|a|O
DDI-DrugBank.d41.s14|52-57|single|O
DDI-DrugBank.d41.s14|59-62|dose|O
DDI-DrugBank.d41.s14|64-65|of|O
DDI-DrugBank.d41.s14|67-71|ARAVA|O
DDI-DrugBank.d41.s14|73-74|to|O
DDI-DrugBank.d41.s14|76-83|subjects|O
DDI-DrugBank.d41.s14|85-93|receiving|O
DDI-DrugBank.d41.s14|95-102|multiple|O
DDI-DrugBank.d41.s14|104-108|doses|O
DDI-DrugBank.d41.s14|110-111|of|O
DDI-DrugBank.d41.s14|113-120|rifampin|O
DDI-DrugBank.d41.s14|121-121|,|O
DDI-DrugBank.d41.s14|123-124|M1|O
DDI-DrugBank.d41.s14|126-129|peak|O
DDI-DrugBank.d41.s14|131-136|levels|O
DDI-DrugBank.d41.s14|138-141|were|O
DDI-DrugBank.d41.s14|143-151|increased|O
DDI-DrugBank.d41.s14|153-153|(|O
DDI-DrugBank.d41.s14|154-156|~40|O
DDI-DrugBank.d41.s14|157-157|%|O
DDI-DrugBank.d41.s14|158-158|)|O
DDI-DrugBank.d41.s14|160-163|over|O
DDI-DrugBank.d41.s14|165-169|those|O
DDI-DrugBank.d41.s14|171-174|seen|O
DDI-DrugBank.d41.s14|176-179|when|O
DDI-DrugBank.d41.s14|181-185|ARAVA|O
DDI-DrugBank.d41.s14|187-189|was|O
DDI-DrugBank.d41.s14|191-195|given|O
DDI-DrugBank.d41.s14|197-201|alone|O
DDI-DrugBank.d41.s14|202-202|.|O
DDI-DrugBank.d41.s15|0-6|Because|O
DDI-DrugBank.d41.s15|8-9|of|O
DDI-DrugBank.d41.s15|11-13|the|O
DDI-DrugBank.d41.s15|15-23|potential|O
DDI-DrugBank.d41.s15|25-27|for|O
DDI-DrugBank.d41.s15|29-33|ARAVA|O
DDI-DrugBank.d41.s15|35-40|levels|O
DDI-DrugBank.d41.s15|42-43|to|O
DDI-DrugBank.d41.s15|45-52|continue|O
DDI-DrugBank.d41.s15|54-55|to|O
DDI-DrugBank.d41.s15|57-64|increase|O
DDI-DrugBank.d41.s15|66-69|with|O
DDI-DrugBank.d41.s15|71-78|multiple|O
DDI-DrugBank.d41.s15|80-85|dosing|O
DDI-DrugBank.d41.s15|86-86|,|O
DDI-DrugBank.d41.s15|88-94|caution|O
DDI-DrugBank.d41.s15|96-101|should|O
DDI-DrugBank.d41.s15|103-104|be|O
DDI-DrugBank.d41.s15|106-109|used|O
DDI-DrugBank.d41.s15|111-112|if|O
DDI-DrugBank.d41.s15|114-121|patients|O
DDI-DrugBank.d41.s15|123-125|are|O
DDI-DrugBank.d41.s15|127-128|to|O
DDI-DrugBank.d41.s15|130-131|be|O
DDI-DrugBank.d41.s15|133-141|receiving|O
DDI-DrugBank.d41.s15|143-146|both|O
DDI-DrugBank.d41.s15|148-152|ARAVA|O
DDI-DrugBank.d41.s15|154-156|and|O
DDI-DrugBank.d41.s15|158-165|rifampin|O
DDI-DrugBank.d41.s15|166-166|.|O
DDI-DrugBank.d41.s16|0-7|Warfarin|O
DDI-DrugBank.d41.s16|8-8|:|O
DDI-DrugBank.d41.s16|10-18|Increased|O
DDI-DrugBank.d41.s16|20-22|INR|O
DDI-DrugBank.d41.s16|24-24|(|O
DDI-DrugBank.d41.s16|25-37|International|O
DDI-DrugBank.d41.s16|39-48|Normalized|O
DDI-DrugBank.d41.s16|50-54|Ratio|O
DDI-DrugBank.d41.s16|55-55|)|O
DDI-DrugBank.d41.s16|57-60|when|O
DDI-DrugBank.d41.s16|62-66|ARAVA|O
DDI-DrugBank.d41.s16|68-70|and|O
DDI-DrugBank.d41.s16|72-79|warfarin|O
DDI-DrugBank.d41.s16|81-84|were|O
DDI-DrugBank.d41.s16|86-100|co-administered|O
DDI-DrugBank.d41.s16|102-104|has|O
DDI-DrugBank.d41.s16|106-109|been|O
DDI-DrugBank.d41.s16|111-116|rarely|O
DDI-DrugBank.d41.s16|118-125|reported|O
DDI-DrugBank.d41.s16|126-126|.|O
DDI-DrugBank.d654.s0|0-16|Co-administration|O
DDI-DrugBank.d654.s0|18-19|of|O
DDI-DrugBank.d654.s0|21-24|oral|O
DDI-DrugBank.d654.s0|26-37|ketoconazole|O
DDI-DrugBank.d654.s0|39-41|200|O
DDI-DrugBank.d654.s0|43-44|mg|O
DDI-DrugBank.d654.s0|46-50|twice|O
DDI-DrugBank.d654.s0|52-56|daily|O
DDI-DrugBank.d654.s0|58-66|increased|O
DDI-DrugBank.d654.s0|68-78|retapamulin|O
DDI-DrugBank.d654.s0|80-88|geometric|O
DDI-DrugBank.d654.s0|90-93|mean|O
DDI-DrugBank.d654.s0|95-97|AUC|O
DDI-DrugBank.d654.s0|98-98|(|O
DDI-DrugBank.d654.s0|99-102|0-24|O
DDI-DrugBank.d654.s0|103-103|)|O
DDI-DrugBank.d654.s0|105-107|and|O
DDI-DrugBank.d654.s0|109-112|Cmax|O
DDI-DrugBank.d654.s0|114-115|by|O
DDI-DrugBank.d654.s0|117-118|81|O
DDI-DrugBank.d654.s0|119-119|%|O
DDI-DrugBank.d654.s0|121-125|after|O
DDI-DrugBank.d654.s0|127-133|topical|O
DDI-DrugBank.d654.s0|135-145|application|O
DDI-DrugBank.d654.s0|147-148|of|O
DDI-DrugBank.d654.s0|150-160|retapamulin|O
DDI-DrugBank.d654.s0|162-169|ointment|O
DDI-DrugBank.d654.s0|170-170|,|O
DDI-DrugBank.d654.s0|172-172|1|O
DDI-DrugBank.d654.s0|173-173|%|O
DDI-DrugBank.d654.s0|175-176|on|O
DDI-DrugBank.d654.s0|178-180|the|O
DDI-DrugBank.d654.s0|182-188|abraded|O
DDI-DrugBank.d654.s0|190-193|skin|O
DDI-DrugBank.d654.s0|195-196|of|O
DDI-DrugBank.d654.s0|198-204|healthy|O
DDI-DrugBank.d654.s0|206-210|adult|O
DDI-DrugBank.d654.s0|212-216|males|O
DDI-DrugBank.d654.s0|217-217|.|O
DDI-DrugBank.d654.s1|0-2|Due|O
DDI-DrugBank.d654.s1|4-5|to|O
DDI-DrugBank.d654.s1|7-9|low|O
DDI-DrugBank.d654.s1|11-18|systemic|O
DDI-DrugBank.d654.s1|20-27|exposure|O
DDI-DrugBank.d654.s1|29-30|to|O
DDI-DrugBank.d654.s1|32-42|retapamulin|O
DDI-DrugBank.d654.s1|44-52|following|O
DDI-DrugBank.d654.s1|54-60|topical|O
DDI-DrugBank.d654.s1|62-72|application|O
DDI-DrugBank.d654.s1|74-75|in|O
DDI-DrugBank.d654.s1|77-84|patients|O
DDI-DrugBank.d654.s1|85-85|,|O
DDI-DrugBank.d654.s1|87-92|dosage|O
DDI-DrugBank.d654.s1|94-104|adjustments|O
DDI-DrugBank.d654.s1|106-108|for|O
DDI-DrugBank.d654.s1|110-120|retapamulin|O
DDI-DrugBank.d654.s1|122-124|are|O
DDI-DrugBank.d654.s1|126-136|unnecessary|O
DDI-DrugBank.d654.s1|138-141|when|O
DDI-DrugBank.d654.s1|143-157|co-administered|O
DDI-DrugBank.d654.s1|159-162|with|O
DDI-DrugBank.d654.s1|164-169|CYP3A4|O
DDI-DrugBank.d654.s1|171-180|inhibitors|O
DDI-DrugBank.d654.s1|181-181|,|O
DDI-DrugBank.d654.s1|183-186|such|O
DDI-DrugBank.d654.s1|188-189|as|O
DDI-DrugBank.d654.s1|191-202|ketoconazole|O
DDI-DrugBank.d654.s1|203-203|.|O
DDI-DrugBank.d654.s2|0-4|Based|O
DDI-DrugBank.d654.s2|6-7|on|O
DDI-DrugBank.d654.s2|9-10|in|O
DDI-DrugBank.d654.s2|12-16|vitro|O
DDI-DrugBank.d654.s2|18-21|P450|O
DDI-DrugBank.d654.s2|23-32|inhibition|O
DDI-DrugBank.d654.s2|34-40|studies|O
DDI-DrugBank.d654.s2|42-44|and|O
DDI-DrugBank.d654.s2|46-48|the|O
DDI-DrugBank.d654.s2|50-52|low|O
DDI-DrugBank.d654.s2|54-61|systemic|O
DDI-DrugBank.d654.s2|63-70|exposure|O
DDI-DrugBank.d654.s2|72-79|observed|O
DDI-DrugBank.d654.s2|81-89|following|O
DDI-DrugBank.d654.s2|91-97|topical|O
DDI-DrugBank.d654.s2|99-109|application|O
DDI-DrugBank.d654.s2|111-112|of|O
DDI-DrugBank.d654.s2|114-120|ALTABAX|O
DDI-DrugBank.d654.s2|121-121|,|O
DDI-DrugBank.d654.s2|123-133|retapamulin|O
DDI-DrugBank.d654.s2|135-136|is|O
DDI-DrugBank.d654.s2|138-145|unlikely|O
DDI-DrugBank.d654.s2|147-148|to|O
DDI-DrugBank.d654.s2|150-155|affect|O
DDI-DrugBank.d654.s2|157-159|the|O
DDI-DrugBank.d654.s2|161-170|metabolism|O
DDI-DrugBank.d654.s2|172-173|of|O
DDI-DrugBank.d654.s2|175-179|other|O
DDI-DrugBank.d654.s2|181-184|P450|O
DDI-DrugBank.d654.s2|186-195|substrates|O
DDI-DrugBank.d654.s2|196-196|.|O
DDI-DrugBank.d654.s3|0-2|The|O
DDI-DrugBank.d654.s3|4-9|effect|O
DDI-DrugBank.d654.s3|11-12|of|O
DDI-DrugBank.d654.s3|14-23|concurrent|O
DDI-DrugBank.d654.s3|25-35|application|O
DDI-DrugBank.d654.s3|37-38|of|O
DDI-DrugBank.d654.s3|40-46|ALTABAX|O
DDI-DrugBank.d654.s3|48-50|and|O
DDI-DrugBank.d654.s3|52-56|other|O
DDI-DrugBank.d654.s3|58-64|topical|O
DDI-DrugBank.d654.s3|66-73|products|O
DDI-DrugBank.d654.s3|75-76|to|O
DDI-DrugBank.d654.s3|78-80|the|O
DDI-DrugBank.d654.s3|82-85|same|O
DDI-DrugBank.d654.s3|87-90|area|O
DDI-DrugBank.d654.s3|92-93|of|O
DDI-DrugBank.d654.s3|95-98|skin|O
DDI-DrugBank.d654.s3|100-102|has|O
DDI-DrugBank.d654.s3|104-106|not|O
DDI-DrugBank.d654.s3|108-111|been|O
DDI-DrugBank.d654.s3|113-119|studied|O
DDI-DrugBank.d654.s3|120-120|.|O
DDI-DrugBank.d107.s0|0-10|Hypotension|O
DDI-DrugBank.d107.s0|11-11|:|O
DDI-DrugBank.d107.s0|13-20|Patients|O
DDI-DrugBank.d107.s0|22-23|on|O
DDI-DrugBank.d107.s0|25-32|Diuretic|O
DDI-DrugBank.d107.s0|34-40|Therapy|O
DDI-DrugBank.d107.s0|41-41|:|O
DDI-DrugBank.d107.s0|43-50|Patients|O
DDI-DrugBank.d107.s0|52-53|on|O
DDI-DrugBank.d107.s0|55-63|diuretics|O
DDI-DrugBank.d107.s0|65-67|and|O
DDI-DrugBank.d107.s0|69-78|especially|O
DDI-DrugBank.d107.s0|80-84|those|O
DDI-DrugBank.d107.s0|86-87|in|O
DDI-DrugBank.d107.s0|89-92|whom|O
DDI-DrugBank.d107.s0|94-101|diuretic|O
DDI-DrugBank.d107.s0|103-109|therapy|O
DDI-DrugBank.d107.s0|111-113|was|O
DDI-DrugBank.d107.s0|115-122|recently|O
DDI-DrugBank.d107.s0|124-133|instituted|O
DDI-DrugBank.d107.s0|134-134|,|O
DDI-DrugBank.d107.s0|136-138|may|O
DDI-DrugBank.d107.s0|140-151|occasionally|O
DDI-DrugBank.d107.s0|153-162|experience|O
DDI-DrugBank.d107.s0|164-165|an|O
DDI-DrugBank.d107.s0|167-175|excessive|O
DDI-DrugBank.d107.s0|177-185|reduction|O
DDI-DrugBank.d107.s0|187-188|of|O
DDI-DrugBank.d107.s0|190-194|blood|O
DDI-DrugBank.d107.s0|196-203|pressure|O
DDI-DrugBank.d107.s0|205-209|after|O
DDI-DrugBank.d107.s0|211-220|initiation|O
DDI-DrugBank.d107.s0|222-223|of|O
DDI-DrugBank.d107.s0|225-231|therapy|O
DDI-DrugBank.d107.s0|233-236|with|O
DDI-DrugBank.d107.s0|238-246|enalapril|O
DDI-DrugBank.d107.s0|248-249|or|O
DDI-DrugBank.d107.s0|251-261|enalaprilat|O
DDI-DrugBank.d107.s0|262-262|.|O
DDI-DrugBank.d107.s1|0-2|The|O
DDI-DrugBank.d107.s1|4-14|possibility|O
DDI-DrugBank.d107.s1|16-17|of|O
DDI-DrugBank.d107.s1|19-29|hypotensive|O
DDI-DrugBank.d107.s1|31-37|effects|O
DDI-DrugBank.d107.s1|39-42|with|O
DDI-DrugBank.d107.s1|44-52|enalapril|O
DDI-DrugBank.d107.s1|54-55|or|O
DDI-DrugBank.d107.s1|57-67|enalaprilat|O
DDI-DrugBank.d107.s1|69-71|can|O
DDI-DrugBank.d107.s1|73-74|be|O
DDI-DrugBank.d107.s1|76-84|minimized|O
DDI-DrugBank.d107.s1|86-87|by|O
DDI-DrugBank.d107.s1|89-94|either|O
DDI-DrugBank.d107.s1|96-108|discontinuing|O
DDI-DrugBank.d107.s1|110-112|the|O
DDI-DrugBank.d107.s1|114-121|diuretic|O
DDI-DrugBank.d107.s1|123-124|or|O
DDI-DrugBank.d107.s1|126-135|increasing|O
DDI-DrugBank.d107.s1|137-139|the|O
DDI-DrugBank.d107.s1|141-144|salt|O
DDI-DrugBank.d107.s1|146-151|intake|O
DDI-DrugBank.d107.s1|153-157|prior|O
DDI-DrugBank.d107.s1|159-160|to|O
DDI-DrugBank.d107.s1|162-171|initiation|O
DDI-DrugBank.d107.s1|173-174|of|O
DDI-DrugBank.d107.s1|176-184|treatment|O
DDI-DrugBank.d107.s1|186-189|with|O
DDI-DrugBank.d107.s1|191-199|enalapril|O
DDI-DrugBank.d107.s1|201-202|or|O
DDI-DrugBank.d107.s1|204-214|enalaprilat|O
DDI-DrugBank.d107.s1|215-215|.|O
DDI-DrugBank.d107.s2|0-1|If|O
DDI-DrugBank.d107.s2|3-4|it|O
DDI-DrugBank.d107.s2|6-7|is|O
DDI-DrugBank.d107.s2|9-17|necessary|O
DDI-DrugBank.d107.s2|19-20|to|O
DDI-DrugBank.d107.s2|22-29|continue|O
DDI-DrugBank.d107.s2|31-33|the|O
DDI-DrugBank.d107.s2|35-42|diuretic|O
DDI-DrugBank.d107.s2|43-43|,|O
DDI-DrugBank.d107.s2|45-51|provide|O
DDI-DrugBank.d107.s2|53-57|close|O
DDI-DrugBank.d107.s2|59-65|medical|O
DDI-DrugBank.d107.s2|67-77|supervision|O
DDI-DrugBank.d107.s2|79-83|after|O
DDI-DrugBank.d107.s2|85-87|the|O
DDI-DrugBank.d107.s2|89-95|initial|O
DDI-DrugBank.d107.s2|97-100|dose|O
DDI-DrugBank.d107.s2|102-104|for|O
DDI-DrugBank.d107.s2|106-107|at|O
DDI-DrugBank.d107.s2|109-113|least|O
DDI-DrugBank.d107.s2|115-117|two|O
DDI-DrugBank.d107.s2|119-123|hours|O
DDI-DrugBank.d107.s2|125-127|and|O
DDI-DrugBank.d107.s2|129-133|until|O
DDI-DrugBank.d107.s2|135-139|blood|O
DDI-DrugBank.d107.s2|141-148|pressure|O
DDI-DrugBank.d107.s2|150-152|has|O
DDI-DrugBank.d107.s2|154-163|stabilized|O
DDI-DrugBank.d107.s2|165-167|for|O
DDI-DrugBank.d107.s2|169-170|at|O
DDI-DrugBank.d107.s2|172-176|least|O
DDI-DrugBank.d107.s2|178-179|an|O
DDI-DrugBank.d107.s2|181-190|additional|O
DDI-DrugBank.d107.s2|192-197|hour..|O
DDI-DrugBank.d107.s3|0-5|Agents|O
DDI-DrugBank.d107.s3|7-13|Causing|O
DDI-DrugBank.d107.s3|15-19|Renin|O
DDI-DrugBank.d107.s3|21-27|Release|O
DDI-DrugBank.d107.s3|28-28|:|O
DDI-DrugBank.d107.s3|30-32|The|O
DDI-DrugBank.d107.s3|34-49|antihypertensive|O
DDI-DrugBank.d107.s3|51-56|effect|O
DDI-DrugBank.d107.s3|58-59|of|O
DDI-DrugBank.d107.s3|61-69|enalapril|O
DDI-DrugBank.d107.s3|71-73|and|O
DDI-DrugBank.d107.s3|75-83|enalapril|O
DDI-DrugBank.d107.s3|85-86|IV|O
DDI-DrugBank.d107.s3|88-89|is|O
DDI-DrugBank.d107.s3|91-99|augmented|O
DDI-DrugBank.d107.s3|101-102|by|O
DDI-DrugBank.d107.s3|104-119|antihypertensive|O
DDI-DrugBank.d107.s3|121-126|agents|O
DDI-DrugBank.d107.s3|128-131|that|O
DDI-DrugBank.d107.s3|133-137|cause|O
DDI-DrugBank.d107.s3|139-143|renin|O
DDI-DrugBank.d107.s3|145-151|release|O
DDI-DrugBank.d107.s3|153-153|(|O
DDI-DrugBank.d107.s3|154-157|e.g.|O
DDI-DrugBank.d107.s3|158-158|,|O
DDI-DrugBank.d107.s3|160-168|diuretics|O
DDI-DrugBank.d107.s3|169-169|)|O
DDI-DrugBank.d107.s3|170-170|.|O
DDI-DrugBank.d107.s4|0-12|Non-steroidal|O
DDI-DrugBank.d107.s4|14-30|Anti-inflammatory|O
DDI-DrugBank.d107.s4|32-37|Agents|O
DDI-DrugBank.d107.s4|38-38|:|O
DDI-DrugBank.d107.s4|40-41|In|O
DDI-DrugBank.d107.s4|43-46|some|O
DDI-DrugBank.d107.s4|48-55|patients|O
DDI-DrugBank.d107.s4|57-60|with|O
DDI-DrugBank.d107.s4|62-72|compromised|O
DDI-DrugBank.d107.s4|74-78|renal|O
DDI-DrugBank.d107.s4|80-87|function|O
DDI-DrugBank.d107.s4|89-91|who|O
DDI-DrugBank.d107.s4|93-95|are|O
DDI-DrugBank.d107.s4|97-101|being|O
DDI-DrugBank.d107.s4|103-109|treated|O
DDI-DrugBank.d107.s4|111-114|with|O
DDI-DrugBank.d107.s4|116-127|nonsteroidal|O
DDI-DrugBank.d107.s4|129-145|anti-inflammatory|O
DDI-DrugBank.d107.s4|147-151|drugs|O
DDI-DrugBank.d107.s4|152-152|,|O
DDI-DrugBank.d107.s4|154-156|the|O
DDI-DrugBank.d107.s4|158-174|co-administration|O
DDI-DrugBank.d107.s4|176-177|of|O
DDI-DrugBank.d107.s4|179-187|enalapril|O
DDI-DrugBank.d107.s4|189-191|may|O
DDI-DrugBank.d107.s4|193-198|result|O
DDI-DrugBank.d107.s4|200-201|in|O
DDI-DrugBank.d107.s4|203-203|a|O
DDI-DrugBank.d107.s4|205-211|further|O
DDI-DrugBank.d107.s4|213-225|deterioration|O
DDI-DrugBank.d107.s4|227-228|of|O
DDI-DrugBank.d107.s4|230-234|renal|O
DDI-DrugBank.d107.s4|236-243|function|O
DDI-DrugBank.d107.s4|244-244|.|O
DDI-DrugBank.d107.s5|0-4|These|O
DDI-DrugBank.d107.s5|6-12|effects|O
DDI-DrugBank.d107.s5|14-16|are|O
DDI-DrugBank.d107.s5|18-24|usually|O
DDI-DrugBank.d107.s5|26-35|reversible|O
DDI-DrugBank.d107.s5|36-36|.|O
DDI-DrugBank.d107.s6|0-1|In|O
DDI-DrugBank.d107.s6|3-3|a|O
DDI-DrugBank.d107.s6|5-12|clinical|O
DDI-DrugBank.d107.s6|14-25|pharmacology|O
DDI-DrugBank.d107.s6|27-31|study|O
DDI-DrugBank.d107.s6|32-32|,|O
DDI-DrugBank.d107.s6|34-45|indomethacin|O
DDI-DrugBank.d107.s6|47-48|or|O
DDI-DrugBank.d107.s6|50-57|sulindac|O
DDI-DrugBank.d107.s6|59-61|was|O
DDI-DrugBank.d107.s6|63-74|administered|O
DDI-DrugBank.d107.s6|76-77|to|O
DDI-DrugBank.d107.s6|79-90|hypertensive|O
DDI-DrugBank.d107.s6|92-99|patients|O
DDI-DrugBank.d107.s6|101-109|receiving|O
DDI-DrugBank.d107.s6|111-117|VASOTEC|O
DDI-DrugBank.d107.s6|118-118|.|O
DDI-DrugBank.d107.s7|0-1|In|O
DDI-DrugBank.d107.s7|3-6|this|O
DDI-DrugBank.d107.s7|8-12|study|O
DDI-DrugBank.d107.s7|14-18|there|O
DDI-DrugBank.d107.s7|20-22|was|O
DDI-DrugBank.d107.s7|24-25|no|O
DDI-DrugBank.d107.s7|27-34|evidence|O
DDI-DrugBank.d107.s7|36-37|of|O
DDI-DrugBank.d107.s7|39-39|a|O
DDI-DrugBank.d107.s7|41-48|blunting|O
DDI-DrugBank.d107.s7|50-51|of|O
DDI-DrugBank.d107.s7|53-55|the|O
DDI-DrugBank.d107.s7|57-72|antihypertensive|O
DDI-DrugBank.d107.s7|74-79|action|O
DDI-DrugBank.d107.s7|81-82|of|O
DDI-DrugBank.d107.s7|84-90|VASOTEC|O
DDI-DrugBank.d107.s7|91-91|.|O
DDI-DrugBank.d107.s8|0-6|However|O
DDI-DrugBank.d107.s8|7-7|,|O
DDI-DrugBank.d107.s8|9-15|reports|O
DDI-DrugBank.d107.s8|17-23|suggest|O
DDI-DrugBank.d107.s8|25-28|that|O
DDI-DrugBank.d107.s8|30-35|NSAIDs|O
DDI-DrugBank.d107.s8|37-39|may|O
DDI-DrugBank.d107.s8|41-48|diminish|O
DDI-DrugBank.d107.s8|50-52|the|O
DDI-DrugBank.d107.s8|54-69|antihypertensive|O
DDI-DrugBank.d107.s8|71-76|effect|O
DDI-DrugBank.d107.s8|78-79|of|O
DDI-DrugBank.d107.s8|81-83|ACE|O
DDI-DrugBank.d107.s8|85-94|inhibitors|O
DDI-DrugBank.d107.s8|95-95|.|O
DDI-DrugBank.d107.s9|0-3|This|O
DDI-DrugBank.d107.s9|5-15|interaction|O
DDI-DrugBank.d107.s9|17-22|should|O
DDI-DrugBank.d107.s9|24-25|be|O
DDI-DrugBank.d107.s9|27-31|given|O
DDI-DrugBank.d107.s9|33-45|consideration|O
DDI-DrugBank.d107.s9|47-48|in|O
DDI-DrugBank.d107.s9|50-57|patients|O
DDI-DrugBank.d107.s9|59-64|taking|O
DDI-DrugBank.d107.s9|66-71|NSAIDs|O
DDI-DrugBank.d107.s9|73-85|concomitantly|O
DDI-DrugBank.d107.s9|87-90|with|O
DDI-DrugBank.d107.s9|92-94|ACE|O
DDI-DrugBank.d107.s9|96-105|inhibitors|O
DDI-DrugBank.d107.s9|106-106|.|O
DDI-DrugBank.d107.s10|0-4|Other|O
DDI-DrugBank.d107.s10|6-19|Cardiovascular|O
DDI-DrugBank.d107.s10|21-26|Agents|O
DDI-DrugBank.d107.s10|27-27|:|O
DDI-DrugBank.d107.s10|29-37|Enalapril|O
DDI-DrugBank.d107.s10|39-41|and|O
DDI-DrugBank.d107.s10|43-51|enalapril|O
DDI-DrugBank.d107.s10|53-54|IV|O
DDI-DrugBank.d107.s10|56-59|have|O
DDI-DrugBank.d107.s10|61-64|been|O
DDI-DrugBank.d107.s10|66-69|used|O
DDI-DrugBank.d107.s10|71-83|concomitantly|O
DDI-DrugBank.d107.s10|85-88|with|O
DDI-DrugBank.d107.s10|90-93|beta|O
DDI-DrugBank.d107.s10|95-113|adrenergic-blocking|O
DDI-DrugBank.d107.s10|115-120|agents|O
DDI-DrugBank.d107.s10|121-121|,|O
DDI-DrugBank.d107.s10|123-132|methyldopa|O
DDI-DrugBank.d107.s10|133-133|,|O
DDI-DrugBank.d107.s10|135-142|nitrates|O
DDI-DrugBank.d107.s10|143-143|,|O
DDI-DrugBank.d107.s10|145-160|calcium-blocking|O
DDI-DrugBank.d107.s10|162-167|agents|O
DDI-DrugBank.d107.s10|168-168|,|O
DDI-DrugBank.d107.s10|170-180|hydralazine|O
DDI-DrugBank.d107.s10|181-181|,|O
DDI-DrugBank.d107.s10|183-190|prazosin|O
DDI-DrugBank.d107.s10|192-194|and|O
DDI-DrugBank.d107.s10|196-202|digoxin|O
DDI-DrugBank.d107.s10|204-210|without|O
DDI-DrugBank.d107.s10|212-219|evidence|O
DDI-DrugBank.d107.s10|221-222|of|O
DDI-DrugBank.d107.s10|224-233|clinically|O
DDI-DrugBank.d107.s10|235-245|significant|O
DDI-DrugBank.d107.s10|247-253|adverse|O
DDI-DrugBank.d107.s10|255-266|interactions|O
DDI-DrugBank.d107.s10|267-267|.|O
DDI-DrugBank.d107.s11|0-8|Enalapril|O
DDI-DrugBank.d107.s11|10-11|IV|O
DDI-DrugBank.d107.s11|13-15|has|O
DDI-DrugBank.d107.s11|17-20|been|O
DDI-DrugBank.d107.s11|22-25|used|O
DDI-DrugBank.d107.s11|27-39|concomitantly|O
DDI-DrugBank.d107.s11|41-44|with|O
DDI-DrugBank.d107.s11|46-54|digitalis|O
DDI-DrugBank.d107.s11|56-62|without|O
DDI-DrugBank.d107.s11|64-71|evidence|O
DDI-DrugBank.d107.s11|73-74|of|O
DDI-DrugBank.d107.s11|76-85|clinically|O
DDI-DrugBank.d107.s11|87-97|significant|O
DDI-DrugBank.d107.s11|99-105|adverse|O
DDI-DrugBank.d107.s11|107-115|reactions|O
DDI-DrugBank.d107.s11|116-116|.|O
DDI-DrugBank.d107.s12|0-5|Agents|O
DDI-DrugBank.d107.s12|7-16|Increasing|O
DDI-DrugBank.d107.s12|18-22|Serum|O
DDI-DrugBank.d107.s12|24-32|Potassium|O
DDI-DrugBank.d107.s12|33-33|:|O
DDI-DrugBank.d107.s12|35-43|Enalapril|O
DDI-DrugBank.d107.s12|45-47|and|O
DDI-DrugBank.d107.s12|49-57|enalapril|O
DDI-DrugBank.d107.s12|59-60|IV|O
DDI-DrugBank.d107.s12|62-70|attenuate|O
DDI-DrugBank.d107.s12|72-80|potassium|O
DDI-DrugBank.d107.s12|82-85|loss|O
DDI-DrugBank.d107.s12|87-92|caused|O
DDI-DrugBank.d107.s12|94-95|by|O
DDI-DrugBank.d107.s12|97-109|thiazide-type|O
DDI-DrugBank.d107.s12|111-119|diuretics|O
DDI-DrugBank.d107.s12|120-120|.|O
DDI-DrugBank.d107.s13|0-16|Potassium-sparing|O
DDI-DrugBank.d107.s13|18-26|diuretics|O
DDI-DrugBank.d107.s13|28-28|(|O
DDI-DrugBank.d107.s13|29-32|e.g.|O
DDI-DrugBank.d107.s13|33-33|,|O
DDI-DrugBank.d107.s13|35-48|spironolactone|O
DDI-DrugBank.d107.s13|49-49|,|O
DDI-DrugBank.d107.s13|51-61|triamterene|O
DDI-DrugBank.d107.s13|62-62|,|O
DDI-DrugBank.d107.s13|64-65|or|O
DDI-DrugBank.d107.s13|67-75|amiloride|O
DDI-DrugBank.d107.s13|76-76|)|O
DDI-DrugBank.d107.s13|77-77|,|O
DDI-DrugBank.d107.s13|79-87|potassium|O
DDI-DrugBank.d107.s13|89-99|supplements|O
DDI-DrugBank.d107.s13|100-100|,|O
DDI-DrugBank.d107.s13|102-103|or|O
DDI-DrugBank.d107.s13|105-124|potassium-containing|O
DDI-DrugBank.d107.s13|126-129|salt|O
DDI-DrugBank.d107.s13|131-141|substitutes|O
DDI-DrugBank.d107.s13|143-145|may|O
DDI-DrugBank.d107.s13|147-150|lead|O
DDI-DrugBank.d107.s13|152-153|to|O
DDI-DrugBank.d107.s13|155-165|significant|O
DDI-DrugBank.d107.s13|167-175|increases|O
DDI-DrugBank.d107.s13|177-178|in|O
DDI-DrugBank.d107.s13|180-184|serum|O
DDI-DrugBank.d107.s13|186-194|potassium|O
DDI-DrugBank.d107.s13|195-195|.|O
DDI-DrugBank.d107.s14|0-8|Therefore|O
DDI-DrugBank.d107.s14|9-9|,|O
DDI-DrugBank.d107.s14|11-12|if|O
DDI-DrugBank.d107.s14|14-24|concomitant|O
DDI-DrugBank.d107.s14|26-28|use|O
DDI-DrugBank.d107.s14|30-31|of|O
DDI-DrugBank.d107.s14|33-37|these|O
DDI-DrugBank.d107.s14|39-44|agents|O
DDI-DrugBank.d107.s14|46-47|is|O
DDI-DrugBank.d107.s14|49-57|indicated|O
DDI-DrugBank.d107.s14|59-65|because|O
DDI-DrugBank.d107.s14|67-68|of|O
DDI-DrugBank.d107.s14|70-81|demonstrated|O
DDI-DrugBank.d107.s14|83-93|hypokalemia|O
DDI-DrugBank.d107.s14|94-94|,|O
DDI-DrugBank.d107.s14|96-99|they|O
DDI-DrugBank.d107.s14|101-106|should|O
DDI-DrugBank.d107.s14|108-109|be|O
DDI-DrugBank.d107.s14|111-114|used|O
DDI-DrugBank.d107.s14|116-119|with|O
DDI-DrugBank.d107.s14|121-127|caution|O
DDI-DrugBank.d107.s14|129-131|and|O
DDI-DrugBank.d107.s14|133-136|with|O
DDI-DrugBank.d107.s14|138-145|frequent|O
DDI-DrugBank.d107.s14|147-156|monitoring|O
DDI-DrugBank.d107.s14|158-159|of|O
DDI-DrugBank.d107.s14|161-165|serum|O
DDI-DrugBank.d107.s14|167-175|potassium|O
DDI-DrugBank.d107.s14|176-176|.|O
DDI-DrugBank.d107.s15|0-8|Potassium|O
DDI-DrugBank.d107.s15|10-16|sparing|O
DDI-DrugBank.d107.s15|18-23|agents|O
DDI-DrugBank.d107.s15|25-30|should|O
DDI-DrugBank.d107.s15|32-40|generally|O
DDI-DrugBank.d107.s15|42-44|not|O
DDI-DrugBank.d107.s15|46-47|be|O
DDI-DrugBank.d107.s15|49-52|used|O
DDI-DrugBank.d107.s15|54-55|in|O
DDI-DrugBank.d107.s15|57-64|patients|O
DDI-DrugBank.d107.s15|66-69|with|O
DDI-DrugBank.d107.s15|71-75|heart|O
DDI-DrugBank.d107.s15|77-83|failure|O
DDI-DrugBank.d107.s15|85-93|receiving|O
DDI-DrugBank.d107.s15|95-103|enalapril|O
DDI-DrugBank.d107.s15|104-104|.|O
DDI-DrugBank.d107.s16|0-6|Lithium|O
DDI-DrugBank.d107.s16|7-7|:|O
DDI-DrugBank.d107.s16|9-15|Lithium|O
DDI-DrugBank.d107.s16|17-24|toxicity|O
DDI-DrugBank.d107.s16|26-28|has|O
DDI-DrugBank.d107.s16|30-33|been|O
DDI-DrugBank.d107.s16|35-42|reported|O
DDI-DrugBank.d107.s16|44-45|in|O
DDI-DrugBank.d107.s16|47-54|patients|O
DDI-DrugBank.d107.s16|56-64|receiving|O
DDI-DrugBank.d107.s16|66-72|lithium|O
DDI-DrugBank.d107.s16|74-86|concomitantly|O
DDI-DrugBank.d107.s16|88-91|with|O
DDI-DrugBank.d107.s16|93-97|drugs|O
DDI-DrugBank.d107.s16|99-103|which|O
DDI-DrugBank.d107.s16|105-109|cause|O
DDI-DrugBank.d107.s16|111-121|elimination|O
DDI-DrugBank.d107.s16|123-124|of|O
DDI-DrugBank.d107.s16|126-131|sodium|O
DDI-DrugBank.d107.s16|132-132|,|O
DDI-DrugBank.d107.s16|134-142|including|O
DDI-DrugBank.d107.s16|144-146|ACE|O
DDI-DrugBank.d107.s16|148-157|inhibitors|O
DDI-DrugBank.d107.s16|158-158|.|O
DDI-DrugBank.d107.s17|0-1|It|O
DDI-DrugBank.d107.s17|3-4|is|O
DDI-DrugBank.d107.s17|6-16|recommended|O
DDI-DrugBank.d107.s17|18-21|that|O
DDI-DrugBank.d107.s17|23-27|serum|O
DDI-DrugBank.d107.s17|29-35|lithium|O
DDI-DrugBank.d107.s17|37-42|levels|O
DDI-DrugBank.d107.s17|44-45|be|O
DDI-DrugBank.d107.s17|47-55|monitored|O
DDI-DrugBank.d107.s17|57-66|frequently|O
DDI-DrugBank.d107.s17|68-69|if|O
DDI-DrugBank.d107.s17|71-79|enalapril|O
DDI-DrugBank.d107.s17|81-82|is|O
DDI-DrugBank.d107.s17|84-95|administered|O
DDI-DrugBank.d107.s17|97-109|concomitantly|O
DDI-DrugBank.d107.s17|111-114|with|O
DDI-DrugBank.d107.s17|116-122|lithium|O
DDI-DrugBank.d107.s17|123-123|.|O
DDI-DrugBank.d739.s0|0-10|Montelukast|O
DDI-DrugBank.d739.s0|12-13|at|O
DDI-DrugBank.d739.s0|15-15|a|O
DDI-DrugBank.d739.s0|17-20|Dose|O
DDI-DrugBank.d739.s0|22-23|of|O
DDI-DrugBank.d739.s0|25-26|10|O
DDI-DrugBank.d739.s0|28-29|mg|O
DDI-DrugBank.d739.s0|31-34|Once|O
DDI-DrugBank.d739.s0|36-40|Daily|O
DDI-DrugBank.d739.s0|42-46|Dosed|O
DDI-DrugBank.d739.s0|48-49|to|O
DDI-DrugBank.d739.s0|51-65|Pharmacokinetic|O
DDI-DrugBank.d739.s0|67-72|Steady|O
DDI-DrugBank.d739.s0|74-78|State|O
DDI-DrugBank.d739.s0|81-81|-|O
DDI-DrugBank.d739.s0|83-85|did|O
DDI-DrugBank.d739.s0|87-89|not|O
DDI-DrugBank.d739.s0|91-95|cause|O
DDI-DrugBank.d739.s0|97-106|clinically|O
DDI-DrugBank.d739.s0|108-118|significant|O
DDI-DrugBank.d739.s0|120-126|changes|O
DDI-DrugBank.d739.s0|128-129|in|O
DDI-DrugBank.d739.s0|131-133|the|O
DDI-DrugBank.d739.s0|135-142|kinetics|O
DDI-DrugBank.d739.s0|144-145|of|O
DDI-DrugBank.d739.s0|147-147|a|O
DDI-DrugBank.d739.s0|149-154|single|O
DDI-DrugBank.d739.s0|156-166|intravenous|O
DDI-DrugBank.d739.s0|168-171|dose|O
DDI-DrugBank.d739.s0|173-174|of|O
DDI-DrugBank.d739.s0|176-187|theophylline|O
DDI-DrugBank.d739.s0|189-189|(|O
DDI-DrugBank.d739.s0|190-202|predominantly|O
DDI-DrugBank.d739.s0|204-204|a|O
DDI-DrugBank.d739.s0|206-215|cytochrome|O
DDI-DrugBank.d739.s0|217-220|P450|O
DDI-DrugBank.d739.s0|222-224|1A2|O
DDI-DrugBank.d739.s0|226-234|substrate|O
DDI-DrugBank.d739.s0|235-235|)|O
DDI-DrugBank.d739.s0|236-236|.|O
DDI-DrugBank.d739.s1|0-0|-|O
DDI-DrugBank.d739.s1|2-4|did|O
DDI-DrugBank.d739.s1|6-8|not|O
DDI-DrugBank.d739.s1|10-15|change|O
DDI-DrugBank.d739.s1|17-19|the|O
DDI-DrugBank.d739.s1|21-35|pharmacokinetic|O
DDI-DrugBank.d739.s1|37-43|profile|O
DDI-DrugBank.d739.s1|45-46|of|O
DDI-DrugBank.d739.s1|48-55|warfarin|O
DDI-DrugBank.d739.s1|57-57|(|O
DDI-DrugBank.d739.s1|58-58|a|O
DDI-DrugBank.d739.s1|60-68|substrate|O
DDI-DrugBank.d739.s1|70-71|of|O
DDI-DrugBank.d739.s1|73-83|cytochromes|O
DDI-DrugBank.d739.s1|85-88|P450|O
DDI-DrugBank.d739.s1|90-92|2A6|O
DDI-DrugBank.d739.s1|94-96|and|O
DDI-DrugBank.d739.s1|98-100|2C9|O
DDI-DrugBank.d739.s1|101-101|)|O
DDI-DrugBank.d739.s1|103-104|or|O
DDI-DrugBank.d739.s1|106-114|influence|O
DDI-DrugBank.d739.s1|116-118|the|O
DDI-DrugBank.d739.s1|120-125|effect|O
DDI-DrugBank.d739.s1|127-128|of|O
DDI-DrugBank.d739.s1|130-130|a|O
DDI-DrugBank.d739.s1|132-137|single|O
DDI-DrugBank.d739.s1|139-143|30-mg|O
DDI-DrugBank.d739.s1|145-148|oral|O
DDI-DrugBank.d739.s1|150-153|dose|O
DDI-DrugBank.d739.s1|155-156|of|O
DDI-DrugBank.d739.s1|158-165|warfarin|O
DDI-DrugBank.d739.s1|167-168|on|O
DDI-DrugBank.d739.s1|170-180|prothrombin|O
DDI-DrugBank.d739.s1|182-185|time|O
DDI-DrugBank.d739.s1|187-188|or|O
DDI-DrugBank.d739.s1|190-192|the|O
DDI-DrugBank.d739.s1|194-196|INR|O
DDI-DrugBank.d739.s1|198-198|(|O
DDI-DrugBank.d739.s1|199-211|International|O
DDI-DrugBank.d739.s1|213-222|Normalized|O
DDI-DrugBank.d739.s1|224-228|Ratio|O
DDI-DrugBank.d739.s1|229-229|)|O
DDI-DrugBank.d739.s1|230-230|.|O
DDI-DrugBank.d739.s2|0-0|-|O
DDI-DrugBank.d739.s2|2-4|did|O
DDI-DrugBank.d739.s2|6-8|not|O
DDI-DrugBank.d739.s2|10-15|change|O
DDI-DrugBank.d739.s2|17-19|the|O
DDI-DrugBank.d739.s2|21-35|pharmacokinetic|O
DDI-DrugBank.d739.s2|37-43|profile|O
DDI-DrugBank.d739.s2|45-46|or|O
DDI-DrugBank.d739.s2|48-54|urinary|O
DDI-DrugBank.d739.s2|56-64|excretion|O
DDI-DrugBank.d739.s2|66-67|of|O
DDI-DrugBank.d739.s2|69-82|immunoreactive|O
DDI-DrugBank.d739.s2|84-90|digoxin|O
DDI-DrugBank.d739.s2|91-91|.|O
DDI-DrugBank.d739.s3|0-0|-|O
DDI-DrugBank.d739.s3|2-4|did|O
DDI-DrugBank.d739.s3|6-8|not|O
DDI-DrugBank.d739.s3|10-15|change|O
DDI-DrugBank.d739.s3|17-19|the|O
DDI-DrugBank.d739.s3|21-26|plasma|O
DDI-DrugBank.d739.s3|28-40|concentration|O
DDI-DrugBank.d739.s3|42-48|profile|O
DDI-DrugBank.d739.s3|50-51|of|O
DDI-DrugBank.d739.s3|53-63|terfenadine|O
DDI-DrugBank.d739.s3|65-65|(|O
DDI-DrugBank.d739.s3|66-66|a|O
DDI-DrugBank.d739.s3|68-76|substrate|O
DDI-DrugBank.d739.s3|78-79|of|O
DDI-DrugBank.d739.s3|81-90|cytochrome|O
DDI-DrugBank.d739.s3|92-95|P450|O
DDI-DrugBank.d739.s3|97-99|3A4|O
DDI-DrugBank.d739.s3|100-100|)|O
DDI-DrugBank.d739.s3|102-103|or|O
DDI-DrugBank.d739.s3|105-116|fexofenadine|O
DDI-DrugBank.d739.s3|117-117|,|O
DDI-DrugBank.d739.s3|119-121|its|O
DDI-DrugBank.d739.s3|123-134|carboxylated|O
DDI-DrugBank.d739.s3|136-145|metabolite|O
DDI-DrugBank.d739.s3|146-146|,|O
DDI-DrugBank.d739.s3|148-150|and|O
DDI-DrugBank.d739.s3|152-154|did|O
DDI-DrugBank.d739.s3|156-158|not|O
DDI-DrugBank.d739.s3|160-166|prolong|O
DDI-DrugBank.d739.s3|168-170|the|O
DDI-DrugBank.d739.s3|172-174|QTc|O
DDI-DrugBank.d739.s3|176-183|interval|O
DDI-DrugBank.d739.s3|185-193|following|O
DDI-DrugBank.d739.s3|195-211|co-administration|O
DDI-DrugBank.d739.s3|213-216|with|O
DDI-DrugBank.d739.s3|218-228|terfenadine|O
DDI-DrugBank.d739.s3|230-231|60|O
DDI-DrugBank.d739.s3|233-234|mg|O
DDI-DrugBank.d739.s3|236-240|twice|O
DDI-DrugBank.d739.s3|242-246|daily|O
DDI-DrugBank.d739.s3|247-247|.|O
DDI-DrugBank.d739.s4|0-10|Montelukast|O
DDI-DrugBank.d739.s4|12-13|at|O
DDI-DrugBank.d739.s4|15-19|Doses|O
DDI-DrugBank.d739.s4|21-22|of|O
DDI-DrugBank.d739.s4|27-29|100|O
DDI-DrugBank.d739.s4|31-32|mg|O
DDI-DrugBank.d739.s4|34-38|Daily|O
DDI-DrugBank.d739.s4|40-44|Dosed|O
DDI-DrugBank.d739.s4|46-47|to|O
DDI-DrugBank.d739.s4|49-63|Pharmacokinetic|O
DDI-DrugBank.d739.s4|65-70|Steady|O
DDI-DrugBank.d739.s4|72-76|State|O
DDI-DrugBank.d739.s4|77-77|:|O
DDI-DrugBank.d739.s4|80-80|-|O
DDI-DrugBank.d739.s4|82-84|did|O
DDI-DrugBank.d739.s4|86-88|not|O
DDI-DrugBank.d739.s4|90-102|significantly|O
DDI-DrugBank.d739.s4|104-108|alter|O
DDI-DrugBank.d739.s4|110-112|the|O
DDI-DrugBank.d739.s4|114-119|plasma|O
DDI-DrugBank.d739.s4|121-134|concentrations|O
DDI-DrugBank.d739.s4|136-137|of|O
DDI-DrugBank.d739.s4|139-144|either|O
DDI-DrugBank.d739.s4|146-154|component|O
DDI-DrugBank.d739.s4|156-157|of|O
DDI-DrugBank.d739.s4|159-160|an|O
DDI-DrugBank.d739.s4|162-165|oral|O
DDI-DrugBank.d739.s4|167-179|contraceptive|O
DDI-DrugBank.d739.s4|181-190|containing|O
DDI-DrugBank.d739.s4|192-204|norethindrone|O
DDI-DrugBank.d739.s4|206-206|1|O
DDI-DrugBank.d739.s4|208-217|mg/ethinyl|O
DDI-DrugBank.d739.s4|219-227|estradiol|O
DDI-DrugBank.d739.s4|229-230|35|O
DDI-DrugBank.d739.s4|232-234|mcg|O
DDI-DrugBank.d739.s4|235-235|.|O
DDI-DrugBank.d739.s5|0-0|-|O
DDI-DrugBank.d739.s5|2-4|did|O
DDI-DrugBank.d739.s5|6-8|not|O
DDI-DrugBank.d739.s5|10-14|cause|O
DDI-DrugBank.d739.s5|16-18|any|O
DDI-DrugBank.d739.s5|20-29|clinically|O
DDI-DrugBank.d739.s5|31-41|significant|O
DDI-DrugBank.d739.s5|43-48|change|O
DDI-DrugBank.d739.s5|50-51|in|O
DDI-DrugBank.d739.s5|53-58|plasma|O
DDI-DrugBank.d739.s5|60-67|profiles|O
DDI-DrugBank.d739.s5|69-70|of|O
DDI-DrugBank.d739.s5|72-81|prednisone|O
DDI-DrugBank.d739.s5|83-84|or|O
DDI-DrugBank.d739.s5|86-97|prednisolone|O
DDI-DrugBank.d739.s5|99-107|following|O
DDI-DrugBank.d739.s5|109-122|administration|O
DDI-DrugBank.d739.s5|124-125|of|O
DDI-DrugBank.d739.s5|127-132|either|O
DDI-DrugBank.d739.s5|134-137|oral|O
DDI-DrugBank.d739.s5|139-148|prednisone|O
DDI-DrugBank.d739.s5|150-151|or|O
DDI-DrugBank.d739.s5|153-163|intravenous|O
DDI-DrugBank.d739.s5|165-176|prednisolone|O
DDI-DrugBank.d739.s5|177-177|.|O
DDI-DrugBank.d739.s6|0-12|Phenobarbital|O
DDI-DrugBank.d739.s6|13-13|,|O
DDI-DrugBank.d739.s6|15-19|which|O
DDI-DrugBank.d739.s6|21-27|induces|O
DDI-DrugBank.d739.s6|29-35|hepatic|O
DDI-DrugBank.d739.s6|37-46|metabolism|O
DDI-DrugBank.d739.s6|47-47|,|O
DDI-DrugBank.d739.s6|49-57|decreased|O
DDI-DrugBank.d739.s6|59-61|the|O
DDI-DrugBank.d739.s6|63-65|AUC|O
DDI-DrugBank.d739.s6|67-68|of|O
DDI-DrugBank.d739.s6|70-80|montelukast|O
DDI-DrugBank.d739.s6|82-94|approximately|O
DDI-DrugBank.d739.s6|96-97|40|O
DDI-DrugBank.d739.s6|98-98|%|O
DDI-DrugBank.d739.s6|100-108|following|O
DDI-DrugBank.d739.s6|110-110|a|O
DDI-DrugBank.d739.s6|112-117|single|O
DDI-DrugBank.d739.s6|119-123|10-mg|O
DDI-DrugBank.d739.s6|125-128|dose|O
DDI-DrugBank.d739.s6|130-131|of|O
DDI-DrugBank.d739.s6|133-143|montelukast|O
DDI-DrugBank.d739.s6|144-144|.|O
DDI-DrugBank.d739.s7|0-1|No|O
DDI-DrugBank.d739.s7|3-8|dosage|O
DDI-DrugBank.d739.s7|10-19|adjustment|O
DDI-DrugBank.d739.s7|21-23|for|O
DDI-DrugBank.d739.s7|25-35|montelukast|O
DDI-DrugBank.d739.s7|37-38|is|O
DDI-DrugBank.d739.s7|40-50|recommended|O
DDI-DrugBank.d739.s7|51-51|.|O
DDI-DrugBank.d739.s8|0-1|It|O
DDI-DrugBank.d739.s8|3-4|is|O
DDI-DrugBank.d739.s8|6-15|reasonable|O
DDI-DrugBank.d739.s8|17-18|to|O
DDI-DrugBank.d739.s8|20-25|employ|O
DDI-DrugBank.d739.s8|27-37|appropriate|O
DDI-DrugBank.d739.s8|39-46|clinical|O
DDI-DrugBank.d739.s8|48-57|monitoring|O
DDI-DrugBank.d739.s8|59-62|when|O
DDI-DrugBank.d739.s8|64-69|potent|O
DDI-DrugBank.d739.s8|71-80|cytochrome|O
DDI-DrugBank.d739.s8|82-85|P450|O
DDI-DrugBank.d739.s8|87-92|enzyme|O
DDI-DrugBank.d739.s8|94-101|inducers|O
DDI-DrugBank.d739.s8|102-102|,|O
DDI-DrugBank.d739.s8|104-107|such|O
DDI-DrugBank.d739.s8|109-110|as|O
DDI-DrugBank.d739.s8|112-124|phenobarbital|O
DDI-DrugBank.d739.s8|126-127|or|O
DDI-DrugBank.d739.s8|129-136|rifampin|O
DDI-DrugBank.d739.s8|137-137|,|O
DDI-DrugBank.d739.s8|139-141|are|O
DDI-DrugBank.d739.s8|143-157|co-administered|O
DDI-DrugBank.d739.s8|159-162|with|O
DDI-DrugBank.d739.s8|164-174|montelukast|O
DDI-DrugBank.d739.s8|175-175|.|O
DDI-DrugBank.d739.s9|0-10|Montelukast|O
DDI-DrugBank.d739.s9|12-14|has|O
DDI-DrugBank.d739.s9|16-19|been|O
DDI-DrugBank.d739.s9|21-32|administered|O
DDI-DrugBank.d739.s9|34-37|with|O
DDI-DrugBank.d739.s9|39-43|other|O
DDI-DrugBank.d739.s9|45-53|therapies|O
DDI-DrugBank.d739.s9|55-63|routinely|O
DDI-DrugBank.d739.s9|65-68|used|O
DDI-DrugBank.d739.s9|70-71|in|O
DDI-DrugBank.d739.s9|73-75|the|O
DDI-DrugBank.d739.s9|77-87|prophylaxis|O
DDI-DrugBank.d739.s9|89-91|and|O
DDI-DrugBank.d739.s9|93-99|chronic|O
DDI-DrugBank.d739.s9|101-109|treatment|O
DDI-DrugBank.d739.s9|111-112|of|O
DDI-DrugBank.d739.s9|114-119|asthma|O
DDI-DrugBank.d739.s9|121-124|with|O
DDI-DrugBank.d739.s9|126-127|no|O
DDI-DrugBank.d739.s9|129-136|apparent|O
DDI-DrugBank.d739.s9|138-145|increase|O
DDI-DrugBank.d739.s9|147-148|in|O
DDI-DrugBank.d739.s9|150-156|adverse|O
DDI-DrugBank.d739.s9|158-166|reactions|O
DDI-DrugBank.d739.s9|167-167|.|O
DDI-DrugBank.d739.s10|0-1|In|O
DDI-DrugBank.d739.s10|3-18|drug-interaction|O
DDI-DrugBank.d739.s10|20-26|studies|O
DDI-DrugBank.d739.s10|27-27|,|O
DDI-DrugBank.d739.s10|29-31|the|O
DDI-DrugBank.d739.s10|33-43|recommended|O
DDI-DrugBank.d739.s10|45-52|clinical|O
DDI-DrugBank.d739.s10|54-57|dose|O
DDI-DrugBank.d739.s10|59-60|of|O
DDI-DrugBank.d739.s10|62-72|montelukast|O
DDI-DrugBank.d739.s10|74-76|did|O
DDI-DrugBank.d739.s10|78-80|not|O
DDI-DrugBank.d739.s10|82-85|have|O
DDI-DrugBank.d739.s10|87-96|clinically|O
DDI-DrugBank.d739.s10|98-106|important|O
DDI-DrugBank.d739.s10|108-114|effects|O
DDI-DrugBank.d739.s10|116-117|on|O
DDI-DrugBank.d739.s10|119-121|the|O
DDI-DrugBank.d739.s10|123-138|pharmacokinetics|O
DDI-DrugBank.d739.s10|140-141|of|O
DDI-DrugBank.d739.s10|143-145|the|O
DDI-DrugBank.d739.s10|147-155|following|O
DDI-DrugBank.d739.s10|157-161|drugs|O
DDI-DrugBank.d739.s10|162-162|:|O
DDI-DrugBank.d739.s10|164-175|theophylline|O
DDI-DrugBank.d739.s10|176-176|,|O
DDI-DrugBank.d739.s10|178-187|prednisone|O
DDI-DrugBank.d739.s10|188-188|,|O
DDI-DrugBank.d739.s10|190-201|prednisolone|O
DDI-DrugBank.d739.s10|202-202|,|O
DDI-DrugBank.d739.s10|204-207|oral|O
DDI-DrugBank.d739.s10|209-222|contraceptives|O
DDI-DrugBank.d739.s10|224-224|(|O
DDI-DrugBank.d739.s10|225-237|norethindrone|O
DDI-DrugBank.d739.s10|239-239|1|O
DDI-DrugBank.d739.s10|241-250|mg/ethinyl|O
DDI-DrugBank.d739.s10|252-260|estradiol|O
DDI-DrugBank.d739.s10|262-263|35|O
DDI-DrugBank.d739.s10|265-267|mcg|O
DDI-DrugBank.d739.s10|268-268|)|O
DDI-DrugBank.d739.s10|269-269|,|O
DDI-DrugBank.d739.s10|271-281|terfenadine|O
DDI-DrugBank.d739.s10|282-282|,|O
DDI-DrugBank.d739.s10|284-290|digoxin|O
DDI-DrugBank.d739.s10|291-291|,|O
DDI-DrugBank.d739.s10|293-295|and|O
DDI-DrugBank.d739.s10|297-304|warfarin|O
DDI-DrugBank.d739.s10|305-305|.|O
DDI-DrugBank.d739.s11|0-7|Although|O
DDI-DrugBank.d739.s11|9-18|additional|O
DDI-DrugBank.d739.s11|20-27|specific|O
DDI-DrugBank.d739.s11|29-39|interaction|O
DDI-DrugBank.d739.s11|41-47|studies|O
DDI-DrugBank.d739.s11|49-52|were|O
DDI-DrugBank.d739.s11|54-56|not|O
DDI-DrugBank.d739.s11|58-66|performed|O
DDI-DrugBank.d739.s11|67-67|,|O
DDI-DrugBank.d739.s11|69-79|montelukast|O
DDI-DrugBank.d739.s11|81-83|was|O
DDI-DrugBank.d739.s11|85-88|used|O
DDI-DrugBank.d739.s11|90-102|concomitantly|O
DDI-DrugBank.d739.s11|104-107|with|O
DDI-DrugBank.d739.s11|109-109|a|O
DDI-DrugBank.d739.s11|111-114|wide|O
DDI-DrugBank.d739.s11|116-120|range|O
DDI-DrugBank.d739.s11|122-123|of|O
DDI-DrugBank.d739.s11|125-132|commonly|O
DDI-DrugBank.d739.s11|134-143|prescribed|O
DDI-DrugBank.d739.s11|145-149|drugs|O
DDI-DrugBank.d739.s11|151-152|in|O
DDI-DrugBank.d739.s11|154-161|clinical|O
DDI-DrugBank.d739.s11|163-169|studies|O
DDI-DrugBank.d739.s11|171-177|without|O
DDI-DrugBank.d739.s11|179-186|evidence|O
DDI-DrugBank.d739.s11|188-189|of|O
DDI-DrugBank.d739.s11|191-198|clinical|O
DDI-DrugBank.d739.s11|200-206|adverse|O
DDI-DrugBank.d739.s11|208-219|interactions|O
DDI-DrugBank.d739.s11|220-220|.|O
DDI-DrugBank.d739.s12|0-4|These|O
DDI-DrugBank.d739.s12|6-16|medications|O
DDI-DrugBank.d739.s12|18-25|included|O
DDI-DrugBank.d739.s12|27-33|thyroid|O
DDI-DrugBank.d739.s12|35-42|hormones|O
DDI-DrugBank.d739.s12|43-43|,|O
DDI-DrugBank.d739.s12|45-52|sedative|O
DDI-DrugBank.d739.s12|54-62|hypnotics|O
DDI-DrugBank.d739.s12|63-63|,|O
DDI-DrugBank.d739.s12|65-77|non-steroidal|O
DDI-DrugBank.d739.s12|79-95|anti-inflammatory|O
DDI-DrugBank.d739.s12|97-102|agents|O
DDI-DrugBank.d739.s12|103-103|,|O
DDI-DrugBank.d739.s12|105-119|benzodiazepines|O
DDI-DrugBank.d739.s12|120-120|,|O
DDI-DrugBank.d739.s12|122-124|and|O
DDI-DrugBank.d739.s12|126-138|decongestants|O
DDI-DrugBank.d739.s12|139-139|.|O
DDI-DrugBank.d739.s13|0-12|Phenobarbital|O
DDI-DrugBank.d739.s13|13-13|,|O
DDI-DrugBank.d739.s13|15-19|which|O
DDI-DrugBank.d739.s13|21-27|induces|O
DDI-DrugBank.d739.s13|29-35|hepatic|O
DDI-DrugBank.d739.s13|37-46|metabolism|O
DDI-DrugBank.d739.s13|47-47|,|O
DDI-DrugBank.d739.s13|49-57|decreased|O
DDI-DrugBank.d739.s13|59-61|the|O
DDI-DrugBank.d739.s13|63-65|AUC|O
DDI-DrugBank.d739.s13|67-68|of|O
DDI-DrugBank.d739.s13|70-80|montelukast|O
DDI-DrugBank.d739.s13|82-94|approximately|O
DDI-DrugBank.d739.s13|96-97|40|O
DDI-DrugBank.d739.s13|98-98|%|O
DDI-DrugBank.d739.s13|100-108|following|O
DDI-DrugBank.d739.s13|110-110|a|O
DDI-DrugBank.d739.s13|112-117|single|O
DDI-DrugBank.d739.s13|119-123|10-mg|O
DDI-DrugBank.d739.s13|125-128|dose|O
DDI-DrugBank.d739.s13|130-131|of|O
DDI-DrugBank.d739.s13|133-143|montelukast|O
DDI-DrugBank.d739.s13|144-144|.|O
DDI-DrugBank.d739.s14|0-1|No|O
DDI-DrugBank.d739.s14|3-8|dosage|O
DDI-DrugBank.d739.s14|10-19|adjustment|O
DDI-DrugBank.d739.s14|21-23|for|O
DDI-DrugBank.d739.s14|25-35|montelukast|O
DDI-DrugBank.d739.s14|37-38|is|O
DDI-DrugBank.d739.s14|40-50|recommended|O
DDI-DrugBank.d739.s14|51-51|.|O
DDI-DrugBank.d739.s15|0-1|It|O
DDI-DrugBank.d739.s15|3-4|is|O
DDI-DrugBank.d739.s15|6-15|reasonable|O
DDI-DrugBank.d739.s15|17-18|to|O
DDI-DrugBank.d739.s15|20-25|employ|O
DDI-DrugBank.d739.s15|27-37|appropriate|O
DDI-DrugBank.d739.s15|39-46|clinical|O
DDI-DrugBank.d739.s15|48-57|monitoring|O
DDI-DrugBank.d739.s15|59-62|when|O
DDI-DrugBank.d739.s15|64-69|potent|O
DDI-DrugBank.d739.s15|71-80|cytochrome|O
DDI-DrugBank.d739.s15|82-85|P450|O
DDI-DrugBank.d739.s15|87-92|enzyme|O
DDI-DrugBank.d739.s15|94-101|inducers|O
DDI-DrugBank.d739.s15|102-102|,|O
DDI-DrugBank.d739.s15|104-107|such|O
DDI-DrugBank.d739.s15|109-110|as|O
DDI-DrugBank.d739.s15|112-124|phenobarbital|O
DDI-DrugBank.d739.s15|126-127|or|O
DDI-DrugBank.d739.s15|129-136|rifampin|O
DDI-DrugBank.d739.s15|137-137|,|O
DDI-DrugBank.d739.s15|139-141|are|O
DDI-DrugBank.d739.s15|143-157|co-administered|O
DDI-DrugBank.d739.s15|159-162|with|O
DDI-DrugBank.d739.s15|164-174|montelukast|O
DDI-DrugBank.d739.s15|175-175|.|O
DDI-DrugBank.d622.s0|0-3|When|O
DDI-DrugBank.d622.s0|5-12|atropine|O
DDI-DrugBank.d622.s0|14-16|and|O
DDI-DrugBank.d622.s0|18-28|pralidoxime|O
DDI-DrugBank.d622.s0|30-32|are|O
DDI-DrugBank.d622.s0|34-37|used|O
DDI-DrugBank.d622.s0|39-46|together|O
DDI-DrugBank.d622.s0|47-47|,|O
DDI-DrugBank.d622.s0|49-51|the|O
DDI-DrugBank.d622.s0|53-57|signs|O
DDI-DrugBank.d622.s0|59-60|of|O
DDI-DrugBank.d622.s0|62-75|atropinization|O
DDI-DrugBank.d622.s0|77-77|(|O
DDI-DrugBank.d622.s0|78-85|flushing|O
DDI-DrugBank.d622.s0|86-86|,|O
DDI-DrugBank.d622.s0|88-96|mydriasis|O
DDI-DrugBank.d622.s0|97-97|,|O
DDI-DrugBank.d622.s0|99-109|tachycardia|O
DDI-DrugBank.d622.s0|110-110|,|O
DDI-DrugBank.d622.s0|112-118|dryness|O
DDI-DrugBank.d622.s0|120-121|of|O
DDI-DrugBank.d622.s0|123-125|the|O
DDI-DrugBank.d622.s0|127-131|mouth|O
DDI-DrugBank.d622.s0|133-135|and|O
DDI-DrugBank.d622.s0|137-140|nose|O
DDI-DrugBank.d622.s0|141-141|)|O
DDI-DrugBank.d622.s0|143-145|may|O
DDI-DrugBank.d622.s0|147-151|occur|O
DDI-DrugBank.d622.s0|153-159|earlier|O
DDI-DrugBank.d622.s0|161-164|than|O
DDI-DrugBank.d622.s0|166-170|might|O
DDI-DrugBank.d622.s0|172-173|be|O
DDI-DrugBank.d622.s0|175-182|expected|O
DDI-DrugBank.d622.s0|184-187|when|O
DDI-DrugBank.d622.s0|189-196|atropine|O
DDI-DrugBank.d622.s0|198-199|is|O
DDI-DrugBank.d622.s0|201-204|used|O
DDI-DrugBank.d622.s0|206-210|alone|O
DDI-DrugBank.d622.s0|211-211|.|O
DDI-DrugBank.d622.s1|0-3|This|O
DDI-DrugBank.d622.s1|5-6|is|O
DDI-DrugBank.d622.s1|8-17|especially|O
DDI-DrugBank.d622.s1|19-22|true|O
DDI-DrugBank.d622.s1|24-25|if|O
DDI-DrugBank.d622.s1|27-29|the|O
DDI-DrugBank.d622.s1|31-35|total|O
DDI-DrugBank.d622.s1|37-40|dose|O
DDI-DrugBank.d622.s1|42-43|of|O
DDI-DrugBank.d622.s1|45-52|atropine|O
DDI-DrugBank.d622.s1|54-56|has|O
DDI-DrugBank.d622.s1|58-61|been|O
DDI-DrugBank.d622.s1|63-67|large|O
DDI-DrugBank.d622.s1|69-71|and|O
DDI-DrugBank.d622.s1|73-75|the|O
DDI-DrugBank.d622.s1|77-90|administration|O
DDI-DrugBank.d622.s1|92-93|of|O
DDI-DrugBank.d622.s1|95-105|pralidoxime|O
DDI-DrugBank.d622.s1|107-109|has|O
DDI-DrugBank.d622.s1|111-114|been|O
DDI-DrugBank.d622.s1|116-122|delayed|O
DDI-DrugBank.d622.s1|123-123|.|O
DDI-DrugBank.d622.s2|0-0|2|O
DDI-DrugBank.d622.s2|2-2|-|O
DDI-DrugBank.d622.s2|4-4|4|O
DDI-DrugBank.d622.s2|6-8|The|O
DDI-DrugBank.d622.s2|10-18|following|O
DDI-DrugBank.d622.s2|20-30|precautions|O
DDI-DrugBank.d622.s2|32-37|should|O
DDI-DrugBank.d622.s2|39-40|be|O
DDI-DrugBank.d622.s2|42-45|kept|O
DDI-DrugBank.d622.s2|47-48|in|O
DDI-DrugBank.d622.s2|50-53|mind|O
DDI-DrugBank.d622.s2|55-56|in|O
DDI-DrugBank.d622.s2|58-60|the|O
DDI-DrugBank.d622.s2|62-70|treatment|O
DDI-DrugBank.d622.s2|72-73|of|O
DDI-DrugBank.d622.s2|75-92|anticholinesterase|O
DDI-DrugBank.d622.s2|94-102|poisoning|O
DDI-DrugBank.d622.s2|103-103|,|O
DDI-DrugBank.d622.s2|105-112|although|O
DDI-DrugBank.d622.s2|114-117|they|O
DDI-DrugBank.d622.s2|119-120|do|O
DDI-DrugBank.d622.s2|122-124|not|O
DDI-DrugBank.d622.s2|126-129|bear|O
DDI-DrugBank.d622.s2|131-138|directly|O
DDI-DrugBank.d622.s2|140-141|on|O
DDI-DrugBank.d622.s2|143-145|the|O
DDI-DrugBank.d622.s2|147-149|use|O
DDI-DrugBank.d622.s2|151-152|of|O
DDI-DrugBank.d622.s2|154-164|pralidoxime|O
DDI-DrugBank.d622.s2|165-165|:|O
DDI-DrugBank.d622.s2|167-171|since|O
DDI-DrugBank.d622.s2|173-184|barbiturates|O
DDI-DrugBank.d622.s2|186-188|are|O
DDI-DrugBank.d622.s2|190-200|potentiated|O
DDI-DrugBank.d622.s2|202-203|by|O
DDI-DrugBank.d622.s2|205-207|the|O
DDI-DrugBank.d622.s2|209-227|anticholinesterases|O
DDI-DrugBank.d622.s2|228-228|,|O
DDI-DrugBank.d622.s2|230-233|they|O
DDI-DrugBank.d622.s2|235-240|should|O
DDI-DrugBank.d622.s2|242-243|be|O
DDI-DrugBank.d622.s2|245-248|used|O
DDI-DrugBank.d622.s2|250-259|cautiously|O
DDI-DrugBank.d622.s2|261-262|in|O
DDI-DrugBank.d622.s2|264-266|the|O
DDI-DrugBank.d622.s2|268-276|treatment|O
DDI-DrugBank.d622.s2|278-279|of|O
DDI-DrugBank.d622.s2|281-291|convulsions|O
DDI-DrugBank.d622.s2|292-292|;|O
DDI-DrugBank.d622.s3|0-7|morphine|O
DDI-DrugBank.d622.s3|8-8|,|O
DDI-DrugBank.d622.s3|10-21|theophylline|O
DDI-DrugBank.d622.s3|22-22|,|O
DDI-DrugBank.d622.s3|24-36|aminophylline|O
DDI-DrugBank.d622.s3|37-37|,|O
DDI-DrugBank.d622.s3|39-53|succinylcholine|O
DDI-DrugBank.d622.s3|54-54|,|O
DDI-DrugBank.d622.s3|56-64|reserpine|O
DDI-DrugBank.d622.s3|65-65|,|O
DDI-DrugBank.d622.s3|67-69|and|O
DDI-DrugBank.d622.s3|71-88|phenothiazine-type|O
DDI-DrugBank.d622.s3|90-102|tranquilizers|O
DDI-DrugBank.d622.s3|104-109|should|O
DDI-DrugBank.d622.s3|111-112|be|O
DDI-DrugBank.d622.s3|114-120|avoided|O
DDI-DrugBank.d622.s3|122-123|in|O
DDI-DrugBank.d622.s3|125-132|patients|O
DDI-DrugBank.d622.s3|134-137|with|O
DDI-DrugBank.d622.s3|139-153|organophosphate|O
DDI-DrugBank.d622.s3|155-163|poisoning|O
DDI-DrugBank.d622.s3|164-164|.|O
DDI-MedLine.d62.s0|0-9|Activation|O
DDI-MedLine.d62.s0|11-12|of|O
DDI-MedLine.d62.s0|14-15|an|O
DDI-MedLine.d62.s0|17-24|effector|O
DDI-MedLine.d62.s0|26-40|immediate-early|O
DDI-MedLine.d62.s0|42-45|gene|O
DDI-MedLine.d62.s0|47-49|arc|O
DDI-MedLine.d62.s0|51-52|by|O
DDI-MedLine.d62.s0|54-68|methamphetamine|O
DDI-MedLine.d62.s0|69-69|.|O
DDI-MedLine.d62.s1|0-1|As|O
DDI-MedLine.d62.s1|3-17|immediate-early|O
DDI-MedLine.d62.s1|19-23|genes|O
DDI-MedLine.d62.s1|25-25|(|O
DDI-MedLine.d62.s1|26-29|IEGs|O
DDI-MedLine.d62.s1|30-30|)|O
DDI-MedLine.d62.s1|32-34|are|O
DDI-MedLine.d62.s1|36-42|thought|O
DDI-MedLine.d62.s1|44-45|to|O
DDI-MedLine.d62.s1|47-50|play|O
DDI-MedLine.d62.s1|52-52|a|O
DDI-MedLine.d62.s1|54-61|critical|O
DDI-MedLine.d62.s1|63-66|role|O
DDI-MedLine.d62.s1|68-69|in|O
DDI-MedLine.d62.s1|71-79|mediating|O
DDI-MedLine.d62.s1|81-96|stimulus-induced|O
DDI-MedLine.d62.s1|98-103|neural|O
DDI-MedLine.d62.s1|105-114|plasticity|O
DDI-MedLine.d62.s1|115-115|,|O
DDI-MedLine.d62.s1|117-119|IEG|O
DDI-MedLine.d62.s1|121-128|response|O
DDI-MedLine.d62.s1|130-136|induced|O
DDI-MedLine.d62.s1|138-139|by|O
DDI-MedLine.d62.s1|141-155|methamphetamine|O
DDI-MedLine.d62.s1|157-157|(|O
DDI-MedLine.d62.s1|158-161|METH|O
DDI-MedLine.d62.s1|162-162|)|O
DDI-MedLine.d62.s1|164-166|has|O
DDI-MedLine.d62.s1|168-171|been|O
DDI-MedLine.d62.s1|173-185|characterized|O
DDI-MedLine.d62.s1|187-188|to|O
DDI-MedLine.d62.s1|190-195|define|O
DDI-MedLine.d62.s1|197-199|the|O
DDI-MedLine.d62.s1|201-207|changes|O
DDI-MedLine.d62.s1|209-210|in|O
DDI-MedLine.d62.s1|212-215|gene|O
DDI-MedLine.d62.s1|217-226|expression|O
DDI-MedLine.d62.s1|228-231|that|O
DDI-MedLine.d62.s1|233-235|may|O
DDI-MedLine.d62.s1|237-244|underlie|O
DDI-MedLine.d62.s1|246-248|its|O
DDI-MedLine.d62.s1|250-261|long-lasting|O
DDI-MedLine.d62.s1|263-272|behavioral|O
DDI-MedLine.d62.s1|274-280|effects|O
DDI-MedLine.d62.s1|281-281|.|O
DDI-MedLine.d62.s2|0-7|Although|O
DDI-MedLine.d62.s2|9-18|activation|O
DDI-MedLine.d62.s2|20-21|of|O
DDI-MedLine.d62.s2|23-29|several|O
DDI-MedLine.d62.s2|31-43|transcription|O
DDI-MedLine.d62.s2|45-50|factor|O
DDI-MedLine.d62.s2|52-55|IEGs|O
DDI-MedLine.d62.s2|57-59|has|O
DDI-MedLine.d62.s2|61-64|been|O
DDI-MedLine.d62.s2|66-74|described|O
DDI-MedLine.d62.s2|75-75|,|O
DDI-MedLine.d62.s2|77-82|little|O
DDI-MedLine.d62.s2|84-85|is|O
DDI-MedLine.d62.s2|87-91|known|O
DDI-MedLine.d62.s2|93-97|about|O
DDI-MedLine.d62.s2|99-106|effector|O
DDI-MedLine.d62.s2|108-111|IEGs|O
DDI-MedLine.d62.s2|112-112|.|O
DDI-MedLine.d62.s3|0-3|Here|O
DDI-MedLine.d62.s3|4-4|,|O
DDI-MedLine.d62.s3|6-7|we|O
DDI-MedLine.d62.s3|9-12|have|O
DDI-MedLine.d62.s3|14-21|examined|O
DDI-MedLine.d62.s3|23-29|whether|O
DDI-MedLine.d62.s3|31-34|METH|O
DDI-MedLine.d62.s3|36-49|administration|O
DDI-MedLine.d62.s3|51-57|affects|O
DDI-MedLine.d62.s3|59-68|expression|O
DDI-MedLine.d62.s3|70-71|of|O
DDI-MedLine.d62.s3|73-74|an|O
DDI-MedLine.d62.s3|76-83|effector|O
DDI-MedLine.d62.s3|85-87|IEG|O
DDI-MedLine.d62.s3|89-91|arc|O
DDI-MedLine.d62.s3|93-93|(|O
DDI-MedLine.d62.s3|94-111|activity-regulated|O
DDI-MedLine.d62.s3|112-112|,|O
DDI-MedLine.d62.s3|114-136|cytoskeleton-associated|O
DDI-MedLine.d62.s3|137-137|)|O
DDI-MedLine.d62.s3|139-142|that|O
DDI-MedLine.d62.s3|144-150|encodes|O
DDI-MedLine.d62.s3|152-152|a|O
DDI-MedLine.d62.s3|154-160|protein|O
DDI-MedLine.d62.s3|162-165|with|O
DDI-MedLine.d62.s3|167-174|homology|O
DDI-MedLine.d62.s3|176-177|to|O
DDI-MedLine.d62.s3|179-186|spectrin|O
DDI-MedLine.d62.s3|187-187|.|O
DDI-MedLine.d62.s4|0-4|Using|O
DDI-MedLine.d62.s4|6-7|in|O
DDI-MedLine.d62.s4|9-12|situ|O
DDI-MedLine.d62.s4|14-26|hybridization|O
DDI-MedLine.d62.s4|27-27|,|O
DDI-MedLine.d62.s4|29-30|we|O
DDI-MedLine.d62.s4|32-39|observed|O
DDI-MedLine.d62.s4|41-44|that|O
DDI-MedLine.d62.s4|46-49|METH|O
DDI-MedLine.d62.s4|51-56|caused|O
DDI-MedLine.d62.s4|58-58|a|O
DDI-MedLine.d62.s4|60-64|rapid|O
DDI-MedLine.d62.s4|66-68|and|O
DDI-MedLine.d62.s4|70-78|transient|O
DDI-MedLine.d62.s4|80-93|dose-dependent|O
DDI-MedLine.d62.s4|95-102|increase|O
DDI-MedLine.d62.s4|104-105|in|O
DDI-MedLine.d62.s4|107-109|arc|O
DDI-MedLine.d62.s4|111-114|mRNA|O
DDI-MedLine.d62.s4|116-120|level|O
DDI-MedLine.d62.s4|122-123|in|O
DDI-MedLine.d62.s4|125-127|the|O
DDI-MedLine.d62.s4|129-136|striatum|O
DDI-MedLine.d62.s4|138-140|and|O
DDI-MedLine.d62.s4|142-147|cortex|O
DDI-MedLine.d62.s4|149-152|that|O
DDI-MedLine.d62.s4|154-156|was|O
DDI-MedLine.d62.s4|158-166|abolished|O
DDI-MedLine.d62.s4|168-169|by|O
DDI-MedLine.d62.s4|171-182|pretreatment|O
DDI-MedLine.d62.s4|184-187|with|O
DDI-MedLine.d62.s4|189-191|the|O
DDI-MedLine.d62.s4|193-200|specific|O
DDI-MedLine.d62.s4|202-209|dopamine|O
DDI-MedLine.d62.s4|211-212|D1|O
DDI-MedLine.d62.s4|214-221|receptor|O
DDI-MedLine.d62.s4|223-232|antagonist|O
DDI-MedLine.d62.s4|234-242|SCH-23390|O
DDI-MedLine.d62.s4|244-246|but|O
DDI-MedLine.d62.s4|248-250|not|O
DDI-MedLine.d62.s4|252-253|by|O
DDI-MedLine.d62.s4|255-256|an|O
DDI-MedLine.d62.s4|258-265|atypical|O
DDI-MedLine.d62.s4|267-277|neuroleptic|O
DDI-MedLine.d62.s4|279-287|clozapine|O
DDI-MedLine.d62.s4|288-288|.|O
DDI-MedLine.d62.s5|0-3|METH|O
DDI-MedLine.d62.s5|5-11|induced|O
DDI-MedLine.d62.s5|13-15|arc|O
DDI-MedLine.d62.s5|17-20|mRNA|O
DDI-MedLine.d62.s5|22-23|in|O
DDI-MedLine.d62.s5|25-30|layers|O
DDI-MedLine.d62.s5|32-33|IV|O
DDI-MedLine.d62.s5|35-37|and|O
DDI-MedLine.d62.s5|39-40|VI|O
DDI-MedLine.d62.s5|42-43|of|O
DDI-MedLine.d62.s5|45-47|the|O
DDI-MedLine.d62.s5|49-54|cortex|O
DDI-MedLine.d62.s5|56-60|which|O
DDI-MedLine.d62.s5|62-69|dopamine|O
DDI-MedLine.d62.s5|71-78|receptor|O
DDI-MedLine.d62.s5|80-82|are|O
DDI-MedLine.d62.s5|84-92|localized|O
DDI-MedLine.d62.s5|94-95|to|O
DDI-MedLine.d62.s5|96-96|.|O
DDI-MedLine.d62.s6|0-4|These|O
DDI-MedLine.d62.s6|6-12|results|O
DDI-MedLine.d62.s6|14-20|suggest|O
DDI-MedLine.d62.s6|22-25|that|O
DDI-MedLine.d62.s6|27-28|D1|O
DDI-MedLine.d62.s6|30-38|receptors|O
DDI-MedLine.d62.s6|40-42|are|O
DDI-MedLine.d62.s6|44-50|coupled|O
DDI-MedLine.d62.s6|52-53|to|O
DDI-MedLine.d62.s6|55-64|activation|O
DDI-MedLine.d62.s6|66-67|of|O
DDI-MedLine.d62.s6|69-71|arc|O
DDI-MedLine.d62.s6|73-76|gene|O
DDI-MedLine.d62.s6|77-77|,|O
DDI-MedLine.d62.s6|79-83|which|O
DDI-MedLine.d62.s6|85-87|may|O
DDI-MedLine.d62.s6|89-90|be|O
DDI-MedLine.d62.s6|92-99|involved|O
DDI-MedLine.d62.s6|101-102|in|O
DDI-MedLine.d62.s6|104-113|functional|O
DDI-MedLine.d62.s6|115-116|or|O
DDI-MedLine.d62.s6|118-127|structural|O
DDI-MedLine.d62.s6|129-139|alterations|O
DDI-MedLine.d62.s6|141-150|underlying|O
DDI-MedLine.d62.s6|152-157|neural|O
DDI-MedLine.d62.s6|159-168|plasticity|O
DDI-MedLine.d62.s6|170-178|triggered|O
DDI-MedLine.d62.s6|180-181|by|O
DDI-MedLine.d62.s6|183-186|METH|O
DDI-MedLine.d62.s6|187-187|.|O
DDI-DrugBank.d95.s0|0-11|Cyclosporine|O
DDI-DrugBank.d95.s0|13-13|-|O
DDI-DrugBank.d95.s0|15-24|L-arginine|O
DDI-DrugBank.d95.s0|26-28|may|O
DDI-DrugBank.d95.s0|30-39|counteract|O
DDI-DrugBank.d95.s0|41-43|the|O
DDI-DrugBank.d95.s0|45-57|antinaturetic|O
DDI-DrugBank.d95.s0|59-64|effect|O
DDI-DrugBank.d95.s0|66-67|of|O
DDI-DrugBank.d95.s0|69-79|cyclosporin|O
DDI-DrugBank.d95.s0|80-80|.|O
DDI-DrugBank.d95.s1|0-8|Ibuprofen|O
DDI-DrugBank.d95.s1|10-10|-|O
DDI-DrugBank.d95.s1|12-21|L-arginine|O
DDI-DrugBank.d95.s1|23-25|may|O
DDI-DrugBank.d95.s1|27-34|increase|O
DDI-DrugBank.d95.s1|36-38|the|O
DDI-DrugBank.d95.s1|40-49|absorption|O
DDI-DrugBank.d95.s1|51-52|of|O
DDI-DrugBank.d95.s1|54-62|ibuprofen|O
DDI-DrugBank.d95.s1|64-65|if|O
DDI-DrugBank.d95.s1|67-71|taken|O
DDI-DrugBank.d95.s1|73-85|concomitantly|O
DDI-DrugBank.d95.s1|86-86|.|O
DDI-DrugBank.d95.s2|0-6|Organic|O
DDI-DrugBank.d95.s2|8-15|nitrates|O
DDI-DrugBank.d95.s2|17-17|-|O
DDI-DrugBank.d95.s2|19-28|L-arginine|O
DDI-DrugBank.d95.s2|30-40|supplements|O
DDI-DrugBank.d95.s2|42-54|theoretically|O
DDI-DrugBank.d95.s2|56-58|may|O
DDI-DrugBank.d95.s2|60-69|potentiate|O
DDI-DrugBank.d95.s2|71-73|the|O
DDI-DrugBank.d95.s2|75-81|effects|O
DDI-DrugBank.d95.s2|83-84|of|O
DDI-DrugBank.d95.s2|86-92|organic|O
DDI-DrugBank.d95.s2|94-101|nitrates|O
DDI-DrugBank.d95.s2|103-104|if|O
DDI-DrugBank.d95.s2|106-110|taken|O
DDI-DrugBank.d95.s2|112-124|concomitantly|O
DDI-DrugBank.d95.s2|125-125|.|O
DDI-DrugBank.d95.s3|0-9|Sildenafil|O
DDI-DrugBank.d95.s3|11-17|citrate|O
DDI-DrugBank.d95.s3|19-19|-|O
DDI-DrugBank.d95.s3|21-33|Theoretically|O
DDI-DrugBank.d95.s3|34-34|,|O
DDI-DrugBank.d95.s3|36-45|L-arginine|O
DDI-DrugBank.d95.s3|47-57|supplements|O
DDI-DrugBank.d95.s3|59-63|taken|O
DDI-DrugBank.d95.s3|65-77|concomitantly|O
DDI-DrugBank.d95.s3|79-82|with|O
DDI-DrugBank.d95.s3|84-93|sildenafil|O
DDI-DrugBank.d95.s3|95-101|citrate|O
DDI-DrugBank.d95.s3|102-102|,|O
DDI-DrugBank.d95.s3|104-106|may|O
DDI-DrugBank.d95.s3|108-117|potentiate|O
DDI-DrugBank.d95.s3|119-121|the|O
DDI-DrugBank.d95.s3|123-129|effects|O
DDI-DrugBank.d95.s3|131-132|of|O
DDI-DrugBank.d95.s3|134-136|the|O
DDI-DrugBank.d95.s3|138-141|drug|O
DDI-DrugBank.d95.s3|142-142|.|O
DDI-DrugBank.d509.s0|0-8|Drug-Drug|O
DDI-DrugBank.d509.s0|10-21|Interactions|O
DDI-DrugBank.d509.s0|23-27|Given|O
DDI-DrugBank.d509.s0|29-31|the|O
DDI-DrugBank.d509.s0|33-39|primary|O
DDI-DrugBank.d509.s0|41-43|CNS|O
DDI-DrugBank.d509.s0|45-51|effects|O
DDI-DrugBank.d509.s0|53-54|of|O
DDI-DrugBank.d509.s0|56-67|aripiprazole|O
DDI-DrugBank.d509.s0|68-68|,|O
DDI-DrugBank.d509.s0|70-76|caution|O
DDI-DrugBank.d509.s0|78-83|should|O
DDI-DrugBank.d509.s0|85-86|be|O
DDI-DrugBank.d509.s0|88-91|used|O
DDI-DrugBank.d509.s0|93-96|when|O
DDI-DrugBank.d509.s0|98-104|ABILIFY|O
DDI-DrugBank.d509.s0|106-107|is|O
DDI-DrugBank.d509.s0|109-113|taken|O
DDI-DrugBank.d509.s0|115-116|in|O
DDI-DrugBank.d509.s0|118-128|combination|O
DDI-DrugBank.d509.s0|130-133|with|O
DDI-DrugBank.d509.s0|135-139|other|O
DDI-DrugBank.d509.s0|141-149|centrally|O
DDI-DrugBank.d509.s0|151-156|acting|O
DDI-DrugBank.d509.s0|158-162|drugs|O
DDI-DrugBank.d509.s0|164-166|and|O
DDI-DrugBank.d509.s0|168-174|alcohol|O
DDI-DrugBank.d509.s0|175-175|.|O
DDI-DrugBank.d509.s1|0-2|Due|O
DDI-DrugBank.d509.s1|4-5|to|O
DDI-DrugBank.d509.s1|7-9|its|O
DDI-DrugBank.d509.s2|0-1|1-|O
DDI-DrugBank.d509.s2|3-12|adrenergic|O
DDI-DrugBank.d509.s2|14-21|receptor|O
DDI-DrugBank.d509.s2|23-32|antagonism|O
DDI-DrugBank.d509.s2|33-33|,|O
DDI-DrugBank.d509.s2|35-46|aripiprazole|O
DDI-DrugBank.d509.s2|48-50|has|O
DDI-DrugBank.d509.s2|52-54|the|O
DDI-DrugBank.d509.s2|56-64|potential|O
DDI-DrugBank.d509.s2|66-67|to|O
DDI-DrugBank.d509.s2|69-75|enhance|O
DDI-DrugBank.d509.s2|77-79|the|O
DDI-DrugBank.d509.s2|81-86|effect|O
DDI-DrugBank.d509.s2|88-89|of|O
DDI-DrugBank.d509.s2|91-97|certain|O
DDI-DrugBank.d509.s2|99-114|antihypertensive|O
DDI-DrugBank.d509.s2|116-121|agents|O
DDI-DrugBank.d509.s2|122-122|.|O
DDI-DrugBank.d509.s3|0-8|Potential|O
DDI-DrugBank.d509.s3|10-12|for|O
DDI-DrugBank.d509.s3|14-18|Other|O
DDI-DrugBank.d509.s3|20-24|Drugs|O
DDI-DrugBank.d509.s3|26-27|to|O
DDI-DrugBank.d509.s3|29-34|Affect|O
DDI-DrugBank.d509.s3|36-42|ABILIFY|O
DDI-DrugBank.d509.s3|44-55|Aripiprazole|O
DDI-DrugBank.d509.s3|57-58|is|O
DDI-DrugBank.d509.s3|60-62|not|O
DDI-DrugBank.d509.s3|64-64|a|O
DDI-DrugBank.d509.s3|66-74|substrate|O
DDI-DrugBank.d509.s3|76-77|of|O
DDI-DrugBank.d509.s3|79-84|CYP1A1|O
DDI-DrugBank.d509.s3|85-85|,|O
DDI-DrugBank.d509.s3|87-92|CYP1A2|O
DDI-DrugBank.d509.s3|93-93|,|O
DDI-DrugBank.d509.s3|95-100|CYP2A6|O
DDI-DrugBank.d509.s3|101-101|,|O
DDI-DrugBank.d509.s3|103-108|CYP2B6|O
DDI-DrugBank.d509.s3|109-109|,|O
DDI-DrugBank.d509.s3|111-116|CYP2C8|O
DDI-DrugBank.d509.s3|117-117|,|O
DDI-DrugBank.d509.s3|119-124|CYP2C9|O
DDI-DrugBank.d509.s3|125-125|,|O
DDI-DrugBank.d509.s3|127-133|CYP2C19|O
DDI-DrugBank.d509.s3|134-134|,|O
DDI-DrugBank.d509.s3|136-137|or|O
DDI-DrugBank.d509.s3|139-144|CYP2E1|O
DDI-DrugBank.d509.s3|146-152|enzymes|O
DDI-DrugBank.d509.s3|153-153|.|O
DDI-DrugBank.d509.s4|0-11|Aripiprazole|O
DDI-DrugBank.d509.s4|13-16|also|O
DDI-DrugBank.d509.s4|18-21|does|O
DDI-DrugBank.d509.s4|23-25|not|O
DDI-DrugBank.d509.s4|27-33|undergo|O
DDI-DrugBank.d509.s4|35-40|direct|O
DDI-DrugBank.d509.s4|42-56|glucuronidation|O
DDI-DrugBank.d509.s4|57-57|.|O
DDI-DrugBank.d509.s5|0-3|This|O
DDI-DrugBank.d509.s5|5-12|suggests|O
DDI-DrugBank.d509.s5|14-17|that|O
DDI-DrugBank.d509.s5|19-20|an|O
DDI-DrugBank.d509.s5|22-32|interaction|O
DDI-DrugBank.d509.s5|34-35|of|O
DDI-DrugBank.d509.s5|37-48|aripiprazole|O
DDI-DrugBank.d509.s5|50-53|with|O
DDI-DrugBank.d509.s5|55-64|inhibitors|O
DDI-DrugBank.d509.s5|66-67|or|O
DDI-DrugBank.d509.s5|69-76|inducers|O
DDI-DrugBank.d509.s5|78-79|of|O
DDI-DrugBank.d509.s5|81-85|these|O
DDI-DrugBank.d509.s5|87-93|enzymes|O
DDI-DrugBank.d509.s5|94-94|,|O
DDI-DrugBank.d509.s5|96-97|or|O
DDI-DrugBank.d509.s5|99-103|other|O
DDI-DrugBank.d509.s5|105-111|factors|O
DDI-DrugBank.d509.s5|112-112|,|O
DDI-DrugBank.d509.s5|114-117|like|O
DDI-DrugBank.d509.s5|119-125|smoking|O
DDI-DrugBank.d509.s5|126-126|,|O
DDI-DrugBank.d509.s5|128-129|is|O
DDI-DrugBank.d509.s5|131-138|unlikely|O
DDI-DrugBank.d509.s5|139-139|.|O
DDI-DrugBank.d509.s6|0-3|Both|O
DDI-DrugBank.d509.s6|5-10|CYP3A4|O
DDI-DrugBank.d509.s6|12-14|and|O
DDI-DrugBank.d509.s6|16-21|CYP2D6|O
DDI-DrugBank.d509.s6|23-25|are|O
DDI-DrugBank.d509.s6|27-37|responsible|O
DDI-DrugBank.d509.s6|39-41|for|O
DDI-DrugBank.d509.s6|43-54|aripiprazole|O
DDI-DrugBank.d509.s6|56-65|metabolism|O
DDI-DrugBank.d509.s6|66-66|.|O
DDI-DrugBank.d509.s7|0-5|Agents|O
DDI-DrugBank.d509.s7|7-10|that|O
DDI-DrugBank.d509.s7|12-17|induce|O
DDI-DrugBank.d509.s7|19-24|CYP3A4|O
DDI-DrugBank.d509.s7|26-26|(|O
DDI-DrugBank.d509.s7|27-28|eg|O
DDI-DrugBank.d509.s7|29-29|,|O
DDI-DrugBank.d509.s7|31-43|carbamazepine|O
DDI-DrugBank.d509.s7|44-44|)|O
DDI-DrugBank.d509.s7|46-50|could|O
DDI-DrugBank.d509.s7|52-56|cause|O
DDI-DrugBank.d509.s7|58-59|an|O
DDI-DrugBank.d509.s7|61-68|increase|O
DDI-DrugBank.d509.s7|70-71|in|O
DDI-DrugBank.d509.s7|73-84|aripiprazole|O
DDI-DrugBank.d509.s7|86-94|clearance|O
DDI-DrugBank.d509.s7|96-98|and|O
DDI-DrugBank.d509.s7|100-104|lower|O
DDI-DrugBank.d509.s7|106-110|blood|O
DDI-DrugBank.d509.s7|112-117|levels|O
DDI-DrugBank.d509.s7|118-118|.|O
DDI-DrugBank.d509.s8|0-9|Inhibitors|O
DDI-DrugBank.d509.s8|11-12|of|O
DDI-DrugBank.d509.s8|14-19|CYP3A4|O
DDI-DrugBank.d509.s8|21-21|(|O
DDI-DrugBank.d509.s8|22-23|eg|O
DDI-DrugBank.d509.s8|24-24|,|O
DDI-DrugBank.d509.s8|26-37|ketoconazole|O
DDI-DrugBank.d509.s8|38-38|)|O
DDI-DrugBank.d509.s8|40-41|or|O
DDI-DrugBank.d509.s8|43-48|CYP2D6|O
DDI-DrugBank.d509.s8|50-50|(|O
DDI-DrugBank.d509.s8|51-52|eg|O
DDI-DrugBank.d509.s8|53-53|,|O
DDI-DrugBank.d509.s8|55-63|quinidine|O
DDI-DrugBank.d509.s8|64-64|,|O
DDI-DrugBank.d509.s8|66-75|fluoxetine|O
DDI-DrugBank.d509.s8|76-76|,|O
DDI-DrugBank.d509.s8|78-79|or|O
DDI-DrugBank.d509.s8|81-90|paroxetine|O
DDI-DrugBank.d509.s8|91-91|)|O
DDI-DrugBank.d509.s8|93-95|can|O
DDI-DrugBank.d509.s8|97-103|inhibit|O
DDI-DrugBank.d509.s8|105-116|aripiprazole|O
DDI-DrugBank.d509.s8|118-128|elimination|O
DDI-DrugBank.d509.s8|130-132|and|O
DDI-DrugBank.d509.s8|134-138|cause|O
DDI-DrugBank.d509.s8|140-148|increased|O
DDI-DrugBank.d509.s8|150-154|blood|O
DDI-DrugBank.d509.s8|156-161|levels|O
DDI-DrugBank.d509.s8|162-162|.|O
DDI-DrugBank.d509.s9|0-11|Ketoconazole|O
DDI-DrugBank.d509.s9|12-12|:|O
DDI-DrugBank.d509.s9|14-29|Coadministration|O
DDI-DrugBank.d509.s9|31-32|of|O
DDI-DrugBank.d509.s9|34-45|ketoconazole|O
DDI-DrugBank.d509.s9|47-47|(|O
DDI-DrugBank.d509.s9|48-50|200|O
DDI-DrugBank.d509.s9|52-57|mg/day|O
DDI-DrugBank.d509.s9|59-61|for|O
DDI-DrugBank.d509.s9|63-64|14|O
DDI-DrugBank.d509.s9|66-69|days|O
DDI-DrugBank.d509.s9|70-70|)|O
DDI-DrugBank.d509.s9|72-75|with|O
DDI-DrugBank.d509.s9|77-77|a|O
DDI-DrugBank.d509.s9|79-83|15-mg|O
DDI-DrugBank.d509.s9|85-90|single|O
DDI-DrugBank.d509.s9|92-95|dose|O
DDI-DrugBank.d509.s9|97-98|of|O
DDI-DrugBank.d509.s9|100-111|aripiprazole|O
DDI-DrugBank.d509.s9|113-121|increased|O
DDI-DrugBank.d509.s9|123-125|the|O
DDI-DrugBank.d509.s9|127-129|AUC|O
DDI-DrugBank.d509.s9|131-132|of|O
DDI-DrugBank.d509.s9|134-145|aripiprazole|O
DDI-DrugBank.d509.s9|147-149|and|O
DDI-DrugBank.d509.s9|151-153|its|O
DDI-DrugBank.d509.s9|155-160|active|O
DDI-DrugBank.d509.s9|162-171|metabolite|O
DDI-DrugBank.d509.s9|173-174|by|O
DDI-DrugBank.d509.s9|176-177|63|O
DDI-DrugBank.d509.s9|178-178|%|O
DDI-DrugBank.d509.s9|180-182|and|O
DDI-DrugBank.d509.s9|184-185|77|O
DDI-DrugBank.d509.s9|186-186|%|O
DDI-DrugBank.d509.s9|187-187|,|O
DDI-DrugBank.d509.s9|189-200|respectively|O
DDI-DrugBank.d509.s9|201-201|.|O
DDI-DrugBank.d509.s10|0-2|The|O
DDI-DrugBank.d509.s10|4-9|effect|O
DDI-DrugBank.d509.s10|11-12|of|O
DDI-DrugBank.d509.s10|14-14|a|O
DDI-DrugBank.d509.s10|16-21|higher|O
DDI-DrugBank.d509.s10|23-34|ketoconazole|O
DDI-DrugBank.d509.s10|36-39|dose|O
DDI-DrugBank.d509.s10|41-41|(|O
DDI-DrugBank.d509.s10|42-44|400|O
DDI-DrugBank.d509.s10|46-51|mg/day|O
DDI-DrugBank.d509.s10|52-52|)|O
DDI-DrugBank.d509.s10|54-56|has|O
DDI-DrugBank.d509.s10|58-60|not|O
DDI-DrugBank.d509.s10|62-65|been|O
DDI-DrugBank.d509.s10|67-73|studied|O
DDI-DrugBank.d509.s10|74-74|.|O
DDI-DrugBank.d509.s11|0-3|When|O
DDI-DrugBank.d509.s11|5-15|concomitant|O
DDI-DrugBank.d509.s11|17-30|administration|O
DDI-DrugBank.d509.s11|32-33|of|O
DDI-DrugBank.d509.s11|35-46|ketoconazole|O
DDI-DrugBank.d509.s11|48-51|with|O
DDI-DrugBank.d509.s11|53-64|aripiprazole|O
DDI-DrugBank.d509.s11|66-71|occurs|O
DDI-DrugBank.d509.s11|72-72|,|O
DDI-DrugBank.d509.s11|74-85|aripiprazole|O
DDI-DrugBank.d509.s11|87-90|dose|O
DDI-DrugBank.d509.s11|92-97|should|O
DDI-DrugBank.d509.s11|99-100|be|O
DDI-DrugBank.d509.s11|102-108|reduced|O
DDI-DrugBank.d509.s11|110-111|to|O
DDI-DrugBank.d509.s11|113-120|one-half|O
DDI-DrugBank.d509.s11|122-123|of|O
DDI-DrugBank.d509.s11|125-127|its|O
DDI-DrugBank.d509.s11|129-134|normal|O
DDI-DrugBank.d509.s11|136-139|dose|O
DDI-DrugBank.d509.s11|140-140|.|O
DDI-DrugBank.d509.s12|0-4|Other|O
DDI-DrugBank.d509.s12|6-11|strong|O
DDI-DrugBank.d509.s12|13-22|inhibitors|O
DDI-DrugBank.d509.s12|24-25|of|O
DDI-DrugBank.d509.s12|27-32|CYP3A4|O
DDI-DrugBank.d509.s12|34-34|(|O
DDI-DrugBank.d509.s12|35-46|itraconazole|O
DDI-DrugBank.d509.s12|47-47|)|O
DDI-DrugBank.d509.s12|49-53|would|O
DDI-DrugBank.d509.s12|55-56|be|O
DDI-DrugBank.d509.s12|58-65|expected|O
DDI-DrugBank.d509.s12|67-68|to|O
DDI-DrugBank.d509.s12|70-73|have|O
DDI-DrugBank.d509.s12|75-81|similar|O
DDI-DrugBank.d509.s12|83-89|effects|O
DDI-DrugBank.d509.s12|91-93|and|O
DDI-DrugBank.d509.s12|95-98|need|O
DDI-DrugBank.d509.s12|100-106|similar|O
DDI-DrugBank.d509.s12|108-111|dose|O
DDI-DrugBank.d509.s12|113-122|reductions|O
DDI-DrugBank.d509.s12|123-123|;|O
DDI-DrugBank.d509.s13|0-5|weaker|O
DDI-DrugBank.d509.s13|7-16|inhibitors|O
DDI-DrugBank.d509.s13|18-18|(|O
DDI-DrugBank.d509.s13|19-30|erythromycin|O
DDI-DrugBank.d509.s13|31-31|,|O
DDI-DrugBank.d509.s13|33-42|grapefruit|O
DDI-DrugBank.d509.s13|44-48|juice|O
DDI-DrugBank.d509.s13|49-49|)|O
DDI-DrugBank.d509.s13|51-54|have|O
DDI-DrugBank.d509.s13|56-58|not|O
DDI-DrugBank.d509.s13|60-63|been|O
DDI-DrugBank.d509.s13|65-71|studied|O
DDI-DrugBank.d509.s13|72-72|.|O
DDI-DrugBank.d509.s14|0-3|When|O
DDI-DrugBank.d509.s14|5-7|the|O
DDI-DrugBank.d509.s14|9-14|CYP3A4|O
DDI-DrugBank.d509.s14|16-24|inhibitor|O
DDI-DrugBank.d509.s14|26-27|is|O
DDI-DrugBank.d509.s14|29-37|withdrawn|O
DDI-DrugBank.d509.s14|39-42|from|O
DDI-DrugBank.d509.s14|44-46|the|O
DDI-DrugBank.d509.s14|48-58|combination|O
DDI-DrugBank.d509.s14|60-66|therapy|O
DDI-DrugBank.d509.s14|67-67|,|O
DDI-DrugBank.d509.s14|69-80|aripiprazole|O
DDI-DrugBank.d509.s14|82-85|dose|O
DDI-DrugBank.d509.s14|87-92|should|O
DDI-DrugBank.d509.s14|94-97|then|O
DDI-DrugBank.d509.s14|99-100|be|O
DDI-DrugBank.d509.s14|102-110|increased|O
DDI-DrugBank.d509.s14|111-111|.|O
DDI-DrugBank.d509.s15|0-8|Quinidine|O
DDI-DrugBank.d509.s15|9-9|:|O
DDI-DrugBank.d509.s15|11-26|Coadministration|O
DDI-DrugBank.d509.s15|28-29|of|O
DDI-DrugBank.d509.s15|31-31|a|O
DDI-DrugBank.d509.s15|33-37|10-mg|O
DDI-DrugBank.d509.s15|39-44|single|O
DDI-DrugBank.d509.s15|46-49|dose|O
DDI-DrugBank.d509.s15|51-52|of|O
DDI-DrugBank.d509.s15|54-65|aripiprazole|O
DDI-DrugBank.d509.s15|67-70|with|O
DDI-DrugBank.d509.s15|72-80|quinidine|O
DDI-DrugBank.d509.s15|82-82|(|O
DDI-DrugBank.d509.s15|83-85|166|O
DDI-DrugBank.d509.s15|87-92|mg/day|O
DDI-DrugBank.d509.s15|94-96|for|O
DDI-DrugBank.d509.s15|98-99|13|O
DDI-DrugBank.d509.s15|101-104|days|O
DDI-DrugBank.d509.s15|105-105|)|O
DDI-DrugBank.d509.s15|106-106|,|O
DDI-DrugBank.d509.s15|108-108|a|O
DDI-DrugBank.d509.s15|110-115|potent|O
DDI-DrugBank.d509.s15|117-125|inhibitor|O
DDI-DrugBank.d509.s15|127-128|of|O
DDI-DrugBank.d509.s15|130-135|CYP2D6|O
DDI-DrugBank.d509.s15|136-136|,|O
DDI-DrugBank.d509.s15|138-146|increased|O
DDI-DrugBank.d509.s15|148-150|the|O
DDI-DrugBank.d509.s15|152-154|AUC|O
DDI-DrugBank.d509.s15|156-157|of|O
DDI-DrugBank.d509.s15|159-170|aripiprazole|O
DDI-DrugBank.d509.s15|172-173|by|O
DDI-DrugBank.d509.s15|175-177|112|O
DDI-DrugBank.d509.s15|178-178|%|O
DDI-DrugBank.d509.s15|180-182|but|O
DDI-DrugBank.d509.s15|184-192|decreased|O
DDI-DrugBank.d509.s15|194-196|the|O
DDI-DrugBank.d509.s15|198-200|AUC|O
DDI-DrugBank.d509.s15|202-203|of|O
DDI-DrugBank.d509.s15|205-207|its|O
DDI-DrugBank.d509.s15|209-214|active|O
DDI-DrugBank.d509.s15|216-225|metabolite|O
DDI-DrugBank.d509.s15|226-226|,|O
DDI-DrugBank.d509.s15|228-246|dehydroaripiprazole|O
DDI-DrugBank.d509.s15|247-247|,|O
DDI-DrugBank.d509.s15|249-250|by|O
DDI-DrugBank.d509.s15|252-253|35|O
DDI-DrugBank.d509.s15|254-254|%|O
DDI-DrugBank.d509.s15|255-255|.|O
DDI-DrugBank.d509.s16|0-11|Aripiprazole|O
DDI-DrugBank.d509.s16|13-16|dose|O
DDI-DrugBank.d509.s16|18-23|should|O
DDI-DrugBank.d509.s16|25-26|be|O
DDI-DrugBank.d509.s16|28-34|reduced|O
DDI-DrugBank.d509.s16|36-37|to|O
DDI-DrugBank.d509.s16|39-46|one-half|O
DDI-DrugBank.d509.s16|48-49|of|O
DDI-DrugBank.d509.s16|51-53|its|O
DDI-DrugBank.d509.s16|55-60|normal|O
DDI-DrugBank.d509.s16|62-65|dose|O
DDI-DrugBank.d509.s16|67-70|when|O
DDI-DrugBank.d509.s16|72-82|concomitant|O
DDI-DrugBank.d509.s16|84-97|administration|O
DDI-DrugBank.d509.s16|99-100|of|O
DDI-DrugBank.d509.s16|102-110|quinidine|O
DDI-DrugBank.d509.s16|112-115|with|O
DDI-DrugBank.d509.s16|117-128|aripiprazole|O
DDI-DrugBank.d509.s16|130-135|occurs|O
DDI-DrugBank.d509.s16|136-136|.|O
DDI-DrugBank.d509.s17|0-4|Other|O
DDI-DrugBank.d509.s17|6-16|significant|O
DDI-DrugBank.d509.s17|18-27|inhibitors|O
DDI-DrugBank.d509.s17|29-30|of|O
DDI-DrugBank.d509.s17|32-37|CYP2D6|O
DDI-DrugBank.d509.s17|38-38|,|O
DDI-DrugBank.d509.s17|40-43|such|O
DDI-DrugBank.d509.s17|45-46|as|O
DDI-DrugBank.d509.s17|48-57|fluoxetine|O
DDI-DrugBank.d509.s17|59-60|or|O
DDI-DrugBank.d509.s17|62-71|paroxetine|O
DDI-DrugBank.d509.s17|72-72|,|O
DDI-DrugBank.d509.s17|74-78|would|O
DDI-DrugBank.d509.s17|80-81|be|O
DDI-DrugBank.d509.s17|83-90|expected|O
DDI-DrugBank.d509.s17|92-93|to|O
DDI-DrugBank.d509.s17|95-98|have|O
DDI-DrugBank.d509.s17|100-106|similar|O
DDI-DrugBank.d509.s17|108-114|effects|O
DDI-DrugBank.d509.s17|116-118|and|O
DDI-DrugBank.d509.s17|119-119|,|O
DDI-DrugBank.d509.s17|121-129|therefore|O
DDI-DrugBank.d509.s17|130-130|,|O
DDI-DrugBank.d509.s17|132-137|should|O
DDI-DrugBank.d509.s17|139-140|be|O
DDI-DrugBank.d509.s17|142-152|accompanied|O
DDI-DrugBank.d509.s17|154-155|by|O
DDI-DrugBank.d509.s17|157-163|similar|O
DDI-DrugBank.d509.s17|165-168|dose|O
DDI-DrugBank.d509.s17|170-179|reductions|O
DDI-DrugBank.d509.s17|180-180|.|O
DDI-DrugBank.d509.s18|0-3|When|O
DDI-DrugBank.d509.s18|5-7|the|O
DDI-DrugBank.d509.s18|9-14|CYP2D6|O
DDI-DrugBank.d509.s18|16-24|inhibitor|O
DDI-DrugBank.d509.s18|26-27|is|O
DDI-DrugBank.d509.s18|29-37|withdrawn|O
DDI-DrugBank.d509.s18|39-42|from|O
DDI-DrugBank.d509.s18|44-46|the|O
DDI-DrugBank.d509.s18|48-58|combination|O
DDI-DrugBank.d509.s18|60-66|therapy|O
DDI-DrugBank.d509.s18|67-67|,|O
DDI-DrugBank.d509.s18|69-80|aripiprazole|O
DDI-DrugBank.d509.s18|82-85|dose|O
DDI-DrugBank.d509.s18|87-92|should|O
DDI-DrugBank.d509.s18|94-97|then|O
DDI-DrugBank.d509.s18|99-100|be|O
DDI-DrugBank.d509.s18|102-110|increased|O
DDI-DrugBank.d509.s18|111-111|.|O
DDI-DrugBank.d509.s19|0-12|Carbamazepine|O
DDI-DrugBank.d509.s19|13-13|:|O
DDI-DrugBank.d509.s19|15-30|Coadministration|O
DDI-DrugBank.d509.s19|32-33|of|O
DDI-DrugBank.d509.s19|35-47|carbamazepine|O
DDI-DrugBank.d509.s19|49-49|(|O
DDI-DrugBank.d509.s19|50-52|200|O
DDI-DrugBank.d509.s19|54-55|mg|O
DDI-DrugBank.d509.s19|57-59|BID|O
DDI-DrugBank.d509.s19|60-60|)|O
DDI-DrugBank.d509.s19|61-61|,|O
DDI-DrugBank.d509.s19|63-63|a|O
DDI-DrugBank.d509.s19|65-70|potent|O
DDI-DrugBank.d509.s19|72-77|CYP3A4|O
DDI-DrugBank.d509.s19|79-85|inducer|O
DDI-DrugBank.d509.s19|86-86|,|O
DDI-DrugBank.d509.s19|88-91|with|O
DDI-DrugBank.d509.s19|93-104|aripiprazole|O
DDI-DrugBank.d509.s19|106-106|(|O
DDI-DrugBank.d509.s19|107-108|30|O
DDI-DrugBank.d509.s19|110-111|mg|O
DDI-DrugBank.d509.s19|113-114|QD|O
DDI-DrugBank.d509.s19|115-115|)|O
DDI-DrugBank.d509.s19|117-124|resulted|O
DDI-DrugBank.d509.s19|126-127|in|O
DDI-DrugBank.d509.s19|129-130|an|O
DDI-DrugBank.d509.s19|132-142|approximate|O
DDI-DrugBank.d509.s19|144-145|70|O
DDI-DrugBank.d509.s19|146-146|%|O
DDI-DrugBank.d509.s19|148-155|decrease|O
DDI-DrugBank.d509.s19|157-158|in|O
DDI-DrugBank.d509.s19|160-163|Cmax|O
DDI-DrugBank.d509.s19|165-167|and|O
DDI-DrugBank.d509.s19|169-171|AUC|O
DDI-DrugBank.d509.s19|173-178|values|O
DDI-DrugBank.d509.s19|180-181|of|O
DDI-DrugBank.d509.s19|183-186|both|O
DDI-DrugBank.d509.s19|188-199|aripiprazole|O
DDI-DrugBank.d509.s19|201-203|and|O
DDI-DrugBank.d509.s19|205-207|its|O
DDI-DrugBank.d509.s19|209-214|active|O
DDI-DrugBank.d509.s19|216-225|metabolite|O
DDI-DrugBank.d509.s19|226-226|,|O
DDI-DrugBank.d509.s19|228-247|dehydro-aripiprazole|O
DDI-DrugBank.d509.s19|248-248|.|O
DDI-DrugBank.d509.s20|0-3|When|O
DDI-DrugBank.d509.s20|5-17|carbamazepine|O
DDI-DrugBank.d509.s20|19-20|is|O
DDI-DrugBank.d509.s20|22-26|added|O
DDI-DrugBank.d509.s20|28-29|to|O
DDI-DrugBank.d509.s20|31-42|aripiprazole|O
DDI-DrugBank.d509.s20|44-50|therapy|O
DDI-DrugBank.d509.s20|51-51|,|O
DDI-DrugBank.d509.s20|53-64|aripiprazole|O
DDI-DrugBank.d509.s20|66-69|dose|O
DDI-DrugBank.d509.s20|71-76|should|O
DDI-DrugBank.d509.s20|78-79|be|O
DDI-DrugBank.d509.s20|81-87|doubled|O
DDI-DrugBank.d509.s20|88-88|.|O
DDI-DrugBank.d509.s21|0-9|Additional|O
DDI-DrugBank.d509.s21|11-14|dose|O
DDI-DrugBank.d509.s21|16-24|increases|O
DDI-DrugBank.d509.s21|26-31|should|O
DDI-DrugBank.d509.s21|33-34|be|O
DDI-DrugBank.d509.s21|36-40|based|O
DDI-DrugBank.d509.s21|42-43|on|O
DDI-DrugBank.d509.s21|45-52|clinical|O
DDI-DrugBank.d509.s21|54-63|evaluation|O
DDI-DrugBank.d509.s21|64-64|.|O
DDI-DrugBank.d509.s22|0-3|When|O
DDI-DrugBank.d509.s22|5-17|carbamazepine|O
DDI-DrugBank.d509.s22|19-20|is|O
DDI-DrugBank.d509.s22|22-30|withdrawn|O
DDI-DrugBank.d509.s22|32-35|from|O
DDI-DrugBank.d509.s22|37-39|the|O
DDI-DrugBank.d509.s22|41-51|combination|O
DDI-DrugBank.d509.s22|53-59|therapy|O
DDI-DrugBank.d509.s22|60-60|,|O
DDI-DrugBank.d509.s22|62-73|aripiprazole|O
DDI-DrugBank.d509.s22|75-78|dose|O
DDI-DrugBank.d509.s22|80-85|should|O
DDI-DrugBank.d509.s22|87-90|then|O
DDI-DrugBank.d509.s22|92-93|be|O
DDI-DrugBank.d509.s22|95-101|reduced|O
DDI-DrugBank.d509.s22|102-102|.|O
DDI-DrugBank.d509.s23|0-1|No|O
DDI-DrugBank.d509.s23|3-12|clinically|O
DDI-DrugBank.d509.s23|14-24|significant|O
DDI-DrugBank.d509.s23|26-31|effect|O
DDI-DrugBank.d509.s23|33-34|of|O
DDI-DrugBank.d509.s23|36-45|famotidine|O
DDI-DrugBank.d509.s23|46-46|,|O
DDI-DrugBank.d509.s23|48-56|valproate|O
DDI-DrugBank.d509.s23|57-57|,|O
DDI-DrugBank.d509.s23|59-60|or|O
DDI-DrugBank.d509.s23|62-68|lithium|O
DDI-DrugBank.d509.s23|70-72|was|O
DDI-DrugBank.d509.s23|74-77|seen|O
DDI-DrugBank.d509.s23|79-80|on|O
DDI-DrugBank.d509.s23|82-84|the|O
DDI-DrugBank.d509.s23|86-101|pharmacokinetics|O
DDI-DrugBank.d509.s23|103-104|of|O
DDI-DrugBank.d509.s23|106-117|aripiprazole|O
DDI-DrugBank.d509.s23|119-119|(|O
DDI-DrugBank.d509.s23|120-122|see|O
DDI-DrugBank.d509.s23|124-131|CLINICAL|O
DDI-DrugBank.d509.s23|133-144|PHARMACOLOGY|O
DDI-DrugBank.d509.s23|145-145|:|O
DDI-DrugBank.d509.s23|147-151|Drug-|O
DDI-DrugBank.d509.s23|153-156|Drug|O
DDI-DrugBank.d509.s23|158-169|Interactions|O
DDI-DrugBank.d509.s23|170-170|)|O
DDI-DrugBank.d509.s23|171-171|.|O
DDI-DrugBank.d509.s24|0-8|Potential|O
DDI-DrugBank.d509.s24|10-12|for|O
DDI-DrugBank.d509.s24|14-20|ABILIFY|O
DDI-DrugBank.d509.s24|22-23|to|O
DDI-DrugBank.d509.s24|25-30|Affect|O
DDI-DrugBank.d509.s24|32-36|Other|O
DDI-DrugBank.d509.s24|38-42|Drugs|O
DDI-DrugBank.d509.s24|44-55|Aripiprazole|O
DDI-DrugBank.d509.s24|57-58|is|O
DDI-DrugBank.d509.s24|60-67|unlikely|O
DDI-DrugBank.d509.s24|69-70|to|O
DDI-DrugBank.d509.s24|72-76|cause|O
DDI-DrugBank.d509.s24|78-87|clinically|O
DDI-DrugBank.d509.s24|89-97|important|O
DDI-DrugBank.d509.s24|99-113|pharmacokinetic|O
DDI-DrugBank.d509.s24|115-126|interactions|O
DDI-DrugBank.d509.s24|128-131|with|O
DDI-DrugBank.d509.s24|133-137|drugs|O
DDI-DrugBank.d509.s24|139-149|metabolized|O
DDI-DrugBank.d509.s24|151-152|by|O
DDI-DrugBank.d509.s24|154-163|cytochrome|O
DDI-DrugBank.d509.s24|165-168|P450|O
DDI-DrugBank.d509.s24|170-176|enzymes|O
DDI-DrugBank.d509.s24|177-177|.|O
DDI-DrugBank.d509.s25|0-1|In|O
DDI-DrugBank.d509.s25|3-4|in|O
DDI-DrugBank.d509.s25|6-9|vivo|O
DDI-DrugBank.d509.s25|11-17|studies|O
DDI-DrugBank.d509.s25|18-18|,|O
DDI-DrugBank.d509.s25|20-22|10-|O
DDI-DrugBank.d509.s25|24-25|to|O
DDI-DrugBank.d509.s25|27-35|30-mg/day|O
DDI-DrugBank.d509.s25|37-41|doses|O
DDI-DrugBank.d509.s25|43-44|of|O
DDI-DrugBank.d509.s25|46-57|aripiprazole|O
DDI-DrugBank.d509.s25|59-61|had|O
DDI-DrugBank.d509.s25|63-64|no|O
DDI-DrugBank.d509.s25|66-76|significant|O
DDI-DrugBank.d509.s25|78-83|effect|O
DDI-DrugBank.d509.s25|85-86|on|O
DDI-DrugBank.d509.s25|88-97|metabolism|O
DDI-DrugBank.d509.s25|99-100|by|O
DDI-DrugBank.d509.s25|102-107|CYP2D6|O
DDI-DrugBank.d509.s25|109-109|(|O
DDI-DrugBank.d509.s25|110-125|dextromethorphan|O
DDI-DrugBank.d509.s25|126-126|)|O
DDI-DrugBank.d509.s25|127-127|,|O
DDI-DrugBank.d509.s25|129-134|CYP2C9|O
DDI-DrugBank.d509.s25|136-136|(|O
DDI-DrugBank.d509.s25|137-144|warfarin|O
DDI-DrugBank.d509.s25|145-145|)|O
DDI-DrugBank.d509.s25|146-146|,|O
DDI-DrugBank.d509.s25|148-154|CYP2C19|O
DDI-DrugBank.d509.s25|156-156|(|O
DDI-DrugBank.d509.s25|157-166|omeprazole|O
DDI-DrugBank.d509.s25|167-167|,|O
DDI-DrugBank.d509.s25|169-176|warfarin|O
DDI-DrugBank.d509.s25|177-177|)|O
DDI-DrugBank.d509.s25|178-178|,|O
DDI-DrugBank.d509.s25|180-182|and|O
DDI-DrugBank.d509.s25|184-189|CYP3A4|O
DDI-DrugBank.d509.s25|191-191|(|O
DDI-DrugBank.d509.s25|192-207|dextromethorphan|O
DDI-DrugBank.d509.s25|208-208|)|O
DDI-DrugBank.d509.s25|210-219|substrates|O
DDI-DrugBank.d509.s25|220-220|.|O
DDI-DrugBank.d509.s26|0-11|Additionally|O
DDI-DrugBank.d509.s26|12-12|,|O
DDI-DrugBank.d509.s26|14-25|aripiprazole|O
DDI-DrugBank.d509.s26|27-29|and|O
DDI-DrugBank.d509.s26|31-49|dehydroaripiprazole|O
DDI-DrugBank.d509.s26|51-53|did|O
DDI-DrugBank.d509.s26|55-57|not|O
DDI-DrugBank.d509.s26|59-62|show|O
DDI-DrugBank.d509.s26|64-72|potential|O
DDI-DrugBank.d509.s26|74-76|for|O
DDI-DrugBank.d509.s26|78-85|altering|O
DDI-DrugBank.d509.s26|87-101|CYP1A2-mediated|O
DDI-DrugBank.d509.s26|103-112|metabolism|O
DDI-DrugBank.d509.s26|114-115|in|O
DDI-DrugBank.d509.s26|117-121|vitro|O
DDI-DrugBank.d509.s26|122-122|.|O
DDI-DrugBank.d509.s27|0-6|Alcohol|O
DDI-DrugBank.d509.s27|7-7|:|O
DDI-DrugBank.d509.s27|9-13|There|O
DDI-DrugBank.d509.s27|15-17|was|O
DDI-DrugBank.d509.s27|19-20|no|O
DDI-DrugBank.d509.s27|22-32|significant|O
DDI-DrugBank.d509.s27|34-43|difference|O
DDI-DrugBank.d509.s27|45-51|between|O
DDI-DrugBank.d509.s27|53-64|aripiprazole|O
DDI-DrugBank.d509.s27|66-79|coadministered|O
DDI-DrugBank.d509.s27|81-84|with|O
DDI-DrugBank.d509.s27|86-92|ethanol|O
DDI-DrugBank.d509.s27|94-96|and|O
DDI-DrugBank.d509.s27|98-104|placebo|O
DDI-DrugBank.d509.s27|106-119|coadministered|O
DDI-DrugBank.d509.s27|121-124|with|O
DDI-DrugBank.d509.s27|126-132|ethanol|O
DDI-DrugBank.d509.s27|134-135|on|O
DDI-DrugBank.d509.s27|137-147|performance|O
DDI-DrugBank.d509.s27|149-150|of|O
DDI-DrugBank.d509.s27|152-156|gross|O
DDI-DrugBank.d509.s27|158-162|motor|O
DDI-DrugBank.d509.s27|164-169|skills|O
DDI-DrugBank.d509.s27|171-172|or|O
DDI-DrugBank.d509.s27|174-181|stimulus|O
DDI-DrugBank.d509.s27|183-190|response|O
DDI-DrugBank.d509.s27|192-193|in|O
DDI-DrugBank.d509.s27|195-201|healthy|O
DDI-DrugBank.d509.s27|203-210|subjects|O
DDI-DrugBank.d509.s27|211-211|.|O
DDI-DrugBank.d509.s28|0-1|As|O
DDI-DrugBank.d509.s28|3-6|with|O
DDI-DrugBank.d509.s28|8-11|most|O
DDI-DrugBank.d509.s28|13-24|psychoactive|O
DDI-DrugBank.d509.s28|26-36|medications|O
DDI-DrugBank.d509.s28|37-37|,|O
DDI-DrugBank.d509.s28|39-46|patients|O
DDI-DrugBank.d509.s28|48-53|should|O
DDI-DrugBank.d509.s28|55-56|be|O
DDI-DrugBank.d509.s28|58-64|advised|O
DDI-DrugBank.d509.s28|66-67|to|O
DDI-DrugBank.d509.s28|69-73|avoid|O
DDI-DrugBank.d509.s28|75-81|alcohol|O
DDI-DrugBank.d509.s28|83-87|while|O
DDI-DrugBank.d509.s28|89-94|taking|O
DDI-DrugBank.d509.s28|96-102|ABILIFY|O
DDI-DrugBank.d509.s29|0-0|.|O
DDI-DrugBank.d761.s0|0-6|Alcohol|O
DDI-DrugBank.d761.s0|7-7|:|O
DDI-DrugBank.d761.s0|9-10|In|O
DDI-DrugBank.d761.s0|12-12|a|O
DDI-DrugBank.d761.s0|14-26|multiple-dose|O
DDI-DrugBank.d761.s0|28-32|study|O
DDI-DrugBank.d761.s0|34-35|in|O
DDI-DrugBank.d761.s0|37-38|30|O
DDI-DrugBank.d761.s0|40-45|normal|O
DDI-DrugBank.d761.s0|47-52|weight|O
DDI-DrugBank.d761.s0|54-61|subjects|O
DDI-DrugBank.d761.s0|62-62|,|O
DDI-DrugBank.d761.s0|64-79|coadministration|O
DDI-DrugBank.d761.s0|81-82|of|O
DDI-DrugBank.d761.s0|84-90|XENICAL|O
DDI-DrugBank.d761.s0|92-94|and|O
DDI-DrugBank.d761.s0|96-97|40|O
DDI-DrugBank.d761.s0|99-103|grams|O
DDI-DrugBank.d761.s0|105-106|of|O
DDI-DrugBank.d761.s0|108-114|alcohol|O
DDI-DrugBank.d761.s0|116-116|(|O
DDI-DrugBank.d761.s0|117-120|e.g.|O
DDI-DrugBank.d761.s0|121-121|,|O
DDI-DrugBank.d761.s0|123-135|approximately|O
DDI-DrugBank.d761.s0|137-137|3|O
DDI-DrugBank.d761.s0|139-145|glasses|O
DDI-DrugBank.d761.s0|147-148|of|O
DDI-DrugBank.d761.s0|150-153|wine|O
DDI-DrugBank.d761.s0|154-154|)|O
DDI-DrugBank.d761.s0|156-158|did|O
DDI-DrugBank.d761.s0|160-162|not|O
DDI-DrugBank.d761.s0|164-169|result|O
DDI-DrugBank.d761.s0|171-172|in|O
DDI-DrugBank.d761.s0|174-183|alteration|O
DDI-DrugBank.d761.s0|185-186|of|O
DDI-DrugBank.d761.s0|188-194|alcohol|O
DDI-DrugBank.d761.s0|196-211|pharmacokinetics|O
DDI-DrugBank.d761.s0|212-212|,|O
DDI-DrugBank.d761.s0|214-221|orlistat|O
DDI-DrugBank.d761.s0|223-238|pharmacodynamics|O
DDI-DrugBank.d761.s0|240-240|(|O
DDI-DrugBank.d761.s0|241-245|fecal|O
DDI-DrugBank.d761.s0|247-249|fat|O
DDI-DrugBank.d761.s0|251-259|excretion|O
DDI-DrugBank.d761.s0|260-260|)|O
DDI-DrugBank.d761.s0|261-261|,|O
DDI-DrugBank.d761.s0|263-264|or|O
DDI-DrugBank.d761.s0|266-273|systemic|O
DDI-DrugBank.d761.s0|275-282|exposure|O
DDI-DrugBank.d761.s0|284-285|to|O
DDI-DrugBank.d761.s0|287-294|orlistat|O
DDI-DrugBank.d761.s0|295-295|.|O
DDI-DrugBank.d761.s1|0-11|Cyclosporine|O
DDI-DrugBank.d761.s1|12-12|:|O
DDI-DrugBank.d761.s1|14-24|Preliminary|O
DDI-DrugBank.d761.s1|26-29|data|O
DDI-DrugBank.d761.s1|31-34|from|O
DDI-DrugBank.d761.s1|36-36|a|O
DDI-DrugBank.d761.s1|38-44|XENICAL|O
DDI-DrugBank.d761.s1|46-48|and|O
DDI-DrugBank.d761.s1|50-61|cyclosporine|O
DDI-DrugBank.d761.s1|63-66|drug|O
DDI-DrugBank.d761.s1|68-78|interaction|O
DDI-DrugBank.d761.s1|80-84|study|O
DDI-DrugBank.d761.s1|86-93|indicate|O
DDI-DrugBank.d761.s1|95-95|a|O
DDI-DrugBank.d761.s1|97-105|reduction|O
DDI-DrugBank.d761.s1|107-108|in|O
DDI-DrugBank.d761.s1|110-121|cyclosporine|O
DDI-DrugBank.d761.s1|123-128|plasma|O
DDI-DrugBank.d761.s1|130-135|levels|O
DDI-DrugBank.d761.s1|137-140|when|O
DDI-DrugBank.d761.s1|142-148|XENICAL|O
DDI-DrugBank.d761.s1|150-152|was|O
DDI-DrugBank.d761.s1|154-167|coadministered|O
DDI-DrugBank.d761.s1|169-172|with|O
DDI-DrugBank.d761.s1|174-185|cyclosporine|O
DDI-DrugBank.d761.s1|186-186|.|O
DDI-DrugBank.d761.s2|0-6|Digoxin|O
DDI-DrugBank.d761.s2|7-7|:|O
DDI-DrugBank.d761.s2|9-10|In|O
DDI-DrugBank.d761.s2|12-13|12|O
DDI-DrugBank.d761.s2|15-27|normal-weight|O
DDI-DrugBank.d761.s2|29-36|subjects|O
DDI-DrugBank.d761.s2|38-46|receiving|O
DDI-DrugBank.d761.s2|48-54|XENICAL|O
DDI-DrugBank.d761.s2|56-58|120|O
DDI-DrugBank.d761.s2|60-61|mg|O
DDI-DrugBank.d761.s2|63-67|three|O
DDI-DrugBank.d761.s2|69-73|times|O
DDI-DrugBank.d761.s2|75-75|a|O
DDI-DrugBank.d761.s2|77-79|day|O
DDI-DrugBank.d761.s2|81-83|for|O
DDI-DrugBank.d761.s2|85-85|6|O
DDI-DrugBank.d761.s2|87-90|days|O
DDI-DrugBank.d761.s2|91-91|,|O
DDI-DrugBank.d761.s2|93-99|XENICAL|O
DDI-DrugBank.d761.s2|101-103|did|O
DDI-DrugBank.d761.s2|105-107|not|O
DDI-DrugBank.d761.s2|109-113|alter|O
DDI-DrugBank.d761.s2|115-117|the|O
DDI-DrugBank.d761.s2|119-134|pharmacokinetics|O
DDI-DrugBank.d761.s2|136-137|of|O
DDI-DrugBank.d761.s2|139-139|a|O
DDI-DrugBank.d761.s2|141-146|single|O
DDI-DrugBank.d761.s2|148-151|dose|O
DDI-DrugBank.d761.s2|153-154|of|O
DDI-DrugBank.d761.s2|156-162|digoxin|O
DDI-DrugBank.d761.s2|163-163|.|O
DDI-DrugBank.d761.s3|0-10|Fat-soluble|O
DDI-DrugBank.d761.s3|12-18|Vitamin|O
DDI-DrugBank.d761.s3|20-30|Supplements|O
DDI-DrugBank.d761.s3|32-34|and|O
DDI-DrugBank.d761.s3|36-44|Analogues|O
DDI-DrugBank.d761.s3|45-45|:|O
DDI-DrugBank.d761.s3|47-47|A|O
DDI-DrugBank.d761.s3|49-63|pharmacokinetic|O
DDI-DrugBank.d761.s3|65-75|interaction|O
DDI-DrugBank.d761.s3|77-81|study|O
DDI-DrugBank.d761.s3|83-88|showed|O
DDI-DrugBank.d761.s3|90-90|a|O
DDI-DrugBank.d761.s3|92-93|30|O
DDI-DrugBank.d761.s3|94-94|%|O
DDI-DrugBank.d761.s3|96-104|reduction|O
DDI-DrugBank.d761.s3|106-107|in|O
DDI-DrugBank.d761.s3|109-121|beta-carotene|O
DDI-DrugBank.d761.s3|123-132|supplement|O
DDI-DrugBank.d761.s3|134-143|absorption|O
DDI-DrugBank.d761.s3|145-148|when|O
DDI-DrugBank.d761.s3|150-162|concomitantly|O
DDI-DrugBank.d761.s3|164-175|administered|O
DDI-DrugBank.d761.s3|177-180|with|O
DDI-DrugBank.d761.s3|182-188|XENICAL|O
DDI-DrugBank.d761.s3|189-189|.|O
DDI-DrugBank.d761.s4|0-6|XENICAL|O
DDI-DrugBank.d761.s4|8-16|inhibited|O
DDI-DrugBank.d761.s4|18-27|absorption|O
DDI-DrugBank.d761.s4|29-30|of|O
DDI-DrugBank.d761.s4|32-32|a|O
DDI-DrugBank.d761.s4|34-40|vitamin|O
DDI-DrugBank.d761.s4|42-42|E|O
DDI-DrugBank.d761.s4|44-50|acetate|O
DDI-DrugBank.d761.s4|52-61|supplement|O
DDI-DrugBank.d761.s4|63-64|by|O
DDI-DrugBank.d761.s4|66-78|approximately|O
DDI-DrugBank.d761.s4|80-81|60|O
DDI-DrugBank.d761.s4|82-82|%|O
DDI-DrugBank.d761.s4|83-83|.|O
DDI-DrugBank.d761.s5|0-2|The|O
DDI-DrugBank.d761.s5|4-9|effect|O
DDI-DrugBank.d761.s5|11-12|of|O
DDI-DrugBank.d761.s5|14-21|orlistat|O
DDI-DrugBank.d761.s5|23-24|on|O
DDI-DrugBank.d761.s5|26-28|the|O
DDI-DrugBank.d761.s5|30-39|absorption|O
DDI-DrugBank.d761.s5|41-42|of|O
DDI-DrugBank.d761.s5|44-55|supplemental|O
DDI-DrugBank.d761.s5|57-63|vitamin|O
DDI-DrugBank.d761.s5|65-65|D|O
DDI-DrugBank.d761.s5|66-66|,|O
DDI-DrugBank.d761.s5|68-74|vitamin|O
DDI-DrugBank.d761.s5|76-76|A|O
DDI-DrugBank.d761.s5|77-77|,|O
DDI-DrugBank.d761.s5|79-81|and|O
DDI-DrugBank.d761.s5|83-103|nutritionally-derived|O
DDI-DrugBank.d761.s5|105-111|vitamin|O
DDI-DrugBank.d761.s5|113-113|K|O
DDI-DrugBank.d761.s5|115-116|is|O
DDI-DrugBank.d761.s5|118-120|not|O
DDI-DrugBank.d761.s5|122-126|known|O
DDI-DrugBank.d761.s5|128-129|at|O
DDI-DrugBank.d761.s5|131-134|this|O
DDI-DrugBank.d761.s5|136-139|time|O
DDI-DrugBank.d761.s5|140-140|.|O
DDI-DrugBank.d761.s6|0-8|Glyburide|O
DDI-DrugBank.d761.s6|9-9|:|O
DDI-DrugBank.d761.s6|11-12|In|O
DDI-DrugBank.d761.s6|14-15|12|O
DDI-DrugBank.d761.s6|17-29|normal-weight|O
DDI-DrugBank.d761.s6|31-38|subjects|O
DDI-DrugBank.d761.s6|40-48|receiving|O
DDI-DrugBank.d761.s6|50-57|orlistat|O
DDI-DrugBank.d761.s6|59-60|80|O
DDI-DrugBank.d761.s6|62-63|mg|O
DDI-DrugBank.d761.s6|65-69|three|O
DDI-DrugBank.d761.s6|71-75|times|O
DDI-DrugBank.d761.s6|77-77|a|O
DDI-DrugBank.d761.s6|79-81|day|O
DDI-DrugBank.d761.s6|83-85|for|O
DDI-DrugBank.d761.s6|87-87|5|O
DDI-DrugBank.d761.s6|89-92|days|O
DDI-DrugBank.d761.s6|93-93|,|O
DDI-DrugBank.d761.s6|95-102|orlistat|O
DDI-DrugBank.d761.s6|104-106|did|O
DDI-DrugBank.d761.s6|108-110|not|O
DDI-DrugBank.d761.s6|112-116|alter|O
DDI-DrugBank.d761.s6|118-120|the|O
DDI-DrugBank.d761.s6|122-137|pharmacokinetics|O
DDI-DrugBank.d761.s6|139-140|or|O
DDI-DrugBank.d761.s6|142-157|pharmacodynamics|O
DDI-DrugBank.d761.s6|159-159|(|O
DDI-DrugBank.d761.s6|160-164|blood|O
DDI-DrugBank.d761.s6|166-181|glucose-lowering|O
DDI-DrugBank.d761.s6|182-182|)|O
DDI-DrugBank.d761.s6|184-185|of|O
DDI-DrugBank.d761.s6|187-195|glyburide|O
DDI-DrugBank.d761.s6|196-196|.|O
DDI-DrugBank.d761.s7|0-9|Nifedipine|O
DDI-DrugBank.d761.s7|11-11|(|O
DDI-DrugBank.d761.s7|12-27|extended-release|O
DDI-DrugBank.d761.s7|29-35|tablets|O
DDI-DrugBank.d761.s7|36-36|)|O
DDI-DrugBank.d761.s7|37-37|:|O
DDI-DrugBank.d761.s7|39-40|In|O
DDI-DrugBank.d761.s7|42-43|17|O
DDI-DrugBank.d761.s7|45-57|normal-weight|O
DDI-DrugBank.d761.s7|59-66|subjects|O
DDI-DrugBank.d761.s7|68-76|receiving|O
DDI-DrugBank.d761.s7|78-84|XENICAL|O
DDI-DrugBank.d761.s7|86-88|120|O
DDI-DrugBank.d761.s7|90-91|mg|O
DDI-DrugBank.d761.s7|93-97|three|O
DDI-DrugBank.d761.s7|99-103|times|O
DDI-DrugBank.d761.s7|105-105|a|O
DDI-DrugBank.d761.s7|107-109|day|O
DDI-DrugBank.d761.s7|111-113|for|O
DDI-DrugBank.d761.s7|115-115|6|O
DDI-DrugBank.d761.s7|117-120|days|O
DDI-DrugBank.d761.s7|121-121|,|O
DDI-DrugBank.d761.s7|123-129|XENICAL|O
DDI-DrugBank.d761.s7|131-133|did|O
DDI-DrugBank.d761.s7|135-137|not|O
DDI-DrugBank.d761.s7|139-143|alter|O
DDI-DrugBank.d761.s7|145-147|the|O
DDI-DrugBank.d761.s7|149-163|bioavailability|O
DDI-DrugBank.d761.s7|165-166|of|O
DDI-DrugBank.d761.s7|168-177|nifedipine|O
DDI-DrugBank.d761.s7|179-179|(|O
DDI-DrugBank.d761.s7|180-195|extended-release|O
DDI-DrugBank.d761.s7|197-203|tablets|O
DDI-DrugBank.d761.s7|204-204|)|O
DDI-DrugBank.d761.s7|205-205|.|O
DDI-DrugBank.d761.s8|0-3|Oral|O
DDI-DrugBank.d761.s8|5-18|Contraceptives|O
DDI-DrugBank.d761.s8|19-19|:|O
DDI-DrugBank.d761.s8|21-22|In|O
DDI-DrugBank.d761.s8|24-25|20|O
DDI-DrugBank.d761.s8|27-39|normal-weight|O
DDI-DrugBank.d761.s8|41-46|female|O
DDI-DrugBank.d761.s8|48-55|subjects|O
DDI-DrugBank.d761.s8|56-56|,|O
DDI-DrugBank.d761.s8|58-60|the|O
DDI-DrugBank.d761.s8|62-70|treatment|O
DDI-DrugBank.d761.s8|72-73|of|O
DDI-DrugBank.d761.s8|75-81|XENICAL|O
DDI-DrugBank.d761.s8|83-85|120|O
DDI-DrugBank.d761.s8|87-88|mg|O
DDI-DrugBank.d761.s8|90-94|three|O
DDI-DrugBank.d761.s8|96-100|times|O
DDI-DrugBank.d761.s8|102-102|a|O
DDI-DrugBank.d761.s8|104-106|day|O
DDI-DrugBank.d761.s8|108-110|for|O
DDI-DrugBank.d761.s8|112-113|23|O
DDI-DrugBank.d761.s8|115-118|days|O
DDI-DrugBank.d761.s8|120-127|resulted|O
DDI-DrugBank.d761.s8|129-130|in|O
DDI-DrugBank.d761.s8|132-133|no|O
DDI-DrugBank.d761.s8|135-141|changes|O
DDI-DrugBank.d761.s8|143-144|in|O
DDI-DrugBank.d761.s8|146-148|the|O
DDI-DrugBank.d761.s8|150-170|ovulation-suppressing|O
DDI-DrugBank.d761.s8|172-177|action|O
DDI-DrugBank.d761.s8|179-180|of|O
DDI-DrugBank.d761.s8|182-185|oral|O
DDI-DrugBank.d761.s8|187-200|contraceptives|O
DDI-DrugBank.d761.s8|201-201|.|O
DDI-DrugBank.d761.s9|0-8|Phenytoin|O
DDI-DrugBank.d761.s9|9-9|:|O
DDI-DrugBank.d761.s9|11-12|In|O
DDI-DrugBank.d761.s9|14-15|12|O
DDI-DrugBank.d761.s9|17-29|normal-weight|O
DDI-DrugBank.d761.s9|31-38|subjects|O
DDI-DrugBank.d761.s9|40-48|receiving|O
DDI-DrugBank.d761.s9|50-56|XENICAL|O
DDI-DrugBank.d761.s9|58-60|120|O
DDI-DrugBank.d761.s9|62-63|mg|O
DDI-DrugBank.d761.s9|65-69|three|O
DDI-DrugBank.d761.s9|71-75|times|O
DDI-DrugBank.d761.s9|77-77|a|O
DDI-DrugBank.d761.s9|79-81|day|O
DDI-DrugBank.d761.s9|83-85|for|O
DDI-DrugBank.d761.s9|87-87|7|O
DDI-DrugBank.d761.s9|89-92|days|O
DDI-DrugBank.d761.s9|93-93|,|O
DDI-DrugBank.d761.s9|95-101|XENICAL|O
DDI-DrugBank.d761.s9|103-105|did|O
DDI-DrugBank.d761.s9|107-109|not|O
DDI-DrugBank.d761.s9|111-115|alter|O
DDI-DrugBank.d761.s9|117-119|the|O
DDI-DrugBank.d761.s9|121-136|pharmacokinetics|O
DDI-DrugBank.d761.s9|138-139|of|O
DDI-DrugBank.d761.s9|141-141|a|O
DDI-DrugBank.d761.s9|143-148|single|O
DDI-DrugBank.d761.s9|150-155|300-mg|O
DDI-DrugBank.d761.s9|157-160|dose|O
DDI-DrugBank.d761.s9|162-163|of|O
DDI-DrugBank.d761.s9|165-173|phenytoin|O
DDI-DrugBank.d761.s9|174-174|.|O
DDI-DrugBank.d761.s10|0-10|Pravastatin|O
DDI-DrugBank.d761.s10|11-11|:|O
DDI-DrugBank.d761.s10|13-14|In|O
DDI-DrugBank.d761.s10|16-16|a|O
DDI-DrugBank.d761.s10|18-22|2-way|O
DDI-DrugBank.d761.s10|24-32|crossover|O
DDI-DrugBank.d761.s10|34-38|study|O
DDI-DrugBank.d761.s10|40-41|of|O
DDI-DrugBank.d761.s10|43-44|24|O
DDI-DrugBank.d761.s10|46-58|normal-weight|O
DDI-DrugBank.d761.s10|59-59|,|O
DDI-DrugBank.d761.s10|61-66|mildly|O
DDI-DrugBank.d761.s10|68-87|hypercholesterolemic|O
DDI-DrugBank.d761.s10|89-96|patients|O
DDI-DrugBank.d761.s10|98-106|receiving|O
DDI-DrugBank.d761.s10|108-114|XENICAL|O
DDI-DrugBank.d761.s10|116-118|120|O
DDI-DrugBank.d761.s10|120-121|mg|O
DDI-DrugBank.d761.s10|123-127|three|O
DDI-DrugBank.d761.s10|129-133|times|O
DDI-DrugBank.d761.s10|135-135|a|O
DDI-DrugBank.d761.s10|137-139|day|O
DDI-DrugBank.d761.s10|141-143|for|O
DDI-DrugBank.d761.s10|145-145|6|O
DDI-DrugBank.d761.s10|147-150|days|O
DDI-DrugBank.d761.s10|151-151|,|O
DDI-DrugBank.d761.s10|153-159|XENICAL|O
DDI-DrugBank.d761.s10|161-163|did|O
DDI-DrugBank.d761.s10|165-167|not|O
DDI-DrugBank.d761.s10|169-174|affect|O
DDI-DrugBank.d761.s10|176-178|the|O
DDI-DrugBank.d761.s10|180-195|pharmacokinetics|O
DDI-DrugBank.d761.s10|197-198|of|O
DDI-DrugBank.d761.s10|200-210|pravastatin|O
DDI-DrugBank.d761.s10|211-211|.|O
DDI-DrugBank.d761.s11|0-7|Warfarin|O
DDI-DrugBank.d761.s11|8-8|:|O
DDI-DrugBank.d761.s11|10-11|In|O
DDI-DrugBank.d761.s11|13-14|12|O
DDI-DrugBank.d761.s11|16-28|normal-weight|O
DDI-DrugBank.d761.s11|30-37|subjects|O
DDI-DrugBank.d761.s11|38-38|,|O
DDI-DrugBank.d761.s11|40-53|administration|O
DDI-DrugBank.d761.s11|55-56|of|O
DDI-DrugBank.d761.s11|58-64|XENICAL|O
DDI-DrugBank.d761.s11|66-68|120|O
DDI-DrugBank.d761.s11|70-71|mg|O
DDI-DrugBank.d761.s11|73-77|three|O
DDI-DrugBank.d761.s11|79-83|times|O
DDI-DrugBank.d761.s11|85-85|a|O
DDI-DrugBank.d761.s11|87-89|day|O
DDI-DrugBank.d761.s11|91-93|for|O
DDI-DrugBank.d761.s11|95-96|16|O
DDI-DrugBank.d761.s11|98-101|days|O
DDI-DrugBank.d761.s11|103-105|did|O
DDI-DrugBank.d761.s11|107-109|not|O
DDI-DrugBank.d761.s11|111-116|result|O
DDI-DrugBank.d761.s11|118-119|in|O
DDI-DrugBank.d761.s11|121-123|any|O
DDI-DrugBank.d761.s11|125-130|change|O
DDI-DrugBank.d761.s11|132-133|in|O
DDI-DrugBank.d761.s11|135-140|either|O
DDI-DrugBank.d761.s11|142-149|warfarin|O
DDI-DrugBank.d761.s11|151-166|pharmacokinetics|O
DDI-DrugBank.d761.s11|168-168|(|O
DDI-DrugBank.d761.s11|169-172|both|O
DDI-DrugBank.d761.s11|174-175|R-|O
DDI-DrugBank.d761.s11|177-179|and|O
DDI-DrugBank.d761.s11|181-193|S-enantiomers|O
DDI-DrugBank.d761.s11|194-194|)|O
DDI-DrugBank.d761.s11|196-197|or|O
DDI-DrugBank.d761.s11|199-214|pharmacodynamics|O
DDI-DrugBank.d761.s11|216-216|(|O
DDI-DrugBank.d761.s11|217-227|prothrombin|O
DDI-DrugBank.d761.s11|229-232|time|O
DDI-DrugBank.d761.s11|234-236|and|O
DDI-DrugBank.d761.s11|238-242|serum|O
DDI-DrugBank.d761.s11|244-249|Factor|O
DDI-DrugBank.d761.s11|251-253|VII|O
DDI-DrugBank.d761.s11|254-254|)|O
DDI-DrugBank.d761.s11|255-255|.|O
DDI-DrugBank.d761.s12|0-7|Although|O
DDI-DrugBank.d761.s12|9-25|undercarboxylated|O
DDI-DrugBank.d761.s12|27-37|osteocalcin|O
DDI-DrugBank.d761.s12|38-38|,|O
DDI-DrugBank.d761.s12|40-40|a|O
DDI-DrugBank.d761.s12|42-47|marker|O
DDI-DrugBank.d761.s12|49-50|of|O
DDI-DrugBank.d761.s12|52-58|vitamin|O
DDI-DrugBank.d761.s12|60-60|K|O
DDI-DrugBank.d761.s12|62-72|nutritional|O
DDI-DrugBank.d761.s12|74-79|status|O
DDI-DrugBank.d761.s12|80-80|,|O
DDI-DrugBank.d761.s12|82-84|was|O
DDI-DrugBank.d761.s12|86-94|unaltered|O
DDI-DrugBank.d761.s12|96-99|with|O
DDI-DrugBank.d761.s12|101-107|XENICAL|O
DDI-DrugBank.d761.s12|109-122|administration|O
DDI-DrugBank.d761.s12|123-123|,|O
DDI-DrugBank.d761.s12|125-131|vitamin|O
DDI-DrugBank.d761.s12|133-133|K|O
DDI-DrugBank.d761.s12|135-140|levels|O
DDI-DrugBank.d761.s12|142-147|tended|O
DDI-DrugBank.d761.s12|149-150|to|O
DDI-DrugBank.d761.s12|152-158|decline|O
DDI-DrugBank.d761.s12|160-161|in|O
DDI-DrugBank.d761.s12|163-170|subjects|O
DDI-DrugBank.d761.s12|172-177|taking|O
DDI-DrugBank.d761.s12|179-185|XENICAL|O
DDI-DrugBank.d761.s12|186-186|.|O
DDI-DrugBank.d761.s13|0-8|Therefore|O
DDI-DrugBank.d761.s13|9-9|,|O
DDI-DrugBank.d761.s13|11-12|as|O
DDI-DrugBank.d761.s13|14-20|vitamin|O
DDI-DrugBank.d761.s13|22-22|K|O
DDI-DrugBank.d761.s13|24-33|absorption|O
DDI-DrugBank.d761.s13|35-37|may|O
DDI-DrugBank.d761.s13|39-40|be|O
DDI-DrugBank.d761.s13|42-50|decreased|O
DDI-DrugBank.d761.s13|52-55|with|O
DDI-DrugBank.d761.s13|57-63|XENICAL|O
DDI-DrugBank.d761.s13|64-64|,|O
DDI-DrugBank.d761.s13|66-73|patients|O
DDI-DrugBank.d761.s13|75-76|on|O
DDI-DrugBank.d761.s13|78-84|chronic|O
DDI-DrugBank.d761.s13|86-91|stable|O
DDI-DrugBank.d761.s13|93-97|doses|O
DDI-DrugBank.d761.s13|99-100|of|O
DDI-DrugBank.d761.s13|102-109|warfarin|O
DDI-DrugBank.d761.s13|111-113|who|O
DDI-DrugBank.d761.s13|115-117|are|O
DDI-DrugBank.d761.s13|119-128|prescribed|O
DDI-DrugBank.d761.s13|130-136|XENICAL|O
DDI-DrugBank.d761.s13|138-143|should|O
DDI-DrugBank.d761.s13|145-146|be|O
DDI-DrugBank.d761.s13|148-156|monitored|O
DDI-DrugBank.d761.s13|158-164|closely|O
DDI-DrugBank.d761.s13|166-168|for|O
DDI-DrugBank.d761.s13|170-176|changes|O
DDI-DrugBank.d761.s13|178-179|in|O
DDI-DrugBank.d761.s13|181-191|coagulation|O
DDI-DrugBank.d761.s13|193-202|parameters|O
DDI-DrugBank.d761.s13|203-203|.|O
DDI-MedLine.d86.s0|0-14|Pharmacokinetic|O
DDI-MedLine.d86.s0|16-26|interaction|O
DDI-MedLine.d86.s0|28-34|between|O
DDI-MedLine.d86.s0|36-41|single|O
DDI-MedLine.d86.s0|43-46|oral|O
DDI-MedLine.d86.s0|48-52|doses|O
DDI-MedLine.d86.s0|54-55|of|O
DDI-MedLine.d86.s0|57-65|diltiazem|O
DDI-MedLine.d86.s0|67-69|and|O
DDI-MedLine.d86.s0|71-79|sirolimus|O
DDI-MedLine.d86.s0|81-82|in|O
DDI-MedLine.d86.s0|84-90|healthy|O
DDI-MedLine.d86.s0|92-101|volunteers|O
DDI-MedLine.d86.s0|102-102|.|O
DDI-MedLine.d86.s1|0-2|AIM|O
DDI-MedLine.d86.s1|4-6|AND|O
DDI-MedLine.d86.s1|8-17|BACKGROUND|O
DDI-MedLine.d86.s1|18-18|:|O
DDI-MedLine.d86.s1|20-22|The|O
DDI-MedLine.d86.s1|24-38|pharmacokinetic|O
DDI-MedLine.d86.s1|40-50|interaction|O
DDI-MedLine.d86.s1|52-58|between|O
DDI-MedLine.d86.s1|60-68|sirolimus|O
DDI-MedLine.d86.s1|69-69|,|O
DDI-MedLine.d86.s1|71-71|a|O
DDI-MedLine.d86.s1|73-81|macrolide|O
DDI-MedLine.d86.s1|83-99|immunosuppressant|O
DDI-MedLine.d86.s1|101-111|metabolized|O
DDI-MedLine.d86.s1|113-114|by|O
DDI-MedLine.d86.s1|116-121|CYP3A4|O
DDI-MedLine.d86.s1|122-122|,|O
DDI-MedLine.d86.s1|124-126|and|O
DDI-MedLine.d86.s1|128-130|the|O
DDI-MedLine.d86.s1|132-138|calcium|O
DDI-MedLine.d86.s1|140-146|channel|O
DDI-MedLine.d86.s1|148-154|blocker|O
DDI-MedLine.d86.s1|156-164|diltiazem|O
DDI-MedLine.d86.s1|166-168|was|O
DDI-MedLine.d86.s1|170-176|studied|O
DDI-MedLine.d86.s1|178-179|in|O
DDI-MedLine.d86.s1|181-182|18|O
DDI-MedLine.d86.s1|184-190|healthy|O
DDI-MedLine.d86.s1|192-199|subjects|O
DDI-MedLine.d86.s1|200-200|.|O
DDI-MedLine.d86.s2|0-6|Several|O
DDI-MedLine.d86.s2|8-17|clinically|O
DDI-MedLine.d86.s2|19-27|important|O
DDI-MedLine.d86.s2|29-40|interactions|O
DDI-MedLine.d86.s2|42-45|have|O
DDI-MedLine.d86.s2|47-56|previously|O
DDI-MedLine.d86.s2|58-61|been|O
DDI-MedLine.d86.s2|63-70|reported|O
DDI-MedLine.d86.s2|72-74|for|O
DDI-MedLine.d86.s2|76-80|other|O
DDI-MedLine.d86.s2|82-98|immunosuppressive|O
DDI-MedLine.d86.s2|100-104|drugs|O
DDI-MedLine.d86.s2|106-109|that|O
DDI-MedLine.d86.s2|111-113|are|O
DDI-MedLine.d86.s2|115-125|metabolized|O
DDI-MedLine.d86.s2|127-128|by|O
DDI-MedLine.d86.s2|130-132|the|O
DDI-MedLine.d86.s2|134-137|same|O
DDI-MedLine.d86.s2|139-144|enzyme|O
DDI-MedLine.d86.s2|146-148|and|O
DDI-MedLine.d86.s2|150-152|for|O
DDI-MedLine.d86.s2|154-160|calcium|O
DDI-MedLine.d86.s2|162-172|antagonists|O
DDI-MedLine.d86.s2|173-173|.|O
DDI-MedLine.d86.s3|0-6|METHODS|O
DDI-MedLine.d86.s3|7-7|:|O
DDI-MedLine.d86.s3|9-15|Healthy|O
DDI-MedLine.d86.s3|17-24|subjects|O
DDI-MedLine.d86.s3|26-28|who|O
DDI-MedLine.d86.s3|30-33|were|O
DDI-MedLine.d86.s3|35-36|20|O
DDI-MedLine.d86.s3|38-39|to|O
DDI-MedLine.d86.s3|41-42|43|O
DDI-MedLine.d86.s3|44-48|years|O
DDI-MedLine.d86.s3|50-52|old|O
DDI-MedLine.d86.s3|54-65|participated|O
DDI-MedLine.d86.s3|67-68|in|O
DDI-MedLine.d86.s3|70-71|an|O
DDI-MedLine.d86.s3|73-76|open|O
DDI-MedLine.d86.s3|77-77|,|O
DDI-MedLine.d86.s3|79-90|three-period|O
DDI-MedLine.d86.s3|91-91|,|O
DDI-MedLine.d86.s3|93-102|randomized|O
DDI-MedLine.d86.s3|103-103|,|O
DDI-MedLine.d86.s3|105-113|crossover|O
DDI-MedLine.d86.s3|115-119|study|O
DDI-MedLine.d86.s3|121-122|of|O
DDI-MedLine.d86.s3|124-126|the|O
DDI-MedLine.d86.s3|128-143|pharmacokinetics|O
DDI-MedLine.d86.s3|145-146|of|O
DDI-MedLine.d86.s3|148-148|a|O
DDI-MedLine.d86.s3|150-155|single|O
DDI-MedLine.d86.s3|157-161|10-mg|O
DDI-MedLine.d86.s3|163-166|oral|O
DDI-MedLine.d86.s3|168-171|dose|O
DDI-MedLine.d86.s3|173-174|of|O
DDI-MedLine.d86.s3|176-184|sirolimus|O
DDI-MedLine.d86.s3|185-185|,|O
DDI-MedLine.d86.s3|187-187|a|O
DDI-MedLine.d86.s3|189-194|single|O
DDI-MedLine.d86.s3|196-199|oral|O
DDI-MedLine.d86.s3|201-206|120-mg|O
DDI-MedLine.d86.s3|208-211|dose|O
DDI-MedLine.d86.s3|213-214|of|O
DDI-MedLine.d86.s3|216-224|diltiazem|O
DDI-MedLine.d86.s3|225-225|,|O
DDI-MedLine.d86.s3|227-229|and|O
DDI-MedLine.d86.s3|231-233|the|O
DDI-MedLine.d86.s3|235-237|two|O
DDI-MedLine.d86.s3|239-243|drugs|O
DDI-MedLine.d86.s3|245-249|given|O
DDI-MedLine.d86.s3|251-258|together|O
DDI-MedLine.d86.s3|259-259|.|O
DDI-MedLine.d86.s4|0-2|The|O
DDI-MedLine.d86.s4|4-8|three|O
DDI-MedLine.d86.s4|10-14|study|O
DDI-MedLine.d86.s4|16-22|periods|O
DDI-MedLine.d86.s4|24-27|were|O
DDI-MedLine.d86.s4|29-37|separated|O
DDI-MedLine.d86.s4|39-40|by|O
DDI-MedLine.d86.s4|42-42|a|O
DDI-MedLine.d86.s4|44-49|21-day|O
DDI-MedLine.d86.s4|51-57|washout|O
DDI-MedLine.d86.s4|59-63|phase|O
DDI-MedLine.d86.s4|64-64|.|O
DDI-MedLine.d86.s5|0-6|RESULTS|O
DDI-MedLine.d86.s5|7-7|:|O
DDI-MedLine.d86.s5|9-11|The|O
DDI-MedLine.d86.s5|13-21|geometric|O
DDI-MedLine.d86.s5|23-26|mean|O
DDI-MedLine.d86.s5|28-28|(|O
DDI-MedLine.d86.s5|29-30|90|O
DDI-MedLine.d86.s5|31-31|%|O
DDI-MedLine.d86.s5|33-42|confidence|O
DDI-MedLine.d86.s5|44-51|interval|O
DDI-MedLine.d86.s5|52-52|)|O
DDI-MedLine.d86.s5|54-58|whole|O
DDI-MedLine.d86.s5|60-64|blood|O
DDI-MedLine.d86.s5|66-74|sirolimus|O
DDI-MedLine.d86.s5|76-79|area|O
DDI-MedLine.d86.s5|81-85|under|O
DDI-MedLine.d86.s5|87-89|the|O
DDI-MedLine.d86.s5|91-96|plasma|O
DDI-MedLine.d86.s5|98-110|concentration|O
DDI-MedLine.d86.s5|112-121|time-curve|O
DDI-MedLine.d86.s5|123-131|increased|O
DDI-MedLine.d86.s5|133-134|60|O
DDI-MedLine.d86.s5|135-135|%|O
DDI-MedLine.d86.s5|137-137|(|O
DDI-MedLine.d86.s5|138-139|35|O
DDI-MedLine.d86.s5|140-140|%|O
DDI-MedLine.d86.s5|141-143|-90|O
DDI-MedLine.d86.s5|144-144|%|O
DDI-MedLine.d86.s5|145-145|)|O
DDI-MedLine.d86.s5|146-146|,|O
DDI-MedLine.d86.s5|148-151|from|O
DDI-MedLine.d86.s5|153-155|736|O
DDI-MedLine.d86.s5|157-158|to|O
DDI-MedLine.d86.s5|160-163|1178|O
DDI-MedLine.d86.s5|165-166|ng|O
DDI-MedLine.d86.s5|168-168|x|O
DDI-MedLine.d86.s5|170-173|h/mL|O
DDI-MedLine.d86.s5|174-174|,|O
DDI-MedLine.d86.s5|176-178|and|O
DDI-MedLine.d86.s5|180-186|maximum|O
DDI-MedLine.d86.s5|188-200|concentration|O
DDI-MedLine.d86.s5|202-210|increased|O
DDI-MedLine.d86.s5|212-213|43|O
DDI-MedLine.d86.s5|214-214|%|O
DDI-MedLine.d86.s5|216-216|(|O
DDI-MedLine.d86.s5|217-218|14|O
DDI-MedLine.d86.s5|219-219|%|O
DDI-MedLine.d86.s5|220-222|-81|O
DDI-MedLine.d86.s5|223-223|%|O
DDI-MedLine.d86.s5|224-224|)|O
DDI-MedLine.d86.s5|225-225|,|O
DDI-MedLine.d86.s5|227-230|from|O
DDI-MedLine.d86.s5|232-233|67|O
DDI-MedLine.d86.s5|235-236|to|O
DDI-MedLine.d86.s5|238-239|96|O
DDI-MedLine.d86.s5|241-245|ng/mL|O
DDI-MedLine.d86.s5|246-246|,|O
DDI-MedLine.d86.s5|248-251|with|O
DDI-MedLine.d86.s5|253-261|diltiazem|O
DDI-MedLine.d86.s5|263-278|coadministration|O
DDI-MedLine.d86.s5|279-279|,|O
DDI-MedLine.d86.s5|281-287|whereas|O
DDI-MedLine.d86.s5|289-291|the|O
DDI-MedLine.d86.s5|293-296|mean|O
DDI-MedLine.d86.s5|298-308|elimination|O
DDI-MedLine.d86.s5|310-318|half-life|O
DDI-MedLine.d86.s5|320-321|of|O
DDI-MedLine.d86.s5|323-331|sirolimus|O
DDI-MedLine.d86.s5|333-341|decreased|O
DDI-MedLine.d86.s5|343-350|slightly|O
DDI-MedLine.d86.s5|351-351|,|O
DDI-MedLine.d86.s5|353-356|from|O
DDI-MedLine.d86.s5|358-359|79|O
DDI-MedLine.d86.s5|361-362|to|O
DDI-MedLine.d86.s5|364-365|67|O
DDI-MedLine.d86.s5|367-371|hours|O
DDI-MedLine.d86.s5|372-372|.|O
DDI-MedLine.d86.s6|0-7|Apparent|O
DDI-MedLine.d86.s6|9-12|oral|O
DDI-MedLine.d86.s6|14-22|clearance|O
DDI-MedLine.d86.s6|24-26|and|O
DDI-MedLine.d86.s6|28-33|volume|O
DDI-MedLine.d86.s6|35-36|of|O
DDI-MedLine.d86.s6|38-49|distribution|O
DDI-MedLine.d86.s6|51-52|of|O
DDI-MedLine.d86.s6|54-62|sirolimus|O
DDI-MedLine.d86.s6|64-72|decreased|O
DDI-MedLine.d86.s6|74-77|with|O
DDI-MedLine.d86.s6|79-80|38|O
DDI-MedLine.d86.s6|81-81|%|O
DDI-MedLine.d86.s6|83-85|and|O
DDI-MedLine.d86.s6|87-88|45|O
DDI-MedLine.d86.s6|89-89|%|O
DDI-MedLine.d86.s6|90-90|,|O
DDI-MedLine.d86.s6|92-103|respectively|O
DDI-MedLine.d86.s6|104-104|,|O
DDI-MedLine.d86.s6|106-109|when|O
DDI-MedLine.d86.s6|111-119|sirolimus|O
DDI-MedLine.d86.s6|121-123|was|O
DDI-MedLine.d86.s6|125-129|given|O
DDI-MedLine.d86.s6|131-134|with|O
DDI-MedLine.d86.s6|136-144|diltiazem|O
DDI-MedLine.d86.s6|145-145|.|O
DDI-MedLine.d86.s7|0-2|The|O
DDI-MedLine.d86.s7|4-9|plasma|O
DDI-MedLine.d86.s7|11-17|maximum|O
DDI-MedLine.d86.s7|19-31|concentration|O
DDI-MedLine.d86.s7|33-35|and|O
DDI-MedLine.d86.s7|37-40|area|O
DDI-MedLine.d86.s7|42-46|under|O
DDI-MedLine.d86.s7|48-50|the|O
DDI-MedLine.d86.s7|52-57|plasma|O
DDI-MedLine.d86.s7|59-76|concentration-time|O
DDI-MedLine.d86.s7|78-82|curve|O
DDI-MedLine.d86.s7|84-85|of|O
DDI-MedLine.d86.s7|87-95|diltiazem|O
DDI-MedLine.d86.s7|96-96|,|O
DDI-MedLine.d86.s7|98-115|desacetyldiltiazem|O
DDI-MedLine.d86.s7|116-116|,|O
DDI-MedLine.d86.s7|118-120|and|O
DDI-MedLine.d86.s7|122-139|desmethyldiltiazem|O
DDI-MedLine.d86.s7|141-144|were|O
DDI-MedLine.d86.s7|146-154|unchanged|O
DDI-MedLine.d86.s7|156-160|after|O
DDI-MedLine.d86.s7|162-177|coadministration|O
DDI-MedLine.d86.s7|179-180|of|O
DDI-MedLine.d86.s7|182-190|sirolimus|O
DDI-MedLine.d86.s7|191-191|,|O
DDI-MedLine.d86.s7|193-195|and|O
DDI-MedLine.d86.s7|197-198|no|O
DDI-MedLine.d86.s7|200-211|potentiation|O
DDI-MedLine.d86.s7|213-214|of|O
DDI-MedLine.d86.s7|216-218|the|O
DDI-MedLine.d86.s7|220-226|effects|O
DDI-MedLine.d86.s7|228-229|of|O
DDI-MedLine.d86.s7|231-239|diltiazem|O
DDI-MedLine.d86.s7|241-242|on|O
DDI-MedLine.d86.s7|244-252|diastolic|O
DDI-MedLine.d86.s7|254-255|or|O
DDI-MedLine.d86.s7|257-264|systolic|O
DDI-MedLine.d86.s7|266-270|blood|O
DDI-MedLine.d86.s7|272-279|pressure|O
DDI-MedLine.d86.s7|281-282|or|O
DDI-MedLine.d86.s7|284-285|on|O
DDI-MedLine.d86.s7|287-289|the|O
DDI-MedLine.d86.s7|291-310|electrocardiographic|O
DDI-MedLine.d86.s7|312-321|parameters|O
DDI-MedLine.d86.s7|323-325|was|O
DDI-MedLine.d86.s7|327-330|seen|O
DDI-MedLine.d86.s7|331-331|.|O
DDI-MedLine.d86.s8|0-10|CONCLUSIONS|O
DDI-MedLine.d86.s8|11-11|:|O
DDI-MedLine.d86.s8|13-23|Single-dose|O
DDI-MedLine.d86.s8|25-33|diltiazem|O
DDI-MedLine.d86.s8|35-50|coadministration|O
DDI-MedLine.d86.s8|52-56|leads|O
DDI-MedLine.d86.s8|58-59|to|O
DDI-MedLine.d86.s8|61-66|higher|O
DDI-MedLine.d86.s8|68-76|sirolimus|O
DDI-MedLine.d86.s8|78-85|exposure|O
DDI-MedLine.d86.s8|86-86|,|O
DDI-MedLine.d86.s8|88-97|presumably|O
DDI-MedLine.d86.s8|99-100|by|O
DDI-MedLine.d86.s8|102-111|inhibition|O
DDI-MedLine.d86.s8|113-114|of|O
DDI-MedLine.d86.s8|116-118|the|O
DDI-MedLine.d86.s8|120-129|first-pass|O
DDI-MedLine.d86.s8|131-140|metabolism|O
DDI-MedLine.d86.s8|142-143|of|O
DDI-MedLine.d86.s8|145-153|sirolimus|O
DDI-MedLine.d86.s8|154-154|.|O
DDI-MedLine.d86.s9|0-6|Because|O
DDI-MedLine.d86.s9|8-9|of|O
DDI-MedLine.d86.s9|11-13|the|O
DDI-MedLine.d86.s9|15-24|pronounced|O
DDI-MedLine.d86.s9|26-37|intersubject|O
DDI-MedLine.d86.s9|39-49|variability|O
DDI-MedLine.d86.s9|51-52|in|O
DDI-MedLine.d86.s9|54-56|the|O
DDI-MedLine.d86.s9|58-63|extent|O
DDI-MedLine.d86.s9|65-66|of|O
DDI-MedLine.d86.s9|68-70|the|O
DDI-MedLine.d86.s9|72-90|sirolimus-diltiazem|O
DDI-MedLine.d86.s9|92-102|interaction|O
DDI-MedLine.d86.s9|103-103|,|O
DDI-MedLine.d86.s9|105-109|whole|O
DDI-MedLine.d86.s9|111-115|blood|O
DDI-MedLine.d86.s9|117-125|sirolimus|O
DDI-MedLine.d86.s9|127-140|concentrations|O
DDI-MedLine.d86.s9|142-147|should|O
DDI-MedLine.d86.s9|149-150|be|O
DDI-MedLine.d86.s9|152-160|monitored|O
DDI-MedLine.d86.s9|162-168|closely|O
DDI-MedLine.d86.s9|170-171|in|O
DDI-MedLine.d86.s9|173-180|patients|O
DDI-MedLine.d86.s9|182-188|treated|O
DDI-MedLine.d86.s9|190-193|with|O
DDI-MedLine.d86.s9|195-197|the|O
DDI-MedLine.d86.s9|199-201|two|O
DDI-MedLine.d86.s9|203-207|drugs|O
DDI-MedLine.d86.s9|208-208|.|O
DDI-DrugBank.d241.s0|0-9|Additional|O
DDI-DrugBank.d241.s0|11-20|reductions|O
DDI-DrugBank.d241.s0|22-23|in|O
DDI-DrugBank.d241.s0|25-29|blood|O
DDI-DrugBank.d241.s0|31-38|pressure|O
DDI-DrugBank.d241.s0|40-42|may|O
DDI-DrugBank.d241.s0|44-48|occur|O
DDI-DrugBank.d241.s0|50-53|when|O
DDI-DrugBank.d241.s0|55-60|FLOLAN|O
DDI-DrugBank.d241.s0|62-63|is|O
DDI-DrugBank.d241.s0|65-76|administered|O
DDI-DrugBank.d241.s0|78-81|with|O
DDI-DrugBank.d241.s0|83-91|diuretics|O
DDI-DrugBank.d241.s0|92-92|,|O
DDI-DrugBank.d241.s0|94-109|antihypertensive|O
DDI-DrugBank.d241.s0|111-116|agents|O
DDI-DrugBank.d241.s0|117-117|,|O
DDI-DrugBank.d241.s0|119-120|or|O
DDI-DrugBank.d241.s0|122-126|other|O
DDI-DrugBank.d241.s0|128-139|vasodilators|O
DDI-DrugBank.d241.s0|140-140|.|O
DDI-DrugBank.d241.s1|0-3|When|O
DDI-DrugBank.d241.s1|5-9|other|O
DDI-DrugBank.d241.s1|11-22|antiplatelet|O
DDI-DrugBank.d241.s1|24-29|agents|O
DDI-DrugBank.d241.s1|31-32|or|O
DDI-DrugBank.d241.s1|34-47|anticoagulants|O
DDI-DrugBank.d241.s1|49-51|are|O
DDI-DrugBank.d241.s1|53-56|used|O
DDI-DrugBank.d241.s1|58-70|concomitantly|O
DDI-DrugBank.d241.s1|71-71|,|O
DDI-DrugBank.d241.s1|73-77|there|O
DDI-DrugBank.d241.s1|79-80|is|O
DDI-DrugBank.d241.s1|82-84|the|O
DDI-DrugBank.d241.s1|86-94|potential|O
DDI-DrugBank.d241.s1|96-98|for|O
DDI-DrugBank.d241.s1|100-105|FLOLAN|O
DDI-DrugBank.d241.s1|107-108|to|O
DDI-DrugBank.d241.s1|110-117|increase|O
DDI-DrugBank.d241.s1|119-121|the|O
DDI-DrugBank.d241.s1|123-126|risk|O
DDI-DrugBank.d241.s1|128-129|of|O
DDI-DrugBank.d241.s1|131-138|bleeding|O
DDI-DrugBank.d241.s1|139-139|.|O
DDI-DrugBank.d241.s2|0-6|However|O
DDI-DrugBank.d241.s2|7-7|,|O
DDI-DrugBank.d241.s2|9-16|patients|O
DDI-DrugBank.d241.s2|18-26|receiving|O
DDI-DrugBank.d241.s2|28-36|infusions|O
DDI-DrugBank.d241.s2|38-39|of|O
DDI-DrugBank.d241.s2|41-46|FLOLAN|O
DDI-DrugBank.d241.s2|48-49|in|O
DDI-DrugBank.d241.s2|51-58|clinical|O
DDI-DrugBank.d241.s2|60-65|trials|O
DDI-DrugBank.d241.s2|67-70|were|O
DDI-DrugBank.d241.s2|72-81|maintained|O
DDI-DrugBank.d241.s2|83-84|on|O
DDI-DrugBank.d241.s2|86-99|anticoagulants|O
DDI-DrugBank.d241.s2|101-107|without|O
DDI-DrugBank.d241.s2|109-116|evidence|O
DDI-DrugBank.d241.s2|118-119|of|O
DDI-DrugBank.d241.s2|121-129|increased|O
DDI-DrugBank.d241.s2|131-138|bleeding|O
DDI-DrugBank.d241.s2|139-139|.|O
DDI-DrugBank.d241.s3|0-1|In|O
DDI-DrugBank.d241.s3|3-10|clinical|O
DDI-DrugBank.d241.s3|12-17|trials|O
DDI-DrugBank.d241.s3|18-18|,|O
DDI-DrugBank.d241.s3|20-25|FLOLAN|O
DDI-DrugBank.d241.s3|27-29|was|O
DDI-DrugBank.d241.s3|31-34|used|O
DDI-DrugBank.d241.s3|36-39|with|O
DDI-DrugBank.d241.s3|41-47|digoxin|O
DDI-DrugBank.d241.s3|48-48|,|O
DDI-DrugBank.d241.s3|50-58|diuretics|O
DDI-DrugBank.d241.s3|59-59|,|O
DDI-DrugBank.d241.s3|61-74|anticoagulants|O
DDI-DrugBank.d241.s3|75-75|,|O
DDI-DrugBank.d241.s3|77-80|oral|O
DDI-DrugBank.d241.s3|82-93|vasodilators|O
DDI-DrugBank.d241.s3|94-94|,|O
DDI-DrugBank.d241.s3|96-98|and|O
DDI-DrugBank.d241.s3|100-111|supplemental|O
DDI-DrugBank.d241.s3|113-121|oxygen.In|O
DDI-DrugBank.d241.s3|123-123|a|O
DDI-DrugBank.d241.s3|125-139|pharmacokinetic|O
DDI-DrugBank.d241.s3|141-148|substudy|O
DDI-DrugBank.d241.s3|150-151|in|O
DDI-DrugBank.d241.s3|153-160|patients|O
DDI-DrugBank.d241.s3|162-165|with|O
DDI-DrugBank.d241.s3|167-176|congestive|O
DDI-DrugBank.d241.s3|178-182|heart|O
DDI-DrugBank.d241.s3|184-190|failure|O
DDI-DrugBank.d241.s3|192-200|receiving|O
DDI-DrugBank.d241.s3|202-211|furosemide|O
DDI-DrugBank.d241.s3|213-214|or|O
DDI-DrugBank.d241.s3|216-222|digoxin|O
DDI-DrugBank.d241.s3|224-225|in|O
DDI-DrugBank.d241.s3|227-230|whom|O
DDI-DrugBank.d241.s3|232-238|therapy|O
DDI-DrugBank.d241.s3|240-243|with|O
DDI-DrugBank.d241.s3|245-250|FLOLAN|O
DDI-DrugBank.d241.s3|252-254|was|O
DDI-DrugBank.d241.s3|256-264|initiated|O
DDI-DrugBank.d241.s3|265-265|,|O
DDI-DrugBank.d241.s3|267-274|apparent|O
DDI-DrugBank.d241.s3|276-279|oral|O
DDI-DrugBank.d241.s3|281-289|clearance|O
DDI-DrugBank.d241.s3|291-296|values|O
DDI-DrugBank.d241.s3|298-300|for|O
DDI-DrugBank.d241.s3|302-311|furosemide|O
DDI-DrugBank.d241.s3|313-313|(|O
DDI-DrugBank.d241.s3|314-314|n|O
DDI-DrugBank.d241.s3|316-316|=|O
DDI-DrugBank.d241.s3|318-319|23|O
DDI-DrugBank.d241.s3|320-320|)|O
DDI-DrugBank.d241.s3|322-324|and|O
DDI-DrugBank.d241.s3|326-332|digoxin|O
DDI-DrugBank.d241.s3|334-334|(|O
DDI-DrugBank.d241.s3|335-335|n|O
DDI-DrugBank.d241.s3|337-337|=|O
DDI-DrugBank.d241.s3|339-340|30|O
DDI-DrugBank.d241.s3|341-341|)|O
DDI-DrugBank.d241.s3|343-346|were|O
DDI-DrugBank.d241.s3|348-356|decreased|O
DDI-DrugBank.d241.s3|358-359|by|O
DDI-DrugBank.d241.s3|361-362|13|O
DDI-DrugBank.d241.s3|363-363|%|O
DDI-DrugBank.d241.s3|365-367|and|O
DDI-DrugBank.d241.s3|369-370|15|O
DDI-DrugBank.d241.s3|371-371|%|O
DDI-DrugBank.d241.s3|372-372|,|O
DDI-DrugBank.d241.s3|374-385|respectively|O
DDI-DrugBank.d241.s3|386-386|,|O
DDI-DrugBank.d241.s3|388-389|on|O
DDI-DrugBank.d241.s3|391-393|the|O
DDI-DrugBank.d241.s3|395-400|second|O
DDI-DrugBank.d241.s3|402-404|day|O
DDI-DrugBank.d241.s3|406-407|of|O
DDI-DrugBank.d241.s3|409-415|therapy|O
DDI-DrugBank.d241.s3|417-419|and|O
DDI-DrugBank.d241.s3|421-423|had|O
DDI-DrugBank.d241.s3|425-432|returned|O
DDI-DrugBank.d241.s3|434-435|to|O
DDI-DrugBank.d241.s3|437-444|baseline|O
DDI-DrugBank.d241.s3|446-451|values|O
DDI-DrugBank.d241.s3|453-454|by|O
DDI-DrugBank.d241.s3|456-458|day|O
DDI-DrugBank.d241.s3|460-461|87|O
DDI-DrugBank.d241.s3|462-462|.|O
DDI-DrugBank.d241.s4|0-2|The|O
DDI-DrugBank.d241.s4|4-9|change|O
DDI-DrugBank.d241.s4|11-12|in|O
DDI-DrugBank.d241.s4|14-23|furosemide|O
DDI-DrugBank.d241.s4|25-33|clearance|O
DDI-DrugBank.d241.s4|35-39|value|O
DDI-DrugBank.d241.s4|41-42|is|O
DDI-DrugBank.d241.s4|44-46|not|O
DDI-DrugBank.d241.s4|48-53|likely|O
DDI-DrugBank.d241.s4|55-56|to|O
DDI-DrugBank.d241.s4|58-59|be|O
DDI-DrugBank.d241.s4|61-70|clinically|O
DDI-DrugBank.d241.s4|72-82|significant|O
DDI-DrugBank.d241.s4|83-83|.|O
DDI-DrugBank.d241.s5|0-6|However|O
DDI-DrugBank.d241.s5|7-7|,|O
DDI-DrugBank.d241.s5|9-16|patients|O
DDI-DrugBank.d241.s5|18-19|on|O
DDI-DrugBank.d241.s5|21-27|digoxin|O
DDI-DrugBank.d241.s5|29-31|may|O
DDI-DrugBank.d241.s5|33-36|show|O
DDI-DrugBank.d241.s5|38-47|elevations|O
DDI-DrugBank.d241.s5|49-50|of|O
DDI-DrugBank.d241.s5|52-58|digoxin|O
DDI-DrugBank.d241.s5|60-73|concentrations|O
DDI-DrugBank.d241.s5|75-79|after|O
DDI-DrugBank.d241.s5|81-90|initiation|O
DDI-DrugBank.d241.s5|92-93|of|O
DDI-DrugBank.d241.s5|95-101|therapy|O
DDI-DrugBank.d241.s5|103-106|with|O
DDI-DrugBank.d241.s5|108-113|FLOLAN|O
DDI-DrugBank.d241.s5|114-114|,|O
DDI-DrugBank.d241.s5|116-120|which|O
DDI-DrugBank.d241.s5|122-124|may|O
DDI-DrugBank.d241.s5|126-127|be|O
DDI-DrugBank.d241.s5|129-138|clinically|O
DDI-DrugBank.d241.s5|140-150|significant|O
DDI-DrugBank.d241.s5|152-153|in|O
DDI-DrugBank.d241.s5|155-162|patients|O
DDI-DrugBank.d241.s5|164-168|prone|O
DDI-DrugBank.d241.s5|170-171|to|O
DDI-DrugBank.d241.s5|173-179|digoxin|O
DDI-DrugBank.d241.s5|181-188|toxicity|O
DDI-DrugBank.d241.s5|189-189|.|O
DDI-DrugBank.d706.s0|0-22|Catecholamine-depleting|O
DDI-DrugBank.d706.s0|24-28|drugs|O
DDI-DrugBank.d706.s0|30-30|(|O
DDI-DrugBank.d706.s0|31-34|e.g.|O
DDI-DrugBank.d706.s0|35-35|,|O
DDI-DrugBank.d706.s0|37-45|reserpine|O
DDI-DrugBank.d706.s0|46-46|)|O
DDI-DrugBank.d706.s0|48-50|may|O
DDI-DrugBank.d706.s0|52-55|have|O
DDI-DrugBank.d706.s0|57-58|an|O
DDI-DrugBank.d706.s0|60-67|additive|O
DDI-DrugBank.d706.s0|69-74|effect|O
DDI-DrugBank.d706.s0|76-79|when|O
DDI-DrugBank.d706.s0|81-85|given|O
DDI-DrugBank.d706.s0|87-90|with|O
DDI-DrugBank.d706.s0|92-104|beta-blocking|O
DDI-DrugBank.d706.s0|106-111|agents|O
DDI-DrugBank.d706.s0|112-112|.|O
DDI-DrugBank.d706.s1|0-7|Patients|O
DDI-DrugBank.d706.s1|9-15|treated|O
DDI-DrugBank.d706.s1|17-20|with|O
DDI-DrugBank.d706.s1|22-29|extended|O
DDI-DrugBank.d706.s1|31-37|release|O
DDI-DrugBank.d706.s1|39-48|metoprolol|O
DDI-DrugBank.d706.s1|50-58|succinate|O
DDI-DrugBank.d706.s1|60-63|plus|O
DDI-DrugBank.d706.s1|65-65|a|O
DDI-DrugBank.d706.s1|67-79|catecholamine|O
DDI-DrugBank.d706.s1|81-88|depletor|O
DDI-DrugBank.d706.s1|90-95|should|O
DDI-DrugBank.d706.s1|97-105|therefore|O
DDI-DrugBank.d706.s1|107-108|be|O
DDI-DrugBank.d706.s1|110-116|closely|O
DDI-DrugBank.d706.s1|118-125|observed|O
DDI-DrugBank.d706.s1|127-129|for|O
DDI-DrugBank.d706.s1|131-138|evidence|O
DDI-DrugBank.d706.s1|140-141|of|O
DDI-DrugBank.d706.s1|143-153|hypotension|O
DDI-DrugBank.d706.s1|155-156|or|O
DDI-DrugBank.d706.s1|158-163|marked|O
DDI-DrugBank.d706.s1|165-175|bradycardia|O
DDI-DrugBank.d706.s1|176-176|,|O
DDI-DrugBank.d706.s1|178-182|which|O
DDI-DrugBank.d706.s1|184-186|may|O
DDI-DrugBank.d706.s1|188-194|produce|O
DDI-DrugBank.d706.s1|196-202|vertigo|O
DDI-DrugBank.d706.s1|203-203|,|O
DDI-DrugBank.d706.s1|205-211|syncope|O
DDI-DrugBank.d706.s1|212-212|,|O
DDI-DrugBank.d706.s1|214-215|or|O
DDI-DrugBank.d706.s1|217-224|postural|O
DDI-DrugBank.d706.s1|226-236|hypotension|O
DDI-DrugBank.d706.s1|237-237|.|O
DDI-MedLine.d193.s0|0-9|Ticagrelor|O
DDI-MedLine.d193.s0|11-11|(|O
DDI-MedLine.d193.s0|12-19|Brilinta|O
DDI-MedLine.d193.s0|20-20|)|O
DDI-MedLine.d193.s0|21-22|--|O
DDI-MedLine.d193.s0|23-28|better|O
DDI-MedLine.d193.s0|30-33|than|O
DDI-MedLine.d193.s0|35-45|clopidogrel|O
DDI-MedLine.d193.s0|47-47|(|O
DDI-MedLine.d193.s0|48-53|Plavix|O
DDI-MedLine.d193.s0|54-54|)|O
DDI-MedLine.d193.s1|0-2|The|O
DDI-MedLine.d193.s1|4-6|FDA|O
DDI-MedLine.d193.s1|8-10|has|O
DDI-MedLine.d193.s1|12-19|approved|O
DDI-MedLine.d193.s1|21-30|ticagrelor|O
DDI-MedLine.d193.s1|32-32|(|O
DDI-MedLine.d193.s1|33-52|Brilinta-AstraZeneca|O
DDI-MedLine.d193.s1|53-53|)|O
DDI-MedLine.d193.s1|54-54|,|O
DDI-MedLine.d193.s1|56-57|an|O
DDI-MedLine.d193.s1|59-62|oral|O
DDI-MedLine.d193.s1|64-75|antiplatelet|O
DDI-MedLine.d193.s1|77-80|drug|O
DDI-MedLine.d193.s1|81-81|,|O
DDI-MedLine.d193.s1|83-85|for|O
DDI-MedLine.d193.s1|87-89|use|O
DDI-MedLine.d193.s1|91-94|with|O
DDI-MedLine.d193.s1|96-103|low-dose|O
DDI-MedLine.d193.s1|105-111|aspirin|O
DDI-MedLine.d193.s1|113-114|to|O
DDI-MedLine.d193.s1|116-121|reduce|O
DDI-MedLine.d193.s1|123-125|the|O
DDI-MedLine.d193.s1|127-130|rate|O
DDI-MedLine.d193.s1|132-133|of|O
DDI-MedLine.d193.s1|135-144|thrombotic|O
DDI-MedLine.d193.s1|146-159|cardiovascular|O
DDI-MedLine.d193.s1|161-166|events|O
DDI-MedLine.d193.s1|168-169|in|O
DDI-MedLine.d193.s1|171-178|patients|O
DDI-MedLine.d193.s1|180-183|with|O
DDI-MedLine.d193.s1|185-189|acute|O
DDI-MedLine.d193.s1|191-198|coronary|O
DDI-MedLine.d193.s1|200-207|syndrome|O
DDI-MedLine.d193.s1|209-209|(|O
DDI-MedLine.d193.s1|210-212|ACS|O
DDI-MedLine.d193.s1|213-213|)|O
DDI-MedLine.d193.s1|214-214|.|O
DDI-MedLine.d193.s2|0-1|It|O
DDI-MedLine.d193.s2|3-6|will|O
DDI-MedLine.d193.s2|8-14|compete|O
DDI-MedLine.d193.s2|16-19|with|O
DDI-MedLine.d193.s2|21-31|clopidogrel|O
DDI-MedLine.d193.s2|33-33|(|O
DDI-MedLine.d193.s2|34-39|Plavix|O
DDI-MedLine.d193.s2|40-40|)|O
DDI-MedLine.d193.s2|42-44|and|O
DDI-MedLine.d193.s2|46-54|prasugrel|O
DDI-MedLine.d193.s2|56-56|(|O
DDI-MedLine.d193.s2|57-63|Effient|O
DDI-MedLine.d193.s2|64-64|)|O
DDI-MedLine.d193.s2|66-68|for|O
DDI-MedLine.d193.s2|70-73|such|O
DDI-MedLine.d193.s2|75-77|use|O
DDI-MedLine.d193.s2|78-78|.|O
DDI-MedLine.d193.s3|0-10|Clopidogrel|O
DDI-MedLine.d193.s3|12-13|is|O
DDI-MedLine.d193.s3|15-22|expected|O
DDI-MedLine.d193.s3|24-25|to|O
DDI-MedLine.d193.s3|27-32|become|O
DDI-MedLine.d193.s3|34-42|available|O
DDI-MedLine.d193.s3|44-54|generically|O
DDI-MedLine.d193.s3|56-57|in|O
DDI-MedLine.d193.s3|59-61|the|O
DDI-MedLine.d193.s3|63-64|US|O
DDI-MedLine.d193.s3|66-71|within|O
DDI-MedLine.d193.s3|73-75|the|O
DDI-MedLine.d193.s3|77-80|next|O
DDI-MedLine.d193.s3|82-84|few|O
DDI-MedLine.d193.s3|86-91|months|O
DDI-MedLine.d193.s3|92-92|.|O
DDI-DrugBank.d124.s0|0-3|DRUG|O
DDI-DrugBank.d124.s0|5-16|INTERACTIONS|O
DDI-DrugBank.d124.s1|0-6|Several|O
DDI-DrugBank.d124.s1|8-11|drug|O
DDI-DrugBank.d124.s1|13-23|interaction|O
DDI-DrugBank.d124.s1|25-31|studies|O
DDI-DrugBank.d124.s1|33-36|have|O
DDI-DrugBank.d124.s1|38-41|been|O
DDI-DrugBank.d124.s1|43-51|completed|O
DDI-DrugBank.d124.s1|53-56|with|O
DDI-DrugBank.d124.s1|58-61|both|O
DDI-DrugBank.d124.s1|63-70|INVIRASE|O
DDI-DrugBank.d124.s1|72-74|and|O
DDI-DrugBank.d124.s1|76-84|FORTOVASE|O
DDI-DrugBank.d124.s1|85-85|.|O
DDI-DrugBank.d124.s2|0-11|Observations|O
DDI-DrugBank.d124.s2|13-16|from|O
DDI-DrugBank.d124.s2|18-21|drug|O
DDI-DrugBank.d124.s2|23-33|interaction|O
DDI-DrugBank.d124.s2|35-41|studies|O
DDI-DrugBank.d124.s2|43-46|with|O
DDI-DrugBank.d124.s2|48-56|FORTOVASE|O
DDI-DrugBank.d124.s2|58-60|may|O
DDI-DrugBank.d124.s2|62-64|not|O
DDI-DrugBank.d124.s2|66-67|be|O
DDI-DrugBank.d124.s2|69-78|predictive|O
DDI-DrugBank.d124.s2|80-82|for|O
DDI-DrugBank.d124.s2|84-91|INVIRASE|O
DDI-DrugBank.d124.s2|92-92|.|O
DDI-DrugBank.d124.s3|0-6|Because|O
DDI-DrugBank.d124.s3|8-16|ritonavir|O
DDI-DrugBank.d124.s3|18-19|is|O
DDI-DrugBank.d124.s3|21-34|coadministered|O
DDI-DrugBank.d124.s3|35-35|,|O
DDI-DrugBank.d124.s3|37-47|prescribers|O
DDI-DrugBank.d124.s3|49-54|should|O
DDI-DrugBank.d124.s3|56-59|also|O
DDI-DrugBank.d124.s3|61-65|refer|O
DDI-DrugBank.d124.s3|67-68|to|O
DDI-DrugBank.d124.s3|70-72|the|O
DDI-DrugBank.d124.s3|74-84|prescribing|O
DDI-DrugBank.d124.s3|86-96|information|O
DDI-DrugBank.d124.s3|98-100|for|O
DDI-DrugBank.d124.s3|102-110|ritonavir|O
DDI-DrugBank.d124.s3|112-120|regarding|O
DDI-DrugBank.d124.s3|122-125|drug|O
DDI-DrugBank.d124.s3|127-138|interactions|O
DDI-DrugBank.d124.s3|140-149|associated|O
DDI-DrugBank.d124.s3|151-154|with|O
DDI-DrugBank.d124.s3|156-159|this|O
DDI-DrugBank.d124.s3|161-165|agent|O
DDI-DrugBank.d124.s3|166-166|.|O
DDI-DrugBank.d124.s4|0-2|The|O
DDI-DrugBank.d124.s4|4-13|metabolism|O
DDI-DrugBank.d124.s4|15-16|of|O
DDI-DrugBank.d124.s4|18-27|saquinavir|O
DDI-DrugBank.d124.s4|29-30|is|O
DDI-DrugBank.d124.s4|32-39|mediated|O
DDI-DrugBank.d124.s4|41-42|by|O
DDI-DrugBank.d124.s4|44-53|cytochrome|O
DDI-DrugBank.d124.s4|55-58|P450|O
DDI-DrugBank.d124.s4|59-59|,|O
DDI-DrugBank.d124.s4|61-64|with|O
DDI-DrugBank.d124.s4|66-68|the|O
DDI-DrugBank.d124.s4|70-77|specific|O
DDI-DrugBank.d124.s4|79-87|isoenzyme|O
DDI-DrugBank.d124.s4|89-94|CYP3A4|O
DDI-DrugBank.d124.s4|96-106|responsible|O
DDI-DrugBank.d124.s4|108-110|for|O
DDI-DrugBank.d124.s4|112-113|90|O
DDI-DrugBank.d124.s4|114-114|%|O
DDI-DrugBank.d124.s4|116-117|of|O
DDI-DrugBank.d124.s4|119-121|the|O
DDI-DrugBank.d124.s4|123-129|hepatic|O
DDI-DrugBank.d124.s4|131-140|metabolism|O
DDI-DrugBank.d124.s4|141-141|.|O
DDI-DrugBank.d124.s5|0-11|Additionally|O
DDI-DrugBank.d124.s5|12-12|,|O
DDI-DrugBank.d124.s5|14-23|saquinavir|O
DDI-DrugBank.d124.s5|25-26|is|O
DDI-DrugBank.d124.s5|28-28|a|O
DDI-DrugBank.d124.s5|30-38|substrate|O
DDI-DrugBank.d124.s5|40-42|for|O
DDI-DrugBank.d124.s5|44-57|P-Glycoprotein|O
DDI-DrugBank.d124.s5|59-59|(|O
DDI-DrugBank.d124.s5|60-62|Pgp|O
DDI-DrugBank.d124.s5|63-63|)|O
DDI-DrugBank.d124.s5|64-64|.|O
DDI-DrugBank.d124.s6|0-8|Therefore|O
DDI-DrugBank.d124.s6|9-9|,|O
DDI-DrugBank.d124.s6|11-15|drugs|O
DDI-DrugBank.d124.s6|17-20|that|O
DDI-DrugBank.d124.s6|22-27|affect|O
DDI-DrugBank.d124.s6|29-34|CYP3A4|O
DDI-DrugBank.d124.s6|36-41|and/or|O
DDI-DrugBank.d124.s6|43-45|Pgp|O
DDI-DrugBank.d124.s6|46-46|,|O
DDI-DrugBank.d124.s6|48-50|may|O
DDI-DrugBank.d124.s6|52-57|modify|O
DDI-DrugBank.d124.s6|59-61|the|O
DDI-DrugBank.d124.s6|63-78|pharmacokinetics|O
DDI-DrugBank.d124.s6|80-81|of|O
DDI-DrugBank.d124.s6|83-92|saquinavir|O
DDI-DrugBank.d124.s6|93-93|.|O
DDI-DrugBank.d124.s7|0-8|Similarly|O
DDI-DrugBank.d124.s7|9-9|,|O
DDI-DrugBank.d124.s7|11-20|saquinavir|O
DDI-DrugBank.d124.s7|22-26|might|O
DDI-DrugBank.d124.s7|28-31|also|O
DDI-DrugBank.d124.s7|33-38|modify|O
DDI-DrugBank.d124.s7|40-42|the|O
DDI-DrugBank.d124.s7|44-59|pharmacokinetics|O
DDI-DrugBank.d124.s7|61-62|of|O
DDI-DrugBank.d124.s7|64-68|other|O
DDI-DrugBank.d124.s7|70-74|drugs|O
DDI-DrugBank.d124.s7|76-79|that|O
DDI-DrugBank.d124.s7|81-83|are|O
DDI-DrugBank.d124.s7|85-94|substrates|O
DDI-DrugBank.d124.s7|96-98|for|O
DDI-DrugBank.d124.s7|100-105|CYP3A4|O
DDI-DrugBank.d124.s7|107-108|or|O
DDI-DrugBank.d124.s7|110-112|Pgp|O
DDI-DrugBank.d124.s7|113-113|.|O
DDI-DrugBank.d124.s8|0-4|Drugs|O
DDI-DrugBank.d124.s8|6-9|that|O
DDI-DrugBank.d124.s8|11-13|are|O
DDI-DrugBank.d124.s8|15-29|contraindicated|O
DDI-DrugBank.d124.s8|31-42|specifically|O
DDI-DrugBank.d124.s8|44-46|due|O
DDI-DrugBank.d124.s8|48-49|to|O
DDI-DrugBank.d124.s8|51-53|the|O
DDI-DrugBank.d124.s8|55-62|expected|O
DDI-DrugBank.d124.s8|64-72|magnitude|O
DDI-DrugBank.d124.s8|74-75|of|O
DDI-DrugBank.d124.s8|77-87|interaction|O
DDI-DrugBank.d124.s8|89-91|and|O
DDI-DrugBank.d124.s8|93-101|potential|O
DDI-DrugBank.d124.s8|103-105|for|O
DDI-DrugBank.d124.s8|107-113|serious|O
DDI-DrugBank.d124.s8|115-121|adverse|O
DDI-DrugBank.d124.s8|123-128|events|O
DDI-DrugBank.d124.s8|130-132|are|O
DDI-DrugBank.d124.s8|134-139|listed|O
DDI-DrugBank.d124.s8|141-157|CONTRAINDICATIONS|O
DDI-DrugBank.d124.s8|158-158|.|O
DDI-DrugBank.d124.s9|0-9|Additional|O
DDI-DrugBank.d124.s9|11-15|drugs|O
DDI-DrugBank.d124.s9|17-20|that|O
DDI-DrugBank.d124.s9|22-24|are|O
DDI-DrugBank.d124.s9|26-28|not|O
DDI-DrugBank.d124.s9|30-40|recommended|O
DDI-DrugBank.d124.s9|42-44|for|O
DDI-DrugBank.d124.s9|46-61|coadministration|O
DDI-DrugBank.d124.s9|63-66|with|O
DDI-DrugBank.d124.s9|68-75|INVIRASE|O
DDI-DrugBank.d124.s9|77-79|and|O
DDI-DrugBank.d124.s9|81-89|ritonavir|O
DDI-DrugBank.d124.s9|91-93|are|O
DDI-DrugBank.d124.s9|95-102|included|O
DDI-DrugBank.d124.s9|104-108|below|O
DDI-DrugBank.d124.s9|109-109|.|O
DDI-DrugBank.d124.s10|0-4|These|O
DDI-DrugBank.d124.s10|6-20|recommendations|O
DDI-DrugBank.d124.s10|22-24|are|O
DDI-DrugBank.d124.s10|26-30|based|O
DDI-DrugBank.d124.s10|32-33|on|O
DDI-DrugBank.d124.s10|35-40|either|O
DDI-DrugBank.d124.s10|42-45|drug|O
DDI-DrugBank.d124.s10|47-57|interaction|O
DDI-DrugBank.d124.s10|59-65|studies|O
DDI-DrugBank.d124.s10|67-68|or|O
DDI-DrugBank.d124.s10|70-78|predicted|O
DDI-DrugBank.d124.s10|80-91|interactions|O
DDI-DrugBank.d124.s10|93-95|due|O
DDI-DrugBank.d124.s10|97-98|to|O
DDI-DrugBank.d124.s10|100-102|the|O
DDI-DrugBank.d124.s10|104-111|expected|O
DDI-DrugBank.d124.s10|113-121|magnitude|O
DDI-DrugBank.d124.s10|123-124|of|O
DDI-DrugBank.d124.s10|126-136|interaction|O
DDI-DrugBank.d124.s10|138-140|and|O
DDI-DrugBank.d124.s10|142-150|potential|O
DDI-DrugBank.d124.s10|152-154|for|O
DDI-DrugBank.d124.s10|156-162|serious|O
DDI-DrugBank.d124.s10|164-169|events|O
DDI-DrugBank.d124.s10|171-172|or|O
DDI-DrugBank.d124.s10|174-177|loss|O
DDI-DrugBank.d124.s10|179-180|of|O
DDI-DrugBank.d124.s10|182-189|efficacy|O
DDI-DrugBank.d124.s10|190-190|.|O
DDI-DrugBank.d124.s11|0-3|With|O
DDI-DrugBank.d124.s11|5-8|some|O
DDI-DrugBank.d124.s11|10-15|agents|O
DDI-DrugBank.d124.s11|16-16|,|O
DDI-DrugBank.d124.s11|18-20|the|O
DDI-DrugBank.d124.s11|22-31|metabolism|O
DDI-DrugBank.d124.s11|33-35|may|O
DDI-DrugBank.d124.s11|37-38|be|O
DDI-DrugBank.d124.s11|40-46|induced|O
DDI-DrugBank.d124.s11|47-47|,|O
DDI-DrugBank.d124.s11|49-57|resulting|O
DDI-DrugBank.d124.s11|59-60|in|O
DDI-DrugBank.d124.s11|62-70|decreased|O
DDI-DrugBank.d124.s11|72-85|concentrations|O
DDI-DrugBank.d124.s11|86-86|.|O
DDI-DrugBank.d124.s12|0-4|Drugs|O
DDI-DrugBank.d124.s12|6-9|That|O
DDI-DrugBank.d124.s12|11-16|Should|O
DDI-DrugBank.d124.s12|18-20|Not|O
DDI-DrugBank.d124.s12|22-23|Be|O
DDI-DrugBank.d124.s12|25-38|Coadministered|O
DDI-DrugBank.d124.s12|40-43|With|O
DDI-DrugBank.d124.s12|45-62|INVIRASE/Ritonavir|O
DDI-DrugBank.d124.s13|0-3|Drug|O
DDI-DrugBank.d124.s13|5-9|Class|O
DDI-DrugBank.d124.s13|10-10|:|O
DDI-DrugBank.d124.s13|12-15|Drug|O
DDI-DrugBank.d124.s13|17-20|Name|O
DDI-DrugBank.d124.s13|22-29|Clinical|O
DDI-DrugBank.d124.s13|31-37|Comment|O
DDI-DrugBank.d124.s14|0-14|Antiarrhythmics|O
DDI-DrugBank.d124.s14|15-15|:|O
DDI-DrugBank.d124.s14|17-26|Amiodarone|O
DDI-DrugBank.d124.s14|27-27|,|O
DDI-DrugBank.d124.s14|29-36|bepridil|O
DDI-DrugBank.d124.s14|37-37|,|O
DDI-DrugBank.d124.s14|39-48|flecainide|O
DDI-DrugBank.d124.s14|49-49|,|O
DDI-DrugBank.d124.s14|51-61|propafenone|O
DDI-DrugBank.d124.s14|62-62|,|O
DDI-DrugBank.d124.s14|64-72|quinidine|O
DDI-DrugBank.d124.s14|74-88|CONTRAINDICATED|O
DDI-DrugBank.d124.s14|90-92|due|O
DDI-DrugBank.d124.s14|94-95|to|O
DDI-DrugBank.d124.s14|97-105|potential|O
DDI-DrugBank.d124.s14|107-109|for|O
DDI-DrugBank.d124.s14|111-117|serious|O
DDI-DrugBank.d124.s14|119-124|and/or|O
DDI-DrugBank.d124.s14|126-141|life-threatening|O
DDI-DrugBank.d124.s14|143-151|reactions|O
DDI-DrugBank.d124.s14|152-152|.|O
DDI-DrugBank.d124.s15|0-13|Antihistamines|O
DDI-DrugBank.d124.s15|14-14|:|O
DDI-DrugBank.d124.s15|16-26|astemizole*|O
DDI-DrugBank.d124.s15|27-27|,|O
DDI-DrugBank.d124.s15|29-40|terfenadine*|O
DDI-DrugBank.d124.s15|42-56|CONTRAINDICATED|O
DDI-DrugBank.d124.s15|58-60|due|O
DDI-DrugBank.d124.s15|62-63|to|O
DDI-DrugBank.d124.s15|65-73|potential|O
DDI-DrugBank.d124.s15|75-77|for|O
DDI-DrugBank.d124.s15|79-85|serious|O
DDI-DrugBank.d124.s15|87-92|and/or|O
DDI-DrugBank.d124.s15|94-109|life-threatening|O
DDI-DrugBank.d124.s15|111-117|cardiac|O
DDI-DrugBank.d124.s15|119-129|arrhythmias|O
DDI-DrugBank.d124.s15|130-130|.|O
DDI-DrugBank.d124.s16|0-4|Ergot|O
DDI-DrugBank.d124.s16|6-16|Derivatives|O
DDI-DrugBank.d124.s16|17-17|:|O
DDI-DrugBank.d124.s16|19-35|Dihydroergotamine|O
DDI-DrugBank.d124.s16|36-36|,|O
DDI-DrugBank.d124.s16|38-47|ergonovine|O
DDI-DrugBank.d124.s16|48-48|,|O
DDI-DrugBank.d124.s16|50-59|ergotamine|O
DDI-DrugBank.d124.s16|60-60|,|O
DDI-DrugBank.d124.s16|62-77|methylergonovine|O
DDI-DrugBank.d124.s16|79-93|CONTRAINDICATED|O
DDI-DrugBank.d124.s16|95-97|due|O
DDI-DrugBank.d124.s16|99-100|to|O
DDI-DrugBank.d124.s16|102-110|potential|O
DDI-DrugBank.d124.s16|112-114|for|O
DDI-DrugBank.d124.s16|116-122|serious|O
DDI-DrugBank.d124.s16|124-126|and|O
DDI-DrugBank.d124.s16|128-143|life-threatening|O
DDI-DrugBank.d124.s16|145-153|reactions|O
DDI-DrugBank.d124.s16|155-158|such|O
DDI-DrugBank.d124.s16|160-161|as|O
DDI-DrugBank.d124.s16|163-167|acute|O
DDI-DrugBank.d124.s16|169-173|ergot|O
DDI-DrugBank.d124.s16|175-182|toxicity|O
DDI-DrugBank.d124.s16|184-196|characterized|O
DDI-DrugBank.d124.s16|198-199|by|O
DDI-DrugBank.d124.s16|201-210|peripheral|O
DDI-DrugBank.d124.s16|212-220|vasospasm|O
DDI-DrugBank.d124.s16|222-224|and|O
DDI-DrugBank.d124.s16|226-233|ischemia|O
DDI-DrugBank.d124.s16|235-236|of|O
DDI-DrugBank.d124.s16|238-240|the|O
DDI-DrugBank.d124.s16|242-252|extremities|O
DDI-DrugBank.d124.s16|254-256|and|O
DDI-DrugBank.d124.s16|258-262|other|O
DDI-DrugBank.d124.s16|264-270|tissues|O
DDI-DrugBank.d124.s16|271-271|.|O
DDI-DrugBank.d124.s17|0-16|Antimycobacterial|O
DDI-DrugBank.d124.s17|18-23|Agents|O
DDI-DrugBank.d124.s17|24-24|:|O
DDI-DrugBank.d124.s17|26-33|rifampin|O
DDI-DrugBank.d124.s17|35-49|CONTRAINDICATED|O
DDI-DrugBank.d124.s17|51-55|since|O
DDI-DrugBank.d124.s17|57-59|the|O
DDI-DrugBank.d124.s17|61-76|coadministration|O
DDI-DrugBank.d124.s17|78-79|of|O
DDI-DrugBank.d124.s17|81-84|this|O
DDI-DrugBank.d124.s17|86-92|product|O
DDI-DrugBank.d124.s17|94-97|with|O
DDI-DrugBank.d124.s17|99-108|saquinavir|O
DDI-DrugBank.d124.s17|110-111|in|O
DDI-DrugBank.d124.s17|113-114|an|O
DDI-DrugBank.d124.s17|116-129|antiretroviral|O
DDI-DrugBank.d124.s17|131-137|regimen|O
DDI-DrugBank.d124.s17|139-145|reduces|O
DDI-DrugBank.d124.s17|147-149|the|O
DDI-DrugBank.d124.s17|151-156|plasma|O
DDI-DrugBank.d124.s17|158-171|concentrations|O
DDI-DrugBank.d124.s17|173-174|of|O
DDI-DrugBank.d124.s17|176-185|saquinavir|O
DDI-DrugBank.d124.s17|186-186|.|O
DDI-DrugBank.d124.s18|0-5|Garlic|O
DDI-DrugBank.d124.s18|7-14|Capsules|O
DDI-DrugBank.d124.s18|16-21|Garlic|O
DDI-DrugBank.d124.s18|23-30|capsules|O
DDI-DrugBank.d124.s18|32-37|should|O
DDI-DrugBank.d124.s18|39-41|not|O
DDI-DrugBank.d124.s18|43-44|be|O
DDI-DrugBank.d124.s18|46-49|used|O
DDI-DrugBank.d124.s18|51-55|while|O
DDI-DrugBank.d124.s18|57-62|taking|O
DDI-DrugBank.d124.s18|64-73|saquinavir|O
DDI-DrugBank.d124.s18|75-75|(|O
DDI-DrugBank.d124.s18|76-84|FORTOVASE|O
DDI-DrugBank.d124.s18|85-85|)|O
DDI-DrugBank.d124.s18|87-88|as|O
DDI-DrugBank.d124.s18|90-92|the|O
DDI-DrugBank.d124.s18|94-97|sole|O
DDI-DrugBank.d124.s18|99-106|protease|O
DDI-DrugBank.d124.s18|108-116|inhibitor|O
DDI-DrugBank.d124.s18|118-120|due|O
DDI-DrugBank.d124.s18|122-123|to|O
DDI-DrugBank.d124.s18|125-127|the|O
DDI-DrugBank.d124.s18|129-132|risk|O
DDI-DrugBank.d124.s18|134-135|of|O
DDI-DrugBank.d124.s18|137-145|decreased|O
DDI-DrugBank.d124.s18|147-156|saquinavir|O
DDI-DrugBank.d124.s18|158-163|plasma|O
DDI-DrugBank.d124.s18|165-178|concentrations|O
DDI-DrugBank.d124.s18|179-179|.|O
DDI-DrugBank.d124.s19|0-1|No|O
DDI-DrugBank.d124.s19|3-6|data|O
DDI-DrugBank.d124.s19|8-10|are|O
DDI-DrugBank.d124.s19|12-20|available|O
DDI-DrugBank.d124.s19|22-24|for|O
DDI-DrugBank.d124.s19|26-28|the|O
DDI-DrugBank.d124.s19|30-45|coadministration|O
DDI-DrugBank.d124.s19|47-48|of|O
DDI-DrugBank.d124.s19|50-67|INVIRASE/ritonavir|O
DDI-DrugBank.d124.s19|69-70|or|O
DDI-DrugBank.d124.s19|72-90|FORTOVASE/ritonavir|O
DDI-DrugBank.d124.s19|92-94|and|O
DDI-DrugBank.d124.s19|96-101|garlic|O
DDI-DrugBank.d124.s19|103-110|capsules|O
DDI-DrugBank.d124.s19|111-111|.|O
DDI-DrugBank.d124.s20|0-1|GI|O
DDI-DrugBank.d124.s20|3-10|Motility|O
DDI-DrugBank.d124.s20|12-16|Agent|O
DDI-DrugBank.d124.s20|17-17|:|O
DDI-DrugBank.d124.s20|19-28|cisapride*|O
DDI-DrugBank.d124.s20|30-44|CONTRAINDICATED|O
DDI-DrugBank.d124.s20|46-48|due|O
DDI-DrugBank.d124.s20|50-51|to|O
DDI-DrugBank.d124.s20|53-61|potential|O
DDI-DrugBank.d124.s20|63-65|for|O
DDI-DrugBank.d124.s20|67-73|serious|O
DDI-DrugBank.d124.s20|75-80|and/or|O
DDI-DrugBank.d124.s20|82-97|life-threatening|O
DDI-DrugBank.d124.s20|99-107|reactions|O
DDI-DrugBank.d124.s20|109-112|such|O
DDI-DrugBank.d124.s20|114-115|as|O
DDI-DrugBank.d124.s20|117-123|cardiac|O
DDI-DrugBank.d124.s20|125-135|arrhythmias|O
DDI-DrugBank.d124.s20|136-136|.|O
DDI-DrugBank.d124.s21|0-5|Herbal|O
DDI-DrugBank.d124.s21|7-14|Products|O
DDI-DrugBank.d124.s21|15-15|:|O
DDI-DrugBank.d124.s21|17-19|St.|O
DDI-DrugBank.d124.s21|21-24|John|O
DDI-DrugBank.d124.s21|26-26|s|O
DDI-DrugBank.d124.s21|28-31|wort|O
DDI-DrugBank.d124.s21|33-33|(|O
DDI-DrugBank.d124.s21|34-42|hypericum|O
DDI-DrugBank.d124.s21|44-53|perforatum|O
DDI-DrugBank.d124.s21|54-54|)|O
DDI-DrugBank.d124.s21|56-62|WARNING|O
DDI-DrugBank.d124.s21|64-79|coadministration|O
DDI-DrugBank.d124.s21|81-83|may|O
DDI-DrugBank.d124.s21|85-88|lead|O
DDI-DrugBank.d124.s21|90-91|to|O
DDI-DrugBank.d124.s21|93-96|loss|O
DDI-DrugBank.d124.s21|98-99|of|O
DDI-DrugBank.d124.s21|101-109|virologic|O
DDI-DrugBank.d124.s21|111-118|response|O
DDI-DrugBank.d124.s21|120-122|and|O
DDI-DrugBank.d124.s21|124-131|possible|O
DDI-DrugBank.d124.s21|133-142|resistance|O
DDI-DrugBank.d124.s21|144-145|to|O
DDI-DrugBank.d124.s21|147-154|INVIRASE|O
DDI-DrugBank.d124.s21|156-157|or|O
DDI-DrugBank.d124.s21|159-160|to|O
DDI-DrugBank.d124.s21|162-164|the|O
DDI-DrugBank.d124.s21|166-170|class|O
DDI-DrugBank.d124.s21|172-173|of|O
DDI-DrugBank.d124.s21|175-182|protease|O
DDI-DrugBank.d124.s21|184-193|inhibitors|O
DDI-DrugBank.d124.s21|194-194|.|O
DDI-DrugBank.d124.s22|0-6|HMG-CoA|O
DDI-DrugBank.d124.s22|8-16|Reductase|O
DDI-DrugBank.d124.s22|18-27|Inhibitors|O
DDI-DrugBank.d124.s22|28-28|:|O
DDI-DrugBank.d124.s22|30-39|lovastatin|O
DDI-DrugBank.d124.s22|40-40|,|O
DDI-DrugBank.d124.s22|42-52|simvastatin|O
DDI-DrugBank.d124.s22|54-60|WARNING|O
DDI-DrugBank.d124.s22|62-70|potential|O
DDI-DrugBank.d124.s22|72-74|for|O
DDI-DrugBank.d124.s22|76-82|serious|O
DDI-DrugBank.d124.s22|84-92|reactions|O
DDI-DrugBank.d124.s22|94-97|such|O
DDI-DrugBank.d124.s22|99-100|as|O
DDI-DrugBank.d124.s22|102-105|risk|O
DDI-DrugBank.d124.s22|107-108|of|O
DDI-DrugBank.d124.s22|110-117|myopathy|O
DDI-DrugBank.d124.s22|119-127|including|O
DDI-DrugBank.d124.s22|129-142|rhabdomyolysis|O
DDI-DrugBank.d124.s22|143-143|.|O
DDI-DrugBank.d124.s23|0-18|Sedatives/Hypnotics|O
DDI-DrugBank.d124.s23|19-19|:|O
DDI-DrugBank.d124.s23|21-29|triazolam|O
DDI-DrugBank.d124.s23|30-30|,|O
DDI-DrugBank.d124.s23|32-40|midazolam|O
DDI-DrugBank.d124.s23|42-56|CONTRAINDICATED|O
DDI-DrugBank.d124.s23|58-60|due|O
DDI-DrugBank.d124.s23|62-63|to|O
DDI-DrugBank.d124.s23|65-73|potential|O
DDI-DrugBank.d124.s23|75-77|for|O
DDI-DrugBank.d124.s23|79-85|serious|O
DDI-DrugBank.d124.s23|87-92|and/or|O
DDI-DrugBank.d124.s23|94-109|life-threatening|O
DDI-DrugBank.d124.s23|111-119|reactions|O
DDI-DrugBank.d124.s23|121-124|such|O
DDI-DrugBank.d124.s23|126-127|as|O
DDI-DrugBank.d124.s23|129-137|prolonged|O
DDI-DrugBank.d124.s23|139-140|or|O
DDI-DrugBank.d124.s23|142-150|increased|O
DDI-DrugBank.d124.s23|152-159|sedation|O
DDI-DrugBank.d124.s23|161-162|or|O
DDI-DrugBank.d124.s23|164-174|respiratory|O
DDI-DrugBank.d124.s23|176-185|depression|O
DDI-DrugBank.d124.s23|186-186|.|O
DDI-DrugBank.d124.s24|0-0|*|O
DDI-DrugBank.d124.s24|2-3|No|O
DDI-DrugBank.d124.s24|5-10|longer|O
DDI-DrugBank.d124.s24|12-19|marketed|O
DDI-DrugBank.d124.s24|21-22|in|O
DDI-DrugBank.d124.s24|24-26|the|O
DDI-DrugBank.d124.s24|28-29|US|O
DDI-DrugBank.d124.s24|30-30|.|O
DDI-DrugBank.d124.s25|0-4|Drugs|O
DDI-DrugBank.d124.s25|6-9|That|O
DDI-DrugBank.d124.s25|11-13|Are|O
DDI-DrugBank.d124.s25|15-20|Mainly|O
DDI-DrugBank.d124.s25|22-32|Metabolized|O
DDI-DrugBank.d124.s25|34-35|by|O
DDI-DrugBank.d124.s25|37-42|CYP3A4|O
DDI-DrugBank.d124.s26|0-7|Although|O
DDI-DrugBank.d124.s26|9-16|specific|O
DDI-DrugBank.d124.s26|18-24|studies|O
DDI-DrugBank.d124.s26|26-29|have|O
DDI-DrugBank.d124.s26|31-33|not|O
DDI-DrugBank.d124.s26|35-38|been|O
DDI-DrugBank.d124.s26|40-48|performed|O
DDI-DrugBank.d124.s26|49-49|,|O
DDI-DrugBank.d124.s26|51-66|coadministration|O
DDI-DrugBank.d124.s26|68-71|with|O
DDI-DrugBank.d124.s26|73-77|drugs|O
DDI-DrugBank.d124.s26|79-82|that|O
DDI-DrugBank.d124.s26|84-86|are|O
DDI-DrugBank.d124.s26|88-93|mainly|O
DDI-DrugBank.d124.s26|95-105|metabolized|O
DDI-DrugBank.d124.s26|107-108|by|O
DDI-DrugBank.d124.s26|110-115|CYP3A4|O
DDI-DrugBank.d124.s26|117-117|(|O
DDI-DrugBank.d124.s26|118-119|eg|O
DDI-DrugBank.d124.s26|120-120|,|O
DDI-DrugBank.d124.s26|122-128|calcium|O
DDI-DrugBank.d124.s26|130-136|channel|O
DDI-DrugBank.d124.s26|138-145|blockers|O
DDI-DrugBank.d124.s26|146-146|,|O
DDI-DrugBank.d124.s26|148-154|dapsone|O
DDI-DrugBank.d124.s26|155-155|,|O
DDI-DrugBank.d124.s26|157-168|disopyramide|O
DDI-DrugBank.d124.s26|169-169|,|O
DDI-DrugBank.d124.s26|171-177|quinine|O
DDI-DrugBank.d124.s26|178-178|,|O
DDI-DrugBank.d124.s26|180-189|amiodarone|O
DDI-DrugBank.d124.s26|190-190|,|O
DDI-DrugBank.d124.s26|192-200|quinidine|O
DDI-DrugBank.d124.s26|201-201|,|O
DDI-DrugBank.d124.s26|203-210|warfarin|O
DDI-DrugBank.d124.s26|211-211|,|O
DDI-DrugBank.d124.s26|213-222|tacrolimus|O
DDI-DrugBank.d124.s26|223-223|,|O
DDI-DrugBank.d124.s26|225-236|cyclosporine|O
DDI-DrugBank.d124.s26|237-237|,|O
DDI-DrugBank.d124.s26|239-243|ergot|O
DDI-DrugBank.d124.s26|245-255|derivatives|O
DDI-DrugBank.d124.s26|256-256|,|O
DDI-DrugBank.d124.s26|258-265|pimozide|O
DDI-DrugBank.d124.s26|266-266|,|O
DDI-DrugBank.d124.s26|268-280|carbamazepine|O
DDI-DrugBank.d124.s26|281-281|,|O
DDI-DrugBank.d124.s26|283-290|fentanyl|O
DDI-DrugBank.d124.s26|291-291|,|O
DDI-DrugBank.d124.s26|293-302|alfentanyl|O
DDI-DrugBank.d124.s26|303-303|,|O
DDI-DrugBank.d124.s26|305-314|alprazolam|O
DDI-DrugBank.d124.s26|315-315|,|O
DDI-DrugBank.d124.s26|317-319|and|O
DDI-DrugBank.d124.s26|321-329|triazolam|O
DDI-DrugBank.d124.s26|330-330|)|O
DDI-DrugBank.d124.s26|332-334|may|O
DDI-DrugBank.d124.s26|336-339|have|O
DDI-DrugBank.d124.s26|341-348|elevated|O
DDI-DrugBank.d124.s26|350-355|plasma|O
DDI-DrugBank.d124.s26|357-370|concentrations|O
DDI-DrugBank.d124.s26|372-375|when|O
DDI-DrugBank.d124.s26|377-390|coadministered|O
DDI-DrugBank.d124.s26|392-395|with|O
DDI-DrugBank.d124.s26|397-406|saquinavir|O
DDI-DrugBank.d124.s26|407-407|;|O
DDI-DrugBank.d124.s27|0-8|therefore|O
DDI-DrugBank.d124.s27|9-9|,|O
DDI-DrugBank.d124.s27|11-15|these|O
DDI-DrugBank.d124.s27|17-28|combinations|O
DDI-DrugBank.d124.s27|30-35|should|O
DDI-DrugBank.d124.s27|37-38|be|O
DDI-DrugBank.d124.s27|40-43|used|O
DDI-DrugBank.d124.s27|45-48|with|O
DDI-DrugBank.d124.s27|50-56|caution|O
DDI-DrugBank.d124.s27|57-57|.|O
DDI-DrugBank.d124.s28|0-4|Since|O
DDI-DrugBank.d124.s28|6-13|INVIRASE|O
DDI-DrugBank.d124.s28|15-16|is|O
DDI-DrugBank.d124.s28|18-31|coadministered|O
DDI-DrugBank.d124.s28|33-36|with|O
DDI-DrugBank.d124.s28|38-46|ritonavir|O
DDI-DrugBank.d124.s28|47-47|,|O
DDI-DrugBank.d124.s28|49-51|the|O
DDI-DrugBank.d124.s28|53-61|ritonavir|O
DDI-DrugBank.d124.s28|63-67|label|O
DDI-DrugBank.d124.s28|69-74|should|O
DDI-DrugBank.d124.s28|76-77|be|O
DDI-DrugBank.d124.s28|79-86|reviewed|O
DDI-DrugBank.d124.s28|88-90|for|O
DDI-DrugBank.d124.s28|92-101|additional|O
DDI-DrugBank.d124.s28|103-107|drugs|O
DDI-DrugBank.d124.s28|109-112|that|O
DDI-DrugBank.d124.s28|114-119|should|O
DDI-DrugBank.d124.s28|121-123|not|O
DDI-DrugBank.d124.s28|125-126|be|O
DDI-DrugBank.d124.s28|128-141|coadministered|O
DDI-DrugBank.d124.s28|142-142|.|O
DDI-DrugBank.d124.s29|0-7|Inducers|O
DDI-DrugBank.d124.s29|9-10|of|O
DDI-DrugBank.d124.s29|12-17|CYP3A4|O
DDI-DrugBank.d124.s30|0-15|Coadministration|O
DDI-DrugBank.d124.s30|17-20|with|O
DDI-DrugBank.d124.s30|22-30|compounds|O
DDI-DrugBank.d124.s30|32-35|that|O
DDI-DrugBank.d124.s30|37-39|are|O
DDI-DrugBank.d124.s30|41-46|potent|O
DDI-DrugBank.d124.s30|48-55|inducers|O
DDI-DrugBank.d124.s30|57-58|of|O
DDI-DrugBank.d124.s30|60-65|CYP3A4|O
DDI-DrugBank.d124.s30|67-67|(|O
DDI-DrugBank.d124.s30|68-69|eg|O
DDI-DrugBank.d124.s30|70-70|,|O
DDI-DrugBank.d124.s30|72-84|phenobarbital|O
DDI-DrugBank.d124.s30|85-85|,|O
DDI-DrugBank.d124.s30|87-95|phenytoin|O
DDI-DrugBank.d124.s30|96-96|,|O
DDI-DrugBank.d124.s30|98-110|dexamethasone|O
DDI-DrugBank.d124.s30|111-111|,|O
DDI-DrugBank.d124.s30|113-125|carbamazepine|O
DDI-DrugBank.d124.s30|126-126|)|O
DDI-DrugBank.d124.s30|128-130|may|O
DDI-DrugBank.d124.s30|132-137|result|O
DDI-DrugBank.d124.s30|139-140|in|O
DDI-DrugBank.d124.s30|142-150|decreased|O
DDI-DrugBank.d124.s30|152-157|plasma|O
DDI-DrugBank.d124.s30|159-164|levels|O
DDI-DrugBank.d124.s30|166-167|of|O
DDI-DrugBank.d124.s30|169-178|saquinavir|O
DDI-DrugBank.d124.s30|179-179|.|O
DDI-DrugBank.d213.s0|0-5|Iodine|O
DDI-DrugBank.d213.s0|7-8|or|O
DDI-DrugBank.d213.s0|10-15|iodine|O
DDI-DrugBank.d213.s0|17-22|excess|O
DDI-DrugBank.d213.s0|24-26|may|O
DDI-DrugBank.d213.s0|28-35|decrease|O
DDI-DrugBank.d213.s0|37-39|the|O
DDI-DrugBank.d213.s0|41-46|effect|O
DDI-DrugBank.d213.s0|48-49|of|O
DDI-DrugBank.d213.s0|51-61|Carbimazole|O
DDI-DrugBank.d213.s0|62-62|,|O
DDI-DrugBank.d213.s0|64-66|and|O
DDI-DrugBank.d213.s0|68-69|an|O
DDI-DrugBank.d213.s0|71-76|iodine|O
DDI-DrugBank.d213.s0|78-87|deficiency|O
DDI-DrugBank.d213.s0|89-91|can|O
DDI-DrugBank.d213.s0|93-100|increase|O
DDI-DrugBank.d213.s0|102-104|the|O
DDI-DrugBank.d213.s0|106-111|effect|O
DDI-DrugBank.d213.s0|113-114|of|O
DDI-DrugBank.d213.s0|116-126|Carbimazole|O
DDI-DrugBank.d213.s0|127-127|.|O
DDI-DrugBank.d213.s1|0-4|Serum|O
DDI-DrugBank.d213.s1|6-18|concentration|O
DDI-DrugBank.d213.s1|20-21|of|O
DDI-DrugBank.d213.s1|23-29|digoxin|O
DDI-DrugBank.d213.s1|31-33|and|O
DDI-DrugBank.d213.s1|35-43|digitoxin|O
DDI-DrugBank.d213.s1|45-47|may|O
DDI-DrugBank.d213.s1|49-56|increase|O
DDI-DrugBank.d213.s1|58-61|when|O
DDI-DrugBank.d213.s1|63-70|patients|O
DDI-DrugBank.d213.s1|72-75|take|O
DDI-DrugBank.d213.s1|77-87|antithyroid|O
DDI-DrugBank.d213.s1|89-94|agents|O
DDI-DrugBank.d213.s1|95-95|.|O
DDI-DrugBank.d213.s2|0-0|A|O
DDI-DrugBank.d213.s2|2-9|decrease|O
DDI-DrugBank.d213.s2|11-12|of|O
DDI-DrugBank.d213.s2|14-16|the|O
DDI-DrugBank.d213.s2|18-23|dosage|O
DDI-DrugBank.d213.s2|25-27|may|O
DDI-DrugBank.d213.s2|29-30|be|O
DDI-DrugBank.d213.s2|32-40|necessary|O
DDI-DrugBank.d213.s2|42-45|when|O
DDI-DrugBank.d213.s2|47-53|patient|O
DDI-DrugBank.d213.s2|55-61|becomes|O
DDI-DrugBank.d213.s2|63-71|euthyroid|O
DDI-DrugBank.d213.s2|72-72|.|O
DDI-DrugBank.d213.s3|0-10|Antithyroid|O
DDI-DrugBank.d213.s3|12-17|agents|O
DDI-DrugBank.d213.s3|19-21|may|O
DDI-DrugBank.d213.s3|23-30|decrease|O
DDI-DrugBank.d213.s3|32-40|thyroidal|O
DDI-DrugBank.d213.s3|42-47|uptake|O
DDI-DrugBank.d213.s3|49-50|of|O
DDI-DrugBank.d213.s3|52-57|sodium|O
DDI-DrugBank.d213.s3|59-64|iodide|O
DDI-DrugBank.d213.s3|66-69|I131|O
DDI-DrugBank.d213.s3|70-70|,|O
DDI-DrugBank.d213.s3|72-72|a|O
DDI-DrugBank.d213.s3|74-80|rebound|O
DDI-DrugBank.d213.s3|82-83|in|O
DDI-DrugBank.d213.s3|85-90|uptake|O
DDI-DrugBank.d213.s3|92-94|may|O
DDI-DrugBank.d213.s3|96-100|occur|O
DDI-DrugBank.d213.s3|102-103|up|O
DDI-DrugBank.d213.s3|105-106|to|O
DDI-DrugBank.d213.s3|108-108|5|O
DDI-DrugBank.d213.s3|110-113|days|O
DDI-DrugBank.d213.s3|115-119|after|O
DDI-DrugBank.d213.s3|121-126|sudden|O
DDI-DrugBank.d213.s3|128-137|withdrawal|O
DDI-DrugBank.d213.s3|139-140|of|O
DDI-DrugBank.d213.s3|142-152|Carbimazole|O
DDI-DrugBank.d213.s3|153-153|.|O
DDI-DrugBank.d213.s4|0-7|Patients|O
DDI-DrugBank.d213.s4|9-16|response|O
DDI-DrugBank.d213.s4|18-19|to|O
DDI-DrugBank.d213.s4|21-24|oral|O
DDI-DrugBank.d213.s4|26-39|anticoagulants|O
DDI-DrugBank.d213.s4|41-43|may|O
DDI-DrugBank.d213.s4|45-46|be|O
DDI-DrugBank.d213.s4|48-55|affected|O
DDI-DrugBank.d213.s4|57-58|by|O
DDI-DrugBank.d213.s4|60-66|his/her|O
DDI-DrugBank.d213.s4|68-74|thyroid|O
DDI-DrugBank.d213.s4|76-78|and|O
DDI-DrugBank.d213.s4|80-88|metabolic|O
DDI-DrugBank.d213.s4|90-95|status|O
DDI-DrugBank.d213.s4|96-96|.|O
DDI-DrugBank.d213.s5|0-1|An|O
DDI-DrugBank.d213.s5|3-12|evaluation|O
DDI-DrugBank.d213.s5|14-15|of|O
DDI-DrugBank.d213.s5|17-27|prothrombin|O
DDI-DrugBank.d213.s5|29-32|time|O
DDI-DrugBank.d213.s5|34-36|and|O
DDI-DrugBank.d213.s5|38-39|an|O
DDI-DrugBank.d213.s5|41-50|adjustment|O
DDI-DrugBank.d213.s5|52-53|of|O
DDI-DrugBank.d213.s5|55-67|anticoagulant|O
DDI-DrugBank.d213.s5|69-74|dosage|O
DDI-DrugBank.d213.s5|76-78|are|O
DDI-DrugBank.d213.s5|80-90|recommended|O
DDI-MedLine.d181.s0|0-3|Drug|O
DDI-MedLine.d181.s0|5-15|interaction|O
DDI-MedLine.d181.s0|17-18|of|O
DDI-MedLine.d181.s0|20-32|levothyroxine|O
DDI-MedLine.d181.s0|34-37|with|O
DDI-MedLine.d181.s0|39-44|infant|O
DDI-MedLine.d181.s0|46-50|colic|O
DDI-MedLine.d181.s0|52-56|drops|O
DDI-MedLine.d181.s0|57-57|.|O
DDI-MedLine.d181.s1|0-6|Infacol|O
DDI-MedLine.d181.s1|8-8|(|O
DDI-MedLine.d181.s1|9-14|Forest|O
DDI-MedLine.d181.s1|16-27|Laboratories|O
DDI-MedLine.d181.s1|29-30|UK|O
DDI-MedLine.d181.s1|31-31|,|O
DDI-MedLine.d181.s1|33-36|Kent|O
DDI-MedLine.d181.s1|37-37|,|O
DDI-MedLine.d181.s1|39-40|UK|O
DDI-MedLine.d181.s1|41-41|)|O
DDI-MedLine.d181.s1|43-44|is|O
DDI-MedLine.d181.s1|46-46|a|O
DDI-MedLine.d181.s1|48-53|widely|O
DDI-MedLine.d181.s1|55-63|available|O
DDI-MedLine.d181.s1|65-80|over-the-counter|O
DDI-MedLine.d181.s1|82-92|preparation|O
DDI-MedLine.d181.s1|94-97|used|O
DDI-MedLine.d181.s1|99-100|to|O
DDI-MedLine.d181.s1|102-108|relieve|O
DDI-MedLine.d181.s1|110-114|colic|O
DDI-MedLine.d181.s1|116-123|symptoms|O
DDI-MedLine.d181.s1|125-126|in|O
DDI-MedLine.d181.s1|128-135|neonates|O
DDI-MedLine.d181.s1|137-139|and|O
DDI-MedLine.d181.s1|141-147|infants|O
DDI-MedLine.d181.s1|148-148|.|O
DDI-MedLine.d181.s2|0-2|The|O
DDI-MedLine.d181.s2|4-9|active|O
DDI-MedLine.d181.s2|11-20|ingredient|O
DDI-MedLine.d181.s2|22-23|is|O
DDI-MedLine.d181.s2|25-34|simeticone|O
DDI-MedLine.d181.s2|35-35|.|O
DDI-MedLine.d181.s3|0-1|No|O
DDI-MedLine.d181.s3|3-6|drug|O
DDI-MedLine.d181.s3|8-19|interactions|O
DDI-MedLine.d181.s3|21-24|with|O
DDI-MedLine.d181.s3|26-35|simeticone|O
DDI-MedLine.d181.s3|37-39|are|O
DDI-MedLine.d181.s3|41-50|documented|O
DDI-MedLine.d181.s3|52-53|in|O
DDI-MedLine.d181.s3|55-57|the|O
DDI-MedLine.d181.s3|59-65|current|O
DDI-MedLine.d181.s3|67-73|summary|O
DDI-MedLine.d181.s3|75-76|of|O
DDI-MedLine.d181.s3|78-84|product|O
DDI-MedLine.d181.s3|86-100|characteristics|O
DDI-MedLine.d181.s3|101-101|.|O
DDI-MedLine.d181.s4|0-2|The|O
DDI-MedLine.d181.s4|4-10|authors|O
DDI-MedLine.d181.s4|12-17|report|O
DDI-MedLine.d181.s4|19-21|the|O
DDI-MedLine.d181.s4|23-26|case|O
DDI-MedLine.d181.s4|28-29|of|O
DDI-MedLine.d181.s4|31-32|an|O
DDI-MedLine.d181.s4|34-39|infant|O
DDI-MedLine.d181.s4|41-44|with|O
DDI-MedLine.d181.s4|46-54|confirmed|O
DDI-MedLine.d181.s4|56-65|congenital|O
DDI-MedLine.d181.s4|67-80|hypothyroidism|O
DDI-MedLine.d181.s4|82-83|on|O
DDI-MedLine.d181.s4|85-97|levothyroxine|O
DDI-MedLine.d181.s4|99-101|who|O
DDI-MedLine.d181.s4|103-113|experienced|O
DDI-MedLine.d181.s4|115-115|a|O
DDI-MedLine.d181.s4|117-124|possible|O
DDI-MedLine.d181.s4|126-129|drug|O
DDI-MedLine.d181.s4|131-141|interaction|O
DDI-MedLine.d181.s4|143-146|with|O
DDI-MedLine.d181.s4|148-157|simeticone|O
DDI-MedLine.d181.s4|158-158|.|O
DDI-MedLine.d181.s5|0-6|Despite|O
DDI-MedLine.d181.s5|8-15|adequate|O
DDI-MedLine.d181.s5|17-29|levothyroxine|O
DDI-MedLine.d181.s5|31-36|dosage|O
DDI-MedLine.d181.s5|37-37|,|O
DDI-MedLine.d181.s5|39-45|thyroid|O
DDI-MedLine.d181.s5|47-57|stimulating|O
DDI-MedLine.d181.s5|59-65|hormone|O
DDI-MedLine.d181.s5|67-67|(|O
DDI-MedLine.d181.s5|68-70|TSH|O
DDI-MedLine.d181.s5|71-71|)|O
DDI-MedLine.d181.s5|73-75|was|O
DDI-MedLine.d181.s5|77-80|high|O
DDI-MedLine.d181.s5|81-81|,|O
DDI-MedLine.d181.s5|83-92|suggesting|O
DDI-MedLine.d181.s5|94-107|undertreatment|O
DDI-MedLine.d181.s5|108-108|.|O
DDI-MedLine.d181.s6|0-10|Questioning|O
DDI-MedLine.d181.s6|12-19|revealed|O
DDI-MedLine.d181.s6|21-23|the|O
DDI-MedLine.d181.s6|25-29|child|O
DDI-MedLine.d181.s6|31-33|was|O
DDI-MedLine.d181.s6|35-40|taking|O
DDI-MedLine.d181.s6|42-48|Infacol|O
DDI-MedLine.d181.s6|50-54|drops|O
DDI-MedLine.d181.s6|56-61|before|O
DDI-MedLine.d181.s6|63-67|feeds|O
DDI-MedLine.d181.s6|69-73|while|O
DDI-MedLine.d181.s6|75-76|on|O
DDI-MedLine.d181.s6|78-90|levothyroxine|O
DDI-MedLine.d181.s6|91-91|.|O
DDI-MedLine.d181.s7|0-2|The|O
DDI-MedLine.d181.s7|4-8|colic|O
DDI-MedLine.d181.s7|10-14|drops|O
DDI-MedLine.d181.s7|16-19|were|O
DDI-MedLine.d181.s7|21-31|immediately|O
DDI-MedLine.d181.s7|33-44|discontinued|O
DDI-MedLine.d181.s7|46-48|and|O
DDI-MedLine.d181.s7|50-52|TSH|O
DDI-MedLine.d181.s7|54-61|promptly|O
DDI-MedLine.d181.s7|63-72|normalised|O
DDI-MedLine.d181.s7|74-77|with|O
DDI-MedLine.d181.s7|79-79|a|O
DDI-MedLine.d181.s7|81-89|reduction|O
DDI-MedLine.d181.s7|91-92|in|O
DDI-MedLine.d181.s7|94-102|thyroxine|O
DDI-MedLine.d181.s7|104-114|requirement|O
DDI-MedLine.d181.s7|116-117|to|O
DDI-MedLine.d181.s7|119-120|an|O
DDI-MedLine.d181.s7|122-124|age|O
DDI-MedLine.d181.s7|126-136|appropriate|O
DDI-MedLine.d181.s7|138-143|dosage|O
DDI-MedLine.d181.s7|144-144|.|O
DDI-MedLine.d181.s8|0-3|Drug|O
DDI-MedLine.d181.s8|5-15|interaction|O
DDI-MedLine.d181.s8|17-18|of|O
DDI-MedLine.d181.s8|20-28|thyroxine|O
DDI-MedLine.d181.s8|30-33|with|O
DDI-MedLine.d181.s8|35-44|simeticone|O
DDI-MedLine.d181.s8|46-48|has|O
DDI-MedLine.d181.s8|50-52|not|O
DDI-MedLine.d181.s8|54-57|been|O
DDI-MedLine.d181.s8|59-66|reported|O
DDI-MedLine.d181.s8|68-77|previously|O
DDI-MedLine.d181.s8|79-81|and|O
DDI-MedLine.d181.s8|83-84|is|O
DDI-MedLine.d181.s8|86-88|not|O
DDI-MedLine.d181.s8|90-95|listed|O
DDI-MedLine.d181.s8|97-98|in|O
DDI-MedLine.d181.s8|100-102|the|O
DDI-MedLine.d181.s8|104-110|British|O
DDI-MedLine.d181.s8|112-119|National|O
DDI-MedLine.d181.s8|121-129|Formulary|O
DDI-MedLine.d181.s8|131-133|for|O
DDI-MedLine.d181.s8|135-142|Children|O
DDI-MedLine.d181.s8|143-143|.|O
DDI-MedLine.d181.s9|0-9|Clinicians|O
DDI-MedLine.d181.s9|11-13|and|O
DDI-MedLine.d181.s9|15-21|parents|O
DDI-MedLine.d181.s9|23-26|need|O
DDI-MedLine.d181.s9|28-29|to|O
DDI-MedLine.d181.s9|31-32|be|O
DDI-MedLine.d181.s9|34-38|aware|O
DDI-MedLine.d181.s9|40-41|of|O
DDI-MedLine.d181.s9|43-46|this|O
DDI-MedLine.d181.s9|48-58|interaction|O
DDI-MedLine.d181.s9|60-61|to|O
DDI-MedLine.d181.s9|63-67|avoid|O
DDI-MedLine.d181.s9|69-79|unnecessary|O
DDI-MedLine.d181.s9|81-94|undertreatment|O
DDI-MedLine.d181.s9|96-98|and|O
DDI-MedLine.d181.s9|100-106|prevent|O
DDI-MedLine.d181.s9|108-116|potential|O
DDI-MedLine.d181.s9|118-126|long-term|O
DDI-MedLine.d181.s9|128-139|neurological|O
DDI-MedLine.d181.s9|141-148|sequelae|O
DDI-MedLine.d181.s9|149-149|.|O
DDI-DrugBank.d464.s0|0-6|Codeine|O
DDI-DrugBank.d464.s0|8-9|in|O
DDI-DrugBank.d464.s0|11-21|combination|O
DDI-DrugBank.d464.s0|23-26|with|O
DDI-DrugBank.d464.s0|28-32|other|O
DDI-DrugBank.d464.s0|34-41|narcotic|O
DDI-DrugBank.d464.s0|43-52|analgesics|O
DDI-DrugBank.d464.s0|53-53|,|O
DDI-DrugBank.d464.s0|55-61|general|O
DDI-DrugBank.d464.s0|63-73|anesthetics|O
DDI-DrugBank.d464.s0|74-74|,|O
DDI-DrugBank.d464.s0|76-89|phenothiazines|O
DDI-DrugBank.d464.s0|90-90|,|O
DDI-DrugBank.d464.s0|92-104|tranquilizers|O
DDI-DrugBank.d464.s0|105-105|,|O
DDI-DrugBank.d464.s0|107-124|sedative-hypnotics|O
DDI-DrugBank.d464.s0|125-125|,|O
DDI-DrugBank.d464.s0|127-128|or|O
DDI-DrugBank.d464.s0|130-134|other|O
DDI-DrugBank.d464.s0|136-138|CNS|O
DDI-DrugBank.d464.s0|140-150|depressants|O
DDI-DrugBank.d464.s0|152-152|(|O
DDI-DrugBank.d464.s0|153-161|including|O
DDI-DrugBank.d464.s0|163-169|alcohol|O
DDI-DrugBank.d464.s0|170-170|)|O
DDI-DrugBank.d464.s0|172-174|has|O
DDI-DrugBank.d464.s0|176-183|additive|O
DDI-DrugBank.d464.s0|185-194|depressant|O
DDI-DrugBank.d464.s0|196-202|effects|O
DDI-DrugBank.d464.s0|203-203|.|O
DDI-DrugBank.d464.s1|0-3|When|O
DDI-DrugBank.d464.s1|5-7|s.c|O
DDI-DrugBank.d464.s1|8-8|.|O
DDI-DrugBank.d464.s2|0-10|combination|O
DDI-DrugBank.d464.s2|12-18|therapy|O
DDI-DrugBank.d464.s2|20-21|is|O
DDI-DrugBank.d464.s2|23-34|contemplated|O
DDI-DrugBank.d464.s2|35-35|,|O
DDI-DrugBank.d464.s2|37-39|the|O
DDI-DrugBank.d464.s2|41-46|dosage|O
DDI-DrugBank.d464.s2|48-49|of|O
DDI-DrugBank.d464.s2|51-53|one|O
DDI-DrugBank.d464.s2|55-56|or|O
DDI-DrugBank.d464.s2|58-61|both|O
DDI-DrugBank.d464.s2|63-68|agents|O
DDI-DrugBank.d464.s2|70-75|should|O
DDI-DrugBank.d464.s2|77-78|be|O
DDI-DrugBank.d464.s2|80-86|reduced|O
DDI-DrugBank.d464.s2|87-87|.|O
DDI-DrugBank.d223.s0|0-4|Drugs|O
DDI-DrugBank.d223.s0|6-16|Metabolized|O
DDI-DrugBank.d223.s0|18-19|by|O
DDI-DrugBank.d223.s0|21-24|P450|O
DDI-DrugBank.d223.s0|26-28|2D6|O
DDI-DrugBank.d223.s0|29-29|:|O
DDI-DrugBank.d223.s0|31-33|The|O
DDI-DrugBank.d223.s0|35-45|biochemical|O
DDI-DrugBank.d223.s0|47-54|activity|O
DDI-DrugBank.d223.s0|56-57|of|O
DDI-DrugBank.d223.s0|59-61|the|O
DDI-DrugBank.d223.s0|63-66|drug|O
DDI-DrugBank.d223.s0|68-79|metabolizing|O
DDI-DrugBank.d223.s0|81-87|isozyme|O
DDI-DrugBank.d223.s0|89-98|cytochrome|O
DDI-DrugBank.d223.s0|100-103|P450|O
DDI-DrugBank.d223.s0|105-107|2D6|O
DDI-DrugBank.d223.s0|109-109|(|O
DDI-DrugBank.d223.s0|110-120|debrisoquin|O
DDI-DrugBank.d223.s0|122-132|hydroxylase|O
DDI-DrugBank.d223.s0|133-133|)|O
DDI-DrugBank.d223.s0|135-136|is|O
DDI-DrugBank.d223.s0|138-144|reduced|O
DDI-DrugBank.d223.s0|146-147|in|O
DDI-DrugBank.d223.s0|149-149|a|O
DDI-DrugBank.d223.s0|151-156|subset|O
DDI-DrugBank.d223.s0|158-159|of|O
DDI-DrugBank.d223.s0|161-163|the|O
DDI-DrugBank.d223.s0|165-173|Caucasian|O
DDI-DrugBank.d223.s0|175-184|population|O
DDI-DrugBank.d223.s0|186-186|(|O
DDI-DrugBank.d223.s0|187-191|about|O
DDI-DrugBank.d223.s0|193-196|7-10|O
DDI-DrugBank.d223.s0|197-197|%|O
DDI-DrugBank.d223.s0|199-200|of|O
DDI-DrugBank.d223.s0|202-211|Caucasians|O
DDI-DrugBank.d223.s0|213-215|are|O
DDI-DrugBank.d223.s0|217-225|so-called|O
DDI-DrugBank.d223.s0|227-230|poor|O
DDI-DrugBank.d223.s0|232-243|metabolizers|O
DDI-DrugBank.d223.s0|244-244|)|O
DDI-DrugBank.d223.s0|245-245|;|O
DDI-DrugBank.d223.s1|0-7|reliable|O
DDI-DrugBank.d223.s1|9-17|estimates|O
DDI-DrugBank.d223.s1|19-20|of|O
DDI-DrugBank.d223.s1|22-24|the|O
DDI-DrugBank.d223.s1|26-35|prevalence|O
DDI-DrugBank.d223.s1|37-38|of|O
DDI-DrugBank.d223.s1|40-46|reduced|O
DDI-DrugBank.d223.s1|48-51|P450|O
DDI-DrugBank.d223.s1|53-55|2D6|O
DDI-DrugBank.d223.s1|57-63|isozyme|O
DDI-DrugBank.d223.s1|65-72|activity|O
DDI-DrugBank.d223.s1|74-78|among|O
DDI-DrugBank.d223.s1|80-84|Asian|O
DDI-DrugBank.d223.s1|85-85|,|O
DDI-DrugBank.d223.s1|87-93|African|O
DDI-DrugBank.d223.s1|95-97|and|O
DDI-DrugBank.d223.s1|99-103|other|O
DDI-DrugBank.d223.s1|105-115|populations|O
DDI-DrugBank.d223.s1|117-119|are|O
DDI-DrugBank.d223.s1|121-123|not|O
DDI-DrugBank.d223.s1|125-127|yet|O
DDI-DrugBank.d223.s1|129-137|available|O
DDI-DrugBank.d223.s1|138-138|.|O
DDI-DrugBank.d223.s2|0-3|Poor|O
DDI-DrugBank.d223.s2|5-16|metabolizers|O
DDI-DrugBank.d223.s2|18-21|have|O
DDI-DrugBank.d223.s2|23-28|higher|O
DDI-DrugBank.d223.s2|30-33|than|O
DDI-DrugBank.d223.s2|35-42|expected|O
DDI-DrugBank.d223.s2|44-49|plasma|O
DDI-DrugBank.d223.s2|51-64|concentrations|O
DDI-DrugBank.d223.s2|66-67|of|O
DDI-DrugBank.d223.s2|69-77|tricyclic|O
DDI-DrugBank.d223.s2|79-93|antidepressants|O
DDI-DrugBank.d223.s2|95-95|(|O
DDI-DrugBank.d223.s2|96-99|TCAs|O
DDI-DrugBank.d223.s2|100-100|)|O
DDI-DrugBank.d223.s2|102-105|when|O
DDI-DrugBank.d223.s2|107-111|given|O
DDI-DrugBank.d223.s2|113-117|usual|O
DDI-DrugBank.d223.s2|119-123|doses|O
DDI-DrugBank.d223.s2|124-124|.|O
DDI-DrugBank.d223.s3|0-8|Depending|O
DDI-DrugBank.d223.s3|10-11|on|O
DDI-DrugBank.d223.s3|13-15|the|O
DDI-DrugBank.d223.s3|17-24|fraction|O
DDI-DrugBank.d223.s3|26-27|of|O
DDI-DrugBank.d223.s3|29-32|drug|O
DDI-DrugBank.d223.s3|34-44|metabolized|O
DDI-DrugBank.d223.s3|46-47|by|O
DDI-DrugBank.d223.s3|49-52|P450|O
DDI-DrugBank.d223.s3|54-56|2D6|O
DDI-DrugBank.d223.s3|57-57|,|O
DDI-DrugBank.d223.s3|59-61|the|O
DDI-DrugBank.d223.s3|63-70|increase|O
DDI-DrugBank.d223.s3|72-73|in|O
DDI-DrugBank.d223.s3|75-80|plasma|O
DDI-DrugBank.d223.s3|82-94|concentration|O
DDI-DrugBank.d223.s3|96-98|may|O
DDI-DrugBank.d223.s3|100-101|be|O
DDI-DrugBank.d223.s3|103-107|small|O
DDI-DrugBank.d223.s3|108-108|,|O
DDI-DrugBank.d223.s3|110-111|or|O
DDI-DrugBank.d223.s3|113-117|quite|O
DDI-DrugBank.d223.s3|119-123|large|O
DDI-DrugBank.d223.s3|125-125|(|O
DDI-DrugBank.d223.s3|126-131|8-fold|O
DDI-DrugBank.d223.s3|133-140|increase|O
DDI-DrugBank.d223.s3|142-143|in|O
DDI-DrugBank.d223.s3|145-150|plasma|O
DDI-DrugBank.d223.s3|152-154|AUC|O
DDI-DrugBank.d223.s3|156-157|of|O
DDI-DrugBank.d223.s3|159-161|the|O
DDI-DrugBank.d223.s3|163-165|TCA|O
DDI-DrugBank.d223.s3|166-166|)|O
DDI-DrugBank.d223.s3|167-167|.|O
DDI-DrugBank.d223.s4|0-1|In|O
DDI-DrugBank.d223.s4|3-10|addition|O
DDI-DrugBank.d223.s4|11-11|,|O
DDI-DrugBank.d223.s4|13-19|certain|O
DDI-DrugBank.d223.s4|21-25|drugs|O
DDI-DrugBank.d223.s4|27-33|inhibit|O
DDI-DrugBank.d223.s4|35-37|the|O
DDI-DrugBank.d223.s4|39-46|activity|O
DDI-DrugBank.d223.s4|48-49|of|O
DDI-DrugBank.d223.s4|51-54|this|O
DDI-DrugBank.d223.s4|56-62|isozyme|O
DDI-DrugBank.d223.s4|64-66|and|O
DDI-DrugBank.d223.s4|68-71|make|O
DDI-DrugBank.d223.s4|73-78|normal|O
DDI-DrugBank.d223.s4|80-91|metabolizers|O
DDI-DrugBank.d223.s4|93-100|resemble|O
DDI-DrugBank.d223.s4|102-105|poor|O
DDI-DrugBank.d223.s4|107-118|metabolizers|O
DDI-DrugBank.d223.s4|119-119|.|O
DDI-DrugBank.d223.s5|0-1|An|O
DDI-DrugBank.d223.s5|3-12|individual|O
DDI-DrugBank.d223.s5|14-16|who|O
DDI-DrugBank.d223.s5|18-19|is|O
DDI-DrugBank.d223.s5|21-26|stable|O
DDI-DrugBank.d223.s5|28-29|on|O
DDI-DrugBank.d223.s5|31-31|a|O
DDI-DrugBank.d223.s5|33-37|given|O
DDI-DrugBank.d223.s5|39-42|dose|O
DDI-DrugBank.d223.s5|44-45|of|O
DDI-DrugBank.d223.s5|47-49|TCA|O
DDI-DrugBank.d223.s5|51-53|may|O
DDI-DrugBank.d223.s5|55-60|become|O
DDI-DrugBank.d223.s5|62-69|abruptly|O
DDI-DrugBank.d223.s5|71-75|toxic|O
DDI-DrugBank.d223.s5|77-80|when|O
DDI-DrugBank.d223.s5|82-86|given|O
DDI-DrugBank.d223.s5|88-90|one|O
DDI-DrugBank.d223.s5|92-93|of|O
DDI-DrugBank.d223.s5|95-99|these|O
DDI-DrugBank.d223.s5|101-110|inhibiting|O
DDI-DrugBank.d223.s5|112-116|drugs|O
DDI-DrugBank.d223.s5|118-119|as|O
DDI-DrugBank.d223.s5|121-131|concomitant|O
DDI-DrugBank.d223.s5|133-139|therapy|O
DDI-DrugBank.d223.s5|140-140|.|O
DDI-DrugBank.d223.s6|0-2|The|O
DDI-DrugBank.d223.s6|4-8|drugs|O
DDI-DrugBank.d223.s6|10-13|that|O
DDI-DrugBank.d223.s6|15-21|inhibit|O
DDI-DrugBank.d223.s6|23-32|cytochrome|O
DDI-DrugBank.d223.s6|34-37|P450|O
DDI-DrugBank.d223.s6|39-41|2D6|O
DDI-DrugBank.d223.s6|43-49|include|O
DDI-DrugBank.d223.s6|51-54|some|O
DDI-DrugBank.d223.s6|56-59|that|O
DDI-DrugBank.d223.s6|61-63|are|O
DDI-DrugBank.d223.s6|65-67|not|O
DDI-DrugBank.d223.s6|69-79|metabolized|O
DDI-DrugBank.d223.s6|81-82|by|O
DDI-DrugBank.d223.s6|84-86|the|O
DDI-DrugBank.d223.s6|88-93|enzyme|O
DDI-DrugBank.d223.s6|95-95|(|O
DDI-DrugBank.d223.s6|96-104|quinidine|O
DDI-DrugBank.d223.s6|105-105|;|O
DDI-DrugBank.d223.s7|0-9|cimetidine|O
DDI-DrugBank.d223.s7|10-10|)|O
DDI-DrugBank.d223.s7|12-14|and|O
DDI-DrugBank.d223.s7|16-19|many|O
DDI-DrugBank.d223.s7|21-24|that|O
DDI-DrugBank.d223.s7|26-28|are|O
DDI-DrugBank.d223.s7|30-39|substrates|O
DDI-DrugBank.d223.s7|41-43|for|O
DDI-DrugBank.d223.s7|45-48|P450|O
DDI-DrugBank.d223.s7|50-52|2D6|O
DDI-DrugBank.d223.s7|54-54|(|O
DDI-DrugBank.d223.s7|55-58|many|O
DDI-DrugBank.d223.s7|60-64|other|O
DDI-DrugBank.d223.s7|66-80|antidepressants|O
DDI-DrugBank.d223.s7|81-81|,|O
DDI-DrugBank.d223.s7|83-96|phenothiazines|O
DDI-DrugBank.d223.s7|97-97|,|O
DDI-DrugBank.d223.s7|99-101|and|O
DDI-DrugBank.d223.s7|103-105|the|O
DDI-DrugBank.d223.s7|107-110|Type|O
DDI-DrugBank.d223.s7|112-113|1C|O
DDI-DrugBank.d223.s7|115-129|antiarrhythmics|O
DDI-DrugBank.d223.s7|131-141|propafenone|O
DDI-DrugBank.d223.s7|143-145|and|O
DDI-DrugBank.d223.s7|147-156|flecainide|O
DDI-DrugBank.d223.s7|157-157|)|O
DDI-DrugBank.d223.s7|158-158|.|O
DDI-DrugBank.d223.s8|0-4|While|O
DDI-DrugBank.d223.s8|6-8|all|O
DDI-DrugBank.d223.s8|10-12|the|O
DDI-DrugBank.d223.s8|14-22|selective|O
DDI-DrugBank.d223.s8|24-32|serotonin|O
DDI-DrugBank.d223.s8|34-41|reuptake|O
DDI-DrugBank.d223.s8|43-52|inhibitors|O
DDI-DrugBank.d223.s8|54-54|(|O
DDI-DrugBank.d223.s8|55-59|SSRIs|O
DDI-DrugBank.d223.s8|60-60|)|O
DDI-DrugBank.d223.s8|61-61|,|O
DDI-DrugBank.d223.s8|63-66|e.g.|O
DDI-DrugBank.d223.s8|67-67|,|O
DDI-DrugBank.d223.s8|69-78|citalopram|O
DDI-DrugBank.d223.s8|79-79|,|O
DDI-DrugBank.d223.s8|81-92|escitalopram|O
DDI-DrugBank.d223.s8|93-93|,|O
DDI-DrugBank.d223.s8|95-104|fluoxetine|O
DDI-DrugBank.d223.s8|105-105|,|O
DDI-DrugBank.d223.s8|107-116|sertraline|O
DDI-DrugBank.d223.s8|117-117|,|O
DDI-DrugBank.d223.s8|119-121|and|O
DDI-DrugBank.d223.s8|123-132|paroxetine|O
DDI-DrugBank.d223.s8|133-133|,|O
DDI-DrugBank.d223.s8|135-141|inhibit|O
DDI-DrugBank.d223.s8|143-146|P450|O
DDI-DrugBank.d223.s8|148-150|2D6|O
DDI-DrugBank.d223.s8|151-151|,|O
DDI-DrugBank.d223.s8|153-156|they|O
DDI-DrugBank.d223.s8|158-160|may|O
DDI-DrugBank.d223.s8|162-165|vary|O
DDI-DrugBank.d223.s8|167-168|in|O
DDI-DrugBank.d223.s8|170-172|the|O
DDI-DrugBank.d223.s8|174-179|extent|O
DDI-DrugBank.d223.s8|181-182|of|O
DDI-DrugBank.d223.s8|184-193|inhibition|O
DDI-DrugBank.d223.s8|194-194|.|O
DDI-DrugBank.d223.s9|0-2|The|O
DDI-DrugBank.d223.s9|4-9|extent|O
DDI-DrugBank.d223.s9|11-12|to|O
DDI-DrugBank.d223.s9|14-18|which|O
DDI-DrugBank.d223.s9|20-27|SSRI-TCA|O
DDI-DrugBank.d223.s9|29-40|interactions|O
DDI-DrugBank.d223.s9|42-44|may|O
DDI-DrugBank.d223.s9|46-49|pose|O
DDI-DrugBank.d223.s9|51-58|clinical|O
DDI-DrugBank.d223.s9|60-67|problems|O
DDI-DrugBank.d223.s9|69-72|will|O
DDI-DrugBank.d223.s9|74-79|depend|O
DDI-DrugBank.d223.s9|81-82|on|O
DDI-DrugBank.d223.s9|84-86|the|O
DDI-DrugBank.d223.s9|88-93|degree|O
DDI-DrugBank.d223.s9|95-96|of|O
DDI-DrugBank.d223.s9|98-107|inhibition|O
DDI-DrugBank.d223.s9|109-111|and|O
DDI-DrugBank.d223.s9|113-115|the|O
DDI-DrugBank.d223.s9|117-132|pharmacokinetics|O
DDI-DrugBank.d223.s9|134-135|of|O
DDI-DrugBank.d223.s9|137-139|the|O
DDI-DrugBank.d223.s9|141-144|SSRI|O
DDI-DrugBank.d223.s9|146-153|involved|O
DDI-DrugBank.d223.s9|154-154|.|O
DDI-DrugBank.d223.s10|0-11|Nevertheless|O
DDI-DrugBank.d223.s10|12-12|,|O
DDI-DrugBank.d223.s10|14-20|caution|O
DDI-DrugBank.d223.s10|22-23|is|O
DDI-DrugBank.d223.s10|25-33|indicated|O
DDI-DrugBank.d223.s10|35-36|in|O
DDI-DrugBank.d223.s10|38-40|the|O
DDI-DrugBank.d223.s10|42-58|co-administration|O
DDI-DrugBank.d223.s10|60-61|of|O
DDI-DrugBank.d223.s10|63-66|TCAs|O
DDI-DrugBank.d223.s10|68-71|with|O
DDI-DrugBank.d223.s10|73-75|any|O
DDI-DrugBank.d223.s10|77-78|of|O
DDI-DrugBank.d223.s10|80-82|the|O
DDI-DrugBank.d223.s10|84-88|SSRIs|O
DDI-DrugBank.d223.s10|90-92|and|O
DDI-DrugBank.d223.s10|94-97|also|O
DDI-DrugBank.d223.s10|99-100|in|O
DDI-DrugBank.d223.s10|102-110|switching|O
DDI-DrugBank.d223.s10|112-115|from|O
DDI-DrugBank.d223.s10|117-119|one|O
DDI-DrugBank.d223.s10|121-125|class|O
DDI-DrugBank.d223.s10|127-128|to|O
DDI-DrugBank.d223.s10|130-132|the|O
DDI-DrugBank.d223.s10|134-138|other|O
DDI-DrugBank.d223.s10|139-139|.|O
DDI-DrugBank.d223.s11|0-1|Of|O
DDI-DrugBank.d223.s11|3-12|particular|O
DDI-DrugBank.d223.s11|14-23|importance|O
DDI-DrugBank.d223.s11|24-24|,|O
DDI-DrugBank.d223.s11|26-35|sufficient|O
DDI-DrugBank.d223.s11|37-40|time|O
DDI-DrugBank.d223.s11|42-45|must|O
DDI-DrugBank.d223.s11|47-52|elapse|O
DDI-DrugBank.d223.s11|54-59|before|O
DDI-DrugBank.d223.s11|61-70|initiating|O
DDI-DrugBank.d223.s11|72-74|TCA|O
DDI-DrugBank.d223.s11|76-84|treatment|O
DDI-DrugBank.d223.s11|86-87|in|O
DDI-DrugBank.d223.s11|89-89|a|O
DDI-DrugBank.d223.s11|91-97|patient|O
DDI-DrugBank.d223.s11|99-103|being|O
DDI-DrugBank.d223.s11|105-113|withdrawn|O
DDI-DrugBank.d223.s11|115-118|from|O
DDI-DrugBank.d223.s11|120-129|fluoxetine|O
DDI-DrugBank.d223.s11|130-130|,|O
DDI-DrugBank.d223.s11|132-136|given|O
DDI-DrugBank.d223.s11|138-140|the|O
DDI-DrugBank.d223.s11|142-145|long|O
DDI-DrugBank.d223.s11|147-155|half-life|O
DDI-DrugBank.d223.s11|157-158|of|O
DDI-DrugBank.d223.s11|160-162|the|O
DDI-DrugBank.d223.s11|164-169|parent|O
DDI-DrugBank.d223.s11|171-173|and|O
DDI-DrugBank.d223.s11|175-180|active|O
DDI-DrugBank.d223.s11|182-191|metabolite|O
DDI-DrugBank.d223.s11|193-193|(|O
DDI-DrugBank.d223.s11|194-195|at|O
DDI-DrugBank.d223.s11|197-201|least|O
DDI-DrugBank.d223.s11|203-203|5|O
DDI-DrugBank.d223.s11|205-209|weeks|O
DDI-DrugBank.d223.s11|211-213|may|O
DDI-DrugBank.d223.s11|215-216|be|O
DDI-DrugBank.d223.s11|218-226|necessary|O
DDI-DrugBank.d223.s11|227-227|)|O
DDI-DrugBank.d223.s11|228-228|.|O
DDI-DrugBank.d223.s12|0-10|Concomitant|O
DDI-DrugBank.d223.s12|12-14|use|O
DDI-DrugBank.d223.s12|16-17|of|O
DDI-DrugBank.d223.s12|19-27|tricyclic|O
DDI-DrugBank.d223.s12|29-43|antidepressants|O
DDI-DrugBank.d223.s12|45-48|with|O
DDI-DrugBank.d223.s12|50-54|drugs|O
DDI-DrugBank.d223.s12|56-59|that|O
DDI-DrugBank.d223.s12|61-63|can|O
DDI-DrugBank.d223.s12|65-71|inhibit|O
DDI-DrugBank.d223.s12|73-82|cytochrome|O
DDI-DrugBank.d223.s12|84-87|P450|O
DDI-DrugBank.d223.s12|89-91|2D6|O
DDI-DrugBank.d223.s12|93-95|may|O
DDI-DrugBank.d223.s12|97-103|require|O
DDI-DrugBank.d223.s12|105-109|lower|O
DDI-DrugBank.d223.s12|111-115|doses|O
DDI-DrugBank.d223.s12|117-120|than|O
DDI-DrugBank.d223.s12|122-128|usually|O
DDI-DrugBank.d223.s12|130-139|prescribed|O
DDI-DrugBank.d223.s12|141-143|for|O
DDI-DrugBank.d223.s12|145-150|either|O
DDI-DrugBank.d223.s12|152-154|the|O
DDI-DrugBank.d223.s12|156-164|tricyclic|O
DDI-DrugBank.d223.s12|166-179|antidepressant|O
DDI-DrugBank.d223.s12|181-182|or|O
DDI-DrugBank.d223.s12|184-186|the|O
DDI-DrugBank.d223.s12|188-192|other|O
DDI-DrugBank.d223.s12|194-197|drug|O
DDI-DrugBank.d223.s12|198-198|.|O
DDI-DrugBank.d223.s13|0-10|Furthermore|O
DDI-DrugBank.d223.s13|11-11|,|O
DDI-DrugBank.d223.s13|13-20|whenever|O
DDI-DrugBank.d223.s13|22-24|one|O
DDI-DrugBank.d223.s13|26-27|of|O
DDI-DrugBank.d223.s13|29-33|these|O
DDI-DrugBank.d223.s13|35-39|other|O
DDI-DrugBank.d223.s13|41-45|drugs|O
DDI-DrugBank.d223.s13|47-48|is|O
DDI-DrugBank.d223.s13|50-58|withdrawn|O
DDI-DrugBank.d223.s13|60-63|from|O
DDI-DrugBank.d223.s13|65-74|co-therapy|O
DDI-DrugBank.d223.s13|75-75|,|O
DDI-DrugBank.d223.s13|77-78|an|O
DDI-DrugBank.d223.s13|80-88|increased|O
DDI-DrugBank.d223.s13|90-93|dose|O
DDI-DrugBank.d223.s13|95-96|of|O
DDI-DrugBank.d223.s13|98-106|tricyclic|O
DDI-DrugBank.d223.s13|108-121|antidepressant|O
DDI-DrugBank.d223.s13|123-125|may|O
DDI-DrugBank.d223.s13|127-128|be|O
DDI-DrugBank.d223.s13|130-137|required|O
DDI-DrugBank.d223.s13|138-138|.|O
DDI-DrugBank.d223.s14|0-1|It|O
DDI-DrugBank.d223.s14|3-4|is|O
DDI-DrugBank.d223.s14|6-14|desirable|O
DDI-DrugBank.d223.s14|16-17|to|O
DDI-DrugBank.d223.s14|19-25|monitor|O
DDI-DrugBank.d223.s14|27-29|TCA|O
DDI-DrugBank.d223.s14|31-36|plasma|O
DDI-DrugBank.d223.s14|38-43|levels|O
DDI-DrugBank.d223.s14|45-52|whenever|O
DDI-DrugBank.d223.s14|54-54|a|O
DDI-DrugBank.d223.s14|56-58|TCA|O
DDI-DrugBank.d223.s14|60-61|is|O
DDI-DrugBank.d223.s14|63-67|going|O
DDI-DrugBank.d223.s14|69-70|to|O
DDI-DrugBank.d223.s14|72-73|be|O
DDI-DrugBank.d223.s14|75-89|co-administered|O
DDI-DrugBank.d223.s14|91-94|with|O
DDI-DrugBank.d223.s14|96-102|another|O
DDI-DrugBank.d223.s14|104-107|drug|O
DDI-DrugBank.d223.s14|109-113|known|O
DDI-DrugBank.d223.s14|115-116|to|O
DDI-DrugBank.d223.s14|118-119|be|O
DDI-DrugBank.d223.s14|121-122|an|O
DDI-DrugBank.d223.s14|124-132|inhibitor|O
DDI-DrugBank.d223.s14|134-135|of|O
DDI-DrugBank.d223.s14|137-140|P450|O
DDI-DrugBank.d223.s14|142-144|2D6|O
DDI-DrugBank.d223.s14|145-145|.|O
DDI-DrugBank.d223.s15|0-6|Doxepin|O
DDI-DrugBank.d223.s15|8-9|is|O
DDI-DrugBank.d223.s15|11-19|primarily|O
DDI-DrugBank.d223.s15|21-31|metabolized|O
DDI-DrugBank.d223.s15|33-34|by|O
DDI-DrugBank.d223.s15|36-41|CYP2D6|O
DDI-DrugBank.d223.s15|43-43|(|O
DDI-DrugBank.d223.s15|44-47|with|O
DDI-DrugBank.d223.s15|49-54|CYP1A2|O
DDI-DrugBank.d223.s15|57-59|and|O
DDI-DrugBank.d223.s15|62-67|CYP3A4|O
DDI-DrugBank.d223.s15|69-70|as|O
DDI-DrugBank.d223.s15|72-76|minor|O
DDI-DrugBank.d223.s15|78-85|pathways|O
DDI-DrugBank.d223.s15|86-86|)|O
DDI-DrugBank.d223.s15|87-87|.|O
DDI-DrugBank.d223.s16|0-9|Inhibitors|O
DDI-DrugBank.d223.s16|11-12|or|O
DDI-DrugBank.d223.s16|14-23|substrates|O
DDI-DrugBank.d223.s16|25-26|of|O
DDI-DrugBank.d223.s16|28-33|CYP2D6|O
DDI-DrugBank.d223.s16|35-35|(|O
DDI-DrugBank.d223.s16|36-39|i.e.|O
DDI-DrugBank.d223.s16|40-40|,|O
DDI-DrugBank.d223.s16|42-50|quinidine|O
DDI-DrugBank.d223.s16|51-51|,|O
DDI-DrugBank.d223.s16|53-61|selective|O
DDI-DrugBank.d223.s16|63-71|serotonin|O
DDI-DrugBank.d223.s16|73-80|reuptake|O
DDI-DrugBank.d223.s16|82-91|inhibitors|O
DDI-DrugBank.d223.s16|93-93|[|O
DDI-DrugBank.d223.s16|94-98|SSRIs|O
DDI-DrugBank.d223.s16|99-99|]|O
DDI-DrugBank.d223.s16|100-100|)|O
DDI-DrugBank.d223.s16|102-104|may|O
DDI-DrugBank.d223.s16|106-113|increase|O
DDI-DrugBank.d223.s16|115-117|the|O
DDI-DrugBank.d223.s16|119-124|plasma|O
DDI-DrugBank.d223.s16|126-138|concentration|O
DDI-DrugBank.d223.s16|140-141|of|O
DDI-DrugBank.d223.s16|143-149|doxepin|O
DDI-DrugBank.d223.s16|151-154|when|O
DDI-DrugBank.d223.s16|156-167|administered|O
DDI-DrugBank.d223.s16|169-181|concomitantly|O
DDI-DrugBank.d223.s16|182-182|.|O
DDI-DrugBank.d223.s17|0-2|The|O
DDI-DrugBank.d223.s17|4-9|extent|O
DDI-DrugBank.d223.s17|11-12|of|O
DDI-DrugBank.d223.s17|14-24|interaction|O
DDI-DrugBank.d223.s17|26-32|depends|O
DDI-DrugBank.d223.s17|34-35|on|O
DDI-DrugBank.d223.s17|37-39|the|O
DDI-DrugBank.d223.s17|41-51|variability|O
DDI-DrugBank.d223.s17|53-54|of|O
DDI-DrugBank.d223.s17|56-61|effect|O
DDI-DrugBank.d223.s17|63-64|on|O
DDI-DrugBank.d223.s17|66-71|CYP2D6|O
DDI-DrugBank.d223.s17|72-72|.|O
DDI-DrugBank.d223.s18|0-2|The|O
DDI-DrugBank.d223.s18|4-11|clinical|O
DDI-DrugBank.d223.s18|13-24|significance|O
DDI-DrugBank.d223.s18|26-27|of|O
DDI-DrugBank.d223.s18|29-32|this|O
DDI-DrugBank.d223.s18|34-44|interaction|O
DDI-DrugBank.d223.s18|46-49|with|O
DDI-DrugBank.d223.s18|51-57|doxepin|O
DDI-DrugBank.d223.s18|59-61|has|O
DDI-DrugBank.d223.s18|63-65|not|O
DDI-DrugBank.d223.s18|67-70|been|O
DDI-DrugBank.d223.s18|72-85|systematically|O
DDI-DrugBank.d223.s18|87-95|evaluated|O
DDI-DrugBank.d223.s18|96-96|.|O
DDI-DrugBank.d223.s19|0-2|MAO|O
DDI-DrugBank.d223.s19|4-13|Inhibitors|O
DDI-DrugBank.d223.s19|14-14|:|O
DDI-DrugBank.d223.s19|16-22|Serious|O
DDI-DrugBank.d223.s19|24-27|side|O
DDI-DrugBank.d223.s19|29-35|effects|O
DDI-DrugBank.d223.s19|37-39|and|O
DDI-DrugBank.d223.s19|41-44|even|O
DDI-DrugBank.d223.s19|46-50|death|O
DDI-DrugBank.d223.s19|52-55|have|O
DDI-DrugBank.d223.s19|57-60|been|O
DDI-DrugBank.d223.s19|62-69|reported|O
DDI-DrugBank.d223.s19|71-79|following|O
DDI-DrugBank.d223.s19|81-83|the|O
DDI-DrugBank.d223.s19|85-95|concomitant|O
DDI-DrugBank.d223.s19|97-99|use|O
DDI-DrugBank.d223.s19|101-102|of|O
DDI-DrugBank.d223.s19|104-110|certain|O
DDI-DrugBank.d223.s19|112-116|drugs|O
DDI-DrugBank.d223.s19|118-121|with|O
DDI-DrugBank.d223.s19|123-125|MAO|O
DDI-DrugBank.d223.s19|127-136|inhibitors|O
DDI-DrugBank.d223.s19|137-137|.|O
DDI-DrugBank.d223.s20|0-8|Therefore|O
DDI-DrugBank.d223.s20|9-9|,|O
DDI-DrugBank.d223.s20|11-13|MAO|O
DDI-DrugBank.d223.s20|15-24|inhibitors|O
DDI-DrugBank.d223.s20|26-31|should|O
DDI-DrugBank.d223.s20|33-34|be|O
DDI-DrugBank.d223.s20|36-47|discontinued|O
DDI-DrugBank.d223.s20|49-50|at|O
DDI-DrugBank.d223.s20|52-56|least|O
DDI-DrugBank.d223.s20|58-60|two|O
DDI-DrugBank.d223.s20|62-66|weeks|O
DDI-DrugBank.d223.s20|68-72|prior|O
DDI-DrugBank.d223.s20|74-75|to|O
DDI-DrugBank.d223.s20|77-79|the|O
DDI-DrugBank.d223.s20|81-88|cautious|O
DDI-DrugBank.d223.s20|90-99|initiation|O
DDI-DrugBank.d223.s20|101-102|of|O
DDI-DrugBank.d223.s20|104-110|therapy|O
DDI-DrugBank.d223.s20|112-115|with|O
DDI-DrugBank.d223.s20|117-124|SINEQUAN|O
DDI-DrugBank.d223.s20|125-125|.|O
DDI-DrugBank.d223.s21|0-2|The|O
DDI-DrugBank.d223.s21|4-8|exact|O
DDI-DrugBank.d223.s21|10-15|length|O
DDI-DrugBank.d223.s21|17-18|of|O
DDI-DrugBank.d223.s21|20-23|time|O
DDI-DrugBank.d223.s21|25-27|may|O
DDI-DrugBank.d223.s21|29-32|vary|O
DDI-DrugBank.d223.s21|34-36|and|O
DDI-DrugBank.d223.s21|38-39|is|O
DDI-DrugBank.d223.s21|41-49|dependent|O
DDI-DrugBank.d223.s21|51-54|upon|O
DDI-DrugBank.d223.s21|56-58|the|O
DDI-DrugBank.d223.s21|60-69|particular|O
DDI-DrugBank.d223.s21|71-73|MAO|O
DDI-DrugBank.d223.s21|75-83|inhibitor|O
DDI-DrugBank.d223.s21|85-89|being|O
DDI-DrugBank.d223.s21|91-94|used|O
DDI-DrugBank.d223.s21|95-95|,|O
DDI-DrugBank.d223.s21|97-99|the|O
DDI-DrugBank.d223.s21|101-106|length|O
DDI-DrugBank.d223.s21|108-109|of|O
DDI-DrugBank.d223.s21|111-114|time|O
DDI-DrugBank.d223.s21|116-117|it|O
DDI-DrugBank.d223.s21|119-121|has|O
DDI-DrugBank.d223.s21|123-126|been|O
DDI-DrugBank.d223.s21|128-139|administered|O
DDI-DrugBank.d223.s21|140-140|,|O
DDI-DrugBank.d223.s21|142-144|and|O
DDI-DrugBank.d223.s21|146-148|the|O
DDI-DrugBank.d223.s21|150-155|dosage|O
DDI-DrugBank.d223.s21|157-164|involved|O
DDI-DrugBank.d223.s21|165-165|.|O
DDI-DrugBank.d223.s22|0-9|Cimetidine|O
DDI-DrugBank.d223.s22|10-10|:|O
DDI-DrugBank.d223.s22|12-21|Cimetidine|O
DDI-DrugBank.d223.s22|23-25|has|O
DDI-DrugBank.d223.s22|27-30|been|O
DDI-DrugBank.d223.s22|32-39|reported|O
DDI-DrugBank.d223.s22|41-42|to|O
DDI-DrugBank.d223.s22|44-50|produce|O
DDI-DrugBank.d223.s22|52-61|clinically|O
DDI-DrugBank.d223.s22|63-73|significant|O
DDI-DrugBank.d223.s22|75-86|fluctuations|O
DDI-DrugBank.d223.s22|88-89|in|O
DDI-DrugBank.d223.s22|91-102|steady-state|O
DDI-DrugBank.d223.s22|104-108|serum|O
DDI-DrugBank.d223.s22|110-123|concentrations|O
DDI-DrugBank.d223.s22|125-126|of|O
DDI-DrugBank.d223.s22|128-134|various|O
DDI-DrugBank.d223.s22|136-144|tricyclic|O
DDI-DrugBank.d223.s22|146-160|antidepressants|O
DDI-DrugBank.d223.s22|161-161|.|O
DDI-DrugBank.d223.s23|0-6|Serious|O
DDI-DrugBank.d223.s23|8-22|anticholinergic|O
DDI-DrugBank.d223.s23|24-31|symptoms|O
DDI-DrugBank.d223.s23|33-33|(|O
DDI-DrugBank.d223.s23|34-37|i.e.|O
DDI-DrugBank.d223.s23|38-38|,|O
DDI-DrugBank.d223.s23|40-45|severe|O
DDI-DrugBank.d223.s23|47-49|dry|O
DDI-DrugBank.d223.s23|51-55|mouth|O
DDI-DrugBank.d223.s23|56-56|,|O
DDI-DrugBank.d223.s23|58-64|urinary|O
DDI-DrugBank.d223.s23|66-74|retention|O
DDI-DrugBank.d223.s23|76-78|and|O
DDI-DrugBank.d223.s23|80-86|blurred|O
DDI-DrugBank.d223.s23|88-93|vision|O
DDI-DrugBank.d223.s23|94-94|)|O
DDI-DrugBank.d223.s23|96-99|have|O
DDI-DrugBank.d223.s23|101-104|been|O
DDI-DrugBank.d223.s23|106-115|associated|O
DDI-DrugBank.d223.s23|117-120|with|O
DDI-DrugBank.d223.s23|122-131|elevations|O
DDI-DrugBank.d223.s23|133-134|in|O
DDI-DrugBank.d223.s23|136-138|the|O
DDI-DrugBank.d223.s23|140-144|serum|O
DDI-DrugBank.d223.s23|146-151|levels|O
DDI-DrugBank.d223.s23|153-154|of|O
DDI-DrugBank.d223.s23|156-164|tricyclic|O
DDI-DrugBank.d223.s23|166-179|antidepressant|O
DDI-DrugBank.d223.s23|181-184|when|O
DDI-DrugBank.d223.s23|186-195|cimetidine|O
DDI-DrugBank.d223.s23|197-203|therapy|O
DDI-DrugBank.d223.s23|205-206|is|O
DDI-DrugBank.d223.s23|208-216|initiated|O
DDI-DrugBank.d223.s23|217-217|.|O
DDI-DrugBank.d223.s24|0-11|Additionally|O
DDI-DrugBank.d223.s24|12-12|,|O
DDI-DrugBank.d223.s24|14-19|higher|O
DDI-DrugBank.d223.s24|21-24|than|O
DDI-DrugBank.d223.s24|26-33|expected|O
DDI-DrugBank.d223.s24|35-43|tricyclic|O
DDI-DrugBank.d223.s24|45-58|antidepressant|O
DDI-DrugBank.d223.s24|60-65|levels|O
DDI-DrugBank.d223.s24|67-70|have|O
DDI-DrugBank.d223.s24|72-75|been|O
DDI-DrugBank.d223.s24|77-84|observed|O
DDI-DrugBank.d223.s24|86-89|when|O
DDI-DrugBank.d223.s24|91-94|they|O
DDI-DrugBank.d223.s24|96-98|are|O
DDI-DrugBank.d223.s24|100-104|begun|O
DDI-DrugBank.d223.s24|106-107|in|O
DDI-DrugBank.d223.s24|109-116|patients|O
DDI-DrugBank.d223.s24|118-124|already|O
DDI-DrugBank.d223.s24|126-131|taking|O
DDI-DrugBank.d223.s24|133-142|cimetidine|O
DDI-DrugBank.d223.s24|143-143|.|O
DDI-DrugBank.d223.s25|0-1|In|O
DDI-DrugBank.d223.s25|3-10|patients|O
DDI-DrugBank.d223.s25|12-14|who|O
DDI-DrugBank.d223.s25|16-19|have|O
DDI-DrugBank.d223.s25|21-24|been|O
DDI-DrugBank.d223.s25|26-33|reported|O
DDI-DrugBank.d223.s25|35-36|to|O
DDI-DrugBank.d223.s25|38-39|be|O
DDI-DrugBank.d223.s25|41-44|well|O
DDI-DrugBank.d223.s25|46-55|controlled|O
DDI-DrugBank.d223.s25|57-58|on|O
DDI-DrugBank.d223.s25|60-68|tricyclic|O
DDI-DrugBank.d223.s25|70-84|antidepressants|O
DDI-DrugBank.d223.s25|86-94|receiving|O
DDI-DrugBank.d223.s25|96-105|concurrent|O
DDI-DrugBank.d223.s25|107-116|cimetidine|O
DDI-DrugBank.d223.s25|118-124|therapy|O
DDI-DrugBank.d223.s25|125-125|,|O
DDI-DrugBank.d223.s25|127-141|discontinuation|O
DDI-DrugBank.d223.s25|143-144|of|O
DDI-DrugBank.d223.s25|146-155|cimetidine|O
DDI-DrugBank.d223.s25|157-159|has|O
DDI-DrugBank.d223.s25|161-164|been|O
DDI-DrugBank.d223.s25|166-173|reported|O
DDI-DrugBank.d223.s25|175-176|to|O
DDI-DrugBank.d223.s25|178-185|decrease|O
DDI-DrugBank.d223.s25|187-197|established|O
DDI-DrugBank.d223.s25|199-210|steady-state|O
DDI-DrugBank.d223.s25|212-216|serum|O
DDI-DrugBank.d223.s25|218-226|tricyclic|O
DDI-DrugBank.d223.s25|228-241|antidepressant|O
DDI-DrugBank.d223.s25|243-248|levels|O
DDI-DrugBank.d223.s25|250-252|and|O
DDI-DrugBank.d223.s25|254-263|compromise|O
DDI-DrugBank.d223.s25|265-269|their|O
DDI-DrugBank.d223.s25|271-281|therapeutic|O
DDI-DrugBank.d223.s25|283-289|effects|O
DDI-DrugBank.d223.s25|290-290|.|O
DDI-DrugBank.d223.s26|0-6|Alcohol|O
DDI-DrugBank.d223.s26|7-7|:|O
DDI-DrugBank.d223.s26|9-10|It|O
DDI-DrugBank.d223.s26|12-17|should|O
DDI-DrugBank.d223.s26|19-20|be|O
DDI-DrugBank.d223.s26|22-26|borne|O
DDI-DrugBank.d223.s26|28-29|in|O
DDI-DrugBank.d223.s26|31-34|mind|O
DDI-DrugBank.d223.s26|36-39|that|O
DDI-DrugBank.d223.s26|41-47|alcohol|O
DDI-DrugBank.d223.s26|49-57|ingestion|O
DDI-DrugBank.d223.s26|59-61|may|O
DDI-DrugBank.d223.s26|63-70|increase|O
DDI-DrugBank.d223.s26|72-74|the|O
DDI-DrugBank.d223.s26|76-81|danger|O
DDI-DrugBank.d223.s26|83-90|inherent|O
DDI-DrugBank.d223.s26|92-93|in|O
DDI-DrugBank.d223.s26|95-97|any|O
DDI-DrugBank.d223.s26|99-109|intentional|O
DDI-DrugBank.d223.s26|111-112|or|O
DDI-DrugBank.d223.s26|114-126|unintentional|O
DDI-DrugBank.d223.s26|128-135|SINEQUAN|O
DDI-DrugBank.d223.s26|137-146|overdosage|O
DDI-DrugBank.d223.s26|147-147|.|O
DDI-DrugBank.d223.s27|0-3|This|O
DDI-DrugBank.d223.s27|5-6|is|O
DDI-DrugBank.d223.s27|8-17|especially|O
DDI-DrugBank.d223.s27|19-27|important|O
DDI-DrugBank.d223.s27|29-30|in|O
DDI-DrugBank.d223.s27|32-39|patients|O
DDI-DrugBank.d223.s27|41-43|who|O
DDI-DrugBank.d223.s27|45-47|may|O
DDI-DrugBank.d223.s27|49-51|use|O
DDI-DrugBank.d223.s27|53-59|alcohol|O
DDI-DrugBank.d223.s27|61-71|excessively|O
DDI-DrugBank.d223.s27|72-72|.|O
DDI-DrugBank.d223.s28|0-9|Tolazamide|O
DDI-DrugBank.d223.s28|10-10|:|O
DDI-DrugBank.d223.s28|12-12|A|O
DDI-DrugBank.d223.s28|14-17|case|O
DDI-DrugBank.d223.s28|19-20|of|O
DDI-DrugBank.d223.s28|22-27|severe|O
DDI-DrugBank.d223.s28|29-40|hypoglycemia|O
DDI-DrugBank.d223.s28|42-44|has|O
DDI-DrugBank.d223.s28|46-49|been|O
DDI-DrugBank.d223.s28|51-58|reported|O
DDI-DrugBank.d223.s28|60-61|in|O
DDI-DrugBank.d223.s28|63-63|a|O
DDI-DrugBank.d223.s28|65-68|type|O
DDI-DrugBank.d223.s28|70-71|II|O
DDI-DrugBank.d223.s28|73-80|diabetic|O
DDI-DrugBank.d223.s28|82-88|patient|O
DDI-DrugBank.d223.s28|90-99|maintained|O
DDI-DrugBank.d223.s28|101-102|on|O
DDI-DrugBank.d223.s28|104-113|tolazamide|O
DDI-DrugBank.d223.s28|115-115|(|O
DDI-DrugBank.d223.s28|116-116|1|O
DDI-DrugBank.d223.s28|118-123|gm/day|O
DDI-DrugBank.d223.s28|124-124|)|O
DDI-DrugBank.d223.s28|126-127|11|O
DDI-DrugBank.d223.s28|129-132|days|O
DDI-DrugBank.d223.s28|134-138|after|O
DDI-DrugBank.d223.s28|140-142|the|O
DDI-DrugBank.d223.s28|144-151|addition|O
DDI-DrugBank.d223.s28|153-154|of|O
DDI-DrugBank.d223.s28|156-162|doxepin|O
DDI-DrugBank.d223.s28|164-164|(|O
DDI-DrugBank.d223.s28|165-166|75|O
DDI-DrugBank.d223.s28|168-173|mg/day|O
DDI-DrugBank.d223.s28|174-174|)|O
DDI-DrugBank.d223.s28|175-175|.|O
DDI-DrugBank.d253.s0|0-14|Beta-adrenergic|O
DDI-DrugBank.d253.s0|16-23|blocking|O
DDI-DrugBank.d253.s0|25-30|agents|O
DDI-DrugBank.d253.s0|31-31|:|O
DDI-DrugBank.d253.s0|33-42|concurrent|O
DDI-DrugBank.d253.s0|44-46|use|O
DDI-DrugBank.d253.s0|48-50|may|O
DDI-DrugBank.d253.s0|52-56|blunt|O
DDI-DrugBank.d253.s0|58-60|the|O
DDI-DrugBank.d253.s0|62-69|response|O
DDI-DrugBank.d253.s0|71-72|to|O
DDI-DrugBank.d253.s0|74-83|arbutamine|O
DDI-DrugBank.d253.s0|84-84|.|O
DDI-DrugBank.d253.s1|0-14|Beta-adrenergic|O
DDI-DrugBank.d253.s1|16-23|blocking|O
DDI-DrugBank.d253.s1|25-30|agents|O
DDI-DrugBank.d253.s1|32-37|should|O
DDI-DrugBank.d253.s1|39-40|be|O
DDI-DrugBank.d253.s1|42-50|withdrawn|O
DDI-DrugBank.d253.s1|52-53|at|O
DDI-DrugBank.d253.s1|55-59|least|O
DDI-DrugBank.d253.s1|61-62|48|O
DDI-DrugBank.d253.s1|64-68|hours|O
DDI-DrugBank.d253.s1|70-75|before|O
DDI-DrugBank.d253.s1|77-86|conducting|O
DDI-DrugBank.d253.s1|88-89|an|O
DDI-DrugBank.d253.s1|91-109|arbutamine-mediated|O
DDI-DrugBank.d253.s1|111-116|stress|O
DDI-DrugBank.d253.s1|118-121|test|O
DDI-DrugBank.d253.s1|122-122|.|O
DDI-DrugBank.d253.s2|0-13|Antiarrhythmic|O
DDI-DrugBank.d253.s2|15-20|agents|O
DDI-DrugBank.d253.s2|21-21|,|O
DDI-DrugBank.d253.s2|23-27|class|O
DDI-DrugBank.d253.s2|29-29|I|O
DDI-DrugBank.d253.s2|31-31|(|O
DDI-DrugBank.d253.s2|32-35|such|O
DDI-DrugBank.d253.s2|37-38|as|O
DDI-DrugBank.d253.s2|40-49|flecainide|O
DDI-DrugBank.d253.s2|50-50|,|O
DDI-DrugBank.d253.s2|52-60|lidocaine|O
DDI-DrugBank.d253.s2|61-61|,|O
DDI-DrugBank.d253.s2|63-64|or|O
DDI-DrugBank.d253.s2|66-74|quinidine|O
DDI-DrugBank.d253.s2|75-75|)|O
DDI-DrugBank.d253.s2|76-76|:|O
DDI-DrugBank.d253.s2|78-87|concurrent|O
DDI-DrugBank.d253.s2|89-91|use|O
DDI-DrugBank.d253.s2|93-96|with|O
DDI-DrugBank.d253.s2|98-107|arbutamine|O
DDI-DrugBank.d253.s2|109-111|may|O
DDI-DrugBank.d253.s2|113-116|have|O
DDI-DrugBank.d253.s2|118-118|a|O
DDI-DrugBank.d253.s2|120-132|proarrhythmic|O
DDI-DrugBank.d253.s2|134-139|effect|O
DDI-DrugBank.d253.s2|140-140|.|O
DDI-DrugBank.d253.s3|0-14|Antidepressants|O
DDI-DrugBank.d253.s3|16-16|(|O
DDI-DrugBank.d253.s3|17-25|tricyclic|O
DDI-DrugBank.d253.s3|26-26|)|O
DDI-DrugBank.d253.s3|27-27|,|O
DDI-DrugBank.d253.s3|29-36|atropine|O
DDI-DrugBank.d253.s3|38-39|or|O
DDI-DrugBank.d253.s3|41-45|other|O
DDI-DrugBank.d253.s3|47-61|anticholinergic|O
DDI-DrugBank.d253.s3|63-68|agents|O
DDI-DrugBank.d253.s3|69-69|,|O
DDI-DrugBank.d253.s3|71-72|or|O
DDI-DrugBank.d253.s3|74-82|digitalis|O
DDI-DrugBank.d253.s3|84-93|glycosides|O
DDI-DrugBank.d253.s3|94-94|:|O
DDI-DrugBank.d253.s3|96-105|concurrent|O
DDI-DrugBank.d253.s3|107-109|use|O
DDI-DrugBank.d253.s3|111-114|with|O
DDI-DrugBank.d253.s3|116-125|arbutamine|O
DDI-DrugBank.d253.s3|127-129|may|O
DDI-DrugBank.d253.s3|131-137|produce|O
DDI-DrugBank.d253.s3|139-146|additive|O
DDI-DrugBank.d253.s3|148-156|inotropic|O
DDI-DrugBank.d253.s3|158-163|and/or|O
DDI-DrugBank.d253.s3|165-176|chronotropic|O
DDI-DrugBank.d253.s3|178-184|effects|O
DDI-DrugBank.d253.s3|185-185|.|O
DDI-DrugBank.d320.s0|0-9|Chirocaine|O
DDI-DrugBank.d320.s0|13-18|should|O
DDI-DrugBank.d320.s0|20-21|be|O
DDI-DrugBank.d320.s0|23-26|used|O
DDI-DrugBank.d320.s0|28-31|with|O
DDI-DrugBank.d320.s0|33-39|caution|O
DDI-DrugBank.d320.s0|41-42|in|O
DDI-DrugBank.d320.s0|44-51|patients|O
DDI-DrugBank.d320.s0|53-61|receiving|O
DDI-DrugBank.d320.s0|63-67|other|O
DDI-DrugBank.d320.s0|69-73|local|O
DDI-DrugBank.d320.s0|75-85|anesthetics|O
DDI-DrugBank.d320.s0|87-88|or|O
DDI-DrugBank.d320.s0|90-95|agents|O
DDI-DrugBank.d320.s0|97-108|structurally|O
DDI-DrugBank.d320.s0|110-116|related|O
DDI-DrugBank.d320.s0|118-119|to|O
DDI-DrugBank.d320.s0|121-130|amide-type|O
DDI-DrugBank.d320.s0|132-136|local|O
DDI-DrugBank.d320.s0|138-148|anesthetics|O
DDI-DrugBank.d320.s0|150-154|since|O
DDI-DrugBank.d320.s0|156-158|the|O
DDI-DrugBank.d320.s0|160-164|toxic|O
DDI-DrugBank.d320.s0|166-172|effects|O
DDI-DrugBank.d320.s0|174-175|of|O
DDI-DrugBank.d320.s0|177-181|these|O
DDI-DrugBank.d320.s0|183-187|drugs|O
DDI-DrugBank.d320.s0|189-193|could|O
DDI-DrugBank.d320.s0|195-196|be|O
DDI-DrugBank.d320.s0|198-205|additive|O
DDI-DrugBank.d320.s0|206-206|.|O
DDI-DrugBank.d320.s1|0-1|In|O
DDI-DrugBank.d320.s1|3-7|vitro|O
DDI-DrugBank.d320.s1|9-15|studies|O
DDI-DrugBank.d320.s1|17-24|indicate|O
DDI-DrugBank.d320.s1|26-31|CYP3A4|O
DDI-DrugBank.d320.s1|33-39|isoform|O
DDI-DrugBank.d320.s1|41-43|and|O
DDI-DrugBank.d320.s1|45-50|CYP1A2|O
DDI-DrugBank.d320.s1|52-58|isoform|O
DDI-DrugBank.d320.s1|60-66|mediate|O
DDI-DrugBank.d320.s1|68-70|the|O
DDI-DrugBank.d320.s1|72-81|metabolism|O
DDI-DrugBank.d320.s1|83-84|of|O
DDI-DrugBank.d320.s1|86-100|levobupivacaine|O
DDI-DrugBank.d320.s1|102-103|to|O
DDI-DrugBank.d320.s1|105-112|desbutyl|O
DDI-DrugBank.d320.s1|114-128|levobupivacaine|O
DDI-DrugBank.d320.s1|130-132|and|O
DDI-DrugBank.d320.s1|134-142|3-hydroxy|O
DDI-DrugBank.d320.s1|144-158|levobupivacaine|O
DDI-DrugBank.d320.s1|159-159|,|O
DDI-DrugBank.d320.s1|161-172|respectively|O
DDI-DrugBank.d320.s1|173-173|.|O
DDI-DrugBank.d320.s2|0-3|Thus|O
DDI-DrugBank.d320.s2|5-10|agents|O
DDI-DrugBank.d320.s2|12-17|likely|O
DDI-DrugBank.d320.s2|19-20|to|O
DDI-DrugBank.d320.s2|22-23|be|O
DDI-DrugBank.d320.s2|25-37|concomitantly|O
DDI-DrugBank.d320.s2|39-50|administered|O
DDI-DrugBank.d320.s2|52-55|with|O
DDI-DrugBank.d320.s2|57-66|Chirocaine|O
DDI-DrugBank.d320.s2|68-71|that|O
DDI-DrugBank.d320.s2|73-75|are|O
DDI-DrugBank.d320.s2|77-87|metabolized|O
DDI-DrugBank.d320.s2|89-90|by|O
DDI-DrugBank.d320.s2|92-95|this|O
DDI-DrugBank.d320.s2|97-105|isoenzyme|O
DDI-DrugBank.d320.s2|107-112|family|O
DDI-DrugBank.d320.s2|114-116|may|O
DDI-DrugBank.d320.s2|118-128|potentially|O
DDI-DrugBank.d320.s2|130-137|interact|O
DDI-DrugBank.d320.s2|139-142|with|O
DDI-DrugBank.d320.s2|144-153|Chirocaine|O
DDI-DrugBank.d320.s2|154-154|.|O
DDI-DrugBank.d320.s3|0-7|Although|O
DDI-DrugBank.d320.s3|9-10|no|O
DDI-DrugBank.d320.s3|12-19|clinical|O
DDI-DrugBank.d320.s3|21-27|studies|O
DDI-DrugBank.d320.s3|29-32|have|O
DDI-DrugBank.d320.s3|34-37|been|O
DDI-DrugBank.d320.s3|39-47|conducted|O
DDI-DrugBank.d320.s3|48-48|,|O
DDI-DrugBank.d320.s3|50-51|it|O
DDI-DrugBank.d320.s3|53-54|is|O
DDI-DrugBank.d320.s3|56-61|likely|O
DDI-DrugBank.d320.s3|63-66|that|O
DDI-DrugBank.d320.s3|68-70|the|O
DDI-DrugBank.d320.s3|72-81|metabolism|O
DDI-DrugBank.d320.s3|83-84|of|O
DDI-DrugBank.d320.s3|86-100|levobupivacaine|O
DDI-DrugBank.d320.s3|102-104|may|O
DDI-DrugBank.d320.s3|106-107|be|O
DDI-DrugBank.d320.s3|109-116|affected|O
DDI-DrugBank.d320.s3|118-119|by|O
DDI-DrugBank.d320.s3|121-123|the|O
DDI-DrugBank.d320.s3|125-129|known|O
DDI-DrugBank.d320.s3|131-136|CYP3A4|O
DDI-DrugBank.d320.s3|138-145|inducers|O
DDI-DrugBank.d320.s3|147-147|(|O
DDI-DrugBank.d320.s3|148-151|such|O
DDI-DrugBank.d320.s3|153-154|as|O
DDI-DrugBank.d320.s3|156-164|phenytoin|O
DDI-DrugBank.d320.s3|165-165|,|O
DDI-DrugBank.d320.s3|167-179|phenobarbital|O
DDI-DrugBank.d320.s3|180-180|,|O
DDI-DrugBank.d320.s3|182-189|rifampin|O
DDI-DrugBank.d320.s3|190-190|)|O
DDI-DrugBank.d320.s3|191-191|,|O
DDI-DrugBank.d320.s3|193-198|CYP3A4|O
DDI-DrugBank.d320.s3|200-209|inhibitors|O
DDI-DrugBank.d320.s3|211-211|(|O
DDI-DrugBank.d320.s3|212-216|azole|O
DDI-DrugBank.d320.s3|218-229|antimycotics|O
DDI-DrugBank.d320.s3|231-234|e.g.|O
DDI-DrugBank.d320.s3|235-235|,|O
DDI-DrugBank.d320.s3|237-248|ketoconazole|O
DDI-DrugBank.d320.s3|249-249|;|O
DDI-DrugBank.d320.s4|0-6|certain|O
DDI-DrugBank.d320.s4|8-15|protease|O
DDI-DrugBank.d320.s4|17-26|inhibitors|O
DDI-DrugBank.d320.s4|28-31|e.g.|O
DDI-DrugBank.d320.s4|32-32|,|O
DDI-DrugBank.d320.s4|34-42|ritanovir|O
DDI-DrugBank.d320.s4|43-43|;|O
DDI-DrugBank.d320.s5|0-8|macrolide|O
DDI-DrugBank.d320.s5|10-20|antibiotics|O
DDI-DrugBank.d320.s5|22-25|e.g.|O
DDI-DrugBank.d320.s5|26-26|,|O
DDI-DrugBank.d320.s5|28-39|erythromycin|O
DDI-DrugBank.d320.s5|40-40|;|O
DDI-DrugBank.d320.s6|0-2|and|O
DDI-DrugBank.d320.s6|4-10|calcium|O
DDI-DrugBank.d320.s6|12-18|channel|O
DDI-DrugBank.d320.s6|20-30|antagonists|O
DDI-DrugBank.d320.s6|32-35|e.g.|O
DDI-DrugBank.d320.s6|36-36|,|O
DDI-DrugBank.d320.s6|38-46|verapamil|O
DDI-DrugBank.d320.s6|47-47|)|O
DDI-DrugBank.d320.s6|48-48|,|O
DDI-DrugBank.d320.s6|50-55|CYP1A2|O
DDI-DrugBank.d320.s6|57-64|inducers|O
DDI-DrugBank.d320.s6|66-66|(|O
DDI-DrugBank.d320.s6|67-76|omeprazole|O
DDI-DrugBank.d320.s6|77-77|)|O
DDI-DrugBank.d320.s6|79-81|and|O
DDI-DrugBank.d320.s6|83-88|CYP1A2|O
DDI-DrugBank.d320.s6|90-99|inhibitors|O
DDI-DrugBank.d320.s6|101-101|(|O
DDI-DrugBank.d320.s6|102-112|furafylline|O
DDI-DrugBank.d320.s6|114-116|and|O
DDI-DrugBank.d320.s6|118-131|clarithromycin|O
DDI-DrugBank.d320.s6|132-132|)|O
DDI-DrugBank.d320.s6|133-133|.|O
DDI-DrugBank.d320.s7|0-5|Dosage|O
DDI-DrugBank.d320.s7|7-16|adjustment|O
DDI-DrugBank.d320.s7|18-20|may|O
DDI-DrugBank.d320.s7|22-23|be|O
DDI-DrugBank.d320.s7|25-33|warranted|O
DDI-DrugBank.d320.s7|35-38|when|O
DDI-DrugBank.d320.s7|40-54|levobupivacaine|O
DDI-DrugBank.d320.s7|56-57|is|O
DDI-DrugBank.d320.s7|59-70|concurrently|O
DDI-DrugBank.d320.s7|72-83|administered|O
DDI-DrugBank.d320.s7|85-88|with|O
DDI-DrugBank.d320.s7|90-95|CYP3A4|O
DDI-DrugBank.d320.s7|97-106|inhibitors|O
DDI-DrugBank.d320.s7|108-110|and|O
DDI-DrugBank.d320.s7|112-117|CYP1A2|O
DDI-DrugBank.d320.s7|119-128|inhibitors|O
DDI-DrugBank.d320.s7|130-131|as|O
DDI-DrugBank.d320.s7|133-140|systemic|O
DDI-DrugBank.d320.s7|142-156|levobupivacaine|O
DDI-DrugBank.d320.s7|158-163|levels|O
DDI-DrugBank.d320.s7|165-167|may|O
DDI-DrugBank.d320.s7|169-172|rise|O
DDI-DrugBank.d320.s7|174-182|resulting|O
DDI-DrugBank.d320.s7|184-185|in|O
DDI-DrugBank.d320.s7|187-194|toxicity|O
DDI-DrugBank.d320.s7|195-195|.|O
DDI-DrugBank.d630.s0|0-12|Methazolamide|O
DDI-DrugBank.d630.s0|14-19|should|O
DDI-DrugBank.d630.s0|21-22|be|O
DDI-DrugBank.d630.s0|24-27|used|O
DDI-DrugBank.d630.s0|29-32|with|O
DDI-DrugBank.d630.s0|34-40|caution|O
DDI-DrugBank.d630.s0|42-43|in|O
DDI-DrugBank.d630.s0|45-52|patients|O
DDI-DrugBank.d630.s0|54-55|on|O
DDI-DrugBank.d630.s0|57-63|steroid|O
DDI-DrugBank.d630.s0|65-71|therapy|O
DDI-DrugBank.d630.s0|73-79|because|O
DDI-DrugBank.d630.s0|81-82|of|O
DDI-DrugBank.d630.s0|84-86|the|O
DDI-DrugBank.d630.s0|88-96|potential|O
DDI-DrugBank.d630.s0|98-100|for|O
DDI-DrugBank.d630.s0|102-111|developing|O
DDI-DrugBank.d630.s0|113-123|hypokalemia|O
DDI-DrugBank.d630.s0|124-124|.|O
DDI-DrugBank.d630.s1|0-6|Caution|O
DDI-DrugBank.d630.s1|8-9|is|O
DDI-DrugBank.d630.s1|11-17|advised|O
DDI-DrugBank.d630.s1|19-21|for|O
DDI-DrugBank.d630.s1|23-30|patients|O
DDI-DrugBank.d630.s1|32-40|receiving|O
DDI-DrugBank.d630.s1|42-50|high-dose|O
DDI-DrugBank.d630.s1|52-58|aspirin|O
DDI-DrugBank.d630.s1|60-62|and|O
DDI-DrugBank.d630.s1|64-76|methazolamide|O
DDI-DrugBank.d630.s1|78-90|concomitantly|O
DDI-DrugBank.d630.s1|91-91|,|O
DDI-DrugBank.d630.s1|93-94|as|O
DDI-DrugBank.d630.s1|96-103|anorexia|O
DDI-DrugBank.d630.s1|104-104|,|O
DDI-DrugBank.d630.s1|106-114|tachypnea|O
DDI-DrugBank.d630.s1|115-115|,|O
DDI-DrugBank.d630.s1|117-124|lethargy|O
DDI-DrugBank.d630.s1|125-125|,|O
DDI-DrugBank.d630.s1|127-130|coma|O
DDI-DrugBank.d630.s1|132-134|and|O
DDI-DrugBank.d630.s1|136-140|death|O
DDI-DrugBank.d630.s1|142-145|have|O
DDI-DrugBank.d630.s1|147-150|been|O
DDI-DrugBank.d630.s1|152-159|reported|O
DDI-DrugBank.d630.s1|161-164|with|O
DDI-DrugBank.d630.s1|166-176|concomitant|O
DDI-DrugBank.d630.s1|178-180|use|O
DDI-DrugBank.d630.s1|182-183|of|O
DDI-DrugBank.d630.s1|185-193|high-dose|O
DDI-DrugBank.d630.s1|195-201|aspirin|O
DDI-DrugBank.d630.s1|203-205|and|O
DDI-DrugBank.d630.s1|207-214|carbonic|O
DDI-DrugBank.d630.s1|216-224|anhydrase|O
DDI-DrugBank.d630.s1|226-235|inhibitors|O
DDI-DrugBank.d630.s1|236-236|.|O
DDI-DrugBank.d185.s0|0-0|A|O
DDI-DrugBank.d185.s0|2-10|drug-drug|O
DDI-DrugBank.d185.s0|12-22|interaction|O
DDI-DrugBank.d185.s0|24-28|study|O
DDI-DrugBank.d185.s0|30-38|evaluated|O
DDI-DrugBank.d185.s0|40-42|the|O
DDI-DrugBank.d185.s0|44-49|effect|O
DDI-DrugBank.d185.s0|51-52|of|O
DDI-DrugBank.d185.s0|54-56|the|O
DDI-DrugBank.d185.s0|58-60|use|O
DDI-DrugBank.d185.s0|62-63|of|O
DDI-DrugBank.d185.s0|65-70|ACZONE|O
DDI-DrugBank.d185.s0|72-74|Gel|O
DDI-DrugBank.d185.s0|75-75|,|O
DDI-DrugBank.d185.s0|77-77|5|O
DDI-DrugBank.d185.s0|78-78|%|O
DDI-DrugBank.d185.s0|79-79|,|O
DDI-DrugBank.d185.s0|81-82|in|O
DDI-DrugBank.d185.s0|84-94|combination|O
DDI-DrugBank.d185.s0|96-99|with|O
DDI-DrugBank.d185.s0|101-106|double|O
DDI-DrugBank.d185.s0|108-115|strength|O
DDI-DrugBank.d185.s0|117-117|(|O
DDI-DrugBank.d185.s0|118-120|160|O
DDI-DrugBank.d185.s0|122-127|mg/800|O
DDI-DrugBank.d185.s0|129-130|mg|O
DDI-DrugBank.d185.s0|131-131|)|O
DDI-DrugBank.d185.s0|133-161|trimethoprim/sulfamethoxazole|O
DDI-DrugBank.d185.s0|163-163|(|O
DDI-DrugBank.d185.s0|164-170|TMP/SMX|O
DDI-DrugBank.d185.s0|171-171|)|O
DDI-DrugBank.d185.s0|172-172|.|O
DDI-DrugBank.d185.s1|0-5|During|O
DDI-DrugBank.d185.s1|7-23|co-administration|O
DDI-DrugBank.d185.s1|24-24|,|O
DDI-DrugBank.d185.s1|26-33|systemic|O
DDI-DrugBank.d185.s1|35-40|levels|O
DDI-DrugBank.d185.s1|42-43|of|O
DDI-DrugBank.d185.s1|45-47|TMP|O
DDI-DrugBank.d185.s1|49-51|and|O
DDI-DrugBank.d185.s1|53-55|SMX|O
DDI-DrugBank.d185.s1|57-60|were|O
DDI-DrugBank.d185.s1|62-72|essentially|O
DDI-DrugBank.d185.s1|74-82|unchanged|O
DDI-DrugBank.d185.s1|83-83|.|O
DDI-DrugBank.d185.s2|0-6|Notably|O
DDI-DrugBank.d185.s2|7-7|,|O
DDI-DrugBank.d185.s2|9-16|systemic|O
DDI-DrugBank.d185.s2|18-25|exposure|O
DDI-DrugBank.d185.s2|27-27|(|O
DDI-DrugBank.d185.s2|28-34|AUC0-12|O
DDI-DrugBank.d185.s2|35-35|)|O
DDI-DrugBank.d185.s2|37-38|of|O
DDI-DrugBank.d185.s2|40-46|dapsone|O
DDI-DrugBank.d185.s2|48-60|hydroxylamine|O
DDI-DrugBank.d185.s2|62-62|(|O
DDI-DrugBank.d185.s2|63-65|DHA|O
DDI-DrugBank.d185.s2|66-66|)|O
DDI-DrugBank.d185.s2|68-70|was|O
DDI-DrugBank.d185.s2|72-75|more|O
DDI-DrugBank.d185.s2|77-80|than|O
DDI-DrugBank.d185.s2|82-88|doubled|O
DDI-DrugBank.d185.s2|90-91|in|O
DDI-DrugBank.d185.s2|93-95|the|O
DDI-DrugBank.d185.s2|97-104|presence|O
DDI-DrugBank.d185.s2|106-107|of|O
DDI-DrugBank.d185.s2|109-115|TMP/SMX|O
DDI-DrugBank.d185.s2|116-116|.|O
DDI-DrugBank.d185.s3|0-7|Exposure|O
DDI-DrugBank.d185.s3|9-12|from|O
DDI-DrugBank.d185.s3|14-16|the|O
DDI-DrugBank.d185.s3|18-25|proposed|O
DDI-DrugBank.d185.s3|27-33|topical|O
DDI-DrugBank.d185.s3|35-38|dose|O
DDI-DrugBank.d185.s3|40-41|is|O
DDI-DrugBank.d185.s3|43-47|about|O
DDI-DrugBank.d185.s3|49-49|1|O
DDI-DrugBank.d185.s3|50-50|%|O
DDI-DrugBank.d185.s3|52-53|of|O
DDI-DrugBank.d185.s3|55-58|that|O
DDI-DrugBank.d185.s3|60-63|from|O
DDI-DrugBank.d185.s3|65-67|the|O
DDI-DrugBank.d185.s3|69-71|100|O
DDI-DrugBank.d185.s3|73-74|mg|O
DDI-DrugBank.d185.s3|76-79|oral|O
DDI-DrugBank.d185.s3|81-84|dose|O
DDI-DrugBank.d185.s3|85-85|,|O
DDI-DrugBank.d185.s3|87-90|even|O
DDI-DrugBank.d185.s3|92-95|when|O
DDI-DrugBank.d185.s3|97-111|co-administered|O
DDI-DrugBank.d185.s3|113-116|with|O
DDI-DrugBank.d185.s3|118-124|TMP/SMX|O
DDI-DrugBank.d185.s3|125-125|.|O
DDI-DrugBank.d185.s4|0-6|Certain|O
DDI-DrugBank.d185.s4|8-18|concomitant|O
DDI-DrugBank.d185.s4|20-30|medications|O
DDI-DrugBank.d185.s4|32-32|(|O
DDI-DrugBank.d185.s4|33-36|such|O
DDI-DrugBank.d185.s4|38-39|as|O
DDI-DrugBank.d185.s4|41-48|rifampin|O
DDI-DrugBank.d185.s4|49-49|,|O
DDI-DrugBank.d185.s4|51-65|anticonvulsants|O
DDI-DrugBank.d185.s4|66-66|,|O
DDI-DrugBank.d185.s4|68-69|St|O
DDI-DrugBank.d185.s4|70-70|.|O
DDI-DrugBank.d185.s5|0-3|John|O
DDI-DrugBank.d185.s5|5-5|s|O
DDI-DrugBank.d185.s5|7-10|wort|O
DDI-DrugBank.d185.s5|11-11|)|O
DDI-DrugBank.d185.s5|13-15|may|O
DDI-DrugBank.d185.s5|17-24|increase|O
DDI-DrugBank.d185.s5|26-28|the|O
DDI-DrugBank.d185.s5|30-38|formation|O
DDI-DrugBank.d185.s5|40-41|of|O
DDI-DrugBank.d185.s5|43-49|dapsone|O
DDI-DrugBank.d185.s5|51-63|hydroxylamine|O
DDI-DrugBank.d185.s5|64-64|,|O
DDI-DrugBank.d185.s5|66-66|a|O
DDI-DrugBank.d185.s5|68-77|metabolite|O
DDI-DrugBank.d185.s5|79-80|of|O
DDI-DrugBank.d185.s5|82-88|dapsone|O
DDI-DrugBank.d185.s5|90-99|associated|O
DDI-DrugBank.d185.s5|101-104|with|O
DDI-DrugBank.d185.s5|106-114|hemolysis|O
DDI-DrugBank.d185.s5|115-115|.|O
DDI-DrugBank.d185.s6|0-3|With|O
DDI-DrugBank.d185.s6|5-8|oral|O
DDI-DrugBank.d185.s6|10-16|dapsone|O
DDI-DrugBank.d185.s6|18-26|treatment|O
DDI-DrugBank.d185.s6|27-27|,|O
DDI-DrugBank.d185.s6|29-33|folic|O
DDI-DrugBank.d185.s6|35-38|acid|O
DDI-DrugBank.d185.s6|40-50|antagonists|O
DDI-DrugBank.d185.s6|52-55|such|O
DDI-DrugBank.d185.s6|57-58|as|O
DDI-DrugBank.d185.s6|60-72|pyrimethamine|O
DDI-DrugBank.d185.s6|74-77|have|O
DDI-DrugBank.d185.s6|79-82|been|O
DDI-DrugBank.d185.s6|84-88|noted|O
DDI-DrugBank.d185.s6|90-91|to|O
DDI-DrugBank.d185.s6|93-100|possibly|O
DDI-DrugBank.d185.s6|102-109|increase|O
DDI-DrugBank.d185.s6|111-113|the|O
DDI-DrugBank.d185.s6|115-124|likelihood|O
DDI-DrugBank.d185.s6|126-127|of|O
DDI-DrugBank.d185.s6|129-139|hematologic|O
DDI-DrugBank.d185.s6|141-149|reactions|O
DDI-DrugBank.d185.s7|0-0|.|O
DDI-DrugBank.d632.s0|0-2|Due|O
DDI-DrugBank.d632.s0|4-5|to|O
DDI-DrugBank.d632.s0|7-9|its|O
DDI-DrugBank.d632.s0|11-17|effects|O
DDI-DrugBank.d632.s0|19-20|on|O
DDI-DrugBank.d632.s0|22-28|gastric|O
DDI-DrugBank.d632.s0|30-37|emptying|O
DDI-DrugBank.d632.s0|38-38|,|O
DDI-DrugBank.d632.s0|40-45|SYMLIN|O
DDI-DrugBank.d632.s0|47-53|therapy|O
DDI-DrugBank.d632.s0|55-60|should|O
DDI-DrugBank.d632.s0|62-64|not|O
DDI-DrugBank.d632.s0|66-67|be|O
DDI-DrugBank.d632.s0|69-78|considered|O
DDI-DrugBank.d632.s0|80-82|for|O
DDI-DrugBank.d632.s0|84-91|patients|O
DDI-DrugBank.d632.s0|93-98|taking|O
DDI-DrugBank.d632.s0|100-104|drugs|O
DDI-DrugBank.d632.s0|106-109|that|O
DDI-DrugBank.d632.s0|111-115|alter|O
DDI-DrugBank.d632.s0|117-132|gastrointestinal|O
DDI-DrugBank.d632.s0|134-141|motility|O
DDI-DrugBank.d632.s0|143-143|(|O
DDI-DrugBank.d632.s0|144-147|e.g.|O
DDI-DrugBank.d632.s0|148-148|,|O
DDI-DrugBank.d632.s0|150-164|anticholinergic|O
DDI-DrugBank.d632.s0|166-171|agents|O
DDI-DrugBank.d632.s0|173-176|such|O
DDI-DrugBank.d632.s0|178-179|as|O
DDI-DrugBank.d632.s0|181-188|atropine|O
DDI-DrugBank.d632.s0|189-189|)|O
DDI-DrugBank.d632.s0|191-193|and|O
DDI-DrugBank.d632.s0|195-200|agents|O
DDI-DrugBank.d632.s0|202-205|that|O
DDI-DrugBank.d632.s0|207-210|slow|O
DDI-DrugBank.d632.s0|212-214|the|O
DDI-DrugBank.d632.s0|216-225|intestinal|O
DDI-DrugBank.d632.s0|227-236|absorption|O
DDI-DrugBank.d632.s0|238-239|of|O
DDI-DrugBank.d632.s0|241-249|nutrients|O
DDI-DrugBank.d632.s0|251-251|(|O
DDI-DrugBank.d632.s0|252-255|e.g.|O
DDI-DrugBank.d632.s0|256-256|,|O
DDI-DrugBank.d632.s0|258-262|alpha|O
DDI-DrugBank.d632.s0|264-274|glucosidase|O
DDI-DrugBank.d632.s0|276-285|inhibitors|O
DDI-DrugBank.d632.s0|286-286|)|O
DDI-DrugBank.d632.s0|287-287|.|O
DDI-DrugBank.d632.s1|0-7|Patients|O
DDI-DrugBank.d632.s1|9-13|using|O
DDI-DrugBank.d632.s1|15-19|these|O
DDI-DrugBank.d632.s1|21-25|drugs|O
DDI-DrugBank.d632.s1|27-30|have|O
DDI-DrugBank.d632.s1|32-34|not|O
DDI-DrugBank.d632.s1|36-39|been|O
DDI-DrugBank.d632.s1|41-47|studied|O
DDI-DrugBank.d632.s1|49-50|in|O
DDI-DrugBank.d632.s1|52-59|clinical|O
DDI-DrugBank.d632.s1|61-66|trials|O
DDI-DrugBank.d632.s1|67-67|.|O
DDI-DrugBank.d632.s2|0-5|SYMLIN|O
DDI-DrugBank.d632.s2|7-9|has|O
DDI-DrugBank.d632.s2|11-13|the|O
DDI-DrugBank.d632.s2|15-23|potential|O
DDI-DrugBank.d632.s2|25-26|to|O
DDI-DrugBank.d632.s2|28-32|delay|O
DDI-DrugBank.d632.s2|34-36|the|O
DDI-DrugBank.d632.s2|38-47|absorption|O
DDI-DrugBank.d632.s2|49-50|of|O
DDI-DrugBank.d632.s2|52-64|concomitantly|O
DDI-DrugBank.d632.s2|66-77|administered|O
DDI-DrugBank.d632.s2|79-82|oral|O
DDI-DrugBank.d632.s2|84-94|medications|O
DDI-DrugBank.d632.s2|95-95|.|O
DDI-DrugBank.d632.s3|0-3|When|O
DDI-DrugBank.d632.s3|5-7|the|O
DDI-DrugBank.d632.s3|9-13|rapid|O
DDI-DrugBank.d632.s3|15-19|onset|O
DDI-DrugBank.d632.s3|21-22|of|O
DDI-DrugBank.d632.s3|24-24|a|O
DDI-DrugBank.d632.s3|26-36|concomitant|O
DDI-DrugBank.d632.s3|38-43|orally|O
DDI-DrugBank.d632.s3|45-56|administered|O
DDI-DrugBank.d632.s3|58-62|agent|O
DDI-DrugBank.d632.s3|64-65|is|O
DDI-DrugBank.d632.s3|67-67|a|O
DDI-DrugBank.d632.s3|69-76|critical|O
DDI-DrugBank.d632.s3|78-88|determinant|O
DDI-DrugBank.d632.s3|90-91|of|O
DDI-DrugBank.d632.s3|93-105|effectiveness|O
DDI-DrugBank.d632.s3|107-107|(|O
DDI-DrugBank.d632.s3|108-111|such|O
DDI-DrugBank.d632.s3|113-114|as|O
DDI-DrugBank.d632.s3|116-125|analgesics|O
DDI-DrugBank.d632.s3|126-126|)|O
DDI-DrugBank.d632.s3|127-127|,|O
DDI-DrugBank.d632.s3|129-131|the|O
DDI-DrugBank.d632.s3|133-137|agent|O
DDI-DrugBank.d632.s3|139-144|should|O
DDI-DrugBank.d632.s3|146-147|be|O
DDI-DrugBank.d632.s3|149-160|administered|O
DDI-DrugBank.d632.s3|162-163|at|O
DDI-DrugBank.d632.s3|165-169|least|O
DDI-DrugBank.d632.s3|171-171|1|O
DDI-DrugBank.d632.s3|173-176|hour|O
DDI-DrugBank.d632.s3|178-182|prior|O
DDI-DrugBank.d632.s3|184-185|to|O
DDI-DrugBank.d632.s3|187-188|or|O
DDI-DrugBank.d632.s3|190-190|2|O
DDI-DrugBank.d632.s3|192-196|hours|O
DDI-DrugBank.d632.s3|198-202|after|O
DDI-DrugBank.d632.s3|204-209|SYMLIN|O
DDI-DrugBank.d632.s3|211-219|injection|O
DDI-DrugBank.d632.s3|220-220|.|O
DDI-DrugBank.d632.s4|0-1|In|O
DDI-DrugBank.d632.s4|3-10|clinical|O
DDI-DrugBank.d632.s4|12-17|trials|O
DDI-DrugBank.d632.s4|18-18|,|O
DDI-DrugBank.d632.s4|20-22|the|O
DDI-DrugBank.d632.s4|24-34|concomitant|O
DDI-DrugBank.d632.s4|36-38|use|O
DDI-DrugBank.d632.s4|40-41|of|O
DDI-DrugBank.d632.s4|43-55|sulfonylureas|O
DDI-DrugBank.d632.s4|57-58|or|O
DDI-DrugBank.d632.s4|60-69|biguanides|O
DDI-DrugBank.d632.s4|71-73|did|O
DDI-DrugBank.d632.s4|75-77|not|O
DDI-DrugBank.d632.s4|79-83|alter|O
DDI-DrugBank.d632.s4|85-87|the|O
DDI-DrugBank.d632.s4|89-95|adverse|O
DDI-DrugBank.d632.s4|97-101|event|O
DDI-DrugBank.d632.s4|103-109|profile|O
DDI-DrugBank.d632.s4|111-112|of|O
DDI-DrugBank.d632.s4|114-119|SYMLIN|O
DDI-DrugBank.d632.s4|120-120|.|O
DDI-DrugBank.d632.s5|0-1|No|O
DDI-DrugBank.d632.s5|3-8|formal|O
DDI-DrugBank.d632.s5|10-20|interaction|O
DDI-DrugBank.d632.s5|22-28|studies|O
DDI-DrugBank.d632.s5|30-33|have|O
DDI-DrugBank.d632.s5|35-38|been|O
DDI-DrugBank.d632.s5|40-48|performed|O
DDI-DrugBank.d632.s5|50-51|to|O
DDI-DrugBank.d632.s5|53-58|assess|O
DDI-DrugBank.d632.s5|60-62|the|O
DDI-DrugBank.d632.s5|64-69|effect|O
DDI-DrugBank.d632.s5|71-72|of|O
DDI-DrugBank.d632.s5|74-79|SYMLIN|O
DDI-DrugBank.d632.s5|81-82|on|O
DDI-DrugBank.d632.s5|84-86|the|O
DDI-DrugBank.d632.s5|88-95|kinetics|O
DDI-DrugBank.d632.s5|97-98|of|O
DDI-DrugBank.d632.s5|100-103|oral|O
DDI-DrugBank.d632.s5|105-116|antidiabetic|O
DDI-DrugBank.d632.s5|118-123|agents|O
DDI-DrugBank.d632.s5|124-124|.|O
DDI-DrugBank.d632.s6|0-5|Mixing|O
DDI-DrugBank.d632.s6|7-12|SYMLIN|O
DDI-DrugBank.d632.s6|14-16|and|O
DDI-DrugBank.d632.s6|18-24|Insulin|O
DDI-DrugBank.d632.s6|26-28|The|O
DDI-DrugBank.d632.s6|30-44|pharmacokinetic|O
DDI-DrugBank.d632.s6|46-55|parameters|O
DDI-DrugBank.d632.s6|57-58|of|O
DDI-DrugBank.d632.s6|60-65|SYMLIN|O
DDI-DrugBank.d632.s6|67-70|were|O
DDI-DrugBank.d632.s6|72-78|altered|O
DDI-DrugBank.d632.s6|80-83|when|O
DDI-DrugBank.d632.s6|85-89|mixed|O
DDI-DrugBank.d632.s6|91-94|with|O
DDI-DrugBank.d632.s6|96-102|regular|O
DDI-DrugBank.d632.s6|103-103|,|O
DDI-DrugBank.d632.s6|105-107|NPH|O
DDI-DrugBank.d632.s6|108-108|,|O
DDI-DrugBank.d632.s6|110-112|and|O
DDI-DrugBank.d632.s6|114-118|70/30|O
DDI-DrugBank.d632.s6|120-127|premixed|O
DDI-DrugBank.d632.s6|129-140|formulations|O
DDI-DrugBank.d632.s6|142-143|of|O
DDI-DrugBank.d632.s6|145-155|recombinant|O
DDI-DrugBank.d632.s6|157-161|human|O
DDI-DrugBank.d632.s6|163-169|insulin|O
DDI-DrugBank.d632.s6|171-181|immediately|O
DDI-DrugBank.d632.s6|183-187|prior|O
DDI-DrugBank.d632.s6|189-190|to|O
DDI-DrugBank.d632.s6|192-200|injection|O
DDI-DrugBank.d632.s6|201-201|.|O
DDI-DrugBank.d632.s7|0-3|Thus|O
DDI-DrugBank.d632.s7|4-4|,|O
DDI-DrugBank.d632.s7|6-11|SYMLIN|O
DDI-DrugBank.d632.s7|13-15|and|O
DDI-DrugBank.d632.s7|17-23|insulin|O
DDI-DrugBank.d632.s7|25-30|should|O
DDI-DrugBank.d632.s7|32-34|not|O
DDI-DrugBank.d632.s7|36-37|be|O
DDI-DrugBank.d632.s7|39-43|mixed|O
DDI-DrugBank.d632.s7|45-47|and|O
DDI-DrugBank.d632.s7|49-52|must|O
DDI-DrugBank.d632.s7|54-55|be|O
DDI-DrugBank.d632.s7|57-68|administered|O
DDI-DrugBank.d632.s7|70-79|separately|O
DDI-DrugBank.d632.s7|80-80|.|O
DDI-DrugBank.d227.s0|0-9|Isoflurane|O
DDI-DrugBank.d227.s0|11-21|potentiates|O
DDI-DrugBank.d227.s0|23-25|the|O
DDI-DrugBank.d227.s0|27-32|muscle|O
DDI-DrugBank.d227.s0|34-41|relaxant|O
DDI-DrugBank.d227.s0|43-48|effect|O
DDI-DrugBank.d227.s0|50-51|of|O
DDI-DrugBank.d227.s0|53-55|all|O
DDI-DrugBank.d227.s0|57-62|muscle|O
DDI-DrugBank.d227.s0|64-72|relaxants|O
DDI-DrugBank.d227.s0|73-73|,|O
DDI-DrugBank.d227.s0|75-78|most|O
DDI-DrugBank.d227.s0|80-86|notably|O
DDI-DrugBank.d227.s0|88-102|nondepolarizing|O
DDI-DrugBank.d227.s0|104-109|muscle|O
DDI-DrugBank.d227.s0|111-119|relaxants|O
DDI-DrugBank.d227.s0|120-120|,|O
DDI-DrugBank.d227.s0|122-124|and|O
DDI-DrugBank.d227.s0|126-128|MAC|O
DDI-DrugBank.d227.s0|130-130|(|O
DDI-DrugBank.d227.s0|131-137|minimum|O
DDI-DrugBank.d227.s0|139-146|alveolar|O
DDI-DrugBank.d227.s0|148-160|concentration|O
DDI-DrugBank.d227.s0|161-161|)|O
DDI-DrugBank.d227.s0|163-164|is|O
DDI-DrugBank.d227.s0|166-172|reduced|O
DDI-DrugBank.d227.s0|174-175|by|O
DDI-DrugBank.d227.s0|177-187|concomitant|O
DDI-DrugBank.d227.s0|189-202|administration|O
DDI-DrugBank.d227.s0|204-205|of|O
DDI-DrugBank.d227.s0|207-207|N|O
DDI-DrugBank.d227.s0|209-210|2O|O
DDI-DrugBank.d227.s0|211-211|.|O
DDI-DrugBank.d227.s1|0-2|See|O
DDI-DrugBank.d227.s1|4-11|CLINICAL|O
DDI-DrugBank.d227.s1|13-24|PHARMACOLOGY|O
DDI-DrugBank.d227.s1|25-25|.|O
DDI-MedLine.d65.s0|0-3|Drug|O
DDI-MedLine.d65.s0|5-16|interactions|O
DDI-MedLine.d65.s0|17-17|:|O
DDI-MedLine.d65.s0|19-21|How|O
DDI-MedLine.d65.s0|23-24|to|O
DDI-MedLine.d65.s0|26-33|identify|O
DDI-MedLine.d65.s0|35-38|them|O
DDI-MedLine.d65.s0|39-39|.|O
DDI-MedLine.d65.s1|0-11|Interactions|O
DDI-MedLine.d65.s1|13-19|between|O
DDI-MedLine.d65.s1|21-30|theraputic|O
DDI-MedLine.d65.s1|32-37|agents|O
DDI-MedLine.d65.s1|39-42|have|O
DDI-MedLine.d65.s1|44-47|been|O
DDI-MedLine.d65.s1|49-58|recognized|O
DDI-MedLine.d65.s1|60-61|as|O
DDI-MedLine.d65.s1|63-74|increasingly|O
DDI-MedLine.d65.s1|76-84|important|O
DDI-MedLine.d65.s1|86-91|causes|O
DDI-MedLine.d65.s1|93-94|of|O
DDI-MedLine.d65.s1|96-99|drug|O
DDI-MedLine.d65.s1|101-102|at|O
DDI-MedLine.d65.s1|104-108|their|O
DDI-MedLine.d65.s1|110-114|usual|O
DDI-MedLine.d65.s1|116-126|recommended|O
DDI-MedLine.d65.s1|128-131|dose|O
DDI-MedLine.d65.s1|133-135|may|O
DDI-MedLine.d65.s1|136-136|,|O
DDI-MedLine.d65.s1|138-142|under|O
DDI-MedLine.d65.s1|144-150|certain|O
DDI-MedLine.d65.s1|152-161|conditions|O
DDI-MedLine.d65.s1|162-162|,|O
DDI-MedLine.d65.s1|164-170|produce|O
DDI-MedLine.d65.s1|172-179|toxicity|O
DDI-MedLine.d65.s1|181-182|of|O
DDI-MedLine.d65.s1|184-199|life-endangering|O
DDI-MedLine.d65.s1|201-211|proportions|O
DDI-MedLine.d65.s1|212-212|.|O
DDI-MedLine.d65.s2|0-4|While|O
DDI-MedLine.d65.s2|6-8|the|O
DDI-MedLine.d65.s2|10-20|recognition|O
DDI-MedLine.d65.s2|22-23|of|O
DDI-MedLine.d65.s2|25-28|drug|O
DDI-MedLine.d65.s2|30-37|toxicity|O
DDI-MedLine.d65.s2|39-47|resulting|O
DDI-MedLine.d65.s2|49-52|from|O
DDI-MedLine.d65.s2|54-65|interactions|O
DDI-MedLine.d65.s2|67-68|is|O
DDI-MedLine.d65.s2|70-71|of|O
DDI-MedLine.d65.s2|73-82|importance|O
DDI-MedLine.d65.s2|84-85|to|O
DDI-MedLine.d65.s2|87-89|all|O
DDI-MedLine.d65.s2|91-100|physciains|O
DDI-MedLine.d65.s2|101-101|,|O
DDI-MedLine.d65.s2|103-104|it|O
DDI-MedLine.d65.s2|106-107|is|O
DDI-MedLine.d65.s2|109-118|especially|O
DDI-MedLine.d65.s2|120-121|so|O
DDI-MedLine.d65.s2|123-125|for|O
DDI-MedLine.d65.s2|127-129|the|O
DDI-MedLine.d65.s2|131-139|clinician|O
DDI-MedLine.d65.s2|141-151|responsible|O
DDI-MedLine.d65.s2|153-155|for|O
DDI-MedLine.d65.s2|157-159|the|O
DDI-MedLine.d65.s2|161-167|welfare|O
DDI-MedLine.d65.s2|169-170|of|O
DDI-MedLine.d65.s2|172-176|those|O
DDI-MedLine.d65.s2|178-179|in|O
DDI-MedLine.d65.s2|181-183|the|O
DDI-MedLine.d65.s2|185-193|aerospace|O
DDI-MedLine.d65.s2|195-205|environment|O
DDI-MedLine.d65.s2|206-206|.|O
DDI-MedLine.d65.s3|0-3|This|O
DDI-MedLine.d65.s3|5-9|paper|O
DDI-MedLine.d65.s3|11-18|attempts|O
DDI-MedLine.d65.s3|20-21|to|O
DDI-MedLine.d65.s3|23-29|provide|O
DDI-MedLine.d65.s3|31-31|a|O
DDI-MedLine.d65.s3|33-37|basis|O
DDI-MedLine.d65.s3|39-41|for|O
DDI-MedLine.d65.s3|43-45|the|O
DDI-MedLine.d65.s3|47-59|understanding|O
DDI-MedLine.d65.s3|61-63|and|O
DDI-MedLine.d65.s3|65-79|identifications|O
DDI-MedLine.d65.s3|81-82|of|O
DDI-MedLine.d65.s3|84-92|important|O
DDI-MedLine.d65.s3|94-97|drug|O
DDI-MedLine.d65.s3|99-110|interactions|O
DDI-MedLine.d65.s3|111-111|.|O
DDI-MedLine.d65.s4|0-9|Guidelines|O
DDI-MedLine.d65.s4|11-13|are|O
DDI-MedLine.d65.s4|15-22|provided|O
DDI-MedLine.d65.s4|24-25|to|O
DDI-MedLine.d65.s4|27-32|assist|O
DDI-MedLine.d65.s4|34-36|the|O
DDI-MedLine.d65.s4|38-46|clinician|O
DDI-MedLine.d65.s4|48-49|in|O
DDI-MedLine.d65.s4|51-53|his|O
DDI-MedLine.d65.s4|55-61|logical|O
DDI-MedLine.d65.s4|63-70|approach|O
DDI-MedLine.d65.s4|72-73|to|O
DDI-MedLine.d65.s4|75-77|the|O
DDI-MedLine.d65.s4|79-92|identification|O
DDI-MedLine.d65.s4|94-95|of|O
DDI-MedLine.d65.s4|97-100|drug|O
DDI-MedLine.d65.s4|102-113|interactions|O
DDI-MedLine.d65.s4|115-118|when|O
DDI-MedLine.d65.s4|120-126|serious|O
DDI-MedLine.d65.s4|128-131|drug|O
DDI-MedLine.d65.s4|133-140|toxicity|O
DDI-MedLine.d65.s4|142-143|is|O
DDI-MedLine.d65.s4|145-155|encountered|O
DDI-MedLine.d65.s4|157-158|in|O
DDI-MedLine.d65.s4|160-160|a|O
DDI-MedLine.d65.s4|162-168|pateint|O
DDI-MedLine.d65.s4|169-169|.|O
DDI-MedLine.d65.s5|0-3|Only|O
DDI-MedLine.d65.s5|5-8|with|O
DDI-MedLine.d65.s5|10-18|knowledge|O
DDI-MedLine.d65.s5|20-21|of|O
DDI-MedLine.d65.s5|23-25|the|O
DDI-MedLine.d65.s5|27-37|interaction|O
DDI-MedLine.d65.s5|39-41|can|O
DDI-MedLine.d65.s5|43-45|the|O
DDI-MedLine.d65.s5|47-57|therapeutic|O
DDI-MedLine.d65.s5|59-65|regimen|O
DDI-MedLine.d65.s5|67-68|be|O
DDI-MedLine.d65.s5|70-76|altered|O
DDI-MedLine.d65.s5|78-79|so|O
DDI-MedLine.d65.s5|81-82|as|O
DDI-MedLine.d65.s5|84-85|to|O
DDI-MedLine.d65.s5|87-93|provide|O
DDI-MedLine.d65.s5|95-105|therapeutic|O
DDI-MedLine.d65.s5|107-112|levels|O
DDI-MedLine.d65.s5|114-115|of|O
DDI-MedLine.d65.s5|117-125|necessary|O
DDI-MedLine.d65.s5|127-131|drugs|O
DDI-MedLine.d65.s5|133-137|while|O
DDI-MedLine.d65.s5|139-146|avoiding|O
DDI-MedLine.d65.s5|148-155|toxicity|O
DDI-MedLine.d65.s5|156-156|.|O
DDI-DrugBank.d104.s0|0-11|Fenfluramine|O
DDI-DrugBank.d104.s0|13-15|may|O
DDI-DrugBank.d104.s0|17-24|increase|O
DDI-DrugBank.d104.s0|26-33|slightly|O
DDI-DrugBank.d104.s0|35-37|the|O
DDI-DrugBank.d104.s0|39-44|effect|O
DDI-DrugBank.d104.s0|46-47|of|O
DDI-DrugBank.d104.s0|49-64|antihypertensive|O
DDI-DrugBank.d104.s0|66-70|drugs|O
DDI-DrugBank.d104.s0|71-71|,|O
DDI-DrugBank.d104.s0|73-76|e.g.|O
DDI-DrugBank.d104.s0|77-77|,|O
DDI-DrugBank.d104.s0|79-90|guanethidine|O
DDI-DrugBank.d104.s0|91-91|,|O
DDI-DrugBank.d104.s0|93-102|methyldopa|O
DDI-DrugBank.d104.s0|103-103|,|O
DDI-DrugBank.d104.s0|105-113|reserpine|O
DDI-DrugBank.d104.s0|114-114|.|O
DDI-DrugBank.d104.s1|0-4|Other|O
DDI-DrugBank.d104.s1|6-8|CNS|O
DDI-DrugBank.d104.s1|10-19|depressant|O
DDI-DrugBank.d104.s1|21-25|drugs|O
DDI-DrugBank.d104.s1|27-32|should|O
DDI-DrugBank.d104.s1|34-35|be|O
DDI-DrugBank.d104.s1|37-40|used|O
DDI-DrugBank.d104.s1|42-45|with|O
DDI-DrugBank.d104.s1|47-53|caution|O
DDI-DrugBank.d104.s1|55-56|in|O
DDI-DrugBank.d104.s1|58-65|patients|O
DDI-DrugBank.d104.s1|67-72|taking|O
DDI-DrugBank.d104.s1|74-85|fenfluramine|O
DDI-DrugBank.d104.s1|86-86|,|O
DDI-DrugBank.d104.s1|88-92|since|O
DDI-DrugBank.d104.s1|94-96|the|O
DDI-DrugBank.d104.s1|98-104|effects|O
DDI-DrugBank.d104.s1|106-108|may|O
DDI-DrugBank.d104.s1|110-111|be|O
DDI-DrugBank.d104.s1|113-120|additive|O
DDI-DrugBank.d104.s1|121-121|.|O
DDI-DrugBank.d514.s0|0-6|Opioids|O
DDI-DrugBank.d514.s0|8-10|are|O
DDI-DrugBank.d514.s0|12-17|strong|O
DDI-DrugBank.d514.s0|19-25|central|O
DDI-DrugBank.d514.s0|27-33|nervous|O
DDI-DrugBank.d514.s0|35-40|system|O
DDI-DrugBank.d514.s0|42-52|depressants|O
DDI-DrugBank.d514.s0|53-53|,|O
DDI-DrugBank.d514.s0|55-57|but|O
DDI-DrugBank.d514.s0|59-65|regular|O
DDI-DrugBank.d514.s0|67-71|users|O
DDI-DrugBank.d514.s0|73-79|develop|O
DDI-DrugBank.d514.s0|81-93|physiological|O
DDI-DrugBank.d514.s0|95-103|tolerance|O
DDI-DrugBank.d514.s0|105-112|allowing|O
DDI-DrugBank.d514.s0|114-122|gradually|O
DDI-DrugBank.d514.s0|124-132|increased|O
DDI-DrugBank.d514.s0|134-140|dosages|O
DDI-DrugBank.d514.s0|141-141|.|O
DDI-DrugBank.d514.s1|0-1|In|O
DDI-DrugBank.d514.s1|3-13|combination|O
DDI-DrugBank.d514.s1|15-18|with|O
DDI-DrugBank.d514.s1|20-24|other|O
DDI-DrugBank.d514.s1|26-32|central|O
DDI-DrugBank.d514.s1|34-40|nervous|O
DDI-DrugBank.d514.s1|42-47|system|O
DDI-DrugBank.d514.s1|49-59|depressants|O
DDI-DrugBank.d514.s1|60-60|,|O
DDI-DrugBank.d514.s1|62-67|heroin|O
DDI-DrugBank.d514.s1|69-71|may|O
DDI-DrugBank.d514.s1|73-77|still|O
DDI-DrugBank.d514.s1|79-82|kill|O
DDI-DrugBank.d514.s1|84-87|even|O
DDI-DrugBank.d514.s1|89-99|experienced|O
DDI-DrugBank.d514.s1|101-105|users|O
DDI-DrugBank.d514.s1|106-106|,|O
DDI-DrugBank.d514.s1|108-119|particularly|O
DDI-DrugBank.d514.s1|121-122|if|O
DDI-DrugBank.d514.s1|124-128|their|O
DDI-DrugBank.d514.s1|130-138|tolerance|O
DDI-DrugBank.d514.s1|140-141|to|O
DDI-DrugBank.d514.s1|143-145|the|O
DDI-DrugBank.d514.s1|147-150|drug|O
DDI-DrugBank.d514.s1|152-154|has|O
DDI-DrugBank.d514.s1|156-162|reduced|O
DDI-DrugBank.d514.s1|164-165|or|O
DDI-DrugBank.d514.s1|167-169|the|O
DDI-DrugBank.d514.s1|171-178|strength|O
DDI-DrugBank.d514.s1|180-181|of|O
DDI-DrugBank.d514.s1|183-187|their|O
DDI-DrugBank.d514.s1|189-193|usual|O
DDI-DrugBank.d514.s1|195-198|dose|O
DDI-DrugBank.d514.s1|200-202|has|O
DDI-DrugBank.d514.s1|204-212|increased|O
DDI-DrugBank.d514.s1|213-213|.|O
DDI-DrugBank.d514.s2|0-9|Toxicology|O
DDI-DrugBank.d514.s2|11-17|studies|O
DDI-DrugBank.d514.s2|19-20|of|O
DDI-DrugBank.d514.s2|22-35|heroin-related|O
DDI-DrugBank.d514.s2|37-42|deaths|O
DDI-DrugBank.d514.s2|44-49|reveal|O
DDI-DrugBank.d514.s2|51-58|frequent|O
DDI-DrugBank.d514.s2|60-70|involvement|O
DDI-DrugBank.d514.s2|72-73|of|O
DDI-DrugBank.d514.s2|75-79|other|O
DDI-DrugBank.d514.s2|81-87|central|O
DDI-DrugBank.d514.s2|89-95|nervous|O
DDI-DrugBank.d514.s2|97-102|system|O
DDI-DrugBank.d514.s2|104-114|depressants|O
DDI-DrugBank.d514.s2|115-115|,|O
DDI-DrugBank.d514.s2|117-125|including|O
DDI-DrugBank.d514.s2|127-133|alcohol|O
DDI-DrugBank.d514.s2|134-134|,|O
DDI-DrugBank.d514.s2|136-150|benzodiazepines|O
DDI-DrugBank.d514.s2|152-155|such|O
DDI-DrugBank.d514.s2|157-158|as|O
DDI-DrugBank.d514.s2|160-167|diazepam|O
DDI-DrugBank.d514.s2|169-169|(|O
DDI-DrugBank.d514.s2|170-175|Valium|O
DDI-DrugBank.d514.s2|176-176|)|O
DDI-DrugBank.d514.s2|177-177|,|O
DDI-DrugBank.d514.s2|179-181|and|O
DDI-DrugBank.d514.s2|182-182|,|O
DDI-DrugBank.d514.s2|184-185|to|O
DDI-DrugBank.d514.s2|187-187|a|O
DDI-DrugBank.d514.s2|189-194|rising|O
DDI-DrugBank.d514.s2|196-201|degree|O
DDI-DrugBank.d514.s2|202-202|,|O
DDI-DrugBank.d514.s2|204-212|methadone|O
DDI-DrugBank.d514.s2|213-213|.|O
DDI-DrugBank.d514.s3|0-9|Ironically|O
DDI-DrugBank.d514.s3|10-10|,|O
DDI-DrugBank.d514.s3|12-26|benzodiazepines|O
DDI-DrugBank.d514.s3|28-30|are|O
DDI-DrugBank.d514.s3|32-36|often|O
DDI-DrugBank.d514.s3|38-41|used|O
DDI-DrugBank.d514.s3|43-44|in|O
DDI-DrugBank.d514.s3|46-48|the|O
DDI-DrugBank.d514.s3|50-58|treatment|O
DDI-DrugBank.d514.s3|60-61|of|O
DDI-DrugBank.d514.s3|63-68|heroin|O
DDI-DrugBank.d514.s3|70-78|addiction|O
DDI-DrugBank.d514.s3|80-84|while|O
DDI-DrugBank.d514.s3|86-89|they|O
DDI-DrugBank.d514.s3|91-95|cause|O
DDI-DrugBank.d514.s3|97-100|much|O
DDI-DrugBank.d514.s3|102-105|more|O
DDI-DrugBank.d514.s3|107-112|severe|O
DDI-DrugBank.d514.s3|114-123|withdrawal|O
DDI-DrugBank.d514.s3|125-132|symptoms|O
DDI-DrugBank.d514.s3|133-133|.|O
DDI-DrugBank.d514.s4|0-6|Cocaine|O
DDI-DrugBank.d514.s4|8-16|sometimes|O
DDI-DrugBank.d514.s4|18-23|proves|O
DDI-DrugBank.d514.s4|25-26|to|O
DDI-DrugBank.d514.s4|28-29|be|O
DDI-DrugBank.d514.s4|31-35|fatal|O
DDI-DrugBank.d514.s4|37-40|when|O
DDI-DrugBank.d514.s4|42-45|used|O
DDI-DrugBank.d514.s4|47-48|in|O
DDI-DrugBank.d514.s4|50-60|combination|O
DDI-DrugBank.d514.s4|62-65|with|O
DDI-DrugBank.d514.s4|67-72|heroin|O
DDI-DrugBank.d514.s4|73-73|.|O
DDI-DrugBank.d580.s0|0-1|In|O
DDI-DrugBank.d580.s0|3-10|clinical|O
DDI-DrugBank.d580.s0|12-18|studies|O
DDI-DrugBank.d580.s0|19-19|,|O
DDI-DrugBank.d580.s0|21-23|the|O
DDI-DrugBank.d580.s0|25-34|concurrent|O
DDI-DrugBank.d580.s0|36-49|administration|O
DDI-DrugBank.d580.s0|51-52|of|O
DDI-DrugBank.d580.s0|54-56|the|O
DDI-DrugBank.d580.s0|58-64|ASMANEX|O
DDI-DrugBank.d580.s0|66-75|TWISTHALER|O
DDI-DrugBank.d580.s0|80-86|inhaler|O
DDI-DrugBank.d580.s0|88-90|and|O
DDI-DrugBank.d580.s0|92-96|other|O
DDI-DrugBank.d580.s0|98-102|drugs|O
DDI-DrugBank.d580.s0|104-111|commonly|O
DDI-DrugBank.d580.s0|113-116|used|O
DDI-DrugBank.d580.s0|118-119|in|O
DDI-DrugBank.d580.s0|121-123|the|O
DDI-DrugBank.d580.s0|125-133|treatment|O
DDI-DrugBank.d580.s0|135-136|of|O
DDI-DrugBank.d580.s0|138-143|asthma|O
DDI-DrugBank.d580.s0|145-147|was|O
DDI-DrugBank.d580.s0|149-151|not|O
DDI-DrugBank.d580.s0|153-162|associated|O
DDI-DrugBank.d580.s0|164-167|with|O
DDI-DrugBank.d580.s0|169-171|any|O
DDI-DrugBank.d580.s0|173-179|unusual|O
DDI-DrugBank.d580.s0|181-187|adverse|O
DDI-DrugBank.d580.s0|189-194|events|O
DDI-DrugBank.d580.s0|195-195|.|O
DDI-DrugBank.d580.s1|0-6|However|O
DDI-DrugBank.d580.s1|7-7|,|O
DDI-DrugBank.d580.s1|9-20|ketoconazole|O
DDI-DrugBank.d580.s1|21-21|,|O
DDI-DrugBank.d580.s1|23-23|a|O
DDI-DrugBank.d580.s1|25-30|potent|O
DDI-DrugBank.d580.s1|32-40|inhibitor|O
DDI-DrugBank.d580.s1|42-43|of|O
DDI-DrugBank.d580.s1|45-54|cytochrome|O
DDI-DrugBank.d580.s1|56-59|P450|O
DDI-DrugBank.d580.s1|61-63|3A4|O
DDI-DrugBank.d580.s1|64-64|,|O
DDI-DrugBank.d580.s1|66-68|may|O
DDI-DrugBank.d580.s1|70-77|increase|O
DDI-DrugBank.d580.s1|79-84|plasma|O
DDI-DrugBank.d580.s1|86-91|levels|O
DDI-DrugBank.d580.s1|93-94|of|O
DDI-DrugBank.d580.s1|96-105|mometasone|O
DDI-DrugBank.d580.s1|107-113|furoate|O
DDI-DrugBank.d580.s1|115-120|during|O
DDI-DrugBank.d580.s1|122-132|concomitant|O
DDI-DrugBank.d580.s1|134-139|dosing|O
DDI-DrugBank.d580.s1|140-140|.|O
DDI-MedLine.d185.s0|0-5|Effect|O
DDI-MedLine.d185.s0|7-8|of|O
DDI-MedLine.d185.s0|10-30|ketoconazole-mediated|O
DDI-MedLine.d185.s0|32-37|CYP3A4|O
DDI-MedLine.d185.s0|39-48|inhibition|O
DDI-MedLine.d185.s0|50-51|on|O
DDI-MedLine.d185.s0|53-60|clinical|O
DDI-MedLine.d185.s0|62-77|pharmacokinetics|O
DDI-MedLine.d185.s0|79-80|of|O
DDI-MedLine.d185.s0|82-93|panobinostat|O
DDI-MedLine.d185.s0|95-95|(|O
DDI-MedLine.d185.s0|96-101|LBH589|O
DDI-MedLine.d185.s0|102-102|)|O
DDI-MedLine.d185.s0|103-103|,|O
DDI-MedLine.d185.s0|105-106|an|O
DDI-MedLine.d185.s0|108-113|orally|O
DDI-MedLine.d185.s0|115-120|active|O
DDI-MedLine.d185.s0|122-128|histone|O
DDI-MedLine.d185.s0|130-140|deacetylase|O
DDI-MedLine.d185.s0|142-150|inhibitor|O
DDI-MedLine.d185.s0|151-151|.|O
DDI-MedLine.d185.s1|0-11|Panobinostat|O
DDI-MedLine.d185.s1|13-14|is|O
DDI-MedLine.d185.s1|16-21|partly|O
DDI-MedLine.d185.s1|23-33|metabolized|O
DDI-MedLine.d185.s1|35-36|by|O
DDI-MedLine.d185.s1|38-43|CYP3A4|O
DDI-MedLine.d185.s1|45-46|in|O
DDI-MedLine.d185.s1|48-52|vitro|O
DDI-MedLine.d185.s1|53-53|.|O
DDI-MedLine.d185.s2|0-3|This|O
DDI-MedLine.d185.s2|5-9|study|O
DDI-MedLine.d185.s2|11-19|evaluated|O
DDI-MedLine.d185.s2|21-23|the|O
DDI-MedLine.d185.s2|25-30|effect|O
DDI-MedLine.d185.s2|32-33|of|O
DDI-MedLine.d185.s2|35-35|a|O
DDI-MedLine.d185.s2|37-42|potent|O
DDI-MedLine.d185.s2|44-48|CYP3A|O
DDI-MedLine.d185.s2|50-58|inhibitor|O
DDI-MedLine.d185.s2|59-59|,|O
DDI-MedLine.d185.s2|61-72|ketoconazole|O
DDI-MedLine.d185.s2|73-73|,|O
DDI-MedLine.d185.s2|75-76|on|O
DDI-MedLine.d185.s2|78-80|the|O
DDI-MedLine.d185.s2|82-97|pharmacokinetics|O
DDI-MedLine.d185.s2|99-101|and|O
DDI-MedLine.d185.s2|103-108|safety|O
DDI-MedLine.d185.s2|110-111|of|O
DDI-MedLine.d185.s2|113-124|panobinostat|O
DDI-MedLine.d185.s2|125-125|.|O
DDI-MedLine.d185.s3|0-7|Patients|O
DDI-MedLine.d185.s3|9-16|received|O
DDI-MedLine.d185.s3|18-18|a|O
DDI-MedLine.d185.s3|20-25|single|O
DDI-MedLine.d185.s3|27-38|panobinostat|O
DDI-MedLine.d185.s3|40-43|oral|O
DDI-MedLine.d185.s3|45-48|dose|O
DDI-MedLine.d185.s3|50-51|on|O
DDI-MedLine.d185.s3|53-55|day|O
DDI-MedLine.d185.s3|57-57|1|O
DDI-MedLine.d185.s3|58-58|,|O
DDI-MedLine.d185.s3|60-67|followed|O
DDI-MedLine.d185.s3|69-70|by|O
DDI-MedLine.d185.s3|72-72|4|O
DDI-MedLine.d185.s3|75-78|days|O
DDI-MedLine.d185.s3|80-87|wash-out|O
DDI-MedLine.d185.s3|89-94|period|O
DDI-MedLine.d185.s3|95-95|.|O
DDI-MedLine.d185.s4|0-1|On|O
DDI-MedLine.d185.s4|3-6|days|O
DDI-MedLine.d185.s4|8-10|5-9|O
DDI-MedLine.d185.s4|11-11|,|O
DDI-MedLine.d185.s4|13-24|ketoconazole|O
DDI-MedLine.d185.s4|26-28|was|O
DDI-MedLine.d185.s4|30-41|administered|O
DDI-MedLine.d185.s4|42-42|.|O
DDI-MedLine.d185.s5|0-1|On|O
DDI-MedLine.d185.s5|3-5|day|O
DDI-MedLine.d185.s5|7-7|8|O
DDI-MedLine.d185.s5|8-8|,|O
DDI-MedLine.d185.s5|10-10|a|O
DDI-MedLine.d185.s5|12-17|single|O
DDI-MedLine.d185.s5|19-30|panobinostat|O
DDI-MedLine.d185.s5|32-35|dose|O
DDI-MedLine.d185.s5|37-39|was|O
DDI-MedLine.d185.s5|41-55|co-administered|O
DDI-MedLine.d185.s5|57-60|with|O
DDI-MedLine.d185.s5|62-73|ketoconazole|O
DDI-MedLine.d185.s5|74-74|.|O
DDI-MedLine.d185.s6|0-11|Panobinostat|O
DDI-MedLine.d185.s6|13-15|was|O
DDI-MedLine.d185.s6|17-28|administered|O
DDI-MedLine.d185.s6|30-31|as|O
DDI-MedLine.d185.s6|33-38|single|O
DDI-MedLine.d185.s6|40-44|agent|O
DDI-MedLine.d185.s6|46-50|three|O
DDI-MedLine.d185.s6|52-56|times|O
DDI-MedLine.d185.s6|58-58|a|O
DDI-MedLine.d185.s6|60-63|week|O
DDI-MedLine.d185.s6|65-66|on|O
DDI-MedLine.d185.s6|68-70|day|O
DDI-MedLine.d185.s6|72-73|15|O
DDI-MedLine.d185.s6|75-77|and|O
DDI-MedLine.d185.s6|79-84|onward|O
DDI-MedLine.d185.s6|85-85|.|O
DDI-MedLine.d185.s7|0-1|In|O
DDI-MedLine.d185.s7|3-5|the|O
DDI-MedLine.d185.s7|7-14|presence|O
DDI-MedLine.d185.s7|16-17|of|O
DDI-MedLine.d185.s7|19-30|ketoconazole|O
DDI-MedLine.d185.s7|31-31|,|O
DDI-MedLine.d185.s7|33-37|there|O
DDI-MedLine.d185.s7|39-41|was|O
DDI-MedLine.d185.s7|43-46|1.6-|O
DDI-MedLine.d185.s7|48-50|and|O
DDI-MedLine.d185.s7|52-59|1.8-fold|O
DDI-MedLine.d185.s7|61-68|increase|O
DDI-MedLine.d185.s7|70-71|in|O
DDI-MedLine.d185.s7|73-73|C|O
DDI-MedLine.d185.s7|75-75|(|O
DDI-MedLine.d185.s7|76-78|max|O
DDI-MedLine.d185.s7|79-79|)|O
DDI-MedLine.d185.s7|81-83|and|O
DDI-MedLine.d185.s7|85-87|AUC|O
DDI-MedLine.d185.s7|89-90|of|O
DDI-MedLine.d185.s7|92-103|panobinostat|O
DDI-MedLine.d185.s7|104-104|,|O
DDI-MedLine.d185.s7|106-117|respectively|O
DDI-MedLine.d185.s7|118-118|.|O
DDI-MedLine.d185.s8|0-1|No|O
DDI-MedLine.d185.s8|3-13|substantial|O
DDI-MedLine.d185.s8|15-20|change|O
DDI-MedLine.d185.s8|22-23|in|O
DDI-MedLine.d185.s8|25-25|T|O
DDI-MedLine.d185.s8|27-27|(|O
DDI-MedLine.d185.s8|28-30|max|O
DDI-MedLine.d185.s8|31-31|)|O
DDI-MedLine.d185.s8|33-34|or|O
DDI-MedLine.d185.s8|36-44|half-life|O
DDI-MedLine.d185.s8|46-48|was|O
DDI-MedLine.d185.s8|50-57|observed|O
DDI-MedLine.d185.s8|58-58|.|O
DDI-MedLine.d185.s9|0-1|No|O
DDI-MedLine.d185.s9|3-12|difference|O
DDI-MedLine.d185.s9|14-15|in|O
DDI-MedLine.d185.s9|17-45|panobinostat-pharmacokinetics|O
DDI-MedLine.d185.s9|47-53|between|O
DDI-MedLine.d185.s9|55-62|patients|O
DDI-MedLine.d185.s9|64-71|carrying|O
DDI-MedLine.d185.s9|73-83|CYP3A5*1/*3|O
DDI-MedLine.d185.s9|85-87|and|O
DDI-MedLine.d185.s9|89-99|CYP3A5*3/*3|O
DDI-MedLine.d185.s9|101-107|alleles|O
DDI-MedLine.d185.s9|109-111|was|O
DDI-MedLine.d185.s9|113-120|observed|O
DDI-MedLine.d185.s9|121-121|.|O
DDI-MedLine.d185.s10|0-3|Most|O
DDI-MedLine.d185.s10|5-14|frequently|O
DDI-MedLine.d185.s10|16-23|reported|O
DDI-MedLine.d185.s10|25-31|adverse|O
DDI-MedLine.d185.s10|33-38|events|O
DDI-MedLine.d185.s10|40-43|were|O
DDI-MedLine.d185.s10|45-60|gastrointestinal|O
DDI-MedLine.d185.s10|62-68|related|O
DDI-MedLine.d185.s10|69-69|.|O
DDI-MedLine.d185.s11|0-7|Patients|O
DDI-MedLine.d185.s11|9-11|had|O
DDI-MedLine.d185.s11|13-24|asymptomatic|O
DDI-MedLine.d185.s11|26-41|hypophosphatemia|O
DDI-MedLine.d185.s11|43-43|(|O
DDI-MedLine.d185.s11|44-45|64|O
DDI-MedLine.d185.s11|46-46|%|O
DDI-MedLine.d185.s11|47-47|)|O
DDI-MedLine.d185.s11|48-48|,|O
DDI-MedLine.d185.s11|50-52|and|O
DDI-MedLine.d185.s11|54-58|urine|O
DDI-MedLine.d185.s11|60-67|analysis|O
DDI-MedLine.d185.s11|69-77|suggested|O
DDI-MedLine.d185.s11|79-83|renal|O
DDI-MedLine.d185.s11|85-93|phosphate|O
DDI-MedLine.d185.s11|95-101|wasting|O
DDI-MedLine.d185.s11|102-102|.|O
DDI-MedLine.d185.s12|0-16|Co-administration|O
DDI-MedLine.d185.s12|18-19|of|O
DDI-MedLine.d185.s12|21-32|panobinostat|O
DDI-MedLine.d185.s12|34-37|with|O
DDI-MedLine.d185.s12|39-43|CYP3A|O
DDI-MedLine.d185.s12|45-54|inhibitors|O
DDI-MedLine.d185.s12|56-57|is|O
DDI-MedLine.d185.s12|59-66|feasible|O
DDI-MedLine.d185.s12|68-69|as|O
DDI-MedLine.d185.s12|71-73|the|O
DDI-MedLine.d185.s12|75-82|observed|O
DDI-MedLine.d185.s12|84-91|increase|O
DDI-MedLine.d185.s12|93-94|in|O
DDI-MedLine.d185.s12|96-107|panobinostat|O
DDI-MedLine.d185.s12|109-110|PK|O
DDI-MedLine.d185.s12|112-121|parameters|O
DDI-MedLine.d185.s12|123-125|was|O
DDI-MedLine.d185.s12|127-129|not|O
DDI-MedLine.d185.s12|131-140|considered|O
DDI-MedLine.d185.s12|142-151|clinically|O
DDI-MedLine.d185.s12|153-160|relevant|O
DDI-MedLine.d185.s12|161-161|.|O
DDI-MedLine.d185.s13|0-10|Considering|O
DDI-MedLine.d185.s13|12-14|the|O
DDI-MedLine.d185.s13|16-26|variability|O
DDI-MedLine.d185.s13|28-29|in|O
DDI-MedLine.d185.s13|31-38|exposure|O
DDI-MedLine.d185.s13|40-48|following|O
DDI-MedLine.d185.s13|50-55|enzyme|O
DDI-MedLine.d185.s13|57-66|inhibition|O
DDI-MedLine.d185.s13|68-70|and|O
DDI-MedLine.d185.s13|72-74|the|O
DDI-MedLine.d185.s13|76-79|fact|O
DDI-MedLine.d185.s13|81-84|that|O
DDI-MedLine.d185.s13|86-92|chronic|O
DDI-MedLine.d185.s13|94-99|dosing|O
DDI-MedLine.d185.s13|101-102|of|O
DDI-MedLine.d185.s13|104-115|panobinostat|O
DDI-MedLine.d185.s13|117-119|was|O
DDI-MedLine.d185.s13|121-123|not|O
DDI-MedLine.d185.s13|125-131|studied|O
DDI-MedLine.d185.s13|133-136|with|O
DDI-MedLine.d185.s13|138-142|CYP3A|O
DDI-MedLine.d185.s13|144-153|inhibitors|O
DDI-MedLine.d185.s13|154-154|,|O
DDI-MedLine.d185.s13|156-160|close|O
DDI-MedLine.d185.s13|162-171|monitoring|O
DDI-MedLine.d185.s13|173-174|of|O
DDI-MedLine.d185.s13|176-195|panobinostat-related|O
DDI-MedLine.d185.s13|197-203|adverse|O
DDI-MedLine.d185.s13|205-210|events|O
DDI-MedLine.d185.s13|212-213|is|O
DDI-MedLine.d185.s13|215-223|necessary|O
DDI-MedLine.d185.s13|224-224|.|O
DDI-DrugBank.d8.s0|0-3|Both|O
DDI-DrugBank.d8.s0|5-7|the|O
DDI-DrugBank.d8.s0|9-17|magnitude|O
DDI-DrugBank.d8.s0|19-21|and|O
DDI-DrugBank.d8.s0|23-30|duration|O
DDI-DrugBank.d8.s0|32-33|of|O
DDI-DrugBank.d8.s0|35-41|central|O
DDI-DrugBank.d8.s0|43-49|nervous|O
DDI-DrugBank.d8.s0|51-56|system|O
DDI-DrugBank.d8.s0|58-60|and|O
DDI-DrugBank.d8.s0|62-75|cardiovascular|O
DDI-DrugBank.d8.s0|77-83|effects|O
DDI-DrugBank.d8.s0|85-87|may|O
DDI-DrugBank.d8.s0|89-90|be|O
DDI-DrugBank.d8.s0|92-99|enhanced|O
DDI-DrugBank.d8.s0|101-104|when|O
DDI-DrugBank.d8.s0|106-112|ALFENTA|O
DDI-DrugBank.d8.s0|114-115|is|O
DDI-DrugBank.d8.s0|117-128|administered|O
DDI-DrugBank.d8.s0|130-131|in|O
DDI-DrugBank.d8.s0|133-143|combination|O
DDI-DrugBank.d8.s0|145-148|with|O
DDI-DrugBank.d8.s0|150-154|other|O
DDI-DrugBank.d8.s0|156-158|CNS|O
DDI-DrugBank.d8.s0|160-170|depressants|O
DDI-DrugBank.d8.s0|172-175|such|O
DDI-DrugBank.d8.s0|177-178|as|O
DDI-DrugBank.d8.s0|180-191|barbiturates|O
DDI-DrugBank.d8.s0|192-192|,|O
DDI-DrugBank.d8.s0|194-206|tranquilizers|O
DDI-DrugBank.d8.s0|207-207|,|O
DDI-DrugBank.d8.s0|209-215|opioids|O
DDI-DrugBank.d8.s0|216-216|,|O
DDI-DrugBank.d8.s0|218-219|or|O
DDI-DrugBank.d8.s0|221-230|inhalation|O
DDI-DrugBank.d8.s0|232-238|general|O
DDI-DrugBank.d8.s0|240-250|anesthetics|O
DDI-DrugBank.d8.s0|251-251|.|O
DDI-DrugBank.d8.s1|0-12|Postoperative|O
DDI-DrugBank.d8.s1|14-24|respiratory|O
DDI-DrugBank.d8.s1|26-35|depression|O
DDI-DrugBank.d8.s1|37-39|may|O
DDI-DrugBank.d8.s1|41-42|be|O
DDI-DrugBank.d8.s1|44-51|enhanced|O
DDI-DrugBank.d8.s1|53-54|or|O
DDI-DrugBank.d8.s1|56-64|prolonged|O
DDI-DrugBank.d8.s1|66-67|by|O
DDI-DrugBank.d8.s1|69-73|these|O
DDI-DrugBank.d8.s1|75-80|agents|O
DDI-DrugBank.d8.s1|81-81|.|O
DDI-DrugBank.d8.s2|0-1|In|O
DDI-DrugBank.d8.s2|3-6|such|O
DDI-DrugBank.d8.s2|8-12|cases|O
DDI-DrugBank.d8.s2|14-15|of|O
DDI-DrugBank.d8.s2|17-24|combined|O
DDI-DrugBank.d8.s2|26-34|treatment|O
DDI-DrugBank.d8.s2|35-35|,|O
DDI-DrugBank.d8.s2|37-39|the|O
DDI-DrugBank.d8.s2|41-44|dose|O
DDI-DrugBank.d8.s2|46-47|of|O
DDI-DrugBank.d8.s2|49-51|one|O
DDI-DrugBank.d8.s2|53-54|or|O
DDI-DrugBank.d8.s2|56-59|both|O
DDI-DrugBank.d8.s2|61-66|agents|O
DDI-DrugBank.d8.s2|68-73|should|O
DDI-DrugBank.d8.s2|75-76|be|O
DDI-DrugBank.d8.s2|78-84|reduced|O
DDI-DrugBank.d8.s2|85-85|.|O
DDI-DrugBank.d8.s3|0-6|Limited|O
DDI-DrugBank.d8.s3|8-15|clinical|O
DDI-DrugBank.d8.s3|17-26|experience|O
DDI-DrugBank.d8.s3|28-36|indicates|O
DDI-DrugBank.d8.s3|38-41|that|O
DDI-DrugBank.d8.s3|43-54|requirements|O
DDI-DrugBank.d8.s3|56-58|for|O
DDI-DrugBank.d8.s3|60-67|volatile|O
DDI-DrugBank.d8.s3|69-78|inhalation|O
DDI-DrugBank.d8.s3|80-90|anesthetics|O
DDI-DrugBank.d8.s3|92-94|are|O
DDI-DrugBank.d8.s3|96-102|reduced|O
DDI-DrugBank.d8.s3|104-105|by|O
DDI-DrugBank.d8.s3|107-108|30|O
DDI-DrugBank.d8.s3|110-111|to|O
DDI-DrugBank.d8.s3|113-114|50|O
DDI-DrugBank.d8.s3|115-115|%|O
DDI-DrugBank.d8.s3|117-119|for|O
DDI-DrugBank.d8.s3|121-123|the|O
DDI-DrugBank.d8.s3|125-129|first|O
DDI-DrugBank.d8.s3|131-135|sixty|O
DDI-DrugBank.d8.s3|137-137|(|O
DDI-DrugBank.d8.s3|138-139|60|O
DDI-DrugBank.d8.s3|140-140|)|O
DDI-DrugBank.d8.s3|142-148|minutes|O
DDI-DrugBank.d8.s3|150-158|following|O
DDI-DrugBank.d8.s3|160-166|ALFENTA|O
DDI-DrugBank.d8.s3|168-176|induction|O
DDI-DrugBank.d8.s3|178-180|The|O
DDI-DrugBank.d8.s3|182-192|concomitant|O
DDI-DrugBank.d8.s3|194-196|use|O
DDI-DrugBank.d8.s3|198-199|of|O
DDI-DrugBank.d8.s3|201-212|erythromycin|O
DDI-DrugBank.d8.s3|214-217|with|O
DDI-DrugBank.d8.s3|219-225|ALFENTA|O
DDI-DrugBank.d8.s3|227-229|can|O
DDI-DrugBank.d8.s3|231-243|significantly|O
DDI-DrugBank.d8.s3|245-251|inhibit|O
DDI-DrugBank.d8.s3|253-259|ALFENTA|O
DDI-DrugBank.d8.s3|261-269|clearance|O
DDI-DrugBank.d8.s3|271-273|and|O
DDI-DrugBank.d8.s3|275-277|may|O
DDI-DrugBank.d8.s3|279-286|increase|O
DDI-DrugBank.d8.s3|288-290|the|O
DDI-DrugBank.d8.s3|292-295|risk|O
DDI-DrugBank.d8.s3|297-298|of|O
DDI-DrugBank.d8.s3|300-308|prolonged|O
DDI-DrugBank.d8.s3|310-311|or|O
DDI-DrugBank.d8.s3|313-319|delayed|O
DDI-DrugBank.d8.s3|321-331|respiratory|O
DDI-DrugBank.d8.s3|333-342|depression|O
DDI-DrugBank.d8.s3|343-343|.|O
DDI-DrugBank.d8.s4|0-9|Cimetidine|O
DDI-DrugBank.d8.s4|11-17|reduces|O
DDI-DrugBank.d8.s4|19-21|the|O
DDI-DrugBank.d8.s4|23-31|clearance|O
DDI-DrugBank.d8.s4|33-34|of|O
DDI-DrugBank.d8.s4|36-42|ALFENTA|O
DDI-DrugBank.d8.s4|43-43|.|O
DDI-DrugBank.d8.s5|0-8|Therefore|O
DDI-DrugBank.d8.s5|10-16|smaller|O
DDI-DrugBank.d8.s5|18-24|ALFENTA|O
DDI-DrugBank.d8.s5|26-30|doses|O
DDI-DrugBank.d8.s5|32-35|will|O
DDI-DrugBank.d8.s5|37-38|be|O
DDI-DrugBank.d8.s5|40-47|required|O
DDI-DrugBank.d8.s5|49-52|with|O
DDI-DrugBank.d8.s5|54-62|prolonged|O
DDI-DrugBank.d8.s5|64-77|administration|O
DDI-DrugBank.d8.s5|79-81|and|O
DDI-DrugBank.d8.s5|83-85|the|O
DDI-DrugBank.d8.s5|87-94|duration|O
DDI-DrugBank.d8.s5|96-97|of|O
DDI-DrugBank.d8.s5|99-104|action|O
DDI-DrugBank.d8.s5|106-107|of|O
DDI-DrugBank.d8.s5|109-115|ALFENTA|O
DDI-DrugBank.d8.s5|117-118|my|O
DDI-DrugBank.d8.s5|120-121|be|O
DDI-DrugBank.d8.s5|123-130|extended|O
DDI-DrugBank.d8.s5|131-131|.|O
DDI-DrugBank.d8.s6|0-12|Perioperative|O
DDI-DrugBank.d8.s6|14-27|administration|O
DDI-DrugBank.d8.s6|29-30|of|O
DDI-DrugBank.d8.s6|32-36|drugs|O
DDI-DrugBank.d8.s6|38-46|affecting|O
DDI-DrugBank.d8.s6|48-54|hepatic|O
DDI-DrugBank.d8.s6|56-60|blood|O
DDI-DrugBank.d8.s6|62-65|flow|O
DDI-DrugBank.d8.s6|67-68|or|O
DDI-DrugBank.d8.s6|70-75|enzyme|O
DDI-DrugBank.d8.s6|77-84|function|O
DDI-DrugBank.d8.s6|86-88|may|O
DDI-DrugBank.d8.s6|90-95|reduce|O
DDI-DrugBank.d8.s6|97-102|plasma|O
DDI-DrugBank.d8.s6|104-112|clearance|O
DDI-DrugBank.d8.s6|114-116|and|O
DDI-DrugBank.d8.s6|118-124|prolong|O
DDI-DrugBank.d8.s6|126-133|recovery|O
DDI-DrugBank.d8.s6|134-134|.|O
DDI-DrugBank.d766.s0|0-4|Since|O
DDI-DrugBank.d766.s0|6-17|trimetrexate|O
DDI-DrugBank.d766.s0|19-20|is|O
DDI-DrugBank.d766.s0|22-32|metabolized|O
DDI-DrugBank.d766.s0|34-35|by|O
DDI-DrugBank.d766.s0|37-37|a|O
DDI-DrugBank.d766.s0|39-42|P450|O
DDI-DrugBank.d766.s0|44-49|enzyme|O
DDI-DrugBank.d766.s0|51-56|system|O
DDI-DrugBank.d766.s0|57-57|,|O
DDI-DrugBank.d766.s0|59-63|drugs|O
DDI-DrugBank.d766.s0|65-68|that|O
DDI-DrugBank.d766.s0|70-75|induce|O
DDI-DrugBank.d766.s0|77-78|or|O
DDI-DrugBank.d766.s0|80-86|inhibit|O
DDI-DrugBank.d766.s0|88-91|this|O
DDI-DrugBank.d766.s0|93-96|drug|O
DDI-DrugBank.d766.s0|98-109|metabolizing|O
DDI-DrugBank.d766.s0|111-116|enzyme|O
DDI-DrugBank.d766.s0|118-123|system|O
DDI-DrugBank.d766.s0|125-127|may|O
DDI-DrugBank.d766.s0|129-134|elicit|O
DDI-DrugBank.d766.s0|136-144|important|O
DDI-DrugBank.d766.s0|146-154|drug-drug|O
DDI-DrugBank.d766.s0|156-167|interactions|O
DDI-DrugBank.d766.s0|169-172|that|O
DDI-DrugBank.d766.s0|174-176|may|O
DDI-DrugBank.d766.s0|178-182|alter|O
DDI-DrugBank.d766.s0|184-195|trimetrexate|O
DDI-DrugBank.d766.s0|197-202|plasma|O
DDI-DrugBank.d766.s0|204-217|concentrations|O
DDI-DrugBank.d766.s0|218-218|.|O
DDI-DrugBank.d766.s1|0-5|Agents|O
DDI-DrugBank.d766.s1|7-10|that|O
DDI-DrugBank.d766.s1|12-16|might|O
DDI-DrugBank.d766.s1|18-19|be|O
DDI-DrugBank.d766.s1|21-34|coadministered|O
DDI-DrugBank.d766.s1|36-39|with|O
DDI-DrugBank.d766.s1|41-52|trimetrexate|O
DDI-DrugBank.d766.s1|54-55|in|O
DDI-DrugBank.d766.s1|57-60|AIDS|O
DDI-DrugBank.d766.s1|62-69|patients|O
DDI-DrugBank.d766.s1|71-73|for|O
DDI-DrugBank.d766.s1|75-79|other|O
DDI-DrugBank.d766.s1|81-91|indications|O
DDI-DrugBank.d766.s1|93-96|that|O
DDI-DrugBank.d766.s1|98-102|could|O
DDI-DrugBank.d766.s1|104-109|elicit|O
DDI-DrugBank.d766.s1|111-114|this|O
DDI-DrugBank.d766.s1|116-123|activity|O
DDI-DrugBank.d766.s1|125-131|include|O
DDI-DrugBank.d766.s1|133-144|erythromycin|O
DDI-DrugBank.d766.s1|145-145|,|O
DDI-DrugBank.d766.s1|147-154|rifampin|O
DDI-DrugBank.d766.s1|155-155|,|O
DDI-DrugBank.d766.s1|157-165|rifabutin|O
DDI-DrugBank.d766.s1|166-166|,|O
DDI-DrugBank.d766.s1|168-179|ketoconazole|O
DDI-DrugBank.d766.s1|180-180|,|O
DDI-DrugBank.d766.s1|182-184|and|O
DDI-DrugBank.d766.s1|186-196|fluconazole|O
DDI-DrugBank.d766.s1|197-197|.|O
DDI-DrugBank.d766.s2|0-1|In|O
DDI-DrugBank.d766.s2|3-7|vitro|O
DDI-DrugBank.d766.s2|9-17|perfusion|O
DDI-DrugBank.d766.s2|19-20|of|O
DDI-DrugBank.d766.s2|22-29|isolated|O
DDI-DrugBank.d766.s2|31-33|rat|O
DDI-DrugBank.d766.s2|35-39|liver|O
DDI-DrugBank.d766.s2|41-43|has|O
DDI-DrugBank.d766.s2|45-49|shown|O
DDI-DrugBank.d766.s2|51-54|that|O
DDI-DrugBank.d766.s2|56-65|cimetidine|O
DDI-DrugBank.d766.s2|67-72|caused|O
DDI-DrugBank.d766.s2|74-74|a|O
DDI-DrugBank.d766.s2|76-86|significant|O
DDI-DrugBank.d766.s2|88-96|reduction|O
DDI-DrugBank.d766.s2|98-99|in|O
DDI-DrugBank.d766.s2|101-112|trimetrexate|O
DDI-DrugBank.d766.s2|114-123|metabolism|O
DDI-DrugBank.d766.s2|125-127|and|O
DDI-DrugBank.d766.s2|129-132|that|O
DDI-DrugBank.d766.s2|134-146|acetaminophen|O
DDI-DrugBank.d766.s2|148-154|altered|O
DDI-DrugBank.d766.s2|156-158|the|O
DDI-DrugBank.d766.s2|160-167|relative|O
DDI-DrugBank.d766.s2|169-181|concentration|O
DDI-DrugBank.d766.s2|183-184|of|O
DDI-DrugBank.d766.s2|186-197|trimetrexate|O
DDI-DrugBank.d766.s2|199-209|metabolites|O
DDI-DrugBank.d766.s2|211-218|possibly|O
DDI-DrugBank.d766.s2|220-221|by|O
DDI-DrugBank.d766.s2|223-231|competing|O
DDI-DrugBank.d766.s2|233-235|for|O
DDI-DrugBank.d766.s2|237-243|sulfate|O
DDI-DrugBank.d766.s2|245-255|metabolites|O
DDI-DrugBank.d766.s2|256-256|.|O
DDI-DrugBank.d766.s3|0-4|Based|O
DDI-DrugBank.d766.s3|6-7|on|O
DDI-DrugBank.d766.s3|9-10|an|O
DDI-DrugBank.d766.s3|12-13|in|O
DDI-DrugBank.d766.s3|15-19|vitro|O
DDI-DrugBank.d766.s3|21-23|rat|O
DDI-DrugBank.d766.s3|25-29|liver|O
DDI-DrugBank.d766.s3|31-35|model|O
DDI-DrugBank.d766.s3|36-36|,|O
DDI-DrugBank.d766.s3|38-45|nitrogen|O
DDI-DrugBank.d766.s3|47-57|substituted|O
DDI-DrugBank.d766.s3|59-67|imidazole|O
DDI-DrugBank.d766.s3|69-73|drugs|O
DDI-DrugBank.d766.s3|75-75|(|O
DDI-DrugBank.d766.s3|76-87|clotrimazole|O
DDI-DrugBank.d766.s3|88-88|,|O
DDI-DrugBank.d766.s3|90-101|ketoconazole|O
DDI-DrugBank.d766.s3|102-102|,|O
DDI-DrugBank.d766.s3|104-113|miconazole|O
DDI-DrugBank.d766.s3|114-114|)|O
DDI-DrugBank.d766.s3|116-119|were|O
DDI-DrugBank.d766.s3|121-126|potent|O
DDI-DrugBank.d766.s3|127-127|,|O
DDI-DrugBank.d766.s3|129-143|non-competitive|O
DDI-DrugBank.d766.s3|145-154|inhibitors|O
DDI-DrugBank.d766.s3|156-157|of|O
DDI-DrugBank.d766.s3|159-170|trimetrexate|O
DDI-DrugBank.d766.s3|172-181|metabolism|O
DDI-DrugBank.d766.s3|182-182|.|O
DDI-DrugBank.d766.s4|0-7|Patients|O
DDI-DrugBank.d766.s4|9-17|medicated|O
DDI-DrugBank.d766.s4|19-22|with|O
DDI-DrugBank.d766.s4|24-28|these|O
DDI-DrugBank.d766.s4|30-34|drugs|O
DDI-DrugBank.d766.s4|36-38|and|O
DDI-DrugBank.d766.s4|40-51|trimetrexate|O
DDI-DrugBank.d766.s4|53-58|should|O
DDI-DrugBank.d766.s4|60-61|be|O
DDI-DrugBank.d766.s4|63-71|carefully|O
DDI-DrugBank.d766.s4|73-81|monitored|O
DDI-DrugBank.d766.s4|82-82|.|O
DDI-DrugBank.d219.s0|0-13|ACE-inhibitors|O
DDI-DrugBank.d219.s0|15-21|Reports|O
DDI-DrugBank.d219.s0|23-29|suggest|O
DDI-DrugBank.d219.s0|31-34|that|O
DDI-DrugBank.d219.s0|36-41|NSAIDs|O
DDI-DrugBank.d219.s0|43-45|may|O
DDI-DrugBank.d219.s0|47-54|diminish|O
DDI-DrugBank.d219.s0|56-58|the|O
DDI-DrugBank.d219.s0|60-75|antihypertensive|O
DDI-DrugBank.d219.s0|77-82|effect|O
DDI-DrugBank.d219.s0|84-85|of|O
DDI-DrugBank.d219.s0|87-100|ACE-inhibitors|O
DDI-DrugBank.d219.s0|101-101|.|O
DDI-DrugBank.d219.s1|0-3|This|O
DDI-DrugBank.d219.s1|5-15|interaction|O
DDI-DrugBank.d219.s1|17-22|should|O
DDI-DrugBank.d219.s1|24-25|be|O
DDI-DrugBank.d219.s1|27-31|given|O
DDI-DrugBank.d219.s1|33-45|consideration|O
DDI-DrugBank.d219.s1|47-48|in|O
DDI-DrugBank.d219.s1|50-57|patients|O
DDI-DrugBank.d219.s1|59-64|taking|O
DDI-DrugBank.d219.s1|66-71|NSAIDs|O
DDI-DrugBank.d219.s1|73-85|concomitantly|O
DDI-DrugBank.d219.s1|87-90|with|O
DDI-DrugBank.d219.s1|92-105|ACE-inhibitors|O
DDI-DrugBank.d219.s1|106-106|.|O
DDI-DrugBank.d219.s2|0-7|Antacids|O
DDI-DrugBank.d219.s2|8-8|:|O
DDI-DrugBank.d219.s2|10-12|The|O
DDI-DrugBank.d219.s2|14-24|concomitant|O
DDI-DrugBank.d219.s2|26-39|administration|O
DDI-DrugBank.d219.s2|41-42|of|O
DDI-DrugBank.d219.s2|44-51|antacids|O
DDI-DrugBank.d219.s2|53-55|has|O
DDI-DrugBank.d219.s2|57-58|no|O
DDI-DrugBank.d219.s2|60-67|apparent|O
DDI-DrugBank.d219.s2|69-74|effect|O
DDI-DrugBank.d219.s2|76-77|on|O
DDI-DrugBank.d219.s2|79-81|the|O
DDI-DrugBank.d219.s2|83-88|extent|O
DDI-DrugBank.d219.s2|90-91|of|O
DDI-DrugBank.d219.s2|93-102|absorption|O
DDI-DrugBank.d219.s2|104-105|of|O
DDI-DrugBank.d219.s2|107-112|Lodine|O
DDI-DrugBank.d219.s2|113-113|.|O
DDI-DrugBank.d219.s3|0-6|However|O
DDI-DrugBank.d219.s3|7-7|,|O
DDI-DrugBank.d219.s3|9-16|antacids|O
DDI-DrugBank.d219.s3|18-20|can|O
DDI-DrugBank.d219.s3|22-29|decrease|O
DDI-DrugBank.d219.s3|31-33|the|O
DDI-DrugBank.d219.s3|35-38|peak|O
DDI-DrugBank.d219.s3|40-52|concentration|O
DDI-DrugBank.d219.s3|54-60|reached|O
DDI-DrugBank.d219.s3|62-63|by|O
DDI-DrugBank.d219.s3|65-66|15|O
DDI-DrugBank.d219.s3|67-67|%|O
DDI-DrugBank.d219.s3|69-70|to|O
DDI-DrugBank.d219.s3|72-73|20|O
DDI-DrugBank.d219.s3|74-74|%|O
DDI-DrugBank.d219.s3|76-78|but|O
DDI-DrugBank.d219.s3|80-83|have|O
DDI-DrugBank.d219.s3|85-86|no|O
DDI-DrugBank.d219.s3|88-97|detectable|O
DDI-DrugBank.d219.s3|99-104|effect|O
DDI-DrugBank.d219.s3|106-107|on|O
DDI-DrugBank.d219.s3|109-111|the|O
DDI-DrugBank.d219.s3|113-124|time-to-peak|O
DDI-DrugBank.d219.s3|125-125|.|O
DDI-DrugBank.d219.s4|0-6|Aspirin|O
DDI-DrugBank.d219.s4|7-7|:|O
DDI-DrugBank.d219.s4|9-12|When|O
DDI-DrugBank.d219.s4|14-19|Lodine|O
DDI-DrugBank.d219.s4|21-22|is|O
DDI-DrugBank.d219.s4|24-35|administered|O
DDI-DrugBank.d219.s4|37-40|with|O
DDI-DrugBank.d219.s4|42-48|aspirin|O
DDI-DrugBank.d219.s4|49-49|,|O
DDI-DrugBank.d219.s4|51-53|its|O
DDI-DrugBank.d219.s4|55-61|protein|O
DDI-DrugBank.d219.s4|63-69|binding|O
DDI-DrugBank.d219.s4|71-72|is|O
DDI-DrugBank.d219.s4|74-80|reduced|O
DDI-DrugBank.d219.s4|81-81|,|O
DDI-DrugBank.d219.s4|83-90|although|O
DDI-DrugBank.d219.s4|92-94|the|O
DDI-DrugBank.d219.s4|96-104|clearance|O
DDI-DrugBank.d219.s4|106-107|of|O
DDI-DrugBank.d219.s4|109-112|free|O
DDI-DrugBank.d219.s4|114-121|etodolac|O
DDI-DrugBank.d219.s4|123-124|is|O
DDI-DrugBank.d219.s4|126-128|not|O
DDI-DrugBank.d219.s4|130-136|altered|O
DDI-DrugBank.d219.s4|137-137|.|O
DDI-DrugBank.d219.s5|0-2|The|O
DDI-DrugBank.d219.s5|4-11|clinical|O
DDI-DrugBank.d219.s5|13-24|significance|O
DDI-DrugBank.d219.s5|26-27|of|O
DDI-DrugBank.d219.s5|29-32|this|O
DDI-DrugBank.d219.s5|34-44|interaction|O
DDI-DrugBank.d219.s5|46-47|is|O
DDI-DrugBank.d219.s5|49-51|not|O
DDI-DrugBank.d219.s5|53-57|known|O
DDI-DrugBank.d219.s5|58-58|;|O
DDI-DrugBank.d219.s6|0-6|however|O
DDI-DrugBank.d219.s6|7-7|,|O
DDI-DrugBank.d219.s6|9-10|as|O
DDI-DrugBank.d219.s6|12-15|with|O
DDI-DrugBank.d219.s6|17-21|other|O
DDI-DrugBank.d219.s6|23-28|NSAIDs|O
DDI-DrugBank.d219.s6|29-29|,|O
DDI-DrugBank.d219.s6|31-41|concomitant|O
DDI-DrugBank.d219.s6|43-56|administration|O
DDI-DrugBank.d219.s6|58-59|of|O
DDI-DrugBank.d219.s6|61-66|Lodine|O
DDI-DrugBank.d219.s6|68-70|and|O
DDI-DrugBank.d219.s6|72-78|aspirin|O
DDI-DrugBank.d219.s6|80-81|is|O
DDI-DrugBank.d219.s6|83-85|not|O
DDI-DrugBank.d219.s6|87-95|generally|O
DDI-DrugBank.d219.s6|97-107|recommended|O
DDI-DrugBank.d219.s6|109-115|because|O
DDI-DrugBank.d219.s6|117-118|of|O
DDI-DrugBank.d219.s6|120-122|the|O
DDI-DrugBank.d219.s6|124-132|potential|O
DDI-DrugBank.d219.s6|134-135|of|O
DDI-DrugBank.d219.s6|137-145|increased|O
DDI-DrugBank.d219.s6|147-153|adverse|O
DDI-DrugBank.d219.s6|155-161|effects|O
DDI-DrugBank.d219.s6|162-162|.|O
DDI-DrugBank.d219.s7|0-11|Cyclosporine|O
DDI-DrugBank.d219.s7|12-12|,|O
DDI-DrugBank.d219.s7|14-20|Digoxin|O
DDI-DrugBank.d219.s7|21-21|,|O
DDI-DrugBank.d219.s7|23-34|Methotrexate|O
DDI-DrugBank.d219.s7|36-41|Lodine|O
DDI-DrugBank.d219.s7|42-42|,|O
DDI-DrugBank.d219.s7|44-47|like|O
DDI-DrugBank.d219.s7|49-53|other|O
DDI-DrugBank.d219.s7|55-60|NSAIDs|O
DDI-DrugBank.d219.s7|61-61|,|O
DDI-DrugBank.d219.s7|63-69|through|O
DDI-DrugBank.d219.s7|71-77|effects|O
DDI-DrugBank.d219.s7|79-80|on|O
DDI-DrugBank.d219.s7|82-86|renal|O
DDI-DrugBank.d219.s7|88-101|prostaglandins|O
DDI-DrugBank.d219.s7|102-102|,|O
DDI-DrugBank.d219.s7|104-106|may|O
DDI-DrugBank.d219.s7|108-112|cause|O
DDI-DrugBank.d219.s7|114-120|changes|O
DDI-DrugBank.d219.s7|122-123|in|O
DDI-DrugBank.d219.s7|125-127|the|O
DDI-DrugBank.d219.s7|129-139|elimination|O
DDI-DrugBank.d219.s7|141-142|of|O
DDI-DrugBank.d219.s7|144-148|these|O
DDI-DrugBank.d219.s7|150-154|drugs|O
DDI-DrugBank.d219.s7|156-162|leading|O
DDI-DrugBank.d219.s7|164-165|to|O
DDI-DrugBank.d219.s7|167-174|elevated|O
DDI-DrugBank.d219.s7|176-180|serum|O
DDI-DrugBank.d219.s7|182-187|levels|O
DDI-DrugBank.d219.s7|189-190|of|O
DDI-DrugBank.d219.s7|192-203|cyclosporine|O
DDI-DrugBank.d219.s7|204-204|,|O
DDI-DrugBank.d219.s7|206-212|digoxin|O
DDI-DrugBank.d219.s7|213-213|,|O
DDI-DrugBank.d219.s7|215-226|methotrexate|O
DDI-DrugBank.d219.s7|227-227|,|O
DDI-DrugBank.d219.s7|229-231|and|O
DDI-DrugBank.d219.s7|233-241|increased|O
DDI-DrugBank.d219.s7|243-250|toxicity|O
DDI-DrugBank.d219.s7|251-251|.|O
DDI-DrugBank.d219.s8|0-13|Nephrotoxicity|O
DDI-DrugBank.d219.s8|15-24|associated|O
DDI-DrugBank.d219.s8|26-29|with|O
DDI-DrugBank.d219.s8|31-42|cyclosporine|O
DDI-DrugBank.d219.s8|44-46|may|O
DDI-DrugBank.d219.s8|48-51|also|O
DDI-DrugBank.d219.s8|53-54|be|O
DDI-DrugBank.d219.s8|56-63|enhanced|O
DDI-DrugBank.d219.s8|64-64|.|O
DDI-DrugBank.d219.s9|0-7|Patients|O
DDI-DrugBank.d219.s9|9-17|receiving|O
DDI-DrugBank.d219.s9|19-23|these|O
DDI-DrugBank.d219.s9|25-29|drugs|O
DDI-DrugBank.d219.s9|31-33|who|O
DDI-DrugBank.d219.s9|35-37|are|O
DDI-DrugBank.d219.s9|39-43|given|O
DDI-DrugBank.d219.s9|45-50|Lodine|O
DDI-DrugBank.d219.s9|51-51|,|O
DDI-DrugBank.d219.s9|53-54|or|O
DDI-DrugBank.d219.s9|56-58|any|O
DDI-DrugBank.d219.s9|60-64|other|O
DDI-DrugBank.d219.s9|66-70|NSAID|O
DDI-DrugBank.d219.s9|71-71|,|O
DDI-DrugBank.d219.s9|73-75|and|O
DDI-DrugBank.d219.s9|77-88|particularly|O
DDI-DrugBank.d219.s9|90-94|those|O
DDI-DrugBank.d219.s9|96-103|patients|O
DDI-DrugBank.d219.s9|105-108|with|O
DDI-DrugBank.d219.s9|110-116|altered|O
DDI-DrugBank.d219.s9|118-122|renal|O
DDI-DrugBank.d219.s9|124-131|function|O
DDI-DrugBank.d219.s9|132-132|,|O
DDI-DrugBank.d219.s9|134-139|should|O
DDI-DrugBank.d219.s9|141-142|be|O
DDI-DrugBank.d219.s9|144-151|observed|O
DDI-DrugBank.d219.s9|153-155|for|O
DDI-DrugBank.d219.s9|157-159|the|O
DDI-DrugBank.d219.s9|161-171|development|O
DDI-DrugBank.d219.s9|173-174|of|O
DDI-DrugBank.d219.s9|176-178|the|O
DDI-DrugBank.d219.s9|180-187|specific|O
DDI-DrugBank.d219.s9|189-198|toxicities|O
DDI-DrugBank.d219.s9|200-201|of|O
DDI-DrugBank.d219.s9|203-207|these|O
DDI-DrugBank.d219.s9|209-213|drugs|O
DDI-DrugBank.d219.s9|214-214|.|O
DDI-DrugBank.d219.s10|0-8|Diuretics|O
DDI-DrugBank.d219.s10|9-9|:|O
DDI-DrugBank.d219.s10|11-18|Etodolac|O
DDI-DrugBank.d219.s10|20-22|has|O
DDI-DrugBank.d219.s10|24-25|no|O
DDI-DrugBank.d219.s10|27-34|apparent|O
DDI-DrugBank.d219.s10|36-50|pharmacokinetic|O
DDI-DrugBank.d219.s10|52-62|interaction|O
DDI-DrugBank.d219.s10|64-67|when|O
DDI-DrugBank.d219.s10|69-80|administered|O
DDI-DrugBank.d219.s10|82-85|with|O
DDI-DrugBank.d219.s10|87-96|furosemide|O
DDI-DrugBank.d219.s10|98-99|or|O
DDI-DrugBank.d219.s10|101-119|hydrochlorothiazide|O
DDI-DrugBank.d219.s10|120-120|.|O
DDI-DrugBank.d219.s11|0-11|Nevertheless|O
DDI-DrugBank.d219.s11|12-12|,|O
DDI-DrugBank.d219.s11|14-21|clinical|O
DDI-DrugBank.d219.s11|23-29|studies|O
DDI-DrugBank.d219.s11|30-30|,|O
DDI-DrugBank.d219.s11|32-33|as|O
DDI-DrugBank.d219.s11|35-38|well|O
DDI-DrugBank.d219.s11|40-41|as|O
DDI-DrugBank.d219.s11|43-55|postmarketing|O
DDI-DrugBank.d219.s11|57-68|observations|O
DDI-DrugBank.d219.s11|70-73|have|O
DDI-DrugBank.d219.s11|75-79|shown|O
DDI-DrugBank.d219.s11|81-84|that|O
DDI-DrugBank.d219.s11|86-91|Lodine|O
DDI-DrugBank.d219.s11|93-95|can|O
DDI-DrugBank.d219.s11|97-102|reduce|O
DDI-DrugBank.d219.s11|104-106|the|O
DDI-DrugBank.d219.s11|108-118|natriuretic|O
DDI-DrugBank.d219.s11|120-125|effect|O
DDI-DrugBank.d219.s11|127-128|of|O
DDI-DrugBank.d219.s11|130-139|furosemide|O
DDI-DrugBank.d219.s11|141-143|and|O
DDI-DrugBank.d219.s11|145-153|thiazides|O
DDI-DrugBank.d219.s11|155-156|in|O
DDI-DrugBank.d219.s11|158-161|some|O
DDI-DrugBank.d219.s11|163-170|patients|O
DDI-DrugBank.d219.s11|171-171|.|O
DDI-DrugBank.d219.s12|0-3|This|O
DDI-DrugBank.d219.s12|5-12|response|O
DDI-DrugBank.d219.s12|14-16|has|O
DDI-DrugBank.d219.s12|18-21|been|O
DDI-DrugBank.d219.s12|23-32|attributed|O
DDI-DrugBank.d219.s12|34-35|to|O
DDI-DrugBank.d219.s12|37-46|inhibition|O
DDI-DrugBank.d219.s12|48-49|of|O
DDI-DrugBank.d219.s12|51-55|renal|O
DDI-DrugBank.d219.s12|57-69|prostaglandin|O
DDI-DrugBank.d219.s12|71-79|synthesis|O
DDI-DrugBank.d219.s12|80-80|.|O
DDI-DrugBank.d219.s13|0-5|During|O
DDI-DrugBank.d219.s13|7-17|concomitant|O
DDI-DrugBank.d219.s13|19-25|therapy|O
DDI-DrugBank.d219.s13|27-30|with|O
DDI-DrugBank.d219.s13|32-37|NSAIDs|O
DDI-DrugBank.d219.s13|38-38|,|O
DDI-DrugBank.d219.s13|40-42|the|O
DDI-DrugBank.d219.s13|44-50|patient|O
DDI-DrugBank.d219.s13|52-57|should|O
DDI-DrugBank.d219.s13|59-60|be|O
DDI-DrugBank.d219.s13|62-69|observed|O
DDI-DrugBank.d219.s13|71-77|closely|O
DDI-DrugBank.d219.s13|79-81|for|O
DDI-DrugBank.d219.s13|83-87|signs|O
DDI-DrugBank.d219.s13|89-90|of|O
DDI-DrugBank.d219.s13|92-96|renal|O
DDI-DrugBank.d219.s13|98-104|failure|O
DDI-DrugBank.d219.s13|105-105|,|O
DDI-DrugBank.d219.s13|107-108|as|O
DDI-DrugBank.d219.s13|110-113|well|O
DDI-DrugBank.d219.s13|115-116|as|O
DDI-DrugBank.d219.s13|118-119|to|O
DDI-DrugBank.d219.s13|121-126|assure|O
DDI-DrugBank.d219.s13|128-135|diuretic|O
DDI-DrugBank.d219.s13|137-144|efficacy|O
DDI-DrugBank.d219.s13|145-145|.|O
DDI-DrugBank.d219.s14|0-8|Glyburide|O
DDI-DrugBank.d219.s14|9-9|:|O
DDI-DrugBank.d219.s14|11-18|Etodolac|O
DDI-DrugBank.d219.s14|20-22|has|O
DDI-DrugBank.d219.s14|24-25|no|O
DDI-DrugBank.d219.s14|27-34|apparent|O
DDI-DrugBank.d219.s14|36-50|pharmacokinetic|O
DDI-DrugBank.d219.s14|52-62|interaction|O
DDI-DrugBank.d219.s14|64-67|when|O
DDI-DrugBank.d219.s14|69-80|administered|O
DDI-DrugBank.d219.s14|82-85|with|O
DDI-DrugBank.d219.s14|87-95|glyburide|O
DDI-DrugBank.d219.s14|96-96|.|O
DDI-DrugBank.d219.s15|0-6|Lithium|O
DDI-DrugBank.d219.s15|7-7|:|O
DDI-DrugBank.d219.s15|9-14|NSAIDs|O
DDI-DrugBank.d219.s15|16-19|have|O
DDI-DrugBank.d219.s15|21-28|produced|O
DDI-DrugBank.d219.s15|30-31|an|O
DDI-DrugBank.d219.s15|33-41|elevation|O
DDI-DrugBank.d219.s15|43-44|of|O
DDI-DrugBank.d219.s15|46-51|plasma|O
DDI-DrugBank.d219.s15|53-59|lithium|O
DDI-DrugBank.d219.s15|61-66|levels|O
DDI-DrugBank.d219.s15|68-70|and|O
DDI-DrugBank.d219.s15|72-72|a|O
DDI-DrugBank.d219.s15|74-82|reduction|O
DDI-DrugBank.d219.s15|84-85|in|O
DDI-DrugBank.d219.s15|87-91|renal|O
DDI-DrugBank.d219.s15|93-99|lithium|O
DDI-DrugBank.d219.s15|101-109|clearance|O
DDI-DrugBank.d219.s15|110-110|.|O
DDI-DrugBank.d219.s16|0-2|The|O
DDI-DrugBank.d219.s16|4-7|mean|O
DDI-DrugBank.d219.s16|9-15|minimum|O
DDI-DrugBank.d219.s16|17-23|lithium|O
DDI-DrugBank.d219.s16|25-37|concentration|O
DDI-DrugBank.d219.s16|39-47|increased|O
DDI-DrugBank.d219.s16|49-50|15|O
DDI-DrugBank.d219.s16|51-51|%|O
DDI-DrugBank.d219.s16|53-55|and|O
DDI-DrugBank.d219.s16|57-59|the|O
DDI-DrugBank.d219.s16|61-65|renal|O
DDI-DrugBank.d219.s16|67-75|clearance|O
DDI-DrugBank.d219.s16|77-79|was|O
DDI-DrugBank.d219.s16|81-89|decreased|O
DDI-DrugBank.d219.s16|91-92|by|O
DDI-DrugBank.d219.s16|94-106|approximately|O
DDI-DrugBank.d219.s16|108-109|20|O
DDI-DrugBank.d219.s16|110-110|%|O
DDI-DrugBank.d219.s16|111-111|.|O
DDI-DrugBank.d219.s17|0-4|These|O
DDI-DrugBank.d219.s17|6-12|effects|O
DDI-DrugBank.d219.s17|14-17|have|O
DDI-DrugBank.d219.s17|19-22|been|O
DDI-DrugBank.d219.s17|24-33|attributed|O
DDI-DrugBank.d219.s17|35-36|to|O
DDI-DrugBank.d219.s17|38-47|inhibition|O
DDI-DrugBank.d219.s17|49-50|of|O
DDI-DrugBank.d219.s17|52-56|renal|O
DDI-DrugBank.d219.s17|58-70|prostaglandin|O
DDI-DrugBank.d219.s17|72-80|synthesis|O
DDI-DrugBank.d219.s17|82-83|by|O
DDI-DrugBank.d219.s17|85-87|the|O
DDI-DrugBank.d219.s17|89-93|NSAID|O
DDI-DrugBank.d219.s17|94-94|.|O
DDI-DrugBank.d219.s18|0-3|Thus|O
DDI-DrugBank.d219.s18|4-4|,|O
DDI-DrugBank.d219.s18|6-9|when|O
DDI-DrugBank.d219.s18|11-16|NSAIDs|O
DDI-DrugBank.d219.s18|18-20|and|O
DDI-DrugBank.d219.s18|22-28|lithium|O
DDI-DrugBank.d219.s18|30-32|are|O
DDI-DrugBank.d219.s18|34-45|administered|O
DDI-DrugBank.d219.s18|47-58|concurrently|O
DDI-DrugBank.d219.s18|59-59|,|O
DDI-DrugBank.d219.s18|61-68|subjects|O
DDI-DrugBank.d219.s18|70-75|should|O
DDI-DrugBank.d219.s18|77-78|be|O
DDI-DrugBank.d219.s18|80-87|observed|O
DDI-DrugBank.d219.s18|89-97|carefully|O
DDI-DrugBank.d219.s18|99-101|for|O
DDI-DrugBank.d219.s18|103-107|signs|O
DDI-DrugBank.d219.s18|109-110|of|O
DDI-DrugBank.d219.s18|112-118|lithium|O
DDI-DrugBank.d219.s18|120-127|toxicity|O
DDI-DrugBank.d219.s18|128-128|.|O
DDI-DrugBank.d219.s19|0-13|Phenylbutazone|O
DDI-DrugBank.d219.s19|14-14|:|O
DDI-DrugBank.d219.s19|16-29|Phenylbutazone|O
DDI-DrugBank.d219.s19|31-36|causes|O
DDI-DrugBank.d219.s19|38-45|increase|O
DDI-DrugBank.d219.s19|47-47|(|O
DDI-DrugBank.d219.s19|48-49|by|O
DDI-DrugBank.d219.s19|51-55|about|O
DDI-DrugBank.d219.s19|57-58|80|O
DDI-DrugBank.d219.s19|59-59|%|O
DDI-DrugBank.d219.s19|60-60|)|O
DDI-DrugBank.d219.s19|62-63|in|O
DDI-DrugBank.d219.s19|65-67|the|O
DDI-DrugBank.d219.s19|69-72|free|O
DDI-DrugBank.d219.s19|74-81|fraction|O
DDI-DrugBank.d219.s19|83-84|of|O
DDI-DrugBank.d219.s19|86-93|etodolac|O
DDI-DrugBank.d219.s19|94-94|.|O
DDI-DrugBank.d219.s20|0-7|Although|O
DDI-DrugBank.d219.s20|9-10|in|O
DDI-DrugBank.d219.s20|12-15|vivo|O
DDI-DrugBank.d219.s20|17-23|studies|O
DDI-DrugBank.d219.s20|25-28|have|O
DDI-DrugBank.d219.s20|30-32|not|O
DDI-DrugBank.d219.s20|34-37|been|O
DDI-DrugBank.d219.s20|39-42|done|O
DDI-DrugBank.d219.s20|44-45|to|O
DDI-DrugBank.d219.s20|47-49|see|O
DDI-DrugBank.d219.s20|51-52|if|O
DDI-DrugBank.d219.s20|54-61|etodolac|O
DDI-DrugBank.d219.s20|63-71|clearance|O
DDI-DrugBank.d219.s20|73-74|is|O
DDI-DrugBank.d219.s20|76-82|changed|O
DDI-DrugBank.d219.s20|84-85|by|O
DDI-DrugBank.d219.s20|87-102|coadministration|O
DDI-DrugBank.d219.s20|104-105|of|O
DDI-DrugBank.d219.s20|107-120|phenylbutazone|O
DDI-DrugBank.d219.s20|121-121|,|O
DDI-DrugBank.d219.s20|123-124|it|O
DDI-DrugBank.d219.s20|126-127|is|O
DDI-DrugBank.d219.s20|129-131|not|O
DDI-DrugBank.d219.s20|133-143|recommended|O
DDI-DrugBank.d219.s20|145-148|that|O
DDI-DrugBank.d219.s20|150-153|they|O
DDI-DrugBank.d219.s20|155-156|be|O
DDI-DrugBank.d219.s20|158-171|coadministered|O
DDI-DrugBank.d219.s20|172-172|.|O
DDI-DrugBank.d219.s21|0-8|Phenytoin|O
DDI-DrugBank.d219.s21|9-9|:|O
DDI-DrugBank.d219.s21|11-18|Etodolac|O
DDI-DrugBank.d219.s21|20-22|has|O
DDI-DrugBank.d219.s21|24-25|no|O
DDI-DrugBank.d219.s21|27-34|apparent|O
DDI-DrugBank.d219.s21|36-50|pharmacokinetic|O
DDI-DrugBank.d219.s21|52-62|interaction|O
DDI-DrugBank.d219.s21|64-67|when|O
DDI-DrugBank.d219.s21|69-80|administered|O
DDI-DrugBank.d219.s21|82-85|with|O
DDI-DrugBank.d219.s21|87-95|phenytoin|O
DDI-DrugBank.d219.s21|96-96|.|O
DDI-DrugBank.d219.s22|0-7|Warfarin|O
DDI-DrugBank.d219.s22|8-8|:|O
DDI-DrugBank.d219.s22|10-12|The|O
DDI-DrugBank.d219.s22|14-20|effects|O
DDI-DrugBank.d219.s22|22-23|of|O
DDI-DrugBank.d219.s22|25-32|warfarin|O
DDI-DrugBank.d219.s22|34-36|and|O
DDI-DrugBank.d219.s22|38-43|NSAIDs|O
DDI-DrugBank.d219.s22|45-46|on|O
DDI-DrugBank.d219.s22|48-49|GI|O
DDI-DrugBank.d219.s22|51-58|bleeding|O
DDI-DrugBank.d219.s22|60-62|are|O
DDI-DrugBank.d219.s22|64-74|synergistic|O
DDI-DrugBank.d219.s22|75-75|,|O
DDI-DrugBank.d219.s22|77-80|such|O
DDI-DrugBank.d219.s22|82-85|that|O
DDI-DrugBank.d219.s22|87-91|users|O
DDI-DrugBank.d219.s22|93-94|of|O
DDI-DrugBank.d219.s22|96-99|both|O
DDI-DrugBank.d219.s22|101-105|drugs|O
DDI-DrugBank.d219.s22|107-114|together|O
DDI-DrugBank.d219.s22|116-119|have|O
DDI-DrugBank.d219.s22|121-121|a|O
DDI-DrugBank.d219.s22|123-126|risk|O
DDI-DrugBank.d219.s22|128-129|of|O
DDI-DrugBank.d219.s22|131-137|serious|O
DDI-DrugBank.d219.s22|139-140|GI|O
DDI-DrugBank.d219.s22|142-149|bleeding|O
DDI-DrugBank.d219.s22|151-156|higher|O
DDI-DrugBank.d219.s22|158-161|than|O
DDI-DrugBank.d219.s22|163-166|that|O
DDI-DrugBank.d219.s22|168-169|of|O
DDI-DrugBank.d219.s22|171-175|users|O
DDI-DrugBank.d219.s22|177-178|of|O
DDI-DrugBank.d219.s22|180-185|either|O
DDI-DrugBank.d219.s22|187-190|drug|O
DDI-DrugBank.d219.s22|192-196|alone|O
DDI-DrugBank.d219.s22|197-197|.|O
DDI-DrugBank.d219.s23|0-9|Short-term|O
DDI-DrugBank.d219.s23|11-25|pharmacokinetic|O
DDI-DrugBank.d219.s23|27-33|studies|O
DDI-DrugBank.d219.s23|35-38|have|O
DDI-DrugBank.d219.s23|40-51|demonstrated|O
DDI-DrugBank.d219.s23|53-56|that|O
DDI-DrugBank.d219.s23|58-68|concomitant|O
DDI-DrugBank.d219.s23|70-83|administration|O
DDI-DrugBank.d219.s23|85-86|of|O
DDI-DrugBank.d219.s23|88-95|warfarin|O
DDI-DrugBank.d219.s23|97-99|and|O
DDI-DrugBank.d219.s23|101-106|Lodine|O
DDI-DrugBank.d219.s23|109-109|(|O
DDI-DrugBank.d219.s23|110-117|etodolac|O
DDI-DrugBank.d219.s23|119-126|capsules|O
DDI-DrugBank.d219.s23|128-130|and|O
DDI-DrugBank.d219.s23|132-138|tablets|O
DDI-DrugBank.d219.s23|139-139|)|O
DDI-DrugBank.d219.s23|141-147|results|O
DDI-DrugBank.d219.s23|149-150|in|O
DDI-DrugBank.d219.s23|152-158|reduced|O
DDI-DrugBank.d219.s23|160-166|protein|O
DDI-DrugBank.d219.s23|168-174|binding|O
DDI-DrugBank.d219.s23|176-177|of|O
DDI-DrugBank.d219.s23|179-186|warfarin|O
DDI-DrugBank.d219.s23|187-187|,|O
DDI-DrugBank.d219.s23|189-191|but|O
DDI-DrugBank.d219.s23|193-197|there|O
DDI-DrugBank.d219.s23|199-201|was|O
DDI-DrugBank.d219.s23|203-204|no|O
DDI-DrugBank.d219.s23|206-211|change|O
DDI-DrugBank.d219.s23|213-214|in|O
DDI-DrugBank.d219.s23|216-218|the|O
DDI-DrugBank.d219.s23|220-228|clearance|O
DDI-DrugBank.d219.s23|230-231|of|O
DDI-DrugBank.d219.s23|233-236|free|O
DDI-DrugBank.d219.s23|238-245|warfarin|O
DDI-DrugBank.d219.s23|246-246|.|O
DDI-DrugBank.d219.s24|0-4|There|O
DDI-DrugBank.d219.s24|6-8|was|O
DDI-DrugBank.d219.s24|10-11|no|O
DDI-DrugBank.d219.s24|13-23|significant|O
DDI-DrugBank.d219.s24|25-34|difference|O
DDI-DrugBank.d219.s24|36-37|in|O
DDI-DrugBank.d219.s24|39-41|the|O
DDI-DrugBank.d219.s24|43-57|pharmacodynamic|O
DDI-DrugBank.d219.s24|59-64|effect|O
DDI-DrugBank.d219.s24|66-67|of|O
DDI-DrugBank.d219.s24|69-76|warfarin|O
DDI-DrugBank.d219.s24|78-89|administered|O
DDI-DrugBank.d219.s24|91-95|alone|O
DDI-DrugBank.d219.s24|97-99|and|O
DDI-DrugBank.d219.s24|101-108|warfarin|O
DDI-DrugBank.d219.s24|110-121|administered|O
DDI-DrugBank.d219.s24|123-126|with|O
DDI-DrugBank.d219.s24|128-133|Lodine|O
DDI-DrugBank.d219.s24|135-136|as|O
DDI-DrugBank.d219.s24|138-145|measured|O
DDI-DrugBank.d219.s24|147-148|by|O
DDI-DrugBank.d219.s24|150-160|prothrombin|O
DDI-DrugBank.d219.s24|162-165|time|O
DDI-DrugBank.d219.s24|166-166|.|O
DDI-DrugBank.d219.s25|0-3|Thus|O
DDI-DrugBank.d219.s25|4-4|,|O
DDI-DrugBank.d219.s25|6-16|concomitant|O
DDI-DrugBank.d219.s25|18-24|therapy|O
DDI-DrugBank.d219.s25|26-29|with|O
DDI-DrugBank.d219.s25|31-38|warfarin|O
DDI-DrugBank.d219.s25|40-42|and|O
DDI-DrugBank.d219.s25|44-49|Lodine|O
DDI-DrugBank.d219.s25|51-56|should|O
DDI-DrugBank.d219.s25|58-60|not|O
DDI-DrugBank.d219.s25|62-68|require|O
DDI-DrugBank.d219.s25|70-75|dosage|O
DDI-DrugBank.d219.s25|77-86|adjustment|O
DDI-DrugBank.d219.s25|88-89|of|O
DDI-DrugBank.d219.s25|91-96|either|O
DDI-DrugBank.d219.s25|98-101|drug|O
DDI-DrugBank.d219.s25|102-102|.|O
DDI-DrugBank.d219.s26|0-6|However|O
DDI-DrugBank.d219.s26|7-7|,|O
DDI-DrugBank.d219.s26|9-15|caution|O
DDI-DrugBank.d219.s26|17-22|should|O
DDI-DrugBank.d219.s26|24-25|be|O
DDI-DrugBank.d219.s26|27-35|exercised|O
DDI-DrugBank.d219.s26|37-43|because|O
DDI-DrugBank.d219.s26|45-49|there|O
DDI-DrugBank.d219.s26|51-54|have|O
DDI-DrugBank.d219.s26|56-59|been|O
DDI-DrugBank.d219.s26|61-61|a|O
DDI-DrugBank.d219.s26|63-65|few|O
DDI-DrugBank.d219.s26|67-77|spontaneous|O
DDI-DrugBank.d219.s26|79-85|reports|O
DDI-DrugBank.d219.s26|87-88|of|O
DDI-DrugBank.d219.s26|90-98|prolonged|O
DDI-DrugBank.d219.s26|100-110|prothrombin|O
DDI-DrugBank.d219.s26|112-116|times|O
DDI-DrugBank.d219.s26|117-117|,|O
DDI-DrugBank.d219.s26|119-122|with|O
DDI-DrugBank.d219.s26|124-125|or|O
DDI-DrugBank.d219.s26|127-133|without|O
DDI-DrugBank.d219.s26|135-142|bleeding|O
DDI-DrugBank.d219.s26|143-143|,|O
DDI-DrugBank.d219.s26|145-146|in|O
DDI-DrugBank.d219.s26|148-163|etodolac-treated|O
DDI-DrugBank.d219.s26|165-172|patients|O
DDI-DrugBank.d219.s26|174-182|receiving|O
DDI-DrugBank.d219.s26|184-194|concomitant|O
DDI-DrugBank.d219.s26|196-203|warfarin|O
DDI-DrugBank.d219.s26|205-211|therapy|O
DDI-DrugBank.d219.s26|212-212|.|O
DDI-DrugBank.d219.s27|0-14|Drug/Laboratory|O
DDI-DrugBank.d219.s27|16-19|Test|O
DDI-DrugBank.d219.s27|21-32|Interactions|O
DDI-DrugBank.d219.s27|34-36|The|O
DDI-DrugBank.d219.s27|38-42|urine|O
DDI-DrugBank.d219.s27|44-45|of|O
DDI-DrugBank.d219.s27|47-54|patients|O
DDI-DrugBank.d219.s27|56-58|who|O
DDI-DrugBank.d219.s27|60-63|take|O
DDI-DrugBank.d219.s27|65-70|Lodine|O
DDI-DrugBank.d219.s27|72-74|can|O
DDI-DrugBank.d219.s27|76-79|give|O
DDI-DrugBank.d219.s27|81-81|a|O
DDI-DrugBank.d219.s27|83-96|false-positive|O
DDI-DrugBank.d219.s27|98-105|reaction|O
DDI-DrugBank.d219.s27|107-109|for|O
DDI-DrugBank.d219.s27|111-117|urinary|O
DDI-DrugBank.d219.s27|119-127|bilirubin|O
DDI-DrugBank.d219.s27|129-129|(|O
DDI-DrugBank.d219.s27|130-137|urobilin|O
DDI-DrugBank.d219.s27|138-138|)|O
DDI-DrugBank.d219.s27|140-142|due|O
DDI-DrugBank.d219.s27|144-145|to|O
DDI-DrugBank.d219.s27|147-149|the|O
DDI-DrugBank.d219.s27|151-158|presence|O
DDI-DrugBank.d219.s27|160-161|of|O
DDI-DrugBank.d219.s27|163-170|phenolic|O
DDI-DrugBank.d219.s27|172-182|metabolites|O
DDI-DrugBank.d219.s27|184-185|of|O
DDI-DrugBank.d219.s27|187-194|etodolac|O
DDI-DrugBank.d219.s27|195-195|.|O
DDI-DrugBank.d219.s28|0-9|Diagnostic|O
DDI-DrugBank.d219.s28|11-19|dip-stick|O
DDI-DrugBank.d219.s28|21-31|methodology|O
DDI-DrugBank.d219.s28|32-32|,|O
DDI-DrugBank.d219.s28|34-37|used|O
DDI-DrugBank.d219.s28|39-40|to|O
DDI-DrugBank.d219.s28|42-47|detect|O
DDI-DrugBank.d219.s28|49-54|ketone|O
DDI-DrugBank.d219.s28|56-61|bodies|O
DDI-DrugBank.d219.s28|63-64|in|O
DDI-DrugBank.d219.s28|66-70|urine|O
DDI-DrugBank.d219.s28|71-71|,|O
DDI-DrugBank.d219.s28|73-75|has|O
DDI-DrugBank.d219.s28|77-84|resulted|O
DDI-DrugBank.d219.s28|86-87|in|O
DDI-DrugBank.d219.s28|89-102|false-positive|O
DDI-DrugBank.d219.s28|104-111|findings|O
DDI-DrugBank.d219.s28|113-114|in|O
DDI-DrugBank.d219.s28|116-119|some|O
DDI-DrugBank.d219.s28|121-128|patients|O
DDI-DrugBank.d219.s28|130-136|treated|O
DDI-DrugBank.d219.s28|138-141|with|O
DDI-DrugBank.d219.s28|143-148|Lodine|O
DDI-DrugBank.d219.s28|149-149|.|O
DDI-DrugBank.d219.s29|0-8|Generally|O
DDI-DrugBank.d219.s29|9-9|,|O
DDI-DrugBank.d219.s29|11-14|this|O
DDI-DrugBank.d219.s29|16-25|phenomenon|O
DDI-DrugBank.d219.s29|27-29|has|O
DDI-DrugBank.d219.s29|31-33|not|O
DDI-DrugBank.d219.s29|35-38|been|O
DDI-DrugBank.d219.s29|40-49|associated|O
DDI-DrugBank.d219.s29|51-54|with|O
DDI-DrugBank.d219.s29|56-60|other|O
DDI-DrugBank.d219.s29|62-71|clinically|O
DDI-DrugBank.d219.s29|73-83|significant|O
DDI-DrugBank.d219.s29|85-90|events|O
DDI-DrugBank.d219.s29|91-91|.|O
DDI-DrugBank.d219.s30|0-1|No|O
DDI-DrugBank.d219.s30|3-6|dose|O
DDI-DrugBank.d219.s30|8-19|relationship|O
DDI-DrugBank.d219.s30|21-23|has|O
DDI-DrugBank.d219.s30|25-28|been|O
DDI-DrugBank.d219.s30|30-37|observed|O
DDI-DrugBank.d219.s30|38-38|.|O
DDI-DrugBank.d219.s31|0-5|Lodine|O
DDI-DrugBank.d219.s31|7-15|treatment|O
DDI-DrugBank.d219.s31|17-18|is|O
DDI-DrugBank.d219.s31|20-29|associated|O
DDI-DrugBank.d219.s31|31-34|with|O
DDI-DrugBank.d219.s31|36-36|a|O
DDI-DrugBank.d219.s31|38-42|small|O
DDI-DrugBank.d219.s31|44-51|decrease|O
DDI-DrugBank.d219.s31|53-54|in|O
DDI-DrugBank.d219.s31|56-60|serum|O
DDI-DrugBank.d219.s31|62-65|uric|O
DDI-DrugBank.d219.s31|67-70|acid|O
DDI-DrugBank.d219.s31|72-77|levels|O
DDI-DrugBank.d219.s31|78-78|.|O
DDI-DrugBank.d219.s32|0-1|In|O
DDI-DrugBank.d219.s32|3-10|clinical|O
DDI-DrugBank.d219.s32|12-17|trials|O
DDI-DrugBank.d219.s32|18-18|,|O
DDI-DrugBank.d219.s32|20-23|mean|O
DDI-DrugBank.d219.s32|25-33|decreases|O
DDI-DrugBank.d219.s32|35-36|of|O
DDI-DrugBank.d219.s32|38-38|1|O
DDI-DrugBank.d219.s32|40-41|to|O
DDI-DrugBank.d219.s32|43-43|2|O
DDI-DrugBank.d219.s32|45-49|mg/dL|O
DDI-DrugBank.d219.s32|51-54|were|O
DDI-DrugBank.d219.s32|56-63|observed|O
DDI-DrugBank.d219.s32|65-66|in|O
DDI-DrugBank.d219.s32|68-76|arthritic|O
DDI-DrugBank.d219.s32|78-85|patients|O
DDI-DrugBank.d219.s32|87-95|receiving|O
DDI-DrugBank.d219.s32|97-104|etodolac|O
DDI-DrugBank.d219.s32|106-106|(|O
DDI-DrugBank.d219.s32|107-109|600|O
DDI-DrugBank.d219.s32|111-112|mg|O
DDI-DrugBank.d219.s32|114-115|to|O
DDI-DrugBank.d219.s32|117-120|1000|O
DDI-DrugBank.d219.s32|122-127|mg/day|O
DDI-DrugBank.d219.s32|128-128|)|O
DDI-DrugBank.d219.s32|130-134|after|O
DDI-DrugBank.d219.s32|136-136|4|O
DDI-DrugBank.d219.s32|138-142|weeks|O
DDI-DrugBank.d219.s32|144-145|of|O
DDI-DrugBank.d219.s32|147-153|therapy|O
DDI-DrugBank.d219.s32|154-154|.|O
DDI-DrugBank.d219.s33|0-4|These|O
DDI-DrugBank.d219.s33|6-11|levels|O
DDI-DrugBank.d219.s33|13-16|then|O
DDI-DrugBank.d219.s33|18-25|remained|O
DDI-DrugBank.d219.s33|27-32|stable|O
DDI-DrugBank.d219.s33|34-36|for|O
DDI-DrugBank.d219.s33|38-39|up|O
DDI-DrugBank.d219.s33|41-42|to|O
DDI-DrugBank.d219.s33|44-44|1|O
DDI-DrugBank.d219.s33|46-49|year|O
DDI-DrugBank.d219.s33|51-52|of|O
DDI-DrugBank.d219.s33|54-60|therapy|O
DDI-DrugBank.d219.s33|61-61|.|O
DDI-DrugBank.d367.s0|0-3|Most|O
DDI-DrugBank.d367.s0|5-5|(|O
DDI-DrugBank.d367.s0|6-7|98|O
DDI-DrugBank.d367.s0|8-8|%|O
DDI-DrugBank.d367.s0|9-9|)|O
DDI-DrugBank.d367.s0|11-12|of|O
DDI-DrugBank.d367.s0|14-19|plasma|O
DDI-DrugBank.d367.s0|21-29|doxazosin|O
DDI-DrugBank.d367.s0|31-32|is|O
DDI-DrugBank.d367.s0|34-40|protein|O
DDI-DrugBank.d367.s0|42-46|bound|O
DDI-DrugBank.d367.s0|47-47|.|O
DDI-DrugBank.d367.s1|0-1|In|O
DDI-DrugBank.d367.s1|3-7|vitro|O
DDI-DrugBank.d367.s1|9-12|data|O
DDI-DrugBank.d367.s1|14-15|in|O
DDI-DrugBank.d367.s1|17-21|human|O
DDI-DrugBank.d367.s1|23-28|plasma|O
DDI-DrugBank.d367.s1|30-37|indicate|O
DDI-DrugBank.d367.s1|39-42|that|O
DDI-DrugBank.d367.s1|44-52|doxazosin|O
DDI-DrugBank.d367.s1|54-61|mesylate|O
DDI-DrugBank.d367.s1|63-65|has|O
DDI-DrugBank.d367.s1|67-68|no|O
DDI-DrugBank.d367.s1|70-75|effect|O
DDI-DrugBank.d367.s1|77-78|on|O
DDI-DrugBank.d367.s1|80-86|protein|O
DDI-DrugBank.d367.s1|88-94|binding|O
DDI-DrugBank.d367.s1|96-97|of|O
DDI-DrugBank.d367.s1|99-105|digoxin|O
DDI-DrugBank.d367.s1|106-106|,|O
DDI-DrugBank.d367.s1|108-115|warfarin|O
DDI-DrugBank.d367.s1|116-116|,|O
DDI-DrugBank.d367.s1|118-126|phenytoin|O
DDI-DrugBank.d367.s1|128-129|or|O
DDI-DrugBank.d367.s1|131-142|indomethacin|O
DDI-DrugBank.d367.s1|143-143|.|O
DDI-DrugBank.d367.s2|0-4|There|O
DDI-DrugBank.d367.s2|6-7|is|O
DDI-DrugBank.d367.s2|9-10|no|O
DDI-DrugBank.d367.s2|12-22|information|O
DDI-DrugBank.d367.s2|24-25|on|O
DDI-DrugBank.d367.s2|27-29|the|O
DDI-DrugBank.d367.s2|31-36|effect|O
DDI-DrugBank.d367.s2|38-39|of|O
DDI-DrugBank.d367.s2|41-45|other|O
DDI-DrugBank.d367.s2|47-52|highly|O
DDI-DrugBank.d367.s2|54-59|plasma|O
DDI-DrugBank.d367.s2|61-67|protein|O
DDI-DrugBank.d367.s2|69-73|bound|O
DDI-DrugBank.d367.s2|75-79|drugs|O
DDI-DrugBank.d367.s2|81-82|on|O
DDI-DrugBank.d367.s2|84-92|doxazosin|O
DDI-DrugBank.d367.s2|94-100|binding|O
DDI-DrugBank.d367.s2|101-101|.|O
DDI-DrugBank.d367.s3|0-8|Doxazosin|O
DDI-DrugBank.d367.s3|10-17|mesylate|O
DDI-DrugBank.d367.s3|19-21|has|O
DDI-DrugBank.d367.s3|23-26|been|O
DDI-DrugBank.d367.s3|28-39|administered|O
DDI-DrugBank.d367.s3|41-47|without|O
DDI-DrugBank.d367.s3|49-51|any|O
DDI-DrugBank.d367.s3|53-60|evidence|O
DDI-DrugBank.d367.s3|62-63|of|O
DDI-DrugBank.d367.s3|65-66|an|O
DDI-DrugBank.d367.s3|68-74|adverse|O
DDI-DrugBank.d367.s3|76-79|drug|O
DDI-DrugBank.d367.s3|81-91|interaction|O
DDI-DrugBank.d367.s3|93-94|to|O
DDI-DrugBank.d367.s3|96-103|patients|O
DDI-DrugBank.d367.s3|105-113|receiving|O
DDI-DrugBank.d367.s3|115-122|thiazide|O
DDI-DrugBank.d367.s3|124-132|diuretics|O
DDI-DrugBank.d367.s3|133-133|,|O
DDI-DrugBank.d367.s3|135-147|beta-blocking|O
DDI-DrugBank.d367.s3|149-154|agents|O
DDI-DrugBank.d367.s3|155-155|,|O
DDI-DrugBank.d367.s3|157-159|and|O
DDI-DrugBank.d367.s3|161-172|nonsteroidal|O
DDI-DrugBank.d367.s3|174-190|anti-inflammatory|O
DDI-DrugBank.d367.s3|192-196|drugs|O
DDI-DrugBank.d367.s3|197-197|.|O
DDI-DrugBank.d367.s4|0-1|In|O
DDI-DrugBank.d367.s4|3-3|a|O
DDI-DrugBank.d367.s4|5-22|placebo-controlled|O
DDI-DrugBank.d367.s4|24-28|trial|O
DDI-DrugBank.d367.s4|30-31|in|O
DDI-DrugBank.d367.s4|33-38|normal|O
DDI-DrugBank.d367.s4|40-49|volunteers|O
DDI-DrugBank.d367.s4|50-50|,|O
DDI-DrugBank.d367.s4|52-54|the|O
DDI-DrugBank.d367.s4|56-69|administration|O
DDI-DrugBank.d367.s4|71-72|of|O
DDI-DrugBank.d367.s4|74-74|a|O
DDI-DrugBank.d367.s4|76-81|single|O
DDI-DrugBank.d367.s4|83-83|1|O
DDI-DrugBank.d367.s4|85-86|mg|O
DDI-DrugBank.d367.s4|88-91|dose|O
DDI-DrugBank.d367.s4|93-94|of|O
DDI-DrugBank.d367.s4|96-104|doxazosin|O
DDI-DrugBank.d367.s4|106-107|on|O
DDI-DrugBank.d367.s4|109-111|day|O
DDI-DrugBank.d367.s4|113-113|1|O
DDI-DrugBank.d367.s4|115-116|of|O
DDI-DrugBank.d367.s4|118-118|a|O
DDI-DrugBank.d367.s4|120-127|four-day|O
DDI-DrugBank.d367.s4|129-135|regimen|O
DDI-DrugBank.d367.s4|137-138|of|O
DDI-DrugBank.d367.s4|140-143|oral|O
DDI-DrugBank.d367.s4|145-154|cimetidine|O
DDI-DrugBank.d367.s4|156-156|(|O
DDI-DrugBank.d367.s4|157-159|400|O
DDI-DrugBank.d367.s4|161-162|mg|O
DDI-DrugBank.d367.s4|164-168|twice|O
DDI-DrugBank.d367.s4|170-174|daily|O
DDI-DrugBank.d367.s4|175-175|)|O
DDI-DrugBank.d367.s4|177-184|resulted|O
DDI-DrugBank.d367.s4|186-187|in|O
DDI-DrugBank.d367.s4|189-189|a|O
DDI-DrugBank.d367.s4|191-192|10|O
DDI-DrugBank.d367.s4|193-193|%|O
DDI-DrugBank.d367.s4|195-202|increase|O
DDI-DrugBank.d367.s4|204-205|in|O
DDI-DrugBank.d367.s4|207-210|mean|O
DDI-DrugBank.d367.s4|212-214|AUC|O
DDI-DrugBank.d367.s4|216-217|of|O
DDI-DrugBank.d367.s4|219-227|doxazosin|O
DDI-DrugBank.d367.s4|229-229|(|O
DDI-DrugBank.d367.s4|230-236|p=0.006|O
DDI-DrugBank.d367.s4|237-237|)|O
DDI-DrugBank.d367.s4|238-238|,|O
DDI-DrugBank.d367.s4|240-242|and|O
DDI-DrugBank.d367.s4|244-244|a|O
DDI-DrugBank.d367.s4|246-251|slight|O
DDI-DrugBank.d367.s4|253-255|but|O
DDI-DrugBank.d367.s4|257-259|not|O
DDI-DrugBank.d367.s4|261-273|statistically|O
DDI-DrugBank.d367.s4|275-285|significant|O
DDI-DrugBank.d367.s4|287-294|increase|O
DDI-DrugBank.d367.s4|296-297|in|O
DDI-DrugBank.d367.s4|299-302|mean|O
DDI-DrugBank.d367.s4|304-307|Cmax|O
DDI-DrugBank.d367.s4|309-311|and|O
DDI-DrugBank.d367.s4|313-316|mean|O
DDI-DrugBank.d367.s4|318-326|half-life|O
DDI-DrugBank.d367.s4|328-329|of|O
DDI-DrugBank.d367.s4|331-339|doxazosin|O
DDI-DrugBank.d367.s4|340-340|.|O
DDI-DrugBank.d367.s5|0-2|The|O
DDI-DrugBank.d367.s5|4-11|clinical|O
DDI-DrugBank.d367.s5|13-24|significance|O
DDI-DrugBank.d367.s5|26-27|of|O
DDI-DrugBank.d367.s5|29-32|this|O
DDI-DrugBank.d367.s5|34-41|increase|O
DDI-DrugBank.d367.s5|43-44|in|O
DDI-DrugBank.d367.s5|46-54|doxazosin|O
DDI-DrugBank.d367.s5|56-58|AUC|O
DDI-DrugBank.d367.s5|60-61|is|O
DDI-DrugBank.d367.s5|63-69|unknown|O
DDI-DrugBank.d367.s5|70-70|.|O
DDI-DrugBank.d367.s6|0-1|In|O
DDI-DrugBank.d367.s6|3-10|clinical|O
DDI-DrugBank.d367.s6|12-17|trials|O
DDI-DrugBank.d367.s6|18-18|,|O
DDI-DrugBank.d367.s6|20-28|doxazosin|O
DDI-DrugBank.d367.s6|30-37|mesylate|O
DDI-DrugBank.d367.s6|39-45|tablets|O
DDI-DrugBank.d367.s6|47-50|have|O
DDI-DrugBank.d367.s6|52-55|been|O
DDI-DrugBank.d367.s6|57-68|administered|O
DDI-DrugBank.d367.s6|70-71|to|O
DDI-DrugBank.d367.s6|73-80|patients|O
DDI-DrugBank.d367.s6|82-83|on|O
DDI-DrugBank.d367.s6|85-85|a|O
DDI-DrugBank.d367.s6|87-93|variety|O
DDI-DrugBank.d367.s6|95-96|of|O
DDI-DrugBank.d367.s6|98-108|concomitant|O
DDI-DrugBank.d367.s6|110-120|medications|O
DDI-DrugBank.d367.s6|121-121|;|O
DDI-DrugBank.d367.s7|0-4|while|O
DDI-DrugBank.d367.s7|6-7|no|O
DDI-DrugBank.d367.s7|9-14|formal|O
DDI-DrugBank.d367.s7|16-26|interaction|O
DDI-DrugBank.d367.s7|28-34|studies|O
DDI-DrugBank.d367.s7|36-39|have|O
DDI-DrugBank.d367.s7|41-44|been|O
DDI-DrugBank.d367.s7|46-54|conducted|O
DDI-DrugBank.d367.s7|55-55|,|O
DDI-DrugBank.d367.s7|57-58|no|O
DDI-DrugBank.d367.s7|60-71|interactions|O
DDI-DrugBank.d367.s7|73-76|were|O
DDI-DrugBank.d367.s7|78-85|observed|O
DDI-DrugBank.d367.s7|86-86|.|O
DDI-DrugBank.d367.s8|0-8|Doxazosin|O
DDI-DrugBank.d367.s8|10-17|mesylate|O
DDI-DrugBank.d367.s8|19-25|tablets|O
DDI-DrugBank.d367.s8|27-30|have|O
DDI-DrugBank.d367.s8|32-35|been|O
DDI-DrugBank.d367.s8|37-40|used|O
DDI-DrugBank.d367.s8|42-45|with|O
DDI-DrugBank.d367.s8|47-49|the|O
DDI-DrugBank.d367.s8|51-59|following|O
DDI-DrugBank.d367.s8|61-65|drugs|O
DDI-DrugBank.d367.s8|67-68|or|O
DDI-DrugBank.d367.s8|70-73|drug|O
DDI-DrugBank.d367.s8|75-81|classes|O
DDI-DrugBank.d367.s8|82-82|:|O
DDI-DrugBank.d367.s8|84-84|1|O
DDI-DrugBank.d367.s8|85-85|.|O
DDI-DrugBank.d367.s9|0-26|Analgesic/anti-inflammatory|O
DDI-DrugBank.d367.s9|28-28|(|O
DDI-DrugBank.d367.s9|29-32|e.g.|O
DDI-DrugBank.d367.s9|33-33|,|O
DDI-DrugBank.d367.s9|35-47|acetaminophen|O
DDI-DrugBank.d367.s9|48-48|,|O
DDI-DrugBank.d367.s9|50-56|aspirin|O
DDI-DrugBank.d367.s9|57-57|,|O
DDI-DrugBank.d367.s9|59-65|codeine|O
DDI-DrugBank.d367.s9|67-69|and|O
DDI-DrugBank.d367.s9|71-77|codeine|O
DDI-DrugBank.d367.s9|79-90|combinations|O
DDI-DrugBank.d367.s9|91-91|,|O
DDI-DrugBank.d367.s9|93-101|ibuprofen|O
DDI-DrugBank.d367.s9|102-102|,|O
DDI-DrugBank.d367.s9|104-115|indomethacin|O
DDI-DrugBank.d367.s9|116-116|)|O
DDI-DrugBank.d367.s9|117-117|.|O
DDI-DrugBank.d367.s10|0-0|2|O
DDI-DrugBank.d367.s10|1-1|.|O
DDI-DrugBank.d367.s11|0-10|Antibiotics|O
DDI-DrugBank.d367.s11|12-12|(|O
DDI-DrugBank.d367.s11|13-16|e.g.|O
DDI-DrugBank.d367.s11|17-17|,|O
DDI-DrugBank.d367.s11|19-30|erythromycin|O
DDI-DrugBank.d367.s11|31-31|,|O
DDI-DrugBank.d367.s11|33-44|trimethoprim|O
DDI-DrugBank.d367.s11|46-48|and|O
DDI-DrugBank.d367.s11|50-65|sulfamethoxazole|O
DDI-DrugBank.d367.s11|66-66|,|O
DDI-DrugBank.d367.s11|68-78|amoxicillin|O
DDI-DrugBank.d367.s11|79-79|)|O
DDI-DrugBank.d367.s11|80-80|.|O
DDI-DrugBank.d367.s12|0-0|3|O
DDI-DrugBank.d367.s12|1-1|.|O
DDI-DrugBank.d367.s13|0-13|Antihistamines|O
DDI-DrugBank.d367.s13|15-15|(|O
DDI-DrugBank.d367.s13|16-19|e.g.|O
DDI-DrugBank.d367.s13|20-20|,|O
DDI-DrugBank.d367.s13|22-37|chlorpheniramine|O
DDI-DrugBank.d367.s13|38-38|)|O
DDI-DrugBank.d367.s13|39-39|.|O
DDI-DrugBank.d367.s14|0-0|4|O
DDI-DrugBank.d367.s14|1-1|.|O
DDI-DrugBank.d367.s15|0-13|Cardiovascular|O
DDI-DrugBank.d367.s15|15-20|agents|O
DDI-DrugBank.d367.s15|22-22|(|O
DDI-DrugBank.d367.s15|23-26|e.g.|O
DDI-DrugBank.d367.s15|27-27|,|O
DDI-DrugBank.d367.s15|29-36|atenolol|O
DDI-DrugBank.d367.s15|37-37|,|O
DDI-DrugBank.d367.s15|39-57|hydrochlorothiazide|O
DDI-DrugBank.d367.s15|58-58|,|O
DDI-DrugBank.d367.s15|60-70|propranolol|O
DDI-DrugBank.d367.s15|71-71|)|O
DDI-DrugBank.d367.s15|72-72|.|O
DDI-DrugBank.d367.s16|0-0|5|O
DDI-DrugBank.d367.s16|1-1|.|O
DDI-DrugBank.d367.s17|0-14|Corticosteroids|O
DDI-DrugBank.d367.s17|15-15|.|O
DDI-DrugBank.d367.s18|0-0|6|O
DDI-DrugBank.d367.s18|1-1|.|O
DDI-DrugBank.d367.s19|0-15|Gastrointestinal|O
DDI-DrugBank.d367.s19|17-22|agents|O
DDI-DrugBank.d367.s19|24-24|(|O
DDI-DrugBank.d367.s19|25-28|e.g.|O
DDI-DrugBank.d367.s19|29-29|,|O
DDI-DrugBank.d367.s19|31-38|antacids|O
DDI-DrugBank.d367.s19|39-39|)|O
DDI-DrugBank.d367.s19|40-40|.|O
DDI-DrugBank.d367.s20|0-0|7|O
DDI-DrugBank.d367.s20|1-1|.|O
DDI-DrugBank.d367.s21|0-12|Hypoglycemics|O
DDI-DrugBank.d367.s21|14-16|and|O
DDI-DrugBank.d367.s21|18-26|endocrine|O
DDI-DrugBank.d367.s21|28-32|drugs|O
DDI-DrugBank.d367.s21|33-33|.|O
DDI-DrugBank.d367.s22|0-0|8|O
DDI-DrugBank.d367.s22|1-1|.|O
DDI-DrugBank.d367.s23|0-8|Sedatives|O
DDI-DrugBank.d367.s23|10-12|and|O
DDI-DrugBank.d367.s23|14-26|tranquilizers|O
DDI-DrugBank.d367.s23|28-28|(|O
DDI-DrugBank.d367.s23|29-32|e.g.|O
DDI-DrugBank.d367.s23|33-33|,|O
DDI-DrugBank.d367.s23|35-42|diazepam|O
DDI-DrugBank.d367.s23|43-43|)|O
DDI-DrugBank.d367.s23|44-44|.|O
DDI-DrugBank.d367.s24|0-0|9|O
DDI-DrugBank.d367.s24|1-1|.|O
DDI-DrugBank.d367.s25|0-3|Cold|O
DDI-DrugBank.d367.s25|5-7|and|O
DDI-DrugBank.d367.s25|9-11|flu|O
DDI-DrugBank.d367.s25|13-20|remedies|O
DDI-DrugBank.d367.s25|21-21|.|O
DDI-MedLine.d169.s0|0-6|Calcium|O
DDI-MedLine.d169.s0|8-11|does|O
DDI-MedLine.d169.s0|13-15|not|O
DDI-MedLine.d169.s0|17-23|inhibit|O
DDI-MedLine.d169.s0|25-27|the|O
DDI-MedLine.d169.s0|29-38|absorption|O
DDI-MedLine.d169.s0|40-41|of|O
DDI-MedLine.d169.s0|43-43|5|O
DDI-MedLine.d169.s0|45-54|milligrams|O
DDI-MedLine.d169.s0|56-57|of|O
DDI-MedLine.d169.s0|59-65|nonheme|O
DDI-MedLine.d169.s0|67-68|or|O
DDI-MedLine.d169.s0|70-73|heme|O
DDI-MedLine.d169.s0|75-78|iron|O
DDI-MedLine.d169.s0|80-81|at|O
DDI-MedLine.d169.s0|83-87|doses|O
DDI-MedLine.d169.s0|89-92|less|O
DDI-MedLine.d169.s0|94-97|than|O
DDI-MedLine.d169.s0|99-101|800|O
DDI-MedLine.d169.s0|103-112|milligrams|O
DDI-MedLine.d169.s0|114-115|in|O
DDI-MedLine.d169.s0|117-127|nonpregnant|O
DDI-MedLine.d169.s0|129-133|women|O
DDI-MedLine.d169.s0|134-134|.|O
DDI-MedLine.d169.s1|0-6|Calcium|O
DDI-MedLine.d169.s1|8-9|is|O
DDI-MedLine.d169.s1|11-13|the|O
DDI-MedLine.d169.s1|15-18|only|O
DDI-MedLine.d169.s1|20-24|known|O
DDI-MedLine.d169.s1|26-34|component|O
DDI-MedLine.d169.s1|36-37|in|O
DDI-MedLine.d169.s1|39-41|the|O
DDI-MedLine.d169.s1|43-46|diet|O
DDI-MedLine.d169.s1|48-51|that|O
DDI-MedLine.d169.s1|53-55|may|O
DDI-MedLine.d169.s1|57-62|affect|O
DDI-MedLine.d169.s1|64-73|absorption|O
DDI-MedLine.d169.s1|75-76|of|O
DDI-MedLine.d169.s1|78-81|both|O
DDI-MedLine.d169.s1|83-89|nonheme|O
DDI-MedLine.d169.s1|91-93|and|O
DDI-MedLine.d169.s1|95-98|heme|O
DDI-MedLine.d169.s1|100-103|iron|O
DDI-MedLine.d169.s1|104-104|.|O
DDI-MedLine.d169.s2|0-6|However|O
DDI-MedLine.d169.s2|7-7|,|O
DDI-MedLine.d169.s2|9-11|the|O
DDI-MedLine.d169.s2|13-20|evidence|O
DDI-MedLine.d169.s2|22-24|for|O
DDI-MedLine.d169.s2|26-26|a|O
DDI-MedLine.d169.s2|28-34|calcium|O
DDI-MedLine.d169.s2|36-41|effect|O
DDI-MedLine.d169.s2|43-44|on|O
DDI-MedLine.d169.s2|46-49|iron|O
DDI-MedLine.d169.s2|51-60|absorption|O
DDI-MedLine.d169.s2|62-67|mainly|O
DDI-MedLine.d169.s2|69-73|comes|O
DDI-MedLine.d169.s2|75-78|from|O
DDI-MedLine.d169.s2|80-86|studies|O
DDI-MedLine.d169.s2|88-91|that|O
DDI-MedLine.d169.s2|93-95|did|O
DDI-MedLine.d169.s2|97-99|not|O
DDI-MedLine.d169.s2|101-107|isolate|O
DDI-MedLine.d169.s2|109-111|the|O
DDI-MedLine.d169.s2|113-118|effect|O
DDI-MedLine.d169.s2|120-121|of|O
DDI-MedLine.d169.s2|123-129|calcium|O
DDI-MedLine.d169.s2|131-134|from|O
DDI-MedLine.d169.s2|136-139|that|O
DDI-MedLine.d169.s2|141-142|of|O
DDI-MedLine.d169.s2|144-148|other|O
DDI-MedLine.d169.s2|150-156|dietary|O
DDI-MedLine.d169.s2|158-167|components|O
DDI-MedLine.d169.s2|168-168|,|O
DDI-MedLine.d169.s2|170-176|because|O
DDI-MedLine.d169.s2|178-179|it|O
DDI-MedLine.d169.s2|181-183|was|O
DDI-MedLine.d169.s2|185-192|detected|O
DDI-MedLine.d169.s2|194-195|in|O
DDI-MedLine.d169.s2|197-207|single-meal|O
DDI-MedLine.d169.s2|209-215|studies|O
DDI-MedLine.d169.s2|216-216|.|O
DDI-MedLine.d169.s3|0-2|Our|O
DDI-MedLine.d169.s3|4-12|objective|O
DDI-MedLine.d169.s3|14-16|was|O
DDI-MedLine.d169.s3|18-19|to|O
DDI-MedLine.d169.s3|21-29|establish|O
DDI-MedLine.d169.s3|31-39|potential|O
DDI-MedLine.d169.s3|41-47|effects|O
DDI-MedLine.d169.s3|49-50|of|O
DDI-MedLine.d169.s3|52-58|calcium|O
DDI-MedLine.d169.s3|60-61|on|O
DDI-MedLine.d169.s3|63-72|absorption|O
DDI-MedLine.d169.s3|74-75|of|O
DDI-MedLine.d169.s3|77-83|nonheme|O
DDI-MedLine.d169.s3|85-87|and|O
DDI-MedLine.d169.s3|89-92|heme|O
DDI-MedLine.d169.s3|94-97|iron|O
DDI-MedLine.d169.s3|99-101|and|O
DDI-MedLine.d169.s3|103-105|the|O
DDI-MedLine.d169.s3|107-110|dose|O
DDI-MedLine.d169.s3|112-119|response|O
DDI-MedLine.d169.s3|121-123|for|O
DDI-MedLine.d169.s3|125-128|this|O
DDI-MedLine.d169.s3|130-135|effect|O
DDI-MedLine.d169.s3|137-138|in|O
DDI-MedLine.d169.s3|140-142|the|O
DDI-MedLine.d169.s3|144-150|absence|O
DDI-MedLine.d169.s3|152-153|of|O
DDI-MedLine.d169.s3|155-155|a|O
DDI-MedLine.d169.s3|157-160|meal|O
DDI-MedLine.d169.s3|161-161|.|O
DDI-MedLine.d169.s4|0-9|Fifty-four|O
DDI-MedLine.d169.s4|11-17|healthy|O
DDI-MedLine.d169.s4|18-18|,|O
DDI-MedLine.d169.s4|20-30|nonpregnant|O
DDI-MedLine.d169.s4|32-36|women|O
DDI-MedLine.d169.s4|38-41|were|O
DDI-MedLine.d169.s4|43-50|selected|O
DDI-MedLine.d169.s4|52-53|to|O
DDI-MedLine.d169.s4|55-65|participate|O
DDI-MedLine.d169.s4|67-68|in|O
DDI-MedLine.d169.s4|70-70|4|O
DDI-MedLine.d169.s4|72-75|iron|O
DDI-MedLine.d169.s4|77-86|absorption|O
DDI-MedLine.d169.s4|88-94|studies|O
DDI-MedLine.d169.s4|96-100|using|O
DDI-MedLine.d169.s4|102-105|iron|O
DDI-MedLine.d169.s4|107-117|radioactive|O
DDI-MedLine.d169.s4|119-125|tracers|O
DDI-MedLine.d169.s4|126-126|.|O
DDI-MedLine.d169.s5|0-1|We|O
DDI-MedLine.d169.s5|3-11|evaluated|O
DDI-MedLine.d169.s5|13-15|the|O
DDI-MedLine.d169.s5|17-23|effects|O
DDI-MedLine.d169.s5|25-26|of|O
DDI-MedLine.d169.s5|28-34|calcium|O
DDI-MedLine.d169.s5|36-40|doses|O
DDI-MedLine.d169.s5|42-48|between|O
DDI-MedLine.d169.s5|50-52|200|O
DDI-MedLine.d169.s5|54-56|and|O
DDI-MedLine.d169.s5|58-61|1500|O
DDI-MedLine.d169.s5|63-64|mg|O
DDI-MedLine.d169.s5|66-67|on|O
DDI-MedLine.d169.s5|69-78|absorption|O
DDI-MedLine.d169.s5|80-81|of|O
DDI-MedLine.d169.s5|83-83|5|O
DDI-MedLine.d169.s5|85-86|mg|O
DDI-MedLine.d169.s5|88-94|nonheme|O
DDI-MedLine.d169.s5|96-99|iron|O
DDI-MedLine.d169.s5|101-101|(|O
DDI-MedLine.d169.s5|102-103|as|O
DDI-MedLine.d169.s5|105-111|ferrous|O
DDI-MedLine.d169.s5|113-119|sulfate|O
DDI-MedLine.d169.s5|120-120|)|O
DDI-MedLine.d169.s5|121-121|.|O
DDI-MedLine.d169.s6|0-1|We|O
DDI-MedLine.d169.s6|3-6|also|O
DDI-MedLine.d169.s6|8-16|evaluated|O
DDI-MedLine.d169.s6|18-20|the|O
DDI-MedLine.d169.s6|22-28|effects|O
DDI-MedLine.d169.s6|30-31|of|O
DDI-MedLine.d169.s6|33-39|calcium|O
DDI-MedLine.d169.s6|41-45|doses|O
DDI-MedLine.d169.s6|47-53|between|O
DDI-MedLine.d169.s6|55-57|200|O
DDI-MedLine.d169.s6|59-61|and|O
DDI-MedLine.d169.s6|63-65|800|O
DDI-MedLine.d169.s6|67-68|mg|O
DDI-MedLine.d169.s6|70-71|on|O
DDI-MedLine.d169.s6|73-82|absorption|O
DDI-MedLine.d169.s6|84-85|of|O
DDI-MedLine.d169.s6|87-87|5|O
DDI-MedLine.d169.s6|89-90|mg|O
DDI-MedLine.d169.s6|92-95|heme|O
DDI-MedLine.d169.s6|97-100|iron|O
DDI-MedLine.d169.s6|102-102|[|O
DDI-MedLine.d169.s6|103-104|as|O
DDI-MedLine.d169.s6|106-117|concentrated|O
DDI-MedLine.d169.s6|119-121|RBC|O
DDI-MedLine.d169.s6|123-123|(|O
DDI-MedLine.d169.s6|124-127|CRBC|O
DDI-MedLine.d169.s6|128-128|)|O
DDI-MedLine.d169.s6|129-129|]|O
DDI-MedLine.d169.s6|130-130|.|O
DDI-MedLine.d169.s7|0-6|Calcium|O
DDI-MedLine.d169.s7|8-10|was|O
DDI-MedLine.d169.s7|12-23|administered|O
DDI-MedLine.d169.s7|25-26|as|O
DDI-MedLine.d169.s7|28-34|calcium|O
DDI-MedLine.d169.s7|36-43|chloride|O
DDI-MedLine.d169.s7|45-46|in|O
DDI-MedLine.d169.s7|48-50|all|O
DDI-MedLine.d169.s7|52-58|studies|O
DDI-MedLine.d169.s7|60-62|and|O
DDI-MedLine.d169.s7|64-71|minerals|O
DDI-MedLine.d169.s7|73-76|were|O
DDI-MedLine.d169.s7|78-85|ingested|O
DDI-MedLine.d169.s7|87-88|on|O
DDI-MedLine.d169.s7|90-91|an|O
DDI-MedLine.d169.s7|93-97|empty|O
DDI-MedLine.d169.s7|99-105|stomach|O
DDI-MedLine.d169.s7|106-106|.|O
DDI-MedLine.d169.s8|0-6|Calcium|O
DDI-MedLine.d169.s8|8-12|doses|O
DDI-MedLine.d169.s8|16-19|1000|O
DDI-MedLine.d169.s8|21-22|mg|O
DDI-MedLine.d169.s8|24-33|diminished|O
DDI-MedLine.d169.s8|35-41|nonheme|O
DDI-MedLine.d169.s8|43-46|iron|O
DDI-MedLine.d169.s8|48-57|absorption|O
DDI-MedLine.d169.s8|59-60|by|O
DDI-MedLine.d169.s8|62-63|an|O
DDI-MedLine.d169.s8|65-71|average|O
DDI-MedLine.d169.s8|73-74|of|O
DDI-MedLine.d169.s8|76-79|49.6|O
DDI-MedLine.d169.s8|80-80|%|O
DDI-MedLine.d169.s8|81-81|.|O
DDI-MedLine.d169.s9|0-0|A|O
DDI-MedLine.d169.s9|2-8|calcium|O
DDI-MedLine.d169.s9|10-13|dose|O
DDI-MedLine.d169.s9|15-16|of|O
DDI-MedLine.d169.s9|18-20|800|O
DDI-MedLine.d169.s9|22-23|mg|O
DDI-MedLine.d169.s9|25-34|diminished|O
DDI-MedLine.d169.s9|36-45|absorption|O
DDI-MedLine.d169.s9|47-48|of|O
DDI-MedLine.d169.s9|50-50|5|O
DDI-MedLine.d169.s9|52-53|mg|O
DDI-MedLine.d169.s9|55-58|heme|O
DDI-MedLine.d169.s9|60-63|iron|O
DDI-MedLine.d169.s9|65-66|by|O
DDI-MedLine.d169.s9|68-71|37.7|O
DDI-MedLine.d169.s9|72-72|%|O
DDI-MedLine.d169.s9|73-73|.|O
DDI-MedLine.d169.s10|0-1|In|O
DDI-MedLine.d169.s10|3-12|conclusion|O
DDI-MedLine.d169.s10|13-13|,|O
DDI-MedLine.d169.s10|15-16|we|O
DDI-MedLine.d169.s10|18-29|demonstrated|O
DDI-MedLine.d169.s10|31-32|an|O
DDI-MedLine.d169.s10|34-41|isolated|O
DDI-MedLine.d169.s10|43-48|effect|O
DDI-MedLine.d169.s10|50-51|of|O
DDI-MedLine.d169.s10|53-59|calcium|O
DDI-MedLine.d169.s10|61-61|(|O
DDI-MedLine.d169.s10|62-63|as|O
DDI-MedLine.d169.s10|65-72|chloride|O
DDI-MedLine.d169.s10|73-73|)|O
DDI-MedLine.d169.s10|75-76|on|O
DDI-MedLine.d169.s10|78-87|absorption|O
DDI-MedLine.d169.s10|89-90|of|O
DDI-MedLine.d169.s10|92-92|5|O
DDI-MedLine.d169.s10|94-95|mg|O
DDI-MedLine.d169.s10|97-98|of|O
DDI-MedLine.d169.s10|100-103|iron|O
DDI-MedLine.d169.s10|105-112|provided|O
DDI-MedLine.d169.s10|114-115|as|O
DDI-MedLine.d169.s10|117-123|nonheme|O
DDI-MedLine.d169.s10|125-125|(|O
DDI-MedLine.d169.s10|126-127|as|O
DDI-MedLine.d169.s10|129-135|sulfate|O
DDI-MedLine.d169.s10|136-136|)|O
DDI-MedLine.d169.s10|138-140|and|O
DDI-MedLine.d169.s10|142-145|heme|O
DDI-MedLine.d169.s10|147-147|(|O
DDI-MedLine.d169.s10|148-149|as|O
DDI-MedLine.d169.s10|151-154|CRBC|O
DDI-MedLine.d169.s10|155-155|)|O
DDI-MedLine.d169.s10|157-160|iron|O
DDI-MedLine.d169.s10|161-161|.|O
DDI-MedLine.d169.s11|0-3|This|O
DDI-MedLine.d169.s11|5-10|effect|O
DDI-MedLine.d169.s11|12-14|was|O
DDI-MedLine.d169.s11|16-23|observed|O
DDI-MedLine.d169.s11|25-26|at|O
DDI-MedLine.d169.s11|28-32|doses|O
DDI-MedLine.d169.s11|34-39|higher|O
DDI-MedLine.d169.s11|41-44|than|O
DDI-MedLine.d169.s11|46-55|previously|O
DDI-MedLine.d169.s11|57-64|reported|O
DDI-MedLine.d169.s11|66-69|from|O
DDI-MedLine.d169.s11|71-81|single-meal|O
DDI-MedLine.d169.s11|83-89|studies|O
DDI-MedLine.d169.s11|90-90|,|O
DDI-MedLine.d169.s11|92-99|starting|O
DDI-MedLine.d169.s11|101-102|at|O
DDI-MedLine.d169.s11|104-107|~800|O
DDI-MedLine.d169.s11|109-110|mg|O
DDI-MedLine.d169.s11|112-113|of|O
DDI-MedLine.d169.s11|115-121|calcium|O
DDI-MedLine.d169.s11|122-122|.|O
DDI-DrugBank.d110.s0|0-2|The|O
DDI-DrugBank.d110.s0|4-17|administration|O
DDI-DrugBank.d110.s0|19-20|of|O
DDI-DrugBank.d110.s0|22-26|local|O
DDI-DrugBank.d110.s0|28-37|anesthetic|O
DDI-DrugBank.d110.s0|39-47|solutions|O
DDI-DrugBank.d110.s0|49-58|containing|O
DDI-DrugBank.d110.s0|60-70|epinephrine|O
DDI-DrugBank.d110.s0|72-73|or|O
DDI-DrugBank.d110.s0|75-88|norepinephrine|O
DDI-DrugBank.d110.s0|90-91|to|O
DDI-DrugBank.d110.s0|93-100|patients|O
DDI-DrugBank.d110.s0|102-110|receiving|O
DDI-DrugBank.d110.s0|112-120|monoamine|O
DDI-DrugBank.d110.s0|122-128|oxidase|O
DDI-DrugBank.d110.s0|130-139|inhibitors|O
DDI-DrugBank.d110.s0|140-140|,|O
DDI-DrugBank.d110.s0|142-150|tricyclic|O
DDI-DrugBank.d110.s0|152-166|antidepressants|O
DDI-DrugBank.d110.s0|168-169|or|O
DDI-DrugBank.d110.s0|171-184|phenothiazines|O
DDI-DrugBank.d110.s0|186-188|may|O
DDI-DrugBank.d110.s0|190-196|produce|O
DDI-DrugBank.d110.s0|198-203|severe|O
DDI-DrugBank.d110.s0|204-204|,|O
DDI-DrugBank.d110.s0|206-214|prolonged|O
DDI-DrugBank.d110.s0|216-226|hypotension|O
DDI-DrugBank.d110.s0|228-229|or|O
DDI-DrugBank.d110.s0|231-242|hypertension|O
DDI-DrugBank.d110.s0|243-243|.|O
DDI-DrugBank.d110.s1|0-9|Concurrent|O
DDI-DrugBank.d110.s1|11-13|use|O
DDI-DrugBank.d110.s1|15-16|of|O
DDI-DrugBank.d110.s1|18-22|these|O
DDI-DrugBank.d110.s1|24-29|agents|O
DDI-DrugBank.d110.s1|31-36|should|O
DDI-DrugBank.d110.s1|38-46|generally|O
DDI-DrugBank.d110.s1|48-49|be|O
DDI-DrugBank.d110.s1|51-57|avoided|O
DDI-DrugBank.d110.s1|58-58|.|O
DDI-DrugBank.d110.s2|0-1|In|O
DDI-DrugBank.d110.s2|3-12|situations|O
DDI-DrugBank.d110.s2|14-17|when|O
DDI-DrugBank.d110.s2|19-28|concurrent|O
DDI-DrugBank.d110.s2|30-36|therapy|O
DDI-DrugBank.d110.s2|38-39|is|O
DDI-DrugBank.d110.s2|41-49|necessary|O
DDI-DrugBank.d110.s2|50-50|,|O
DDI-DrugBank.d110.s2|52-58|careful|O
DDI-DrugBank.d110.s2|60-66|patient|O
DDI-DrugBank.d110.s2|68-77|monitoring|O
DDI-DrugBank.d110.s2|79-80|is|O
DDI-DrugBank.d110.s2|82-90|essential|O
DDI-DrugBank.d110.s2|91-91|.|O
DDI-DrugBank.d110.s3|0-9|Concurrent|O
DDI-DrugBank.d110.s3|11-24|administration|O
DDI-DrugBank.d110.s3|26-27|of|O
DDI-DrugBank.d110.s3|29-39|vasopressor|O
DDI-DrugBank.d110.s3|41-45|drugs|O
DDI-DrugBank.d110.s3|47-47|(|O
DDI-DrugBank.d110.s3|48-50|for|O
DDI-DrugBank.d110.s3|52-54|the|O
DDI-DrugBank.d110.s3|56-64|treatment|O
DDI-DrugBank.d110.s3|66-67|of|O
DDI-DrugBank.d110.s3|69-79|hypotension|O
DDI-DrugBank.d110.s3|81-87|related|O
DDI-DrugBank.d110.s3|89-90|to|O
DDI-DrugBank.d110.s3|92-100|obstetric|O
DDI-DrugBank.d110.s3|102-107|blocks|O
DDI-DrugBank.d110.s3|108-108|)|O
DDI-DrugBank.d110.s3|110-112|and|O
DDI-DrugBank.d110.s3|114-123|ergot-type|O
DDI-DrugBank.d110.s3|125-132|oxytocic|O
DDI-DrugBank.d110.s3|134-138|drugs|O
DDI-DrugBank.d110.s3|140-142|may|O
DDI-DrugBank.d110.s3|144-148|cause|O
DDI-DrugBank.d110.s3|150-155|severe|O
DDI-DrugBank.d110.s3|156-156|,|O
DDI-DrugBank.d110.s3|158-167|persistent|O
DDI-DrugBank.d110.s3|169-180|hypertension|O
DDI-DrugBank.d110.s3|182-183|or|O
DDI-DrugBank.d110.s3|185-199|cerebrovascular|O
DDI-DrugBank.d110.s3|201-209|accidents|O
DDI-DrugBank.d110.s3|210-210|.|O
DDI-DrugBank.d110.s4|0-2|The|O
DDI-DrugBank.d110.s4|4-20|para-aminobenzoic|O
DDI-DrugBank.d110.s4|22-25|acid|O
DDI-DrugBank.d110.s4|27-36|metabolite|O
DDI-DrugBank.d110.s4|38-39|of|O
DDI-DrugBank.d110.s4|41-54|chloroprocaine|O
DDI-DrugBank.d110.s4|56-63|inhibits|O
DDI-DrugBank.d110.s4|65-67|the|O
DDI-DrugBank.d110.s4|69-74|action|O
DDI-DrugBank.d110.s4|76-77|of|O
DDI-DrugBank.d110.s4|79-90|sulfonamides|O
DDI-DrugBank.d110.s4|91-91|.|O
DDI-DrugBank.d110.s5|0-8|Therefore|O
DDI-DrugBank.d110.s5|9-9|,|O
DDI-DrugBank.d110.s5|11-24|chloroprocaine|O
DDI-DrugBank.d110.s5|26-31|should|O
DDI-DrugBank.d110.s5|33-35|not|O
DDI-DrugBank.d110.s5|37-38|be|O
DDI-DrugBank.d110.s5|40-43|used|O
DDI-DrugBank.d110.s5|45-46|in|O
DDI-DrugBank.d110.s5|48-50|any|O
DDI-DrugBank.d110.s5|52-60|condition|O
DDI-DrugBank.d110.s5|62-63|in|O
DDI-DrugBank.d110.s5|65-69|which|O
DDI-DrugBank.d110.s5|71-71|a|O
DDI-DrugBank.d110.s5|73-83|sulfonamide|O
DDI-DrugBank.d110.s5|85-88|drug|O
DDI-DrugBank.d110.s5|90-91|is|O
DDI-DrugBank.d110.s5|93-97|being|O
DDI-DrugBank.d110.s5|99-106|employed|O
DDI-DrugBank.d110.s5|107-107|.|O
DDI-DrugBank.d245.s0|0-2|The|O
DDI-DrugBank.d245.s0|4-15|hypoglycemic|O
DDI-DrugBank.d245.s0|17-22|action|O
DDI-DrugBank.d245.s0|24-25|of|O
DDI-DrugBank.d245.s0|27-38|sulfonylurea|O
DDI-DrugBank.d245.s0|40-42|may|O
DDI-DrugBank.d245.s0|44-45|be|O
DDI-DrugBank.d245.s0|47-57|potentiated|O
DDI-DrugBank.d245.s0|59-60|by|O
DDI-DrugBank.d245.s0|62-68|certain|O
DDI-DrugBank.d245.s0|70-74|drugs|O
DDI-DrugBank.d245.s0|76-84|including|O
DDI-DrugBank.d245.s0|86-97|nonsteroidal|O
DDI-DrugBank.d245.s0|99-115|anti-inflammatory|O
DDI-DrugBank.d245.s0|117-122|agents|O
DDI-DrugBank.d245.s0|124-126|and|O
DDI-DrugBank.d245.s0|128-132|other|O
DDI-DrugBank.d245.s0|134-138|drugs|O
DDI-DrugBank.d245.s0|140-143|that|O
DDI-DrugBank.d245.s0|145-147|are|O
DDI-DrugBank.d245.s0|149-154|highly|O
DDI-DrugBank.d245.s0|156-162|protein|O
DDI-DrugBank.d245.s0|164-168|bound|O
DDI-DrugBank.d245.s0|169-169|,|O
DDI-DrugBank.d245.s0|171-181|salicylates|O
DDI-DrugBank.d245.s0|182-182|,|O
DDI-DrugBank.d245.s0|184-195|sulfonamides|O
DDI-DrugBank.d245.s0|196-196|,|O
DDI-DrugBank.d245.s0|198-212|chloramphenicol|O
DDI-DrugBank.d245.s0|213-213|,|O
DDI-DrugBank.d245.s0|215-224|probenecid|O
DDI-DrugBank.d245.s0|225-225|,|O
DDI-DrugBank.d245.s0|227-235|coumarins|O
DDI-DrugBank.d245.s0|236-236|,|O
DDI-DrugBank.d245.s0|238-246|monoamine|O
DDI-DrugBank.d245.s0|248-254|oxidase|O
DDI-DrugBank.d245.s0|256-265|inhibitors|O
DDI-DrugBank.d245.s0|266-266|,|O
DDI-DrugBank.d245.s0|268-270|and|O
DDI-DrugBank.d245.s0|272-275|beta|O
DDI-DrugBank.d245.s0|277-286|adrenergic|O
DDI-DrugBank.d245.s0|288-295|blocking|O
DDI-DrugBank.d245.s0|297-302|agents|O
DDI-DrugBank.d245.s0|303-303|.|O
DDI-DrugBank.d245.s1|0-3|When|O
DDI-DrugBank.d245.s1|5-8|such|O
DDI-DrugBank.d245.s1|10-14|drugs|O
DDI-DrugBank.d245.s1|16-18|are|O
DDI-DrugBank.d245.s1|20-31|administered|O
DDI-DrugBank.d245.s1|33-34|to|O
DDI-DrugBank.d245.s1|36-36|a|O
DDI-DrugBank.d245.s1|38-44|patient|O
DDI-DrugBank.d245.s1|46-54|receiving|O
DDI-DrugBank.d245.s1|56-64|DIABINESE|O
DDI-DrugBank.d245.s1|65-65|,|O
DDI-DrugBank.d245.s1|67-69|the|O
DDI-DrugBank.d245.s1|71-77|patient|O
DDI-DrugBank.d245.s1|79-84|should|O
DDI-DrugBank.d245.s1|86-87|be|O
DDI-DrugBank.d245.s1|89-96|observed|O
DDI-DrugBank.d245.s1|98-104|closely|O
DDI-DrugBank.d245.s1|106-108|for|O
DDI-DrugBank.d245.s1|110-121|hypoglycemia|O
DDI-DrugBank.d245.s1|122-122|.|O
DDI-DrugBank.d245.s2|0-3|When|O
DDI-DrugBank.d245.s2|5-8|such|O
DDI-DrugBank.d245.s2|10-14|drugs|O
DDI-DrugBank.d245.s2|16-18|are|O
DDI-DrugBank.d245.s2|20-28|withdrawn|O
DDI-DrugBank.d245.s2|30-33|from|O
DDI-DrugBank.d245.s2|35-35|a|O
DDI-DrugBank.d245.s2|37-43|patient|O
DDI-DrugBank.d245.s2|45-53|receiving|O
DDI-DrugBank.d245.s2|55-63|DIABINESE|O
DDI-DrugBank.d245.s2|64-64|,|O
DDI-DrugBank.d245.s2|66-68|the|O
DDI-DrugBank.d245.s2|70-76|patient|O
DDI-DrugBank.d245.s2|78-83|should|O
DDI-DrugBank.d245.s2|85-86|be|O
DDI-DrugBank.d245.s2|88-95|observed|O
DDI-DrugBank.d245.s2|97-103|closely|O
DDI-DrugBank.d245.s2|105-107|for|O
DDI-DrugBank.d245.s2|109-112|loss|O
DDI-DrugBank.d245.s2|114-115|of|O
DDI-DrugBank.d245.s2|117-123|control|O
DDI-DrugBank.d245.s2|124-124|.|O
DDI-DrugBank.d245.s3|0-6|Certain|O
DDI-DrugBank.d245.s3|8-12|drugs|O
DDI-DrugBank.d245.s3|14-17|tend|O
DDI-DrugBank.d245.s3|19-20|to|O
DDI-DrugBank.d245.s3|22-28|produce|O
DDI-DrugBank.d245.s3|30-42|hyperglycemia|O
DDI-DrugBank.d245.s3|44-46|and|O
DDI-DrugBank.d245.s3|48-50|may|O
DDI-DrugBank.d245.s3|52-55|lead|O
DDI-DrugBank.d245.s3|57-58|to|O
DDI-DrugBank.d245.s3|60-63|loss|O
DDI-DrugBank.d245.s3|65-66|of|O
DDI-DrugBank.d245.s3|68-74|control|O
DDI-DrugBank.d245.s3|75-75|.|O
DDI-DrugBank.d245.s4|0-4|These|O
DDI-DrugBank.d245.s4|6-10|drugs|O
DDI-DrugBank.d245.s4|12-18|include|O
DDI-DrugBank.d245.s4|20-22|the|O
DDI-DrugBank.d245.s4|24-32|thiazides|O
DDI-DrugBank.d245.s4|34-36|and|O
DDI-DrugBank.d245.s4|38-42|other|O
DDI-DrugBank.d245.s4|44-52|diuretics|O
DDI-DrugBank.d245.s4|53-53|,|O
DDI-DrugBank.d245.s4|55-69|corticosteroids|O
DDI-DrugBank.d245.s4|70-70|,|O
DDI-DrugBank.d245.s4|72-85|phenothiazines|O
DDI-DrugBank.d245.s4|86-86|,|O
DDI-DrugBank.d245.s4|88-94|thyroid|O
DDI-DrugBank.d245.s4|96-103|products|O
DDI-DrugBank.d245.s4|104-104|,|O
DDI-DrugBank.d245.s4|106-114|estrogens|O
DDI-DrugBank.d245.s4|115-115|,|O
DDI-DrugBank.d245.s4|117-120|oral|O
DDI-DrugBank.d245.s4|122-135|contraceptives|O
DDI-DrugBank.d245.s4|136-136|,|O
DDI-DrugBank.d245.s4|138-146|phenytoin|O
DDI-DrugBank.d245.s4|147-147|,|O
DDI-DrugBank.d245.s4|149-157|nicotinic|O
DDI-DrugBank.d245.s4|159-162|acid|O
DDI-DrugBank.d245.s4|163-163|,|O
DDI-DrugBank.d245.s4|165-180|sympathomimetics|O
DDI-DrugBank.d245.s4|181-181|,|O
DDI-DrugBank.d245.s4|183-189|calcium|O
DDI-DrugBank.d245.s4|191-197|channel|O
DDI-DrugBank.d245.s4|199-206|blocking|O
DDI-DrugBank.d245.s4|208-212|drugs|O
DDI-DrugBank.d245.s4|213-213|,|O
DDI-DrugBank.d245.s4|215-217|and|O
DDI-DrugBank.d245.s4|219-227|isoniazid|O
DDI-DrugBank.d245.s4|228-228|.|O
DDI-DrugBank.d245.s5|0-3|When|O
DDI-DrugBank.d245.s5|5-8|such|O
DDI-DrugBank.d245.s5|10-14|drugs|O
DDI-DrugBank.d245.s5|16-18|are|O
DDI-DrugBank.d245.s5|20-31|administered|O
DDI-DrugBank.d245.s5|33-34|to|O
DDI-DrugBank.d245.s5|36-36|a|O
DDI-DrugBank.d245.s5|38-44|patient|O
DDI-DrugBank.d245.s5|46-54|receiving|O
DDI-DrugBank.d245.s5|56-64|DIABINESE|O
DDI-DrugBank.d245.s5|65-65|,|O
DDI-DrugBank.d245.s5|67-69|the|O
DDI-DrugBank.d245.s5|71-77|patient|O
DDI-DrugBank.d245.s5|79-84|should|O
DDI-DrugBank.d245.s5|86-87|be|O
DDI-DrugBank.d245.s5|89-95|closely|O
DDI-DrugBank.d245.s5|97-104|observed|O
DDI-DrugBank.d245.s5|106-108|for|O
DDI-DrugBank.d245.s5|110-113|loss|O
DDI-DrugBank.d245.s5|115-116|of|O
DDI-DrugBank.d245.s5|118-124|control|O
DDI-DrugBank.d245.s5|125-125|.|O
DDI-DrugBank.d245.s6|0-3|When|O
DDI-DrugBank.d245.s6|5-8|such|O
DDI-DrugBank.d245.s6|10-14|drugs|O
DDI-DrugBank.d245.s6|16-18|are|O
DDI-DrugBank.d245.s6|20-28|withdrawn|O
DDI-DrugBank.d245.s6|30-33|from|O
DDI-DrugBank.d245.s6|35-35|a|O
DDI-DrugBank.d245.s6|37-43|patient|O
DDI-DrugBank.d245.s6|45-53|receiving|O
DDI-DrugBank.d245.s6|55-63|DIABINESE|O
DDI-DrugBank.d245.s6|64-64|,|O
DDI-DrugBank.d245.s6|66-68|the|O
DDI-DrugBank.d245.s6|70-76|patient|O
DDI-DrugBank.d245.s6|78-83|should|O
DDI-DrugBank.d245.s6|85-86|be|O
DDI-DrugBank.d245.s6|88-95|observed|O
DDI-DrugBank.d245.s6|97-103|closely|O
DDI-DrugBank.d245.s6|105-107|for|O
DDI-DrugBank.d245.s6|109-120|hypoglycemia|O
DDI-DrugBank.d245.s6|121-121|.|O
DDI-DrugBank.d245.s7|0-4|Since|O
DDI-DrugBank.d245.s7|6-11|animal|O
DDI-DrugBank.d245.s7|13-19|studies|O
DDI-DrugBank.d245.s7|21-27|suggest|O
DDI-DrugBank.d245.s7|29-32|that|O
DDI-DrugBank.d245.s7|34-36|the|O
DDI-DrugBank.d245.s7|38-43|action|O
DDI-DrugBank.d245.s7|45-46|of|O
DDI-DrugBank.d245.s7|48-59|barbiturates|O
DDI-DrugBank.d245.s7|61-63|may|O
DDI-DrugBank.d245.s7|65-66|be|O
DDI-DrugBank.d245.s7|68-76|prolonged|O
DDI-DrugBank.d245.s7|78-79|by|O
DDI-DrugBank.d245.s7|81-87|therapy|O
DDI-DrugBank.d245.s7|89-92|with|O
DDI-DrugBank.d245.s7|94-107|chlorpropamide|O
DDI-DrugBank.d245.s7|108-108|,|O
DDI-DrugBank.d245.s7|110-121|barbiturates|O
DDI-DrugBank.d245.s7|123-128|should|O
DDI-DrugBank.d245.s7|130-131|be|O
DDI-DrugBank.d245.s7|133-140|employed|O
DDI-DrugBank.d245.s7|142-145|with|O
DDI-DrugBank.d245.s7|147-153|caution|O
DDI-DrugBank.d245.s7|154-154|.|O
DDI-DrugBank.d245.s8|0-1|In|O
DDI-DrugBank.d245.s8|3-6|some|O
DDI-DrugBank.d245.s8|8-15|patients|O
DDI-DrugBank.d245.s8|16-16|,|O
DDI-DrugBank.d245.s8|18-18|a|O
DDI-DrugBank.d245.s8|20-34|disulfiram-like|O
DDI-DrugBank.d245.s8|36-43|reaction|O
DDI-DrugBank.d245.s8|45-47|may|O
DDI-DrugBank.d245.s8|49-50|be|O
DDI-DrugBank.d245.s8|52-59|produced|O
DDI-DrugBank.d245.s8|61-62|by|O
DDI-DrugBank.d245.s8|64-66|the|O
DDI-DrugBank.d245.s8|68-76|ingestion|O
DDI-DrugBank.d245.s8|78-79|of|O
DDI-DrugBank.d245.s8|81-87|alcohol|O
DDI-DrugBank.d245.s8|88-88|.|O
DDI-DrugBank.d245.s9|0-0|A|O
DDI-DrugBank.d245.s9|2-10|potential|O
DDI-DrugBank.d245.s9|12-22|interaction|O
DDI-DrugBank.d245.s9|24-30|between|O
DDI-DrugBank.d245.s9|32-35|oral|O
DDI-DrugBank.d245.s9|37-46|miconazole|O
DDI-DrugBank.d245.s9|48-50|and|O
DDI-DrugBank.d245.s9|52-55|oral|O
DDI-DrugBank.d245.s9|57-68|hypoglycemic|O
DDI-DrugBank.d245.s9|70-75|agents|O
DDI-DrugBank.d245.s9|77-83|leading|O
DDI-DrugBank.d245.s9|85-86|to|O
DDI-DrugBank.d245.s9|88-93|severe|O
DDI-DrugBank.d245.s9|95-106|hypoglycemia|O
DDI-DrugBank.d245.s9|108-110|has|O
DDI-DrugBank.d245.s9|112-115|been|O
DDI-DrugBank.d245.s9|117-124|reported|O
DDI-DrugBank.d245.s9|125-125|.|O
DDI-DrugBank.d245.s10|0-6|Whether|O
DDI-DrugBank.d245.s10|8-11|this|O
DDI-DrugBank.d245.s10|13-23|interaction|O
DDI-DrugBank.d245.s10|25-28|also|O
DDI-DrugBank.d245.s10|30-35|occurs|O
DDI-DrugBank.d245.s10|37-40|with|O
DDI-DrugBank.d245.s10|42-44|the|O
DDI-DrugBank.d245.s10|46-56|intravenous|O
DDI-DrugBank.d245.s10|57-57|,|O
DDI-DrugBank.d245.s10|59-65|topical|O
DDI-DrugBank.d245.s10|66-66|,|O
DDI-DrugBank.d245.s10|68-69|or|O
DDI-DrugBank.d245.s10|71-77|vaginal|O
DDI-DrugBank.d245.s10|79-90|preparations|O
DDI-DrugBank.d245.s10|92-93|of|O
DDI-DrugBank.d245.s10|95-104|miconazole|O
DDI-DrugBank.d245.s10|106-107|is|O
DDI-DrugBank.d245.s10|109-111|not|O
DDI-DrugBank.d245.s10|113-117|known|O
DDI-DrugBank.d245.s10|118-118|.|O
DDI-DrugBank.d81.s0|0-12|Nitroglycerin|O
DDI-DrugBank.d81.s0|13-13|:|O
DDI-DrugBank.d81.s0|15-22|DynaCirc|O
DDI-DrugBank.d81.s0|25-25|(|O
DDI-DrugBank.d81.s0|26-35|isradipine|O
DDI-DrugBank.d81.s0|36-36|)|O
DDI-DrugBank.d81.s0|38-40|has|O
DDI-DrugBank.d81.s0|42-45|been|O
DDI-DrugBank.d81.s0|47-52|safely|O
DDI-DrugBank.d81.s0|54-67|coadministered|O
DDI-DrugBank.d81.s0|69-72|with|O
DDI-DrugBank.d81.s0|74-86|nitroglycerin|O
DDI-DrugBank.d81.s0|87-87|.|O
DDI-DrugBank.d81.s1|0-18|Hydrochlorothiazide|O
DDI-DrugBank.d81.s1|19-19|:|O
DDI-DrugBank.d81.s1|21-21|A|O
DDI-DrugBank.d81.s1|23-27|study|O
DDI-DrugBank.d81.s1|29-30|in|O
DDI-DrugBank.d81.s1|32-37|normal|O
DDI-DrugBank.d81.s1|39-45|healthy|O
DDI-DrugBank.d81.s1|47-56|volunteers|O
DDI-DrugBank.d81.s1|58-60|has|O
DDI-DrugBank.d81.s1|62-66|shown|O
DDI-DrugBank.d81.s1|68-71|that|O
DDI-DrugBank.d81.s1|73-83|concomitant|O
DDI-DrugBank.d81.s1|85-98|administration|O
DDI-DrugBank.d81.s1|100-101|of|O
DDI-DrugBank.d81.s1|103-110|DynaCirc|O
DDI-DrugBank.d81.s1|113-113|(|O
DDI-DrugBank.d81.s1|114-123|isradipine|O
DDI-DrugBank.d81.s1|124-124|)|O
DDI-DrugBank.d81.s1|126-128|and|O
DDI-DrugBank.d81.s1|130-148|hydrochlorothiazide|O
DDI-DrugBank.d81.s1|150-153|does|O
DDI-DrugBank.d81.s1|155-157|not|O
DDI-DrugBank.d81.s1|159-164|result|O
DDI-DrugBank.d81.s1|166-167|in|O
DDI-DrugBank.d81.s1|169-175|altered|O
DDI-DrugBank.d81.s1|177-192|pharmacoktnetics|O
DDI-DrugBank.d81.s1|194-195|of|O
DDI-DrugBank.d81.s1|197-202|either|O
DDI-DrugBank.d81.s1|204-207|drug|O
DDI-DrugBank.d81.s1|208-208|.|O
DDI-DrugBank.d81.s2|0-1|In|O
DDI-DrugBank.d81.s2|3-3|a|O
DDI-DrugBank.d81.s2|5-9|study|O
DDI-DrugBank.d81.s2|11-12|in|O
DDI-DrugBank.d81.s2|14-25|hypertensive|O
DDI-DrugBank.d81.s2|27-34|patients|O
DDI-DrugBank.d81.s2|35-35|,|O
DDI-DrugBank.d81.s2|37-44|addition|O
DDI-DrugBank.d81.s2|46-47|of|O
DDI-DrugBank.d81.s2|49-58|isradipine|O
DDI-DrugBank.d81.s2|60-61|to|O
DDI-DrugBank.d81.s2|63-70|existing|O
DDI-DrugBank.d81.s2|72-90|hydrochlorothiazide|O
DDI-DrugBank.d81.s2|92-98|therapy|O
DDI-DrugBank.d81.s2|100-102|did|O
DDI-DrugBank.d81.s2|104-106|not|O
DDI-DrugBank.d81.s2|108-113|result|O
DDI-DrugBank.d81.s2|115-116|in|O
DDI-DrugBank.d81.s2|118-120|any|O
DDI-DrugBank.d81.s2|122-131|unexpected|O
DDI-DrugBank.d81.s2|133-139|adverse|O
DDI-DrugBank.d81.s2|141-147|effects|O
DDI-DrugBank.d81.s2|148-148|,|O
DDI-DrugBank.d81.s2|150-152|and|O
DDI-DrugBank.d81.s2|154-163|isradipine|O
DDI-DrugBank.d81.s2|165-167|had|O
DDI-DrugBank.d81.s2|169-170|an|O
DDI-DrugBank.d81.s2|172-181|additional|O
DDI-DrugBank.d81.s2|183-198|antihypertensive|O
DDI-DrugBank.d81.s2|200-205|effect|O
DDI-DrugBank.d81.s2|206-206|.|O
DDI-DrugBank.d81.s3|0-10|Propranolol|O
DDI-DrugBank.d81.s3|11-11|:|O
DDI-DrugBank.d81.s3|13-14|In|O
DDI-DrugBank.d81.s3|16-16|a|O
DDI-DrugBank.d81.s3|18-23|single|O
DDI-DrugBank.d81.s3|25-28|dose|O
DDI-DrugBank.d81.s3|30-34|study|O
DDI-DrugBank.d81.s3|36-37|in|O
DDI-DrugBank.d81.s3|39-44|normal|O
DDI-DrugBank.d81.s3|46-55|volunteers|O
DDI-DrugBank.d81.s3|56-56|,|O
DDI-DrugBank.d81.s3|58-73|coadministration|O
DDI-DrugBank.d81.s3|75-76|of|O
DDI-DrugBank.d81.s3|78-88|propranolol|O
DDI-DrugBank.d81.s3|90-92|had|O
DDI-DrugBank.d81.s3|94-94|a|O
DDI-DrugBank.d81.s3|96-100|small|O
DDI-DrugBank.d81.s3|102-107|effect|O
DDI-DrugBank.d81.s3|109-110|on|O
DDI-DrugBank.d81.s3|112-114|the|O
DDI-DrugBank.d81.s3|116-119|rate|O
DDI-DrugBank.d81.s3|121-123|but|O
DDI-DrugBank.d81.s3|125-126|no|O
DDI-DrugBank.d81.s3|128-133|effect|O
DDI-DrugBank.d81.s3|135-136|on|O
DDI-DrugBank.d81.s3|138-140|the|O
DDI-DrugBank.d81.s3|142-147|extent|O
DDI-DrugBank.d81.s3|149-150|of|O
DDI-DrugBank.d81.s3|152-161|isradipine|O
DDI-DrugBank.d81.s3|163-177|bioavailability|O
DDI-DrugBank.d81.s3|178-178|.|O
DDI-DrugBank.d81.s4|0-10|Significant|O
DDI-DrugBank.d81.s4|12-20|increases|O
DDI-DrugBank.d81.s4|22-23|In|O
DDI-DrugBank.d81.s4|25-27|AUC|O
DDI-DrugBank.d81.s4|29-29|(|O
DDI-DrugBank.d81.s4|30-31|27|O
DDI-DrugBank.d81.s4|32-32|%|O
DDI-DrugBank.d81.s4|33-33|)|O
DDI-DrugBank.d81.s4|35-37|and|O
DDI-DrugBank.d81.s4|39-42|Cmax|O
DDI-DrugBank.d81.s4|44-44|(|O
DDI-DrugBank.d81.s4|45-46|58|O
DDI-DrugBank.d81.s4|47-47|%|O
DDI-DrugBank.d81.s4|48-48|)|O
DDI-DrugBank.d81.s4|50-52|and|O
DDI-DrugBank.d81.s4|54-62|decreases|O
DDI-DrugBank.d81.s4|64-65|in|O
DDI-DrugBank.d81.s4|67-70|tmax|O
DDI-DrugBank.d81.s4|72-72|(|O
DDI-DrugBank.d81.s4|73-74|23|O
DDI-DrugBank.d81.s4|75-75|%|O
DDI-DrugBank.d81.s4|76-76|)|O
DDI-DrugBank.d81.s4|78-79|of|O
DDI-DrugBank.d81.s4|81-91|propranolol|O
DDI-DrugBank.d81.s4|93-96|were|O
DDI-DrugBank.d81.s4|98-102|noted|O
DDI-DrugBank.d81.s4|104-105|in|O
DDI-DrugBank.d81.s4|107-110|this|O
DDI-DrugBank.d81.s4|112-116|study|O
DDI-DrugBank.d81.s4|117-117|.|O
DDI-DrugBank.d81.s5|0-6|However|O
DDI-DrugBank.d81.s5|7-7|,|O
DDI-DrugBank.d81.s5|9-19|concomitant|O
DDI-DrugBank.d81.s5|21-34|administration|O
DDI-DrugBank.d81.s5|36-37|of|O
DDI-DrugBank.d81.s5|39-39|5|O
DDI-DrugBank.d81.s5|41-42|mg|O
DDI-DrugBank.d81.s5|44-49|b.i.d.|O
DDI-DrugBank.d81.s5|51-60|isradipine|O
DDI-DrugBank.d81.s5|62-64|and|O
DDI-DrugBank.d81.s5|66-67|40|O
DDI-DrugBank.d81.s5|69-70|mg|O
DDI-DrugBank.d81.s5|72-76|b.i.d|O
DDI-DrugBank.d81.s5|77-77|.|O
DDI-DrugBank.d81.s6|0-10|propranolol|O
DDI-DrugBank.d81.s6|12-13|to|O
DDI-DrugBank.d81.s6|15-21|healthy|O
DDI-DrugBank.d81.s6|23-32|volunteers|O
DDI-DrugBank.d81.s6|34-38|under|O
DDI-DrugBank.d81.s6|40-51|steady-state|O
DDI-DrugBank.d81.s6|53-62|conditions|O
DDI-DrugBank.d81.s6|64-66|had|O
DDI-DrugBank.d81.s6|68-69|no|O
DDI-DrugBank.d81.s6|71-78|relevant|O
DDI-DrugBank.d81.s6|80-85|effect|O
DDI-DrugBank.d81.s6|87-88|on|O
DDI-DrugBank.d81.s6|90-95|either|O
DDI-DrugBank.d81.s6|97-100|drug|O
DDI-DrugBank.d81.s6|102-102|s|O
DDI-DrugBank.d81.s6|104-118|bioavailability|O
DDI-DrugBank.d81.s6|119-119|,|O
DDI-DrugBank.d81.s6|121-123|AUC|O
DDI-DrugBank.d81.s6|125-127|and|O
DDI-DrugBank.d81.s6|129-132|Cmax|O
DDI-DrugBank.d81.s6|133-133|,|O
DDI-DrugBank.d81.s6|135-145|differences|O
DDI-DrugBank.d81.s6|147-150|were|O
DDI-DrugBank.d81.s6|153-154|20|O
DDI-DrugBank.d81.s6|155-155|%|O
DDI-DrugBank.d81.s6|157-163|between|O
DDI-DrugBank.d81.s6|165-174|isradipine|O
DDI-DrugBank.d81.s6|176-180|given|O
DDI-DrugBank.d81.s6|182-187|singly|O
DDI-DrugBank.d81.s6|189-191|and|O
DDI-DrugBank.d81.s6|193-194|in|O
DDI-DrugBank.d81.s6|196-206|combination|O
DDI-DrugBank.d81.s6|208-211|with|O
DDI-DrugBank.d81.s6|213-223|propranolol|O
DDI-DrugBank.d81.s6|224-224|,|O
DDI-DrugBank.d81.s6|226-228|and|O
DDI-DrugBank.d81.s6|230-236|between|O
DDI-DrugBank.d81.s6|238-248|propranolol|O
DDI-DrugBank.d81.s6|250-254|given|O
DDI-DrugBank.d81.s6|256-261|singly|O
DDI-DrugBank.d81.s6|263-265|and|O
DDI-DrugBank.d81.s6|267-268|in|O
DDI-DrugBank.d81.s6|270-280|combination|O
DDI-DrugBank.d81.s6|282-285|with|O
DDI-DrugBank.d81.s6|287-296|isradipine|O
DDI-DrugBank.d81.s6|297-297|.|O
DDI-DrugBank.d81.s7|0-9|Cimetidine|O
DDI-DrugBank.d81.s7|10-10|:|O
DDI-DrugBank.d81.s7|12-13|In|O
DDI-DrugBank.d81.s7|15-15|a|O
DDI-DrugBank.d81.s7|17-21|study|O
DDI-DrugBank.d81.s7|23-24|in|O
DDI-DrugBank.d81.s7|26-32|healthy|O
DDI-DrugBank.d81.s7|34-43|volunteers|O
DDI-DrugBank.d81.s7|44-44|,|O
DDI-DrugBank.d81.s7|46-46|a|O
DDI-DrugBank.d81.s7|48-55|one-week|O
DDI-DrugBank.d81.s7|57-62|course|O
DDI-DrugBank.d81.s7|64-65|of|O
DDI-DrugBank.d81.s7|67-76|cimetidine|O
DDI-DrugBank.d81.s7|78-79|at|O
DDI-DrugBank.d81.s7|81-83|400|O
DDI-DrugBank.d81.s7|85-86|mg|O
DDI-DrugBank.d81.s7|88-93|b.i.d.|O
DDI-DrugBank.d81.s7|95-98|with|O
DDI-DrugBank.d81.s7|100-100|a|O
DDI-DrugBank.d81.s7|102-107|single|O
DDI-DrugBank.d81.s7|109-109|5|O
DDI-DrugBank.d81.s7|111-112|mg|O
DDI-DrugBank.d81.s7|114-117|dose|O
DDI-DrugBank.d81.s7|119-120|of|O
DDI-DrugBank.d81.s7|122-131|isradipine|O
DDI-DrugBank.d81.s7|133-134|on|O
DDI-DrugBank.d81.s7|136-138|the|O
DDI-DrugBank.d81.s7|140-144|sixth|O
DDI-DrugBank.d81.s7|146-148|day|O
DDI-DrugBank.d81.s7|150-155|showed|O
DDI-DrugBank.d81.s7|157-158|an|O
DDI-DrugBank.d81.s7|160-167|increase|O
DDI-DrugBank.d81.s7|169-170|in|O
DDI-DrugBank.d81.s7|172-181|isradipine|O
DDI-DrugBank.d81.s7|183-186|mean|O
DDI-DrugBank.d81.s7|188-191|peak|O
DDI-DrugBank.d81.s7|193-198|plasma|O
DDI-DrugBank.d81.s7|200-213|concentrations|O
DDI-DrugBank.d81.s7|215-215|(|O
DDI-DrugBank.d81.s7|216-217|36|O
DDI-DrugBank.d81.s7|218-218|%|O
DDI-DrugBank.d81.s7|219-219|)|O
DDI-DrugBank.d81.s7|221-223|and|O
DDI-DrugBank.d81.s7|225-235|significant|O
DDI-DrugBank.d81.s7|237-244|increase|O
DDI-DrugBank.d81.s7|246-247|in|O
DDI-DrugBank.d81.s7|249-252|area|O
DDI-DrugBank.d81.s7|254-258|under|O
DDI-DrugBank.d81.s7|260-262|the|O
DDI-DrugBank.d81.s7|264-268|curve|O
DDI-DrugBank.d81.s7|270-270|(|O
DDI-DrugBank.d81.s7|271-272|50|O
DDI-DrugBank.d81.s7|273-273|%|O
DDI-DrugBank.d81.s7|274-274|)|O
DDI-DrugBank.d81.s7|275-275|.|O
DDI-DrugBank.d81.s8|0-1|If|O
DDI-DrugBank.d81.s8|3-12|isradipine|O
DDI-DrugBank.d81.s8|14-20|therapy|O
DDI-DrugBank.d81.s8|22-23|is|O
DDI-DrugBank.d81.s8|25-33|initiated|O
DDI-DrugBank.d81.s8|35-36|in|O
DDI-DrugBank.d81.s8|38-38|a|O
DDI-DrugBank.d81.s8|40-46|patient|O
DDI-DrugBank.d81.s8|48-56|currently|O
DDI-DrugBank.d81.s8|58-66|receiving|O
DDI-DrugBank.d81.s8|68-77|cimetidine|O
DDI-DrugBank.d81.s8|79-85|careful|O
DDI-DrugBank.d81.s8|87-96|monitoring|O
DDI-DrugBank.d81.s8|98-100|for|O
DDI-DrugBank.d81.s8|102-108|adverse|O
DDI-DrugBank.d81.s8|110-118|reactions|O
DDI-DrugBank.d81.s8|120-121|is|O
DDI-DrugBank.d81.s8|123-129|advised|O
DDI-DrugBank.d81.s8|131-133|and|O
DDI-DrugBank.d81.s8|135-142|downward|O
DDI-DrugBank.d81.s8|144-147|dose|O
DDI-DrugBank.d81.s8|149-158|adjustment|O
DDI-DrugBank.d81.s8|160-162|may|O
DDI-DrugBank.d81.s8|164-165|be|O
DDI-DrugBank.d81.s8|167-174|required|O
DDI-DrugBank.d81.s8|175-175|.|O
DDI-DrugBank.d81.s9|0-9|Rifampicin|O
DDI-DrugBank.d81.s9|10-10|:|O
DDI-DrugBank.d81.s9|12-13|In|O
DDI-DrugBank.d81.s9|15-15|a|O
DDI-DrugBank.d81.s9|17-21|study|O
DDI-DrugBank.d81.s9|23-24|in|O
DDI-DrugBank.d81.s9|26-32|healthy|O
DDI-DrugBank.d81.s9|34-43|volunteers|O
DDI-DrugBank.d81.s9|44-44|,|O
DDI-DrugBank.d81.s9|46-46|a|O
DDI-DrugBank.d81.s9|48-54|six-day|O
DDI-DrugBank.d81.s9|56-61|course|O
DDI-DrugBank.d81.s9|63-64|of|O
DDI-DrugBank.d81.s9|66-75|rifampicin|O
DDI-DrugBank.d81.s9|77-78|at|O
DDI-DrugBank.d81.s9|80-82|600|O
DDI-DrugBank.d81.s9|84-89|mg/day|O
DDI-DrugBank.d81.s9|91-98|followed|O
DDI-DrugBank.d81.s9|100-101|by|O
DDI-DrugBank.d81.s9|103-103|a|O
DDI-DrugBank.d81.s9|105-110|single|O
DDI-DrugBank.d81.s9|112-112|5|O
DDI-DrugBank.d81.s9|114-115|mg|O
DDI-DrugBank.d81.s9|117-120|dose|O
DDI-DrugBank.d81.s9|122-123|of|O
DDI-DrugBank.d81.s9|125-134|isradipine|O
DDI-DrugBank.d81.s9|136-143|resulted|O
DDI-DrugBank.d81.s9|145-146|in|O
DDI-DrugBank.d81.s9|148-148|a|O
DDI-DrugBank.d81.s9|150-158|reduction|O
DDI-DrugBank.d81.s9|160-161|in|O
DDI-DrugBank.d81.s9|163-172|isradipine|O
DDI-DrugBank.d81.s9|174-179|levels|O
DDI-DrugBank.d81.s9|181-182|to|O
DDI-DrugBank.d81.s9|184-188|below|O
DDI-DrugBank.d81.s9|190-199|detectable|O
DDI-DrugBank.d81.s9|201-206|limits|O
DDI-DrugBank.d81.s9|207-207|.|O
DDI-DrugBank.d81.s10|0-1|If|O
DDI-DrugBank.d81.s10|3-12|rifampicin|O
DDI-DrugBank.d81.s10|14-20|therapy|O
DDI-DrugBank.d81.s10|22-23|is|O
DDI-DrugBank.d81.s10|25-32|required|O
DDI-DrugBank.d81.s10|33-33|,|O
DDI-DrugBank.d81.s10|35-44|isradipine|O
DDI-DrugBank.d81.s10|46-59|concentrations|O
DDI-DrugBank.d81.s10|61-63|and|O
DDI-DrugBank.d81.s10|65-75|therapeutic|O
DDI-DrugBank.d81.s10|77-83|effects|O
DDI-DrugBank.d81.s10|85-87|are|O
DDI-DrugBank.d81.s10|89-94|likely|O
DDI-DrugBank.d81.s10|96-97|to|O
DDI-DrugBank.d81.s10|99-100|be|O
DDI-DrugBank.d81.s10|102-109|markedly|O
DDI-DrugBank.d81.s10|111-117|reduced|O
DDI-DrugBank.d81.s10|119-120|or|O
DDI-DrugBank.d81.s10|122-130|abolished|O
DDI-DrugBank.d81.s10|132-133|as|O
DDI-DrugBank.d81.s10|135-135|a|O
DDI-DrugBank.d81.s10|137-147|consequence|O
DDI-DrugBank.d81.s10|149-150|of|O
DDI-DrugBank.d81.s10|152-160|increased|O
DDI-DrugBank.d81.s10|162-171|metabolism|O
DDI-DrugBank.d81.s10|173-175|and|O
DDI-DrugBank.d81.s10|177-182|higher|O
DDI-DrugBank.d81.s10|184-192|clearance|O
DDI-DrugBank.d81.s10|194-195|of|O
DDI-DrugBank.d81.s10|197-206|isradipine|O
DDI-DrugBank.d81.s10|207-207|.|O
DDI-DrugBank.d81.s11|0-7|Warfarin|O
DDI-DrugBank.d81.s11|8-8|:|O
DDI-DrugBank.d81.s11|10-11|In|O
DDI-DrugBank.d81.s11|13-13|a|O
DDI-DrugBank.d81.s11|15-19|study|O
DDI-DrugBank.d81.s11|21-22|in|O
DDI-DrugBank.d81.s11|24-30|healthy|O
DDI-DrugBank.d81.s11|32-41|volunteers|O
DDI-DrugBank.d81.s11|42-42|,|O
DDI-DrugBank.d81.s11|44-45|no|O
DDI-DrugBank.d81.s11|47-56|clinically|O
DDI-DrugBank.d81.s11|58-65|relevant|O
DDI-DrugBank.d81.s11|67-81|pharmacokinetic|O
DDI-DrugBank.d81.s11|83-84|or|O
DDI-DrugBank.d81.s11|86-100|pharmacodynamic|O
DDI-DrugBank.d81.s11|102-112|interaction|O
DDI-DrugBank.d81.s11|114-120|between|O
DDI-DrugBank.d81.s11|122-131|isradipine|O
DDI-DrugBank.d81.s11|133-135|and|O
DDI-DrugBank.d81.s11|137-143|racemic|O
DDI-DrugBank.d81.s11|145-152|warfarin|O
DDI-DrugBank.d81.s11|154-156|was|O
DDI-DrugBank.d81.s11|158-161|seen|O
DDI-DrugBank.d81.s11|163-166|when|O
DDI-DrugBank.d81.s11|168-170|two|O
DDI-DrugBank.d81.s11|172-177|single|O
DDI-DrugBank.d81.s11|179-182|oral|O
DDI-DrugBank.d81.s11|184-188|doses|O
DDI-DrugBank.d81.s11|190-191|of|O
DDI-DrugBank.d81.s11|193-200|warfarin|O
DDI-DrugBank.d81.s11|202-202|(|O
DDI-DrugBank.d81.s11|203-205|0.7|O
DDI-DrugBank.d81.s11|207-211|mg/kg|O
DDI-DrugBank.d81.s11|213-216|body|O
DDI-DrugBank.d81.s11|218-223|weight|O
DDI-DrugBank.d81.s11|224-224|)|O
DDI-DrugBank.d81.s11|226-229|were|O
DDI-DrugBank.d81.s11|231-242|administered|O
DDI-DrugBank.d81.s11|244-249|during|O
DDI-DrugBank.d81.s11|251-252|11|O
DDI-DrugBank.d81.s11|254-257|days|O
DDI-DrugBank.d81.s11|259-260|of|O
DDI-DrugBank.d81.s11|262-273|multipledose|O
DDI-DrugBank.d81.s11|275-283|treatment|O
DDI-DrugBank.d81.s11|285-288|with|O
DDI-DrugBank.d81.s11|290-290|5|O
DDI-DrugBank.d81.s11|292-293|mg|O
DDI-DrugBank.d81.s11|295-300|b.i.d.|O
DDI-DrugBank.d81.s11|302-311|isradipine|O
DDI-DrugBank.d81.s11|312-312|.|O
DDI-DrugBank.d81.s12|0-6|Neither|O
DDI-DrugBank.d81.s12|8-14|racemic|O
DDI-DrugBank.d81.s12|16-23|warfarin|O
DDI-DrugBank.d81.s12|25-27|nor|O
DDI-DrugBank.d81.s12|29-38|isradipine|O
DDI-DrugBank.d81.s12|40-46|binding|O
DDI-DrugBank.d81.s12|48-49|to|O
DDI-DrugBank.d81.s12|51-56|plasma|O
DDI-DrugBank.d81.s12|58-65|proteins|O
DDI-DrugBank.d81.s12|67-68|in|O
DDI-DrugBank.d81.s12|70-74|vitro|O
DDI-DrugBank.d81.s12|76-78|was|O
DDI-DrugBank.d81.s12|80-86|altered|O
DDI-DrugBank.d81.s12|88-89|by|O
DDI-DrugBank.d81.s12|91-93|the|O
DDI-DrugBank.d81.s12|95-102|addition|O
DDI-DrugBank.d81.s12|104-105|of|O
DDI-DrugBank.d81.s12|107-109|the|O
DDI-DrugBank.d81.s12|111-115|other|O
DDI-DrugBank.d81.s12|117-120|drug|O
DDI-DrugBank.d81.s12|121-121|.|O
DDI-DrugBank.d81.s13|0-6|Digoxin|O
DDI-DrugBank.d81.s13|7-7|:|O
DDI-DrugBank.d81.s13|9-11|The|O
DDI-DrugBank.d81.s13|13-23|concomitant|O
DDI-DrugBank.d81.s13|25-38|administration|O
DDI-DrugBank.d81.s13|40-41|of|O
DDI-DrugBank.d81.s13|43-50|DynaCirc|O
DDI-DrugBank.d81.s13|53-53|(|O
DDI-DrugBank.d81.s13|54-63|isradipine|O
DDI-DrugBank.d81.s13|64-64|)|O
DDI-DrugBank.d81.s13|66-68|and|O
DDI-DrugBank.d81.s13|70-76|digoxin|O
DDI-DrugBank.d81.s13|78-79|in|O
DDI-DrugBank.d81.s13|81-81|a|O
DDI-DrugBank.d81.s13|83-93|single-dose|O
DDI-DrugBank.d81.s13|95-109|pharmacokinetic|O
DDI-DrugBank.d81.s13|111-115|study|O
DDI-DrugBank.d81.s13|117-119|did|O
DDI-DrugBank.d81.s13|121-123|not|O
DDI-DrugBank.d81.s13|125-130|affect|O
DDI-DrugBank.d81.s13|132-136|renal|O
DDI-DrugBank.d81.s13|137-137|,|O
DDI-DrugBank.d81.s13|139-146|nonrenal|O
DDI-DrugBank.d81.s13|148-150|and|O
DDI-DrugBank.d81.s13|152-156|total|O
DDI-DrugBank.d81.s13|158-161|body|O
DDI-DrugBank.d81.s13|163-171|clearance|O
DDI-DrugBank.d81.s13|173-174|of|O
DDI-DrugBank.d81.s13|176-182|digoxin|O
DDI-DrugBank.d81.s13|183-183|.|O
DDI-DrugBank.d81.s14|0-7|Fentanyl|O
DDI-DrugBank.d81.s14|9-18|Anesthesia|O
DDI-DrugBank.d81.s14|19-19|:|O
DDI-DrugBank.d81.s14|21-26|Severe|O
DDI-DrugBank.d81.s14|28-38|hypotension|O
DDI-DrugBank.d81.s14|40-42|has|O
DDI-DrugBank.d81.s14|44-47|been|O
DDI-DrugBank.d81.s14|49-56|reported|O
DDI-DrugBank.d81.s14|58-63|during|O
DDI-DrugBank.d81.s14|65-72|fentanyl|O
DDI-DrugBank.d81.s14|74-83|anesthesia|O
DDI-DrugBank.d81.s14|85-88|with|O
DDI-DrugBank.d81.s14|90-100|concomitant|O
DDI-DrugBank.d81.s14|102-104|use|O
DDI-DrugBank.d81.s14|106-107|of|O
DDI-DrugBank.d81.s14|109-109|a|O
DDI-DrugBank.d81.s14|111-114|beta|O
DDI-DrugBank.d81.s14|116-122|blocker|O
DDI-DrugBank.d81.s14|124-126|and|O
DDI-DrugBank.d81.s14|128-128|a|O
DDI-DrugBank.d81.s14|130-136|calcium|O
DDI-DrugBank.d81.s14|138-144|channel|O
DDI-DrugBank.d81.s14|146-152|blocker|O
DDI-DrugBank.d81.s14|153-153|.|O
DDI-DrugBank.d81.s15|0-3|Even|O
DDI-DrugBank.d81.s15|5-10|though|O
DDI-DrugBank.d81.s15|12-15|such|O
DDI-DrugBank.d81.s15|17-28|interactions|O
DDI-DrugBank.d81.s15|30-33|have|O
DDI-DrugBank.d81.s15|35-37|not|O
DDI-DrugBank.d81.s15|39-42|been|O
DDI-DrugBank.d81.s15|44-47|seen|O
DDI-DrugBank.d81.s15|49-50|in|O
DDI-DrugBank.d81.s15|52-59|clinical|O
DDI-DrugBank.d81.s15|61-67|studies|O
DDI-DrugBank.d81.s15|69-72|with|O
DDI-DrugBank.d81.s15|74-81|DynaCirc|O
DDI-DrugBank.d81.s15|84-84|(|O
DDI-DrugBank.d81.s15|85-94|isradipine|O
DDI-DrugBank.d81.s15|95-95|)|O
DDI-DrugBank.d81.s15|96-96|,|O
DDI-DrugBank.d81.s15|98-99|an|O
DDI-DrugBank.d81.s15|101-109|increased|O
DDI-DrugBank.d81.s15|111-116|volume|O
DDI-DrugBank.d81.s15|118-119|of|O
DDI-DrugBank.d81.s15|121-131|circulating|O
DDI-DrugBank.d81.s15|133-138|fluids|O
DDI-DrugBank.d81.s15|140-144|might|O
DDI-DrugBank.d81.s15|146-147|be|O
DDI-DrugBank.d81.s15|149-156|required|O
DDI-DrugBank.d81.s15|158-159|if|O
DDI-DrugBank.d81.s15|161-164|such|O
DDI-DrugBank.d81.s15|166-167|an|O
DDI-DrugBank.d81.s15|169-179|interaction|O
DDI-DrugBank.d81.s15|181-184|were|O
DDI-DrugBank.d81.s15|186-187|to|O
DDI-DrugBank.d81.s15|189-193|occur|O
DDI-DrugBank.d81.s15|194-194|.|O
DDI-MedLine.d100.s0|0-8|Influence|O
DDI-MedLine.d100.s0|10-11|of|O
DDI-MedLine.d100.s0|13-27|calcium-channel|O
DDI-MedLine.d100.s0|29-36|blockers|O
DDI-MedLine.d100.s0|38-39|on|O
DDI-MedLine.d100.s0|41-48|platelet|O
DDI-MedLine.d100.s0|50-57|function|O
DDI-MedLine.d100.s0|59-61|and|O
DDI-MedLine.d100.s0|63-73|arachidonic|O
DDI-MedLine.d100.s0|75-78|acid|O
DDI-MedLine.d100.s0|80-89|metabolism|O
DDI-MedLine.d100.s0|90-90|.|O
DDI-MedLine.d100.s1|0-8|Available|O
DDI-MedLine.d100.s1|10-13|data|O
DDI-MedLine.d100.s1|15-22|indicate|O
DDI-MedLine.d100.s1|24-27|that|O
DDI-MedLine.d100.s1|29-36|platelet|O
DDI-MedLine.d100.s1|38-45|function|O
DDI-MedLine.d100.s1|47-49|and|O
DDI-MedLine.d100.s1|51-61|arachidonic|O
DDI-MedLine.d100.s1|63-66|acid|O
DDI-MedLine.d100.s1|68-77|metabolism|O
DDI-MedLine.d100.s1|79-81|are|O
DDI-MedLine.d100.s1|83-91|important|O
DDI-MedLine.d100.s1|93-99|factors|O
DDI-MedLine.d100.s1|101-102|in|O
DDI-MedLine.d100.s1|104-113|hemostasis|O
DDI-MedLine.d100.s1|115-117|and|O
DDI-MedLine.d100.s1|119-128|regulation|O
DDI-MedLine.d100.s1|130-131|of|O
DDI-MedLine.d100.s1|133-140|vascular|O
DDI-MedLine.d100.s1|142-145|tone|O
DDI-MedLine.d100.s1|146-146|.|O
DDI-MedLine.d100.s2|0-5|Plasma|O
DDI-MedLine.d100.s2|7-14|membrane|O
DDI-MedLine.d100.s2|16-18|and|O
DDI-MedLine.d100.s2|20-32|intracellular|O
DDI-MedLine.d100.s2|34-45|mobilization|O
DDI-MedLine.d100.s2|47-48|of|O
DDI-MedLine.d100.s2|50-56|calcium|O
DDI-MedLine.d100.s2|58-61|ions|O
DDI-MedLine.d100.s2|63-65|are|O
DDI-MedLine.d100.s2|67-76|intimately|O
DDI-MedLine.d100.s2|78-84|related|O
DDI-MedLine.d100.s2|86-87|to|O
DDI-MedLine.d100.s2|89-96|platelet|O
DDI-MedLine.d100.s2|98-107|activation|O
DDI-MedLine.d100.s2|109-111|and|O
DDI-MedLine.d100.s2|113-119|release|O
DDI-MedLine.d100.s2|121-122|of|O
DDI-MedLine.d100.s2|124-131|platelet|O
DDI-MedLine.d100.s2|133-140|contents|O
DDI-MedLine.d100.s2|141-141|.|O
DDI-MedLine.d100.s3|0-6|Release|O
DDI-MedLine.d100.s3|8-9|of|O
DDI-MedLine.d100.s3|11-21|arachidonic|O
DDI-MedLine.d100.s3|23-26|acid|O
DDI-MedLine.d100.s3|28-31|from|O
DDI-MedLine.d100.s3|33-40|membrane|O
DDI-MedLine.d100.s3|42-54|phospholipids|O
DDI-MedLine.d100.s3|56-57|as|O
DDI-MedLine.d100.s3|59-62|well|O
DDI-MedLine.d100.s3|64-65|as|O
DDI-MedLine.d100.s3|67-76|subsequent|O
DDI-MedLine.d100.s3|78-86|synthesis|O
DDI-MedLine.d100.s3|88-90|and|O
DDI-MedLine.d100.s3|92-98|release|O
DDI-MedLine.d100.s3|100-101|of|O
DDI-MedLine.d100.s3|103-117|vasoconstrictor|O
DDI-MedLine.d100.s3|119-129|thromboxane|O
DDI-MedLine.d100.s3|131-132|A2|O
DDI-MedLine.d100.s3|134-136|are|O
DDI-MedLine.d100.s3|138-141|also|O
DDI-MedLine.d100.s3|143-151|regulated|O
DDI-MedLine.d100.s3|153-154|by|O
DDI-MedLine.d100.s3|156-163|movement|O
DDI-MedLine.d100.s3|165-166|of|O
DDI-MedLine.d100.s3|168-174|calcium|O
DDI-MedLine.d100.s3|176-179|ions|O
DDI-MedLine.d100.s3|180-180|.|O
DDI-MedLine.d100.s4|0-8|Adenosine|O
DDI-MedLine.d100.s4|10-21|3':5'-cyclic|O
DDI-MedLine.d100.s4|23-31|phosphate|O
DDI-MedLine.d100.s4|33-34|in|O
DDI-MedLine.d100.s4|36-39|turn|O
DDI-MedLine.d100.s4|41-48|controls|O
DDI-MedLine.d100.s4|50-55|levels|O
DDI-MedLine.d100.s4|57-58|of|O
DDI-MedLine.d100.s4|60-63|free|O
DDI-MedLine.d100.s4|65-71|calcium|O
DDI-MedLine.d100.s4|73-76|ions|O
DDI-MedLine.d100.s4|78-79|in|O
DDI-MedLine.d100.s4|81-89|platelets|O
DDI-MedLine.d100.s4|91-93|and|O
DDI-MedLine.d100.s4|95-103|regulates|O
DDI-MedLine.d100.s4|105-121|calcium-dependent|O
DDI-MedLine.d100.s4|123-131|reactions|O
DDI-MedLine.d100.s4|132-132|.|O
DDI-MedLine.d100.s5|0-11|Slow-channel|O
DDI-MedLine.d100.s5|13-19|calcium|O
DDI-MedLine.d100.s5|21-28|blockers|O
DDI-MedLine.d100.s5|29-29|,|O
DDI-MedLine.d100.s5|31-34|such|O
DDI-MedLine.d100.s5|36-37|as|O
DDI-MedLine.d100.s5|39-47|verapamil|O
DDI-MedLine.d100.s5|48-48|,|O
DDI-MedLine.d100.s5|50-58|diltiazem|O
DDI-MedLine.d100.s5|60-62|and|O
DDI-MedLine.d100.s5|64-73|nifedipine|O
DDI-MedLine.d100.s5|74-74|,|O
DDI-MedLine.d100.s5|76-82|inhibit|O
DDI-MedLine.d100.s5|84-91|platelet|O
DDI-MedLine.d100.s5|93-102|activation|O
DDI-MedLine.d100.s5|104-105|in|O
DDI-MedLine.d100.s5|107-111|vitro|O
DDI-MedLine.d100.s5|112-112|,|O
DDI-MedLine.d100.s5|114-116|and|O
DDI-MedLine.d100.s5|118-125|decrease|O
DDI-MedLine.d100.s5|127-134|platelet|O
DDI-MedLine.d100.s5|136-143|adhesion|O
DDI-MedLine.d100.s5|145-159|intravascularly|O
DDI-MedLine.d100.s5|160-160|.|O
DDI-MedLine.d100.s6|0-4|These|O
DDI-MedLine.d100.s6|6-11|agents|O
DDI-MedLine.d100.s6|13-16|have|O
DDI-MedLine.d100.s6|18-21|also|O
DDI-MedLine.d100.s6|23-26|been|O
DDI-MedLine.d100.s6|28-32|shown|O
DDI-MedLine.d100.s6|34-35|to|O
DDI-MedLine.d100.s6|37-44|decrease|O
DDI-MedLine.d100.s6|46-53|platelet|O
DDI-MedLine.d100.s6|55-64|nucleotide|O
DDI-MedLine.d100.s6|66-72|release|O
DDI-MedLine.d100.s6|74-76|and|O
DDI-MedLine.d100.s6|78-88|thromboxane|O
DDI-MedLine.d100.s6|90-91|A2|O
DDI-MedLine.d100.s6|93-102|generation|O
DDI-MedLine.d100.s6|103-103|.|O
DDI-MedLine.d100.s7|0-3|Some|O
DDI-MedLine.d100.s7|5-15|preliminary|O
DDI-MedLine.d100.s7|17-20|data|O
DDI-MedLine.d100.s7|22-28|suggest|O
DDI-MedLine.d100.s7|30-33|that|O
DDI-MedLine.d100.s7|35-41|calcium|O
DDI-MedLine.d100.s7|43-50|blockers|O
DDI-MedLine.d100.s7|52-55|also|O
DDI-MedLine.d100.s7|57-64|increase|O
DDI-MedLine.d100.s7|66-75|generation|O
DDI-MedLine.d100.s7|77-78|of|O
DDI-MedLine.d100.s7|80-90|vasodilator|O
DDI-MedLine.d100.s7|92-94|and|O
DDI-MedLine.d100.s7|96-103|platelet|O
DDI-MedLine.d100.s7|105-117|antiaggregant|O
DDI-MedLine.d100.s7|119-130|prostacyclin|O
DDI-MedLine.d100.s7|131-131|,|O
DDI-MedLine.d100.s7|133-137|which|O
DDI-MedLine.d100.s7|139-143|could|O
DDI-MedLine.d100.s7|145-154|contribute|O
DDI-MedLine.d100.s7|156-157|to|O
DDI-MedLine.d100.s7|159-166|decrease|O
DDI-MedLine.d100.s7|168-169|in|O
DDI-MedLine.d100.s7|171-178|platelet|O
DDI-MedLine.d100.s7|180-187|function|O
DDI-MedLine.d100.s7|188-188|.|O
DDI-MedLine.d100.s8|0-4|These|O
DDI-MedLine.d100.s8|6-12|effects|O
DDI-MedLine.d100.s8|14-15|of|O
DDI-MedLine.d100.s8|17-23|calcium|O
DDI-MedLine.d100.s8|25-32|blockers|O
DDI-MedLine.d100.s8|34-35|on|O
DDI-MedLine.d100.s8|37-44|platelet|O
DDI-MedLine.d100.s8|46-53|function|O
DDI-MedLine.d100.s8|55-57|and|O
DDI-MedLine.d100.s8|59-69|arachidonic|O
DDI-MedLine.d100.s8|71-74|acid|O
DDI-MedLine.d100.s8|76-85|metabolism|O
DDI-MedLine.d100.s8|87-91|could|O
DDI-MedLine.d100.s8|93-102|contribute|O
DDI-MedLine.d100.s8|104-105|in|O
DDI-MedLine.d100.s8|107-110|part|O
DDI-MedLine.d100.s8|112-113|to|O
DDI-MedLine.d100.s8|115-119|their|O
DDI-MedLine.d100.s8|121-128|efficacy|O
DDI-MedLine.d100.s8|130-131|in|O
DDI-MedLine.d100.s8|133-140|patients|O
DDI-MedLine.d100.s8|142-145|with|O
DDI-MedLine.d100.s8|147-154|ischemic|O
DDI-MedLine.d100.s8|156-160|heart|O
DDI-MedLine.d100.s8|162-168|disease|O
DDI-MedLine.d100.s8|169-169|.|O
DDI-DrugBank.d371.s0|0-4|There|O
DDI-DrugBank.d371.s0|6-9|have|O
DDI-DrugBank.d371.s0|11-14|been|O
DDI-DrugBank.d371.s0|16-17|no|O
DDI-DrugBank.d371.s0|19-24|formal|O
DDI-DrugBank.d371.s0|26-33|clinical|O
DDI-DrugBank.d371.s0|35-41|studies|O
DDI-DrugBank.d371.s0|43-44|to|O
DDI-DrugBank.d371.s0|46-53|evaluate|O
DDI-DrugBank.d371.s0|55-57|the|O
DDI-DrugBank.d371.s0|59-62|drug|O
DDI-DrugBank.d371.s0|64-75|interactions|O
DDI-DrugBank.d371.s0|77-78|of|O
DDI-DrugBank.d371.s0|80-87|TAXOTERE|O
DDI-DrugBank.d371.s0|89-92|with|O
DDI-DrugBank.d371.s0|94-98|other|O
DDI-DrugBank.d371.s0|100-110|medications|O
DDI-DrugBank.d371.s0|111-111|.|O
DDI-DrugBank.d371.s1|0-1|In|O
DDI-DrugBank.d371.s1|3-7|vitro|O
DDI-DrugBank.d371.s1|9-15|studies|O
DDI-DrugBank.d371.s1|17-20|have|O
DDI-DrugBank.d371.s1|22-26|shown|O
DDI-DrugBank.d371.s1|28-31|that|O
DDI-DrugBank.d371.s1|33-35|the|O
DDI-DrugBank.d371.s1|37-46|metabolism|O
DDI-DrugBank.d371.s1|48-49|of|O
DDI-DrugBank.d371.s1|51-59|docetaxel|O
DDI-DrugBank.d371.s1|61-63|may|O
DDI-DrugBank.d371.s1|65-66|be|O
DDI-DrugBank.d371.s1|68-75|modified|O
DDI-DrugBank.d371.s1|77-78|by|O
DDI-DrugBank.d371.s1|80-82|the|O
DDI-DrugBank.d371.s1|84-94|concomitant|O
DDI-DrugBank.d371.s1|96-109|administration|O
DDI-DrugBank.d371.s1|111-112|of|O
DDI-DrugBank.d371.s1|114-122|compounds|O
DDI-DrugBank.d371.s1|124-127|that|O
DDI-DrugBank.d371.s1|129-134|induce|O
DDI-DrugBank.d371.s1|135-135|,|O
DDI-DrugBank.d371.s1|137-143|inhibit|O
DDI-DrugBank.d371.s1|144-144|,|O
DDI-DrugBank.d371.s1|146-147|or|O
DDI-DrugBank.d371.s1|149-151|are|O
DDI-DrugBank.d371.s1|153-163|metabolized|O
DDI-DrugBank.d371.s1|165-166|by|O
DDI-DrugBank.d371.s1|168-177|cytochrome|O
DDI-DrugBank.d371.s1|179-182|P450|O
DDI-DrugBank.d371.s1|184-186|3A4|O
DDI-DrugBank.d371.s1|187-187|,|O
DDI-DrugBank.d371.s1|189-192|such|O
DDI-DrugBank.d371.s1|194-195|as|O
DDI-DrugBank.d371.s1|197-208|cyclosporine|O
DDI-DrugBank.d371.s1|209-209|,|O
DDI-DrugBank.d371.s1|211-221|terfenadine|O
DDI-DrugBank.d371.s1|222-222|,|O
DDI-DrugBank.d371.s1|224-235|ketoconazole|O
DDI-DrugBank.d371.s1|236-236|,|O
DDI-DrugBank.d371.s1|238-249|erythromycin|O
DDI-DrugBank.d371.s1|250-250|,|O
DDI-DrugBank.d371.s1|252-254|and|O
DDI-DrugBank.d371.s1|256-269|troleandomycin|O
DDI-DrugBank.d371.s1|270-270|.|O
DDI-DrugBank.d371.s2|0-6|Caution|O
DDI-DrugBank.d371.s2|8-13|should|O
DDI-DrugBank.d371.s2|15-16|be|O
DDI-DrugBank.d371.s2|18-26|exercised|O
DDI-DrugBank.d371.s2|28-31|with|O
DDI-DrugBank.d371.s2|33-37|these|O
DDI-DrugBank.d371.s2|39-43|drugs|O
DDI-DrugBank.d371.s2|45-48|when|O
DDI-DrugBank.d371.s2|50-57|treating|O
DDI-DrugBank.d371.s2|59-66|patients|O
DDI-DrugBank.d371.s2|68-76|receiving|O
DDI-DrugBank.d371.s2|78-85|TAXOTERE|O
DDI-DrugBank.d371.s2|87-88|as|O
DDI-DrugBank.d371.s2|90-94|there|O
DDI-DrugBank.d371.s2|96-97|is|O
DDI-DrugBank.d371.s2|99-99|a|O
DDI-DrugBank.d371.s2|101-109|potential|O
DDI-DrugBank.d371.s2|111-113|for|O
DDI-DrugBank.d371.s2|115-115|a|O
DDI-DrugBank.d371.s2|117-127|significant|O
DDI-DrugBank.d371.s2|129-139|interaction|O
DDI-DrugBank.d371.s2|140-140|.|O
DDI-MedLine.d59.s0|0-0|A|O
DDI-MedLine.d59.s0|2-9|proposed|O
DDI-MedLine.d59.s0|11-19|mechanism|O
DDI-MedLine.d59.s0|21-23|for|O
DDI-MedLine.d59.s0|25-27|the|O
DDI-MedLine.d59.s0|29-40|potentiation|O
DDI-MedLine.d59.s0|42-43|of|O
DDI-MedLine.d59.s0|45-57|cAMP-mediated|O
DDI-MedLine.d59.s0|59-62|acid|O
DDI-MedLine.d59.s0|64-72|secretion|O
DDI-MedLine.d59.s0|74-75|by|O
DDI-MedLine.d59.s0|77-85|carbachol|O
DDI-MedLine.d59.s0|86-86|.|O
DDI-MedLine.d59.s1|0-3|Acid|O
DDI-MedLine.d59.s1|5-13|secretion|O
DDI-MedLine.d59.s1|15-16|in|O
DDI-MedLine.d59.s1|18-25|isolated|O
DDI-MedLine.d59.s1|27-32|rabbit|O
DDI-MedLine.d59.s1|34-40|gastric|O
DDI-MedLine.d59.s1|42-47|glands|O
DDI-MedLine.d59.s1|49-51|was|O
DDI-MedLine.d59.s1|53-61|monitored|O
DDI-MedLine.d59.s1|63-64|by|O
DDI-MedLine.d59.s1|66-68|the|O
DDI-MedLine.d59.s1|70-81|accumulation|O
DDI-MedLine.d59.s1|83-84|of|O
DDI-MedLine.d59.s1|86-86|[|O
DDI-MedLine.d59.s1|87-87|(|O
DDI-MedLine.d59.s1|88-89|14|O
DDI-MedLine.d59.s1|90-90|)|O
DDI-MedLine.d59.s1|91-91|C|O
DDI-MedLine.d59.s1|92-92|]|O
DDI-MedLine.d59.s1|93-103|aminopyrine|O
DDI-MedLine.d59.s1|104-104|.|O
DDI-MedLine.d59.s2|0-10|Stimulation|O
DDI-MedLine.d59.s2|12-13|of|O
DDI-MedLine.d59.s2|15-17|the|O
DDI-MedLine.d59.s2|19-24|glands|O
DDI-MedLine.d59.s2|26-29|with|O
DDI-MedLine.d59.s2|31-39|carbachol|O
DDI-MedLine.d59.s2|41-55|synergistically|O
DDI-MedLine.d59.s2|57-65|augmented|O
DDI-MedLine.d59.s2|67-69|the|O
DDI-MedLine.d59.s2|71-78|response|O
DDI-MedLine.d59.s2|80-81|to|O
DDI-MedLine.d59.s2|83-91|dibutyryl|O
DDI-MedLine.d59.s2|93-96|cAMP|O
DDI-MedLine.d59.s2|97-97|.|O
DDI-MedLine.d59.s3|0-2|The|O
DDI-MedLine.d59.s3|4-15|augmentation|O
DDI-MedLine.d59.s3|17-25|persisted|O
DDI-MedLine.d59.s3|27-30|even|O
DDI-MedLine.d59.s3|32-36|after|O
DDI-MedLine.d59.s3|38-46|carbachol|O
DDI-MedLine.d59.s3|48-50|was|O
DDI-MedLine.d59.s3|52-57|washed|O
DDI-MedLine.d59.s3|59-61|out|O
DDI-MedLine.d59.s3|63-65|and|O
DDI-MedLine.d59.s3|67-69|was|O
DDI-MedLine.d59.s3|71-79|resistant|O
DDI-MedLine.d59.s3|81-82|to|O
DDI-MedLine.d59.s3|84-91|chelated|O
DDI-MedLine.d59.s3|93-105|extracellular|O
DDI-MedLine.d59.s3|107-108|Ca|O
DDI-MedLine.d59.s3|109-109|(|O
DDI-MedLine.d59.s3|110-111|2+|O
DDI-MedLine.d59.s3|112-112|)|O
DDI-MedLine.d59.s3|114-116|and|O
DDI-MedLine.d59.s3|118-119|to|O
DDI-MedLine.d59.s3|121-130|inhibitors|O
DDI-MedLine.d59.s3|132-133|of|O
DDI-MedLine.d59.s3|135-140|either|O
DDI-MedLine.d59.s3|142-148|protein|O
DDI-MedLine.d59.s3|150-155|kinase|O
DDI-MedLine.d59.s3|157-157|C|O
DDI-MedLine.d59.s3|159-160|or|O
DDI-MedLine.d59.s3|162-171|calmodulin|O
DDI-MedLine.d59.s3|173-178|kinase|O
DDI-MedLine.d59.s3|180-181|II|O
DDI-MedLine.d59.s3|182-182|.|O
DDI-MedLine.d59.s4|0-11|Cytochalasin|O
DDI-MedLine.d59.s4|13-13|D|O
DDI-MedLine.d59.s4|15-16|at|O
DDI-MedLine.d59.s4|18-19|10|O
DDI-MedLine.d59.s4|21-26|microM|O
DDI-MedLine.d59.s4|28-41|preferentially|O
DDI-MedLine.d59.s4|43-49|blocked|O
DDI-MedLine.d59.s4|51-53|the|O
DDI-MedLine.d59.s4|55-63|secretory|O
DDI-MedLine.d59.s4|65-70|effect|O
DDI-MedLine.d59.s4|72-73|of|O
DDI-MedLine.d59.s4|75-83|carbachol|O
DDI-MedLine.d59.s4|85-87|and|O
DDI-MedLine.d59.s4|89-91|its|O
DDI-MedLine.d59.s4|93-101|synergism|O
DDI-MedLine.d59.s4|103-106|with|O
DDI-MedLine.d59.s4|108-111|cAMP|O
DDI-MedLine.d59.s4|112-112|,|O
DDI-MedLine.d59.s4|114-120|whereas|O
DDI-MedLine.d59.s4|122-123|it|O
DDI-MedLine.d59.s4|125-127|had|O
DDI-MedLine.d59.s4|129-130|no|O
DDI-MedLine.d59.s4|132-137|effect|O
DDI-MedLine.d59.s4|139-140|on|O
DDI-MedLine.d59.s4|142-151|histamine-|O
DDI-MedLine.d59.s4|153-154|or|O
DDI-MedLine.d59.s4|156-170|cAMP-stimulated|O
DDI-MedLine.d59.s4|172-175|acid|O
DDI-MedLine.d59.s4|177-185|secretion|O
DDI-MedLine.d59.s4|187-192|within|O
DDI-MedLine.d59.s4|194-195|15|O
DDI-MedLine.d59.s4|197-199|min|O
DDI-MedLine.d59.s4|200-200|.|O
DDI-MedLine.d59.s5|0-11|Cytochalasin|O
DDI-MedLine.d59.s5|13-13|D|O
DDI-MedLine.d59.s5|15-23|inhibited|O
DDI-MedLine.d59.s5|25-27|the|O
DDI-MedLine.d59.s5|29-48|carbachol-stimulated|O
DDI-MedLine.d59.s5|50-62|intracellular|O
DDI-MedLine.d59.s5|64-65|Ca|O
DDI-MedLine.d59.s5|66-66|(|O
DDI-MedLine.d59.s5|67-68|2+|O
DDI-MedLine.d59.s5|69-69|)|O
DDI-MedLine.d59.s5|71-83|concentration|O
DDI-MedLine.d59.s5|85-85|(|O
DDI-MedLine.d59.s5|86-86|[|O
DDI-MedLine.d59.s5|87-88|Ca|O
DDI-MedLine.d59.s5|89-89|(|O
DDI-MedLine.d59.s5|90-91|2+|O
DDI-MedLine.d59.s5|92-92|)|O
DDI-MedLine.d59.s5|93-93|]|O
DDI-MedLine.d59.s5|94-94|(|O
DDI-MedLine.d59.s5|95-95|i|O
DDI-MedLine.d59.s5|96-96|)|O
DDI-MedLine.d59.s5|97-97|)|O
DDI-MedLine.d59.s5|99-106|increase|O
DDI-MedLine.d59.s5|108-110|due|O
DDI-MedLine.d59.s5|112-113|to|O
DDI-MedLine.d59.s5|115-121|release|O
DDI-MedLine.d59.s5|123-126|from|O
DDI-MedLine.d59.s5|128-130|the|O
DDI-MedLine.d59.s5|132-133|Ca|O
DDI-MedLine.d59.s5|134-134|(|O
DDI-MedLine.d59.s5|135-136|2+|O
DDI-MedLine.d59.s5|137-137|)|O
DDI-MedLine.d59.s5|139-143|store|O
DDI-MedLine.d59.s5|144-144|.|O
DDI-MedLine.d59.s6|0-8|Treatment|O
DDI-MedLine.d59.s6|10-11|of|O
DDI-MedLine.d59.s6|13-15|the|O
DDI-MedLine.d59.s6|17-22|glands|O
DDI-MedLine.d59.s6|24-27|with|O
DDI-MedLine.d59.s6|29-40|cytochalasin|O
DDI-MedLine.d59.s6|42-42|D|O
DDI-MedLine.d59.s6|44-56|redistributed|O
DDI-MedLine.d59.s6|58-61|type|O
DDI-MedLine.d59.s6|63-63|3|O
DDI-MedLine.d59.s6|65-72|inositol|O
DDI-MedLine.d59.s6|74-92|1,4,5-trisphosphate|O
DDI-MedLine.d59.s6|94-101|receptor|O
DDI-MedLine.d59.s6|103-103|(|O
DDI-MedLine.d59.s6|104-106|the|O
DDI-MedLine.d59.s6|108-112|major|O
DDI-MedLine.d59.s6|114-120|subtype|O
DDI-MedLine.d59.s6|122-123|in|O
DDI-MedLine.d59.s6|125-127|the|O
DDI-MedLine.d59.s6|129-136|parietal|O
DDI-MedLine.d59.s6|138-141|cell|O
DDI-MedLine.d59.s6|142-142|)|O
DDI-MedLine.d59.s6|144-147|from|O
DDI-MedLine.d59.s6|149-151|the|O
DDI-MedLine.d59.s6|153-160|fraction|O
DDI-MedLine.d59.s6|162-171|containing|O
DDI-MedLine.d59.s6|173-181|membranes|O
DDI-MedLine.d59.s6|183-184|of|O
DDI-MedLine.d59.s6|186-190|large|O
DDI-MedLine.d59.s6|192-195|size|O
DDI-MedLine.d59.s6|197-198|to|O
DDI-MedLine.d59.s6|200-202|the|O
DDI-MedLine.d59.s6|204-213|microsomal|O
DDI-MedLine.d59.s6|215-222|fraction|O
DDI-MedLine.d59.s6|223-223|,|O
DDI-MedLine.d59.s6|225-234|suggesting|O
DDI-MedLine.d59.s6|236-236|a|O
DDI-MedLine.d59.s6|238-249|dissociation|O
DDI-MedLine.d59.s6|251-252|of|O
DDI-MedLine.d59.s6|254-256|the|O
DDI-MedLine.d59.s6|258-262|store|O
DDI-MedLine.d59.s6|264-267|from|O
DDI-MedLine.d59.s6|269-271|the|O
DDI-MedLine.d59.s6|273-278|plasma|O
DDI-MedLine.d59.s6|280-287|membrane|O
DDI-MedLine.d59.s6|288-288|.|O
DDI-MedLine.d59.s7|0-4|These|O
DDI-MedLine.d59.s7|6-13|findings|O
DDI-MedLine.d59.s7|15-21|suggest|O
DDI-MedLine.d59.s7|23-26|that|O
DDI-MedLine.d59.s7|28-40|intracellular|O
DDI-MedLine.d59.s7|42-43|Ca|O
DDI-MedLine.d59.s7|44-44|(|O
DDI-MedLine.d59.s7|45-46|2+|O
DDI-MedLine.d59.s7|47-47|)|O
DDI-MedLine.d59.s7|49-55|release|O
DDI-MedLine.d59.s7|57-58|by|O
DDI-MedLine.d59.s7|60-70|cholinergic|O
DDI-MedLine.d59.s7|72-82|stimulation|O
DDI-MedLine.d59.s7|84-85|is|O
DDI-MedLine.d59.s7|87-94|critical|O
DDI-MedLine.d59.s7|96-98|for|O
DDI-MedLine.d59.s7|100-110|determining|O
DDI-MedLine.d59.s7|112-120|synergism|O
DDI-MedLine.d59.s7|122-125|with|O
DDI-MedLine.d59.s7|127-130|cAMP|O
DDI-MedLine.d59.s7|132-133|in|O
DDI-MedLine.d59.s7|135-142|parietal|O
DDI-MedLine.d59.s7|144-147|cell|O
DDI-MedLine.d59.s7|149-158|activation|O
DDI-MedLine.d59.s7|160-162|and|O
DDI-MedLine.d59.s7|164-167|that|O
DDI-MedLine.d59.s7|169-178|functional|O
DDI-MedLine.d59.s7|180-187|coupling|O
DDI-MedLine.d59.s7|189-195|between|O
DDI-MedLine.d59.s7|197-199|the|O
DDI-MedLine.d59.s7|201-202|Ca|O
DDI-MedLine.d59.s7|203-203|(|O
DDI-MedLine.d59.s7|204-205|2+|O
DDI-MedLine.d59.s7|206-206|)|O
DDI-MedLine.d59.s7|208-212|store|O
DDI-MedLine.d59.s7|214-216|and|O
DDI-MedLine.d59.s7|218-220|the|O
DDI-MedLine.d59.s7|222-229|receptor|O
DDI-MedLine.d59.s7|231-232|is|O
DDI-MedLine.d59.s7|234-243|maintained|O
DDI-MedLine.d59.s7|245-246|by|O
DDI-MedLine.d59.s7|248-252|actin|O
DDI-MedLine.d59.s7|254-267|microfilaments|O
DDI-MedLine.d59.s7|268-268|.|O
DDI-MedLine.d118.s0|0-8|Sirolimus|O
DDI-MedLine.d118.s0|9-9|:|O
DDI-MedLine.d118.s0|11-19|mammalian|O
DDI-MedLine.d118.s0|21-26|target|O
DDI-MedLine.d118.s0|28-29|of|O
DDI-MedLine.d118.s0|31-39|rapamycin|O
DDI-MedLine.d118.s0|41-49|inhibitor|O
DDI-MedLine.d118.s0|51-52|to|O
DDI-MedLine.d118.s0|54-60|prevent|O
DDI-MedLine.d118.s0|62-67|kidney|O
DDI-MedLine.d118.s0|69-77|rejection|O
DDI-MedLine.d118.s0|78-78|.|O
DDI-MedLine.d118.s1|0-6|Current|O
DDI-MedLine.d118.s1|8-24|immunosuppressive|O
DDI-MedLine.d118.s1|26-34|therapies|O
DDI-MedLine.d118.s1|36-38|are|O
DDI-MedLine.d118.s1|40-48|effective|O
DDI-MedLine.d118.s1|50-52|but|O
DDI-MedLine.d118.s1|54-56|can|O
DDI-MedLine.d118.s1|58-59|be|O
DDI-MedLine.d118.s1|61-70|associated|O
DDI-MedLine.d118.s1|72-75|with|O
DDI-MedLine.d118.s1|77-87|significant|O
DDI-MedLine.d118.s1|89-95|adverse|O
DDI-MedLine.d118.s1|97-105|reactions|O
DDI-MedLine.d118.s1|106-106|.|O
DDI-MedLine.d118.s2|0-8|Sirolimus|O
DDI-MedLine.d118.s2|10-14|works|O
DDI-MedLine.d118.s2|16-26|differently|O
DDI-MedLine.d118.s2|28-31|from|O
DDI-MedLine.d118.s2|33-35|the|O
DDI-MedLine.d118.s2|37-54|immunosuppressants|O
DDI-MedLine.d118.s2|56-64|currently|O
DDI-MedLine.d118.s2|66-74|available|O
DDI-MedLine.d118.s2|75-75|,|O
DDI-MedLine.d118.s2|77-79|and|O
DDI-MedLine.d118.s2|81-86|except|O
DDI-MedLine.d118.s2|88-90|for|O
DDI-MedLine.d118.s2|92-100|increased|O
DDI-MedLine.d118.s2|102-106|lipid|O
DDI-MedLine.d118.s2|108-113|levels|O
DDI-MedLine.d118.s2|114-114|,|O
DDI-MedLine.d118.s2|116-118|the|O
DDI-MedLine.d118.s2|120-126|adverse|O
DDI-MedLine.d118.s2|128-135|reaction|O
DDI-MedLine.d118.s2|137-143|profile|O
DDI-MedLine.d118.s2|145-146|of|O
DDI-MedLine.d118.s2|148-156|sirolimus|O
DDI-MedLine.d118.s2|158-161|does|O
DDI-MedLine.d118.s2|163-165|not|O
DDI-MedLine.d118.s2|167-172|appear|O
DDI-MedLine.d118.s2|174-175|to|O
DDI-MedLine.d118.s2|177-183|overlap|O
DDI-MedLine.d118.s2|185-186|to|O
DDI-MedLine.d118.s2|188-190|any|O
DDI-MedLine.d118.s2|192-196|great|O
DDI-MedLine.d118.s2|198-203|extent|O
DDI-MedLine.d118.s2|205-208|with|O
DDI-MedLine.d118.s2|210-213|that|O
DDI-MedLine.d118.s2|215-224|associated|O
DDI-MedLine.d118.s2|226-229|with|O
DDI-MedLine.d118.s2|231-242|cyclosporine|O
DDI-MedLine.d118.s2|244-245|or|O
DDI-MedLine.d118.s2|247-256|tacrolimus|O
DDI-MedLine.d118.s2|257-257|.|O
DDI-MedLine.d118.s3|0-4|While|O
DDI-MedLine.d118.s3|6-15|additional|O
DDI-MedLine.d118.s3|17-24|research|O
DDI-MedLine.d118.s3|26-27|is|O
DDI-MedLine.d118.s3|29-34|needed|O
DDI-MedLine.d118.s3|35-35|,|O
DDI-MedLine.d118.s3|37-39|the|O
DDI-MedLine.d118.s3|41-47|initial|O
DDI-MedLine.d118.s3|49-56|clinical|O
DDI-MedLine.d118.s3|58-61|data|O
DDI-MedLine.d118.s3|63-64|in|O
DDI-MedLine.d118.s3|66-71|kidney|O
DDI-MedLine.d118.s3|73-82|recipients|O
DDI-MedLine.d118.s3|84-90|suggest|O
DDI-MedLine.d118.s3|92-95|that|O
DDI-MedLine.d118.s3|97-105|sirolimus|O
DDI-MedLine.d118.s3|106-106|,|O
DDI-MedLine.d118.s3|108-109|in|O
DDI-MedLine.d118.s3|111-121|combination|O
DDI-MedLine.d118.s3|123-126|with|O
DDI-MedLine.d118.s3|128-139|cyclosporine|O
DDI-MedLine.d118.s3|141-142|or|O
DDI-MedLine.d118.s3|144-153|tacrolimus|O
DDI-MedLine.d118.s3|154-154|,|O
DDI-MedLine.d118.s3|156-160|might|O
DDI-MedLine.d118.s3|162-165|have|O
DDI-MedLine.d118.s3|167-169|the|O
DDI-MedLine.d118.s3|171-179|potential|O
DDI-MedLine.d118.s3|181-182|to|O
DDI-MedLine.d118.s3|184-189|reduce|O
DDI-MedLine.d118.s3|191-193|the|O
DDI-MedLine.d118.s3|195-203|frequency|O
DDI-MedLine.d118.s3|205-206|of|O
DDI-MedLine.d118.s3|208-216|rejection|O
DDI-MedLine.d118.s3|218-225|episodes|O
DDI-MedLine.d118.s3|226-226|,|O
DDI-MedLine.d118.s3|228-233|permit|O
DDI-MedLine.d118.s3|235-244|reductions|O
DDI-MedLine.d118.s3|246-247|in|O
DDI-MedLine.d118.s3|249-260|cyclosporine|O
DDI-MedLine.d118.s3|262-263|or|O
DDI-MedLine.d118.s3|265-274|tacrolimus|O
DDI-MedLine.d118.s3|276-281|dosage|O
DDI-MedLine.d118.s3|282-282|,|O
DDI-MedLine.d118.s3|284-286|and|O
DDI-MedLine.d118.s3|288-293|permit|O
DDI-MedLine.d118.s3|295-301|steroid|O
DDI-MedLine.d118.s3|303-312|withdrawal|O
DDI-MedLine.d118.s3|314-314|(|O
DDI-MedLine.d118.s3|315-319|Kelly|O
DDI-MedLine.d118.s3|320-320|,|O
DDI-MedLine.d118.s3|322-325|1999|O
DDI-MedLine.d118.s3|326-326|)|O
DDI-MedLine.d118.s3|327-327|.|O
DDI-DrugBank.d308.s0|0-2|THE|O
DDI-DrugBank.d308.s0|4-15|POTENTIATING|O
DDI-DrugBank.d308.s0|17-22|ACTION|O
DDI-DrugBank.d308.s0|24-25|OF|O
DDI-DrugBank.d308.s0|27-37|HYDROXYZINE|O
DDI-DrugBank.d308.s0|39-42|MUST|O
DDI-DrugBank.d308.s0|44-45|BE|O
DDI-DrugBank.d308.s0|47-56|CONSIDERED|O
DDI-DrugBank.d308.s0|58-61|WHEN|O
DDI-DrugBank.d308.s0|63-65|THE|O
DDI-DrugBank.d308.s0|67-70|DRUG|O
DDI-DrugBank.d308.s0|72-73|IS|O
DDI-DrugBank.d308.s0|75-78|USED|O
DDI-DrugBank.d308.s0|80-81|IN|O
DDI-DrugBank.d308.s0|83-93|CONJUNCTION|O
DDI-DrugBank.d308.s0|95-98|WITH|O
DDI-DrugBank.d308.s0|100-106|CENTRAL|O
DDI-DrugBank.d308.s0|108-114|NERVOUS|O
DDI-DrugBank.d308.s0|116-121|SYSTEM|O
DDI-DrugBank.d308.s0|123-133|DEPRESSANTS|O
DDI-DrugBank.d308.s0|135-138|SUCH|O
DDI-DrugBank.d308.s0|140-141|AS|O
DDI-DrugBank.d308.s0|143-151|NARCOTICS|O
DDI-DrugBank.d308.s0|152-152|,|O
DDI-DrugBank.d308.s0|154-165|NON-NARCOTIC|O
DDI-DrugBank.d308.s0|167-176|ANALGESICS|O
DDI-DrugBank.d308.s0|178-180|AND|O
DDI-DrugBank.d308.s0|182-193|BARBITURATES|O
DDI-DrugBank.d308.s0|194-194|.|O
DDI-DrugBank.d308.s1|0-8|Therefore|O
DDI-DrugBank.d308.s1|10-13|when|O
DDI-DrugBank.d308.s1|15-21|central|O
DDI-DrugBank.d308.s1|23-29|nervous|O
DDI-DrugBank.d308.s1|31-36|system|O
DDI-DrugBank.d308.s1|38-48|depressants|O
DDI-DrugBank.d308.s1|50-52|are|O
DDI-DrugBank.d308.s1|54-65|administered|O
DDI-DrugBank.d308.s1|67-79|concomitantly|O
DDI-DrugBank.d308.s1|81-84|with|O
DDI-DrugBank.d308.s1|86-96|hydroxyzine|O
DDI-DrugBank.d308.s1|98-102|their|O
DDI-DrugBank.d308.s1|104-109|dosage|O
DDI-DrugBank.d308.s1|111-116|should|O
DDI-DrugBank.d308.s1|118-119|be|O
DDI-DrugBank.d308.s1|121-127|reduced|O
DDI-DrugBank.d308.s1|128-128|.|O
DDI-DrugBank.d308.s2|0-4|Since|O
DDI-DrugBank.d308.s2|6-15|drowsiness|O
DDI-DrugBank.d308.s2|17-19|may|O
DDI-DrugBank.d308.s2|21-25|occur|O
DDI-DrugBank.d308.s2|27-30|with|O
DDI-DrugBank.d308.s2|32-34|use|O
DDI-DrugBank.d308.s2|36-37|of|O
DDI-DrugBank.d308.s2|39-42|this|O
DDI-DrugBank.d308.s2|44-47|drug|O
DDI-DrugBank.d308.s2|48-48|,|O
DDI-DrugBank.d308.s2|50-57|patients|O
DDI-DrugBank.d308.s2|59-64|should|O
DDI-DrugBank.d308.s2|66-67|be|O
DDI-DrugBank.d308.s2|69-74|warned|O
DDI-DrugBank.d308.s2|76-77|of|O
DDI-DrugBank.d308.s2|79-82|this|O
DDI-DrugBank.d308.s2|84-94|possibility|O
DDI-DrugBank.d308.s2|96-98|and|O
DDI-DrugBank.d308.s2|100-108|cautioned|O
DDI-DrugBank.d308.s2|110-116|against|O
DDI-DrugBank.d308.s2|118-124|driving|O
DDI-DrugBank.d308.s2|126-126|a|O
DDI-DrugBank.d308.s2|128-130|car|O
DDI-DrugBank.d308.s2|132-133|or|O
DDI-DrugBank.d308.s2|135-143|operating|O
DDI-DrugBank.d308.s2|145-153|dangerous|O
DDI-DrugBank.d308.s2|155-163|machinery|O
DDI-DrugBank.d308.s2|165-169|while|O
DDI-DrugBank.d308.s2|171-176|taking|O
DDI-DrugBank.d308.s2|178-183|Atarax|O
DDI-DrugBank.d308.s2|184-184|.|O
DDI-DrugBank.d308.s3|0-7|Patients|O
DDI-DrugBank.d308.s3|9-14|should|O
DDI-DrugBank.d308.s3|16-17|be|O
DDI-DrugBank.d308.s3|19-25|advised|O
DDI-DrugBank.d308.s3|27-33|against|O
DDI-DrugBank.d308.s3|35-37|the|O
DDI-DrugBank.d308.s3|39-50|simultaneous|O
DDI-DrugBank.d308.s3|52-54|use|O
DDI-DrugBank.d308.s3|56-57|of|O
DDI-DrugBank.d308.s3|59-63|other|O
DDI-DrugBank.d308.s3|65-67|CNS|O
DDI-DrugBank.d308.s3|69-78|depressant|O
DDI-DrugBank.d308.s3|80-84|drugs|O
DDI-DrugBank.d308.s3|85-85|,|O
DDI-DrugBank.d308.s3|87-89|and|O
DDI-DrugBank.d308.s3|91-99|cautioned|O
DDI-DrugBank.d308.s3|101-104|that|O
DDI-DrugBank.d308.s3|106-108|the|O
DDI-DrugBank.d308.s3|110-115|effect|O
DDI-DrugBank.d308.s3|117-118|of|O
DDI-DrugBank.d308.s3|120-126|alcohol|O
DDI-DrugBank.d308.s3|128-130|may|O
DDI-DrugBank.d308.s3|132-133|be|O
DDI-DrugBank.d308.s3|135-143|increased|O
DDI-DrugBank.d308.s3|144-144|.|O
DDI-DrugBank.d287.s0|0-9|Cevimeline|O
DDI-DrugBank.d287.s0|11-16|should|O
DDI-DrugBank.d287.s0|18-19|be|O
DDI-DrugBank.d287.s0|21-32|administered|O
DDI-DrugBank.d287.s0|34-37|with|O
DDI-DrugBank.d287.s0|39-45|caution|O
DDI-DrugBank.d287.s0|47-48|to|O
DDI-DrugBank.d287.s0|50-57|patients|O
DDI-DrugBank.d287.s0|59-64|taking|O
DDI-DrugBank.d287.s0|66-69|beta|O
DDI-DrugBank.d287.s0|71-80|adrenergic|O
DDI-DrugBank.d287.s0|82-92|antagonists|O
DDI-DrugBank.d287.s0|93-93|,|O
DDI-DrugBank.d287.s0|95-101|because|O
DDI-DrugBank.d287.s0|103-104|of|O
DDI-DrugBank.d287.s0|106-108|the|O
DDI-DrugBank.d287.s0|110-120|possibility|O
DDI-DrugBank.d287.s0|122-123|of|O
DDI-DrugBank.d287.s0|125-134|conduction|O
DDI-DrugBank.d287.s0|136-147|disturbances|O
DDI-DrugBank.d287.s0|148-148|.|O
DDI-DrugBank.d287.s1|0-4|Drugs|O
DDI-DrugBank.d287.s1|6-9|with|O
DDI-DrugBank.d287.s1|11-29|parasympathomimetic|O
DDI-DrugBank.d287.s1|31-37|effects|O
DDI-DrugBank.d287.s1|39-50|administered|O
DDI-DrugBank.d287.s1|52-63|concurrently|O
DDI-DrugBank.d287.s1|65-68|with|O
DDI-DrugBank.d287.s1|70-79|cevimeline|O
DDI-DrugBank.d287.s1|81-83|can|O
DDI-DrugBank.d287.s1|85-86|be|O
DDI-DrugBank.d287.s1|88-95|expected|O
DDI-DrugBank.d287.s1|97-98|to|O
DDI-DrugBank.d287.s1|100-103|have|O
DDI-DrugBank.d287.s1|105-112|additive|O
DDI-DrugBank.d287.s1|114-120|effects|O
DDI-DrugBank.d287.s1|121-121|.|O
DDI-DrugBank.d287.s2|0-9|Cevimeline|O
DDI-DrugBank.d287.s2|11-15|might|O
DDI-DrugBank.d287.s2|17-25|interfere|O
DDI-DrugBank.d287.s2|27-30|with|O
DDI-DrugBank.d287.s2|32-40|desirable|O
DDI-DrugBank.d287.s2|42-55|antimuscarinic|O
DDI-DrugBank.d287.s2|57-63|effects|O
DDI-DrugBank.d287.s2|65-66|of|O
DDI-DrugBank.d287.s2|68-72|drugs|O
DDI-DrugBank.d287.s2|74-77|used|O
DDI-DrugBank.d287.s2|79-91|concomitantly|O
DDI-DrugBank.d287.s2|92-92|.|O
DDI-DrugBank.d287.s3|0-4|Drugs|O
DDI-DrugBank.d287.s3|6-10|which|O
DDI-DrugBank.d287.s3|12-18|inhibit|O
DDI-DrugBank.d287.s3|20-25|CYP2D6|O
DDI-DrugBank.d287.s3|27-29|and|O
DDI-DrugBank.d287.s3|31-38|CYP3A3/4|O
DDI-DrugBank.d287.s3|40-43|also|O
DDI-DrugBank.d287.s3|45-51|inhibit|O
DDI-DrugBank.d287.s3|53-55|the|O
DDI-DrugBank.d287.s3|57-66|metabolism|O
DDI-DrugBank.d287.s3|68-69|of|O
DDI-DrugBank.d287.s3|71-80|cevimeline|O
DDI-DrugBank.d287.s3|81-81|.|O
DDI-DrugBank.d287.s4|0-9|Cevimeline|O
DDI-DrugBank.d287.s4|11-16|should|O
DDI-DrugBank.d287.s4|18-19|be|O
DDI-DrugBank.d287.s4|21-24|used|O
DDI-DrugBank.d287.s4|26-29|with|O
DDI-DrugBank.d287.s4|31-37|caution|O
DDI-DrugBank.d287.s4|39-40|in|O
DDI-DrugBank.d287.s4|42-52|individuals|O
DDI-DrugBank.d287.s4|54-58|known|O
DDI-DrugBank.d287.s4|60-61|or|O
DDI-DrugBank.d287.s4|63-71|suspected|O
DDI-DrugBank.d287.s4|73-74|to|O
DDI-DrugBank.d287.s4|76-77|be|O
DDI-DrugBank.d287.s4|79-87|deficient|O
DDI-DrugBank.d287.s4|89-90|in|O
DDI-DrugBank.d287.s4|92-97|CYP2D6|O
DDI-DrugBank.d287.s4|99-106|activity|O
DDI-DrugBank.d287.s4|107-107|,|O
DDI-DrugBank.d287.s4|109-113|based|O
DDI-DrugBank.d287.s4|115-116|on|O
DDI-DrugBank.d287.s4|118-125|previous|O
DDI-DrugBank.d287.s4|127-136|experience|O
DDI-DrugBank.d287.s4|137-137|,|O
DDI-DrugBank.d287.s4|139-140|as|O
DDI-DrugBank.d287.s4|142-145|they|O
DDI-DrugBank.d287.s4|147-149|may|O
DDI-DrugBank.d287.s4|151-152|be|O
DDI-DrugBank.d287.s4|154-155|at|O
DDI-DrugBank.d287.s4|157-157|a|O
DDI-DrugBank.d287.s4|159-164|higher|O
DDI-DrugBank.d287.s4|166-169|risk|O
DDI-DrugBank.d287.s4|171-172|of|O
DDI-DrugBank.d287.s4|174-180|adverse|O
DDI-DrugBank.d287.s4|182-187|events|O
DDI-DrugBank.d287.s4|188-188|.|O
DDI-DrugBank.d287.s5|0-1|In|O
DDI-DrugBank.d287.s5|3-4|an|O
DDI-DrugBank.d287.s5|6-7|in|O
DDI-DrugBank.d287.s5|9-13|vitro|O
DDI-DrugBank.d287.s5|15-19|study|O
DDI-DrugBank.d287.s5|20-20|,|O
DDI-DrugBank.d287.s5|22-31|cytochrome|O
DDI-DrugBank.d287.s5|33-36|P450|O
DDI-DrugBank.d287.s5|38-45|isozymes|O
DDI-DrugBank.d287.s5|47-49|1A2|O
DDI-DrugBank.d287.s5|50-50|,|O
DDI-DrugBank.d287.s5|52-54|2A6|O
DDI-DrugBank.d287.s5|55-55|,|O
DDI-DrugBank.d287.s5|57-59|2C9|O
DDI-DrugBank.d287.s5|60-60|,|O
DDI-DrugBank.d287.s5|62-65|2C19|O
DDI-DrugBank.d287.s5|66-66|,|O
DDI-DrugBank.d287.s5|68-70|2D6|O
DDI-DrugBank.d287.s5|71-71|,|O
DDI-DrugBank.d287.s5|73-75|2E1|O
DDI-DrugBank.d287.s5|76-76|,|O
DDI-DrugBank.d287.s5|78-80|and|O
DDI-DrugBank.d287.s5|82-84|3A4|O
DDI-DrugBank.d287.s5|86-89|were|O
DDI-DrugBank.d287.s5|91-93|not|O
DDI-DrugBank.d287.s5|95-103|inhibited|O
DDI-DrugBank.d287.s5|105-106|by|O
DDI-DrugBank.d287.s5|108-115|exposure|O
DDI-DrugBank.d287.s5|117-118|to|O
DDI-DrugBank.d287.s5|120-129|cevimeline|O
DDI-DrugBank.d287.s5|130-130|.|O
DDI-DrugBank.d465.s0|0-2|The|O
DDI-DrugBank.d465.s0|4-15|vasodilating|O
DDI-DrugBank.d465.s0|17-23|effects|O
DDI-DrugBank.d465.s0|25-26|of|O
DDI-DrugBank.d465.s0|28-37|isosorbide|O
DDI-DrugBank.d465.s0|39-47|dinitrate|O
DDI-DrugBank.d465.s0|49-51|may|O
DDI-DrugBank.d465.s0|53-54|be|O
DDI-DrugBank.d465.s0|56-63|additive|O
DDI-DrugBank.d465.s0|65-68|with|O
DDI-DrugBank.d465.s0|70-74|those|O
DDI-DrugBank.d465.s0|76-77|of|O
DDI-DrugBank.d465.s0|79-83|other|O
DDI-DrugBank.d465.s0|85-96|vasodilators|O
DDI-DrugBank.d465.s0|97-97|.|O
DDI-DrugBank.d465.s1|0-6|Alcohol|O
DDI-DrugBank.d465.s1|7-7|,|O
DDI-DrugBank.d465.s1|9-10|in|O
DDI-DrugBank.d465.s1|12-21|particular|O
DDI-DrugBank.d465.s1|22-22|,|O
DDI-DrugBank.d465.s1|24-26|has|O
DDI-DrugBank.d465.s1|28-31|been|O
DDI-DrugBank.d465.s1|33-37|found|O
DDI-DrugBank.d465.s1|39-40|to|O
DDI-DrugBank.d465.s1|42-48|exhibit|O
DDI-DrugBank.d465.s1|50-57|additive|O
DDI-DrugBank.d465.s1|59-65|effects|O
DDI-DrugBank.d465.s1|67-68|of|O
DDI-DrugBank.d465.s1|70-73|this|O
DDI-DrugBank.d465.s1|75-81|variety|O
DDI-DrugBank.d465.s1|82-82|.|O
DDI-DrugBank.d97.s0|0-8|Indinavir|O
DDI-DrugBank.d97.s0|10-11|is|O
DDI-DrugBank.d97.s0|13-14|an|O
DDI-DrugBank.d97.s0|16-24|inhibitor|O
DDI-DrugBank.d97.s0|26-27|of|O
DDI-DrugBank.d97.s0|29-31|the|O
DDI-DrugBank.d97.s0|33-42|cytochrome|O
DDI-DrugBank.d97.s0|44-47|P450|O
DDI-DrugBank.d97.s0|49-55|isoform|O
DDI-DrugBank.d97.s0|57-62|CYP3A4|O
DDI-DrugBank.d97.s0|63-63|.|O
DDI-DrugBank.d97.s1|0-15|Coadministration|O
DDI-DrugBank.d97.s1|17-18|of|O
DDI-DrugBank.d97.s1|20-27|CRIXIVAN|O
DDI-DrugBank.d97.s1|29-31|and|O
DDI-DrugBank.d97.s1|33-37|drugs|O
DDI-DrugBank.d97.s1|39-47|primarily|O
DDI-DrugBank.d97.s1|49-59|metabolized|O
DDI-DrugBank.d97.s1|61-62|by|O
DDI-DrugBank.d97.s1|64-69|CYP3A4|O
DDI-DrugBank.d97.s1|71-73|may|O
DDI-DrugBank.d97.s1|75-80|result|O
DDI-DrugBank.d97.s1|82-83|in|O
DDI-DrugBank.d97.s1|85-93|increased|O
DDI-DrugBank.d97.s1|95-100|plasma|O
DDI-DrugBank.d97.s1|102-115|concentrations|O
DDI-DrugBank.d97.s1|117-118|of|O
DDI-DrugBank.d97.s1|120-122|the|O
DDI-DrugBank.d97.s1|124-128|other|O
DDI-DrugBank.d97.s1|130-133|drug|O
DDI-DrugBank.d97.s1|134-134|,|O
DDI-DrugBank.d97.s1|136-140|which|O
DDI-DrugBank.d97.s1|142-146|could|O
DDI-DrugBank.d97.s1|148-155|increase|O
DDI-DrugBank.d97.s1|157-158|or|O
DDI-DrugBank.d97.s1|160-166|prolong|O
DDI-DrugBank.d97.s1|168-170|its|O
DDI-DrugBank.d97.s1|172-182|therapeutic|O
DDI-DrugBank.d97.s1|184-186|and|O
DDI-DrugBank.d97.s1|188-194|adverse|O
DDI-DrugBank.d97.s1|196-202|effects|O
DDI-DrugBank.d97.s1|203-203|.|O
DDI-DrugBank.d97.s2|0-8|Indinavir|O
DDI-DrugBank.d97.s2|10-11|is|O
DDI-DrugBank.d97.s2|13-23|metabolized|O
DDI-DrugBank.d97.s2|25-26|by|O
DDI-DrugBank.d97.s2|28-33|CYP3A4|O
DDI-DrugBank.d97.s2|34-34|.|O
DDI-DrugBank.d97.s3|0-4|Drugs|O
DDI-DrugBank.d97.s3|6-9|that|O
DDI-DrugBank.d97.s3|11-16|induce|O
DDI-DrugBank.d97.s3|18-23|CYP3A4|O
DDI-DrugBank.d97.s3|25-32|activity|O
DDI-DrugBank.d97.s3|34-38|would|O
DDI-DrugBank.d97.s3|40-41|be|O
DDI-DrugBank.d97.s3|43-50|expected|O
DDI-DrugBank.d97.s3|52-53|to|O
DDI-DrugBank.d97.s3|55-62|increase|O
DDI-DrugBank.d97.s3|64-66|the|O
DDI-DrugBank.d97.s3|68-76|clearance|O
DDI-DrugBank.d97.s3|78-79|of|O
DDI-DrugBank.d97.s3|81-89|indinavir|O
DDI-DrugBank.d97.s3|90-90|,|O
DDI-DrugBank.d97.s3|92-100|resulting|O
DDI-DrugBank.d97.s3|102-103|in|O
DDI-DrugBank.d97.s3|105-111|lowered|O
DDI-DrugBank.d97.s3|113-118|plasma|O
DDI-DrugBank.d97.s3|120-133|concentrations|O
DDI-DrugBank.d97.s3|135-136|of|O
DDI-DrugBank.d97.s3|138-146|indinavir|O
DDI-DrugBank.d97.s3|147-147|.|O
DDI-DrugBank.d97.s4|0-15|Coadministration|O
DDI-DrugBank.d97.s4|17-18|of|O
DDI-DrugBank.d97.s4|20-27|CRIXIVAN|O
DDI-DrugBank.d97.s4|29-31|and|O
DDI-DrugBank.d97.s4|33-37|other|O
DDI-DrugBank.d97.s4|39-43|drugs|O
DDI-DrugBank.d97.s4|45-48|that|O
DDI-DrugBank.d97.s4|50-56|inhibit|O
DDI-DrugBank.d97.s4|58-63|CYP3A4|O
DDI-DrugBank.d97.s4|65-67|may|O
DDI-DrugBank.d97.s4|69-76|decrease|O
DDI-DrugBank.d97.s4|78-80|the|O
DDI-DrugBank.d97.s4|82-90|clearance|O
DDI-DrugBank.d97.s4|92-93|of|O
DDI-DrugBank.d97.s4|95-103|indinavir|O
DDI-DrugBank.d97.s4|105-107|and|O
DDI-DrugBank.d97.s4|109-111|may|O
DDI-DrugBank.d97.s4|113-118|result|O
DDI-DrugBank.d97.s4|120-121|in|O
DDI-DrugBank.d97.s4|123-131|increased|O
DDI-DrugBank.d97.s4|133-138|plasma|O
DDI-DrugBank.d97.s4|140-153|concentrations|O
DDI-DrugBank.d97.s4|155-156|of|O
DDI-DrugBank.d97.s4|158-166|indinavir|O
DDI-DrugBank.d97.s4|167-167|.|O
DDI-DrugBank.d97.s5|0-4|Table|O
DDI-DrugBank.d97.s5|6-6|8|O
DDI-DrugBank.d97.s6|0-4|Drugs|O
DDI-DrugBank.d97.s6|6-9|That|O
DDI-DrugBank.d97.s6|11-16|Should|O
DDI-DrugBank.d97.s6|18-20|Not|O
DDI-DrugBank.d97.s6|22-23|Be|O
DDI-DrugBank.d97.s6|25-38|Coadministered|O
DDI-DrugBank.d97.s6|40-43|with|O
DDI-DrugBank.d97.s6|45-52|CRIXIVAN|O
DDI-DrugBank.d97.s7|0-3|Drug|O
DDI-DrugBank.d97.s7|5-9|Class|O
DDI-DrugBank.d97.s7|10-10|:|O
DDI-DrugBank.d97.s7|12-15|Drug|O
DDI-DrugBank.d97.s7|17-20|Name|O
DDI-DrugBank.d97.s7|22-29|Clinical|O
DDI-DrugBank.d97.s7|31-37|Comment|O
DDI-DrugBank.d97.s8|0-14|Antiarrhythmics|O
DDI-DrugBank.d97.s8|15-15|:|O
DDI-DrugBank.d97.s8|17-26|amiodarone|O
DDI-DrugBank.d97.s9|0-14|CONTRAINDICATED|O
DDI-DrugBank.d97.s9|16-18|due|O
DDI-DrugBank.d97.s9|20-21|to|O
DDI-DrugBank.d97.s9|23-31|potential|O
DDI-DrugBank.d97.s9|33-35|for|O
DDI-DrugBank.d97.s9|37-43|serious|O
DDI-DrugBank.d97.s9|45-50|and/or|O
DDI-DrugBank.d97.s9|52-67|life-threatening|O
DDI-DrugBank.d97.s9|69-77|reactions|O
DDI-DrugBank.d97.s9|79-82|such|O
DDI-DrugBank.d97.s9|84-85|as|O
DDI-DrugBank.d97.s9|87-93|cardiac|O
DDI-DrugBank.d97.s9|95-105|arrhythmias|O
DDI-DrugBank.d97.s9|106-106|.|O
DDI-DrugBank.d97.s10|0-4|Ergot|O
DDI-DrugBank.d97.s10|6-16|derivatives|O
DDI-DrugBank.d97.s10|17-17|:|O
DDI-DrugBank.d97.s10|19-35|dihydroergotamine|O
DDI-DrugBank.d97.s10|36-36|,|O
DDI-DrugBank.d97.s10|38-47|ergonovine|O
DDI-DrugBank.d97.s10|48-48|,|O
DDI-DrugBank.d97.s10|50-59|ergotamine|O
DDI-DrugBank.d97.s10|60-60|,|O
DDI-DrugBank.d97.s10|62-77|methylergonovine|O
DDI-DrugBank.d97.s11|0-14|CONTRAINDICATED|O
DDI-DrugBank.d97.s11|16-18|due|O
DDI-DrugBank.d97.s11|20-21|to|O
DDI-DrugBank.d97.s11|23-31|potential|O
DDI-DrugBank.d97.s11|33-35|for|O
DDI-DrugBank.d97.s11|37-43|serious|O
DDI-DrugBank.d97.s11|45-50|and/or|O
DDI-DrugBank.d97.s11|52-67|life-threatening|O
DDI-DrugBank.d97.s11|69-77|reactions|O
DDI-DrugBank.d97.s11|79-82|such|O
DDI-DrugBank.d97.s11|84-85|as|O
DDI-DrugBank.d97.s11|87-91|acute|O
DDI-DrugBank.d97.s11|93-97|ergot|O
DDI-DrugBank.d97.s11|99-106|toxicity|O
DDI-DrugBank.d97.s11|108-120|characterized|O
DDI-DrugBank.d97.s11|122-123|by|O
DDI-DrugBank.d97.s11|125-134|peripheral|O
DDI-DrugBank.d97.s11|136-144|vasospasm|O
DDI-DrugBank.d97.s11|146-148|and|O
DDI-DrugBank.d97.s11|150-157|ischemia|O
DDI-DrugBank.d97.s11|159-160|of|O
DDI-DrugBank.d97.s11|162-164|the|O
DDI-DrugBank.d97.s11|166-176|extremities|O
DDI-DrugBank.d97.s11|178-180|and|O
DDI-DrugBank.d97.s11|182-186|other|O
DDI-DrugBank.d97.s11|188-194|tissues|O
DDI-DrugBank.d97.s11|195-195|.|O
DDI-DrugBank.d97.s12|0-17|Sedative/hypnotics|O
DDI-DrugBank.d97.s12|18-18|:|O
DDI-DrugBank.d97.s12|20-28|midazolam|O
DDI-DrugBank.d97.s12|29-29|,|O
DDI-DrugBank.d97.s12|31-39|triazolam|O
DDI-DrugBank.d97.s13|0-14|CONTRAINDICATED|O
DDI-DrugBank.d97.s13|16-18|due|O
DDI-DrugBank.d97.s13|20-21|to|O
DDI-DrugBank.d97.s13|23-31|potential|O
DDI-DrugBank.d97.s13|33-35|for|O
DDI-DrugBank.d97.s13|37-43|serious|O
DDI-DrugBank.d97.s13|45-50|and/or|O
DDI-DrugBank.d97.s13|52-67|life-threatening|O
DDI-DrugBank.d97.s13|69-77|reactions|O
DDI-DrugBank.d97.s13|79-82|such|O
DDI-DrugBank.d97.s13|84-85|as|O
DDI-DrugBank.d97.s13|87-95|prolonged|O
DDI-DrugBank.d97.s13|97-98|or|O
DDI-DrugBank.d97.s13|100-108|increased|O
DDI-DrugBank.d97.s13|110-117|sedation|O
DDI-DrugBank.d97.s13|119-120|or|O
DDI-DrugBank.d97.s13|122-132|respiratory|O
DDI-DrugBank.d97.s13|134-143|depression|O
DDI-DrugBank.d97.s13|144-144|.|O
DDI-DrugBank.d97.s14|0-1|GI|O
DDI-DrugBank.d97.s14|3-10|motility|O
DDI-DrugBank.d97.s14|12-17|agents|O
DDI-DrugBank.d97.s14|18-18|:|O
DDI-DrugBank.d97.s14|20-28|cisapride|O
DDI-DrugBank.d97.s15|0-14|CONTRAINDICATED|O
DDI-DrugBank.d97.s15|16-18|due|O
DDI-DrugBank.d97.s15|20-21|to|O
DDI-DrugBank.d97.s15|23-31|potential|O
DDI-DrugBank.d97.s15|33-35|for|O
DDI-DrugBank.d97.s15|37-43|serious|O
DDI-DrugBank.d97.s15|45-50|and/or|O
DDI-DrugBank.d97.s15|52-67|life-threatening|O
DDI-DrugBank.d97.s15|69-77|reactions|O
DDI-DrugBank.d97.s15|79-82|such|O
DDI-DrugBank.d97.s15|84-85|as|O
DDI-DrugBank.d97.s15|87-93|cardiac|O
DDI-DrugBank.d97.s15|95-105|arrhythmias|O
DDI-DrugBank.d97.s15|106-106|.|O
DDI-DrugBank.d97.s16|0-10|Neuroleptic|O
DDI-DrugBank.d97.s16|11-11|:|O
DDI-DrugBank.d97.s16|13-20|pimozide|O
DDI-DrugBank.d97.s17|0-14|CONTRAINDICATED|O
DDI-DrugBank.d97.s17|16-18|due|O
DDI-DrugBank.d97.s17|20-21|to|O
DDI-DrugBank.d97.s17|23-31|potential|O
DDI-DrugBank.d97.s17|33-35|for|O
DDI-DrugBank.d97.s17|37-43|serious|O
DDI-DrugBank.d97.s17|45-50|and/or|O
DDI-DrugBank.d97.s17|52-67|life-threatening|O
DDI-DrugBank.d97.s17|69-77|reactions|O
DDI-DrugBank.d97.s17|79-82|such|O
DDI-DrugBank.d97.s17|84-85|as|O
DDI-DrugBank.d97.s17|87-93|cardiac|O
DDI-DrugBank.d97.s17|95-105|arrhythmias|O
DDI-DrugBank.d97.s17|106-106|.|O
DDI-DrugBank.d97.s18|0-5|Herbal|O
DDI-DrugBank.d97.s18|7-14|products|O
DDI-DrugBank.d97.s18|15-15|:|O
DDI-DrugBank.d97.s18|17-19|St.|O
DDI-DrugBank.d97.s18|21-24|John|O
DDI-DrugBank.d97.s18|26-26|s|O
DDI-DrugBank.d97.s18|28-31|wort|O
DDI-DrugBank.d97.s18|33-33|(|O
DDI-DrugBank.d97.s18|34-42|Hypericum|O
DDI-DrugBank.d97.s18|44-53|perforatum|O
DDI-DrugBank.d97.s18|54-54|)|O
DDI-DrugBank.d97.s19|0-2|May|O
DDI-DrugBank.d97.s19|4-7|lead|O
DDI-DrugBank.d97.s19|9-10|to|O
DDI-DrugBank.d97.s19|12-15|loss|O
DDI-DrugBank.d97.s19|17-18|of|O
DDI-DrugBank.d97.s19|20-28|virologic|O
DDI-DrugBank.d97.s19|30-37|response|O
DDI-DrugBank.d97.s19|39-41|and|O
DDI-DrugBank.d97.s19|43-50|possible|O
DDI-DrugBank.d97.s19|52-61|resistance|O
DDI-DrugBank.d97.s19|63-64|to|O
DDI-DrugBank.d97.s19|66-73|CRIXIVAN|O
DDI-DrugBank.d97.s19|75-76|or|O
DDI-DrugBank.d97.s19|78-79|to|O
DDI-DrugBank.d97.s19|81-83|the|O
DDI-DrugBank.d97.s19|85-89|class|O
DDI-DrugBank.d97.s19|91-92|of|O
DDI-DrugBank.d97.s19|94-101|protease|O
DDI-DrugBank.d97.s19|103-112|inhibitors|O
DDI-DrugBank.d97.s19|113-113|.|O
DDI-DrugBank.d97.s20|0-16|Antimycobacterial|O
DDI-DrugBank.d97.s20|17-17|:|O
DDI-DrugBank.d97.s20|19-26|rifampin|O
DDI-DrugBank.d97.s21|0-2|May|O
DDI-DrugBank.d97.s21|4-7|lead|O
DDI-DrugBank.d97.s21|9-10|to|O
DDI-DrugBank.d97.s21|12-15|loss|O
DDI-DrugBank.d97.s21|17-18|of|O
DDI-DrugBank.d97.s21|20-28|virologic|O
DDI-DrugBank.d97.s21|30-37|response|O
DDI-DrugBank.d97.s21|39-41|and|O
DDI-DrugBank.d97.s21|43-50|possible|O
DDI-DrugBank.d97.s21|52-61|resistance|O
DDI-DrugBank.d97.s21|63-64|to|O
DDI-DrugBank.d97.s21|66-73|CRIXIVAN|O
DDI-DrugBank.d97.s21|75-76|or|O
DDI-DrugBank.d97.s21|78-79|to|O
DDI-DrugBank.d97.s21|81-83|the|O
DDI-DrugBank.d97.s21|85-89|class|O
DDI-DrugBank.d97.s21|91-92|of|O
DDI-DrugBank.d97.s21|94-101|protease|O
DDI-DrugBank.d97.s21|103-112|inhibitors|O
DDI-DrugBank.d97.s21|114-115|or|O
DDI-DrugBank.d97.s21|117-121|other|O
DDI-DrugBank.d97.s21|123-136|coadministered|O
DDI-DrugBank.d97.s21|138-151|antiretroviral|O
DDI-DrugBank.d97.s21|153-158|agents|O
DDI-DrugBank.d97.s21|159-159|.|O
DDI-DrugBank.d97.s22|0-6|HMG-CoA|O
DDI-DrugBank.d97.s22|8-16|Reductase|O
DDI-DrugBank.d97.s22|18-27|inhibitors|O
DDI-DrugBank.d97.s22|28-28|:|O
DDI-DrugBank.d97.s22|30-39|lovastatin|O
DDI-DrugBank.d97.s22|40-40|,|O
DDI-DrugBank.d97.s22|42-52|simvastatin|O
DDI-DrugBank.d97.s23|0-8|Potential|O
DDI-DrugBank.d97.s23|10-12|for|O
DDI-DrugBank.d97.s23|14-20|serious|O
DDI-DrugBank.d97.s23|22-30|reactions|O
DDI-DrugBank.d97.s23|32-35|such|O
DDI-DrugBank.d97.s23|37-38|as|O
DDI-DrugBank.d97.s23|40-43|risk|O
DDI-DrugBank.d97.s23|45-46|of|O
DDI-DrugBank.d97.s23|48-55|myopathy|O
DDI-DrugBank.d97.s23|57-65|including|O
DDI-DrugBank.d97.s23|67-80|rhabdomyolysis|O
DDI-DrugBank.d97.s23|81-81|.|O
DDI-DrugBank.d97.s24|0-7|Protease|O
DDI-DrugBank.d97.s24|9-17|inhibitor|O
DDI-DrugBank.d97.s24|18-18|:|O
DDI-DrugBank.d97.s24|20-29|atazanavir|O
DDI-DrugBank.d97.s25|0-3|Both|O
DDI-DrugBank.d97.s25|5-12|CRIXIVAN|O
DDI-DrugBank.d97.s25|14-16|and|O
DDI-DrugBank.d97.s25|18-27|atazanavir|O
DDI-DrugBank.d97.s25|29-31|are|O
DDI-DrugBank.d97.s25|33-42|associated|O
DDI-DrugBank.d97.s25|44-47|with|O
DDI-DrugBank.d97.s25|49-56|indirect|O
DDI-DrugBank.d97.s25|58-58|(|O
DDI-DrugBank.d97.s25|59-70|unconjugated|O
DDI-DrugBank.d97.s25|71-71|)|O
DDI-DrugBank.d97.s25|73-90|hyperbilirubinemia|O
DDI-DrugBank.d97.s25|91-91|.|O
DDI-DrugBank.d97.s26|0-11|Combinations|O
DDI-DrugBank.d97.s26|13-14|of|O
DDI-DrugBank.d97.s26|16-20|these|O
DDI-DrugBank.d97.s26|22-26|drugs|O
DDI-DrugBank.d97.s26|28-31|have|O
DDI-DrugBank.d97.s26|33-35|not|O
DDI-DrugBank.d97.s26|37-40|been|O
DDI-DrugBank.d97.s26|42-48|studied|O
DDI-DrugBank.d97.s26|50-52|and|O
DDI-DrugBank.d97.s26|54-69|coadministration|O
DDI-DrugBank.d97.s26|71-72|of|O
DDI-DrugBank.d97.s26|74-81|CRIXIVAN|O
DDI-DrugBank.d97.s26|83-85|and|O
DDI-DrugBank.d97.s26|87-96|atazanavir|O
DDI-DrugBank.d97.s26|98-99|is|O
DDI-DrugBank.d97.s26|101-103|not|O
DDI-DrugBank.d97.s26|105-115|recommended|O
DDI-DrugBank.d97.s26|116-116|.|O
DDI-DrugBank.d97.s27|0-4|Table|O
DDI-DrugBank.d97.s27|6-6|9|O
DDI-DrugBank.d97.s28|0-10|Established|O
DDI-DrugBank.d97.s28|12-14|and|O
DDI-DrugBank.d97.s28|16-20|Other|O
DDI-DrugBank.d97.s28|22-32|Potentially|O
DDI-DrugBank.d97.s28|34-44|Significant|O
DDI-DrugBank.d97.s28|46-49|Drug|O
DDI-DrugBank.d97.s28|51-62|Interactions|O
DDI-DrugBank.d97.s28|63-63|:|O
DDI-DrugBank.d97.s28|65-74|Alteration|O
DDI-DrugBank.d97.s28|76-77|in|O
DDI-DrugBank.d97.s28|79-82|Dose|O
DDI-DrugBank.d97.s28|84-85|or|O
DDI-DrugBank.d97.s28|87-93|Regimen|O
DDI-DrugBank.d97.s28|95-97|May|O
DDI-DrugBank.d97.s28|99-100|Be|O
DDI-DrugBank.d97.s28|102-112|Recommended|O
DDI-DrugBank.d97.s28|114-118|Based|O
DDI-DrugBank.d97.s28|120-121|on|O
DDI-DrugBank.d97.s28|123-126|Drug|O
DDI-DrugBank.d97.s28|128-138|Interaction|O
DDI-DrugBank.d97.s28|140-146|Studies|O
DDI-DrugBank.d97.s28|148-149|or|O
DDI-DrugBank.d97.s28|151-159|Predicted|O
DDI-DrugBank.d97.s28|161-171|Interaction|O
DDI-DrugBank.d97.s29|0-3|Drug|O
DDI-DrugBank.d97.s29|5-8|Name|O
DDI-DrugBank.d97.s30|0-5|Effect|O
DDI-DrugBank.d97.s31|0-7|Clinical|O
DDI-DrugBank.d97.s31|9-15|Comment|O
DDI-DrugBank.d97.s32|0-2|HIV|O
DDI-DrugBank.d97.s32|4-12|Antiviral|O
DDI-DrugBank.d97.s32|14-19|Agents|O
DDI-DrugBank.d97.s33|0-10|Delavirdine|O
DDI-DrugBank.d97.s34|0-8|indinavir|O
DDI-DrugBank.d97.s34|10-22|concentration|O
DDI-DrugBank.d97.s35|0-3|Dose|O
DDI-DrugBank.d97.s35|5-13|reduction|O
DDI-DrugBank.d97.s35|15-16|of|O
DDI-DrugBank.d97.s35|18-25|CRIXIVAN|O
DDI-DrugBank.d97.s35|27-28|to|O
DDI-DrugBank.d97.s35|30-32|600|O
DDI-DrugBank.d97.s35|34-35|mg|O
DDI-DrugBank.d97.s35|37-41|every|O
DDI-DrugBank.d97.s35|43-43|8|O
DDI-DrugBank.d97.s35|45-49|hours|O
DDI-DrugBank.d97.s35|51-56|should|O
DDI-DrugBank.d97.s35|58-59|be|O
DDI-DrugBank.d97.s35|61-70|considered|O
DDI-DrugBank.d97.s35|72-75|when|O
DDI-DrugBank.d97.s35|77-82|taking|O
DDI-DrugBank.d97.s35|84-94|delavirdine|O
DDI-DrugBank.d97.s35|96-98|400|O
DDI-DrugBank.d97.s35|100-101|mg|O
DDI-DrugBank.d97.s35|103-107|three|O
DDI-DrugBank.d97.s35|109-113|times|O
DDI-DrugBank.d97.s35|115-115|a|O
DDI-DrugBank.d97.s35|117-119|day|O
DDI-DrugBank.d97.s35|120-120|.|O
DDI-DrugBank.d97.s36|0-9|Didanosine|O
DDI-DrugBank.d97.s37|0-8|Indinavir|O
DDI-DrugBank.d97.s37|10-12|and|O
DDI-DrugBank.d97.s37|14-23|didanosine|O
DDI-DrugBank.d97.s37|25-36|formulations|O
DDI-DrugBank.d97.s37|38-47|containing|O
DDI-DrugBank.d97.s37|49-54|buffer|O
DDI-DrugBank.d97.s37|56-61|should|O
DDI-DrugBank.d97.s37|63-64|be|O
DDI-DrugBank.d97.s37|66-77|administered|O
DDI-DrugBank.d97.s37|79-80|at|O
DDI-DrugBank.d97.s37|82-86|least|O
DDI-DrugBank.d97.s37|88-90|one|O
DDI-DrugBank.d97.s37|92-95|hour|O
DDI-DrugBank.d97.s37|97-101|apart|O
DDI-DrugBank.d97.s37|103-104|on|O
DDI-DrugBank.d97.s37|106-107|an|O
DDI-DrugBank.d97.s37|109-113|empty|O
DDI-DrugBank.d97.s37|115-121|stomach|O
DDI-DrugBank.d97.s37|122-122|.|O
DDI-DrugBank.d97.s38|0-8|Efavirenz|O
DDI-DrugBank.d97.s39|0-8|indinavir|O
DDI-DrugBank.d97.s39|10-22|concentration|O
DDI-DrugBank.d97.s40|0-2|The|O
DDI-DrugBank.d97.s40|4-10|optimal|O
DDI-DrugBank.d97.s40|12-15|dose|O
DDI-DrugBank.d97.s40|17-18|of|O
DDI-DrugBank.d97.s40|20-28|indinavir|O
DDI-DrugBank.d97.s40|29-29|,|O
DDI-DrugBank.d97.s40|31-34|when|O
DDI-DrugBank.d97.s40|36-40|given|O
DDI-DrugBank.d97.s40|42-43|in|O
DDI-DrugBank.d97.s40|45-55|combination|O
DDI-DrugBank.d97.s40|57-60|with|O
DDI-DrugBank.d97.s40|62-70|efavirenz|O
DDI-DrugBank.d97.s40|71-71|,|O
DDI-DrugBank.d97.s40|73-74|is|O
DDI-DrugBank.d97.s40|76-78|not|O
DDI-DrugBank.d97.s40|80-84|known|O
DDI-DrugBank.d97.s40|85-85|.|O
DDI-DrugBank.d97.s41|0-9|Increasing|O
DDI-DrugBank.d97.s41|11-13|the|O
DDI-DrugBank.d97.s41|15-23|indinavir|O
DDI-DrugBank.d97.s41|25-28|dose|O
DDI-DrugBank.d97.s41|30-31|to|O
DDI-DrugBank.d97.s41|33-36|1000|O
DDI-DrugBank.d97.s41|38-39|mg|O
DDI-DrugBank.d97.s41|41-45|every|O
DDI-DrugBank.d97.s41|47-47|8|O
DDI-DrugBank.d97.s41|49-53|hours|O
DDI-DrugBank.d97.s41|55-58|does|O
DDI-DrugBank.d97.s41|60-62|not|O
DDI-DrugBank.d97.s41|64-73|compensate|O
DDI-DrugBank.d97.s41|75-77|for|O
DDI-DrugBank.d97.s41|79-81|the|O
DDI-DrugBank.d97.s41|83-91|increased|O
DDI-DrugBank.d97.s41|93-101|indinavir|O
DDI-DrugBank.d97.s41|103-112|metabolism|O
DDI-DrugBank.d97.s41|114-116|due|O
DDI-DrugBank.d97.s41|118-119|to|O
DDI-DrugBank.d97.s41|121-129|efavirenz|O
DDI-DrugBank.d97.s41|130-130|.|O
DDI-DrugBank.d97.s42|0-9|Nelfinavir|O
DDI-DrugBank.d97.s43|0-8|indinavir|O
DDI-DrugBank.d97.s43|10-22|concentration|O
DDI-DrugBank.d97.s44|0-2|The|O
DDI-DrugBank.d97.s44|4-14|appropriate|O
DDI-DrugBank.d97.s44|16-20|doses|O
DDI-DrugBank.d97.s44|22-24|for|O
DDI-DrugBank.d97.s44|26-29|this|O
DDI-DrugBank.d97.s44|31-41|combination|O
DDI-DrugBank.d97.s44|42-42|,|O
DDI-DrugBank.d97.s44|44-47|with|O
DDI-DrugBank.d97.s44|49-55|respect|O
DDI-DrugBank.d97.s44|57-58|to|O
DDI-DrugBank.d97.s44|60-67|efficacy|O
DDI-DrugBank.d97.s44|69-71|and|O
DDI-DrugBank.d97.s44|73-78|safety|O
DDI-DrugBank.d97.s44|79-79|,|O
DDI-DrugBank.d97.s44|81-84|have|O
DDI-DrugBank.d97.s44|86-88|not|O
DDI-DrugBank.d97.s44|90-93|been|O
DDI-DrugBank.d97.s44|95-105|established|O
DDI-DrugBank.d97.s44|106-106|.|O
DDI-DrugBank.d97.s45|0-9|Nevirapine|O
DDI-DrugBank.d97.s46|0-8|indinavir|O
DDI-DrugBank.d97.s46|10-22|concentration|O
DDI-DrugBank.d97.s47|0-8|Indinavir|O
DDI-DrugBank.d97.s47|10-23|concentrations|O
DDI-DrugBank.d97.s47|25-27|may|O
DDI-DrugBank.d97.s47|29-30|be|O
DDI-DrugBank.d97.s47|32-40|decreased|O
DDI-DrugBank.d97.s47|42-43|in|O
DDI-DrugBank.d97.s47|45-47|the|O
DDI-DrugBank.d97.s47|49-56|presence|O
DDI-DrugBank.d97.s47|58-59|of|O
DDI-DrugBank.d97.s47|61-70|nevirapine|O
DDI-DrugBank.d97.s47|71-71|.|O
DDI-DrugBank.d97.s48|0-2|The|O
DDI-DrugBank.d97.s48|4-14|appropriate|O
DDI-DrugBank.d97.s48|16-20|doses|O
DDI-DrugBank.d97.s48|22-24|for|O
DDI-DrugBank.d97.s48|26-29|this|O
DDI-DrugBank.d97.s48|31-41|combination|O
DDI-DrugBank.d97.s48|42-42|,|O
DDI-DrugBank.d97.s48|44-47|with|O
DDI-DrugBank.d97.s48|49-55|respect|O
DDI-DrugBank.d97.s48|57-58|to|O
DDI-DrugBank.d97.s48|60-67|efficacy|O
DDI-DrugBank.d97.s48|69-71|and|O
DDI-DrugBank.d97.s48|73-78|safety|O
DDI-DrugBank.d97.s48|79-79|,|O
DDI-DrugBank.d97.s48|81-84|have|O
DDI-DrugBank.d97.s48|86-88|not|O
DDI-DrugBank.d97.s48|90-93|been|O
DDI-DrugBank.d97.s48|95-105|established|O
DDI-DrugBank.d97.s48|106-106|.|O
DDI-DrugBank.d97.s49|0-8|Ritonavir|O
DDI-DrugBank.d97.s50|0-8|indinavir|O
DDI-DrugBank.d97.s50|10-22|concentration|O
DDI-DrugBank.d97.s50|26-34|ritonavir|O
DDI-DrugBank.d97.s50|36-48|concentration|O
DDI-DrugBank.d97.s51|0-2|The|O
DDI-DrugBank.d97.s51|4-14|appropriate|O
DDI-DrugBank.d97.s51|16-20|doses|O
DDI-DrugBank.d97.s51|22-24|for|O
DDI-DrugBank.d97.s51|26-29|this|O
DDI-DrugBank.d97.s51|31-41|combination|O
DDI-DrugBank.d97.s51|42-42|,|O
DDI-DrugBank.d97.s51|44-47|with|O
DDI-DrugBank.d97.s51|49-55|respect|O
DDI-DrugBank.d97.s51|57-58|to|O
DDI-DrugBank.d97.s51|60-67|efficacy|O
DDI-DrugBank.d97.s51|69-71|and|O
DDI-DrugBank.d97.s51|73-78|safety|O
DDI-DrugBank.d97.s51|79-79|,|O
DDI-DrugBank.d97.s51|81-84|have|O
DDI-DrugBank.d97.s51|86-88|not|O
DDI-DrugBank.d97.s51|90-93|been|O
DDI-DrugBank.d97.s51|95-105|established|O
DDI-DrugBank.d97.s51|106-106|.|O
DDI-DrugBank.d97.s52|0-10|Preliminary|O
DDI-DrugBank.d97.s52|12-19|clinical|O
DDI-DrugBank.d97.s52|21-24|data|O
DDI-DrugBank.d97.s52|26-32|suggest|O
DDI-DrugBank.d97.s52|34-37|that|O
DDI-DrugBank.d97.s52|39-41|the|O
DDI-DrugBank.d97.s52|43-51|incidence|O
DDI-DrugBank.d97.s52|53-54|of|O
DDI-DrugBank.d97.s52|56-70|nephrolithiasis|O
DDI-DrugBank.d97.s52|72-73|is|O
DDI-DrugBank.d97.s52|75-80|higher|O
DDI-DrugBank.d97.s52|82-83|in|O
DDI-DrugBank.d97.s52|85-92|patients|O
DDI-DrugBank.d97.s52|94-102|receiving|O
DDI-DrugBank.d97.s52|104-112|indinavir|O
DDI-DrugBank.d97.s52|114-115|in|O
DDI-DrugBank.d97.s52|117-127|combination|O
DDI-DrugBank.d97.s52|129-132|with|O
DDI-DrugBank.d97.s52|134-142|ritonavir|O
DDI-DrugBank.d97.s52|144-147|than|O
DDI-DrugBank.d97.s52|149-153|those|O
DDI-DrugBank.d97.s52|155-163|receiving|O
DDI-DrugBank.d97.s52|165-172|CRIXIVAN|O
DDI-DrugBank.d97.s52|174-176|800|O
DDI-DrugBank.d97.s52|178-179|mg|O
DDI-DrugBank.d97.s52|181-183|q8h|O
DDI-DrugBank.d97.s52|184-184|.|O
DDI-DrugBank.d97.s53|0-9|Saquinavir|O
DDI-DrugBank.d97.s54|0-9|saquinavir|O
DDI-DrugBank.d97.s54|11-23|concentration|O
DDI-DrugBank.d97.s55|0-2|The|O
DDI-DrugBank.d97.s55|4-14|appropriate|O
DDI-DrugBank.d97.s55|16-20|doses|O
DDI-DrugBank.d97.s55|22-24|for|O
DDI-DrugBank.d97.s55|26-29|this|O
DDI-DrugBank.d97.s55|31-41|combination|O
DDI-DrugBank.d97.s55|42-42|,|O
DDI-DrugBank.d97.s55|44-47|with|O
DDI-DrugBank.d97.s55|49-55|respect|O
DDI-DrugBank.d97.s55|57-58|to|O
DDI-DrugBank.d97.s55|60-67|efficacy|O
DDI-DrugBank.d97.s55|69-71|and|O
DDI-DrugBank.d97.s55|73-78|safety|O
DDI-DrugBank.d97.s55|79-79|,|O
DDI-DrugBank.d97.s55|81-84|have|O
DDI-DrugBank.d97.s55|86-88|not|O
DDI-DrugBank.d97.s55|90-93|been|O
DDI-DrugBank.d97.s55|95-105|established|O
DDI-DrugBank.d97.s55|106-106|.|O
DDI-DrugBank.d97.s56|0-4|Other|O
DDI-DrugBank.d97.s56|6-11|Agents|O
DDI-DrugBank.d97.s57|0-14|Antiarrhythmics|O
DDI-DrugBank.d97.s57|15-15|:|O
DDI-DrugBank.d97.s57|17-24|bepridil|O
DDI-DrugBank.d97.s57|25-25|,|O
DDI-DrugBank.d97.s57|27-35|lidocaine|O
DDI-DrugBank.d97.s57|37-37|(|O
DDI-DrugBank.d97.s57|38-45|systemic|O
DDI-DrugBank.d97.s57|46-46|)|O
DDI-DrugBank.d97.s57|48-50|and|O
DDI-DrugBank.d97.s57|52-60|quinidine|O
DDI-DrugBank.d97.s58|0-13|antiarrhythmic|O
DDI-DrugBank.d97.s58|15-20|agents|O
DDI-DrugBank.d97.s58|22-34|concentration|O
DDI-DrugBank.d97.s59|0-6|Caution|O
DDI-DrugBank.d97.s59|8-9|is|O
DDI-DrugBank.d97.s59|11-19|warranted|O
DDI-DrugBank.d97.s59|21-23|and|O
DDI-DrugBank.d97.s59|25-35|therapeutic|O
DDI-DrugBank.d97.s59|37-49|concentration|O
DDI-DrugBank.d97.s59|51-60|monitoring|O
DDI-DrugBank.d97.s59|62-63|is|O
DDI-DrugBank.d97.s59|65-75|recommended|O
DDI-DrugBank.d97.s59|77-79|for|O
DDI-DrugBank.d97.s59|81-95|antiarrhythmics|O
DDI-DrugBank.d97.s59|97-100|when|O
DDI-DrugBank.d97.s59|102-115|coadministered|O
DDI-DrugBank.d97.s59|117-120|with|O
DDI-DrugBank.d97.s59|122-129|CRIXIVAN|O
DDI-DrugBank.d97.s59|130-130|.|O
DDI-DrugBank.d97.s60|0-14|Anticonvulsants|O
DDI-DrugBank.d97.s60|15-15|:|O
DDI-DrugBank.d97.s60|17-29|carbamazepine|O
DDI-DrugBank.d97.s60|30-30|,|O
DDI-DrugBank.d97.s60|32-44|phenobarbital|O
DDI-DrugBank.d97.s60|45-45|,|O
DDI-DrugBank.d97.s60|47-55|phenytoin|O
DDI-DrugBank.d97.s61|0-8|indinavir|O
DDI-DrugBank.d97.s61|10-22|concentration|O
DDI-DrugBank.d97.s62|0-2|Use|O
DDI-DrugBank.d97.s62|4-7|with|O
DDI-DrugBank.d97.s62|9-15|caution|O
DDI-DrugBank.d97.s62|16-16|.|O
DDI-DrugBank.d97.s63|0-7|CRIXIVAN|O
DDI-DrugBank.d97.s63|9-11|may|O
DDI-DrugBank.d97.s63|13-15|not|O
DDI-DrugBank.d97.s63|17-18|be|O
DDI-DrugBank.d97.s63|20-28|effective|O
DDI-DrugBank.d97.s63|30-32|due|O
DDI-DrugBank.d97.s63|34-35|to|O
DDI-DrugBank.d97.s63|37-45|decreased|O
DDI-DrugBank.d97.s63|47-55|indinavir|O
DDI-DrugBank.d97.s63|57-70|concentrations|O
DDI-DrugBank.d97.s63|72-73|in|O
DDI-DrugBank.d97.s63|75-82|patients|O
DDI-DrugBank.d97.s63|84-89|taking|O
DDI-DrugBank.d97.s63|91-95|these|O
DDI-DrugBank.d97.s63|97-102|agents|O
DDI-DrugBank.d97.s63|104-116|concomitantly|O
DDI-DrugBank.d97.s63|117-117|.|O
DDI-DrugBank.d97.s64|0-6|Calcium|O
DDI-DrugBank.d97.s64|8-14|Channel|O
DDI-DrugBank.d97.s64|16-23|Blockers|O
DDI-DrugBank.d97.s64|24-24|,|O
DDI-DrugBank.d97.s64|26-40|Dihydropyridine|O
DDI-DrugBank.d97.s64|41-41|:|O
DDI-DrugBank.d97.s64|43-46|e.g.|O
DDI-DrugBank.d97.s64|47-47|,|O
DDI-DrugBank.d97.s64|49-58|felodipine|O
DDI-DrugBank.d97.s64|59-59|,|O
DDI-DrugBank.d97.s64|61-70|nifedipine|O
DDI-DrugBank.d97.s64|71-71|,|O
DDI-DrugBank.d97.s64|73-83|nicardipine|O
DDI-DrugBank.d97.s65|0-14|dihydropyridine|O
DDI-DrugBank.d97.s65|16-22|calcium|O
DDI-DrugBank.d97.s65|24-30|channel|O
DDI-DrugBank.d97.s65|32-39|blockers|O
DDI-DrugBank.d97.s65|41-53|concentration|O
DDI-DrugBank.d97.s66|0-6|Caution|O
DDI-DrugBank.d97.s66|8-9|is|O
DDI-DrugBank.d97.s66|11-19|warranted|O
DDI-DrugBank.d97.s66|21-23|and|O
DDI-DrugBank.d97.s66|25-32|clinical|O
DDI-DrugBank.d97.s66|34-43|monitoring|O
DDI-DrugBank.d97.s66|45-46|of|O
DDI-DrugBank.d97.s66|48-55|patients|O
DDI-DrugBank.d97.s66|57-58|is|O
DDI-DrugBank.d97.s66|60-70|recommended|O
DDI-DrugBank.d97.s66|71-71|.|O
DDI-DrugBank.d97.s67|0-13|Clarithromycin|O
DDI-DrugBank.d97.s68|0-13|clarithromycin|O
DDI-DrugBank.d97.s68|15-27|concentration|O
DDI-DrugBank.d97.s68|31-39|indinavir|O
DDI-DrugBank.d97.s68|41-53|concentration|O
DDI-DrugBank.d97.s69|0-2|The|O
DDI-DrugBank.d97.s69|4-14|appropriate|O
DDI-DrugBank.d97.s69|16-20|doses|O
DDI-DrugBank.d97.s69|22-24|for|O
DDI-DrugBank.d97.s69|26-29|this|O
DDI-DrugBank.d97.s69|31-41|combination|O
DDI-DrugBank.d97.s69|42-42|,|O
DDI-DrugBank.d97.s69|44-47|with|O
DDI-DrugBank.d97.s69|49-55|respect|O
DDI-DrugBank.d97.s69|57-58|to|O
DDI-DrugBank.d97.s69|60-67|efficacy|O
DDI-DrugBank.d97.s69|69-71|and|O
DDI-DrugBank.d97.s69|73-78|safety|O
DDI-DrugBank.d97.s69|79-79|,|O
DDI-DrugBank.d97.s69|81-84|have|O
DDI-DrugBank.d97.s69|86-88|not|O
DDI-DrugBank.d97.s69|90-93|been|O
DDI-DrugBank.d97.s69|95-105|established|O
DDI-DrugBank.d97.s69|106-106|.|O
DDI-DrugBank.d97.s70|0-6|HMG-CoA|O
DDI-DrugBank.d97.s70|8-16|Reductase|O
DDI-DrugBank.d97.s70|18-26|Inhibitor|O
DDI-DrugBank.d97.s70|27-27|:|O
DDI-DrugBank.d97.s70|29-40|atorvastatin|O
DDI-DrugBank.d97.s71|0-11|atorvastatin|O
DDI-DrugBank.d97.s71|13-25|concentration|O
DDI-DrugBank.d97.s72|0-2|Use|O
DDI-DrugBank.d97.s72|4-9|lowest|O
DDI-DrugBank.d97.s72|11-18|possible|O
DDI-DrugBank.d97.s72|20-23|dose|O
DDI-DrugBank.d97.s72|25-26|of|O
DDI-DrugBank.d97.s72|28-39|atorvastatin|O
DDI-DrugBank.d97.s72|41-44|with|O
DDI-DrugBank.d97.s72|46-52|careful|O
DDI-DrugBank.d97.s72|54-63|monitoring|O
DDI-DrugBank.d97.s72|64-64|,|O
DDI-DrugBank.d97.s72|66-67|or|O
DDI-DrugBank.d97.s72|69-76|consider|O
DDI-DrugBank.d97.s72|78-84|HMG-CoA|O
DDI-DrugBank.d97.s72|86-94|reductase|O
DDI-DrugBank.d97.s72|96-105|inhibitors|O
DDI-DrugBank.d97.s72|107-110|that|O
DDI-DrugBank.d97.s72|112-114|are|O
DDI-DrugBank.d97.s72|116-118|not|O
DDI-DrugBank.d97.s72|120-128|primarily|O
DDI-DrugBank.d97.s72|130-140|metabolized|O
DDI-DrugBank.d97.s72|142-143|by|O
DDI-DrugBank.d97.s72|145-150|CYP3A4|O
DDI-DrugBank.d97.s72|151-151|,|O
DDI-DrugBank.d97.s72|153-156|such|O
DDI-DrugBank.d97.s72|158-159|as|O
DDI-DrugBank.d97.s72|161-171|pravastatin|O
DDI-DrugBank.d97.s72|172-172|,|O
DDI-DrugBank.d97.s72|174-184|fluvastatin|O
DDI-DrugBank.d97.s72|185-185|,|O
DDI-DrugBank.d97.s72|187-188|or|O
DDI-DrugBank.d97.s72|190-201|rosuvastatin|O
DDI-DrugBank.d97.s72|203-204|in|O
DDI-DrugBank.d97.s72|206-216|combination|O
DDI-DrugBank.d97.s72|218-221|with|O
DDI-DrugBank.d97.s72|223-230|CRIXIVAN|O
DDI-DrugBank.d97.s72|231-231|.|O
DDI-DrugBank.d97.s73|0-17|Immunosuppressants|O
DDI-DrugBank.d97.s73|18-18|:|O
DDI-DrugBank.d97.s73|20-31|cyclosporine|O
DDI-DrugBank.d97.s73|32-32|,|O
DDI-DrugBank.d97.s73|34-43|tacrolimus|O
DDI-DrugBank.d97.s73|44-44|,|O
DDI-DrugBank.d97.s73|46-54|sirolimus|O
DDI-DrugBank.d97.s74|0-16|immunosuppressant|O
DDI-DrugBank.d97.s74|18-23|agents|O
DDI-DrugBank.d97.s74|25-37|concentration|O
DDI-DrugBank.d97.s75|0-5|Plasma|O
DDI-DrugBank.d97.s75|7-20|concentrations|O
DDI-DrugBank.d97.s75|22-24|may|O
DDI-DrugBank.d97.s75|26-27|be|O
DDI-DrugBank.d97.s75|29-37|increased|O
DDI-DrugBank.d97.s75|39-40|by|O
DDI-DrugBank.d97.s75|42-49|CRIXIVAN|O
DDI-DrugBank.d97.s75|50-50|.|O
DDI-DrugBank.d97.s76|0-11|Itraconazole|O
DDI-DrugBank.d97.s77|0-8|indinavir|O
DDI-DrugBank.d97.s77|10-22|concentration|O
DDI-DrugBank.d97.s78|0-3|Dose|O
DDI-DrugBank.d97.s78|5-13|reduction|O
DDI-DrugBank.d97.s78|15-16|of|O
DDI-DrugBank.d97.s78|18-25|CRIXIVAN|O
DDI-DrugBank.d97.s78|27-28|to|O
DDI-DrugBank.d97.s78|30-32|600|O
DDI-DrugBank.d97.s78|34-35|mg|O
DDI-DrugBank.d97.s78|37-41|every|O
DDI-DrugBank.d97.s78|43-43|8|O
DDI-DrugBank.d97.s78|45-49|hours|O
DDI-DrugBank.d97.s78|51-52|is|O
DDI-DrugBank.d97.s78|54-64|recommended|O
DDI-DrugBank.d97.s78|66-69|when|O
DDI-DrugBank.d97.s78|71-83|administering|O
DDI-DrugBank.d97.s78|85-96|itraconazole|O
DDI-DrugBank.d97.s78|98-109|concurrently|O
DDI-DrugBank.d97.s78|110-110|.|O
DDI-DrugBank.d97.s79|0-11|Ketoconazole|O
DDI-DrugBank.d97.s80|0-8|indinavir|O
DDI-DrugBank.d97.s80|10-22|concentration|O
DDI-DrugBank.d97.s81|0-3|Dose|O
DDI-DrugBank.d97.s81|5-13|reduction|O
DDI-DrugBank.d97.s81|15-16|of|O
DDI-DrugBank.d97.s81|18-25|CRIXIVAN|O
DDI-DrugBank.d97.s81|27-28|to|O
DDI-DrugBank.d97.s81|30-32|600|O
DDI-DrugBank.d97.s81|34-35|mg|O
DDI-DrugBank.d97.s81|37-41|every|O
DDI-DrugBank.d97.s81|43-43|8|O
DDI-DrugBank.d97.s81|45-49|hours|O
DDI-DrugBank.d97.s81|51-56|should|O
DDI-DrugBank.d97.s81|58-59|be|O
DDI-DrugBank.d97.s81|61-70|considered|O
DDI-DrugBank.d97.s81|71-71|.|O
DDI-DrugBank.d97.s82|0-8|Rifabutin|O
DDI-DrugBank.d97.s83|0-8|indinavir|O
DDI-DrugBank.d97.s83|10-22|concentration|O
DDI-DrugBank.d97.s83|26-34|rifabutin|O
DDI-DrugBank.d97.s83|36-48|concentration|O
DDI-DrugBank.d97.s84|0-3|Dose|O
DDI-DrugBank.d97.s84|5-13|reduction|O
DDI-DrugBank.d97.s84|15-16|of|O
DDI-DrugBank.d97.s84|18-26|rifabutin|O
DDI-DrugBank.d97.s84|28-29|to|O
DDI-DrugBank.d97.s84|31-34|half|O
DDI-DrugBank.d97.s84|36-38|the|O
DDI-DrugBank.d97.s84|40-47|standard|O
DDI-DrugBank.d97.s84|49-52|dose|O
DDI-DrugBank.d97.s84|54-56|and|O
DDI-DrugBank.d97.s84|58-58|a|O
DDI-DrugBank.d97.s84|60-63|dose|O
DDI-DrugBank.d97.s84|65-72|increase|O
DDI-DrugBank.d97.s84|74-75|of|O
DDI-DrugBank.d97.s84|77-84|CRIXIVAN|O
DDI-DrugBank.d97.s84|86-87|to|O
DDI-DrugBank.d97.s84|89-92|1000|O
DDI-DrugBank.d97.s84|94-95|mg|O
DDI-DrugBank.d97.s84|97-97|(|O
DDI-DrugBank.d97.s84|98-102|three|O
DDI-DrugBank.d97.s84|104-109|333-mg|O
DDI-DrugBank.d97.s84|111-118|capsules|O
DDI-DrugBank.d97.s84|119-119|)|O
DDI-DrugBank.d97.s84|121-125|every|O
DDI-DrugBank.d97.s84|127-127|8|O
DDI-DrugBank.d97.s84|129-133|hours|O
DDI-DrugBank.d97.s84|135-137|are|O
DDI-DrugBank.d97.s84|139-149|recommended|O
DDI-DrugBank.d97.s84|151-154|when|O
DDI-DrugBank.d97.s84|156-164|rifabutin|O
DDI-DrugBank.d97.s84|166-168|and|O
DDI-DrugBank.d97.s84|170-177|CRIXIVAN|O
DDI-DrugBank.d97.s84|179-181|are|O
DDI-DrugBank.d97.s84|183-196|coadministered|O
DDI-DrugBank.d97.s84|197-197|.|O
DDI-DrugBank.d97.s85|0-9|Sildenafil|O
DDI-DrugBank.d97.s86|0-9|sildenafil|O
DDI-DrugBank.d97.s86|11-23|concentration|O
DDI-DrugBank.d97.s87|0-9|Sildenafil|O
DDI-DrugBank.d97.s87|11-14|dose|O
DDI-DrugBank.d97.s87|16-21|should|O
DDI-DrugBank.d97.s87|23-25|not|O
DDI-DrugBank.d97.s87|27-32|exceed|O
DDI-DrugBank.d97.s87|34-34|a|O
DDI-DrugBank.d97.s87|36-42|maximum|O
DDI-DrugBank.d97.s87|44-45|of|O
DDI-DrugBank.d97.s87|47-48|25|O
DDI-DrugBank.d97.s87|50-51|mg|O
DDI-DrugBank.d97.s87|53-54|in|O
DDI-DrugBank.d97.s87|56-56|a|O
DDI-DrugBank.d97.s87|58-60|48-|O
DDI-DrugBank.d97.s87|62-65|hour|O
DDI-DrugBank.d97.s87|67-72|period|O
DDI-DrugBank.d97.s87|74-75|in|O
DDI-DrugBank.d97.s87|77-84|patients|O
DDI-DrugBank.d97.s87|86-94|receiving|O
DDI-DrugBank.d97.s87|96-106|concomitant|O
DDI-DrugBank.d97.s87|108-116|indinavir|O
DDI-DrugBank.d97.s87|118-124|therapy|O
DDI-DrugBank.d97.s87|125-125|.|O
DDI-DrugBank.d97.s88|0-8|Tadalafil|O
DDI-DrugBank.d97.s89|0-8|tadalafil|O
DDI-DrugBank.d97.s89|10-22|concentration|O
DDI-DrugBank.d97.s90|0-8|Tadalafil|O
DDI-DrugBank.d97.s90|10-13|dose|O
DDI-DrugBank.d97.s90|15-20|should|O
DDI-DrugBank.d97.s90|22-24|not|O
DDI-DrugBank.d97.s90|26-31|exceed|O
DDI-DrugBank.d97.s90|33-33|a|O
DDI-DrugBank.d97.s90|35-41|maximum|O
DDI-DrugBank.d97.s90|43-44|of|O
DDI-DrugBank.d97.s90|46-47|10|O
DDI-DrugBank.d97.s90|49-50|mg|O
DDI-DrugBank.d97.s90|52-53|in|O
DDI-DrugBank.d97.s90|55-55|a|O
DDI-DrugBank.d97.s90|57-59|72-|O
DDI-DrugBank.d97.s90|61-64|hour|O
DDI-DrugBank.d97.s90|66-71|period|O
DDI-DrugBank.d97.s90|73-74|in|O
DDI-DrugBank.d97.s90|76-83|patients|O
DDI-DrugBank.d97.s90|85-93|receiving|O
DDI-DrugBank.d97.s90|95-105|concomitant|O
DDI-DrugBank.d97.s90|107-115|indinavir|O
DDI-DrugBank.d97.s90|117-123|therapy|O
DDI-DrugBank.d97.s90|124-124|.|O
DDI-DrugBank.d97.s91|0-9|Vardenafil|O
DDI-DrugBank.d97.s92|0-9|vardenafil|O
DDI-DrugBank.d97.s92|11-23|concentration|O
DDI-DrugBank.d97.s93|0-9|Vardenafil|O
DDI-DrugBank.d97.s93|11-14|dose|O
DDI-DrugBank.d97.s93|16-21|should|O
DDI-DrugBank.d97.s93|23-25|not|O
DDI-DrugBank.d97.s93|27-32|exceed|O
DDI-DrugBank.d97.s93|34-34|a|O
DDI-DrugBank.d97.s93|36-42|maximum|O
DDI-DrugBank.d97.s93|44-45|of|O
DDI-DrugBank.d97.s93|47-49|2.5|O
DDI-DrugBank.d97.s93|51-52|mg|O
DDI-DrugBank.d97.s93|54-55|in|O
DDI-DrugBank.d97.s93|57-57|a|O
DDI-DrugBank.d97.s93|59-65|24-hour|O
DDI-DrugBank.d97.s93|67-72|period|O
DDI-DrugBank.d97.s93|74-75|in|O
DDI-DrugBank.d97.s93|77-84|patients|O
DDI-DrugBank.d97.s93|86-94|receiving|O
DDI-DrugBank.d97.s93|96-106|concomitant|O
DDI-DrugBank.d97.s93|108-116|indinavir|O
DDI-DrugBank.d97.s93|118-124|therapy|O
DDI-DrugBank.d97.s93|125-125|.|O
DDI-DrugBank.d97.s94|0-3|Note|O
DDI-DrugBank.d97.s94|4-4|:|O
DDI-DrugBank.d97.s95|0-0|=|O
DDI-DrugBank.d97.s95|2-9|increase|O
DDI-DrugBank.d97.s95|10-10|;|O
DDI-DrugBank.d97.s96|0-0|=|O
DDI-DrugBank.d97.s96|2-9|decrease|O
DDI-DrugBank.d168.s0|0-3|This|O
DDI-DrugBank.d168.s0|5-8|drug|O
DDI-DrugBank.d168.s0|10-12|may|O
DDI-DrugBank.d168.s0|14-21|interact|O
DDI-DrugBank.d168.s0|23-26|with|O
DDI-DrugBank.d168.s0|28-34|alcohol|O
DDI-DrugBank.d168.s0|36-37|or|O
DDI-DrugBank.d168.s0|39-43|other|O
DDI-DrugBank.d168.s0|45-47|CNS|O
DDI-DrugBank.d168.s0|49-59|depressants|O
DDI-DrugBank.d168.s0|61-61|(|O
DDI-DrugBank.d168.s0|62-64|may|O
DDI-DrugBank.d168.s0|66-75|potentiate|O
DDI-DrugBank.d168.s0|77-79|the|O
DDI-DrugBank.d168.s0|81-83|CNS|O
DDI-DrugBank.d168.s0|85-94|depressant|O
DDI-DrugBank.d168.s0|96-102|effects|O
DDI-DrugBank.d168.s0|104-105|of|O
DDI-DrugBank.d168.s0|107-112|either|O
DDI-DrugBank.d168.s0|114-118|these|O
DDI-DrugBank.d168.s0|120-130|medications|O
DDI-DrugBank.d168.s0|132-133|or|O
DDI-DrugBank.d168.s0|135-148|antihistamines|O
DDI-DrugBank.d168.s0|149-149|)|O
DDI-DrugBank.d168.s0|150-150|,|O
DDI-DrugBank.d168.s0|152-167|anticholinergics|O
DDI-DrugBank.d168.s0|169-170|or|O
DDI-DrugBank.d168.s0|172-176|other|O
DDI-DrugBank.d168.s0|178-188|medications|O
DDI-DrugBank.d168.s0|190-193|with|O
DDI-DrugBank.d168.s0|195-209|anticholinergic|O
DDI-DrugBank.d168.s0|211-218|activity|O
DDI-DrugBank.d168.s0|220-220|(|O
DDI-DrugBank.d168.s0|221-235|anticholinergic|O
DDI-DrugBank.d168.s0|237-243|effects|O
DDI-DrugBank.d168.s0|245-247|may|O
DDI-DrugBank.d168.s0|249-250|be|O
DDI-DrugBank.d168.s0|252-262|potentiated|O
DDI-DrugBank.d168.s0|264-267|when|O
DDI-DrugBank.d168.s0|269-273|these|O
DDI-DrugBank.d168.s0|275-285|medications|O
DDI-DrugBank.d168.s0|287-289|are|O
DDI-DrugBank.d168.s0|291-294|used|O
DDI-DrugBank.d168.s0|296-307|concurrently|O
DDI-DrugBank.d168.s0|309-312|with|O
DDI-DrugBank.d168.s0|314-327|antihistamines|O
DDI-DrugBank.d168.s0|328-328|)|O
DDI-DrugBank.d168.s0|329-329|,|O
DDI-DrugBank.d168.s0|331-333|and|O
DDI-DrugBank.d168.s0|335-343|monoamine|O
DDI-DrugBank.d168.s0|345-351|oxidase|O
DDI-DrugBank.d168.s0|353-353|(|O
DDI-DrugBank.d168.s0|354-356|MAO|O
DDI-DrugBank.d168.s0|357-357|)|O
DDI-DrugBank.d168.s0|359-368|inhibitors|O
DDI-DrugBank.d168.s0|370-370|(|O
DDI-DrugBank.d168.s0|371-380|concurrent|O
DDI-DrugBank.d168.s0|382-384|use|O
DDI-DrugBank.d168.s0|386-389|with|O
DDI-DrugBank.d168.s0|391-404|antihistamines|O
DDI-DrugBank.d168.s0|406-408|may|O
DDI-DrugBank.d168.s0|410-416|prolong|O
DDI-DrugBank.d168.s0|418-420|and|O
DDI-DrugBank.d168.s0|422-430|intensify|O
DDI-DrugBank.d168.s0|432-434|the|O
DDI-DrugBank.d168.s0|436-450|anticholinergic|O
DDI-DrugBank.d168.s0|452-454|and|O
DDI-DrugBank.d168.s0|456-458|CNS|O
DDI-DrugBank.d168.s0|460-469|depressant|O
DDI-DrugBank.d168.s0|471-477|effects|O
DDI-DrugBank.d168.s0|479-480|of|O
DDI-DrugBank.d168.s0|482-495|antihistamines|O
DDI-DrugBank.d168.s0|496-496|)|O
DDI-DrugBank.d168.s0|497-497|.|O
DDI-DrugBank.d17.s0|0-13|Anticoagulants|O
DDI-DrugBank.d17.s0|14-14|,|O
DDI-DrugBank.d17.s0|16-19|oral|O
DDI-DrugBank.d17.s1|0-0|(|O
DDI-DrugBank.d17.s1|1-7|Effects|O
DDI-DrugBank.d17.s1|9-11|may|O
DDI-DrugBank.d17.s1|13-14|be|O
DDI-DrugBank.d17.s1|16-24|decreased|O
DDI-DrugBank.d17.s1|26-29|when|O
DDI-DrugBank.d17.s1|31-34|used|O
DDI-DrugBank.d17.s1|36-47|concurrently|O
DDI-DrugBank.d17.s1|49-52|with|O
DDI-DrugBank.d17.s1|54-61|thiazide|O
DDI-DrugBank.d17.s1|63-71|diuretics|O
DDI-DrugBank.d17.s1|72-72|;|O
DDI-DrugBank.d17.s2|0-5|dosage|O
DDI-DrugBank.d17.s2|7-17|adjustments|O
DDI-DrugBank.d17.s2|19-21|may|O
DDI-DrugBank.d17.s2|23-24|be|O
DDI-DrugBank.d17.s2|26-34|necessary|O
DDI-DrugBank.d17.s2|35-35|.|O
DDI-DrugBank.d17.s2|36-36|)|O
DDI-DrugBank.d17.s3|0-7|Antigout|O
DDI-DrugBank.d17.s3|9-19|medications|O
DDI-DrugBank.d17.s4|0-0|(|O
DDI-DrugBank.d17.s4|1-8|Thiazide|O
DDI-DrugBank.d17.s4|10-18|diuretics|O
DDI-DrugBank.d17.s4|20-22|may|O
DDI-DrugBank.d17.s4|24-28|raise|O
DDI-DrugBank.d17.s4|30-32|the|O
DDI-DrugBank.d17.s4|34-38|level|O
DDI-DrugBank.d17.s4|40-41|of|O
DDI-DrugBank.d17.s4|43-47|blood|O
DDI-DrugBank.d17.s4|49-52|uric|O
DDI-DrugBank.d17.s4|54-57|acid|O
DDI-DrugBank.d17.s4|58-58|;|O
DDI-DrugBank.d17.s5|0-5|dosage|O
DDI-DrugBank.d17.s5|7-16|adjustment|O
DDI-DrugBank.d17.s5|18-19|of|O
DDI-DrugBank.d17.s5|21-28|antigout|O
DDI-DrugBank.d17.s5|30-40|medications|O
DDI-DrugBank.d17.s5|42-44|may|O
DDI-DrugBank.d17.s5|46-47|be|O
DDI-DrugBank.d17.s5|49-57|necessary|O
DDI-DrugBank.d17.s5|59-60|to|O
DDI-DrugBank.d17.s5|62-68|control|O
DDI-DrugBank.d17.s5|70-82|hyperuricemia|O
DDI-DrugBank.d17.s5|84-86|and|O
DDI-DrugBank.d17.s5|88-91|gout|O
DDI-DrugBank.d17.s5|92-92|.|O
DDI-DrugBank.d17.s5|93-93|)|O
DDI-DrugBank.d17.s6|0-15|Antihypertensive|O
DDI-DrugBank.d17.s6|17-27|medications|O
DDI-DrugBank.d17.s6|28-28|,|O
DDI-DrugBank.d17.s6|30-34|other|O
DDI-DrugBank.d17.s6|35-35|,|O
DDI-DrugBank.d17.s6|37-46|especially|O
DDI-DrugBank.d17.s6|48-56|diazoxide|O
DDI-DrugBank.d17.s6|57-57|,|O
DDI-DrugBank.d17.s6|59-60|or|O
DDI-DrugBank.d17.s6|62-74|preanesthetic|O
DDI-DrugBank.d17.s6|76-78|and|O
DDI-DrugBank.d17.s6|80-89|anesthetic|O
DDI-DrugBank.d17.s6|91-96|agents|O
DDI-DrugBank.d17.s6|98-101|used|O
DDI-DrugBank.d17.s6|103-104|in|O
DDI-DrugBank.d17.s6|106-112|surgery|O
DDI-DrugBank.d17.s6|114-115|or|O
DDI-DrugBank.d17.s6|117-131|skeletal-muscle|O
DDI-DrugBank.d17.s6|133-141|relaxants|O
DDI-DrugBank.d17.s6|142-142|,|O
DDI-DrugBank.d17.s6|144-158|nondepolarizing|O
DDI-DrugBank.d17.s6|159-159|,|O
DDI-DrugBank.d17.s6|161-164|used|O
DDI-DrugBank.d17.s6|166-167|in|O
DDI-DrugBank.d17.s6|169-175|surgery|O
DDI-DrugBank.d17.s7|0-0|(|O
DDI-DrugBank.d17.s7|1-7|Effects|O
DDI-DrugBank.d17.s7|9-11|may|O
DDI-DrugBank.d17.s7|13-14|be|O
DDI-DrugBank.d17.s7|16-26|potentiated|O
DDI-DrugBank.d17.s7|28-31|when|O
DDI-DrugBank.d17.s7|33-36|used|O
DDI-DrugBank.d17.s7|38-49|concurrently|O
DDI-DrugBank.d17.s7|51-54|with|O
DDI-DrugBank.d17.s7|56-63|thiazide|O
DDI-DrugBank.d17.s7|65-73|diuretics|O
DDI-DrugBank.d17.s7|74-74|;|O
DDI-DrugBank.d17.s8|0-5|dosage|O
DDI-DrugBank.d17.s8|7-17|adjustments|O
DDI-DrugBank.d17.s8|19-21|may|O
DDI-DrugBank.d17.s8|23-24|be|O
DDI-DrugBank.d17.s8|26-34|necessary|O
DDI-DrugBank.d17.s8|35-35|.|O
DDI-DrugBank.d17.s8|36-36|)|O
DDI-DrugBank.d17.s9|0-11|Amphotericin|O
DDI-DrugBank.d17.s9|13-13|B|O
DDI-DrugBank.d17.s9|15-16|or|O
DDI-DrugBank.d17.s9|18-32|Corticosteroids|O
DDI-DrugBank.d17.s9|34-35|or|O
DDI-DrugBank.d17.s9|37-49|Corticotropin|O
DDI-DrugBank.d17.s9|51-51|(|O
DDI-DrugBank.d17.s9|52-55|ACTH|O
DDI-DrugBank.d17.s9|56-56|)|O
DDI-DrugBank.d17.s10|0-0|(|O
DDI-DrugBank.d17.s10|1-10|Concurrent|O
DDI-DrugBank.d17.s10|12-14|use|O
DDI-DrugBank.d17.s10|16-19|with|O
DDI-DrugBank.d17.s10|21-28|thiazide|O
DDI-DrugBank.d17.s10|30-38|diuretics|O
DDI-DrugBank.d17.s10|40-42|may|O
DDI-DrugBank.d17.s10|44-52|intensify|O
DDI-DrugBank.d17.s10|54-64|electrolyte|O
DDI-DrugBank.d17.s10|66-74|imbalance|O
DDI-DrugBank.d17.s10|75-75|,|O
DDI-DrugBank.d17.s10|77-88|particularly|O
DDI-DrugBank.d17.s10|90-100|hypokalemia|O
DDI-DrugBank.d17.s10|101-101|.|O
DDI-DrugBank.d17.s10|102-102|)|O
DDI-DrugBank.d17.s11|0-6|Cardiac|O
DDI-DrugBank.d17.s11|8-17|glycosides|O
DDI-DrugBank.d17.s12|0-0|(|O
DDI-DrugBank.d17.s12|1-10|Concurrent|O
DDI-DrugBank.d17.s12|12-14|use|O
DDI-DrugBank.d17.s12|16-19|with|O
DDI-DrugBank.d17.s12|21-28|thiazide|O
DDI-DrugBank.d17.s12|30-38|diuretics|O
DDI-DrugBank.d17.s12|40-42|may|O
DDI-DrugBank.d17.s12|44-50|enhance|O
DDI-DrugBank.d17.s12|52-54|the|O
DDI-DrugBank.d17.s12|56-66|possibility|O
DDI-DrugBank.d17.s12|68-69|of|O
DDI-DrugBank.d17.s12|71-79|digitalis|O
DDI-DrugBank.d17.s12|81-88|toxicity|O
DDI-DrugBank.d17.s12|90-99|associated|O
DDI-DrugBank.d17.s12|101-104|with|O
DDI-DrugBank.d17.s12|106-116|hypokalemia|O
DDI-DrugBank.d17.s12|117-117|.|O
DDI-DrugBank.d17.s12|118-118|)|O
DDI-DrugBank.d17.s13|0-9|Colestipol|O
DDI-DrugBank.d17.s14|0-0|(|O
DDI-DrugBank.d17.s14|1-3|May|O
DDI-DrugBank.d17.s14|5-11|inhibit|O
DDI-DrugBank.d17.s14|13-28|gastrointestinal|O
DDI-DrugBank.d17.s14|30-39|absorption|O
DDI-DrugBank.d17.s14|41-42|of|O
DDI-DrugBank.d17.s14|44-46|the|O
DDI-DrugBank.d17.s14|48-55|thiazide|O
DDI-DrugBank.d17.s14|57-65|diuretics|O
DDI-DrugBank.d17.s14|66-66|;|O
DDI-DrugBank.d17.s15|0-13|administration|O
DDI-DrugBank.d17.s15|15-15|1|O
DDI-DrugBank.d17.s15|17-20|hour|O
DDI-DrugBank.d17.s15|22-27|before|O
DDI-DrugBank.d17.s15|29-30|or|O
DDI-DrugBank.d17.s15|32-32|4|O
DDI-DrugBank.d17.s15|34-38|hours|O
DDI-DrugBank.d17.s15|40-44|after|O
DDI-DrugBank.d17.s15|46-55|colestipol|O
DDI-DrugBank.d17.s15|57-58|is|O
DDI-DrugBank.d17.s15|60-70|recommended|O
DDI-DrugBank.d17.s15|71-71|.|O
DDI-DrugBank.d17.s15|72-72|)|O
DDI-DrugBank.d17.s16|0-12|Hypoglycemics|O
DDI-DrugBank.d17.s17|0-0|(|O
DDI-DrugBank.d17.s17|1-8|Thiazide|O
DDI-DrugBank.d17.s17|10-18|diuretics|O
DDI-DrugBank.d17.s17|20-22|may|O
DDI-DrugBank.d17.s17|24-28|raise|O
DDI-DrugBank.d17.s17|30-34|blood|O
DDI-DrugBank.d17.s17|36-42|glucose|O
DDI-DrugBank.d17.s17|44-49|levels|O
DDI-DrugBank.d17.s17|50-50|;|O
DDI-DrugBank.d17.s18|0-2|for|O
DDI-DrugBank.d17.s18|4-14|adult-onset|O
DDI-DrugBank.d17.s18|16-24|diabetics|O
DDI-DrugBank.d17.s18|25-25|,|O
DDI-DrugBank.d17.s18|27-32|dosage|O
DDI-DrugBank.d17.s18|34-43|adjustment|O
DDI-DrugBank.d17.s18|45-46|of|O
DDI-DrugBank.d17.s18|48-59|hypoglycemic|O
DDI-DrugBank.d17.s18|61-71|medications|O
DDI-DrugBank.d17.s18|73-75|may|O
DDI-DrugBank.d17.s18|77-78|be|O
DDI-DrugBank.d17.s18|80-88|necessary|O
DDI-DrugBank.d17.s18|90-95|during|O
DDI-DrugBank.d17.s18|97-99|and|O
DDI-DrugBank.d17.s18|101-105|after|O
DDI-DrugBank.d17.s18|107-114|thiazide|O
DDI-DrugBank.d17.s18|116-123|diuretic|O
DDI-DrugBank.d17.s18|125-131|therapy|O
DDI-DrugBank.d17.s18|132-132|;|O
DDI-DrugBank.d17.s19|0-6|insulin|O
DDI-DrugBank.d17.s19|8-19|requirements|O
DDI-DrugBank.d17.s19|21-23|may|O
DDI-DrugBank.d17.s19|25-26|be|O
DDI-DrugBank.d17.s19|28-36|increased|O
DDI-DrugBank.d17.s19|37-37|,|O
DDI-DrugBank.d17.s19|39-47|decreased|O
DDI-DrugBank.d17.s19|48-48|,|O
DDI-DrugBank.d17.s19|50-51|or|O
DDI-DrugBank.d17.s19|53-61|unchanged|O
DDI-DrugBank.d17.s19|62-62|.|O
DDI-DrugBank.d17.s19|63-63|)|O
DDI-DrugBank.d17.s20|0-6|Lithium|O
DDI-DrugBank.d17.s20|8-12|salts|O
DDI-DrugBank.d17.s21|0-0|(|O
DDI-DrugBank.d17.s21|1-10|Concurrent|O
DDI-DrugBank.d17.s21|12-14|use|O
DDI-DrugBank.d17.s21|16-19|with|O
DDI-DrugBank.d17.s21|21-28|thiazide|O
DDI-DrugBank.d17.s21|30-38|diuretics|O
DDI-DrugBank.d17.s21|40-41|is|O
DDI-DrugBank.d17.s21|43-45|not|O
DDI-DrugBank.d17.s21|47-57|recommended|O
DDI-DrugBank.d17.s21|58-58|,|O
DDI-DrugBank.d17.s21|60-61|as|O
DDI-DrugBank.d17.s21|63-66|they|O
DDI-DrugBank.d17.s21|68-70|may|O
DDI-DrugBank.d17.s21|72-78|provoke|O
DDI-DrugBank.d17.s21|80-86|lithium|O
DDI-DrugBank.d17.s21|88-95|toxicity|O
DDI-DrugBank.d17.s21|97-103|because|O
DDI-DrugBank.d17.s21|105-106|of|O
DDI-DrugBank.d17.s21|108-114|reduced|O
DDI-DrugBank.d17.s21|116-120|renal|O
DDI-DrugBank.d17.s21|122-130|clearance|O
DDI-DrugBank.d17.s21|131-131|.|O
DDI-DrugBank.d17.s21|132-132|)|O
DDI-DrugBank.d17.s22|0-10|Methenamine|O
DDI-DrugBank.d17.s23|0-0|(|O
DDI-DrugBank.d17.s23|1-13|Effectiveness|O
DDI-DrugBank.d17.s23|15-17|may|O
DDI-DrugBank.d17.s23|19-20|be|O
DDI-DrugBank.d17.s23|22-30|decreased|O
DDI-DrugBank.d17.s23|32-35|when|O
DDI-DrugBank.d17.s23|37-40|used|O
DDI-DrugBank.d17.s23|42-53|concurrently|O
DDI-DrugBank.d17.s23|55-58|with|O
DDI-DrugBank.d17.s23|60-67|thiazide|O
DDI-DrugBank.d17.s23|69-77|diuretics|O
DDI-DrugBank.d17.s23|79-85|because|O
DDI-DrugBank.d17.s23|87-88|of|O
DDI-DrugBank.d17.s23|90-103|alkalinization|O
DDI-DrugBank.d17.s23|105-106|of|O
DDI-DrugBank.d17.s23|108-110|the|O
DDI-DrugBank.d17.s23|112-116|urine|O
DDI-DrugBank.d17.s23|117-117|.|O
DDI-DrugBank.d17.s23|118-118|)|O
DDI-DrugBank.d17.s24|0-11|Nonsteroidal|O
DDI-DrugBank.d17.s24|13-29|anti-inflammatory|O
DDI-DrugBank.d17.s24|31-36|agents|O
DDI-DrugBank.d17.s25|0-0|(|O
DDI-DrugBank.d17.s25|1-2|In|O
DDI-DrugBank.d17.s25|4-7|some|O
DDI-DrugBank.d17.s25|9-16|patients|O
DDI-DrugBank.d17.s25|17-17|,|O
DDI-DrugBank.d17.s25|19-21|the|O
DDI-DrugBank.d17.s25|23-31|steroidal|O
DDI-DrugBank.d17.s25|33-49|anti-inflammatory|O
DDI-DrugBank.d17.s25|51-55|agent|O
DDI-DrugBank.d17.s25|57-59|can|O
DDI-DrugBank.d17.s25|61-66|reduce|O
DDI-DrugBank.d17.s25|68-70|the|O
DDI-DrugBank.d17.s25|72-79|diuretic|O
DDI-DrugBank.d17.s25|80-80|,|O
DDI-DrugBank.d17.s25|82-92|natriuretic|O
DDI-DrugBank.d17.s25|93-93|,|O
DDI-DrugBank.d17.s25|95-97|and|O
DDI-DrugBank.d17.s25|99-114|antihypertensive|O
DDI-DrugBank.d17.s25|116-122|effects|O
DDI-DrugBank.d17.s25|124-125|of|O
DDI-DrugBank.d17.s25|127-130|loop|O
DDI-DrugBank.d17.s25|131-131|,|O
DDI-DrugBank.d17.s25|133-141|potassium|O
DDI-DrugBank.d17.s25|143-149|sparing|O
DDI-DrugBank.d17.s25|150-150|,|O
DDI-DrugBank.d17.s25|152-154|and|O
DDI-DrugBank.d17.s25|156-163|thiazide|O
DDI-DrugBank.d17.s25|165-173|diuretics|O
DDI-DrugBank.d17.s25|174-174|.|O
DDI-DrugBank.d17.s26|0-8|Therefore|O
DDI-DrugBank.d17.s26|9-9|,|O
DDI-DrugBank.d17.s26|11-14|when|O
DDI-DrugBank.d17.s26|16-33|hydroflumethiazide|O
DDI-DrugBank.d17.s26|35-37|and|O
DDI-DrugBank.d17.s26|39-50|nonsteroidal|O
DDI-DrugBank.d17.s26|52-68|anti-inflammatory|O
DDI-DrugBank.d17.s26|70-75|agents|O
DDI-DrugBank.d17.s26|77-79|are|O
DDI-DrugBank.d17.s26|81-84|used|O
DDI-DrugBank.d17.s26|86-98|concomitantly|O
DDI-DrugBank.d17.s26|99-99|,|O
DDI-DrugBank.d17.s26|101-103|the|O
DDI-DrugBank.d17.s26|105-111|patient|O
DDI-DrugBank.d17.s26|113-118|should|O
DDI-DrugBank.d17.s26|120-121|be|O
DDI-DrugBank.d17.s26|123-130|observed|O
DDI-DrugBank.d17.s26|132-138|closely|O
DDI-DrugBank.d17.s26|140-141|to|O
DDI-DrugBank.d17.s26|143-151|determine|O
DDI-DrugBank.d17.s26|153-154|if|O
DDI-DrugBank.d17.s26|156-158|the|O
DDI-DrugBank.d17.s26|160-166|desired|O
DDI-DrugBank.d17.s26|168-173|effect|O
DDI-DrugBank.d17.s26|175-176|of|O
DDI-DrugBank.d17.s26|178-180|the|O
DDI-DrugBank.d17.s26|182-189|diuretic|O
DDI-DrugBank.d17.s26|191-192|is|O
DDI-DrugBank.d17.s26|194-201|obtained|O
DDI-DrugBank.d17.s26|202-202|.|O
DDI-DrugBank.d17.s26|203-203|)|O
DDI-DrugBank.d17.s27|0-13|Norepinephrine|O
DDI-DrugBank.d17.s28|0-0|(|O
DDI-DrugBank.d17.s28|1-9|Thiazides|O
DDI-DrugBank.d17.s28|11-13|may|O
DDI-DrugBank.d17.s28|15-22|decrease|O
DDI-DrugBank.d17.s28|24-31|arterial|O
DDI-DrugBank.d17.s28|33-46|responsiveness|O
DDI-DrugBank.d17.s28|48-49|to|O
DDI-DrugBank.d17.s28|51-64|norepinephrine|O
DDI-DrugBank.d17.s28|65-65|.|O
DDI-DrugBank.d17.s29|0-3|This|O
DDI-DrugBank.d17.s29|5-14|diminution|O
DDI-DrugBank.d17.s29|16-17|is|O
DDI-DrugBank.d17.s29|19-21|not|O
DDI-DrugBank.d17.s29|23-32|sufficient|O
DDI-DrugBank.d17.s29|34-35|to|O
DDI-DrugBank.d17.s29|37-44|preclude|O
DDI-DrugBank.d17.s29|46-58|effectiveness|O
DDI-DrugBank.d17.s29|60-61|of|O
DDI-DrugBank.d17.s29|63-65|the|O
DDI-DrugBank.d17.s29|67-73|pressor|O
DDI-DrugBank.d17.s29|75-79|agent|O
DDI-DrugBank.d17.s29|81-83|for|O
DDI-DrugBank.d17.s29|85-95|therapeutic|O
DDI-DrugBank.d17.s29|97-99|use|O
DDI-DrugBank.d17.s29|100-100|.|O
DDI-DrugBank.d17.s29|101-101|)|O
DDI-DrugBank.d17.s30|0-11|Tubocurarine|O
DDI-DrugBank.d17.s31|0-0|(|O
DDI-DrugBank.d17.s31|1-8|Thiazide|O
DDI-DrugBank.d17.s31|10-14|drugs|O
DDI-DrugBank.d17.s31|16-18|may|O
DDI-DrugBank.d17.s31|20-27|increase|O
DDI-DrugBank.d17.s31|29-31|the|O
DDI-DrugBank.d17.s31|33-46|responsiveness|O
DDI-DrugBank.d17.s31|48-49|to|O
DDI-DrugBank.d17.s31|51-62|tubocurarine|O
DDI-DrugBank.d17.s31|63-63|.|O
DDI-DrugBank.d17.s31|64-64|)|O
DDI-DrugBank.d17.s32|0-9|DIAGNOSTIC|O
DDI-DrugBank.d17.s32|11-22|INTERFERENCE|O
DDI-DrugBank.d17.s32|24-27|With|O
DDI-DrugBank.d17.s32|29-36|expected|O
DDI-DrugBank.d17.s32|38-48|physiologic|O
DDI-DrugBank.d17.s32|50-56|effects|O
DDI-DrugBank.d17.s32|57-57|:|O
DDI-DrugBank.d17.s32|59-63|Blood|O
DDI-DrugBank.d17.s32|65-67|and|O
DDI-DrugBank.d17.s32|69-73|urine|O
DDI-DrugBank.d17.s32|75-81|glucose|O
DDI-DrugBank.d17.s32|83-88|levels|O
DDI-DrugBank.d17.s32|90-90|(|O
DDI-DrugBank.d17.s32|91-97|usually|O
DDI-DrugBank.d17.s32|99-102|only|O
DDI-DrugBank.d17.s32|104-105|in|O
DDI-DrugBank.d17.s32|107-114|patients|O
DDI-DrugBank.d17.s32|116-119|with|O
DDI-DrugBank.d17.s32|121-121|a|O
DDI-DrugBank.d17.s32|123-136|predisposition|O
DDI-DrugBank.d17.s32|138-140|for|O
DDI-DrugBank.d17.s32|142-148|glucose|O
DDI-DrugBank.d17.s32|150-160|intolerance|O
DDI-DrugBank.d17.s32|161-161|)|O
DDI-DrugBank.d17.s32|163-165|and|O
DDI-DrugBank.d17.s32|167-171|Serum|O
DDI-DrugBank.d17.s32|173-181|bilirubin|O
DDI-DrugBank.d17.s32|183-188|levels|O
DDI-DrugBank.d17.s32|190-190|(|O
DDI-DrugBank.d17.s32|191-192|by|O
DDI-DrugBank.d17.s32|194-205|displacement|O
DDI-DrugBank.d17.s32|207-210|from|O
DDI-DrugBank.d17.s32|212-218|albumin|O
DDI-DrugBank.d17.s32|220-226|binding|O
DDI-DrugBank.d17.s32|227-227|)|O
DDI-DrugBank.d17.s32|229-231|and|O
DDI-DrugBank.d17.s32|233-237|Serum|O
DDI-DrugBank.d17.s32|239-245|calcium|O
DDI-DrugBank.d17.s32|247-252|levels|O
DDI-DrugBank.d17.s32|254-254|(|O
DDI-DrugBank.d17.s32|255-262|thiazide|O
DDI-DrugBank.d17.s32|264-272|diuretics|O
DDI-DrugBank.d17.s32|274-279|should|O
DDI-DrugBank.d17.s32|281-282|be|O
DDI-DrugBank.d17.s32|284-295|discontinued|O
DDI-DrugBank.d17.s32|297-302|before|O
DDI-DrugBank.d17.s32|304-323|parathyroid-function|O
DDI-DrugBank.d17.s32|325-329|tests|O
DDI-DrugBank.d17.s32|331-333|are|O
DDI-DrugBank.d17.s32|335-341|carried|O
DDI-DrugBank.d17.s32|343-345|out|O
DDI-DrugBank.d17.s32|346-346|)|O
DDI-DrugBank.d17.s32|348-350|and|O
DDI-DrugBank.d17.s32|352-356|Serum|O
DDI-DrugBank.d17.s32|358-361|uric|O
DDI-DrugBank.d17.s32|363-366|acid|O
DDI-DrugBank.d17.s32|368-373|levels|O
DDI-DrugBank.d17.s32|375-375|(|O
DDI-DrugBank.d17.s32|376-378|may|O
DDI-DrugBank.d17.s32|380-381|be|O
DDI-DrugBank.d17.s32|383-391|increased|O
DDI-DrugBank.d17.s32|392-392|)|O
DDI-DrugBank.d17.s32|394-398|Serum|O
DDI-DrugBank.d17.s32|400-408|magnesium|O
DDI-DrugBank.d17.s32|409-409|,|O
DDI-DrugBank.d17.s32|411-419|potassium|O
DDI-DrugBank.d17.s32|420-420|,|O
DDI-DrugBank.d17.s32|422-424|and|O
DDI-DrugBank.d17.s32|426-431|sodium|O
DDI-DrugBank.d17.s32|433-438|levels|O
DDI-DrugBank.d17.s32|440-440|(|O
DDI-DrugBank.d17.s32|441-443|may|O
DDI-DrugBank.d17.s32|445-446|be|O
DDI-DrugBank.d17.s32|448-456|decreased|O
DDI-DrugBank.d17.s32|457-457|;|O
DDI-DrugBank.d17.s33|0-4|serum|O
DDI-DrugBank.d17.s33|6-14|magnesium|O
DDI-DrugBank.d17.s33|16-21|levels|O
DDI-DrugBank.d17.s33|23-25|may|O
DDI-DrugBank.d17.s33|27-34|increase|O
DDI-DrugBank.d17.s33|36-37|in|O
DDI-DrugBank.d17.s33|39-44|uremic|O
DDI-DrugBank.d17.s33|46-53|patients|O
DDI-DrugBank.d17.s33|54-54|)|O
DDI-DrugBank.d17.s33|56-60|Serum|O
DDI-DrugBank.d17.s33|62-74|protein-bound|O
DDI-DrugBank.d17.s33|76-81|iodine|O
DDI-DrugBank.d17.s33|83-83|(|O
DDI-DrugBank.d17.s33|84-86|PBI|O
DDI-DrugBank.d17.s33|87-87|)|O
DDI-DrugBank.d17.s33|89-94|levels|O
DDI-DrugBank.d17.s33|96-96|(|O
DDI-DrugBank.d17.s33|97-99|may|O
DDI-DrugBank.d17.s33|101-102|be|O
DDI-DrugBank.d17.s33|104-112|decreased|O
DDI-DrugBank.d17.s33|113-113|)|O
DDI-DrugBank.d17.s33|115-123|Thiazides|O
DDI-DrugBank.d17.s33|125-130|should|O
DDI-DrugBank.d17.s33|132-133|be|O
DDI-DrugBank.d17.s33|135-146|discontinued|O
DDI-DrugBank.d17.s33|148-153|before|O
DDI-DrugBank.d17.s33|155-162|carrying|O
DDI-DrugBank.d17.s33|164-166|out|O
DDI-DrugBank.d17.s33|168-172|tests|O
DDI-DrugBank.d17.s33|174-176|for|O
DDI-DrugBank.d17.s33|178-188|parathyroid|O
DDI-DrugBank.d17.s33|190-197|function|O
DDI-DrugBank.d17.s33|198-198|.|O
DDI-DrugBank.d109.s0|0-24|Ketoconazole/Itraconazole|O
DDI-DrugBank.d109.s0|25-25|,|O
DDI-DrugBank.d109.s0|27-36|Macrolides|O
DDI-DrugBank.d109.s0|37-37|,|O
DDI-DrugBank.d109.s0|39-47|Including|O
DDI-DrugBank.d109.s0|49-60|Erythromycin|O
DDI-DrugBank.d671.s0|0-2|The|O
DDI-DrugBank.d671.s0|4-14|interaction|O
DDI-DrugBank.d671.s0|16-17|of|O
DDI-DrugBank.d671.s0|19-24|CYLERT|O
DDI-DrugBank.d671.s0|26-26|(|O
DDI-DrugBank.d671.s0|27-34|pemoline|O
DDI-DrugBank.d671.s0|35-35|)|O
DDI-DrugBank.d671.s0|37-40|with|O
DDI-DrugBank.d671.s0|42-46|other|O
DDI-DrugBank.d671.s0|48-52|drugs|O
DDI-DrugBank.d671.s0|54-56|has|O
DDI-DrugBank.d671.s0|58-60|not|O
DDI-DrugBank.d671.s0|62-65|been|O
DDI-DrugBank.d671.s0|67-73|studied|O
DDI-DrugBank.d671.s0|75-76|in|O
DDI-DrugBank.d671.s0|78-83|humans|O
DDI-DrugBank.d671.s0|84-84|.|O
DDI-DrugBank.d671.s1|0-7|Patients|O
DDI-DrugBank.d671.s1|9-11|who|O
DDI-DrugBank.d671.s1|13-15|are|O
DDI-DrugBank.d671.s1|17-25|receiving|O
DDI-DrugBank.d671.s1|27-32|CYLERT|O
DDI-DrugBank.d671.s1|34-45|concurrently|O
DDI-DrugBank.d671.s1|47-50|with|O
DDI-DrugBank.d671.s1|52-56|other|O
DDI-DrugBank.d671.s1|58-62|drugs|O
DDI-DrugBank.d671.s1|63-63|,|O
DDI-DrugBank.d671.s1|65-74|especially|O
DDI-DrugBank.d671.s1|76-80|drugs|O
DDI-DrugBank.d671.s1|82-85|with|O
DDI-DrugBank.d671.s1|87-89|CNS|O
DDI-DrugBank.d671.s1|91-98|activity|O
DDI-DrugBank.d671.s1|99-99|,|O
DDI-DrugBank.d671.s1|101-106|should|O
DDI-DrugBank.d671.s1|108-109|be|O
DDI-DrugBank.d671.s1|111-119|monitored|O
DDI-DrugBank.d671.s1|121-129|carefully|O
DDI-DrugBank.d671.s1|130-130|.|O
DDI-DrugBank.d671.s2|0-8|Decreased|O
DDI-DrugBank.d671.s2|10-16|seizure|O
DDI-DrugBank.d671.s2|18-26|threshold|O
DDI-DrugBank.d671.s2|28-30|has|O
DDI-DrugBank.d671.s2|32-35|been|O
DDI-DrugBank.d671.s2|37-44|reported|O
DDI-DrugBank.d671.s2|46-47|in|O
DDI-DrugBank.d671.s2|49-56|patients|O
DDI-DrugBank.d671.s2|58-66|receiving|O
DDI-DrugBank.d671.s2|68-73|CYLERT|O
DDI-DrugBank.d671.s2|75-87|concomitantly|O
DDI-DrugBank.d671.s2|89-92|with|O
DDI-DrugBank.d671.s2|94-106|antiepileptic|O
DDI-DrugBank.d671.s2|108-118|medications|O
DDI-DrugBank.d671.s2|119-119|.|O
DDI-MedLine.d164.s0|0-8|Lapatinib|O
DDI-MedLine.d164.s0|10-17|enhances|O
DDI-MedLine.d164.s0|19-36|herceptin-mediated|O
DDI-MedLine.d164.s0|38-55|antibody-dependent|O
DDI-MedLine.d164.s0|57-64|cellular|O
DDI-MedLine.d164.s0|66-77|cytotoxicity|O
DDI-MedLine.d164.s0|79-80|by|O
DDI-MedLine.d164.s0|82-94|up-regulation|O
DDI-MedLine.d164.s0|96-97|of|O
DDI-MedLine.d164.s0|99-102|cell|O
DDI-MedLine.d164.s0|104-110|surface|O
DDI-MedLine.d164.s0|112-115|HER2|O
DDI-MedLine.d164.s0|117-126|expression|O
DDI-MedLine.d164.s0|127-127|.|O
DDI-MedLine.d164.s1|0-7|Although|O
DDI-MedLine.d164.s1|9-10|it|O
DDI-MedLine.d164.s1|12-14|was|O
DDI-MedLine.d164.s1|16-25|previously|O
DDI-MedLine.d164.s1|27-34|reported|O
DDI-MedLine.d164.s1|36-39|that|O
DDI-MedLine.d164.s1|41-49|lapatinib|O
DDI-MedLine.d164.s1|51-58|combined|O
DDI-MedLine.d164.s1|60-63|with|O
DDI-MedLine.d164.s1|65-73|Herceptin|O
DDI-MedLine.d164.s1|75-82|improved|O
DDI-MedLine.d164.s1|84-86|the|O
DDI-MedLine.d164.s1|88-103|progression-free|O
DDI-MedLine.d164.s1|105-112|survival|O
DDI-MedLine.d164.s1|114-117|rate|O
DDI-MedLine.d164.s1|119-126|compared|O
DDI-MedLine.d164.s1|128-131|with|O
DDI-MedLine.d164.s1|133-141|lapatinib|O
DDI-MedLine.d164.s1|143-147|alone|O
DDI-MedLine.d164.s1|149-151|for|O
DDI-MedLine.d164.s1|153-160|patients|O
DDI-MedLine.d164.s1|162-165|with|O
DDI-MedLine.d164.s1|167-186|Herceptin-refractory|O
DDI-MedLine.d164.s1|188-200|HER2-positive|O
DDI-MedLine.d164.s1|202-211|metastatic|O
DDI-MedLine.d164.s1|213-218|breast|O
DDI-MedLine.d164.s1|220-225|cancer|O
DDI-MedLine.d164.s1|226-226|,|O
DDI-MedLine.d164.s1|228-230|the|O
DDI-MedLine.d164.s1|232-240|mechanism|O
DDI-MedLine.d164.s1|242-243|is|O
DDI-MedLine.d164.s1|245-253|purported|O
DDI-MedLine.d164.s1|255-256|to|O
DDI-MedLine.d164.s1|258-259|be|O
DDI-MedLine.d164.s1|261-262|an|O
DDI-MedLine.d164.s1|264-280|antiproliferative|O
DDI-MedLine.d164.s1|282-287|effect|O
DDI-MedLine.d164.s1|289-296|relating|O
DDI-MedLine.d164.s1|298-299|to|O
DDI-MedLine.d164.s1|301-303|the|O
DDI-MedLine.d164.s1|305-313|synergism|O
DDI-MedLine.d164.s1|315-316|of|O
DDI-MedLine.d164.s1|318-322|these|O
DDI-MedLine.d164.s1|324-326|two|O
DDI-MedLine.d164.s1|328-333|agents|O
DDI-MedLine.d164.s1|334-334|.|O
DDI-MedLine.d164.s2|0-1|We|O
DDI-MedLine.d164.s2|3-11|evaluated|O
DDI-MedLine.d164.s2|13-15|how|O
DDI-MedLine.d164.s2|17-25|lapatinib|O
DDI-MedLine.d164.s2|27-35|interacts|O
DDI-MedLine.d164.s2|37-40|with|O
DDI-MedLine.d164.s2|42-50|Herceptin|O
DDI-MedLine.d164.s2|52-53|in|O
DDI-MedLine.d164.s2|55-67|HER2-positive|O
DDI-MedLine.d164.s2|69-74|breast|O
DDI-MedLine.d164.s2|76-81|cancer|O
DDI-MedLine.d164.s2|82-82|,|O
DDI-MedLine.d164.s2|84-87|with|O
DDI-MedLine.d164.s2|89-89|a|O
DDI-MedLine.d164.s2|91-100|particular|O
DDI-MedLine.d164.s2|102-106|focus|O
DDI-MedLine.d164.s2|108-109|on|O
DDI-MedLine.d164.s2|111-128|Herceptin-mediated|O
DDI-MedLine.d164.s2|130-147|antibody-dependent|O
DDI-MedLine.d164.s2|149-156|cellular|O
DDI-MedLine.d164.s2|158-169|cytotoxicity|O
DDI-MedLine.d164.s2|171-171|(|O
DDI-MedLine.d164.s2|172-175|ADCC|O
DDI-MedLine.d164.s2|176-176|)|O
DDI-MedLine.d164.s2|177-177|.|O
DDI-MedLine.d164.s3|0-1|In|O
DDI-MedLine.d164.s3|3-4|an|O
DDI-MedLine.d164.s3|6-7|in|O
DDI-MedLine.d164.s3|9-13|vitro|O
DDI-MedLine.d164.s3|15-19|assay|O
DDI-MedLine.d164.s3|20-20|,|O
DDI-MedLine.d164.s3|22-30|lapatinib|O
DDI-MedLine.d164.s3|32-38|induced|O
DDI-MedLine.d164.s3|40-43|HER2|O
DDI-MedLine.d164.s3|45-54|expression|O
DDI-MedLine.d164.s3|56-57|at|O
DDI-MedLine.d164.s3|59-61|the|O
DDI-MedLine.d164.s3|63-66|cell|O
DDI-MedLine.d164.s3|68-74|surface|O
DDI-MedLine.d164.s3|76-77|of|O
DDI-MedLine.d164.s3|79-91|HER2-positive|O
DDI-MedLine.d164.s3|93-98|breast|O
DDI-MedLine.d164.s3|100-105|cancer|O
DDI-MedLine.d164.s3|107-110|cell|O
DDI-MedLine.d164.s3|112-116|lines|O
DDI-MedLine.d164.s3|117-117|,|O
DDI-MedLine.d164.s3|119-125|leading|O
DDI-MedLine.d164.s3|127-128|to|O
DDI-MedLine.d164.s3|130-132|the|O
DDI-MedLine.d164.s3|134-144|enhancement|O
DDI-MedLine.d164.s3|146-147|of|O
DDI-MedLine.d164.s3|149-166|Herceptin-mediated|O
DDI-MedLine.d164.s3|168-171|ADCC|O
DDI-MedLine.d164.s3|172-172|.|O
DDI-MedLine.d164.s4|0-10|Furthermore|O
DDI-MedLine.d164.s4|11-11|,|O
DDI-MedLine.d164.s4|13-14|we|O
DDI-MedLine.d164.s4|16-22|present|O
DDI-MedLine.d164.s4|24-24|a|O
DDI-MedLine.d164.s4|26-29|case|O
DDI-MedLine.d164.s4|31-36|report|O
DDI-MedLine.d164.s4|38-39|in|O
DDI-MedLine.d164.s4|41-45|which|O
DDI-MedLine.d164.s4|47-47|a|O
DDI-MedLine.d164.s4|49-54|second|O
DDI-MedLine.d164.s4|56-64|Herceptin|O
DDI-MedLine.d164.s4|66-74|treatment|O
DDI-MedLine.d164.s4|76-84|following|O
DDI-MedLine.d164.s4|86-94|lapatinib|O
DDI-MedLine.d164.s4|96-103|resulted|O
DDI-MedLine.d164.s4|105-106|in|O
DDI-MedLine.d164.s4|108-110|the|O
DDI-MedLine.d164.s4|112-117|marked|O
DDI-MedLine.d164.s4|119-127|shrinkage|O
DDI-MedLine.d164.s4|129-130|of|O
DDI-MedLine.d164.s4|132-139|multiple|O
DDI-MedLine.d164.s4|141-150|metastatic|O
DDI-MedLine.d164.s4|152-157|tumors|O
DDI-MedLine.d164.s4|159-160|in|O
DDI-MedLine.d164.s4|162-174|HER2-positive|O
DDI-MedLine.d164.s4|176-181|breast|O
DDI-MedLine.d164.s4|183-188|cancer|O
DDI-MedLine.d164.s4|189-189|.|O
DDI-MedLine.d164.s5|0-8|Lapatinib|O
DDI-MedLine.d164.s5|10-12|may|O
DDI-MedLine.d164.s5|14-17|have|O
DDI-MedLine.d164.s5|19-21|the|O
DDI-MedLine.d164.s5|23-31|potential|O
DDI-MedLine.d164.s5|33-34|to|O
DDI-MedLine.d164.s5|36-42|convert|O
DDI-MedLine.d164.s5|44-63|Herceptin-refractory|O
DDI-MedLine.d164.s5|65-66|to|O
DDI-MedLine.d164.s5|68-86|Herceptin-sensitive|O
DDI-MedLine.d164.s5|88-93|tumors|O
DDI-MedLine.d164.s5|95-96|in|O
DDI-MedLine.d164.s5|98-110|HER2-positive|O
DDI-MedLine.d164.s5|112-117|breast|O
DDI-MedLine.d164.s5|119-124|cancer|O
DDI-MedLine.d164.s5|126-127|by|O
DDI-MedLine.d164.s5|129-141|up-regulation|O
DDI-MedLine.d164.s5|143-144|of|O
DDI-MedLine.d164.s5|146-148|the|O
DDI-MedLine.d164.s5|150-153|cell|O
DDI-MedLine.d164.s5|155-161|surface|O
DDI-MedLine.d164.s5|163-172|expression|O
DDI-MedLine.d164.s5|174-175|of|O
DDI-MedLine.d164.s5|177-180|HER2|O
DDI-MedLine.d164.s5|181-181|.|O
DDI-DrugBank.d746.s0|0-6|ARAMINE|O
DDI-DrugBank.d746.s0|8-13|should|O
DDI-DrugBank.d746.s0|15-16|be|O
DDI-DrugBank.d746.s0|18-21|used|O
DDI-DrugBank.d746.s0|23-26|with|O
DDI-DrugBank.d746.s0|28-34|caution|O
DDI-DrugBank.d746.s0|36-37|in|O
DDI-DrugBank.d746.s0|39-49|digitalized|O
DDI-DrugBank.d746.s0|51-58|patients|O
DDI-DrugBank.d746.s0|59-59|,|O
DDI-DrugBank.d746.s0|61-65|since|O
DDI-DrugBank.d746.s0|67-69|the|O
DDI-DrugBank.d746.s0|71-81|combination|O
DDI-DrugBank.d746.s0|83-84|of|O
DDI-DrugBank.d746.s0|86-94|digitalis|O
DDI-DrugBank.d746.s0|96-98|and|O
DDI-DrugBank.d746.s0|100-114|sympathomimetic|O
DDI-DrugBank.d746.s0|116-121|amines|O
DDI-DrugBank.d746.s0|123-125|may|O
DDI-DrugBank.d746.s0|127-131|cause|O
DDI-DrugBank.d746.s0|133-139|ectopic|O
DDI-DrugBank.d746.s0|141-151|arrhythmias|O
DDI-DrugBank.d746.s0|152-152|.|O
DDI-DrugBank.d746.s1|0-8|Monoamine|O
DDI-DrugBank.d746.s1|10-16|oxidase|O
DDI-DrugBank.d746.s1|18-27|inhibitors|O
DDI-DrugBank.d746.s1|29-30|or|O
DDI-DrugBank.d746.s1|32-40|tricyclic|O
DDI-DrugBank.d746.s1|42-56|antidepressants|O
DDI-DrugBank.d746.s1|58-60|may|O
DDI-DrugBank.d746.s1|62-71|potentiate|O
DDI-DrugBank.d746.s1|73-75|the|O
DDI-DrugBank.d746.s1|77-82|action|O
DDI-DrugBank.d746.s1|84-85|of|O
DDI-DrugBank.d746.s1|87-101|sympathomimetic|O
DDI-DrugBank.d746.s1|103-108|amines|O
DDI-DrugBank.d746.s1|109-109|.|O
DDI-DrugBank.d746.s2|0-8|Therefore|O
DDI-DrugBank.d746.s2|9-9|,|O
DDI-DrugBank.d746.s2|11-14|when|O
DDI-DrugBank.d746.s2|16-25|initiating|O
DDI-DrugBank.d746.s2|27-33|pressor|O
DDI-DrugBank.d746.s2|35-41|therapy|O
DDI-DrugBank.d746.s2|43-44|in|O
DDI-DrugBank.d746.s2|46-53|patients|O
DDI-DrugBank.d746.s2|55-63|receiving|O
DDI-DrugBank.d746.s2|65-69|these|O
DDI-DrugBank.d746.s2|71-75|drugs|O
DDI-DrugBank.d746.s2|76-76|,|O
DDI-DrugBank.d746.s2|78-80|the|O
DDI-DrugBank.d746.s2|82-88|initial|O
DDI-DrugBank.d746.s2|90-93|dose|O
DDI-DrugBank.d746.s2|95-100|should|O
DDI-DrugBank.d746.s2|102-103|be|O
DDI-DrugBank.d746.s2|105-109|small|O
DDI-DrugBank.d746.s2|111-113|and|O
DDI-DrugBank.d746.s2|115-119|given|O
DDI-DrugBank.d746.s2|121-124|with|O
DDI-DrugBank.d746.s2|126-132|caution|O
DDI-DrugBank.d746.s2|133-133|.|O
DDI-MedLine.d44.s0|0-6|Effects|O
DDI-MedLine.d44.s0|8-9|of|O
DDI-MedLine.d44.s0|11-20|etofibrate|O
DDI-MedLine.d44.s0|22-25|upon|O
DDI-MedLine.d44.s0|27-29|the|O
DDI-MedLine.d44.s0|31-40|metabolism|O
DDI-MedLine.d44.s0|42-43|of|O
DDI-MedLine.d44.s0|45-60|chylomicron-like|O
DDI-MedLine.d44.s0|62-70|emulsions|O
DDI-MedLine.d44.s0|72-73|in|O
DDI-MedLine.d44.s0|75-82|patients|O
DDI-MedLine.d44.s0|84-87|with|O
DDI-MedLine.d44.s0|89-96|coronary|O
DDI-MedLine.d44.s0|98-103|artery|O
DDI-MedLine.d44.s0|105-111|disease|O
DDI-MedLine.d44.s0|112-112|.|O
DDI-MedLine.d44.s1|0-3|Slow|O
DDI-MedLine.d44.s1|5-15|chylomicron|O
DDI-MedLine.d44.s1|17-29|intravascular|O
DDI-MedLine.d44.s1|31-40|catabolism|O
DDI-MedLine.d44.s1|42-44|has|O
DDI-MedLine.d44.s1|46-49|been|O
DDI-MedLine.d44.s1|51-60|associated|O
DDI-MedLine.d44.s1|62-65|with|O
DDI-MedLine.d44.s1|67-74|coronary|O
DDI-MedLine.d44.s1|76-81|artery|O
DDI-MedLine.d44.s1|83-89|disease|O
DDI-MedLine.d44.s1|91-93|and|O
DDI-MedLine.d44.s1|95-103|screening|O
DDI-MedLine.d44.s1|105-107|for|O
DDI-MedLine.d44.s1|109-113|drugs|O
DDI-MedLine.d44.s1|115-118|that|O
DDI-MedLine.d44.s1|120-122|can|O
DDI-MedLine.d44.s1|124-131|speed-up|O
DDI-MedLine.d44.s1|133-136|this|O
DDI-MedLine.d44.s1|138-144|process|O
DDI-MedLine.d44.s1|146-148|can|O
DDI-MedLine.d44.s1|150-151|be|O
DDI-MedLine.d44.s1|153-161|important|O
DDI-MedLine.d44.s1|162-162|.|O
DDI-MedLine.d44.s2|0-1|In|O
DDI-MedLine.d44.s2|3-6|this|O
DDI-MedLine.d44.s2|8-12|study|O
DDI-MedLine.d44.s2|13-13|,|O
DDI-MedLine.d44.s2|15-17|the|O
DDI-MedLine.d44.s2|19-25|effects|O
DDI-MedLine.d44.s2|27-28|of|O
DDI-MedLine.d44.s2|30-39|etofibrate|O
DDI-MedLine.d44.s2|41-44|upon|O
DDI-MedLine.d44.s2|46-56|chylomicron|O
DDI-MedLine.d44.s2|58-67|metabolism|O
DDI-MedLine.d44.s2|69-71|was|O
DDI-MedLine.d44.s2|73-78|tested|O
DDI-MedLine.d44.s2|80-81|by|O
DDI-MedLine.d44.s2|83-95|determination|O
DDI-MedLine.d44.s2|97-98|of|O
DDI-MedLine.d44.s2|100-102|the|O
DDI-MedLine.d44.s2|104-109|plasma|O
DDI-MedLine.d44.s2|111-118|kinetics|O
DDI-MedLine.d44.s2|120-121|of|O
DDI-MedLine.d44.s2|123-123|a|O
DDI-MedLine.d44.s2|125-140|chylomicron-like|O
DDI-MedLine.d44.s2|142-149|emulsion|O
DDI-MedLine.d44.s2|151-155|model|O
DDI-MedLine.d44.s2|157-158|in|O
DDI-MedLine.d44.s2|160-161|12|O
DDI-MedLine.d44.s2|163-170|patients|O
DDI-MedLine.d44.s2|172-175|with|O
DDI-MedLine.d44.s2|177-184|coronary|O
DDI-MedLine.d44.s2|186-191|artery|O
DDI-MedLine.d44.s2|193-199|disease|O
DDI-MedLine.d44.s2|200-200|,|O
DDI-MedLine.d44.s2|202-205|aged|O
DDI-MedLine.d44.s2|207-213|59+/-11|O
DDI-MedLine.d44.s2|215-219|years|O
DDI-MedLine.d44.s2|220-220|,|O
DDI-MedLine.d44.s2|222-222|(|O
DDI-MedLine.d44.s2|223-227|total|O
DDI-MedLine.d44.s2|229-239|cholesterol|O
DDI-MedLine.d44.s2|240-240|:|O
DDI-MedLine.d44.s2|242-249|240+/-41|O
DDI-MedLine.d44.s2|251-255|mg/dl|O
DDI-MedLine.d44.s2|256-256|;|O
DDI-MedLine.d44.s2|258-270|triglycerides|O
DDI-MedLine.d44.s2|271-271|:|O
DDI-MedLine.d44.s2|273-280|188+/-42|O
DDI-MedLine.d44.s2|282-286|mg/dl|O
DDI-MedLine.d44.s2|287-287|)|O
DDI-MedLine.d44.s2|289-297|submitted|O
DDI-MedLine.d44.s2|299-300|to|O
DDI-MedLine.d44.s2|302-302|a|O
DDI-MedLine.d44.s2|304-313|randomized|O
DDI-MedLine.d44.s2|314-314|,|O
DDI-MedLine.d44.s2|316-324|crossover|O
DDI-MedLine.d44.s2|325-325|,|O
DDI-MedLine.d44.s2|327-338|double-blind|O
DDI-MedLine.d44.s2|339-339|,|O
DDI-MedLine.d44.s2|341-358|placebo-controlled|O
DDI-MedLine.d44.s2|360-364|study|O
DDI-MedLine.d44.s2|366-369|with|O
DDI-MedLine.d44.s2|371-384|administration|O
DDI-MedLine.d44.s2|386-387|of|O
DDI-MedLine.d44.s2|389-389|1|O
DDI-MedLine.d44.s2|391-391|g|O
DDI-MedLine.d44.s2|393-395|per|O
DDI-MedLine.d44.s2|397-399|day|O
DDI-MedLine.d44.s2|401-410|etofibrate|O
DDI-MedLine.d44.s2|412-413|or|O
DDI-MedLine.d44.s2|415-421|placebo|O
DDI-MedLine.d44.s2|423-425|for|O
DDI-MedLine.d44.s2|427-433|1-month|O
DDI-MedLine.d44.s2|434-434|.|O
DDI-MedLine.d44.s3|0-0|A|O
DDI-MedLine.d44.s3|2-8|1-month|O
DDI-MedLine.d44.s3|10-16|washout|O
DDI-MedLine.d44.s3|18-23|period|O
DDI-MedLine.d44.s3|25-27|was|O
DDI-MedLine.d44.s3|29-36|inserted|O
DDI-MedLine.d44.s3|38-44|between|O
DDI-MedLine.d44.s3|46-48|the|O
DDI-MedLine.d44.s3|50-58|treatment|O
DDI-MedLine.d44.s3|60-66|periods|O
DDI-MedLine.d44.s3|67-67|.|O
DDI-MedLine.d44.s4|0-7|Patients|O
DDI-MedLine.d44.s4|9-12|were|O
DDI-MedLine.d44.s4|14-26|intravenously|O
DDI-MedLine.d44.s4|28-35|injected|O
DDI-MedLine.d44.s4|37-37|a|O
DDI-MedLine.d44.s4|39-54|chylomicron-like|O
DDI-MedLine.d44.s4|56-63|emulsion|O
DDI-MedLine.d44.s4|65-70|doubly|O
DDI-MedLine.d44.s4|72-78|labeled|O
DDI-MedLine.d44.s4|80-83|with|O
DDI-MedLine.d44.s4|85-99|14C-cholesteryl|O
DDI-MedLine.d44.s4|101-106|oleate|O
DDI-MedLine.d44.s4|108-110|and|O
DDI-MedLine.d44.s4|112-122|3H-triolein|O
DDI-MedLine.d44.s4|124-125|at|O
DDI-MedLine.d44.s4|127-134|baseline|O
DDI-MedLine.d44.s4|136-138|and|O
DDI-MedLine.d44.s4|140-144|after|O
DDI-MedLine.d44.s4|146-155|treatments|O
DDI-MedLine.d44.s4|156-156|.|O
DDI-MedLine.d44.s5|0-4|After|O
DDI-MedLine.d44.s5|6-15|etofibrate|O
DDI-MedLine.d44.s5|17-25|treatment|O
DDI-MedLine.d44.s5|26-26|,|O
DDI-MedLine.d44.s5|28-32|there|O
DDI-MedLine.d44.s5|34-36|was|O
DDI-MedLine.d44.s5|38-45|decrease|O
DDI-MedLine.d44.s5|47-48|of|O
DDI-MedLine.d44.s5|50-54|total|O
DDI-MedLine.d44.s5|56-66|cholesterol|O
DDI-MedLine.d44.s5|68-70|and|O
DDI-MedLine.d44.s5|72-83|triglyceride|O
DDI-MedLine.d44.s5|85-90|plasma|O
DDI-MedLine.d44.s5|92-97|levels|O
DDI-MedLine.d44.s5|99-101|and|O
DDI-MedLine.d44.s5|103-103|a|O
DDI-MedLine.d44.s5|105-109|trend|O
DDI-MedLine.d44.s5|111-112|to|O
DDI-MedLine.d44.s5|114-121|increase|O
DDI-MedLine.d44.s5|123-134|high-density|O
DDI-MedLine.d44.s5|136-146|lipoprotein|O
DDI-MedLine.d44.s5|148-158|cholesterol|O
DDI-MedLine.d44.s5|160-165|plasma|O
DDI-MedLine.d44.s5|167-172|levels|O
DDI-MedLine.d44.s5|173-173|.|O
DDI-MedLine.d44.s6|0-9|Etofibrate|O
DDI-MedLine.d44.s6|11-18|elicited|O
DDI-MedLine.d44.s6|20-21|62|O
DDI-MedLine.d44.s6|22-22|%|O
DDI-MedLine.d44.s6|24-34|enhancement|O
DDI-MedLine.d44.s6|36-37|of|O
DDI-MedLine.d44.s6|39-50|post-heparin|O
DDI-MedLine.d44.s6|52-60|lipolytic|O
DDI-MedLine.d44.s6|62-69|activity|O
DDI-MedLine.d44.s6|71-73|and|O
DDI-MedLine.d44.s6|75-77|100|O
DDI-MedLine.d44.s6|78-78|%|O
DDI-MedLine.d44.s6|80-87|increase|O
DDI-MedLine.d44.s6|89-90|of|O
DDI-MedLine.d44.s6|92-106|3H-triglyceride|O
DDI-MedLine.d44.s6|108-117|fractional|O
DDI-MedLine.d44.s6|119-127|clearance|O
DDI-MedLine.d44.s6|129-132|rate|O
DDI-MedLine.d44.s6|134-141|compared|O
DDI-MedLine.d44.s6|143-146|with|O
DDI-MedLine.d44.s6|148-154|placebo|O
DDI-MedLine.d44.s6|156-164|treatment|O
DDI-MedLine.d44.s6|165-165|.|O
DDI-MedLine.d44.s7|0-14|14C-cholesterol|O
DDI-MedLine.d44.s7|16-20|ester|O
DDI-MedLine.d44.s7|22-31|fractional|O
DDI-MedLine.d44.s7|33-41|clearance|O
DDI-MedLine.d44.s7|43-46|rate|O
DDI-MedLine.d44.s7|48-50|was|O
DDI-MedLine.d44.s7|52-54|260|O
DDI-MedLine.d44.s7|55-55|%|O
DDI-MedLine.d44.s7|57-63|greater|O
DDI-MedLine.d44.s7|65-69|after|O
DDI-MedLine.d44.s7|71-80|etofibrate|O
DDI-MedLine.d44.s7|82-85|than|O
DDI-MedLine.d44.s7|87-91|after|O
DDI-MedLine.d44.s7|93-99|placebo|O
DDI-MedLine.d44.s7|100-100|.|O
DDI-MedLine.d44.s8|0-8|Therefore|O
DDI-MedLine.d44.s8|9-9|,|O
DDI-MedLine.d44.s8|11-11|a|O
DDI-MedLine.d44.s8|13-18|potent|O
DDI-MedLine.d44.s8|20-25|effect|O
DDI-MedLine.d44.s8|27-28|of|O
DDI-MedLine.d44.s8|30-39|etofibrate|O
DDI-MedLine.d44.s8|41-42|on|O
DDI-MedLine.d44.s8|44-47|both|O
DDI-MedLine.d44.s8|49-59|chylomicron|O
DDI-MedLine.d44.s8|61-69|lipolysis|O
DDI-MedLine.d44.s8|71-73|and|O
DDI-MedLine.d44.s8|75-81|remnant|O
DDI-MedLine.d44.s8|83-89|removal|O
DDI-MedLine.d44.s8|91-93|was|O
DDI-MedLine.d44.s8|95-102|achieved|O
DDI-MedLine.d44.s8|103-103|,|O
DDI-MedLine.d44.s8|105-114|indicating|O
DDI-MedLine.d44.s8|116-119|that|O
DDI-MedLine.d44.s8|121-124|this|O
DDI-MedLine.d44.s8|126-129|drug|O
DDI-MedLine.d44.s8|131-133|can|O
DDI-MedLine.d44.s8|135-136|be|O
DDI-MedLine.d44.s8|138-141|used|O
DDI-MedLine.d44.s8|143-144|to|O
DDI-MedLine.d44.s8|146-152|improve|O
DDI-MedLine.d44.s8|154-157|this|O
DDI-MedLine.d44.s8|159-168|metabolism|O
DDI-MedLine.d44.s8|170-171|in|O
DDI-MedLine.d44.s8|173-178|future|O
DDI-MedLine.d44.s8|180-190|prospective|O
DDI-MedLine.d44.s8|192-198|studies|O
DDI-MedLine.d44.s8|199-199|.|O
DDI-DrugBank.d69.s0|0-2|Use|O
DDI-DrugBank.d69.s0|4-5|of|O
DDI-DrugBank.d69.s0|7-16|Cerubidine|O
DDI-DrugBank.d69.s0|18-19|in|O
DDI-DrugBank.d69.s0|21-21|a|O
DDI-DrugBank.d69.s0|23-29|patient|O
DDI-DrugBank.d69.s0|31-33|who|O
DDI-DrugBank.d69.s0|35-37|has|O
DDI-DrugBank.d69.s0|39-48|previously|O
DDI-DrugBank.d69.s0|50-57|received|O
DDI-DrugBank.d69.s0|59-69|doxorubicin|O
DDI-DrugBank.d69.s0|71-79|increases|O
DDI-DrugBank.d69.s0|81-83|the|O
DDI-DrugBank.d69.s0|85-88|risk|O
DDI-DrugBank.d69.s0|90-91|of|O
DDI-DrugBank.d69.s0|93-106|cardiotoxicity|O
DDI-DrugBank.d69.s0|107-107|.|O
DDI-DrugBank.d69.s1|0-9|Cerubidine|O
DDI-DrugBank.d69.s1|11-16|should|O
DDI-DrugBank.d69.s1|18-20|not|O
DDI-DrugBank.d69.s1|22-23|be|O
DDI-DrugBank.d69.s1|25-28|used|O
DDI-DrugBank.d69.s1|30-31|in|O
DDI-DrugBank.d69.s1|33-40|patients|O
DDI-DrugBank.d69.s1|42-44|who|O
DDI-DrugBank.d69.s1|46-49|have|O
DDI-DrugBank.d69.s1|51-60|previously|O
DDI-DrugBank.d69.s1|62-69|received|O
DDI-DrugBank.d69.s1|71-73|the|O
DDI-DrugBank.d69.s1|75-85|recommended|O
DDI-DrugBank.d69.s1|87-93|maximum|O
DDI-DrugBank.d69.s1|95-104|cumulative|O
DDI-DrugBank.d69.s1|106-110|doses|O
DDI-DrugBank.d69.s1|112-113|of|O
DDI-DrugBank.d69.s1|115-125|doxorubicin|O
DDI-DrugBank.d69.s1|127-128|or|O
DDI-DrugBank.d69.s1|130-139|Cerubidine|O
DDI-DrugBank.d69.s1|140-140|.|O
DDI-DrugBank.d69.s2|0-15|Cyclophosphamide|O
DDI-DrugBank.d69.s2|17-20|used|O
DDI-DrugBank.d69.s2|22-33|concurrently|O
DDI-DrugBank.d69.s2|35-38|with|O
DDI-DrugBank.d69.s2|40-49|Cerubidine|O
DDI-DrugBank.d69.s2|51-53|may|O
DDI-DrugBank.d69.s2|55-58|also|O
DDI-DrugBank.d69.s2|60-65|result|O
DDI-DrugBank.d69.s2|67-68|in|O
DDI-DrugBank.d69.s2|70-78|increased|O
DDI-DrugBank.d69.s2|80-93|cardiotoxicity|O
DDI-DrugBank.d69.s2|94-94|.|O
DDI-DrugBank.d69.s3|0-5|Dosage|O
DDI-DrugBank.d69.s3|7-15|reduction|O
DDI-DrugBank.d69.s3|17-18|of|O
DDI-DrugBank.d69.s3|20-29|Cerubidine|O
DDI-DrugBank.d69.s3|31-33|may|O
DDI-DrugBank.d69.s3|35-36|be|O
DDI-DrugBank.d69.s3|38-45|required|O
DDI-DrugBank.d69.s3|47-50|when|O
DDI-DrugBank.d69.s3|52-55|used|O
DDI-DrugBank.d69.s3|57-68|concurrently|O
DDI-DrugBank.d69.s3|70-73|with|O
DDI-DrugBank.d69.s3|75-79|other|O
DDI-DrugBank.d69.s3|81-96|myelosuppressive|O
DDI-DrugBank.d69.s3|98-103|agents|O
DDI-DrugBank.d69.s3|104-104|.|O
DDI-DrugBank.d69.s4|0-10|Hepatotoxic|O
DDI-DrugBank.d69.s4|12-22|medications|O
DDI-DrugBank.d69.s4|23-23|,|O
DDI-DrugBank.d69.s4|25-28|such|O
DDI-DrugBank.d69.s4|30-31|as|O
DDI-DrugBank.d69.s4|33-41|high-dose|O
DDI-DrugBank.d69.s4|43-54|methotrexate|O
DDI-DrugBank.d69.s4|55-55|,|O
DDI-DrugBank.d69.s4|57-59|may|O
DDI-DrugBank.d69.s4|61-66|impair|O
DDI-DrugBank.d69.s4|68-72|liver|O
DDI-DrugBank.d69.s4|74-81|function|O
DDI-DrugBank.d69.s4|83-85|and|O
DDI-DrugBank.d69.s4|87-94|increase|O
DDI-DrugBank.d69.s4|96-98|the|O
DDI-DrugBank.d69.s4|100-103|risk|O
DDI-DrugBank.d69.s4|105-106|of|O
DDI-DrugBank.d69.s4|108-115|toxicity|O
DDI-DrugBank.d69.s4|116-116|.|O
DDI-DrugBank.d237.s0|0-8|Cisapride|O
DDI-DrugBank.d237.s0|10-11|is|O
DDI-DrugBank.d237.s0|13-23|metabolized|O
DDI-DrugBank.d237.s0|25-30|mainly|O
DDI-DrugBank.d237.s0|32-34|via|O
DDI-DrugBank.d237.s0|36-38|the|O
DDI-DrugBank.d237.s0|40-49|cytochrome|O
DDI-DrugBank.d237.s0|51-54|P450|O
DDI-DrugBank.d237.s0|56-58|3A4|O
DDI-DrugBank.d237.s0|60-65|enzyme|O
DDI-DrugBank.d237.s0|66-66|.|O
DDI-DrugBank.d237.s1|0-1|In|O
DDI-DrugBank.d237.s1|3-6|some|O
DDI-DrugBank.d237.s1|8-12|cases|O
DDI-DrugBank.d237.s1|14-18|where|O
DDI-DrugBank.d237.s1|20-26|serious|O
DDI-DrugBank.d237.s1|28-38|ventricular|O
DDI-DrugBank.d237.s1|40-50|arrhythmias|O
DDI-DrugBank.d237.s1|51-51|,|O
DDI-DrugBank.d237.s1|53-54|QT|O
DDI-DrugBank.d237.s1|56-67|prolongation|O
DDI-DrugBank.d237.s1|68-68|,|O
DDI-DrugBank.d237.s1|70-72|and|O
DDI-DrugBank.d237.s1|74-81|torsades|O
DDI-DrugBank.d237.s1|83-84|de|O
DDI-DrugBank.d237.s1|86-92|pointes|O
DDI-DrugBank.d237.s1|94-97|have|O
DDI-DrugBank.d237.s1|99-106|occurred|O
DDI-DrugBank.d237.s1|108-111|when|O
DDI-DrugBank.d237.s1|113-121|cisapride|O
DDI-DrugBank.d237.s1|123-125|was|O
DDI-DrugBank.d237.s1|127-131|taken|O
DDI-DrugBank.d237.s1|133-134|in|O
DDI-DrugBank.d237.s1|136-146|conjunction|O
DDI-DrugBank.d237.s1|148-151|with|O
DDI-DrugBank.d237.s1|153-155|one|O
DDI-DrugBank.d237.s1|157-158|of|O
DDI-DrugBank.d237.s1|160-162|the|O
DDI-DrugBank.d237.s1|164-173|cytochrome|O
DDI-DrugBank.d237.s1|175-178|P450|O
DDI-DrugBank.d237.s1|180-182|3A4|O
DDI-DrugBank.d237.s1|184-193|inhibitors|O
DDI-DrugBank.d237.s1|194-194|,|O
DDI-DrugBank.d237.s1|196-203|elevated|O
DDI-DrugBank.d237.s1|205-209|blood|O
DDI-DrugBank.d237.s1|211-219|cisapride|O
DDI-DrugBank.d237.s1|221-226|levels|O
DDI-DrugBank.d237.s1|228-231|were|O
DDI-DrugBank.d237.s1|233-237|noted|O
DDI-DrugBank.d237.s1|239-240|at|O
DDI-DrugBank.d237.s1|242-244|the|O
DDI-DrugBank.d237.s1|246-249|time|O
DDI-DrugBank.d237.s1|251-252|of|O
DDI-DrugBank.d237.s1|254-256|the|O
DDI-DrugBank.d237.s1|258-259|QT|O
DDI-DrugBank.d237.s1|261-272|prolongation|O
DDI-DrugBank.d237.s1|273-273|.|O
DDI-DrugBank.d237.s2|0-10|Antibiotics|O
DDI-DrugBank.d237.s2|11-11|:|O
DDI-DrugBank.d237.s2|13-14|In|O
DDI-DrugBank.d237.s2|16-20|vitro|O
DDI-DrugBank.d237.s2|22-27|and/or|O
DDI-DrugBank.d237.s2|29-30|in|O
DDI-DrugBank.d237.s2|32-35|vivo|O
DDI-DrugBank.d237.s2|37-40|data|O
DDI-DrugBank.d237.s2|42-45|show|O
DDI-DrugBank.d237.s2|47-50|that|O
DDI-DrugBank.d237.s2|52-65|clarithromycin|O
DDI-DrugBank.d237.s2|66-66|,|O
DDI-DrugBank.d237.s2|68-79|erythromycin|O
DDI-DrugBank.d237.s2|80-80|,|O
DDI-DrugBank.d237.s2|82-84|and|O
DDI-DrugBank.d237.s2|86-99|troleandomycin|O
DDI-DrugBank.d237.s2|101-108|markedly|O
DDI-DrugBank.d237.s2|110-116|inhibit|O
DDI-DrugBank.d237.s2|118-120|the|O
DDI-DrugBank.d237.s2|122-131|metabolism|O
DDI-DrugBank.d237.s2|133-134|of|O
DDI-DrugBank.d237.s2|136-144|cisapride|O
DDI-DrugBank.d237.s2|145-145|,|O
DDI-DrugBank.d237.s2|147-151|which|O
DDI-DrugBank.d237.s2|153-155|can|O
DDI-DrugBank.d237.s2|157-162|result|O
DDI-DrugBank.d237.s2|164-165|in|O
DDI-DrugBank.d237.s2|167-168|an|O
DDI-DrugBank.d237.s2|170-177|increase|O
DDI-DrugBank.d237.s2|179-180|in|O
DDI-DrugBank.d237.s2|182-187|plasma|O
DDI-DrugBank.d237.s2|189-197|cisapride|O
DDI-DrugBank.d237.s2|199-204|levels|O
DDI-DrugBank.d237.s2|206-208|and|O
DDI-DrugBank.d237.s2|210-221|prolongation|O
DDI-DrugBank.d237.s2|223-224|of|O
DDI-DrugBank.d237.s2|226-228|the|O
DDI-DrugBank.d237.s2|230-231|QT|O
DDI-DrugBank.d237.s2|233-240|interval|O
DDI-DrugBank.d237.s2|242-243|on|O
DDI-DrugBank.d237.s2|245-247|the|O
DDI-DrugBank.d237.s2|249-251|ECG|O
DDI-DrugBank.d237.s2|252-252|.|O
DDI-DrugBank.d237.s3|0-15|Anticholinergics|O
DDI-DrugBank.d237.s3|16-16|:|O
DDI-DrugBank.d237.s3|18-27|Concurrent|O
DDI-DrugBank.d237.s3|29-42|administration|O
DDI-DrugBank.d237.s3|44-45|of|O
DDI-DrugBank.d237.s3|47-53|certain|O
DDI-DrugBank.d237.s3|55-69|anticholinergic|O
DDI-DrugBank.d237.s3|71-79|compounds|O
DDI-DrugBank.d237.s3|80-80|,|O
DDI-DrugBank.d237.s3|82-85|such|O
DDI-DrugBank.d237.s3|87-88|as|O
DDI-DrugBank.d237.s3|90-99|belladonna|O
DDI-DrugBank.d237.s3|101-109|alkaloids|O
DDI-DrugBank.d237.s3|111-113|and|O
DDI-DrugBank.d237.s3|115-125|dicyclomine|O
DDI-DrugBank.d237.s3|126-126|,|O
DDI-DrugBank.d237.s3|128-132|would|O
DDI-DrugBank.d237.s3|134-135|be|O
DDI-DrugBank.d237.s3|137-144|expected|O
DDI-DrugBank.d237.s3|146-147|to|O
DDI-DrugBank.d237.s3|149-158|compromise|O
DDI-DrugBank.d237.s3|160-162|the|O
DDI-DrugBank.d237.s3|164-173|beneficial|O
DDI-DrugBank.d237.s3|175-181|effects|O
DDI-DrugBank.d237.s3|183-184|of|O
DDI-DrugBank.d237.s3|186-194|cisapride|O
DDI-DrugBank.d237.s3|195-195|.|O
DDI-DrugBank.d237.s4|0-13|Anticoagulants|O
DDI-DrugBank.d237.s4|15-15|(|O
DDI-DrugBank.d237.s4|16-19|Oral|O
DDI-DrugBank.d237.s4|20-20|)|O
DDI-DrugBank.d237.s4|21-21|:|O
DDI-DrugBank.d237.s4|23-24|In|O
DDI-DrugBank.d237.s4|26-33|patients|O
DDI-DrugBank.d237.s4|35-43|receiving|O
DDI-DrugBank.d237.s4|45-48|oral|O
DDI-DrugBank.d237.s4|50-63|anticoagulants|O
DDI-DrugBank.d237.s4|64-64|,|O
DDI-DrugBank.d237.s4|66-68|the|O
DDI-DrugBank.d237.s4|70-80|coagulation|O
DDI-DrugBank.d237.s4|82-86|times|O
DDI-DrugBank.d237.s4|88-91|were|O
DDI-DrugBank.d237.s4|93-101|increased|O
DDI-DrugBank.d237.s4|103-104|in|O
DDI-DrugBank.d237.s4|106-109|some|O
DDI-DrugBank.d237.s4|111-115|cases|O
DDI-DrugBank.d237.s4|116-116|.|O
DDI-DrugBank.d237.s5|0-1|It|O
DDI-DrugBank.d237.s5|3-4|is|O
DDI-DrugBank.d237.s5|6-14|advisable|O
DDI-DrugBank.d237.s5|16-17|to|O
DDI-DrugBank.d237.s5|19-23|check|O
DDI-DrugBank.d237.s5|25-35|coagulation|O
DDI-DrugBank.d237.s5|37-40|time|O
DDI-DrugBank.d237.s5|42-47|within|O
DDI-DrugBank.d237.s5|49-51|the|O
DDI-DrugBank.d237.s5|53-57|first|O
DDI-DrugBank.d237.s5|59-61|few|O
DDI-DrugBank.d237.s5|63-66|days|O
DDI-DrugBank.d237.s5|68-72|after|O
DDI-DrugBank.d237.s5|74-76|the|O
DDI-DrugBank.d237.s5|78-82|start|O
DDI-DrugBank.d237.s5|84-86|and|O
DDI-DrugBank.d237.s5|88-102|discontinuation|O
DDI-DrugBank.d237.s5|104-105|of|O
DDI-DrugBank.d237.s5|107-115|cisapride|O
DDI-DrugBank.d237.s5|117-123|therapy|O
DDI-DrugBank.d237.s5|124-124|,|O
DDI-DrugBank.d237.s5|126-129|with|O
DDI-DrugBank.d237.s5|131-132|an|O
DDI-DrugBank.d237.s5|134-144|appropriate|O
DDI-DrugBank.d237.s5|146-155|adjustment|O
DDI-DrugBank.d237.s5|157-158|of|O
DDI-DrugBank.d237.s5|160-162|the|O
DDI-DrugBank.d237.s5|164-176|anticoagulant|O
DDI-DrugBank.d237.s5|178-181|dose|O
DDI-DrugBank.d237.s5|182-182|,|O
DDI-DrugBank.d237.s5|184-185|if|O
DDI-DrugBank.d237.s5|187-195|necessary|O
DDI-DrugBank.d237.s5|196-196|.|O
DDI-DrugBank.d237.s6|0-14|Antidepressants|O
DDI-DrugBank.d237.s6|15-15|:|O
DDI-DrugBank.d237.s6|17-18|In|O
DDI-DrugBank.d237.s6|20-24|vitro|O
DDI-DrugBank.d237.s6|26-29|data|O
DDI-DrugBank.d237.s6|31-38|indicate|O
DDI-DrugBank.d237.s6|40-43|that|O
DDI-DrugBank.d237.s6|45-54|nefazodone|O
DDI-DrugBank.d237.s6|56-63|inhibits|O
DDI-DrugBank.d237.s6|65-67|the|O
DDI-DrugBank.d237.s6|69-78|metabolism|O
DDI-DrugBank.d237.s6|80-81|of|O
DDI-DrugBank.d237.s6|83-91|cisapride|O
DDI-DrugBank.d237.s6|92-92|,|O
DDI-DrugBank.d237.s6|94-98|which|O
DDI-DrugBank.d237.s6|100-102|can|O
DDI-DrugBank.d237.s6|104-109|result|O
DDI-DrugBank.d237.s6|111-112|in|O
DDI-DrugBank.d237.s6|114-115|an|O
DDI-DrugBank.d237.s6|117-124|increase|O
DDI-DrugBank.d237.s6|126-127|in|O
DDI-DrugBank.d237.s6|129-134|plasma|O
DDI-DrugBank.d237.s6|136-144|cisapride|O
DDI-DrugBank.d237.s6|146-151|levels|O
DDI-DrugBank.d237.s6|153-155|and|O
DDI-DrugBank.d237.s6|157-168|prolongation|O
DDI-DrugBank.d237.s6|170-171|of|O
DDI-DrugBank.d237.s6|173-175|the|O
DDI-DrugBank.d237.s6|177-178|QT|O
DDI-DrugBank.d237.s6|180-187|interval|O
DDI-DrugBank.d237.s6|189-190|on|O
DDI-DrugBank.d237.s6|192-194|the|O
DDI-DrugBank.d237.s6|196-198|ECG|O
DDI-DrugBank.d237.s6|199-199|.|O
DDI-DrugBank.d237.s7|0-10|Antifungals|O
DDI-DrugBank.d237.s7|11-11|:|O
DDI-DrugBank.d237.s7|13-14|In|O
DDI-DrugBank.d237.s7|16-20|vitro|O
DDI-DrugBank.d237.s7|22-27|and/or|O
DDI-DrugBank.d237.s7|29-30|in|O
DDI-DrugBank.d237.s7|32-35|vivo|O
DDI-DrugBank.d237.s7|37-40|data|O
DDI-DrugBank.d237.s7|42-49|indicate|O
DDI-DrugBank.d237.s7|51-54|that|O
DDI-DrugBank.d237.s7|56-66|fluconazole|O
DDI-DrugBank.d237.s7|67-67|,|O
DDI-DrugBank.d237.s7|69-80|itraconazole|O
DDI-DrugBank.d237.s7|81-81|,|O
DDI-DrugBank.d237.s7|83-85|and|O
DDI-DrugBank.d237.s7|87-90|oral|O
DDI-DrugBank.d237.s7|92-103|ketoconazole|O
DDI-DrugBank.d237.s7|105-112|markedly|O
DDI-DrugBank.d237.s7|114-120|inhibit|O
DDI-DrugBank.d237.s7|122-124|the|O
DDI-DrugBank.d237.s7|126-135|metabolism|O
DDI-DrugBank.d237.s7|137-138|of|O
DDI-DrugBank.d237.s7|140-148|cisapride|O
DDI-DrugBank.d237.s7|149-149|,|O
DDI-DrugBank.d237.s7|151-155|which|O
DDI-DrugBank.d237.s7|157-159|can|O
DDI-DrugBank.d237.s7|161-166|result|O
DDI-DrugBank.d237.s7|168-169|in|O
DDI-DrugBank.d237.s7|171-172|an|O
DDI-DrugBank.d237.s7|174-181|increase|O
DDI-DrugBank.d237.s7|183-184|in|O
DDI-DrugBank.d237.s7|186-191|plasma|O
DDI-DrugBank.d237.s7|193-201|cisapride|O
DDI-DrugBank.d237.s7|203-208|levels|O
DDI-DrugBank.d237.s7|210-212|and|O
DDI-DrugBank.d237.s7|214-225|prolongation|O
DDI-DrugBank.d237.s7|227-228|of|O
DDI-DrugBank.d237.s7|230-232|the|O
DDI-DrugBank.d237.s7|234-235|QT|O
DDI-DrugBank.d237.s7|237-244|interval|O
DDI-DrugBank.d237.s7|246-247|on|O
DDI-DrugBank.d237.s7|249-251|the|O
DDI-DrugBank.d237.s7|253-255|ECG|O
DDI-DrugBank.d237.s7|256-256|.|O
DDI-DrugBank.d237.s8|0-4|Human|O
DDI-DrugBank.d237.s8|6-20|pharmacokinetic|O
DDI-DrugBank.d237.s8|22-25|data|O
DDI-DrugBank.d237.s8|27-34|indicate|O
DDI-DrugBank.d237.s8|36-39|that|O
DDI-DrugBank.d237.s8|41-44|oral|O
DDI-DrugBank.d237.s8|46-57|ketoconazole|O
DDI-DrugBank.d237.s8|59-66|markedly|O
DDI-DrugBank.d237.s8|68-75|inhibits|O
DDI-DrugBank.d237.s8|77-79|the|O
DDI-DrugBank.d237.s8|81-90|metabolism|O
DDI-DrugBank.d237.s8|92-93|of|O
DDI-DrugBank.d237.s8|95-103|cisapride|O
DDI-DrugBank.d237.s8|104-104|,|O
DDI-DrugBank.d237.s8|106-114|resulting|O
DDI-DrugBank.d237.s8|116-117|in|O
DDI-DrugBank.d237.s8|119-119|a|O
DDI-DrugBank.d237.s8|121-124|mean|O
DDI-DrugBank.d237.s8|126-135|eight-fold|O
DDI-DrugBank.d237.s8|137-144|increase|O
DDI-DrugBank.d237.s8|146-147|in|O
DDI-DrugBank.d237.s8|149-151|AUC|O
DDI-DrugBank.d237.s8|153-154|of|O
DDI-DrugBank.d237.s8|156-164|cisapride|O
DDI-DrugBank.d237.s8|165-165|.|O
DDI-DrugBank.d237.s9|0-0|A|O
DDI-DrugBank.d237.s9|2-6|study|O
DDI-DrugBank.d237.s9|8-9|in|O
DDI-DrugBank.d237.s9|11-12|14|O
DDI-DrugBank.d237.s9|14-19|normal|O
DDI-DrugBank.d237.s9|21-24|male|O
DDI-DrugBank.d237.s9|26-28|and|O
DDI-DrugBank.d237.s9|30-35|female|O
DDI-DrugBank.d237.s9|37-46|volunteers|O
DDI-DrugBank.d237.s9|48-55|suggests|O
DDI-DrugBank.d237.s9|57-60|that|O
DDI-DrugBank.d237.s9|62-77|coadministration|O
DDI-DrugBank.d237.s9|79-80|of|O
DDI-DrugBank.d237.s9|82-90|cisapride|O
DDI-DrugBank.d237.s9|92-94|and|O
DDI-DrugBank.d237.s9|96-107|ketoconazole|O
DDI-DrugBank.d237.s9|109-111|can|O
DDI-DrugBank.d237.s9|113-118|result|O
DDI-DrugBank.d237.s9|120-121|in|O
DDI-DrugBank.d237.s9|123-134|prolongation|O
DDI-DrugBank.d237.s9|136-137|of|O
DDI-DrugBank.d237.s9|139-141|the|O
DDI-DrugBank.d237.s9|143-144|QT|O
DDI-DrugBank.d237.s9|146-153|interval|O
DDI-DrugBank.d237.s9|155-156|on|O
DDI-DrugBank.d237.s9|158-160|the|O
DDI-DrugBank.d237.s9|162-164|ECG|O
DDI-DrugBank.d237.s9|165-165|.|O
DDI-DrugBank.d237.s10|0-1|H2|O
DDI-DrugBank.d237.s10|3-10|Receptor|O
DDI-DrugBank.d237.s10|12-22|Antagonists|O
DDI-DrugBank.d237.s10|23-23|:|O
DDI-DrugBank.d237.s10|25-34|Cimetidine|O
DDI-DrugBank.d237.s10|36-51|coadministration|O
DDI-DrugBank.d237.s10|53-57|leads|O
DDI-DrugBank.d237.s10|59-60|to|O
DDI-DrugBank.d237.s10|62-63|an|O
DDI-DrugBank.d237.s10|65-73|increased|O
DDI-DrugBank.d237.s10|75-78|peak|O
DDI-DrugBank.d237.s10|80-85|plasma|O
DDI-DrugBank.d237.s10|87-99|concentration|O
DDI-DrugBank.d237.s10|101-103|and|O
DDI-DrugBank.d237.s10|105-107|AUC|O
DDI-DrugBank.d237.s10|109-110|of|O
DDI-DrugBank.d237.s10|112-120|cisapride|O
DDI-DrugBank.d237.s10|121-121|,|O
DDI-DrugBank.d237.s10|123-127|there|O
DDI-DrugBank.d237.s10|129-130|is|O
DDI-DrugBank.d237.s10|132-133|no|O
DDI-DrugBank.d237.s10|135-140|effect|O
DDI-DrugBank.d237.s10|142-143|on|O
DDI-DrugBank.d237.s10|145-153|cisapride|O
DDI-DrugBank.d237.s10|155-164|absorption|O
DDI-DrugBank.d237.s10|166-169|when|O
DDI-DrugBank.d237.s10|171-172|it|O
DDI-DrugBank.d237.s10|174-175|is|O
DDI-DrugBank.d237.s10|177-190|coadministered|O
DDI-DrugBank.d237.s10|192-195|with|O
DDI-DrugBank.d237.s10|197-206|ranitidine|O
DDI-DrugBank.d237.s10|207-207|.|O
DDI-DrugBank.d237.s11|0-2|The|O
DDI-DrugBank.d237.s11|4-19|gastrointestinal|O
DDI-DrugBank.d237.s11|21-30|absorption|O
DDI-DrugBank.d237.s11|32-33|of|O
DDI-DrugBank.d237.s11|35-44|cimetidine|O
DDI-DrugBank.d237.s11|46-48|and|O
DDI-DrugBank.d237.s11|50-59|ranitidine|O
DDI-DrugBank.d237.s11|61-62|is|O
DDI-DrugBank.d237.s11|64-74|accelerated|O
DDI-DrugBank.d237.s11|76-79|when|O
DDI-DrugBank.d237.s11|81-84|they|O
DDI-DrugBank.d237.s11|86-88|are|O
DDI-DrugBank.d237.s11|90-103|coadministered|O
DDI-DrugBank.d237.s11|105-108|with|O
DDI-DrugBank.d237.s11|110-118|cisapride|O
DDI-DrugBank.d237.s11|119-119|.|O
DDI-DrugBank.d237.s12|0-7|Protease|O
DDI-DrugBank.d237.s12|9-18|Inhibitors|O
DDI-DrugBank.d237.s12|19-19|:|O
DDI-DrugBank.d237.s12|21-22|In|O
DDI-DrugBank.d237.s12|24-28|vitro|O
DDI-DrugBank.d237.s12|30-33|data|O
DDI-DrugBank.d237.s12|35-42|indicate|O
DDI-DrugBank.d237.s12|44-47|that|O
DDI-DrugBank.d237.s12|49-57|indinavir|O
DDI-DrugBank.d237.s12|59-61|and|O
DDI-DrugBank.d237.s12|63-71|ritonavir|O
DDI-DrugBank.d237.s12|73-80|markedly|O
DDI-DrugBank.d237.s12|82-88|inhibit|O
DDI-DrugBank.d237.s12|90-92|the|O
DDI-DrugBank.d237.s12|94-103|metabolism|O
DDI-DrugBank.d237.s12|105-106|of|O
DDI-DrugBank.d237.s12|108-116|cisapride|O
DDI-DrugBank.d237.s12|118-122|which|O
DDI-DrugBank.d237.s12|124-126|can|O
DDI-DrugBank.d237.s12|128-133|result|O
DDI-DrugBank.d237.s12|135-136|in|O
DDI-DrugBank.d237.s12|138-139|an|O
DDI-DrugBank.d237.s12|141-148|increase|O
DDI-DrugBank.d237.s12|150-151|in|O
DDI-DrugBank.d237.s12|153-158|plasma|O
DDI-DrugBank.d237.s12|160-168|cisapride|O
DDI-DrugBank.d237.s12|170-175|levels|O
DDI-DrugBank.d237.s12|177-179|and|O
DDI-DrugBank.d237.s12|181-192|prolongation|O
DDI-DrugBank.d237.s12|194-195|of|O
DDI-DrugBank.d237.s12|197-199|the|O
DDI-DrugBank.d237.s12|201-202|QT|O
DDI-DrugBank.d237.s12|204-211|interval|O
DDI-DrugBank.d237.s12|213-214|on|O
DDI-DrugBank.d237.s12|216-218|the|O
DDI-DrugBank.d237.s12|220-222|ECG|O
DDI-DrugBank.d237.s12|223-223|.|O
DDI-DrugBank.d237.s13|0-4|Other|O
DDI-DrugBank.d237.s13|5-5|:|O
DDI-DrugBank.d237.s13|7-22|Coadministration|O
DDI-DrugBank.d237.s13|24-25|of|O
DDI-DrugBank.d237.s13|27-36|grapefruit|O
DDI-DrugBank.d237.s13|38-42|juice|O
DDI-DrugBank.d237.s13|44-47|with|O
DDI-DrugBank.d237.s13|49-57|cisapride|O
DDI-DrugBank.d237.s13|59-67|increases|O
DDI-DrugBank.d237.s13|69-71|the|O
DDI-DrugBank.d237.s13|73-87|bioavailability|O
DDI-DrugBank.d237.s13|89-90|of|O
DDI-DrugBank.d237.s13|92-100|cisapride|O
DDI-DrugBank.d237.s13|102-104|and|O
DDI-DrugBank.d237.s13|106-116|concomitant|O
DDI-DrugBank.d237.s13|118-120|use|O
DDI-DrugBank.d237.s13|122-127|should|O
DDI-DrugBank.d237.s13|129-130|be|O
DDI-DrugBank.d237.s13|132-138|avoided|O
DDI-DrugBank.d237.s13|139-139|.|O
DDI-DrugBank.d237.s14|0-8|Cisapride|O
DDI-DrugBank.d237.s14|10-15|should|O
DDI-DrugBank.d237.s14|17-19|not|O
DDI-DrugBank.d237.s14|21-22|be|O
DDI-DrugBank.d237.s14|24-27|used|O
DDI-DrugBank.d237.s14|29-41|concomitantly|O
DDI-DrugBank.d237.s14|43-46|with|O
DDI-DrugBank.d237.s14|48-52|other|O
DDI-DrugBank.d237.s14|54-58|drugs|O
DDI-DrugBank.d237.s14|60-64|known|O
DDI-DrugBank.d237.s14|66-67|to|O
DDI-DrugBank.d237.s14|69-75|prolong|O
DDI-DrugBank.d237.s14|77-79|the|O
DDI-DrugBank.d237.s14|81-82|QT|O
DDI-DrugBank.d237.s14|84-91|interval|O
DDI-DrugBank.d237.s14|92-92|:|O
DDI-DrugBank.d237.s14|94-100|certain|O
DDI-DrugBank.d237.s14|102-116|antiarrhythmics|O
DDI-DrugBank.d237.s14|117-117|,|O
DDI-DrugBank.d237.s14|119-127|including|O
DDI-DrugBank.d237.s14|129-133|those|O
DDI-DrugBank.d237.s14|135-136|of|O
DDI-DrugBank.d237.s14|138-142|Class|O
DDI-DrugBank.d237.s14|144-145|IA|O
DDI-DrugBank.d237.s14|147-147|(|O
DDI-DrugBank.d237.s14|148-151|such|O
DDI-DrugBank.d237.s14|153-154|as|O
DDI-DrugBank.d237.s14|156-164|quinidine|O
DDI-DrugBank.d237.s14|166-168|and|O
DDI-DrugBank.d237.s14|170-181|procainamide|O
DDI-DrugBank.d237.s14|182-182|)|O
DDI-DrugBank.d237.s14|184-186|and|O
DDI-DrugBank.d237.s14|188-192|Class|O
DDI-DrugBank.d237.s14|194-196|III|O
DDI-DrugBank.d237.s14|198-198|(|O
DDI-DrugBank.d237.s14|199-202|such|O
DDI-DrugBank.d237.s14|204-205|as|O
DDI-DrugBank.d237.s14|207-213|sotalol|O
DDI-DrugBank.d237.s14|214-214|)|O
DDI-DrugBank.d237.s14|215-215|;|O
DDI-DrugBank.d237.s15|0-8|tricyclic|O
DDI-DrugBank.d237.s15|10-24|antidepressants|O
DDI-DrugBank.d237.s15|26-26|(|O
DDI-DrugBank.d237.s15|27-30|such|O
DDI-DrugBank.d237.s15|32-33|as|O
DDI-DrugBank.d237.s15|35-47|amitriptyline|O
DDI-DrugBank.d237.s15|48-48|)|O
DDI-DrugBank.d237.s15|49-49|;|O
DDI-DrugBank.d237.s16|0-6|certain|O
DDI-DrugBank.d237.s16|8-18|tetracyclic|O
DDI-DrugBank.d237.s16|20-34|antidepressants|O
DDI-DrugBank.d237.s16|36-36|(|O
DDI-DrugBank.d237.s16|37-40|such|O
DDI-DrugBank.d237.s16|42-43|as|O
DDI-DrugBank.d237.s16|45-55|maprotiline|O
DDI-DrugBank.d237.s16|56-56|)|O
DDI-DrugBank.d237.s16|57-57|;|O
DDI-DrugBank.d237.s17|0-6|certain|O
DDI-DrugBank.d237.s17|8-20|antipsychotic|O
DDI-DrugBank.d237.s17|22-32|medications|O
DDI-DrugBank.d237.s17|34-34|(|O
DDI-DrugBank.d237.s17|35-38|such|O
DDI-DrugBank.d237.s17|40-41|as|O
DDI-DrugBank.d237.s17|43-52|sertindole|O
DDI-DrugBank.d237.s17|53-53|)|O
DDI-DrugBank.d237.s17|54-54|;|O
DDI-DrugBank.d237.s18|0-9|astemizole|O
DDI-DrugBank.d237.s18|10-10|,|O
DDI-DrugBank.d237.s18|12-19|bepridil|O
DDI-DrugBank.d237.s18|20-20|,|O
DDI-DrugBank.d237.s18|22-33|sparfloxacin|O
DDI-DrugBank.d237.s18|34-34|,|O
DDI-DrugBank.d237.s18|36-38|and|O
DDI-DrugBank.d237.s18|40-49|terodiline|O
DDI-DrugBank.d237.s18|50-50|.|O
DDI-DrugBank.d237.s19|0-2|The|O
DDI-DrugBank.d237.s19|4-12|preceding|O
DDI-DrugBank.d237.s19|14-18|lists|O
DDI-DrugBank.d237.s19|20-21|of|O
DDI-DrugBank.d237.s19|23-27|drugs|O
DDI-DrugBank.d237.s19|29-31|are|O
DDI-DrugBank.d237.s19|33-35|not|O
DDI-DrugBank.d237.s19|37-49|comprehensive|O
DDI-DrugBank.d237.s19|50-50|.|O
DDI-DrugBank.d237.s20|0-2|The|O
DDI-DrugBank.d237.s20|4-15|acceleration|O
DDI-DrugBank.d237.s20|17-18|of|O
DDI-DrugBank.d237.s20|20-26|gastric|O
DDI-DrugBank.d237.s20|28-35|emptying|O
DDI-DrugBank.d237.s20|37-38|by|O
DDI-DrugBank.d237.s20|40-48|cisapride|O
DDI-DrugBank.d237.s20|50-54|could|O
DDI-DrugBank.d237.s20|56-61|affect|O
DDI-DrugBank.d237.s20|63-65|the|O
DDI-DrugBank.d237.s20|67-70|rate|O
DDI-DrugBank.d237.s20|72-73|of|O
DDI-DrugBank.d237.s20|75-84|absorption|O
DDI-DrugBank.d237.s20|86-87|of|O
DDI-DrugBank.d237.s20|89-93|other|O
DDI-DrugBank.d237.s20|95-99|drugs|O
DDI-DrugBank.d237.s20|100-100|.|O
DDI-DrugBank.d237.s21|0-7|Patients|O
DDI-DrugBank.d237.s21|9-17|receiving|O
DDI-DrugBank.d237.s21|19-24|narrow|O
DDI-DrugBank.d237.s21|26-36|therapeutic|O
DDI-DrugBank.d237.s21|38-42|ratio|O
DDI-DrugBank.d237.s21|44-48|drugs|O
DDI-DrugBank.d237.s21|50-51|or|O
DDI-DrugBank.d237.s21|53-57|other|O
DDI-DrugBank.d237.s21|59-63|drugs|O
DDI-DrugBank.d237.s21|65-68|that|O
DDI-DrugBank.d237.s21|70-76|require|O
DDI-DrugBank.d237.s21|78-84|careful|O
DDI-DrugBank.d237.s21|86-94|titration|O
DDI-DrugBank.d237.s21|96-101|should|O
DDI-DrugBank.d237.s21|103-104|be|O
DDI-DrugBank.d237.s21|106-113|followed|O
DDI-DrugBank.d237.s21|115-121|closely|O
DDI-DrugBank.d237.s21|122-122|;|O
DDI-DrugBank.d237.s22|0-1|if|O
DDI-DrugBank.d237.s22|3-8|plasma|O
DDI-DrugBank.d237.s22|10-15|levels|O
DDI-DrugBank.d237.s22|17-19|are|O
DDI-DrugBank.d237.s22|21-25|being|O
DDI-DrugBank.d237.s22|27-35|monitored|O
DDI-DrugBank.d237.s22|36-36|,|O
DDI-DrugBank.d237.s22|38-41|they|O
DDI-DrugBank.d237.s22|43-48|should|O
DDI-DrugBank.d237.s22|50-51|be|O
DDI-DrugBank.d237.s22|53-62|reassessed|O
DDI-DrugBank.d237.s22|63-63|.|O
DDI-DrugBank.d252.s0|0-7|Although|O
DDI-DrugBank.d252.s0|9-15|BETAGAN|O
DDI-DrugBank.d252.s0|17-20|used|O
DDI-DrugBank.d252.s0|22-26|alone|O
DDI-DrugBank.d252.s0|28-30|has|O
DDI-DrugBank.d252.s0|32-37|little|O
DDI-DrugBank.d252.s0|39-40|or|O
DDI-DrugBank.d252.s0|42-43|no|O
DDI-DrugBank.d252.s0|45-50|effect|O
DDI-DrugBank.d252.s0|52-53|on|O
DDI-DrugBank.d252.s0|55-59|pupil|O
DDI-DrugBank.d252.s0|61-64|size|O
DDI-DrugBank.d252.s0|65-65|,|O
DDI-DrugBank.d252.s0|67-75|mydriasis|O
DDI-DrugBank.d252.s0|77-85|resulting|O
DDI-DrugBank.d252.s0|87-90|from|O
DDI-DrugBank.d252.s0|92-102|concomitant|O
DDI-DrugBank.d252.s0|104-110|therapy|O
DDI-DrugBank.d252.s0|112-115|with|O
DDI-DrugBank.d252.s0|117-123|BETAGAN|O
DDI-DrugBank.d252.s0|125-127|and|O
DDI-DrugBank.d252.s0|129-139|epinephrine|O
DDI-DrugBank.d252.s0|141-143|may|O
DDI-DrugBank.d252.s0|145-149|occur|O
DDI-DrugBank.d252.s0|150-150|.|O
DDI-DrugBank.d252.s1|0-4|Close|O
DDI-DrugBank.d252.s1|6-16|observation|O
DDI-DrugBank.d252.s1|18-19|of|O
DDI-DrugBank.d252.s1|21-23|the|O
DDI-DrugBank.d252.s1|25-31|patient|O
DDI-DrugBank.d252.s1|33-34|is|O
DDI-DrugBank.d252.s1|36-46|recommended|O
DDI-DrugBank.d252.s1|48-51|when|O
DDI-DrugBank.d252.s1|53-53|a|O
DDI-DrugBank.d252.s1|55-66|beta-blocker|O
DDI-DrugBank.d252.s1|68-69|is|O
DDI-DrugBank.d252.s1|71-82|administered|O
DDI-DrugBank.d252.s1|84-85|to|O
DDI-DrugBank.d252.s1|87-94|patients|O
DDI-DrugBank.d252.s1|96-104|receiving|O
DDI-DrugBank.d252.s1|106-128|catecholamine-depleting|O
DDI-DrugBank.d252.s1|130-134|drugs|O
DDI-DrugBank.d252.s1|136-139|such|O
DDI-DrugBank.d252.s1|141-142|as|O
DDI-DrugBank.d252.s1|144-152|reserpine|O
DDI-DrugBank.d252.s1|153-153|,|O
DDI-DrugBank.d252.s1|155-161|because|O
DDI-DrugBank.d252.s1|163-164|of|O
DDI-DrugBank.d252.s1|166-173|possible|O
DDI-DrugBank.d252.s1|175-182|additive|O
DDI-DrugBank.d252.s1|184-190|effects|O
DDI-DrugBank.d252.s1|192-194|and|O
DDI-DrugBank.d252.s1|196-198|the|O
DDI-DrugBank.d252.s1|200-209|production|O
DDI-DrugBank.d252.s1|211-212|of|O
DDI-DrugBank.d252.s1|214-224|hypotension|O
DDI-DrugBank.d252.s1|226-231|and/or|O
DDI-DrugBank.d252.s1|233-238|marked|O
DDI-DrugBank.d252.s1|240-250|bradycardia|O
DDI-DrugBank.d252.s1|251-251|,|O
DDI-DrugBank.d252.s1|253-257|which|O
DDI-DrugBank.d252.s1|259-261|may|O
DDI-DrugBank.d252.s1|263-269|produce|O
DDI-DrugBank.d252.s1|271-277|vertigo|O
DDI-DrugBank.d252.s1|278-278|,|O
DDI-DrugBank.d252.s1|280-286|syncope|O
DDI-DrugBank.d252.s1|288-289|or|O
DDI-DrugBank.d252.s1|291-298|postural|O
DDI-DrugBank.d252.s1|300-310|hypotension|O
DDI-DrugBank.d252.s1|311-311|.|O
DDI-DrugBank.d252.s2|0-7|Patients|O
DDI-DrugBank.d252.s2|9-17|receiving|O
DDI-DrugBank.d252.s2|19-33|beta-adrenergic|O
DDI-DrugBank.d252.s2|35-42|blocking|O
DDI-DrugBank.d252.s2|44-49|agents|O
DDI-DrugBank.d252.s2|51-55|along|O
DDI-DrugBank.d252.s2|57-60|with|O
DDI-DrugBank.d252.s2|62-67|either|O
DDI-DrugBank.d252.s2|69-72|oral|O
DDI-DrugBank.d252.s2|74-75|or|O
DDI-DrugBank.d252.s2|77-87|intravenous|O
DDI-DrugBank.d252.s2|89-95|calcium|O
DDI-DrugBank.d252.s2|97-107|antagonists|O
DDI-DrugBank.d252.s2|109-114|should|O
DDI-DrugBank.d252.s2|116-117|be|O
DDI-DrugBank.d252.s2|119-127|monitored|O
DDI-DrugBank.d252.s2|129-131|for|O
DDI-DrugBank.d252.s2|133-140|possible|O
DDI-DrugBank.d252.s2|142-157|atrioventricular|O
DDI-DrugBank.d252.s2|159-168|conduction|O
DDI-DrugBank.d252.s2|170-181|disturbances|O
DDI-DrugBank.d252.s2|182-182|,|O
DDI-DrugBank.d252.s2|184-187|left|O
DDI-DrugBank.d252.s2|189-199|ventricular|O
DDI-DrugBank.d252.s2|201-207|failure|O
DDI-DrugBank.d252.s2|209-211|and|O
DDI-DrugBank.d252.s2|213-223|hypotension|O
DDI-DrugBank.d252.s2|224-224|.|O
DDI-DrugBank.d252.s3|0-1|In|O
DDI-DrugBank.d252.s3|3-10|patients|O
DDI-DrugBank.d252.s3|12-15|with|O
DDI-DrugBank.d252.s3|17-24|impaired|O
DDI-DrugBank.d252.s3|26-32|cardiac|O
DDI-DrugBank.d252.s3|34-41|function|O
DDI-DrugBank.d252.s3|42-42|,|O
DDI-DrugBank.d252.s3|44-55|simultaneous|O
DDI-DrugBank.d252.s3|57-59|use|O
DDI-DrugBank.d252.s3|61-66|should|O
DDI-DrugBank.d252.s3|68-69|be|O
DDI-DrugBank.d252.s3|71-77|avoided|O
DDI-DrugBank.d252.s3|79-88|altogether|O
DDI-DrugBank.d252.s3|89-89|.|O
DDI-DrugBank.d252.s4|0-2|The|O
DDI-DrugBank.d252.s4|4-14|concomitant|O
DDI-DrugBank.d252.s4|16-18|use|O
DDI-DrugBank.d252.s4|20-21|of|O
DDI-DrugBank.d252.s4|23-37|beta-adrenergic|O
DDI-DrugBank.d252.s4|39-46|blocking|O
DDI-DrugBank.d252.s4|48-53|agents|O
DDI-DrugBank.d252.s4|55-58|with|O
DDI-DrugBank.d252.s4|60-68|digitalis|O
DDI-DrugBank.d252.s4|70-72|and|O
DDI-DrugBank.d252.s4|74-80|calcium|O
DDI-DrugBank.d252.s4|82-92|antagonists|O
DDI-DrugBank.d252.s4|94-96|may|O
DDI-DrugBank.d252.s4|98-101|have|O
DDI-DrugBank.d252.s4|103-110|additive|O
DDI-DrugBank.d252.s4|112-118|effects|O
DDI-DrugBank.d252.s4|120-121|on|O
DDI-DrugBank.d252.s4|123-132|prolonging|O
DDI-DrugBank.d252.s4|134-149|atrioventricular|O
DDI-DrugBank.d252.s4|151-160|conduction|O
DDI-DrugBank.d252.s4|162-165|time|O
DDI-DrugBank.d252.s4|166-166|.|O
DDI-DrugBank.d252.s5|0-20|Phenothiazine-related|O
DDI-DrugBank.d252.s5|22-30|compounds|O
DDI-DrugBank.d252.s5|32-34|and|O
DDI-DrugBank.d252.s5|36-50|beta-adrenergic|O
DDI-DrugBank.d252.s5|52-59|blocking|O
DDI-DrugBank.d252.s5|61-66|agents|O
DDI-DrugBank.d252.s5|68-70|may|O
DDI-DrugBank.d252.s5|72-75|have|O
DDI-DrugBank.d252.s5|77-84|additive|O
DDI-DrugBank.d252.s5|86-96|hypotensite|O
DDI-DrugBank.d252.s5|98-104|effects|O
DDI-DrugBank.d252.s5|106-108|due|O
DDI-DrugBank.d252.s5|110-111|to|O
DDI-DrugBank.d252.s5|113-115|the|O
DDI-DrugBank.d252.s5|117-126|inhibition|O
DDI-DrugBank.d252.s5|128-129|of|O
DDI-DrugBank.d252.s5|131-134|each|O
DDI-DrugBank.d252.s5|136-140|other|O
DDI-DrugBank.d252.s5|142-142|s|O
DDI-DrugBank.d252.s5|144-153|metabolism|O
DDI-DrugBank.d252.s5|154-154|.|O
DDI-DrugBank.d744.s0|0-10|Acromegalic|O
DDI-DrugBank.d744.s0|12-19|patients|O
DDI-DrugBank.d744.s0|21-24|with|O
DDI-DrugBank.d744.s0|26-33|diabetes|O
DDI-DrugBank.d744.s0|35-42|mellitus|O
DDI-DrugBank.d744.s0|44-48|being|O
DDI-DrugBank.d744.s0|50-56|treated|O
DDI-DrugBank.d744.s0|58-61|with|O
DDI-DrugBank.d744.s0|63-69|insulin|O
DDI-DrugBank.d744.s0|71-76|and/or|O
DDI-DrugBank.d744.s0|78-81|oral|O
DDI-DrugBank.d744.s0|83-94|hypoglycemic|O
DDI-DrugBank.d744.s0|96-101|agents|O
DDI-DrugBank.d744.s0|103-105|may|O
DDI-DrugBank.d744.s0|107-113|require|O
DDI-DrugBank.d744.s0|115-118|dose|O
DDI-DrugBank.d744.s0|120-129|reductions|O
DDI-DrugBank.d744.s0|131-132|of|O
DDI-DrugBank.d744.s0|134-138|these|O
DDI-DrugBank.d744.s0|140-150|therapeutic|O
DDI-DrugBank.d744.s0|152-157|agents|O
DDI-DrugBank.d744.s0|159-163|after|O
DDI-DrugBank.d744.s0|165-167|the|O
DDI-DrugBank.d744.s0|169-178|initiation|O
DDI-DrugBank.d744.s0|180-181|of|O
DDI-DrugBank.d744.s0|183-189|therapy|O
DDI-DrugBank.d744.s0|191-194|with|O
DDI-DrugBank.d744.s0|196-203|SOMAVERT|O
DDI-DrugBank.d744.s0|204-204|.|O
DDI-DrugBank.d744.s1|0-1|In|O
DDI-DrugBank.d744.s1|3-10|clinical|O
DDI-DrugBank.d744.s1|12-18|studies|O
DDI-DrugBank.d744.s1|19-19|,|O
DDI-DrugBank.d744.s1|21-28|patients|O
DDI-DrugBank.d744.s1|30-31|on|O
DDI-DrugBank.d744.s1|33-39|opioids|O
DDI-DrugBank.d744.s1|41-45|often|O
DDI-DrugBank.d744.s1|47-52|needed|O
DDI-DrugBank.d744.s1|54-59|higher|O
DDI-DrugBank.d744.s1|61-65|serum|O
DDI-DrugBank.d744.s1|67-77|pegvisomant|O
DDI-DrugBank.d744.s1|79-92|concentrations|O
DDI-DrugBank.d744.s1|94-95|to|O
DDI-DrugBank.d744.s1|97-103|achieve|O
DDI-DrugBank.d744.s1|105-115|appropriate|O
DDI-DrugBank.d744.s1|117-121|IGF-I|O
DDI-DrugBank.d744.s1|123-133|suppression|O
DDI-DrugBank.d744.s1|135-142|compared|O
DDI-DrugBank.d744.s1|144-147|with|O
DDI-DrugBank.d744.s1|149-156|patients|O
DDI-DrugBank.d744.s1|158-160|not|O
DDI-DrugBank.d744.s1|162-170|receiving|O
DDI-DrugBank.d744.s1|172-178|opioids|O
DDI-DrugBank.d744.s1|179-179|.|O
DDI-DrugBank.d744.s2|0-2|The|O
DDI-DrugBank.d744.s2|4-12|mechanism|O
DDI-DrugBank.d744.s2|14-15|of|O
DDI-DrugBank.d744.s2|17-20|this|O
DDI-DrugBank.d744.s2|22-32|interaction|O
DDI-DrugBank.d744.s2|34-35|is|O
DDI-DrugBank.d744.s2|37-39|not|O
DDI-DrugBank.d744.s2|41-45|known|O
DDI-DrugBank.d744.s2|46-46|.|O
DDI-DrugBank.d515.s0|0-2|The|O
DDI-DrugBank.d515.s0|4-12|physician|O
DDI-DrugBank.d515.s0|14-19|should|O
DDI-DrugBank.d515.s0|21-22|be|O
DDI-DrugBank.d515.s0|24-28|alert|O
DDI-DrugBank.d515.s0|30-32|for|O
DDI-DrugBank.d515.s0|34-41|possible|O
DDI-DrugBank.d515.s0|43-50|combined|O
DDI-DrugBank.d515.s0|52-55|drug|O
DDI-DrugBank.d515.s0|57-63|actions|O
DDI-DrugBank.d515.s0|64-64|,|O
DDI-DrugBank.d515.s0|66-74|desirable|O
DDI-DrugBank.d515.s0|76-77|or|O
DDI-DrugBank.d515.s0|79-89|undesirable|O
DDI-DrugBank.d515.s0|90-90|,|O
DDI-DrugBank.d515.s0|92-100|involving|O
DDI-DrugBank.d515.s0|102-111|ifosfamide|O
DDI-DrugBank.d515.s0|113-116|even|O
DDI-DrugBank.d515.s0|118-123|though|O
DDI-DrugBank.d515.s0|125-134|ifosfamide|O
DDI-DrugBank.d515.s0|136-138|has|O
DDI-DrugBank.d515.s0|140-143|been|O
DDI-DrugBank.d515.s0|145-148|used|O
DDI-DrugBank.d515.s0|150-161|successfully|O
DDI-DrugBank.d515.s0|163-174|concurrently|O
DDI-DrugBank.d515.s0|176-179|with|O
DDI-DrugBank.d515.s0|181-185|other|O
DDI-DrugBank.d515.s0|187-191|drugs|O
DDI-DrugBank.d515.s0|192-192|,|O
DDI-DrugBank.d515.s0|194-202|including|O
DDI-DrugBank.d515.s0|204-208|other|O
DDI-DrugBank.d515.s0|210-218|cytotoxic|O
DDI-DrugBank.d515.s0|220-224|drugs|O
DDI-DrugBank.d515.s0|225-225|.|O
DDI-MedLine.d43.s0|0-4|Tumor|O
DDI-MedLine.d43.s0|6-14|phenotype|O
DDI-MedLine.d43.s0|16-18|and|O
DDI-MedLine.d43.s0|20-33|susceptibility|O
DDI-MedLine.d43.s0|35-36|to|O
DDI-MedLine.d43.s0|38-48|progression|O
DDI-MedLine.d43.s0|50-51|as|O
DDI-MedLine.d43.s0|53-54|an|O
DDI-MedLine.d43.s0|56-65|expression|O
DDI-MedLine.d43.s0|67-68|of|O
DDI-MedLine.d43.s0|70-83|subpopulations|O
DDI-MedLine.d43.s0|85-86|of|O
DDI-MedLine.d43.s0|88-96|initiated|O
DDI-MedLine.d43.s0|98-103|murine|O
DDI-MedLine.d43.s0|105-109|cells|O
DDI-MedLine.d43.s0|110-110|.|O
DDI-MedLine.d43.s1|0-8|Currently|O
DDI-MedLine.d43.s1|9-9|,|O
DDI-MedLine.d43.s1|11-12|it|O
DDI-MedLine.d43.s1|14-15|is|O
DDI-MedLine.d43.s1|17-25|conceived|O
DDI-MedLine.d43.s1|27-30|that|O
DDI-MedLine.d43.s1|32-32|a|O
DDI-MedLine.d43.s1|34-39|number|O
DDI-MedLine.d43.s1|41-42|of|O
DDI-MedLine.d43.s1|44-49|events|O
DDI-MedLine.d43.s1|50-50|,|O
DDI-MedLine.d43.s1|52-53|or|O
DDI-MedLine.d43.s1|55-58|hits|O
DDI-MedLine.d43.s1|59-59|,|O
DDI-MedLine.d43.s1|61-63|are|O
DDI-MedLine.d43.s1|65-72|required|O
DDI-MedLine.d43.s1|74-76|for|O
DDI-MedLine.d43.s1|78-80|the|O
DDI-MedLine.d43.s1|82-90|induction|O
DDI-MedLine.d43.s1|92-93|of|O
DDI-MedLine.d43.s1|95-100|tumors|O
DDI-MedLine.d43.s1|102-103|by|O
DDI-MedLine.d43.s1|105-112|chemical|O
DDI-MedLine.d43.s1|114-119|agents|O
DDI-MedLine.d43.s1|120-120|.|O
DDI-MedLine.d43.s2|0-2|The|O
DDI-MedLine.d43.s2|4-8|first|O
DDI-MedLine.d43.s2|10-14|phase|O
DDI-MedLine.d43.s2|16-17|of|O
DDI-MedLine.d43.s2|19-22|this|O
DDI-MedLine.d43.s2|24-31|sequence|O
DDI-MedLine.d43.s2|32-32|,|O
DDI-MedLine.d43.s2|34-43|initiation|O
DDI-MedLine.d43.s2|44-44|,|O
DDI-MedLine.d43.s2|46-47|is|O
DDI-MedLine.d43.s2|49-58|considered|O
DDI-MedLine.d43.s2|60-61|to|O
DDI-MedLine.d43.s2|63-68|result|O
DDI-MedLine.d43.s2|70-73|from|O
DDI-MedLine.d43.s2|75-76|at|O
DDI-MedLine.d43.s2|78-82|least|O
DDI-MedLine.d43.s2|84-86|one|O
DDI-MedLine.d43.s2|88-92|event|O
DDI-MedLine.d43.s2|94-95|in|O
DDI-MedLine.d43.s2|97-99|the|O
DDI-MedLine.d43.s2|101-107|genetic|O
DDI-MedLine.d43.s2|109-117|apparatus|O
DDI-MedLine.d43.s2|118-118|.|O
DDI-MedLine.d43.s3|0-7|Analyses|O
DDI-MedLine.d43.s3|9-10|of|O
DDI-MedLine.d43.s3|12-15|this|O
DDI-MedLine.d43.s3|17-24|sequence|O
DDI-MedLine.d43.s3|25-25|,|O
DDI-MedLine.d43.s3|27-33|however|O
DDI-MedLine.d43.s3|34-34|,|O
DDI-MedLine.d43.s3|36-42|usually|O
DDI-MedLine.d43.s3|44-47|give|O
DDI-MedLine.d43.s3|49-54|little|O
DDI-MedLine.d43.s3|56-68|consideration|O
DDI-MedLine.d43.s3|70-71|to|O
DDI-MedLine.d43.s3|73-75|the|O
DDI-MedLine.d43.s3|77-82|nature|O
DDI-MedLine.d43.s3|84-85|of|O
DDI-MedLine.d43.s3|87-89|the|O
DDI-MedLine.d43.s3|91-96|target|O
DDI-MedLine.d43.s3|98-101|cell|O
DDI-MedLine.d43.s3|103-104|or|O
DDI-MedLine.d43.s3|106-107|to|O
DDI-MedLine.d43.s3|109-111|the|O
DDI-MedLine.d43.s3|113-127|characteristics|O
DDI-MedLine.d43.s3|129-130|of|O
DDI-MedLine.d43.s3|132-134|the|O
DDI-MedLine.d43.s3|136-144|resultant|O
DDI-MedLine.d43.s3|146-151|tumors|O
DDI-MedLine.d43.s3|152-152|.|O
DDI-MedLine.d43.s4|0-13|Vesselinovitch|O
DDI-MedLine.d43.s4|15-16|et|O
DDI-MedLine.d43.s4|18-19|al|O
DDI-MedLine.d43.s4|20-20|.|O
DDI-MedLine.d43.s5|0-0|(|O
DDI-MedLine.d43.s5|1-6|Cancer|O
DDI-MedLine.d43.s5|8-11|Res.|O
DDI-MedLine.d43.s5|12-12|,|O
DDI-MedLine.d43.s5|14-15|38|O
DDI-MedLine.d43.s5|16-16|:|O
DDI-MedLine.d43.s5|18-26|2003-2010|O
DDI-MedLine.d43.s5|27-27|,|O
DDI-MedLine.d43.s5|29-32|1978|O
DDI-MedLine.d43.s5|33-33|)|O
DDI-MedLine.d43.s5|35-38|have|O
DDI-MedLine.d43.s5|40-47|reported|O
DDI-MedLine.d43.s5|49-52|that|O
DDI-MedLine.d43.s5|54-54|a|O
DDI-MedLine.d43.s5|56-61|single|O
DDI-MedLine.d43.s5|62-62|,|O
DDI-MedLine.d43.s5|64-68|small|O
DDI-MedLine.d43.s5|70-74|pulse|O
DDI-MedLine.d43.s5|76-77|of|O
DDI-MedLine.d43.s5|79-88|carcinogen|O
DDI-MedLine.d43.s5|90-92|can|O
DDI-MedLine.d43.s5|94-99|induce|O
DDI-MedLine.d43.s5|101-105|early|O
DDI-MedLine.d43.s5|107-109|and|O
DDI-MedLine.d43.s5|111-118|numerous|O
DDI-MedLine.d43.s5|120-124|liver|O
DDI-MedLine.d43.s5|126-131|tumors|O
DDI-MedLine.d43.s5|133-136|when|O
DDI-MedLine.d43.s5|138-149|administered|O
DDI-MedLine.d43.s5|151-160|neonatally|O
DDI-MedLine.d43.s5|162-163|to|O
DDI-MedLine.d43.s5|165-168|mice|O
DDI-MedLine.d43.s5|170-173|with|O
DDI-MedLine.d43.s5|175-175|a|O
DDI-MedLine.d43.s5|177-183|genetic|O
DDI-MedLine.d43.s5|185-198|predisposition|O
DDI-MedLine.d43.s5|200-201|to|O
DDI-MedLine.d43.s5|203-221|hepatotumorigenesis|O
DDI-MedLine.d43.s5|222-222|.|O
DDI-MedLine.d43.s6|0-1|In|O
DDI-MedLine.d43.s6|3-5|the|O
DDI-MedLine.d43.s6|7-13|current|O
DDI-MedLine.d43.s6|15-19|study|O
DDI-MedLine.d43.s6|20-20|,|O
DDI-MedLine.d43.s6|22-24|the|O
DDI-MedLine.d43.s6|26-39|nonpredisposed|O
DDI-MedLine.d43.s6|41-46|strain|O
DDI-MedLine.d43.s6|48-55|C57BL/6N|O
DDI-MedLine.d43.s6|57-59|was|O
DDI-MedLine.d43.s6|61-64|also|O
DDI-MedLine.d43.s6|66-70|shown|O
DDI-MedLine.d43.s6|72-73|to|O
DDI-MedLine.d43.s6|75-76|be|O
DDI-MedLine.d43.s6|78-83|highly|O
DDI-MedLine.d43.s6|85-95|susceptible|O
DDI-MedLine.d43.s6|97-98|to|O
DDI-MedLine.d43.s6|100-117|diethylnitrosamine|O
DDI-MedLine.d43.s6|119-124|during|O
DDI-MedLine.d43.s6|126-128|the|O
DDI-MedLine.d43.s6|130-137|neonatal|O
DDI-MedLine.d43.s6|139-144|period|O
DDI-MedLine.d43.s6|145-145|.|O
DDI-MedLine.d43.s7|0-7|C57BL/6N|O
DDI-MedLine.d43.s7|9-20|demonstrated|O
DDI-MedLine.d43.s7|22-26|large|O
DDI-MedLine.d43.s7|28-34|numbers|O
DDI-MedLine.d43.s7|36-37|of|O
DDI-MedLine.d43.s7|39-41|two|O
DDI-MedLine.d43.s7|43-44|of|O
DDI-MedLine.d43.s7|46-48|the|O
DDI-MedLine.d43.s7|50-54|three|O
DDI-MedLine.d43.s7|56-60|types|O
DDI-MedLine.d43.s7|62-63|of|O
DDI-MedLine.d43.s7|65-69|liver|O
DDI-MedLine.d43.s7|71-76|tumors|O
DDI-MedLine.d43.s7|78-81|seen|O
DDI-MedLine.d43.s7|83-84|in|O
DDI-MedLine.d43.s7|86-91|livers|O
DDI-MedLine.d43.s7|93-94|of|O
DDI-MedLine.d43.s7|96-106|genetically|O
DDI-MedLine.d43.s7|108-118|predisposed|O
DDI-MedLine.d43.s7|120-123|mice|O
DDI-MedLine.d43.s7|124-124|,|O
DDI-MedLine.d43.s7|126-128|one|O
DDI-MedLine.d43.s7|130-131|of|O
DDI-MedLine.d43.s7|133-137|which|O
DDI-MedLine.d43.s7|139-146|required|O
DDI-MedLine.d43.s7|148-150|the|O
DDI-MedLine.d43.s7|152-161|additional|O
DDI-MedLine.d43.s7|163-170|stimulus|O
DDI-MedLine.d43.s7|172-173|of|O
DDI-MedLine.d43.s7|175-181|dietary|O
DDI-MedLine.d43.s7|183-195|phenobarbital|O
DDI-MedLine.d43.s7|197-199|for|O
DDI-MedLine.d43.s7|201-206|growth|O
DDI-MedLine.d43.s7|207-207|.|O
DDI-MedLine.d43.s8|0-5|Tumors|O
DDI-MedLine.d43.s8|7-8|of|O
DDI-MedLine.d43.s8|10-13|more|O
DDI-MedLine.d43.s8|15-23|malignant|O
DDI-MedLine.d43.s8|25-33|phenotype|O
DDI-MedLine.d43.s8|35-38|were|O
DDI-MedLine.d43.s8|40-51|demonstrated|O
DDI-MedLine.d43.s8|53-56|only|O
DDI-MedLine.d43.s8|58-59|in|O
DDI-MedLine.d43.s8|61-71|genetically|O
DDI-MedLine.d43.s8|73-83|predisposed|O
DDI-MedLine.d43.s8|85-88|mice|O
DDI-MedLine.d43.s8|90-90|(|O
DDI-MedLine.d43.s8|91-98|C57BL/6N|O
DDI-MedLine.d43.s8|100-100|X|O
DDI-MedLine.d43.s8|102-108|C3H/HeN|O
DDI-MedLine.d43.s8|110-111|F1|O
DDI-MedLine.d43.s8|112-112|)|O
DDI-MedLine.d43.s8|114-117|that|O
DDI-MedLine.d43.s8|119-126|received|O
DDI-MedLine.d43.s8|128-130|one|O
DDI-MedLine.d43.s8|132-135|dose|O
DDI-MedLine.d43.s8|137-138|of|O
DDI-MedLine.d43.s8|140-149|carcinogen|O
DDI-MedLine.d43.s8|150-150|.|O
DDI-MedLine.d43.s9|0-4|These|O
DDI-MedLine.d43.s9|6-13|findings|O
DDI-MedLine.d43.s9|15-21|suggest|O
DDI-MedLine.d43.s9|23-26|that|O
DDI-MedLine.d43.s9|28-30|the|O
DDI-MedLine.d43.s9|32-40|phenotype|O
DDI-MedLine.d43.s9|42-43|of|O
DDI-MedLine.d43.s9|45-45|a|O
DDI-MedLine.d43.s9|47-51|tumor|O
DDI-MedLine.d43.s9|53-56|that|O
DDI-MedLine.d43.s9|58-64|results|O
DDI-MedLine.d43.s9|66-69|from|O
DDI-MedLine.d43.s9|71-71|a|O
DDI-MedLine.d43.s9|73-77|pulse|O
DDI-MedLine.d43.s9|79-80|of|O
DDI-MedLine.d43.s9|82-82|a|O
DDI-MedLine.d43.s9|84-91|chemical|O
DDI-MedLine.d43.s9|93-102|carcinogen|O
DDI-MedLine.d43.s9|104-106|may|O
DDI-MedLine.d43.s9|108-113|depend|O
DDI-MedLine.d43.s9|115-118|upon|O
DDI-MedLine.d43.s9|120-122|the|O
DDI-MedLine.d43.s9|124-129|target|O
DDI-MedLine.d43.s9|131-134|cell|O
DDI-MedLine.d43.s9|135-135|.|O
DDI-MedLine.d43.s10|0-2|The|O
DDI-MedLine.d43.s10|4-12|initiated|O
DDI-MedLine.d43.s10|14-18|cells|O
DDI-MedLine.d43.s10|20-23|that|O
DDI-MedLine.d43.s10|25-30|result|O
DDI-MedLine.d43.s10|32-35|from|O
DDI-MedLine.d43.s10|37-40|this|O
DDI-MedLine.d43.s10|42-44|hit|O
DDI-MedLine.d43.s10|46-48|may|O
DDI-MedLine.d43.s10|50-53|vary|O
DDI-MedLine.d43.s10|55-58|from|O
DDI-MedLine.d43.s10|60-64|those|O
DDI-MedLine.d43.s10|66-69|that|O
DDI-MedLine.d43.s10|71-81|demonstrate|O
DDI-MedLine.d43.s10|83-86|very|O
DDI-MedLine.d43.s10|88-93|little|O
DDI-MedLine.d43.s10|95-105|progression|O
DDI-MedLine.d43.s10|107-108|in|O
DDI-MedLine.d43.s10|110-113|cell|O
DDI-MedLine.d43.s10|115-118|type|O
DDI-MedLine.d43.s10|120-122|and|O
DDI-MedLine.d43.s10|124-126|may|O
DDI-MedLine.d43.s10|128-129|or|O
DDI-MedLine.d43.s10|131-133|may|O
DDI-MedLine.d43.s10|135-137|not|O
DDI-MedLine.d43.s10|139-145|require|O
DDI-MedLine.d43.s10|147-155|exogenous|O
DDI-MedLine.d43.s10|157-167|enhancement|O
DDI-MedLine.d43.s10|169-170|of|O
DDI-MedLine.d43.s10|172-177|growth|O
DDI-MedLine.d43.s10|179-180|to|O
DDI-MedLine.d43.s10|182-186|those|O
DDI-MedLine.d43.s10|188-191|that|O
DDI-MedLine.d43.s10|193-195|can|O
DDI-MedLine.d43.s10|197-204|progress|O
DDI-MedLine.d43.s10|206-209|very|O
DDI-MedLine.d43.s10|211-217|rapidly|O
DDI-MedLine.d43.s10|219-220|to|O
DDI-MedLine.d43.s10|222-226|fully|O
DDI-MedLine.d43.s10|228-236|malignant|O
DDI-MedLine.d43.s10|238-245|behavior|O
DDI-MedLine.d43.s10|246-246|.|O
DDI-MedLine.d43.s11|0-2|The|O
DDI-MedLine.d43.s11|4-9|latter|O
DDI-MedLine.d43.s11|11-15|might|O
DDI-MedLine.d43.s11|17-21|arise|O
DDI-MedLine.d43.s11|23-26|from|O
DDI-MedLine.d43.s11|28-28|a|O
DDI-MedLine.d43.s11|30-32|hit|O
DDI-MedLine.d43.s11|34-35|in|O
DDI-MedLine.d43.s11|37-37|a|O
DDI-MedLine.d43.s11|39-49|genetically|O
DDI-MedLine.d43.s11|51-59|initiated|O
DDI-MedLine.d43.s11|61-64|cell|O
DDI-MedLine.d43.s11|65-65|,|O
DDI-MedLine.d43.s11|67-69|the|O
DDI-MedLine.d43.s11|71-76|result|O
DDI-MedLine.d43.s11|78-79|of|O
DDI-MedLine.d43.s11|81-85|which|O
DDI-MedLine.d43.s11|87-88|is|O
DDI-MedLine.d43.s11|90-90|a|O
DDI-MedLine.d43.s11|92-95|more|O
DDI-MedLine.d43.s11|97-101|rapid|O
DDI-MedLine.d43.s11|103-113|progression|O
DDI-MedLine.d43.s11|115-116|in|O
DDI-MedLine.d43.s11|118-122|tumor|O
DDI-MedLine.d43.s11|124-127|type|O
DDI-MedLine.d43.s11|128-128|.|O
DDI-MedLine.d23.s0|0-2|The|O
DDI-MedLine.d23.s0|4-10|effects|O
DDI-MedLine.d23.s0|12-13|of|O
DDI-MedLine.d23.s0|15-22|ketamine|O
DDI-MedLine.d23.s0|24-26|and|O
DDI-MedLine.d23.s0|28-29|of|O
DDI-MedLine.d23.s0|31-37|Innovar|O
DDI-MedLine.d23.s0|39-48|anesthesia|O
DDI-MedLine.d23.s0|50-51|on|O
DDI-MedLine.d23.s0|53-61|digitalis|O
DDI-MedLine.d23.s0|63-71|tolerance|O
DDI-MedLine.d23.s0|73-74|in|O
DDI-MedLine.d23.s0|76-79|dogs|O
DDI-MedLine.d23.s0|80-80|.|O
DDI-MedLine.d23.s1|0-1|In|O
DDI-MedLine.d23.s1|3-3|a|O
DDI-MedLine.d23.s1|5-14|comparison|O
DDI-MedLine.d23.s1|16-17|of|O
DDI-MedLine.d23.s1|19-27|digitalis|O
DDI-MedLine.d23.s1|29-37|tolerance|O
DDI-MedLine.d23.s1|39-40|in|O
DDI-MedLine.d23.s1|42-45|dogs|O
DDI-MedLine.d23.s1|47-58|anesthetized|O
DDI-MedLine.d23.s1|60-63|with|O
DDI-MedLine.d23.s1|65-72|ketamine|O
DDI-MedLine.d23.s1|73-73|,|O
DDI-MedLine.d23.s1|75-81|Innovar|O
DDI-MedLine.d23.s1|83-85|Vet|O
DDI-MedLine.d23.s1|86-86|,|O
DDI-MedLine.d23.s1|88-89|or|O
DDI-MedLine.d23.s1|91-103|pentobarbital|O
DDI-MedLine.d23.s1|104-104|,|O
DDI-MedLine.d23.s1|106-108|the|O
DDI-MedLine.d23.s1|110-115|dosage|O
DDI-MedLine.d23.s1|117-118|of|O
DDI-MedLine.d23.s1|120-126|ouabain|O
DDI-MedLine.d23.s1|128-133|needed|O
DDI-MedLine.d23.s1|135-136|to|O
DDI-MedLine.d23.s1|138-142|cause|O
DDI-MedLine.d23.s1|144-154|ventricular|O
DDI-MedLine.d23.s1|156-166|tachycardia|O
DDI-MedLine.d23.s1|168-170|was|O
DDI-MedLine.d23.s1|172-184|significantly|O
DDI-MedLine.d23.s1|186-191|higher|O
DDI-MedLine.d23.s1|192-192|,|O
DDI-MedLine.d23.s1|194-195|as|O
DDI-MedLine.d23.s1|197-199|was|O
DDI-MedLine.d23.s1|201-203|the|O
DDI-MedLine.d23.s1|205-208|LD50|O
DDI-MedLine.d23.s1|210-211|of|O
DDI-MedLine.d23.s1|213-219|ouabain|O
DDI-MedLine.d23.s1|220-220|,|O
DDI-MedLine.d23.s1|222-225|with|O
DDI-MedLine.d23.s1|227-234|ketamine|O
DDI-MedLine.d23.s1|236-237|or|O
DDI-MedLine.d23.s1|239-245|Innovar|O
DDI-MedLine.d23.s1|247-250|than|O
DDI-MedLine.d23.s1|252-255|with|O
DDI-MedLine.d23.s1|257-269|pentobarbital|O
DDI-MedLine.d23.s1|270-270|.|O
DDI-MedLine.d23.s2|0-10|Ventricular|O
DDI-MedLine.d23.s2|12-22|tachycardia|O
DDI-MedLine.d23.s2|24-30|induced|O
DDI-MedLine.d23.s2|32-33|by|O
DDI-MedLine.d23.s2|35-41|ouabain|O
DDI-MedLine.d23.s2|43-45|was|O
DDI-MedLine.d23.s2|47-55|generally|O
DDI-MedLine.d23.s2|57-65|converted|O
DDI-MedLine.d23.s2|67-68|to|O
DDI-MedLine.d23.s2|70-74|sinus|O
DDI-MedLine.d23.s2|76-81|rhythm|O
DDI-MedLine.d23.s2|83-91|following|O
DDI-MedLine.d23.s2|93-106|administration|O
DDI-MedLine.d23.s2|108-109|of|O
DDI-MedLine.d23.s2|111-117|Innovar|O
DDI-MedLine.d23.s2|118-118|,|O
DDI-MedLine.d23.s2|120-127|ketamine|O
DDI-MedLine.d23.s2|128-128|,|O
DDI-MedLine.d23.s2|130-131|or|O
DDI-MedLine.d23.s2|133-142|droperidol|O
DDI-MedLine.d23.s2|144-146|but|O
DDI-MedLine.d23.s2|148-150|not|O
DDI-MedLine.d23.s2|152-156|after|O
DDI-MedLine.d23.s2|158-171|administration|O
DDI-MedLine.d23.s2|173-174|of|O
DDI-MedLine.d23.s2|176-182|fentayl|O
DDI-MedLine.d23.s2|184-188|alone|O
DDI-MedLine.d23.s2|190-191|or|O
DDI-MedLine.d23.s2|193-197|after|O
DDI-MedLine.d23.s2|199-211|pentobarbital|O
DDI-MedLine.d23.s2|212-212|.|O
DDI-MedLine.d138.s0|0-10|Interaction|O
DDI-MedLine.d138.s0|12-18|between|O
DDI-MedLine.d138.s0|20-27|oxytocin|O
DDI-MedLine.d138.s0|29-31|and|O
DDI-MedLine.d138.s0|33-44|antidiuretic|O
DDI-MedLine.d138.s0|46-52|hormone|O
DDI-MedLine.d138.s0|54-56|and|O
DDI-MedLine.d138.s0|58-60|its|O
DDI-MedLine.d138.s0|62-67|effect|O
DDI-MedLine.d138.s0|69-70|on|O
DDI-MedLine.d138.s0|72-74|the|O
DDI-MedLine.d138.s0|76-79|milk|O
DDI-MedLine.d138.s0|81-89|secretion|O
DDI-MedLine.d138.s0|91-92|by|O
DDI-MedLine.d138.s0|94-100|alveoli|O
DDI-MedLine.d138.s0|102-103|of|O
DDI-MedLine.d138.s0|105-107|the|O
DDI-MedLine.d138.s0|109-115|mammary|O
DDI-MedLine.d138.s0|117-121|gland|O
DDI-MedLine.d138.s0|123-124|of|O
DDI-MedLine.d138.s0|126-134|lactating|O
DDI-MedLine.d138.s0|136-139|rats|O
DDI-MedLine.d138.s0|140-140|.|O
DDI-MedLine.d138.s1|0-10|Interaction|O
DDI-MedLine.d138.s1|12-18|between|O
DDI-MedLine.d138.s1|20-28|exogenous|O
DDI-MedLine.d138.s1|30-32|and|O
DDI-MedLine.d138.s1|34-43|endogenous|O
DDI-MedLine.d138.s1|45-52|oxytocin|O
DDI-MedLine.d138.s1|54-56|and|O
DDI-MedLine.d138.s1|58-68|vasopressin|O
DDI-MedLine.d138.s1|70-72|was|O
DDI-MedLine.d138.s1|74-78|found|O
DDI-MedLine.d138.s1|80-81|to|O
DDI-MedLine.d138.s1|83-88|affect|O
DDI-MedLine.d138.s1|90-92|the|O
DDI-MedLine.d138.s1|94-102|mechanism|O
DDI-MedLine.d138.s1|104-105|of|O
DDI-MedLine.d138.s1|107-110|milk|O
DDI-MedLine.d138.s1|112-119|ejection|O
DDI-MedLine.d138.s1|121-122|by|O
DDI-MedLine.d138.s1|124-126|the|O
DDI-MedLine.d138.s1|128-134|alveoli|O
DDI-MedLine.d138.s1|136-137|of|O
DDI-MedLine.d138.s1|139-141|the|O
DDI-MedLine.d138.s1|143-149|mammary|O
DDI-MedLine.d138.s1|151-155|gland|O
DDI-MedLine.d138.s1|157-158|in|O
DDI-MedLine.d138.s1|160-168|lactating|O
DDI-MedLine.d138.s1|170-173|rats|O
DDI-MedLine.d138.s1|174-174|.|O
DDI-MedLine.d138.s2|0-9|Inhibition|O
DDI-MedLine.d138.s2|11-13|and|O
DDI-MedLine.d138.s2|15-25|stimulation|O
DDI-MedLine.d138.s2|27-28|of|O
DDI-MedLine.d138.s2|30-32|the|O
DDI-MedLine.d138.s2|34-39|effect|O
DDI-MedLine.d138.s2|41-42|of|O
DDI-MedLine.d138.s2|44-51|oxytocin|O
DDI-MedLine.d138.s2|53-54|on|O
DDI-MedLine.d138.s2|56-59|milk|O
DDI-MedLine.d138.s2|61-68|ejection|O
DDI-MedLine.d138.s2|70-71|by|O
DDI-MedLine.d138.s2|73-83|vasopressin|O
DDI-MedLine.d138.s2|85-87|was|O
DDI-MedLine.d138.s2|89-100|demonstrated|O
DDI-MedLine.d138.s2|101-101|.|O
DDI-MedLine.d138.s3|0-1|On|O
DDI-MedLine.d138.s3|3-5|the|O
DDI-MedLine.d138.s3|7-11|basis|O
DDI-MedLine.d138.s3|13-14|of|O
DDI-MedLine.d138.s3|16-18|the|O
DDI-MedLine.d138.s3|20-29|principles|O
DDI-MedLine.d138.s3|31-38|observed|O
DDI-MedLine.d138.s3|40-42|the|O
DDI-MedLine.d138.s3|44-57|concentrations|O
DDI-MedLine.d138.s3|59-60|fo|O
DDI-MedLine.d138.s3|62-66|these|O
DDI-MedLine.d138.s3|68-75|hormones|O
DDI-MedLine.d138.s3|77-80|were|O
DDI-MedLine.d138.s3|82-93|investigated|O
DDI-MedLine.d138.s3|95-96|in|O
DDI-MedLine.d138.s3|98-100|the|O
DDI-MedLine.d138.s3|102-107|plasma|O
DDI-MedLine.d138.s3|109-110|of|O
DDI-MedLine.d138.s3|112-115|dogs|O
DDI-MedLine.d138.s3|117-124|deprived|O
DDI-MedLine.d138.s3|126-127|of|O
DDI-MedLine.d138.s3|129-133|water|O
DDI-MedLine.d138.s3|135-137|for|O
DDI-MedLine.d138.s3|139-139|3|O
DDI-MedLine.d138.s3|141-144|days|O
DDI-MedLine.d138.s3|146-148|and|O
DDI-MedLine.d138.s3|150-153|then|O
DDI-MedLine.d138.s3|155-161|allowed|O
DDI-MedLine.d138.s3|163-164|to|O
DDI-MedLine.d138.s3|166-170|drink|O
DDI-MedLine.d138.s3|171-171|.|O
DDI-DrugBank.d152.s0|0-6|Certain|O
DDI-DrugBank.d152.s0|8-16|endocrine|O
DDI-DrugBank.d152.s0|18-20|and|O
DDI-DrugBank.d152.s0|22-26|liver|O
DDI-DrugBank.d152.s0|28-35|function|O
DDI-DrugBank.d152.s0|37-41|tests|O
DDI-DrugBank.d152.s0|43-45|may|O
DDI-DrugBank.d152.s0|47-48|be|O
DDI-DrugBank.d152.s0|50-57|affected|O
DDI-DrugBank.d152.s0|59-60|by|O
DDI-DrugBank.d152.s0|62-80|estrogen-containing|O
DDI-DrugBank.d152.s0|82-85|oral|O
DDI-DrugBank.d152.s0|87-100|contraceptives|O
DDI-DrugBank.d152.s0|101-101|.|O
DDI-DrugBank.d152.s1|0-2|The|O
DDI-DrugBank.d152.s1|4-12|following|O
DDI-DrugBank.d152.s1|14-20|similar|O
DDI-DrugBank.d152.s1|22-28|changes|O
DDI-DrugBank.d152.s1|30-32|may|O
DDI-DrugBank.d152.s1|34-35|be|O
DDI-DrugBank.d152.s1|37-44|expected|O
DDI-DrugBank.d152.s1|46-49|with|O
DDI-DrugBank.d152.s1|51-56|larger|O
DDI-DrugBank.d152.s1|58-62|doses|O
DDI-DrugBank.d152.s1|64-65|of|O
DDI-DrugBank.d152.s1|67-74|estrogen|O
DDI-DrugBank.d152.s1|75-75|:|O
DDI-DrugBank.d152.s1|77-85|Increased|O
DDI-DrugBank.d152.s1|87-105|sulfobromophthalein|O
DDI-DrugBank.d152.s1|107-115|retention|O
DDI-DrugBank.d152.s1|116-116|;|O
DDI-DrugBank.d152.s2|0-8|increased|O
DDI-DrugBank.d152.s2|10-20|prothrombin|O
DDI-DrugBank.d152.s2|22-24|and|O
DDI-DrugBank.d152.s2|26-32|factors|O
DDI-DrugBank.d152.s2|34-36|VII|O
DDI-DrugBank.d152.s2|37-37|,|O
DDI-DrugBank.d152.s2|39-42|VIII|O
DDI-DrugBank.d152.s2|43-43|,|O
DDI-DrugBank.d152.s2|45-46|IX|O
DDI-DrugBank.d152.s2|47-47|,|O
DDI-DrugBank.d152.s2|49-51|and|O
DDI-DrugBank.d152.s2|53-53|X|O
DDI-DrugBank.d152.s2|54-54|;|O
DDI-DrugBank.d152.s3|0-8|decreased|O
DDI-DrugBank.d152.s3|10-21|antithrombin|O
DDI-DrugBank.d152.s3|23-23|3|O
DDI-DrugBank.d152.s3|24-24|;|O
DDI-DrugBank.d152.s4|0-8|increased|O
DDI-DrugBank.d152.s4|10-31|norepinephrine-induced|O
DDI-DrugBank.d152.s4|33-38|platel|O
DDI-DrugBank.d152.s4|40-41|et|O
DDI-DrugBank.d152.s4|43-53|aggregation|O
DDI-DrugBank.d152.s4|54-54|;|O
DDI-DrugBank.d152.s5|0-8|increased|O
DDI-DrugBank.d152.s5|10-16|thyroid|O
DDI-DrugBank.d152.s5|18-24|binding|O
DDI-DrugBank.d152.s5|26-33|globulin|O
DDI-DrugBank.d152.s5|35-35|(|O
DDI-DrugBank.d152.s5|36-38|TBG|O
DDI-DrugBank.d152.s5|39-39|)|O
DDI-DrugBank.d152.s5|41-47|leading|O
DDI-DrugBank.d152.s5|49-50|to|O
DDI-DrugBank.d152.s5|52-60|increased|O
DDI-DrugBank.d152.s5|62-72|circulating|O
DDI-DrugBank.d152.s5|74-78|total|O
DDI-DrugBank.d152.s5|80-86|thyroid|O
DDI-DrugBank.d152.s5|88-94|hormone|O
DDI-DrugBank.d152.s5|95-95|,|O
DDI-DrugBank.d152.s5|97-98|as|O
DDI-DrugBank.d152.s5|100-107|measured|O
DDI-DrugBank.d152.s5|109-110|by|O
DDI-DrugBank.d152.s5|112-114|PBI|O
DDI-DrugBank.d152.s5|115-115|,|O
DDI-DrugBank.d152.s5|117-118|T4|O
DDI-DrugBank.d152.s5|120-121|by|O
DDI-DrugBank.d152.s5|123-128|column|O
DDI-DrugBank.d152.s5|129-129|,|O
DDI-DrugBank.d152.s5|131-132|or|O
DDI-DrugBank.d152.s5|134-135|T4|O
DDI-DrugBank.d152.s5|137-138|by|O
DDI-DrugBank.d152.s5|140-155|radioimmunoassay|O
DDI-DrugBank.d152.s5|156-156|.|O
DDI-DrugBank.d152.s6|0-3|Free|O
DDI-DrugBank.d152.s6|5-6|T3|O
DDI-DrugBank.d152.s6|8-12|resin|O
DDI-DrugBank.d152.s6|14-19|uptake|O
DDI-DrugBank.d152.s6|21-22|is|O
DDI-DrugBank.d152.s6|24-32|decreased|O
DDI-DrugBank.d152.s6|33-33|,|O
DDI-DrugBank.d152.s6|35-44|reflecting|O
DDI-DrugBank.d152.s6|46-48|the|O
DDI-DrugBank.d152.s6|50-57|elevated|O
DDI-DrugBank.d152.s6|59-61|TBG|O
DDI-DrugBank.d152.s6|62-62|;|O
DDI-DrugBank.d152.s7|0-3|free|O
DDI-DrugBank.d152.s7|5-6|T4|O
DDI-DrugBank.d152.s7|8-20|concentration|O
DDI-DrugBank.d152.s7|22-23|is|O
DDI-DrugBank.d152.s7|25-33|unaltered|O
DDI-DrugBank.d152.s7|34-34|:|O
DDI-DrugBank.d152.s7|36-43|impaired|O
DDI-DrugBank.d152.s7|45-51|glucose|O
DDI-DrugBank.d152.s7|53-61|tolerance|O
DDI-DrugBank.d152.s7|62-62|;|O
DDI-DrugBank.d152.s8|0-8|decreased|O
DDI-DrugBank.d152.s8|10-21|pregnanediol|O
DDI-DrugBank.d152.s8|23-31|excretion|O
DDI-DrugBank.d152.s8|32-32|;|O
DDI-DrugBank.d152.s9|0-6|reduced|O
DDI-DrugBank.d152.s9|8-15|response|O
DDI-DrugBank.d152.s9|17-18|to|O
DDI-DrugBank.d152.s9|20-29|metyrapone|O
DDI-DrugBank.d152.s9|31-34|test|O
DDI-DrugBank.d152.s9|35-35|;|O
DDI-DrugBank.d152.s10|0-6|reduced|O
DDI-DrugBank.d152.s10|8-12|serum|O
DDI-DrugBank.d152.s10|14-19|folate|O
DDI-DrugBank.d152.s10|21-33|concentration|O
DDI-DrugBank.d152.s10|34-34|;|O
DDI-DrugBank.d152.s11|0-8|increased|O
DDI-DrugBank.d152.s11|10-14|serum|O
DDI-DrugBank.d152.s11|16-27|triglyceride|O
DDI-DrugBank.d152.s11|29-31|and|O
DDI-DrugBank.d152.s11|33-44|phospholipid|O
DDI-DrugBank.d152.s11|46-58|concentration|O
DDI-DrugBank.d152.s11|59-59|.|O
DDI-DrugBank.d357.s0|0-3|5HT3|O
DDI-DrugBank.d357.s0|5-15|Antagonists|O
DDI-DrugBank.d357.s0|16-16|:|O
DDI-DrugBank.d357.s0|18-22|Based|O
DDI-DrugBank.d357.s0|24-25|on|O
DDI-DrugBank.d357.s0|27-33|reports|O
DDI-DrugBank.d357.s0|35-36|of|O
DDI-DrugBank.d357.s0|38-45|profound|O
DDI-DrugBank.d357.s0|47-57|hypotension|O
DDI-DrugBank.d357.s0|59-61|and|O
DDI-DrugBank.d357.s0|63-66|loss|O
DDI-DrugBank.d357.s0|68-69|of|O
DDI-DrugBank.d357.s0|71-83|consciousness|O
DDI-DrugBank.d357.s0|85-88|when|O
DDI-DrugBank.d357.s0|90-100|apomorphine|O
DDI-DrugBank.d357.s0|102-104|was|O
DDI-DrugBank.d357.s0|106-117|administered|O
DDI-DrugBank.d357.s0|119-122|with|O
DDI-DrugBank.d357.s0|124-134|ondansetron|O
DDI-DrugBank.d357.s0|135-135|,|O
DDI-DrugBank.d357.s0|137-139|the|O
DDI-DrugBank.d357.s0|141-151|concomitant|O
DDI-DrugBank.d357.s0|153-155|use|O
DDI-DrugBank.d357.s0|157-158|of|O
DDI-DrugBank.d357.s0|160-170|apomorphine|O
DDI-DrugBank.d357.s0|172-175|with|O
DDI-DrugBank.d357.s0|177-181|drugs|O
DDI-DrugBank.d357.s0|183-184|of|O
DDI-DrugBank.d357.s0|186-188|the|O
DDI-DrugBank.d357.s0|190-193|5HT3|O
DDI-DrugBank.d357.s0|195-204|antagonist|O
DDI-DrugBank.d357.s0|206-210|class|O
DDI-DrugBank.d357.s0|212-212|(|O
DDI-DrugBank.d357.s0|213-221|including|O
DDI-DrugBank.d357.s0|222-222|,|O
DDI-DrugBank.d357.s0|224-226|for|O
DDI-DrugBank.d357.s0|228-234|example|O
DDI-DrugBank.d357.s0|235-235|,|O
DDI-DrugBank.d357.s0|237-247|ondansetron|O
DDI-DrugBank.d357.s0|248-248|,|O
DDI-DrugBank.d357.s0|250-260|granisetron|O
DDI-DrugBank.d357.s0|261-261|,|O
DDI-DrugBank.d357.s0|263-272|dolasetron|O
DDI-DrugBank.d357.s0|273-273|,|O
DDI-DrugBank.d357.s0|275-286|palonosetron|O
DDI-DrugBank.d357.s0|287-287|,|O
DDI-DrugBank.d357.s0|289-291|and|O
DDI-DrugBank.d357.s0|293-301|alosetron|O
DDI-DrugBank.d357.s0|302-302|)|O
DDI-DrugBank.d357.s0|304-305|is|O
DDI-DrugBank.d357.s0|307-321|contraindicated|O
DDI-DrugBank.d357.s0|323-323|.|O
DDI-DrugBank.d357.s1|0-15|Antihypertensive|O
DDI-DrugBank.d357.s1|17-27|Medications|O
DDI-DrugBank.d357.s1|29-31|and|O
DDI-DrugBank.d357.s1|33-44|Vasodilators|O
DDI-DrugBank.d357.s1|45-45|:|O
DDI-DrugBank.d357.s1|47-49|The|O
DDI-DrugBank.d357.s1|51-59|following|O
DDI-DrugBank.d357.s1|61-67|adverse|O
DDI-DrugBank.d357.s1|69-74|events|O
DDI-DrugBank.d357.s1|76-79|were|O
DDI-DrugBank.d357.s1|81-91|experienced|O
DDI-DrugBank.d357.s1|93-96|more|O
DDI-DrugBank.d357.s1|98-105|commonly|O
DDI-DrugBank.d357.s1|107-108|in|O
DDI-DrugBank.d357.s1|110-117|patients|O
DDI-DrugBank.d357.s1|119-127|receiving|O
DDI-DrugBank.d357.s1|129-139|concomitant|O
DDI-DrugBank.d357.s1|141-156|antihypertensive|O
DDI-DrugBank.d357.s1|158-168|medications|O
DDI-DrugBank.d357.s1|170-171|or|O
DDI-DrugBank.d357.s1|173-184|vasodilators|O
DDI-DrugBank.d357.s1|186-186|(|O
DDI-DrugBank.d357.s1|187-187|n|O
DDI-DrugBank.d357.s1|189-189|=|O
DDI-DrugBank.d357.s1|191-192|94|O
DDI-DrugBank.d357.s1|193-193|)|O
DDI-DrugBank.d357.s1|195-202|compared|O
DDI-DrugBank.d357.s1|204-205|to|O
DDI-DrugBank.d357.s1|207-214|patients|O
DDI-DrugBank.d357.s1|216-218|not|O
DDI-DrugBank.d357.s1|220-228|receiving|O
DDI-DrugBank.d357.s1|230-234|these|O
DDI-DrugBank.d357.s1|236-246|concomitant|O
DDI-DrugBank.d357.s1|248-252|drugs|O
DDI-DrugBank.d357.s1|254-254|(|O
DDI-DrugBank.d357.s1|255-255|n|O
DDI-DrugBank.d357.s1|257-257|=|O
DDI-DrugBank.d357.s1|259-261|456|O
DDI-DrugBank.d357.s1|262-262|)|O
DDI-DrugBank.d357.s1|263-263|:|O
DDI-DrugBank.d357.s1|265-275|hypotension|O
DDI-DrugBank.d357.s1|277-278|10|O
DDI-DrugBank.d357.s1|279-279|%|O
DDI-DrugBank.d357.s1|281-282|vs|O
DDI-DrugBank.d357.s1|284-284|4|O
DDI-DrugBank.d357.s1|285-285|%|O
DDI-DrugBank.d357.s1|286-286|,|O
DDI-DrugBank.d357.s1|288-297|myocardial|O
DDI-DrugBank.d357.s1|299-308|infarction|O
DDI-DrugBank.d357.s1|310-310|3|O
DDI-DrugBank.d357.s1|311-311|%|O
DDI-DrugBank.d357.s1|313-314|vs|O
DDI-DrugBank.d357.s1|316-316|1|O
DDI-DrugBank.d357.s1|317-317|%|O
DDI-DrugBank.d357.s1|318-318|,|O
DDI-DrugBank.d357.s1|320-326|serious|O
DDI-DrugBank.d357.s1|328-336|pneumonia|O
DDI-DrugBank.d357.s1|338-338|5|O
DDI-DrugBank.d357.s1|339-339|%|O
DDI-DrugBank.d357.s1|341-342|vs|O
DDI-DrugBank.d357.s1|344-344|3|O
DDI-DrugBank.d357.s1|345-345|%|O
DDI-DrugBank.d357.s1|346-346|,|O
DDI-DrugBank.d357.s1|348-354|serious|O
DDI-DrugBank.d357.s1|356-360|falls|O
DDI-DrugBank.d357.s1|362-362|9|O
DDI-DrugBank.d357.s1|363-363|%|O
DDI-DrugBank.d357.s1|365-366|vs|O
DDI-DrugBank.d357.s1|368-368|3|O
DDI-DrugBank.d357.s1|369-369|%|O
DDI-DrugBank.d357.s1|370-370|,|O
DDI-DrugBank.d357.s1|372-374|and|O
DDI-DrugBank.d357.s1|376-379|bone|O
DDI-DrugBank.d357.s1|381-383|and|O
DDI-DrugBank.d357.s1|385-389|joint|O
DDI-DrugBank.d357.s1|391-398|injuries|O
DDI-DrugBank.d357.s1|400-400|6|O
DDI-DrugBank.d357.s1|401-401|%|O
DDI-DrugBank.d357.s1|403-404|vs|O
DDI-DrugBank.d357.s1|406-406|2|O
DDI-DrugBank.d357.s1|407-407|%|O
DDI-DrugBank.d357.s1|408-408|.|O
DDI-DrugBank.d357.s2|0-2|The|O
DDI-DrugBank.d357.s2|4-12|mechanism|O
DDI-DrugBank.d357.s2|14-23|underlying|O
DDI-DrugBank.d357.s2|25-28|many|O
DDI-DrugBank.d357.s2|30-31|of|O
DDI-DrugBank.d357.s2|33-37|these|O
DDI-DrugBank.d357.s2|39-44|events|O
DDI-DrugBank.d357.s2|46-47|is|O
DDI-DrugBank.d357.s2|49-55|unknown|O
DDI-DrugBank.d357.s2|56-56|,|O
DDI-DrugBank.d357.s2|58-60|but|O
DDI-DrugBank.d357.s2|62-64|may|O
DDI-DrugBank.d357.s2|66-74|represent|O
DDI-DrugBank.d357.s2|76-84|increased|O
DDI-DrugBank.d357.s2|86-96|hypotension|O
DDI-DrugBank.d357.s2|98-98|.|O
DDI-DrugBank.d357.s3|0-7|Dopamine|O
DDI-DrugBank.d357.s3|9-19|Antagonists|O
DDI-DrugBank.d357.s3|20-20|:|O
DDI-DrugBank.d357.s3|22-26|Since|O
DDI-DrugBank.d357.s3|28-38|apomorphine|O
DDI-DrugBank.d357.s3|40-41|is|O
DDI-DrugBank.d357.s3|43-43|a|O
DDI-DrugBank.d357.s3|45-52|dopamine|O
DDI-DrugBank.d357.s3|54-60|agonist|O
DDI-DrugBank.d357.s3|61-61|,|O
DDI-DrugBank.d357.s3|63-64|it|O
DDI-DrugBank.d357.s3|66-67|is|O
DDI-DrugBank.d357.s3|69-76|possible|O
DDI-DrugBank.d357.s3|78-81|that|O
DDI-DrugBank.d357.s3|83-90|dopamine|O
DDI-DrugBank.d357.s3|92-102|antagonists|O
DDI-DrugBank.d357.s3|103-103|,|O
DDI-DrugBank.d357.s3|105-108|such|O
DDI-DrugBank.d357.s3|110-111|as|O
DDI-DrugBank.d357.s3|113-115|the|O
DDI-DrugBank.d357.s3|117-128|neuroleptics|O
DDI-DrugBank.d357.s3|130-130|(|O
DDI-DrugBank.d357.s3|131-144|phenothiazines|O
DDI-DrugBank.d357.s3|145-145|,|O
DDI-DrugBank.d357.s3|147-160|butyrophenones|O
DDI-DrugBank.d357.s3|161-161|,|O
DDI-DrugBank.d357.s3|163-175|thioxanthenes|O
DDI-DrugBank.d357.s3|176-176|)|O
DDI-DrugBank.d357.s3|178-179|or|O
DDI-DrugBank.d357.s3|181-194|metoclopramide|O
DDI-DrugBank.d357.s3|195-195|,|O
DDI-DrugBank.d357.s3|197-199|may|O
DDI-DrugBank.d357.s3|201-208|diminish|O
DDI-DrugBank.d357.s3|210-212|the|O
DDI-DrugBank.d357.s3|214-226|effectiveness|O
DDI-DrugBank.d357.s3|228-229|of|O
DDI-DrugBank.d357.s3|231-236|APOKYN|O
DDI-DrugBank.d357.s3|237-237|.|O
DDI-DrugBank.d357.s4|0-7|Patients|O
DDI-DrugBank.d357.s4|9-12|with|O
DDI-DrugBank.d357.s4|14-18|major|O
DDI-DrugBank.d357.s4|20-28|psychotic|O
DDI-DrugBank.d357.s4|30-38|disorders|O
DDI-DrugBank.d357.s4|39-39|,|O
DDI-DrugBank.d357.s4|41-47|treated|O
DDI-DrugBank.d357.s4|49-52|with|O
DDI-DrugBank.d357.s4|54-65|neuroleptics|O
DDI-DrugBank.d357.s4|66-66|,|O
DDI-DrugBank.d357.s4|68-73|should|O
DDI-DrugBank.d357.s4|75-76|be|O
DDI-DrugBank.d357.s4|78-84|treated|O
DDI-DrugBank.d357.s4|86-89|with|O
DDI-DrugBank.d357.s4|91-98|dopamine|O
DDI-DrugBank.d357.s4|100-107|agonists|O
DDI-DrugBank.d357.s4|109-112|only|O
DDI-DrugBank.d357.s4|114-115|if|O
DDI-DrugBank.d357.s4|117-119|the|O
DDI-DrugBank.d357.s4|121-129|potential|O
DDI-DrugBank.d357.s4|131-138|benefits|O
DDI-DrugBank.d357.s4|140-147|outweigh|O
DDI-DrugBank.d357.s4|149-151|the|O
DDI-DrugBank.d357.s4|153-157|risks|O
DDI-DrugBank.d357.s4|158-158|.|O
DDI-DrugBank.d357.s5|0-4|Drugs|O
DDI-DrugBank.d357.s5|6-15|Prolonging|O
DDI-DrugBank.d357.s5|17-19|the|O
DDI-DrugBank.d357.s5|21-26|QT/QTc|O
DDI-DrugBank.d357.s5|28-35|Interval|O
DDI-DrugBank.d357.s5|37-43|Caution|O
DDI-DrugBank.d357.s5|45-50|should|O
DDI-DrugBank.d357.s5|52-53|be|O
DDI-DrugBank.d357.s5|55-63|exercised|O
DDI-DrugBank.d357.s5|65-68|when|O
DDI-DrugBank.d357.s5|70-80|prescribing|O
DDI-DrugBank.d357.s5|82-92|apomorphine|O
DDI-DrugBank.d357.s5|94-106|concomitantly|O
DDI-DrugBank.d357.s5|108-111|with|O
DDI-DrugBank.d357.s5|113-117|drugs|O
DDI-DrugBank.d357.s5|119-122|that|O
DDI-DrugBank.d357.s5|124-130|prolong|O
DDI-DrugBank.d357.s5|132-134|the|O
DDI-DrugBank.d357.s5|136-141|QT/QTc|O
DDI-DrugBank.d357.s5|143-150|interval|O
DDI-DrugBank.d357.s5|151-151|.|O
DDI-DrugBank.d357.s6|0-14|Drug/Laboratory|O
DDI-DrugBank.d357.s6|16-19|Test|O
DDI-DrugBank.d357.s6|21-32|Interactions|O
DDI-DrugBank.d357.s6|34-38|There|O
DDI-DrugBank.d357.s6|40-42|are|O
DDI-DrugBank.d357.s6|44-45|no|O
DDI-DrugBank.d357.s6|47-51|known|O
DDI-DrugBank.d357.s6|53-64|interactions|O
DDI-DrugBank.d357.s6|66-72|between|O
DDI-DrugBank.d357.s6|74-79|APOKYN|O
DDI-DrugBank.d357.s6|81-83|and|O
DDI-DrugBank.d357.s6|85-94|laboratory|O
DDI-DrugBank.d357.s6|96-100|tests|O
DDI-DrugBank.d357.s6|101-101|.|O
DDI-MedLine.d29.s0|0-5|Effect|O
DDI-MedLine.d29.s0|7-8|of|O
DDI-MedLine.d29.s0|10-19|probenecid|O
DDI-MedLine.d29.s0|21-22|on|O
DDI-MedLine.d29.s0|24-26|the|O
DDI-MedLine.d29.s0|28-35|apparent|O
DDI-MedLine.d29.s0|37-42|volume|O
DDI-MedLine.d29.s0|44-45|of|O
DDI-MedLine.d29.s0|47-58|distribution|O
DDI-MedLine.d29.s0|60-62|and|O
DDI-MedLine.d29.s0|64-74|elimination|O
DDI-MedLine.d29.s0|76-77|of|O
DDI-MedLine.d29.s0|79-89|cloxacillin|O
DDI-MedLine.d29.s0|90-90|.|O
DDI-MedLine.d29.s1|0-8|According|O
DDI-MedLine.d29.s1|10-11|to|O
DDI-MedLine.d29.s1|13-19|Gibaldi|O
DDI-MedLine.d29.s1|21-22|et|O
DDI-MedLine.d29.s1|24-25|al|O
DDI-MedLine.d29.s1|26-26|.|O
DDI-MedLine.d29.s2|0-0|(|O
DDI-MedLine.d29.s2|1-4|1968|O
DDI-MedLine.d29.s2|5-5|,|O
DDI-MedLine.d29.s2|7-10|1970|O
DDI-MedLine.d29.s2|11-11|)|O
DDI-MedLine.d29.s2|12-12|,|O
DDI-MedLine.d29.s2|14-16|the|O
DDI-MedLine.d29.s2|18-23|higher|O
DDI-MedLine.d29.s2|25-29|serum|O
DDI-MedLine.d29.s2|31-44|concentrations|O
DDI-MedLine.d29.s2|46-47|of|O
DDI-MedLine.d29.s2|49-59|penicillins|O
DDI-MedLine.d29.s2|61-63|and|O
DDI-MedLine.d29.s2|65-77|cephaloridine|O
DDI-MedLine.d29.s2|79-85|reached|O
DDI-MedLine.d29.s2|87-91|after|O
DDI-MedLine.d29.s2|93-106|administration|O
DDI-MedLine.d29.s2|108-109|of|O
DDI-MedLine.d29.s2|111-120|probenecid|O
DDI-MedLine.d29.s2|122-124|are|O
DDI-MedLine.d29.s2|126-128|due|O
DDI-MedLine.d29.s2|130-132|not|O
DDI-MedLine.d29.s2|134-137|only|O
DDI-MedLine.d29.s2|139-140|to|O
DDI-MedLine.d29.s2|142-147|slower|O
DDI-MedLine.d29.s2|149-153|renal|O
DDI-MedLine.d29.s2|155-165|elimination|O
DDI-MedLine.d29.s2|167-169|but|O
DDI-MedLine.d29.s2|171-174|also|O
DDI-MedLine.d29.s2|176-177|to|O
DDI-MedLine.d29.s2|179-180|an|O
DDI-MedLine.d29.s2|182-188|altered|O
DDI-MedLine.d29.s2|190-201|distribution|O
DDI-MedLine.d29.s2|203-204|in|O
DDI-MedLine.d29.s2|206-208|the|O
DDI-MedLine.d29.s2|210-213|body|O
DDI-MedLine.d29.s2|214-214|.|O
DDI-MedLine.d29.s3|0-1|To|O
DDI-MedLine.d29.s3|3-11|determine|O
DDI-MedLine.d29.s3|13-19|whether|O
DDI-MedLine.d29.s3|21-30|probenecid|O
DDI-MedLine.d29.s3|32-34|has|O
DDI-MedLine.d29.s3|36-36|a|O
DDI-MedLine.d29.s3|38-43|direct|O
DDI-MedLine.d29.s3|45-50|effect|O
DDI-MedLine.d29.s3|52-53|on|O
DDI-MedLine.d29.s3|55-57|the|O
DDI-MedLine.d29.s3|59-70|distribution|O
DDI-MedLine.d29.s3|72-73|of|O
DDI-MedLine.d29.s3|75-85|cloxacillin|O
DDI-MedLine.d29.s3|86-86|,|O
DDI-MedLine.d29.s3|88-90|the|O
DDI-MedLine.d29.s3|92-102|elimination|O
DDI-MedLine.d29.s3|104-106|and|O
DDI-MedLine.d29.s3|108-119|distribution|O
DDI-MedLine.d29.s3|121-122|of|O
DDI-MedLine.d29.s3|124-134|cloxacillin|O
DDI-MedLine.d29.s3|136-138|was|O
DDI-MedLine.d29.s3|140-146|studied|O
DDI-MedLine.d29.s3|148-149|in|O
DDI-MedLine.d29.s3|151-153|six|O
DDI-MedLine.d29.s3|155-162|patients|O
DDI-MedLine.d29.s3|163-163|,|O
DDI-MedLine.d29.s3|165-168|five|O
DDI-MedLine.d29.s3|170-176|lacking|O
DDI-MedLine.d29.s3|178-183|kidney|O
DDI-MedLine.d29.s3|185-192|function|O
DDI-MedLine.d29.s3|194-196|and|O
DDI-MedLine.d29.s3|198-200|one|O
DDI-MedLine.d29.s3|202-205|with|O
DDI-MedLine.d29.s3|207-207|a|O
DDI-MedLine.d29.s3|209-217|partially|O
DDI-MedLine.d29.s3|219-226|impaired|O
DDI-MedLine.d29.s3|228-232|renal|O
DDI-MedLine.d29.s3|234-241|function|O
DDI-MedLine.d29.s3|242-242|,|O
DDI-MedLine.d29.s3|244-245|in|O
DDI-MedLine.d29.s3|247-249|the|O
DDI-MedLine.d29.s3|251-258|presence|O
DDI-MedLine.d29.s3|260-261|or|O
DDI-MedLine.d29.s3|263-269|absence|O
DDI-MedLine.d29.s3|271-272|of|O
DDI-MedLine.d29.s3|274-283|probenecid|O
DDI-MedLine.d29.s3|284-284|.|O
DDI-MedLine.d29.s4|0-1|No|O
DDI-MedLine.d29.s4|3-13|significant|O
DDI-MedLine.d29.s4|15-24|difference|O
DDI-MedLine.d29.s4|26-28|was|O
DDI-MedLine.d29.s4|30-34|found|O
DDI-MedLine.d29.s4|36-42|between|O
DDI-MedLine.d29.s4|44-46|the|O
DDI-MedLine.d29.s4|48-51|mean|O
DDI-MedLine.d29.s4|53-58|values|O
DDI-MedLine.d29.s4|60-61|of|O
DDI-MedLine.d29.s4|63-65|the|O
DDI-MedLine.d29.s4|67-72|volume|O
DDI-MedLine.d29.s4|74-75|of|O
DDI-MedLine.d29.s4|77-88|distribution|O
DDI-MedLine.d29.s4|90-91|of|O
DDI-MedLine.d29.s4|93-103|cloxacillin|O
DDI-MedLine.d29.s4|105-108|with|O
DDI-MedLine.d29.s4|110-112|and|O
DDI-MedLine.d29.s4|114-120|without|O
DDI-MedLine.d29.s4|122-131|probenecid|O
DDI-MedLine.d29.s4|133-133|(|O
DDI-MedLine.d29.s4|134-137|13.0|O
DDI-MedLine.d29.s4|139-141|and|O
DDI-MedLine.d29.s4|143-146|12.6|O
DDI-MedLine.d29.s4|148-153|liters|O
DDI-MedLine.d29.s4|154-154|,|O
DDI-MedLine.d29.s4|156-167|respectively|O
DDI-MedLine.d29.s4|168-168|)|O
DDI-MedLine.d29.s4|169-169|.|O
DDI-MedLine.d29.s5|0-3|Thus|O
DDI-MedLine.d29.s5|4-4|,|O
DDI-MedLine.d29.s5|6-8|the|O
DDI-MedLine.d29.s5|10-19|hypothesis|O
DDI-MedLine.d29.s5|21-22|of|O
DDI-MedLine.d29.s5|24-30|Gibaldi|O
DDI-MedLine.d29.s5|32-33|et|O
DDI-MedLine.d29.s5|35-36|al|O
DDI-MedLine.d29.s5|37-37|.|O
DDI-MedLine.d29.s6|0-4|could|O
DDI-MedLine.d29.s6|6-8|not|O
DDI-MedLine.d29.s6|10-11|be|O
DDI-MedLine.d29.s6|13-21|confirmed|O
DDI-MedLine.d29.s6|23-25|for|O
DDI-MedLine.d29.s6|27-37|cloxacillin|O
DDI-MedLine.d29.s6|39-40|in|O
DDI-MedLine.d29.s6|42-49|patients|O
DDI-MedLine.d29.s6|51-57|lacking|O
DDI-MedLine.d29.s6|59-64|kidney|O
DDI-MedLine.d29.s6|66-73|function|O
DDI-MedLine.d29.s6|74-74|.|O
DDI-MedLine.d29.s7|0-1|In|O
DDI-MedLine.d29.s7|3-7|spite|O
DDI-MedLine.d29.s7|9-10|of|O
DDI-MedLine.d29.s7|12-14|the|O
DDI-MedLine.d29.s7|16-22|absence|O
DDI-MedLine.d29.s7|24-25|of|O
DDI-MedLine.d29.s7|27-32|kidney|O
DDI-MedLine.d29.s7|34-41|function|O
DDI-MedLine.d29.s7|42-42|,|O
DDI-MedLine.d29.s7|44-46|the|O
DDI-MedLine.d29.s7|48-52|value|O
DDI-MedLine.d29.s7|54-55|of|O
DDI-MedLine.d29.s7|57-59|the|O
DDI-MedLine.d29.s7|61-71|elimination|O
DDI-MedLine.d29.s7|73-76|rate|O
DDI-MedLine.d29.s7|78-85|constant|O
DDI-MedLine.d29.s7|87-89|was|O
DDI-MedLine.d29.s7|91-103|significantly|O
DDI-MedLine.d29.s7|105-113|decreased|O
DDI-MedLine.d29.s7|115-116|in|O
DDI-MedLine.d29.s7|118-120|the|O
DDI-MedLine.d29.s7|122-129|presence|O
DDI-MedLine.d29.s7|131-132|of|O
DDI-MedLine.d29.s7|134-143|probenecid|O
DDI-MedLine.d29.s7|145-145|(|O
DDI-MedLine.d29.s7|146-149|from|O
DDI-MedLine.d29.s7|151-155|0.326|O
DDI-MedLine.d29.s7|157-158|to|O
DDI-MedLine.d29.s7|160-166|0.263/h|O
DDI-MedLine.d29.s7|167-167|)|O
DDI-MedLine.d29.s7|168-168|.|O
DDI-MedLine.d29.s8|0-3|This|O
DDI-MedLine.d29.s8|5-9|might|O
DDI-MedLine.d29.s8|11-12|be|O
DDI-MedLine.d29.s8|14-22|explained|O
DDI-MedLine.d29.s8|24-25|by|O
DDI-MedLine.d29.s8|27-27|a|O
DDI-MedLine.d29.s8|29-36|blockade|O
DDI-MedLine.d29.s8|38-39|by|O
DDI-MedLine.d29.s8|41-50|probenecid|O
DDI-MedLine.d29.s8|52-53|of|O
DDI-MedLine.d29.s8|55-57|the|O
DDI-MedLine.d29.s8|59-69|elimination|O
DDI-MedLine.d29.s8|71-72|of|O
DDI-MedLine.d29.s8|74-84|cloxacillin|O
DDI-MedLine.d29.s8|86-87|by|O
DDI-MedLine.d29.s8|89-91|the|O
DDI-MedLine.d29.s8|93-97|liver|O
DDI-MedLine.d29.s8|98-98|.|O
DDI-DrugBank.d163.s0|0-6|Vitamin|O
DDI-DrugBank.d163.s0|8-8|A|O
DDI-DrugBank.d163.s0|9-9|:|O
DDI-DrugBank.d163.s0|11-17|Because|O
DDI-DrugBank.d163.s0|19-20|of|O
DDI-DrugBank.d163.s0|22-24|the|O
DDI-DrugBank.d163.s0|26-37|relationship|O
DDI-DrugBank.d163.s0|39-40|of|O
DDI-DrugBank.d163.s0|42-49|Accutane|O
DDI-DrugBank.d163.s0|51-52|to|O
DDI-DrugBank.d163.s0|54-60|vitamin|O
DDI-DrugBank.d163.s0|62-62|A|O
DDI-DrugBank.d163.s0|63-63|,|O
DDI-DrugBank.d163.s0|65-72|patients|O
DDI-DrugBank.d163.s0|74-79|should|O
DDI-DrugBank.d163.s0|81-82|be|O
DDI-DrugBank.d163.s0|84-90|advised|O
DDI-DrugBank.d163.s0|92-98|against|O
DDI-DrugBank.d163.s0|100-105|taking|O
DDI-DrugBank.d163.s0|107-113|vitamin|O
DDI-DrugBank.d163.s0|115-125|supplements|O
DDI-DrugBank.d163.s0|127-136|containing|O
DDI-DrugBank.d163.s0|138-144|vitamin|O
DDI-DrugBank.d163.s0|146-146|A|O
DDI-DrugBank.d163.s0|148-149|to|O
DDI-DrugBank.d163.s0|151-155|avoid|O
DDI-DrugBank.d163.s0|157-164|additive|O
DDI-DrugBank.d163.s0|166-170|toxic|O
DDI-DrugBank.d163.s0|172-178|effects|O
DDI-DrugBank.d163.s1|0-0|.|O
DDI-DrugBank.d163.s2|0-12|Tetracyclines|O
DDI-DrugBank.d163.s2|13-13|:|O
DDI-DrugBank.d163.s2|15-25|Concomitant|O
DDI-DrugBank.d163.s2|27-35|treatment|O
DDI-DrugBank.d163.s2|37-40|with|O
DDI-DrugBank.d163.s2|42-49|Accutane|O
DDI-DrugBank.d163.s2|51-53|and|O
DDI-DrugBank.d163.s2|55-67|tetracyclines|O
DDI-DrugBank.d163.s2|69-74|should|O
DDI-DrugBank.d163.s2|76-77|be|O
DDI-DrugBank.d163.s2|79-85|avoided|O
DDI-DrugBank.d163.s2|87-93|because|O
DDI-DrugBank.d163.s2|95-102|Accutane|O
DDI-DrugBank.d163.s2|104-106|use|O
DDI-DrugBank.d163.s2|108-110|has|O
DDI-DrugBank.d163.s2|112-115|been|O
DDI-DrugBank.d163.s2|117-126|associated|O
DDI-DrugBank.d163.s2|128-131|with|O
DDI-DrugBank.d163.s2|133-133|a|O
DDI-DrugBank.d163.s2|135-140|number|O
DDI-DrugBank.d163.s2|142-143|of|O
DDI-DrugBank.d163.s2|145-149|cases|O
DDI-DrugBank.d163.s2|151-152|of|O
DDI-DrugBank.d163.s2|154-164|pseudotumor|O
DDI-DrugBank.d163.s2|166-172|cerebri|O
DDI-DrugBank.d163.s2|174-174|(|O
DDI-DrugBank.d163.s2|175-180|benign|O
DDI-DrugBank.d163.s2|182-193|intracranial|O
DDI-DrugBank.d163.s2|195-206|hypertension|O
DDI-DrugBank.d163.s2|207-207|)|O
DDI-DrugBank.d163.s2|208-208|,|O
DDI-DrugBank.d163.s2|210-213|some|O
DDI-DrugBank.d163.s2|215-216|of|O
DDI-DrugBank.d163.s2|218-222|which|O
DDI-DrugBank.d163.s2|224-231|involved|O
DDI-DrugBank.d163.s2|233-243|concomitant|O
DDI-DrugBank.d163.s2|245-247|use|O
DDI-DrugBank.d163.s2|249-250|of|O
DDI-DrugBank.d163.s2|252-264|tetracyclines|O
DDI-DrugBank.d163.s3|0-0|.|O
DDI-DrugBank.d163.s4|0-10|Micro-dosed|O
DDI-DrugBank.d163.s4|12-23|Progesterone|O
DDI-DrugBank.d163.s4|25-36|Preparations|O
DDI-DrugBank.d163.s4|37-37|:|O
DDI-DrugBank.d163.s4|39-49|Micro-dosed|O
DDI-DrugBank.d163.s4|51-62|progesterone|O
DDI-DrugBank.d163.s4|64-75|preparations|O
DDI-DrugBank.d163.s4|77-77|(|O
DDI-DrugBank.d163.s4|78-86|minipills|O
DDI-DrugBank.d163.s4|88-91|that|O
DDI-DrugBank.d163.s4|93-94|do|O
DDI-DrugBank.d163.s4|96-98|not|O
DDI-DrugBank.d163.s4|100-106|contain|O
DDI-DrugBank.d163.s4|108-109|an|O
DDI-DrugBank.d163.s4|111-118|estrogen|O
DDI-DrugBank.d163.s4|119-119|)|O
DDI-DrugBank.d163.s4|121-123|may|O
DDI-DrugBank.d163.s4|125-126|be|O
DDI-DrugBank.d163.s4|128-129|an|O
DDI-DrugBank.d163.s4|131-140|inadequate|O
DDI-DrugBank.d163.s4|142-147|method|O
DDI-DrugBank.d163.s4|149-150|of|O
DDI-DrugBank.d163.s4|152-164|contraception|O
DDI-DrugBank.d163.s4|166-171|during|O
DDI-DrugBank.d163.s4|173-180|Accutane|O
DDI-DrugBank.d163.s4|182-188|therapy|O
DDI-DrugBank.d163.s4|189-189|.|O
DDI-DrugBank.d163.s5|0-7|Although|O
DDI-DrugBank.d163.s5|9-13|other|O
DDI-DrugBank.d163.s5|15-22|hormonal|O
DDI-DrugBank.d163.s5|24-37|contraceptives|O
DDI-DrugBank.d163.s5|39-41|are|O
DDI-DrugBank.d163.s5|43-48|highly|O
DDI-DrugBank.d163.s5|50-58|effective|O
DDI-DrugBank.d163.s5|59-59|,|O
DDI-DrugBank.d163.s5|61-65|there|O
DDI-DrugBank.d163.s5|67-70|have|O
DDI-DrugBank.d163.s5|72-75|been|O
DDI-DrugBank.d163.s5|77-83|reports|O
DDI-DrugBank.d163.s5|85-86|of|O
DDI-DrugBank.d163.s5|88-96|pregnancy|O
DDI-DrugBank.d163.s5|98-101|from|O
DDI-DrugBank.d163.s5|103-107|women|O
DDI-DrugBank.d163.s5|109-111|who|O
DDI-DrugBank.d163.s5|113-116|have|O
DDI-DrugBank.d163.s5|118-121|used|O
DDI-DrugBank.d163.s5|123-130|combined|O
DDI-DrugBank.d163.s5|132-135|oral|O
DDI-DrugBank.d163.s5|137-150|contraceptives|O
DDI-DrugBank.d163.s5|151-151|,|O
DDI-DrugBank.d163.s5|153-154|as|O
DDI-DrugBank.d163.s5|156-159|well|O
DDI-DrugBank.d163.s5|161-162|as|O
DDI-DrugBank.d163.s5|164-204|topical/injectable/implantable/insertable|O
DDI-DrugBank.d163.s5|206-213|hormonal|O
DDI-DrugBank.d163.s5|215-219|birth|O
DDI-DrugBank.d163.s5|221-227|control|O
DDI-DrugBank.d163.s5|229-236|products|O
DDI-DrugBank.d163.s5|237-237|.|O
DDI-DrugBank.d163.s6|0-4|These|O
DDI-DrugBank.d163.s6|6-12|reports|O
DDI-DrugBank.d163.s6|14-16|are|O
DDI-DrugBank.d163.s6|18-21|more|O
DDI-DrugBank.d163.s6|23-30|frequent|O
DDI-DrugBank.d163.s6|32-34|for|O
DDI-DrugBank.d163.s6|36-40|women|O
DDI-DrugBank.d163.s6|42-44|who|O
DDI-DrugBank.d163.s6|46-48|use|O
DDI-DrugBank.d163.s6|50-53|only|O
DDI-DrugBank.d163.s6|55-55|a|O
DDI-DrugBank.d163.s6|57-62|single|O
DDI-DrugBank.d163.s6|64-69|method|O
DDI-DrugBank.d163.s6|71-72|of|O
DDI-DrugBank.d163.s6|74-86|contraception|O
DDI-DrugBank.d163.s6|87-87|.|O
DDI-DrugBank.d163.s7|0-1|It|O
DDI-DrugBank.d163.s7|3-4|is|O
DDI-DrugBank.d163.s7|6-8|not|O
DDI-DrugBank.d163.s7|10-14|known|O
DDI-DrugBank.d163.s7|16-17|if|O
DDI-DrugBank.d163.s7|19-26|hormonal|O
DDI-DrugBank.d163.s7|28-41|contraceptives|O
DDI-DrugBank.d163.s7|43-48|differ|O
DDI-DrugBank.d163.s7|50-51|in|O
DDI-DrugBank.d163.s7|53-57|their|O
DDI-DrugBank.d163.s7|59-71|effectiveness|O
DDI-DrugBank.d163.s7|73-76|when|O
DDI-DrugBank.d163.s7|78-81|used|O
DDI-DrugBank.d163.s7|83-86|with|O
DDI-DrugBank.d163.s7|88-95|Accutane|O
DDI-DrugBank.d163.s7|96-96|.|O
DDI-DrugBank.d163.s8|0-8|Therefore|O
DDI-DrugBank.d163.s8|9-9|,|O
DDI-DrugBank.d163.s8|11-12|it|O
DDI-DrugBank.d163.s8|14-15|is|O
DDI-DrugBank.d163.s8|17-26|critically|O
DDI-DrugBank.d163.s8|28-36|important|O
DDI-DrugBank.d163.s8|38-40|for|O
DDI-DrugBank.d163.s8|42-46|women|O
DDI-DrugBank.d163.s8|48-49|of|O
DDI-DrugBank.d163.s8|51-62|childbearing|O
DDI-DrugBank.d163.s8|64-72|potential|O
DDI-DrugBank.d163.s8|74-75|to|O
DDI-DrugBank.d163.s8|77-82|select|O
DDI-DrugBank.d163.s8|84-86|and|O
DDI-DrugBank.d163.s8|88-93|commit|O
DDI-DrugBank.d163.s8|95-96|to|O
DDI-DrugBank.d163.s8|98-100|use|O
DDI-DrugBank.d163.s8|102-102|2|O
DDI-DrugBank.d163.s8|104-108|forms|O
DDI-DrugBank.d163.s8|110-111|of|O
DDI-DrugBank.d163.s8|113-121|effective|O
DDI-DrugBank.d163.s8|123-135|contraception|O
DDI-DrugBank.d163.s8|137-150|simultaneously|O
DDI-DrugBank.d163.s8|151-151|,|O
DDI-DrugBank.d163.s8|153-154|at|O
DDI-DrugBank.d163.s8|156-160|least|O
DDI-DrugBank.d163.s8|162-162|1|O
DDI-DrugBank.d163.s8|164-165|of|O
DDI-DrugBank.d163.s8|167-171|which|O
DDI-DrugBank.d163.s8|173-176|must|O
DDI-DrugBank.d163.s8|178-179|be|O
DDI-DrugBank.d163.s8|181-181|a|O
DDI-DrugBank.d163.s8|183-189|primary|O
DDI-DrugBank.d163.s8|191-194|form|O
DDI-DrugBank.d163.s8|195-195|,|O
DDI-DrugBank.d163.s8|197-202|unless|O
DDI-DrugBank.d163.s8|204-211|absolute|O
DDI-DrugBank.d163.s8|213-222|abstinence|O
DDI-DrugBank.d163.s8|224-225|is|O
DDI-DrugBank.d163.s8|227-229|the|O
DDI-DrugBank.d163.s8|231-236|chosen|O
DDI-DrugBank.d163.s8|238-243|method|O
DDI-DrugBank.d163.s8|244-244|,|O
DDI-DrugBank.d163.s8|246-247|or|O
DDI-DrugBank.d163.s8|249-251|the|O
DDI-DrugBank.d163.s8|253-259|patient|O
DDI-DrugBank.d163.s8|261-263|has|O
DDI-DrugBank.d163.s8|265-273|undergone|O
DDI-DrugBank.d163.s8|275-275|a|O
DDI-DrugBank.d163.s8|277-288|hysterectomy|O
DDI-DrugBank.d163.s9|0-0|.|O
DDI-DrugBank.d163.s10|0-8|Phenytoin|O
DDI-DrugBank.d163.s10|9-9|:|O
DDI-DrugBank.d163.s10|11-18|Accutane|O
DDI-DrugBank.d163.s10|20-22|has|O
DDI-DrugBank.d163.s10|24-26|not|O
DDI-DrugBank.d163.s10|28-31|been|O
DDI-DrugBank.d163.s10|33-37|shown|O
DDI-DrugBank.d163.s10|39-40|to|O
DDI-DrugBank.d163.s10|42-46|alter|O
DDI-DrugBank.d163.s10|48-50|the|O
DDI-DrugBank.d163.s10|52-67|pharmacokinetics|O
DDI-DrugBank.d163.s10|69-70|of|O
DDI-DrugBank.d163.s10|72-80|phenytoin|O
DDI-DrugBank.d163.s10|82-83|in|O
DDI-DrugBank.d163.s10|85-85|a|O
DDI-DrugBank.d163.s10|87-91|study|O
DDI-DrugBank.d163.s10|93-94|in|O
DDI-DrugBank.d163.s10|96-100|seven|O
DDI-DrugBank.d163.s10|102-108|healthy|O
DDI-DrugBank.d163.s10|110-119|volunteers|O
DDI-DrugBank.d163.s10|120-120|.|O
DDI-DrugBank.d163.s11|0-4|These|O
DDI-DrugBank.d163.s11|6-12|results|O
DDI-DrugBank.d163.s11|14-16|are|O
DDI-DrugBank.d163.s11|18-27|consistent|O
DDI-DrugBank.d163.s11|29-32|with|O
DDI-DrugBank.d163.s11|34-36|the|O
DDI-DrugBank.d163.s11|38-39|in|O
DDI-DrugBank.d163.s11|41-45|vitro|O
DDI-DrugBank.d163.s11|47-53|finding|O
DDI-DrugBank.d163.s11|55-58|that|O
DDI-DrugBank.d163.s11|60-66|neither|O
DDI-DrugBank.d163.s11|68-79|isotretinoin|O
DDI-DrugBank.d163.s11|81-83|nor|O
DDI-DrugBank.d163.s11|85-87|its|O
DDI-DrugBank.d163.s11|89-99|metabolites|O
DDI-DrugBank.d163.s11|101-106|induce|O
DDI-DrugBank.d163.s11|108-109|or|O
DDI-DrugBank.d163.s11|111-117|inhibit|O
DDI-DrugBank.d163.s11|119-121|the|O
DDI-DrugBank.d163.s11|123-130|activity|O
DDI-DrugBank.d163.s11|132-133|of|O
DDI-DrugBank.d163.s11|135-137|the|O
DDI-DrugBank.d163.s11|139-141|CYP|O
DDI-DrugBank.d163.s11|143-145|2C9|O
DDI-DrugBank.d163.s11|147-151|human|O
DDI-DrugBank.d163.s11|153-159|hepatic|O
DDI-DrugBank.d163.s11|161-164|P450|O
DDI-DrugBank.d163.s11|166-171|enzyme|O
DDI-DrugBank.d163.s11|172-172|.|O
DDI-DrugBank.d163.s12|0-8|Phenytoin|O
DDI-DrugBank.d163.s12|10-11|is|O
DDI-DrugBank.d163.s12|13-17|known|O
DDI-DrugBank.d163.s12|19-20|to|O
DDI-DrugBank.d163.s12|22-26|cause|O
DDI-DrugBank.d163.s12|28-39|osteomalacia|O
DDI-DrugBank.d163.s12|40-40|.|O
DDI-DrugBank.d163.s13|0-1|No|O
DDI-DrugBank.d163.s13|3-8|formal|O
DDI-DrugBank.d163.s13|10-17|clinical|O
DDI-DrugBank.d163.s13|19-25|studies|O
DDI-DrugBank.d163.s13|27-30|have|O
DDI-DrugBank.d163.s13|32-35|been|O
DDI-DrugBank.d163.s13|37-45|conducted|O
DDI-DrugBank.d163.s13|47-48|to|O
DDI-DrugBank.d163.s13|50-55|assess|O
DDI-DrugBank.d163.s13|57-58|if|O
DDI-DrugBank.d163.s13|60-64|there|O
DDI-DrugBank.d163.s13|66-67|is|O
DDI-DrugBank.d163.s13|69-70|an|O
DDI-DrugBank.d163.s13|72-82|interactive|O
DDI-DrugBank.d163.s13|84-89|effect|O
DDI-DrugBank.d163.s13|91-92|on|O
DDI-DrugBank.d163.s13|94-97|bone|O
DDI-DrugBank.d163.s13|99-102|loss|O
DDI-DrugBank.d163.s13|104-110|between|O
DDI-DrugBank.d163.s13|112-120|phenytoin|O
DDI-DrugBank.d163.s13|122-124|and|O
DDI-DrugBank.d163.s13|126-133|Accutane|O
DDI-DrugBank.d163.s13|134-134|.|O
DDI-DrugBank.d163.s14|0-8|Therefore|O
DDI-DrugBank.d163.s14|9-9|,|O
DDI-DrugBank.d163.s14|11-17|caution|O
DDI-DrugBank.d163.s14|19-24|should|O
DDI-DrugBank.d163.s14|26-27|be|O
DDI-DrugBank.d163.s14|29-37|exercised|O
DDI-DrugBank.d163.s14|39-42|when|O
DDI-DrugBank.d163.s14|44-48|using|O
DDI-DrugBank.d163.s14|50-54|these|O
DDI-DrugBank.d163.s14|56-60|drugs|O
DDI-DrugBank.d163.s14|62-69|together|O
DDI-DrugBank.d163.s15|0-0|.|O
DDI-DrugBank.d163.s16|0-7|Systemic|O
DDI-DrugBank.d163.s16|9-23|Corticosteroids|O
DDI-DrugBank.d163.s16|24-24|:|O
DDI-DrugBank.d163.s16|26-33|Systemic|O
DDI-DrugBank.d163.s16|35-49|corticosteroids|O
DDI-DrugBank.d163.s16|51-53|are|O
DDI-DrugBank.d163.s16|55-59|known|O
DDI-DrugBank.d163.s16|61-62|to|O
DDI-DrugBank.d163.s16|64-68|cause|O
DDI-DrugBank.d163.s16|70-81|osteoporosis|O
DDI-DrugBank.d163.s16|82-82|.|O
DDI-DrugBank.d163.s17|0-1|No|O
DDI-DrugBank.d163.s17|3-8|formal|O
DDI-DrugBank.d163.s17|10-17|clinical|O
DDI-DrugBank.d163.s17|19-25|studies|O
DDI-DrugBank.d163.s17|27-30|have|O
DDI-DrugBank.d163.s17|32-35|been|O
DDI-DrugBank.d163.s17|37-45|conducted|O
DDI-DrugBank.d163.s17|47-48|to|O
DDI-DrugBank.d163.s17|50-55|assess|O
DDI-DrugBank.d163.s17|57-58|if|O
DDI-DrugBank.d163.s17|60-64|there|O
DDI-DrugBank.d163.s17|66-67|is|O
DDI-DrugBank.d163.s17|69-70|an|O
DDI-DrugBank.d163.s17|72-82|interactive|O
DDI-DrugBank.d163.s17|84-89|effect|O
DDI-DrugBank.d163.s17|91-92|on|O
DDI-DrugBank.d163.s17|94-97|bone|O
DDI-DrugBank.d163.s17|99-102|loss|O
DDI-DrugBank.d163.s17|104-110|between|O
DDI-DrugBank.d163.s17|112-119|systemic|O
DDI-DrugBank.d163.s17|121-135|corticosteroids|O
DDI-DrugBank.d163.s17|137-139|and|O
DDI-DrugBank.d163.s17|141-148|Accutane|O
DDI-DrugBank.d163.s17|149-149|.|O
DDI-DrugBank.d163.s18|0-8|Therefore|O
DDI-DrugBank.d163.s18|9-9|,|O
DDI-DrugBank.d163.s18|11-17|caution|O
DDI-DrugBank.d163.s18|19-24|should|O
DDI-DrugBank.d163.s18|26-27|be|O
DDI-DrugBank.d163.s18|29-37|exercised|O
DDI-DrugBank.d163.s18|39-42|when|O
DDI-DrugBank.d163.s18|44-48|using|O
DDI-DrugBank.d163.s18|50-54|these|O
DDI-DrugBank.d163.s18|56-60|drugs|O
DDI-DrugBank.d163.s18|62-69|together|O
DDI-DrugBank.d163.s18|70-70|.|O
DDI-DrugBank.d163.s19|0-10|Prescribers|O
DDI-DrugBank.d163.s19|12-14|are|O
DDI-DrugBank.d163.s19|16-22|advised|O
DDI-DrugBank.d163.s19|24-25|to|O
DDI-DrugBank.d163.s19|27-33|consult|O
DDI-DrugBank.d163.s19|35-37|the|O
DDI-DrugBank.d163.s19|39-45|package|O
DDI-DrugBank.d163.s19|47-52|insert|O
DDI-DrugBank.d163.s19|54-55|of|O
DDI-DrugBank.d163.s19|57-66|medication|O
DDI-DrugBank.d163.s19|68-79|administered|O
DDI-DrugBank.d163.s19|81-93|concomitantly|O
DDI-DrugBank.d163.s19|95-98|with|O
DDI-DrugBank.d163.s19|100-107|hormonal|O
DDI-DrugBank.d163.s19|109-122|contraceptives|O
DDI-DrugBank.d163.s19|123-123|,|O
DDI-DrugBank.d163.s19|125-129|since|O
DDI-DrugBank.d163.s19|131-134|some|O
DDI-DrugBank.d163.s19|136-146|medications|O
DDI-DrugBank.d163.s19|148-150|may|O
DDI-DrugBank.d163.s19|152-159|decrease|O
DDI-DrugBank.d163.s19|161-163|the|O
DDI-DrugBank.d163.s19|165-177|effectiveness|O
DDI-DrugBank.d163.s19|179-180|of|O
DDI-DrugBank.d163.s19|182-186|these|O
DDI-DrugBank.d163.s19|188-192|birth|O
DDI-DrugBank.d163.s19|194-200|control|O
DDI-DrugBank.d163.s19|202-209|products|O
DDI-DrugBank.d163.s19|210-210|.|O
DDI-DrugBank.d163.s20|0-7|Accutane|O
DDI-DrugBank.d163.s20|9-11|use|O
DDI-DrugBank.d163.s20|13-14|is|O
DDI-DrugBank.d163.s20|16-25|associated|O
DDI-DrugBank.d163.s20|27-30|with|O
DDI-DrugBank.d163.s20|32-41|depression|O
DDI-DrugBank.d163.s20|43-44|in|O
DDI-DrugBank.d163.s20|46-49|some|O
DDI-DrugBank.d163.s20|51-58|patients|O
DDI-DrugBank.d163.s20|59-59|.|O
DDI-DrugBank.d163.s21|0-10|Pregnancies|O
DDI-DrugBank.d163.s21|12-15|have|O
DDI-DrugBank.d163.s21|17-20|been|O
DDI-DrugBank.d163.s21|22-29|reported|O
DDI-DrugBank.d163.s21|31-32|by|O
DDI-DrugBank.d163.s21|34-38|users|O
DDI-DrugBank.d163.s21|40-41|of|O
DDI-DrugBank.d163.s21|43-50|combined|O
DDI-DrugBank.d163.s21|52-59|hormonal|O
DDI-DrugBank.d163.s21|61-74|contraceptives|O
DDI-DrugBank.d163.s21|76-78|who|O
DDI-DrugBank.d163.s21|80-83|also|O
DDI-DrugBank.d163.s21|85-88|used|O
DDI-DrugBank.d163.s21|90-93|some|O
DDI-DrugBank.d163.s21|95-98|form|O
DDI-DrugBank.d163.s21|100-101|of|O
DDI-DrugBank.d163.s21|103-105|St.|O
DDI-DrugBank.d163.s21|107-111|Johns|O
DDI-DrugBank.d163.s21|113-116|Wort|O
DDI-DrugBank.d163.s21|117-117|.|O
DDI-DrugBank.d163.s22|0-9|Laboratory|O
DDI-DrugBank.d163.s22|11-15|Tests|O
DDI-DrugBank.d163.s22|17-25|Pregnancy|O
DDI-DrugBank.d163.s22|27-30|Test|O
DDI-DrugBank.d163.s22|32-37|Female|O
DDI-DrugBank.d163.s22|39-46|patients|O
DDI-DrugBank.d163.s22|48-49|of|O
DDI-DrugBank.d163.s22|51-62|childbearing|O
DDI-DrugBank.d163.s22|64-72|potential|O
DDI-DrugBank.d163.s22|74-77|must|O
DDI-DrugBank.d163.s22|79-82|have|O
DDI-DrugBank.d163.s22|84-91|negative|O
DDI-DrugBank.d163.s22|93-99|results|O
DDI-DrugBank.d163.s22|101-104|from|O
DDI-DrugBank.d163.s22|106-106|2|O
DDI-DrugBank.d163.s22|108-112|urine|O
DDI-DrugBank.d163.s22|114-115|or|O
DDI-DrugBank.d163.s22|117-121|serum|O
DDI-DrugBank.d163.s22|123-131|pregnancy|O
DDI-DrugBank.d163.s22|133-137|tests|O
DDI-DrugBank.d163.s22|139-142|with|O
DDI-DrugBank.d163.s22|144-144|a|O
DDI-DrugBank.d163.s22|146-156|sensitivity|O
DDI-DrugBank.d163.s22|158-159|of|O
DDI-DrugBank.d163.s22|161-162|at|O
DDI-DrugBank.d163.s22|164-168|least|O
DDI-DrugBank.d163.s22|170-171|25|O
DDI-DrugBank.d163.s22|173-178|mIU/mL|O
DDI-DrugBank.d163.s22|180-185|before|O
DDI-DrugBank.d163.s22|187-195|receiving|O
DDI-DrugBank.d163.s22|197-199|the|O
DDI-DrugBank.d163.s22|201-207|initial|O
DDI-DrugBank.d163.s22|209-216|Accutane|O
DDI-DrugBank.d163.s22|218-229|prescription|O
DDI-DrugBank.d163.s22|230-230|.|O
DDI-DrugBank.d163.s23|0-2|The|O
DDI-DrugBank.d163.s23|4-8|first|O
DDI-DrugBank.d163.s23|10-13|test|O
DDI-DrugBank.d163.s23|15-16|is|O
DDI-DrugBank.d163.s23|18-25|obtained|O
DDI-DrugBank.d163.s23|27-28|by|O
DDI-DrugBank.d163.s23|30-32|the|O
DDI-DrugBank.d163.s23|34-43|prescriber|O
DDI-DrugBank.d163.s23|45-48|when|O
DDI-DrugBank.d163.s23|50-52|the|O
DDI-DrugBank.d163.s23|54-61|decision|O
DDI-DrugBank.d163.s23|63-64|is|O
DDI-DrugBank.d163.s23|66-69|made|O
DDI-DrugBank.d163.s23|71-72|to|O
DDI-DrugBank.d163.s23|74-79|pursue|O
DDI-DrugBank.d163.s23|81-93|qualification|O
DDI-DrugBank.d163.s23|95-96|of|O
DDI-DrugBank.d163.s23|98-100|the|O
DDI-DrugBank.d163.s23|102-108|patient|O
DDI-DrugBank.d163.s23|110-112|for|O
DDI-DrugBank.d163.s23|114-121|Accutane|O
DDI-DrugBank.d163.s23|123-123|(|O
DDI-DrugBank.d163.s23|124-124|a|O
DDI-DrugBank.d163.s23|126-134|screening|O
DDI-DrugBank.d163.s23|136-139|test|O
DDI-DrugBank.d163.s23|140-140|)|O
DDI-DrugBank.d163.s23|141-141|.|O
DDI-DrugBank.d163.s24|0-2|The|O
DDI-DrugBank.d163.s24|4-9|second|O
DDI-DrugBank.d163.s24|11-19|pregnancy|O
DDI-DrugBank.d163.s24|21-24|test|O
DDI-DrugBank.d163.s24|26-26|(|O
DDI-DrugBank.d163.s24|27-27|a|O
DDI-DrugBank.d163.s24|29-40|confirmation|O
DDI-DrugBank.d163.s24|42-45|test|O
DDI-DrugBank.d163.s24|46-46|)|O
DDI-DrugBank.d163.s24|48-53|should|O
DDI-DrugBank.d163.s24|55-56|be|O
DDI-DrugBank.d163.s24|58-61|done|O
DDI-DrugBank.d163.s24|63-68|during|O
DDI-DrugBank.d163.s24|70-72|the|O
DDI-DrugBank.d163.s24|74-78|first|O
DDI-DrugBank.d163.s24|80-80|5|O
DDI-DrugBank.d163.s24|82-85|days|O
DDI-DrugBank.d163.s24|87-88|of|O
DDI-DrugBank.d163.s24|90-92|the|O
DDI-DrugBank.d163.s24|94-102|menstrual|O
DDI-DrugBank.d163.s24|104-109|period|O
DDI-DrugBank.d163.s24|111-121|immediately|O
DDI-DrugBank.d163.s24|123-131|preceding|O
DDI-DrugBank.d163.s24|133-135|the|O
DDI-DrugBank.d163.s24|137-145|beginning|O
DDI-DrugBank.d163.s24|147-148|of|O
DDI-DrugBank.d163.s24|150-157|Accutane|O
DDI-DrugBank.d163.s24|159-165|therapy|O
DDI-DrugBank.d163.s24|166-166|.|O
DDI-DrugBank.d163.s25|0-2|For|O
DDI-DrugBank.d163.s25|4-11|patients|O
DDI-DrugBank.d163.s25|13-16|with|O
DDI-DrugBank.d163.s25|18-27|amenorrhea|O
DDI-DrugBank.d163.s25|28-28|,|O
DDI-DrugBank.d163.s25|30-32|the|O
DDI-DrugBank.d163.s25|34-39|second|O
DDI-DrugBank.d163.s25|41-44|test|O
DDI-DrugBank.d163.s25|46-51|should|O
DDI-DrugBank.d163.s25|53-54|be|O
DDI-DrugBank.d163.s25|56-59|done|O
DDI-DrugBank.d163.s25|61-62|at|O
DDI-DrugBank.d163.s25|64-68|least|O
DDI-DrugBank.d163.s25|70-71|11|O
DDI-DrugBank.d163.s25|73-76|days|O
DDI-DrugBank.d163.s25|78-82|after|O
DDI-DrugBank.d163.s25|84-86|the|O
DDI-DrugBank.d163.s25|88-91|last|O
DDI-DrugBank.d163.s25|93-95|act|O
DDI-DrugBank.d163.s25|97-98|of|O
DDI-DrugBank.d163.s25|100-110|unprotected|O
DDI-DrugBank.d163.s25|112-117|sexual|O
DDI-DrugBank.d163.s25|119-129|intercourse|O
DDI-DrugBank.d163.s25|131-131|(|O
DDI-DrugBank.d163.s25|132-138|without|O
DDI-DrugBank.d163.s25|140-144|using|O
DDI-DrugBank.d163.s25|146-146|2|O
DDI-DrugBank.d163.s25|148-156|effective|O
DDI-DrugBank.d163.s25|158-162|forms|O
DDI-DrugBank.d163.s25|164-165|of|O
DDI-DrugBank.d163.s25|167-179|contraception|O
DDI-DrugBank.d163.s25|180-180|)|O
DDI-DrugBank.d163.s25|181-181|.|O
DDI-DrugBank.d163.s26|0-3|Each|O
DDI-DrugBank.d163.s26|5-9|month|O
DDI-DrugBank.d163.s26|11-12|of|O
DDI-DrugBank.d163.s26|14-20|therapy|O
DDI-DrugBank.d163.s26|21-21|,|O
DDI-DrugBank.d163.s26|23-25|the|O
DDI-DrugBank.d163.s26|27-33|patient|O
DDI-DrugBank.d163.s26|35-38|must|O
DDI-DrugBank.d163.s26|40-43|have|O
DDI-DrugBank.d163.s26|45-45|a|O
DDI-DrugBank.d163.s26|47-54|negative|O
DDI-DrugBank.d163.s26|56-61|result|O
DDI-DrugBank.d163.s26|63-66|from|O
DDI-DrugBank.d163.s26|68-68|a|O
DDI-DrugBank.d163.s26|70-74|urine|O
DDI-DrugBank.d163.s26|76-77|or|O
DDI-DrugBank.d163.s26|79-83|serum|O
DDI-DrugBank.d163.s26|85-93|pregnancy|O
DDI-DrugBank.d163.s26|95-98|test|O
DDI-DrugBank.d163.s26|99-99|.|O
DDI-DrugBank.d163.s27|0-0|A|O
DDI-DrugBank.d163.s27|2-10|pregnancy|O
DDI-DrugBank.d163.s27|12-15|test|O
DDI-DrugBank.d163.s27|17-20|must|O
DDI-DrugBank.d163.s27|22-23|be|O
DDI-DrugBank.d163.s27|25-32|repeated|O
DDI-DrugBank.d163.s27|34-37|each|O
DDI-DrugBank.d163.s27|39-43|month|O
DDI-DrugBank.d163.s27|45-49|prior|O
DDI-DrugBank.d163.s27|51-52|to|O
DDI-DrugBank.d163.s27|54-56|the|O
DDI-DrugBank.d163.s27|58-63|female|O
DDI-DrugBank.d163.s27|65-71|patient|O
DDI-DrugBank.d163.s27|73-81|receiving|O
DDI-DrugBank.d163.s27|83-86|each|O
DDI-DrugBank.d163.s27|88-99|prescription|O
DDI-DrugBank.d163.s28|0-0|.|O
DDI-DrugBank.d163.s29|0-5|Lipids|O
DDI-DrugBank.d163.s29|6-6|:|O
DDI-DrugBank.d163.s29|8-19|Pretreatment|O
DDI-DrugBank.d163.s29|21-23|and|O
DDI-DrugBank.d163.s29|25-33|follow-up|O
DDI-DrugBank.d163.s29|35-39|blood|O
DDI-DrugBank.d163.s29|41-46|lipids|O
DDI-DrugBank.d163.s29|48-53|should|O
DDI-DrugBank.d163.s29|55-56|be|O
DDI-DrugBank.d163.s29|58-65|obtained|O
DDI-DrugBank.d163.s29|67-71|under|O
DDI-DrugBank.d163.s29|73-79|fasting|O
DDI-DrugBank.d163.s29|81-90|conditions|O
DDI-DrugBank.d163.s29|91-91|.|O
DDI-DrugBank.d163.s30|0-4|After|O
DDI-DrugBank.d163.s30|6-16|consumption|O
DDI-DrugBank.d163.s30|18-19|of|O
DDI-DrugBank.d163.s30|21-27|alcohol|O
DDI-DrugBank.d163.s30|28-28|,|O
DDI-DrugBank.d163.s30|30-31|at|O
DDI-DrugBank.d163.s30|33-37|least|O
DDI-DrugBank.d163.s30|39-40|36|O
DDI-DrugBank.d163.s30|42-46|hours|O
DDI-DrugBank.d163.s30|48-53|should|O
DDI-DrugBank.d163.s30|55-60|elapse|O
DDI-DrugBank.d163.s30|62-67|before|O
DDI-DrugBank.d163.s30|69-73|these|O
DDI-DrugBank.d163.s30|75-88|determinations|O
DDI-DrugBank.d163.s30|90-92|are|O
DDI-DrugBank.d163.s30|94-97|made|O
DDI-DrugBank.d163.s30|98-98|.|O
DDI-DrugBank.d163.s31|0-1|It|O
DDI-DrugBank.d163.s31|3-4|is|O
DDI-DrugBank.d163.s31|6-16|recommended|O
DDI-DrugBank.d163.s31|18-21|that|O
DDI-DrugBank.d163.s31|23-27|these|O
DDI-DrugBank.d163.s31|29-33|tests|O
DDI-DrugBank.d163.s31|35-36|be|O
DDI-DrugBank.d163.s31|38-46|performed|O
DDI-DrugBank.d163.s31|48-49|at|O
DDI-DrugBank.d163.s31|51-56|weekly|O
DDI-DrugBank.d163.s31|58-59|or|O
DDI-DrugBank.d163.s31|61-68|biweekly|O
DDI-DrugBank.d163.s31|70-78|intervals|O
DDI-DrugBank.d163.s31|80-84|until|O
DDI-DrugBank.d163.s31|86-88|the|O
DDI-DrugBank.d163.s31|90-94|lipid|O
DDI-DrugBank.d163.s31|96-103|response|O
DDI-DrugBank.d163.s31|105-106|to|O
DDI-DrugBank.d163.s31|108-115|Accutane|O
DDI-DrugBank.d163.s31|117-118|is|O
DDI-DrugBank.d163.s31|120-130|established|O
DDI-DrugBank.d163.s31|131-131|.|O
DDI-DrugBank.d163.s32|0-2|The|O
DDI-DrugBank.d163.s32|4-12|incidence|O
DDI-DrugBank.d163.s32|14-15|of|O
DDI-DrugBank.d163.s32|17-36|hypertriglyceridemia|O
DDI-DrugBank.d163.s32|38-39|is|O
DDI-DrugBank.d163.s32|41-41|1|O
DDI-DrugBank.d163.s32|43-49|patient|O
DDI-DrugBank.d163.s32|51-52|in|O
DDI-DrugBank.d163.s32|54-54|4|O
DDI-DrugBank.d163.s32|56-57|on|O
DDI-DrugBank.d163.s32|59-66|Accutane|O
DDI-DrugBank.d163.s32|68-74|therapy|O
DDI-DrugBank.d163.s33|0-0|.|O
DDI-DrugBank.d163.s34|0-4|Liver|O
DDI-DrugBank.d163.s34|6-13|Function|O
DDI-DrugBank.d163.s34|15-19|Tests|O
DDI-DrugBank.d163.s34|20-20|:|O
DDI-DrugBank.d163.s34|22-26|Since|O
DDI-DrugBank.d163.s34|28-37|elevations|O
DDI-DrugBank.d163.s34|39-40|of|O
DDI-DrugBank.d163.s34|42-46|liver|O
DDI-DrugBank.d163.s34|48-54|enzymes|O
DDI-DrugBank.d163.s34|56-59|have|O
DDI-DrugBank.d163.s34|61-64|been|O
DDI-DrugBank.d163.s34|66-73|observed|O
DDI-DrugBank.d163.s34|75-80|during|O
DDI-DrugBank.d163.s34|82-89|clinical|O
DDI-DrugBank.d163.s34|91-96|trials|O
DDI-DrugBank.d163.s34|97-97|,|O
DDI-DrugBank.d163.s34|99-101|and|O
DDI-DrugBank.d163.s34|103-111|hepatitis|O
DDI-DrugBank.d163.s34|113-115|has|O
DDI-DrugBank.d163.s34|117-120|been|O
DDI-DrugBank.d163.s34|122-129|reported|O
DDI-DrugBank.d163.s34|130-130|,|O
DDI-DrugBank.d163.s34|132-143|pretreatment|O
DDI-DrugBank.d163.s34|145-147|and|O
DDI-DrugBank.d163.s34|149-157|follow-up|O
DDI-DrugBank.d163.s34|159-163|liver|O
DDI-DrugBank.d163.s34|165-172|function|O
DDI-DrugBank.d163.s34|174-178|tests|O
DDI-DrugBank.d163.s34|180-185|should|O
DDI-DrugBank.d163.s34|187-188|be|O
DDI-DrugBank.d163.s34|190-198|performed|O
DDI-DrugBank.d163.s34|200-201|at|O
DDI-DrugBank.d163.s34|203-208|weekly|O
DDI-DrugBank.d163.s34|210-211|or|O
DDI-DrugBank.d163.s34|213-220|biweekly|O
DDI-DrugBank.d163.s34|222-230|intervals|O
DDI-DrugBank.d163.s34|232-236|until|O
DDI-DrugBank.d163.s34|238-240|the|O
DDI-DrugBank.d163.s34|242-249|response|O
DDI-DrugBank.d163.s34|251-252|to|O
DDI-DrugBank.d163.s34|254-261|Accutane|O
DDI-DrugBank.d163.s34|263-265|has|O
DDI-DrugBank.d163.s34|267-270|been|O
DDI-DrugBank.d163.s34|272-282|established|O
DDI-DrugBank.d163.s35|0-0|.|O
DDI-DrugBank.d163.s36|0-6|Glucose|O
DDI-DrugBank.d163.s36|7-7|:|O
DDI-DrugBank.d163.s36|9-12|Some|O
DDI-DrugBank.d163.s36|14-21|patients|O
DDI-DrugBank.d163.s36|23-31|receiving|O
DDI-DrugBank.d163.s36|33-40|Accutane|O
DDI-DrugBank.d163.s36|42-45|have|O
DDI-DrugBank.d163.s36|47-57|experienced|O
DDI-DrugBank.d163.s36|59-66|problems|O
DDI-DrugBank.d163.s36|68-69|in|O
DDI-DrugBank.d163.s36|71-73|the|O
DDI-DrugBank.d163.s36|75-81|control|O
DDI-DrugBank.d163.s36|83-84|of|O
DDI-DrugBank.d163.s36|86-90|their|O
DDI-DrugBank.d163.s36|92-96|blood|O
DDI-DrugBank.d163.s36|98-102|sugar|O
DDI-DrugBank.d163.s36|103-103|.|O
DDI-DrugBank.d163.s37|0-1|In|O
DDI-DrugBank.d163.s37|3-10|addition|O
DDI-DrugBank.d163.s37|11-11|,|O
DDI-DrugBank.d163.s37|13-15|new|O
DDI-DrugBank.d163.s37|17-21|cases|O
DDI-DrugBank.d163.s37|23-24|of|O
DDI-DrugBank.d163.s37|26-33|diabetes|O
DDI-DrugBank.d163.s37|35-38|have|O
DDI-DrugBank.d163.s37|40-43|been|O
DDI-DrugBank.d163.s37|45-53|diagnosed|O
DDI-DrugBank.d163.s37|55-60|during|O
DDI-DrugBank.d163.s37|62-69|Accutane|O
DDI-DrugBank.d163.s37|71-77|therapy|O
DDI-DrugBank.d163.s37|78-78|,|O
DDI-DrugBank.d163.s37|80-87|although|O
DDI-DrugBank.d163.s37|89-90|no|O
DDI-DrugBank.d163.s37|92-97|causal|O
DDI-DrugBank.d163.s37|99-110|relationship|O
DDI-DrugBank.d163.s37|112-114|has|O
DDI-DrugBank.d163.s37|116-119|been|O
DDI-DrugBank.d163.s37|121-131|established|O
DDI-DrugBank.d163.s38|0-0|.|O
DDI-DrugBank.d163.s39|0-2|CPK|O
DDI-DrugBank.d163.s39|3-3|:|O
DDI-DrugBank.d163.s39|5-8|Some|O
DDI-DrugBank.d163.s39|10-17|patients|O
DDI-DrugBank.d163.s39|19-28|undergoing|O
DDI-DrugBank.d163.s39|30-37|vigorous|O
DDI-DrugBank.d163.s39|39-46|physical|O
DDI-DrugBank.d163.s39|48-55|activity|O
DDI-DrugBank.d163.s39|57-61|while|O
DDI-DrugBank.d163.s39|63-64|on|O
DDI-DrugBank.d163.s39|66-73|Accutane|O
DDI-DrugBank.d163.s39|75-81|therapy|O
DDI-DrugBank.d163.s39|83-86|have|O
DDI-DrugBank.d163.s39|88-98|experienced|O
DDI-DrugBank.d163.s39|100-107|elevated|O
DDI-DrugBank.d163.s39|109-111|CPK|O
DDI-DrugBank.d163.s39|113-118|levels|O
DDI-DrugBank.d163.s39|119-119|;|O
DDI-DrugBank.d163.s40|0-6|however|O
DDI-DrugBank.d163.s40|7-7|,|O
DDI-DrugBank.d163.s40|9-11|the|O
DDI-DrugBank.d163.s40|13-20|clinical|O
DDI-DrugBank.d163.s40|22-33|significance|O
DDI-DrugBank.d163.s40|35-36|is|O
DDI-DrugBank.d163.s40|38-44|unknown|O
DDI-DrugBank.d163.s40|45-45|.|O
DDI-DrugBank.d163.s41|0-4|There|O
DDI-DrugBank.d163.s41|6-9|have|O
DDI-DrugBank.d163.s41|11-14|been|O
DDI-DrugBank.d163.s41|16-19|rare|O
DDI-DrugBank.d163.s41|21-33|postmarketing|O
DDI-DrugBank.d163.s41|35-41|reports|O
DDI-DrugBank.d163.s41|43-44|of|O
DDI-DrugBank.d163.s41|46-59|rhabdomyolysis|O
DDI-DrugBank.d163.s41|60-60|,|O
DDI-DrugBank.d163.s41|62-65|some|O
DDI-DrugBank.d163.s41|67-76|associated|O
DDI-DrugBank.d163.s41|78-81|with|O
DDI-DrugBank.d163.s41|83-91|strenuous|O
DDI-DrugBank.d163.s41|93-100|physical|O
DDI-DrugBank.d163.s41|102-109|activity|O
DDI-DrugBank.d163.s41|110-110|.|O
DDI-DrugBank.d163.s42|0-1|In|O
DDI-DrugBank.d163.s42|3-3|a|O
DDI-DrugBank.d163.s42|5-12|clinical|O
DDI-DrugBank.d163.s42|14-18|trial|O
DDI-DrugBank.d163.s42|20-21|of|O
DDI-DrugBank.d163.s42|23-25|217|O
DDI-DrugBank.d163.s42|27-35|pediatric|O
DDI-DrugBank.d163.s42|37-44|patients|O
DDI-DrugBank.d163.s42|46-46|(|O
DDI-DrugBank.d163.s42|47-48|12|O
DDI-DrugBank.d163.s42|50-51|to|O
DDI-DrugBank.d163.s42|53-54|17|O
DDI-DrugBank.d163.s42|56-60|years|O
DDI-DrugBank.d163.s42|61-61|)|O
DDI-DrugBank.d163.s42|63-66|with|O
DDI-DrugBank.d163.s42|68-73|severe|O
DDI-DrugBank.d163.s42|75-86|recalcitrant|O
DDI-DrugBank.d163.s42|88-94|nodular|O
DDI-DrugBank.d163.s42|96-99|acne|O
DDI-DrugBank.d163.s42|100-100|,|O
DDI-DrugBank.d163.s42|102-110|transient|O
DDI-DrugBank.d163.s42|112-121|elevations|O
DDI-DrugBank.d163.s42|123-124|in|O
DDI-DrugBank.d163.s42|126-128|CPK|O
DDI-DrugBank.d163.s42|130-133|were|O
DDI-DrugBank.d163.s42|135-142|observed|O
DDI-DrugBank.d163.s42|144-145|in|O
DDI-DrugBank.d163.s42|147-148|12|O
DDI-DrugBank.d163.s42|149-149|%|O
DDI-DrugBank.d163.s42|151-152|of|O
DDI-DrugBank.d163.s42|154-161|patients|O
DDI-DrugBank.d163.s42|162-162|,|O
DDI-DrugBank.d163.s42|164-172|including|O
DDI-DrugBank.d163.s42|174-178|those|O
DDI-DrugBank.d163.s42|180-189|undergoing|O
DDI-DrugBank.d163.s42|191-199|strenuous|O
DDI-DrugBank.d163.s42|201-208|physical|O
DDI-DrugBank.d163.s42|210-217|activity|O
DDI-DrugBank.d163.s42|219-220|in|O
DDI-DrugBank.d163.s42|222-232|association|O
DDI-DrugBank.d163.s42|234-237|with|O
DDI-DrugBank.d163.s42|239-246|reported|O
DDI-DrugBank.d163.s42|248-262|musculoskeletal|O
DDI-DrugBank.d163.s42|264-270|adverse|O
DDI-DrugBank.d163.s42|272-277|events|O
DDI-DrugBank.d163.s42|279-282|such|O
DDI-DrugBank.d163.s42|284-285|as|O
DDI-DrugBank.d163.s42|287-290|back|O
DDI-DrugBank.d163.s42|292-295|pain|O
DDI-DrugBank.d163.s42|296-296|,|O
DDI-DrugBank.d163.s42|298-307|arthralgia|O
DDI-DrugBank.d163.s42|308-308|,|O
DDI-DrugBank.d163.s42|310-313|limb|O
DDI-DrugBank.d163.s42|315-320|injury|O
DDI-DrugBank.d163.s42|321-321|,|O
DDI-DrugBank.d163.s42|323-324|or|O
DDI-DrugBank.d163.s42|326-331|muscle|O
DDI-DrugBank.d163.s42|333-338|sprain|O
DDI-DrugBank.d163.s42|339-339|.|O
DDI-DrugBank.d163.s43|0-1|In|O
DDI-DrugBank.d163.s43|3-7|these|O
DDI-DrugBank.d163.s43|9-16|patients|O
DDI-DrugBank.d163.s43|17-17|,|O
DDI-DrugBank.d163.s43|19-31|approximately|O
DDI-DrugBank.d163.s43|33-36|half|O
DDI-DrugBank.d163.s43|38-39|of|O
DDI-DrugBank.d163.s43|41-43|the|O
DDI-DrugBank.d163.s43|45-47|CPK|O
DDI-DrugBank.d163.s43|49-58|elevations|O
DDI-DrugBank.d163.s43|60-67|returned|O
DDI-DrugBank.d163.s43|69-70|to|O
DDI-DrugBank.d163.s43|72-77|normal|O
DDI-DrugBank.d163.s43|79-84|within|O
DDI-DrugBank.d163.s43|86-86|2|O
DDI-DrugBank.d163.s43|88-92|weeks|O
DDI-DrugBank.d163.s43|94-96|and|O
DDI-DrugBank.d163.s43|98-101|half|O
DDI-DrugBank.d163.s43|103-110|returned|O
DDI-DrugBank.d163.s43|112-113|to|O
DDI-DrugBank.d163.s43|115-120|normal|O
DDI-DrugBank.d163.s43|122-127|within|O
DDI-DrugBank.d163.s43|129-129|4|O
DDI-DrugBank.d163.s43|131-135|weeks|O
DDI-DrugBank.d163.s43|136-136|.|O
DDI-DrugBank.d163.s44|0-1|No|O
DDI-DrugBank.d163.s44|3-7|cases|O
DDI-DrugBank.d163.s44|9-10|of|O
DDI-DrugBank.d163.s44|12-25|rhabdomyolysis|O
DDI-DrugBank.d163.s44|27-30|were|O
DDI-DrugBank.d163.s44|32-39|reported|O
DDI-DrugBank.d163.s44|41-42|in|O
DDI-DrugBank.d163.s44|44-47|this|O
DDI-DrugBank.d163.s44|49-53|trial|O
DDI-DrugBank.d163.s44|54-54|.|O
DDI-DrugBank.d530.s0|0-12|Non-selective|O
DDI-DrugBank.d530.s0|14-22|monoamine|O
DDI-DrugBank.d530.s0|24-30|oxidase|O
DDI-DrugBank.d530.s0|32-32|(|O
DDI-DrugBank.d530.s0|33-35|MAO|O
DDI-DrugBank.d530.s0|36-36|)|O
DDI-DrugBank.d530.s0|38-47|inhibitors|O
DDI-DrugBank.d530.s0|49-49|-|O
DDI-DrugBank.d530.s0|51-59|including|O
DDI-DrugBank.d530.s0|61-70|phenelzine|O
DDI-DrugBank.d530.s0|72-78|sulfate|O
DDI-DrugBank.d530.s0|79-79|,|O
DDI-DrugBank.d530.s0|81-95|tranylcypromine|O
DDI-DrugBank.d530.s0|97-103|sulfate|O
DDI-DrugBank.d530.s0|105-107|and|O
DDI-DrugBank.d530.s0|109-117|pargyline|O
DDI-DrugBank.d530.s0|119-121|HC1|O
DDI-DrugBank.d530.s0|122-122|.|O
DDI-DrugBank.d530.s1|0-10|Concomitant|O
DDI-DrugBank.d530.s1|12-14|use|O
DDI-DrugBank.d530.s1|16-17|of|O
DDI-DrugBank.d530.s1|19-33|L-phenylalanine|O
DDI-DrugBank.d530.s1|35-37|and|O
DDI-DrugBank.d530.s1|39-51|non-selective|O
DDI-DrugBank.d530.s1|53-55|MAO|O
DDI-DrugBank.d530.s1|57-66|inhibitors|O
DDI-DrugBank.d530.s1|68-70|may|O
DDI-DrugBank.d530.s1|72-76|cause|O
DDI-DrugBank.d530.s1|78-89|hypertension|O
DDI-DrugBank.d530.s1|90-90|.|O
DDI-DrugBank.d530.s2|0-9|Selegiline|O
DDI-DrugBank.d530.s2|11-11|-|O
DDI-DrugBank.d530.s2|13-27|L-phenylalanine|O
DDI-DrugBank.d530.s2|29-31|and|O
DDI-DrugBank.d530.s2|33-35|the|O
DDI-DrugBank.d530.s2|37-45|selective|O
DDI-DrugBank.d530.s2|47-49|MAO|O
DDI-DrugBank.d530.s2|51-59|inhibitor|O
DDI-DrugBank.d530.s2|61-70|selegiline|O
DDI-DrugBank.d530.s2|72-74|may|O
DDI-DrugBank.d530.s2|76-79|have|O
DDI-DrugBank.d530.s2|81-91|synergistic|O
DDI-DrugBank.d530.s2|93-106|antidepressant|O
DDI-DrugBank.d530.s2|108-115|activity|O
DDI-DrugBank.d530.s2|117-118|if|O
DDI-DrugBank.d530.s2|120-123|used|O
DDI-DrugBank.d530.s2|125-137|concomitantly|O
DDI-DrugBank.d530.s2|138-138|.|O
DDI-DrugBank.d530.s3|0-10|Neuroleptic|O
DDI-DrugBank.d530.s3|12-16|Drugs|O
DDI-DrugBank.d530.s3|18-18|-|O
DDI-DrugBank.d530.s3|20-34|L-phenylalanine|O
DDI-DrugBank.d530.s3|36-38|may|O
DDI-DrugBank.d530.s3|40-49|potentiate|O
DDI-DrugBank.d530.s3|51-53|the|O
DDI-DrugBank.d530.s3|55-61|tardive|O
DDI-DrugBank.d530.s3|63-72|dyskinesia|O
DDI-DrugBank.d530.s3|74-77|side|O
DDI-DrugBank.d530.s3|79-87|reactions|O
DDI-DrugBank.d530.s3|89-90|of|O
DDI-DrugBank.d530.s3|92-102|neuroleptic|O
DDI-DrugBank.d530.s3|104-108|drugs|O
DDI-DrugBank.d530.s3|110-111|if|O
DDI-DrugBank.d530.s3|113-116|used|O
DDI-DrugBank.d530.s3|118-130|concomitantly|O
DDI-DrugBank.d530.s3|132-135|with|O
DDI-DrugBank.d530.s3|137-140|them|O
DDI-DrugBank.d530.s3|141-141|.|O
DDI-DrugBank.d19.s0|0-9|Disulfiram|O
DDI-DrugBank.d19.s0|11-17|appears|O
DDI-DrugBank.d19.s0|19-20|to|O
DDI-DrugBank.d19.s0|22-29|decrease|O
DDI-DrugBank.d19.s0|31-33|the|O
DDI-DrugBank.d19.s0|35-38|rate|O
DDI-DrugBank.d19.s0|40-41|at|O
DDI-DrugBank.d19.s0|43-47|which|O
DDI-DrugBank.d19.s0|49-55|certain|O
DDI-DrugBank.d19.s0|57-61|drugs|O
DDI-DrugBank.d19.s0|63-65|are|O
DDI-DrugBank.d19.s0|67-77|metabolized|O
DDI-DrugBank.d19.s0|79-81|and|O
DDI-DrugBank.d19.s0|83-91|therefore|O
DDI-DrugBank.d19.s0|93-95|may|O
DDI-DrugBank.d19.s0|97-104|increase|O
DDI-DrugBank.d19.s0|106-108|the|O
DDI-DrugBank.d19.s0|110-114|blood|O
DDI-DrugBank.d19.s0|116-121|levels|O
DDI-DrugBank.d19.s0|123-125|and|O
DDI-DrugBank.d19.s0|127-129|the|O
DDI-DrugBank.d19.s0|131-141|possibility|O
DDI-DrugBank.d19.s0|143-144|of|O
DDI-DrugBank.d19.s0|146-153|clinical|O
DDI-DrugBank.d19.s0|155-162|toxicity|O
DDI-DrugBank.d19.s0|164-165|of|O
DDI-DrugBank.d19.s0|167-171|drugs|O
DDI-DrugBank.d19.s0|173-177|given|O
DDI-DrugBank.d19.s0|179-191|concomitantly|O
DDI-DrugBank.d19.s0|192-192|.|O
DDI-DrugBank.d19.s1|0-9|DISULFIRAM|O
DDI-DrugBank.d19.s1|11-16|SHOULD|O
DDI-DrugBank.d19.s1|18-19|BE|O
DDI-DrugBank.d19.s1|21-24|USED|O
DDI-DrugBank.d19.s1|26-29|WITH|O
DDI-DrugBank.d19.s1|31-37|CAUTION|O
DDI-DrugBank.d19.s1|39-40|IN|O
DDI-DrugBank.d19.s1|42-46|THOSE|O
DDI-DrugBank.d19.s1|48-55|PATIENTS|O
DDI-DrugBank.d19.s1|57-65|REVEIVING|O
DDI-DrugBank.d19.s1|67-75|PHENYTOIN|O
DDI-DrugBank.d19.s1|77-79|AND|O
DDI-DrugBank.d19.s1|81-83|ITS|O
DDI-DrugBank.d19.s1|85-93|CONGENERS|O
DDI-DrugBank.d19.s1|94-94|.|O
DDI-DrugBank.d19.s2|0-4|SINCE|O
DDI-DrugBank.d19.s2|6-8|THE|O
DDI-DrugBank.d19.s2|10-20|CONCOMITANT|O
DDI-DrugBank.d19.s2|22-35|ADMINISTRATION|O
DDI-DrugBank.d19.s2|37-38|OF|O
DDI-DrugBank.d19.s2|40-44|THESE|O
DDI-DrugBank.d19.s2|46-48|TWO|O
DDI-DrugBank.d19.s2|50-54|DRUGS|O
DDI-DrugBank.d19.s2|56-58|CAN|O
DDI-DrugBank.d19.s2|60-63|LEAD|O
DDI-DrugBank.d19.s2|65-66|TO|O
DDI-DrugBank.d19.s2|68-76|PHENYTOIN|O
DDI-DrugBank.d19.s2|78-89|INTOXICATION|O
DDI-DrugBank.d19.s2|90-90|,|O
DDI-DrugBank.d19.s2|92-96|PRIOR|O
DDI-DrugBank.d19.s2|98-99|TO|O
DDI-DrugBank.d19.s2|101-113|ADMINISTERING|O
DDI-DrugBank.d19.s2|115-124|DISULFIRAM|O
DDI-DrugBank.d19.s2|126-127|TO|O
DDI-DrugBank.d19.s2|129-129|A|O
DDI-DrugBank.d19.s2|131-137|PATIENT|O
DDI-DrugBank.d19.s2|139-140|ON|O
DDI-DrugBank.d19.s2|142-150|PHENYTOIN|O
DDI-DrugBank.d19.s2|152-158|THERAPY|O
DDI-DrugBank.d19.s2|159-159|,|O
DDI-DrugBank.d19.s2|161-161|A|O
DDI-DrugBank.d19.s2|163-170|BASELINE|O
DDI-DrugBank.d19.s2|172-180|PHENYTOIN|O
DDI-DrugBank.d19.s2|182-186|SERUM|O
DDI-DrugBank.d19.s2|188-192|LEVEL|O
DDI-DrugBank.d19.s2|194-199|SHOULD|O
DDI-DrugBank.d19.s2|201-202|BE|O
DDI-DrugBank.d19.s2|204-211|OBTAINED|O
DDI-DrugBank.d19.s2|212-212|.|O
DDI-DrugBank.d19.s3|0-9|SUBSEQUENT|O
DDI-DrugBank.d19.s3|11-12|TO|O
DDI-DrugBank.d19.s3|14-23|INITIATION|O
DDI-DrugBank.d19.s3|25-26|OF|O
DDI-DrugBank.d19.s3|28-37|DISULFIRAM|O
DDI-DrugBank.d19.s3|39-45|THERAPY|O
DDI-DrugBank.d19.s3|46-46|.|O
DDI-DrugBank.d19.s4|0-4|SERUM|O
DDI-DrugBank.d19.s4|6-11|LEVELS|O
DDI-DrugBank.d19.s4|13-14|OF|O
DDI-DrugBank.d19.s4|16-24|PHENYTOIN|O
DDI-DrugBank.d19.s4|26-31|SHOULD|O
DDI-DrugBank.d19.s4|33-34|BE|O
DDI-DrugBank.d19.s4|36-45|DETERMINED|O
DDI-DrugBank.d19.s4|47-48|ON|O
DDI-DrugBank.d19.s4|50-58|DIFFERENT|O
DDI-DrugBank.d19.s4|60-63|DAYS|O
DDI-DrugBank.d19.s4|65-67|FOR|O
DDI-DrugBank.d19.s4|69-76|EVIDENCE|O
DDI-DrugBank.d19.s4|78-79|OF|O
DDI-DrugBank.d19.s4|81-82|AN|O
DDI-DrugBank.d19.s4|84-91|INCREASE|O
DDI-DrugBank.d19.s4|93-94|OR|O
DDI-DrugBank.d19.s4|96-98|FOR|O
DDI-DrugBank.d19.s4|100-100|A|O
DDI-DrugBank.d19.s4|102-111|CONTINUING|O
DDI-DrugBank.d19.s4|113-116|RISE|O
DDI-DrugBank.d19.s4|118-119|IN|O
DDI-DrugBank.d19.s4|121-126|LEVELS|O
DDI-DrugBank.d19.s4|127-127|.|O
DDI-DrugBank.d19.s5|0-8|INCREASED|O
DDI-DrugBank.d19.s5|10-18|PHENYTOIN|O
DDI-DrugBank.d19.s5|20-25|LEVELS|O
DDI-DrugBank.d19.s5|27-32|SHOULD|O
DDI-DrugBank.d19.s5|34-35|BE|O
DDI-DrugBank.d19.s5|37-43|TREATED|O
DDI-DrugBank.d19.s5|45-48|WITH|O
DDI-DrugBank.d19.s5|50-60|APPROPRIATE|O
DDI-DrugBank.d19.s5|62-67|DOSAGE|O
DDI-DrugBank.d19.s5|69-78|ADJUSTMENT|O
DDI-DrugBank.d19.s5|79-79|.|O
DDI-DrugBank.d19.s6|0-1|It|O
DDI-DrugBank.d19.s6|3-5|may|O
DDI-DrugBank.d19.s6|7-8|be|O
DDI-DrugBank.d19.s6|10-18|necessary|O
DDI-DrugBank.d19.s6|20-21|to|O
DDI-DrugBank.d19.s6|23-28|adjust|O
DDI-DrugBank.d19.s6|30-32|the|O
DDI-DrugBank.d19.s6|34-39|dosage|O
DDI-DrugBank.d19.s6|41-42|of|O
DDI-DrugBank.d19.s6|44-47|oral|O
DDI-DrugBank.d19.s6|49-62|anticoagulants|O
DDI-DrugBank.d19.s6|64-67|upon|O
DDI-DrugBank.d19.s6|69-77|beginning|O
DDI-DrugBank.d19.s6|79-80|or|O
DDI-DrugBank.d19.s6|82-89|stopping|O
DDI-DrugBank.d19.s6|91-101|disulfiram.|O
DDI-DrugBank.d19.s6|103-107|since|O
DDI-DrugBank.d19.s6|109-118|disulfiram|O
DDI-DrugBank.d19.s6|120-122|may|O
DDI-DrugBank.d19.s6|124-130|prolong|O
DDI-DrugBank.d19.s6|132-142|prothrombin|O
DDI-DrugBank.d19.s6|144-147|time|O
DDI-DrugBank.d19.s6|148-148|.|O
DDI-DrugBank.d19.s7|0-7|Patients|O
DDI-DrugBank.d19.s7|9-14|taking|O
DDI-DrugBank.d19.s7|16-24|isoniazid|O
DDI-DrugBank.d19.s7|26-29|when|O
DDI-DrugBank.d19.s7|31-40|disulfiram|O
DDI-DrugBank.d19.s7|42-43|is|O
DDI-DrugBank.d19.s7|45-49|given|O
DDI-DrugBank.d19.s7|51-56|should|O
DDI-DrugBank.d19.s7|58-59|be|O
DDI-DrugBank.d19.s7|61-68|observed|O
DDI-DrugBank.d19.s7|70-72|for|O
DDI-DrugBank.d19.s7|74-76|the|O
DDI-DrugBank.d19.s7|78-87|appearance|O
DDI-DrugBank.d19.s7|89-90|of|O
DDI-DrugBank.d19.s7|92-99|unsteady|O
DDI-DrugBank.d19.s7|101-104|gait|O
DDI-DrugBank.d19.s7|106-107|or|O
DDI-DrugBank.d19.s7|109-114|marked|O
DDI-DrugBank.d19.s7|116-122|changes|O
DDI-DrugBank.d19.s7|124-125|in|O
DDI-DrugBank.d19.s7|127-132|mental|O
DDI-DrugBank.d19.s7|134-139|status|O
DDI-DrugBank.d19.s7|140-140|;|O
DDI-DrugBank.d19.s8|0-2|the|O
DDI-DrugBank.d19.s8|4-13|disulfiram|O
DDI-DrugBank.d19.s8|15-20|should|O
DDI-DrugBank.d19.s8|22-23|be|O
DDI-DrugBank.d19.s8|25-36|discontinued|O
DDI-DrugBank.d19.s8|38-39|if|O
DDI-DrugBank.d19.s8|41-44|such|O
DDI-DrugBank.d19.s8|46-50|signs|O
DDI-DrugBank.d19.s8|52-57|appear|O
DDI-DrugBank.d19.s8|58-58|.|O
DDI-DrugBank.d19.s9|0-1|In|O
DDI-DrugBank.d19.s9|3-6|rats|O
DDI-DrugBank.d19.s9|7-7|,|O
DDI-DrugBank.d19.s9|9-20|simultaneous|O
DDI-DrugBank.d19.s9|22-30|ingestion|O
DDI-DrugBank.d19.s9|32-33|of|O
DDI-DrugBank.d19.s9|35-44|disulfiram|O
DDI-DrugBank.d19.s9|46-48|and|O
DDI-DrugBank.d19.s9|50-56|nitrite|O
DDI-DrugBank.d19.s9|58-59|in|O
DDI-DrugBank.d19.s9|61-63|the|O
DDI-DrugBank.d19.s9|65-68|diet|O
DDI-DrugBank.d19.s9|70-72|for|O
DDI-DrugBank.d19.s9|74-75|78|O
DDI-DrugBank.d19.s9|77-81|weeks|O
DDI-DrugBank.d19.s9|83-85|has|O
DDI-DrugBank.d19.s9|87-90|been|O
DDI-DrugBank.d19.s9|92-99|reported|O
DDI-DrugBank.d19.s9|101-102|to|O
DDI-DrugBank.d19.s9|104-108|cause|O
DDI-DrugBank.d19.s9|110-115|tumors|O
DDI-DrugBank.d19.s9|116-116|,|O
DDI-DrugBank.d19.s9|118-120|and|O
DDI-DrugBank.d19.s9|122-123|it|O
DDI-DrugBank.d19.s9|125-127|has|O
DDI-DrugBank.d19.s9|129-132|been|O
DDI-DrugBank.d19.s9|134-142|suggested|O
DDI-DrugBank.d19.s9|144-147|that|O
DDI-DrugBank.d19.s9|149-158|disulfiram|O
DDI-DrugBank.d19.s9|160-162|may|O
DDI-DrugBank.d19.s9|164-168|react|O
DDI-DrugBank.d19.s9|170-173|with|O
DDI-DrugBank.d19.s9|175-182|nitrites|O
DDI-DrugBank.d19.s9|184-185|in|O
DDI-DrugBank.d19.s9|187-189|the|O
DDI-DrugBank.d19.s9|191-193|rat|O
DDI-DrugBank.d19.s9|195-201|stomach|O
DDI-DrugBank.d19.s9|203-204|to|O
DDI-DrugBank.d19.s9|206-209|form|O
DDI-DrugBank.d19.s9|211-211|a|O
DDI-DrugBank.d19.s9|213-223|nitrosamine|O
DDI-DrugBank.d19.s9|224-224|,|O
DDI-DrugBank.d19.s9|226-230|which|O
DDI-DrugBank.d19.s9|232-233|is|O
DDI-DrugBank.d19.s9|235-245|tumorigenic|O
DDI-DrugBank.d19.s9|246-246|.|O
DDI-DrugBank.d19.s10|0-9|Disulfiram|O
DDI-DrugBank.d19.s10|11-15|alone|O
DDI-DrugBank.d19.s10|17-18|in|O
DDI-DrugBank.d19.s10|20-22|the|O
DDI-DrugBank.d19.s10|24-26|rat|O
DDI-DrugBank.d19.s10|28-28|s|O
DDI-DrugBank.d19.s10|30-33|diet|O
DDI-DrugBank.d19.s10|35-37|did|O
DDI-DrugBank.d19.s10|39-41|not|O
DDI-DrugBank.d19.s10|43-46|lead|O
DDI-DrugBank.d19.s10|48-49|to|O
DDI-DrugBank.d19.s10|51-54|such|O
DDI-DrugBank.d19.s10|56-61|tumors|O
DDI-DrugBank.d19.s10|62-62|.|O
DDI-DrugBank.d19.s11|0-2|The|O
DDI-DrugBank.d19.s11|4-12|relevance|O
DDI-DrugBank.d19.s11|14-15|of|O
DDI-DrugBank.d19.s11|17-20|this|O
DDI-DrugBank.d19.s11|22-28|finding|O
DDI-DrugBank.d19.s11|30-31|to|O
DDI-DrugBank.d19.s11|33-38|humans|O
DDI-DrugBank.d19.s11|40-41|is|O
DDI-DrugBank.d19.s11|43-45|not|O
DDI-DrugBank.d19.s11|47-51|known|O
DDI-DrugBank.d19.s11|53-54|at|O
DDI-DrugBank.d19.s11|56-59|this|O
DDI-DrugBank.d19.s11|61-64|time|O
DDI-DrugBank.d19.s11|65-65|.|O
DDI-DrugBank.d429.s0|0-7|Antacids|O
DDI-DrugBank.d429.s0|9-11|and|O
DDI-DrugBank.d429.s0|13-18|kaolin|O
DDI-DrugBank.d429.s0|19-19|:|O
DDI-DrugBank.d429.s0|21-28|Antacids|O
DDI-DrugBank.d429.s0|30-32|and|O
DDI-DrugBank.d429.s0|34-39|kaolin|O
DDI-DrugBank.d429.s0|41-43|can|O
DDI-DrugBank.d429.s0|45-50|reduce|O
DDI-DrugBank.d429.s0|52-61|absorption|O
DDI-DrugBank.d429.s0|63-64|of|O
DDI-DrugBank.d429.s0|66-76|chloroquine|O
DDI-DrugBank.d429.s0|77-77|;|O
DDI-DrugBank.d429.s1|0-1|an|O
DDI-DrugBank.d429.s1|3-10|interval|O
DDI-DrugBank.d429.s1|12-13|of|O
DDI-DrugBank.d429.s1|15-16|at|O
DDI-DrugBank.d429.s1|18-22|least|O
DDI-DrugBank.d429.s1|24-24|4|O
DDI-DrugBank.d429.s1|26-30|hours|O
DDI-DrugBank.d429.s1|32-38|between|O
DDI-DrugBank.d429.s1|40-45|intake|O
DDI-DrugBank.d429.s1|47-48|of|O
DDI-DrugBank.d429.s1|50-54|these|O
DDI-DrugBank.d429.s1|56-61|agents|O
DDI-DrugBank.d429.s1|63-65|and|O
DDI-DrugBank.d429.s1|67-77|chloroquine|O
DDI-DrugBank.d429.s1|79-84|should|O
DDI-DrugBank.d429.s1|86-87|be|O
DDI-DrugBank.d429.s1|89-96|observed|O
DDI-DrugBank.d429.s1|97-97|.|O
DDI-DrugBank.d429.s2|0-9|Cimetidine|O
DDI-DrugBank.d429.s2|10-10|:|O
DDI-DrugBank.d429.s2|12-21|Cimetidine|O
DDI-DrugBank.d429.s2|23-25|can|O
DDI-DrugBank.d429.s2|27-33|inhibit|O
DDI-DrugBank.d429.s2|35-37|the|O
DDI-DrugBank.d429.s2|39-48|metabolism|O
DDI-DrugBank.d429.s2|50-51|of|O
DDI-DrugBank.d429.s2|53-63|chloroquine|O
DDI-DrugBank.d429.s2|64-64|,|O
DDI-DrugBank.d429.s2|66-75|increasing|O
DDI-DrugBank.d429.s2|77-79|its|O
DDI-DrugBank.d429.s2|81-86|plasma|O
DDI-DrugBank.d429.s2|88-92|level|O
DDI-DrugBank.d429.s2|93-93|.|O
DDI-DrugBank.d429.s3|0-10|Concomitant|O
DDI-DrugBank.d429.s3|12-14|use|O
DDI-DrugBank.d429.s3|16-17|of|O
DDI-DrugBank.d429.s3|19-28|cimetidine|O
DDI-DrugBank.d429.s3|30-35|should|O
DDI-DrugBank.d429.s3|37-38|be|O
DDI-DrugBank.d429.s3|40-46|avoided|O
DDI-DrugBank.d429.s3|47-47|.|O
DDI-DrugBank.d429.s4|0-9|Ampicillin|O
DDI-DrugBank.d429.s4|10-10|:|O
DDI-DrugBank.d429.s4|12-13|In|O
DDI-DrugBank.d429.s4|15-15|a|O
DDI-DrugBank.d429.s4|17-21|study|O
DDI-DrugBank.d429.s4|23-24|of|O
DDI-DrugBank.d429.s4|26-32|healthy|O
DDI-DrugBank.d429.s4|34-43|volunteers|O
DDI-DrugBank.d429.s4|44-44|,|O
DDI-DrugBank.d429.s4|46-56|chloroquine|O
DDI-DrugBank.d429.s4|58-70|significantly|O
DDI-DrugBank.d429.s4|72-78|reduced|O
DDI-DrugBank.d429.s4|80-82|the|O
DDI-DrugBank.d429.s4|84-98|bioavailability|O
DDI-DrugBank.d429.s4|100-101|of|O
DDI-DrugBank.d429.s4|103-112|ampicillin|O
DDI-DrugBank.d429.s4|113-113|.|O
DDI-DrugBank.d429.s5|0-1|An|O
DDI-DrugBank.d429.s5|3-10|interval|O
DDI-DrugBank.d429.s5|12-13|of|O
DDI-DrugBank.d429.s5|15-16|at|O
DDI-DrugBank.d429.s5|18-22|least|O
DDI-DrugBank.d429.s5|24-26|two|O
DDI-DrugBank.d429.s5|28-32|hours|O
DDI-DrugBank.d429.s5|34-40|between|O
DDI-DrugBank.d429.s5|42-47|intake|O
DDI-DrugBank.d429.s5|49-50|of|O
DDI-DrugBank.d429.s5|52-55|this|O
DDI-DrugBank.d429.s5|57-61|agent|O
DDI-DrugBank.d429.s5|63-65|and|O
DDI-DrugBank.d429.s5|67-77|chloroquine|O
DDI-DrugBank.d429.s5|79-84|should|O
DDI-DrugBank.d429.s5|86-87|be|O
DDI-DrugBank.d429.s5|89-96|observed|O
DDI-DrugBank.d429.s5|97-97|.|O
DDI-DrugBank.d429.s6|0-10|Cyclosporin|O
DDI-DrugBank.d429.s6|11-11|:|O
DDI-DrugBank.d429.s6|13-17|After|O
DDI-DrugBank.d429.s6|19-30|introduction|O
DDI-DrugBank.d429.s6|32-33|of|O
DDI-DrugBank.d429.s6|35-45|chloroquine|O
DDI-DrugBank.d429.s6|47-47|(|O
DDI-DrugBank.d429.s6|48-51|oral|O
DDI-DrugBank.d429.s6|53-56|form|O
DDI-DrugBank.d429.s6|57-57|)|O
DDI-DrugBank.d429.s6|58-58|,|O
DDI-DrugBank.d429.s6|60-60|a|O
DDI-DrugBank.d429.s6|62-67|sudden|O
DDI-DrugBank.d429.s6|69-76|increase|O
DDI-DrugBank.d429.s6|78-79|in|O
DDI-DrugBank.d429.s6|81-85|serum|O
DDI-DrugBank.d429.s6|87-97|cyclosporin|O
DDI-DrugBank.d429.s6|99-103|level|O
DDI-DrugBank.d429.s6|105-107|has|O
DDI-DrugBank.d429.s6|109-112|been|O
DDI-DrugBank.d429.s6|114-121|reported|O
DDI-DrugBank.d429.s6|122-122|.|O
DDI-DrugBank.d429.s7|0-8|Therefore|O
DDI-DrugBank.d429.s7|9-9|,|O
DDI-DrugBank.d429.s7|11-15|close|O
DDI-DrugBank.d429.s7|17-26|monitoring|O
DDI-DrugBank.d429.s7|28-29|of|O
DDI-DrugBank.d429.s7|31-35|serum|O
DDI-DrugBank.d429.s7|37-47|cyclosporin|O
DDI-DrugBank.d429.s7|49-53|level|O
DDI-DrugBank.d429.s7|55-56|is|O
DDI-DrugBank.d429.s7|58-68|recommended|O
DDI-DrugBank.d429.s7|70-72|and|O
DDI-DrugBank.d429.s7|73-73|,|O
DDI-DrugBank.d429.s7|75-76|if|O
DDI-DrugBank.d429.s7|78-86|necessary|O
DDI-DrugBank.d429.s7|87-87|,|O
DDI-DrugBank.d429.s7|89-99|chloroquine|O
DDI-DrugBank.d429.s7|101-106|should|O
DDI-DrugBank.d429.s7|108-109|be|O
DDI-DrugBank.d429.s7|111-122|discontinued|O
DDI-DrugBank.d429.s7|123-123|.|O
DDI-DrugBank.d640.s0|0-8|Diuretics|O
DDI-DrugBank.d640.s0|9-9|:|O
DDI-DrugBank.d640.s0|11-19|Excessive|O
DDI-DrugBank.d640.s0|21-30|reductions|O
DDI-DrugBank.d640.s0|32-33|in|O
DDI-DrugBank.d640.s0|35-39|blood|O
DDI-DrugBank.d640.s0|41-48|pressure|O
DDI-DrugBank.d640.s0|50-52|may|O
DDI-DrugBank.d640.s0|54-58|occur|O
DDI-DrugBank.d640.s0|60-61|in|O
DDI-DrugBank.d640.s0|63-70|patients|O
DDI-DrugBank.d640.s0|72-73|on|O
DDI-DrugBank.d640.s0|75-82|diuretic|O
DDI-DrugBank.d640.s0|84-90|therapy|O
DDI-DrugBank.d640.s0|92-95|when|O
DDI-DrugBank.d640.s0|97-99|ACE|O
DDI-DrugBank.d640.s0|101-110|inhibitors|O
DDI-DrugBank.d640.s0|112-114|are|O
DDI-DrugBank.d640.s0|116-122|started|O
DDI-DrugBank.d640.s0|123-123|.|O
DDI-DrugBank.d640.s1|0-2|The|O
DDI-DrugBank.d640.s1|4-14|possibility|O
DDI-DrugBank.d640.s1|16-17|of|O
DDI-DrugBank.d640.s1|19-29|hypotensive|O
DDI-DrugBank.d640.s1|31-37|effects|O
DDI-DrugBank.d640.s1|39-42|with|O
DDI-DrugBank.d640.s1|44-50|UNIVASC|O
DDI-DrugBank.d640.s1|55-57|can|O
DDI-DrugBank.d640.s1|59-60|be|O
DDI-DrugBank.d640.s1|62-70|minimized|O
DDI-DrugBank.d640.s1|72-73|by|O
DDI-DrugBank.d640.s1|75-87|discontinuing|O
DDI-DrugBank.d640.s1|89-96|diuretic|O
DDI-DrugBank.d640.s1|98-104|therapy|O
DDI-DrugBank.d640.s1|106-108|for|O
DDI-DrugBank.d640.s1|110-116|several|O
DDI-DrugBank.d640.s1|118-121|days|O
DDI-DrugBank.d640.s1|123-124|or|O
DDI-DrugBank.d640.s1|126-135|cautiously|O
DDI-DrugBank.d640.s1|137-146|increasing|O
DDI-DrugBank.d640.s1|148-151|salt|O
DDI-DrugBank.d640.s1|153-158|intake|O
DDI-DrugBank.d640.s1|160-165|before|O
DDI-DrugBank.d640.s1|167-176|initiation|O
DDI-DrugBank.d640.s1|178-179|of|O
DDI-DrugBank.d640.s1|181-189|treatment|O
DDI-DrugBank.d640.s1|191-194|with|O
DDI-DrugBank.d640.s1|196-202|UNIVASC|O
DDI-DrugBank.d640.s1|206-206|.|O
DDI-DrugBank.d640.s1|208-209|If|O
DDI-DrugBank.d640.s1|211-214|this|O
DDI-DrugBank.d640.s1|216-217|is|O
DDI-DrugBank.d640.s1|219-221|not|O
DDI-DrugBank.d640.s1|223-230|possible|O
DDI-DrugBank.d640.s1|231-231|,|O
DDI-DrugBank.d640.s1|233-235|the|O
DDI-DrugBank.d640.s1|237-244|starting|O
DDI-DrugBank.d640.s1|246-249|dose|O
DDI-DrugBank.d640.s1|251-252|of|O
DDI-DrugBank.d640.s1|254-261|moexpril|O
DDI-DrugBank.d640.s1|263-268|should|O
DDI-DrugBank.d640.s1|270-271|be|O
DDI-DrugBank.d640.s1|273-281|reduced..|O
DDI-DrugBank.d640.s2|0-8|Potassium|O
DDI-DrugBank.d640.s2|10-20|Supplements|O
DDI-DrugBank.d640.s2|22-24|and|O
DDI-DrugBank.d640.s2|26-42|Potassium-Sparing|O
DDI-DrugBank.d640.s2|44-52|Diuretics|O
DDI-DrugBank.d640.s2|53-53|:|O
DDI-DrugBank.d640.s2|55-61|UNIVASC|O
DDI-DrugBank.d640.s2|66-68|can|O
DDI-DrugBank.d640.s2|70-77|increase|O
DDI-DrugBank.d640.s2|79-83|serum|O
DDI-DrugBank.d640.s2|85-93|potassium|O
DDI-DrugBank.d640.s2|95-101|because|O
DDI-DrugBank.d640.s2|103-104|it|O
DDI-DrugBank.d640.s2|106-114|decreases|O
DDI-DrugBank.d640.s2|116-126|aldosterone|O
DDI-DrugBank.d640.s2|128-136|secretion|O
DDI-DrugBank.d640.s2|137-137|.|O
DDI-DrugBank.d640.s3|0-2|Use|O
DDI-DrugBank.d640.s3|4-5|of|O
DDI-DrugBank.d640.s3|7-23|potassium-sparing|O
DDI-DrugBank.d640.s3|25-33|diuretics|O
DDI-DrugBank.d640.s3|35-35|(|O
DDI-DrugBank.d640.s3|36-49|spironolactone|O
DDI-DrugBank.d640.s3|50-50|,|O
DDI-DrugBank.d640.s3|52-62|triamterene|O
DDI-DrugBank.d640.s3|63-63|,|O
DDI-DrugBank.d640.s3|65-73|amiloride|O
DDI-DrugBank.d640.s3|74-74|)|O
DDI-DrugBank.d640.s3|76-77|or|O
DDI-DrugBank.d640.s3|79-87|potassium|O
DDI-DrugBank.d640.s3|89-99|supplements|O
DDI-DrugBank.d640.s3|101-113|concomitantly|O
DDI-DrugBank.d640.s3|115-118|with|O
DDI-DrugBank.d640.s3|120-122|ACE|O
DDI-DrugBank.d640.s3|124-133|inhibitors|O
DDI-DrugBank.d640.s3|135-137|can|O
DDI-DrugBank.d640.s3|139-146|increase|O
DDI-DrugBank.d640.s3|148-150|the|O
DDI-DrugBank.d640.s3|152-155|risk|O
DDI-DrugBank.d640.s3|157-158|of|O
DDI-DrugBank.d640.s3|160-171|hyperkalemia|O
DDI-DrugBank.d640.s3|172-172|.|O
DDI-DrugBank.d640.s4|0-8|Therefore|O
DDI-DrugBank.d640.s4|9-9|,|O
DDI-DrugBank.d640.s4|11-12|if|O
DDI-DrugBank.d640.s4|14-24|concomitant|O
DDI-DrugBank.d640.s4|26-28|use|O
DDI-DrugBank.d640.s4|30-31|of|O
DDI-DrugBank.d640.s4|33-36|such|O
DDI-DrugBank.d640.s4|38-43|agents|O
DDI-DrugBank.d640.s4|45-46|is|O
DDI-DrugBank.d640.s4|48-56|indicated|O
DDI-DrugBank.d640.s4|57-57|,|O
DDI-DrugBank.d640.s4|59-62|they|O
DDI-DrugBank.d640.s4|64-69|should|O
DDI-DrugBank.d640.s4|71-72|be|O
DDI-DrugBank.d640.s4|74-78|given|O
DDI-DrugBank.d640.s4|80-83|with|O
DDI-DrugBank.d640.s4|85-91|caution|O
DDI-DrugBank.d640.s4|93-95|and|O
DDI-DrugBank.d640.s4|97-99|the|O
DDI-DrugBank.d640.s4|101-107|patient|O
DDI-DrugBank.d640.s4|108-109|'s|O
DDI-DrugBank.d640.s4|111-115|serum|O
DDI-DrugBank.d640.s4|117-125|potassium|O
DDI-DrugBank.d640.s4|127-132|should|O
DDI-DrugBank.d640.s4|134-135|be|O
DDI-DrugBank.d640.s4|137-145|monitored|O
DDI-DrugBank.d640.s4|146-146|.|O
DDI-DrugBank.d640.s5|0-3|Oral|O
DDI-DrugBank.d640.s5|5-18|Anticoagulants|O
DDI-DrugBank.d640.s5|19-19|:|O
DDI-DrugBank.d640.s5|21-31|Interaction|O
DDI-DrugBank.d640.s5|33-39|studies|O
DDI-DrugBank.d640.s5|41-44|with|O
DDI-DrugBank.d640.s5|46-53|warfarin|O
DDI-DrugBank.d640.s5|55-60|failed|O
DDI-DrugBank.d640.s5|62-63|to|O
DDI-DrugBank.d640.s5|65-72|identify|O
DDI-DrugBank.d640.s5|74-76|any|O
DDI-DrugBank.d640.s5|78-87|clinically|O
DDI-DrugBank.d640.s5|89-97|important|O
DDI-DrugBank.d640.s5|99-104|effect|O
DDI-DrugBank.d640.s5|106-107|on|O
DDI-DrugBank.d640.s5|109-111|the|O
DDI-DrugBank.d640.s5|113-117|serum|O
DDI-DrugBank.d640.s5|119-132|concentrations|O
DDI-DrugBank.d640.s5|134-135|of|O
DDI-DrugBank.d640.s5|137-139|the|O
DDI-DrugBank.d640.s5|141-153|anticoagulant|O
DDI-DrugBank.d640.s5|155-156|or|O
DDI-DrugBank.d640.s5|158-159|on|O
DDI-DrugBank.d640.s5|161-163|its|O
DDI-DrugBank.d640.s5|165-177|anticoagulant|O
DDI-DrugBank.d640.s5|179-184|effect|O
DDI-DrugBank.d640.s5|185-185|.|O
DDI-DrugBank.d640.s6|0-6|Lithium|O
DDI-DrugBank.d640.s6|7-7|:|O
DDI-DrugBank.d640.s6|9-17|Increased|O
DDI-DrugBank.d640.s6|19-23|serum|O
DDI-DrugBank.d640.s6|25-31|lithium|O
DDI-DrugBank.d640.s6|33-38|levels|O
DDI-DrugBank.d640.s6|40-42|and|O
DDI-DrugBank.d640.s6|44-51|symptoms|O
DDI-DrugBank.d640.s6|53-54|of|O
DDI-DrugBank.d640.s6|56-62|lithium|O
DDI-DrugBank.d640.s6|64-71|toxicity|O
DDI-DrugBank.d640.s6|73-76|have|O
DDI-DrugBank.d640.s6|78-81|been|O
DDI-DrugBank.d640.s6|83-90|reported|O
DDI-DrugBank.d640.s6|92-93|in|O
DDI-DrugBank.d640.s6|95-102|patients|O
DDI-DrugBank.d640.s6|104-112|receiving|O
DDI-DrugBank.d640.s6|114-116|ACE|O
DDI-DrugBank.d640.s6|118-127|inhibitors|O
DDI-DrugBank.d640.s6|129-134|during|O
DDI-DrugBank.d640.s6|136-142|therapy|O
DDI-DrugBank.d640.s6|144-147|with|O
DDI-DrugBank.d640.s6|149-155|lithium|O
DDI-DrugBank.d640.s6|156-156|.|O
DDI-DrugBank.d640.s7|0-4|These|O
DDI-DrugBank.d640.s7|6-10|drugs|O
DDI-DrugBank.d640.s7|12-17|should|O
DDI-DrugBank.d640.s7|19-20|be|O
DDI-DrugBank.d640.s7|22-35|coadministered|O
DDI-DrugBank.d640.s7|37-40|with|O
DDI-DrugBank.d640.s7|42-48|caution|O
DDI-DrugBank.d640.s7|49-49|,|O
DDI-DrugBank.d640.s7|51-53|and|O
DDI-DrugBank.d640.s7|55-62|frequent|O
DDI-DrugBank.d640.s7|64-73|monitoring|O
DDI-DrugBank.d640.s7|75-76|of|O
DDI-DrugBank.d640.s7|78-82|serum|O
DDI-DrugBank.d640.s7|84-90|lithium|O
DDI-DrugBank.d640.s7|92-97|levels|O
DDI-DrugBank.d640.s7|99-100|is|O
DDI-DrugBank.d640.s7|102-112|recommended|O
DDI-DrugBank.d640.s7|113-113|.|O
DDI-DrugBank.d640.s8|0-1|If|O
DDI-DrugBank.d640.s8|3-3|a|O
DDI-DrugBank.d640.s8|5-12|diuretic|O
DDI-DrugBank.d640.s8|14-15|is|O
DDI-DrugBank.d640.s8|17-20|also|O
DDI-DrugBank.d640.s8|22-25|used|O
DDI-DrugBank.d640.s8|26-26|,|O
DDI-DrugBank.d640.s8|28-30|the|O
DDI-DrugBank.d640.s8|32-35|risk|O
DDI-DrugBank.d640.s8|37-38|of|O
DDI-DrugBank.d640.s8|40-46|lithium|O
DDI-DrugBank.d640.s8|48-55|toxicity|O
DDI-DrugBank.d640.s8|57-59|may|O
DDI-DrugBank.d640.s8|61-62|be|O
DDI-DrugBank.d640.s8|64-72|increased|O
DDI-DrugBank.d640.s8|73-73|.|O
DDI-DrugBank.d640.s9|0-4|Other|O
DDI-DrugBank.d640.s9|6-11|Agents|O
DDI-DrugBank.d640.s9|12-12|:|O
DDI-DrugBank.d640.s9|14-15|No|O
DDI-DrugBank.d640.s9|17-26|clinically|O
DDI-DrugBank.d640.s9|28-36|important|O
DDI-DrugBank.d640.s9|38-52|pharmacokinetic|O
DDI-DrugBank.d640.s9|54-65|interactions|O
DDI-DrugBank.d640.s9|67-74|occurred|O
DDI-DrugBank.d640.s9|76-79|when|O
DDI-DrugBank.d640.s9|81-87|UNIVASC|O
DDI-DrugBank.d640.s9|92-94|was|O
DDI-DrugBank.d640.s9|96-107|administered|O
DDI-DrugBank.d640.s9|109-121|concomitantly|O
DDI-DrugBank.d640.s9|123-126|with|O
DDI-DrugBank.d640.s9|128-146|hydrochlorothiazide|O
DDI-DrugBank.d640.s9|147-147|,|O
DDI-DrugBank.d640.s9|149-155|digoxin|O
DDI-DrugBank.d640.s9|156-156|,|O
DDI-DrugBank.d640.s9|158-159|or|O
DDI-DrugBank.d640.s9|161-170|cimetidine|O
DDI-DrugBank.d640.s9|171-171|.|O
DDI-DrugBank.d640.s10|0-6|UNIVASC|O
DDI-DrugBank.d640.s10|11-13|has|O
DDI-DrugBank.d640.s10|15-18|been|O
DDI-DrugBank.d640.s10|20-23|used|O
DDI-DrugBank.d640.s10|25-26|in|O
DDI-DrugBank.d640.s10|28-35|clinical|O
DDI-DrugBank.d640.s10|37-42|trials|O
DDI-DrugBank.d640.s10|44-56|concomitantly|O
DDI-DrugBank.d640.s10|58-61|with|O
DDI-DrugBank.d640.s10|63-86|calcium-channel-blocking|O
DDI-DrugBank.d640.s10|88-93|agents|O
DDI-DrugBank.d640.s10|94-94|,|O
DDI-DrugBank.d640.s10|96-104|diuretics|O
DDI-DrugBank.d640.s10|105-105|,|O
DDI-DrugBank.d640.s10|107-108|H2|O
DDI-DrugBank.d640.s10|110-117|blockers|O
DDI-DrugBank.d640.s10|118-118|,|O
DDI-DrugBank.d640.s10|120-126|digoxin|O
DDI-DrugBank.d640.s10|127-127|,|O
DDI-DrugBank.d640.s10|129-132|oral|O
DDI-DrugBank.d640.s10|134-145|hypoglycemic|O
DDI-DrugBank.d640.s10|147-152|agents|O
DDI-DrugBank.d640.s10|153-153|,|O
DDI-DrugBank.d640.s10|155-157|and|O
DDI-DrugBank.d640.s10|159-178|cholesterol-lowering|O
DDI-DrugBank.d640.s10|180-185|agents|O
DDI-DrugBank.d640.s10|186-186|.|O
DDI-DrugBank.d640.s11|0-4|There|O
DDI-DrugBank.d640.s11|6-8|was|O
DDI-DrugBank.d640.s11|10-11|no|O
DDI-DrugBank.d640.s11|13-20|evidence|O
DDI-DrugBank.d640.s11|22-23|of|O
DDI-DrugBank.d640.s11|25-34|clinically|O
DDI-DrugBank.d640.s11|36-44|important|O
DDI-DrugBank.d640.s11|46-52|adverse|O
DDI-DrugBank.d640.s11|54-65|interactions|O
DDI-DrugBank.d640.s11|66-66|.|O
DDI-DrugBank.d278.s0|0-9|Enoxaparin|O
DDI-DrugBank.d278.s0|11-15|dosed|O
DDI-DrugBank.d278.s0|17-18|as|O
DDI-DrugBank.d278.s0|20-20|a|O
DDI-DrugBank.d278.s0|22-24|1.0|O
DDI-DrugBank.d278.s0|26-30|mg/kg|O
DDI-DrugBank.d278.s0|32-43|subcutaneous|O
DDI-DrugBank.d278.s0|45-53|injection|O
DDI-DrugBank.d278.s0|55-58|q12h|O
DDI-DrugBank.d278.s0|60-62|for|O
DDI-DrugBank.d278.s0|64-67|four|O
DDI-DrugBank.d278.s0|69-73|doses|O
DDI-DrugBank.d278.s0|75-77|did|O
DDI-DrugBank.d278.s0|79-81|not|O
DDI-DrugBank.d278.s0|83-87|alter|O
DDI-DrugBank.d278.s0|89-91|the|O
DDI-DrugBank.d278.s0|93-108|pharmacokinetics|O
DDI-DrugBank.d278.s0|110-111|of|O
DDI-DrugBank.d278.s0|113-124|eptifibatide|O
DDI-DrugBank.d278.s0|126-127|or|O
DDI-DrugBank.d278.s0|129-131|the|O
DDI-DrugBank.d278.s0|133-137|level|O
DDI-DrugBank.d278.s0|139-140|of|O
DDI-DrugBank.d278.s0|142-149|platelet|O
DDI-DrugBank.d278.s0|151-161|aggregation|O
DDI-DrugBank.d278.s0|163-164|in|O
DDI-DrugBank.d278.s0|166-172|healthy|O
DDI-DrugBank.d278.s0|174-179|adults|O
DDI-DrugBank.d278.s0|180-180|.|O
DDI-DrugBank.d186.s0|0-1|An|O
DDI-DrugBank.d186.s0|3-17|encephalopathic|O
DDI-DrugBank.d186.s0|19-26|syndrome|O
DDI-DrugBank.d186.s0|28-28|(|O
DDI-DrugBank.d186.s0|29-41|characterized|O
DDI-DrugBank.d186.s0|43-44|by|O
DDI-DrugBank.d186.s0|46-53|weakness|O
DDI-DrugBank.d186.s0|54-54|,|O
DDI-DrugBank.d186.s0|56-63|lethargy|O
DDI-DrugBank.d186.s0|64-64|,|O
DDI-DrugBank.d186.s0|66-70|fever|O
DDI-DrugBank.d186.s0|71-71|,|O
DDI-DrugBank.d186.s0|73-85|tremulousness|O
DDI-DrugBank.d186.s0|87-89|and|O
DDI-DrugBank.d186.s0|91-99|confusion|O
DDI-DrugBank.d186.s0|100-100|,|O
DDI-DrugBank.d186.s0|102-115|extrapyramidal|O
DDI-DrugBank.d186.s0|117-124|symptoms|O
DDI-DrugBank.d186.s0|125-125|,|O
DDI-DrugBank.d186.s0|127-138|leukocytosis|O
DDI-DrugBank.d186.s0|139-139|,|O
DDI-DrugBank.d186.s0|141-148|elevated|O
DDI-DrugBank.d186.s0|150-154|serum|O
DDI-DrugBank.d186.s0|156-162|enzymes|O
DDI-DrugBank.d186.s0|163-163|,|O
DDI-DrugBank.d186.s0|165-167|BUN|O
DDI-DrugBank.d186.s0|168-168|,|O
DDI-DrugBank.d186.s0|170-172|and|O
DDI-DrugBank.d186.s0|174-176|FBS|O
DDI-DrugBank.d186.s0|177-177|)|O
DDI-DrugBank.d186.s0|179-186|followed|O
DDI-DrugBank.d186.s0|188-189|by|O
DDI-DrugBank.d186.s0|191-202|irreversible|O
DDI-DrugBank.d186.s0|204-208|brain|O
DDI-DrugBank.d186.s0|210-215|damage|O
DDI-DrugBank.d186.s0|217-219|has|O
DDI-DrugBank.d186.s0|221-228|occurred|O
DDI-DrugBank.d186.s0|230-231|in|O
DDI-DrugBank.d186.s0|233-233|a|O
DDI-DrugBank.d186.s0|235-237|few|O
DDI-DrugBank.d186.s0|239-246|patients|O
DDI-DrugBank.d186.s0|248-254|treated|O
DDI-DrugBank.d186.s0|256-259|with|O
DDI-DrugBank.d186.s0|261-267|lithium|O
DDI-DrugBank.d186.s0|269-272|plus|O
DDI-DrugBank.d186.s0|274-279|HALDOL|O
DDI-DrugBank.d186.s0|280-280|.|O
DDI-DrugBank.d186.s1|0-0|A|O
DDI-DrugBank.d186.s1|2-7|causal|O
DDI-DrugBank.d186.s1|9-20|relationship|O
DDI-DrugBank.d186.s1|22-28|between|O
DDI-DrugBank.d186.s1|30-34|these|O
DDI-DrugBank.d186.s1|36-41|events|O
DDI-DrugBank.d186.s1|43-45|and|O
DDI-DrugBank.d186.s1|47-49|the|O
DDI-DrugBank.d186.s1|51-61|concomitant|O
DDI-DrugBank.d186.s1|63-76|administration|O
DDI-DrugBank.d186.s1|78-79|of|O
DDI-DrugBank.d186.s1|81-87|lithium|O
DDI-DrugBank.d186.s1|89-91|and|O
DDI-DrugBank.d186.s1|93-98|HALDOL|O
DDI-DrugBank.d186.s1|100-102|has|O
DDI-DrugBank.d186.s1|104-106|not|O
DDI-DrugBank.d186.s1|108-111|been|O
DDI-DrugBank.d186.s1|113-123|established|O
DDI-DrugBank.d186.s1|124-124|;|O
DDI-DrugBank.d186.s2|0-6|however|O
DDI-DrugBank.d186.s2|7-7|,|O
DDI-DrugBank.d186.s2|9-16|patients|O
DDI-DrugBank.d186.s2|18-26|receiving|O
DDI-DrugBank.d186.s2|28-31|such|O
DDI-DrugBank.d186.s2|33-40|combined|O
DDI-DrugBank.d186.s2|42-48|therapy|O
DDI-DrugBank.d186.s2|50-55|should|O
DDI-DrugBank.d186.s2|57-58|be|O
DDI-DrugBank.d186.s2|60-68|monitored|O
DDI-DrugBank.d186.s2|70-76|closely|O
DDI-DrugBank.d186.s2|78-80|for|O
DDI-DrugBank.d186.s2|82-86|early|O
DDI-DrugBank.d186.s2|88-95|evidence|O
DDI-DrugBank.d186.s2|97-98|of|O
DDI-DrugBank.d186.s2|100-111|neurological|O
DDI-DrugBank.d186.s2|113-120|toxicity|O
DDI-DrugBank.d186.s2|122-124|and|O
DDI-DrugBank.d186.s2|126-134|treatment|O
DDI-DrugBank.d186.s2|136-147|discontinued|O
DDI-DrugBank.d186.s2|149-156|promptly|O
DDI-DrugBank.d186.s2|158-159|if|O
DDI-DrugBank.d186.s2|161-164|such|O
DDI-DrugBank.d186.s2|166-170|signs|O
DDI-DrugBank.d186.s2|172-177|appear|O
DDI-DrugBank.d186.s2|178-178|.|O
DDI-DrugBank.d186.s3|0-1|As|O
DDI-DrugBank.d186.s3|3-6|with|O
DDI-DrugBank.d186.s3|8-12|other|O
DDI-DrugBank.d186.s3|14-26|antipsychotic|O
DDI-DrugBank.d186.s3|28-33|agents|O
DDI-DrugBank.d186.s3|34-34|,|O
DDI-DrugBank.d186.s3|36-37|it|O
DDI-DrugBank.d186.s3|39-44|should|O
DDI-DrugBank.d186.s3|46-47|be|O
DDI-DrugBank.d186.s3|49-53|noted|O
DDI-DrugBank.d186.s3|55-58|that|O
DDI-DrugBank.d186.s3|60-65|HALDOL|O
DDI-DrugBank.d186.s3|67-69|may|O
DDI-DrugBank.d186.s3|71-72|be|O
DDI-DrugBank.d186.s3|74-80|capable|O
DDI-DrugBank.d186.s3|82-83|of|O
DDI-DrugBank.d186.s3|85-96|potentiating|O
DDI-DrugBank.d186.s3|98-100|CNS|O
DDI-DrugBank.d186.s3|102-112|depressants|O
DDI-DrugBank.d186.s3|114-117|such|O
DDI-DrugBank.d186.s3|119-120|as|O
DDI-DrugBank.d186.s3|122-132|anesthetics|O
DDI-DrugBank.d186.s3|133-133|,|O
DDI-DrugBank.d186.s3|135-141|opiates|O
DDI-DrugBank.d186.s3|142-142|,|O
DDI-DrugBank.d186.s3|144-146|and|O
DDI-DrugBank.d186.s3|148-154|alcohol|O
DDI-DrugBank.d186.s3|155-155|.|O
DDI-DrugBank.d186.s4|0-1|In|O
DDI-DrugBank.d186.s4|3-3|a|O
DDI-DrugBank.d186.s4|5-9|study|O
DDI-DrugBank.d186.s4|11-12|of|O
DDI-DrugBank.d186.s4|14-15|12|O
DDI-DrugBank.d186.s4|17-29|schizophrenic|O
DDI-DrugBank.d186.s4|31-38|patients|O
DDI-DrugBank.d186.s4|40-53|coadministered|O
DDI-DrugBank.d186.s4|55-58|oral|O
DDI-DrugBank.d186.s4|60-70|haloperidol|O
DDI-DrugBank.d186.s4|72-74|and|O
DDI-DrugBank.d186.s4|76-83|rifampin|O
DDI-DrugBank.d186.s4|84-84|,|O
DDI-DrugBank.d186.s4|86-91|plasma|O
DDI-DrugBank.d186.s4|93-103|haloperidol|O
DDI-DrugBank.d186.s4|105-110|levels|O
DDI-DrugBank.d186.s4|112-115|were|O
DDI-DrugBank.d186.s4|117-125|decreased|O
DDI-DrugBank.d186.s4|127-128|by|O
DDI-DrugBank.d186.s4|130-130|a|O
DDI-DrugBank.d186.s4|132-135|mean|O
DDI-DrugBank.d186.s4|137-138|of|O
DDI-DrugBank.d186.s4|140-141|70|O
DDI-DrugBank.d186.s4|142-142|%|O
DDI-DrugBank.d186.s4|144-146|and|O
DDI-DrugBank.d186.s4|148-151|mean|O
DDI-DrugBank.d186.s4|153-158|scores|O
DDI-DrugBank.d186.s4|160-161|on|O
DDI-DrugBank.d186.s4|163-165|the|O
DDI-DrugBank.d186.s4|167-171|Brief|O
DDI-DrugBank.d186.s4|173-183|Psychiatric|O
DDI-DrugBank.d186.s4|185-190|Rating|O
DDI-DrugBank.d186.s4|192-196|Scale|O
DDI-DrugBank.d186.s4|198-201|were|O
DDI-DrugBank.d186.s4|203-211|increased|O
DDI-DrugBank.d186.s4|213-216|from|O
DDI-DrugBank.d186.s4|218-225|baseline|O
DDI-DrugBank.d186.s4|226-226|.|O
DDI-DrugBank.d186.s5|0-1|In|O
DDI-DrugBank.d186.s5|3-3|5|O
DDI-DrugBank.d186.s5|5-9|other|O
DDI-DrugBank.d186.s5|11-23|schizophrenic|O
DDI-DrugBank.d186.s5|25-32|patients|O
DDI-DrugBank.d186.s5|34-40|treated|O
DDI-DrugBank.d186.s5|42-45|with|O
DDI-DrugBank.d186.s5|47-50|oral|O
DDI-DrugBank.d186.s5|52-62|haloperidol|O
DDI-DrugBank.d186.s5|64-66|and|O
DDI-DrugBank.d186.s5|68-75|rifampin|O
DDI-DrugBank.d186.s5|76-76|,|O
DDI-DrugBank.d186.s5|78-92|discontinuation|O
DDI-DrugBank.d186.s5|94-95|of|O
DDI-DrugBank.d186.s5|97-104|rifampin|O
DDI-DrugBank.d186.s5|106-113|produced|O
DDI-DrugBank.d186.s5|115-115|a|O
DDI-DrugBank.d186.s5|117-120|mean|O
DDI-DrugBank.d186.s5|122-129|3.3-fold|O
DDI-DrugBank.d186.s5|131-138|increase|O
DDI-DrugBank.d186.s5|140-141|in|O
DDI-DrugBank.d186.s5|143-153|haloperidol|O
DDI-DrugBank.d186.s5|155-168|concentrations|O
DDI-DrugBank.d186.s5|169-169|.|O
DDI-DrugBank.d186.s6|0-3|Thus|O
DDI-DrugBank.d186.s6|4-4|,|O
DDI-DrugBank.d186.s6|6-12|careful|O
DDI-DrugBank.d186.s6|14-23|monitoring|O
DDI-DrugBank.d186.s6|25-26|of|O
DDI-DrugBank.d186.s6|28-35|clinical|O
DDI-DrugBank.d186.s6|37-42|status|O
DDI-DrugBank.d186.s6|44-45|is|O
DDI-DrugBank.d186.s6|47-55|warranted|O
DDI-DrugBank.d186.s6|57-60|when|O
DDI-DrugBank.d186.s6|62-69|rifampin|O
DDI-DrugBank.d186.s6|71-72|is|O
DDI-DrugBank.d186.s6|74-85|administered|O
DDI-DrugBank.d186.s6|87-88|or|O
DDI-DrugBank.d186.s6|90-101|discontinued|O
DDI-DrugBank.d186.s6|103-104|in|O
DDI-DrugBank.d186.s6|106-124|haloperidol-treated|O
DDI-DrugBank.d186.s6|126-133|patients|O
DDI-DrugBank.d186.s6|134-134|.|O
DDI-DrugBank.d181.s0|0-7|Oxytocin|O
DDI-DrugBank.d181.s0|9-10|or|O
DDI-DrugBank.d181.s0|12-16|other|O
DDI-DrugBank.d181.s0|18-26|oxytocics|O
DDI-DrugBank.d181.s0|28-28|(|O
DDI-DrugBank.d181.s0|29-38|concurrent|O
DDI-DrugBank.d181.s0|40-42|use|O
DDI-DrugBank.d181.s0|44-47|with|O
DDI-DrugBank.d181.s0|49-57|dinoprost|O
DDI-DrugBank.d181.s0|59-61|may|O
DDI-DrugBank.d181.s0|63-68|result|O
DDI-DrugBank.d181.s0|70-71|in|O
DDI-DrugBank.d181.s0|73-79|uterine|O
DDI-DrugBank.d181.s0|81-90|hypertonus|O
DDI-DrugBank.d181.s0|91-91|,|O
DDI-DrugBank.d181.s0|93-100|possibly|O
DDI-DrugBank.d181.s0|102-108|causing|O
DDI-DrugBank.d181.s0|110-116|uterine|O
DDI-DrugBank.d181.s0|118-124|rupture|O
DDI-DrugBank.d181.s0|126-127|or|O
DDI-DrugBank.d181.s0|129-136|cervical|O
DDI-DrugBank.d181.s0|138-147|laceration|O
DDI-DrugBank.d181.s0|148-148|,|O
DDI-DrugBank.d181.s0|150-159|especially|O
DDI-DrugBank.d181.s0|161-162|in|O
DDI-DrugBank.d181.s0|164-166|the|O
DDI-DrugBank.d181.s0|168-174|absence|O
DDI-DrugBank.d181.s0|176-177|of|O
DDI-DrugBank.d181.s0|179-186|adequate|O
DDI-DrugBank.d181.s0|188-195|cervical|O
DDI-DrugBank.d181.s0|197-206|dilatation|O
DDI-DrugBank.d181.s0|207-207|;|O
DDI-DrugBank.d181.s1|0-7|although|O
DDI-DrugBank.d181.s1|9-20|combinations|O
DDI-DrugBank.d181.s1|22-24|are|O
DDI-DrugBank.d181.s1|26-34|sometimes|O
DDI-DrugBank.d181.s1|36-39|used|O
DDI-DrugBank.d181.s1|41-43|for|O
DDI-DrugBank.d181.s1|45-55|therapeutic|O
DDI-DrugBank.d181.s1|57-65|advantage|O
DDI-DrugBank.d181.s1|66-66|,|O
DDI-DrugBank.d181.s1|68-71|when|O
DDI-DrugBank.d181.s1|73-76|used|O
DDI-DrugBank.d181.s1|78-89|concurrently|O
DDI-DrugBank.d181.s1|90-90|,|O
DDI-DrugBank.d181.s1|92-98|patient|O
DDI-DrugBank.d181.s1|100-105|should|O
DDI-DrugBank.d181.s1|107-108|be|O
DDI-DrugBank.d181.s1|110-116|closely|O
DDI-DrugBank.d181.s1|118-126|monitored|O
DDI-DrugBank.d181.s1|127-127|.|O
DDI-DrugBank.d433.s0|0-1|No|O
DDI-DrugBank.d433.s0|3-8|formal|O
DDI-DrugBank.d433.s0|10-13|drug|O
DDI-DrugBank.d433.s0|15-25|interaction|O
DDI-DrugBank.d433.s0|27-33|studies|O
DDI-DrugBank.d433.s0|35-38|have|O
DDI-DrugBank.d433.s0|40-43|been|O
DDI-DrugBank.d433.s0|45-53|conducted|O
DDI-DrugBank.d433.s0|55-58|with|O
DDI-DrugBank.d433.s0|60-64|Rebif|O
DDI-DrugBank.d433.s0|66-66|.|O
DDI-DrugBank.d433.s1|0-2|Due|O
DDI-DrugBank.d433.s1|4-5|to|O
DDI-DrugBank.d433.s1|7-9|its|O
DDI-DrugBank.d433.s1|11-19|potential|O
DDI-DrugBank.d433.s1|21-22|to|O
DDI-DrugBank.d433.s1|24-28|cause|O
DDI-DrugBank.d433.s1|30-40|neutropenia|O
DDI-DrugBank.d433.s1|42-44|and|O
DDI-DrugBank.d433.s1|46-56|lymphopenia|O
DDI-DrugBank.d433.s1|57-57|,|O
DDI-DrugBank.d433.s1|59-64|proper|O
DDI-DrugBank.d433.s1|66-75|monitoring|O
DDI-DrugBank.d433.s1|77-78|of|O
DDI-DrugBank.d433.s1|80-87|patients|O
DDI-DrugBank.d433.s1|89-90|is|O
DDI-DrugBank.d433.s1|92-99|required|O
DDI-DrugBank.d433.s1|101-102|if|O
DDI-DrugBank.d433.s1|104-108|Rebif|O
DDI-DrugBank.d433.s1|111-112|is|O
DDI-DrugBank.d433.s1|114-118|given|O
DDI-DrugBank.d433.s1|120-121|in|O
DDI-DrugBank.d433.s1|123-133|combination|O
DDI-DrugBank.d433.s1|135-138|with|O
DDI-DrugBank.d433.s1|140-155|myelosuppressive|O
DDI-DrugBank.d433.s1|157-162|agents|O
DDI-DrugBank.d433.s1|163-163|.|O
DDI-DrugBank.d433.s2|0-3|Also|O
DDI-DrugBank.d433.s2|4-4|,|O
DDI-DrugBank.d433.s2|6-8|the|O
DDI-DrugBank.d433.s2|10-18|potential|O
DDI-DrugBank.d433.s2|20-22|for|O
DDI-DrugBank.d433.s2|24-30|hepatic|O
DDI-DrugBank.d433.s2|32-37|injury|O
DDI-DrugBank.d433.s2|39-44|should|O
DDI-DrugBank.d433.s2|46-47|be|O
DDI-DrugBank.d433.s2|49-58|considered|O
DDI-DrugBank.d433.s2|60-63|when|O
DDI-DrugBank.d433.s2|65-69|Rebif|O
DDI-DrugBank.d433.s2|72-73|is|O
DDI-DrugBank.d433.s2|75-78|used|O
DDI-DrugBank.d433.s2|80-81|in|O
DDI-DrugBank.d433.s2|83-93|combination|O
DDI-DrugBank.d433.s2|95-98|with|O
DDI-DrugBank.d433.s2|100-104|other|O
DDI-DrugBank.d433.s2|106-113|products|O
DDI-DrugBank.d433.s2|115-124|associated|O
DDI-DrugBank.d433.s2|126-129|with|O
DDI-DrugBank.d433.s2|131-137|hepatic|O
DDI-DrugBank.d433.s2|139-144|injury|O
DDI-DrugBank.d433.s2|145-145|,|O
DDI-DrugBank.d433.s2|147-148|or|O
DDI-DrugBank.d433.s2|150-153|when|O
DDI-DrugBank.d433.s2|155-157|new|O
DDI-DrugBank.d433.s2|159-164|agents|O
DDI-DrugBank.d433.s2|166-168|are|O
DDI-DrugBank.d433.s2|170-174|added|O
DDI-DrugBank.d433.s2|176-177|to|O
DDI-DrugBank.d433.s2|179-181|the|O
DDI-DrugBank.d433.s2|183-189|regimen|O
DDI-DrugBank.d433.s2|191-192|of|O
DDI-DrugBank.d433.s2|194-201|patients|O
DDI-DrugBank.d433.s2|203-209|already|O
DDI-DrugBank.d433.s2|211-212|on|O
DDI-DrugBank.d433.s2|214-218|Rebif|O
DDI-DrugBank.d433.s2|220-220|.|O
DDI-DrugBank.d734.s0|0-7|Thiazide|O
DDI-DrugBank.d734.s0|9-17|diuretics|O
DDI-DrugBank.d734.s0|19-21|may|O
DDI-DrugBank.d734.s0|23-32|accentuate|O
DDI-DrugBank.d734.s0|34-36|the|O
DDI-DrugBank.d734.s0|38-48|orthostatic|O
DDI-DrugBank.d734.s0|50-60|hypotension|O
DDI-DrugBank.d734.s0|62-65|that|O
DDI-DrugBank.d734.s0|67-69|may|O
DDI-DrugBank.d734.s0|71-75|occur|O
DDI-DrugBank.d734.s0|77-80|with|O
DDI-DrugBank.d734.s0|82-95|phenothiazines|O
DDI-DrugBank.d734.s0|96-96|.|O
DDI-DrugBank.d734.s1|0-15|Antihypertensive|O
DDI-DrugBank.d734.s1|17-23|effects|O
DDI-DrugBank.d734.s1|25-26|of|O
DDI-DrugBank.d734.s1|28-39|guanethidine|O
DDI-DrugBank.d734.s1|41-43|and|O
DDI-DrugBank.d734.s1|45-51|related|O
DDI-DrugBank.d734.s1|53-61|compounds|O
DDI-DrugBank.d734.s1|63-65|may|O
DDI-DrugBank.d734.s1|67-68|be|O
DDI-DrugBank.d734.s1|70-81|counteracted|O
DDI-DrugBank.d734.s1|83-86|when|O
DDI-DrugBank.d734.s1|88-101|phenothiazines|O
DDI-DrugBank.d734.s1|103-105|are|O
DDI-DrugBank.d734.s1|107-110|used|O
DDI-DrugBank.d734.s1|112-124|concomitantly|O
DDI-DrugBank.d734.s1|125-125|.|O
DDI-DrugBank.d734.s2|0-10|Concomitant|O
DDI-DrugBank.d734.s2|12-25|administration|O
DDI-DrugBank.d734.s2|27-28|of|O
DDI-DrugBank.d734.s2|30-40|propranolol|O
DDI-DrugBank.d734.s2|42-45|with|O
DDI-DrugBank.d734.s2|47-60|phenothiazines|O
DDI-DrugBank.d734.s2|62-68|results|O
DDI-DrugBank.d734.s2|70-71|in|O
DDI-DrugBank.d734.s2|73-81|increased|O
DDI-DrugBank.d734.s2|83-88|plasma|O
DDI-DrugBank.d734.s2|90-95|levels|O
DDI-DrugBank.d734.s2|97-98|of|O
DDI-DrugBank.d734.s2|100-103|both|O
DDI-DrugBank.d734.s2|105-109|drugs|O
DDI-DrugBank.d734.s2|110-110|.|O
DDI-DrugBank.d328.s0|0-2|The|O
DDI-DrugBank.d328.s0|4-7|drug|O
DDI-DrugBank.d328.s0|9-19|interaction|O
DDI-DrugBank.d328.s0|21-27|studies|O
DDI-DrugBank.d328.s0|29-32|with|O
DDI-DrugBank.d328.s0|34-43|valdecoxib|O
DDI-DrugBank.d328.s0|45-48|were|O
DDI-DrugBank.d328.s0|50-58|performed|O
DDI-DrugBank.d328.s0|60-63|both|O
DDI-DrugBank.d328.s0|65-68|with|O
DDI-DrugBank.d328.s0|70-79|valdecoxib|O
DDI-DrugBank.d328.s0|81-83|and|O
DDI-DrugBank.d328.s0|85-85|a|O
DDI-DrugBank.d328.s0|87-93|rapidly|O
DDI-DrugBank.d328.s0|95-104|hydrolyzed|O
DDI-DrugBank.d328.s0|106-116|intravenous|O
DDI-DrugBank.d328.s0|118-124|prodrug|O
DDI-DrugBank.d328.s0|126-129|form|O
DDI-DrugBank.d328.s0|130-130|.|O
DDI-DrugBank.d328.s1|0-2|The|O
DDI-DrugBank.d328.s1|4-10|results|O
DDI-DrugBank.d328.s1|12-15|from|O
DDI-DrugBank.d328.s1|17-22|trials|O
DDI-DrugBank.d328.s1|24-28|using|O
DDI-DrugBank.d328.s1|30-32|the|O
DDI-DrugBank.d328.s1|34-44|intravenous|O
DDI-DrugBank.d328.s1|46-52|prodrug|O
DDI-DrugBank.d328.s1|54-56|are|O
DDI-DrugBank.d328.s1|58-65|reported|O
DDI-DrugBank.d328.s1|67-68|in|O
DDI-DrugBank.d328.s1|70-73|this|O
DDI-DrugBank.d328.s1|75-81|section|O
DDI-DrugBank.d328.s1|83-84|as|O
DDI-DrugBank.d328.s1|86-89|they|O
DDI-DrugBank.d328.s1|91-96|relate|O
DDI-DrugBank.d328.s1|98-99|to|O
DDI-DrugBank.d328.s1|101-103|the|O
DDI-DrugBank.d328.s1|105-108|role|O
DDI-DrugBank.d328.s1|110-111|of|O
DDI-DrugBank.d328.s1|113-122|valdecoxib|O
DDI-DrugBank.d328.s1|124-125|in|O
DDI-DrugBank.d328.s1|127-130|drug|O
DDI-DrugBank.d328.s1|132-143|interactions|O
DDI-DrugBank.d328.s1|144-144|.|O
DDI-DrugBank.d328.s2|0-6|General|O
DDI-DrugBank.d328.s2|7-7|:|O
DDI-DrugBank.d328.s2|9-10|In|O
DDI-DrugBank.d328.s2|12-17|humans|O
DDI-DrugBank.d328.s2|18-18|,|O
DDI-DrugBank.d328.s2|20-29|valdecoxib|O
DDI-DrugBank.d328.s2|31-40|metabolism|O
DDI-DrugBank.d328.s2|42-43|is|O
DDI-DrugBank.d328.s2|45-57|predominantly|O
DDI-DrugBank.d328.s2|59-66|mediated|O
DDI-DrugBank.d328.s2|68-70|via|O
DDI-DrugBank.d328.s2|72-74|CYP|O
DDI-DrugBank.d328.s2|76-78|3A4|O
DDI-DrugBank.d328.s2|80-82|and|O
DDI-DrugBank.d328.s2|84-86|2C9|O
DDI-DrugBank.d328.s2|88-91|with|O
DDI-DrugBank.d328.s2|93-107|glucuronidation|O
DDI-DrugBank.d328.s2|109-113|being|O
DDI-DrugBank.d328.s2|115-115|a|O
DDI-DrugBank.d328.s2|117-123|further|O
DDI-DrugBank.d328.s2|125-125|(|O
DDI-DrugBank.d328.s2|126-127|20|O
DDI-DrugBank.d328.s2|128-128|%|O
DDI-DrugBank.d328.s2|129-129|)|O
DDI-DrugBank.d328.s2|131-135|route|O
DDI-DrugBank.d328.s2|137-138|of|O
DDI-DrugBank.d328.s2|140-149|metabolism|O
DDI-DrugBank.d328.s2|150-150|.|O
DDI-DrugBank.d328.s3|0-1|In|O
DDI-DrugBank.d328.s3|3-7|vitro|O
DDI-DrugBank.d328.s3|9-15|studies|O
DDI-DrugBank.d328.s3|17-24|indicate|O
DDI-DrugBank.d328.s3|26-29|that|O
DDI-DrugBank.d328.s3|31-40|valdecoxib|O
DDI-DrugBank.d328.s3|42-43|is|O
DDI-DrugBank.d328.s3|45-45|a|O
DDI-DrugBank.d328.s3|47-54|moderate|O
DDI-DrugBank.d328.s3|56-64|inhibitor|O
DDI-DrugBank.d328.s3|66-67|of|O
DDI-DrugBank.d328.s3|69-71|CYP|O
DDI-DrugBank.d328.s3|73-76|2C19|O
DDI-DrugBank.d328.s3|78-78|(|O
DDI-DrugBank.d328.s3|79-82|IC50|O
DDI-DrugBank.d328.s3|84-84|=|O
DDI-DrugBank.d328.s3|86-86|6|O
DDI-DrugBank.d328.s3|89-92|g/mL|O
DDI-DrugBank.d328.s3|94-95|or|O
DDI-DrugBank.d328.s3|97-98|19|O
DDI-DrugBank.d328.s3|101-101|M|O
DDI-DrugBank.d328.s3|102-102|)|O
DDI-DrugBank.d328.s3|104-106|and|O
DDI-DrugBank.d328.s3|108-110|2C9|O
DDI-DrugBank.d328.s3|112-112|(|O
DDI-DrugBank.d328.s3|113-116|IC50|O
DDI-DrugBank.d328.s3|118-118|=|O
DDI-DrugBank.d328.s3|120-121|13|O
DDI-DrugBank.d328.s3|124-127|g/mL|O
DDI-DrugBank.d328.s3|129-130|or|O
DDI-DrugBank.d328.s3|132-133|41|O
DDI-DrugBank.d328.s3|136-136|M|O
DDI-DrugBank.d328.s3|137-137|)|O
DDI-DrugBank.d328.s3|138-138|,|O
DDI-DrugBank.d328.s3|140-142|and|O
DDI-DrugBank.d328.s3|144-144|a|O
DDI-DrugBank.d328.s3|146-149|weak|O
DDI-DrugBank.d328.s3|151-159|inhibitor|O
DDI-DrugBank.d328.s3|161-162|of|O
DDI-DrugBank.d328.s3|164-166|CYP|O
DDI-DrugBank.d328.s3|168-170|2D6|O
DDI-DrugBank.d328.s3|172-172|(|O
DDI-DrugBank.d328.s3|173-176|IC50|O
DDI-DrugBank.d328.s3|178-178|=|O
DDI-DrugBank.d328.s3|180-181|31|O
DDI-DrugBank.d328.s3|184-187|g/mL|O
DDI-DrugBank.d328.s3|189-190|or|O
DDI-DrugBank.d328.s3|192-194|100|O
DDI-DrugBank.d328.s3|197-197|M|O
DDI-DrugBank.d328.s3|198-198|)|O
DDI-DrugBank.d328.s3|200-202|and|O
DDI-DrugBank.d328.s3|204-206|3A4|O
DDI-DrugBank.d328.s3|208-208|(|O
DDI-DrugBank.d328.s3|209-212|IC50|O
DDI-DrugBank.d328.s3|214-214|=|O
DDI-DrugBank.d328.s3|216-217|44|O
DDI-DrugBank.d328.s3|220-223|g/mL|O
DDI-DrugBank.d328.s3|225-226|or|O
DDI-DrugBank.d328.s3|228-230|141|O
DDI-DrugBank.d328.s3|233-233|M|O
DDI-DrugBank.d328.s3|235-235|)|O
DDI-DrugBank.d328.s3|236-237|..|O
DDI-DrugBank.d328.s4|0-6|Aspirin|O
DDI-DrugBank.d328.s4|7-7|:|O
DDI-DrugBank.d328.s4|9-19|Concomitant|O
DDI-DrugBank.d328.s4|21-34|administration|O
DDI-DrugBank.d328.s4|36-37|of|O
DDI-DrugBank.d328.s4|39-45|aspirin|O
DDI-DrugBank.d328.s4|47-50|with|O
DDI-DrugBank.d328.s4|52-61|valdecoxib|O
DDI-DrugBank.d328.s4|63-65|may|O
DDI-DrugBank.d328.s4|67-72|result|O
DDI-DrugBank.d328.s4|74-75|in|O
DDI-DrugBank.d328.s4|77-78|an|O
DDI-DrugBank.d328.s4|80-88|increased|O
DDI-DrugBank.d328.s4|90-93|risk|O
DDI-DrugBank.d328.s4|95-96|of|O
DDI-DrugBank.d328.s4|98-99|GI|O
DDI-DrugBank.d328.s4|101-110|ulceration|O
DDI-DrugBank.d328.s4|112-114|and|O
DDI-DrugBank.d328.s4|116-128|complications|O
DDI-DrugBank.d328.s4|130-137|compared|O
DDI-DrugBank.d328.s4|139-140|to|O
DDI-DrugBank.d328.s4|142-151|valdecoxib|O
DDI-DrugBank.d328.s4|153-157|alone|O
DDI-DrugBank.d328.s4|158-158|.|O
DDI-DrugBank.d328.s5|0-6|Because|O
DDI-DrugBank.d328.s5|8-9|of|O
DDI-DrugBank.d328.s5|11-13|its|O
DDI-DrugBank.d328.s5|15-18|lack|O
DDI-DrugBank.d328.s5|20-21|of|O
DDI-DrugBank.d328.s5|23-35|anti-platelet|O
DDI-DrugBank.d328.s5|37-42|effect|O
DDI-DrugBank.d328.s5|44-53|valdecoxib|O
DDI-DrugBank.d328.s5|55-56|is|O
DDI-DrugBank.d328.s5|58-60|not|O
DDI-DrugBank.d328.s5|62-62|a|O
DDI-DrugBank.d328.s5|64-73|substitute|O
DDI-DrugBank.d328.s5|75-77|for|O
DDI-DrugBank.d328.s5|79-85|aspirin|O
DDI-DrugBank.d328.s5|87-89|for|O
DDI-DrugBank.d328.s5|91-104|cardiovascular|O
DDI-DrugBank.d328.s5|106-116|prophylaxis|O
DDI-DrugBank.d328.s5|117-117|.|O
DDI-DrugBank.d328.s6|0-1|In|O
DDI-DrugBank.d328.s6|3-3|a|O
DDI-DrugBank.d328.s6|5-12|parallel|O
DDI-DrugBank.d328.s6|14-18|group|O
DDI-DrugBank.d328.s6|20-23|drug|O
DDI-DrugBank.d328.s6|25-35|interaction|O
DDI-DrugBank.d328.s6|37-41|study|O
DDI-DrugBank.d328.s6|43-51|comparing|O
DDI-DrugBank.d328.s6|53-55|the|O
DDI-DrugBank.d328.s6|57-67|intravenous|O
DDI-DrugBank.d328.s6|69-75|prodrug|O
DDI-DrugBank.d328.s6|77-80|form|O
DDI-DrugBank.d328.s6|82-83|of|O
DDI-DrugBank.d328.s6|85-94|valdecoxib|O
DDI-DrugBank.d328.s6|96-97|at|O
DDI-DrugBank.d328.s6|99-100|40|O
DDI-DrugBank.d328.s6|102-103|mg|O
DDI-DrugBank.d328.s6|105-107|BID|O
DDI-DrugBank.d328.s6|109-109|(|O
DDI-DrugBank.d328.s6|110-113|n=10|O
DDI-DrugBank.d328.s6|114-114|)|O
DDI-DrugBank.d328.s6|116-117|vs|O
DDI-DrugBank.d328.s6|119-125|placebo|O
DDI-DrugBank.d328.s6|127-127|(|O
DDI-DrugBank.d328.s6|128-130|n=9|O
DDI-DrugBank.d328.s6|131-131|)|O
DDI-DrugBank.d328.s6|132-132|,|O
DDI-DrugBank.d328.s6|134-143|valdecoxib|O
DDI-DrugBank.d328.s6|145-147|had|O
DDI-DrugBank.d328.s6|149-150|no|O
DDI-DrugBank.d328.s6|152-157|effect|O
DDI-DrugBank.d328.s6|159-160|on|O
DDI-DrugBank.d328.s6|162-163|in|O
DDI-DrugBank.d328.s6|165-169|vitro|O
DDI-DrugBank.d328.s6|171-186|aspirin-mediated|O
DDI-DrugBank.d328.s6|188-197|inhibition|O
DDI-DrugBank.d328.s6|199-200|of|O
DDI-DrugBank.d328.s6|202-214|arachidonate-|O
DDI-DrugBank.d328.s6|216-217|or|O
DDI-DrugBank.d328.s6|219-237|collagen-stimulated|O
DDI-DrugBank.d328.s6|239-246|platelet|O
DDI-DrugBank.d328.s6|248-258|aggregation|O
DDI-DrugBank.d328.s6|259-259|.|O
DDI-DrugBank.d328.s7|0-11|Methotrexate|O
DDI-DrugBank.d328.s7|12-12|:|O
DDI-DrugBank.d328.s7|14-23|Valdecoxib|O
DDI-DrugBank.d328.s7|25-26|10|O
DDI-DrugBank.d328.s7|28-29|mg|O
DDI-DrugBank.d328.s7|31-33|BID|O
DDI-DrugBank.d328.s7|35-37|did|O
DDI-DrugBank.d328.s7|39-41|not|O
DDI-DrugBank.d328.s7|43-46|show|O
DDI-DrugBank.d328.s7|48-48|a|O
DDI-DrugBank.d328.s7|50-60|significant|O
DDI-DrugBank.d328.s7|62-67|effect|O
DDI-DrugBank.d328.s7|69-70|on|O
DDI-DrugBank.d328.s7|72-74|the|O
DDI-DrugBank.d328.s7|76-81|plasma|O
DDI-DrugBank.d328.s7|83-90|exposure|O
DDI-DrugBank.d328.s7|92-93|or|O
DDI-DrugBank.d328.s7|95-99|renal|O
DDI-DrugBank.d328.s7|101-109|clearance|O
DDI-DrugBank.d328.s7|111-112|of|O
DDI-DrugBank.d328.s7|114-125|methotrexate|O
DDI-DrugBank.d328.s7|126-126|.|O
DDI-DrugBank.d328.s8|0-13|ACE-inhibitors|O
DDI-DrugBank.d328.s8|14-14|:|O
DDI-DrugBank.d328.s8|15-21|Reports|O
DDI-DrugBank.d328.s8|23-29|suggest|O
DDI-DrugBank.d328.s8|31-34|that|O
DDI-DrugBank.d328.s8|36-41|NSAIDs|O
DDI-DrugBank.d328.s8|43-45|may|O
DDI-DrugBank.d328.s8|47-54|diminish|O
DDI-DrugBank.d328.s8|56-58|the|O
DDI-DrugBank.d328.s8|60-75|antihypertensive|O
DDI-DrugBank.d328.s8|77-82|effect|O
DDI-DrugBank.d328.s8|84-85|of|O
DDI-DrugBank.d328.s8|87-100|ACE-inhibitors|O
DDI-DrugBank.d328.s8|101-101|.|O
DDI-DrugBank.d328.s9|0-3|This|O
DDI-DrugBank.d328.s9|5-15|interaction|O
DDI-DrugBank.d328.s9|17-22|should|O
DDI-DrugBank.d328.s9|24-25|be|O
DDI-DrugBank.d328.s9|27-31|given|O
DDI-DrugBank.d328.s9|33-45|consideration|O
DDI-DrugBank.d328.s9|47-48|in|O
DDI-DrugBank.d328.s9|50-57|patients|O
DDI-DrugBank.d328.s9|59-64|taking|O
DDI-DrugBank.d328.s9|66-71|BEXTRA|O
DDI-DrugBank.d328.s9|73-85|concomitantly|O
DDI-DrugBank.d328.s9|87-90|with|O
DDI-DrugBank.d328.s9|92-105|ACE-inhibitors|O
DDI-DrugBank.d328.s9|106-106|.|O
DDI-DrugBank.d328.s10|0-9|Furosemide|O
DDI-DrugBank.d328.s10|10-10|:|O
DDI-DrugBank.d328.s10|12-19|Clinical|O
DDI-DrugBank.d328.s10|21-27|studies|O
DDI-DrugBank.d328.s10|28-28|,|O
DDI-DrugBank.d328.s10|30-31|as|O
DDI-DrugBank.d328.s10|33-36|well|O
DDI-DrugBank.d328.s10|38-39|as|O
DDI-DrugBank.d328.s10|41-54|post-marketing|O
DDI-DrugBank.d328.s10|56-67|observations|O
DDI-DrugBank.d328.s10|68-68|,|O
DDI-DrugBank.d328.s10|70-73|have|O
DDI-DrugBank.d328.s10|75-79|shown|O
DDI-DrugBank.d328.s10|81-84|that|O
DDI-DrugBank.d328.s10|86-91|NSAIDs|O
DDI-DrugBank.d328.s10|93-95|can|O
DDI-DrugBank.d328.s10|97-102|reduce|O
DDI-DrugBank.d328.s10|104-106|the|O
DDI-DrugBank.d328.s10|108-118|natriuretic|O
DDI-DrugBank.d328.s10|120-125|effect|O
DDI-DrugBank.d328.s10|127-128|of|O
DDI-DrugBank.d328.s10|130-139|furosemide|O
DDI-DrugBank.d328.s10|141-143|and|O
DDI-DrugBank.d328.s10|145-153|thiazides|O
DDI-DrugBank.d328.s10|155-156|in|O
DDI-DrugBank.d328.s10|158-161|some|O
DDI-DrugBank.d328.s10|163-170|patients|O
DDI-DrugBank.d328.s10|171-171|.|O
DDI-DrugBank.d328.s11|0-3|This|O
DDI-DrugBank.d328.s11|5-12|response|O
DDI-DrugBank.d328.s11|14-16|has|O
DDI-DrugBank.d328.s11|18-21|been|O
DDI-DrugBank.d328.s11|23-32|attributed|O
DDI-DrugBank.d328.s11|34-35|to|O
DDI-DrugBank.d328.s11|37-46|inhibition|O
DDI-DrugBank.d328.s11|48-49|of|O
DDI-DrugBank.d328.s11|51-55|renal|O
DDI-DrugBank.d328.s11|57-69|prostaglandin|O
DDI-DrugBank.d328.s11|71-79|synthesis|O
DDI-DrugBank.d328.s11|80-80|.|O
DDI-DrugBank.d328.s12|0-14|Anticonvulsants|O
DDI-DrugBank.d328.s12|16-16|(|O
DDI-DrugBank.d328.s12|17-25|Phenytoin|O
DDI-DrugBank.d328.s12|26-26|)|O
DDI-DrugBank.d328.s12|27-27|:|O
DDI-DrugBank.d328.s12|29-34|Steady|O
DDI-DrugBank.d328.s12|36-40|state|O
DDI-DrugBank.d328.s12|42-47|plasma|O
DDI-DrugBank.d328.s12|49-56|exposure|O
DDI-DrugBank.d328.s12|58-58|(|O
DDI-DrugBank.d328.s12|59-61|AUC|O
DDI-DrugBank.d328.s12|62-62|)|O
DDI-DrugBank.d328.s12|64-65|of|O
DDI-DrugBank.d328.s12|67-76|valdecoxib|O
DDI-DrugBank.d328.s12|78-78|(|O
DDI-DrugBank.d328.s12|79-80|40|O
DDI-DrugBank.d328.s12|82-83|mg|O
DDI-DrugBank.d328.s12|85-87|BID|O
DDI-DrugBank.d328.s12|89-91|for|O
DDI-DrugBank.d328.s12|93-94|12|O
DDI-DrugBank.d328.s12|96-99|days|O
DDI-DrugBank.d328.s12|100-100|)|O
DDI-DrugBank.d328.s12|102-104|was|O
DDI-DrugBank.d328.s12|106-114|decreased|O
DDI-DrugBank.d328.s12|116-117|by|O
DDI-DrugBank.d328.s12|119-120|27|O
DDI-DrugBank.d328.s12|121-121|%|O
DDI-DrugBank.d328.s12|123-126|when|O
DDI-DrugBank.d328.s12|128-142|co-administered|O
DDI-DrugBank.d328.s12|144-147|with|O
DDI-DrugBank.d328.s12|149-156|multiple|O
DDI-DrugBank.d328.s12|158-162|doses|O
DDI-DrugBank.d328.s12|164-164|(|O
DDI-DrugBank.d328.s12|165-167|300|O
DDI-DrugBank.d328.s12|169-170|mg|O
DDI-DrugBank.d328.s12|172-173|QD|O
DDI-DrugBank.d328.s12|175-177|for|O
DDI-DrugBank.d328.s12|179-180|12|O
DDI-DrugBank.d328.s12|182-185|days|O
DDI-DrugBank.d328.s12|186-186|)|O
DDI-DrugBank.d328.s12|188-189|of|O
DDI-DrugBank.d328.s12|191-199|phenytoin|O
DDI-DrugBank.d328.s12|201-201|(|O
DDI-DrugBank.d328.s12|202-202|a|O
DDI-DrugBank.d328.s12|204-206|CYP|O
DDI-DrugBank.d328.s12|208-210|3A4|O
DDI-DrugBank.d328.s12|212-218|inducer|O
DDI-DrugBank.d328.s12|219-219|)|O
DDI-DrugBank.d328.s12|220-220|.|O
DDI-DrugBank.d328.s13|0-7|Patients|O
DDI-DrugBank.d328.s13|9-15|already|O
DDI-DrugBank.d328.s13|17-26|stabilized|O
DDI-DrugBank.d328.s13|28-29|on|O
DDI-DrugBank.d328.s13|31-40|valdecoxib|O
DDI-DrugBank.d328.s13|42-47|should|O
DDI-DrugBank.d328.s13|49-50|be|O
DDI-DrugBank.d328.s13|52-58|closely|O
DDI-DrugBank.d328.s13|60-68|monitored|O
DDI-DrugBank.d328.s13|70-72|for|O
DDI-DrugBank.d328.s13|74-77|loss|O
DDI-DrugBank.d328.s13|79-80|of|O
DDI-DrugBank.d328.s13|82-88|symptom|O
DDI-DrugBank.d328.s13|90-96|control|O
DDI-DrugBank.d328.s13|98-101|with|O
DDI-DrugBank.d328.s13|103-111|phenytoin|O
DDI-DrugBank.d328.s13|113-128|coadministration|O
DDI-DrugBank.d328.s13|129-129|.|O
DDI-DrugBank.d328.s14|0-9|Valdecoxib|O
DDI-DrugBank.d328.s14|11-13|did|O
DDI-DrugBank.d328.s14|15-17|not|O
DDI-DrugBank.d328.s14|19-22|have|O
DDI-DrugBank.d328.s14|24-24|a|O
DDI-DrugBank.d328.s14|26-38|statistically|O
DDI-DrugBank.d328.s14|40-50|significant|O
DDI-DrugBank.d328.s14|52-57|effect|O
DDI-DrugBank.d328.s14|59-60|on|O
DDI-DrugBank.d328.s14|62-64|the|O
DDI-DrugBank.d328.s14|66-81|pharmacokinetics|O
DDI-DrugBank.d328.s14|83-84|of|O
DDI-DrugBank.d328.s14|86-94|phenytoin|O
DDI-DrugBank.d328.s14|96-96|(|O
DDI-DrugBank.d328.s14|97-97|a|O
DDI-DrugBank.d328.s14|99-101|CYP|O
DDI-DrugBank.d328.s14|103-105|2C9|O
DDI-DrugBank.d328.s14|107-109|and|O
DDI-DrugBank.d328.s14|111-113|CYP|O
DDI-DrugBank.d328.s14|115-118|2C19|O
DDI-DrugBank.d328.s14|120-128|substrate|O
DDI-DrugBank.d328.s14|129-129|)|O
DDI-DrugBank.d328.s14|130-130|.|O
DDI-DrugBank.d328.s15|0-3|Drug|O
DDI-DrugBank.d328.s15|5-15|interaction|O
DDI-DrugBank.d328.s15|17-23|studies|O
DDI-DrugBank.d328.s15|25-28|with|O
DDI-DrugBank.d328.s15|30-34|other|O
DDI-DrugBank.d328.s15|36-50|anticonvulsants|O
DDI-DrugBank.d328.s15|52-55|have|O
DDI-DrugBank.d328.s15|57-59|not|O
DDI-DrugBank.d328.s15|61-64|been|O
DDI-DrugBank.d328.s15|66-74|conducted|O
DDI-DrugBank.d328.s15|75-75|.|O
DDI-DrugBank.d328.s16|0-6|Routine|O
DDI-DrugBank.d328.s16|8-17|monitoring|O
DDI-DrugBank.d328.s16|19-24|should|O
DDI-DrugBank.d328.s16|26-27|be|O
DDI-DrugBank.d328.s16|29-37|performed|O
DDI-DrugBank.d328.s16|39-42|when|O
DDI-DrugBank.d328.s16|44-50|therapy|O
DDI-DrugBank.d328.s16|52-55|with|O
DDI-DrugBank.d328.s16|57-62|BEXTRA|O
DDI-DrugBank.d328.s16|64-65|is|O
DDI-DrugBank.d328.s16|67-72|either|O
DDI-DrugBank.d328.s16|74-82|initiated|O
DDI-DrugBank.d328.s16|84-85|or|O
DDI-DrugBank.d328.s16|87-98|discontinued|O
DDI-DrugBank.d328.s16|100-101|in|O
DDI-DrugBank.d328.s16|103-110|patients|O
DDI-DrugBank.d328.s16|112-113|on|O
DDI-DrugBank.d328.s16|115-128|anticonvulsant|O
DDI-DrugBank.d328.s16|130-136|therapy|O
DDI-DrugBank.d328.s16|137-137|.|O
DDI-DrugBank.d328.s17|0-15|Dextromethorphan|O
DDI-DrugBank.d328.s17|16-16|:|O
DDI-DrugBank.d328.s17|18-33|Dextromethorphan|O
DDI-DrugBank.d328.s17|35-36|is|O
DDI-DrugBank.d328.s17|38-46|primarily|O
DDI-DrugBank.d328.s17|48-58|metabolized|O
DDI-DrugBank.d328.s17|60-61|by|O
DDI-DrugBank.d328.s17|63-65|CYP|O
DDI-DrugBank.d328.s17|67-69|2D6|O
DDI-DrugBank.d328.s17|71-73|and|O
DDI-DrugBank.d328.s17|75-76|to|O
DDI-DrugBank.d328.s17|78-78|a|O
DDI-DrugBank.d328.s17|80-85|lesser|O
DDI-DrugBank.d328.s17|87-92|extent|O
DDI-DrugBank.d328.s17|94-95|by|O
DDI-DrugBank.d328.s17|97-99|3A4|O
DDI-DrugBank.d328.s17|100-100|.|O
DDI-DrugBank.d328.s18|0-15|Coadministration|O
DDI-DrugBank.d328.s18|17-20|with|O
DDI-DrugBank.d328.s18|22-31|valdecoxib|O
DDI-DrugBank.d328.s18|33-33|(|O
DDI-DrugBank.d328.s18|34-35|40|O
DDI-DrugBank.d328.s18|37-38|mg|O
DDI-DrugBank.d328.s18|40-42|BID|O
DDI-DrugBank.d328.s18|44-46|for|O
DDI-DrugBank.d328.s18|48-48|7|O
DDI-DrugBank.d328.s18|50-53|days|O
DDI-DrugBank.d328.s18|54-54|)|O
DDI-DrugBank.d328.s18|56-63|resulted|O
DDI-DrugBank.d328.s18|65-66|in|O
DDI-DrugBank.d328.s18|68-68|a|O
DDI-DrugBank.d328.s18|70-80|significant|O
DDI-DrugBank.d328.s18|82-89|increase|O
DDI-DrugBank.d328.s18|91-92|in|O
DDI-DrugBank.d328.s18|94-109|dextromethorphan|O
DDI-DrugBank.d328.s18|111-116|plasma|O
DDI-DrugBank.d328.s18|118-123|levels|O
DDI-DrugBank.d328.s18|125-134|suggesting|O
DDI-DrugBank.d328.s18|136-139|that|O
DDI-DrugBank.d328.s18|140-140|,|O
DDI-DrugBank.d328.s18|142-143|at|O
DDI-DrugBank.d328.s18|145-149|these|O
DDI-DrugBank.d328.s18|151-155|doses|O
DDI-DrugBank.d328.s18|156-156|,|O
DDI-DrugBank.d328.s18|158-167|valdecoxib|O
DDI-DrugBank.d328.s18|169-170|is|O
DDI-DrugBank.d328.s18|172-172|a|O
DDI-DrugBank.d328.s18|174-177|weak|O
DDI-DrugBank.d328.s18|179-187|inhibitor|O
DDI-DrugBank.d328.s18|189-190|of|O
DDI-DrugBank.d328.s18|192-194|2D6|O
DDI-DrugBank.d328.s18|195-195|.|O
DDI-DrugBank.d328.s19|0-3|Even|O
DDI-DrugBank.d328.s19|5-6|so|O
DDI-DrugBank.d328.s19|8-23|dextromethorphan|O
DDI-DrugBank.d328.s19|25-30|plasma|O
DDI-DrugBank.d328.s19|32-45|concentrations|O
DDI-DrugBank.d328.s19|47-48|in|O
DDI-DrugBank.d328.s19|50-52|the|O
DDI-DrugBank.d328.s19|54-61|presence|O
DDI-DrugBank.d328.s19|63-64|of|O
DDI-DrugBank.d328.s19|66-69|high|O
DDI-DrugBank.d328.s19|71-75|doses|O
DDI-DrugBank.d328.s19|77-78|of|O
DDI-DrugBank.d328.s19|80-89|valdecoxib|O
DDI-DrugBank.d328.s19|91-94|were|O
DDI-DrugBank.d328.s19|96-101|almost|O
DDI-DrugBank.d328.s19|103-108|5-fold|O
DDI-DrugBank.d328.s19|110-114|lower|O
DDI-DrugBank.d328.s19|116-119|than|O
DDI-DrugBank.d328.s19|121-125|those|O
DDI-DrugBank.d328.s19|127-130|seen|O
DDI-DrugBank.d328.s19|132-133|in|O
DDI-DrugBank.d328.s19|135-137|CYP|O
DDI-DrugBank.d328.s19|139-141|2D6|O
DDI-DrugBank.d328.s19|143-146|poor|O
DDI-DrugBank.d328.s19|148-159|metabolizers|O
DDI-DrugBank.d328.s19|161-170|suggesting|O
DDI-DrugBank.d328.s19|172-175|that|O
DDI-DrugBank.d328.s19|177-180|dose|O
DDI-DrugBank.d328.s19|182-191|adjustment|O
DDI-DrugBank.d328.s19|193-194|is|O
DDI-DrugBank.d328.s19|196-198|not|O
DDI-DrugBank.d328.s19|200-208|necessary|O
DDI-DrugBank.d328.s19|209-209|.|O
DDI-DrugBank.d328.s20|0-6|Lithium|O
DDI-DrugBank.d328.s20|7-7|:|O
DDI-DrugBank.d328.s20|9-18|Valdecoxib|O
DDI-DrugBank.d328.s20|20-21|40|O
DDI-DrugBank.d328.s20|23-24|mg|O
DDI-DrugBank.d328.s20|26-28|BID|O
DDI-DrugBank.d328.s20|30-32|for|O
DDI-DrugBank.d328.s20|34-34|7|O
DDI-DrugBank.d328.s20|36-39|days|O
DDI-DrugBank.d328.s20|41-48|produced|O
DDI-DrugBank.d328.s20|50-60|significant|O
DDI-DrugBank.d328.s20|62-70|decreases|O
DDI-DrugBank.d328.s20|72-73|in|O
DDI-DrugBank.d328.s20|75-81|lithium|O
DDI-DrugBank.d328.s20|83-87|serum|O
DDI-DrugBank.d328.s20|89-97|clearance|O
DDI-DrugBank.d328.s20|99-99|(|O
DDI-DrugBank.d328.s20|100-101|25|O
DDI-DrugBank.d328.s20|102-102|%|O
DDI-DrugBank.d328.s20|103-103|)|O
DDI-DrugBank.d328.s20|105-107|and|O
DDI-DrugBank.d328.s20|109-113|renal|O
DDI-DrugBank.d328.s20|115-123|clearance|O
DDI-DrugBank.d328.s20|125-125|(|O
DDI-DrugBank.d328.s20|126-127|30|O
DDI-DrugBank.d328.s20|128-128|%|O
DDI-DrugBank.d328.s20|129-129|)|O
DDI-DrugBank.d328.s20|131-134|with|O
DDI-DrugBank.d328.s20|136-136|a|O
DDI-DrugBank.d328.s20|138-139|34|O
DDI-DrugBank.d328.s20|140-140|%|O
DDI-DrugBank.d328.s20|142-147|higher|O
DDI-DrugBank.d328.s20|149-153|serum|O
DDI-DrugBank.d328.s20|155-162|exposure|O
DDI-DrugBank.d328.s20|164-171|compared|O
DDI-DrugBank.d328.s20|173-174|to|O
DDI-DrugBank.d328.s20|176-182|lithium|O
DDI-DrugBank.d328.s20|184-188|alone|O
DDI-DrugBank.d328.s20|189-189|.|O
DDI-DrugBank.d328.s21|0-6|Lithium|O
DDI-DrugBank.d328.s21|8-12|serum|O
DDI-DrugBank.d328.s21|14-27|concentrations|O
DDI-DrugBank.d328.s21|29-34|should|O
DDI-DrugBank.d328.s21|36-37|be|O
DDI-DrugBank.d328.s21|39-47|monitored|O
DDI-DrugBank.d328.s21|49-55|closely|O
DDI-DrugBank.d328.s21|57-60|when|O
DDI-DrugBank.d328.s21|62-71|initiating|O
DDI-DrugBank.d328.s21|73-74|or|O
DDI-DrugBank.d328.s21|76-83|changing|O
DDI-DrugBank.d328.s21|85-91|therapy|O
DDI-DrugBank.d328.s21|93-96|with|O
DDI-DrugBank.d328.s21|98-103|BEXTRA|O
DDI-DrugBank.d328.s21|105-106|in|O
DDI-DrugBank.d328.s21|108-115|patients|O
DDI-DrugBank.d328.s21|117-125|receiving|O
DDI-DrugBank.d328.s21|127-133|lithium|O
DDI-DrugBank.d328.s21|134-134|.|O
DDI-DrugBank.d328.s22|0-6|Lithium|O
DDI-DrugBank.d328.s22|8-16|carbonate|O
DDI-DrugBank.d328.s22|18-18|(|O
DDI-DrugBank.d328.s22|19-21|450|O
DDI-DrugBank.d328.s22|23-24|mg|O
DDI-DrugBank.d328.s22|26-28|BID|O
DDI-DrugBank.d328.s22|30-32|for|O
DDI-DrugBank.d328.s22|34-34|7|O
DDI-DrugBank.d328.s22|36-39|days|O
DDI-DrugBank.d328.s22|40-40|)|O
DDI-DrugBank.d328.s22|42-44|had|O
DDI-DrugBank.d328.s22|46-47|no|O
DDI-DrugBank.d328.s22|49-54|effect|O
DDI-DrugBank.d328.s22|56-57|on|O
DDI-DrugBank.d328.s22|59-68|valdecoxib|O
DDI-DrugBank.d328.s22|70-85|pharmacokinetics|O
DDI-DrugBank.d328.s22|86-86|.|O
DDI-DrugBank.d328.s23|0-7|Warfarin|O
DDI-DrugBank.d328.s23|8-8|:|O
DDI-DrugBank.d328.s23|10-12|The|O
DDI-DrugBank.d328.s23|14-19|effect|O
DDI-DrugBank.d328.s23|21-22|of|O
DDI-DrugBank.d328.s23|24-33|valdecoxib|O
DDI-DrugBank.d328.s23|35-36|on|O
DDI-DrugBank.d328.s23|38-40|the|O
DDI-DrugBank.d328.s23|42-54|anticoagulant|O
DDI-DrugBank.d328.s23|56-61|effect|O
DDI-DrugBank.d328.s23|63-64|of|O
DDI-DrugBank.d328.s23|66-73|warfarin|O
DDI-DrugBank.d328.s23|75-75|(|O
DDI-DrugBank.d328.s23|76-76|1|O
DDI-DrugBank.d328.s23|78-78|-|O
DDI-DrugBank.d328.s23|80-80|8|O
DDI-DrugBank.d328.s23|82-87|mg/day|O
DDI-DrugBank.d328.s23|88-88|)|O
DDI-DrugBank.d328.s23|90-92|was|O
DDI-DrugBank.d328.s23|94-100|studied|O
DDI-DrugBank.d328.s23|102-103|in|O
DDI-DrugBank.d328.s23|105-111|healthy|O
DDI-DrugBank.d328.s23|113-120|subjects|O
DDI-DrugBank.d328.s23|122-123|by|O
DDI-DrugBank.d328.s23|125-140|coadministration|O
DDI-DrugBank.d328.s23|142-143|of|O
DDI-DrugBank.d328.s23|145-150|BEXTRA|O
DDI-DrugBank.d328.s23|152-153|40|O
DDI-DrugBank.d328.s23|155-156|mg|O
DDI-DrugBank.d328.s23|158-160|BID|O
DDI-DrugBank.d328.s23|162-164|for|O
DDI-DrugBank.d328.s23|166-166|7|O
DDI-DrugBank.d328.s23|168-171|days|O
DDI-DrugBank.d328.s23|172-172|.|O
DDI-DrugBank.d328.s24|0-9|Valdecoxib|O
DDI-DrugBank.d328.s24|11-16|caused|O
DDI-DrugBank.d328.s24|18-18|a|O
DDI-DrugBank.d328.s24|20-32|statistically|O
DDI-DrugBank.d328.s24|34-44|significant|O
DDI-DrugBank.d328.s24|46-53|increase|O
DDI-DrugBank.d328.s24|55-56|in|O
DDI-DrugBank.d328.s24|58-63|plasma|O
DDI-DrugBank.d328.s24|65-73|exposures|O
DDI-DrugBank.d328.s24|75-76|of|O
DDI-DrugBank.d328.s24|78-87|R-warfarin|O
DDI-DrugBank.d328.s24|89-91|and|O
DDI-DrugBank.d328.s24|93-102|S-warfarin|O
DDI-DrugBank.d328.s24|104-104|(|O
DDI-DrugBank.d328.s24|105-106|12|O
DDI-DrugBank.d328.s24|107-107|%|O
DDI-DrugBank.d328.s24|109-111|and|O
DDI-DrugBank.d328.s24|113-114|15|O
DDI-DrugBank.d328.s24|115-115|%|O
DDI-DrugBank.d328.s24|116-116|,|O
DDI-DrugBank.d328.s24|118-129|respectively|O
DDI-DrugBank.d328.s24|130-130|)|O
DDI-DrugBank.d328.s24|131-131|,|O
DDI-DrugBank.d328.s24|133-135|and|O
DDI-DrugBank.d328.s24|137-138|in|O
DDI-DrugBank.d328.s24|140-142|the|O
DDI-DrugBank.d328.s24|144-158|pharmacodynamic|O
DDI-DrugBank.d328.s24|160-166|effects|O
DDI-DrugBank.d328.s24|168-168|(|O
DDI-DrugBank.d328.s24|169-179|prothrombin|O
DDI-DrugBank.d328.s24|181-184|time|O
DDI-DrugBank.d328.s24|185-185|,|O
DDI-DrugBank.d328.s24|187-194|measured|O
DDI-DrugBank.d328.s24|196-197|as|O
DDI-DrugBank.d328.s24|199-201|INR|O
DDI-DrugBank.d328.s24|202-202|)|O
DDI-DrugBank.d328.s24|204-205|of|O
DDI-DrugBank.d328.s24|207-214|warfarin|O
DDI-DrugBank.d328.s24|215-215|.|O
DDI-DrugBank.d328.s25|0-4|While|O
DDI-DrugBank.d328.s25|6-9|mean|O
DDI-DrugBank.d328.s25|11-13|INR|O
DDI-DrugBank.d328.s25|15-20|values|O
DDI-DrugBank.d328.s25|22-25|were|O
DDI-DrugBank.d328.s25|27-30|only|O
DDI-DrugBank.d328.s25|32-39|slightly|O
DDI-DrugBank.d328.s25|41-49|increased|O
DDI-DrugBank.d328.s25|51-54|with|O
DDI-DrugBank.d328.s25|56-71|coadministration|O
DDI-DrugBank.d328.s25|73-74|of|O
DDI-DrugBank.d328.s25|76-85|valdecoxib|O
DDI-DrugBank.d328.s25|86-86|,|O
DDI-DrugBank.d328.s25|88-90|the|O
DDI-DrugBank.d328.s25|92-101|day-to-day|O
DDI-DrugBank.d328.s25|103-113|variability|O
DDI-DrugBank.d328.s25|115-116|in|O
DDI-DrugBank.d328.s25|118-127|individual|O
DDI-DrugBank.d328.s25|129-131|INR|O
DDI-DrugBank.d328.s25|133-138|values|O
DDI-DrugBank.d328.s25|140-142|was|O
DDI-DrugBank.d328.s25|144-152|increased|O
DDI-DrugBank.d328.s25|153-153|.|O
DDI-DrugBank.d328.s26|0-12|Anticoagulant|O
DDI-DrugBank.d328.s26|14-20|therapy|O
DDI-DrugBank.d328.s26|22-27|should|O
DDI-DrugBank.d328.s26|29-30|be|O
DDI-DrugBank.d328.s26|32-40|monitored|O
DDI-DrugBank.d328.s26|41-41|,|O
DDI-DrugBank.d328.s26|43-54|particularly|O
DDI-DrugBank.d328.s26|56-61|during|O
DDI-DrugBank.d328.s26|63-65|the|O
DDI-DrugBank.d328.s26|67-71|first|O
DDI-DrugBank.d328.s26|73-75|few|O
DDI-DrugBank.d328.s26|77-81|weeks|O
DDI-DrugBank.d328.s26|82-82|,|O
DDI-DrugBank.d328.s26|84-88|after|O
DDI-DrugBank.d328.s26|90-99|initiating|O
DDI-DrugBank.d328.s26|101-107|therapy|O
DDI-DrugBank.d328.s26|109-112|with|O
DDI-DrugBank.d328.s26|114-119|BEXTRA|O
DDI-DrugBank.d328.s26|121-122|in|O
DDI-DrugBank.d328.s26|124-131|patients|O
DDI-DrugBank.d328.s26|133-141|receiving|O
DDI-DrugBank.d328.s26|143-150|warfarin|O
DDI-DrugBank.d328.s26|152-153|or|O
DDI-DrugBank.d328.s26|155-161|similar|O
DDI-DrugBank.d328.s26|163-168|agents|O
DDI-DrugBank.d328.s26|169-169|.|O
DDI-DrugBank.d328.s27|0-10|Fluconazole|O
DDI-DrugBank.d328.s27|12-14|and|O
DDI-DrugBank.d328.s27|16-27|Ketoconazole|O
DDI-DrugBank.d328.s27|28-28|:|O
DDI-DrugBank.d328.s27|30-41|Ketoconazole|O
DDI-DrugBank.d328.s27|43-45|and|O
DDI-DrugBank.d328.s27|47-57|fluconazole|O
DDI-DrugBank.d328.s27|59-61|are|O
DDI-DrugBank.d328.s27|63-75|predominantly|O
DDI-DrugBank.d328.s27|77-79|CYP|O
DDI-DrugBank.d328.s27|81-83|3A4|O
DDI-DrugBank.d328.s27|85-87|and|O
DDI-DrugBank.d328.s27|89-91|2C9|O
DDI-DrugBank.d328.s27|93-102|inhibitors|O
DDI-DrugBank.d328.s27|103-103|,|O
DDI-DrugBank.d328.s27|105-116|respectively|O
DDI-DrugBank.d328.s27|117-117|.|O
DDI-DrugBank.d328.s28|0-10|Concomitant|O
DDI-DrugBank.d328.s28|12-17|single|O
DDI-DrugBank.d328.s28|19-22|dose|O
DDI-DrugBank.d328.s28|24-37|administration|O
DDI-DrugBank.d328.s28|39-40|of|O
DDI-DrugBank.d328.s28|42-51|valdecoxib|O
DDI-DrugBank.d328.s28|53-54|20|O
DDI-DrugBank.d328.s28|56-57|mg|O
DDI-DrugBank.d328.s28|59-62|with|O
DDI-DrugBank.d328.s28|64-71|multiple|O
DDI-DrugBank.d328.s28|73-77|doses|O
DDI-DrugBank.d328.s28|79-80|of|O
DDI-DrugBank.d328.s28|82-93|ketoconazole|O
DDI-DrugBank.d328.s28|95-97|and|O
DDI-DrugBank.d328.s28|99-109|fluconazole|O
DDI-DrugBank.d328.s28|111-118|produced|O
DDI-DrugBank.d328.s28|120-120|a|O
DDI-DrugBank.d328.s28|122-132|significant|O
DDI-DrugBank.d328.s28|134-141|increase|O
DDI-DrugBank.d328.s28|143-144|in|O
DDI-DrugBank.d328.s28|146-153|exposure|O
DDI-DrugBank.d328.s28|155-156|of|O
DDI-DrugBank.d328.s28|158-167|valdecoxib|O
DDI-DrugBank.d328.s28|168-168|.|O
DDI-DrugBank.d328.s29|0-5|Plasma|O
DDI-DrugBank.d328.s29|7-14|exposure|O
DDI-DrugBank.d328.s29|16-16|(|O
DDI-DrugBank.d328.s29|17-19|AUC|O
DDI-DrugBank.d328.s29|20-20|)|O
DDI-DrugBank.d328.s29|22-23|to|O
DDI-DrugBank.d328.s29|25-34|valdecoxib|O
DDI-DrugBank.d328.s29|36-38|was|O
DDI-DrugBank.d328.s29|40-48|increased|O
DDI-DrugBank.d328.s29|50-51|62|O
DDI-DrugBank.d328.s29|52-52|%|O
DDI-DrugBank.d328.s29|54-57|when|O
DDI-DrugBank.d328.s29|59-72|coadministered|O
DDI-DrugBank.d328.s29|74-77|with|O
DDI-DrugBank.d328.s29|79-89|fluconazole|O
DDI-DrugBank.d328.s29|91-93|and|O
DDI-DrugBank.d328.s29|95-96|38|O
DDI-DrugBank.d328.s29|97-97|%|O
DDI-DrugBank.d328.s29|99-102|when|O
DDI-DrugBank.d328.s29|104-117|coadministered|O
DDI-DrugBank.d328.s29|119-122|with|O
DDI-DrugBank.d328.s29|124-135|ketoconazole|O
DDI-DrugBank.d328.s29|136-136|.|O
DDI-DrugBank.d328.s30|0-8|Glyburide|O
DDI-DrugBank.d328.s30|9-9|:|O
DDI-DrugBank.d328.s30|11-19|Glyburide|O
DDI-DrugBank.d328.s30|21-22|is|O
DDI-DrugBank.d328.s30|24-24|a|O
DDI-DrugBank.d328.s30|26-28|CYP|O
DDI-DrugBank.d328.s30|30-32|2C9|O
DDI-DrugBank.d328.s30|34-42|substrate|O
DDI-DrugBank.d328.s30|43-43|.|O
DDI-DrugBank.d328.s31|0-15|Coadministration|O
DDI-DrugBank.d328.s31|17-18|of|O
DDI-DrugBank.d328.s31|20-29|valdecoxib|O
DDI-DrugBank.d328.s31|31-31|(|O
DDI-DrugBank.d328.s31|32-33|10|O
DDI-DrugBank.d328.s31|35-36|mg|O
DDI-DrugBank.d328.s31|38-40|BID|O
DDI-DrugBank.d328.s31|42-44|for|O
DDI-DrugBank.d328.s31|46-46|7|O
DDI-DrugBank.d328.s31|48-51|days|O
DDI-DrugBank.d328.s31|52-52|)|O
DDI-DrugBank.d328.s31|54-57|with|O
DDI-DrugBank.d328.s31|59-67|glyburide|O
DDI-DrugBank.d328.s31|69-69|(|O
DDI-DrugBank.d328.s31|70-70|5|O
DDI-DrugBank.d328.s31|72-73|mg|O
DDI-DrugBank.d328.s31|75-76|QD|O
DDI-DrugBank.d328.s31|78-79|or|O
DDI-DrugBank.d328.s31|81-82|10|O
DDI-DrugBank.d328.s31|84-85|mg|O
DDI-DrugBank.d328.s31|87-89|BID|O
DDI-DrugBank.d328.s31|90-90|)|O
DDI-DrugBank.d328.s31|92-94|did|O
DDI-DrugBank.d328.s31|96-98|not|O
DDI-DrugBank.d328.s31|100-105|affect|O
DDI-DrugBank.d328.s31|107-109|the|O
DDI-DrugBank.d328.s31|111-126|pharmacokinetics|O
DDI-DrugBank.d328.s31|128-128|(|O
DDI-DrugBank.d328.s31|129-136|exposure|O
DDI-DrugBank.d328.s31|137-137|)|O
DDI-DrugBank.d328.s31|139-140|of|O
DDI-DrugBank.d328.s31|142-150|glyburide|O
DDI-DrugBank.d328.s31|151-151|.|O
DDI-DrugBank.d328.s32|0-15|Coadministration|O
DDI-DrugBank.d328.s32|17-18|of|O
DDI-DrugBank.d328.s32|20-29|valdecoxib|O
DDI-DrugBank.d328.s32|31-31|(|O
DDI-DrugBank.d328.s32|32-33|40|O
DDI-DrugBank.d328.s32|35-36|mg|O
DDI-DrugBank.d328.s32|38-40|BID|O
DDI-DrugBank.d328.s32|42-42|(|O
DDI-DrugBank.d328.s32|43-45|day|O
DDI-DrugBank.d328.s32|47-47|1|O
DDI-DrugBank.d328.s32|48-48|)|O
DDI-DrugBank.d328.s32|50-52|and|O
DDI-DrugBank.d328.s32|54-55|40|O
DDI-DrugBank.d328.s32|57-58|mg|O
DDI-DrugBank.d328.s32|60-61|QD|O
DDI-DrugBank.d328.s32|63-63|(|O
DDI-DrugBank.d328.s32|64-67|days|O
DDI-DrugBank.d328.s32|69-71|2-7|O
DDI-DrugBank.d328.s32|72-72|)|O
DDI-DrugBank.d328.s32|73-73|)|O
DDI-DrugBank.d328.s32|75-78|with|O
DDI-DrugBank.d328.s32|80-88|glyburide|O
DDI-DrugBank.d328.s32|90-90|(|O
DDI-DrugBank.d328.s32|91-91|5|O
DDI-DrugBank.d328.s32|93-94|mg|O
DDI-DrugBank.d328.s32|96-97|QD|O
DDI-DrugBank.d328.s32|98-98|)|O
DDI-DrugBank.d328.s32|100-102|did|O
DDI-DrugBank.d328.s32|104-106|not|O
DDI-DrugBank.d328.s32|108-113|affect|O
DDI-DrugBank.d328.s32|115-120|either|O
DDI-DrugBank.d328.s32|122-124|the|O
DDI-DrugBank.d328.s32|126-141|pharmacokinetics|O
DDI-DrugBank.d328.s32|143-143|(|O
DDI-DrugBank.d328.s32|144-151|exposure|O
DDI-DrugBank.d328.s32|152-152|)|O
DDI-DrugBank.d328.s32|154-155|or|O
DDI-DrugBank.d328.s32|157-159|the|O
DDI-DrugBank.d328.s32|161-176|pharmacodynamics|O
DDI-DrugBank.d328.s32|178-178|(|O
DDI-DrugBank.d328.s32|179-183|blood|O
DDI-DrugBank.d328.s32|185-191|glucose|O
DDI-DrugBank.d328.s32|193-195|and|O
DDI-DrugBank.d328.s32|197-203|insulin|O
DDI-DrugBank.d328.s32|205-210|levels|O
DDI-DrugBank.d328.s32|211-211|)|O
DDI-DrugBank.d328.s32|213-214|of|O
DDI-DrugBank.d328.s32|216-224|glyburide|O
DDI-DrugBank.d328.s32|225-225|.|O
DDI-DrugBank.d328.s33|0-15|Coadministration|O
DDI-DrugBank.d328.s33|17-18|of|O
DDI-DrugBank.d328.s33|20-29|valdecoxib|O
DDI-DrugBank.d328.s33|31-31|(|O
DDI-DrugBank.d328.s33|32-33|40|O
DDI-DrugBank.d328.s33|35-36|mg|O
DDI-DrugBank.d328.s33|38-40|BID|O
DDI-DrugBank.d328.s33|42-42|(|O
DDI-DrugBank.d328.s33|43-45|day|O
DDI-DrugBank.d328.s33|47-47|1|O
DDI-DrugBank.d328.s33|48-48|)|O
DDI-DrugBank.d328.s33|50-52|and|O
DDI-DrugBank.d328.s33|54-55|40|O
DDI-DrugBank.d328.s33|57-58|mg|O
DDI-DrugBank.d328.s33|60-61|QD|O
DDI-DrugBank.d328.s33|63-63|(|O
DDI-DrugBank.d328.s33|64-67|days|O
DDI-DrugBank.d328.s33|69-71|2-7|O
DDI-DrugBank.d328.s33|72-72|)|O
DDI-DrugBank.d328.s33|73-73|)|O
DDI-DrugBank.d328.s33|75-78|with|O
DDI-DrugBank.d328.s33|80-88|glyburide|O
DDI-DrugBank.d328.s33|90-90|(|O
DDI-DrugBank.d328.s33|91-92|10|O
DDI-DrugBank.d328.s33|94-95|mg|O
DDI-DrugBank.d328.s33|97-105|glyburide|O
DDI-DrugBank.d328.s33|107-109|BID|O
DDI-DrugBank.d328.s33|110-110|)|O
DDI-DrugBank.d328.s33|112-119|resulted|O
DDI-DrugBank.d328.s33|121-122|in|O
DDI-DrugBank.d328.s33|124-125|21|O
DDI-DrugBank.d328.s33|126-126|%|O
DDI-DrugBank.d328.s33|128-135|increase|O
DDI-DrugBank.d328.s33|137-138|in|O
DDI-DrugBank.d328.s33|140-148|glyburide|O
DDI-DrugBank.d328.s33|150-156|AUC0-12|O
DDI-DrugBank.d328.s33|158-160|and|O
DDI-DrugBank.d328.s33|162-162|a|O
DDI-DrugBank.d328.s33|164-165|16|O
DDI-DrugBank.d328.s33|166-166|%|O
DDI-DrugBank.d328.s33|168-175|increase|O
DDI-DrugBank.d328.s33|177-178|in|O
DDI-DrugBank.d328.s33|180-188|glyburide|O
DDI-DrugBank.d328.s33|190-193|Cmax|O
DDI-DrugBank.d328.s33|195-201|leading|O
DDI-DrugBank.d328.s33|203-204|to|O
DDI-DrugBank.d328.s33|206-206|a|O
DDI-DrugBank.d328.s33|208-209|16|O
DDI-DrugBank.d328.s33|210-210|%|O
DDI-DrugBank.d328.s33|212-219|decrease|O
DDI-DrugBank.d328.s33|221-222|in|O
DDI-DrugBank.d328.s33|224-230|glucose|O
DDI-DrugBank.d328.s33|232-238|AUC0-24|O
DDI-DrugBank.d328.s33|239-239|.|O
DDI-DrugBank.d328.s34|0-6|Insulin|O
DDI-DrugBank.d328.s34|8-17|parameters|O
DDI-DrugBank.d328.s34|19-22|were|O
DDI-DrugBank.d328.s34|24-26|not|O
DDI-DrugBank.d328.s34|28-35|affected|O
DDI-DrugBank.d328.s34|36-36|.|O
DDI-DrugBank.d328.s35|0-6|Because|O
DDI-DrugBank.d328.s35|8-14|changes|O
DDI-DrugBank.d328.s35|16-17|in|O
DDI-DrugBank.d328.s35|19-25|glucose|O
DDI-DrugBank.d328.s35|27-40|concentrations|O
DDI-DrugBank.d328.s35|42-45|with|O
DDI-DrugBank.d328.s35|47-56|valdecoxib|O
DDI-DrugBank.d328.s35|58-73|coadministration|O
DDI-DrugBank.d328.s35|75-78|were|O
DDI-DrugBank.d328.s35|80-85|within|O
DDI-DrugBank.d328.s35|87-89|the|O
DDI-DrugBank.d328.s35|91-96|normal|O
DDI-DrugBank.d328.s35|98-108|variability|O
DDI-DrugBank.d328.s35|110-112|and|O
DDI-DrugBank.d328.s35|114-123|individual|O
DDI-DrugBank.d328.s35|125-131|glucose|O
DDI-DrugBank.d328.s35|133-146|concentrations|O
DDI-DrugBank.d328.s35|148-151|were|O
DDI-DrugBank.d328.s35|153-157|above|O
DDI-DrugBank.d328.s35|159-160|or|O
DDI-DrugBank.d328.s35|162-165|near|O
DDI-DrugBank.d328.s35|167-168|70|O
DDI-DrugBank.d328.s35|170-174|mg/dL|O
DDI-DrugBank.d328.s35|175-175|,|O
DDI-DrugBank.d328.s35|177-180|dose|O
DDI-DrugBank.d328.s35|182-191|adjustment|O
DDI-DrugBank.d328.s35|193-195|for|O
DDI-DrugBank.d328.s35|197-205|glyburide|O
DDI-DrugBank.d328.s35|207-207|(|O
DDI-DrugBank.d328.s35|208-208|5|O
DDI-DrugBank.d328.s35|210-211|mg|O
DDI-DrugBank.d328.s35|213-214|QD|O
DDI-DrugBank.d328.s35|216-218|and|O
DDI-DrugBank.d328.s35|220-221|10|O
DDI-DrugBank.d328.s35|223-224|mg|O
DDI-DrugBank.d328.s35|226-228|BID|O
DDI-DrugBank.d328.s35|229-229|)|O
DDI-DrugBank.d328.s35|231-234|with|O
DDI-DrugBank.d328.s35|236-245|valdecoxib|O
DDI-DrugBank.d328.s35|247-262|coadministration|O
DDI-DrugBank.d328.s35|264-264|(|O
DDI-DrugBank.d328.s35|265-266|up|O
DDI-DrugBank.d328.s35|268-269|to|O
DDI-DrugBank.d328.s35|271-272|40|O
DDI-DrugBank.d328.s35|274-275|mg|O
DDI-DrugBank.d328.s35|277-278|QD|O
DDI-DrugBank.d328.s35|279-279|)|O
DDI-DrugBank.d328.s35|281-282|is|O
DDI-DrugBank.d328.s35|284-286|not|O
DDI-DrugBank.d328.s35|288-296|indicated|O
DDI-DrugBank.d328.s35|297-297|.|O
DDI-DrugBank.d328.s36|0-15|Coadministration|O
DDI-DrugBank.d328.s36|17-18|of|O
DDI-DrugBank.d328.s36|20-28|glyburide|O
DDI-DrugBank.d328.s36|30-33|with|O
DDI-DrugBank.d328.s36|35-39|doses|O
DDI-DrugBank.d328.s36|41-46|higher|O
DDI-DrugBank.d328.s36|48-51|than|O
DDI-DrugBank.d328.s36|53-54|40|O
DDI-DrugBank.d328.s36|56-57|mg|O
DDI-DrugBank.d328.s36|59-68|valdecoxib|O
DDI-DrugBank.d328.s36|70-70|(|O
DDI-DrugBank.d328.s36|71-74|e.g.|O
DDI-DrugBank.d328.s36|75-75|,|O
DDI-DrugBank.d328.s36|77-78|40|O
DDI-DrugBank.d328.s36|80-81|mg|O
DDI-DrugBank.d328.s36|83-85|BID|O
DDI-DrugBank.d328.s36|86-86|)|O
DDI-DrugBank.d328.s36|88-91|have|O
DDI-DrugBank.d328.s36|93-95|not|O
DDI-DrugBank.d328.s36|97-100|been|O
DDI-DrugBank.d328.s36|102-108|studied|O
DDI-DrugBank.d328.s36|109-109|.|O
DDI-DrugBank.d328.s37|0-9|Omeprazole|O
DDI-DrugBank.d328.s37|10-10|:|O
DDI-DrugBank.d328.s37|12-21|Omeprazole|O
DDI-DrugBank.d328.s37|23-24|is|O
DDI-DrugBank.d328.s37|26-26|a|O
DDI-DrugBank.d328.s37|28-30|CYP|O
DDI-DrugBank.d328.s37|32-34|3A4|O
DDI-DrugBank.d328.s37|36-44|substrate|O
DDI-DrugBank.d328.s37|46-48|and|O
DDI-DrugBank.d328.s37|50-52|CYP|O
DDI-DrugBank.d328.s37|54-57|2C19|O
DDI-DrugBank.d328.s37|59-67|substrate|O
DDI-DrugBank.d328.s37|69-71|and|O
DDI-DrugBank.d328.s37|73-81|inhibitor|O
DDI-DrugBank.d328.s37|82-82|.|O
DDI-DrugBank.d328.s38|0-9|Valdecoxib|O
DDI-DrugBank.d328.s38|11-16|steady|O
DDI-DrugBank.d328.s38|18-22|state|O
DDI-DrugBank.d328.s38|24-29|plasma|O
DDI-DrugBank.d328.s38|31-44|concentrations|O
DDI-DrugBank.d328.s38|46-46|(|O
DDI-DrugBank.d328.s38|47-48|40|O
DDI-DrugBank.d328.s38|50-51|mg|O
DDI-DrugBank.d328.s38|53-55|BID|O
DDI-DrugBank.d328.s38|56-56|)|O
DDI-DrugBank.d328.s38|58-61|were|O
DDI-DrugBank.d328.s38|63-65|not|O
DDI-DrugBank.d328.s38|67-74|affected|O
DDI-DrugBank.d328.s38|76-88|significantly|O
DDI-DrugBank.d328.s38|90-93|with|O
DDI-DrugBank.d328.s38|95-102|multiple|O
DDI-DrugBank.d328.s38|104-108|doses|O
DDI-DrugBank.d328.s38|110-111|of|O
DDI-DrugBank.d328.s38|113-122|omeprazole|O
DDI-DrugBank.d328.s38|124-124|(|O
DDI-DrugBank.d328.s38|125-126|40|O
DDI-DrugBank.d328.s38|128-129|mg|O
DDI-DrugBank.d328.s38|131-132|QD|O
DDI-DrugBank.d328.s38|133-133|)|O
DDI-DrugBank.d328.s38|134-134|.|O
DDI-DrugBank.d328.s39|0-15|Coadministration|O
DDI-DrugBank.d328.s39|17-20|with|O
DDI-DrugBank.d328.s39|22-31|valdecoxib|O
DDI-DrugBank.d328.s39|33-41|increased|O
DDI-DrugBank.d328.s39|43-50|exposure|O
DDI-DrugBank.d328.s39|52-53|of|O
DDI-DrugBank.d328.s39|55-64|omeprazole|O
DDI-DrugBank.d328.s39|66-66|(|O
DDI-DrugBank.d328.s39|67-69|AUC|O
DDI-DrugBank.d328.s39|70-70|)|O
DDI-DrugBank.d328.s39|72-73|by|O
DDI-DrugBank.d328.s39|75-76|46|O
DDI-DrugBank.d328.s39|77-77|%|O
DDI-DrugBank.d328.s39|78-78|.|O
DDI-DrugBank.d328.s40|0-4|Drugs|O
DDI-DrugBank.d328.s40|6-10|whose|O
DDI-DrugBank.d328.s40|12-21|absorption|O
DDI-DrugBank.d328.s40|23-24|is|O
DDI-DrugBank.d328.s40|26-34|sensitive|O
DDI-DrugBank.d328.s40|36-37|to|O
DDI-DrugBank.d328.s40|39-40|pH|O
DDI-DrugBank.d328.s40|42-44|may|O
DDI-DrugBank.d328.s40|46-47|be|O
DDI-DrugBank.d328.s40|49-58|negatively|O
DDI-DrugBank.d328.s40|60-67|impacted|O
DDI-DrugBank.d328.s40|69-70|by|O
DDI-DrugBank.d328.s40|72-82|concomitant|O
DDI-DrugBank.d328.s40|84-97|administration|O
DDI-DrugBank.d328.s40|99-100|of|O
DDI-DrugBank.d328.s40|102-111|omeprazole|O
DDI-DrugBank.d328.s40|113-115|and|O
DDI-DrugBank.d328.s40|117-126|valdecoxib|O
DDI-DrugBank.d328.s40|127-127|.|O
DDI-DrugBank.d328.s41|0-6|However|O
DDI-DrugBank.d328.s41|7-7|,|O
DDI-DrugBank.d328.s41|9-15|because|O
DDI-DrugBank.d328.s41|17-22|higher|O
DDI-DrugBank.d328.s41|24-28|doses|O
DDI-DrugBank.d328.s41|30-30|(|O
DDI-DrugBank.d328.s41|31-32|up|O
DDI-DrugBank.d328.s41|34-35|to|O
DDI-DrugBank.d328.s41|37-39|360|O
DDI-DrugBank.d328.s41|41-42|mg|O
DDI-DrugBank.d328.s41|44-45|QD|O
DDI-DrugBank.d328.s41|46-46|)|O
DDI-DrugBank.d328.s41|48-49|of|O
DDI-DrugBank.d328.s41|51-60|omeprazole|O
DDI-DrugBank.d328.s41|62-64|are|O
DDI-DrugBank.d328.s41|66-74|tolerated|O
DDI-DrugBank.d328.s41|76-77|in|O
DDI-DrugBank.d328.s41|79-95|Zollinger-Ellison|O
DDI-DrugBank.d328.s41|97-97|(|O
DDI-DrugBank.d328.s41|98-99|ZE|O
DDI-DrugBank.d328.s41|100-100|)|O
DDI-DrugBank.d328.s41|102-109|patients|O
DDI-DrugBank.d328.s41|110-110|,|O
DDI-DrugBank.d328.s41|112-113|no|O
DDI-DrugBank.d328.s41|115-118|dose|O
DDI-DrugBank.d328.s41|120-129|adjustment|O
DDI-DrugBank.d328.s41|131-133|for|O
DDI-DrugBank.d328.s41|135-144|omeprazole|O
DDI-DrugBank.d328.s41|146-147|is|O
DDI-DrugBank.d328.s41|149-159|recommended|O
DDI-DrugBank.d328.s41|161-162|at|O
DDI-DrugBank.d328.s41|164-170|current|O
DDI-DrugBank.d328.s41|172-176|doses|O
DDI-DrugBank.d328.s41|177-177|.|O
DDI-DrugBank.d328.s42|0-15|Coadministration|O
DDI-DrugBank.d328.s42|17-18|of|O
DDI-DrugBank.d328.s42|20-29|valdecoxib|O
DDI-DrugBank.d328.s42|31-34|with|O
DDI-DrugBank.d328.s42|36-40|doses|O
DDI-DrugBank.d328.s42|42-47|higher|O
DDI-DrugBank.d328.s42|49-52|than|O
DDI-DrugBank.d328.s42|54-55|40|O
DDI-DrugBank.d328.s42|57-58|mg|O
DDI-DrugBank.d328.s42|60-61|QD|O
DDI-DrugBank.d328.s42|63-72|omeprazole|O
DDI-DrugBank.d328.s42|74-76|has|O
DDI-DrugBank.d328.s42|78-80|not|O
DDI-DrugBank.d328.s42|82-85|been|O
DDI-DrugBank.d328.s42|87-93|studied|O
DDI-DrugBank.d328.s42|94-94|.|O
DDI-DrugBank.d328.s43|0-3|Oral|O
DDI-DrugBank.d328.s43|5-18|Contraceptives|O
DDI-DrugBank.d328.s43|19-19|:|O
DDI-DrugBank.d328.s43|21-30|Valdecoxib|O
DDI-DrugBank.d328.s43|32-32|(|O
DDI-DrugBank.d328.s43|33-34|40|O
DDI-DrugBank.d328.s43|36-37|mg|O
DDI-DrugBank.d328.s43|39-41|BID|O
DDI-DrugBank.d328.s43|42-42|)|O
DDI-DrugBank.d328.s43|44-46|did|O
DDI-DrugBank.d328.s43|48-50|not|O
DDI-DrugBank.d328.s43|52-57|induce|O
DDI-DrugBank.d328.s43|59-61|the|O
DDI-DrugBank.d328.s43|63-72|metabolism|O
DDI-DrugBank.d328.s43|74-75|of|O
DDI-DrugBank.d328.s43|77-79|the|O
DDI-DrugBank.d328.s43|81-91|combination|O
DDI-DrugBank.d328.s43|93-96|oral|O
DDI-DrugBank.d328.s43|98-110|contraceptive|O
DDI-DrugBank.d328.s43|112-132|norethindrone/ethinyl|O
DDI-DrugBank.d328.s43|134-142|estradiol|O
DDI-DrugBank.d328.s43|144-144|(|O
DDI-DrugBank.d328.s43|145-145|1|O
DDI-DrugBank.d328.s43|147-148|mg|O
DDI-DrugBank.d328.s43|150-152|/35|O
DDI-DrugBank.d328.s43|154-156|mcg|O
DDI-DrugBank.d328.s43|158-168|combination|O
DDI-DrugBank.d328.s43|169-169|,|O
DDI-DrugBank.d328.s43|171-181|Ortho-Novum|O
DDI-DrugBank.d328.s43|183-186|1/35|O
DDI-DrugBank.d328.s43|188-188|)|O
DDI-DrugBank.d328.s43|189-189|.|O
DDI-DrugBank.d328.s44|0-15|Coadministration|O
DDI-DrugBank.d328.s44|17-18|of|O
DDI-DrugBank.d328.s44|20-29|valdecoxib|O
DDI-DrugBank.d328.s44|31-33|and|O
DDI-DrugBank.d328.s44|35-45|Ortho-Novum|O
DDI-DrugBank.d328.s44|47-50|1/35|O
DDI-DrugBank.d328.s44|53-61|increased|O
DDI-DrugBank.d328.s44|63-65|the|O
DDI-DrugBank.d328.s44|67-74|exposure|O
DDI-DrugBank.d328.s44|76-77|of|O
DDI-DrugBank.d328.s44|79-91|norethindrone|O
DDI-DrugBank.d328.s44|93-95|and|O
DDI-DrugBank.d328.s44|97-103|ethinyl|O
DDI-DrugBank.d328.s44|105-113|estradiol|O
DDI-DrugBank.d328.s44|115-116|by|O
DDI-DrugBank.d328.s44|118-119|20|O
DDI-DrugBank.d328.s44|120-120|%|O
DDI-DrugBank.d328.s44|122-124|and|O
DDI-DrugBank.d328.s44|126-127|34|O
DDI-DrugBank.d328.s44|128-128|%|O
DDI-DrugBank.d328.s44|129-129|,|O
DDI-DrugBank.d328.s44|131-142|respectively|O
DDI-DrugBank.d328.s44|143-143|.|O
DDI-DrugBank.d328.s45|0-7|Although|O
DDI-DrugBank.d328.s45|9-13|there|O
DDI-DrugBank.d328.s45|15-16|is|O
DDI-DrugBank.d328.s45|18-23|little|O
DDI-DrugBank.d328.s45|25-28|risk|O
DDI-DrugBank.d328.s45|30-32|for|O
DDI-DrugBank.d328.s45|34-37|loss|O
DDI-DrugBank.d328.s45|39-40|of|O
DDI-DrugBank.d328.s45|42-54|contraceptive|O
DDI-DrugBank.d328.s45|56-63|efficacy|O
DDI-DrugBank.d328.s45|64-64|,|O
DDI-DrugBank.d328.s45|66-68|the|O
DDI-DrugBank.d328.s45|70-77|clinical|O
DDI-DrugBank.d328.s45|79-90|significance|O
DDI-DrugBank.d328.s45|92-93|of|O
DDI-DrugBank.d328.s45|95-99|these|O
DDI-DrugBank.d328.s45|101-109|increased|O
DDI-DrugBank.d328.s45|111-119|exposures|O
DDI-DrugBank.d328.s45|121-122|in|O
DDI-DrugBank.d328.s45|124-128|terms|O
DDI-DrugBank.d328.s45|130-131|of|O
DDI-DrugBank.d328.s45|133-138|safety|O
DDI-DrugBank.d328.s45|140-141|is|O
DDI-DrugBank.d328.s45|143-145|not|O
DDI-DrugBank.d328.s45|147-151|known|O
DDI-DrugBank.d328.s45|152-152|.|O
DDI-DrugBank.d328.s46|0-4|These|O
DDI-DrugBank.d328.s46|6-14|increased|O
DDI-DrugBank.d328.s46|16-24|exposures|O
DDI-DrugBank.d328.s46|26-27|of|O
DDI-DrugBank.d328.s46|29-41|norethindrone|O
DDI-DrugBank.d328.s46|43-45|and|O
DDI-DrugBank.d328.s46|47-53|ethinyl|O
DDI-DrugBank.d328.s46|55-63|estradiol|O
DDI-DrugBank.d328.s46|65-70|should|O
DDI-DrugBank.d328.s46|72-73|be|O
DDI-DrugBank.d328.s46|75-79|taken|O
DDI-DrugBank.d328.s46|81-84|into|O
DDI-DrugBank.d328.s46|86-98|consideration|O
DDI-DrugBank.d328.s46|100-103|when|O
DDI-DrugBank.d328.s46|105-113|selecting|O
DDI-DrugBank.d328.s46|115-116|an|O
DDI-DrugBank.d328.s46|118-121|oral|O
DDI-DrugBank.d328.s46|123-135|contraceptive|O
DDI-DrugBank.d328.s46|137-139|for|O
DDI-DrugBank.d328.s46|141-145|women|O
DDI-DrugBank.d328.s46|147-152|taking|O
DDI-DrugBank.d328.s46|154-163|valdecoxib|O
DDI-DrugBank.d328.s46|164-164|.|O
DDI-DrugBank.d328.s47|0-7|Diazepam|O
DDI-DrugBank.d328.s47|8-8|:|O
DDI-DrugBank.d328.s47|10-17|Diazepam|O
DDI-DrugBank.d328.s47|19-19|(|O
DDI-DrugBank.d328.s47|20-25|Valium|O
DDI-DrugBank.d328.s47|26-26|)|O
DDI-DrugBank.d328.s47|28-29|is|O
DDI-DrugBank.d328.s47|31-31|a|O
DDI-DrugBank.d328.s47|33-35|CYP|O
DDI-DrugBank.d328.s47|37-39|3A4|O
DDI-DrugBank.d328.s47|41-43|and|O
DDI-DrugBank.d328.s47|45-47|CYP|O
DDI-DrugBank.d328.s47|49-52|2C19|O
DDI-DrugBank.d328.s47|54-62|substrate|O
DDI-DrugBank.d328.s47|63-63|.|O
DDI-DrugBank.d328.s48|0-5|Plasma|O
DDI-DrugBank.d328.s48|7-14|exposure|O
DDI-DrugBank.d328.s48|16-17|of|O
DDI-DrugBank.d328.s48|19-26|diazepam|O
DDI-DrugBank.d328.s48|28-28|(|O
DDI-DrugBank.d328.s48|29-30|10|O
DDI-DrugBank.d328.s48|32-33|mg|O
DDI-DrugBank.d328.s48|35-37|BID|O
DDI-DrugBank.d328.s48|38-38|)|O
DDI-DrugBank.d328.s48|40-42|was|O
DDI-DrugBank.d328.s48|44-52|increased|O
DDI-DrugBank.d328.s48|54-55|by|O
DDI-DrugBank.d328.s48|57-58|28|O
DDI-DrugBank.d328.s48|59-59|%|O
DDI-DrugBank.d328.s48|61-69|following|O
DDI-DrugBank.d328.s48|71-84|administration|O
DDI-DrugBank.d328.s48|86-87|of|O
DDI-DrugBank.d328.s48|89-98|valdecoxib|O
DDI-DrugBank.d328.s48|100-100|(|O
DDI-DrugBank.d328.s48|101-102|40|O
DDI-DrugBank.d328.s48|104-105|mg|O
DDI-DrugBank.d328.s48|107-109|BID|O
DDI-DrugBank.d328.s48|110-110|)|O
DDI-DrugBank.d328.s48|112-114|for|O
DDI-DrugBank.d328.s48|116-117|12|O
DDI-DrugBank.d328.s48|119-122|days|O
DDI-DrugBank.d328.s48|123-123|,|O
DDI-DrugBank.d328.s48|125-129|while|O
DDI-DrugBank.d328.s48|131-136|plasma|O
DDI-DrugBank.d328.s48|138-145|exposure|O
DDI-DrugBank.d328.s48|147-148|of|O
DDI-DrugBank.d328.s48|150-159|valdecoxib|O
DDI-DrugBank.d328.s48|161-161|(|O
DDI-DrugBank.d328.s48|162-163|40|O
DDI-DrugBank.d328.s48|165-166|mg|O
DDI-DrugBank.d328.s48|168-170|BID|O
DDI-DrugBank.d328.s48|171-171|)|O
DDI-DrugBank.d328.s48|173-175|was|O
DDI-DrugBank.d328.s48|177-179|not|O
DDI-DrugBank.d328.s48|181-193|substantially|O
DDI-DrugBank.d328.s48|195-203|increased|O
DDI-DrugBank.d328.s48|205-213|following|O
DDI-DrugBank.d328.s48|215-228|administration|O
DDI-DrugBank.d328.s48|230-231|of|O
DDI-DrugBank.d328.s48|233-240|diazepam|O
DDI-DrugBank.d328.s48|242-242|(|O
DDI-DrugBank.d328.s48|243-244|10|O
DDI-DrugBank.d328.s48|246-247|mg|O
DDI-DrugBank.d328.s48|249-251|BID|O
DDI-DrugBank.d328.s48|252-252|)|O
DDI-DrugBank.d328.s48|254-256|for|O
DDI-DrugBank.d328.s48|258-259|12|O
DDI-DrugBank.d328.s48|261-264|days|O
DDI-DrugBank.d328.s48|265-265|.|O
DDI-DrugBank.d328.s49|0-7|Although|O
DDI-DrugBank.d328.s49|9-11|the|O
DDI-DrugBank.d328.s49|13-21|magnitude|O
DDI-DrugBank.d328.s49|23-24|of|O
DDI-DrugBank.d328.s49|26-32|changes|O
DDI-DrugBank.d328.s49|34-35|in|O
DDI-DrugBank.d328.s49|37-44|diazepam|O
DDI-DrugBank.d328.s49|46-51|plasma|O
DDI-DrugBank.d328.s49|53-60|exposure|O
DDI-DrugBank.d328.s49|62-65|when|O
DDI-DrugBank.d328.s49|67-80|coadministered|O
DDI-DrugBank.d328.s49|82-85|with|O
DDI-DrugBank.d328.s49|87-96|valdecoxib|O
DDI-DrugBank.d328.s49|98-101|were|O
DDI-DrugBank.d328.s49|103-105|not|O
DDI-DrugBank.d328.s49|107-116|sufficient|O
DDI-DrugBank.d328.s49|118-119|to|O
DDI-DrugBank.d328.s49|121-127|warrant|O
DDI-DrugBank.d328.s49|129-134|dosage|O
DDI-DrugBank.d328.s49|136-146|adjustments|O
DDI-DrugBank.d328.s49|147-147|,|O
DDI-DrugBank.d328.s49|149-156|patients|O
DDI-DrugBank.d328.s49|158-160|may|O
DDI-DrugBank.d328.s49|162-171|experience|O
DDI-DrugBank.d328.s49|173-180|enhanced|O
DDI-DrugBank.d328.s49|182-189|sedative|O
DDI-DrugBank.d328.s49|191-194|side|O
DDI-DrugBank.d328.s49|196-202|effects|O
DDI-DrugBank.d328.s49|204-209|caused|O
DDI-DrugBank.d328.s49|211-212|by|O
DDI-DrugBank.d328.s49|214-222|increased|O
DDI-DrugBank.d328.s49|224-231|exposure|O
DDI-DrugBank.d328.s49|233-234|of|O
DDI-DrugBank.d328.s49|236-243|diazepam|O
DDI-DrugBank.d328.s49|245-249|under|O
DDI-DrugBank.d328.s49|251-254|this|O
DDI-DrugBank.d328.s49|256-267|circumstance|O
DDI-DrugBank.d328.s49|268-268|.|O
DDI-DrugBank.d328.s50|0-7|Patients|O
DDI-DrugBank.d328.s50|9-14|should|O
DDI-DrugBank.d328.s50|16-17|be|O
DDI-DrugBank.d328.s50|19-27|cautioned|O
DDI-DrugBank.d328.s50|29-35|against|O
DDI-DrugBank.d328.s50|37-44|engaging|O
DDI-DrugBank.d328.s50|46-47|in|O
DDI-DrugBank.d328.s50|49-57|hazardous|O
DDI-DrugBank.d328.s50|59-68|activities|O
DDI-DrugBank.d328.s50|70-78|requiring|O
DDI-DrugBank.d328.s50|80-87|complete|O
DDI-DrugBank.d328.s50|89-94|mental|O
DDI-DrugBank.d328.s50|96-104|alertness|O
DDI-DrugBank.d328.s50|106-109|such|O
DDI-DrugBank.d328.s50|111-112|as|O
DDI-DrugBank.d328.s50|114-122|operating|O
DDI-DrugBank.d328.s50|124-132|machinery|O
DDI-DrugBank.d328.s50|134-135|or|O
DDI-DrugBank.d328.s50|137-143|driving|O
DDI-DrugBank.d328.s50|145-145|a|O
DDI-DrugBank.d328.s50|147-151|motor|O
DDI-DrugBank.d328.s50|153-159|vehicle|O
DDI-DrugBank.d328.s50|160-160|.|O
DDI-DrugBank.d22.s0|0-13|Aminosalicylic|O
DDI-DrugBank.d22.s0|15-18|acid|O
DDI-DrugBank.d22.s0|20-22|may|O
DDI-DrugBank.d22.s0|24-31|decrease|O
DDI-DrugBank.d22.s0|33-35|the|O
DDI-DrugBank.d22.s0|37-42|amount|O
DDI-DrugBank.d22.s0|44-45|of|O
DDI-DrugBank.d22.s0|47-53|digoxin|O
DDI-DrugBank.d22.s0|55-55|(|O
DDI-DrugBank.d22.s0|56-62|Lanoxin|O
DDI-DrugBank.d22.s0|63-63|,|O
DDI-DrugBank.d22.s0|65-74|Lanoxicaps|O
DDI-DrugBank.d22.s0|75-75|)|O
DDI-DrugBank.d22.s0|77-80|that|O
DDI-DrugBank.d22.s0|82-85|gets|O
DDI-DrugBank.d22.s0|87-94|absorbed|O
DDI-DrugBank.d22.s0|96-99|into|O
DDI-DrugBank.d22.s0|101-104|your|O
DDI-DrugBank.d22.s0|106-109|body|O
DDI-DrugBank.d22.s0|110-110|.|O
DDI-DrugBank.d22.s1|0-1|In|O
DDI-DrugBank.d22.s1|3-5|the|O
DDI-DrugBank.d22.s1|7-10|case|O
DDI-DrugBank.d22.s1|12-15|that|O
DDI-DrugBank.d22.s1|17-19|you|O
DDI-DrugBank.d22.s1|21-23|are|O
DDI-DrugBank.d22.s1|25-30|taking|O
DDI-DrugBank.d22.s1|32-38|digoxin|O
DDI-DrugBank.d22.s1|40-44|while|O
DDI-DrugBank.d22.s1|46-51|taking|O
DDI-DrugBank.d22.s1|53-66|aminosalicylic|O
DDI-DrugBank.d22.s1|68-71|acid|O
DDI-DrugBank.d22.s1|72-72|,|O
DDI-DrugBank.d22.s1|74-79|higher|O
DDI-DrugBank.d22.s1|81-85|doses|O
DDI-DrugBank.d22.s1|87-88|of|O
DDI-DrugBank.d22.s1|90-96|digoxin|O
DDI-DrugBank.d22.s1|98-100|may|O
DDI-DrugBank.d22.s1|102-103|be|O
DDI-DrugBank.d22.s1|105-110|needed|O
DDI-DrugBank.d22.s1|111-111|.|O
DDI-DrugBank.d22.s2|0-13|Aminosalicylic|O
DDI-DrugBank.d22.s2|15-18|acid|O
DDI-DrugBank.d22.s2|20-22|may|O
DDI-DrugBank.d22.s2|24-27|also|O
DDI-DrugBank.d22.s2|29-36|decrease|O
DDI-DrugBank.d22.s2|38-40|the|O
DDI-DrugBank.d22.s2|42-51|absorption|O
DDI-DrugBank.d22.s2|53-54|of|O
DDI-DrugBank.d22.s2|56-62|vitamin|O
DDI-DrugBank.d22.s2|64-66|B12|O
DDI-DrugBank.d22.s2|67-67|,|O
DDI-DrugBank.d22.s2|69-73|which|O
DDI-DrugBank.d22.s2|75-77|can|O
DDI-DrugBank.d22.s2|79-82|lead|O
DDI-DrugBank.d22.s2|84-85|to|O
DDI-DrugBank.d22.s2|87-87|a|O
DDI-DrugBank.d22.s2|89-98|deficiency|O
DDI-DrugBank.d22.s2|99-99|.|O
DDI-DrugBank.d22.s3|0-8|Therefore|O
DDI-DrugBank.d22.s3|10-12|you|O
DDI-DrugBank.d22.s3|14-16|may|O
DDI-DrugBank.d22.s3|18-21|need|O
DDI-DrugBank.d22.s3|23-24|to|O
DDI-DrugBank.d22.s3|26-29|take|O
DDI-DrugBank.d22.s3|31-31|a|O
DDI-DrugBank.d22.s3|33-39|vitamin|O
DDI-DrugBank.d22.s3|41-43|B12|O
DDI-DrugBank.d22.s3|45-54|supplement|O
DDI-DrugBank.d22.s3|56-60|while|O
DDI-DrugBank.d22.s3|62-67|taking|O
DDI-DrugBank.d22.s3|69-82|aminosalicylic|O
DDI-DrugBank.d22.s3|84-87|acid|O
DDI-DrugBank.d22.s3|88-88|.|O
DDI-DrugBank.d475.s0|0-1|No|O
DDI-DrugBank.d475.s0|3-14|interactions|O
DDI-DrugBank.d475.s0|16-19|have|O
DDI-DrugBank.d475.s0|21-24|been|O
DDI-DrugBank.d475.s0|26-33|observed|O
DDI-DrugBank.d475.s0|35-41|between|O
DDI-DrugBank.d475.s0|43-52|nizatidine|O
DDI-DrugBank.d475.s0|54-56|and|O
DDI-DrugBank.d475.s0|58-69|theophylline|O
DDI-DrugBank.d475.s0|70-70|,|O
DDI-DrugBank.d475.s0|72-87|chlordiazepoxide|O
DDI-DrugBank.d475.s0|88-88|,|O
DDI-DrugBank.d475.s0|90-98|lorazepam|O
DDI-DrugBank.d475.s0|99-99|,|O
DDI-DrugBank.d475.s0|101-109|lidocaine|O
DDI-DrugBank.d475.s0|110-110|,|O
DDI-DrugBank.d475.s0|112-120|phenytoin|O
DDI-DrugBank.d475.s0|121-121|,|O
DDI-DrugBank.d475.s0|123-125|and|O
DDI-DrugBank.d475.s0|127-134|warfarin|O
DDI-DrugBank.d475.s0|135-135|.|O
DDI-DrugBank.d475.s1|0-9|Nizatidine|O
DDI-DrugBank.d475.s1|11-14|does|O
DDI-DrugBank.d475.s1|16-18|not|O
DDI-DrugBank.d475.s1|20-26|inhibit|O
DDI-DrugBank.d475.s1|28-30|the|O
DDI-DrugBank.d475.s1|32-41|cytochrome|O
DDI-DrugBank.d475.s1|43-54|P-450-linked|O
DDI-DrugBank.d475.s1|56-72|drug-metabolizing|O
DDI-DrugBank.d475.s1|74-79|enzyme|O
DDI-DrugBank.d475.s1|81-86|system|O
DDI-DrugBank.d475.s1|87-87|;|O
DDI-DrugBank.d475.s2|0-8|therefore|O
DDI-DrugBank.d475.s2|9-9|,|O
DDI-DrugBank.d475.s2|11-14|drug|O
DDI-DrugBank.d475.s2|16-27|interactions|O
DDI-DrugBank.d475.s2|29-36|mediated|O
DDI-DrugBank.d475.s2|38-39|by|O
DDI-DrugBank.d475.s2|41-50|inhibition|O
DDI-DrugBank.d475.s2|52-53|of|O
DDI-DrugBank.d475.s2|55-61|hepatic|O
DDI-DrugBank.d475.s2|63-72|metabolism|O
DDI-DrugBank.d475.s2|74-76|are|O
DDI-DrugBank.d475.s2|78-80|not|O
DDI-DrugBank.d475.s2|82-89|expected|O
DDI-DrugBank.d475.s2|91-92|to|O
DDI-DrugBank.d475.s2|94-98|occur|O
DDI-DrugBank.d475.s2|99-99|.|O
DDI-DrugBank.d475.s3|0-1|In|O
DDI-DrugBank.d475.s3|3-10|patients|O
DDI-DrugBank.d475.s3|12-16|given|O
DDI-DrugBank.d475.s3|18-21|very|O
DDI-DrugBank.d475.s3|23-26|high|O
DDI-DrugBank.d475.s3|28-32|doses|O
DDI-DrugBank.d475.s3|34-34|(|O
DDI-DrugBank.d475.s3|35-38|3900|O
DDI-DrugBank.d475.s3|40-41|mg|O
DDI-DrugBank.d475.s3|42-42|)|O
DDI-DrugBank.d475.s3|44-45|of|O
DDI-DrugBank.d475.s3|47-53|aspirin|O
DDI-DrugBank.d475.s3|55-59|daily|O
DDI-DrugBank.d475.s3|60-60|,|O
DDI-DrugBank.d475.s3|62-70|increases|O
DDI-DrugBank.d475.s3|72-73|in|O
DDI-DrugBank.d475.s3|75-79|serum|O
DDI-DrugBank.d475.s3|81-90|salicylate|O
DDI-DrugBank.d475.s3|92-97|levels|O
DDI-DrugBank.d475.s3|99-102|were|O
DDI-DrugBank.d475.s3|104-107|seen|O
DDI-DrugBank.d475.s3|109-112|when|O
DDI-DrugBank.d475.s3|114-123|nizatidine|O
DDI-DrugBank.d475.s3|124-124|,|O
DDI-DrugBank.d475.s3|126-128|150|O
DDI-DrugBank.d475.s3|130-131|mg|O
DDI-DrugBank.d475.s3|133-138|b.i.d.|O
DDI-DrugBank.d475.s3|139-139|,|O
DDI-DrugBank.d475.s3|141-143|was|O
DDI-DrugBank.d475.s3|145-156|administered|O
DDI-DrugBank.d475.s3|158-169|concurrently|O
DDI-DrugBank.d475.s3|170-170|.|O
DDI-DrugBank.d179.s0|0-10|Interations|O
DDI-DrugBank.d179.s1|0-12|Sulfapyridine|O
DDI-DrugBank.d179.s1|14-16|may|O
DDI-DrugBank.d179.s1|18-25|interact|O
DDI-DrugBank.d179.s1|27-30|with|O
DDI-DrugBank.d179.s1|32-34|any|O
DDI-DrugBank.d179.s1|36-37|of|O
DDI-DrugBank.d179.s1|39-41|the|O
DDI-DrugBank.d179.s1|43-51|following|O
DDI-DrugBank.d179.s1|52-52|:|O
DDI-DrugBank.d179.s1|54-54|-|O
DDI-DrugBank.d179.s1|56-68|Acetaminophen|O
DDI-DrugBank.d179.s1|70-70|(|O
DDI-DrugBank.d179.s1|71-74|e.g.|O
DDI-DrugBank.d179.s1|75-75|,|O
DDI-DrugBank.d179.s1|77-83|Tylenol|O
DDI-DrugBank.d179.s1|84-84|)|O
DDI-DrugBank.d179.s1|86-86|(|O
DDI-DrugBank.d179.s1|87-90|with|O
DDI-DrugBank.d179.s1|92-100|long-term|O
DDI-DrugBank.d179.s1|101-101|,|O
DDI-DrugBank.d179.s1|103-111|high-dose|O
DDI-DrugBank.d179.s1|113-115|use|O
DDI-DrugBank.d179.s1|116-116|)|O
DDI-DrugBank.d179.s1|118-119|or|O
DDI-DrugBank.d179.s2|0-0|-|O
DDI-DrugBank.d179.s2|2-11|Amiodarone|O
DDI-DrugBank.d179.s2|13-13|(|O
DDI-DrugBank.d179.s2|14-17|e.g.|O
DDI-DrugBank.d179.s2|18-18|,|O
DDI-DrugBank.d179.s2|20-28|Cordarone|O
DDI-DrugBank.d179.s2|29-29|)|O
DDI-DrugBank.d179.s2|31-32|or|O
DDI-DrugBank.d179.s3|0-0|-|O
DDI-DrugBank.d179.s3|2-9|Anabolic|O
DDI-DrugBank.d179.s3|11-18|steroids|O
DDI-DrugBank.d179.s3|20-20|(|O
DDI-DrugBank.d179.s3|21-30|nandrolone|O
DDI-DrugBank.d179.s3|32-32|[|O
DDI-DrugBank.d179.s3|33-36|e.g.|O
DDI-DrugBank.d179.s3|37-37|,|O
DDI-DrugBank.d179.s3|39-46|Anabolin|O
DDI-DrugBank.d179.s3|47-47|]|O
DDI-DrugBank.d179.s3|48-48|,|O
DDI-DrugBank.d179.s3|50-60|oxandrolone|O
DDI-DrugBank.d179.s3|62-62|[|O
DDI-DrugBank.d179.s3|63-66|e.g.|O
DDI-DrugBank.d179.s3|67-67|,|O
DDI-DrugBank.d179.s3|69-74|Anavar|O
DDI-DrugBank.d179.s3|75-75|]|O
DDI-DrugBank.d179.s3|76-76|,|O
DDI-DrugBank.d179.s3|78-89|oxymetholone|O
DDI-DrugBank.d179.s3|91-91|[|O
DDI-DrugBank.d179.s3|92-95|e.g.|O
DDI-DrugBank.d179.s3|96-96|,|O
DDI-DrugBank.d179.s3|98-104|Anadrol|O
DDI-DrugBank.d179.s3|105-105|]|O
DDI-DrugBank.d179.s3|106-106|,|O
DDI-DrugBank.d179.s3|108-117|stanozolol|O
DDI-DrugBank.d179.s3|119-119|[|O
DDI-DrugBank.d179.s3|120-123|e.g.|O
DDI-DrugBank.d179.s3|124-124|,|O
DDI-DrugBank.d179.s3|126-133|Winstrol|O
DDI-DrugBank.d179.s3|134-134|]|O
DDI-DrugBank.d179.s3|135-135|)|O
DDI-DrugBank.d179.s3|137-138|or|O
DDI-DrugBank.d179.s4|0-0|-|O
DDI-DrugBank.d179.s4|2-10|Androgens|O
DDI-DrugBank.d179.s4|12-12|(|O
DDI-DrugBank.d179.s4|13-16|male|O
DDI-DrugBank.d179.s4|18-25|hormones|O
DDI-DrugBank.d179.s4|26-26|)|O
DDI-DrugBank.d179.s4|28-29|or|O
DDI-DrugBank.d179.s5|0-0|-|O
DDI-DrugBank.d179.s5|2-12|Antithyroid|O
DDI-DrugBank.d179.s5|14-19|agents|O
DDI-DrugBank.d179.s5|21-21|(|O
DDI-DrugBank.d179.s5|22-29|medicine|O
DDI-DrugBank.d179.s5|31-33|for|O
DDI-DrugBank.d179.s5|35-44|overactive|O
DDI-DrugBank.d179.s5|46-52|thyroid|O
DDI-DrugBank.d179.s5|53-53|)|O
DDI-DrugBank.d179.s5|55-56|or|O
DDI-DrugBank.d179.s6|0-0|-|O
DDI-DrugBank.d179.s6|2-14|Carbamazepine|O
DDI-DrugBank.d179.s6|16-16|(|O
DDI-DrugBank.d179.s6|17-20|e.g.|O
DDI-DrugBank.d179.s6|21-21|,|O
DDI-DrugBank.d179.s6|23-30|Tegretol|O
DDI-DrugBank.d179.s6|31-31|)|O
DDI-DrugBank.d179.s6|33-34|or|O
DDI-DrugBank.d179.s7|0-0|-|O
DDI-DrugBank.d179.s7|2-11|Carmustine|O
DDI-DrugBank.d179.s7|13-13|(|O
DDI-DrugBank.d179.s7|14-17|e.g.|O
DDI-DrugBank.d179.s7|18-18|,|O
DDI-DrugBank.d179.s7|20-24|BiCNU|O
DDI-DrugBank.d179.s7|25-25|)|O
DDI-DrugBank.d179.s7|27-28|or|O
DDI-DrugBank.d179.s8|0-0|-|O
DDI-DrugBank.d179.s8|2-12|Chloroquine|O
DDI-DrugBank.d179.s8|14-14|(|O
DDI-DrugBank.d179.s8|15-18|e.g.|O
DDI-DrugBank.d179.s8|19-19|,|O
DDI-DrugBank.d179.s8|21-26|Aralen|O
DDI-DrugBank.d179.s8|27-27|)|O
DDI-DrugBank.d179.s8|29-30|or|O
DDI-DrugBank.d179.s9|0-0|-|O
DDI-DrugBank.d179.s9|2-11|Dantrolene|O
DDI-DrugBank.d179.s9|13-13|(|O
DDI-DrugBank.d179.s9|14-17|e.g.|O
DDI-DrugBank.d179.s9|18-18|,|O
DDI-DrugBank.d179.s9|20-27|Dantrium|O
DDI-DrugBank.d179.s9|28-28|)|O
DDI-DrugBank.d179.s9|30-31|or|O
DDI-DrugBank.d179.s10|0-0|-|O
DDI-DrugBank.d179.s10|2-13|Daunorubicin|O
DDI-DrugBank.d179.s10|15-15|(|O
DDI-DrugBank.d179.s10|16-19|e.g.|O
DDI-DrugBank.d179.s10|20-20|,|O
DDI-DrugBank.d179.s10|22-31|Cerubidine|O
DDI-DrugBank.d179.s10|32-32|)|O
DDI-DrugBank.d179.s10|34-35|or|O
DDI-DrugBank.d179.s11|0-0|-|O
DDI-DrugBank.d179.s11|2-11|Disulfiram|O
DDI-DrugBank.d179.s11|13-13|(|O
DDI-DrugBank.d179.s11|14-17|e.g.|O
DDI-DrugBank.d179.s11|18-18|,|O
DDI-DrugBank.d179.s11|20-27|Antabuse|O
DDI-DrugBank.d179.s11|28-28|)|O
DDI-DrugBank.d179.s11|30-31|or|O
DDI-DrugBank.d179.s12|0-0|-|O
DDI-DrugBank.d179.s12|2-11|Divalproex|O
DDI-DrugBank.d179.s12|13-13|(|O
DDI-DrugBank.d179.s12|14-17|e.g.|O
DDI-DrugBank.d179.s12|18-18|,|O
DDI-DrugBank.d179.s12|20-27|Depakote|O
DDI-DrugBank.d179.s12|28-28|)|O
DDI-DrugBank.d179.s12|30-31|or|O
DDI-DrugBank.d179.s13|0-0|-|O
DDI-DrugBank.d179.s13|2-10|Estrogens|O
DDI-DrugBank.d179.s13|12-12|(|O
DDI-DrugBank.d179.s13|13-18|female|O
DDI-DrugBank.d179.s13|20-27|hormones|O
DDI-DrugBank.d179.s13|28-28|)|O
DDI-DrugBank.d179.s13|30-31|or|O
DDI-DrugBank.d179.s14|0-0|-|O
DDI-DrugBank.d179.s14|2-11|Etretinate|O
DDI-DrugBank.d179.s14|13-13|(|O
DDI-DrugBank.d179.s14|14-17|e.g.|O
DDI-DrugBank.d179.s14|18-18|,|O
DDI-DrugBank.d179.s14|20-26|Tegison|O
DDI-DrugBank.d179.s14|27-27|)|O
DDI-DrugBank.d179.s14|29-30|or|O
DDI-DrugBank.d179.s15|0-0|-|O
DDI-DrugBank.d179.s15|2-5|Gold|O
DDI-DrugBank.d179.s15|7-11|salts|O
DDI-DrugBank.d179.s15|13-13|(|O
DDI-DrugBank.d179.s15|14-21|medicine|O
DDI-DrugBank.d179.s15|23-25|for|O
DDI-DrugBank.d179.s15|27-35|arthritis|O
DDI-DrugBank.d179.s15|36-36|)|O
DDI-DrugBank.d179.s15|38-39|or|O
DDI-DrugBank.d179.s16|0-0|-|O
DDI-DrugBank.d179.s16|2-19|Hydroxychloroquine|O
DDI-DrugBank.d179.s16|21-21|(|O
DDI-DrugBank.d179.s16|22-25|e.g.|O
DDI-DrugBank.d179.s16|26-26|,|O
DDI-DrugBank.d179.s16|28-36|Plaquenil|O
DDI-DrugBank.d179.s16|37-37|)|O
DDI-DrugBank.d179.s16|39-40|or|O
DDI-DrugBank.d179.s17|0-0|-|O
DDI-DrugBank.d179.s17|2-15|Mercaptopurine|O
DDI-DrugBank.d179.s17|17-17|(|O
DDI-DrugBank.d179.s17|18-21|e.g.|O
DDI-DrugBank.d179.s17|22-22|,|O
DDI-DrugBank.d179.s17|24-33|Purinethol|O
DDI-DrugBank.d179.s17|34-34|)|O
DDI-DrugBank.d179.s17|36-37|or|O
DDI-DrugBank.d179.s18|0-0|-|O
DDI-DrugBank.d179.s18|2-11|Naltrexone|O
DDI-DrugBank.d179.s18|13-13|(|O
DDI-DrugBank.d179.s18|14-17|e.g.|O
DDI-DrugBank.d179.s18|18-18|,|O
DDI-DrugBank.d179.s18|20-25|Trexan|O
DDI-DrugBank.d179.s18|26-26|)|O
DDI-DrugBank.d179.s18|28-28|(|O
DDI-DrugBank.d179.s18|29-32|with|O
DDI-DrugBank.d179.s18|34-42|long-term|O
DDI-DrugBank.d179.s18|43-43|,|O
DDI-DrugBank.d179.s18|45-53|high-dose|O
DDI-DrugBank.d179.s18|55-57|use|O
DDI-DrugBank.d179.s18|58-58|)|O
DDI-DrugBank.d179.s18|60-61|or|O
DDI-DrugBank.d179.s19|0-0|-|O
DDI-DrugBank.d179.s19|2-5|Oral|O
DDI-DrugBank.d179.s19|7-20|contraceptives|O
DDI-DrugBank.d179.s19|22-22|(|O
DDI-DrugBank.d179.s19|23-27|birth|O
DDI-DrugBank.d179.s19|29-35|control|O
DDI-DrugBank.d179.s19|37-41|pills|O
DDI-DrugBank.d179.s19|42-42|)|O
DDI-DrugBank.d179.s19|44-53|containing|O
DDI-DrugBank.d179.s19|55-62|estrogen|O
DDI-DrugBank.d179.s19|64-65|or|O
DDI-DrugBank.d179.s20|0-0|-|O
DDI-DrugBank.d179.s20|2-6|Other|O
DDI-DrugBank.d179.s20|8-22|anti-infectives|O
DDI-DrugBank.d179.s20|24-25|by|O
DDI-DrugBank.d179.s20|27-31|mouth|O
DDI-DrugBank.d179.s20|33-34|or|O
DDI-DrugBank.d179.s20|36-37|by|O
DDI-DrugBank.d179.s20|39-47|injection|O
DDI-DrugBank.d179.s20|49-49|(|O
DDI-DrugBank.d179.s20|50-57|medicine|O
DDI-DrugBank.d179.s20|59-61|for|O
DDI-DrugBank.d179.s20|63-71|infection|O
DDI-DrugBank.d179.s20|72-72|)|O
DDI-DrugBank.d179.s20|74-75|or|O
DDI-DrugBank.d179.s21|0-0|-|O
DDI-DrugBank.d179.s21|2-15|Phenothiazines|O
DDI-DrugBank.d179.s21|17-17|(|O
DDI-DrugBank.d179.s21|18-31|acetophenazine|O
DDI-DrugBank.d179.s21|33-33|[|O
DDI-DrugBank.d179.s21|34-37|e.g.|O
DDI-DrugBank.d179.s21|38-38|,|O
DDI-DrugBank.d179.s21|40-45|Tindal|O
DDI-DrugBank.d179.s21|46-46|]|O
DDI-DrugBank.d179.s21|47-47|,|O
DDI-DrugBank.d179.s21|49-62|chlorpromazine|O
DDI-DrugBank.d179.s21|64-64|[|O
DDI-DrugBank.d179.s21|65-68|e.g.|O
DDI-DrugBank.d179.s21|69-69|,|O
DDI-DrugBank.d179.s21|71-79|Thorazine|O
DDI-DrugBank.d179.s21|80-80|]|O
DDI-DrugBank.d179.s21|81-81|,|O
DDI-DrugBank.d179.s21|83-94|fluphenazine|O
DDI-DrugBank.d179.s21|96-96|[|O
DDI-DrugBank.d179.s21|97-100|e.g.|O
DDI-DrugBank.d179.s21|101-101|,|O
DDI-DrugBank.d179.s21|103-110|Prolixin|O
DDI-DrugBank.d179.s21|111-111|]|O
DDI-DrugBank.d179.s21|112-112|,|O
DDI-DrugBank.d179.s21|114-125|mesoridazine|O
DDI-DrugBank.d179.s21|127-127|[|O
DDI-DrugBank.d179.s21|128-131|e.g.|O
DDI-DrugBank.d179.s21|132-132|,|O
DDI-DrugBank.d179.s21|134-141|Serentil|O
DDI-DrugBank.d179.s21|142-142|]|O
DDI-DrugBank.d179.s21|143-143|,|O
DDI-DrugBank.d179.s21|145-156|perphenazine|O
DDI-DrugBank.d179.s21|158-158|[|O
DDI-DrugBank.d179.s21|159-162|e.g.|O
DDI-DrugBank.d179.s21|163-163|,|O
DDI-DrugBank.d179.s21|165-172|Trilafon|O
DDI-DrugBank.d179.s21|173-173|]|O
DDI-DrugBank.d179.s21|174-174|,|O
DDI-DrugBank.d179.s21|176-191|prochlorperazine|O
DDI-DrugBank.d179.s21|193-193|[|O
DDI-DrugBank.d179.s21|194-197|e.g.|O
DDI-DrugBank.d179.s21|198-198|,|O
DDI-DrugBank.d179.s21|200-208|Compazine|O
DDI-DrugBank.d179.s21|209-209|]|O
DDI-DrugBank.d179.s21|210-210|,|O
DDI-DrugBank.d179.s21|212-220|promazine|O
DDI-DrugBank.d179.s21|222-222|[|O
DDI-DrugBank.d179.s21|223-226|e.g.|O
DDI-DrugBank.d179.s21|227-227|,|O
DDI-DrugBank.d179.s21|229-235|Sparine|O
DDI-DrugBank.d179.s21|236-236|]|O
DDI-DrugBank.d179.s21|237-237|,|O
DDI-DrugBank.d179.s21|239-250|promethazine|O
DDI-DrugBank.d179.s21|252-252|[|O
DDI-DrugBank.d179.s21|253-256|e.g.|O
DDI-DrugBank.d179.s21|257-257|,|O
DDI-DrugBank.d179.s21|259-267|Phenergan|O
DDI-DrugBank.d179.s21|268-268|]|O
DDI-DrugBank.d179.s21|269-269|,|O
DDI-DrugBank.d179.s21|271-282|thioridazine|O
DDI-DrugBank.d179.s21|284-284|[|O
DDI-DrugBank.d179.s21|285-288|e.g.|O
DDI-DrugBank.d179.s21|289-289|,|O
DDI-DrugBank.d179.s21|291-298|Mellaril|O
DDI-DrugBank.d179.s21|299-299|]|O
DDI-DrugBank.d179.s21|300-300|,|O
DDI-DrugBank.d179.s21|302-316|trifluoperazine|O
DDI-DrugBank.d179.s21|318-318|[|O
DDI-DrugBank.d179.s21|319-322|e.g.|O
DDI-DrugBank.d179.s21|323-323|,|O
DDI-DrugBank.d179.s21|325-333|Stelazine|O
DDI-DrugBank.d179.s21|334-334|]|O
DDI-DrugBank.d179.s21|335-335|,|O
DDI-DrugBank.d179.s21|337-351|triflupromazine|O
DDI-DrugBank.d179.s21|353-353|[|O
DDI-DrugBank.d179.s21|354-357|e.g.|O
DDI-DrugBank.d179.s21|358-358|,|O
DDI-DrugBank.d179.s21|360-366|Vesprin|O
DDI-DrugBank.d179.s21|367-367|]|O
DDI-DrugBank.d179.s21|368-368|,|O
DDI-DrugBank.d179.s21|370-381|trimeprazine|O
DDI-DrugBank.d179.s21|383-383|[|O
DDI-DrugBank.d179.s21|384-387|e.g.|O
DDI-DrugBank.d179.s21|388-388|,|O
DDI-DrugBank.d179.s21|390-396|Temaril|O
DDI-DrugBank.d179.s21|397-397|]|O
DDI-DrugBank.d179.s21|398-398|)|O
DDI-DrugBank.d179.s21|400-401|or|O
DDI-DrugBank.d179.s22|0-0|-|O
DDI-DrugBank.d179.s22|2-11|Plicamycin|O
DDI-DrugBank.d179.s22|13-13|(|O
DDI-DrugBank.d179.s22|14-17|e.g.|O
DDI-DrugBank.d179.s22|18-18|,|O
DDI-DrugBank.d179.s22|20-28|Mithracin|O
DDI-DrugBank.d179.s22|29-29|)|O
DDI-DrugBank.d179.s22|31-32|or|O
DDI-DrugBank.d179.s23|0-0|-|O
DDI-DrugBank.d179.s23|2-9|Valproic|O
DDI-DrugBank.d179.s23|11-14|acid|O
DDI-DrugBank.d179.s23|16-16|(|O
DDI-DrugBank.d179.s23|17-20|e.g.|O
DDI-DrugBank.d179.s23|21-21|,|O
DDI-DrugBank.d179.s23|23-30|Depakene|O
DDI-DrugBank.d179.s23|31-31|)|O
DDI-DrugBank.d179.s23|33-35|Use|O
DDI-DrugBank.d179.s23|37-38|of|O
DDI-DrugBank.d179.s23|40-52|sulfapyridine|O
DDI-DrugBank.d179.s23|54-57|with|O
DDI-DrugBank.d179.s23|59-63|these|O
DDI-DrugBank.d179.s23|65-73|medicines|O
DDI-DrugBank.d179.s23|75-77|may|O
DDI-DrugBank.d179.s23|79-86|increase|O
DDI-DrugBank.d179.s23|88-90|the|O
DDI-DrugBank.d179.s23|92-97|chance|O
DDI-DrugBank.d179.s23|99-100|of|O
DDI-DrugBank.d179.s23|102-105|side|O
DDI-DrugBank.d179.s23|107-113|effects|O
DDI-DrugBank.d179.s23|115-123|affecting|O
DDI-DrugBank.d179.s23|125-127|the|O
DDI-DrugBank.d179.s23|129-133|liver|O
DDI-DrugBank.d179.s24|0-0|-|O
DDI-DrugBank.d179.s24|2-16|Acetohydroxamic|O
DDI-DrugBank.d179.s24|18-21|acid|O
DDI-DrugBank.d179.s24|23-23|(|O
DDI-DrugBank.d179.s24|24-27|e.g.|O
DDI-DrugBank.d179.s24|28-28|,|O
DDI-DrugBank.d179.s24|30-38|Lithostat|O
DDI-DrugBank.d179.s24|39-39|)|O
DDI-DrugBank.d179.s24|41-42|or|O
DDI-DrugBank.d179.s25|0-0|-|O
DDI-DrugBank.d179.s25|2-8|Dapsone|O
DDI-DrugBank.d179.s25|10-11|or|O
DDI-DrugBank.d179.s26|0-0|-|O
DDI-DrugBank.d179.s26|2-13|Furazolidone|O
DDI-DrugBank.d179.s26|15-15|(|O
DDI-DrugBank.d179.s26|16-19|e.g.|O
DDI-DrugBank.d179.s26|20-20|,|O
DDI-DrugBank.d179.s26|22-29|Furoxone|O
DDI-DrugBank.d179.s26|30-30|)|O
DDI-DrugBank.d179.s26|32-33|or|O
DDI-DrugBank.d179.s27|0-0|-|O
DDI-DrugBank.d179.s27|2-15|Nitrofurantoin|O
DDI-DrugBank.d179.s27|17-17|(|O
DDI-DrugBank.d179.s27|18-21|e.g.|O
DDI-DrugBank.d179.s27|22-22|,|O
DDI-DrugBank.d179.s27|24-33|Furadantin|O
DDI-DrugBank.d179.s27|34-34|)|O
DDI-DrugBank.d179.s27|36-37|or|O
DDI-DrugBank.d179.s28|0-0|-|O
DDI-DrugBank.d179.s28|2-11|Primaquine|O
DDI-DrugBank.d179.s28|13-14|or|O
DDI-DrugBank.d179.s29|0-0|-|O
DDI-DrugBank.d179.s29|2-13|Procainamide|O
DDI-DrugBank.d179.s29|15-15|(|O
DDI-DrugBank.d179.s29|16-19|e.g.|O
DDI-DrugBank.d179.s29|20-20|,|O
DDI-DrugBank.d179.s29|22-30|Pronestyl|O
DDI-DrugBank.d179.s29|31-31|)|O
DDI-DrugBank.d179.s29|33-34|or|O
DDI-DrugBank.d179.s30|0-0|-|O
DDI-DrugBank.d179.s30|2-10|Quinidine|O
DDI-DrugBank.d179.s30|12-12|(|O
DDI-DrugBank.d179.s30|13-16|e.g.|O
DDI-DrugBank.d179.s30|17-17|,|O
DDI-DrugBank.d179.s30|19-26|Quinidex|O
DDI-DrugBank.d179.s30|27-27|)|O
DDI-DrugBank.d179.s30|29-30|or|O
DDI-DrugBank.d179.s31|0-0|-|O
DDI-DrugBank.d179.s31|2-8|Quinine|O
DDI-DrugBank.d179.s31|10-10|(|O
DDI-DrugBank.d179.s31|11-14|e.g.|O
DDI-DrugBank.d179.s31|15-15|,|O
DDI-DrugBank.d179.s31|17-23|Quinamm|O
DDI-DrugBank.d179.s31|24-24|)|O
DDI-DrugBank.d179.s31|26-27|or|O
DDI-DrugBank.d179.s32|0-0|-|O
DDI-DrugBank.d179.s32|2-10|Sulfoxone|O
DDI-DrugBank.d179.s32|12-12|(|O
DDI-DrugBank.d179.s32|13-16|e.g.|O
DDI-DrugBank.d179.s32|17-17|,|O
DDI-DrugBank.d179.s32|19-25|Diasone|O
DDI-DrugBank.d179.s32|26-26|)|O
DDI-DrugBank.d179.s32|28-29|or|O
DDI-DrugBank.d179.s33|0-0|-|O
DDI-DrugBank.d179.s33|2-8|Vitamin|O
DDI-DrugBank.d179.s33|10-10|K|O
DDI-DrugBank.d179.s33|12-12|(|O
DDI-DrugBank.d179.s33|13-16|e.g.|O
DDI-DrugBank.d179.s33|17-17|,|O
DDI-DrugBank.d179.s33|19-30|AquaMEPHYTON|O
DDI-DrugBank.d179.s33|31-31|,|O
DDI-DrugBank.d179.s33|33-42|Synkayvite|O
DDI-DrugBank.d179.s33|43-43|)|O
DDI-DrugBank.d179.s33|45-47|Use|O
DDI-DrugBank.d179.s33|49-50|of|O
DDI-DrugBank.d179.s33|52-64|sulfapyridine|O
DDI-DrugBank.d179.s33|66-69|with|O
DDI-DrugBank.d179.s33|71-75|these|O
DDI-DrugBank.d179.s33|77-85|medicines|O
DDI-DrugBank.d179.s33|87-89|may|O
DDI-DrugBank.d179.s33|91-98|increase|O
DDI-DrugBank.d179.s33|100-102|the|O
DDI-DrugBank.d179.s33|104-109|chance|O
DDI-DrugBank.d179.s33|111-112|of|O
DDI-DrugBank.d179.s33|114-117|side|O
DDI-DrugBank.d179.s33|119-125|effects|O
DDI-DrugBank.d179.s33|127-135|affecting|O
DDI-DrugBank.d179.s33|137-139|the|O
DDI-DrugBank.d179.s33|141-145|blood|O
DDI-DrugBank.d179.s34|0-0|-|O
DDI-DrugBank.d179.s34|2-15|Anticoagulants|O
DDI-DrugBank.d179.s34|17-17|(|O
DDI-DrugBank.d179.s34|18-22|blood|O
DDI-DrugBank.d179.s34|24-31|thinners|O
DDI-DrugBank.d179.s34|32-32|)|O
DDI-DrugBank.d179.s34|34-35|or|O
DDI-DrugBank.d179.s35|0-0|-|O
DDI-DrugBank.d179.s35|2-9|Ethotoin|O
DDI-DrugBank.d179.s35|11-11|(|O
DDI-DrugBank.d179.s35|12-15|e.g.|O
DDI-DrugBank.d179.s35|16-16|,|O
DDI-DrugBank.d179.s35|18-25|Peganone|O
DDI-DrugBank.d179.s35|26-26|)|O
DDI-DrugBank.d179.s35|28-29|or|O
DDI-DrugBank.d179.s36|0-0|-|O
DDI-DrugBank.d179.s36|2-12|Mephenytoin|O
DDI-DrugBank.d179.s36|14-14|(|O
DDI-DrugBank.d179.s36|15-18|e.g.|O
DDI-DrugBank.d179.s36|19-19|,|O
DDI-DrugBank.d179.s36|21-29|Mesantoin|O
DDI-DrugBank.d179.s36|30-30|)|O
DDI-DrugBank.d179.s36|32-34|Use|O
DDI-DrugBank.d179.s36|36-37|of|O
DDI-DrugBank.d179.s36|39-51|sulfapyridine|O
DDI-DrugBank.d179.s36|53-56|with|O
DDI-DrugBank.d179.s36|58-62|these|O
DDI-DrugBank.d179.s36|64-72|medicines|O
DDI-DrugBank.d179.s36|74-76|may|O
DDI-DrugBank.d179.s36|78-85|increase|O
DDI-DrugBank.d179.s36|87-89|the|O
DDI-DrugBank.d179.s36|91-96|chance|O
DDI-DrugBank.d179.s36|98-99|of|O
DDI-DrugBank.d179.s36|101-104|side|O
DDI-DrugBank.d179.s36|106-112|effects|O
DDI-DrugBank.d179.s36|114-115|of|O
DDI-DrugBank.d179.s36|117-121|these|O
DDI-DrugBank.d179.s36|123-131|medicines|O
DDI-DrugBank.d179.s37|0-0|-|O
DDI-DrugBank.d179.s37|2-14|Antidiabetics|O
DDI-DrugBank.d179.s37|15-15|,|O
DDI-DrugBank.d179.s37|17-20|oral|O
DDI-DrugBank.d179.s37|22-22|(|O
DDI-DrugBank.d179.s37|23-30|diabetes|O
DDI-DrugBank.d179.s37|32-39|medicine|O
DDI-DrugBank.d179.s37|41-43|you|O
DDI-DrugBank.d179.s37|45-48|take|O
DDI-DrugBank.d179.s37|50-51|by|O
DDI-DrugBank.d179.s37|53-57|mouth|O
DDI-DrugBank.d179.s37|58-58|)|O
DDI-DrugBank.d179.s37|60-62|Use|O
DDI-DrugBank.d179.s37|64-65|of|O
DDI-DrugBank.d179.s37|67-70|oral|O
DDI-DrugBank.d179.s37|72-84|antidiabetics|O
DDI-DrugBank.d179.s37|86-89|with|O
DDI-DrugBank.d179.s37|91-103|sulfapyridine|O
DDI-DrugBank.d179.s37|105-107|may|O
DDI-DrugBank.d179.s37|109-116|increase|O
DDI-DrugBank.d179.s37|118-120|the|O
DDI-DrugBank.d179.s37|122-127|chance|O
DDI-DrugBank.d179.s37|129-130|of|O
DDI-DrugBank.d179.s37|132-135|side|O
DDI-DrugBank.d179.s37|137-143|effects|O
DDI-DrugBank.d179.s37|145-153|affecting|O
DDI-DrugBank.d179.s37|155-157|the|O
DDI-DrugBank.d179.s37|159-163|blood|O
DDI-DrugBank.d179.s37|165-170|and/or|O
DDI-DrugBank.d179.s37|172-174|the|O
DDI-DrugBank.d179.s37|176-179|side|O
DDI-DrugBank.d179.s37|181-187|effects|O
DDI-DrugBank.d179.s37|189-190|or|O
DDI-DrugBank.d179.s37|192-195|oral|O
DDI-DrugBank.d179.s37|197-209|antidiabetics|O
DDI-DrugBank.d179.s38|0-0|-|O
DDI-DrugBank.d179.s38|2-13|Methotrexate|O
DDI-DrugBank.d179.s38|15-15|(|O
DDI-DrugBank.d179.s38|16-19|e.g.|O
DDI-DrugBank.d179.s38|20-20|,|O
DDI-DrugBank.d179.s38|22-27|Mexate|O
DDI-DrugBank.d179.s38|28-28|)|O
DDI-DrugBank.d179.s38|30-32|Use|O
DDI-DrugBank.d179.s38|34-35|of|O
DDI-DrugBank.d179.s38|37-48|methotrexate|O
DDI-DrugBank.d179.s38|50-53|with|O
DDI-DrugBank.d179.s38|55-67|sulfapyridine|O
DDI-DrugBank.d179.s38|69-71|may|O
DDI-DrugBank.d179.s38|73-80|increase|O
DDI-DrugBank.d179.s38|82-84|the|O
DDI-DrugBank.d179.s38|86-91|chance|O
DDI-DrugBank.d179.s38|93-94|of|O
DDI-DrugBank.d179.s38|96-99|side|O
DDI-DrugBank.d179.s38|101-107|effects|O
DDI-DrugBank.d179.s38|109-117|affecting|O
DDI-DrugBank.d179.s38|119-121|the|O
DDI-DrugBank.d179.s38|123-127|liver|O
DDI-DrugBank.d179.s38|129-134|and/or|O
DDI-DrugBank.d179.s38|136-138|the|O
DDI-DrugBank.d179.s38|140-143|side|O
DDI-DrugBank.d179.s38|145-151|effects|O
DDI-DrugBank.d179.s38|153-154|of|O
DDI-DrugBank.d179.s38|156-167|methotrexate|O
DDI-DrugBank.d179.s39|0-0|-|O
DDI-DrugBank.d179.s39|2-11|Methyldopa|O
DDI-DrugBank.d179.s39|13-13|(|O
DDI-DrugBank.d179.s39|14-17|e.g.|O
DDI-DrugBank.d179.s39|18-18|,|O
DDI-DrugBank.d179.s39|20-26|Aldomet|O
DDI-DrugBank.d179.s39|27-27|)|O
DDI-DrugBank.d179.s39|29-31|Use|O
DDI-DrugBank.d179.s39|33-34|of|O
DDI-DrugBank.d179.s39|36-45|methyldopa|O
DDI-DrugBank.d179.s39|47-50|with|O
DDI-DrugBank.d179.s39|52-64|sulfapyridine|O
DDI-DrugBank.d179.s39|66-68|may|O
DDI-DrugBank.d179.s39|70-77|increase|O
DDI-DrugBank.d179.s39|79-81|the|O
DDI-DrugBank.d179.s39|83-88|chance|O
DDI-DrugBank.d179.s39|90-91|of|O
DDI-DrugBank.d179.s39|93-96|side|O
DDI-DrugBank.d179.s39|98-104|effects|O
DDI-DrugBank.d179.s39|106-114|affecting|O
DDI-DrugBank.d179.s39|116-118|the|O
DDI-DrugBank.d179.s39|120-124|liver|O
DDI-DrugBank.d179.s39|126-131|and/or|O
DDI-DrugBank.d179.s39|133-135|the|O
DDI-DrugBank.d179.s39|137-141|blood|O
DDI-DrugBank.d179.s40|0-0|-|O
DDI-DrugBank.d179.s40|2-10|Phenytoin|O
DDI-DrugBank.d179.s40|12-12|(|O
DDI-DrugBank.d179.s40|13-16|e.g.|O
DDI-DrugBank.d179.s40|17-17|,|O
DDI-DrugBank.d179.s40|19-26|Dilantin|O
DDI-DrugBank.d179.s40|27-27|)|O
DDI-DrugBank.d179.s40|29-31|Use|O
DDI-DrugBank.d179.s40|33-34|of|O
DDI-DrugBank.d179.s40|36-44|phenytoin|O
DDI-DrugBank.d179.s40|46-49|with|O
DDI-DrugBank.d179.s40|51-63|sulfapyridine|O
DDI-DrugBank.d179.s40|65-67|may|O
DDI-DrugBank.d179.s40|69-76|increase|O
DDI-DrugBank.d179.s40|78-80|the|O
DDI-DrugBank.d179.s40|82-87|chance|O
DDI-DrugBank.d179.s40|89-90|of|O
DDI-DrugBank.d179.s40|92-95|side|O
DDI-DrugBank.d179.s40|97-103|effects|O
DDI-DrugBank.d179.s40|105-113|affecting|O
DDI-DrugBank.d179.s40|115-117|the|O
DDI-DrugBank.d179.s40|119-123|liver|O
DDI-DrugBank.d179.s40|125-130|and/or|O
DDI-DrugBank.d179.s40|132-134|the|O
DDI-DrugBank.d179.s40|136-139|side|O
DDI-DrugBank.d179.s40|141-147|effects|O
DDI-DrugBank.d179.s40|149-150|of|O
DDI-DrugBank.d179.s40|152-160|phenytoin|O
DDI-DrugBank.d446.s0|0-15|Chlorotrianisene|O
DDI-DrugBank.d446.s0|17-19|may|O
DDI-DrugBank.d446.s0|21-28|interact|O
DDI-DrugBank.d446.s0|30-33|with|O
DDI-DrugBank.d446.s0|35-49|antidepressants|O
DDI-DrugBank.d446.s0|50-50|,|O
DDI-DrugBank.d446.s0|52-58|aspirin|O
DDI-DrugBank.d446.s0|59-59|,|O
DDI-DrugBank.d446.s0|61-72|barbiturates|O
DDI-DrugBank.d446.s0|73-73|,|O
DDI-DrugBank.d446.s0|75-87|bromocriptine|O
DDI-DrugBank.d446.s0|88-88|,|O
DDI-DrugBank.d446.s0|90-96|calcium|O
DDI-DrugBank.d446.s0|98-108|supplements|O
DDI-DrugBank.d446.s0|109-109|,|O
DDI-DrugBank.d446.s0|111-125|corticosteroids|O
DDI-DrugBank.d446.s0|126-126|,|O
DDI-DrugBank.d446.s0|128-140|corticotropin|O
DDI-DrugBank.d446.s0|141-141|,|O
DDI-DrugBank.d446.s0|143-154|cyclosporine|O
DDI-DrugBank.d446.s0|155-155|,|O
DDI-DrugBank.d446.s0|157-166|dantrolene|O
DDI-DrugBank.d446.s0|167-167|,|O
DDI-DrugBank.d446.s0|169-176|nicotine|O
DDI-DrugBank.d446.s0|177-177|,|O
DDI-DrugBank.d446.s0|179-188|somatropin|O
DDI-DrugBank.d446.s0|189-189|,|O
DDI-DrugBank.d446.s0|191-199|tamoxifen|O
DDI-DrugBank.d446.s0|200-200|,|O
DDI-DrugBank.d446.s0|202-204|and|O
DDI-DrugBank.d446.s0|206-213|warfarin|O
DDI-DrugBank.d446.s0|214-214|.|O
DDI-DrugBank.d105.s0|0-13|Anticoagulants|O
DDI-DrugBank.d105.s0|15-23|including|O
DDI-DrugBank.d105.s0|25-32|coumarin|O
DDI-DrugBank.d105.s0|34-44|derivatives|O
DDI-DrugBank.d105.s0|45-45|,|O
DDI-DrugBank.d105.s0|47-56|indandione|O
DDI-DrugBank.d105.s0|58-68|derivatives|O
DDI-DrugBank.d105.s0|69-69|,|O
DDI-DrugBank.d105.s0|71-73|and|O
DDI-DrugBank.d105.s0|75-82|platelet|O
DDI-DrugBank.d105.s0|84-94|aggregation|O
DDI-DrugBank.d105.s0|96-105|inhibitors|O
DDI-DrugBank.d105.s0|107-110|such|O
DDI-DrugBank.d105.s0|112-113|as|O
DDI-DrugBank.d105.s0|115-126|nonsteroidal|O
DDI-DrugBank.d105.s0|128-144|anti-inflammatory|O
DDI-DrugBank.d105.s0|146-150|drugs|O
DDI-DrugBank.d105.s0|152-152|(|O
DDI-DrugBank.d105.s0|153-158|NSAIDs|O
DDI-DrugBank.d105.s0|159-159|)|O
DDI-DrugBank.d105.s0|160-160|,|O
DDI-DrugBank.d105.s0|162-164|and|O
DDI-DrugBank.d105.s0|166-172|aspirin|O
DDI-DrugBank.d105.s0|174-176|may|O
DDI-DrugBank.d105.s0|178-185|increase|O
DDI-DrugBank.d105.s0|187-189|the|O
DDI-DrugBank.d105.s0|191-194|risk|O
DDI-DrugBank.d105.s0|196-197|of|O
DDI-DrugBank.d105.s0|199-206|bleeding|O
DDI-DrugBank.d105.s0|208-211|when|O
DDI-DrugBank.d105.s0|213-224|administered|O
DDI-DrugBank.d105.s0|226-238|concomitantly|O
DDI-DrugBank.d105.s0|240-243|with|O
DDI-DrugBank.d105.s0|245-253|ardeparin|O
DDI-DrugBank.d105.s0|254-254|.|O
DDI-MedLine.d73.s0|0-12|Neurochemical|O
DDI-MedLine.d73.s0|14-16|and|O
DDI-MedLine.d73.s0|18-27|functional|O
DDI-MedLine.d73.s0|29-40|consequences|O
DDI-MedLine.d73.s0|42-50|following|O
DDI-MedLine.d73.s0|52-95|1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine|O
DDI-MedLine.d73.s0|97-97|(|O
DDI-MedLine.d73.s0|98-101|MPTP|O
DDI-MedLine.d73.s0|102-102|)|O
DDI-MedLine.d73.s0|104-106|and|O
DDI-MedLine.d73.s0|108-122|methamphetamine|O
DDI-MedLine.d73.s0|123-123|.|O
DDI-MedLine.d73.s1|0-2|The|O
DDI-MedLine.d73.s1|4-16|neurochemical|O
DDI-MedLine.d73.s1|18-20|and|O
DDI-MedLine.d73.s1|22-31|functional|O
DDI-MedLine.d73.s1|33-44|consequences|O
DDI-MedLine.d73.s1|46-54|following|O
DDI-MedLine.d73.s1|56-59|MPTP|O
DDI-MedLine.d73.s1|61-74|administration|O
DDI-MedLine.d73.s1|76-77|to|O
DDI-MedLine.d73.s1|79-81|the|O
DDI-MedLine.d73.s1|83-85|rat|O
DDI-MedLine.d73.s1|87-90|were|O
DDI-MedLine.d73.s1|92-100|evaluated|O
DDI-MedLine.d73.s1|102-104|and|O
DDI-MedLine.d73.s1|106-113|compared|O
DDI-MedLine.d73.s1|115-116|to|O
DDI-MedLine.d73.s1|118-124|similar|O
DDI-MedLine.d73.s1|126-132|effects|O
DDI-MedLine.d73.s1|134-142|following|O
DDI-MedLine.d73.s1|144-158|methamphetamine|O
DDI-MedLine.d73.s1|160-173|administration|O
DDI-MedLine.d73.s1|174-174|.|O
DDI-MedLine.d73.s2|0-1|It|O
DDI-MedLine.d73.s2|3-5|was|O
DDI-MedLine.d73.s2|7-14|observed|O
DDI-MedLine.d73.s2|16-19|that|O
DDI-MedLine.d73.s2|21-24|MPTP|O
DDI-MedLine.d73.s2|26-32|induced|O
DDI-MedLine.d73.s2|34-37|long|O
DDI-MedLine.d73.s2|39-45|lasting|O
DDI-MedLine.d73.s2|47-56|depletions|O
DDI-MedLine.d73.s2|58-59|of|O
DDI-MedLine.d73.s2|61-68|striatal|O
DDI-MedLine.d73.s2|70-77|dopamine|O
DDI-MedLine.d73.s2|79-92|concentrations|O
DDI-MedLine.d73.s2|94-96|and|O
DDI-MedLine.d73.s2|98-101|this|O
DDI-MedLine.d73.s2|103-112|neurotoxic|O
DDI-MedLine.d73.s2|114-119|effect|O
DDI-MedLine.d73.s2|121-125|could|O
DDI-MedLine.d73.s2|127-128|be|O
DDI-MedLine.d73.s2|130-138|prevented|O
DDI-MedLine.d73.s2|140-141|by|O
DDI-MedLine.d73.s2|143-151|pargyline|O
DDI-MedLine.d73.s2|153-164|pretreatment|O
DDI-MedLine.d73.s2|165-165|.|O
DDI-MedLine.d73.s3|0-2|The|O
DDI-MedLine.d73.s3|4-15|MPTP-induced|O
DDI-MedLine.d73.s3|17-24|neuronal|O
DDI-MedLine.d73.s3|26-31|damage|O
DDI-MedLine.d73.s3|33-40|produced|O
DDI-MedLine.d73.s3|42-42|a|O
DDI-MedLine.d73.s3|44-52|tolerance|O
DDI-MedLine.d73.s3|54-55|to|O
DDI-MedLine.d73.s3|57-59|the|O
DDI-MedLine.d73.s3|61-70|disruptive|O
DDI-MedLine.d73.s3|72-78|effects|O
DDI-MedLine.d73.s3|80-81|of|O
DDI-MedLine.d73.s3|83-93|amphetamine|O
DDI-MedLine.d73.s3|95-97|and|O
DDI-MedLine.d73.s3|99-99|a|O
DDI-MedLine.d73.s3|101-116|supersensitivity|O
DDI-MedLine.d73.s3|118-119|to|O
DDI-MedLine.d73.s3|121-123|the|O
DDI-MedLine.d73.s3|125-134|disruptive|O
DDI-MedLine.d73.s3|136-142|effects|O
DDI-MedLine.d73.s3|144-145|of|O
DDI-MedLine.d73.s3|147-157|apomorphine|O
DDI-MedLine.d73.s3|159-160|in|O
DDI-MedLine.d73.s3|162-165|rats|O
DDI-MedLine.d73.s3|167-176|responding|O
DDI-MedLine.d73.s3|178-179|in|O
DDI-MedLine.d73.s3|181-181|a|O
DDI-MedLine.d73.s3|183-190|schedule|O
DDI-MedLine.d73.s3|192-201|controlled|O
DDI-MedLine.d73.s3|203-210|paradigm|O
DDI-MedLine.d73.s3|211-211|.|O
DDI-MedLine.d73.s4|0-14|Methamphetamine|O
DDI-MedLine.d73.s4|15-15|,|O
DDI-MedLine.d73.s4|17-20|like|O
DDI-MedLine.d73.s4|22-25|MPTP|O
DDI-MedLine.d73.s4|26-26|,|O
DDI-MedLine.d73.s4|28-35|produced|O
DDI-MedLine.d73.s4|37-46|depletions|O
DDI-MedLine.d73.s4|48-49|of|O
DDI-MedLine.d73.s4|51-58|striatal|O
DDI-MedLine.d73.s4|60-67|dopamine|O
DDI-MedLine.d73.s4|69-71|but|O
DDI-MedLine.d73.s4|73-77|these|O
DDI-MedLine.d73.s4|79-85|actions|O
DDI-MedLine.d73.s4|87-90|were|O
DDI-MedLine.d73.s4|92-102|potentiated|O
DDI-MedLine.d73.s4|104-105|by|O
DDI-MedLine.d73.s4|107-115|pargyline|O
DDI-MedLine.d73.s4|117-128|pretreatment|O
DDI-MedLine.d73.s4|129-129|.|O
DDI-MedLine.d73.s5|0-4|These|O
DDI-MedLine.d73.s5|6-17|observations|O
DDI-MedLine.d73.s5|19-21|are|O
DDI-MedLine.d73.s5|23-31|discussed|O
DDI-MedLine.d73.s5|33-34|in|O
DDI-MedLine.d73.s5|36-44|reference|O
DDI-MedLine.d73.s5|46-47|to|O
DDI-MedLine.d73.s5|49-56|possible|O
DDI-MedLine.d73.s5|58-68|deleterious|O
DDI-MedLine.d73.s5|70-76|effects|O
DDI-MedLine.d73.s5|78-86|following|O
DDI-MedLine.d73.s5|88-90|the|O
DDI-MedLine.d73.s5|92-105|administration|O
DDI-MedLine.d73.s5|107-108|of|O
DDI-MedLine.d73.s5|110-118|pargyline|O
DDI-MedLine.d73.s5|120-121|to|O
DDI-MedLine.d73.s5|123-130|patients|O
DDI-MedLine.d73.s5|132-135|with|O
DDI-MedLine.d73.s5|137-145|Parkinson|O
DDI-MedLine.d73.s5|146-147|'s|O
DDI-MedLine.d73.s5|149-155|Disease|O
DDI-MedLine.d73.s5|156-156|.|O
DDI-DrugBank.d346.s0|0-6|Studies|O
DDI-DrugBank.d346.s0|8-9|to|O
DDI-DrugBank.d346.s0|11-18|evaluate|O
DDI-DrugBank.d346.s0|20-27|possible|O
DDI-DrugBank.d346.s0|29-40|interactions|O
DDI-DrugBank.d346.s0|42-48|between|O
DDI-DrugBank.d346.s0|50-54|REVIA|O
DDI-DrugBank.d346.s0|56-58|and|O
DDI-DrugBank.d346.s0|60-64|drugs|O
DDI-DrugBank.d346.s0|66-70|other|O
DDI-DrugBank.d346.s0|72-75|than|O
DDI-DrugBank.d346.s0|77-83|opiates|O
DDI-DrugBank.d346.s0|85-88|have|O
DDI-DrugBank.d346.s0|90-92|not|O
DDI-DrugBank.d346.s0|94-97|been|O
DDI-DrugBank.d346.s0|99-107|performed|O
DDI-DrugBank.d346.s0|108-108|.|O
DDI-DrugBank.d346.s1|0-11|Consequently|O
DDI-DrugBank.d346.s1|12-12|,|O
DDI-DrugBank.d346.s1|14-20|caution|O
DDI-DrugBank.d346.s1|22-23|is|O
DDI-DrugBank.d346.s1|25-31|advised|O
DDI-DrugBank.d346.s1|33-34|if|O
DDI-DrugBank.d346.s1|36-38|the|O
DDI-DrugBank.d346.s1|40-50|concomitant|O
DDI-DrugBank.d346.s1|52-65|administration|O
DDI-DrugBank.d346.s1|67-68|of|O
DDI-DrugBank.d346.s1|70-74|REVIA|O
DDI-DrugBank.d346.s1|76-78|and|O
DDI-DrugBank.d346.s1|80-84|other|O
DDI-DrugBank.d346.s1|86-90|drugs|O
DDI-DrugBank.d346.s1|92-93|is|O
DDI-DrugBank.d346.s1|95-102|required|O
DDI-DrugBank.d346.s1|103-103|.|O
DDI-DrugBank.d346.s2|0-2|The|O
DDI-DrugBank.d346.s2|4-9|safety|O
DDI-DrugBank.d346.s2|11-13|and|O
DDI-DrugBank.d346.s2|15-22|efficacy|O
DDI-DrugBank.d346.s2|24-25|of|O
DDI-DrugBank.d346.s2|27-37|concomitant|O
DDI-DrugBank.d346.s2|39-41|use|O
DDI-DrugBank.d346.s2|43-44|of|O
DDI-DrugBank.d346.s2|46-50|REVIA|O
DDI-DrugBank.d346.s2|52-54|and|O
DDI-DrugBank.d346.s2|56-65|disulfiram|O
DDI-DrugBank.d346.s2|67-68|is|O
DDI-DrugBank.d346.s2|70-76|unknown|O
DDI-DrugBank.d346.s2|77-77|,|O
DDI-DrugBank.d346.s2|79-81|and|O
DDI-DrugBank.d346.s2|83-85|the|O
DDI-DrugBank.d346.s2|87-97|concomitant|O
DDI-DrugBank.d346.s2|99-101|use|O
DDI-DrugBank.d346.s2|103-104|of|O
DDI-DrugBank.d346.s2|106-108|two|O
DDI-DrugBank.d346.s2|110-120|potentially|O
DDI-DrugBank.d346.s2|122-132|hepatotoxic|O
DDI-DrugBank.d346.s2|134-144|medications|O
DDI-DrugBank.d346.s2|146-147|is|O
DDI-DrugBank.d346.s2|149-151|not|O
DDI-DrugBank.d346.s2|153-162|ordinarily|O
DDI-DrugBank.d346.s2|164-174|recommended|O
DDI-DrugBank.d346.s2|176-181|unless|O
DDI-DrugBank.d346.s2|183-185|the|O
DDI-DrugBank.d346.s2|187-194|probable|O
DDI-DrugBank.d346.s2|196-203|benefits|O
DDI-DrugBank.d346.s2|205-212|outweigh|O
DDI-DrugBank.d346.s2|214-216|the|O
DDI-DrugBank.d346.s2|218-222|known|O
DDI-DrugBank.d346.s2|224-228|risks|O
DDI-DrugBank.d346.s2|229-229|.|O
DDI-DrugBank.d346.s3|0-7|Lethargy|O
DDI-DrugBank.d346.s3|9-11|and|O
DDI-DrugBank.d346.s3|13-22|somnolence|O
DDI-DrugBank.d346.s3|24-27|have|O
DDI-DrugBank.d346.s3|29-32|been|O
DDI-DrugBank.d346.s3|34-41|reported|O
DDI-DrugBank.d346.s3|43-51|following|O
DDI-DrugBank.d346.s3|53-57|doses|O
DDI-DrugBank.d346.s3|59-60|of|O
DDI-DrugBank.d346.s3|62-66|REVIA|O
DDI-DrugBank.d346.s3|68-70|and|O
DDI-DrugBank.d346.s3|72-83|thioridazine|O
DDI-DrugBank.d346.s3|84-84|.|O
DDI-DrugBank.d346.s4|0-7|Patients|O
DDI-DrugBank.d346.s4|9-14|taking|O
DDI-DrugBank.d346.s4|16-20|REVIA|O
DDI-DrugBank.d346.s4|22-24|may|O
DDI-DrugBank.d346.s4|26-28|not|O
DDI-DrugBank.d346.s4|30-36|benefit|O
DDI-DrugBank.d346.s4|38-41|from|O
DDI-DrugBank.d346.s4|43-48|opioid|O
DDI-DrugBank.d346.s4|50-59|containing|O
DDI-DrugBank.d346.s4|61-69|medicines|O
DDI-DrugBank.d346.s4|70-70|,|O
DDI-DrugBank.d346.s4|72-75|such|O
DDI-DrugBank.d346.s4|77-78|as|O
DDI-DrugBank.d346.s4|80-84|cough|O
DDI-DrugBank.d346.s4|86-88|and|O
DDI-DrugBank.d346.s4|90-93|cold|O
DDI-DrugBank.d346.s4|95-106|preparations|O
DDI-DrugBank.d346.s4|107-107|,|O
DDI-DrugBank.d346.s4|109-121|antidiarrheal|O
DDI-DrugBank.d346.s4|123-134|preparations|O
DDI-DrugBank.d346.s4|135-135|,|O
DDI-DrugBank.d346.s4|137-139|and|O
DDI-DrugBank.d346.s4|141-146|opioid|O
DDI-DrugBank.d346.s4|148-157|analgesics|O
DDI-DrugBank.d346.s4|158-158|.|O
DDI-DrugBank.d346.s5|0-1|In|O
DDI-DrugBank.d346.s5|3-4|an|O
DDI-DrugBank.d346.s5|6-14|emergency|O
DDI-DrugBank.d346.s5|16-24|situation|O
DDI-DrugBank.d346.s5|26-29|when|O
DDI-DrugBank.d346.s5|31-36|opioid|O
DDI-DrugBank.d346.s5|38-46|analgesia|O
DDI-DrugBank.d346.s5|48-51|must|O
DDI-DrugBank.d346.s5|53-54|be|O
DDI-DrugBank.d346.s5|56-67|administered|O
DDI-DrugBank.d346.s5|69-70|to|O
DDI-DrugBank.d346.s5|72-72|a|O
DDI-DrugBank.d346.s5|74-80|patient|O
DDI-DrugBank.d346.s5|82-90|receiving|O
DDI-DrugBank.d346.s5|92-96|REVIA|O
DDI-DrugBank.d346.s5|97-97|,|O
DDI-DrugBank.d346.s5|99-101|the|O
DDI-DrugBank.d346.s5|103-108|amount|O
DDI-DrugBank.d346.s5|110-111|of|O
DDI-DrugBank.d346.s5|113-118|opioid|O
DDI-DrugBank.d346.s5|120-127|required|O
DDI-DrugBank.d346.s5|129-131|may|O
DDI-DrugBank.d346.s5|133-134|be|O
DDI-DrugBank.d346.s5|136-142|greater|O
DDI-DrugBank.d346.s5|144-147|than|O
DDI-DrugBank.d346.s5|149-153|usual|O
DDI-DrugBank.d346.s5|154-154|,|O
DDI-DrugBank.d346.s5|156-158|and|O
DDI-DrugBank.d346.s5|160-162|the|O
DDI-DrugBank.d346.s5|164-172|resulting|O
DDI-DrugBank.d346.s5|174-184|respiratory|O
DDI-DrugBank.d346.s5|186-195|depression|O
DDI-DrugBank.d346.s5|197-199|may|O
DDI-DrugBank.d346.s5|201-202|be|O
DDI-DrugBank.d346.s5|204-209|deeper|O
DDI-DrugBank.d346.s5|211-213|and|O
DDI-DrugBank.d346.s5|215-218|more|O
DDI-DrugBank.d346.s5|220-228|prolonged|O
DDI-DrugBank.d346.s5|229-229|.|O
DDI-DrugBank.d317.s0|0-14|DRUG/LABORATORY|O
DDI-DrugBank.d317.s0|16-19|TEST|O
DDI-DrugBank.d317.s0|21-32|INTERACTIONS|O
DDI-DrugBank.d317.s0|34-34|1|O
DDI-DrugBank.d317.s0|35-35|.|O
DDI-DrugBank.d317.s1|0-10|Accelerated|O
DDI-DrugBank.d317.s1|12-22|prothrombin|O
DDI-DrugBank.d317.s1|24-27|time|O
DDI-DrugBank.d317.s1|28-28|,|O
DDI-DrugBank.d317.s1|30-36|partial|O
DDI-DrugBank.d317.s1|38-51|thromboplastin|O
DDI-DrugBank.d317.s1|53-56|time|O
DDI-DrugBank.d317.s1|57-57|,|O
DDI-DrugBank.d317.s1|59-61|and|O
DDI-DrugBank.d317.s1|63-70|platelet|O
DDI-DrugBank.d317.s1|72-82|aggregation|O
DDI-DrugBank.d317.s1|84-87|time|O
DDI-DrugBank.d317.s1|88-88|;|O
DDI-DrugBank.d317.s2|0-8|increased|O
DDI-DrugBank.d317.s2|10-17|platelet|O
DDI-DrugBank.d317.s2|19-23|count|O
DDI-DrugBank.d317.s2|24-24|;|O
DDI-DrugBank.d317.s3|0-8|increased|O
DDI-DrugBank.d317.s3|10-16|factors|O
DDI-DrugBank.d317.s3|18-19|II|O
DDI-DrugBank.d317.s3|20-20|,|O
DDI-DrugBank.d317.s3|22-24|VII|O
DDI-DrugBank.d317.s3|26-32|antigen|O
DDI-DrugBank.d317.s3|33-33|,|O
DDI-DrugBank.d317.s3|35-38|VIII|O
DDI-DrugBank.d317.s3|40-46|antigen|O
DDI-DrugBank.d317.s3|47-47|,|O
DDI-DrugBank.d317.s3|49-52|VIII|O
DDI-DrugBank.d317.s3|54-62|coagulant|O
DDI-DrugBank.d317.s3|64-71|activity|O
DDI-DrugBank.d317.s3|72-72|,|O
DDI-DrugBank.d317.s3|74-75|IX|O
DDI-DrugBank.d317.s3|76-76|,|O
DDI-DrugBank.d317.s3|78-78|X|O
DDI-DrugBank.d317.s3|79-79|,|O
DDI-DrugBank.d317.s3|81-83|XII|O
DDI-DrugBank.d317.s3|84-84|,|O
DDI-DrugBank.d317.s3|86-90|VII-X|O
DDI-DrugBank.d317.s3|92-98|complex|O
DDI-DrugBank.d317.s3|99-99|,|O
DDI-DrugBank.d317.s3|101-108|II-VII-X|O
DDI-DrugBank.d317.s3|110-116|complex|O
DDI-DrugBank.d317.s3|117-117|,|O
DDI-DrugBank.d317.s3|119-121|and|O
DDI-DrugBank.d317.s3|123-142|beta-thromboglobulin|O
DDI-DrugBank.d317.s3|143-143|;|O
DDI-DrugBank.d317.s4|0-8|decreased|O
DDI-DrugBank.d317.s4|10-15|levels|O
DDI-DrugBank.d317.s4|17-18|of|O
DDI-DrugBank.d317.s4|20-30|anti-factor|O
DDI-DrugBank.d317.s4|32-33|Xa|O
DDI-DrugBank.d317.s4|35-37|and|O
DDI-DrugBank.d317.s4|39-50|antithrombin|O
DDI-DrugBank.d317.s4|52-54|III|O
DDI-DrugBank.d317.s4|55-55|,|O
DDI-DrugBank.d317.s4|57-65|decreased|O
DDI-DrugBank.d317.s4|67-78|antithrombin|O
DDI-DrugBank.d317.s4|80-82|III|O
DDI-DrugBank.d317.s4|84-91|activity|O
DDI-DrugBank.d317.s4|92-92|;|O
DDI-DrugBank.d317.s5|0-8|increased|O
DDI-DrugBank.d317.s5|10-15|levels|O
DDI-DrugBank.d317.s5|17-18|of|O
DDI-DrugBank.d317.s5|20-29|fibrinogen|O
DDI-DrugBank.d317.s5|31-33|and|O
DDI-DrugBank.d317.s5|35-44|fibrinogen|O
DDI-DrugBank.d317.s5|46-53|activity|O
DDI-DrugBank.d317.s5|54-54|;|O
DDI-DrugBank.d317.s6|0-8|increased|O
DDI-DrugBank.d317.s6|10-20|plasminogen|O
DDI-DrugBank.d317.s6|22-28|antigen|O
DDI-DrugBank.d317.s6|30-32|and|O
DDI-DrugBank.d317.s6|34-41|activity|O
DDI-DrugBank.d317.s6|42-42|.|O
DDI-DrugBank.d317.s7|0-0|2|O
DDI-DrugBank.d317.s7|1-1|.|O
DDI-DrugBank.d317.s8|0-8|Increased|O
DDI-DrugBank.d317.s8|10-24|thyroid-binding|O
DDI-DrugBank.d317.s8|26-33|globulin|O
DDI-DrugBank.d317.s8|35-35|(|O
DDI-DrugBank.d317.s8|36-38|TBG|O
DDI-DrugBank.d317.s8|39-39|)|O
DDI-DrugBank.d317.s8|41-46|levels|O
DDI-DrugBank.d317.s8|48-54|leading|O
DDI-DrugBank.d317.s8|56-57|to|O
DDI-DrugBank.d317.s8|59-67|increased|O
DDI-DrugBank.d317.s8|69-79|circulating|O
DDI-DrugBank.d317.s8|81-85|total|O
DDI-DrugBank.d317.s8|87-93|thyroid|O
DDI-DrugBank.d317.s8|95-101|hormone|O
DDI-DrugBank.d317.s8|103-108|levels|O
DDI-DrugBank.d317.s8|110-111|as|O
DDI-DrugBank.d317.s8|113-120|measured|O
DDI-DrugBank.d317.s8|122-123|by|O
DDI-DrugBank.d317.s8|125-137|protein-bound|O
DDI-DrugBank.d317.s8|139-144|iodine|O
DDI-DrugBank.d317.s8|146-146|(|O
DDI-DrugBank.d317.s8|147-149|PBI|O
DDI-DrugBank.d317.s8|150-150|)|O
DDI-DrugBank.d317.s8|151-151|,|O
DDI-DrugBank.d317.s8|153-154|T4|O
DDI-DrugBank.d317.s8|156-161|levels|O
DDI-DrugBank.d317.s8|163-163|(|O
DDI-DrugBank.d317.s8|164-165|by|O
DDI-DrugBank.d317.s8|167-172|column|O
DDI-DrugBank.d317.s8|174-175|or|O
DDI-DrugBank.d317.s8|177-178|by|O
DDI-DrugBank.d317.s8|180-195|radioimmunoassay|O
DDI-DrugBank.d317.s8|196-196|)|O
DDI-DrugBank.d317.s8|198-199|or|O
DDI-DrugBank.d317.s8|201-202|T3|O
DDI-DrugBank.d317.s8|204-209|levels|O
DDI-DrugBank.d317.s8|211-212|by|O
DDI-DrugBank.d317.s8|214-229|radioimmunoassay|O
DDI-DrugBank.d317.s8|230-230|.|O
DDI-DrugBank.d317.s9|0-1|T3|O
DDI-DrugBank.d317.s9|3-7|resin|O
DDI-DrugBank.d317.s9|9-14|uptake|O
DDI-DrugBank.d317.s9|16-17|is|O
DDI-DrugBank.d317.s9|19-27|decreased|O
DDI-DrugBank.d317.s9|28-28|,|O
DDI-DrugBank.d317.s9|30-39|reflecting|O
DDI-DrugBank.d317.s9|41-43|the|O
DDI-DrugBank.d317.s9|45-52|elevated|O
DDI-DrugBank.d317.s9|54-56|TBG|O
DDI-DrugBank.d317.s9|57-57|.|O
DDI-DrugBank.d317.s10|0-3|Free|O
DDI-DrugBank.d317.s10|5-6|T4|O
DDI-DrugBank.d317.s10|8-10|and|O
DDI-DrugBank.d317.s10|12-15|free|O
DDI-DrugBank.d317.s10|17-18|T3|O
DDI-DrugBank.d317.s10|20-33|concentrations|O
DDI-DrugBank.d317.s10|35-37|are|O
DDI-DrugBank.d317.s10|39-47|unaltered|O
DDI-DrugBank.d317.s10|48-48|.|O
DDI-DrugBank.d317.s11|0-7|Patients|O
DDI-DrugBank.d317.s11|9-10|on|O
DDI-DrugBank.d317.s11|12-18|thyroid|O
DDI-DrugBank.d317.s11|20-30|replacement|O
DDI-DrugBank.d317.s11|32-38|therapy|O
DDI-DrugBank.d317.s11|40-42|may|O
DDI-DrugBank.d317.s11|44-50|require|O
DDI-DrugBank.d317.s11|52-57|higher|O
DDI-DrugBank.d317.s11|59-63|doses|O
DDI-DrugBank.d317.s11|65-66|of|O
DDI-DrugBank.d317.s11|68-74|thyroid|O
DDI-DrugBank.d317.s11|76-82|hormone|O
DDI-DrugBank.d317.s11|83-83|.|O
DDI-DrugBank.d317.s12|0-0|3|O
DDI-DrugBank.d317.s12|1-1|.|O
DDI-DrugBank.d317.s13|0-4|Other|O
DDI-DrugBank.d317.s13|6-12|binding|O
DDI-DrugBank.d317.s13|14-21|proteins|O
DDI-DrugBank.d317.s13|23-25|may|O
DDI-DrugBank.d317.s13|27-28|be|O
DDI-DrugBank.d317.s13|30-37|elevated|O
DDI-DrugBank.d317.s13|39-40|in|O
DDI-DrugBank.d317.s13|42-46|serum|O
DDI-DrugBank.d317.s13|47-47|,|O
DDI-DrugBank.d317.s13|49-49|(|O
DDI-DrugBank.d317.s13|50-53|i.e.|O
DDI-DrugBank.d317.s13|54-54|,|O
DDI-DrugBank.d317.s13|56-69|corticosteroid|O
DDI-DrugBank.d317.s13|71-77|binding|O
DDI-DrugBank.d317.s13|79-86|globulin|O
DDI-DrugBank.d317.s13|88-88|(|O
DDI-DrugBank.d317.s13|89-91|CBG|O
DDI-DrugBank.d317.s13|92-92|)|O
DDI-DrugBank.d317.s13|93-93|,|O
DDI-DrugBank.d317.s13|95-97|sex|O
DDI-DrugBank.d317.s13|99-105|hormone|O
DDI-DrugBank.d317.s13|107-113|binding|O
DDI-DrugBank.d317.s13|115-122|globulin|O
DDI-DrugBank.d317.s13|124-124|(|O
DDI-DrugBank.d317.s13|125-128|SHBG|O
DDI-DrugBank.d317.s13|129-129|)|O
DDI-DrugBank.d317.s13|130-130|)|O
DDI-DrugBank.d317.s13|132-138|leading|O
DDI-DrugBank.d317.s13|140-141|to|O
DDI-DrugBank.d317.s13|143-151|increased|O
DDI-DrugBank.d317.s13|153-157|total|O
DDI-DrugBank.d317.s13|159-169|circulating|O
DDI-DrugBank.d317.s13|171-185|corticosteroids|O
DDI-DrugBank.d317.s13|187-189|and|O
DDI-DrugBank.d317.s13|191-193|sex|O
DDI-DrugBank.d317.s13|195-202|steroids|O
DDI-DrugBank.d317.s13|203-203|,|O
DDI-DrugBank.d317.s13|205-216|respectively|O
DDI-DrugBank.d317.s13|217-217|.|O
DDI-DrugBank.d317.s14|0-3|Free|O
DDI-DrugBank.d317.s14|5-11|hormone|O
DDI-DrugBank.d317.s14|13-26|concentrations|O
DDI-DrugBank.d317.s14|28-30|may|O
DDI-DrugBank.d317.s14|32-33|be|O
DDI-DrugBank.d317.s14|35-43|decreased|O
DDI-DrugBank.d317.s14|44-44|.|O
DDI-DrugBank.d317.s15|0-4|Other|O
DDI-DrugBank.d317.s15|6-11|plasma|O
DDI-DrugBank.d317.s15|13-20|proteins|O
DDI-DrugBank.d317.s15|22-24|may|O
DDI-DrugBank.d317.s15|26-27|be|O
DDI-DrugBank.d317.s15|29-37|increased|O
DDI-DrugBank.d317.s15|39-39|(|O
DDI-DrugBank.d317.s15|40-60|angiotensinogen/renin|O
DDI-DrugBank.d317.s15|62-70|substrate|O
DDI-DrugBank.d317.s15|71-71|,|O
DDI-DrugBank.d317.s15|73-91|alpha-1-antitrypsin|O
DDI-DrugBank.d317.s15|92-92|,|O
DDI-DrugBank.d317.s15|94-106|ceruloplasmin|O
DDI-DrugBank.d317.s15|107-107|)|O
DDI-DrugBank.d317.s15|108-108|.|O
DDI-DrugBank.d317.s16|0-0|4|O
DDI-DrugBank.d317.s16|1-1|.|O
DDI-DrugBank.d317.s17|0-8|Increased|O
DDI-DrugBank.d317.s17|10-15|plasma|O
DDI-DrugBank.d317.s17|17-19|HDL|O
DDI-DrugBank.d317.s17|21-23|and|O
DDI-DrugBank.d317.s17|25-28|HDL2|O
DDI-DrugBank.d317.s17|30-40|cholesterol|O
DDI-DrugBank.d317.s17|42-52|subfraction|O
DDI-DrugBank.d317.s17|54-67|concentrations|O
DDI-DrugBank.d317.s17|68-68|,|O
DDI-DrugBank.d317.s17|70-76|reduced|O
DDI-DrugBank.d317.s17|78-80|LDL|O
DDI-DrugBank.d317.s17|82-92|cholesterol|O
DDI-DrugBank.d317.s17|94-106|concentration|O
DDI-DrugBank.d317.s17|107-107|,|O
DDI-DrugBank.d317.s17|109-117|increased|O
DDI-DrugBank.d317.s17|119-130|triglyceride|O
DDI-DrugBank.d317.s17|132-137|levels|O
DDI-DrugBank.d317.s17|138-138|.|O
DDI-DrugBank.d317.s18|0-0|5|O
DDI-DrugBank.d317.s18|1-1|.|O
DDI-DrugBank.d317.s19|0-7|Impaired|O
DDI-DrugBank.d317.s19|9-15|glucose|O
DDI-DrugBank.d317.s19|17-25|tolerance|O
DDI-DrugBank.d317.s19|26-26|.|O
DDI-DrugBank.d317.s20|0-0|6|O
DDI-DrugBank.d317.s20|1-1|.|O
DDI-DrugBank.d317.s21|0-6|Reduced|O
DDI-DrugBank.d317.s21|8-15|response|O
DDI-DrugBank.d317.s21|17-18|to|O
DDI-DrugBank.d317.s21|20-29|metyrapone|O
DDI-DrugBank.d317.s21|31-34|test|O
DDI-DrugBank.d317.s21|35-35|.|O
DDI-MedLine.d179.s0|0-10|Synergistic|O
DDI-MedLine.d179.s0|12-22|interaction|O
DDI-MedLine.d179.s0|24-30|between|O
DDI-MedLine.d179.s0|32-40|sunitinib|O
DDI-MedLine.d179.s0|42-44|and|O
DDI-MedLine.d179.s0|46-54|docetaxel|O
DDI-MedLine.d179.s0|56-57|is|O
DDI-MedLine.d179.s0|59-66|sequence|O
DDI-MedLine.d179.s0|68-76|dependent|O
DDI-MedLine.d179.s0|78-79|in|O
DDI-MedLine.d179.s0|81-85|human|O
DDI-MedLine.d179.s0|87-95|non-small|O
DDI-MedLine.d179.s0|97-100|lung|O
DDI-MedLine.d179.s0|102-107|cancer|O
DDI-MedLine.d179.s0|109-112|with|O
DDI-MedLine.d179.s0|114-117|EGFR|O
DDI-MedLine.d179.s0|119-132|TKIs-resistant|O
DDI-MedLine.d179.s0|134-141|mutation|O
DDI-MedLine.d179.s0|142-142|.|O
DDI-MedLine.d179.s1|0-7|Previous|O
DDI-MedLine.d179.s1|9-15|studies|O
DDI-MedLine.d179.s1|17-20|have|O
DDI-MedLine.d179.s1|22-33|demonstrated|O
DDI-MedLine.d179.s1|35-38|that|O
DDI-MedLine.d179.s1|40-48|sunitinib|O
DDI-MedLine.d179.s1|50-52|has|O
DDI-MedLine.d179.s1|54-56|the|O
DDI-MedLine.d179.s1|58-67|anti-tumor|O
DDI-MedLine.d179.s1|69-76|activity|O
DDI-MedLine.d179.s1|78-79|in|O
DDI-MedLine.d179.s1|81-85|human|O
DDI-MedLine.d179.s1|87-95|non-small|O
DDI-MedLine.d179.s1|97-100|cell|O
DDI-MedLine.d179.s1|102-105|lung|O
DDI-MedLine.d179.s1|107-112|cancer|O
DDI-MedLine.d179.s1|114-114|(|O
DDI-MedLine.d179.s1|115-119|NSCLC|O
DDI-MedLine.d179.s1|120-120|)|O
DDI-MedLine.d179.s1|121-121|.|O
DDI-MedLine.d179.s2|0-3|This|O
DDI-MedLine.d179.s2|5-9|study|O
DDI-MedLine.d179.s2|11-13|was|O
DDI-MedLine.d179.s2|15-19|aimed|O
DDI-MedLine.d179.s2|21-22|to|O
DDI-MedLine.d179.s2|24-34|investigate|O
DDI-MedLine.d179.s2|36-38|the|O
DDI-MedLine.d179.s2|40-47|efficacy|O
DDI-MedLine.d179.s2|49-50|of|O
DDI-MedLine.d179.s2|52-57|single|O
DDI-MedLine.d179.s2|59-61|use|O
DDI-MedLine.d179.s2|63-64|of|O
DDI-MedLine.d179.s2|66-74|sunitinib|O
DDI-MedLine.d179.s2|76-78|and|O
DDI-MedLine.d179.s2|80-83|that|O
DDI-MedLine.d179.s2|85-86|of|O
DDI-MedLine.d179.s2|88-97|concurrent|O
DDI-MedLine.d179.s2|99-100|or|O
DDI-MedLine.d179.s2|102-111|sequential|O
DDI-MedLine.d179.s2|113-126|administration|O
DDI-MedLine.d179.s2|128-129|of|O
DDI-MedLine.d179.s2|131-139|sunitinib|O
DDI-MedLine.d179.s2|141-143|and|O
DDI-MedLine.d179.s2|145-153|docetaxel|O
DDI-MedLine.d179.s2|155-156|in|O
DDI-MedLine.d179.s2|158-162|NSCLC|O
DDI-MedLine.d179.s2|164-167|cell|O
DDI-MedLine.d179.s2|169-173|lines|O
DDI-MedLine.d179.s2|175-178|that|O
DDI-MedLine.d179.s2|180-182|are|O
DDI-MedLine.d179.s2|184-192|resistant|O
DDI-MedLine.d179.s2|194-195|to|O
DDI-MedLine.d179.s2|197-200|EGFR|O
DDI-MedLine.d179.s2|202-205|TKIs|O
DDI-MedLine.d179.s2|206-206|.|O
DDI-MedLine.d179.s3|0-4|NSCLC|O
DDI-MedLine.d179.s3|6-9|cell|O
DDI-MedLine.d179.s3|11-15|lines|O
DDI-MedLine.d179.s3|17-20|with|O
DDI-MedLine.d179.s3|22-25|EGFR|O
DDI-MedLine.d179.s3|27-31|T790M|O
DDI-MedLine.d179.s3|33-40|mutation|O
DDI-MedLine.d179.s3|42-44|and|O
DDI-MedLine.d179.s3|46-50|K-ras|O
DDI-MedLine.d179.s3|52-59|mutation|O
DDI-MedLine.d179.s3|61-64|were|O
DDI-MedLine.d179.s3|66-72|exposed|O
DDI-MedLine.d179.s3|74-75|to|O
DDI-MedLine.d179.s3|77-82|either|O
DDI-MedLine.d179.s3|84-92|sunitinib|O
DDI-MedLine.d179.s3|94-95|or|O
DDI-MedLine.d179.s3|97-105|docetaxel|O
DDI-MedLine.d179.s3|107-108|or|O
DDI-MedLine.d179.s3|110-113|both|O
DDI-MedLine.d179.s3|115-119|based|O
DDI-MedLine.d179.s3|121-122|on|O
DDI-MedLine.d179.s3|124-130|various|O
DDI-MedLine.d179.s3|132-141|sequential|O
DDI-MedLine.d179.s3|143-157|administrations|O
DDI-MedLine.d179.s3|158-158|.|O
DDI-MedLine.d179.s4|0-4|After|O
DDI-MedLine.d179.s4|6-13|exposure|O
DDI-MedLine.d179.s4|14-14|,|O
DDI-MedLine.d179.s4|16-18|the|O
DDI-MedLine.d179.s4|20-23|cell|O
DDI-MedLine.d179.s4|25-33|viability|O
DDI-MedLine.d179.s4|35-37|was|O
DDI-MedLine.d179.s4|39-46|measured|O
DDI-MedLine.d179.s4|48-49|by|O
DDI-MedLine.d179.s4|51-53|MTT|O
DDI-MedLine.d179.s4|55-59|assay|O
DDI-MedLine.d179.s4|60-60|,|O
DDI-MedLine.d179.s4|62-65|cell|O
DDI-MedLine.d179.s4|67-71|cycle|O
DDI-MedLine.d179.s4|73-84|distribution|O
DDI-MedLine.d179.s4|86-88|was|O
DDI-MedLine.d179.s4|90-97|analyzed|O
DDI-MedLine.d179.s4|99-100|by|O
DDI-MedLine.d179.s4|102-105|flow|O
DDI-MedLine.d179.s4|107-115|cytometry|O
DDI-MedLine.d179.s4|116-116|,|O
DDI-MedLine.d179.s4|118-120|and|O
DDI-MedLine.d179.s4|122-132|alterations|O
DDI-MedLine.d179.s4|134-135|in|O
DDI-MedLine.d179.s4|137-145|signaling|O
DDI-MedLine.d179.s4|147-153|pathway|O
DDI-MedLine.d179.s4|155-158|were|O
DDI-MedLine.d179.s4|160-169|determined|O
DDI-MedLine.d179.s4|171-172|by|O
DDI-MedLine.d179.s4|174-187|immunoblotting|O
DDI-MedLine.d179.s4|188-188|.|O
DDI-MedLine.d179.s5|0-8|Sunitinib|O
DDI-MedLine.d179.s5|10-18|exhibited|O
DDI-MedLine.d179.s5|20-33|dose-dependent|O
DDI-MedLine.d179.s5|35-40|growth|O
DDI-MedLine.d179.s5|42-51|inhibition|O
DDI-MedLine.d179.s5|53-54|in|O
DDI-MedLine.d179.s5|56-60|NSCLC|O
DDI-MedLine.d179.s5|62-65|cell|O
DDI-MedLine.d179.s5|67-71|lines|O
DDI-MedLine.d179.s5|73-75|and|O
DDI-MedLine.d179.s5|77-84|arrested|O
DDI-MedLine.d179.s5|86-89|cell|O
DDI-MedLine.d179.s5|91-95|cycle|O
DDI-MedLine.d179.s5|97-98|at|O
DDI-MedLine.d179.s5|100-101|G1|O
DDI-MedLine.d179.s5|103-107|phase|O
DDI-MedLine.d179.s5|108-108|,|O
DDI-MedLine.d179.s5|110-116|whereas|O
DDI-MedLine.d179.s5|118-126|docetaxel|O
DDI-MedLine.d179.s5|128-135|arrested|O
DDI-MedLine.d179.s5|137-138|at|O
DDI-MedLine.d179.s5|140-140|S|O
DDI-MedLine.d179.s5|142-146|phase|O
DDI-MedLine.d179.s5|147-147|.|O
DDI-MedLine.d179.s6|0-7|Although|O
DDI-MedLine.d179.s6|9-14|single|O
DDI-MedLine.d179.s6|16-17|or|O
DDI-MedLine.d179.s6|19-28|concurrent|O
DDI-MedLine.d179.s6|30-32|use|O
DDI-MedLine.d179.s6|34-35|of|O
DDI-MedLine.d179.s6|37-45|sunitinib|O
DDI-MedLine.d179.s6|47-49|and|O
DDI-MedLine.d179.s6|51-59|docetaxel|O
DDI-MedLine.d179.s6|61-63|has|O
DDI-MedLine.d179.s6|65-68|some|O
DDI-MedLine.d179.s6|70-87|anti-proliferative|O
DDI-MedLine.d179.s6|89-95|effects|O
DDI-MedLine.d179.s6|96-96|,|O
DDI-MedLine.d179.s6|98-100|the|O
DDI-MedLine.d179.s6|102-111|sequential|O
DDI-MedLine.d179.s6|113-127|administrations|O
DDI-MedLine.d179.s6|129-130|of|O
DDI-MedLine.d179.s6|132-135|both|O
DDI-MedLine.d179.s6|137-141|drugs|O
DDI-MedLine.d179.s6|143-152|remarkably|O
DDI-MedLine.d179.s6|154-161|enhanced|O
DDI-MedLine.d179.s6|163-172|anti-tumor|O
DDI-MedLine.d179.s6|174-181|activity|O
DDI-MedLine.d179.s6|182-182|.|O
DDI-MedLine.d179.s7|0-3|When|O
DDI-MedLine.d179.s7|5-9|cells|O
DDI-MedLine.d179.s7|11-14|were|O
DDI-MedLine.d179.s7|16-22|exposed|O
DDI-MedLine.d179.s7|24-25|to|O
DDI-MedLine.d179.s7|27-35|docetaxel|O
DDI-MedLine.d179.s7|37-44|followed|O
DDI-MedLine.d179.s7|46-47|by|O
DDI-MedLine.d179.s7|49-57|sunitinib|O
DDI-MedLine.d179.s7|58-58|,|O
DDI-MedLine.d179.s7|60-68|synergism|O
DDI-MedLine.d179.s7|70-72|was|O
DDI-MedLine.d179.s7|74-81|observed|O
DDI-MedLine.d179.s7|82-82|.|O
DDI-MedLine.d179.s8|0-2|The|O
DDI-MedLine.d179.s8|4-12|molecular|O
DDI-MedLine.d179.s8|14-18|basis|O
DDI-MedLine.d179.s8|20-21|of|O
DDI-MedLine.d179.s8|23-26|this|O
DDI-MedLine.d179.s8|28-36|synergism|O
DDI-MedLine.d179.s8|38-39|is|O
DDI-MedLine.d179.s8|41-44|that|O
DDI-MedLine.d179.s8|46-48|the|O
DDI-MedLine.d179.s8|50-58|signaling|O
DDI-MedLine.d179.s8|60-67|pathways|O
DDI-MedLine.d179.s8|69-72|that|O
DDI-MedLine.d179.s8|74-77|were|O
DDI-MedLine.d179.s8|79-87|initially|O
DDI-MedLine.d179.s8|89-97|activated|O
DDI-MedLine.d179.s8|99-100|by|O
DDI-MedLine.d179.s8|102-110|docetaxel|O
DDI-MedLine.d179.s8|112-119|exposure|O
DDI-MedLine.d179.s8|121-124|were|O
DDI-MedLine.d179.s8|126-136|efficiently|O
DDI-MedLine.d179.s8|138-147|suppressed|O
DDI-MedLine.d179.s8|149-150|by|O
DDI-MedLine.d179.s8|152-154|the|O
DDI-MedLine.d179.s8|156-165|subsequent|O
DDI-MedLine.d179.s8|167-174|exposure|O
DDI-MedLine.d179.s8|176-177|to|O
DDI-MedLine.d179.s8|179-187|sunitinib|O
DDI-MedLine.d179.s8|188-188|.|O
DDI-MedLine.d179.s9|0-1|In|O
DDI-MedLine.d179.s9|3-10|contrast|O
DDI-MedLine.d179.s9|11-11|,|O
DDI-MedLine.d179.s9|13-15|the|O
DDI-MedLine.d179.s9|17-23|reverse|O
DDI-MedLine.d179.s9|25-26|of|O
DDI-MedLine.d179.s9|28-31|this|O
DDI-MedLine.d179.s9|33-42|sequential|O
DDI-MedLine.d179.s9|44-57|administration|O
DDI-MedLine.d179.s9|59-66|resulted|O
DDI-MedLine.d179.s9|68-69|in|O
DDI-MedLine.d179.s9|71-80|antagonism|O
DDI-MedLine.d179.s9|81-81|,|O
DDI-MedLine.d179.s9|83-87|which|O
DDI-MedLine.d179.s9|89-91|may|O
DDI-MedLine.d179.s9|93-94|be|O
DDI-MedLine.d179.s9|96-98|due|O
DDI-MedLine.d179.s9|100-101|to|O
DDI-MedLine.d179.s9|103-114|differential|O
DDI-MedLine.d179.s9|116-122|effects|O
DDI-MedLine.d179.s9|124-125|on|O
DDI-MedLine.d179.s9|127-130|cell|O
DDI-MedLine.d179.s9|132-136|cycle|O
DDI-MedLine.d179.s9|138-143|arrest|O
DDI-MedLine.d179.s9|144-144|.|O
DDI-MedLine.d179.s10|0-8|Sunitinib|O
DDI-MedLine.d179.s10|10-11|as|O
DDI-MedLine.d179.s10|13-13|a|O
DDI-MedLine.d179.s10|15-20|single|O
DDI-MedLine.d179.s10|22-26|agent|O
DDI-MedLine.d179.s10|28-35|exhibits|O
DDI-MedLine.d179.s10|37-54|anti-proliferative|O
DDI-MedLine.d179.s10|56-62|effects|O
DDI-MedLine.d179.s10|64-65|in|O
DDI-MedLine.d179.s10|67-71|vitro|O
DDI-MedLine.d179.s10|73-74|in|O
DDI-MedLine.d179.s10|76-80|NSCLC|O
DDI-MedLine.d179.s10|82-85|cell|O
DDI-MedLine.d179.s10|87-91|lines|O
DDI-MedLine.d179.s10|93-96|with|O
DDI-MedLine.d179.s10|98-101|EGFR|O
DDI-MedLine.d179.s10|103-107|T790M|O
DDI-MedLine.d179.s10|109-111|and|O
DDI-MedLine.d179.s10|113-117|K-ras|O
DDI-MedLine.d179.s10|119-127|mutations|O
DDI-MedLine.d179.s10|129-131|but|O
DDI-MedLine.d179.s10|133-135|the|O
DDI-MedLine.d179.s10|137-146|sequential|O
DDI-MedLine.d179.s10|148-161|administration|O
DDI-MedLine.d179.s10|163-164|of|O
DDI-MedLine.d179.s10|166-174|docetaxel|O
DDI-MedLine.d179.s10|176-183|followed|O
DDI-MedLine.d179.s10|185-186|by|O
DDI-MedLine.d179.s10|188-196|sunitinib|O
DDI-MedLine.d179.s10|198-199|is|O
DDI-MedLine.d179.s10|201-208|superior|O
DDI-MedLine.d179.s10|210-211|to|O
DDI-MedLine.d179.s10|213-221|sunitinib|O
DDI-MedLine.d179.s10|223-230|followed|O
DDI-MedLine.d179.s10|232-233|by|O
DDI-MedLine.d179.s10|235-243|docetaxel|O
DDI-MedLine.d179.s10|245-247|and|O
DDI-MedLine.d179.s10|249-258|concurrent|O
DDI-MedLine.d179.s10|260-273|administration|O
DDI-MedLine.d179.s10|274-274|.|O
DDI-DrugBank.d14.s0|0-2|The|O
DDI-DrugBank.d14.s0|4-15|vasodilating|O
DDI-DrugBank.d14.s0|17-23|effects|O
DDI-DrugBank.d14.s0|25-26|of|O
DDI-DrugBank.d14.s0|28-40|nitroglycerin|O
DDI-DrugBank.d14.s0|42-44|may|O
DDI-DrugBank.d14.s0|46-47|be|O
DDI-DrugBank.d14.s0|49-56|additive|O
DDI-DrugBank.d14.s0|58-61|with|O
DDI-DrugBank.d14.s0|63-67|those|O
DDI-DrugBank.d14.s0|69-70|of|O
DDI-DrugBank.d14.s0|72-76|other|O
DDI-DrugBank.d14.s0|78-89|vasodilators|O
DDI-DrugBank.d14.s0|90-90|.|O
DDI-DrugBank.d14.s1|0-6|Alcohol|O
DDI-DrugBank.d14.s1|7-7|,|O
DDI-DrugBank.d14.s1|9-10|in|O
DDI-DrugBank.d14.s1|12-21|particular|O
DDI-DrugBank.d14.s1|22-22|,|O
DDI-DrugBank.d14.s1|24-26|has|O
DDI-DrugBank.d14.s1|28-31|been|O
DDI-DrugBank.d14.s1|33-37|found|O
DDI-DrugBank.d14.s1|39-40|to|O
DDI-DrugBank.d14.s1|42-48|exhibit|O
DDI-DrugBank.d14.s1|50-57|additive|O
DDI-DrugBank.d14.s1|59-65|effects|O
DDI-DrugBank.d14.s1|67-68|of|O
DDI-DrugBank.d14.s1|70-73|this|O
DDI-DrugBank.d14.s1|75-81|variety|O
DDI-DrugBank.d14.s1|82-82|.|O
DDI-DrugBank.d14.s2|0-5|Marked|O
DDI-DrugBank.d14.s2|7-17|symptomatic|O
DDI-DrugBank.d14.s2|19-29|orthostatic|O
DDI-DrugBank.d14.s2|31-41|hypotension|O
DDI-DrugBank.d14.s2|43-45|has|O
DDI-DrugBank.d14.s2|47-50|been|O
DDI-DrugBank.d14.s2|52-59|reported|O
DDI-DrugBank.d14.s2|61-64|when|O
DDI-DrugBank.d14.s2|66-72|calcium|O
DDI-DrugBank.d14.s2|74-80|channel|O
DDI-DrugBank.d14.s2|82-89|blockers|O
DDI-DrugBank.d14.s2|91-93|and|O
DDI-DrugBank.d14.s2|95-101|organic|O
DDI-DrugBank.d14.s2|103-110|nitrates|O
DDI-DrugBank.d14.s2|112-115|were|O
DDI-DrugBank.d14.s2|117-120|used|O
DDI-DrugBank.d14.s2|122-123|in|O
DDI-DrugBank.d14.s2|125-135|combination|O
DDI-DrugBank.d14.s2|136-136|.|O
DDI-DrugBank.d14.s3|0-3|Dose|O
DDI-DrugBank.d14.s3|5-15|adjustments|O
DDI-DrugBank.d14.s3|17-18|of|O
DDI-DrugBank.d14.s3|20-25|either|O
DDI-DrugBank.d14.s3|27-31|class|O
DDI-DrugBank.d14.s3|33-34|of|O
DDI-DrugBank.d14.s3|36-41|agents|O
DDI-DrugBank.d14.s3|43-45|may|O
DDI-DrugBank.d14.s3|47-48|be|O
DDI-DrugBank.d14.s3|50-58|necessary|O
DDI-DrugBank.d14.s3|59-59|.|O
DDI-DrugBank.d416.s0|0-4|Renal|O
DDI-DrugBank.d416.s0|6-14|clearance|O
DDI-DrugBank.d416.s0|16-27|measurements|O
DDI-DrugBank.d416.s0|29-30|of|O
DDI-DrugBank.d416.s0|32-34|PAH|O
DDI-DrugBank.d416.s0|36-38|can|O
DDI-DrugBank.d416.s0|39-41|not|O
DDI-DrugBank.d416.s0|43-44|be|O
DDI-DrugBank.d416.s0|46-49|made|O
DDI-DrugBank.d416.s0|51-54|with|O
DDI-DrugBank.d416.s0|56-58|any|O
DDI-DrugBank.d416.s0|60-70|significant|O
DDI-DrugBank.d416.s0|72-79|accuracy|O
DDI-DrugBank.d416.s0|81-82|in|O
DDI-DrugBank.d416.s0|84-91|patients|O
DDI-DrugBank.d416.s0|93-101|receiving|O
DDI-DrugBank.d416.s0|103-114|sulfonamides|O
DDI-DrugBank.d416.s0|115-115|,|O
DDI-DrugBank.d416.s0|117-124|procaine|O
DDI-DrugBank.d416.s0|125-125|,|O
DDI-DrugBank.d416.s0|127-128|or|O
DDI-DrugBank.d416.s0|130-144|thiazolesulfone|O
DDI-DrugBank.d416.s0|145-145|.|O
DDI-DrugBank.d416.s1|0-4|These|O
DDI-DrugBank.d416.s1|6-14|compounds|O
DDI-DrugBank.d416.s1|16-24|interfere|O
DDI-DrugBank.d416.s1|26-29|with|O
DDI-DrugBank.d416.s1|31-38|chemical|O
DDI-DrugBank.d416.s1|40-44|color|O
DDI-DrugBank.d416.s1|46-56|development|O
DDI-DrugBank.d416.s1|58-66|essential|O
DDI-DrugBank.d416.s1|68-69|to|O
DDI-DrugBank.d416.s1|71-73|the|O
DDI-DrugBank.d416.s1|75-84|analytical|O
DDI-DrugBank.d416.s1|86-95|procedures|O
DDI-DrugBank.d416.s1|96-96|.|O
DDI-DrugBank.d416.s2|0-9|Probenecid|O
DDI-DrugBank.d416.s2|11-19|depresses|O
DDI-DrugBank.d416.s2|21-27|tubular|O
DDI-DrugBank.d416.s2|29-37|secretion|O
DDI-DrugBank.d416.s2|39-40|of|O
DDI-DrugBank.d416.s2|42-48|certain|O
DDI-DrugBank.d416.s2|50-53|weak|O
DDI-DrugBank.d416.s2|55-59|acids|O
DDI-DrugBank.d416.s2|61-64|such|O
DDI-DrugBank.d416.s2|66-67|as|O
DDI-DrugBank.d416.s2|69-71|PAH|O
DDI-DrugBank.d416.s2|72-72|.|O
DDI-DrugBank.d416.s3|0-8|Therefore|O
DDI-DrugBank.d416.s3|9-9|,|O
DDI-DrugBank.d416.s3|11-18|patients|O
DDI-DrugBank.d416.s3|20-28|receiving|O
DDI-DrugBank.d416.s3|30-39|probenecid|O
DDI-DrugBank.d416.s3|41-44|will|O
DDI-DrugBank.d416.s3|46-49|have|O
DDI-DrugBank.d416.s3|51-61|erroneously|O
DDI-DrugBank.d416.s3|63-65|low|O
DDI-DrugBank.d416.s3|67-70|ERPF|O
DDI-DrugBank.d416.s3|72-74|and|O
DDI-DrugBank.d416.s3|76-77|Tm|O
DDI-DrugBank.d416.s3|79-81|PAH|O
DDI-DrugBank.d416.s3|83-88|values|O
DDI-DrugBank.d416.s3|89-89|.|O
DDI-DrugBank.d520.s0|0-2|The|O
DDI-DrugBank.d520.s0|4-8|renal|O
DDI-DrugBank.d520.s0|10-16|effects|O
DDI-DrugBank.d520.s0|18-19|of|O
DDI-DrugBank.d520.s0|21-31|nephrotoxic|O
DDI-DrugBank.d520.s0|33-41|compounds|O
DDI-DrugBank.d520.s0|43-45|may|O
DDI-DrugBank.d520.s0|47-48|be|O
DDI-DrugBank.d520.s0|50-60|potentiated|O
DDI-DrugBank.d520.s0|62-63|by|O
DDI-DrugBank.d520.s0|65-75|Carboplatin|O
DDI-DrugBank.d520.s0|76-76|.|O
DDI-DrugBank.d101.s0|0-5|Steady|O
DDI-DrugBank.d101.s0|7-11|state|O
DDI-DrugBank.d101.s0|13-18|plasma|O
DDI-DrugBank.d101.s0|20-28|digitoxin|O
DDI-DrugBank.d101.s0|30-43|concentrations|O
DDI-DrugBank.d101.s0|45-47|did|O
DDI-DrugBank.d101.s0|49-51|not|O
DDI-DrugBank.d101.s0|53-58|appear|O
DDI-DrugBank.d101.s0|60-61|to|O
DDI-DrugBank.d101.s0|63-68|change|O
DDI-DrugBank.d101.s0|69-69|.|O
DDI-DrugBank.d101.s1|0-8|Therefore|O
DDI-DrugBank.d101.s1|9-9|,|O
DDI-DrugBank.d101.s1|11-20|monitoring|O
DDI-DrugBank.d101.s1|22-23|of|O
DDI-DrugBank.d101.s1|25-30|plasma|O
DDI-DrugBank.d101.s1|32-38|digoxin|O
DDI-DrugBank.d101.s1|40-45|levels|O
DDI-DrugBank.d101.s1|47-49|may|O
DDI-DrugBank.d101.s1|51-52|be|O
DDI-DrugBank.d101.s1|54-62|indicated|O
DDI-DrugBank.d101.s1|64-65|in|O
DDI-DrugBank.d101.s1|67-74|patients|O
DDI-DrugBank.d101.s1|76-84|receiving|O
DDI-DrugBank.d101.s1|86-92|similar|O
DDI-DrugBank.d101.s1|94-104|combination|O
DDI-DrugBank.d101.s1|106-117|chemotherapy|O
DDI-DrugBank.d101.s1|119-126|regimens|O
DDI-DrugBank.d101.s1|127-127|.|O
DDI-DrugBank.d101.s2|0-2|The|O
DDI-DrugBank.d101.s2|4-14|utilization|O
DDI-DrugBank.d101.s2|16-17|of|O
DDI-DrugBank.d101.s2|19-27|digitoxin|O
DDI-DrugBank.d101.s2|29-31|for|O
DDI-DrugBank.d101.s2|33-36|such|O
DDI-DrugBank.d101.s2|38-45|patients|O
DDI-DrugBank.d101.s2|47-49|may|O
DDI-DrugBank.d101.s2|51-52|be|O
DDI-DrugBank.d101.s2|54-63|considered|O
DDI-DrugBank.d101.s2|65-66|as|O
DDI-DrugBank.d101.s2|68-69|an|O
DDI-DrugBank.d101.s2|71-81|alternative|O
DDI-DrugBank.d101.s2|82-82|.|O
DDI-DrugBank.d101.s3|0-3|Also|O
DDI-DrugBank.d101.s3|5-15|flucytosine|O
DDI-DrugBank.d101.s3|16-16|.|O
DDI-DrugBank.d736.s0|0-10|Hypokalemia|O
DDI-DrugBank.d736.s0|12-14|can|O
DDI-DrugBank.d736.s0|16-24|sensitize|O
DDI-DrugBank.d736.s0|26-27|or|O
DDI-DrugBank.d736.s0|29-38|exaggerate|O
DDI-DrugBank.d736.s0|40-42|the|O
DDI-DrugBank.d736.s0|44-51|response|O
DDI-DrugBank.d736.s0|53-54|of|O
DDI-DrugBank.d736.s0|56-58|the|O
DDI-DrugBank.d736.s0|60-64|heart|O
DDI-DrugBank.d736.s0|66-67|to|O
DDI-DrugBank.d736.s0|69-71|the|O
DDI-DrugBank.d736.s0|73-77|toxic|O
DDI-DrugBank.d736.s0|79-85|effects|O
DDI-DrugBank.d736.s0|87-88|of|O
DDI-DrugBank.d736.s0|90-98|digitalis|O
DDI-DrugBank.d736.s0|100-100|(|O
DDI-DrugBank.d736.s0|101-104|e.g.|O
DDI-DrugBank.d736.s0|105-105|,|O
DDI-DrugBank.d736.s0|107-115|increased|O
DDI-DrugBank.d736.s0|117-127|ventricular|O
DDI-DrugBank.d736.s0|129-140|irritability|O
DDI-DrugBank.d736.s0|141-141|)|O
DDI-DrugBank.d736.s0|142-142|.|O
DDI-DrugBank.d736.s1|0-10|Hypokalemia|O
DDI-DrugBank.d736.s1|12-14|may|O
DDI-DrugBank.d736.s1|16-22|develop|O
DDI-DrugBank.d736.s1|24-29|during|O
DDI-DrugBank.d736.s1|31-41|concomitant|O
DDI-DrugBank.d736.s1|43-45|use|O
DDI-DrugBank.d736.s1|47-48|of|O
DDI-DrugBank.d736.s1|50-57|steroids|O
DDI-DrugBank.d736.s1|59-60|or|O
DDI-DrugBank.d736.s1|62-65|ACTH|O
DDI-DrugBank.d736.s1|66-66|.|O
DDI-DrugBank.d736.s2|0-6|Insulin|O
DDI-DrugBank.d736.s2|8-19|requirements|O
DDI-DrugBank.d736.s2|21-22|in|O
DDI-DrugBank.d736.s2|24-31|diabetic|O
DDI-DrugBank.d736.s2|33-40|patients|O
DDI-DrugBank.d736.s2|42-44|may|O
DDI-DrugBank.d736.s2|46-47|be|O
DDI-DrugBank.d736.s2|49-57|increased|O
DDI-DrugBank.d736.s2|58-58|,|O
DDI-DrugBank.d736.s2|60-68|decreased|O
DDI-DrugBank.d736.s2|69-69|,|O
DDI-DrugBank.d736.s2|71-72|or|O
DDI-DrugBank.d736.s2|74-82|unchanged|O
DDI-DrugBank.d736.s2|83-83|.|O
DDI-DrugBank.d736.s3|0-8|Thiazides|O
DDI-DrugBank.d736.s3|10-12|may|O
DDI-DrugBank.d736.s3|14-21|decrease|O
DDI-DrugBank.d736.s3|23-30|arterial|O
DDI-DrugBank.d736.s3|32-45|responsiveness|O
DDI-DrugBank.d736.s3|47-48|to|O
DDI-DrugBank.d736.s3|50-63|norepinephrine|O
DDI-DrugBank.d736.s3|64-64|.|O
DDI-DrugBank.d736.s4|0-3|This|O
DDI-DrugBank.d736.s4|5-14|diminution|O
DDI-DrugBank.d736.s4|16-17|is|O
DDI-DrugBank.d736.s4|19-21|not|O
DDI-DrugBank.d736.s4|23-32|sufficient|O
DDI-DrugBank.d736.s4|34-35|to|O
DDI-DrugBank.d736.s4|37-44|preclude|O
DDI-DrugBank.d736.s4|46-58|effectiveness|O
DDI-DrugBank.d736.s4|60-61|of|O
DDI-DrugBank.d736.s4|63-65|the|O
DDI-DrugBank.d736.s4|67-73|pressor|O
DDI-DrugBank.d736.s4|75-79|agent|O
DDI-DrugBank.d736.s4|81-83|for|O
DDI-DrugBank.d736.s4|85-95|therapeutic|O
DDI-DrugBank.d736.s4|97-99|use|O
DDI-DrugBank.d736.s4|100-100|.|O
DDI-DrugBank.d736.s5|0-7|Thiazide|O
DDI-DrugBank.d736.s5|9-13|drugs|O
DDI-DrugBank.d736.s5|15-17|may|O
DDI-DrugBank.d736.s5|19-26|increase|O
DDI-DrugBank.d736.s5|28-30|the|O
DDI-DrugBank.d736.s5|32-45|responsiveness|O
DDI-DrugBank.d736.s5|47-48|of|O
DDI-DrugBank.d736.s5|50-61|tubocurarine|O
DDI-DrugBank.d736.s5|62-62|.|O
DDI-DrugBank.d736.s6|0-6|Lithium|O
DDI-DrugBank.d736.s6|8-12|renal|O
DDI-DrugBank.d736.s6|14-22|clearance|O
DDI-DrugBank.d736.s6|24-25|is|O
DDI-DrugBank.d736.s6|27-33|reduced|O
DDI-DrugBank.d736.s6|35-36|by|O
DDI-DrugBank.d736.s6|38-46|thiazides|O
DDI-DrugBank.d736.s6|47-47|,|O
DDI-DrugBank.d736.s6|49-58|increasing|O
DDI-DrugBank.d736.s6|60-62|the|O
DDI-DrugBank.d736.s6|64-67|risk|O
DDI-DrugBank.d736.s6|69-70|of|O
DDI-DrugBank.d736.s6|72-78|lithium|O
DDI-DrugBank.d736.s6|80-87|toxicity|O
DDI-DrugBank.d736.s6|88-88|.|O
DDI-DrugBank.d736.s7|0-8|Thiazides|O
DDI-DrugBank.d736.s7|10-12|may|O
DDI-DrugBank.d736.s7|14-16|add|O
DDI-DrugBank.d736.s7|18-19|to|O
DDI-DrugBank.d736.s7|21-22|or|O
DDI-DrugBank.d736.s7|24-33|potentiate|O
DDI-DrugBank.d736.s7|35-37|the|O
DDI-DrugBank.d736.s7|39-44|action|O
DDI-DrugBank.d736.s7|46-47|of|O
DDI-DrugBank.d736.s7|49-53|other|O
DDI-DrugBank.d736.s7|55-70|antihypertensive|O
DDI-DrugBank.d736.s7|72-76|drugs|O
DDI-DrugBank.d736.s7|77-77|.|O
DDI-DrugBank.d736.s8|0-11|Potentiation|O
DDI-DrugBank.d736.s8|13-18|occurs|O
DDI-DrugBank.d736.s8|20-23|with|O
DDI-DrugBank.d736.s8|25-34|ganglionic|O
DDI-DrugBank.d736.s8|36-37|or|O
DDI-DrugBank.d736.s8|39-48|peripheral|O
DDI-DrugBank.d736.s8|50-59|adrenergic|O
DDI-DrugBank.d736.s8|61-68|blocking|O
DDI-DrugBank.d736.s8|70-74|drugs|O
DDI-DrugBank.d736.s8|75-75|.|O
DDI-DrugBank.d153.s0|0-2|The|O
DDI-DrugBank.d153.s0|4-17|administration|O
DDI-DrugBank.d153.s0|19-20|of|O
DDI-DrugBank.d153.s0|22-26|local|O
DDI-DrugBank.d153.s0|28-37|anesthetic|O
DDI-DrugBank.d153.s0|39-47|solutions|O
DDI-DrugBank.d153.s0|49-58|containing|O
DDI-DrugBank.d153.s0|60-70|epinephrine|O
DDI-DrugBank.d153.s0|72-73|or|O
DDI-DrugBank.d153.s0|75-88|norepinephrine|O
DDI-DrugBank.d153.s0|90-91|to|O
DDI-DrugBank.d153.s0|93-100|patients|O
DDI-DrugBank.d153.s0|102-110|receiving|O
DDI-DrugBank.d153.s0|112-120|monoamine|O
DDI-DrugBank.d153.s0|122-128|oxidase|O
DDI-DrugBank.d153.s0|130-139|inhibitors|O
DDI-DrugBank.d153.s0|141-142|or|O
DDI-DrugBank.d153.s0|144-152|tricyclic|O
DDI-DrugBank.d153.s0|154-168|antidepressants|O
DDI-DrugBank.d153.s0|170-172|may|O
DDI-DrugBank.d153.s0|174-180|produce|O
DDI-DrugBank.d153.s0|182-187|severe|O
DDI-DrugBank.d153.s0|188-188|,|O
DDI-DrugBank.d153.s0|190-198|prolonged|O
DDI-DrugBank.d153.s0|200-211|hypertension|O
DDI-DrugBank.d153.s0|212-212|.|O
DDI-DrugBank.d153.s1|0-9|Concurrent|O
DDI-DrugBank.d153.s1|11-13|use|O
DDI-DrugBank.d153.s1|15-16|of|O
DDI-DrugBank.d153.s1|18-22|these|O
DDI-DrugBank.d153.s1|24-29|agents|O
DDI-DrugBank.d153.s1|31-36|should|O
DDI-DrugBank.d153.s1|38-46|generally|O
DDI-DrugBank.d153.s1|48-49|be|O
DDI-DrugBank.d153.s1|51-57|avoided|O
DDI-DrugBank.d153.s1|58-58|.|O
DDI-DrugBank.d153.s2|0-1|In|O
DDI-DrugBank.d153.s2|3-12|situations|O
DDI-DrugBank.d153.s2|14-15|in|O
DDI-DrugBank.d153.s2|17-21|which|O
DDI-DrugBank.d153.s2|23-32|concurrent|O
DDI-DrugBank.d153.s2|34-40|therapy|O
DDI-DrugBank.d153.s2|42-43|is|O
DDI-DrugBank.d153.s2|45-53|necessary|O
DDI-DrugBank.d153.s2|54-54|,|O
DDI-DrugBank.d153.s2|56-62|careful|O
DDI-DrugBank.d153.s2|64-70|patient|O
DDI-DrugBank.d153.s2|72-81|monitoring|O
DDI-DrugBank.d153.s2|83-84|is|O
DDI-DrugBank.d153.s2|86-94|essential|O
DDI-DrugBank.d153.s2|95-95|.|O
DDI-DrugBank.d153.s3|0-9|Concurrent|O
DDI-DrugBank.d153.s3|11-24|administration|O
DDI-DrugBank.d153.s3|26-27|of|O
DDI-DrugBank.d153.s3|29-39|vasopressor|O
DDI-DrugBank.d153.s3|41-45|drugs|O
DDI-DrugBank.d153.s3|47-49|and|O
DDI-DrugBank.d153.s3|51-52|of|O
DDI-DrugBank.d153.s3|54-63|ergot-type|O
DDI-DrugBank.d153.s3|65-72|oxytocic|O
DDI-DrugBank.d153.s3|74-78|drugs|O
DDI-DrugBank.d153.s3|80-82|may|O
DDI-DrugBank.d153.s3|84-88|cause|O
DDI-DrugBank.d153.s3|90-95|severe|O
DDI-DrugBank.d153.s3|96-96|,|O
DDI-DrugBank.d153.s3|98-107|persistent|O
DDI-DrugBank.d153.s3|109-120|hypertension|O
DDI-DrugBank.d153.s3|122-123|or|O
DDI-DrugBank.d153.s3|125-139|cerebrovascular|O
DDI-DrugBank.d153.s3|141-149|accidents|O
DDI-DrugBank.d153.s3|150-150|.|O
DDI-DrugBank.d153.s4|0-13|Phenothiazines|O
DDI-DrugBank.d153.s4|15-17|and|O
DDI-DrugBank.d153.s4|19-32|butyrophenones|O
DDI-DrugBank.d153.s4|34-36|may|O
DDI-DrugBank.d153.s4|38-43|reduce|O
DDI-DrugBank.d153.s4|45-46|or|O
DDI-DrugBank.d153.s4|48-54|reverse|O
DDI-DrugBank.d153.s4|56-58|the|O
DDI-DrugBank.d153.s4|60-66|pressor|O
DDI-DrugBank.d153.s4|68-73|effect|O
DDI-DrugBank.d153.s4|75-76|of|O
DDI-DrugBank.d153.s4|78-88|epinephrine|O
DDI-DrugBank.d153.s4|89-89|.|O
DDI-DrugBank.d250.s0|0-6|Certain|O
DDI-DrugBank.d250.s0|8-12|other|O
DDI-DrugBank.d250.s0|14-24|antibiotics|O
DDI-DrugBank.d250.s0|26-26|(|O
DDI-DrugBank.d250.s0|27-41|aminoglycosides|O
DDI-DrugBank.d250.s0|43-45|and|O
DDI-DrugBank.d250.s0|47-55|polymyxin|O
DDI-DrugBank.d250.s0|56-56|)|O
DDI-DrugBank.d250.s0|58-61|have|O
DDI-DrugBank.d250.s0|63-66|also|O
DDI-DrugBank.d250.s0|68-71|been|O
DDI-DrugBank.d250.s0|73-80|reported|O
DDI-DrugBank.d250.s0|82-83|to|O
DDI-DrugBank.d250.s0|85-93|interfere|O
DDI-DrugBank.d250.s0|95-98|with|O
DDI-DrugBank.d250.s0|100-102|the|O
DDI-DrugBank.d250.s0|104-108|nerve|O
DDI-DrugBank.d250.s0|110-121|transmission|O
DDI-DrugBank.d250.s0|123-124|at|O
DDI-DrugBank.d250.s0|126-128|the|O
DDI-DrugBank.d250.s0|130-142|neuromuscular|O
DDI-DrugBank.d250.s0|144-151|junction|O
DDI-DrugBank.d250.s0|152-152|.|O
DDI-DrugBank.d250.s1|0-4|Based|O
DDI-DrugBank.d250.s1|6-7|on|O
DDI-DrugBank.d250.s1|9-12|this|O
DDI-DrugBank.d250.s1|14-21|reported|O
DDI-DrugBank.d250.s1|23-30|activity|O
DDI-DrugBank.d250.s1|31-31|,|O
DDI-DrugBank.d250.s1|33-36|they|O
DDI-DrugBank.d250.s1|38-43|should|O
DDI-DrugBank.d250.s1|45-47|not|O
DDI-DrugBank.d250.s1|49-50|be|O
DDI-DrugBank.d250.s1|52-56|given|O
DDI-DrugBank.d250.s1|58-70|concomitantly|O
DDI-DrugBank.d250.s1|72-75|with|O
DDI-DrugBank.d250.s1|77-86|Coly-Mycin|O
DDI-DrugBank.d250.s1|88-88|M|O
DDI-DrugBank.d250.s1|90-99|Parenteral|O
DDI-DrugBank.d250.s1|101-106|except|O
DDI-DrugBank.d250.s1|108-111|with|O
DDI-DrugBank.d250.s1|113-115|the|O
DDI-DrugBank.d250.s1|117-124|greatest|O
DDI-DrugBank.d250.s1|126-132|caution|O
DDI-DrugBank.d250.s1|133-133|.|O
DDI-DrugBank.d250.s2|0-9|Curariform|O
DDI-DrugBank.d250.s2|11-16|muscle|O
DDI-DrugBank.d250.s2|18-26|relaxants|O
DDI-DrugBank.d250.s2|28-28|(|O
DDI-DrugBank.d250.s2|29-30|eg|O
DDI-DrugBank.d250.s2|31-31|,|O
DDI-DrugBank.d250.s2|33-44|tubocurarine|O
DDI-DrugBank.d250.s2|45-45|)|O
DDI-DrugBank.d250.s2|47-49|and|O
DDI-DrugBank.d250.s2|51-55|other|O
DDI-DrugBank.d250.s2|57-61|drugs|O
DDI-DrugBank.d250.s2|62-62|,|O
DDI-DrugBank.d250.s2|64-72|including|O
DDI-DrugBank.d250.s2|74-78|ether|O
DDI-DrugBank.d250.s2|79-79|,|O
DDI-DrugBank.d250.s2|81-95|succinylcholine|O
DDI-DrugBank.d250.s2|96-96|,|O
DDI-DrugBank.d250.s2|98-106|gallamine|O
DDI-DrugBank.d250.s2|107-107|,|O
DDI-DrugBank.d250.s2|109-121|decamethonium|O
DDI-DrugBank.d250.s2|123-125|and|O
DDI-DrugBank.d250.s2|127-132|sodium|O
DDI-DrugBank.d250.s2|134-140|citrate|O
DDI-DrugBank.d250.s2|141-141|,|O
DDI-DrugBank.d250.s2|143-152|potentiate|O
DDI-DrugBank.d250.s2|154-156|the|O
DDI-DrugBank.d250.s2|158-170|neuromuscular|O
DDI-DrugBank.d250.s2|172-179|blocking|O
DDI-DrugBank.d250.s2|181-186|effect|O
DDI-DrugBank.d250.s2|188-190|and|O
DDI-DrugBank.d250.s2|192-197|should|O
DDI-DrugBank.d250.s2|199-200|be|O
DDI-DrugBank.d250.s2|202-205|used|O
DDI-DrugBank.d250.s2|207-210|with|O
DDI-DrugBank.d250.s2|212-218|extreme|O
DDI-DrugBank.d250.s2|220-226|caution|O
DDI-DrugBank.d250.s2|228-229|in|O
DDI-DrugBank.d250.s2|231-238|patients|O
DDI-DrugBank.d250.s2|240-244|being|O
DDI-DrugBank.d250.s2|246-252|treated|O
DDI-DrugBank.d250.s2|254-257|with|O
DDI-DrugBank.d250.s2|259-268|Coly-Mycin|O
DDI-DrugBank.d250.s2|270-270|M|O
DDI-DrugBank.d250.s2|272-281|Parenteral|O
DDI-DrugBank.d250.s2|282-282|.|O
DDI-DrugBank.d250.s3|0-5|Sodium|O
DDI-DrugBank.d250.s3|7-17|cephalothin|O
DDI-DrugBank.d250.s3|19-21|may|O
DDI-DrugBank.d250.s3|23-29|enhance|O
DDI-DrugBank.d250.s3|31-33|the|O
DDI-DrugBank.d250.s3|35-48|nephrotoxicity|O
DDI-DrugBank.d250.s3|50-51|of|O
DDI-DrugBank.d250.s3|53-62|Coly-Mycin|O
DDI-DrugBank.d250.s3|64-64|M|O
DDI-DrugBank.d250.s3|66-75|Parenteral|O
DDI-DrugBank.d250.s3|76-76|.|O
DDI-DrugBank.d250.s4|0-2|The|O
DDI-DrugBank.d250.s4|4-14|concomitant|O
DDI-DrugBank.d250.s4|16-18|use|O
DDI-DrugBank.d250.s4|20-21|of|O
DDI-DrugBank.d250.s4|23-28|sodium|O
DDI-DrugBank.d250.s4|30-40|cephalothin|O
DDI-DrugBank.d250.s4|42-44|and|O
DDI-DrugBank.d250.s4|46-55|Coly-Mycin|O
DDI-DrugBank.d250.s4|57-57|M|O
DDI-DrugBank.d250.s4|59-68|Parenteral|O
DDI-DrugBank.d250.s4|70-75|should|O
DDI-DrugBank.d250.s4|77-78|be|O
DDI-DrugBank.d250.s4|80-86|avoided|O
DDI-DrugBank.d250.s4|87-87|.|O
DDI-DrugBank.d658.s0|0-3|When|O
DDI-DrugBank.d658.s0|5-16|administered|O
DDI-DrugBank.d658.s0|18-29|concurrently|O
DDI-DrugBank.d658.s0|30-30|,|O
DDI-DrugBank.d658.s0|32-43|testolactone|O
DDI-DrugBank.d658.s0|45-47|may|O
DDI-DrugBank.d658.s0|49-56|increase|O
DDI-DrugBank.d658.s0|58-60|the|O
DDI-DrugBank.d658.s0|62-68|effects|O
DDI-DrugBank.d658.s0|70-71|of|O
DDI-DrugBank.d658.s0|73-76|oral|O
DDI-DrugBank.d658.s0|78-91|anticoagulants|O
DDI-DrugBank.d658.s0|92-92|;|O
DDI-DrugBank.d658.s1|0-6|monitor|O
DDI-DrugBank.d658.s1|8-10|and|O
DDI-DrugBank.d658.s1|12-17|adjust|O
DDI-DrugBank.d658.s1|19-31|anticoagulant|O
DDI-DrugBank.d658.s1|33-38|dosage|O
DDI-DrugBank.d658.s1|40-50|accordingly|O
DDI-DrugBank.d658.s1|51-51|.|O
DDI-DrugBank.d658.s2|0-14|Drug/Laboratory|O
DDI-DrugBank.d658.s2|16-19|Test|O
DDI-DrugBank.d658.s2|21-32|Interactions|O
DDI-DrugBank.d658.s2|33-33|:|O
DDI-DrugBank.d658.s2|35-45|Physiologic|O
DDI-DrugBank.d658.s2|47-53|effects|O
DDI-DrugBank.d658.s2|55-56|of|O
DDI-DrugBank.d658.s2|58-69|testolactone|O
DDI-DrugBank.d658.s2|71-73|may|O
DDI-DrugBank.d658.s2|75-80|result|O
DDI-DrugBank.d658.s2|82-83|in|O
DDI-DrugBank.d658.s2|85-93|decreased|O
DDI-DrugBank.d658.s2|95-103|estradiol|O
DDI-DrugBank.d658.s2|105-118|concentrations|O
DDI-DrugBank.d658.s2|120-123|with|O
DDI-DrugBank.d658.s2|125-141|radioimmunoassays|O
DDI-DrugBank.d658.s2|143-145|for|O
DDI-DrugBank.d658.s2|147-155|estradiol|O
DDI-DrugBank.d658.s2|156-156|,|O
DDI-DrugBank.d658.s2|158-166|increased|O
DDI-DrugBank.d658.s2|168-173|plasma|O
DDI-DrugBank.d658.s2|175-181|calcium|O
DDI-DrugBank.d658.s2|183-196|concentrations|O
DDI-DrugBank.d658.s2|197-197|,|O
DDI-DrugBank.d658.s2|199-201|and|O
DDI-DrugBank.d658.s2|203-211|increased|O
DDI-DrugBank.d658.s2|213-219|24-hour|O
DDI-DrugBank.d658.s2|221-227|urinary|O
DDI-DrugBank.d658.s2|229-237|excretion|O
DDI-DrugBank.d658.s2|239-240|of|O
DDI-DrugBank.d658.s2|242-249|creatine|O
DDI-DrugBank.d658.s2|251-253|and|O
DDI-DrugBank.d658.s2|255-269|17-ketosteroids|O
DDI-DrugBank.d658.s2|270-270|.|O
DDI-MedLine.d31.s0|0-5|Cancer|O
DDI-MedLine.d31.s0|7-8|in|O
DDI-MedLine.d31.s0|10-12|the|O
DDI-MedLine.d31.s0|14-20|elderly|O
DDI-MedLine.d31.s0|21-21|:|O
DDI-MedLine.d31.s0|23-27|basic|O
DDI-MedLine.d31.s0|29-35|science|O
DDI-MedLine.d31.s0|37-39|and|O
DDI-MedLine.d31.s0|41-48|clinical|O
DDI-MedLine.d31.s0|50-56|aspects|O
DDI-MedLine.d31.s0|57-57|.|O
DDI-MedLine.d31.s1|0-2|The|O
DDI-MedLine.d31.s1|4-12|incidence|O
DDI-MedLine.d31.s1|14-15|of|O
DDI-MedLine.d31.s1|17-22|cancer|O
DDI-MedLine.d31.s1|24-32|increases|O
DDI-MedLine.d31.s1|34-46|progressively|O
DDI-MedLine.d31.s1|48-51|with|O
DDI-MedLine.d31.s1|53-55|age|O
DDI-MedLine.d31.s1|56-56|.|O
DDI-MedLine.d31.s2|0-13|Rearrangements|O
DDI-MedLine.d31.s2|15-16|of|O
DDI-MedLine.d31.s2|18-24|genomes|O
DDI-MedLine.d31.s2|26-29|have|O
DDI-MedLine.d31.s2|31-34|been|O
DDI-MedLine.d31.s2|36-40|found|O
DDI-MedLine.d31.s2|42-43|to|O
DDI-MedLine.d31.s2|45-53|accompany|O
DDI-MedLine.d31.s2|55-62|cellular|O
DDI-MedLine.d31.s2|64-68|aging|O
DDI-MedLine.d31.s2|69-69|.|O
DDI-MedLine.d31.s3|0-4|These|O
DDI-MedLine.d31.s3|6-12|factors|O
DDI-MedLine.d31.s3|13-13|,|O
DDI-MedLine.d31.s3|15-16|in|O
DDI-MedLine.d31.s3|18-24|concert|O
DDI-MedLine.d31.s3|26-29|with|O
DDI-MedLine.d31.s3|31-43|age-dependent|O
DDI-MedLine.d31.s3|45-55|alterations|O
DDI-MedLine.d31.s3|57-58|in|O
DDI-MedLine.d31.s3|60-65|immune|O
DDI-MedLine.d31.s3|67-74|function|O
DDI-MedLine.d31.s3|76-78|and|O
DDI-MedLine.d31.s3|80-83|host|O
DDI-MedLine.d31.s3|85-91|defense|O
DDI-MedLine.d31.s3|92-92|,|O
DDI-MedLine.d31.s3|94-96|may|O
DDI-MedLine.d31.s3|98-101|help|O
DDI-MedLine.d31.s3|103-104|to|O
DDI-MedLine.d31.s3|106-112|explain|O
DDI-MedLine.d31.s3|114-116|the|O
DDI-MedLine.d31.s3|118-126|increased|O
DDI-MedLine.d31.s3|128-131|risk|O
DDI-MedLine.d31.s3|133-134|of|O
DDI-MedLine.d31.s3|136-144|malignant|O
DDI-MedLine.d31.s3|146-152|disease|O
DDI-MedLine.d31.s3|154-155|in|O
DDI-MedLine.d31.s3|157-160|aged|O
DDI-MedLine.d31.s3|162-168|persons|O
DDI-MedLine.d31.s3|169-169|.|O
DDI-MedLine.d31.s4|0-2|The|O
DDI-MedLine.d31.s4|4-11|clinical|O
DDI-MedLine.d31.s4|13-24|presentation|O
DDI-MedLine.d31.s4|26-28|and|O
DDI-MedLine.d31.s4|30-36|natural|O
DDI-MedLine.d31.s4|38-44|history|O
DDI-MedLine.d31.s4|46-47|of|O
DDI-MedLine.d31.s4|49-57|neoplasia|O
DDI-MedLine.d31.s4|59-61|are|O
DDI-MedLine.d31.s4|63-66|also|O
DDI-MedLine.d31.s4|68-75|affected|O
DDI-MedLine.d31.s4|77-78|by|O
DDI-MedLine.d31.s4|80-84|aging|O
DDI-MedLine.d31.s4|85-85|.|O
DDI-MedLine.d31.s5|0-3|This|O
DDI-MedLine.d31.s5|5-14|conference|O
DDI-MedLine.d31.s5|16-22|reviews|O
DDI-MedLine.d31.s5|24-29|recent|O
DDI-MedLine.d31.s5|31-42|developments|O
DDI-MedLine.d31.s5|44-45|in|O
DDI-MedLine.d31.s5|47-51|these|O
DDI-MedLine.d31.s5|53-57|areas|O
DDI-MedLine.d31.s5|58-58|,|O
DDI-MedLine.d31.s5|60-67|examines|O
DDI-MedLine.d31.s5|69-71|the|O
DDI-MedLine.d31.s5|73-79|effects|O
DDI-MedLine.d31.s5|81-82|of|O
DDI-MedLine.d31.s5|84-87|drug|O
DDI-MedLine.d31.s5|89-91|use|O
DDI-MedLine.d31.s5|93-94|in|O
DDI-MedLine.d31.s5|96-98|the|O
DDI-MedLine.d31.s5|100-106|elderly|O
DDI-MedLine.d31.s5|108-110|and|O
DDI-MedLine.d31.s5|112-123|implications|O
DDI-MedLine.d31.s5|125-127|for|O
DDI-MedLine.d31.s5|129-138|management|O
DDI-MedLine.d31.s5|139-139|,|O
DDI-MedLine.d31.s5|141-143|and|O
DDI-MedLine.d31.s5|145-153|discusses|O
DDI-MedLine.d31.s5|155-161|current|O
DDI-MedLine.d31.s5|163-173|information|O
DDI-MedLine.d31.s5|175-176|on|O
DDI-MedLine.d31.s5|178-180|how|O
DDI-MedLine.d31.s5|182-184|age|O
DDI-MedLine.d31.s5|186-188|may|O
DDI-MedLine.d31.s5|190-198|influence|O
DDI-MedLine.d31.s5|200-202|the|O
DDI-MedLine.d31.s5|204-211|response|O
DDI-MedLine.d31.s5|213-214|of|O
DDI-MedLine.d31.s5|216-221|cancer|O
DDI-MedLine.d31.s5|223-224|to|O
DDI-MedLine.d31.s5|226-232|therapy|O
DDI-MedLine.d31.s5|233-233|.|O
DDI-DrugBank.d302.s0|0-3|http|O
DDI-DrugBank.d302.s0|4-4|:|O
DDI-DrugBank.d302.s0|5-53|//www.rxlist.com/cgi/generic3/guanethidine_od.htm|O
DDI-MedLine.d159.s0|0-9|Protective|O
DDI-MedLine.d159.s0|11-16|effect|O
DDI-MedLine.d159.s0|18-19|of|O
DDI-MedLine.d159.s0|21-38|acetyl-l-carnitine|O
DDI-MedLine.d159.s0|40-42|and|O
DDI-MedLine.d159.s0|45-49|alpha|O
DDI-MedLine.d159.s0|51-56|lipoic|O
DDI-MedLine.d159.s0|58-61|acid|O
DDI-MedLine.d159.s0|63-69|against|O
DDI-MedLine.d159.s0|71-73|the|O
DDI-MedLine.d159.s0|75-79|acute|O
DDI-MedLine.d159.s0|81-88|toxicity|O
DDI-MedLine.d159.s0|90-91|of|O
DDI-MedLine.d159.s0|93-105|diepoxybutane|O
DDI-MedLine.d159.s0|107-108|to|O
DDI-MedLine.d159.s0|110-114|human|O
DDI-MedLine.d159.s0|116-126|lymphocytes|O
DDI-MedLine.d159.s0|127-127|.|O
DDI-MedLine.d159.s1|0-2|The|O
DDI-MedLine.d159.s1|4-20|biotransformation|O
DDI-MedLine.d159.s1|22-24|and|O
DDI-MedLine.d159.s1|26-34|oxidative|O
DDI-MedLine.d159.s1|36-41|stress|O
DDI-MedLine.d159.s1|43-45|may|O
DDI-MedLine.d159.s1|47-56|contribute|O
DDI-MedLine.d159.s1|58-59|to|O
DDI-MedLine.d159.s1|61-81|1,2:3,4-diepoxybutane|O
DDI-MedLine.d159.s1|83-83|(|O
DDI-MedLine.d159.s1|84-86|DEB|O
DDI-MedLine.d159.s1|87-87|)|O
DDI-MedLine.d159.s1|88-95|-induced|O
DDI-MedLine.d159.s1|97-104|toxicity|O
DDI-MedLine.d159.s1|106-107|to|O
DDI-MedLine.d159.s1|109-113|human|O
DDI-MedLine.d159.s1|115-125|lymphocytes|O
DDI-MedLine.d159.s1|127-128|of|O
DDI-MedLine.d159.s1|130-136|Fanconi|O
DDI-MedLine.d159.s1|138-143|Anemia|O
DDI-MedLine.d159.s1|145-145|(|O
DDI-MedLine.d159.s1|146-147|FA|O
DDI-MedLine.d159.s1|148-148|)|O
DDI-MedLine.d159.s1|150-157|patients|O
DDI-MedLine.d159.s1|158-158|.|O
DDI-MedLine.d159.s2|0-3|Thus|O
DDI-MedLine.d159.s2|4-4|,|O
DDI-MedLine.d159.s2|6-8|the|O
DDI-MedLine.d159.s2|10-23|identification|O
DDI-MedLine.d159.s2|25-26|of|O
DDI-MedLine.d159.s2|28-35|putative|O
DDI-MedLine.d159.s2|37-46|inhibitors|O
DDI-MedLine.d159.s2|48-49|of|O
DDI-MedLine.d159.s2|51-63|bioactivation|O
DDI-MedLine.d159.s2|64-64|,|O
DDI-MedLine.d159.s2|66-67|as|O
DDI-MedLine.d159.s2|69-72|well|O
DDI-MedLine.d159.s2|74-75|as|O
DDI-MedLine.d159.s2|77-79|the|O
DDI-MedLine.d159.s2|81-93|determination|O
DDI-MedLine.d159.s2|95-96|of|O
DDI-MedLine.d159.s2|98-100|the|O
DDI-MedLine.d159.s2|102-111|protective|O
DDI-MedLine.d159.s2|113-116|role|O
DDI-MedLine.d159.s2|118-119|of|O
DDI-MedLine.d159.s2|121-127|oxidant|O
DDI-MedLine.d159.s2|129-136|defenses|O
DDI-MedLine.d159.s2|137-137|,|O
DDI-MedLine.d159.s2|139-140|on|O
DDI-MedLine.d159.s2|142-152|DEB-induced|O
DDI-MedLine.d159.s2|154-161|toxicity|O
DDI-MedLine.d159.s2|162-162|,|O
DDI-MedLine.d159.s2|164-166|can|O
DDI-MedLine.d159.s2|168-171|help|O
DDI-MedLine.d159.s2|173-174|to|O
DDI-MedLine.d159.s2|176-185|understand|O
DDI-MedLine.d159.s2|187-190|what|O
DDI-MedLine.d159.s2|192-193|is|O
DDI-MedLine.d159.s2|195-201|failing|O
DDI-MedLine.d159.s2|203-204|in|O
DDI-MedLine.d159.s2|206-207|FA|O
DDI-MedLine.d159.s2|209-213|cells|O
DDI-MedLine.d159.s2|214-214|.|O
DDI-MedLine.d159.s3|0-1|In|O
DDI-MedLine.d159.s3|3-5|the|O
DDI-MedLine.d159.s3|7-13|present|O
DDI-MedLine.d159.s3|15-18|work|O
DDI-MedLine.d159.s3|20-21|we|O
DDI-MedLine.d159.s3|23-29|studied|O
DDI-MedLine.d159.s3|31-33|the|O
DDI-MedLine.d159.s3|35-46|contribution|O
DDI-MedLine.d159.s3|48-49|of|O
DDI-MedLine.d159.s3|51-57|several|O
DDI-MedLine.d159.s3|59-69|biochemical|O
DDI-MedLine.d159.s3|71-78|pathways|O
DDI-MedLine.d159.s3|80-82|for|O
DDI-MedLine.d159.s3|84-94|DEB-induced|O
DDI-MedLine.d159.s3|96-100|acute|O
DDI-MedLine.d159.s3|102-109|toxicity|O
DDI-MedLine.d159.s3|111-112|in|O
DDI-MedLine.d159.s3|114-118|human|O
DDI-MedLine.d159.s3|120-129|lymphocyte|O
DDI-MedLine.d159.s3|131-141|suspensions|O
DDI-MedLine.d159.s3|142-142|,|O
DDI-MedLine.d159.s3|144-145|by|O
DDI-MedLine.d159.s3|147-151|using|O
DDI-MedLine.d159.s3|153-162|inhibitors|O
DDI-MedLine.d159.s3|164-165|of|O
DDI-MedLine.d159.s3|167-173|epoxide|O
DDI-MedLine.d159.s3|175-184|hydrolases|O
DDI-MedLine.d159.s3|185-185|,|O
DDI-MedLine.d159.s3|187-196|inhibitors|O
DDI-MedLine.d159.s3|198-199|of|O
DDI-MedLine.d159.s3|201-210|protective|O
DDI-MedLine.d159.s3|212-218|enzymes|O
DDI-MedLine.d159.s3|220-221|as|O
DDI-MedLine.d159.s3|223-233|glutathione|O
DDI-MedLine.d159.s3|235-247|S-transferase|O
DDI-MedLine.d159.s3|249-251|and|O
DDI-MedLine.d159.s3|253-260|catalase|O
DDI-MedLine.d159.s3|261-261|,|O
DDI-MedLine.d159.s3|263-265|the|O
DDI-MedLine.d159.s3|267-275|depletion|O
DDI-MedLine.d159.s3|277-278|of|O
DDI-MedLine.d159.s3|280-290|glutathione|O
DDI-MedLine.d159.s3|292-292|(|O
DDI-MedLine.d159.s3|293-295|GSH|O
DDI-MedLine.d159.s3|296-296|)|O
DDI-MedLine.d159.s3|297-297|,|O
DDI-MedLine.d159.s3|299-301|and|O
DDI-MedLine.d159.s3|303-305|the|O
DDI-MedLine.d159.s3|307-316|inhibition|O
DDI-MedLine.d159.s3|318-319|of|O
DDI-MedLine.d159.s3|321-327|protein|O
DDI-MedLine.d159.s3|329-337|synthesis|O
DDI-MedLine.d159.s3|338-338|;|O
DDI-MedLine.d159.s4|0-2|and|O
DDI-MedLine.d159.s4|4-4|a|O
DDI-MedLine.d159.s4|6-12|variety|O
DDI-MedLine.d159.s4|14-15|of|O
DDI-MedLine.d159.s4|17-24|putative|O
DDI-MedLine.d159.s4|26-35|protective|O
DDI-MedLine.d159.s4|37-45|compounds|O
DDI-MedLine.d159.s4|46-46|,|O
DDI-MedLine.d159.s4|48-56|including|O
DDI-MedLine.d159.s4|58-69|antioxidants|O
DDI-MedLine.d159.s4|70-70|,|O
DDI-MedLine.d159.s4|72-74|and|O
DDI-MedLine.d159.s4|76-88|mitochondrial|O
DDI-MedLine.d159.s4|90-99|protective|O
DDI-MedLine.d159.s4|101-106|agents|O
DDI-MedLine.d159.s4|107-107|.|O
DDI-MedLine.d159.s5|0-2|The|O
DDI-MedLine.d159.s5|4-10|present|O
DDI-MedLine.d159.s5|12-16|study|O
DDI-MedLine.d159.s5|18-24|reports|O
DDI-MedLine.d159.s5|26-28|two|O
DDI-MedLine.d159.s5|30-34|novel|O
DDI-MedLine.d159.s5|36-43|findings|O
DDI-MedLine.d159.s5|44-44|:|O
DDI-MedLine.d159.s5|46-46|(|O
DDI-MedLine.d159.s5|47-47|i|O
DDI-MedLine.d159.s5|48-48|)|O
DDI-MedLine.d159.s5|50-51|it|O
DDI-MedLine.d159.s5|53-55|was|O
DDI-MedLine.d159.s5|57-63|clearly|O
DDI-MedLine.d159.s5|65-73|evidenced|O
DDI-MedLine.d159.s5|74-74|,|O
DDI-MedLine.d159.s5|76-78|for|O
DDI-MedLine.d159.s5|80-82|the|O
DDI-MedLine.d159.s5|84-88|first|O
DDI-MedLine.d159.s5|90-93|time|O
DDI-MedLine.d159.s5|94-94|,|O
DDI-MedLine.d159.s5|96-99|that|O
DDI-MedLine.d159.s5|101-103|the|O
DDI-MedLine.d159.s5|105-109|acute|O
DDI-MedLine.d159.s5|111-118|exposure|O
DDI-MedLine.d159.s5|120-121|of|O
DDI-MedLine.d159.s5|123-129|freshly|O
DDI-MedLine.d159.s5|131-138|isolated|O
DDI-MedLine.d159.s5|140-144|human|O
DDI-MedLine.d159.s5|146-156|lymphocytes|O
DDI-MedLine.d159.s5|158-159|to|O
DDI-MedLine.d159.s5|161-163|DEB|O
DDI-MedLine.d159.s5|165-171|results|O
DDI-MedLine.d159.s5|173-174|in|O
DDI-MedLine.d159.s5|176-181|severe|O
DDI-MedLine.d159.s5|183-185|GSH|O
DDI-MedLine.d159.s5|187-195|depletion|O
DDI-MedLine.d159.s5|197-199|and|O
DDI-MedLine.d159.s5|201-204|loss|O
DDI-MedLine.d159.s5|206-207|of|O
DDI-MedLine.d159.s5|209-211|ATP|O
DDI-MedLine.d159.s5|212-212|,|O
DDI-MedLine.d159.s5|214-221|followed|O
DDI-MedLine.d159.s5|223-224|by|O
DDI-MedLine.d159.s5|226-229|cell|O
DDI-MedLine.d159.s5|231-235|death|O
DDI-MedLine.d159.s5|236-236|;|O
DDI-MedLine.d159.s6|0-0|(|O
DDI-MedLine.d159.s6|1-2|ii|O
DDI-MedLine.d159.s6|3-3|)|O
DDI-MedLine.d159.s6|5-22|acetyl-l-carnitine|O
DDI-MedLine.d159.s6|24-30|elicits|O
DDI-MedLine.d159.s6|32-32|a|O
DDI-MedLine.d159.s6|34-44|significant|O
DDI-MedLine.d159.s6|46-55|protective|O
DDI-MedLine.d159.s6|57-62|effect|O
DDI-MedLine.d159.s6|64-65|on|O
DDI-MedLine.d159.s6|67-69|DEB|O
DDI-MedLine.d159.s6|71-77|induced|O
DDI-MedLine.d159.s6|79-86|toxicity|O
DDI-MedLine.d159.s6|87-87|,|O
DDI-MedLine.d159.s6|89-93|which|O
DDI-MedLine.d159.s6|95-97|was|O
DDI-MedLine.d159.s6|99-109|potentiated|O
DDI-MedLine.d159.s6|111-112|by|O
DDI-MedLine.d159.s6|115-126|alpha-lipoic|O
DDI-MedLine.d159.s6|128-131|acid|O
DDI-MedLine.d159.s6|132-132|.|O
DDI-MedLine.d159.s7|0-11|Collectively|O
DDI-MedLine.d159.s7|12-12|,|O
DDI-MedLine.d159.s7|14-18|these|O
DDI-MedLine.d159.s7|20-27|findings|O
DDI-MedLine.d159.s7|29-38|contribute|O
DDI-MedLine.d159.s7|40-41|to|O
DDI-MedLine.d159.s7|43-50|increase|O
DDI-MedLine.d159.s7|52-54|our|O
DDI-MedLine.d159.s7|56-64|knowledge|O
DDI-MedLine.d159.s7|66-67|of|O
DDI-MedLine.d159.s7|69-78|DEB-induce|O
DDI-MedLine.d159.s7|80-87|toxicity|O
DDI-MedLine.d159.s7|89-91|and|O
DDI-MedLine.d159.s7|93-96|will|O
DDI-MedLine.d159.s7|98-99|be|O
DDI-MedLine.d159.s7|101-104|very|O
DDI-MedLine.d159.s7|106-111|useful|O
DDI-MedLine.d159.s7|113-116|when|O
DDI-MedLine.d159.s7|118-124|applied|O
DDI-MedLine.d159.s7|126-127|in|O
DDI-MedLine.d159.s7|129-135|studies|O
DDI-MedLine.d159.s7|137-140|with|O
DDI-MedLine.d159.s7|142-152|lymphocytes|O
DDI-MedLine.d159.s7|154-157|from|O
DDI-MedLine.d159.s7|159-160|FA|O
DDI-MedLine.d159.s7|162-169|patients|O
DDI-MedLine.d159.s7|170-170|,|O
DDI-MedLine.d159.s7|172-173|in|O
DDI-MedLine.d159.s7|175-179|order|O
DDI-MedLine.d159.s7|181-182|to|O
DDI-MedLine.d159.s7|184-187|find|O
DDI-MedLine.d159.s7|189-191|out|O
DDI-MedLine.d159.s7|193-193|a|O
DDI-MedLine.d159.s7|195-204|protective|O
DDI-MedLine.d159.s7|206-210|agent|O
DDI-MedLine.d159.s7|212-218|against|O
DDI-MedLine.d159.s7|220-230|spontaneous|O
DDI-MedLine.d159.s7|232-234|and|O
DDI-MedLine.d159.s7|236-246|DEB-induced|O
DDI-MedLine.d159.s7|248-257|chromosome|O
DDI-MedLine.d159.s7|259-269|instability|O
DDI-MedLine.d159.s7|270-270|.|O
DDI-DrugBank.d531.s0|0-8|Efavirenz|O
DDI-DrugBank.d531.s0|10-12|has|O
DDI-DrugBank.d531.s0|14-17|been|O
DDI-DrugBank.d531.s0|19-23|shown|O
DDI-DrugBank.d531.s0|25-26|in|O
DDI-DrugBank.d531.s0|28-31|vivo|O
DDI-DrugBank.d531.s0|33-34|to|O
DDI-DrugBank.d531.s0|36-41|induce|O
DDI-DrugBank.d531.s0|43-48|CYP3A4|O
DDI-DrugBank.d531.s0|49-49|.|O
DDI-DrugBank.d531.s1|0-4|Other|O
DDI-DrugBank.d531.s1|6-14|compounds|O
DDI-DrugBank.d531.s1|16-19|that|O
DDI-DrugBank.d531.s1|21-23|are|O
DDI-DrugBank.d531.s1|25-34|substrates|O
DDI-DrugBank.d531.s1|36-37|of|O
DDI-DrugBank.d531.s1|39-44|CYP3A4|O
DDI-DrugBank.d531.s1|46-48|may|O
DDI-DrugBank.d531.s1|50-53|have|O
DDI-DrugBank.d531.s1|55-63|decreased|O
DDI-DrugBank.d531.s1|65-70|plasma|O
DDI-DrugBank.d531.s1|72-85|concentrations|O
DDI-DrugBank.d531.s1|87-90|when|O
DDI-DrugBank.d531.s1|92-105|coadministered|O
DDI-DrugBank.d531.s1|107-110|with|O
DDI-DrugBank.d531.s1|112-118|SUSTIVA|O
DDI-DrugBank.d531.s1|120-120|(|O
DDI-DrugBank.d531.s1|121-129|efavirenz|O
DDI-DrugBank.d531.s1|130-130|)|O
DDI-DrugBank.d531.s1|131-131|.|O
DDI-DrugBank.d531.s2|0-1|In|O
DDI-DrugBank.d531.s2|3-7|vitro|O
DDI-DrugBank.d531.s2|9-15|studies|O
DDI-DrugBank.d531.s2|17-20|have|O
DDI-DrugBank.d531.s2|22-33|demonstrated|O
DDI-DrugBank.d531.s2|35-38|that|O
DDI-DrugBank.d531.s2|40-48|efavirenz|O
DDI-DrugBank.d531.s2|50-57|inhibits|O
DDI-DrugBank.d531.s2|59-61|2C9|O
DDI-DrugBank.d531.s2|62-62|,|O
DDI-DrugBank.d531.s2|64-67|2C19|O
DDI-DrugBank.d531.s2|68-68|,|O
DDI-DrugBank.d531.s2|70-72|and|O
DDI-DrugBank.d531.s2|74-76|3A4|O
DDI-DrugBank.d531.s2|78-85|isozymes|O
DDI-DrugBank.d531.s2|87-88|in|O
DDI-DrugBank.d531.s2|90-92|the|O
DDI-DrugBank.d531.s2|94-98|range|O
DDI-DrugBank.d531.s2|100-101|of|O
DDI-DrugBank.d531.s2|103-110|observed|O
DDI-DrugBank.d531.s2|112-120|efavirenz|O
DDI-DrugBank.d531.s2|122-127|plasma|O
DDI-DrugBank.d531.s2|129-142|concentrations|O
DDI-DrugBank.d531.s2|143-143|.|O
DDI-DrugBank.d531.s3|0-15|Coadministration|O
DDI-DrugBank.d531.s3|17-18|of|O
DDI-DrugBank.d531.s3|20-28|efavirenz|O
DDI-DrugBank.d531.s3|30-33|with|O
DDI-DrugBank.d531.s3|35-39|drugs|O
DDI-DrugBank.d531.s3|41-49|primarily|O
DDI-DrugBank.d531.s3|51-61|metabolized|O
DDI-DrugBank.d531.s3|63-64|by|O
DDI-DrugBank.d531.s3|66-70|these|O
DDI-DrugBank.d531.s3|72-79|isozymes|O
DDI-DrugBank.d531.s3|81-83|may|O
DDI-DrugBank.d531.s3|85-90|result|O
DDI-DrugBank.d531.s3|92-93|in|O
DDI-DrugBank.d531.s3|95-101|altered|O
DDI-DrugBank.d531.s3|103-108|plasma|O
DDI-DrugBank.d531.s3|110-123|concentrations|O
DDI-DrugBank.d531.s3|125-126|of|O
DDI-DrugBank.d531.s3|128-130|the|O
DDI-DrugBank.d531.s3|132-145|coadministered|O
DDI-DrugBank.d531.s3|147-150|drug|O
DDI-DrugBank.d531.s3|151-151|.|O
DDI-DrugBank.d531.s4|0-8|Therefore|O
DDI-DrugBank.d531.s4|9-9|,|O
DDI-DrugBank.d531.s4|11-21|appropriate|O
DDI-DrugBank.d531.s4|23-26|dose|O
DDI-DrugBank.d531.s4|28-38|adjustments|O
DDI-DrugBank.d531.s4|40-42|may|O
DDI-DrugBank.d531.s4|44-45|be|O
DDI-DrugBank.d531.s4|47-55|necessary|O
DDI-DrugBank.d531.s4|57-59|for|O
DDI-DrugBank.d531.s4|61-65|these|O
DDI-DrugBank.d531.s4|67-71|drugs|O
DDI-DrugBank.d531.s4|72-72|.|O
DDI-DrugBank.d531.s5|0-4|Drugs|O
DDI-DrugBank.d531.s5|6-10|which|O
DDI-DrugBank.d531.s5|12-17|induce|O
DDI-DrugBank.d531.s5|19-24|CYP3A4|O
DDI-DrugBank.d531.s5|26-33|activity|O
DDI-DrugBank.d531.s5|35-35|(|O
DDI-DrugBank.d531.s5|36-37|eg|O
DDI-DrugBank.d531.s5|38-38|,|O
DDI-DrugBank.d531.s5|40-52|phenobarbital|O
DDI-DrugBank.d531.s5|53-53|,|O
DDI-DrugBank.d531.s5|55-62|rifampin|O
DDI-DrugBank.d531.s5|63-63|,|O
DDI-DrugBank.d531.s5|65-73|rifabutin|O
DDI-DrugBank.d531.s5|74-74|)|O
DDI-DrugBank.d531.s5|76-80|would|O
DDI-DrugBank.d531.s5|82-83|be|O
DDI-DrugBank.d531.s5|85-92|expected|O
DDI-DrugBank.d531.s5|94-95|to|O
DDI-DrugBank.d531.s5|97-104|increase|O
DDI-DrugBank.d531.s5|106-108|the|O
DDI-DrugBank.d531.s5|110-118|clearance|O
DDI-DrugBank.d531.s5|120-121|of|O
DDI-DrugBank.d531.s5|123-131|efavirenz|O
DDI-DrugBank.d531.s5|133-141|resulting|O
DDI-DrugBank.d531.s5|143-144|in|O
DDI-DrugBank.d531.s5|146-152|lowered|O
DDI-DrugBank.d531.s5|154-159|plasma|O
DDI-DrugBank.d531.s5|161-174|concentrations|O
DDI-DrugBank.d531.s5|175-175|.|O
DDI-DrugBank.d531.s6|0-3|Drug|O
DDI-DrugBank.d531.s6|5-16|interactions|O
DDI-DrugBank.d531.s6|18-21|with|O
DDI-DrugBank.d531.s6|23-29|SUSTIVA|O
DDI-DrugBank.d531.s6|31-33|are|O
DDI-DrugBank.d531.s6|35-44|summarized|O
DDI-DrugBank.d531.s6|46-47|in|O
DDI-DrugBank.d531.s6|49-53|Table|O
DDI-DrugBank.d531.s6|55-55|5|O
DDI-DrugBank.d531.s6|56-56|.|O
DDI-DrugBank.d531.s7|0-4|Table|O
DDI-DrugBank.d531.s7|6-7|5a|O
DDI-DrugBank.d531.s7|8-8|:|O
DDI-DrugBank.d531.s7|10-14|Drugs|O
DDI-DrugBank.d531.s7|16-19|That|O
DDI-DrugBank.d531.s7|21-26|Should|O
DDI-DrugBank.d531.s7|28-30|Not|O
DDI-DrugBank.d531.s7|32-33|Be|O
DDI-DrugBank.d531.s7|35-48|Coadministered|O
DDI-DrugBank.d531.s7|50-53|With|O
DDI-DrugBank.d531.s7|55-61|SUSTIVA|O
DDI-DrugBank.d531.s8|0-3|Drug|O
DDI-DrugBank.d531.s8|5-9|Class|O
DDI-DrugBank.d531.s9|0-4|Drugs|O
DDI-DrugBank.d531.s9|6-11|Within|O
DDI-DrugBank.d531.s9|13-17|Class|O
DDI-DrugBank.d531.s9|19-21|Not|O
DDI-DrugBank.d531.s9|23-24|To|O
DDI-DrugBank.d531.s9|26-27|Be|O
DDI-DrugBank.d531.s9|29-42|Coadministered|O
DDI-DrugBank.d531.s9|44-47|With|O
DDI-DrugBank.d531.s9|49-55|SUSTIVA|O
DDI-DrugBank.d531.s10|0-13|Antihistamines|O
DDI-DrugBank.d531.s10|14-14|:|O
DDI-DrugBank.d531.s10|16-30|Benzodiazepines|O
DDI-DrugBank.d531.s10|32-33|GI|O
DDI-DrugBank.d531.s10|35-42|Motility|O
DDI-DrugBank.d531.s10|44-49|Agents|O
DDI-DrugBank.d531.s10|51-63|Anti-Migraine|O
DDI-DrugBank.d531.s10|65-74|Antifungal|O
DDI-DrugBank.d531.s11|0-9|astemizole|O
DDI-DrugBank.d531.s11|11-19|midazolam|O
DDI-DrugBank.d531.s11|20-20|,|O
DDI-DrugBank.d531.s11|22-30|triazolam|O
DDI-DrugBank.d531.s11|32-40|cisapride|O
DDI-DrugBank.d531.s11|42-46|ergot|O
DDI-DrugBank.d531.s11|48-58|derivatives|O
DDI-DrugBank.d531.s11|60-71|voriconazole|O
DDI-DrugBank.d531.s12|0-10|Established|O
DDI-DrugBank.d531.s12|12-15|Drug|O
DDI-DrugBank.d531.s12|17-28|Interactions|O
DDI-DrugBank.d531.s14|0-3|Drug|O
DDI-DrugBank.d531.s14|5-8|Name|O
DDI-DrugBank.d531.s15|0-5|Effect|O
DDI-DrugBank.d531.s16|0-7|Clinical|O
DDI-DrugBank.d531.s16|9-15|Comment|O
DDI-DrugBank.d531.s17|0-9|Atazanavir|O
DDI-DrugBank.d531.s18|0-9|atazanavir|O
DDI-DrugBank.d531.s19|0-3|When|O
DDI-DrugBank.d531.s19|5-18|coadministered|O
DDI-DrugBank.d531.s19|20-23|with|O
DDI-DrugBank.d531.s19|25-31|SUSTIVA|O
DDI-DrugBank.d531.s19|33-34|in|O
DDI-DrugBank.d531.s19|36-50|treatment-naive|O
DDI-DrugBank.d531.s19|52-59|patients|O
DDI-DrugBank.d531.s19|60-60|,|O
DDI-DrugBank.d531.s19|62-64|the|O
DDI-DrugBank.d531.s19|66-76|recommended|O
DDI-DrugBank.d531.s19|78-81|dose|O
DDI-DrugBank.d531.s19|83-84|of|O
DDI-DrugBank.d531.s19|86-95|atazanavir|O
DDI-DrugBank.d531.s19|97-98|is|O
DDI-DrugBank.d531.s19|100-102|300|O
DDI-DrugBank.d531.s19|104-105|mg|O
DDI-DrugBank.d531.s19|107-110|with|O
DDI-DrugBank.d531.s19|112-120|ritonavir|O
DDI-DrugBank.d531.s19|122-124|100|O
DDI-DrugBank.d531.s19|126-127|mg|O
DDI-DrugBank.d531.s19|129-131|and|O
DDI-DrugBank.d531.s19|133-139|SUSTIVA|O
DDI-DrugBank.d531.s19|141-143|600|O
DDI-DrugBank.d531.s19|145-146|mg|O
DDI-DrugBank.d531.s19|148-148|(|O
DDI-DrugBank.d531.s19|149-151|all|O
DDI-DrugBank.d531.s19|153-156|once|O
DDI-DrugBank.d531.s19|158-162|daily|O
DDI-DrugBank.d531.s19|163-163|)|O
DDI-DrugBank.d531.s19|164-164|.|O
DDI-DrugBank.d531.s20|0-5|Dosing|O
DDI-DrugBank.d531.s20|7-21|recommendations|O
DDI-DrugBank.d531.s20|23-25|for|O
DDI-DrugBank.d531.s20|27-33|SUSTIVA|O
DDI-DrugBank.d531.s20|35-37|and|O
DDI-DrugBank.d531.s20|39-48|atazanavir|O
DDI-DrugBank.d531.s20|50-51|in|O
DDI-DrugBank.d531.s20|53-73|treatment-experienced|O
DDI-DrugBank.d531.s20|75-82|patients|O
DDI-DrugBank.d531.s20|84-87|have|O
DDI-DrugBank.d531.s20|89-91|not|O
DDI-DrugBank.d531.s20|93-96|been|O
DDI-DrugBank.d531.s20|98-108|established|O
DDI-DrugBank.d531.s20|109-109|.|O
DDI-DrugBank.d531.s21|0-10|Established|O
DDI-DrugBank.d531.s21|12-15|Drug|O
DDI-DrugBank.d531.s21|17-28|Interactions|O
DDI-DrugBank.d531.s21|30-30|(|O
DDI-DrugBank.d531.s21|31-39|continued|O
DDI-DrugBank.d531.s21|40-40|)|O
DDI-DrugBank.d531.s22|0-3|Drug|O
DDI-DrugBank.d531.s22|5-8|Name|O
DDI-DrugBank.d531.s23|0-5|Effect|O
DDI-DrugBank.d531.s24|0-7|Clinical|O
DDI-DrugBank.d531.s24|9-15|Comment|O
DDI-DrugBank.d531.s25|0-13|Clarithromycin|O
DDI-DrugBank.d531.s26|0-13|clarithromycin|O
DDI-DrugBank.d531.s26|15-27|concentration|O
DDI-DrugBank.d531.s27|0-5|Plasma|O
DDI-DrugBank.d531.s27|7-20|concentrations|O
DDI-DrugBank.d531.s27|22-30|decreased|O
DDI-DrugBank.d531.s27|32-33|by|O
DDI-DrugBank.d531.s27|35-41|SUSTIVA|O
DDI-DrugBank.d531.s27|42-42|;|O
DDI-DrugBank.d531.s28|0-7|clinical|O
DDI-DrugBank.d531.s28|9-20|significance|O
DDI-DrugBank.d531.s28|22-28|unknown|O
DDI-DrugBank.d531.s28|29-29|.|O
DDI-DrugBank.d531.s29|0-1|In|O
DDI-DrugBank.d531.s29|3-12|uninfected|O
DDI-DrugBank.d531.s29|14-23|volunteers|O
DDI-DrugBank.d531.s29|24-24|,|O
DDI-DrugBank.d531.s29|26-27|46|O
DDI-DrugBank.d531.s29|28-28|%|O
DDI-DrugBank.d531.s29|30-38|developed|O
DDI-DrugBank.d531.s29|40-43|rash|O
DDI-DrugBank.d531.s29|45-49|while|O
DDI-DrugBank.d531.s29|51-59|receiving|O
DDI-DrugBank.d531.s29|61-67|SUSTIVA|O
DDI-DrugBank.d531.s29|69-71|and|O
DDI-DrugBank.d531.s29|73-86|clarithromycin|O
DDI-DrugBank.d531.s29|87-87|.|O
DDI-DrugBank.d531.s30|0-1|No|O
DDI-DrugBank.d531.s30|3-6|dose|O
DDI-DrugBank.d531.s30|8-17|adjustment|O
DDI-DrugBank.d531.s30|19-20|of|O
DDI-DrugBank.d531.s30|22-28|SUSTIVA|O
DDI-DrugBank.d531.s30|30-31|is|O
DDI-DrugBank.d531.s30|33-43|recommended|O
DDI-DrugBank.d531.s30|45-48|when|O
DDI-DrugBank.d531.s30|50-54|given|O
DDI-DrugBank.d531.s30|56-59|with|O
DDI-DrugBank.d531.s30|61-74|clarithromycin|O
DDI-DrugBank.d531.s30|75-75|.|O
DDI-DrugBank.d531.s31|0-11|Alternatives|O
DDI-DrugBank.d531.s31|13-14|to|O
DDI-DrugBank.d531.s31|16-29|clarithromycin|O
DDI-DrugBank.d531.s31|30-30|,|O
DDI-DrugBank.d531.s31|32-35|such|O
DDI-DrugBank.d531.s31|37-38|as|O
DDI-DrugBank.d531.s31|40-51|azithromycin|O
DDI-DrugBank.d531.s31|52-52|,|O
DDI-DrugBank.d531.s31|54-59|should|O
DDI-DrugBank.d531.s31|61-62|be|O
DDI-DrugBank.d531.s31|64-73|considered|O
DDI-DrugBank.d531.s31|74-74|.|O
DDI-DrugBank.d531.s32|0-4|Other|O
DDI-DrugBank.d531.s32|6-14|macrolide|O
DDI-DrugBank.d531.s32|16-26|antibiotics|O
DDI-DrugBank.d531.s32|27-27|,|O
DDI-DrugBank.d531.s32|29-32|such|O
DDI-DrugBank.d531.s32|34-35|as|O
DDI-DrugBank.d531.s32|37-48|erythromycin|O
DDI-DrugBank.d531.s32|49-49|,|O
DDI-DrugBank.d531.s32|51-54|have|O
DDI-DrugBank.d531.s32|56-58|not|O
DDI-DrugBank.d531.s32|60-63|been|O
DDI-DrugBank.d531.s32|65-71|studied|O
DDI-DrugBank.d531.s32|73-74|in|O
DDI-DrugBank.d531.s32|76-86|combination|O
DDI-DrugBank.d531.s32|88-91|with|O
DDI-DrugBank.d531.s32|93-99|SUSTIVA|O
DDI-DrugBank.d531.s32|100-100|.|O
DDI-DrugBank.d531.s34|0-4|14-OH|O
DDI-DrugBank.d531.s34|6-15|metabolite|O
DDI-DrugBank.d531.s34|17-29|concentration|O
DDI-DrugBank.d531.s35|0-8|Indinavir|O
DDI-DrugBank.d531.s36|0-8|indinavir|O
DDI-DrugBank.d531.s36|10-22|concentration|O
DDI-DrugBank.d531.s37|0-2|The|O
DDI-DrugBank.d531.s37|4-10|optimal|O
DDI-DrugBank.d531.s37|12-15|dose|O
DDI-DrugBank.d531.s37|17-18|of|O
DDI-DrugBank.d531.s37|20-28|indinavir|O
DDI-DrugBank.d531.s37|29-29|,|O
DDI-DrugBank.d531.s37|31-34|when|O
DDI-DrugBank.d531.s37|36-40|given|O
DDI-DrugBank.d531.s37|42-43|in|O
DDI-DrugBank.d531.s37|45-55|combination|O
DDI-DrugBank.d531.s37|57-60|with|O
DDI-DrugBank.d531.s37|62-68|SUSTIVA|O
DDI-DrugBank.d531.s37|69-69|,|O
DDI-DrugBank.d531.s37|71-72|is|O
DDI-DrugBank.d531.s37|74-76|not|O
DDI-DrugBank.d531.s37|78-82|known|O
DDI-DrugBank.d531.s37|83-83|.|O
DDI-DrugBank.d531.s38|0-9|Increasing|O
DDI-DrugBank.d531.s38|11-13|the|O
DDI-DrugBank.d531.s38|15-23|indinavir|O
DDI-DrugBank.d531.s38|25-28|dose|O
DDI-DrugBank.d531.s38|30-31|to|O
DDI-DrugBank.d531.s38|33-36|1000|O
DDI-DrugBank.d531.s38|38-39|mg|O
DDI-DrugBank.d531.s38|41-45|every|O
DDI-DrugBank.d531.s38|47-47|8|O
DDI-DrugBank.d531.s38|49-53|hours|O
DDI-DrugBank.d531.s38|55-58|does|O
DDI-DrugBank.d531.s38|60-62|not|O
DDI-DrugBank.d531.s38|64-73|compensate|O
DDI-DrugBank.d531.s38|75-77|for|O
DDI-DrugBank.d531.s38|79-81|the|O
DDI-DrugBank.d531.s38|83-91|increased|O
DDI-DrugBank.d531.s38|93-101|indinavir|O
DDI-DrugBank.d531.s38|103-112|metabolism|O
DDI-DrugBank.d531.s38|114-116|due|O
DDI-DrugBank.d531.s38|118-119|to|O
DDI-DrugBank.d531.s38|121-127|SUSTIVA|O
DDI-DrugBank.d531.s38|128-128|.|O
DDI-DrugBank.d531.s39|0-3|When|O
DDI-DrugBank.d531.s39|5-13|indinavir|O
DDI-DrugBank.d531.s39|15-16|at|O
DDI-DrugBank.d531.s39|18-19|an|O
DDI-DrugBank.d531.s39|21-29|increased|O
DDI-DrugBank.d531.s39|31-34|dose|O
DDI-DrugBank.d531.s39|36-36|(|O
DDI-DrugBank.d531.s39|37-40|1000|O
DDI-DrugBank.d531.s39|42-43|mg|O
DDI-DrugBank.d531.s39|45-49|every|O
DDI-DrugBank.d531.s39|51-51|8|O
DDI-DrugBank.d531.s39|53-57|hours|O
DDI-DrugBank.d531.s39|58-58|)|O
DDI-DrugBank.d531.s39|60-62|was|O
DDI-DrugBank.d531.s39|64-68|given|O
DDI-DrugBank.d531.s39|70-73|with|O
DDI-DrugBank.d531.s39|75-81|SUSTIVA|O
DDI-DrugBank.d531.s39|83-83|(|O
DDI-DrugBank.d531.s39|84-86|600|O
DDI-DrugBank.d531.s39|88-89|mg|O
DDI-DrugBank.d531.s39|91-94|once|O
DDI-DrugBank.d531.s39|96-100|daily|O
DDI-DrugBank.d531.s39|101-101|)|O
DDI-DrugBank.d531.s39|102-102|,|O
DDI-DrugBank.d531.s39|104-106|the|O
DDI-DrugBank.d531.s39|108-116|indinavir|O
DDI-DrugBank.d531.s39|118-120|AUC|O
DDI-DrugBank.d531.s39|122-124|and|O
DDI-DrugBank.d531.s39|126-129|Cmin|O
DDI-DrugBank.d531.s39|131-134|were|O
DDI-DrugBank.d531.s39|136-144|decreased|O
DDI-DrugBank.d531.s39|146-147|on|O
DDI-DrugBank.d531.s39|149-155|average|O
DDI-DrugBank.d531.s39|157-158|by|O
DDI-DrugBank.d531.s39|160-164|33-46|O
DDI-DrugBank.d531.s39|165-165|%|O
DDI-DrugBank.d531.s39|167-169|and|O
DDI-DrugBank.d531.s39|171-175|39-57|O
DDI-DrugBank.d531.s39|176-176|%|O
DDI-DrugBank.d531.s39|177-177|,|O
DDI-DrugBank.d531.s39|179-190|respectively|O
DDI-DrugBank.d531.s39|191-191|,|O
DDI-DrugBank.d531.s39|193-200|compared|O
DDI-DrugBank.d531.s39|202-203|to|O
DDI-DrugBank.d531.s39|205-208|when|O
DDI-DrugBank.d531.s39|210-218|indinavir|O
DDI-DrugBank.d531.s39|220-220|(|O
DDI-DrugBank.d531.s39|221-223|800|O
DDI-DrugBank.d531.s39|225-226|mg|O
DDI-DrugBank.d531.s39|228-232|every|O
DDI-DrugBank.d531.s39|234-234|8|O
DDI-DrugBank.d531.s39|236-240|hours|O
DDI-DrugBank.d531.s39|241-241|)|O
DDI-DrugBank.d531.s39|243-245|was|O
DDI-DrugBank.d531.s39|247-251|given|O
DDI-DrugBank.d531.s39|253-257|alone|O
DDI-DrugBank.d531.s39|258-258|.|O
DDI-DrugBank.d531.s40|0-18|Lopinavir/ritonavir|O
DDI-DrugBank.d531.s41|0-8|lopinavir|O
DDI-DrugBank.d531.s41|10-22|concentration|O
DDI-DrugBank.d531.s42|0-0|A|O
DDI-DrugBank.d531.s42|2-5|dose|O
DDI-DrugBank.d531.s42|7-14|increase|O
DDI-DrugBank.d531.s42|16-17|of|O
DDI-DrugBank.d531.s42|19-37|lopinavir/ritonavir|O
DDI-DrugBank.d531.s42|39-40|to|O
DDI-DrugBank.d531.s42|42-48|533/133|O
DDI-DrugBank.d531.s42|50-51|mg|O
DDI-DrugBank.d531.s42|53-53|(|O
DDI-DrugBank.d531.s42|54-54|4|O
DDI-DrugBank.d531.s42|56-63|capsules|O
DDI-DrugBank.d531.s42|65-66|or|O
DDI-DrugBank.d531.s42|68-70|6.5|O
DDI-DrugBank.d531.s42|72-73|mL|O
DDI-DrugBank.d531.s42|74-74|)|O
DDI-DrugBank.d531.s42|76-80|twice|O
DDI-DrugBank.d531.s42|82-86|daily|O
DDI-DrugBank.d531.s42|88-92|taken|O
DDI-DrugBank.d531.s42|94-97|with|O
DDI-DrugBank.d531.s42|99-102|food|O
DDI-DrugBank.d531.s42|104-105|is|O
DDI-DrugBank.d531.s42|107-117|recommended|O
DDI-DrugBank.d531.s42|119-122|when|O
DDI-DrugBank.d531.s42|124-127|used|O
DDI-DrugBank.d531.s42|129-130|in|O
DDI-DrugBank.d531.s42|132-142|combination|O
DDI-DrugBank.d531.s42|144-147|with|O
DDI-DrugBank.d531.s42|149-155|SUSTIVA|O
DDI-DrugBank.d531.s42|156-156|.|O
DDI-DrugBank.d531.s43|0-8|Methadone|O
DDI-DrugBank.d531.s44|0-8|methadone|O
DDI-DrugBank.d531.s44|10-22|concentration|O
DDI-DrugBank.d531.s45|0-15|Coadministration|O
DDI-DrugBank.d531.s45|17-18|in|O
DDI-DrugBank.d531.s45|20-31|HIV-infected|O
DDI-DrugBank.d531.s45|33-43|individuals|O
DDI-DrugBank.d531.s45|45-48|with|O
DDI-DrugBank.d531.s45|50-50|a|O
DDI-DrugBank.d531.s45|52-58|history|O
DDI-DrugBank.d531.s45|60-61|of|O
DDI-DrugBank.d531.s45|63-71|injection|O
DDI-DrugBank.d531.s45|73-76|drug|O
DDI-DrugBank.d531.s45|78-80|use|O
DDI-DrugBank.d531.s45|82-89|resulted|O
DDI-DrugBank.d531.s45|91-92|in|O
DDI-DrugBank.d531.s45|94-102|decreased|O
DDI-DrugBank.d531.s45|104-109|plasma|O
DDI-DrugBank.d531.s45|111-116|levels|O
DDI-DrugBank.d531.s45|118-119|of|O
DDI-DrugBank.d531.s45|121-129|methadone|O
DDI-DrugBank.d531.s45|131-133|and|O
DDI-DrugBank.d531.s45|135-139|signs|O
DDI-DrugBank.d531.s45|141-142|of|O
DDI-DrugBank.d531.s45|144-149|opiate|O
DDI-DrugBank.d531.s45|151-160|withdrawal|O
DDI-DrugBank.d531.s45|161-161|.|O
DDI-DrugBank.d531.s46|0-8|Methadone|O
DDI-DrugBank.d531.s46|10-13|dose|O
DDI-DrugBank.d531.s46|15-17|was|O
DDI-DrugBank.d531.s46|19-27|increased|O
DDI-DrugBank.d531.s46|29-30|by|O
DDI-DrugBank.d531.s46|32-32|a|O
DDI-DrugBank.d531.s46|34-37|mean|O
DDI-DrugBank.d531.s46|39-40|of|O
DDI-DrugBank.d531.s46|42-43|22|O
DDI-DrugBank.d531.s46|44-44|%|O
DDI-DrugBank.d531.s46|46-47|to|O
DDI-DrugBank.d531.s46|49-57|alleviate|O
DDI-DrugBank.d531.s46|59-68|withdrawal|O
DDI-DrugBank.d531.s46|70-77|symptoms|O
DDI-DrugBank.d531.s46|78-78|.|O
DDI-DrugBank.d531.s47|0-7|Patients|O
DDI-DrugBank.d531.s47|9-14|should|O
DDI-DrugBank.d531.s47|16-17|be|O
DDI-DrugBank.d531.s47|19-27|monitored|O
DDI-DrugBank.d531.s47|29-31|for|O
DDI-DrugBank.d531.s47|33-37|signs|O
DDI-DrugBank.d531.s47|39-40|of|O
DDI-DrugBank.d531.s47|42-51|withdrawal|O
DDI-DrugBank.d531.s47|53-55|and|O
DDI-DrugBank.d531.s47|57-61|their|O
DDI-DrugBank.d531.s47|63-71|methadone|O
DDI-DrugBank.d531.s47|73-76|dose|O
DDI-DrugBank.d531.s47|78-86|increased|O
DDI-DrugBank.d531.s47|88-89|as|O
DDI-DrugBank.d531.s47|91-98|required|O
DDI-DrugBank.d531.s47|100-101|to|O
DDI-DrugBank.d531.s47|103-111|alleviate|O
DDI-DrugBank.d531.s47|113-122|withdrawal|O
DDI-DrugBank.d531.s47|124-131|symptoms|O
DDI-DrugBank.d531.s47|132-132|.|O
DDI-DrugBank.d531.s48|0-6|Ethinyl|O
DDI-DrugBank.d531.s48|8-16|estradiol|O
DDI-DrugBank.d531.s49|0-6|ethinyl|O
DDI-DrugBank.d531.s49|8-16|estradiol|O
DDI-DrugBank.d531.s49|18-30|concentration|O
DDI-DrugBank.d531.s50|0-5|Plasma|O
DDI-DrugBank.d531.s50|7-20|concentrations|O
DDI-DrugBank.d531.s50|22-30|increased|O
DDI-DrugBank.d531.s50|32-33|by|O
DDI-DrugBank.d531.s50|35-41|SUSTIVA|O
DDI-DrugBank.d531.s50|43-43|(|O
DDI-DrugBank.d531.s50|44-52|efavirenz|O
DDI-DrugBank.d531.s50|53-53|)|O
DDI-DrugBank.d531.s50|54-54|;|O
DDI-DrugBank.d531.s51|0-7|clinical|O
DDI-DrugBank.d531.s51|9-20|significance|O
DDI-DrugBank.d531.s51|22-28|unknown|O
DDI-DrugBank.d531.s51|29-29|.|O
DDI-DrugBank.d531.s52|0-6|Because|O
DDI-DrugBank.d531.s52|8-10|the|O
DDI-DrugBank.d531.s52|12-20|potential|O
DDI-DrugBank.d531.s52|22-32|interaction|O
DDI-DrugBank.d531.s52|34-35|of|O
DDI-DrugBank.d531.s52|37-45|efavirenz|O
DDI-DrugBank.d531.s52|47-50|with|O
DDI-DrugBank.d531.s52|52-55|oral|O
DDI-DrugBank.d531.s52|57-70|contraceptives|O
DDI-DrugBank.d531.s52|72-74|has|O
DDI-DrugBank.d531.s52|76-78|not|O
DDI-DrugBank.d531.s52|80-83|been|O
DDI-DrugBank.d531.s52|85-89|fully|O
DDI-DrugBank.d531.s52|91-103|characterized|O
DDI-DrugBank.d531.s52|104-104|,|O
DDI-DrugBank.d531.s52|106-106|a|O
DDI-DrugBank.d531.s52|108-115|reliable|O
DDI-DrugBank.d531.s52|117-122|method|O
DDI-DrugBank.d531.s52|124-125|of|O
DDI-DrugBank.d531.s52|127-133|barrier|O
DDI-DrugBank.d531.s52|135-147|contraception|O
DDI-DrugBank.d531.s52|149-154|should|O
DDI-DrugBank.d531.s52|156-157|be|O
DDI-DrugBank.d531.s52|159-162|used|O
DDI-DrugBank.d531.s52|164-165|in|O
DDI-DrugBank.d531.s52|167-174|addition|O
DDI-DrugBank.d531.s52|176-177|to|O
DDI-DrugBank.d531.s52|179-182|oral|O
DDI-DrugBank.d531.s52|184-197|contraceptives|O
DDI-DrugBank.d531.s52|198-198|.|O
DDI-DrugBank.d531.s53|0-8|Rifabutin|O
DDI-DrugBank.d531.s54|0-8|rifabutin|O
DDI-DrugBank.d531.s54|10-22|concentration|O
DDI-DrugBank.d531.s55|0-7|Increase|O
DDI-DrugBank.d531.s55|9-13|daily|O
DDI-DrugBank.d531.s55|15-18|dose|O
DDI-DrugBank.d531.s55|20-21|of|O
DDI-DrugBank.d531.s55|23-31|rifabutin|O
DDI-DrugBank.d531.s55|33-34|by|O
DDI-DrugBank.d531.s55|36-37|50|O
DDI-DrugBank.d531.s55|38-38|%|O
DDI-DrugBank.d531.s55|39-39|.|O
DDI-DrugBank.d531.s56|0-7|Consider|O
DDI-DrugBank.d531.s56|9-16|doubling|O
DDI-DrugBank.d531.s56|18-20|the|O
DDI-DrugBank.d531.s56|22-30|rifabutin|O
DDI-DrugBank.d531.s56|32-35|dose|O
DDI-DrugBank.d531.s56|37-38|in|O
DDI-DrugBank.d531.s56|40-47|regimens|O
DDI-DrugBank.d531.s56|49-53|where|O
DDI-DrugBank.d531.s56|55-63|rifabutin|O
DDI-DrugBank.d531.s56|65-66|is|O
DDI-DrugBank.d531.s56|68-72|given|O
DDI-DrugBank.d531.s56|74-74|2|O
DDI-DrugBank.d531.s56|76-77|or|O
DDI-DrugBank.d531.s56|79-79|3|O
DDI-DrugBank.d531.s56|81-85|times|O
DDI-DrugBank.d531.s56|87-87|a|O
DDI-DrugBank.d531.s56|89-92|week|O
DDI-DrugBank.d531.s56|93-93|.|O
DDI-DrugBank.d531.s57|0-7|Rifampin|O
DDI-DrugBank.d531.s58|0-8|efavirenz|O
DDI-DrugBank.d531.s58|10-22|concentration|O
DDI-DrugBank.d531.s59|0-7|Clinical|O
DDI-DrugBank.d531.s59|9-20|significance|O
DDI-DrugBank.d531.s59|22-23|of|O
DDI-DrugBank.d531.s59|25-31|reduced|O
DDI-DrugBank.d531.s59|33-41|efavirenz|O
DDI-DrugBank.d531.s59|43-56|concentrations|O
DDI-DrugBank.d531.s59|58-64|unknown|O
DDI-DrugBank.d531.s59|65-65|.|O
DDI-DrugBank.d531.s60|0-8|Ritonavir|O
DDI-DrugBank.d531.s61|0-8|ritonavir|O
DDI-DrugBank.d531.s61|10-22|concentration|O
DDI-DrugBank.d531.s62|0-10|Combination|O
DDI-DrugBank.d531.s62|12-14|was|O
DDI-DrugBank.d531.s62|16-25|associated|O
DDI-DrugBank.d531.s62|27-30|with|O
DDI-DrugBank.d531.s62|32-32|a|O
DDI-DrugBank.d531.s62|34-39|higher|O
DDI-DrugBank.d531.s62|41-49|frequency|O
DDI-DrugBank.d531.s62|51-52|of|O
DDI-DrugBank.d531.s62|54-60|adverse|O
DDI-DrugBank.d531.s62|62-69|clinical|O
DDI-DrugBank.d531.s62|71-81|experiences|O
DDI-DrugBank.d531.s62|83-83|(|O
DDI-DrugBank.d531.s62|84-85|eg|O
DDI-DrugBank.d531.s62|86-86|,|O
DDI-DrugBank.d531.s62|88-96|dizziness|O
DDI-DrugBank.d531.s62|97-97|,|O
DDI-DrugBank.d531.s62|99-104|nausea|O
DDI-DrugBank.d531.s62|105-105|,|O
DDI-DrugBank.d531.s62|107-117|paresthesia|O
DDI-DrugBank.d531.s62|118-118|)|O
DDI-DrugBank.d531.s62|120-122|and|O
DDI-DrugBank.d531.s62|124-133|laboratory|O
DDI-DrugBank.d531.s62|135-147|abnormalities|O
DDI-DrugBank.d531.s62|149-149|(|O
DDI-DrugBank.d531.s62|150-157|elevated|O
DDI-DrugBank.d531.s62|159-163|liver|O
DDI-DrugBank.d531.s62|165-171|enzymes|O
DDI-DrugBank.d531.s62|172-172|)|O
DDI-DrugBank.d531.s62|173-173|.|O
DDI-DrugBank.d531.s63|0-9|Monitoring|O
DDI-DrugBank.d531.s63|11-12|of|O
DDI-DrugBank.d531.s63|14-18|liver|O
DDI-DrugBank.d531.s63|20-26|enzymes|O
DDI-DrugBank.d531.s63|28-29|is|O
DDI-DrugBank.d531.s63|31-41|recommended|O
DDI-DrugBank.d531.s63|43-46|when|O
DDI-DrugBank.d531.s63|48-54|SUSTIVA|O
DDI-DrugBank.d531.s63|56-57|is|O
DDI-DrugBank.d531.s63|59-62|used|O
DDI-DrugBank.d531.s63|64-65|in|O
DDI-DrugBank.d531.s63|67-77|combination|O
DDI-DrugBank.d531.s63|79-82|with|O
DDI-DrugBank.d531.s63|84-92|ritonavir|O
DDI-DrugBank.d531.s63|93-93|.|O
DDI-DrugBank.d531.s64|0-8|efavirenz|O
DDI-DrugBank.d531.s64|10-22|concentration|O
DDI-DrugBank.d531.s65|0-9|Saquinavir|O
DDI-DrugBank.d531.s66|0-9|saquinavir|O
DDI-DrugBank.d531.s66|11-23|concentration|O
DDI-DrugBank.d531.s67|0-5|Should|O
DDI-DrugBank.d531.s67|7-9|not|O
DDI-DrugBank.d531.s67|11-12|be|O
DDI-DrugBank.d531.s67|14-17|used|O
DDI-DrugBank.d531.s67|19-20|as|O
DDI-DrugBank.d531.s67|22-25|sole|O
DDI-DrugBank.d531.s67|27-34|protease|O
DDI-DrugBank.d531.s67|36-44|inhibitor|O
DDI-DrugBank.d531.s67|46-47|in|O
DDI-DrugBank.d531.s67|49-59|combination|O
DDI-DrugBank.d531.s67|61-64|with|O
DDI-DrugBank.d531.s67|66-72|SUSTIVA|O
DDI-DrugBank.d531.s67|73-73|.|O
DDI-DrugBank.d531.s68|0-9|Sertraline|O
DDI-DrugBank.d531.s69|0-9|sertraline|O
DDI-DrugBank.d531.s69|11-23|concentration|O
DDI-DrugBank.d531.s70|0-8|Increases|O
DDI-DrugBank.d531.s70|10-11|in|O
DDI-DrugBank.d531.s70|13-22|sertraline|O
DDI-DrugBank.d531.s70|24-27|dose|O
DDI-DrugBank.d531.s70|29-34|should|O
DDI-DrugBank.d531.s70|36-37|be|O
DDI-DrugBank.d531.s70|39-44|guided|O
DDI-DrugBank.d531.s70|46-47|by|O
DDI-DrugBank.d531.s70|49-56|clinical|O
DDI-DrugBank.d531.s70|58-65|response|O
DDI-DrugBank.d531.s70|66-66|.|O
DDI-DrugBank.d531.s71|0-4|Other|O
DDI-DrugBank.d531.s71|6-16|Potentially|O
DDI-DrugBank.d531.s71|18-27|Clinically|O
DDI-DrugBank.d531.s71|29-39|Significant|O
DDI-DrugBank.d531.s71|41-44|Drug|O
DDI-DrugBank.d531.s71|46-47|or|O
DDI-DrugBank.d531.s71|49-54|Herbal|O
DDI-DrugBank.d531.s71|56-62|Product|O
DDI-DrugBank.d531.s71|64-75|Interactions|O
DDI-DrugBank.d531.s71|77-80|With|O
DDI-DrugBank.d531.s71|82-89|SUSTIVAb|O
DDI-DrugBank.d531.s72|0-13|Anticoagulants|O
DDI-DrugBank.d531.s72|14-14|:|O
DDI-DrugBank.d531.s72|16-23|Warfarin|O
DDI-DrugBank.d531.s73|0-5|Plasma|O
DDI-DrugBank.d531.s73|7-20|concentrations|O
DDI-DrugBank.d531.s73|22-24|and|O
DDI-DrugBank.d531.s73|26-32|effects|O
DDI-DrugBank.d531.s73|34-44|potentially|O
DDI-DrugBank.d531.s73|46-54|increased|O
DDI-DrugBank.d531.s73|56-57|or|O
DDI-DrugBank.d531.s73|59-67|decreased|O
DDI-DrugBank.d531.s73|69-70|by|O
DDI-DrugBank.d531.s73|72-78|SUSTIVA|O
DDI-DrugBank.d531.s73|79-79|.|O
DDI-DrugBank.d531.s74|0-14|Anticonvulsants|O
DDI-DrugBank.d531.s74|15-15|:|O
DDI-DrugBank.d531.s74|17-25|Phenytoin|O
DDI-DrugBank.d531.s74|27-39|Phenobarbital|O
DDI-DrugBank.d531.s74|41-53|Carbamazepine|O
DDI-DrugBank.d531.s75|0-8|Potential|O
DDI-DrugBank.d531.s75|10-12|for|O
DDI-DrugBank.d531.s75|14-22|reduction|O
DDI-DrugBank.d531.s75|24-25|in|O
DDI-DrugBank.d531.s75|27-40|anticonvulsant|O
DDI-DrugBank.d531.s75|42-47|and/or|O
DDI-DrugBank.d531.s75|49-57|efavirenz|O
DDI-DrugBank.d531.s75|59-64|plasma|O
DDI-DrugBank.d531.s75|66-71|levels|O
DDI-DrugBank.d531.s75|72-72|;|O
DDI-DrugBank.d531.s76|0-7|periodic|O
DDI-DrugBank.d531.s76|9-18|monitoring|O
DDI-DrugBank.d531.s76|20-21|of|O
DDI-DrugBank.d531.s76|23-36|anticonvulsant|O
DDI-DrugBank.d531.s76|38-43|plasma|O
DDI-DrugBank.d531.s76|45-50|levels|O
DDI-DrugBank.d531.s76|52-57|should|O
DDI-DrugBank.d531.s76|59-60|be|O
DDI-DrugBank.d531.s76|62-70|conducted|O
DDI-DrugBank.d531.s76|71-71|.|O
DDI-DrugBank.d531.s77|0-10|Antifungals|O
DDI-DrugBank.d531.s77|11-11|:|O
DDI-DrugBank.d531.s77|13-24|Itraconazole|O
DDI-DrugBank.d531.s77|26-37|Ketoconazole|O
DDI-DrugBank.d531.s78|0-3|Drug|O
DDI-DrugBank.d531.s78|5-15|interaction|O
DDI-DrugBank.d531.s78|17-23|studies|O
DDI-DrugBank.d531.s78|25-28|with|O
DDI-DrugBank.d531.s78|30-36|SUSTIVA|O
DDI-DrugBank.d531.s78|38-40|and|O
DDI-DrugBank.d531.s78|42-46|these|O
DDI-DrugBank.d531.s78|48-56|imidazole|O
DDI-DrugBank.d531.s78|58-60|and|O
DDI-DrugBank.d531.s78|62-69|triazole|O
DDI-DrugBank.d531.s78|71-81|antifungals|O
DDI-DrugBank.d531.s78|83-86|have|O
DDI-DrugBank.d531.s78|88-90|not|O
DDI-DrugBank.d531.s78|92-95|been|O
DDI-DrugBank.d531.s78|97-105|conducted|O
DDI-DrugBank.d531.s78|106-106|.|O
DDI-DrugBank.d531.s79|0-6|SUSTIVA|O
DDI-DrugBank.d531.s79|8-10|has|O
DDI-DrugBank.d531.s79|12-14|the|O
DDI-DrugBank.d531.s79|16-24|potential|O
DDI-DrugBank.d531.s79|26-27|to|O
DDI-DrugBank.d531.s79|29-36|decrease|O
DDI-DrugBank.d531.s79|38-43|plasma|O
DDI-DrugBank.d531.s79|45-58|concentrations|O
DDI-DrugBank.d531.s79|60-61|of|O
DDI-DrugBank.d531.s79|63-74|itraconazole|O
DDI-DrugBank.d531.s79|76-78|and|O
DDI-DrugBank.d531.s79|80-91|ketoconazole|O
DDI-DrugBank.d531.s79|92-92|.|O
DDI-DrugBank.d531.s80|0-7|Anti-HIV|O
DDI-DrugBank.d531.s80|9-16|protease|O
DDI-DrugBank.d531.s80|18-27|inhibitors|O
DDI-DrugBank.d531.s80|28-28|:|O
DDI-DrugBank.d531.s80|30-49|Saquinavir/ritonavir|O
DDI-DrugBank.d531.s80|51-61|combination|O
DDI-DrugBank.d531.s81|0-1|No|O
DDI-DrugBank.d531.s81|3-17|pharmacokinetic|O
DDI-DrugBank.d531.s81|19-22|data|O
DDI-DrugBank.d531.s81|24-26|are|O
DDI-DrugBank.d531.s81|28-36|available|O
DDI-DrugBank.d531.s81|37-37|.|O
DDI-DrugBank.d531.s82|0-9|Amprenavir|O
DDI-DrugBank.d531.s83|0-9|SUSTIVAhas|O
DDI-DrugBank.d531.s83|11-13|the|O
DDI-DrugBank.d531.s83|15-23|potential|O
DDI-DrugBank.d531.s83|25-26|to|O
DDI-DrugBank.d531.s83|28-35|decrease|O
DDI-DrugBank.d531.s83|37-41|serum|O
DDI-DrugBank.d531.s83|43-56|concentrations|O
DDI-DrugBank.d531.s83|58-59|of|O
DDI-DrugBank.d531.s83|61-70|amprenavir|O
DDI-DrugBank.d531.s83|71-71|.|O
DDI-DrugBank.d531.s84|0-13|Non-nucleoside|O
DDI-DrugBank.d531.s84|15-21|reverse|O
DDI-DrugBank.d531.s84|23-35|transcriptase|O
DDI-DrugBank.d531.s84|37-46|inhibitors|O
DDI-DrugBank.d531.s85|0-1|No|O
DDI-DrugBank.d531.s85|3-9|studies|O
DDI-DrugBank.d531.s85|11-14|have|O
DDI-DrugBank.d531.s85|16-19|been|O
DDI-DrugBank.d531.s85|21-29|performed|O
DDI-DrugBank.d531.s85|31-34|with|O
DDI-DrugBank.d531.s85|36-40|other|O
DDI-DrugBank.d531.s85|42-47|NNRTIs|O
DDI-DrugBank.d531.s85|48-48|.|O
DDI-DrugBank.d531.s86|0-2|St.|O
DDI-DrugBank.d531.s86|4-7|John|O
DDI-DrugBank.d531.s86|9-9|s|O
DDI-DrugBank.d531.s86|11-14|wort|O
DDI-DrugBank.d531.s86|16-16|(|O
DDI-DrugBank.d531.s86|17-25|Hypericum|O
DDI-DrugBank.d531.s86|27-36|perforatum|O
DDI-DrugBank.d531.s86|37-37|)|O
DDI-DrugBank.d531.s87|0-7|Expected|O
DDI-DrugBank.d531.s87|9-10|to|O
DDI-DrugBank.d531.s87|12-24|substantially|O
DDI-DrugBank.d531.s87|26-33|decrease|O
DDI-DrugBank.d531.s87|35-40|plasma|O
DDI-DrugBank.d531.s87|42-47|levels|O
DDI-DrugBank.d531.s87|49-50|of|O
DDI-DrugBank.d531.s87|52-60|efavirenz|O
DDI-DrugBank.d531.s87|61-61|;|O
DDI-DrugBank.d531.s87|62-64|has|O
DDI-DrugBank.d531.s87|66-68|not|O
DDI-DrugBank.d531.s87|70-73|been|O
DDI-DrugBank.d531.s87|75-81|studied|O
DDI-DrugBank.d531.s87|83-84|in|O
DDI-DrugBank.d531.s87|86-96|combination|O
DDI-DrugBank.d531.s87|98-101|with|O
DDI-DrugBank.d531.s87|103-109|SUSTIVA|O
DDI-DrugBank.d531.s87|110-110|.|O
DDI-DrugBank.d531.s88|0-0|a|O
DDI-DrugBank.d531.s88|2-4|See|O
DDI-DrugBank.d531.s88|6-11|Tables|O
DDI-DrugBank.d531.s88|13-13|1|O
DDI-DrugBank.d531.s88|15-17|and|O
DDI-DrugBank.d531.s88|19-19|2|O
DDI-DrugBank.d531.s88|20-20|.|O
DDI-DrugBank.d531.s89|0-0|b|O
DDI-DrugBank.d531.s89|2-5|This|O
DDI-DrugBank.d531.s89|7-11|table|O
DDI-DrugBank.d531.s89|13-14|is|O
DDI-DrugBank.d531.s89|16-18|not|O
DDI-DrugBank.d531.s89|20-32|all-inclusive|O
DDI-DrugBank.d531.s89|33-33|.|O
DDI-DrugBank.d531.s90|0-4|Other|O
DDI-DrugBank.d531.s90|6-10|Drugs|O
DDI-DrugBank.d531.s90|11-11|:|O
DDI-DrugBank.d531.s90|13-17|Based|O
DDI-DrugBank.d531.s90|19-20|on|O
DDI-DrugBank.d531.s90|22-24|the|O
DDI-DrugBank.d531.s90|26-32|results|O
DDI-DrugBank.d531.s90|34-35|of|O
DDI-DrugBank.d531.s90|37-40|drug|O
DDI-DrugBank.d531.s90|42-52|interaction|O
DDI-DrugBank.d531.s90|54-60|studies|O
DDI-DrugBank.d531.s90|61-61|,|O
DDI-DrugBank.d531.s90|63-64|no|O
DDI-DrugBank.d531.s90|66-71|dosage|O
DDI-DrugBank.d531.s90|73-82|adjustment|O
DDI-DrugBank.d531.s90|84-85|is|O
DDI-DrugBank.d531.s90|87-97|recommended|O
DDI-DrugBank.d531.s90|99-102|when|O
DDI-DrugBank.d531.s90|104-110|SUSTIVA|O
DDI-DrugBank.d531.s90|112-112|(|O
DDI-DrugBank.d531.s90|113-121|efavirenz|O
DDI-DrugBank.d531.s90|122-122|)|O
DDI-DrugBank.d531.s90|124-125|is|O
DDI-DrugBank.d531.s90|127-131|given|O
DDI-DrugBank.d531.s90|133-136|with|O
DDI-DrugBank.d531.s90|138-140|the|O
DDI-DrugBank.d531.s90|142-150|following|O
DDI-DrugBank.d531.s90|151-151|:|O
DDI-DrugBank.d531.s90|153-170|aluminum/magnesium|O
DDI-DrugBank.d531.s90|172-180|hydroxide|O
DDI-DrugBank.d531.s90|182-189|antacids|O
DDI-DrugBank.d531.s90|190-190|,|O
DDI-DrugBank.d531.s90|192-203|azithromycin|O
DDI-DrugBank.d531.s90|204-204|,|O
DDI-DrugBank.d531.s90|206-215|cetirizine|O
DDI-DrugBank.d531.s90|216-216|,|O
DDI-DrugBank.d531.s90|218-227|famotidine|O
DDI-DrugBank.d531.s90|228-228|,|O
DDI-DrugBank.d531.s90|230-240|fluconazole|O
DDI-DrugBank.d531.s90|241-241|,|O
DDI-DrugBank.d531.s90|243-252|lamivudine|O
DDI-DrugBank.d531.s90|253-253|,|O
DDI-DrugBank.d531.s90|255-263|lorazepam|O
DDI-DrugBank.d531.s90|264-264|,|O
DDI-DrugBank.d531.s90|266-275|nelfinavir|O
DDI-DrugBank.d531.s90|276-276|,|O
DDI-DrugBank.d531.s90|278-287|paroxetine|O
DDI-DrugBank.d531.s90|288-288|,|O
DDI-DrugBank.d531.s90|290-292|and|O
DDI-DrugBank.d531.s90|294-303|zidovudine|O
DDI-DrugBank.d531.s90|304-304|.|O
DDI-DrugBank.d531.s91|0-7|Specific|O
DDI-DrugBank.d531.s91|9-12|drug|O
DDI-DrugBank.d531.s91|14-24|interaction|O
DDI-DrugBank.d531.s91|26-32|studies|O
DDI-DrugBank.d531.s91|34-37|have|O
DDI-DrugBank.d531.s91|39-41|not|O
DDI-DrugBank.d531.s91|43-46|been|O
DDI-DrugBank.d531.s91|48-56|performed|O
DDI-DrugBank.d531.s91|58-61|with|O
DDI-DrugBank.d531.s91|63-69|SUSTIVA|O
DDI-DrugBank.d531.s91|71-73|and|O
DDI-DrugBank.d531.s91|75-79|NRTIs|O
DDI-DrugBank.d531.s91|81-85|other|O
DDI-DrugBank.d531.s91|87-90|than|O
DDI-DrugBank.d531.s91|92-101|lamivudine|O
DDI-DrugBank.d531.s91|103-105|and|O
DDI-DrugBank.d531.s91|107-116|zidovudine|O
DDI-DrugBank.d531.s91|117-117|.|O
DDI-DrugBank.d531.s92|0-9|Clinically|O
DDI-DrugBank.d531.s92|11-21|significant|O
DDI-DrugBank.d531.s92|23-34|interactions|O
DDI-DrugBank.d531.s92|36-40|would|O
DDI-DrugBank.d531.s92|42-44|not|O
DDI-DrugBank.d531.s92|46-47|be|O
DDI-DrugBank.d531.s92|49-56|expected|O
DDI-DrugBank.d531.s92|58-62|since|O
DDI-DrugBank.d531.s92|64-66|the|O
DDI-DrugBank.d531.s92|68-72|NRTIs|O
DDI-DrugBank.d531.s92|74-76|are|O
DDI-DrugBank.d531.s92|78-88|metabolized|O
DDI-DrugBank.d531.s92|90-92|via|O
DDI-DrugBank.d531.s92|94-94|a|O
DDI-DrugBank.d531.s92|96-104|different|O
DDI-DrugBank.d531.s92|106-110|route|O
DDI-DrugBank.d531.s92|112-115|than|O
DDI-DrugBank.d531.s92|117-125|efavirenz|O
DDI-DrugBank.d531.s92|127-129|and|O
DDI-DrugBank.d531.s92|131-135|would|O
DDI-DrugBank.d531.s92|137-138|be|O
DDI-DrugBank.d531.s92|140-147|unlikely|O
DDI-DrugBank.d531.s92|149-150|to|O
DDI-DrugBank.d531.s92|152-158|compete|O
DDI-DrugBank.d531.s92|160-162|for|O
DDI-DrugBank.d531.s92|164-166|the|O
DDI-DrugBank.d531.s92|168-171|same|O
DDI-DrugBank.d531.s92|173-181|metabolic|O
DDI-DrugBank.d531.s92|183-189|enzymes|O
DDI-DrugBank.d531.s92|191-193|and|O
DDI-DrugBank.d531.s92|195-205|elimination|O
DDI-DrugBank.d531.s92|207-214|pathways|O
DDI-DrugBank.d531.s92|215-215|.|O
DDI-DrugBank.d395.s0|0-6|Bismuth|O
DDI-DrugBank.d395.s0|7-7|:|O
DDI-DrugBank.d395.s0|9-15|Bismuth|O
DDI-DrugBank.d395.s0|17-29|subsalicylate|O
DDI-DrugBank.d395.s0|30-30|,|O
DDI-DrugBank.d395.s0|32-36|given|O
DDI-DrugBank.d395.s0|38-50|concomitantly|O
DDI-DrugBank.d395.s0|52-55|with|O
DDI-DrugBank.d395.s0|57-64|enoxacin|O
DDI-DrugBank.d395.s0|66-67|or|O
DDI-DrugBank.d395.s0|69-70|60|O
DDI-DrugBank.d395.s0|72-78|minutes|O
DDI-DrugBank.d395.s0|80-88|following|O
DDI-DrugBank.d395.s0|90-97|enoxacin|O
DDI-DrugBank.d395.s0|99-112|administration|O
DDI-DrugBank.d395.s0|113-113|,|O
DDI-DrugBank.d395.s0|115-123|decreased|O
DDI-DrugBank.d395.s0|125-132|enoxacin|O
DDI-DrugBank.d395.s0|134-148|bioavailability|O
DDI-DrugBank.d395.s0|150-151|by|O
DDI-DrugBank.d395.s0|153-165|approximately|O
DDI-DrugBank.d395.s0|167-168|25|O
DDI-DrugBank.d395.s0|169-169|%|O
DDI-DrugBank.d395.s0|170-170|.|O
DDI-DrugBank.d395.s1|0-3|Thus|O
DDI-DrugBank.d395.s1|4-4|,|O
DDI-DrugBank.d395.s1|6-16|concomitant|O
DDI-DrugBank.d395.s1|18-31|administration|O
DDI-DrugBank.d395.s1|33-34|of|O
DDI-DrugBank.d395.s1|36-43|enoxacin|O
DDI-DrugBank.d395.s1|45-47|and|O
DDI-DrugBank.d395.s1|49-55|bismuth|O
DDI-DrugBank.d395.s1|57-69|subsalicylate|O
DDI-DrugBank.d395.s1|71-76|should|O
DDI-DrugBank.d395.s1|78-79|be|O
DDI-DrugBank.d395.s1|81-87|avoided|O
DDI-DrugBank.d395.s1|88-88|.|O
DDI-DrugBank.d395.s2|0-7|Caffeine|O
DDI-DrugBank.d395.s2|8-8|:|O
DDI-DrugBank.d395.s2|10-17|Enoxacin|O
DDI-DrugBank.d395.s2|19-20|is|O
DDI-DrugBank.d395.s2|22-22|a|O
DDI-DrugBank.d395.s2|24-29|potent|O
DDI-DrugBank.d395.s2|31-39|inhibitor|O
DDI-DrugBank.d395.s2|41-42|of|O
DDI-DrugBank.d395.s2|44-46|the|O
DDI-DrugBank.d395.s2|48-57|cytochrome|O
DDI-DrugBank.d395.s2|59-63|P-450|O
DDI-DrugBank.d395.s2|65-72|isozymes|O
DDI-DrugBank.d395.s2|74-84|responsible|O
DDI-DrugBank.d395.s2|86-88|for|O
DDI-DrugBank.d395.s2|90-92|the|O
DDI-DrugBank.d395.s2|94-103|metabolism|O
DDI-DrugBank.d395.s2|105-106|of|O
DDI-DrugBank.d395.s2|108-122|methylxanthines|O
DDI-DrugBank.d395.s2|123-123|.|O
DDI-DrugBank.d395.s3|0-1|In|O
DDI-DrugBank.d395.s3|3-3|a|O
DDI-DrugBank.d395.s3|5-17|multiple-dose|O
DDI-DrugBank.d395.s3|19-23|study|O
DDI-DrugBank.d395.s3|24-24|,|O
DDI-DrugBank.d395.s3|26-33|enoxacin|O
DDI-DrugBank.d395.s3|35-40|caused|O
DDI-DrugBank.d395.s3|42-42|a|O
DDI-DrugBank.d395.s3|44-55|dose-related|O
DDI-DrugBank.d395.s3|57-64|increase|O
DDI-DrugBank.d395.s3|66-67|in|O
DDI-DrugBank.d395.s3|69-71|the|O
DDI-DrugBank.d395.s3|73-76|mean|O
DDI-DrugBank.d395.s3|78-88|elimination|O
DDI-DrugBank.d395.s3|90-98|half-life|O
DDI-DrugBank.d395.s3|100-101|of|O
DDI-DrugBank.d395.s3|103-110|caffeine|O
DDI-DrugBank.d395.s3|111-111|,|O
DDI-DrugBank.d395.s3|113-119|thereby|O
DDI-DrugBank.d395.s3|121-130|decreasing|O
DDI-DrugBank.d395.s3|132-134|the|O
DDI-DrugBank.d395.s3|136-144|clearance|O
DDI-DrugBank.d395.s3|146-147|of|O
DDI-DrugBank.d395.s3|149-156|caffeine|O
DDI-DrugBank.d395.s3|158-159|by|O
DDI-DrugBank.d395.s3|161-162|up|O
DDI-DrugBank.d395.s3|164-165|to|O
DDI-DrugBank.d395.s3|167-168|80|O
DDI-DrugBank.d395.s3|169-169|%|O
DDI-DrugBank.d395.s3|171-173|and|O
DDI-DrugBank.d395.s3|175-181|leading|O
DDI-DrugBank.d395.s3|183-184|to|O
DDI-DrugBank.d395.s3|186-186|a|O
DDI-DrugBank.d395.s3|188-196|five-fold|O
DDI-DrugBank.d395.s3|198-205|increase|O
DDI-DrugBank.d395.s3|207-208|in|O
DDI-DrugBank.d395.s3|210-212|the|O
DDI-DrugBank.d395.s3|214-216|AUC|O
DDI-DrugBank.d395.s3|218-220|and|O
DDI-DrugBank.d395.s3|222-224|the|O
DDI-DrugBank.d395.s3|226-234|half-life|O
DDI-DrugBank.d395.s3|236-237|of|O
DDI-DrugBank.d395.s3|239-246|caffeine|O
DDI-DrugBank.d395.s3|247-247|.|O
DDI-DrugBank.d395.s4|0-5|Trough|O
DDI-DrugBank.d395.s4|7-12|plasma|O
DDI-DrugBank.d395.s4|14-21|enoxacin|O
DDI-DrugBank.d395.s4|23-28|levels|O
DDI-DrugBank.d395.s4|30-33|were|O
DDI-DrugBank.d395.s4|35-38|also|O
DDI-DrugBank.d395.s4|40-41|20|O
DDI-DrugBank.d395.s4|42-42|%|O
DDI-DrugBank.d395.s4|44-49|higher|O
DDI-DrugBank.d395.s4|51-54|when|O
DDI-DrugBank.d395.s4|56-63|caffeine|O
DDI-DrugBank.d395.s4|65-67|and|O
DDI-DrugBank.d395.s4|69-76|enoxacin|O
DDI-DrugBank.d395.s4|78-81|were|O
DDI-DrugBank.d395.s4|83-94|administered|O
DDI-DrugBank.d395.s4|96-108|concomitantly|O
DDI-DrugBank.d395.s4|109-109|.|O
DDI-DrugBank.d395.s5|0-15|Caffeine-related|O
DDI-DrugBank.d395.s5|17-23|adverse|O
DDI-DrugBank.d395.s5|25-31|effects|O
DDI-DrugBank.d395.s5|33-36|have|O
DDI-DrugBank.d395.s5|38-45|occurred|O
DDI-DrugBank.d395.s5|47-48|in|O
DDI-DrugBank.d395.s5|50-57|patients|O
DDI-DrugBank.d395.s5|59-67|consuming|O
DDI-DrugBank.d395.s5|69-76|caffeine|O
DDI-DrugBank.d395.s5|78-82|while|O
DDI-DrugBank.d395.s5|84-85|on|O
DDI-DrugBank.d395.s5|87-93|therapy|O
DDI-DrugBank.d395.s5|95-98|with|O
DDI-DrugBank.d395.s5|100-107|enoxacin|O
DDI-DrugBank.d395.s5|108-108|.|O
DDI-DrugBank.d395.s6|0-11|Cyclosporine|O
DDI-DrugBank.d395.s6|12-12|:|O
DDI-DrugBank.d395.s6|14-21|Elevated|O
DDI-DrugBank.d395.s6|23-27|serum|O
DDI-DrugBank.d395.s6|29-34|levels|O
DDI-DrugBank.d395.s6|36-37|of|O
DDI-DrugBank.d395.s6|39-50|cyclosporine|O
DDI-DrugBank.d395.s6|52-55|have|O
DDI-DrugBank.d395.s6|57-60|been|O
DDI-DrugBank.d395.s6|62-69|reported|O
DDI-DrugBank.d395.s6|71-74|with|O
DDI-DrugBank.d395.s6|76-86|concomitant|O
DDI-DrugBank.d395.s6|88-90|use|O
DDI-DrugBank.d395.s6|92-93|of|O
DDI-DrugBank.d395.s6|95-106|cyclosporine|O
DDI-DrugBank.d395.s6|108-111|with|O
DDI-DrugBank.d395.s6|113-117|other|O
DDI-DrugBank.d395.s6|119-125|members|O
DDI-DrugBank.d395.s6|127-128|of|O
DDI-DrugBank.d395.s6|130-132|the|O
DDI-DrugBank.d395.s6|134-142|quinolone|O
DDI-DrugBank.d395.s6|144-148|class|O
DDI-DrugBank.d395.s6|149-149|.|O
DDI-DrugBank.d395.s7|0-6|Digoxin|O
DDI-DrugBank.d395.s7|7-7|:|O
DDI-DrugBank.d395.s7|9-16|Enoxacin|O
DDI-DrugBank.d395.s7|18-20|may|O
DDI-DrugBank.d395.s7|22-26|raise|O
DDI-DrugBank.d395.s7|28-32|serum|O
DDI-DrugBank.d395.s7|34-40|digoxin|O
DDI-DrugBank.d395.s7|42-47|levels|O
DDI-DrugBank.d395.s7|49-50|in|O
DDI-DrugBank.d395.s7|52-55|some|O
DDI-DrugBank.d395.s7|57-67|individuals|O
DDI-DrugBank.d395.s7|68-68|.|O
DDI-DrugBank.d395.s8|0-1|If|O
DDI-DrugBank.d395.s8|3-7|signs|O
DDI-DrugBank.d395.s8|9-11|and|O
DDI-DrugBank.d395.s8|13-20|symptoms|O
DDI-DrugBank.d395.s8|22-31|suggestive|O
DDI-DrugBank.d395.s8|33-34|of|O
DDI-DrugBank.d395.s8|36-42|digoxin|O
DDI-DrugBank.d395.s8|44-51|toxicity|O
DDI-DrugBank.d395.s8|53-57|occur|O
DDI-DrugBank.d395.s8|59-62|when|O
DDI-DrugBank.d395.s8|64-71|enoxacin|O
DDI-DrugBank.d395.s8|73-75|and|O
DDI-DrugBank.d395.s8|77-83|digoxin|O
DDI-DrugBank.d395.s8|85-87|are|O
DDI-DrugBank.d395.s8|89-93|given|O
DDI-DrugBank.d395.s8|95-107|concomitantly|O
DDI-DrugBank.d395.s8|108-108|,|O
DDI-DrugBank.d395.s8|110-119|physicians|O
DDI-DrugBank.d395.s8|121-123|are|O
DDI-DrugBank.d395.s8|125-131|advised|O
DDI-DrugBank.d395.s8|133-134|to|O
DDI-DrugBank.d395.s8|136-141|obtain|O
DDI-DrugBank.d395.s8|143-147|serum|O
DDI-DrugBank.d395.s8|149-155|digoxin|O
DDI-DrugBank.d395.s8|157-162|levels|O
DDI-DrugBank.d395.s8|164-166|and|O
DDI-DrugBank.d395.s8|168-173|adjust|O
DDI-DrugBank.d395.s8|175-181|digoxin|O
DDI-DrugBank.d395.s8|183-187|doses|O
DDI-DrugBank.d395.s8|189-201|appropriately|O
DDI-DrugBank.d395.s8|202-202|.|O
DDI-DrugBank.d395.s9|0-12|Non-steroidal|O
DDI-DrugBank.d395.s9|14-30|anti-inflammatory|O
DDI-DrugBank.d395.s9|32-37|agents|O
DDI-DrugBank.d395.s9|38-38|:|O
DDI-DrugBank.d395.s9|40-47|Seizures|O
DDI-DrugBank.d395.s9|49-52|have|O
DDI-DrugBank.d395.s9|54-57|been|O
DDI-DrugBank.d395.s9|59-66|reported|O
DDI-DrugBank.d395.s9|68-69|in|O
DDI-DrugBank.d395.s9|71-78|patients|O
DDI-DrugBank.d395.s9|80-85|taking|O
DDI-DrugBank.d395.s9|87-94|enoxacin|O
DDI-DrugBank.d395.s9|96-108|concomitantly|O
DDI-DrugBank.d395.s9|110-113|with|O
DDI-DrugBank.d395.s9|115-117|the|O
DDI-DrugBank.d395.s9|119-130|nonsteroidal|O
DDI-DrugBank.d395.s9|132-148|anti-inflammatory|O
DDI-DrugBank.d395.s9|150-153|drug|O
DDI-DrugBank.d395.s9|155-162|fenbufen|O
DDI-DrugBank.d395.s9|163-163|.|O
DDI-DrugBank.d395.s10|0-5|Animal|O
DDI-DrugBank.d395.s10|7-13|studies|O
DDI-DrugBank.d395.s10|15-18|also|O
DDI-DrugBank.d395.s10|20-26|suggest|O
DDI-DrugBank.d395.s10|28-29|an|O
DDI-DrugBank.d395.s10|31-39|increased|O
DDI-DrugBank.d395.s10|41-49|potential|O
DDI-DrugBank.d395.s10|51-53|for|O
DDI-DrugBank.d395.s10|55-62|seizures|O
DDI-DrugBank.d395.s10|64-67|when|O
DDI-DrugBank.d395.s10|69-73|these|O
DDI-DrugBank.d395.s10|75-77|two|O
DDI-DrugBank.d395.s10|79-83|drugs|O
DDI-DrugBank.d395.s10|85-87|are|O
DDI-DrugBank.d395.s10|89-93|given|O
DDI-DrugBank.d395.s10|95-107|concomitantly|O
DDI-DrugBank.d395.s10|108-108|.|O
DDI-DrugBank.d395.s11|0-7|Fenbufen|O
DDI-DrugBank.d395.s11|9-10|is|O
DDI-DrugBank.d395.s11|12-14|not|O
DDI-DrugBank.d395.s11|16-23|approved|O
DDI-DrugBank.d395.s11|25-26|in|O
DDI-DrugBank.d395.s11|28-30|the|O
DDI-DrugBank.d395.s11|32-37|United|O
DDI-DrugBank.d395.s11|39-44|States|O
DDI-DrugBank.d395.s11|46-47|at|O
DDI-DrugBank.d395.s11|49-52|this|O
DDI-DrugBank.d395.s11|54-57|time|O
DDI-DrugBank.d395.s11|58-58|.|O
DDI-DrugBank.d395.s12|0-9|Sucralfate|O
DDI-DrugBank.d395.s12|11-13|and|O
DDI-DrugBank.d395.s12|15-22|antacids|O
DDI-DrugBank.d395.s12|23-23|:|O
DDI-DrugBank.d395.s12|25-34|Quinolones|O
DDI-DrugBank.d395.s12|36-39|form|O
DDI-DrugBank.d395.s12|41-48|chelates|O
DDI-DrugBank.d395.s12|50-53|with|O
DDI-DrugBank.d395.s12|55-59|metal|O
DDI-DrugBank.d395.s12|61-67|cations|O
DDI-DrugBank.d395.s12|68-68|.|O
DDI-DrugBank.d395.s13|0-8|Therefore|O
DDI-DrugBank.d395.s13|9-9|,|O
DDI-DrugBank.d395.s13|11-24|administration|O
DDI-DrugBank.d395.s13|26-27|of|O
DDI-DrugBank.d395.s13|29-38|quinolones|O
DDI-DrugBank.d395.s13|40-43|with|O
DDI-DrugBank.d395.s13|45-52|antacids|O
DDI-DrugBank.d395.s13|54-63|containing|O
DDI-DrugBank.d395.s13|65-71|calcium|O
DDI-DrugBank.d395.s13|72-72|,|O
DDI-DrugBank.d395.s13|74-82|magnesium|O
DDI-DrugBank.d395.s13|83-83|,|O
DDI-DrugBank.d395.s13|85-86|or|O
DDI-DrugBank.d395.s13|88-95|aluminum|O
DDI-DrugBank.d395.s13|96-96|;|O
DDI-DrugBank.d395.s14|0-3|with|O
DDI-DrugBank.d395.s14|5-14|sucralfate|O
DDI-DrugBank.d395.s14|15-15|;|O
DDI-DrugBank.d395.s15|0-3|with|O
DDI-DrugBank.d395.s15|5-12|divalent|O
DDI-DrugBank.d395.s15|14-15|or|O
DDI-DrugBank.d395.s15|17-25|trivalent|O
DDI-DrugBank.d395.s15|27-33|cations|O
DDI-DrugBank.d395.s15|35-38|such|O
DDI-DrugBank.d395.s15|40-41|as|O
DDI-DrugBank.d395.s15|43-46|iron|O
DDI-DrugBank.d395.s15|47-47|;|O
DDI-DrugBank.d395.s16|0-1|or|O
DDI-DrugBank.d395.s16|3-6|with|O
DDI-DrugBank.d395.s16|8-20|multivitamins|O
DDI-DrugBank.d395.s16|22-31|containing|O
DDI-DrugBank.d395.s16|33-36|zinc|O
DDI-DrugBank.d395.s16|38-40|may|O
DDI-DrugBank.d395.s16|42-54|substantially|O
DDI-DrugBank.d395.s16|56-64|interfere|O
DDI-DrugBank.d395.s16|66-69|with|O
DDI-DrugBank.d395.s16|71-74|drug|O
DDI-DrugBank.d395.s16|76-85|absorption|O
DDI-DrugBank.d395.s16|87-89|and|O
DDI-DrugBank.d395.s16|91-96|result|O
DDI-DrugBank.d395.s16|98-99|in|O
DDI-DrugBank.d395.s16|101-112|insufficient|O
DDI-DrugBank.d395.s16|114-119|plasma|O
DDI-DrugBank.d395.s16|121-123|and|O
DDI-DrugBank.d395.s16|125-130|tissue|O
DDI-DrugBank.d395.s16|132-140|quinolone|O
DDI-DrugBank.d395.s16|142-155|concentrations|O
DDI-DrugBank.d395.s16|156-156|.|O
DDI-DrugBank.d395.s17|0-7|Antacids|O
DDI-DrugBank.d395.s17|9-18|containing|O
DDI-DrugBank.d395.s17|20-27|aluminum|O
DDI-DrugBank.d395.s17|29-37|hydroxide|O
DDI-DrugBank.d395.s17|39-41|and|O
DDI-DrugBank.d395.s17|43-51|magnesium|O
DDI-DrugBank.d395.s17|53-61|hydroxide|O
DDI-DrugBank.d395.s17|63-68|reduce|O
DDI-DrugBank.d395.s17|70-72|the|O
DDI-DrugBank.d395.s17|74-77|oral|O
DDI-DrugBank.d395.s17|79-88|absorption|O
DDI-DrugBank.d395.s17|90-91|of|O
DDI-DrugBank.d395.s17|93-100|enoxacin|O
DDI-DrugBank.d395.s17|102-103|by|O
DDI-DrugBank.d395.s17|105-106|75|O
DDI-DrugBank.d395.s17|107-107|%|O
DDI-DrugBank.d395.s17|108-108|.|O
DDI-DrugBank.d395.s18|0-2|The|O
DDI-DrugBank.d395.s18|4-7|oral|O
DDI-DrugBank.d395.s18|9-23|bioavailability|O
DDI-DrugBank.d395.s18|25-26|of|O
DDI-DrugBank.d395.s18|28-35|enoxacin|O
DDI-DrugBank.d395.s18|37-38|is|O
DDI-DrugBank.d395.s18|40-46|reduced|O
DDI-DrugBank.d395.s18|48-49|by|O
DDI-DrugBank.d395.s18|51-52|60|O
DDI-DrugBank.d395.s18|53-53|%|O
DDI-DrugBank.d395.s18|55-58|with|O
DDI-DrugBank.d395.s18|60-75|coadministration|O
DDI-DrugBank.d395.s18|77-78|of|O
DDI-DrugBank.d395.s18|80-89|ranitidine|O
DDI-DrugBank.d395.s18|90-90|.|O
DDI-DrugBank.d395.s19|0-4|These|O
DDI-DrugBank.d395.s19|6-11|agents|O
DDI-DrugBank.d395.s19|13-18|should|O
DDI-DrugBank.d395.s19|20-22|not|O
DDI-DrugBank.d395.s19|24-25|be|O
DDI-DrugBank.d395.s19|27-31|taken|O
DDI-DrugBank.d395.s19|33-35|for|O
DDI-DrugBank.d395.s19|37-37|8|O
DDI-DrugBank.d395.s19|39-43|hours|O
DDI-DrugBank.d395.s19|45-50|before|O
DDI-DrugBank.d395.s19|52-53|or|O
DDI-DrugBank.d395.s19|55-57|for|O
DDI-DrugBank.d395.s19|59-59|2|O
DDI-DrugBank.d395.s19|61-65|hours|O
DDI-DrugBank.d395.s19|67-71|after|O
DDI-DrugBank.d395.s19|73-80|enoxacin|O
DDI-DrugBank.d395.s19|82-95|administration|O
DDI-DrugBank.d395.s19|96-96|.|O
DDI-DrugBank.d395.s20|0-11|Theophylline|O
DDI-DrugBank.d395.s20|12-12|:|O
DDI-DrugBank.d395.s20|14-21|Enoxacin|O
DDI-DrugBank.d395.s20|23-24|is|O
DDI-DrugBank.d395.s20|26-26|a|O
DDI-DrugBank.d395.s20|28-33|potent|O
DDI-DrugBank.d395.s20|35-43|inhibitor|O
DDI-DrugBank.d395.s20|45-46|of|O
DDI-DrugBank.d395.s20|48-50|the|O
DDI-DrugBank.d395.s20|52-61|cytochrome|O
DDI-DrugBank.d395.s20|63-67|P-450|O
DDI-DrugBank.d395.s20|69-76|isozymes|O
DDI-DrugBank.d395.s20|78-88|responsible|O
DDI-DrugBank.d395.s20|90-92|for|O
DDI-DrugBank.d395.s20|94-96|the|O
DDI-DrugBank.d395.s20|98-107|metabolism|O
DDI-DrugBank.d395.s20|109-110|of|O
DDI-DrugBank.d395.s20|112-126|methylxanthines|O
DDI-DrugBank.d395.s20|127-127|.|O
DDI-DrugBank.d395.s21|0-7|Enoxacin|O
DDI-DrugBank.d395.s21|9-18|interferes|O
DDI-DrugBank.d395.s21|20-23|with|O
DDI-DrugBank.d395.s21|25-27|the|O
DDI-DrugBank.d395.s21|29-38|metabolism|O
DDI-DrugBank.d395.s21|40-41|of|O
DDI-DrugBank.d395.s21|43-54|theophylline|O
DDI-DrugBank.d395.s21|56-64|resulting|O
DDI-DrugBank.d395.s21|66-67|in|O
DDI-DrugBank.d395.s21|69-69|a|O
DDI-DrugBank.d395.s21|71-72|42|O
DDI-DrugBank.d395.s21|73-73|%|O
DDI-DrugBank.d395.s21|75-76|to|O
DDI-DrugBank.d395.s21|78-79|74|O
DDI-DrugBank.d395.s21|80-80|%|O
DDI-DrugBank.d395.s21|82-93|dose-related|O
DDI-DrugBank.d395.s21|95-102|decrease|O
DDI-DrugBank.d395.s21|104-105|in|O
DDI-DrugBank.d395.s21|107-118|theophylline|O
DDI-DrugBank.d395.s21|120-128|clearance|O
DDI-DrugBank.d395.s21|130-132|and|O
DDI-DrugBank.d395.s21|134-134|a|O
DDI-DrugBank.d395.s21|136-145|subsequent|O
DDI-DrugBank.d395.s21|147-149|260|O
DDI-DrugBank.d395.s21|150-150|%|O
DDI-DrugBank.d395.s21|152-153|to|O
DDI-DrugBank.d395.s21|155-157|350|O
DDI-DrugBank.d395.s21|158-158|%|O
DDI-DrugBank.d395.s21|160-167|increase|O
DDI-DrugBank.d395.s21|169-170|in|O
DDI-DrugBank.d395.s21|172-176|serum|O
DDI-DrugBank.d395.s21|178-189|theophylline|O
DDI-DrugBank.d395.s21|191-196|levels|O
DDI-DrugBank.d395.s21|197-197|.|O
DDI-DrugBank.d395.s22|0-19|Theophylline-related|O
DDI-DrugBank.d395.s22|21-27|adverse|O
DDI-DrugBank.d395.s22|29-35|effects|O
DDI-DrugBank.d395.s22|37-40|have|O
DDI-DrugBank.d395.s22|42-49|occurred|O
DDI-DrugBank.d395.s22|51-52|in|O
DDI-DrugBank.d395.s22|54-61|patients|O
DDI-DrugBank.d395.s22|63-66|when|O
DDI-DrugBank.d395.s22|68-79|theophylline|O
DDI-DrugBank.d395.s22|81-83|and|O
DDI-DrugBank.d395.s22|85-92|enoxacin|O
DDI-DrugBank.d395.s22|94-97|were|O
DDI-DrugBank.d395.s22|99-112|coadministered|O
DDI-DrugBank.d395.s22|113-113|.|O
DDI-DrugBank.d395.s23|0-7|Warfarin|O
DDI-DrugBank.d395.s23|8-8|:|O
DDI-DrugBank.d395.s23|10-19|Quinolones|O
DDI-DrugBank.d395.s23|20-20|,|O
DDI-DrugBank.d395.s23|22-30|including|O
DDI-DrugBank.d395.s23|32-39|enoxacin|O
DDI-DrugBank.d395.s23|40-40|,|O
DDI-DrugBank.d395.s23|42-49|decrease|O
DDI-DrugBank.d395.s23|51-53|the|O
DDI-DrugBank.d395.s23|55-63|clearance|O
DDI-DrugBank.d395.s23|65-66|of|O
DDI-DrugBank.d395.s23|68-77|R-warfarin|O
DDI-DrugBank.d395.s23|78-78|,|O
DDI-DrugBank.d395.s23|80-82|the|O
DDI-DrugBank.d395.s23|84-87|less|O
DDI-DrugBank.d395.s23|89-94|active|O
DDI-DrugBank.d395.s23|96-101|isomer|O
DDI-DrugBank.d395.s23|103-104|of|O
DDI-DrugBank.d395.s23|106-112|racemic|O
DDI-DrugBank.d395.s23|114-121|warfarin|O
DDI-DrugBank.d395.s23|122-122|.|O
DDI-DrugBank.d395.s24|0-7|Enoxacin|O
DDI-DrugBank.d395.s24|9-12|does|O
DDI-DrugBank.d395.s24|14-16|not|O
DDI-DrugBank.d395.s24|18-23|affect|O
DDI-DrugBank.d395.s24|25-27|the|O
DDI-DrugBank.d395.s24|29-37|clearance|O
DDI-DrugBank.d395.s24|39-40|of|O
DDI-DrugBank.d395.s24|42-44|the|O
DDI-DrugBank.d395.s24|46-51|active|O
DDI-DrugBank.d395.s24|53-60|S-isomer|O
DDI-DrugBank.d395.s24|61-61|,|O
DDI-DrugBank.d395.s24|63-65|and|O
DDI-DrugBank.d395.s24|67-73|changes|O
DDI-DrugBank.d395.s24|75-76|in|O
DDI-DrugBank.d395.s24|78-85|clotting|O
DDI-DrugBank.d395.s24|87-90|time|O
DDI-DrugBank.d395.s24|92-95|have|O
DDI-DrugBank.d395.s24|97-99|not|O
DDI-DrugBank.d395.s24|101-104|been|O
DDI-DrugBank.d395.s24|106-113|observed|O
DDI-DrugBank.d395.s24|115-118|when|O
DDI-DrugBank.d395.s24|120-127|enoxacin|O
DDI-DrugBank.d395.s24|129-131|and|O
DDI-DrugBank.d395.s24|133-140|warfarin|O
DDI-DrugBank.d395.s24|142-145|were|O
DDI-DrugBank.d395.s24|147-160|coadministered|O
DDI-DrugBank.d395.s24|161-161|.|O
DDI-DrugBank.d395.s25|0-11|Nevertheless|O
DDI-DrugBank.d395.s25|12-12|,|O
DDI-DrugBank.d395.s25|14-16|the|O
DDI-DrugBank.d395.s25|18-28|prothrombin|O
DDI-DrugBank.d395.s25|30-33|time|O
DDI-DrugBank.d395.s25|35-36|or|O
DDI-DrugBank.d395.s25|38-42|other|O
DDI-DrugBank.d395.s25|44-51|suitable|O
DDI-DrugBank.d395.s25|53-63|coagulation|O
DDI-DrugBank.d395.s25|65-68|test|O
DDI-DrugBank.d395.s25|70-75|should|O
DDI-DrugBank.d395.s25|77-78|be|O
DDI-DrugBank.d395.s25|80-88|monitored|O
DDI-DrugBank.d395.s25|90-93|when|O
DDI-DrugBank.d395.s25|95-102|warfarin|O
DDI-DrugBank.d395.s25|104-105|or|O
DDI-DrugBank.d395.s25|107-109|its|O
DDI-DrugBank.d395.s25|111-121|derivatives|O
DDI-DrugBank.d395.s25|123-125|and|O
DDI-DrugBank.d395.s25|127-134|enoxacin|O
DDI-DrugBank.d395.s25|136-138|are|O
DDI-DrugBank.d395.s25|140-144|given|O
DDI-DrugBank.d395.s25|146-158|concomitantly|O
DDI-DrugBank.d395.s25|159-159|.|O
DDI-DrugBank.d723.s0|0-4|Other|O
DDI-DrugBank.d723.s0|6-8|eye|O
DDI-DrugBank.d723.s0|10-14|drops|O
DDI-DrugBank.d723.s0|16-17|or|O
DDI-DrugBank.d723.s0|19-29|medications|O
DDI-DrugBank.d723.s0|31-34|such|O
DDI-DrugBank.d723.s0|36-37|as|O
DDI-DrugBank.d723.s0|39-51|acetylcholine|O
DDI-DrugBank.d723.s0|53-60|chloride|O
DDI-DrugBank.d723.s0|62-62|(|O
DDI-DrugBank.d723.s0|63-69|Miochol|O
DDI-DrugBank.d723.s0|70-70|)|O
DDI-DrugBank.d723.s0|72-74|and|O
DDI-DrugBank.d723.s0|76-84|carbachol|O
DDI-DrugBank.d723.s0|86-86|(|O
DDI-DrugBank.d723.s0|87-95|Carboptic|O
DDI-DrugBank.d723.s0|96-96|,|O
DDI-DrugBank.d723.s0|98-103|Isopto|O
DDI-DrugBank.d723.s0|105-113|Carbachol|O
DDI-DrugBank.d723.s0|114-114|)|O
DDI-DrugBank.d723.s0|116-118|may|O
DDI-DrugBank.d723.s0|120-127|decrease|O
DDI-DrugBank.d723.s0|129-131|the|O
DDI-DrugBank.d723.s0|133-139|effects|O
DDI-DrugBank.d723.s0|141-142|of|O
DDI-DrugBank.d723.s0|144-151|suprofen|O
DDI-DrugBank.d723.s0|153-162|ophthalmic|O
DDI-DrugBank.d723.s0|163-163|.|O
DDI-DrugBank.d449.s0|0-16|Co-administration|O
DDI-DrugBank.d449.s0|18-21|with|O
DDI-DrugBank.d449.s0|23-32|antifungal|O
DDI-DrugBank.d449.s0|34-39|agents|O
DDI-DrugBank.d449.s0|41-44|such|O
DDI-DrugBank.d449.s0|46-47|as|O
DDI-DrugBank.d449.s0|49-60|ketoconazole|O
DDI-DrugBank.d449.s0|62-63|or|O
DDI-DrugBank.d449.s0|65-76|itraconazole|O
DDI-DrugBank.d449.s0|78-79|is|O
DDI-DrugBank.d449.s0|81-83|not|O
DDI-DrugBank.d449.s0|85-95|recommended|O
DDI-DrugBank.d449.s0|96-96|.|O
DDI-DrugBank.d449.s1|0-9|Nafazodone|O
DDI-DrugBank.d449.s1|10-10|,|O
DDI-DrugBank.d449.s1|12-22|fluvoxamine|O
DDI-DrugBank.d449.s1|23-23|,|O
DDI-DrugBank.d449.s1|25-34|cimetidine|O
DDI-DrugBank.d449.s1|36-36|(|O
DDI-DrugBank.d449.s1|37-44|consider|O
DDI-DrugBank.d449.s1|46-50|Xanax|O
DDI-DrugBank.d449.s1|52-55|dose|O
DDI-DrugBank.d449.s1|57-65|reduction|O
DDI-DrugBank.d449.s1|66-66|)|O
DDI-DrugBank.d449.s1|67-67|.|O
DDI-DrugBank.d449.s2|0-9|Fluoxetine|O
DDI-DrugBank.d449.s2|10-10|,|O
DDI-DrugBank.d449.s2|12-14|OCs|O
DDI-DrugBank.d449.s2|15-15|,|O
DDI-DrugBank.d449.s2|17-26|sertraline|O
DDI-DrugBank.d449.s2|27-27|,|O
DDI-DrugBank.d449.s2|29-37|diltiazem|O
DDI-DrugBank.d449.s2|38-38|,|O
DDI-DrugBank.d449.s2|40-48|macrolide|O
DDI-DrugBank.d449.s2|50-60|antibiotics|O
DDI-DrugBank.d449.s2|62-62|(|O
DDI-DrugBank.d449.s2|63-70|exercise|O
DDI-DrugBank.d449.s2|72-78|caution|O
DDI-DrugBank.d449.s2|79-79|)|O
DDI-DrugBank.d449.s2|80-80|.|O
DDI-DrugBank.d525.s0|0-9|Eprosartan|O
DDI-DrugBank.d525.s0|11-13|has|O
DDI-DrugBank.d525.s0|15-18|been|O
DDI-DrugBank.d525.s0|20-24|shown|O
DDI-DrugBank.d525.s0|26-27|to|O
DDI-DrugBank.d525.s0|29-32|have|O
DDI-DrugBank.d525.s0|34-35|no|O
DDI-DrugBank.d525.s0|37-42|effect|O
DDI-DrugBank.d525.s0|44-45|on|O
DDI-DrugBank.d525.s0|47-49|the|O
DDI-DrugBank.d525.s0|51-66|pharmacokinetics|O
DDI-DrugBank.d525.s0|68-69|of|O
DDI-DrugBank.d525.s0|71-77|digoxin|O
DDI-DrugBank.d525.s0|79-81|and|O
DDI-DrugBank.d525.s0|83-85|the|O
DDI-DrugBank.d525.s0|87-102|pharmacodynamics|O
DDI-DrugBank.d525.s0|104-105|of|O
DDI-DrugBank.d525.s0|107-114|warfarin|O
DDI-DrugBank.d525.s0|116-118|and|O
DDI-DrugBank.d525.s0|120-128|glyburide|O
DDI-DrugBank.d525.s0|129-129|.|O
DDI-DrugBank.d525.s1|0-3|Thus|O
DDI-DrugBank.d525.s1|5-6|no|O
DDI-DrugBank.d525.s1|8-13|dosing|O
DDI-DrugBank.d525.s1|15-25|adjustments|O
DDI-DrugBank.d525.s1|27-29|are|O
DDI-DrugBank.d525.s1|31-39|necessary|O
DDI-DrugBank.d525.s1|41-46|during|O
DDI-DrugBank.d525.s1|48-58|concomitant|O
DDI-DrugBank.d525.s1|60-62|use|O
DDI-DrugBank.d525.s1|64-67|with|O
DDI-DrugBank.d525.s1|69-73|these|O
DDI-DrugBank.d525.s1|75-80|agents|O
DDI-DrugBank.d525.s1|81-81|.|O
DDI-DrugBank.d525.s2|0-6|Because|O
DDI-DrugBank.d525.s2|8-17|eprosartan|O
DDI-DrugBank.d525.s2|19-20|is|O
DDI-DrugBank.d525.s2|22-24|not|O
DDI-DrugBank.d525.s2|26-36|metabolized|O
DDI-DrugBank.d525.s2|38-39|by|O
DDI-DrugBank.d525.s2|41-43|the|O
DDI-DrugBank.d525.s2|45-54|cytochrome|O
DDI-DrugBank.d525.s2|56-59|P450|O
DDI-DrugBank.d525.s2|61-66|system|O
DDI-DrugBank.d525.s2|67-67|,|O
DDI-DrugBank.d525.s2|69-78|inhibitors|O
DDI-DrugBank.d525.s2|80-81|of|O
DDI-DrugBank.d525.s2|83-88|CYP450|O
DDI-DrugBank.d525.s2|90-95|enzyme|O
DDI-DrugBank.d525.s2|97-101|would|O
DDI-DrugBank.d525.s2|103-105|not|O
DDI-DrugBank.d525.s2|107-108|be|O
DDI-DrugBank.d525.s2|110-117|expected|O
DDI-DrugBank.d525.s2|119-120|to|O
DDI-DrugBank.d525.s2|122-127|affect|O
DDI-DrugBank.d525.s2|129-131|its|O
DDI-DrugBank.d525.s2|133-142|metabolism|O
DDI-DrugBank.d525.s2|143-143|,|O
DDI-DrugBank.d525.s2|145-147|and|O
DDI-DrugBank.d525.s2|149-160|ketoconazole|O
DDI-DrugBank.d525.s2|162-164|and|O
DDI-DrugBank.d525.s2|166-176|fluconazole|O
DDI-DrugBank.d525.s2|177-177|,|O
DDI-DrugBank.d525.s2|179-184|potent|O
DDI-DrugBank.d525.s2|186-195|inhibitors|O
DDI-DrugBank.d525.s2|197-198|of|O
DDI-DrugBank.d525.s2|200-204|CYP3A|O
DDI-DrugBank.d525.s2|206-208|and|O
DDI-DrugBank.d525.s2|210-212|2C9|O
DDI-DrugBank.d525.s2|213-213|,|O
DDI-DrugBank.d525.s2|215-226|respectively|O
DDI-DrugBank.d525.s2|227-227|,|O
DDI-DrugBank.d525.s2|229-232|have|O
DDI-DrugBank.d525.s2|234-237|been|O
DDI-DrugBank.d525.s2|239-243|shown|O
DDI-DrugBank.d525.s2|245-246|to|O
DDI-DrugBank.d525.s2|248-251|have|O
DDI-DrugBank.d525.s2|253-254|no|O
DDI-DrugBank.d525.s2|256-261|effect|O
DDI-DrugBank.d525.s2|263-264|on|O
DDI-DrugBank.d525.s2|266-275|eprosartan|O
DDI-DrugBank.d525.s2|277-292|pharmacokinetics|O
DDI-DrugBank.d525.s2|293-293|.|O
DDI-DrugBank.d525.s3|0-9|Ranitidine|O
DDI-DrugBank.d525.s3|11-14|also|O
DDI-DrugBank.d525.s3|16-18|has|O
DDI-DrugBank.d525.s3|20-21|no|O
DDI-DrugBank.d525.s3|23-28|effect|O
DDI-DrugBank.d525.s3|30-31|on|O
DDI-DrugBank.d525.s3|33-42|eprosartan|O
DDI-DrugBank.d525.s3|44-59|pharmacokinetics|O
DDI-DrugBank.d525.s3|60-60|.|O
DDI-DrugBank.d525.s4|0-9|Eprosartan|O
DDI-DrugBank.d525.s4|11-11|(|O
DDI-DrugBank.d525.s4|12-13|up|O
DDI-DrugBank.d525.s4|15-16|to|O
DDI-DrugBank.d525.s4|18-20|400|O
DDI-DrugBank.d525.s4|22-23|mg|O
DDI-DrugBank.d525.s4|25-30|b.i.d.|O
DDI-DrugBank.d525.s4|32-33|or|O
DDI-DrugBank.d525.s4|35-37|800|O
DDI-DrugBank.d525.s4|39-40|mg|O
DDI-DrugBank.d525.s4|42-45|q.d.|O
DDI-DrugBank.d525.s4|46-46|)|O
DDI-DrugBank.d525.s4|48-52|doses|O
DDI-DrugBank.d525.s4|54-57|have|O
DDI-DrugBank.d525.s4|59-62|been|O
DDI-DrugBank.d525.s4|64-69|safely|O
DDI-DrugBank.d525.s4|71-74|used|O
DDI-DrugBank.d525.s4|76-88|concomitantly|O
DDI-DrugBank.d525.s4|90-93|with|O
DDI-DrugBank.d525.s4|95-95|a|O
DDI-DrugBank.d525.s4|97-104|thiazide|O
DDI-DrugBank.d525.s4|106-113|diuretic|O
DDI-DrugBank.d525.s4|115-115|(|O
DDI-DrugBank.d525.s4|116-134|hydrochlorothiazide|O
DDI-DrugBank.d525.s4|135-135|)|O
DDI-DrugBank.d525.s4|136-136|.|O
DDI-DrugBank.d525.s5|0-9|Eprosartan|O
DDI-DrugBank.d525.s5|11-15|doses|O
DDI-DrugBank.d525.s5|17-18|of|O
DDI-DrugBank.d525.s5|20-21|up|O
DDI-DrugBank.d525.s5|23-24|to|O
DDI-DrugBank.d525.s5|26-28|300|O
DDI-DrugBank.d525.s5|30-31|mg|O
DDI-DrugBank.d525.s5|33-38|b.i.d.|O
DDI-DrugBank.d525.s5|40-43|have|O
DDI-DrugBank.d525.s5|45-48|been|O
DDI-DrugBank.d525.s5|50-55|safely|O
DDI-DrugBank.d525.s5|57-60|used|O
DDI-DrugBank.d525.s5|62-74|concomitantly|O
DDI-DrugBank.d525.s5|76-79|with|O
DDI-DrugBank.d525.s5|81-97|sustained-release|O
DDI-DrugBank.d525.s5|99-105|calcium|O
DDI-DrugBank.d525.s5|107-113|channel|O
DDI-DrugBank.d525.s5|115-122|blockers|O
DDI-DrugBank.d525.s5|124-124|(|O
DDI-DrugBank.d525.s5|125-141|sustained-release|O
DDI-DrugBank.d525.s5|143-152|nifedipine|O
DDI-DrugBank.d525.s5|153-153|)|O
DDI-DrugBank.d525.s5|155-158|with|O
DDI-DrugBank.d525.s5|160-161|no|O
DDI-DrugBank.d525.s5|163-172|clinically|O
DDI-DrugBank.d525.s5|174-184|significant|O
DDI-DrugBank.d525.s5|186-192|adverse|O
DDI-DrugBank.d525.s5|194-205|interactions|O
DDI-DrugBank.d525.s5|206-206|.|O
DDI-DrugBank.d704.s0|0-8|Drug-Drug|O
DDI-DrugBank.d704.s0|10-21|Interactions|O
DDI-DrugBank.d704.s0|22-22|:|O
DDI-DrugBank.d704.s0|24-26|The|O
DDI-DrugBank.d704.s0|28-42|pharmacokinetic|O
DDI-DrugBank.d704.s0|44-46|and|O
DDI-DrugBank.d704.s0|48-62|pharmacodynamic|O
DDI-DrugBank.d704.s0|64-75|interactions|O
DDI-DrugBank.d704.s0|77-83|between|O
DDI-DrugBank.d704.s0|85-90|FLOMAX|O
DDI-DrugBank.d704.s0|92-99|capsules|O
DDI-DrugBank.d704.s0|101-103|and|O
DDI-DrugBank.d704.s0|105-109|other|O
DDI-DrugBank.d704.s0|111-126|alpha-adrenergic|O
DDI-DrugBank.d704.s0|128-135|blocking|O
DDI-DrugBank.d704.s0|137-142|agents|O
DDI-DrugBank.d704.s0|144-147|have|O
DDI-DrugBank.d704.s0|149-151|not|O
DDI-DrugBank.d704.s0|153-156|been|O
DDI-DrugBank.d704.s0|158-167|determined|O
DDI-DrugBank.d704.s0|168-168|.|O
DDI-DrugBank.d704.s1|0-6|However|O
DDI-DrugBank.d704.s1|7-7|,|O
DDI-DrugBank.d704.s1|9-20|interactions|O
DDI-DrugBank.d704.s1|22-24|may|O
DDI-DrugBank.d704.s1|26-27|be|O
DDI-DrugBank.d704.s1|29-36|expected|O
DDI-DrugBank.d704.s1|38-40|and|O
DDI-DrugBank.d704.s1|42-47|FLOMAX|O
DDI-DrugBank.d704.s1|49-56|capsules|O
DDI-DrugBank.d704.s1|58-63|should|O
DDI-DrugBank.d704.s1|65-67|NOT|O
DDI-DrugBank.d704.s1|69-70|be|O
DDI-DrugBank.d704.s1|72-75|used|O
DDI-DrugBank.d704.s1|77-78|in|O
DDI-DrugBank.d704.s1|80-90|combination|O
DDI-DrugBank.d704.s1|92-95|with|O
DDI-DrugBank.d704.s1|97-101|other|O
DDI-DrugBank.d704.s1|103-118|alpha-adrenergic|O
DDI-DrugBank.d704.s1|120-127|blocking|O
DDI-DrugBank.d704.s1|129-134|agents|O
DDI-DrugBank.d704.s1|135-135|.|O
DDI-DrugBank.d704.s2|0-2|The|O
DDI-DrugBank.d704.s2|4-18|pharmacokinetic|O
DDI-DrugBank.d704.s2|20-30|interaction|O
DDI-DrugBank.d704.s2|32-38|between|O
DDI-DrugBank.d704.s2|40-49|cimetidine|O
DDI-DrugBank.d704.s2|51-53|and|O
DDI-DrugBank.d704.s2|55-60|FLOMAX|O
DDI-DrugBank.d704.s2|62-69|capsules|O
DDI-DrugBank.d704.s2|71-73|was|O
DDI-DrugBank.d704.s2|75-86|investigated|O
DDI-DrugBank.d704.s2|87-87|.|O
DDI-DrugBank.d704.s3|0-2|The|O
DDI-DrugBank.d704.s3|4-10|results|O
DDI-DrugBank.d704.s3|12-19|indicate|O
DDI-DrugBank.d704.s3|21-31|significant|O
DDI-DrugBank.d704.s3|33-39|changes|O
DDI-DrugBank.d704.s3|41-42|in|O
DDI-DrugBank.d704.s3|44-53|tamsulosin|O
DDI-DrugBank.d704.s3|55-57|HCI|O
DDI-DrugBank.d704.s3|59-67|clearance|O
DDI-DrugBank.d704.s3|69-69|(|O
DDI-DrugBank.d704.s3|70-71|26|O
DDI-DrugBank.d704.s3|72-72|%|O
DDI-DrugBank.d704.s3|74-81|decrease|O
DDI-DrugBank.d704.s3|82-82|)|O
DDI-DrugBank.d704.s3|84-86|and|O
DDI-DrugBank.d704.s3|88-90|AUC|O
DDI-DrugBank.d704.s3|92-92|(|O
DDI-DrugBank.d704.s3|93-94|44|O
DDI-DrugBank.d704.s3|95-95|%|O
DDI-DrugBank.d704.s3|97-104|increase|O
DDI-DrugBank.d704.s3|105-105|)|O
DDI-DrugBank.d704.s3|106-106|.|O
DDI-DrugBank.d704.s4|0-8|Therefore|O
DDI-DrugBank.d704.s4|9-9|,|O
DDI-DrugBank.d704.s4|11-16|FLOMAX|O
DDI-DrugBank.d704.s4|18-25|capsules|O
DDI-DrugBank.d704.s4|27-32|should|O
DDI-DrugBank.d704.s4|34-35|be|O
DDI-DrugBank.d704.s4|37-40|used|O
DDI-DrugBank.d704.s4|42-45|with|O
DDI-DrugBank.d704.s4|47-53|caution|O
DDI-DrugBank.d704.s4|55-56|in|O
DDI-DrugBank.d704.s4|58-68|combination|O
DDI-DrugBank.d704.s4|70-73|with|O
DDI-DrugBank.d704.s4|75-84|cimetidine|O
DDI-DrugBank.d704.s4|85-85|,|O
DDI-DrugBank.d704.s4|87-98|particularly|O
DDI-DrugBank.d704.s4|100-101|at|O
DDI-DrugBank.d704.s4|103-107|doses|O
DDI-DrugBank.d704.s4|109-114|higher|O
DDI-DrugBank.d704.s4|116-119|than|O
DDI-DrugBank.d704.s4|121-123|0.4|O
DDI-DrugBank.d704.s4|125-126|mg|O
DDI-DrugBank.d704.s4|127-127|.|O
DDI-DrugBank.d704.s5|0-6|Results|O
DDI-DrugBank.d704.s5|8-11|from|O
DDI-DrugBank.d704.s5|13-19|limited|O
DDI-DrugBank.d704.s5|21-22|in|O
DDI-DrugBank.d704.s5|24-28|vitro|O
DDI-DrugBank.d704.s5|30-32|and|O
DDI-DrugBank.d704.s5|34-35|in|O
DDI-DrugBank.d704.s5|37-40|vivo|O
DDI-DrugBank.d704.s5|42-50|drug-drug|O
DDI-DrugBank.d704.s5|52-62|interaction|O
DDI-DrugBank.d704.s5|64-70|studies|O
DDI-DrugBank.d704.s5|72-78|between|O
DDI-DrugBank.d704.s5|80-89|tamsulosin|O
DDI-DrugBank.d704.s5|91-93|HCI|O
DDI-DrugBank.d704.s5|95-97|and|O
DDI-DrugBank.d704.s5|99-106|warfarin|O
DDI-DrugBank.d704.s5|108-110|are|O
DDI-DrugBank.d704.s5|112-123|inconclusive|O
DDI-DrugBank.d704.s5|124-124|.|O
DDI-DrugBank.d704.s6|0-8|Therefore|O
DDI-DrugBank.d704.s6|9-9|,|O
DDI-DrugBank.d704.s6|11-17|caution|O
DDI-DrugBank.d704.s6|19-24|should|O
DDI-DrugBank.d704.s6|26-27|be|O
DDI-DrugBank.d704.s6|29-37|exercised|O
DDI-DrugBank.d704.s6|39-42|with|O
DDI-DrugBank.d704.s6|44-54|concomitant|O
DDI-DrugBank.d704.s6|56-69|administration|O
DDI-DrugBank.d704.s6|71-72|of|O
DDI-DrugBank.d704.s6|74-81|warfarin|O
DDI-DrugBank.d704.s6|83-85|and|O
DDI-DrugBank.d704.s6|87-92|FLOMAX|O
DDI-DrugBank.d704.s6|94-101|capsules|O
DDI-DrugBank.d704.s6|102-102|.|O
DDI-DrugBank.d269.s0|0-9|Inhibitors|O
DDI-DrugBank.d269.s0|11-12|of|O
DDI-DrugBank.d269.s0|14-19|CYP2D6|O
DDI-DrugBank.d269.s0|20-20|;|O
DDI-DrugBank.d269.s1|0-3|poor|O
DDI-DrugBank.d269.s1|5-16|metabolizers|O
DDI-DrugBank.d269.s1|18-19|of|O
DDI-DrugBank.d269.s1|21-31|debrisoquin|O
DDI-DrugBank.d269.s1|32-32|:|O
DDI-DrugBank.d269.s1|34-45|Interactions|O
DDI-DrugBank.d269.s1|47-48|of|O
DDI-DrugBank.d269.s1|50-59|carvedilol|O
DDI-DrugBank.d269.s1|61-64|with|O
DDI-DrugBank.d269.s1|66-71|strong|O
DDI-DrugBank.d269.s1|73-82|inhibitors|O
DDI-DrugBank.d269.s1|84-85|of|O
DDI-DrugBank.d269.s1|87-92|CYP2D6|O
DDI-DrugBank.d269.s1|94-94|(|O
DDI-DrugBank.d269.s1|95-98|such|O
DDI-DrugBank.d269.s1|100-101|as|O
DDI-DrugBank.d269.s1|103-111|quinidine|O
DDI-DrugBank.d269.s1|112-112|,|O
DDI-DrugBank.d269.s1|114-123|fluoxetine|O
DDI-DrugBank.d269.s1|124-124|,|O
DDI-DrugBank.d269.s1|126-135|paroxetine|O
DDI-DrugBank.d269.s1|136-136|,|O
DDI-DrugBank.d269.s1|138-140|and|O
DDI-DrugBank.d269.s1|142-152|propafenone|O
DDI-DrugBank.d269.s1|153-153|)|O
DDI-DrugBank.d269.s1|155-158|have|O
DDI-DrugBank.d269.s1|160-162|not|O
DDI-DrugBank.d269.s1|164-167|been|O
DDI-DrugBank.d269.s1|169-175|studied|O
DDI-DrugBank.d269.s1|176-176|,|O
DDI-DrugBank.d269.s1|178-180|but|O
DDI-DrugBank.d269.s1|182-186|these|O
DDI-DrugBank.d269.s1|188-192|drugs|O
DDI-DrugBank.d269.s1|194-198|would|O
DDI-DrugBank.d269.s1|200-201|be|O
DDI-DrugBank.d269.s1|203-210|expected|O
DDI-DrugBank.d269.s1|212-213|to|O
DDI-DrugBank.d269.s1|215-222|increase|O
DDI-DrugBank.d269.s1|224-228|blood|O
DDI-DrugBank.d269.s1|230-235|levels|O
DDI-DrugBank.d269.s1|237-238|of|O
DDI-DrugBank.d269.s1|240-242|the|O
DDI-DrugBank.d269.s1|244-244|R|O
DDI-DrugBank.d269.s1|245-245|(|O
DDI-DrugBank.d269.s1|246-246|+|O
DDI-DrugBank.d269.s1|247-247|)|O
DDI-DrugBank.d269.s1|249-258|enantiomer|O
DDI-DrugBank.d269.s1|260-261|of|O
DDI-DrugBank.d269.s1|263-272|carvedilol|O
DDI-DrugBank.d269.s1|274-274|.|O
DDI-DrugBank.d269.s2|0-12|Retrospective|O
DDI-DrugBank.d269.s2|14-21|analysis|O
DDI-DrugBank.d269.s2|23-24|of|O
DDI-DrugBank.d269.s2|26-29|side|O
DDI-DrugBank.d269.s2|31-37|effects|O
DDI-DrugBank.d269.s2|39-40|in|O
DDI-DrugBank.d269.s2|42-49|clinical|O
DDI-DrugBank.d269.s2|51-56|trials|O
DDI-DrugBank.d269.s2|58-63|showed|O
DDI-DrugBank.d269.s2|65-68|that|O
DDI-DrugBank.d269.s2|70-73|poor|O
DDI-DrugBank.d269.s2|75-77|2D6|O
DDI-DrugBank.d269.s2|79-90|metabolizers|O
DDI-DrugBank.d269.s2|92-94|had|O
DDI-DrugBank.d269.s2|96-96|a|O
DDI-DrugBank.d269.s2|98-103|higher|O
DDI-DrugBank.d269.s2|105-108|rate|O
DDI-DrugBank.d269.s2|110-111|of|O
DDI-DrugBank.d269.s2|113-121|dizziness|O
DDI-DrugBank.d269.s2|123-128|during|O
DDI-DrugBank.d269.s2|130-141|up-titration|O
DDI-DrugBank.d269.s2|142-142|,|O
DDI-DrugBank.d269.s2|144-153|presumably|O
DDI-DrugBank.d269.s2|155-163|resulting|O
DDI-DrugBank.d269.s2|165-168|from|O
DDI-DrugBank.d269.s2|170-181|vasodilating|O
DDI-DrugBank.d269.s2|183-189|effects|O
DDI-DrugBank.d269.s2|191-192|of|O
DDI-DrugBank.d269.s2|194-196|the|O
DDI-DrugBank.d269.s2|198-203|higher|O
DDI-DrugBank.d269.s2|205-218|concentrations|O
DDI-DrugBank.d269.s2|220-221|of|O
DDI-DrugBank.d269.s2|223-225|the|O
DDI-DrugBank.d269.s2|227-236|a-blocking|O
DDI-DrugBank.d269.s2|238-238|R|O
DDI-DrugBank.d269.s2|239-239|(|O
DDI-DrugBank.d269.s2|240-240|+|O
DDI-DrugBank.d269.s2|241-241|)|O
DDI-DrugBank.d269.s2|243-252|enantiomer|O
DDI-DrugBank.d269.s2|253-253|.|O
DDI-DrugBank.d269.s3|0-22|Catecholamine-depleting|O
DDI-DrugBank.d269.s3|24-29|Agents|O
DDI-DrugBank.d269.s3|30-30|:|O
DDI-DrugBank.d269.s3|32-39|Patients|O
DDI-DrugBank.d269.s3|41-46|taking|O
DDI-DrugBank.d269.s3|48-51|both|O
DDI-DrugBank.d269.s3|53-58|agents|O
DDI-DrugBank.d269.s3|60-63|with|O
DDI-DrugBank.d269.s3|65-74|b-blocking|O
DDI-DrugBank.d269.s3|76-85|properties|O
DDI-DrugBank.d269.s3|87-89|and|O
DDI-DrugBank.d269.s3|91-91|a|O
DDI-DrugBank.d269.s3|93-96|drug|O
DDI-DrugBank.d269.s3|98-101|that|O
DDI-DrugBank.d269.s3|103-105|can|O
DDI-DrugBank.d269.s3|107-113|deplete|O
DDI-DrugBank.d269.s3|115-128|catecholamines|O
DDI-DrugBank.d269.s3|130-130|(|O
DDI-DrugBank.d269.s3|131-134|e.g.|O
DDI-DrugBank.d269.s3|135-135|,|O
DDI-DrugBank.d269.s3|137-145|reserpine|O
DDI-DrugBank.d269.s3|147-149|and|O
DDI-DrugBank.d269.s3|151-159|monoamine|O
DDI-DrugBank.d269.s3|161-167|oxidase|O
DDI-DrugBank.d269.s3|169-178|inhibitors|O
DDI-DrugBank.d269.s3|179-179|)|O
DDI-DrugBank.d269.s3|181-186|should|O
DDI-DrugBank.d269.s3|188-189|be|O
DDI-DrugBank.d269.s3|191-198|observed|O
DDI-DrugBank.d269.s3|200-206|closely|O
DDI-DrugBank.d269.s3|208-210|for|O
DDI-DrugBank.d269.s3|212-216|signs|O
DDI-DrugBank.d269.s3|218-219|of|O
DDI-DrugBank.d269.s3|221-231|hypotension|O
DDI-DrugBank.d269.s3|233-238|and/or|O
DDI-DrugBank.d269.s3|240-245|severe|O
DDI-DrugBank.d269.s3|247-257|bradycardia|O
DDI-DrugBank.d269.s3|258-258|.|O
DDI-DrugBank.d269.s4|0-8|Clonidine|O
DDI-DrugBank.d269.s4|9-9|:|O
DDI-DrugBank.d269.s4|11-21|Concomitant|O
DDI-DrugBank.d269.s4|23-36|administration|O
DDI-DrugBank.d269.s4|38-39|of|O
DDI-DrugBank.d269.s4|41-49|clonidine|O
DDI-DrugBank.d269.s4|51-54|with|O
DDI-DrugBank.d269.s4|56-61|agents|O
DDI-DrugBank.d269.s4|63-66|with|O
DDI-DrugBank.d269.s4|68-77|b-blocking|O
DDI-DrugBank.d269.s4|79-88|properties|O
DDI-DrugBank.d269.s4|90-92|may|O
DDI-DrugBank.d269.s4|94-103|potentiate|O
DDI-DrugBank.d269.s4|105-119|blood-pressure-|O
DDI-DrugBank.d269.s4|121-123|and|O
DDI-DrugBank.d269.s4|125-143|heart-rate-lowering|O
DDI-DrugBank.d269.s4|145-151|effects|O
DDI-DrugBank.d269.s4|152-152|.|O
DDI-DrugBank.d269.s5|0-3|When|O
DDI-DrugBank.d269.s5|5-15|concomitant|O
DDI-DrugBank.d269.s5|17-25|treatment|O
DDI-DrugBank.d269.s5|27-30|with|O
DDI-DrugBank.d269.s5|32-37|agents|O
DDI-DrugBank.d269.s5|39-42|with|O
DDI-DrugBank.d269.s5|44-53|b-blocking|O
DDI-DrugBank.d269.s5|55-64|properties|O
DDI-DrugBank.d269.s5|66-68|and|O
DDI-DrugBank.d269.s5|70-78|clonidine|O
DDI-DrugBank.d269.s5|80-81|is|O
DDI-DrugBank.d269.s5|83-84|to|O
DDI-DrugBank.d269.s5|86-87|be|O
DDI-DrugBank.d269.s5|89-98|terminated|O
DDI-DrugBank.d269.s5|99-99|,|O
DDI-DrugBank.d269.s5|101-103|the|O
DDI-DrugBank.d269.s5|105-114|b-blocking|O
DDI-DrugBank.d269.s5|116-120|agent|O
DDI-DrugBank.d269.s5|122-127|should|O
DDI-DrugBank.d269.s5|129-130|be|O
DDI-DrugBank.d269.s5|132-143|discontinued|O
DDI-DrugBank.d269.s5|145-149|first|O
DDI-DrugBank.d269.s5|150-150|.|O
DDI-DrugBank.d269.s6|0-8|Clonidine|O
DDI-DrugBank.d269.s6|10-16|therapy|O
DDI-DrugBank.d269.s6|18-20|can|O
DDI-DrugBank.d269.s6|22-25|then|O
DDI-DrugBank.d269.s6|27-28|be|O
DDI-DrugBank.d269.s6|30-41|discontinued|O
DDI-DrugBank.d269.s6|43-49|several|O
DDI-DrugBank.d269.s6|51-54|days|O
DDI-DrugBank.d269.s6|56-60|later|O
DDI-DrugBank.d269.s6|62-63|by|O
DDI-DrugBank.d269.s6|65-73|gradually|O
DDI-DrugBank.d269.s6|75-84|decreasing|O
DDI-DrugBank.d269.s6|86-88|the|O
DDI-DrugBank.d269.s6|90-95|dosage|O
DDI-DrugBank.d269.s6|96-96|.|O
DDI-DrugBank.d269.s7|0-11|Cyclosporine|O
DDI-DrugBank.d269.s7|12-12|:|O
DDI-DrugBank.d269.s7|14-19|Modest|O
DDI-DrugBank.d269.s7|21-29|increases|O
DDI-DrugBank.d269.s7|31-32|in|O
DDI-DrugBank.d269.s7|34-37|mean|O
DDI-DrugBank.d269.s7|39-44|trough|O
DDI-DrugBank.d269.s7|46-57|cyclosporine|O
DDI-DrugBank.d269.s7|59-72|concentrations|O
DDI-DrugBank.d269.s7|74-77|were|O
DDI-DrugBank.d269.s7|79-86|observed|O
DDI-DrugBank.d269.s7|88-96|following|O
DDI-DrugBank.d269.s7|98-107|initiation|O
DDI-DrugBank.d269.s7|109-110|of|O
DDI-DrugBank.d269.s7|112-121|carvedilol|O
DDI-DrugBank.d269.s7|123-131|treatment|O
DDI-DrugBank.d269.s7|133-134|in|O
DDI-DrugBank.d269.s7|136-137|21|O
DDI-DrugBank.d269.s7|139-143|renal|O
DDI-DrugBank.d269.s7|145-154|transplant|O
DDI-DrugBank.d269.s7|156-163|patients|O
DDI-DrugBank.d269.s7|165-173|suffering|O
DDI-DrugBank.d269.s7|175-178|from|O
DDI-DrugBank.d269.s7|180-186|chronic|O
DDI-DrugBank.d269.s7|188-195|vascular|O
DDI-DrugBank.d269.s7|197-205|rejection|O
DDI-DrugBank.d269.s7|206-206|.|O
DDI-DrugBank.d269.s8|0-1|In|O
DDI-DrugBank.d269.s8|3-7|about|O
DDI-DrugBank.d269.s8|9-10|30|O
DDI-DrugBank.d269.s8|11-11|%|O
DDI-DrugBank.d269.s8|13-14|of|O
DDI-DrugBank.d269.s8|16-23|patients|O
DDI-DrugBank.d269.s8|24-24|,|O
DDI-DrugBank.d269.s8|26-28|the|O
DDI-DrugBank.d269.s8|30-33|dose|O
DDI-DrugBank.d269.s8|35-36|of|O
DDI-DrugBank.d269.s8|38-49|cyclosporine|O
DDI-DrugBank.d269.s8|51-53|had|O
DDI-DrugBank.d269.s8|55-56|to|O
DDI-DrugBank.d269.s8|58-59|be|O
DDI-DrugBank.d269.s8|61-67|reduced|O
DDI-DrugBank.d269.s8|69-70|in|O
DDI-DrugBank.d269.s8|72-76|order|O
DDI-DrugBank.d269.s8|78-79|to|O
DDI-DrugBank.d269.s8|81-88|maintain|O
DDI-DrugBank.d269.s8|90-101|cyclosporine|O
DDI-DrugBank.d269.s8|103-116|concentrations|O
DDI-DrugBank.d269.s8|118-123|within|O
DDI-DrugBank.d269.s8|125-127|the|O
DDI-DrugBank.d269.s8|129-139|therapeutic|O
DDI-DrugBank.d269.s8|141-145|range|O
DDI-DrugBank.d269.s8|146-146|,|O
DDI-DrugBank.d269.s8|148-152|while|O
DDI-DrugBank.d269.s8|154-155|in|O
DDI-DrugBank.d269.s8|157-159|the|O
DDI-DrugBank.d269.s8|161-169|remainder|O
DDI-DrugBank.d269.s8|171-172|no|O
DDI-DrugBank.d269.s8|174-183|adjustment|O
DDI-DrugBank.d269.s8|185-187|was|O
DDI-DrugBank.d269.s8|189-194|needed|O
DDI-DrugBank.d269.s8|195-195|.|O
DDI-DrugBank.d269.s9|0-1|On|O
DDI-DrugBank.d269.s9|3-5|the|O
DDI-DrugBank.d269.s9|7-13|average|O
DDI-DrugBank.d269.s9|15-17|for|O
DDI-DrugBank.d269.s9|19-21|the|O
DDI-DrugBank.d269.s9|23-27|group|O
DDI-DrugBank.d269.s9|28-28|,|O
DDI-DrugBank.d269.s9|30-32|the|O
DDI-DrugBank.d269.s9|34-37|dose|O
DDI-DrugBank.d269.s9|39-40|of|O
DDI-DrugBank.d269.s9|42-53|cyclosporine|O
DDI-DrugBank.d269.s9|55-57|was|O
DDI-DrugBank.d269.s9|59-65|reduced|O
DDI-DrugBank.d269.s9|67-71|about|O
DDI-DrugBank.d269.s9|73-74|20|O
DDI-DrugBank.d269.s9|75-75|%|O
DDI-DrugBank.d269.s9|77-78|in|O
DDI-DrugBank.d269.s9|80-84|these|O
DDI-DrugBank.d269.s9|86-93|patients|O
DDI-DrugBank.d269.s9|94-94|.|O
DDI-DrugBank.d269.s10|0-2|Due|O
DDI-DrugBank.d269.s10|4-5|to|O
DDI-DrugBank.d269.s10|7-10|wide|O
DDI-DrugBank.d269.s10|12-26|interindividual|O
DDI-DrugBank.d269.s10|28-38|variability|O
DDI-DrugBank.d269.s10|40-41|in|O
DDI-DrugBank.d269.s10|43-45|the|O
DDI-DrugBank.d269.s10|47-50|dose|O
DDI-DrugBank.d269.s10|52-61|adjustment|O
DDI-DrugBank.d269.s10|63-70|required|O
DDI-DrugBank.d269.s10|71-71|,|O
DDI-DrugBank.d269.s10|73-74|it|O
DDI-DrugBank.d269.s10|76-77|is|O
DDI-DrugBank.d269.s10|79-89|recommended|O
DDI-DrugBank.d269.s10|91-94|that|O
DDI-DrugBank.d269.s10|96-107|cyclosporine|O
DDI-DrugBank.d269.s10|109-122|concentrations|O
DDI-DrugBank.d269.s10|124-125|be|O
DDI-DrugBank.d269.s10|127-135|monitored|O
DDI-DrugBank.d269.s10|137-143|closely|O
DDI-DrugBank.d269.s10|145-149|after|O
DDI-DrugBank.d269.s10|151-160|initiation|O
DDI-DrugBank.d269.s10|162-163|of|O
DDI-DrugBank.d269.s10|165-174|carvedilol|O
DDI-DrugBank.d269.s10|176-182|therapy|O
DDI-DrugBank.d269.s10|184-186|and|O
DDI-DrugBank.d269.s10|188-191|that|O
DDI-DrugBank.d269.s10|193-195|the|O
DDI-DrugBank.d269.s10|197-200|dose|O
DDI-DrugBank.d269.s10|202-203|of|O
DDI-DrugBank.d269.s10|205-216|cyclosporine|O
DDI-DrugBank.d269.s10|218-219|be|O
DDI-DrugBank.d269.s10|221-228|adjusted|O
DDI-DrugBank.d269.s10|230-231|as|O
DDI-DrugBank.d269.s10|233-243|appropriate|O
DDI-DrugBank.d269.s10|244-244|.|O
DDI-DrugBank.d269.s11|0-6|Digoxin|O
DDI-DrugBank.d269.s11|7-7|:|O
DDI-DrugBank.d269.s11|9-15|Digoxin|O
DDI-DrugBank.d269.s11|17-30|concentrations|O
DDI-DrugBank.d269.s11|32-34|are|O
DDI-DrugBank.d269.s11|36-44|increased|O
DDI-DrugBank.d269.s11|46-47|by|O
DDI-DrugBank.d269.s11|49-53|about|O
DDI-DrugBank.d269.s11|55-56|15|O
DDI-DrugBank.d269.s11|57-57|%|O
DDI-DrugBank.d269.s11|59-62|when|O
DDI-DrugBank.d269.s11|64-70|digoxin|O
DDI-DrugBank.d269.s11|72-74|and|O
DDI-DrugBank.d269.s11|76-85|carvedilol|O
DDI-DrugBank.d269.s11|87-89|are|O
DDI-DrugBank.d269.s11|91-102|administered|O
DDI-DrugBank.d269.s11|104-116|concomitantly|O
DDI-DrugBank.d269.s11|117-117|.|O
DDI-DrugBank.d269.s12|0-3|Both|O
DDI-DrugBank.d269.s12|5-11|digoxin|O
DDI-DrugBank.d269.s12|13-15|and|O
DDI-DrugBank.d269.s12|17-21|COREG|O
DDI-DrugBank.d269.s12|23-26|slow|O
DDI-DrugBank.d269.s12|28-29|AV|O
DDI-DrugBank.d269.s12|31-40|conduction|O
DDI-DrugBank.d269.s12|41-41|.|O
DDI-DrugBank.d269.s13|0-8|Therefore|O
DDI-DrugBank.d269.s13|9-9|,|O
DDI-DrugBank.d269.s13|11-19|increased|O
DDI-DrugBank.d269.s13|21-30|monitoring|O
DDI-DrugBank.d269.s13|32-33|of|O
DDI-DrugBank.d269.s13|35-41|digoxin|O
DDI-DrugBank.d269.s13|43-44|is|O
DDI-DrugBank.d269.s13|46-56|recommended|O
DDI-DrugBank.d269.s13|58-61|when|O
DDI-DrugBank.d269.s13|63-72|initiating|O
DDI-DrugBank.d269.s13|73-73|,|O
DDI-DrugBank.d269.s13|75-83|adjusting|O
DDI-DrugBank.d269.s13|84-84|,|O
DDI-DrugBank.d269.s13|86-87|or|O
DDI-DrugBank.d269.s13|89-101|discontinuing|O
DDI-DrugBank.d269.s13|103-107|COREG|O
DDI-DrugBank.d269.s13|108-108|.|O
DDI-DrugBank.d269.s14|0-7|Inducers|O
DDI-DrugBank.d269.s14|9-11|and|O
DDI-DrugBank.d269.s14|13-22|Inhibitors|O
DDI-DrugBank.d269.s14|24-25|of|O
DDI-DrugBank.d269.s14|27-33|Hepatic|O
DDI-DrugBank.d269.s14|35-44|Metabolism|O
DDI-DrugBank.d269.s14|45-45|:|O
DDI-DrugBank.d269.s14|47-54|Rifampin|O
DDI-DrugBank.d269.s14|56-62|reduced|O
DDI-DrugBank.d269.s14|64-69|plasma|O
DDI-DrugBank.d269.s14|71-84|concentrations|O
DDI-DrugBank.d269.s14|86-87|of|O
DDI-DrugBank.d269.s14|89-98|carvedilol|O
DDI-DrugBank.d269.s14|100-101|by|O
DDI-DrugBank.d269.s14|103-107|about|O
DDI-DrugBank.d269.s14|109-110|70|O
DDI-DrugBank.d269.s14|111-111|%|O
DDI-DrugBank.d269.s14|112-112|.|O
DDI-DrugBank.d269.s15|0-9|Cimetidine|O
DDI-DrugBank.d269.s15|11-19|increased|O
DDI-DrugBank.d269.s15|21-23|AUC|O
DDI-DrugBank.d269.s15|25-26|by|O
DDI-DrugBank.d269.s15|28-32|about|O
DDI-DrugBank.d269.s15|34-35|30|O
DDI-DrugBank.d269.s15|36-36|%|O
DDI-DrugBank.d269.s15|38-40|but|O
DDI-DrugBank.d269.s15|42-47|caused|O
DDI-DrugBank.d269.s15|49-50|no|O
DDI-DrugBank.d269.s15|52-57|change|O
DDI-DrugBank.d269.s15|59-60|in|O
DDI-DrugBank.d269.s15|62-65|Cmax|O
DDI-DrugBank.d269.s15|66-66|.|O
DDI-DrugBank.d269.s16|0-6|Calcium|O
DDI-DrugBank.d269.s16|8-14|Channel|O
DDI-DrugBank.d269.s16|16-23|Blockers|O
DDI-DrugBank.d269.s16|24-24|:|O
DDI-DrugBank.d269.s16|26-33|Isolated|O
DDI-DrugBank.d269.s16|35-39|cases|O
DDI-DrugBank.d269.s16|41-42|of|O
DDI-DrugBank.d269.s16|44-53|conduction|O
DDI-DrugBank.d269.s16|55-65|disturbance|O
DDI-DrugBank.d269.s16|67-67|(|O
DDI-DrugBank.d269.s16|68-73|rarely|O
DDI-DrugBank.d269.s16|75-78|with|O
DDI-DrugBank.d269.s16|80-90|hemodynamic|O
DDI-DrugBank.d269.s16|92-101|compromise|O
DDI-DrugBank.d269.s16|102-102|)|O
DDI-DrugBank.d269.s16|104-107|have|O
DDI-DrugBank.d269.s16|109-112|been|O
DDI-DrugBank.d269.s16|114-121|observed|O
DDI-DrugBank.d269.s16|123-126|when|O
DDI-DrugBank.d269.s16|128-132|COREG|O
DDI-DrugBank.d269.s16|134-135|is|O
DDI-DrugBank.d269.s16|137-151|co-administered|O
DDI-DrugBank.d269.s16|153-156|with|O
DDI-DrugBank.d269.s16|158-166|diltiazem|O
DDI-DrugBank.d269.s16|167-167|.|O
DDI-DrugBank.d269.s17|0-1|As|O
DDI-DrugBank.d269.s17|3-6|with|O
DDI-DrugBank.d269.s17|8-12|other|O
DDI-DrugBank.d269.s17|14-19|agents|O
DDI-DrugBank.d269.s17|21-24|with|O
DDI-DrugBank.d269.s17|26-35|b-blocking|O
DDI-DrugBank.d269.s17|37-46|properties|O
DDI-DrugBank.d269.s17|47-47|,|O
DDI-DrugBank.d269.s17|49-50|if|O
DDI-DrugBank.d269.s17|52-56|COREG|O
DDI-DrugBank.d269.s17|58-59|is|O
DDI-DrugBank.d269.s17|61-62|to|O
DDI-DrugBank.d269.s17|64-65|be|O
DDI-DrugBank.d269.s17|67-78|administered|O
DDI-DrugBank.d269.s17|80-85|orally|O
DDI-DrugBank.d269.s17|87-90|with|O
DDI-DrugBank.d269.s17|92-98|calcium|O
DDI-DrugBank.d269.s17|100-106|channel|O
DDI-DrugBank.d269.s17|108-115|blockers|O
DDI-DrugBank.d269.s17|117-118|of|O
DDI-DrugBank.d269.s17|120-122|the|O
DDI-DrugBank.d269.s17|124-132|verapamil|O
DDI-DrugBank.d269.s17|134-135|or|O
DDI-DrugBank.d269.s17|137-145|diltiazem|O
DDI-DrugBank.d269.s17|147-150|type|O
DDI-DrugBank.d269.s17|151-151|,|O
DDI-DrugBank.d269.s17|153-154|it|O
DDI-DrugBank.d269.s17|156-157|is|O
DDI-DrugBank.d269.s17|159-169|recommended|O
DDI-DrugBank.d269.s17|171-174|that|O
DDI-DrugBank.d269.s17|176-178|ECG|O
DDI-DrugBank.d269.s17|180-182|and|O
DDI-DrugBank.d269.s17|184-188|blood|O
DDI-DrugBank.d269.s17|190-197|pressure|O
DDI-DrugBank.d269.s17|199-200|be|O
DDI-DrugBank.d269.s17|202-210|monitored|O
DDI-DrugBank.d269.s17|211-211|.|O
DDI-DrugBank.d269.s18|0-6|Insulin|O
DDI-DrugBank.d269.s18|8-9|or|O
DDI-DrugBank.d269.s18|11-14|Oral|O
DDI-DrugBank.d269.s18|16-28|Hypoglycemics|O
DDI-DrugBank.d269.s18|29-29|:|O
DDI-DrugBank.d269.s18|31-36|Agents|O
DDI-DrugBank.d269.s18|38-41|with|O
DDI-DrugBank.d269.s18|43-52|b-blocking|O
DDI-DrugBank.d269.s18|54-63|properties|O
DDI-DrugBank.d269.s18|65-67|may|O
DDI-DrugBank.d269.s18|69-75|enhance|O
DDI-DrugBank.d269.s18|77-79|the|O
DDI-DrugBank.d269.s18|81-100|blood-sugar-reducing|O
DDI-DrugBank.d269.s18|102-107|effect|O
DDI-DrugBank.d269.s18|109-110|of|O
DDI-DrugBank.d269.s18|112-118|insulin|O
DDI-DrugBank.d269.s18|120-122|and|O
DDI-DrugBank.d269.s18|124-127|oral|O
DDI-DrugBank.d269.s18|129-141|hypoglycemics|O
DDI-DrugBank.d269.s18|142-142|.|O
DDI-DrugBank.d269.s19|0-8|Therefore|O
DDI-DrugBank.d269.s19|9-9|,|O
DDI-DrugBank.d269.s19|11-12|in|O
DDI-DrugBank.d269.s19|14-21|patients|O
DDI-DrugBank.d269.s19|23-28|taking|O
DDI-DrugBank.d269.s19|30-36|insulin|O
DDI-DrugBank.d269.s19|38-39|or|O
DDI-DrugBank.d269.s19|41-44|oral|O
DDI-DrugBank.d269.s19|46-58|hypoglycemics|O
DDI-DrugBank.d269.s19|59-59|,|O
DDI-DrugBank.d269.s19|61-67|regular|O
DDI-DrugBank.d269.s19|69-78|monitoring|O
DDI-DrugBank.d269.s19|80-81|of|O
DDI-DrugBank.d269.s19|83-87|blood|O
DDI-DrugBank.d269.s19|89-95|glucose|O
DDI-DrugBank.d269.s19|97-98|is|O
DDI-DrugBank.d269.s19|100-110|recommended|O
DDI-DrugBank.d269.s19|111-111|.|O
